Figure	NN	O
4	CD	O

Adjustments	NNS	O
in	IN	O
dose	NN	O
should	MD	O
not	RB	O
be	VB	O
made	VBN	O
more	RBR	O
frequently	RB	O
than	IN	O
once	RB	FREQ
every	DT	FREQ
2	CD	FREQ
days	NNS	FREQ
and	CC	O
should	MD	O
not	RB	O
exceed	VB	O
more	JJR	O
than	IN	O
75	CD	DOS
to	TO	O
150	CD	DOS
IU	NNP	UNIT
per	IN	O
adjustment	NN	O
.	.	O

If	IN	O
SYMMETREL	NNP	O
(	(	O
amantadine	JJ	O
hydrochloride	NN	O
)	)	O
is	VBZ	O
used	VBN	O
chemoprophylactically	RB	O
in	IN	O
conjunction	NN	O
with	IN	O
inactivated	JJ	O
influenza	NN	O
A	NNP	O
virus	NN	O
vaccine	NN	O
until	IN	O
protective	JJ	O
antibody	NN	O
responses	NNS	O
develop	VBP	O
,	,	O
then	RB	O
it	PRP	O
should	MD	O
be	VB	O
administered	VBN	O
for	IN	O
2	CD	PER
to	TO	O
4	CD	PER
weeks	NNS	PER
after	IN	O
the	DT	O
vaccine	NN	O
has	VBZ	O
been	VBN	O
given	VBN	O
.	.	O

Step	NN	O
5	CD	O
:	:	O
Transferring	VBG	O
the	DT	O
liquid	NN	O
to	TO	O
the	DT	O
syringe	NN	O

Figure	NN	O
1	CD	O

Base	NNP	O
changes	NNS	O
in	IN	O
the	DT	O
chronic	JJ	O
infusion	NN	O
rate	NN	O
on	IN	O
persistence	NN	O
,	,	O
recurrence	NN	O
,	,	O
or	CC	O
worsening	NN	O
of	IN	O
the	DT	O
patient	NN	O
's	POS	O
symptoms	NNS	O
of	IN	O
pulmonary	JJ	O
hypertension	NN	O
and	CC	O
the	DT	O
occurrence	NN	O
of	IN	O
adverse	JJ	O
vasodilatory	NN	O
reactions	NNS	O
.	.	O

An	DT	O
INR	NNP	O
of	IN	O
greater	JJR	O
than	IN	O
4.0	CD	O
appears	VBZ	O
to	TO	O
provide	VB	O
no	DT	O
additional	JJ	O
therapeutic	JJ	O
benefit	NN	O
in	IN	O
most	JJS	WHO
patients	NNS	WHO
and	CC	O
is	VBZ	O
associated	VBN	O
with	IN	O
a	DT	O
higher	JJR	O
risk	NN	O
of	IN	O
bleeding	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Osserman	NNP	O
and	CC	O
Takatsuki	NNP	O
have	VBP	O
used	VBN	O
an	DT	O
initial	JJ	O
course	NN	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
for	IN	O
7	CD	PER
to	TO	O
10	CD	PER
days	NNS	PER
.	.	O

Exocrine	NNP	O
pancreas	NNS	O
dysfunction	NN	O
typically	RB	O
associated	VBN	O
with	IN	O
chronic	JJ	O
pancreatitis	NN	O
is	VBZ	O
indicated	VBN	O
if	IN	O
the	DT	O
peak	NN	O
bicarbonate	NN	O
concentration	NN	O
for	IN	O
any	DT	O
sample	JJ	O
≤	NN	O
80	CD	O
mEq	NN	O
/	NNP	O
L	NNP	O
.	.	O

Immediately	RB	O
following	VBG	O
the	DT	O
intravitreal	JJ	O
injection	NN	O
,	,	O
patients	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
for	IN	O
elevation	NN	O
in	IN	O
intraocular	JJ	O
pressure	NN	O
.	.	O

8	CD	O

Concomitant	JJ	O
therapy	NN	O
should	MD	O
be	VB	O
based	VBN	O
on	IN	O
a	DT	O
patient	NN	O
's	POS	O
prior	JJ	O
drug	NN	O
exposure	NN	O
.	.	O

After	IN	O
both	DT	O
ventricular	JJ	O
and	CC	O
coronary	JJ	O
injection	NN	O
,	,	O
decreases	VBZ	O
in	IN	O
systolic	JJ	O
pressure	NN	O
were	VBD	O
less	JJR	O
pronounced	JJ	O
and	CC	O
returned	VBN	O
to	TO	O
baseline	VB	O
values	NNS	O
earlier	RBR	O
with	IN	O
OMNIPAQUE	NNP	O
350	CD	O
than	IN	O
with	IN	O
diatrizoate	JJ	O
meglumine	NN	O
and	CC	O
diatrizoate	VB	O
sodium	NN	O
injection	NN	O
.	.	O

A	DT	O
.	.	O

The	DT	O
combination	NN	O
of	IN	O
promethazine	JJ	O
hydrochloride	NN	O
and	CC	O
codeine	NN	O
phosphate	NN	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
less	RBR	WHO
than	IN	WHO
6	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
,	,	O
because	IN	O
the	DT	O
combination	NN	O
may	MD	O
cause	VB	O
fatal	JJ	O
respiratory	NN	O
depression	NN	O
in	IN	O
this	DT	O
age	NN	O
population	NN	O
.	.	O

Initially	RB	O
,	,	O
Azmacort	NNP	O
(	(	O
triamcinolone	JJ	O
acetonide	NN	O
)	)	O
Inhalation	NNP	O
Aerosol	NNP	O
should	MD	O
be	VB	O
used	VBN	O
concurrently	RB	O
with	IN	O
the	DT	O
patient	NN	O
's	POS	O
usual	JJ	O
maintenance	NN	O
dose	NN	O
of	IN	O
systemic	JJ	O
corticosteroid	NN	O
.	.	O

The	DT	O
following	JJ	O
schedule	NN	O
is	VBZ	O
suggested	VBN	O
as	IN	O
a	DT	O
guide	NN	O
to	TO	O
dosage	VB	O
adjustment	NN	O
:	:	O

Table	JJ	O
1	CD	O
:	:	O
(	(	O
adapted	VBN	O
from	IN	O
20	CD	O
)	)	O
Recommendations	NNPS	O
for	IN	O
Hepatitis	NNP	O
B	NNP	O
Prophylaxis	NNP	O
Following	NNP	O
Percutaneous	NNP	O
or	CC	O
Permucosal	NNP	O
Exposure	NNP	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
experience	VBP	WHO
intolerance	NN	WHO
,	,	O
ARTHROTEC	NNP	O
75	CD	O
two	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
or	CC	O
ARTHROTEC	$	O
50	CD	O
two	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
can	MD	O
be	VB	O
used	VBN	O
,	,	O
but	CC	O
are	VBP	O
less	RBR	O
effective	JJ	O
in	IN	O
preventing	VBG	O
ulcers	NNS	O
.	.	O

GLUCOTROL	NNP	O
XL	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
orally	RB	O
with	IN	O
breakfast	NN	O
or	CC	O
the	DT	O
first	JJ	O
main	JJ	O
meal	NN	O
of	IN	O
the	DT	O
day	NN	O
.	.	O

Remove	VB	O
the	DT	O
tab	JJ	O
portion	NN	O
of	IN	O
the	DT	O
vial	JJ	O
cap	NN	O
and	CC	O
clean	VB	O
the	DT	O
rubber	NN	O
stopper	NN	O
with	IN	O
70	CD	O
%	NN	O
alcohol	NN	O
or	CC	O
equivalent	NN	O
.	.	O

BUNAVAIL	NNP	O
buccal	JJ	O
film	NN	O
should	MD	O
be	VB	O
used	VBN	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
been	VBN	WHO
initially	RB	WHO
inducted	VBN	WHO
using	VBG	WHO
buprenorphine	JJ	WHO
sublingual	JJ	WHO
tablets	NNS	WHO
.	.	O

When	WRB	O
SORIATANE	NNP	O
is	VBZ	O
used	VBN	O
with	IN	O
phototherapy	NN	O
,	,	O
the	DT	O
prescriber	NN	O
should	MD	O
decrease	VB	O
the	DT	O
phototherapy	NN	O
dose	NN	O
,	,	O
dependent	NN	O
on	IN	O
the	DT	O
patient	NN	O
's	POS	O
individual	JJ	O
response	NN	O
(	(	O
see	JJ	O
PRECAUTIONS	NNP	O
:	:	O
General	NNP	O
)	)	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
elderly	JJ	WHO
or	CC	WHO
debilitated	JJ	WHO
patients	NNS	WHO
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

Dissolve	VB	O
the	DT	O
contents	NNS	O
of	IN	O
one	CD	DOS
to	TO	O
6	CD	DOS
vials	NNS	UNIT
of	IN	O
Repronex®	NNP	O
(	(	O
menotropins	NNS	O
for	IN	O
injection	NN	O
)	)	O
in	IN	O
one	CD	DOS
to	TO	O
two	CD	DOS
mL	NN	UNIT
of	IN	O
sterile	JJ	O
saline	NN	O
and	CC	O
ADMINISTER	NNP	O
SUBCUTANEOUSLY	NNP	O
OR	NNP	O
INTRAMUSCULARLY	NNP	O
immediately	RB	O
.	.	O

Toviaz	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
with	IN	O
liquid	NN	O
and	CC	O
swallowed	VBD	O
whole	JJ	O
.	.	O

NEVER	RB	O
ADMINISTER	NNP	O
TO	NNP	O
THE	NNP	O
NEONATE	NNP	O
.	.	O

Different	JJ	O
formulations	NNS	O
of	IN	O
diclofenac	NN	O
[	NNP	O
VOLTAREN®	NNP	O
(	(	O
diclofenac	JJ	O
sodium	NN	O
enteric	JJ	O
-	:	O
coated	VBN	O
tablets	NNS	O
)	)	O
;	:	O
VOLTAREN®	NNP	O
-	:	O
XR	NN	O
(	(	O
diclofenac	JJ	O
sodium	NN	O
extended	VBD	O
-	:	O
release	NN	O
tablets	NNS	O
)	)	O
;	:	O
CATAFLAM®	NNP	O
(	(	O
diclofenac	JJ	O
potassium	NN	O
immediate	JJ	O
-	:	O
release	NN	O
tablets	NNS	O
)	)	O
]	NNS	O
are	VBP	O
not	RB	O
necessarily	RB	O
bioequivalent	VB	O
even	RB	O
if	IN	O
the	DT	O
milligram	NN	O
strength	NN	O
is	VBZ	O
the	DT	O
same	JJ	O
.	.	O

Symptomatic	JJ	O
relief	NN	O
usually	RB	O
occurs	VBZ	O
within	IN	O
a	DT	O
few	JJ	O
days	NNS	O
after	IN	O
starting	VBG	O
EXELDERM	NNP	O
(	(	O
sulconazole	JJ	O
nitrate	NN	O
)	)	O
SOLUTION	NNP	O
,	,	O
1.0	CD	O
%	NN	O
,	,	O
and	CC	O
clinical	JJ	O
improvement	NN	O
usually	RB	O
occurs	VBZ	O
within	IN	O
one	CD	PER
week	NN	PER
.	.	O

Monitor	NN	O
patients	NNS	O
closely	RB	O
for	IN	O
signs	NNS	O
of	IN	O
respiratory	NN	O
or	CC	O
central	JJ	O
nervous	JJ	O
system	NN	O
depression	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Figure	NN	O
1	CD	O

For	IN	O
adults	NNS	WHO
,	,	O
the	DT	O
admixture	NN	O
should	MD	O
not	RB	O
contain	VB	O
more	JJR	O
than	IN	O
330	CD	DOS
mL	NN	UNIT
of	IN	O
Liposyn	NNP	O
III	NNP	O
30	CD	O
%	NN	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
therapy	NN	O
.	.	O

Some	DT	O
opacity	NN	O
of	IN	O
the	DT	O
plastic	NN	O
,	,	O
due	JJ	O
to	TO	O
moisture	VB	O
absorption	NN	O
during	IN	O
the	DT	O
sterilization	NN	O
process	NN	O
,	,	O
may	MD	O
be	VB	O
observed	VBN	O
.	.	O

Methadone	NN	O
has	VBZ	O
a	DT	O
long	JJ	O
half	NN	O
-	:	O
life	NN	O
and	CC	O
can	MD	O
accumulate	VB	O
in	IN	O
the	DT	O
plasma	NN	O
.	.	O

Using	VBG	O
index	NN	O
finger	NN	O
,	,	O
gently	RB	O
press	IN	O
the	DT	O
plunger	NN	O
to	TO	O
inject	VB	O
the	DT	O
vaccine	NN	O
.	.	O

Fig	NNP	O
.	.	O

Do	VB	O
not	RB	O
take	VB	O
capsules	NNS	O
which	WDT	O
appear	VBP	O
deformed	VBN	O
or	CC	O
show	VB	O
evidence	NN	O
of	IN	O
leakage	NN	O
[	NNP	O
see	VB	O
HOW	NNP	O
SUPPLIED	NNP	O
]	NNP	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
Lutera	NNP	O
tablets	NNS	O
be	VB	O
taken	VBN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
each	DT	FREQ
day	NN	FREQ
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
dosed	VBN	WHO
initially	RB	WHO
at	IN	WHO
DOCEFREZ	NNP	WHO
75	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
in	IN	O
combination	NN	O
with	IN	O
cisplatin	NN	O
,	,	O
and	CC	O
whose	WP$	O
nadir	NN	O
of	IN	O
platelet	NN	O
count	NN	O
during	IN	O
the	DT	O
previous	JJ	O
course	NN	O
of	IN	O
therapy	NN	O
is	VBZ	O
<	JJ	O
25,000	CD	DOS
cells	NNS	UNIT
/	JJ	O
mm³	NN	O
,	,	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
experience	VBP	WHO
febrile	JJ	WHO
neutropenia	NN	WHO
,	,	O
and	CC	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
serious	JJ	WHO
non	SYM	WHO
-	:	O
hematologic	NN	O
toxicities	NNS	O
,	,	O
the	DT	O
DOCEFREZ	NNP	O
dosage	NN	O
in	IN	O
subsequent	JJ	O
cycles	NNS	O
should	MD	O
be	VB	O
reduced	VBN	O
to	TO	O
65	CD	DOS
mg	NNS	UNIT
/	JJ	O
m²	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
QOLIANA®	NNP	O
(	(	O
brimonidine	JJ	O
tartrate	NN	O
ophthalmic	JJ	O
solution	NN	O
)	)	O
,	,	O
0.15	CD	O
%	NN	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	NN	O
)	)	O
three	CD	FREQ
-	:	O
times	NNS	FREQ
daily	RB	FREQ
,	,	O
approximately	RB	O
8	CD	O
hours	NNS	O
apart	RB	O
.	.	O

The	DT	O
wick	NN	O
should	MD	O
be	VB	O
replaced	VBN	O
at	IN	O
least	JJS	O
once	RB	FREQ
every	DT	FREQ
24	CD	FREQ
hours	NNS	FREQ
.	.	O

Usually	RB	O
,	,	O
half	NN	O
of	IN	O
the	DT	O
prescribed	JJ	O
ZENPEP	NNP	O
dose	NN	O
for	IN	O
an	DT	O
individualized	JJ	O
full	JJ	O
meal	NN	O
should	MD	O
be	VB	O
given	VBN	O
with	IN	O
each	DT	O
snack	NN	O
.	.	O

Plasma	NNP	O
methionine	NN	O
concentrations	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
CBS	NNP	WHO
deficiency	NN	WHO
[	NNP	O
See	NNP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Do	NNP	O
not	RB	O
add	VB	O
supplementary	JJ	O
medication	NN	O
to	TO	O
the	DT	O
bag	NN	O
.	.	O

Dosage	NN	O
titration	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
2.5	CD	DOS
micrograms	NNS	UNIT
of	IN	O
alprostadil	NN	O
.	.	O

The	DT	O
same	JJ	O
clinical	JJ	O
findings	NNS	O
of	IN	O
hyperadrenocorticism	NN	O
may	MD	O
be	VB	O
noted	VBN	O
during	IN	O
the	DT	O
long	JJ	O
-	:	O
term	NN	O
pharmacologic	NN	O
dose	VBP	O
corticoid	JJ	O
therapy	NN	O
administered	VBN	O
in	IN	O
conventional	JJ	O
daily	JJ	FREQ
divided	VBN	O
doses	NNS	O
.	.	O

The	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O

10	CD	O
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
can	MD	O
vary	VB	O
from	IN	O
as	RB	O
much	JJ	O
as	IN	O
1	CD	DOS
or	CC	O
2	CD	DOS
drops	NNS	UNIT
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
to	TO	O
as	RB	O
little	JJ	O
as	IN	O
1	CD	DOS
or	CC	O
2	CD	DOS
drops	NNS	UNIT
twice	RB	FREQ
a	DT	FREQ
week	NN	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
range	NN	O
is	VBZ	O
20	CD	DOS
-	:	O
60	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
in	IN	O
single	JJ	DOS
doses	NNS	UNIT
taken	VBN	O
in	IN	O
the	DT	O
evening	NN	O
at	IN	O
bedtime	NN	O
.	.	O

Refer	NN	O
to	TO	O
bortezomib	VB	O
manufacturer	NN	O
's	POS	O
prescribing	NN	O
information	NN	O
.	.	O

No	DT	O
overall	JJ	O
differences	NNS	O
in	IN	O
safety	NN	O
or	CC	O
effectiveness	NN	O
were	VBD	O
observed	VBN	O
between	IN	O
these	DT	O
subjects	NNS	O
and	CC	O
younger	JJR	O
subjects	NNS	O
,	,	O
and	CC	O
other	JJ	O
reported	VBD	O
clinical	JJ	O
experience	NN	O
has	VBZ	O
not	RB	O
identified	VBN	O
differences	NNS	O
in	IN	O
responses	NNS	WHO
between	IN	WHO
the	DT	WHO
elderly	JJ	WHO
and	CC	WHO
younger	JJR	WHO
patients	NNS	WHO
,	,	WHO
but	CC	WHO
greater	JJR	WHO
sensitivity	NN	WHO
of	IN	WHO
some	DT	WHO
older	JJR	WHO
individuals	NNS	O
can	MD	O
not	RB	O
be	VB	O
ruled	VBN	O
out	RP	O
.	.	O

Dermal	JJ	O
absorption	NN	O
of	IN	O
spilled	JJ	O
REVEX	NNP	O
should	MD	O
be	VB	O
prevented	VBN	O
by	IN	O
prompt	JJ	O
removal	NN	O
of	IN	O
contaminated	VBN	O
clothing	NN	O
and	CC	O
rinsing	VBG	O
the	DT	O
skin	NN	O
thoroughly	RB	O
with	IN	O
cool	JJ	O
water	NN	O
.	.	O

Conduct	VB	O
the	DT	O
following	JJ	O
laboratory	NN	O
tests	NNS	O
at	IN	O
baseline	NN	O
and	CC	O
at	IN	O
periodic	JJ	O
intervals	NNS	O
for	IN	O
48	CD	PER
months	NNS	PER
following	VBG	O
the	DT	O
last	JJ	O
treatment	NN	O
course	NN	O
of	IN	O
LEMTRADA	NNP	O
in	IN	O
order	NN	O
to	TO	O
monitor	VB	O
for	IN	O
early	JJ	O
signs	NNS	O
of	IN	O
potentially	RB	O
serious	JJ	O
adverse	JJ	O
effects	NNS	O
:	:	O

For	IN	O
the	DT	O
multi	NN	O
-	:	O
dose	JJ	O
vial	NN	O
,	,	O
use	VB	O
a	DT	O
sterile	JJ	O
needle	NN	O
and	CC	O
sterile	JJ	O
syringe	NN	O
to	TO	O
withdraw	VB	O
the	DT	O
0.5	CD	DOS
-	:	O
mL	NN	UNIT
dose	NN	UNIT
from	IN	O
the	DT	O
multi	NN	O
-	:	O
dose	JJ	O
vial	JJ	O
and	CC	O
administer	JJ	O
intramuscularly	RB	O
.	.	O

Vials	NNS	O
should	MD	O
be	VB	O
used	VBN	O
only	RB	O
for	IN	O
subcutaneous	JJ	O
administration	NN	O
and	CC	O
not	RB	O
intravenous	JJ	O
infusion	NN	O
.	.	O

Perform	VB	O
the	DT	O
procedure	NN	O
within	IN	O
10	CD	O
minutes	NNS	O
after	IN	O
ZINGO®	NNP	O
administration	NN	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
FORADIL	NNP	O
CERTIHALER	NNP	O
(	(	O
formoterol	JJ	O
fumarate	NN	O
inhalation	NN	O
powder	NN	O
)	)	O
for	IN	O
patients	NNS	WHO
whose	WP$	WHO
asthma	NN	WHO
is	VBZ	O
adequately	RB	O
controlled	VBN	O
on	IN	O
low	JJ	O
or	CC	O
medium	NN	O
dose	NN	O
inhaled	JJ	O
corticosteroids	NNS	O
.	.	O

The	DT	O
U.S.	NNP	O
RDA	NNP	O
for	IN	O
calcium	NN	O
in	IN	O
adults	NNS	WHO
is	VBZ	O
800	CD	DOS
mg	NN	UNIT
to	TO	O
1200	CD	DOS
mg.	NN	UNIT
To	TO	O
ensure	VB	O
that	IN	O
each	DT	O
patient	NN	O
receives	VBZ	O
an	DT	O
adequate	JJ	O
daily	JJ	FREQ
intake	NN	O
of	IN	O
calcium	NN	O
,	,	O
the	DT	O
physician	NN	O
should	MD	O
either	VB	O
prescribe	VB	O
a	DT	O
calcium	NN	O
supplement	NN	O
or	CC	O
instruct	VB	O
the	DT	O
patient	NN	O
in	IN	O
proper	JJ	O
dietary	JJ	O
measures	NNS	O
.	.	O

For	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
with	IN	WHO
less	JJR	WHO
severe	JJ	WHO
disease	NN	WHO
(	(	WHO
greater	JJR	WHO
than	IN	WHO
8	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
weighing	VBG	WHO
less	JJR	WHO
than	IN	WHO
45	CD	WHO
kg	NN	WHO
)	)	WHO
,	,	O
the	DT	O
recommended	JJ	O
dosage	NN	O
schedule	NN	O
is	VBZ	O
4.4	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
divided	VBN	O
into	IN	O
two	CD	DOS
doses	NNS	UNIT
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
2.2	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
(	(	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	FREQ
dose	NN	UNIT
or	CC	O
divided	VBN	O
into	IN	O
twice	JJ	FREQ
daily	JJ	FREQ
doses	NNS	O
)	)	O
.	.	O

For	IN	O
topical	JJ	O
use	NN	O
only	RB	O
.	.	O

Yasmin	NN	O
should	MD	O
be	VB	O
taken	VBN	O
in	IN	O
the	DT	O
order	NN	O
directed	VBD	O
on	IN	O
the	DT	O
package	NN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
each	DT	FREQ
day	NN	FREQ
,	,	O
preferably	RB	O
after	IN	O
the	DT	O
evening	NN	O
meal	NN	O
or	CC	O
at	IN	O
bedtime	NN	O
with	IN	O
some	DT	O
liquid	NN	O
,	,	O
as	IN	O
needed	VBN	O
.	.	O

Gently	RB	O
invert	VBZ	O
the	DT	O
bag	NN	O
to	TO	O
mix	VB	O
the	DT	O
solution	NN	O
.	.	O

Dislodge	NNP	O
syringe	NN	O
and	CC	O
place	NN	O
onto	IN	O
sterile	JJ	O
field	NN	O
.	.	O

Clinically	RB	O
effective	JJ	O
neuromuscular	JJ	O
block	NN	O
may	MD	O
be	VB	O
expected	VBN	O
to	TO	O
last	JJ	O
for	IN	O
15	CD	O
to	TO	O
20	CD	O
minutes	NNS	O
(	(	O
range	NN	O
:	:	O
9	CD	O
to	TO	O
38	CD	O
minutes	NNS	O
)	)	O
and	CC	O
spontaneous	JJ	O
recovery	NN	O
may	MD	O
be	VB	O
expected	VBN	O
to	TO	O
be	VB	O
95	CD	O
%	NN	O
complete	JJ	O
in	IN	O
25	CD	O
to	TO	O
30	CD	O
minutes	NNS	O
(	(	O
range	NN	O
:	:	O
16	CD	O
to	TO	O
41	CD	O
minutes	NNS	O
)	)	O
following	VBG	O
0.15	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
MIVACRON	NNP	O
administered	VBD	O
to	TO	O
patients	NNS	WHO
receiving	VBG	WHO
opioid	JJ	WHO
/	NNP	O
nitrous	JJ	O
oxide	RB	O
/	NNP	O
oxygen	NN	O
anesthesia	NN	O
.	.	O

ZORVOLEX	NNP	O
capsules	NNS	O
are	VBP	O
not	RB	O
interchangeable	JJ	O
with	IN	O
other	JJ	O
formulations	NNS	O
of	IN	O
oral	JJ	O
diclofenac	NNS	O
even	RB	O
if	IN	O
the	DT	O
milligram	NN	O
strength	NN	O
is	VBZ	O
the	DT	O
same	JJ	O
.	.	O

DaTscan	JJ	O
images	NNS	O
are	VBP	O
interpreted	VBN	O
visually	RB	O
,	,	O
based	VBN	O
upon	IN	O
the	DT	O
appearance	NN	O
of	IN	O
the	DT	O
striata	NN	O
.	.	O

Any	DT	O
unused	JJ	O
portion	NN	O
of	IN	O
capsule	NN	O
contents	NNS	O
should	MD	O
be	VB	O
discarded	VBN	O
,	,	O
and	CC	O
not	RB	O
used	VBN	O
for	IN	O
subsequent	JJ	O
dosing	NN	O
.	.	O

THE	DT	O
PRIME	JJ	O
DESTABILIZERS	NNP	O
OF	NNP	O
EMULSIONS	NNP	O
ARE	NNP	O
EXCESSIVE	NNP	O
ACIDITY	NNP	O
(	(	O
LOW	NNP	O
PH	NNP	O
)	)	O
AND	NNP	O
INAPPROPRIATE	NNP	O
ELECTROLYTE	NNP	O
CONTENT	NNP	O
.	.	O

More	RBR	O
frequent	JJ	O
monitoring	NN	O
may	MD	O
be	VB	O
required	VBN	O
for	IN	O
some	DT	WHO
patients	NNS	WHO
.	.	O

IT	NNP	O
SHOULD	NNP	O
BE	NNP	O
EMPHASIZED	NNP	O
THAT	NNP	O
DOSAGE	NNP	O
REQUIREMENTS	NNP	O
ARE	NNP	O
VARIABLE	NNP	O
AND	NNP	O
MUST	NNP	O
BE	NNP	O
INDIVIDUALIZED	NNP	O
ON	NNP	O
THE	NNP	O
BASIS	NNP	O
OF	IN	O
THE	NNP	O
DISEASE	NNP	O
UNDER	NNP	O
TREATMENT	NNP	O
AND	NNP	O
THE	NNP	O
RESPONSE	NNP	O
OF	IN	O
THE	NNP	O
PATIENT	NNP	O
.	.	O

A	DT	O
lower	JJR	O
starting	VBG	O
dose	NN	O
of	IN	O
2.5	CD	DOS
mg	JJ	UNIT
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
is	VBZ	O
recommended	VBN	O
for	IN	O
the	DT	O
frail	NN	O
elderly	RB	O
.	.	O

Blood	NNP	O
pressure	NN	O
is	VBZ	O
recorded	VBN	O
immediately	RB	O
after	IN	O
injection	NN	O
,	,	O
at	IN	O
30	CD	O
-	:	O
second	JJ	O
intervals	NNS	O
for	IN	O
the	DT	O
first	JJ	O
3	CD	O
minutes	NNS	O
,	,	O
and	CC	O
at	IN	O
60	CD	O
-	:	O
second	JJ	O
intervals	NNS	O
for	IN	O
the	DT	O
next	JJ	O
7	CD	O
minutes	NNS	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
unable	JJ	WHO
to	TO	WHO
swallow	VB	WHO
XTAMPZA	NNP	WHO
ER	NNP	WHO
should	MD	O
be	VB	O
instructed	VBN	O
to	TO	O
sprinkle	VB	O
the	DT	O
capsule	NN	O
contents	NNS	O
on	IN	O
soft	JJ	O
foods	NNS	O
or	CC	O
into	IN	O
a	DT	O
cup	NN	O
and	CC	O
then	RB	O
administer	VB	O
directly	RB	O
into	IN	O
the	DT	O
mouth	NN	O
and	CC	O
immediately	RB	O
swallow	VB	O
.	.	O

Administration	NN	O
:	:	O
SECRETIN	NNP	O
STIMULATION	NNP	O
TESTING	NN	O
:	:	O

Perform	NNP	O
MR	NNP	O
imaging	VBG	O
no	RB	O
later	RB	O
than	IN	O
60	CD	O
minutes	NNS	O
following	VBG	O
EOVIST	NNP	O
administration	NN	O
to	TO	O
patients	NNS	WHO
with	IN	WHO
these	DT	WHO
laboratory	NN	WHO
abnormalities	NNS	WHO
,	,	WHO
including	VBG	WHO
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
elevated	VBN	WHO
ferritin	NN	WHO
levels	NNS	WHO
due	JJ	O
to	TO	O
hemodialysis	VB	O
[	NNP	O
see	VB	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

For	IN	O
ophthalmic	JJ	O
intravitreal	JJ	O
injection	NN	O
.	.	O

No	DT	O
interference	NN	O
of	IN	O
Extraneal	NNP	O
(	(	O
icodextrin	JJ	O
peritoneal	NN	O
dialysis	NN	O
solution	NN	O
)	)	O
with	IN	O
insulin	JJ	O
absorption	NN	O
from	IN	O
the	DT	O
peritoneal	JJ	O
cavity	NN	O
or	CC	O
with	IN	O
insulin	NN	O
's	POS	O
ability	NN	O
to	TO	O
control	VB	O
blood	NN	O
glucose	NN	O
was	VBD	O
observed	VBN	O
(	(	O
See	VB	O
Drug	NNP	O
/	NNP	O
Laboratory	NNP	O
Test	NNP	O
Interactions	NNP	O
)	)	O
.	.	O

NOTE	NN	O
:	:	O
INTRATHECAL	JJ	O
DOSAGE	NNP	O
IS	NNP	O
USUALLY	NNP	O
1	CD	O
/	VBD	O
10	CD	O
THAT	NNP	O
OF	NNP	O
EPIDURAL	NNP	O
DOSAGE	NNP	O
.	.	O

CAPRELSA	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
and	CC	WHO
severe	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
[	NNP	O
see	NN	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Doses	NNS	O
for	IN	O
children	NNS	WHO
should	MD	O
not	RB	O
exceed	VB	O
doses	NNS	O
recommended	VBN	O
for	IN	O
adults	NNS	WHO
,	,	O

The	DT	O
recommended	JJ	O
treatment	NN	O
regimen	NNS	O
is	VBZ	O
three	CD	O
treatment	NN	O
sessions	NNS	O
,	,	O
administering	VBG	O
up	RP	O
to	TO	O
2	CD	O
milliliters	NNS	O
(	(	O
2	CD	O
vials	NNS	O
)	)	O
of	IN	O
LAVIV	NNP	O
per	IN	O
session	NN	O
,	,	O
at	IN	O
3	CD	O
-	:	O
6	CD	PER
week	NN	PER
intervals	NNS	O
.	.	O

(	(	O
see	VB	O
also	RB	O
pictures	VBZ	O
next	JJ	O
page	NN	O
)	)	O

For	IN	O
endotracheal	JJ	O
instillation	NN	O
using	VBG	O
the	DT	O
secondary	JJ	O
lumen	NNS	O
of	IN	O
a	DT	O
dual	JJ	O
lumen	NNS	O
endotracheal	VBP	O
tube	NN	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
titrated	VBN	O
upward	JJ	O
until	IN	O
:	:	O

These	DT	O
doses	NNS	O
may	MD	O
be	VB	O
repeated	VBN	O
as	RB	O
often	RB	O
as	IN	O
required	VBN	O
to	TO	O
the	DT	O
limit	NN	O
of	IN	O
the	DT	O
maximum	NN	O
recommended	VBD	FREQ
daily	RB	FREQ
dose	NN	UNIT
of	IN	O
8	CD	DOS
grams	NNS	UNIT
of	IN	O
lincomycin	NN	O
.	.	O

Once	RB	O
the	DT	O
application	NN	O
site	NN	O
is	VBZ	O
dry	JJ	O
,	,	O
the	DT	O
site	NN	O
should	MD	O
be	VB	O
covered	VBN	O
with	IN	O
clothing	NN	O
[	NNS	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

When	WRB	O
respiratory	NN	O
function	NN	O
is	VBZ	O
impaired	JJ	O
,	,	O
as	IN	O
may	MD	O
occur	VB	O
in	IN	O
severe	JJ	O
exacerbation	NN	O
of	IN	O
asthma	NN	O
,	,	O
a	DT	O
temporary	JJ	O
increase	NN	O
in	IN	O
the	DT	O
amount	NN	O
of	IN	O
corticosteroids	NNS	O
may	MD	O
be	VB	O
required	VBN	O
to	TO	O
regain	VB	O
control	NN	O
of	IN	O
the	DT	O
patient	NN	O
's	POS	O
asthma	NN	O
.	.	O

In	IN	O
a	DT	O
TROXYCA	NNP	O
ER	NNP	O
clinical	JJ	O
trial	NN	O
with	IN	O
an	DT	O
open	JJ	O
-	:	O
label	JJ	O
titration	NN	O
period	NN	O
,	,	O
patients	NNS	O
were	VBD	O
converted	VBN	O
from	IN	O
their	PRP$	O
prior	JJ	O
opioid	NN	O
to	TO	O
TROXYCA	NNP	O
ER	NNP	O
using	VBG	O
Table	JJ	O
1	CD	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
creatinine	JJ	WHO
clearance	NN	WHO
between	IN	WHO
10	CD	DOS
and	CC	O
49	CD	DOS
ml	NN	UNIT
/	NNP	O
min	NN	O
may	MD	O
be	VB	O
given	VBN	O
half	NN	O
of	IN	O
the	DT	O
recommended	VBN	O
dose	NN	O
at	IN	O
the	DT	O
usual	JJ	O
dosage	NN	O
interval	NN	O
,	,	O
or	CC	O
the	DT	O
normal	JJ	O
recommended	VBD	O
dose	NN	O
at	IN	O
twice	RB	O
the	DT	O
usual	JJ	O
dosage	NN	O
interval	NN	O
.	.	O

VASCOR	NNP	O
(	(	O
bepridil	NN	O
)	)	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
adequately	RB	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
hepatic	JJ	WHO
or	CC	WHO
renal	JJ	WHO
function	NN	WHO
.	.	O

Since	IN	O
ORLAAM	NNP	O
(	(	O
levomethadyl	JJ	O
acetate	NN	O
)	)	O
can	MD	O
be	VB	O
potentially	RB	O
dangerous	JJ	O
if	IN	O
diverted	VBN	O
,	,	O
appropriate	JJ	O
security	NN	O
measures	NNS	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
safeguard	VB	O
stock	NN	O
of	IN	O
ORLAAM	NNP	O
(	(	O
levomethadyl	JJ	O
acetate	NN	O
)	)	O
as	IN	O
required	VBN	O
by	IN	O
21	CD	O
CFR	NNP	O
1301.74	CD	O
.	.	O

In	IN	O
addition	NN	O
to	TO	O
the	DT	O
general	JJ	O
precautions	NNS	O
previously	RB	O
described	VBN	O
,	,	O
the	DT	O
risks	NNS	O
associated	VBN	O
with	IN	O
IV	NNP	O
DSA	NNP	O
include	VBP	O
those	DT	O
usually	RB	O
attendant	VBP	O
with	IN	O
catheter	NN	O
procedures	NNS	O
and	CC	O
include	VBP	O
intramural	JJ	O
injections	NNS	O
,	,	O
vessel	JJ	O
dissection	NN	O
and	CC	O
tissue	NN	O
extravasation	NN	O
.	.	O

In	IN	O
such	JJ	O
cases	NNS	O
,	,	O
consider	VB	O
dose	JJ	O
reduction	NN	O
,	,	O
but	CC	O
such	PDT	O
an	DT	O
increase	NN	O
does	VBZ	O
not	RB	O
imply	VB	O
that	IN	O
chronic	JJ	O
treatment	NN	O
is	VBZ	O
contraindicated	VBN	O
.	.	O

It	PRP	O
is	VBZ	O
not	RB	O
necessary	JJ	O
to	TO	O
cover	VB	O
the	DT	O
infusion	NN	O
drip	VBZ	O
chamber	NN	O
or	CC	O
the	DT	O
tubing	NN	O
.	.	O

Usual	JJ	O
precautions	NNS	O
for	IN	O
administration	NN	O
of	IN	O
warm	JJ	O
saturated	VBN	O
nebulae	NN	O
should	MD	O
be	VB	O
observed	VBN	O
.	.	O

Monitor	NNP	O
heart	NN	O
rate	NN	O
and	CC	O
blood	NN	O
pressure	NN	O
for	IN	O
2	CD	O
hours	NNS	O
after	IN	O
HEMANGEOL	NNP	O
initiation	NN	O
or	CC	O
dose	NN	O
increases	NNS	O
[	VBP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Gram	NNP	O
-	:	O
negative	JJ	O
bacillary	JJ	O
infections	NNS	O
(	(	O
E.	NNP	O
coli	NNS	O
,	,	O
Enterobacter	NNP	O
aerogenes	NNS	O
,	,	O
A.	NN	O
faecalis	NNS	O
,	,	O
Salmonella	NNP	O
,	,	O
Shigella	NNP	O
and	CC	O
Proteus	NNP	O
mirabilis	NN	O
)	)	O

Select	JJ	O
patients	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
advanced	JJ	O
ovarian	JJ	O
cancer	NN	O
with	IN	O
Rubraca	NNP	O
based	VBN	O
on	IN	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
deleterious	JJ	O
BRCA	NNP	O
mutation	NN	O
(	(	O
germline	NN	O
and	CC	O
/	NN	O
or	CC	O
somatic	JJ	O
)	)	O
[	FW	O
see	VBP	O
INDICATIONS	NNP	O
AND	NNP	O
USAGE	NNP	O
and	CC	O
Clinical	NNP	O
Studies	NNP	O
]	NNP	O
.	.	O

To	TO	O
Open	VB	O
Diluent	NNP	O
Container	NNP	O

2	CD	O
.	.	O

A	DT	O
simple	JJ	O
formula	NN	O
for	IN	O
calculating	VBG	O
dosage	NN	O
,	,	O
based	VBN	O
upon	IN	O
a	DT	O
patient	NN	O
's	POS	O
glomerular	JJ	O
filtration	NN	O
rate	NN	O
(	(	O
GFR	NNP	O
in	IN	O
mL	NN	O
/	NNP	O
min	NN	O
)	)	O
and	CC	O
carboplatin	JJ	O
injection	NN	O
target	NN	O
area	NN	O
under	IN	O
the	DT	O
concentration	NN	O
versus	NN	O
time	NN	O
curve	NN	O
(	(	O
AUC	NNP	O
in	IN	O
mg	NN	UNIT
/	NNP	O
mL•min	NN	O
)	)	O
,	,	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
by	IN	O
Calvert	NNP	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
AVANDAMET	NNP	O
may	MD	O
be	VB	O
increased	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
2	CD	DOS
mg	NNS	UNIT
/	VBD	O
500	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
if	IN	O
patients	NNS	O
are	VBP	O
not	RB	O
adequately	RB	O
controlled	VBN	O
after	IN	O
4	CD	PER
weeks	NNS	PER
.	.	O

Rate	NNP	O
of	IN	O
Administration	NNP	O

Aminosyn	NNP	O
II	NNP	O
8.5	CD	O
%	NN	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
with	IN	O
electrolytes	NNS	O
)	)	O
WITH	VBP	O
ELECTROLYTES	NNP	O
does	VBZ	O
not	RB	O
contain	VB	O
calcium	NN	O
,	,	O
and	CC	O
this	DT	O
should	MD	O
be	VB	O
added	VBN	O
as	IN	O
indicated	JJ	O
.	.	O

The	DT	O
suspension	NN	O
of	IN	O
PRIMAXIN	NNP	O
I.M	NNP	O
.	.	O

High	JJ	O
-	:	O
fat	JJ	O
meals	NNS	O
decrease	VBP	O
absorption	NN	O
of	IN	O
aliskiren	NNS	O
substantially	RB	O
[	VBP	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Determine	NNP	O
labeling	VBG	O
efficiency	NN	O
of	IN	O
Ga	NNP	O
68	CD	O
dotatate	NN	O
:	:	O

[	NNS	O
See	VBP	O
the	DT	O
Patient	NNP	O
Instructions	NNP	O
for	IN	O
Use	NNP	O
]	NN	O

Short	NNP	O
-	:	O
acting	VBG	O
bronchodilators	NNS	O
can	MD	O
be	VB	O
taken	VBN	O
between	IN	O
15	CD	O
minutes	NNS	O
and	CC	O
4	CD	O
hours	NNS	O
prior	RB	O
to	TO	O
each	DT	O
dose	NN	O
of	IN	O
CAYSTON	NNP	O
.	.	O

The	DT	O
target	NN	O
maintenance	NN	O
dose	NN	O
,	,	O
achieved	VBN	O
over	IN	O
two	CD	PER
to	TO	O
three	CD	PER
weeks	NNS	PER
,	,	O
is	VBZ	O
displayed	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
.	.	O

Distributed	VBN	O
by	IN	O
:	:	O
Novartis	NN	O
Pharmaceuticals	NNS	O
Corporation	NNP	O
East	NNP	O
Hanover	NNP	O
,	,	O
New	NNP	O
Jersey	NNP	O
07936	CD	O
.	.	O

If	IN	O
blood	NN	O
pressure	NN	O
is	VBZ	O
not	RB	O
controlled	VBN	O
by	IN	O
ATACAND	NNP	O
alone	RB	O
,	,	O
a	DT	O
diuretic	JJ	O
may	MD	O
be	VB	O
added	VBN	O
.	.	O

Care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
allow	VB	O
the	DT	O
solution	NN	O
to	TO	O
dry	VB	O
before	IN	O
allowing	VBG	O
the	DT	O
return	NN	O
of	IN	O
opposing	VBG	O
skin	JJ	O
surfaces	NNS	O
to	TO	O
their	PRP$	O
normal	JJ	O
positions	NNS	O
.	.	O

Disperse	NNP	O
doses	NNS	O
of	IN	O
less	JJR	O
than	IN	O
1	CD	DOS
g	NN	UNIT
in	IN	O
3.5	CD	O
ounces	NNS	O
of	IN	O
liquid	NN	O
and	CC	O
doses	NNS	O
of	IN	O
1	CD	DOS
g	NN	UNIT
or	CC	O
greater	JJR	O
in	IN	O
7	CD	O
ounces	NNS	O
of	IN	O
liquid	NN	O
.	.	O

If	IN	O
not	RB	O
used	VBN	O
immediately	RB	O
after	IN	O
dilution	NN	O
with	IN	O
infusion	NN	O
media	NNS	O
,	,	O
for	IN	O
microbiological	JJ	O
integrity	NN	O
,	,	O
the	DT	O
solution	NN	O
should	MD	O
be	VB	O
refrigerated	VBN	O
at	IN	O
2°C	CD	O
–	JJ	O
8°C	CD	O
(	(	O
36°F	CD	O
–	RB	O
46°F	CD	O
)	)	O
.	.	O

Following	VBG	O
withdrawal	NN	O
from	IN	O
the	DT	O
vial	JJ	O
DepoDur	NNP	O
(	(	O
morphine	JJ	O
sulfate	NN	O
xr	NNP	O
liposome	NNP	O
injection	NN	O
)	)	O
may	MD	O
be	VB	O
held	VBN	O
at	IN	O
15°	CD	O
to	TO	O
30°C	CD	O
(	(	O
59°	CD	O
to	TO	O
86°F	CD	O
)	)	O
for	IN	O
up	IN	O
to	TO	O
4	CD	O
hours	NNS	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

TOPAMAX®	NN	O
can	MD	O
be	VB	O
taken	VBN	O
without	IN	O
regard	NN	O
to	TO	O
meals	NNS	O
.	.	O

The	DT	O
dosages	NNS	O
suggested	VBN	O
in	IN	O
this	DT	O
table	NN	O
are	VBP	O
for	IN	O
normal	JJ	WHO
healthy	JJ	WHO
adults	NNS	WHO
,	,	O
administered	VBN	O
by	IN	O
submucosal	JJ	O
infiltration	NN	O
or	CC	O
nerve	NN	O
block	NN	O
.	.	O

Frequent	JJ	O
communication	NN	O
is	VBZ	O
important	JJ	O
among	IN	O
the	DT	O
prescriber	NN	O
,	,	O
other	JJ	O
members	NNS	O
of	IN	O
the	DT	O
healthcare	NN	O
team	NN	O
,	,	O
the	DT	O
patient	NN	O
,	,	O
and	CC	O
the	DT	O
caregiver	NN	O
/	NNP	O
family	NN	O
during	IN	O
periods	NNS	O
of	IN	O
changing	VBG	O
analgesic	JJ	O
requirements	NNS	O
,	,	O
including	VBG	O
initial	JJ	O
titration	NN	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
phosphate	NN	O
added	VBN	O
to	TO	O
a	DT	O
liter	NN	O
of	IN	O
TPN	NNP	O
solution	NN	O
(	(	O
containing	VBG	O
25	CD	O
%	NN	O
dextrose	NN	O
)	)	O
is	VBZ	O
12	CD	DOS
mM	NN	UNIT
.	.	O

Remove	NNP	O
protective	JJ	O
covering	NN	O
from	IN	O
the	DT	O
spike	NN	O
at	IN	O
one	CD	O
end	NN	O
of	IN	O
the	DT	O
transfer	NN	O
device	NN	O
(	(	O
Fig	NNP	O
.	.	O

Step	NN	O
5	CD	O

Intravenous	JJ	O
Infusion	NN	O
:	:	O
4	CD	DOS
g	NN	UNIT
in	IN	O
250	CD	DOS
mL	NN	UNIT
of	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
at	IN	O
a	DT	O
rate	NN	O
not	RB	O
exceeding	VBG	O
3	CD	DOS
mL	NNS	UNIT
per	IN	O
minute	NN	O
.	.	O

Two	CD	WHO
to	TO	WHO
five	CD	WHO
years	NNS	WHO
:	:	O
1	CD	DOS
mg	NN	UNIT
t.i.d	NN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
well	RB	O
hydrated	VBN	O
prior	RB	O
to	TO	O
and	CC	O
following	VBG	O
ISOVUE	NNP	O
(	(	O
lopamidol	JJ	O
Injection	NNP	O
)	)	O
administration	NN	O
.	.	O

This	DT	O
will	MD	O
result	VB	O
in	IN	O
desired	JJ	O
concentrations	NNS	O
of	IN	O
0.1	CD	DOS
to	TO	O
1.0	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
.	.	O

The	DT	O
recommended	JJ	O
maximum	JJ	O
duration	NN	O
of	IN	O
Soma	NNP	O
Compound	NNP	O
(	(	O
carisoprodol	NN	O
and	CC	O
aspirin	NN	O
)	)	O
use	NN	O
is	VBZ	O
up	RP	O
to	TO	O
two	CD	PER
or	CC	O
three	CD	PER
weeks	NNS	PER
.	.	O

Two	CD	DOS
to	TO	O
four	CD	DOS
mL	NN	UNIT
of	IN	O
Ethiodol	NNP	O
(	(	O
ethiodized	VBN	O
oil	NN	O
)	)	O
injected	VBD	O
into	IN	O
the	DT	O
upper	JJ	O
extremity	NN	O
will	MD	O
suffice	VB	O
to	TO	O
demonstrate	VB	O
the	DT	O
axillary	JJ	O
and	CC	O
supraclavicular	JJ	O
nodes	NNS	O
.	.	O

An	DT	O
insulin	NN	O
bolus	NN	O
should	MD	O
be	VB	O
followed	VBN	O
by	IN	O
a	DT	O
meal	NN	O
within	IN	O
30	CD	O
minutes	NNS	O
.	.	O

Inspect	NNP	O
for	IN	O
extraneous	JJ	O
particulate	NN	O
matter	NN	O
and	CC	O
/	NN	O
or	CC	O
discoloration	NN	O
before	IN	O
use	NN	O
.	.	O

Vials	NNS	O
:	:	O
A	DT	O
5	CD	O
-	:	O
micron	NN	O
sterile	JJ	O
filter	NN	O
needle	NN	O
(	(	O
19	CD	O
-	:	O
gauge	NN	O
x	VBZ	O
1	CD	O
-	:	O
½	NN	O
inch	NN	O
)	)	O
,	,	O
a	DT	O
1	CD	DOS
-	:	O
mL	NN	O
Luer	NNP	O
lock	NN	O
syringe	NN	O
and	CC	O
a	DT	O
30	CD	O
-	:	O
gauge	NN	O
x	NN	O
½	NNP	O
inch	NN	O
sterile	JJ	O
injection	NN	O
needle	NNS	O
are	VBP	O
needed	VBN	O
but	CC	O
not	RB	O
included	VBD	O
.	.	O

Refer	NN	O
to	TO	O
INDICATIONS	NNP	O
AND	NNP	O
USAGE	NNP	O
section	NN	O
for	IN	O
description	NN	O
of	IN	O
response	NN	O
to	TO	O
be	VB	O
anticipated	VBN	O
.	.	O

Greater	NNP	O
activity	NN	O
has	VBZ	O
been	VBN	O
observed	VBN	O
when	WRB	O
new	JJ	O
antiretroviral	JJ	O
therapies	NNS	O
are	VBP	O
begun	VBN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
as	IN	O
HIVID	NNP	O
(	(	O
zalcitabine	NN	O
)	)	O
.	.	O

Use	VB	O
the	DT	O
lowest	JJS	O
effective	JJ	O
dosage	NN	O
for	IN	O
the	DT	O
shortest	JJS	O
duration	NN	O
consistent	NN	O
with	IN	O
individual	JJ	O
patient	NN	O
treatment	NN	O
goals	NNS	O
[	VBP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
JRA	NNP	WHO
who	WP	WHO
are	VBP	WHO
known	VBN	WHO
or	CC	WHO
suspected	VBN	WHO
to	TO	WHO
be	VB	WHO
poor	JJ	WHO
CYP2C9	NNP	WHO
metabolizers	NNS	WHO
,	,	O
consider	VB	O
using	VBG	O
alternative	JJ	O
treatments	NNS	O
.	.	O

After	IN	O
preparation	NN	O
of	IN	O
the	DT	O
injection	NN	O
site	NN	O
,	,	O
using	VBG	O
a	DT	O
suitable	JJ	O
sterile	JJ	O
needle	NN	O
and	CC	O
aseptic	JJ	O
technique	NN	O
,	,	O
immediately	RB	O
administer	JJ	O
IPOL	NNP	O
vaccine	NN	O
intramuscularly	RB	O
or	CC	O
subcutaneously	RB	O
.	.	O

Discard	NNP	O
any	DT	O
unused	JJ	O
portion	NN	O
.	.	O

9	CD	O
.	.	O

A	DT	O
dose	NN	O
of	IN	O
2	CD	DOS
mL	NN	UNIT
of	IN	O
45	CD	O
%	NN	O
alcohol	NN	O
has	VBZ	O
been	VBN	O
used	VBN	O
for	IN	O
injecting	VBG	O
individual	JJ	O
motor	NN	O
nerves	NNS	O
,	,	O
or	CC	O
from	IN	O
1.5	CD	DOS
to	TO	O
4.0	CD	DOS
mL	NN	UNIT
for	IN	O
epidural	JJ	O
injection	NN	O
in	IN	O
children	NNS	WHO
with	IN	WHO
spastic	JJ	WHO
cerebral	JJ	WHO
palsy	NN	WHO
;	:	O
50	CD	DOS
mL	NN	UNIT
of	IN	O
50	CD	O
%	NN	O
alcohol	NN	O
has	VBZ	O
been	VBN	O
used	VBN	O
for	IN	O
celiac	JJ	O
plexus	NN	O
blockade	NN	O
.	.	O

Approximately	RB	O
7.3	CD	DOS
mg	NNS	UNIT
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
per	IN	FREQ
day	NN	FREQ
of	IN	O
ultramicrosize	JJ	O
griseofulvin	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
dose	NN	O
for	IN	O
most	JJS	WHO
pediatric	JJ	WHO
patients	NNS	WHO
.	.	O

represent	VB	O
the	DT	O
quantity	NN	O
of	IN	O
imipenem	NN	O
to	TO	O
be	VB	O
administered	VBN	O
.	.	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
by	IN	O
1.25	CD	DOS
micrograms	NNS	UNIT
to	TO	O
a	DT	O
dose	NN	O
of	IN	O
2.5	CD	DOS
micrograms	NNS	UNIT
,	,	O
followed	VBN	O
by	IN	O
an	DT	O
increment	NN	O
of	IN	O
2.5	CD	DOS
micrograms	NNS	UNIT
to	TO	O
a	DT	O
dose	NN	O
of	IN	O
5	CD	DOS
micrograms	NNS	UNIT
,	,	O
and	CC	O
then	RB	O
in	IN	O
5	CD	DOS
-	:	O
microgram	NN	O
increments	NNS	O
until	IN	O
the	DT	O
dose	NN	O
that	WDT	O
produces	VBZ	O
an	DT	O
erection	NN	O
suitable	NN	O
for	IN	O
intercourse	NN	O
and	CC	O
not	RB	O
exceeding	VBG	O
a	DT	O
duration	NN	O
of	IN	O
1	CD	O
hour	NN	O
is	VBZ	O
reached	VBN	O
.	.	O

Each	DT	O
sprayer	NN	O
contains	VBZ	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
(	(	O
0.2	CD	DOS
mL	NN	UNIT
)	)	O
of	IN	O
FluMist	NNP	O
Quadrivalent	NNP	O
;	:	O
administer	RBR	O
approximately	RB	O
one	CD	DOS
half	NN	UNIT
of	IN	O
the	DT	O
contents	NNS	O
of	IN	O
the	DT	O
single	JJ	O
-	:	O
dose	NN	O
intranasal	NN	O
sprayer	NN	O
into	IN	O
each	DT	O
nostril	NN	O
(	(	O
each	DT	O
sprayer	NN	O
contains	VBZ	O
0.2	CD	DOS
mL	NN	UNIT
of	IN	O
vaccine	NN	O
)	)	O
.	.	O

Reevaluate	NNP	O
eGFR	VBD	O
48	CD	O
hours	NNS	O
after	IN	O
the	DT	O
imaging	JJ	O
procedure	NN	O
;	:	O
restart	VB	O
JANUMET	NNP	O
XR	NNP	O
if	IN	O
renal	JJ	O
function	NN	O
is	VBZ	O
stable	JJ	O
[	NNS	O
see	VBP	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Tight	NNP	O
-	:	O
fitting	NN	O
diapers	NNS	O
or	CC	O
plastic	JJ	O
pants	NNS	O
may	MD	O
constitute	VB	O
occlusive	JJ	O
dressings	NNS	O
.	.	O

With	IN	O
the	DT	O
exception	NN	O
of	IN	O
heparin	NN	O
at	IN	O
1	CD	DOS
to	TO	O
2	CD	DOS
units	NNS	UNIT
/	NNP	O
mL	NN	O
of	IN	O
fat	JJ	O
emulsion	NN	O
,	,	O
additives	VBZ	O
to	TO	O
the	DT	O
Liposyn	NNP	O
II	NNP	O
(	(	O
intravenous	JJ	O
fat	JJ	O
emulsion	NN	O
)	)	O
bottle	NN	O
are	VBP	O
contraindicated	VBN	O
.	.	O

Efficacy	NN	O
is	VBZ	O
better	RBR	O
if	IN	O
the	DT	O
tablet	NN	O
is	VBZ	O
taken	VBN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
after	IN	O
unprotected	JJ	O
intercourse	NN	O
.	.	O

Sedation	NN	O
with	IN	O
phenobarbital	JJ	O
or	CC	O
mild	JJ	O
tranquilizers	NNS	O
may	MD	O
be	VB	O
used	VBN	O
if	IN	O
indicated	VBN	O
,	,	O
but	CC	O
not	RB	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
respiratory	JJ	O
failure	NN	O
.	.	O

There	EX	O
is	VBZ	O
no	DT	O
experience	NN	O
with	IN	O
more	RBR	O
rapid	JJ	O
infusions	NNS	O
in	IN	O
patients	NNS	WHO
receiving	VBG	WHO
Depacon	NNP	WHO
as	IN	O
replacement	NN	O
therapy	NN	O
.	.	O

A	DT	O
sudden	JJ	O
large	JJ	O
requirement	NN	O
for	IN	O
dose	JJ	O
escalation	NN	O
suggests	VBZ	O
a	DT	O
catheter	NN	O
complication	NN	O
(	(	O
i.e	JJ	O
,	,	O
catheter	JJ	O
kink	NN	O
or	CC	O
dislodgement	NN	O
)	)	O
.	.	O

Administer	NNP	O
TIROSINT	NNP	O
-	:	O
SOL	NNP	O
as	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	FREQ
oral	JJ	O
dose	NN	O
,	,	O
on	IN	O
an	DT	O
empty	JJ	O
stomach	NN	O
,	,	O
one	CD	O
-	:	O
half	NN	O
to	TO	O
one	CD	O
hour	NN	O
before	IN	O
breakfast	NN	O
.	.	O

DIANEAL	NNP	O
is	VBZ	O
intended	VBN	O
for	IN	O
use	NN	O
in	IN	O
Continuous	JJ	O
Ambulatory	NNP	O
Peritoneal	NNP	O
Dialysis	NNP	O
(	(	O
CAPD	NNP	O
)	)	O
or	CC	O
Automated	VBN	O
Peritoneal	JJ	O
Dialysis	NNP	O
(	(	O
APD	NNP	O
)	)	O
.	.	O

Any	DT	O
unused	JJ	O
portions	NNS	O
of	IN	O
propofol	NN	O
injectable	JJ	O
emulsion	NN	O
,	,	O
reservoirs	NNS	O
,	,	O
dedicated	VBN	O
administration	NN	O
tubing	VBG	O
and	CC	O
/	NNP	O
or	CC	O
solutions	NNS	O
containing	VBG	O
propofol	NN	O
injectable	JJ	O
emulsion	NN	O
must	MD	O
be	VB	O
discarded	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
anesthetic	JJ	O
procedure	NN	O
or	CC	O
at	IN	O
12	CD	O
hours	NNS	O
,	,	O
whichever	WDT	O
occurs	VBZ	O
sooner	NN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
stops	VBZ	O
using	VBG	O
the	DT	O
prescription	NN	O
,	,	O
each	DT	O
unused	JJ	O
patch	NN	O
should	MD	O
be	VB	O
removed	VBN	O
from	IN	O
its	PRP$	O
individual	JJ	O
pouch	NN	O
,	,	O
separated	VBN	O
from	IN	O
the	DT	O
protective	JJ	O
liner	NN	O
,	,	O
folded	VBD	O
onto	IN	O
itself	PRP	O
,	,	O
and	CC	O
disposed	VBD	O
of	IN	O
in	IN	O
the	DT	O
same	JJ	O
manner	NN	O
as	IN	O
used	JJ	O
patches	NNS	O
.	.	O

Occasional	JJ	O
patients	NNS	O
required	VBN	O
as	RB	O
much	JJ	O
as	IN	O
10	CD	DOS
mg	NNS	UNIT
a	DT	FREQ
day	NN	FREQ
to	TO	O
achieve	VB	O
a	DT	O
successful	JJ	O
response	NN	O
.	.	O

A	DT	O
single	JJ	DOS
1.0	CD	DOS
gram	JJ	UNIT
initial	JJ	O
dose	NN	O
of	IN	O
Zn	NNP	O
-	:	O
DTPA	NNP	O
(	(	O
pentetate	VB	O
zinc	NN	O
trisodium	NN	O
injection	NN	O
)	)	O
administered	VBD	O
intravenously	RB	O
.	.	O

Remove	VB	O
the	DT	O
syringe	NN	O
and	CC	O
needle	JJ	O
,	,	O
and	CC	O
mix	VB	O
manually	RB	O
by	IN	O
repeated	VBN	O
inversions	NNS	O
.	.	O

The	DT	O
volume	NN	O
of	IN	O
solution	NN	O
required	VBN	O
will	MD	O
vary	VB	O
depending	VBG	O
upon	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
.	.	O

If	IN	O
paradoxical	JJ	O
aggravation	NN	O
of	IN	O
symptoms	NNS	O
or	CC	O
other	JJ	O
adverse	JJ	O
effects	NNS	O
occur	VBP	O
,	,	O
reduce	VB	O
dosage	NN	O
,	,	O
or	CC	O
,	,	O
if	IN	O
necessary	JJ	O
,	,	O
discontinue	VB	O
the	DT	O
drug	NN	O
.	.	O

Regulate	NNP	O
rate	NN	O
of	IN	O
administration	NN	O
with	IN	O
flow	JJ	O
control	NN	O
clamp	NN	O
.	.	O

MIRAPEX	NNP	O
ER	NNP	O
tablets	NNS	O
may	MD	O
be	VB	O
tapered	VBN	O
off	RP	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
0.75	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
until	IN	O
the	DT	O
daily	JJ	FREQ
dose	NN	O
has	VBZ	O
been	VBN	O
reduced	VBN	O
to	TO	O
0.75	CD	DOS
mg	NNS	UNIT
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
is	VBZ	O
40	CD	DOS
to	TO	O
120	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

Control	NN	O
of	IN	O
pain	NN	O
can	MD	O
be	VB	O
maintained	VBN	O
in	IN	O
most	JJS	WHO
patients	NNS	WHO
with	IN	O
400	CD	DOS
to	TO	O
800	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
.	.	O

in	IN	O
lidocaine	JJ	O
HCl	NNP	O
should	MD	O
be	VB	O
used	VBN	O
within	IN	O
one	CD	O
hour	NN	O
after	IN	O
preparation	NN	O
.	.	O

If	IN	O
the	DT	O
coadministered	JJ	O
drug	NN	O
is	VBZ	O
discontinued	VBN	O
,	,	O
adjust	VBP	O
the	DT	O
REXULTI	NNP	O
dosage	NN	O
to	TO	O
its	PRP$	O
original	JJ	O
level	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Doses	NNS	O
may	MD	O
be	VB	O
adjusted	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
renal	JJ	WHO
function	NN	WHO
either	RB	O
by	IN	O
administering	VBG	O
normal	JJ	O
doses	NNS	O
at	IN	O
prolonged	JJ	O
intervals	NNS	O
or	CC	O
by	IN	O
administering	VBG	O
reduced	JJ	O
doses	NNS	O
at	IN	O
afixed	JJ	O
interval	NN	O
.	.	O

Discard	NNP	O
unused	VBD	O
portions	NNS	O
after	IN	O
storage	NN	O
for	IN	O
24	CD	PER
hours	NNS	PER
at	IN	O
room	NN	O
temperature	NN	O
or	CC	O
after	IN	O
storage	NN	O
for	IN	O
48	CD	PER
hours	NNS	PER
at	IN	O
refrigerated	JJ	O
temperature	NN	O
(	(	O
2°C	CD	O
to	TO	O
8°C	CD	O
[	NNS	O
36°F	CD	O
to	TO	O
46°F	CD	O
]	NN	O
)	)	O
.	.	O

Infusion	NN	O
of	IN	O
undiluted	JJ	O
Persantine®	NNP	O
may	MD	O
cause	VB	O
local	JJ	O
irritation	NN	O
.	.	O

These	DT	O
solutions	NNS	O
have	VBP	O
the	DT	O
potential	JJ	O
to	TO	O
increase	VB	O
the	DT	O
rate	NN	O
of	IN	O
degradation	NN	O
of	IN	O
VIDAZA	NNP	O
and	CC	O
should	MD	O
therefore	RB	O
be	VB	O
avoided	VBN	O
.	.	O

The	DT	O
safety	NN	O
of	IN	O
once	RB	FREQ
daily	JJ	FREQ
dosing	VBG	O
with	IN	O
Accutane	NNP	O
(	(	O
isotretinoin	NN	O
)	)	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	O

And	CC	O
the	DT	O
median	JJ	O
spontaneous	JJ	O
recovery	NN	O
time	NN	O
is	VBZ	O
not	RB	O
different	JJ	O
from	IN	O
that	DT	O
in	IN	O
other	JJ	WHO
adults	NNS	WHO
.	.	O

If	IN	O
satisfactory	JJ	O
reduction	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
achieved	VBN	O
after	IN	O
one	CD	PER
or	CC	O
two	CD	PER
weeks	NNS	PER
,	,	O
the	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
50	CD	DOS
mg	NN	UNIT
b.i.d	NN	O
.	.	O

The	DT	O
maximum	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
evaluated	VBN	O
in	IN	O
clinical	JJ	O
studies	NNS	O
was	VBD	O
45	CD	DOS
mcg	NN	UNIT
(	(	O
5	CD	DOS
mcg	RB	UNIT
9	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
day	NN	FREQ
)	)	O
.	.	O

There	EX	O
are	VBP	O
no	DT	O
well	RB	O
-	:	O
controlled	VBN	O
studies	NNS	O
in	IN	O
children	NNS	WHO
to	TO	O
establish	VB	O
appropriate	JJ	O
dosing	NN	O
;	:	O
however	RB	O
,	,	O
the	DT	O
American	NNP	O
Heart	NNP	O
Association	NNP	O
recommends	VBZ	O
an	DT	O
initial	JJ	O
infusion	NN	O
rate	NN	O
of	IN	O
0.1	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
,	,	O
with	IN	O
the	DT	O
usual	JJ	O
range	NN	O
being	VBG	O
0.1	CD	DOS
mcg	NN	UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
min	NN	O
to	TO	O
1	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	FW	O
/	JJ	O
min	NN	O
.	.	O

In	IN	O
the	DT	O
2	CD	O
clinical	JJ	O
trials	NNS	O
evaluating	VBG	O
these	DT	O
schedules	NNS	O
(	(	O
see	VB	O
Clinical	JJ	O
Studies	NNS	O
:	:	O
AIDS	NNP	O
-	:	O
Related	VBN	O
Kaposi	NNP	O
's	POS	O
Sarcoma	NNP	O
)	)	O
,	,	O
the	DT	O
former	JJ	O
schedule	NN	O
(	(	O
135	CD	DOS
mg	NN	UNIT
/	NN	O
m²	NN	O
every	DT	FREQ
3	CD	FREQ
weeks	NNS	FREQ
)	)	O
was	VBD	O
more	RBR	O
toxic	JJ	O
than	IN	O
the	DT	O
latter	NN	O
.	.	O

Shake	VB	O
the	DT	O
vial	JJ	O
gently	RB	O
to	TO	O
dissolve	VB	O
the	DT	O
powder	NN	O
.	.	O

The	DT	O
dosage	NN	O
is	VBZ	O
determined	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
weight	NN	O
.	.	O

When	WRB	O
tetanus	NN	O
toxoid	NN	O
and	CC	O
TIG	NNP	O
are	VBP	O
administered	VBN	O
concurrently	RB	O
,	,	O
separate	JJ	O
syringes	NNS	O
and	CC	O
separate	JJ	O
sites	NNS	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

[	NNS	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NN	O

(	(	O
See	VB	O
WARNINGS	NNP	O
.	.	O
)	)	O

Do	NNP	O
not	RB	O
use	VB	O
the	DT	O
solution	NN	O
if	IN	O
it	PRP	O
is	VBZ	O
discolored	VBN	O
or	CC	O
particulate	JJ	O
matter	NN	O
is	VBZ	O
present	JJ	O
.	.	O

Table	JJ	O
8	CD	O
:	:	O
Dosing	NN	O
for	IN	O
Renal	NNP	O
Impairmentt	NNP	O

ZOSYN	NNP	O
containing	VBG	O
EDTA	NNP	O
is	VBZ	O
compatible	JJ	O
for	IN	O
co	JJ	O
-	:	O
administration	NN	O
via	IN	O
a	DT	O
Y	NNP	O
-	:	O
site	NN	O
intravenous	JJ	O
tube	NN	O
with	IN	O
Lactated	NNP	O
Ringer	NNP	O
's	POS	O
injection	NN	O
,	,	O
USP	NNP	O
.	.	O

While	IN	O
the	DT	O
Corifact	NNP	O
vial	NN	O
is	VBZ	O
upright	JJ	O
,	,	O
screw	VBD	O
the	DT	O
syringe	NN	O
to	TO	O
the	DT	O
Mix2Vial	NNP	O
transfer	NN	O
set	NN	O
.	.	O

To	TO	O
do	VB	O
so	RB	O
,	,	O
with	IN	O
the	DT	O
canister	NN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
,	,	O
slowly	RB	O
and	CC	O
fully	RB	O
depress	VB	O
the	DT	O
actuator	NN	O
eight	CD	FREQ
times	NNS	FREQ
.	.	O

DO	NNP	O
NOT	NNP	O
SHAKE	NNP	O
VIAL	NNP	O
;	:	O
AVOID	NNP	O
FOAMING.Parenteral	NNP	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

Extreme	JJ	O
caution	NN	O
during	IN	O
injection	NN	O
of	IN	O
contrast	NN	O
media	NNS	O
is	VBZ	O
necessary	JJ	O
to	TO	O
avoid	VB	O
extravasation	NN	O
and	CC	O
fluoroscopy	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

Instruct	NNP	WHO
caregivers	NNS	WHO
of	IN	WHO
young	JJ	WHO
children	NNS	WHO
who	WP	WHO
are	VBP	WHO
prescribed	VBN	WHO
an	DT	WHO
Adrenaclick	NNP	WHO
and	CC	O
who	WP	O
may	MD	O
be	VB	O
uncooperative	JJ	O
and	CC	O
kick	NN	O
or	CC	O
move	NN	O
during	IN	O
an	DT	O
injection	NN	O
to	TO	O
hold	VB	O
the	DT	O
leg	NN	O
firmly	RB	O
in	IN	O
place	NN	O
and	CC	O
limit	NN	O
movement	NN	O
prior	RB	O
to	TO	O
and	CC	O
during	IN	O
an	DT	O
injection	NN	O
[	NN	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Instruct	NN	O
patients	NNS	O
to	TO	O
shake	VB	O
can	MD	O
prior	VB	O
to	TO	O
using	VBG	O
Enstilar®	NNP	O
Foam	NNP	O
and	CC	O
to	TO	O
wash	VB	O
their	PRP$	O
hands	NNS	O
after	IN	O
applying	VBG	O
the	DT	O
product	NN	O
.	.	O

Do	NNP	O
not	RB	O
reuse	VB	O
or	CC	O
save	VB	O
VIGIV	NNP	O
(	(	O
vaccinia	FW	O
immune	NN	O
globulin	VBP	O
intravenous	JJ	O
)	)	O
for	IN	O
future	JJ	O
use	NN	O
.	.	O

is	VBZ	O
added	VBN	O
to	TO	O
the	DT	O
therapy	NN	O
,	,	O
the	DT	O
LATUDA	NNP	O
dose	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
to	TO	O
half	NN	O
of	IN	O
the	DT	O
original	JJ	O
dose	JJ	O
level	NN	O
.	.	O

For	IN	O
infants	NNS	WHO
and	CC	WHO
in	IN	WHO
children	NNS	WHO
under	IN	WHO
3	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
,	,	O
the	DT	O
solution	NN	O
should	MD	O
be	VB	O
accurately	RB	O
measured	VBN	O
and	CC	O
no	DT	O
more	JJR	O
than	IN	O
1.2	CD	DOS
mL	JJ	UNIT
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
immediate	JJ	O
area	NN	O
with	IN	O
a	DT	O
cotton	NN	O
-	:	O
tipped	JJ	O
applicator	NN	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
tinea	JJ	WHO
versicolor	NNS	WHO
usually	RB	O
exhibit	VBP	O
clinical	JJ	O
and	CC	O
mycological	JJ	O
clearing	NN	O
after	IN	O
two	CD	PER
weeks	NNS	PER
of	IN	O
treatment	NN	O
.	.	O

Strict	JJ	O
adherence	NN	O
to	TO	O
the	DT	O
following	JJ	O
precautions	NNS	O
is	VBZ	O
advised	VBN	O
in	IN	O
order	NN	O
to	TO	O
minimize	VB	O
the	DT	O
potential	NN	O
for	IN	O
secondary	JJ	O
exposure	NN	O
to	TO	O
testosterone	VB	O
from	IN	O
Vogelxo	NNP	O
treated	VBD	O
skin	NN	O
:	:	O

Treatment	NN	O
should	MD	O
be	VB	O
instituted	VBN	O
in	IN	O
a	DT	O
hospital	NN	O
until	IN	O
a	DT	O
stable	JJ	O
dosage	NN	O
regimen	NNS	O
is	VBZ	O
achieved	VBN	O
.	.	O

Continually	RB	O
reevaluate	JJ	O
patients	NNS	O
receiving	VBG	O
NUCYNTA	NNP	O
oral	JJ	O
solution	NN	O
to	TO	O
assess	VB	O
the	DT	O
maintenance	NN	O
of	IN	O
pain	NN	O
control	NN	O
and	CC	O
the	DT	O
relative	JJ	O
incidence	NN	O
of	IN	O
adverse	JJ	O
reactions	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
monitoring	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
addiction	NN	O
,	,	O
abuse	NN	O
,	,	O
or	CC	O
misuse	VB	O
[	JJ	O
see	NN	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Limited	JJ	O
storage	NN	O
periods	NNS	O
at	IN	O
15°	CD	O
to	TO	O
30°C	CD	O
(	(	O
59°	CD	O
to	TO	O
86°F	CD	O
)	)	O
are	VBP	O
acceptable	JJ	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
the	DT	O
following	JJ	O
dosage	NN	O
schedule	NN	O
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
guideline	NN	O
:	:	O

Figure	NN	O
A	DT	O

Dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
2	CD	DOS
tablets	NNS	UNIT
t.i.d	RB	O
.	.	O

3	CD	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

This	DT	O
may	MD	O
be	VB	O
followed	VBN	O
by	IN	O
spontaneous	JJ	O
normal	JJ	O
cycles	NNS	O
.	.	O

Appropriate	JJ	O
infusion	NN	O
solutions	NNS	O
include	VBP	O
:	:	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
;	:	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
;	:	O
or	CC	O
Lactated	NNP	O
Ringer	NNP	O
's	POS	O
Injection	NNP	O
,	,	O
USP	NNP	O
.	.	O

Do	MD	O
not	RB	O
apply	VB	O
more	JJR	O
than	IN	O
8	CD	DOS
g	JJ	UNIT
daily	RB	FREQ
to	TO	O
any	DT	O
single	JJ	O
joint	NN	O
of	IN	O
the	DT	O
upper	JJ	O
extremities	NNS	O
.	.	O

For	IN	O
intravenous	JJ	O
injection	NN	O
after	IN	O
reconstitution	NN	O
only	RB	O
.	.	O

ELOCON	NNP	O
Cream	NNP	O
may	MD	O
be	VB	O
used	VBN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
2	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
or	CC	WHO
older	JJR	WHO
.	.	O

Exchange	NNP	O
the	DT	O
18	CD	O
G	NNP	O
x	VBD	O
1	CD	O
½	JJ	O
”	NNP	O
needle	NN	O
with	IN	O
the	DT	O
enclosed	JJ	O
22	CD	O
G	NNP	O
x	VBD	O
1½	CD	O
”	NNP	O
Safety	NNP	O
Glide™	NNP	O
injection	NN	O
needle	NN	O
.	.	O

DO	NNP	O
NOT	NNP	O
USE	NNP	O
EQUIPMENT	NNP	O
CONTAINING	NNP	O
ALUMINUM	NNP	O
(	(	O
e.g	NN	O
,	,	O
NEEDLES	NNP	O
,	,	O
CANNULAE	NNP	O
)	)	O
THAT	NNP	O
WOULD	NNP	O
COME	NNP	O
IN	NNP	O
CONTACT	NNP	O
WITH	NNP	O
THE	NNP	O
DRUG	NNP	O
SOLUTION	NNP	O
.	.	O

For	IN	O
prevention	NN	O
of	IN	O
osteoporosis	NN	O
.	.	O

When	WRB	O
discontinuing	VBG	O
KAPVAY	NNP	O
,	,	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
should	MD	O
be	VB	O
tapered	VBN	O
in	IN	O
decrements	NNS	O
of	IN	O
no	DT	O
more	JJR	O
than	IN	O
0.1	CD	DOS
mg	JJ	UNIT
every	DT	FREQ
3	CD	FREQ
to	TO	O
7	CD	PER
days	NNS	PER
to	TO	O
avoid	VB	O
rebound	NN	O
hypertension	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Figure	NN	O
3	CD	O

Not	RB	O
all	DT	WHO
patients	NNS	WHO
will	MD	O
respond	VB	O
to	TO	O
the	DT	O
recommended	VBN	O
dose	NN	O
and	CC	O
there	EX	O
is	VBZ	O
evidence	NN	O
to	TO	O
suggest	VB	O
,	,	O
at	IN	O
least	JJS	O
in	IN	O
younger	JJR	WHO
patients	NNS	WHO
,	,	O
that	IN	O
a	DT	O
lower	JJR	O
dose	NN	O
may	MD	O
provide	VB	O
efficacy	NN	O
.	.	O

The	DT	O
antihypertensive	JJ	O
effects	NNS	O
of	IN	O
CALAN	NNP	O
SR	NNP	O
are	VBP	O
evident	JJ	O
within	IN	O
the	DT	O
first	JJ	O
week	NN	PER
of	IN	O
therapy	NN	O
.	.	O

The	DT	O
pharmacokinetics	NNS	O
of	IN	O
olaparib	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
evaluated	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
or	CC	O
end	VB	O
-	:	O
stage	NN	O
renal	JJ	O
disease	NN	O
(	(	O
CLcr	NNP	O
≤30	NNP	O
mL	NN	O
/	NNP	O
min	NN	O
)	)	O
[	NN	O
see	VBP	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

At	IN	O
any	DT	O
time	NN	O
,	,	O
each	DT	O
administered	VBN	O
dose	NN	O
may	MD	O
be	VB	O
decreased	VBN	O
by	IN	O
1	CD	DOS
mcg	NNS	UNIT
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	O
i.e	JJ	O
,	,	O
Child	NNP	O
-	:	O
Pugh	NNP	O
C	NNP	O
)	)	O
,	,	O
reduce	VB	O
the	DT	O
starting	NN	O
dose	NN	O
and	CC	O
reduce	VB	O
the	DT	O
titration	NN	O
dose	NN	O
by	IN	O
half	PDT	O
that	DT	O
of	IN	O
patients	NNS	WHO
with	IN	WHO
normal	JJ	WHO
liver	NN	WHO
function	NN	WHO
,	,	O
from	IN	O
150	CD	DOS
mcg	NNS	UNIT
to	TO	O
75	CD	DOS
mcg	NNS	UNIT
.	.	O

If	IN	O
non	JJ	O
-	:	O
disposable	JJ	O
equipment	NN	O
is	VBZ	O
used	VBN	O
,	,	O
scrupulous	JJ	O
care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
prevent	VB	O
residual	JJ	O
contamination	NN	O
with	IN	O
traces	NNS	O
of	IN	O
cleaning	VBG	O
agents	NNS	O
.	.	O

Routine	JJ	O
administration	NN	O
of	IN	O
DTP	NNP	O
(	(	O
diphtheria	NN	O
,	,	O
tetanus	NN	O
,	,	O
pertussis	NN	O
)	)	O
and	CC	O
/	$	O
or	CC	O
OPV	NNP	O
(	(	O
oral	JJ	O
poliovirus	NN	O
vaccine	NN	O
)	)	O
concurrently	RB	O
with	IN	O
measles	NNS	O
,	,	O
mumps	NNS	O
and	CC	O
rubella	NN	O
vaccines	NNS	O
is	VBZ	O
not	RB	O
recommended	VBN	O
because	IN	O
there	EX	O
are	VBP	O
limited	JJ	O
data	NNS	O
relating	VBG	O
to	TO	O
the	DT	O
simultaneous	JJ	O
administration	NN	O
of	IN	O
these	DT	O
antigens	NNS	O
.	.	O

The	DT	O
application	NN	O
site	NN	O
and	CC	O
dose	NN	O
of	IN	O
AndroGel	NNP	O
1.62	CD	O
%	NN	O
are	VBP	O
not	RB	O
interchangeable	JJ	O
with	IN	O
other	JJ	O
topical	JJ	O
testosterone	NN	O
products	NNS	O
.	.	O

Doses	NNS	O
above	IN	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
(	(	O
or	CC	O
in	IN	O
excess	NN	O
of	IN	O
200	CD	DOS
mg	NN	UNIT
)	)	O
once	RB	FREQ
daily	RB	FREQ
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
[	VBP	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

The	DT	O
malaria	NN	O
risk	NN	O
must	MD	O
be	VB	O
carefully	RB	O
weighed	VBN	O
against	IN	O
the	DT	O
risk	NN	O
of	IN	O
serious	JJ	O
adverse	JJ	O
drug	NN	O
reactions	NNS	O
(	(	O
see	VB	O
INDICATIONS	NNP	O
AND	NNP	O
USAGE	NNP	O
)	)	O
.	.	O

There	EX	O
has	VBZ	O
been	VBN	O
no	DT	O
clinical	JJ	O
experience	NN	O
with	IN	O
TRACRIUM	NNP	O
(	(	O
atracurium	JJ	O
besylate	NN	O
)	)	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
,	,	O
and	CC	O
no	DT	O
specific	JJ	O
dosage	NN	O
adjustments	NNS	O
can	MD	O
be	VB	O
recommended	VBN	O
.	.	O

The	DT	O
patient	NN	O
should	MD	O
be	VB	O
instructed	VBN	O
to	TO	O
omit	VB	O
the	DT	O
meal	NN	O
that	WDT	O
precedes	VBZ	O
the	DT	O
examination	NN	O
.	.	O

The	DT	O
maintenance	NN	O
dose	NN	O
may	MD	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
or	CC	O
as	IN	O
50	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
intolerance	NN	WHO
,	,	O
discontinue	NN	O
Lopressor	NNP	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

ATTENTION	NN	O
:	:	O
Keep	VB	O
the	DT	O
plunger	NN	O
pressed	VBN	O
and	CC	O
shake	VB	O
the	DT	O
vial	JJ	O
moderately	RB	O
in	IN	O
a	DT	O
horizontal	JJ	O
direction	NN	O
for	IN	O
a	DT	O
minimum	NN	O
of	IN	O
30	CD	O
seconds	NNS	O
so	RB	O
that	IN	O
the	DT	O
powder	NN	O
is	VBZ	O
completely	RB	O
suspended	VBN	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
hypogammaglobulinemia	NN	WHO
and	CC	O
/	NN	O
or	CC	O
recurrent	JJ	O
bacterial	JJ	O
infections	NNS	O
due	JJ	O
to	TO	O
B	NNP	O
-	:	O
cell	NN	O
Chronic	NNP	O
Lymphocytic	NNP	O
Leukemia	NNP	O
,	,	O
a	DT	O
dose	NN	O
of	IN	O
400	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
every	DT	FREQ
3	CD	FREQ
to	TO	O
4	CD	PER
weeks	NNS	PER
is	VBZ	O
recommended	VBN	O
.	.	O

Because	IN	O
steady	JJ	O
-	:	O
state	NN	O
plasma	NN	O
concentrations	NNS	O
are	VBP	O
approximated	VBN	O
in	IN	O
1	CD	DOS
day	NN	UNIT
,	,	O
ARYMO	NNP	O
ER	NNP	O
dosage	NN	O
adjustments	NNS	O
may	MD	O
be	VB	O
done	VBN	O
every	DT	FREQ
1	CD	FREQ
to	TO	O
2	CD	PER
days	NNS	PER
.	.	O

TABLE	NN	O
4	CD	O

OMNIPAQUE	RB	O
240	CD	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
240	CD	DOS
mgI	NNS	UNIT
/	JJ	O
mL	NN	O
and	CC	O
OMNIPAQUE	NNP	O
300	CD	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
300	CD	DOS
mgI	NNS	UNIT
/	JJ	O
mL	NNS	O
are	VBP	O
indicated	VBN	O
in	IN	O
children	NNS	WHO
for	IN	O
use	NN	O
in	IN	O
intravenous	JJ	O
contrast	NN	O
enhanced	VBD	O
computed	JJ	O
tomographic	JJ	O
head	NN	O
imaging	NN	O
by	IN	O
rapid	JJ	O
bolus	JJ	O
injection	NN	O
.	.	O

ZYVOX	NNP	O
I.V	NNP	O
.	.	O

10	CD	DOS
mg	NN	UNIT
/	VBD	O
400	CD	DOS
mg	NN	UNIT
:	:	O
The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
every	DT	FREQ
four	CD	FREQ
to	TO	O
six	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

While	IN	O
applying	VBG	O
countertraction	NN	O
to	TO	O
the	DT	O
skin	NN	O
,	,	O
insert	VBZ	O
only	RB	O
the	DT	O
tip	NN	O
of	IN	O
the	DT	O
applicator	NN	O
at	IN	O
a	DT	O
slight	JJ	O
angle	NN	O
(	(	O
no	DT	O
greater	JJR	O
than	IN	O
20	CD	O
degrees	NNS	O
)	)	O
,	,	O
into	IN	O
the	DT	O
subdermal	JJ	O
space	NN	O
(	(	O
depth	NN	O
of	IN	O
3	CD	O
-	:	O
4	CD	O
mm	NN	O
below	IN	O
the	DT	O
skin	NN	O
)	)	O
,	,	O
with	IN	O
the	DT	O
bevel	NN	O
-	:	O
up	RB	O
stop	VB	O
marking	NN	O
on	IN	O
the	DT	O
cannula	NN	O
facing	NN	O
upwards	NNS	O
and	CC	O
visible	JJ	O
with	IN	O
the	DT	O
obturator	NN	O
locked	VBD	O
fully	RB	O
into	IN	O
the	DT	O
cannula	NN	O
(	(	O
Figure	NNP	O
5	CD	O
)	)	O
.	.	O

For	IN	O
intratracheal	JJ	O
administration	NN	O
only	RB	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
bolus	NN	O
dose	NN	O
and	CC	O
the	DT	O
infusion	NN	O
rate	NN	O
must	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
case	NN	O
of	IN	O
known	VBN	O
or	CC	O
suspected	VBN	O
renal	JJ	O
insufficiency	NN	O
(	(	O
creatinine	JJ	O
clearance	NN	O
below	IN	O
60mL	CD	O
/	JJ	O
min	NN	O
or	CC	O
serum	JJ	O
creatinine	NN	O
above	IN	O
1.5mg	CD	DOS
/	NNP	O
dL	NN	O
)	)	O
.	.	O

Discard	NNP	O
the	DT	O
vial	NN	O
and	CC	O
needle	NN	O
in	IN	O
accordance	NN	O
with	IN	O
local	JJ	O
regulations	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
oral	JJ	O
rifampin	NN	O
be	VB	O
administered	VBN	O
once	RB	FREQ
daily	JJ	FREQ
,	,	O
either	RB	O
1	CD	O
hour	NN	O
before	IN	O
or	CC	O
2	CD	O
hours	NNS	O
after	IN	O
a	DT	O
meal	NN	O
with	IN	O
a	DT	O
full	JJ	O
glass	NN	O
of	IN	O
water	NN	O
.	.	O

Six	CD	O
different	JJ	O
“	NNS	FREQ
day	NN	FREQ
label	VBZ	O
strips	NNS	O
”	NNS	O
are	VBP	O
provided	VBN	O
with	IN	O
each	DT	O
cycle	NN	O
pack	NN	O
blister	NN	O
card	NN	O
in	IN	O
order	NN	O
to	TO	O
accommodate	VB	O
a	DT	O
Day	NNP	O
1	CD	O
start	NN	O
regimen	NNS	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
KALETRA	NNP	O
must	MD	O
be	VB	O
increased	VBN	O
when	WRB	O
administered	VBN	O
in	IN	O
combination	NN	O
with	IN	O
efavirenz	NN	O
,	,	O
nevirapine	NN	O
or	CC	O
nelfinavir	NN	O
.	.	O

IU	NNP	O
/	NNP	O
dL	NN	O
(	(	O
or	CC	O
%	NN	O
normal	JJ	O
)	)	O
=Total	VBP	O
Dose	NNP	O
(	(	O
IU	NNP	O
)	)	O
/	VBZ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
x	VBZ	O
2	CD	DOS
[	JJ	O
IU	NNP	O
/	NNP	O
dL	NN	O
]	NNP	O
/	NNP	O
[	NNP	O
IU	NNP	O
/	NNP	O
kg	VBD	O
]	NN	O

49	CD	O

Vibramycin	NNP	O
IV	NNP	O
in	IN	O
these	DT	O
solutions	NNS	O
is	VBZ	O
stable	JJ	O
under	IN	O
fluorescent	JJ	O
light	NN	O
for	IN	O
48	CD	O
hours	NNS	O
,	,	O
but	CC	O
must	MD	O
be	VB	O
protected	VBN	O
from	IN	O
direct	JJ	O
sunlight	NN	O
during	IN	O
storage	NN	O
and	CC	O
infusion	NN	O
.	.	O

Lovenox	NNP	O
prefilled	VBD	O
syringes	NNS	O
and	CC	O
graduated	VBD	O
prefilled	VBN	O
syringes	NNS	O
are	VBP	O
for	IN	O
single	JJ	O
,	,	O
one	CD	O
-	:	O
time	NN	O
use	IN	O
only	RB	O
and	CC	O
are	VBP	O
available	JJ	O
with	IN	O
a	DT	O
system	NN	O
that	WDT	O
shields	VBZ	O
the	DT	O
needle	NN	O
after	IN	O
injection	NN	O
.	.	O

Always	NNS	O
mix	VBP	O
the	DT	O
dry	JJ	O
powder	NN	O
with	IN	O
water	NN	O
or	CC	O
other	JJ	O
fluids	NNS	O
before	IN	O
ingesting	NN	O
.	.	O

Second	JJ	O
dose	NN	O
:	:	O
(	(	O
6	CD	O
hours	NNS	O
after	IN	O
first	JJ	O
dose	NN	O
)	)	O
5	CD	DOS
mg	JJ	UNIT
base	NN	UNIT
per	IN	O
kg	NN	O
(	(	O
but	CC	O
not	RB	O
exceeding	VBG	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
of	IN	O
300	CD	DOS
mg	JJ	UNIT
base	NN	UNIT
)	)	O
.	.	O

Entex	NNP	O
PSE	NNP	O
(	(	O
pseudoephedrine	NN	O
and	CC	O
guaifenesin	NN	O
)	)	O
tablets	NNS	O
are	VBP	O
not	RB	O
recommended	VBN	O
for	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
under	IN	WHO
6	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
ZOLOFT	NNP	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
(	(	WHO
Child	NNP	WHO
Pugh	NNP	WHO
scores	VBZ	WHO
7	CD	WHO
to	TO	WHO
9	CD	WHO
)	)	WHO
or	CC	WHO
severe	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	WHO
Child	NNP	WHO
Pugh	NNP	WHO
scores	VBZ	WHO
10	CD	WHO
-	:	WHO
15	CD	WHO
)	)	WHO
is	VBZ	O
not	RB	O
recommended	JJ	O
[	NNS	O
See	VBP	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Crushing	NNP	O
,	,	O
chewing	VBG	O
,	,	O
or	CC	O
dissolving	VBG	O
EMBEDA	NNP	O
capsules	NNS	O
will	MD	O
result	VB	O
in	IN	O
uncontrolled	JJ	O
delivery	NN	O
of	IN	O
morphine	NN	O
and	CC	O
can	MD	O
lead	VB	O
to	TO	O
overdose	VB	O
or	CC	O
death	NN	O
[	NNS	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Before	IN	O
use	NN	O
,	,	O
warm	VBP	O
the	DT	O
vial	NN	O
for	IN	O
15	CD	O
minutes	NNS	O
in	IN	O
a	DT	O
preheated	JJ	O
dry	JJ	O
block	NN	O
heater	NN	O
set	VBN	O
at	IN	O
44°C	CD	O
(	(	O
111°F	CD	O
)	)	O
.	.	O

SYMBYAX	NNP	O
has	VBZ	O
not	RB	O
been	VBN	O
systematically	RB	O
studied	VBN	O
in	IN	O
patients	NNS	WHO
>	JJ	WHO
65	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
or	CC	WHO
in	IN	WHO
patients	NNS	WHO
<	JJ	WHO
10	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Administration	NN	O
of	IN	O
50	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
will	MD	O
produce	VB	O
blood	NN	O
levels	NNS	O
of	IN	O
the	DT	O
magnitude	NN	O
to	TO	O
which	WDT	O
the	DT	O
majority	NN	O
of	IN	O
susceptible	JJ	O
microorganisms	NNS	O
will	MD	O
respond	VB	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
reduce	VB	O
secondary	JJ	O
Dapsone	NNP	O
resistance	NN	O
,	,	O
the	DT	O
WHO	NNP	O
Expert	NNP	O
Committee	NNP	O
on	IN	O
Leprosy	NNP	O
and	CC	O
the	DT	O
USPHS	NNP	O
at	IN	O
Carville	NNP	O
,	,	O
LA	NNP	O
,	,	O
recommended	VBD	O
that	IN	O
Dapsone	NNP	O
should	MD	O
be	VB	O
commenced	VBN	O
in	IN	O
combination	NN	O
with	IN	O
one	CD	DOS
or	CC	O
more	JJR	O
anti	JJ	O
-	:	O
leprosy	JJ	O
drugs	NNS	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
instructed	VBN	O
not	RB	O
to	TO	O
increase	VB	O
the	DT	O
dosage	NN	O
on	IN	O
their	PRP$	O
own	JJ	O
.	.	O

CAUTION	NN	O
:	:	O
The	DT	O
assembled	JJ	O
components	NNS	O
are	VBP	O
intended	VBN	O
for	IN	O
one	CD	PER
-	:	O
time	NN	O
use	IN	O
only	RB	O
.	.	O

Total	JJ	O
fluid	NN	O
requirements	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
electrolyte	NN	O
and	CC	O
acid	JJ	O
-	:	O
base	NN	O
needs	NNS	O
,	,	O
should	MD	O
be	VB	O
estimated	VBN	O
and	CC	O
appropriately	RB	O
administered	VBN	O
.	.	O

Calculate	VB	O
the	DT	O
estimated	JJ	O
daily	JJ	FREQ
hydromorphone	NN	O
requirement	NN	O
using	VBG	O
Table	JJ	O
1	CD	O
.	.	O

Figure	NN	O
14	CD	O

Do	NNP	O
not	RB	O
dispense	VB	O
directly	RB	O
onto	JJ	O
hands	NNS	O
as	IN	O
foam	NN	O
will	MD	O
begin	VB	O
to	TO	O
melt	VB	O
immediately	RB	O
upon	IN	O
contact	NN	O
with	IN	O
warm	JJ	O
skin	NN	O
.	.	O

The	DT	O
vial	JJ	O
must	MD	O
be	VB	O
discarded	VBN	O
after	IN	O
reconstitution	NN	O
and	CC	O
withdrawal	NN	O
of	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
.	.	O

Dosage	NNP	O
adjustment	NN	O
may	MD	O
be	VB	O
necessary	JJ	O
when	WRB	O
Edluar	NNP	O
is	VBZ	O
combined	VBN	O
with	IN	O
other	JJ	O
CNS	NNP	O
-	:	O
depressant	NN	O
drugs	NNS	O
because	IN	O
of	IN	O
the	DT	O
potentially	RB	O
additive	JJ	O
effects	NNS	O
[	VBP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Radiopharmaceuticals	NNS	O
,	,	O
including	VBG	O
Amyvid	NNP	O
,	,	O
should	MD	O
only	RB	O
be	VB	O
used	VBN	O
by	IN	O
or	CC	O
under	IN	O
the	DT	O
control	NN	O
of	IN	O
physicians	NNS	O
who	WP	O
are	VBP	O
qualified	VBN	O
by	IN	O
specific	JJ	O
training	NN	O
and	CC	O
experience	NN	O
in	IN	O
the	DT	O
safe	JJ	O
use	NN	O
and	CC	O
handling	NN	O
of	IN	O
radioactive	JJ	O
materials	NNS	O
,	,	O
and	CC	O
whose	WP$	O
experience	NN	O
and	CC	O
training	NN	O
have	VBP	O
been	VBN	O
approved	VBN	O
by	IN	O
the	DT	O
appropriate	JJ	O
governmental	JJ	O
agency	NN	O
authorized	VBD	O
to	TO	O
license	VB	O
the	DT	O
use	NN	O
of	IN	O
radiopharmaceuticals	NNS	O
.	.	O

On	IN	O
Sunday	NNP	O
the	DT	O
patient	NN	O
should	MD	O
throw	VB	O
out	RP	O
the	DT	O
rest	NN	O
of	IN	O
the	DT	O
pack	NN	O
and	CC	O
start	VB	O
a	DT	O
new	JJ	O
pack	NN	O
that	WDT	O
same	JJ	FREQ
day	NN	FREQ
.	.	O

In	IN	O
inpatient	NN	O
(	(	O
hospital	NN	O
)	)	O
treatment	NN	O
,	,	O
patients	NNS	WHO
with	IN	WHO
acute	JJ	WHO
deep	JJ	WHO
vein	NN	WHO
thrombosis	NN	WHO
with	IN	WHO
pulmonary	JJ	WHO
embolism	NN	WHO
or	CC	WHO
patients	NNS	WHO
with	IN	WHO
acute	JJ	WHO
deep	JJ	WHO
vein	NN	WHO
thrombosis	NN	WHO
without	IN	WHO
pulmonary	JJ	WHO
embolism	NN	WHO
(	(	WHO
who	WP	WHO
are	VBP	WHO
not	RB	WHO
candidates	NNS	WHO
for	IN	WHO
outpatient	JJ	WHO
treatment	NN	WHO
)	)	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Lovenox	NNP	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
/	NN	O
kg	NN	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
administered	VBN	O
SC	NNP	O
or	CC	O
1.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
administered	VBN	O
SC	NNP	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
every	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
reconstituted	JJ	O
ABILIFY	NNP	O
MAINTENA	NNP	O
suspension	NN	O
should	MD	O
appear	VB	O
to	TO	O
be	VB	O
a	DT	O
uniform	JJ	O
,	,	O
homogeneous	JJ	O
suspension	NN	O
that	WDT	O
is	VBZ	O
opaque	JJ	O
and	CC	O
milky	JJ	O
-	:	O
white	JJ	O
in	IN	O
color	NN	O
.	.	O

Initiate	NNP	O
dosing	NN	O
of	IN	O
an	DT	WHO
elderly	JJ	WHO
patient	NN	WHO
(	(	WHO
over	IN	WHO
65	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
)	)	O
should	MD	O
be	VB	O
initiated	VBN	O
cautiously	RB	O
,	,	O
usually	RB	O
starting	VBG	O
at	IN	O
the	DT	O
low	JJ	O
end	NN	O
of	IN	O
the	DT	O
dosing	NN	O
range	NN	O
,	,	O
reflecting	VBG	O
the	DT	O
greater	JJR	O
frequency	NN	O
of	IN	O
decreased	JJ	O
hepatic	JJ	O
,	,	O
renal	JJ	O
or	CC	O
cardiac	JJ	O
function	NN	O
and	CC	O
of	IN	O
concomitant	JJ	O
disease	NN	O
or	CC	O
other	JJ	O
drug	NN	O
therapy	NN	O
.	.	O

Once	RB	O
sufficient	JJ	O
clinical	JJ	O
response	NN	O
has	VBZ	O
been	VBN	O
achieved	VBN	O
and	CC	O
maintained	VBN	O
,	,	O
consider	VB	O
gradually	RB	O
lowering	VBG	O
the	DT	O
dose	NN	O
to	TO	O
achieve	VB	O
the	DT	O
optimal	JJ	O
balance	NN	O
of	IN	O
efficacy	NN	O
and	CC	O
safety	NN	O
.	.	O

Further	JJ	O
dosage	NN	O
adjustments	NNS	O
,	,	O
if	IN	O
indicated	VBN	O
,	,	O
should	MD	O
generally	RB	O
occur	VB	O
at	IN	O
intervals	NNS	O
of	IN	O
not	RB	O
less	JJR	O
than	IN	O
1	CD	PER
week	NN	PER
,	,	O
since	IN	O
steady	JJ	O
state	NN	O
for	IN	O
olanzapine	NN	O
would	MD	O
not	RB	O
be	VB	O
achieved	VBN	O
for	IN	O
approximately	RB	O
1	CD	PER
week	NN	PER
in	IN	O
the	DT	O
typical	JJ	O
patient	NN	O
.	.	O

Do	NNP	O
not	RB	O
start	VB	O
EFFEXOR	NNP	O
XR	NNP	O
in	IN	O
a	DT	O
patient	NN	WHO
who	WP	WHO
is	VBZ	WHO
being	VBG	WHO
treated	VBN	WHO
with	IN	WHO
linezolid	JJ	WHO
or	CC	WHO
intravenous	JJ	WHO
methylene	NN	WHO
blue	NN	WHO
,	,	O
because	IN	O
there	EX	O
is	VBZ	O
an	DT	O
increased	JJ	O
risk	NN	O
of	IN	O
serotonin	JJ	O
syndrome	NN	O
.	.	O

Liquid	NNP	O
and	CC	O
solid	JJ	O
oral	JJ	O
formulations	NNS	O
of	IN	O
the	DT	O
individual	JJ	O
components	NNS	O
of	IN	O
COMBIVIR	NNP	O
are	VBP	O
available	JJ	O
for	IN	O
these	DT	O
populations	NNS	O
.	.	O

Permanently	RB	O
discontinue	JJ	O
POMALYST	NNP	O
for	IN	O
angioedema	NN	O
,	,	O
skin	JJ	O
exfoliation	NN	O
,	,	O
bullae	NN	O
,	,	O
or	CC	O
any	DT	O
other	JJ	O
severe	JJ	O
dermatologic	JJ	O
reaction	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
first	JJ	O
dose	NN	O
of	IN	O
1	CD	DOS
gram	NN	UNIT
is	VBZ	O
administered	VBN	O
intravenously	RB	O
as	RB	O
soon	RB	O
as	IN	O
the	DT	O
umbilical	JJ	O
cord	NN	O
is	VBZ	O
clamped	VBN	O
.	.	O

Allow	IN	O
the	DT	O
suspension	NN	O
to	TO	O
stand	VB	O
for	IN	O
a	DT	O
minimum	NN	O
of	IN	O
1	CD	O
hour	NN	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
ORACEA	NNP	O
differs	NNS	O
from	IN	O
that	DT	O
of	IN	O
doxycycline	NN	O
used	VBN	O
to	TO	O
treat	VB	O
infections	NNS	O
.	.	O

Rare	JJ	O
cases	NNS	O
of	IN	O
self	NN	O
-	:	O
administration	NN	O
of	IN	O
DIPRIVAN	NNP	O
Injectable	NNP	O
Emulsion	NNP	O
by	IN	O
health	NN	O
care	NN	O
professionals	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
,	,	O
including	VBG	O
some	DT	O
fatalities	NNS	O
(	(	O
see	VB	O
Drug	NNP	O
Abuse	NNP	O
And	CC	O
Dependence	NNP	O
)	)	O
.	.	O

[	NNS	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NN	O

Vaccination	NN	O
schedule	NN	O
for	IN	O
infants	NNS	WHO
and	CC	WHO
toddlers	NNS	WHO

Do	MD	O
not	RB	O
store	VB	O
unused	JJ	O
mixtures	NNS	O
.	.	O

For	IN	O
IM	NNP	O
injection	NN	O
,	,	O
IV	NNP	O
direct	VBP	O
(	(	O
bolus	NN	O
)	)	O
injection	NN	O
or	CC	O
IV	NNP	O
infusion	NN	O
,	,	O
reconstitute	NN	O
with	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
according	VBG	O
to	TO	O
the	DT	O
following	VBG	O
table	NN	O
.	.	O

The	DT	O
patient	NN	O
completes	VBZ	O
her	PRP$	O
21	CD	O
-	:	O
tablet	NN	O
regimen	NNS	O
when	WRB	O
she	PRP	O
has	VBZ	O
taken	VBN	O
the	DT	O
last	JJ	O
tablet	NN	O
in	IN	O
the	DT	O
tablet	NN	O
dispenser	NN	O
.	.	O

Figure	NN	O
5	CD	O

Turn	VB	O
the	DT	O
package	NN	O
over	IN	O
.	.	O

(	(	O
19	CD	O
)	)	O

The	DT	O
maximum	NN	O
recommended	VBD	O
daily	RB	FREQ
dose	NN	O
is	VBZ	O
2500	CD	DOS
mg	NN	UNIT
for	IN	O
GLUCOPHAGE	NNP	O
and	CC	O
2000	CD	DOS
mg	NN	UNIT
for	IN	O
GLUCOPHAGE	NNP	O
XR	NNP	O
.	.	O

PERJETA	NNP	O
should	MD	O
be	VB	O
discontinued	VBN	O
if	IN	O
trastuzumab	JJ	O
treatment	NN	O
is	VBZ	O
discontinued	VBN	O
.	.	O

A	DT	O
lower	JJR	O
dose	NN	O
of	IN	O
600	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
may	MD	O
suffice	VB	O
for	IN	O
long	JJ	O
-	:	O
term	NN	O
administration	NN	O
.	.	O

Dosage	NN	O
for	IN	O
elderly	JJ	WHO
4	CD	WHO

Because	IN	O
vaccination	NN	O
recommendations	NNS	O
limited	VBD	O
to	TO	O
high	JJ	O
-	:	O
risk	NN	O
individuals	NNS	O
have	VBP	O
failed	VBN	O
to	TO	O
substantially	RB	O
lower	VB	O
the	DT	O
overall	JJ	O
incidence	NN	O
of	IN	O
hepatitis	NN	O
B	NNP	O
infection	NN	O
,	,	O
both	CC	O
the	DT	O
Advisory	NNP	O
Committee	NNP	O
on	IN	O
Immunization	NNP	O
Practices	NNP	O
(	(	O
ACIP	NNP	O
)	)	O
and	CC	O
the	DT	O
Committee	NNP	O
on	IN	O
Infectious	NNP	O
Diseases	NNP	O
of	IN	O
the	DT	O
American	NNP	O
Academy	NNP	O
of	IN	O
Pediatrics	NNP	O
(	(	O
AAP	NNP	O
)	)	O
have	VBP	O
endorsed	VBN	O
universal	JJ	O
infant	JJ	WHO
immunization	NN	O
as	IN	O
part	NN	O
of	IN	O
a	DT	O
comprehensive	JJ	O
strategy	NN	O
for	IN	O
the	DT	O
control	NN	O
of	IN	O
hepatitis	NN	O
B	NNP	O
infection.32,50	NN	O

This	DT	O
insert	NN	O
is	VBZ	O
for	IN	O
a	DT	O
Pharmacy	NNP	O
Bulk	NNP	O
Package	NNP	O
and	CC	O
is	VBZ	O
intended	VBN	O
for	IN	O
preparing	VBG	O
intravenous	JJ	O
admixtures	NNS	O
only	RB	O
.	.	O

12	CD	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Capecitabine	NNP	O
Tablets	NNP	O
Dose	NNP	O
Calculation	NNP	O
According	VBG	O
to	TO	O
Body	NNP	O
Surface	NNP	O
Area	NNP	O

The	DT	O
2	CD	O
g	NN	O
line	NN	O
is	VBZ	O
2.25	CD	DOS
inches	NNS	UNIT
long	RB	O
.	.	O

The	DT	O
total	JJ	O
duration	NN	O
of	IN	O
use	NN	O
of	IN	O
SPRIX	NNP	O
alone	RB	O
or	CC	O
sequentially	RB	O
with	IN	O
other	JJ	O
formulations	NNS	O
of	IN	O
ketorolac	NN	O
(	(	O
IM	NNP	O
/	NNP	O
IV	NNP	O
or	CC	O
oral	JJ	O
)	)	O
must	MD	O
not	RB	O
exceed	VB	O
5	CD	PER
days	NNS	PER
because	IN	O
of	IN	O
the	DT	O
potential	NN	O
for	IN	O
increasing	VBG	O
the	DT	O
frequency	NN	O
and	CC	O
severity	NN	O
of	IN	O
adverse	JJ	O
reactions	NNS	O
associated	VBN	O
with	IN	O
the	DT	O
recommended	JJ	O
doses	NNS	O
[	VBP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
ENTYVIO	NNP	O
in	IN	O
adults	NNS	WHO
with	IN	WHO
ulcerative	JJ	WHO
colitis	NN	WHO
or	CC	WHO
Crohn	NNP	WHO
's	POS	WHO
disease	NN	WHO
is	VBZ	O
300	CD	DOS
mg	NN	UNIT
administered	VBN	O
by	IN	O
intravenous	JJ	O
infusion	NN	O
at	IN	O
zero	CD	O
,	,	O
two	CD	PER
and	CC	O
six	CD	PER
weeks	NNS	PER
and	CC	O
then	RB	O
every	DT	FREQ
eight	CD	FREQ
weeks	NNS	FREQ
thereafter	RB	O
.	.	O

Although	IN	O
occasional	JJ	WHO
patients	NNS	WHO
have	VBP	O
responded	VBN	O
to	TO	O
higher	JJR	O
doses	NNS	O
,	,	O
the	DT	O
maximum	NN	O
recommended	VBD	O
daily	JJ	FREQ
dosage	NN	O
is	VBZ	O
3	CD	DOS
g.	NN	UNIT
Once	NNP	O
an	DT	O
effective	JJ	O
dosage	NN	O
range	NN	O
is	VBZ	O
attained	VBN	O
,	,	O
a	DT	O
smooth	JJ	O
blood	NN	O
pressure	NN	O
response	NN	O
occurs	VBZ	O
in	IN	O
most	JJS	WHO
patients	NNS	WHO
in	IN	O
12	CD	O
to	TO	O
24	CD	O
hours	NNS	O
.	.	O

However	RB	O
,	,	O
since	IN	O
valproate	NN	O
may	MD	O
interact	VB	O
with	IN	O
these	DT	O
or	CC	O
other	JJ	O
concurrently	RB	O
administered	VBN	O
AEDs	NNP	O
as	RB	O
well	RB	O
as	IN	O
other	JJ	O
drugs	NNS	O
,	,	O
periodic	JJ	O
plasma	NN	O
concentration	NN	O
determinations	NNS	O
of	IN	O
concomitant	JJ	O
AEDs	NNP	O
are	VBP	O
recommended	VBN	O
during	IN	O
the	DT	O
early	JJ	O
course	NN	O
of	IN	O
therapy	NN	O
[	NNP	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
maximum	JJ	O
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
75	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

4	CD	O
-	:	O
10	CD	O
The	DT	O
risk	NN	O
of	IN	O
false	JJ	O
negative	JJ	O
results	NNS	O
from	IN	O
the	DT	O
Mono	NNP	O
-	:	O
Vacc	NN	O
®Test	JJS	O
(	(	O
O.T	NNP	O
.	.	O
)	)	O

Fat	NNP	O
emulsion	NN	O
administration	NN	O
should	MD	O
be	VB	O
considered	VBN	O
when	WRB	O
prolonged	JJ	O
parenteral	JJ	O
nutrition	NN	O
is	VBZ	O
required	VBN	O
in	IN	O
order	NN	O
to	TO	O
prevent	VB	O
essential	JJ	O
fatty	JJ	O
acid	NN	O
deficiency	NN	O
(	(	O
EFAD	NNP	O
)	)	O
.	.	O

The	DT	O
usual	JJ	O
single	JJ	O
injection	NN	O
volumes	NNS	O
or	CC	O
total	JJ	O
dose	JJ	O
per	IN	O
patient	NN	O
(	(	O
mL	JJ	O
/	NNP	O
kg	NN	O
)	)	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
adolescents	NNS	WHO
over	IN	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
are	VBP	O
listed	VBN	O
in	IN	O
the	DT	O
tables	NNS	O
below	IN	O
.	.	O

They	PRP	O
report	VBP	O
that	IN	O
maximal	JJ	O
suppression	NN	O
of	IN	O
the	DT	O
leukocyte	NN	O
and	CC	O
platelet	NN	O
counts	NNS	O
occurs	VBZ	O
within	IN	O
3	CD	O
to	TO	O
5	CD	PER
weeks	NNS	PER
and	CC	O
recovery	NN	O
within	IN	O
4	CD	O
to	TO	O
8	CD	PER
weeks	NNS	PER
.	.	O

Appropriate	JJ	O
steps	NNS	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
avoid	VB	O
conception	NN	O
during	IN	O
methotrexate	JJ	O
therapy	NN	O
.	.	O

The	DT	O
radiochemical	JJ	O
purity	NN	O
was	VBD	O
determined	VBN	O
by	IN	O
the	DT	O
following	JJ	O
method	NN	O
.	.	O

Dosage	NN	O
adjustment	NN	O
guided	VBN	O
by	IN	O
serum	JJ	O
theophylline	JJ	O
concentration	NN	O
.	.	O

VARIVAX	NNP	O
is	VBZ	O
administered	VBN	O
as	IN	O
an	DT	O
approximately	RB	O
0.5	CD	DOS
-	:	O
mL	NN	UNIT
dose	NN	UNIT
by	IN	O
subcutaneous	JJ	O
injection	NN	O
into	IN	O
the	DT	O
outer	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
(	(	O
deltoid	JJ	O
region	NN	O
)	)	O
or	CC	O
the	DT	O
anterolateral	JJ	O
thigh	NN	O
.	.	O

The	DT	O
clinician	NN	O
should	MD	O
,	,	O
nevertheless	RB	O
,	,	O
be	VB	O
aware	JJ	O
of	IN	O
the	DT	O
possibility	NN	O
of	IN	O
emergent	NN	O
symptoms	NNS	O
of	IN	O
serotonin	JJ	O
syndrome	NN	O
with	IN	O
such	JJ	O
use	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Postmenopausal	NNP	O
women	NNS	O
should	MD	O
be	VB	O
re	VBN	O
-	:	O
evaluated	VBN	O
periodically	RB	O
as	IN	O
clinically	RB	O
appropriate	JJ	O
to	TO	O
determine	VB	O
if	IN	O
treatment	NN	O
is	VBZ	O
still	RB	O
necessary	JJ	O
.	.	O

For	IN	O
patients	NNS	WHO
treated	VBN	WHO
with	IN	WHO
300	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
,	,	O
decrease	VB	O
the	DT	O
dose	NN	O
to	TO	O
150	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	JJ	FREQ
before	IN	O
discontinuing	VBG	O
WELLBUTRIN	NNP	O
XL	NNP	O
.	.	O

If	IN	O
patient	JJ	O
response	NN	O
is	VBZ	O
inadequate	JJ	O
,	,	O
the	DT	O
oral	JJ	O
maintenance	NN	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
from	IN	O
200	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
(	(	O
similar	JJ	O
to	TO	O
3	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
IV	NNP	O
q12h	NN	O
)	)	O
to	TO	O
300	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
(	(	O
similar	JJ	O
to	TO	O
4	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
IV	NNP	O
q12h	NN	O
)	)	O
.	.	O

Indications	NNS	O
and	CC	O
Recommended	NNP	O
Dosage	NNP	O

Dosage	NN	O
and	CC	O
Administration	NN	O

(	(	O
See	VB	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
)	)	O

Step	NN	O
2	CD	O
:	:	O
Calculate	VB	O
the	DT	O
approximate	JJ	O
equivalent	NN	O
dose	NN	O
of	IN	O
oral	JJ	O
(	(	O
active	JJ	O
opioid	NN	O
)	)	O
based	VBN	O
on	IN	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
the	DT	O
current	JJ	O
opioid	NN	O
using	VBG	O
Table	JJ	O
1	CD	DOS
40	CD	DOS
mg	NNS	UNIT
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
former	JJ	O
opioid	NN	O
x	NN	O
0.5	CD	DOS
mg	JJ	UNIT
Conversion	NNP	O
Factor	NNP	O
=	VBD	O
20	CD	DOS
mg	NN	UNIT
of	IN	O
oral	JJ	O
(	(	O
active	JJ	O
opioid	NN	O
)	)	O
daily	RB	FREQ

Insert	NNP	O
the	DT	O
cannula	NN	O
tip	NN	O
into	IN	O
the	DT	O
incision	NN	O
with	IN	O
the	DT	O
bevel	NN	O
up	RB	O
and	CC	O
advance	VB	O
it	PRP	O
subcutaneously	RB	O
along	IN	O
the	DT	O
intended	JJ	O
track	NN	O
.	.	O

For	IN	O
maximum	JJ	O
therapeutic	JJ	O
effect	NN	O
,	,	O
the	DT	O
dosage	NN	O
of	IN	O
Marplan	NNP	O
must	MD	O
be	VB	O
individually	RB	O
adjusted	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
careful	JJ	O
observation	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

For	IN	O
most	JJS	WHO
patients	NNS	WHO
older	JJR	WHO
than	IN	WHO
50	CD	WHO
years	NNS	WHO
or	CC	WHO
for	IN	WHO
patients	NNS	WHO
under	IN	WHO
50	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
with	IN	WHO
underlying	JJ	WHO
cardiac	JJ	WHO
disease	NN	WHO
,	,	O
an	DT	O
initial	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
25	CD	DOS
-	:	O
50	CD	DOS
mcg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
of	IN	O
levothyroxine	JJ	O
sodium	NN	O
is	VBZ	O
recommended	VBN	O
,	,	O
with	IN	O
gradual	JJ	O
increments	NNS	O
in	IN	O
dose	NN	O
at	IN	O
6	CD	O
-	:	O
8	CD	PER
week	NN	PER
intervals	NNS	O
,	,	O
as	IN	O
needed	VBN	O
.	.	O

Add	$	O
80	CD	DOS
mL	NN	UNIT
of	IN	O
Ora	NNP	O
-	:	O
Plus®*	NNP	O
oral	JJ	O
suspending	VBG	O
vehicle	NN	O
to	TO	O
an	DT	O
amber	JJ	O
glass	NN	O
bottle	NN	O
containing	VBG	O
8	CD	DOS
Diovan	NNP	O
80	CD	DOS
mg	NN	UNIT
tablets	NNS	UNIT
,	,	O
and	CC	O
shake	VB	O
for	IN	O
a	DT	O
minimum	NN	O
of	IN	O
2	CD	O
minutes	NNS	O
.	.	O

For	IN	O
the	DT	O
first	JJ	O
2	CD	O
-	:	O
3	CD	O
infusions	NNS	O
,	,	O
Flebogamma	NNP	O
10	CD	O
%	NN	O
DIF	NNP	O
may	MD	O
be	VB	O
administered	VBN	O
at	IN	O
infusion	NN	O
rates	NNS	O
slower	JJR	O
than	IN	O
recommended	VBN	O
rates	NNS	O
.	.	O

A	DT	O
basic	JJ	O
solution	NN	O
for	IN	O
pediatric	JJ	O
use	NN	O
should	MD	O
contain	VB	O
25	CD	DOS
grams	NNS	UNIT
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
200	CD	DOS
to	TO	O
250	CD	DOS
grams	NNS	UNIT
of	IN	O
glucose	NN	O
per	IN	O
1000	CD	DOS
mL	NN	UNIT
,	,	O
administered	VBN	O
from	IN	O
containers	NNS	O
containing	VBG	O
250	CD	DOS
or	CC	O
500	CD	DOS
mL	NN	UNIT
.	.	O

For	IN	O
these	DT	O
vascular	JJ	O
lesions	NNS	O
the	DT	O
enhancement	NN	O
is	VBZ	O
probably	RB	O
dependent	JJ	O
on	IN	O
the	DT	O
iodine	JJ	O
content	NN	O
of	IN	O
the	DT	O
circulating	VBG	O
blood	NN	O
pool	NN	O
.	.	O

The	DT	O
patient	NN	O
should	MD	O
write	VB	O
in	IN	O
the	DT	O
space	NN	O
provided	VBD	O
on	IN	O
the	DT	O
outer	NN	O
carton	VBD	O
the	DT	O
date	NN	O
the	DT	O
product	NN	O
was	VBD	O
placed	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
.	.	O

In	IN	O
addition	NN	O
to	TO	O
dexamethasone	VB	O
,	,	O
complete	JJ	O
administration	NN	O
of	IN	O
the	DT	O
following	JJ	O
medications	NNS	O
45	CD	O
to	TO	O
90	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
EMPLICITI	NNP	O
infusion	NN	O
:	:	O

A	DT	O
weight	NN	O
-	:	O
based	VBN	O
dosing	VBG	O
guide	NN	O
for	IN	O
patients	NNS	WHO
aged	VBN	WHO
2	CD	WHO
to	TO	WHO
12	CD	WHO
years	NNS	WHO
on	IN	WHO
concomitant	JJ	WHO
valproate	NN	WHO
is	VBZ	O
provided	VBN	O
in	IN	O
Table	JJ	O
3	CD	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
this	DT	O
product	NN	O
intravenously	RB	O
or	CC	O
subcutaneously	RB	O
.	.	O

Inject	NNP	O
all	PDT	O
the	DT	O
diluent	NN	O
in	IN	O
the	DT	O
syringe	NN	O
into	IN	O
the	DT	O
vial	NN	O
of	IN	O
lyophilized	JJ	O
vaccine	NN	O
,	,	O
and	CC	O
agitate	VB	O
to	TO	O
mix	VB	O
thoroughly	RB	O
.	.	O

The	DT	O
final	JJ	O
admixed	NN	O
Soliris	NNP	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	VBZ	O
infusion	NN	O
volume	NN	O
is	VBZ	O
60	CD	DOS
mL	NN	UNIT
for	IN	O
300	CD	DOS
mg	NN	UNIT
doses	NNS	UNIT
,	,	O
120	CD	DOS
mL	NN	UNIT
for	IN	O
600	CD	DOS
mg	NN	UNIT
doses	NNS	UNIT
,	,	O
180	CD	DOS
mL	NN	UNIT
for	IN	O
900	CD	DOS
mg	NN	UNIT
doses	NNS	UNIT
or	CC	O
240	CD	DOS
mL	NN	UNIT
for	IN	O
1200	CD	DOS
mg	NN	UNIT
doses	NNS	UNIT
(	(	O
Table	JJ	O
3	CD	O
)	)	O
.	.	O

Frequent	JJ	O
communication	NN	O
is	VBZ	O
important	JJ	O
among	IN	O
the	DT	O
prescriber	NN	O
,	,	O
other	JJ	O
members	NNS	O
of	IN	O
the	DT	O
healthcare	NN	O
team	NN	O
,	,	O
the	DT	O
patient	NN	O
,	,	O
and	CC	O
the	DT	O
caregiver	NN	O
/	NNP	O
family	NN	O
during	IN	O
periods	NNS	O
of	IN	O
changing	VBG	O
analgesic	JJ	O
requirements	NNS	O
,	,	O
including	VBG	O
initial	JJ	O
titration	NN	O
.	.	O

With	IN	O
the	DT	O
opposite	JJ	O
hand	NN	O
pull	VBZ	O
the	DT	O
needle	JJ	O
cap	NN	O
upward	RB	O
without	IN	O
twisting	VBG	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
if	IN	O
the	DT	O
solution	NN	O
changes	VBZ	O
color	NN	O
or	CC	O
becomes	NNS	O
cloudy	VBP	O
,	,	O
it	PRP	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
.	.	O

Pediatric	JJ	WHO
Patients	NNS	WHO
:	:	O
Pediatric	JJ	WHO
patients	NNS	WHO
1	CD	WHO
month	NN	WHO
of	IN	WHO
age	NN	WHO
or	CC	WHO
older	JJR	WHO
:	:	O
10	CD	DOS
mg	NN	UNIT
/	NN	O
kg	NN	O
(	(	O
not	RB	O
to	TO	O
exceed	VB	O
600	CD	DOS
mg	JJ	UNIT
per	IN	O
dose	NN	O
)	)	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
for	IN	O
two	CD	PER
days	NNS	PER
.	.	O

Because	IN	O
dialysis	NN	O
fluid	NN	O
will	MD	O
become	VB	O
radioactive	JJ	O
,	,	O
radiation	NN	O
precautions	NNS	O
must	MD	O
be	VB	O
taken	VBN	O
to	TO	O
protect	VB	O
personnel	NNS	O
,	,	O
other	JJ	O
patients	NNS	O
,	,	O
and	CC	O
the	DT	O
general	JJ	O
public	NN	O
.	.	O

Modify	VB	O
the	DT	O
dose	NN	O
of	IN	O
Jakafi	NNP	O
when	WRB	O
given	VBN	O
concomitantly	RB	O
with	IN	O
strong	JJ	O
CYP3A4	NNP	O
inhibitors	NNS	O
(	(	O
such	JJ	O
as	IN	O
but	CC	O
not	RB	O
limited	JJ	O
to	TO	O
boceprevir	VB	O
,	,	O
clarithromycin	NN	O
,	,	O
conivaptan	NN	O
,	,	O
grapefruit	NN	O
juice	NN	O
,	,	O
indinavir	NN	O
,	,	O
itraconazole	NN	O
,	,	O
ketoconazole	NN	O
,	,	O
lopinavir	JJ	O
/	NNP	O
ritonavir	NN	O
,	,	O
mibefradil	NN	O
,	,	O
nefazodone	NN	O
,	,	O
nelfinavir	RB	O
,	,	O
posaconazole	NN	O
,	,	O
ritonavir	NN	O
,	,	O
saquinavir	NN	O
,	,	O
telaprevir	NN	O
,	,	O
telithromycin	NN	O
,	,	O
voriconazole	NN	O
)	)	O
and	CC	O
fluconazole	JJ	O
doses	NNS	O
of	IN	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
200	CD	DOS
mg	NN	UNIT
as	IN	O
follows	VBZ	O
[	NNP	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
,	,	O
according	VBG	O
to	TO	O
Table	NNP	O
7	CD	O
.	.	O

In	IN	O
such	JJ	O
cases	NNS	O
,	,	O
the	DT	O
physician	NN	O
may	MD	O
want	VB	O
to	TO	O
assess	VB	O
whether	IN	O
to	TO	O
refer	VB	O
the	DT	O
patient	NN	O
to	TO	O
a	DT	O
specialist	NN	O
or	CC	O
more	RBR	O
intensive	JJ	O
behavioral	JJ	O
treatment	NN	O
environment	NN	O
.	.	O

The	DT	O
bottle	NN	O
should	MD	O
be	VB	O
discarded	VBN	O
after	IN	O
25	CD	DOS
doses	NNS	UNIT
since	IN	O
the	DT	O
amount	NN	O
delivered	VBD	O
thereafter	RB	O
per	IN	O
spray	NN	O
may	MD	O
be	VB	O
substantially	RB	O
less	JJR	O
than	IN	O
150	CD	DOS
mcg	NNS	UNIT
of	IN	O
drug	NN	O
.	.	O

For	IN	O
Product	NNP	O
Inquiry	NNP	O
1	CD	O
800	CD	O
ANA	NNP	O
DRUG	NNP	O
(	(	O
1	CD	O
-	:	O
800	CD	O
-	:	O
262	CD	O
-	:	O
3784	CD	O
)	)	O
.	.	O

Do	NNP	O
not	RB	O
add	VB	O
supplementary	JJ	O
medication	NN	O
to	TO	O
Nafcillin	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Reconstitution	NN	O
for	IN	O
Direct	NNP	O
Intravenous	NNP	O
Injection	NNP	O

Correct	NNP	O
or	CC	O
exclude	VB	O
other	JJ	O
causes	NNS	O
of	IN	O
anemia	NN	O
(	(	O
e.g	JJ	O
,	,	O
vitamin	JJ	O
deficiency	NN	O
,	,	O
metabolic	NN	O
or	CC	O
chronic	JJ	O
inflammatory	JJ	O
conditions	NNS	O
,	,	O
bleeding	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O

Occasionally	RB	O
,	,	O
after	IN	O
refrigeration	NN	O
,	,	O
you	PRP	O
may	MD	O
notice	VB	O
that	IN	O
small	JJ	O
colorless	NN	O
particles	NNS	O
of	IN	O
protein	NN	O
are	VBP	O
present	JJ	O
in	IN	O
the	DT	O
solution	NN	O
.	.	O

Such	JJ	O
use	NN	O
could	MD	O
result	VB	O
in	IN	O
air	NN	O
embolism	NN	O
due	JJ	O
to	TO	O
residual	JJ	O
air	NN	O
being	VBG	O
drawn	VBN	O
from	IN	O
the	DT	O
primary	JJ	O
container	NN	O
before	IN	O
administration	NN	O
of	IN	O
the	DT	O
fluid	NN	O
from	IN	O
the	DT	O
secondary	JJ	O
container	NN	O
is	VBZ	O
complete	JJ	O
.	.	O

In	IN	O
some	DT	O
instances	NNS	O
it	PRP	O
may	MD	O
be	VB	O
necessary	JJ	O
to	TO	O
exceed	VB	O
these	DT	O
dosages	NNS	O
,	,	O
but	CC	O
the	DT	O
possibility	NN	O
of	IN	O
cholinergic	JJ	O
crisis	NN	O
must	MD	O
be	VB	O
recognized	VBN	O
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
and	CC	O
frequency	NN	O
of	IN	O
administration	NN	O
of	IN	O
doxycycline	JJ	O
differs	NNS	O
from	IN	O
that	DT	O
of	IN	O
the	DT	O
other	JJ	O
tetracyclines	NNS	O
.	.	O

In	IN	O
some	DT	WHO
cases	NNS	WHO
,	,	O
poor	JJ	O
arterial	JJ	O
visualization	NN	O
has	VBZ	O
been	VBN	O
attributed	VBN	O
to	TO	O
patient	VB	O
movement	NN	O
.	.	O

Slight	JJ	O
discoloration	NN	O
does	VBZ	O
not	RB	O
alter	VB	O
potency	NN	O
.	.	O

Under	IN	O
these	DT	O
circumstances	NNS	O
,	,	O
the	DT	O
therapeutic	JJ	O
regimen	NNS	O
should	MD	O
be	VB	O
reevaluated	VBN	O
and	CC	O
additional	JJ	O
therapeutic	NN	O
options	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

Plastic	NNP	O
disposable	JJ	O
syringes	NNS	O
are	VBP	O
recommended	VBN	O
with	IN	O
Monoclate	NNP	O
-	:	O
P®	NNP	O
solution	NN	O
.	.	O

The	DT	O
pulse	JJ	O
rate	NN	O
should	MD	O
be	VB	O
determined	VBN	O
before	IN	O
and	CC	O
during	IN	O
administration	NN	O
of	IN	O
RECOMBINATE	NNP	O
(	(	O
antihemophilic	JJ	O
factor	NN	O
(	(	O
recombinant	JJ	O
)	)	O
)	)	O
rAHF	NN	O
.	.	O

There	EX	O
have	VBP	O
been	VBN	O
rare	JJ	O
reports	NNS	O
of	IN	O
the	DT	O
need	NN	O
for	IN	O
patch	NN	O
changes	NNS	O
prior	RB	O
to	TO	O
7	CD	PER
days	NNS	PER
to	TO	O
maintain	VB	O
blood	NN	O
pressure	NN	O
control	NN	O
.	.	O

Intramuscular	JJ	O
injection	NN	O
should	MD	O
not	RB	O
be	VB	O
made	VBN	O
directly	RB	O
into	IN	O
or	CC	O
near	IN	O
a	DT	O
major	JJ	O
nerve	NN	O
,	,	O
and	CC	O
the	DT	O
site	NN	O
of	IN	O
injection	NN	O
should	MD	O
be	VB	O
varied	VBN	O
on	IN	O
repeated	VBN	O
injection	NN	O
.	.	O

For	IN	O
ZINECARD	NNP	O
250	CD	DOS
mg	NN	UNIT
vials	NNS	O
,	,	O
reconstitute	NN	O
with	IN	O
25	CD	DOS
mL	NNS	UNIT
.	.	O

Adults	NNP	WHO
-	:	O
5.0	CD	DOS
mg	NN	UNIT
Children	NNP	WHO
-	:	O
2.5	CD	DOS
mg	NN	UNIT
Infants	NNP	WHO
-	:	O
1.25	CD	DOS
mg	NN	UNIT

The	DT	O
protein	NNS	O
intake	VBP	O
may	MD	O
be	VB	O
increased	VBN	O
as	IN	O
tolerated	JJ	O
and	CC	O
determined	VBN	O
by	IN	O
plasma	JJ	O
glutamine	NN	O
and	CC	O
other	JJ	O
amino	NN	O
acid	NN	O
levels	NNS	O
.	.	O

If	IN	O
the	DT	O
level	NN	O
of	IN	O
pain	NN	O
increases	NNS	O
after	IN	O
dose	JJ	O
stabilization	NN	O
,	,	O
attempt	NN	O
to	TO	O
identify	VB	O
the	DT	O
source	NN	O
of	IN	O
increased	VBN	O
pain	NN	O
before	IN	O
increasing	VBG	O
the	DT	O
TROXYCA	NNP	O
ER	NNP	O
dosage	NN	O
.	.	O

If	IN	O
the	DT	O
resulting	VBG	O
solution	NN	O
is	VBZ	O
cloudy	JJ	O
or	CC	O
contains	NNS	O
particulate	VBP	O
matter	NN	O
,	,	O
the	DT	O
contents	NNS	O
MUST	NNP	O
NOT	NNP	O
be	VB	O
injected	VBN	O
.	.	O

NEURONTIN	NNP	O
capsules	NNS	O
should	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
with	IN	O
water	NN	O
.	.	O

AHF	NNP	O
concentrates	NNS	O
may	MD	O
also	RB	O
be	VB	O
administered	VBN	O
on	IN	O
a	DT	O
regular	JJ	O
schedule	NN	O
for	IN	O
prophylaxis	NN	O
of	IN	O
bleeding	NN	O
,	,	O
as	IN	O
reported	VBN	O
by	IN	O
Nilsson	NNP	O
et	FW	O
al.10	NN	O

Table	JJ	O
1*	CD	O
:	:	O
Summary	NN	O
of	IN	O
Pharmacodynamic	NNP	O
Properties	NNP	O
of	IN	O
Insulin	NNP	O
Products	NNP	O
(	(	O
Pooled	NNP	O
Cross	NNP	O
-	:	O
Study	NNP	O
Comparison	NNP	O
)	)	O

4	CD	O
.	.	O

Totect®	NNP	O
must	MD	O
not	RB	O
be	VB	O
mixed	JJ	O
with	IN	O
any	DT	O
other	JJ	O
drugs	NNS	O
.	.	O

The	DT	O
injection	NN	O
site	NN	O
should	MD	O
be	VB	O
varied	VBN	O
daily	JJ	FREQ
.	.	O

Pediatric	JJ	WHO
Patients	NNS	WHO
Above	IN	WHO
3	CD	WHO
Months	NNS	WHO
of	IN	WHO
Age	NNP	WHO
:	:	O
Administration	NN	O
of	IN	O
50	CD	DOS
to	TO	O
100	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
in	IN	O
equally	RB	O
divided	JJ	O
doses	NNS	O
every	DT	O
6	CD	O
to	TO	O
8	CD	O
hours	NNS	O
has	VBZ	O
been	VBN	O
successful	JJ	O
for	IN	O
most	JJS	O
infections	NNS	O
susceptible	JJ	O
to	TO	O
cefuroxime	VB	O
(	(	O
cefuroxime	NN	O
(	(	O
cefuroxime	JJ	O
injection	NN	O
)	)	O
injection	NN	O
)	)	O
.	.	O

Electrocardiograms	NNS	O
and	CC	O
vital	JJ	O
signs	NNS	O
should	MD	O
be	VB	O
routinely	RB	O
monitored	VBN	O
throughout	IN	O
the	DT	O
procedure	NN	O
.	.	O

The	DT	O
patient	NN	O
should	MD	O
continue	VB	O
dosing	VBG	O
as	IN	O
prescribed	NN	O
.	.	O

NULOJIX	NNP	O
is	VBZ	O
for	IN	O
intravenous	JJ	O
infusion	NN	O
only	RB	O
.	.	O

All	DT	O
vials	NNS	O
of	IN	O
Tazicef	NNP	O
as	IN	O
supplied	VBN	O
are	VBP	O
under	IN	O
reduced	JJ	O
pressure	NN	O
.	.	O

The	DT	O
following	JJ	O
recommendations	NNS	O
are	VBP	O
related	VBN	O
to	TO	O
acute	VB	O
acetaminophen	JJ	O
ingestion	NN	O
.	.	O

In	IN	O
this	DT	O
latter	JJ	O
situation	NN	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
necessary	JJ	O
to	TO	O
increase	VB	O
the	DT	O
dosage	NN	O
of	IN	O
the	DT	O
corticosteroid	NN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
time	NN	O
consistent	JJ	O
with	IN	O
the	DT	O
patient	NN	O
's	POS	O
condition	NN	O
.	.	O

Once	RB	O
fluid	JJ	O
falls	NNS	O
below	IN	O
the	DT	O
level	NN	O
of	IN	O
the	DT	O
center	NN	O
tube	NN	O
,	,	O
remaining	VBG	O
sprays	NNS	O
will	MD	O
not	RB	O
deliver	VB	O
intended	VBN	O
dose	NN	O
.	.	O

Note	NN	O
:	:	O
Anaphylactic	JJ	O
reactions	NNS	O
have	VBP	O
occurred	VBN	O
with	IN	O
Sandimmune	NNP	O
Injection	NNP	O
(	(	O
cyclosporine	JJ	O
injection	NN	O
,	,	O
USP	NNP	O
)	)	O
.	.	O

The	DT	O
compatibility	NN	O
and	CC	O
duration	NN	O
of	IN	O
stability	NN	O
of	IN	O
drug	NN	O
admixtures	NNS	O
will	MD	O
vary	VB	O
depending	VBG	O
on	IN	O
concentration	NN	O
and	CC	O
other	JJ	O
conditions	NNS	O
.	.	O

Incautious	JJ	O
administration	NN	O
of	IN	O
sodium	JJ	O
nitroprusside	NN	O
must	MD	O
still	RB	O
be	VB	O
avoided	VBN	O
,	,	O
and	CC	O
all	DT	O
of	IN	O
the	DT	O
precautions	NNS	O
concerning	VBG	O
sodium	NN	O
nitroprusside	JJ	O
administration	NN	O
must	MD	O
still	RB	O
be	VB	O
observed	VBN	O
.	.	O

There	EX	O
is	VBZ	O
no	DT	O
experience	NN	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
24	CD	DOS
mg	NN	UNIT
dosage	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
.	.	O

Since	IN	O
methyldopa	NN	O
has	VBZ	O
a	DT	O
relatively	RB	O
short	JJ	O
duration	NN	O
of	IN	O
action	NN	O
,	,	O
withdrawal	NN	O
is	VBZ	O
followed	VBN	O
by	IN	O
return	NN	O
of	IN	O
hypertension	NN	O
usually	RB	O
within	IN	O
48	CD	O
hours	NNS	O
.	.	O

NovoLog	NNP	O
Mix	NNP	O
70	CD	O
/	NN	O
30	CD	O
(	(	O
insulin	JJ	O
aspart	NN	O
protamine	NN	O
and	CC	O
insulin	JJ	O
aspart	NN	O
(	(	O
rdna	JJ	O
origin	NN	O
)	)	O
)	)	O
is	VBZ	O
an	DT	O
insulin	NN	O
analog	NN	O
with	IN	O
an	DT	O
earlier	JJR	O
onset	NN	O
and	CC	O
intermediate	JJ	O
duration	NN	O
of	IN	O
action	NN	O
in	IN	O
comparison	NN	O
to	TO	O
the	DT	O
basal	NN	O
human	JJ	O
insulin	NN	O
premix	NN	O
.	.	O

These	DT	O
solutions	NNS	O
are	VBP	O
too	RB	O
concentrated	JJ	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
less	RBR	WHO
than	IN	WHO
1	CD	WHO
year	NN	WHO
old	JJ	WHO
,	,	O
who	WP	O
generally	RB	O
receive	VBP	O
a	DT	O
2.5	CD	O
%	NN	O
amino	NN	O
acid	JJ	O
solution	NN	O
.	.	O

Read	VB	O
all	PDT	O
the	DT	O
instructions	NNS	O
carefully	RB	O
before	IN	O
using	VBG	O
the	DT	O
prefilled	JJ	O
syringe	NN	O
.	.	O

After	IN	O
the	DT	O
counter	NN	O
has	VBZ	O
advanced	VBN	O
to	TO	O
“	VB	O
8	CD	O
”	NN	O
,	,	O
the	DT	O
patient	NN	O
should	MD	O
continue	VB	O
to	TO	O
push	VB	O
down	RP	O
on	IN	O
the	DT	O
finger	NN	O
grips	VBZ	O
a	DT	O
total	NN	O
of	IN	O
four	CD	DOS
times	NNS	UNIT
in	IN	O
order	NN	O
to	TO	O
expel	VB	O
any	DT	O
residual	JJ	O
medicine	NN	O
from	IN	O
the	DT	O
bottle	NN	O
.	.	O

Note	NN	O
:	:	O
Do	NNP	O
not	RB	O
administer	VB	O
OraVerse	NNP	O
if	IN	O
particulate	JJ	O
matter	NN	O
,	,	O
discoloration	NN	O
,	,	O
cracks	NNS	O
in	IN	O
the	DT	O
glass	NN	O
,	,	O
protruding	VBG	O
plungers	NNS	O
or	CC	O
other	JJ	O
defects	NNS	O
are	VBP	O
observed	VBN	O
.	.	O

The	DT	O
patient	NN	O
's	POS	O
asthma	NN	O
should	MD	O
be	VB	O
reasonably	RB	O
stable	JJ	O
before	IN	O
treatment	NN	O
with	IN	O
AEROBID	NNP	O
is	VBZ	O
started	VBN	O
.	.	O

Propofol	NNP	O
injectable	JJ	O
emulsion	NN	O
has	VBZ	O
been	VBN	O
well	RB	O
-	:	O
studied	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
coronary	JJ	WHO
artery	NN	WHO
disease	NN	WHO
,	,	O
but	CC	O
experience	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hemodynamically	RB	WHO
significant	JJ	WHO
valvular	NN	WHO
or	CC	O
congenital	JJ	O
heart	NN	O
disease	NN	O
is	VBZ	O
limited	VBN	O
.	.	O

Dosage	NN	O
is	VBZ	O
not	RB	O
based	VBN	O
on	IN	O
weight	NN	O
or	CC	O
adjusted	VBN	O
for	IN	O
age	NN	O
.	.	O

Figure	NN	O
J	NNP	O

Intermittent	JJ	O
courses	NNS	O
of	IN	O
carboplatin	NN	O
injection	NN	O
in	IN	O
combination	NN	O
with	IN	O
cyclophosphamide	NN	O
should	MD	O
not	RB	O
be	VB	O
repeated	VBN	O
until	IN	O
the	DT	O
neutrophil	JJ	O
count	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
2,000	CD	O
and	CC	O
the	DT	O
platelet	NN	O
count	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
100,000	CD	O
.	.	O

While	IN	O
no	DT	O
fixed	JJ	O
relationship	NN	O
has	VBZ	O
been	VBN	O
established	VBN	O
,	,	O
blood	NN	O
concentration	NN	O
monitoring	NN	O
may	MD	O
assist	VB	O
in	IN	O
the	DT	O
clinical	JJ	O
evaluation	NN	O
of	IN	O
rejection	NN	O
and	CC	O
toxicity	NN	O
,	,	O
dose	JJ	O
adjustments	NNS	O
,	,	O
and	CC	O
the	DT	O
assessment	NN	O
of	IN	O
compliance	NN	O
.	.	O

Frequent	JJ	O
communication	NN	O
is	VBZ	O
important	JJ	O
among	IN	O
the	DT	O
prescriber	NN	O
,	,	O
other	JJ	O
members	NNS	O
of	IN	O
the	DT	O
healthcare	NN	O
team	NN	O
,	,	O
the	DT	O
patient	NN	O
,	,	O
and	CC	O
the	DT	O
caregiver	NN	O
/	NNP	O
family	NN	O
during	IN	O
periods	NNS	O
of	IN	O
changing	VBG	O
analgesic	JJ	O
requirements	NNS	O
,	,	O
including	VBG	O
initial	JJ	O
titration	NN	O
.	.	O

In	IN	O
addition	NN	O
to	TO	O
the	DT	O
general	JJ	O
precautions	NNS	O
previously	RB	O
described	VBN	O
,	,	O
moderate	JJ	O
decreases	NNS	O
in	IN	O
blood	NN	O
pressure	NN	O
occur	VBZ	O
frequently	RB	O
with	IN	O
intra	JJ	O
-	:	O
arterial	NN	O
(	(	O
brachial	JJ	O
)	)	O
injections	NNS	O
.	.	O

Each	DT	O
patient	NN	O
should	MD	O
be	VB	O
titrated	VBN	O
to	TO	O
their	PRP$	O
optimal	JJ	O
dosage	NN	O
based	VBN	O
on	IN	O
blood	NN	O
glucose	JJ	O
monitoring	NN	O
results	NNS	O
.	.	O

Acute	NNP	O
lymphoblastic	JJ	O
leukemia	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
and	CC	WHO
young	JJ	WHO
adolescents	NNS	WHO
is	VBZ	O
the	DT	O
most	RBS	O
responsive	JJ	O
to	TO	O
present	JJ	O
day	NN	O
chemotherapy	NN	O
.	.	O

Dosage	NN	O
for	IN	O
infants	NNS	WHO
and	CC	WHO
children	NNS	WHO
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
proportion	NN	O
to	TO	O
age	NN	O
and	CC	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	O
oral	JJ	O
dose	NN	O
is	VBZ	O
240	CD	DOS
mL	NN	UNIT
(	(	O
8fl	CD	O
.	.	O

The	DT	O
reusable	JJ	O
edex®	NN	O
(	(	O
alprostadil	NN	O
for	IN	O
injection	NN	O
)	)	O
injection	NN	O
device	NN	O
is	VBZ	O
for	IN	O
use	NN	O
only	RB	O
with	IN	O
the	DT	O
cartridges	NNS	O
and	CC	O
needles	NNS	O
included	VBN	O
in	IN	O
the	DT	O
edex®	NN	O
(	(	O
alprostadil	NN	O
for	IN	O
injection	NN	O
)	)	O
Cartridge	NN	O
Packs	NNP	O
.	.	O

The	DT	O
required	JJ	O
illumination	NN	O
time	NN	O
(	(	O
7	CD	O
-	:	O
10	CD	O
minutes	NNS	O
)	)	O
is	VBZ	O
calculated	VBN	O
automatically	RB	O
,	,	O
and	CC	O
remaining	VBG	O
time	NN	O
will	MD	O
be	VB	O
displayed	VBN	O
at	IN	O
the	DT	O
control	NN	O
panel	NN	O
.	.	O

Subcutaneous	JJ	O
or	CC	O
Intramuscular	JJ	O
Administration	NN	O

The	DT	O
dose	NN	O
of	IN	O
lactulose	NN	O
for	IN	O
this	DT	O
purpose	NN	O
is	VBZ	O
the	DT	O
same	JJ	O
as	IN	O
the	DT	O
recommended	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
.	.	O

Therefore	RB	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
Lactated	NNP	O
Ringer†s	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
not	RB	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
diluent	NN	O
in	IN	O
preparing	VBG	O
solutions	NNS	O
of	IN	O
TRACRIUM	NNP	O
(	(	O
atracurium	JJ	O
besylate	NN	O
)	)	O
for	IN	O
infusion	NN	O
.	.	O

Most	JJS	WHO
patients	NNS	WHO
require	VBP	WHO
3	CD	WHO
-	:	WHO
4	CD	WHO
tablets	NNS	WHO
with	IN	O
each	DT	O
meal	NN	O
.	.	O

Increases	NNS	O
in	IN	O
serum	NN	O
uric	JJ	O
acid	NN	O
and	CC	O
decreases	NNS	O
in	IN	O
serum	NN	O
potassium	NN	O
are	VBP	O
dose	JJ	O
-	:	O
related	VBN	O
over	IN	O
the	DT	O
15	CD	DOS
-	:	O
50	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
range	NN	O
and	CC	O
beyond	IN	O
.	.	O

Follow	NNP	O
applicable	JJ	O
special	JJ	O
handling	NN	O
and	CC	O
disposal	NN	O
procedures	NNS	O
[	VBP	O
see	VB	O
REFERENCES	NNP	O
]	NNP	O
.	.	O

More	RBR	O
recently	RB	O
corticosteroid	JJ	O
therapy	NN	O
,	,	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
antileukemic	JJ	O
drugs	NNS	O
or	CC	O
in	IN	O
cyclic	JJ	O
combinations	NNS	O
with	IN	O
methotrexate	NN	O
included	VBN	O
,	,	O
has	VBZ	O
appeared	VBN	O
to	TO	O
produce	VB	O
rapid	JJ	O
and	CC	O
effective	JJ	O
remissions	NNS	O
.	.	O

This	DT	O
may	MD	O
be	VB	O
prevented	VBN	O
by	IN	O
using	VBG	O
solutions	NNS	O
containing	VBG	O
adequate	JJ	O
amounts	NNS	O
of	IN	O
inorganic	JJ	O
electrolytes	NNS	O
and	CC	O
/	NN	O
or	CC	O
controlling	VBG	O
the	DT	O
volume	NN	O
and	CC	O
speed	NN	O
of	IN	O
administration	NN	O
.	.	O

Instruct	NN	O
patients	NNS	O
to	TO	O
prepare	VB	O
the	DT	O
inhaler	NN	O
for	IN	O
use	NN	O
by	IN	O
pulling	VBG	O
the	DT	O
built	VBN	O
-	:	O
in	IN	O
purple	JJ	O
actuator	NN	O
out	IN	O
from	IN	O
the	DT	O
gray	JJ	O
spacer	NN	O
and	CC	O
snapping	VBG	O
into	IN	O
an	DT	O
“	JJ	O
L	NNP	O
”	NNP	O
shape	NN	O
prior	RB	O
to	TO	O
use	VB	O
.	.	O

These	DT	O
patients	NNS	O
were	VBD	O
discontinued	VBN	O
from	IN	O
those	DT	O
medications	NNS	O
and	CC	O
randomized	VBN	O
to	TO	O
either	DT	O
aripiprazole	JJ	O
15	CD	DOS
mg	JJ	UNIT
/	JJ	FREQ
day	NN	FREQ
or	CC	O
placebo	NN	O
,	,	O
and	CC	O
observed	VBD	O
for	IN	O
relapse	NN	O
[	NNP	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

Symptoms	NNS	O
associated	VBN	O
with	IN	O
discontinuation	NN	O
of	IN	O
PAXIL	NNP	O
have	VBP	O
been	VBN	O
reported	VBN	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
:	:	O
Discontinuation	NN	O
of	IN	O
Treatment	NNP	O
With	IN	O
PAXIL	NNP	O
)	)	O
.	.	O

This	DT	O
should	MD	O
include	VB	O
measurement	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
just	RB	O
prior	RB	O
to	TO	O
the	DT	O
next	JJ	O
dose	NN	O
(	(	O
“	JJ	O
trough	IN	O
”	JJ	O
blood	NN	O
pressure	NN	O
)	)	O
to	TO	O
ensure	VB	O
that	IN	O
the	DT	O
treatment	NN	O
effect	NN	O
is	VBZ	O
present	JJ	O
for	IN	O
a	DT	O
full	JJ	O
24	CD	O
hours	NNS	O
.	.	O

Always	NNS	O
wear	VBP	O
gloves	NNS	O
when	WRB	O
handling	VBG	O
IONSYS	NNP	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
Tenex	NNP	O
(	(	O
guanfacine	JJ	O
hydrochloride	NN	O
)	)	O
when	WRB	O
given	VBN	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
another	DT	O
antihypertensive	JJ	O
drug	NN	O
is	VBZ	O
1	CD	DOS
mg	JJ	UNIT
daily	JJ	FREQ
given	VBN	O
at	IN	O
bedtime	NN	O
to	TO	O
minimize	VB	O
somnolence	NN	O
.	.	O

8	CD	O
.	.	O

The	DT	O
factor	NN	O
VIII	NNP	O
level	NN	O
should	MD	O
be	VB	O
checked	VBN	O
to	TO	O
assure	VB	O
that	IN	O
the	DT	O
expected	JJ	O
level	NN	O
is	VBZ	O
achieved	VBN	O
before	IN	O
the	DT	O
patient	NN	O
goes	VBZ	O
to	TO	O
surgery	VB	O
.	.	O

Various	JJ	O
assays	NNS	O
have	VBP	O
been	VBN	O
used	VBN	O
to	TO	O
measure	VB	O
blood	NN	O
concentrations	NNS	O
of	IN	O
cyclosporine	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

ACAM2000	NN	O
should	MD	O
only	RB	O
be	VB	O
reconstituted	VBN	O
with	IN	O
0.3	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
diluent	NN	O
provided	VBD	O
.	.	O

During	IN	O
treatment	NN	O
,	,	O
the	DT	O
dose	NN	O
may	MD	O
be	VB	O
adjusted	VBN	O
according	VBG	O
to	TO	O
response	NN	O
of	IN	O
the	DT	O
disease	NN	O
and	CC	O
/	NN	O
or	CC	O
the	DT	O
appearance	NN	O
of	IN	O
clinical	JJ	O
side	NN	O
effects	NNS	O
-	:	O
some	DT	O
of	IN	O
which	WDT	O
may	MD	O
be	VB	O
dose	RB	O
related	VBN	O
.	.	O

Further	JJ	O
adjustment	NN	O
may	MD	O
be	VB	O
needed	VBN	O
depending	VBG	O
upon	JJ	O
clinical	JJ	O
condition	NN	O
.	.	O

Dosage	NN	O
is	VBZ	O
considered	VBN	O
adequate	JJ	O
when	WRB	O
the	DT	O
activated	VBN	O
partial	JJ	O
thromboplastin	NN	O
time	NN	O
(	(	O
APTT	NNP	O
)	)	O
is	VBZ	O
1.5	CD	DOS
to	TO	O
2	CD	O
times	NNS	O
normal	JJ	O
or	CC	O
when	WRB	O
the	DT	O
whole	JJ	O
blood	NN	O
clotting	NN	O
time	NN	O
is	VBZ	O
elevated	VBN	O
approximately	RB	O
2.5	CD	DOS
to	TO	O
3	CD	FREQ
times	NNS	O
the	DT	O
control	NN	O
value	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
treatment	NN	O
of	IN	O
nasal	JJ	O
congestion	NN	O
associated	VBN	O
with	IN	O
seasonal	JJ	O
allergic	JJ	O
rhinitis	NN	O
is	VBZ	O
two	CD	DOS
sprays	NNS	UNIT
(	(	O
50	CD	DOS
mcg	NN	UNIT
of	IN	O
mometasone	NN	O
furoate	NN	O
in	IN	O
each	DT	O
spray	NN	O
)	)	O
in	IN	O
each	DT	O
nostril	NN	O
once	RB	FREQ
daily	JJ	FREQ
(	(	O
total	JJ	O
daily	RB	FREQ
dose	NN	O
of	IN	O
200	CD	DOS
mcg	NN	UNIT
)	)	O
.	.	O

Due	NNP	O
to	TO	O
an	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
post	NN	O
-	:	O
transplant	NN	O
lymphoproliferative	JJ	O
disorder	NN	O
(	(	O
PTLD	NNP	O
)	)	O
predominantly	RB	O
involving	VBG	O
the	DT	O
central	JJ	O
nervous	JJ	O
system	NN	O
(	(	O
CNS	NNP	O
)	)	O
,	,	O
progressive	JJ	O
multifocal	JJ	O
leukoencephalopathy	NN	O
(	(	O
PML	NNP	O
)	)	O
,	,	O
and	CC	O
serious	JJ	O
CNS	NNP	O
infections	NNS	O
,	,	O
administration	NN	O
of	IN	O
higher	JJR	O
than	IN	O
the	DT	O
recommended	JJ	O
doses	NNS	O
or	CC	O
more	JJR	O
frequent	JJ	O
dosing	NN	O
of	IN	O
NULOJIX	NNP	O
is	VBZ	O
not	RB	O
recommended	JJ	O
[	NNS	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
ADVERSE	NNP	O
REACTIONS	NNP	O
]	NNP	O
.	.	O

Administer	NNP	O
NEURONTIN	NNP	O
orally	RB	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

It	PRP	O
is	VBZ	O
important	JJ	O
that	IN	O
these	DT	O
recommendations	NNS	O
be	VB	O
followed	VBN	O
closely	RB	O
.	.	O

Dosage	NN	O
is	VBZ	O
500	CD	DOS
mg	NN	UNIT
to	TO	O
1000	CD	DOS
mg	NN	UNIT
daily	RB	FREQ
,	,	O
in	IN	O
divided	JJ	O
doses	NNS	O
using	VBG	O
tablets	NNS	O
or	CC	O
sustained	VBN	O
-	:	O
release	NN	O
capsules	NNS	O
as	IN	O
appropriate	NN	O
.	.	O

Dosage	NN	O
should	MD	O
be	VB	O
increased	VBN	O
more	RBR	O
gradually	RB	O
in	IN	O
elderly	JJ	WHO
patients	NNS	WHO
.	.	O

This	DT	O
is	VBZ	O
due	JJ	O
,	,	O
in	IN	O
part	NN	O
,	,	O
to	TO	O
the	DT	O
action	NN	O
of	IN	O
the	DT	O
medication	NN	O
on	IN	O
deep	JJ	O
,	,	O
previously	RB	O
unseen	JJ	O
lesions	NNS	O
and	CC	O
should	MD	O
not	RB	O
be	VB	O
considered	VBN	O
a	DT	O
reason	NN	O
to	TO	O
discontinue	VB	O
therapy	NN	O
.	.	O

Remove	VB	O
the	DT	O
vial	NN	O
(	(	O
2.5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
corresponding	VBG	O
to	TO	O
0.5	CD	DOS
mg	NNS	UNIT
ocriplasmin	RB	O
)	)	O
from	IN	O
the	DT	O
freezer	NN	O
and	CC	O
allow	VB	O
to	TO	O
thaw	VB	O
at	IN	O
room	NN	O
temperature	NN	O
(	(	O
within	IN	O
a	DT	O
few	JJ	O
minutes	NNS	O
)	)	O
.	.	O

An	DT	O
audible	JJ	O
and	CC	O
tactile	JJ	O
“	NNP	O
click	NN	O
”	NNP	O
verifies	VBZ	O
a	DT	O
locked	JJ	O
position	NN	O
for	IN	O
the	DT	O
safety	NN	O
shield	NN	O
(	(	O
Figure	NNP	O
17	CD	O
)	)	O
.	.	O

For	IN	O
other	JJ	O
wounds	NNS	O
,	,	O
a	DT	O
booster	NN	O
is	VBZ	O
appropriate	JJ	O
if	IN	O
the	DT	O
patient	NN	O
has	VBZ	O
not	RB	O
received	VBN	O
tetanus	NN	O
toxoid	NN	O
(	(	O
tetanus	NN	O
(	(	O
tetanus	IN	O
toxoid	NN	O
)	)	O
toxoid	NN	O
)	)	O
within	IN	O
the	DT	O
preceding	VBG	O
five	CD	O
years	NNS	O
.	.	O

If	IN	O
the	DT	O
duration	NN	O
of	IN	O
erection	NN	O
is	VBZ	O
longer	JJR	O
than	IN	O
1	CD	O
hour	NN	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
edex®	NN	O
(	(	O
alprostadil	NN	O
for	IN	O
injection	NN	O
)	)	O
should	MD	O
be	VB	O
reduced	VBN	O
.	.	O

The	DT	O
starting	VBG	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
the	DT	O
tablet	NN	O
formulation	NN	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
was	VBD	O
2	CD	DOS
mg	NN	UNIT
,	,	O
which	WDT	O
was	VBD	O
titrated	VBN	O
to	TO	O
5	CD	DOS
mg	NNS	UNIT
after	IN	O
2	CD	O
days	NNS	O
and	CC	O
to	TO	O
the	DT	O
target	NN	O
dose	NN	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
after	IN	O
2	CD	O
additional	JJ	O
days	NNS	O
.	.	O

Any	DT	O
patient	JJ	O
complaint	NN	O
of	IN	O
pain	NN	O
warrants	NNS	O
stopping	VBG	O
the	DT	O
injection	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
failure	NN	WHO
and	CC	O
hepatic	JJ	O
insufficiency	NN	O
,	,	O
measurement	NN	O
of	IN	O
serum	NN	O
levels	NNS	O
of	IN	O
piperacillin	NN	O
will	MD	O
provide	VB	O
additional	JJ	O
guidance	NN	O
for	IN	O
adjusting	VBG	O
dosage	NN	O
.	.	O

Table	JJ	O
3	CD	O
:	:	O
Kyprolis	NNP	O
Monotherapy	NNP	O
(	(	O
10	CD	O
-	:	O
Minute	NNP	O
Infusion	NNP	O
)	)	O

10	CD	DOS
to	TO	O
30	CD	DOS
mg	NN	UNIT
every	DT	FREQ
4	CD	FREQ
hours	NNS	FREQ
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
physician	NN	O
.	.	O

Use	NNP	O
lower	JJR	O
initial	JJ	O
doses	NNS	O
for	IN	O
patients	NNS	WHO
whose	WP$	WHO
tolerance	NN	WHO
is	VBZ	O
expected	VBN	O
to	TO	O
be	VB	O
low	JJ	O
at	IN	O
treatment	NN	O
entry	NN	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
atrophic	JJ	O
vaginitis	NN	O
,	,	O
or	CC	O
kraurosis	NN	O
vulvae	NN	O
associated	VBN	O
with	IN	O
the	DT	O
menopause	NN	O
.	.	O

Periodic	NNP	O
re	SYM	O
-	:	O
evaluation	NN	O
of	IN	O
the	DT	O
need	NN	O
for	IN	O
therapy	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

If	IN	O
a	DT	O
patient	NN	O
has	VBZ	O
been	VBN	O
receiving	VBG	O
opioid	JJ	O
-	:	O
containing	NN	O
medications	NNS	O
prior	RB	O
to	TO	O
taking	VBG	O
ROXICODONE®	NNP	O
,	,	O
the	DT	O
potency	NN	O
of	IN	O
the	DT	O
prior	JJ	O
opioid	JJ	O
relative	NN	O
to	TO	O
oxycodone	VB	O
should	MD	O
be	VB	O
factored	VBN	O
into	IN	O
the	DT	O
selection	NN	O
of	IN	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
(	(	O
TDD	NNP	O
)	)	O
of	IN	O
oxycodone	NN	O
.	.	O

The	DT	O
dose	NN	O
should	MD	O
be	VB	O
titrated	VBN	O
to	TO	O
the	DT	O
needs	NNS	O
of	IN	O
the	DT	O
patient	NN	O
and	CC	O
will	MD	O
depend	VB	O
on	IN	O
the	DT	O
premedication	NN	O
and	CC	O
type	NN	O
of	IN	O
anesthesia	NN	O
being	VBG	O
employed	VBN	O
,	,	O
the	DT	O
characteristics	NNS	O
of	IN	O
the	DT	O
particular	JJ	O
patient	NN	O
,	,	O
and	CC	O
the	DT	O
nature	NN	O
and	CC	O
duration	NN	O
of	IN	O
the	DT	O
operative	JJ	O
procedure	NN	O
.	.	O

This	DT	O
drug	NN	O
should	MD	O
be	VB	O
administered	VBN	O
by	IN	O
or	CC	O
under	IN	O
the	DT	O
supervision	NN	O
of	IN	O
experienced	JJ	O
clinicians	NNS	O
familiar	JJ	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
agents	NNS	O
which	WDT	O
reverse	VBP	O
or	CC	O
antagonize	VBP	O
the	DT	O
effects	NNS	O
of	IN	O
neuromuscular	JJ	O
blocking	VBG	O
agents	NNS	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Dosage	NN	O
of	IN	O
ZERBAXA	NNP	O
1.5	CD	DOS
g	NN	UNIT
(	(	O
ceftolozane	JJ	O
1	CD	DOS
g	NN	UNIT
and	CC	O
tazobactam	$	O
0.5	CD	DOS
g	NN	UNIT
)	)	O
by	IN	O
Infection	NNP	O
in	IN	O
Patients	NNP	WHO
with	IN	WHO
Creatinine	NNP	WHO
Clearance	NNP	WHO
(	(	WHO
CrCl	NNP	WHO
)	)	O
Greater	NNP	O
than	IN	O
50	CD	DOS
mL	JJ	UNIT
/	CD	O
min	NN	O

Conversion	NN	O
from	IN	O
the	DT	O
same	JJ	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
another	DT	O
extended	VBN	O
-	:	O
release	NN	O
morphine	JJ	O
product	NN	O
to	TO	O
KADIAN	NNP	O
may	MD	O
lead	VB	O
to	TO	O
either	DT	O
excessive	JJ	O
sedation	NN	O
at	IN	O
peak	NN	O
or	CC	O
inadequate	JJ	O
analgesia	NN	O
at	IN	O
trough	NN	O
.	.	O

Allow	IN	O
the	DT	O
XYNTHA	NNP	O
vial	NN	O
and	CC	O
the	DT	O
prefilled	JJ	O
diluent	NN	O
syringe	NN	O
to	TO	O
reach	VB	O
room	NN	O
temperature	NN	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
disseminated	JJ	O
infection	NN	O
due	JJ	O
to	TO	O
Mycobacterium	NNP	O
avium	NN	O
complex	NN	O
(	(	O
MAC	NNP	O
)	)	O
,	,	O
BIAXIN	NNP	O
Filmtab	NNP	O
and	CC	O
BIAXIN	NNP	O
Granules	NNP	O
are	VBP	O
recommended	VBN	O
as	IN	O
the	DT	O
primary	JJ	O
agents	NNS	O
.	.	O

The	DT	O
dose	NN	O
is	VBZ	O
dependent	JJ	O
upon	IN	O
the	DT	O
individual	JJ	O
requirements	NNS	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

Dosage	NN	O
adjustment	NN	O
is	VBZ	O
not	RB	O
required	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
renal	JJ	WHO
function	NN	WHO
.	.	O

FUNGIZONE	NNP	O
Intravenous	NNP	O
(	(	O
Amphotericin	NNP	O
B	NNP	O
for	IN	O
Injection	NNP	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
by	IN	O
slow	JJ	O
intravenous	JJ	O
infusion	NN	O
.	.	O

Step	NN	O
18	CD	O
.	.	O

Each	DT	O
200	CD	DOS
mg	NN	UNIT
of	IN	O
Vibramycin	NNP	O
(	(	O
i.e	NN	O
,	,	O
withdraw	JJ	O
entire	JJ	O
solution	NN	O
from	IN	O
the	DT	O
200	CD	DOS
mg	JJ	UNIT
vial	NN	UNIT
)	)	O
is	VBZ	O
further	JJ	O
diluted	VBN	O
with	IN	O
200	CD	DOS
mL	NNS	UNIT
to	TO	O
2000	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
following	VBG	O
intravenous	JJ	O
solutions	NNS	O
:	:	O

Areas	NNS	O
to	TO	O
be	VB	O
treated	VBN	O
should	MD	O
be	VB	O
cleansed	VBN	O
before	IN	O
application	NN	O
of	IN	O
METROGEL®	NNP	O
(	(	O
metronidazole	JJ	O
topical	JJ	O
gel	NN	O
)	)	O
Topical	NNP	O
Gel	NNP	O
.	.	O

DOSAGE	NN	O
MUST	NNP	O
BE	NNP	O
INDIVIDUALIZED	NNP	O
.	.	O

To	TO	O
determine	VB	O
the	DT	O
injection	NN	O
volume	NN	O
to	TO	O
be	VB	O
administered	VBN	O
,	,	O
first	JJ	O
identify	VB	O
the	DT	O
patient	NN	O
's	POS	O
total	JJ	O
dose	NN	O
in	IN	O
micrograms	NNS	O
(	(	O
mcg	NN	O
)	)	O
using	VBG	O
the	DT	O
dosing	VBG	O
information	NN	O
in	IN	O
Section	NN	O
2.1	CD	O
.	.	O

After	IN	O
several	JJ	O
months	NNS	O
on	IN	O
treatment	NN	O
,	,	O
bleeding	NN	O
may	MD	O
be	VB	O
reduced	VBN	O
to	TO	O
a	DT	O
point	NN	O
of	IN	O
virtual	JJ	O
absence	NN	O
.	.	O

Note	NN	O
:	:	O
Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

When	WRB	O
frequent	JJ	O
injections	NNS	O
are	VBP	O
needed	VBN	O
,	,	O
the	DT	O
drug	NN	O
should	MD	O
be	VB	O
administered	VBN	O
intramuscularly	RB	O
.	.	O

It	PRP	O
is	VBZ	O
advisable	JJ	O
that	IN	O
a	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
more	JJR	O
than	IN	O
100	CD	DOS
mg	NN	UNIT
should	MD	O
be	VB	O
given	VBN	O
in	IN	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

Children	NNS	WHO

For	IN	O
intermittent	JJ	O
IV	NNP	O
infusion	NN	O
with	IN	O
a	DT	O
Y	NNP	O
-	:	O
type	NN	O
administration	NN	O
set	VBN	O
,	,	O
dosing	VBG	O
can	MD	O
be	VB	O
accomplished	VBN	O
through	IN	O
the	DT	O
tubing	NN	O
system	NN	O
by	IN	O
which	WDT	O
the	DT	O
patient	NN	O
may	MD	O
be	VB	O
receiving	VBG	O
other	JJ	O
IV	NNP	O
solutions	NNS	O
.	.	O

Injection	NN	O
sites	NNS	O
should	MD	O
be	VB	O
separated	VBN	O
by	IN	O
at	IN	O
least	JJS	O
2	CD	O
inches	NNS	O
(	(	O
5	CD	DOS
cm	NN	UNIT
)	)	O
and	CC	O
away	RB	O
from	IN	O
the	DT	O
anatomical	JJ	O
site	NN	O
of	IN	O
attack	NN	O
.	.	O

Although	IN	O
drug	NN	O
dependence	NN	O
does	VBZ	O
not	RB	O
occur	VB	O
,	,	O
sudden	JJ	O
withdrawal	NN	O
of	IN	O
H.P	NNP	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
the	DT	O
solution	NN	O
if	IN	O
it	PRP	O
is	VBZ	O
discolored	VBN	O
or	CC	O
not	RB	O
clear	JJ	O
,	,	O
or	CC	O
if	IN	O
particulates	NNS	O
are	VBP	O
present	JJ	O
.	.	O

The	DT	O
probability	NN	O
of	IN	O
thrombocytopenia	NN	O
increases	NNS	O
significantly	RB	O
at	IN	O
total	JJ	O
trough	JJ	O
valproate	NN	O
plasma	NN	O
concentrations	NNS	O
above	IN	O
110	CD	DOS
mcg	NNS	UNIT
/	JJ	O
mL	NN	O
in	IN	O
females	NNS	O
and	CC	O
135	CD	DOS
mcg	NN	UNIT
/	NNP	O
mL	NN	O
in	IN	O
males	NNS	O
.	.	O

Discard	NNP	O
any	DT	O
unused	JJ	O
portion	NN	O
after	IN	O
24	CD	O
hours	NNS	O
if	IN	O
stored	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
(	(	O
20°	CD	O
to	TO	O
25°C	CD	O
[	NNS	O
68°	CD	O
to	TO	O
77°F	CD	O
]	NN	O
)	)	O
,	,	O
or	CC	O
after	IN	O
48	CD	O
hours	NNS	O
if	IN	O
stored	VBN	O
at	IN	O
refrigerated	JJ	O
temperature	NN	O
(	(	O
2°	CD	O
to	TO	O
8°C	CD	O
[	NNS	O
36°	CD	O
to	TO	O
46°F	CD	O
]	NN	O
)	)	O
.	.	O

Such	JJ	O
exposures	NNS	O
should	MD	O
be	VB	O
treated	VBN	O
like	IN	O
sexual	JJ	O
exposures	NNS	O
.	.	O

Continued	JJ	O
treatment	NN	O
is	VBZ	O
needed	VBN	O
to	TO	O
achieve	VB	O
maximum	JJ	O
therapeutic	JJ	O
benefits	NNS	O
;	:	O
further	JJ	O
adjustments	NNS	O
in	IN	O
dosage	NN	O
may	MD	O
be	VB	O
necessary	JJ	O
during	IN	O
the	DT	O
course	NN	O
of	IN	O
therapy	NN	O
to	TO	O
meet	VB	O
the	DT	O
patient	NN	O
's	POS	O
requirements	NNS	O
.	.	O

When	WRB	O
placed	VBN	O
within	IN	O
a	DT	O
periodontal	JJ	O
pocket	NN	O
,	,	O
Actisite	NNP	O
(	(	O
tetracycline	JJ	O
periodontal	NN	O
)	)	O
fiber	NN	O
provides	VBZ	O
continuous	JJ	O
release	NN	O
of	IN	O
tetracycline	NN	O
for	IN	O
10	CD	PER
days	NNS	PER
.	.	O

After	IN	O
observing	VBG	O
the	DT	O
response	NN	O
to	TO	O
initial	JJ	O
therapy	NN	O
with	IN	O
mefenamic	JJ	O
acid	NN	O
,	,	O
the	DT	O
dose	NN	O
and	CC	O
frequency	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
to	TO	O
suit	VB	O
an	DT	O
individual	JJ	O
patient	NN	O
's	POS	O
needs	NNS	O
.	.	O

1	CD	O
.	.	O

BUDEPRION	NNP	O
XL™	NNP	O
(	(	O
bupropion	NN	O
hydrochloride	NN	O
extended	VBD	O
-	:	O
release	NN	O
tablets	NNS	O
)	)	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	O
including	VBG	O
mild	NN	O
to	TO	O
moderate	VB	O
hepatic	JJ	O
cirrhosis	NN	O
)	)	O
and	CC	O
a	DT	O
reduced	JJ	O
frequency	NN	O
and	CC	O
/	NN	O
or	CC	O
dose	VB	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
to	TO	WHO
moderate	VB	WHO
hepatic	JJ	WHO
cirrhosis	NN	WHO
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
,	,	O
WARNINGS	NNP	O
,	,	O
and	CC	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

To	TO	O
wean	VB	O
INOmax	NNP	O
,	,	O
downtitrate	NN	O
in	IN	O
several	JJ	O
steps	NNS	O
,	,	O
pausing	VBG	O
several	JJ	O
hours	NNS	O
at	IN	O
each	DT	O
step	NN	O
to	TO	O
monitor	VB	O
for	IN	O
hypoxemia	NN	O
.	.	O

The	DT	O
recommended	JJ	O
total	NN	O
dose	NN	O
of	IN	O
VISIPAQUE	NNP	O
should	MD	O
not	RB	O
exceed	VB	O
2	CD	DOS
mL	JJ	UNIT
/	NNP	O
kg	NN	O
.	.	O

However	RB	O
,	,	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
to	TO	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
given	VBN	O
STIOLTO	NNP	O
RESPIMAT	NNP	O
should	MD	O
be	VB	O
monitored	VBN	O
closely	RB	O
for	IN	O
anticholinergic	JJ	O
effects	NNS	O
[	VBP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Average	JJ	O
daily	JJ	FREQ
dose	NN	O
for	IN	O
patients	NNS	WHO
under	IN	WHO
12	CD	WHO
years	NNS	WHO
was	VBD	WHO
274	CD	DOS
mcg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
with	IN	O
a	DT	O
range	NN	O
of	IN	O
24	CD	DOS
mcg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
to	TO	O
1,199	CD	DOS
mcg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

Chewable	JJ	O
Tablets	NNS	O
:	:	O
Start	NNP	O
with	IN	O
5	CD	DOS
mg	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
(	(	O
before	IN	O
breakfast	NN	O
and	CC	O
lunch	NN	O
)	)	O
with	IN	O
gradual	JJ	O
increments	NNS	O
of	IN	O
5	CD	DOS
to	TO	O
10	CD	DOS
mg	NNS	UNIT
weekly	RB	FREQ
.	.	O

As	IN	O
with	IN	O
other	JJ	O
bisphosphonates	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
Didronel	NNP	O
should	MD	O
be	VB	O
swallowed	VBN	O
with	IN	O
a	DT	O
full	JJ	O
glass	NN	O
of	IN	O
water	NN	O
(	(	O
6	CD	DOS
to	TO	O
8	CD	DOS
oz	NN	UNIT
)	)	O
.	.	O

For	IN	O
immunogenicity	NN	O
data	NNS	O
on	IN	O
the	DT	O
concomitant	JJ	O
administration	NN	O
of	IN	O
Tripedia	NNP	O
(	(	O
diphtheria	NN	O
and	CC	O
tetanus	NN	O
toxoids	NNS	O
and	CC	O
acellular	JJ	O
pertussis	NN	O
vaccine	NN	O
)	)	O
vaccine	NN	O
with	IN	O
ActHIB	NNP	O
vaccine	NN	O
,	,	O
OPV	NNP	O
vaccine	NN	O
,	,	O
and	CC	O
hepatitis	NN	O
B	NNP	O
vaccine	NN	O
,	,	O
and	CC	O
on	IN	O
the	DT	O
concomitant	JJ	O
administration	NN	O
of	IN	O
TriHIBit	NNP	O
vaccine	NN	O
(	(	O
ActHIB	NNP	O
vaccine	NN	O
reconstituted	VBN	O
with	IN	O
Tripedia	NNP	O
(	(	O
diphtheria	NN	O
and	CC	O
tetanus	NN	O
toxoids	NNS	O
and	CC	O
acellular	JJ	O
pertussis	NN	O
vaccine	NN	O
)	)	O
vaccine	NN	O
)	)	O
with	IN	O
MMR	NNP	O
vaccine	NN	O
,	,	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
section	NN	O
.	.	O

(	(	O
See	VB	O
PATIENT	NNP	O
INFORMATION	NNP	O
)	)	O

When	WRB	O
switching	VBG	O
dosage	NN	O
regimens	NNS	O
,	,	O
administer	VBP	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
the	DT	O
new	JJ	O
regimen	NNS	O
on	IN	O
the	DT	O
next	JJ	O
scheduled	JJ	O
date	NN	O
of	IN	O
the	DT	O
prior	JJ	O
regimen	NNS	O
.	.	O

Administration	NN	O
should	MD	O
not	RB	O
exceed	VB	O
4	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
/	NNP	O
hour	NN	O
unless	IN	O
the	DT	O
benefits	NNS	O
outweigh	VBP	O
the	DT	O
risks	NNS	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
HUMIRA	NNP	O
for	IN	O
patients	NNS	WHO
2	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
with	IN	WHO
polyarticular	JJ	WHO
juvenile	NN	WHO
idiopathic	JJ	WHO
arthritis	NN	WHO
(	(	O
JIA	NNP	O
)	)	O
is	VBZ	O
based	VBN	O
on	IN	O
weight	NN	O
as	IN	O
shown	VBN	O
below	IN	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
Gengraf®	NNP	O
(	(	O
cyclosporine	JJ	O
oral	JJ	O
solution	NN	O
,	,	O
USP	NNP	O
[	NNP	O
MODIFIED	NNP	O
]	NNP	O
)	)	O
should	MD	O
be	VB	O
2.5	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

When	WRB	O
the	DT	O
drug	NN	O
is	VBZ	O
used	VBN	O
chronically	RB	O
at	IN	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
,	,	O
patients	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
periodically	RB	O
for	IN	O
effects	NNS	O
on	IN	O
the	DT	O
hypothalamic	JJ	O
-	:	O
pituitary	JJ	O
-	:	O
adrenal	NN	O
(	(	O
HPA	NNP	O
)	)	O
axis	NN	O
.	.	O

FOR	IN	O
INTRAVENOUS	NNP	O
USE	NNP	O
ONLY	NNP	O
”	NNP	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

For	IN	O
children	NNS	WHO
over	IN	WHO
3	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
who	WP	WHO
have	VBP	WHO
a	DT	WHO
normal	JJ	WHO
lean	JJ	WHO
body	NN	WHO
mass	NN	WHO
and	CC	O
normal	JJ	O
body	NN	O
development	NN	O
,	,	O
the	DT	O
maximum	JJ	O
dose	NN	O
is	VBZ	O
determined	VBN	O
by	IN	O
the	DT	O
child	NN	O
's	POS	O
weight	NN	O
or	CC	O
age	NN	O
.	.	O

If	IN	O
a	DT	O
patient	NN	O
is	VBZ	O
taking	VBG	O
the	DT	O
lowest	JJS	O
dose	NN	O
,	,	O
1	CD	DOS
mcg	NN	UNIT
,	,	O
on	IN	O
the	DT	O
daily	JJ	FREQ
regimen	NNS	O
and	CC	O
a	DT	O
dose	JJ	O
reduction	NN	O
is	VBZ	O
needed	VBN	O
,	,	O
the	DT	O
dose	NN	O
can	MD	O
be	VB	O
decreased	VBN	O
to	TO	O
1	CD	DOS
mcg	NNS	UNIT
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
week	NN	FREQ
.	.	O

Administer	NNP	O
ZARXIO	NNP	O
at	IN	O
least	JJS	O
24	CD	O
hours	NNS	O
after	IN	O
cytotoxic	JJ	O
chemotherapy	NN	O
.	.	O

Dosages	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
angina	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
to	TO	O
each	DT	O
patient	NN	O
's	POS	O
needs	NNS	O
,	,	O
starting	VBG	O
with	IN	O
a	DT	O
dose	NN	O
of	IN	O
120	CD	DOS
or	CC	O
180	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Lexapro	NNP	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
.	.	O

When	WRB	O
transferring	VBG	O
patients	NNS	WHO
receiving	VBG	WHO
more	JJR	WHO
than	IN	O
40	CD	DOS
units	NNS	UNIT
of	IN	O
insulin	JJ	O
daily	JJ	FREQ
,	,	O
they	PRP	O
may	MD	O
be	VB	O
started	VBN	O
on	IN	O
a	DT	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
MICRONASE	NNP	O
Tablets	NNP	O
5	CD	DOS
mg	NN	UNIT
concomitantly	RB	O
with	IN	O
a	DT	O
50	CD	O
%	NN	O
reduction	NN	O
in	IN	O
insulin	NN	O
dose	NN	O
.	.	O

If	IN	O
acceptable	JJ	O
alternatives	NNS	O
to	TO	O
linezolid	VB	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	JJ	O
treatment	NN	O
are	VBP	O
not	RB	O
available	JJ	O
and	CC	O
the	DT	O
potential	JJ	O
benefits	NNS	O
of	IN	O
linezolid	JJ	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	JJ	O
treatment	NN	O
are	VBP	O
judged	VBN	O
to	TO	O
outweigh	VB	O
the	DT	O
risks	NNS	O
of	IN	O
hypertensive	JJ	O
reactions	NNS	O
in	IN	O
a	DT	O
particular	JJ	WHO
patient	NN	WHO
,	,	O
APLENZIN	NNP	O
should	MD	O
be	VB	O
stopped	VBN	O
promptly	RB	O
,	,	O
and	CC	O
linezolid	VBD	O
or	CC	O
intravenous	JJ	O
methylene	NNS	O
blue	VBP	O
can	MD	O
be	VB	O
administered	VBN	O
.	.	O

If	IN	O
such	JJ	O
bleeding	NN	O
occurs	NNS	O
,	,	O
discontinuance	NN	O
of	IN	O
heparin	NN	O
and	CC	O
neutralization	NN	O
with	IN	O
protamine	JJ	O
sulfate	NN	O
are	VBP	O
advisable	JJ	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Avoid	IN	O
the	DT	O
concomitant	JJ	O
use	NN	O
of	IN	O
potent	NN	O
UGT	NNP	O
inducers	NNS	O
(	(	O
e.g	NN	O
,	,	O
rifampicin	NN	O
,	,	O
phenytoin	NN	O
,	,	O
phenobarbital	NN	O
,	,	O
ritonavir	NN	O
)	)	O
with	IN	O
Exjade	NNP	O
.	.	O

Do	NNP	O
not	RB	O
crush	VB	O
,	,	O
break	VB	O
,	,	O
dissolve	VB	O
,	,	O
or	CC	O
chew	JJ	O
tablets	NNS	O
.	.	O

Apply	NNP	O
HALOG	NNP	O
SOLUTION	NNP	O
(	(	O
Halcinonide	NNP	O
Topical	NNP	O
Solution	NNP	O
,	,	O
USP	NNP	O
)	)	O
0.1	CD	O
%	NN	O
to	TO	O
the	DT	O
affected	JJ	O
area	NN	O
two	CD	FREQ
to	TO	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

OXILAN®	NNP	O
Injection	NNP	O
(	(	O
350	CD	DOS
mgI	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O
is	VBZ	O
indicated	VBN	O
for	IN	O
intraarterial	JJ	O
injection	NN	O
in	IN	O
the	DT	O
radiographic	JJ	O
contrast	NN	O
evaluation	NN	O
of	IN	O
the	DT	O
aorta	NN	O
and	CC	O
major	JJ	O
visceral	JJ	O
arterial	JJ	O
branches	NNS	O
.	.	O

Screw	NNP	O
the	DT	O
plastic	NN	O
rod	NN	O
into	IN	O
the	DT	O
blue	JJ	O
plunger	NN	O
.	.	O

The	DT	O
250	CD	DOS
mg	JJ	UNIT
solution	NN	UNIT
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
250	CD	DOS
to	TO	O
1000	CD	DOS
mL	NN	UNIT
,	,	O
the	DT	O
500	CD	DOS
mg	JJ	UNIT
solution	NN	UNIT
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
500	CD	DOS
to	TO	O
1000	CD	DOS
mL	NN	UNIT
,	,	O
and	CC	O
the	DT	O
1000	CD	DOS
mg	NN	UNIT
solution	NN	UNIT
to	TO	O
1000	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
same	JJ	O
diluents	NNS	O
.	.	O

With	IN	O
the	DT	O
syringe	NN	O
still	RB	O
connected	VBN	O
to	TO	O
the	DT	O
adapter	NN	O
,	,	O
gently	RB	O
swirl	VBZ	O
the	DT	O
vial	JJ	O
until	IN	O
the	DT	O
product	NN	O
is	VBZ	O
completely	RB	O
dissolved	VBN	O
.	.	O

Clinical	JJ	O
response	NN	O
,	,	O
side	NN	O
effects	NNS	O
,	,	O
and	CC	O
determination	NN	O
of	IN	O
age	NN	O
-	:	O
and	CC	O
gender	VB	O
-	:	O
adjusted	VBN	O
serum	NN	O
IGF	NNP	O
-	:	O
I	PRP	O
levels	NNS	O
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
guidance	NN	O
in	IN	O
dose	JJ	O
titration	NN	O
.	.	O

The	DT	O
patient	NN	O
then	RB	O
fully	RB	O
presses	NNS	O
and	CC	O
promptly	RB	O
releases	VBZ	O
the	DT	O
white	JJ	O
piercing	VBG	O
button	NN	O
on	IN	O
the	DT	O
device	NN	O
body	NN	O
to	TO	O
pierce	VB	O
the	DT	O
capsule	NN	O
inside	IN	O
the	DT	O
nosepiece	NN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
using	VBG	O
the	DT	O
sprinkle	JJ	O
administration	NN	O
method	NN	O
,	,	O
the	DT	O
sprinkled	JJ	O
applesauce	NN	O
should	MD	O
be	VB	O
consumed	VBN	O
immediately	RB	O
;	:	O
it	PRP	O
should	MD	O
not	RB	O
be	VB	O
stored	VBN	O
.	.	O

Combination	NN	O
therapy	NN	O
:	:	O

Neutrexin	NNP	O
(	(	O
trimetrexate	JJ	O
glucuronate	NN	O
inj	NN	O
)	)	O
should	MD	O
not	RB	O
be	VB	O
mixed	JJ	O
with	IN	O
solutions	NNS	O
containing	VBG	O
either	CC	O
chloride	JJ	O
ion	NN	O
or	CC	O
leucovorin	NN	O
,	,	O
since	IN	O
precipitation	NN	O
occurs	VBZ	O
instantly	RB	O
.	.	O

For	IN	O
active	JJ	O
tetanus	NN	O
immunization	NN	O
in	IN	O
wound	JJ	O
management	NN	O
of	IN	O
patients	NNS	WHO
7	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
,	,	O
a	DT	O
preparation	NN	O
containing	VBG	O
tetanus	NN	O
and	CC	O
diphtheria	NN	O
toxoids	NNS	O
is	VBZ	O
preferred	VBN	O
instead	RB	O
of	IN	O
single	JJ	DOS
-	:	O
antigen	NN	O
tetanus	NN	O
toxoid	NN	O
to	TO	O
enhance	VB	O
diphtheria	NN	O
protection.2	NN	O
DECAVAC	NNP	O
vaccine	NN	O
is	VBZ	O
approved	VBN	O
for	IN	O
wound	JJ	O
management	NN	O
of	IN	O
patients	NNS	WHO
7	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
.	.	O

Then	RB	O
apply	VB	O
gentle	JJ	O
pressure	NN	O
and	CC	O
snap	VB	O
the	DT	O
tablet	NN	O
segments	NNS	O
apart	RB	O
(	(	O
segments	NNS	O
breaking	VBG	O
incorrectly	RB	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
)	)	O
.	.	O

Usual	JJ	O
standard	NN	O
regimen	NNS	O

Such	JJ	O
doses	NNS	O
will	MD	O
normally	RB	O
produce	VB	O
an	DT	O
effective	JJ	O
serum	NN	O
lithium	NN	O
concentration	NN	O
ranging	VBG	O
between	IN	O
1.0	CD	O
and	CC	O
1.5	CD	O
mEq	NN	O
/	NNP	O
L	NNP	O
.	.	O

If	IN	O
necessary	JJ	O
,	,	O
the	DT	O
diluted	JJ	O
infusion	NN	O
solution	NN	O
may	MD	O
be	VB	O
stored	VBN	O
for	IN	O
up	RB	O
to	TO	O
4	CD	O
hours	NNS	O
at	IN	O
room	NN	O
temperature	NN	O
up	IN	O
to	TO	O
25°C	CD	O
(	(	O
77°F	CD	O
)	)	O
.	.	O

7	CD	O
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
rebound	NN	O
hypertension	NN	O
is	VBZ	O
low	JJ	O
,	,	O
but	CC	O
it	PRP	O
can	MD	O
occur	VB	O
.	.	O

Reduce	VB	O
the	DT	O
dose	NN	O
of	IN	O
DROXIA	NNP	O
by	IN	O
50	CD	O
%	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
creatinine	JJ	WHO
clearance	NN	WHO
of	IN	WHO
less	JJR	WHO
than	IN	O
60	CD	DOS
mL	JJ	UNIT
/	NNP	O
min	NN	O
or	CC	O
with	IN	O
end	JJ	O
-	:	O
stage	NN	O
renal	JJ	O
disease	NN	O
(	(	O
ESRD	NNP	O
)	)	O
[	NNP	O
see	VBP	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Transfer	NN	O
From	IN	O
Other	JJ	O
Hypoglycemic	NNP	O
Therapy	NNP	O
Patients	NNPS	O
Receiving	VBG	O
Other	JJ	O
Oral	NNP	O
Antidiabetic	NNP	O
Therapyγ¢††Transfer	NNP	O
of	IN	O
patients	NNS	O
from	IN	O
other	JJ	O
oral	JJ	O
antidiabetes	NNS	O
regimens	NNS	O
to	TO	O
TOLINASE	NNP	O
(	(	O
tolazamide	NN	O
)	)	O
should	MD	O
be	VB	O
done	VBN	O
conservatively	RB	O
.	.	O

In	IN	O
a	DT	O
patient	NN	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
a	DT	O
patient	NN	O
who	WP	O
is	VBZ	O
on	IN	O
a	DT	O
regimen	NN	O
of	IN	O
5	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
of	IN	O
NAMENDA	NNP	O
be	VB	O
switched	VBN	O
to	TO	O
NAMENDA	NNP	O
XR	NNP	O
14	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
capsules	NNS	O
the	DT	O
day	NN	O
following	VBG	O
the	DT	O
last	JJ	O
dose	NN	O
of	IN	O
5	CD	DOS
mg	JJ	UNIT
NAMENDA	NNP	O
.	.	O

To	TO	O
administer	VB	O
a	DT	O
third	JJ	O
vial	NN	O
,	,	O
open	VB	O
a	DT	O
new	JJ	O
RaplixaSpray	NNP	O
delivery	NN	O
device	NN	O
(	(	O
repeat	JJ	O
steps	NNS	O
1	CD	O
-	:	O
13	CD	O
)	)	O

Loss	NNP	O
of	IN	O
tolerance	NN	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
any	DT	WHO
patient	NN	WHO
who	WP	WHO
has	VBZ	WHO
not	RB	WHO
taken	VBN	WHO
opioids	NNS	WHO
for	IN	WHO
more	JJR	WHO
than	IN	WHO
5	CD	WHO
days	NNS	WHO
.	.	O

The	DT	O
safety	NN	O
of	IN	O
treating	VBG	O
,	,	O
on	IN	O
average	NN	O
,	,	O
more	JJR	O
than	IN	O
four	CD	DOS
headaches	NNS	UNIT
in	IN	O
a	DT	O
30	CD	O
-	:	O
day	NN	O
period	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	O

Because	IN	O
the	DT	O
sodium	NN	O
salt	NN	O
of	IN	O
naproxen	NN	O
is	VBZ	O
more	RBR	O
rapidly	RB	O
absorbed	VBN	O
,	,	O
ANAPROX	NNP	O
DS	NNP	O
is	VBZ	O
recommended	VBN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
acute	JJ	O
painful	JJ	O
conditions	NNS	O
when	WRB	O
prompt	JJ	O
onset	NN	O
of	IN	O
pain	NN	O
relief	NN	O
is	VBZ	O
desired	VBN	O
.	.	O

If	IN	O
continuous	JJ	O
IV	NNP	O
heparin	NN	O
infusion	NN	O
is	VBZ	O
used	VBN	O
,	,	O
prothrombin	JJ	O
time	NN	O
can	MD	O
usually	RB	O
be	VB	O
measured	VBN	O
at	IN	O
any	DT	O
time	NN	O
.	.	O

Rapid	JJ	O
drinking	NN	O
of	IN	O
each	DT	O
portion	NN	O
is	VBZ	O
preferred	VBN	O
to	TO	O
drinking	VBG	O
small	JJ	O
amounts	NNS	O
continuously	RB	O
.	.	O

Check	NNP	O
applicator	NN	O
function	NN	O
by	IN	O
removing	VBG	O
the	DT	O
obturator	NN	O
from	IN	O
the	DT	O
cannula	NN	O
and	CC	O
relocking	VBG	O
it	PRP	O
.	.	O

Very	RB	O
often	RB	O
,	,	O
the	DT	O
maintenance	NN	O
dose	NN	O
needs	NNS	O
to	TO	O
be	VB	O
adjusted	VBN	O
during	IN	O
the	DT	O
first	JJ	O
few	JJ	O
months	NNS	O
of	IN	O
therapy	NN	O
while	IN	O
patients	NNS	O
adjust	VBP	O
to	TO	O
changes	NNS	O
in	IN	O
lifestyle	NN	O
due	JJ	O
to	TO	O
the	DT	O
alleviation	NN	O
of	IN	O
spasticity	NN	O
.	.	O

The	DT	O
patient	NN	O
is	VBZ	O
given	VBN	O
instructions	NNS	O
in	IN	O
five	CD	O
(	(	O
5	CD	O
)	)	O
categories	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
of	IN	O
moexipril	NN	O
is	VBZ	O
7.5	CD	DOS
to	TO	O
30	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
,	,	O
administered	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
or	CC	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
one	CD	O
hour	NN	O
before	IN	O
meals	NNS	O
,	,	O
while	IN	O
hydrochlorothiazide	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
a	DT	O
dosage	NN	O
of	IN	O
12.5	CD	DOS
to	TO	O
50	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
.	.	O

A	DT	O
lower	JJR	O
starting	VBG	O
dose	JJ	O
and	CC	O
smaller	JJR	O
dose	NN	O
increments	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
for	IN	O
older	JJR	WHO
patients	NNS	WHO
,	,	WHO
who	WP	WHO
are	VBP	WHO
more	JJR	WHO
prone	NN	WHO
to	TO	O
the	DT	O
adverse	JJ	O
effects	NNS	O
of	IN	O
somatropin	NN	O
than	IN	O
younger	JJR	O
individuals	NNS	O
.	.	O

Tap	VB	O
the	DT	O
vial	NN	O
to	TO	O
reduce	VB	O
foaming	NN	O
and	CC	O
swirl	VB	O
the	DT	O
vial	JJ	O
occasionally	RB	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
if	IN	O
the	DT	O
solution	NN	O
is	VBZ	O
cloudy	JJ	O
or	CC	O
contains	VBZ	O
particulates	NNS	O
.	.	O

Major	JJ	O
electrolytes	NNS	O
are	VBP	O
sodium	JJ	O
,	,	O
chloride	NN	O
,	,	O
potassium	NN	O
,	,	O
phosphate	NN	O
,	,	O
magnesium	NN	O
and	CC	O
calcium	NN	O
.	.	O

Early	JJ	O
relief	NN	O
of	IN	O
symptoms	NNS	O
(	(	O
2	CD	DOS
to	TO	O
3	CD	PER
days	NNS	PER
)	)	O
is	VBZ	O
experienced	VBN	O
by	IN	O
the	DT	O
majority	NN	O
of	IN	O
patients	NNS	WHO
and	CC	WHO
clinical	JJ	WHO
improvement	NN	WHO
may	MD	O
be	VB	O
seen	VBN	O
fairly	RB	O
soon	RB	O
after	IN	O
treatment	NN	O
is	VBZ	O
begun	VBN	O
;	:	O
however	RB	O
,	,	O
Candida	NNP	O
infections	NNS	O
and	CC	O
tinea	NN	O
cruris	NNS	O
and	CC	O
corporis	NN	O
should	MD	O
be	VB	O
treated	VBN	O
for	IN	O
two	CD	PER
weeks	NNS	PER
and	CC	O
tinea	NN	O
pedis	NN	O
for	IN	O
one	CD	PER
month	NN	PER
in	IN	O
order	NN	O
to	TO	O
reduce	VB	O
the	DT	O
possibility	NN	O
of	IN	O
recurrence	NN	O
.	.	O

Previously	RB	WHO
unvaccinated	JJ	WHO
children	NNS	WHO
15	CD	WHO
to	TO	WHO
71	CD	WHO
months	NNS	WHO
of	IN	WHO
age	NN	WHO
receive	VBP	WHO
a	DT	WHO
single	JJ	WHO
injection	NN	WHO
of	IN	WHO
HibTITER	NNP	WHO
(	(	WHO
diphtheria	JJ	WHO
crm197	NN	WHO
protein	NN	WHO
conjugate	NN	WHO
)	)	WHO
.32,33	VBZ	WHO
Preterm	JJ	WHO
infants	NNS	WHO
should	MD	O
be	VB	O
vaccinated	VBN	O
with	IN	O
HibTITER	NNP	O
(	(	O
diphtheria	JJ	O
crm197	NN	O
protein	NN	O
conjugate	NN	O
)	)	O
according	VBG	O
to	TO	O
their	PRP$	O
chronological	JJ	O
age	NN	O
,	,	O
from	IN	O
birth.32	NN	O

There	EX	O
are	VBP	O
insufficient	JJ	O
data	NNS	O
to	TO	O
recommend	VB	O
a	DT	O
specific	JJ	O
dosage	NN	O
of	IN	O
EPIVIR	NNP	O
-	:	O
HBV	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
.	.	O

VPRIV	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
under	IN	O
the	DT	O
supervision	NN	O
of	IN	O
a	DT	O
healthcare	JJ	O
professional	NN	O
as	IN	O
a	DT	O
60	CD	DOS
-	:	O
minute	NN	O
intravenous	JJ	O
infusion	NN	O
.	.	O

OMNIPAQUE	RB	O
180	CD	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
180	CD	DOS
mgI	NNS	UNIT
/	JJ	O
mL	NN	O
administered	VBN	O
orally	RB	O
or	CC	O
rectally	RB	O
is	VBZ	O
indicated	VBN	O
in	IN	O
children	NNS	WHO
for	IN	O
use	NN	O
in	IN	O
examination	NN	O
of	IN	O
the	DT	O
gastrointestinal	JJ	O
tract	NN	O
.	.	O

The	DT	O
Neoral®	NNP	O
dose	NN	O
should	MD	O
subsequently	RB	O
be	VB	O
adjusted	VBN	O
to	TO	O
attain	VB	O
the	DT	O
pre	NN	O
-	:	O
conversion	NN	O
cyclosporine	NN	O
blood	NN	O
trough	IN	O
concentration	NN	O
.	.	O

ULTIVA	NNP	O
(	(	O
remifentanil	NN	O
)	)	O
is	VBZ	O
stable	JJ	O
for	IN	O
4	CD	PER
hours	NNS	PER
at	IN	O
room	NN	O
temperature	NN	O
after	IN	O
reconstitution	NN	O
and	CC	O
further	JJ	O
dilution	NN	O
to	TO	O
concentrations	NNS	O
of	IN	O
20	CD	DOS
to	TO	O
250	CD	DOS
mcg	NNS	UNIT
/	JJ	O
mL	NN	O
with	IN	O
Lactated	NNP	O
Ringer	NNP	O
's	POS	O
Injection	NNP	O
,	,	O
USP	NNP	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

(	(	O
See	VB	O
ADVERSE	NNP	O
REACTIONS	NNP	O
.	.	O
)	)	O

The	DT	O
use	NN	O
of	IN	O
DOT	NNP	O
can	MD	O
help	VB	O
assure	VB	O
patient	JJ	O
compliance	NN	O
with	IN	O
drug	NN	O
therapy	NN	O
.	.	O

General	NNP	O
:	:	O
Recommended	VBD	O
dosages	NNS	O
of	IN	O
digoxin	NN	O
may	MD	O
require	VB	O
considerable	JJ	O
modification	NN	O
because	IN	O
of	IN	O
individual	JJ	O
sensitivity	NN	O
of	IN	O
the	DT	O
patient	NN	O
to	TO	O
the	DT	O
drug	NN	O
,	,	O
the	DT	O
presence	NN	O
of	IN	O
associated	JJ	O
conditions	NNS	O
,	,	O
or	CC	O
the	DT	O
use	NN	O
of	IN	O
concurrent	JJ	O
medications	NNS	O
.	.	O

Usual	NNP	O
dose	VBD	O
5	CD	DOS
mg	NN	UNIT
to	TO	O
60	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
response	NN	O
.	.	O

If	IN	O
dose	JJ	O
reduction	NN	O
is	VBZ	O
required	VBN	O
for	IN	O
patients	NNS	WHO
receiving	VBG	WHO
the	DT	WHO
lowest	JJS	WHO
available	JJ	WHO
strength	NN	WHO
,	,	O
administer	NN	O
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
.	.	O

For	IN	O
use	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
pruritus	NN	O
due	JJ	O
to	TO	O
allergic	JJ	O
conditions	NNS	O
such	JJ	O
as	IN	O
chronic	JJ	O
urticaria	NN	O
and	CC	O
atopic	NN	O
and	CC	O
contact	NN	O
dermatoses	NNS	O
,	,	O
and	CC	O
in	IN	O
histamine	JJ	O
-	:	O
mediated	VBN	O
pruritus	NN	O
:	:	O
in	IN	O
adults	NNS	WHO
,	,	O
25	CD	DOS
mg	NN	UNIT
t.i.d	NN	O
.	.	O

34	CD	O

Since	IN	O
grapefruit	NN	O
juice	NN	O
is	VBZ	O
known	VBN	O
to	TO	O
inhibit	VB	O
CYP3A4	NNP	O
-	:	O
mediated	VBD	O
metabolism	NN	O
of	IN	O
oral	JJ	O
amiodarone	NN	O
in	IN	O
the	DT	O
intestinal	JJ	O
mucosa	NN	O
,	,	O
resulting	VBG	O
in	IN	O
increased	VBN	O
plasma	NN	O
levels	NNS	O
of	IN	O
amiodarone	NN	O
,	,	O
grapefruit	NN	O
juice	NN	O
should	MD	O
not	RB	O
be	VB	O
taken	VBN	O
during	IN	O
treatment	NN	O
with	IN	O
oral	JJ	O
amiodarone	NN	O
(	(	O
see	JJ	O
PRECAUTIONS	NNP	O
:	:	O
DRUG	NNP	O
INTERACTIONS	NNP	O
)	)	O
.	.	O

Zemplar	JJ	O
doses	NNS	O
may	MD	O
need	VB	O
to	TO	O
be	VB	O
decreased	VBN	O
as	IN	O
the	DT	O
PTH	NNP	O
levels	NNS	O
decrease	NN	O
in	IN	O
response	NN	O
to	TO	O
therapy	NN	O
.	.	O

The	DT	O
1	CD	O
-	:	O
and	CC	O
2	CD	O
-	:	O
g	NN	O
FORTAZ	NNP	O
TwistVial™	NNP	O
vials	NNS	O
,	,	O
when	WRB	O
diluted	VBN	O
in	IN	O
50	CD	DOS
or	CC	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
or	CC	O
0.45	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
may	MD	O
be	VB	O
stored	VBN	O
for	IN	O
up	RB	O
to	TO	O
12	CD	O
hours	NNS	O
at	IN	O
room	NN	O
temperature	NN	O
or	CC	O
for	IN	O
3	CD	PER
days	NNS	PER
under	IN	O
refrigeration	NN	O
.	.	O

Pitressin	NNP	O
used	VBD	O
in	IN	O
this	DT	O
manner	NN	O
will	MD	O
frequently	RB	O
prevent	VB	O
or	CC	O
relieve	VB	O
postoperative	JJ	O
distention	NN	O
.	.	O

Table	JJ	O
5	CD	O
:	:	O
PEGASYS	NNP	O
Dosage	NNP	O
Modification	NNP	O
for	IN	O
Adults	NNP	WHO
with	IN	WHO
Renal	NNP	WHO
Impairment	NNP	WHO

Step	NN	O
11	CD	O
.	.	O

A	DT	O
suggested	JJ	O
regimen	NN	O
includes	VBZ	O
five	CD	DOS
consecutive	JJ	UNIT
daily	JJ	FREQ
doses	NNS	O
followed	VBN	O
by	IN	O
two	CD	O
days	NNS	O
without	IN	O
medication	NN	O
,	,	O
with	IN	O
repeated	JJ	O
courses	NNS	O
as	IN	O
necessary	JJ	O
to	TO	O
a	DT	O
total	NN	O
of	IN	O
15	CD	DOS
doses	NNS	UNIT
.	.	O

29	CD	O

FENTORA	NNP	O
is	VBZ	O
not	RB	O
bioequivalent	JJ	O
with	IN	O
other	JJ	O
fentanyl	NN	O
products	NNS	O
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
experienced	VBD	WHO
no	DT	WHO
toxicity	NN	WHO
in	IN	O
the	DT	O
prior	JJ	O
treatment	NN	O
course	NN	O
,	,	O
5	CD	O
-	:	O
FU	NNP	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
by	IN	O
10	CD	O
%	NN	O
.	.	O

The	DT	O
beta	NN	O
emission	NN	O
has	VBZ	O
a	DT	O
range	NN	O
in	IN	O
water	NN	O
of	IN	O
about	IN	O
8	CD	O
mm	NNS	O
(	(	O
max	NN	O
.	.	O
)	)	O

For	IN	O
the	DT	O
first	JJ	O
few	JJ	O
hours	NNS	O
following	VBG	O
injection	NN	O
,	,	O
there	EX	O
may	MD	O
be	VB	O
local	JJ	O
discomfort	NN	O
in	IN	O
the	DT	O
joint	JJ	O
but	CC	O
this	DT	O
is	VBZ	O
usually	RB	O
followed	VBN	O
rapidly	RB	O
by	IN	O
effective	JJ	O
relief	NN	O
of	IN	O
pain	NN	O
and	CC	O
improvement	NN	O
in	IN	O
local	JJ	O
function	NN	O
.	.	O

REYATAZ	NNP	O
oral	JJ	O
powder	NN	O
must	MD	O
be	VB	O
mixed	JJ	O
with	IN	O
food	NN	O
or	CC	O
beverage	NN	O
for	IN	O
administration	NN	O
and	CC	O
ritonavir	VB	O
must	MD	O
be	VB	O
given	VBN	O
immediately	RB	O
afterwards	NNS	O
.	.	O

KOMBIGLYZE	NNP	O
XR	NNP	O
should	MD	O
generally	RB	O
be	VB	O
administered	VBN	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
the	DT	O
evening	NN	O
meal	NN	O
,	,	O
with	IN	O
gradual	JJ	O
dose	JJ	O
titration	NN	O
to	TO	O
reduce	VB	O
the	DT	O
gastrointestinal	JJ	O
side	NN	O
effects	NNS	O
associated	VBN	O
with	IN	O
metformin	NN	O
.	.	O

Serious	JJ	O
toxicity	NN	O
has	VBZ	O
been	VBN	O
associated	VBN	O
with	IN	O
serum	NN	O
levels	NNS	O
greater	JJR	O
than	IN	O
50	CD	DOS
mg	JJ	UNIT
/	NNP	O
L	NNP	O
.	.	O

*	JJ	O
=	NNP	O
[	NNP	O
See	NNP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
)	)	O
]	NN	O
.	.	O

Instructions	NNS	O
for	IN	O
preparing	VBG	O
solutions	NNS	O
supplied	VBN	O
in	IN	O
a	DT	O
two	CD	O
-	:	O
compartment	NN	O
,	,	O
polyvinyl	JJ	O
chloride	NN	O
(	(	O
PVC	NNP	O
)	)	O
bag	NN	O
with	IN	O
a	DT	O
red	JJ	O
frangible	JJ	O
pin	NN	O
:	:	O

Ongoing	VBG	O
use	NN	O
of	IN	O
supplemental	JJ	O
dosing	VBG	O
with	IN	O
transmucosal	JJ	O
buprenorphine	NN	O
indicates	VBZ	O
that	IN	O
the	DT	O
amount	NN	O
of	IN	O
buprenorphine	NN	O
delivered	VBN	O
by	IN	O
PROBUPHINE	NNP	O
is	VBZ	O
not	RB	O
adequate	JJ	O
for	IN	O
stable	JJ	O
maintenance	NN	O
.	.	O

If	IN	O
this	DT	O
happens	VBZ	O
,	,	O
the	DT	O
vial	NN	O
should	MD	O
be	VB	O
warmed	VBN	O
in	IN	O
the	DT	O
hand	NN	O
until	IN	O
the	DT	O
solution	NN	O
is	VBZ	O
clear	JJ	O
.	.	O

Levothyroxine	NNP	O
Sodium	NNP	O
for	IN	O
Injection	NNP	O
produces	VBZ	O
a	DT	O
gradual	JJ	O
increase	NN	O
in	IN	O
the	DT	O
circulating	NN	O
concentrations	NNS	O
of	IN	O
the	DT	O
hormone	NN	O
with	IN	O
an	DT	O
approximate	JJ	O
half	NN	O
-	:	O
life	NN	O
of	IN	O
9	CD	PER
to	TO	O
10	CD	PER
days	NNS	PER
in	IN	O
hypothyroid	JJ	WHO
patients	NNS	WHO
.	.	O

Limited	JJ	O
information	NN	O
suggests	VBZ	O
that	IN	O
infusion	NN	O
rates	NNS	O
required	VBN	O
for	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
in	IN	O
the	DT	O
ICU	NNP	O
may	MD	O
be	VB	O
higher	JJR	O
than	IN	O
in	IN	O
adult	NN	WHO
patients	NNS	WHO
.	.	O

Prophylaxis	NNP	O
of	IN	O
an	DT	O
infant	NN	WHO
less	JJR	WHO
than	IN	WHO
12	CD	WHO
months	NNS	WHO
of	IN	WHO
age	NN	WHO
with	IN	O
0.5	CD	DOS
mL	NNS	UNIT
HepaGam	NNP	O
B	NNP	O
(	(	O
hepatitis	NN	O
b	NN	O
immune	NN	O
globulin	NN	O
(	(	O
human	JJ	O
)	)	O
)	)	O
and	CC	O
Hepatitis	NNP	O
B	NNP	O
Vaccine	NNP	O
is	VBZ	O
indicated	VBN	O
if	IN	O
the	DT	O
mother	NN	O
or	CC	O
primary	JJ	O
caregiver	NN	O
has	VBZ	O
acute	VBN	O
HBV	NNP	O
infection	NN	O
.	.	O

Each	DT	O
regimen	NN	O
requires	VBZ	O
different	JJ	O
dosing	VBG	O
times	NNS	O
:	:	O

However	RB	O
,	,	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
should	MD	O
be	VB	O
treated	VBN	O
with	IN	O
caution	NN	O
.	.	O

AMJEVITA	NNP	O
is	VBZ	O
intended	VBN	O
for	IN	O
use	NN	O
under	IN	O
the	DT	O
guidance	NN	O
and	CC	O
supervision	NN	O
of	IN	O
a	DT	O
physician	NN	O
.	.	O

Examine	NNP	O
each	DT	O
prefilled	VBD	O
syringe	NN	O
for	IN	O
the	DT	O
expiration	NN	O
date	NN	O
.	.	O

Allow	IN	O
the	DT	O
vial	JJ	O
to	TO	O
stand	VB	O
for	IN	O
approximately	RB	O
2	CD	O
minutes	NNS	O
.	.	O

Dosage	NN	O
adjustments	NNS	O
should	MD	O
be	VB	O
made	VBN	O
to	TO	O
maintain	VB	O
the	DT	O
patient	NN	O
on	IN	O
the	DT	O
lowest	JJS	O
effective	JJ	O
dosage	NN	O
,	,	O
and	CC	O
patients	NNS	O
should	MD	O
be	VB	O
periodically	RB	O
reassessed	VBN	O
to	TO	O
determine	VB	O
the	DT	O
need	NN	O
for	IN	O
continued	JJ	O
treatment	NN	O
.	.	O

Studies	NNS	O
to	TO	O
date	NN	O
have	VB	O
indicated	VBN	O
that	DT	O
administration	NN	O
of	IN	O
doxycycline	NN	O
at	IN	O
the	DT	O
usual	JJ	O
recommended	JJ	O
doses	NNS	O
does	VBZ	O
not	RB	O
lead	VB	O
to	TO	O
excessive	JJ	O
accumulation	NN	O
of	IN	O
doxycycline	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
.	.	O

CREON	NNP	O
is	VBZ	O
orally	RB	O
administered	VBN	O
.	.	O

As	IN	O
with	IN	O
all	DT	O
contrast	NN	O
media	NNS	O
,	,	O
because	IN	O
of	IN	O
the	DT	O
potential	NN	O
for	IN	O
chemical	NN	O
incompatibility	NN	O
,	,	O
OXILAN®	NNP	O
Injection	NNP	O
should	MD	O
not	RB	O
be	VB	O
mixed	JJ	O
with	IN	O
,	,	O
or	CC	O
injected	VBN	O
in	IN	O
,	,	O
intravenous	JJ	O
administration	NN	O
lines	NNS	O
containing	VBG	O
other	JJ	O
drugs	NNS	O
,	,	O
solutions	NNS	O
,	,	O
or	CC	O
total	JJ	O
nutritional	JJ	O
admixtures	NNS	O
.	.	O

The	DT	O
suspension	NN	O
should	MD	O
be	VB	O
administered	VBN	O
immediately	RB	O
after	IN	O
constitution	NN	O
.	.	O

MANAGEMENT	NNP	O
OF	NNP	O
SOME	NNP	O
COMPLICATIONS	NNP	O

The	DT	O
CombiPatch	NNP	O
system	NN	O
should	MD	O
be	VB	O
replaced	VBN	O
every	DT	FREQ
3	CD	FREQ
to	TO	O
4	CD	PER
days	NNS	PER
(	(	O
twice	JJ	FREQ
weekly	RB	FREQ
)	)	O
during	IN	O
this	DT	O
14	CD	O
-	:	O
day	NN	O
period	NN	O
in	IN	O
the	DT	O
28	CD	O
-	:	O
day	NN	O
cycle	NN	O
.	.	O

Wash	NNP	O
hands	NNS	O
immediately	RB	O
after	IN	O
applying	VBG	O
RHOFADE	NNP	O
cream	NN	O
.	.	O

SEROQUEL	NNP	O
dose	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
to	TO	O
one	CD	DOS
sixth	NN	UNIT
of	IN	O
original	JJ	O
dose	NN	O
when	WRB	O
co	NN	O
-	:	O
medicated	VBN	O
with	IN	O
a	DT	O
potent	JJ	O
CYP3A4	NNP	O
inhibitor	NN	O
(	(	O
e.g	JJ	O
,	,	O
ketoconazole	JJ	O
,	,	O
itraconazole	JJ	O
,	,	O
indinavir	JJ	O
,	,	O
ritonavir	NN	O
,	,	O
nefazodone	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
.	.	O

If	IN	O
,	,	O
in	IN	O
the	DT	O
informed	JJ	O
judgment	NN	O
of	IN	O
the	DT	O
physician	NN	O
,	,	O
it	PRP	O
is	VBZ	O
deemed	VBN	O
advisable	JJ	O
to	TO	O
introduce	VB	O
additives	NNS	O
,	,	O
use	VBP	O
aseptic	JJ	O
technique	NN	O
.	.	O

Hematologic	NNP	O
toxicity	NN	O
:	:	O
Neutrexin	NNP	O
(	(	O
trimetrexate	JJ	O
glucuronate	NN	O
for	IN	O
injection	NN	O
)	)	O
and	CC	O
leucovorin	JJ	O
doses	NNS	O
should	MD	O
be	VB	O
modified	VBN	O
based	VBN	O
on	IN	O
the	DT	O
worst	JJS	O
hematologic	NN	O
toxicity	NN	O
according	VBG	O
to	TO	O
the	DT	O
following	VBG	O
table	NN	O
.	.	O

Dose	JJ	O
Adjustments	NNS	O
of	IN	O
PROMACTA	NNP	O
in	IN	O
Adults	NNP	WHO
with	IN	WHO
Thrombocytopenia	NNP	WHO
due	JJ	WHO
to	TO	WHO
Chronic	NNP	WHO
Hepatitis	NNP	WHO
C	NNP	WHO

An	DT	O
extra	JJ	O
needle	NN	O
has	VBZ	O
been	VBN	O
provided	VBN	O
in	IN	O
the	DT	O
kit	NN	O
.	.	O

Longer	JJR	O
-	:	O
term	NN	O
efficacy	NN	O
of	IN	O
PRISTIQ	NNP	O
(	(	O
50	CD	DOS
-	:	O
400	CD	DOS
mg	NN	UNIT
)	)	O
was	VBD	O
established	VBN	O
in	IN	O
two	CD	O
maintenance	NN	O
trials	NNS	O
[	VBP	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

TANZEUM	NNP	O
must	MD	O
not	RB	O
be	VB	O
administered	VBN	O
intravenously	RB	O
or	CC	O
intramuscularly	RB	O
.	.	O

The	DT	O
highest	JJS	O
recommended	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
is	VBZ	O
200	CD	DOS
mcg	NN	UNIT
.	.	O

Appropriate	JJ	O
tests	NNS	O
to	TO	O
determine	VB	O
ovulation	NN	O
may	MD	O
be	VB	O
useful	JJ	O
during	IN	O
this	DT	O
time	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
clinical	JJ	O
safety	NN	O
parameters	NNS	O
such	JJ	O
as	IN	O
serum	JJ	O
creatinine	NN	O
and	CC	O
blood	NN	O
pressure	NN	O
should	MD	O
be	VB	O
monitored	VBN	O
every	DT	FREQ
two	CD	FREQ
weeks	NNS	FREQ
during	IN	O
the	DT	O
first	JJ	O
two	CD	O
months	NNS	O
after	IN	O
conversion	NN	O
.	.	O

NOTE	NN	O
:	:	O
Aluminum	NN	O
reacts	NNS	O
with	IN	O
carboplatin	NN	O
causing	VBG	O
precipitate	JJ	O
formation	NN	O
and	CC	O
loss	NN	O
of	IN	O
potency	NN	O
,	,	O
therefore	RB	O
,	,	O
needles	NNS	O
or	CC	O
intravenous	JJ	O
sets	NNS	O
containing	VBG	O
aluminum	NN	O
parts	NNS	O
that	WDT	O
may	MD	O
come	VB	O
in	IN	O
contact	NN	O
with	IN	O
the	DT	O
drug	NN	O
must	MD	O
not	RB	O
be	VB	O
used	VBN	O
for	IN	O
the	DT	O
preparation	NN	O
or	CC	O
administration	NN	O
of	IN	O
PARAPLATIN	NNP	O
(	(	O
carboplatin	NN	O
)	)	O
.	.	O

If	IN	O
nondisposable	JJ	O
equipment	NN	O
is	VBZ	O
used	VBN	O
,	,	O
scrupulous	JJ	O
care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
prevent	VB	O
residual	JJ	O
contamination	NN	O
with	IN	O
traces	NNS	O
of	IN	O
cleansing	VBG	O
agents	NNS	O
.	.	O

Additional	JJ	O
doses	NNS	O
needed	VBN	O
to	TO	O
complete	VB	O
a	DT	O
primary	JJ	O
series	NN	O
should	MD	O
be	VB	O
given	VBN	O
if	IN	O
time	NN	O
permits.28	NN	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
0.125	CD	DOS
mg	NN	UNIT
(	(	O
0.1	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
diluted	JJ	O
solution	NN	O
)	)	O
administered	VBN	O
by	IN	O
intravitreal	JJ	O
injection	NN	O
to	TO	O
the	DT	O
affected	JJ	O
eye	NN	O
once	RB	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
always	RB	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

She	PRP	O
should	MD	O
not	RB	O
wait	VB	O
any	DT	O
days	NNS	O
between	IN	O
packs	NNS	O
.	.	O

If	IN	O
for	IN	O
any	DT	O
reason	NN	O
an	DT	O
incomplete	NN	O
dose	NN	O
is	VBZ	O
administered	VBN	O
(	(	O
e.g	NN	O
,	,	O
infant	JJ	WHO
spits	NNS	O
or	CC	O
regurgitates	VBZ	O
the	DT	O
vaccine	NN	O
)	)	O
,	,	O
a	DT	O
replacement	NN	O
dose	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
,	,	O
since	IN	O
such	JJ	O
dosing	NN	O
was	VBD	O
not	RB	O
studied	VBN	O
in	IN	O
the	DT	O
clinical	JJ	O
trials	NNS	O
.	.	O

Each	DT	O
oval	NN	O
yellow	JJ	O
tablet	NN	O
contains	VBZ	O
1.25	CD	DOS
mg	NN	UNIT
,	,	O
in	IN	O
bottles	NNS	O
of	IN	O
100	CD	DOS
(	(	O
NDC	NNP	O
0046	CD	O
-	:	O
1104	CD	O
-	:	O
81	CD	O
)	)	O
and	CC	O
1,000	CD	DOS
(	(	O
NDC	NNP	O
0046	CD	O
-	:	O
1104	CD	O
-	:	O
91	CD	O
)	)	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
CETYLEV	JJ	O
Maintenance	NNP	O
Dose	NNP	O

Titrate	NNP	O
to	TO	O
2	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	JJ	FREQ
on	IN	O
Day	NNP	O
5	CD	O
through	IN	O
Day	NNP	O
7	CD	O
,	,	O
then	RB	O
to	TO	O
4	CD	DOS
mg	NNS	UNIT
on	IN	O
Day	NNP	O
8	CD	O
based	VBN	O
on	IN	O
the	DT	O
patient	NN	O
’	NNP	O
s	VBD	O
clinical	JJ	O
response	NN	O
and	CC	O
tolerability	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Reconstitution	NN	O
of	IN	O
DOCEFREZ	NNP	O
(	(	O
docetaxel	NN	O
)	)	O
for	IN	O
Injection	NN	O

Any	DT	O
unused	JJ	O
portion	NN	O
of	IN	O
the	DT	O
vial	JJ	O
contents	NNS	O
should	MD	O
be	VB	O
discarded	VBN	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
scalp	JJ	O
psoriasis	NN	O
,	,	O
wet	NN	O
or	CC	O
dampen	VB	O
hair	NN	O
and	CC	O
scalp	NN	O
thoroughly	RB	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
severely	RB	WHO
impaired	JJ	WHO
renal	JJ	WHO
function	NN	WHO
(	(	O
CrCl	NNP	O
<	VBZ	O
30	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
,	,	O
monitor	NN	O
anti	SYM	O
-	:	O
Xa	NN	O
levels	NNS	O
to	TO	O
determine	VB	O
the	DT	O
appropriate	JJ	O
FRAGMIN	NNP	O
dose	NN	O
.	.	O

Do	NNP	O
not	RB	O
tape	VB	O
if	IN	O
evidence	NN	O
of	IN	O
blistered	JJ	O
or	CC	O
broken	JJ	O
skin	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
obese	JJ	O
individuals	NNS	O
are	VBP	O
more	RBR	O
likely	JJ	O
to	TO	O
manifest	VB	O
adverse	JJ	O
effects	NNS	O
when	WRB	O
treated	VBN	O
with	IN	O
a	DT	O
weight	NN	O
-	:	O
based	VBN	O
regimen	NNS	O
.	.	O

Complete	JJ	O
information	NN	O
is	VBZ	O
not	RB	O
available	JJ	O
.	.	O

BENDEKA	NNP	O
(	(	O
bendamustine	VB	O
hydrochloride	NN	O
)	)	O
injection	NN	O
contains	VBZ	O
no	DT	O
antimicrobial	JJ	O
preservative	NN	O
.	.	O

The	DT	O
nasal	NN	O
spray	NN	O
pump	NN	O
can	MD	O
only	RB	O
deliver	VB	O
doses	NNS	O
of	IN	O
0.1	CD	DOS
mL	NN	UNIT
(	(	O
150	CD	DOS
mcg	NN	UNIT
)	)	O
or	CC	O
multiples	NNS	O
of	IN	O
0.1	CD	DOS
mL	NN	UNIT
.	.	O

(	(	O
See	VB	O
DRUG	NNP	O
INTERACTIONS	NNP	O
section	NN	O
.	.	O
)	)	O

ZELAPAR	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
and	CC	WHO
patients	NNS	WHO
with	IN	WHO
end	JJ	WHO
-	:	O
stage	NN	O
renal	JJ	O
disease	NN	O
[	NNP	O
ESRD	NNP	O
]	NNP	O
(	(	O
creatinine	JJ	O
clearance	NN	O
[	NNP	O
CLcr	NNP	O
]	NNP	O
<	VBD	O
30	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
[	NN	O
see	VBP	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

If	IN	O
a	DT	O
patient	NN	O
misses	VBZ	O
a	DT	O
dose	NN	O
of	IN	O
Lynparza	NNP	O
,	,	O
instruct	NN	O
patients	NNS	O
to	TO	O
take	VB	O
their	PRP$	O
next	JJ	O
dose	NN	O
at	IN	O
its	PRP$	O
scheduled	JJ	O
time	NN	O
.	.	O

Warning	NN	O
:	:	O
If	IN	O
the	DT	O
test	NN	O
is	VBZ	O
positive	JJ	O
,	,	O
do	VBP	O
NOT	NNP	O
initiate	VB	O
REVIA	NNP	O
therapy	NN	O
.	.	O

(	(	O
b	NN	O
)	)	O
Connect	VBP	O
the	DT	O
syringe	NN	O
to	TO	O
the	DT	O
vial	JJ	O
adapter	NN	O
by	IN	O
screwing	VBG	O
it	PRP	O
clockwise	VB	O
into	IN	O
the	DT	O
opening	NN	O
on	IN	O
the	DT	O
side	NN	O
of	IN	O
the	DT	O
vial	JJ	O
adapter	NN	O
.	.	O

The	DT	O
patient	NN	O
should	MD	O
be	VB	O
advised	VBN	O
to	TO	O
avoid	VB	O
swimming	NN	O
or	CC	O
showering	NN	O
for	IN	O
at	IN	O
least	JJS	O
5	CD	O
hours	NNS	O
after	IN	O
the	DT	O
application	NN	O
of	IN	O
AndroGel	NNP	O
1	CD	O
%	NN	O
.	.	O

Periodic	JJ	O
assessment	NN	O
is	VBZ	O
necessary	JJ	O
to	TO	O
determine	VB	O
compliance	NN	O
with	IN	O
the	DT	O
dosing	VBG	O
regimen	NNS	O
,	,	O
effectiveness	NN	O
of	IN	O
the	DT	O
treatment	NN	O
plan	NN	O
,	,	O
and	CC	O
overall	JJ	O
patient	NN	O
progress	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
4.5	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
,	,	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

The	DT	O
contents	NNS	O
of	IN	O
Teflaro	NNP	O
vial	NN	O
should	MD	O
be	VB	O
constituted	VBN	O
with	IN	O
20	CD	DOS
mL	NNS	UNIT
Sterile	JJ	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
;	:	O
or	CC	O
0.9	CD	O
%	NN	O
of	IN	O
sodium	NN	O
chloride	NN	O
injection	NN	O
(	(	O
normal	JJ	O
saline	NN	O
)	)	O
;	:	O
or	CC	O
5	CD	O
%	NN	O
of	IN	O
dextrose	JJ	O
injection	NN	O
;	:	O
or	CC	O
lactated	VBD	O
ringer	NN	O
's	POS	O
injection	NN	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Recommended	VBN	O
Dos	NNP	O
age	NN	O
in	IN	O
Patients	NNS	WHO
with	IN	WHO
Renal	NNP	WHO
Impairment	NNP	WHO

Administer	NNP	O
Otrexup	NNP	O
in	IN	O
the	DT	WHO
abdomen	NNS	WHO
or	CC	O
the	DT	O
thigh	NN	O
.	.	O

RECOMMENDED	NNP	O
DOSING	NN	O

The	DT	O
dosage	NN	O
requirements	NNS	O
for	IN	O
continuous	JJ	O
treatment	NN	O
of	IN	O
hereditary	JJ	O
angioedema	NN	O
with	IN	O
WINSTROL	NNP	O
(	(	O
anabolic	JJ	O
steroids	NNS	O
)	)	O
should	MD	O
be	VB	O
individualized	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
the	DT	O
clinical	JJ	O
response	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

Stability	NNP	O
studies	NNS	O
of	IN	O
CUBICIN	NNP	O
solutions	NNS	O
stored	VBD	O
in	IN	O
ReadyMED®	NNP	O
elastomeric	JJ	O
infusion	NN	O
pumps	NNS	O
identified	VBD	O
an	DT	O
impurity	NN	O
(	(	O
2	CD	O
-	:	O
mercaptobenzothiazole	NN	O
)	)	O
leaching	VBG	O
from	IN	O
this	DT	O
pump	NN	O
system	NN	O
into	IN	O
the	DT	O
CUBICIN	NNP	O
solution	NN	O
.	.	O

Dosing	VBG	O
must	MD	O
be	VB	O
individualized	VBN	O
and	CC	O
based	VBN	O
on	IN	O
iPTH	NN	O
levels	NNS	O
with	IN	O
monitoring	NN	O
of	IN	O
serum	JJ	O
calcium	NN	O
and	CC	O
serum	NN	O
phosphorus	NN	O
levels	NNS	O
.	.	O

The	DT	O
ground	NN	O
glass	NN	O
surfaces	NNS	O
of	IN	O
all	DT	O
-	:	O
glass	NN	O
syringes	NNS	O
tend	VBP	O
to	TO	O
stick	VB	O
with	IN	O
solutions	NNS	O
of	IN	O
this	DT	O
type	NN	O
.	.	O

If	IN	O
,	,	O
in	IN	O
the	DT	O
informed	JJ	O
judgement	NN	O
of	IN	O
the	DT	O
physician	NN	O
,	,	O
it	PRP	O
is	VBZ	O
deemed	VBN	O
advisable	JJ	O
to	TO	O
introduce	VB	O
additives	NNS	O
,	,	O
use	VBP	O
aseptic	JJ	O
technique	NN	O
.	.	O

6	CD	O
]	NN	O

Treatment	NN	O
with	IN	O
cysteamine	NN	O
should	MD	O
be	VB	O
started	VBN	O
immediately	RB	O
after	IN	O
diagnosis	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Dose	NN	O
and	CC	O
Schedule	NNP	O
for	IN	O
Fluzone	NNP	O

Growth	NNP	O
hormone	NN	O
deficiency	NN	O
-	:	O
The	DT	O
recommended	JJ	O
weekly	JJ	FREQ
dose	NN	O
is	VBZ	O
0.18	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VBZ	O
body	NN	O
weight	VBD	O
to	TO	O
0.3	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
(	(	O
0.90	CD	DOS
IU	NNP	UNIT
/	NNP	O
kg	NN	O
)	)	O
body	NN	O
weight	NN	O
.	.	O

Start	NNP	WHO
all	DT	WHO
patients	NNS	WHO
with	IN	O
a	DT	O
single	JJ	DOS
100	CD	DOS
mcg	JJ	UNIT
tablet	NN	UNIT
.	.	O

Experience	NN	O
does	VBZ	O
suggest	VB	O
,	,	O
however	RB	O
,	,	O
that	IN	O
children	NNS	O
receiving	VBG	O
20	CD	DOS
to	TO	O
30	CD	DOS
mg	NNS	UNIT
/	JJ	O
m²	JJ	O
/	NN	O
wk	NN	O
(	(	O
0.65	CD	DOS
to	TO	O
1.0	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
/	NNP	O
wk	NN	O
)	)	O
may	MD	O
have	VB	O
better	JJR	O
absorption	NN	O
and	CC	O
fewer	JJR	O
gastrointestinal	JJ	O
side	NN	O
effects	NNS	O
if	IN	O
methotrexate	NN	O
is	VBZ	O
administered	VBN	O
either	RB	O
intramuscularly	RB	O
or	CC	O
subcutaneously	RB	O
.	.	O

In	IN	O
a	DT	O
clinical	JJ	O
study	NN	O
,	,	O
renal	JJ	O
deterioration	NN	O
was	VBD	O
defined	VBN	O
as	IN	O
follows	VBZ	O
:	:	O

infusion	NN	O
over	IN	O
30	CD	O
minutes	NNS	O
for	IN	O
up	IN	PER
to	TO	PER
7	CD	PER
days	NNS	PER
.	.	O

The	DT	O
patient	NN	O
is	VBZ	O
observed	VBN	O
over	IN	O
the	DT	O
ensuing	VBG	O
4	CD	O
to	TO	O
8	CD	O
hours	NNS	O
.	.	O

PROTOPAM	NNP	O
(	(	O
pralidoxime	JJ	O
chloride	NN	O
)	)	O
is	VBZ	O
supplied	VBN	O
as	IN	O
1000	CD	DOS
mg	NN	UNIT
single	JJ	O
-	:	O
dose	NN	O
vials	NNS	O
for	IN	O
injection	NN	O
.	.	O

VUSION	NNP	O
(	(	O
miconazole	JJ	O
nitrate	NN	O
,	,	O
15	CD	O
%	NN	O
zinc	NN	O
oxide	NN	O
,	,	O
and	CC	O
81.35	CD	O
%	NN	O
white	JJ	O
petrolatum	NN	O
)	)	O
is	VBZ	O
not	RB	O
for	IN	O
oral	JJ	O
,	,	O
ophthalmic	JJ	O
,	,	O
or	CC	O
intravaginal	JJ	O
use	NN	O
.	.	O

The	DT	O
ratio	NN	O
between	IN	O
methadone	NN	O
and	CC	O
other	JJ	O
opioid	JJ	O
agonists	NNS	O
may	MD	O
vary	VB	O
widely	RB	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
previous	JJ	O
dose	JJ	O
exposure	NN	O
.	.	O

This	DT	O
dose	NN	O
is	VBZ	O
usually	RB	O
administered	VBN	O
at	IN	O
4	CD	O
to	TO	O
6	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	O

A	DT	O
guide	NN	O
for	IN	O
calculating	VBG	O
the	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
RIXUBIS	NNP	O
for	IN	O
treatment	NN	O
of	IN	O
bleeding	VBG	O
episodes	NNS	O
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O

7	CD	O
.	.	O

The	DT	O
750	CD	DOS
-	:	O
mg	NN	UNIT
and	CC	O
1.5	CD	O
-	:	O
g	NN	O
ZINACEF	NNP	O
TwistVial™	NNP	O
vials	NNS	O
,	,	O
when	WRB	O
diluted	VBN	O
in	IN	O
50	CD	DOS
or	CC	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
or	CC	O
0.45	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
may	MD	O
be	VB	O
stored	VBN	O
for	IN	O
up	RB	O
to	TO	O
24	CD	O
hours	NNS	O
at	IN	O
room	NN	O
temperature	NN	O
or	CC	O
for	IN	O
7	CD	PER
days	NNS	PER
under	IN	O
refrigeration	NN	O
.	.	O

Dosing	VBG	O
should	MD	O
be	VB	O
continued	VBN	O
with	IN	O
a	DT	O
once	RB	O
-	:	O
weekly	JJ	O
injection	NN	O
of	IN	O
160	CD	DOS
mg	NNS	UNIT
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
,	,	O
2	CD	O
-	:	O
mL	NN	O
,	,	O
subcutaneous	JJ	O
injection	NN	O
.	.	O

If	IN	O
anatomically	RB	O
feasible	JJ	O
,	,	O
up	RB	O
to	TO	O
the	DT	O
full	JJ	O
dose	NN	O
of	IN	O
BayRab	NNP	O
(	(	O
rabies	NNS	O
immune	VBP	O
globulin	NN	O
(	(	O
human	JJ	O
)	)	O
solvent	NN	O
/	JJ	O
detergent	NN	O
treated	VBD	O
)	)	O
should	MD	O
be	VB	O
thoroughly	RB	O
infiltrated	VBN	O
in	IN	O
the	DT	O
area	NN	O
around	IN	O
the	DT	O
wound	NN	O
and	CC	O
the	DT	O
rest	NN	O
should	MD	O
be	VB	O
administered	VBN	O
intramuscularly	RB	O
in	IN	O
the	DT	O
gluteal	JJ	O
area	NN	O
or	CC	O
lateral	JJ	O
thigh	JJ	O
muscle	NN	O
.	.	O

CellCept	NNP	O
Intravenous	NNP	O
is	VBZ	O
incompatible	JJ	O
with	IN	O
other	JJ	O
intravenous	JJ	O
infusion	NN	O
solutions	NNS	O
.	.	O

DAPTACEL	NNP	O
vaccine	NN	O
should	MD	O
not	RB	O
be	VB	O
combined	VBN	O
through	IN	O
reconstitution	NN	O
or	CC	O
mixed	JJ	O
with	IN	O
any	DT	O
other	JJ	O
vaccine	NN	O
.	.	O

For	IN	O
the	DT	O
relief	NN	O
of	IN	O
ankylosing	VBG	O
spondylitis	NN	O
,	,	O
the	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
100	CD	DOS
-	:	O
125	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
administered	VBN	O
as	IN	O
25	CD	DOS
mg	NN	UNIT
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
,	,	O
with	IN	O
an	DT	O
extra	JJ	O
25	CD	DOS
-	:	O
mg	NN	UNIT
dose	NN	UNIT
at	IN	O
bedtime	NN	O
if	IN	O
necessary	JJ	O
.	.	O

Check	NNP	O
for	IN	O
leaks	NNS	O
by	IN	O
squeezing	VBG	O
container	NN	O
firmly	RB	O
.	.	O

[	NNS	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NN	O

Parenteral	JJ	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
and	CC	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
if	IN	O
particulates	NNS	O
are	VBP	O
observed	VBN	O
or	CC	O
marked	VBN	O
discoloration	NN	O
has	VBZ	O
occurred	VBN	O
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
conditions	NNS	O
such	JJ	O
as	IN	O
tendinitis	NN	O
or	CC	O
tenosynovitis	NN	O
,	,	O
care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
following	VBG	O
application	NN	O
of	IN	O
a	DT	O
suitable	JJ	O
antiseptic	JJ	O
to	TO	O
the	DT	O
overlying	VBG	O
skin	NN	O
to	TO	O
inject	VB	O
the	DT	O
suspension	NN	O
into	IN	O
the	DT	O
tendon	JJ	O
sheath	NN	O
rather	RB	O
than	IN	O
into	IN	O
the	DT	O
substance	NN	O
of	IN	O
the	DT	O
tendon	NN	O
.	.	O

Unless	IN	O
otherwise	RB	O
directed	VBN	O
by	IN	O
a	DT	O
prescribing	NN	O
healthcare	NN	O
practitioner	NN	O
,	,	O
NEOSALUS	NNP	O
CREAM	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
affected	JJ	O
area	NN	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
(	(	O
or	CC	O
as	IN	O
needed	VBN	O
)	)	O
.	.	O

After	IN	O
reconstitution	NN	O
,	,	O
ARCALYST	NNP	O
may	MD	O
be	VB	O
kept	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
,	,	O
should	MD	O
be	VB	O
protected	VBN	O
from	IN	O
light	NN	O
,	,	O
and	CC	O
should	MD	O
be	VB	O
used	VBN	O
within	IN	O
three	CD	O
hours	NNS	O
of	IN	O
reconstitution	NN	O
.	.	O

(	(	O
Normal	NNP	O
Hb	NNP	O
for	IN	O
Children	NNP	WHO
15	CD	WHO
kg	NN	WHO
or	CC	WHO
less	JJR	WHO
is	VBZ	O
12	CD	DOS
g	NN	UNIT
/	NNP	O
dl	NN	O
)	)	O
W	NNP	O
=	NNP	O
Weight	NNP	O
in	IN	O
kg	NN	O
.	.	O

If	IN	O
pregnancy	NN	O
occurs	VBZ	O
,	,	O
treatment	NN	O
may	MD	O
be	VB	O
continued	VBN	O
until	IN	O
placental	JJ	O
autonomy	NN	O
is	VBZ	O
achieved	VBN	O
,	,	O
up	RB	O
to	TO	O
10	CD	PER
-	:	O
12	CD	PER
weeks	NNS	PER
.	.	O

Do	MD	O
not	RB	O
store	VB	O
Enbrel	NNP	O
in	IN	O
extreme	JJ	O
heat	NN	O
or	CC	O
cold	NN	O
.	.	O

Not	RB	O
more	JJR	O
than	IN	O
8	CD	DOS
g	NN	UNIT
should	MD	O
be	VB	O
prescribed	VBN	O
initially	RB	O
and	CC	O
the	DT	O
prescription	NN	O
should	MD	O
not	RB	O
be	VB	O
refilled	VBN	O
without	IN	O
further	JJ	O
evaluation	NN	O
as	IN	O
outlined	VBN	O
in	IN	O
PRECAUTIONS	NNP	O
above	IN	O
.	.	O

IMPAIRED	NNP	O
RENAL	NNP	O
FUNCTION	NNP	O
:	:	O
No	DT	O
adjustment	NN	O
in	IN	O
the	DT	O
dosage	NN	O
of	IN	O
TROVAN	NNP	O
is	VBZ	O
necessary	JJ	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
renal	JJ	WHO
function	NN	WHO
.	.	O

Discard	NNP	O
the	DT	O
entire	JJ	O
infusion	NN	O
line	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
concomitantly	RB	WHO
receiving	VBG	WHO
rifabutin	NN	WHO
,	,	O
the	DT	O
EDURANT	NNP	O
dose	NN	O
should	MD	O
be	VB	O
increased	VBN	O
to	TO	O
50	CD	DOS
mg	NNS	UNIT
(	(	O
two	CD	DOS
tablets	NNS	UNIT
of	IN	O
25	CD	DOS
mg	NNS	UNIT
each	DT	O
)	)	O
once	RB	FREQ
daily	JJ	FREQ
,	,	O
taken	VBN	O
with	IN	O
a	DT	O
meal	NN	O
.	.	O

Use	NNP	O
twice	JJ	FREQ
daily	RB	FREQ
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

Neoral®	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
twice	RB	FREQ
daily	RB	FREQ
,	,	O
as	IN	O
a	DT	O
divided	VBN	O
(	(	O
1.25	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NNP	O
BID	NNP	O
)	)	O
oral	VBP	O
dose	NN	O
.	.	O

The	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
the	DT	O
solution	NN	O
depends	VBZ	O
on	IN	O
the	DT	O
daily	JJ	FREQ
protein	NN	O
requirements	NNS	O
and	CC	O
on	IN	O
the	DT	O
patient	NN	O
's	POS	O
metabolic	NN	O
and	CC	O
clinical	JJ	O
response	NN	O
.	.	O

Initiation	NN	O
of	IN	O
sotalol	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
creatinine	JJ	WHO
clearance	NN	WHO
<	VBD	WHO
40	CD	DOS
ml	NN	UNIT
/	NNP	O
min	NN	O
or	CC	O
QTc	NNP	O
>	$	O
450	CD	O
is	VBZ	O
contraindicated	VBN	O
[	JJ	O
see	NN	O
CONTRAINDICATIONS	NNP	O
]	NNP	O
.	.	O

There	EX	O
is	VBZ	O
no	DT	O
experience	NN	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
ondansetron	NN	O
hydrochloride	NN	O
tablets	NNS	O
in	IN	O
the	DT	O
prevention	NN	O
of	IN	O
radiationinduced	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
.	.	O

STEP	NN	O
2	CD	O
:	:	O
Using	VBG	O
a	DT	O
sterile	JJ	O
1	CD	O
-	:	O
mL	NN	O
syringe	NN	O
and	CC	O
18	CD	O
-	:	O
gauge	NN	O
x	VBZ	O
2	CD	O
”	NN	O
needle	NN	O
,	,	O
carefully	RB	O
withdraw	VBZ	O
the	DT	O
required	JJ	O
volume	NN	O
depending	VBG	O
on	IN	O
the	DT	O
dose	NN	O
to	TO	O
be	VB	O
administered	VBN	O
and	CC	O
subcutaneously	RB	O
inject	JJ	O
using	VBG	O
a	DT	O
27	CD	O
-	:	O
gauge	NN	O
x	VBZ	O
0.5	CD	O
”	JJ	O
needle	NN	O
.	.	O

During	IN	O
treatment	NN	O
with	IN	O
Follistim®	NNP	O
AQ	NNP	O
(	(	O
follitropin	JJ	O
beta	NN	O
)	)	O
and	CC	O
during	IN	O
a	DT	O
two	CD	DOS
-	:	O
week	NN	PER
post	NN	O
-	:	O
treatment	NN	O
period	NN	O
,	,	O
patients	NNS	O
should	MD	O
be	VB	O
examined	VBN	O
at	IN	O
least	JJS	O
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
for	IN	O
signs	NNS	O
of	IN	O
excessive	JJ	O
ovarian	JJ	O
stimulation	NN	O
.	.	O

Pediatric	JJ	O
requirements	NNS	O
for	IN	O
parenteral	JJ	O
nutrition	NN	O
are	VBP	O
constrained	VBN	O
by	IN	O
the	DT	O
greater	JJR	O
relative	JJ	O
fluid	NN	O
requirements	NNS	O
of	IN	O
the	DT	O
infant	NN	WHO
and	CC	O
greater	JJR	O
caloric	NN	O
requirements	NNS	O
per	IN	O
kilogram	NN	O
.	.	O

To	TO	O
avoid	VB	O
these	DT	O
adverse	JJ	O
reactions	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
the	DT	O
dose	NN	O
be	VB	O
decreased	VBN	O
to	TO	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
for	IN	O
one	CD	PER
week	NN	PER
before	IN	O
full	JJ	O
discontinuation	NN	O
of	IN	O
BRINTELLIX	NNP	O
15	CD	DOS
mg	NN	UNIT
/	NNP	FREQ
day	NN	FREQ
or	CC	O
20	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
[	NNP	O
see	VBP	O
ADVERSE	NNP	O
REACTIONS	NNP	O
]	NNP	O
.	.	O

When	WRB	O
tetanus	NN	O
toxoid	NN	O
and	CC	O
TIG	NNP	O
(	(	O
Human	NNP	O
)	)	O
are	VBP	O
given	VBN	O
concurrently	RB	O
,	,	O
separate	JJ	O
syringes	NNS	O
and	CC	O
separate	JJ	O
sites	NNS	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

If	IN	O
LATUDA	NNP	O
is	VBZ	O
being	VBG	O
prescribed	VBN	O
and	CC	O
a	DT	O
moderate	JJ	O
CYP3A4	NNP	O
inhibitor	NN	O
(	(	O
e.g	NN	O
.	.	O

If	IN	O
repeat	JJ	O
neurosurgical	JJ	O
intervention	NN	O
is	VBZ	O
indicated	VBN	O
,	,	O
handle	VB	O
residual	JJ	O
wafers	NNS	O
or	CC	O
wafer	NN	O
remnants	NNS	O
as	IN	O
potential	JJ	O
cytotoxic	NN	O
agents	NNS	O
.	.	O

Blood	NNP	O
calcium	NN	O
and	CC	O
phosphorus	NN	O
determinations	NNS	O
must	MD	O
be	VB	O
made	VBN	O
every	DT	FREQ
2	CD	FREQ
weeks	NNS	FREQ
or	CC	O
more	RBR	O
frequently	RB	O
if	IN	O
necessary	JJ	O
.	.	O

The	DT	O
following	JJ	O
concentrations	NNS	O
and	CC	O
volumes	NNS	O
are	VBP	O
recommended	VBN	O
for	IN	O
normal	JJ	WHO
adult	NN	WHO
knee	NN	WHO
,	,	O
shoulder	NN	O
,	,	O
and	CC	O
temporomandibular	JJ	O
joints	NNS	O
but	CC	O
should	MD	O
serve	VB	O
as	IN	O
guidelines	NNS	O
since	IN	O
joints	NNS	O
may	MD	O
require	VB	O
more	JJR	O
or	CC	O
less	RBR	O
contrast	JJ	O
medium	NN	O
for	IN	O
optimal	JJ	O
visualization	NN	O
.	.	O

Reducing	VBG	O
head	NN	O
movement	NN	O
with	IN	O
tape	NN	O
or	CC	O
other	JJ	O
flexible	JJ	O
head	NN	O
restraints	NNS	O
may	MD	O
be	VB	O
employed	VBN	O
.	.	O

Table	JJ	O
5	CD	O
:	:	O
Usual	JJ	O
Daily	NNP	FREQ
Maintenance	NNP	O
Dose	NNP	O
Requirements	NNP	O
(	(	O
mcg	NN	O
)	)	O
of	IN	O
Digoxin	NNP	O
for	IN	O
Estimated	NNP	O
Peak	NNP	O
Body	NNP	O
Stores	NNP	O
of	IN	O
10	CD	DOS
mcg	NNS	UNIT
/	CD	O
kg	NNS	O

Do	NNP	O
not	RB	O
rub	VB	O
MELPAQUE	NNP	O
HP	NNP	O
4	CD	O
%	NN	O
CREAM	NNP	O
in	IN	O
.	.	O

DUETACT	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
the	DT	O
first	JJ	O
main	JJ	O
meal	NN	O
.	.	O

Patients	NNS	WHO
requiring	VBG	WHO
further	JJ	WHO
reduction	NN	WHO
in	IN	O
blood	NN	O
pressure	NN	O
should	MD	O
be	VB	O
titrated	VBN	O
to	TO	O
32	CD	DOS
mg.	NN	UNIT
Doses	NNP	O
larger	JJR	O
than	IN	O
32	CD	DOS
mg	NNS	UNIT
do	VBP	O
not	RB	O
appear	VB	O
to	TO	O
have	VB	O
a	DT	O
greater	JJR	O
blood	NN	O
pressure	NN	O
lowering	VBG	O
effect	NN	O
.	.	O

In	IN	O
infants	NNS	WHO
and	CC	WHO
children	NNS	WHO
,	,	O
a	DT	O
minimum	NN	O
of	IN	O
1	CD	DOS
mL	NNS	UNIT
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
6	CD	DOS
mL	NNS	UNIT
should	MD	O
be	VB	O
employed	VBN	O
.	.	O

Dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
40	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
PAXIL	NNP	O
CR	NNP	O
is	VBZ	O
12.5	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
for	IN	O
elderly	JJ	WHO
patients	NNS	WHO
,	,	WHO
debilitated	VBD	WHO
patients	NNS	WHO
,	,	O
and	CC	O
/	NNP	O
or	CC	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	NN	WHO
or	CC	WHO
hepatic	JJ	WHO
impairment	NN	WHO
.	.	O

CIMZIA	NNP	O
is	VBZ	O
administered	VBN	O
by	IN	O
subcutaneous	JJ	O
injection	NN	O
.	.	O

Since	IN	O
metabolism	NN	O
and	CC	O
excretion	NN	O
are	VBP	O
primarily	RB	O
hepatic	JJ	O
,	,	O
no	DT	O
modification	NN	O
is	VBZ	O
recommended	VBN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
renal	JJ	WHO
function	NN	WHO
.	.	O

LONSURF	NNP	O
is	VBZ	O
a	DT	O
cytotoxic	JJ	O
drug	NN	O
.	.	O

Removal	NN	O
of	IN	O
deeply	NN	O
inserted	JJ	O
implants	NNS	O
should	MD	O
be	VB	O
conducted	VBN	O
with	IN	O
caution	NN	O
in	IN	O
order	NN	O
to	TO	O
prevent	VB	O
injury	NN	O
to	TO	O
deeper	VB	O
neural	JJ	O
or	CC	O
vascular	JJ	O
structures	NNS	O
in	IN	O
the	DT	O
arm	NN	O
and	CC	O
be	VB	O
performed	VBN	O
by	IN	O
healthcare	NN	O
providers	NNS	O
familiar	JJ	O
with	IN	O
the	DT	O
anatomy	NN	O
of	IN	O
the	DT	O
arm	NN	O
.	.	O

For	IN	O
additional	JJ	O
patient	NN	O
instructions	NNS	O
regarding	VBG	O
missed	JJ	O
pills	NNS	O
,	,	O
see	VBP	O
the	DT	O
``	``	O
WHAT	NNP	O
TO	NNP	O
DO	VB	O
IF	NNP	O
YOU	NNP	O
MISS	NNP	O
PILLS	NNP	O
''	''	O
section	NN	O
in	IN	O
the	DT	O
DETAILED	NNP	O
PATIENT	NNP	O
LABELING	NNP	O
below	IN	O
.	.	O

Theophylline	NNP	O
distributes	VBZ	O
poorly	RB	O
into	IN	O
body	NN	O
fat	JJ	O
,	,	O
therefore	RB	O
,	,	O
mg	PRP	UNIT
/	VBP	O
kg	NNS	O
dose	VB	O
should	MD	O
be	VB	O
calculated	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
ideal	JJ	O
body	NN	O
weight	NN	O
.	.	O

0.045	CD	O

Therefore	RB	O
,	,	O
in	IN	O
some	DT	WHO
images	NNS	WHO
,	,	O
flutemetamol	VBP	O
F	NNP	O
18	CD	O
signal	NN	O
in	IN	O
these	DT	O
regions	NNS	O
may	MD	O
not	RB	O
be	VB	O
as	RB	O
intense	JJ	O
as	IN	O
in	IN	O
the	DT	O
frontal	JJ	O
lobes	NN	O
or	CC	O
the	DT	O
posterior	JJ	O
cingulate	NN	O
and	CC	O
precuneus	NN	O
regions	NNS	O
.	.	O

CHILDREN	NNP	WHO
12	CD	WHO
YEARS	NNP	WHO
OF	NNP	WHO
AGE	NNP	WHO
AND	NNP	WHO
UNDER	NNP	WHO
:	:	O
0.5	CD	DOS
mg	NN	UNIT
of	IN	O
each	DT	O
component	NN	O
per	IN	O
pound	NN	O
of	IN	O
body	NN	O
weight	NN	O
.	.	O

If	IN	O
necessary	JJ	O
,	,	O
interrupt	JJ	O
therapy	NN	O
with	IN	O
desirudin	NN	O
until	IN	O
aPTT	JJ	O
falls	NNS	O
to	TO	O
less	JJR	O
than	IN	O
two	CD	O
times	NNS	O
control	NN	O
,	,	O
at	IN	O
which	WDT	O
time	NN	O
treatment	NN	O
with	IN	O
desirudin	NN	O
can	MD	O
be	VB	O
resumed	VBN	O
at	IN	O
a	DT	O
reduced	JJ	O
dose	NN	O
.	.	O

Each	DT	O
0.5	CD	DOS
mL	NNS	UNIT
dose	JJ	UNIT
contains	NNS	O
25	CD	O
µg	NN	O
of	IN	O
purified	JJ	O
capsular	JJ	O
polysaccharide	NN	O
and	CC	O
18	CD	O
µg	NN	O
of	IN	O
conjugated	JJ	O
diphtheria	NN	O
toxoid	NN	O
protein	NN	O
.	.	O

Prior	RB	O
to	TO	O
dosing	VBG	O
with	IN	O
BENLYSTA	NNP	O
,	,	O
consider	VB	O
administering	VBG	O
premedication	NN	O
for	IN	O
prophylaxis	NN	O
against	IN	O
infusion	NN	O
reactions	NNS	O
and	CC	O
hypersensitivity	NN	O
reactions	NNS	O
[	VBP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
ADVERSE	NNP	O
REACTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	JJ	O
maintenance	NN	O
dosage	NN	O
is	VBZ	O
a	DT	O
subcutaneous	JJ	O
90	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
administered	VBD	O
8	CD	PER
weeks	NNS	PER
after	IN	O
the	DT	O
initial	JJ	O
intravenous	JJ	O
dose	NN	O
,	,	O
then	RB	O
every	DT	FREQ
8	CD	FREQ
weeks	NNS	FREQ
thereafter	RB	O
.	.	O

As	IN	O
ELELYSO	NNP	O
contains	VBZ	O
no	DT	O
preservative	NN	O
,	,	O
the	DT	O
product	NN	O
should	MD	O
be	VB	O
used	VBN	O
immediately	RB	O
once	RB	O
reconstituted	VBN	O
.	.	O

Before	IN	O
reconstitution	NN	O
:	:	O

Sulfonylurea	JJ	O
agents	NNS	O
or	CC	O
insulin	NN	O
may	MD	O
cause	VB	O
hypoglycemia	NN	O
.	.	O

Administration	NNP	O
Poliovirus	NNP	O
vaccine	VBP	O
live	JJ	O
oral	NN	O
,	,	O
OPV	NNP	O
is	VBZ	O
administered	VBN	O
orally	RB	O
.	.	O

In	IN	O
elderly	JJ	WHO
patients	NNS	WHO
,	,	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
advanced	JJ	WHO
liver	NN	WHO
disease	NN	WHO
or	CC	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
debilitating	VBG	WHO
disease	NN	WHO
,	,	O
the	DT	O
usual	JJ	O
starting	NN	O
dose	NN	O
is	VBZ	O
0.25	CD	DOS
mg	NN	UNIT
,	,	O
given	VBN	O
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Not	RB	O
for	IN	O
injection	NN	O
.	.	O

4	CD	O
.	.	O

Withdraw	JJ	O
0.5	CD	DOS
mL	NN	UNIT
from	IN	O
the	DT	O
vial	JJ	O
using	VBG	O
a	DT	O
sterile	JJ	O
needle	NN	O
and	CC	O
syringe	NN	O
free	JJ	O
of	IN	O
preservatives	NNS	O
,	,	O
antiseptics	NNS	O
,	,	O
and	CC	O
detergents	NNS	O
.	.	O

Enzyme	NNP	O
doses	NNS	O
expressed	VBD	O
as	IN	O
lipase	NN	O
units	NNS	O
/	VBP	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
per	IN	O
meal	NN	O
should	MD	O
be	VB	O
decreased	VBN	O
in	IN	O
older	JJR	WHO
patients	NNS	WHO
because	IN	O
they	PRP	O
weigh	VBP	O
more	JJR	O
but	CC	O
tend	VBP	O
to	TO	O
ingest	VB	O
less	JJR	O
fat	JJ	O
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	NN	O
.	.	O

In	IN	O
addition	NN	O
to	TO	O
the	DT	O
general	JJ	O
precautions	NNS	O
previously	RB	O
described	VBN	O
,	,	O
the	DT	O
hazards	NNS	O
of	IN	O
aortography	NN	O
include	VBP	O
those	DT	O
associated	VBN	O
with	IN	O
the	DT	O
particular	JJ	O
technique	NN	O
employed	VBN	O
,	,	O
the	DT	O
contrast	NN	O
medium	NN	O
and	CC	O
the	DT	O
underlying	VBG	O
pathology	NN	O
which	WDT	O
warrants	NNS	O
the	DT	O
procedure	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
PEGASYS	NN	O
and	CC	O
COPEGUS	NNP	O
Dosing	NNP	O
Recommendations	NNS	O

Thereafter	RB	O
,	,	O
schedule	NN	O
injections	NNS	O
every	DT	FREQ
6	CD	FREQ
months	NNS	FREQ
from	IN	O
the	DT	O
date	NN	O
of	IN	O
the	DT	O
last	JJ	O
injection	NN	O
.	.	O

If	IN	O
prolonged	VBN	O
hypotension	NN	O
occurs	VBZ	O
(	(	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
<	VBZ	O
90	CD	O
mmHg	NN	O
for	IN	O
more	JJR	O
than	IN	O
1	CD	O
hour	NN	O
)	)	O
QBRELIS	NN	O
should	MD	O
be	VB	O
withdrawn	VBN	O
.	.	O

Based	VBN	O
on	IN	O
clinical	JJ	O
studies	NNS	O
,	,	O
on	IN	O
average	JJ	WHO
patients	NNS	WHO
required	VBD	WHO
3	CD	WHO
to	TO	WHO
4	CD	WHO
tablets	NNS	WHO
(	(	O
1,500	CD	DOS
mg	NN	UNIT
to	TO	O
2,000	CD	DOS
mg	NN	UNIT
)	)	O
a	DT	FREQ
day	NN	FREQ
to	TO	O
control	VB	O
serum	JJ	O
phosphorus	NN	O
levels	NNS	O
.	.	O

For	IN	O
specific	JJ	O
techniques	NNS	O
and	CC	O
procedures	NNS	O
refer	VBP	O
to	TO	O
standard	VB	O
textbooks	NNS	O
.	.	O

Thyroid	NNP	O
hormones	NNS	O
should	MD	O
be	VB	O
administered	VBN	O
cautiously	RB	O
to	TO	O
patients	NNS	WHO
in	IN	WHO
whom	WP	WHO
there	EX	WHO
is	VBZ	O
strong	JJ	O
suspicion	NN	O
of	IN	O
thyroid	JJ	O
gland	NN	O
autonomy	NN	O
,	,	O
in	IN	O
view	NN	O
of	IN	O
the	DT	O
fact	NN	O
that	IN	O
the	DT	O
exogenous	JJ	O
hormone	NN	O
effects	NNS	O
will	MD	O
be	VB	O
additive	JJ	O
to	TO	O
the	DT	O
endogenous	JJ	O
source	NN	O
.	.	O

1976	CD	O
;	:	O
16:31	CD	O
-	:	O
41	CD	O
.	.	O

This	DT	O
risk	NN	O
increases	VBZ	O
with	IN	O
age	NN	O
and	CC	O
with	IN	O
heavy	JJ	O
smoking	NN	O
(	(	O
15	CD	O
or	CC	O
more	JJR	O
cigarettes	NNS	O
per	IN	FREQ
day	NN	FREQ
)	)	O
and	CC	O
is	VBZ	O
quite	RB	O
marked	VBN	O
in	IN	O
women	NNS	WHO
over	IN	WHO
35	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

Use	NNP	O
of	IN	O
estrogen	NN	O
-	:	O
alone	RB	O
,	,	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
progestin	NN	O
,	,	O
should	MD	O
be	VB	O
with	IN	O
the	DT	O
lowest	JJS	O
effective	JJ	O
dose	NN	O
and	CC	O
for	IN	O
the	DT	O
shortest	JJS	O
duration	NN	O
consistent	NN	O
with	IN	O
treatment	NN	O
goals	NNS	O
and	CC	O
risks	NNS	O
for	IN	O
the	DT	O
individual	JJ	O
woman	NN	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
Seasonale®	NNP	O
(	(	O
levonorgestrel	NN	O
,	,	O
ethinyl	FW	O
estradiol	NN	O
)	)	O
is	VBZ	O
one	CD	DOS
pink	NN	UNIT
(	(	O
active	JJ	O
)	)	O
tablet	VBP	O
daily	JJ	FREQ
for	IN	O
84	CD	PER
consecutive	JJ	PER
days	NNS	PER
,	,	O
followed	VBN	O
by	IN	O
7	CD	PER
days	NNS	PER
of	IN	O
white	JJ	O
(	(	O
inert	NN	O
)	)	O
tablets	NNS	O
.	.	O

Discard	NNP	O
any	DT	O
unused	JJ	O
product	NN	O
or	CC	O
waste	NN	O
material	NN	O
in	IN	O
accordance	NN	O
with	IN	O
local	JJ	O
requirements	NNS	O
.	.	O

Recommended	VBN	O
doses	NNS	O
and	CC	O
adjustment	NN	O
for	IN	O
dose	NN	O
for	IN	O
adults	NNS	WHO
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
.	.	O

Register	NNP	O
and	CC	O
document	NN	O
(	(	O
map	NN	O
)	)	O
the	DT	O
location	NN	O
and	CC	O
appearance	NN	O
(	(	O
e.g	NN	O
.	.	O

Withdraw	IN	O
the	DT	O
needle	NN	O
and	CC	O
allow	VB	O
protective	JJ	O
sleeve	NN	O
to	TO	O
slide	VB	O
and	CC	O
cover	VB	O
needle	NN	O
.	.	O

Nervous	JJ	O
system	NN	O
:	:	O
Swelling	VBG	O
sensation	NN	O
(	(	O
42	CD	O
%	NN	O
)	)	O
,	,	O
pain	NN	O
(	(	O
29	CD	O
%	NN	O
)	)	O
,	,	O
heat	JJ	O
sensation	NN	O
(	(	O
13	CD	O
%	NN	O
)	)	O
,	,	O
and	CC	O
muscle	NN	O
weakness	NN	O
(	(	O
0.7	CD	O
%	NN	O
)	)	O
.	.	O

Each	DT	O
0.5	CD	DOS
mL	NN	UNIT
dose	NN	UNIT
is	VBZ	O
to	TO	O
be	VB	O
injected	VBN	O
intramuscularly	RB	O
using	VBG	O
a	DT	O
sterile	JJ	O
needle	NN	O
attached	VBN	O
to	TO	O
the	DT	O
supplied	VBN	O
prefilled	JJ	O
syringe	NN	O
.	.	O

The	DT	O
suggested	VBN	O
dose	NN	O
is	VBZ	O
0.5	CD	DOS
to	TO	O
5	CD	DOS
mg	NN	UNIT
(	(	O
0.05	CD	DOS
to	TO	O
0.5	CD	DOS
mL	NN	UNIT
)	)	O
,	,	O
followed	VBN	O
by	IN	O
an	DT	O
infusion	NN	O
of	IN	O
15	CD	DOS
to	TO	O
100	CD	DOS
mg	NN	UNIT
(	(	O
1.5	CD	DOS
to	TO	O
10	CD	DOS
mL	NN	UNIT
)	)	O
in	IN	O
500	CD	DOS
mL	NN	UNIT
of	IN	O
infusion	NN	O
fluid	NN	O
as	IN	O
described	VBN	O
previously	RB	O
.	.	O

As	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

Children	NNS	WHO
:	:	O
In	IN	O
children	NNS	WHO
2	CD	WHO
to	TO	WHO
5	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
(	(	WHO
20	CD	WHO
kg	NN	WHO
or	CC	WHO
less	JJR	WHO
)	)	WHO
,	,	O
the	DT	O
non	JJ	O
-	:	O
prescription	NN	O
liquid	JJ	O
formulation	NN	O
(	(	O
IMODIUM®	NNP	O
(	(	O
loperamide	JJ	O
hcl	NN	O
)	)	O
A	DT	O
-	:	O
D	NN	O
1	CD	DOS
mg	NN	UNIT
/	VBD	O
5	CD	DOS
mL	NN	UNIT
)	)	O
should	MD	O
be	VB	O
used	VBN	O
;	:	O
for	IN	O
ages	NNS	WHO
6	CD	WHO
to	TO	WHO
12	CD	WHO
,	,	O
either	DT	O
IMODIUM®	NNP	O
(	(	O
loperamide	JJ	O
hcl	NN	O
)	)	O
Capsules	VBZ	O
or	CC	O
IMODIUM®	NNP	O
(	(	O
loperamide	JJ	O
hcl	NN	O
)	)	O
A	DT	O
-	:	O
D	NNP	O
Liquid	NNP	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

Higher	JJR	O
doses	NNS	O
of	IN	O
DIPRIVAN	NNP	O
Injectable	NNP	O
Emulsion	NNP	O
will	MD	O
reduce	VB	O
the	DT	O
opioid	NN	O
requirements	NNS	O
(	(	O
see	VB	O
Table	NNP	O
4	CD	O
)	)	O
.	.	O

Do	MD	O
not	RB	O
store	VB	O
for	IN	O
future	JJ	O
use	NN	O
.	.	O

Consult	NN	WHO
with	IN	WHO
pharmacist	NN	WHO
,	,	O
if	IN	O
available	JJ	O
.	.	O

All	DT	WHO
patients	NNS	WHO
should	MD	O
be	VB	O
counseled	VBN	O
to	TO	O
anticipate	VB	O
supplemental	JJ	O
implantations	NNS	O
to	TO	O
achieve	VB	O
and	CC	O
maintain	VB	O
optimal	JJ	O
correction	NN	O
.	.	O

Due	JJ	O
to	TO	O
the	DT	O
absence	NN	O
of	IN	O
data	NNS	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
,	,	O
no	DT	O
dosage	NN	O
recommendation	NN	O
can	MD	O
be	VB	O
made	VBN	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
:	:	O
General	NNP	O
)	)	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
unless	IN	O
solution	NN	O
is	VBZ	O
clear	JJ	O
and	CC	O
seal	NN	O
is	VBZ	O
intact	JJ	O
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
interdigital	JJ	O
tinea	NN	O
pedis	NN	O
,	,	O
Mentax®	NNP	O
(	(	O
butenafine	NN	O
)	)	O
should	MD	O
be	VB	O
applied	VBN	O
twice	JJ	FREQ
daily	RB	FREQ
for	IN	O
7	CD	PER
days	NNS	PER
OR	NNP	O
once	RB	FREQ
daily	RB	FREQ
for	IN	O
4	CD	PER
weeks	NNS	PER
(	(	O
NOTE	NN	O
:	:	O
in	IN	O
separate	JJ	O
clinical	JJ	O
trials	NNS	O
,	,	O
the	DT	O
7	CD	O
-	:	O
day	NN	O
dosing	VBG	O
regimen	NNS	O
was	VBD	O
less	RBR	O
efficacious	JJ	O
than	IN	O
the	DT	O
4	CD	O
-	:	O
week	NN	PER
regimen	NNS	O
(	(	O
see	VB	O
Clinical	NNP	O
Studies	NNP	O
Section	NNP	O
)	)	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
's	POS	O
symptoms	NNS	O
are	VBP	O
well	RB	O
controlled	VBN	O
,	,	O
there	EX	O
are	VBP	O
no	DT	O
apparent	JJ	O
adverse	JJ	O
effects	NNS	O
,	,	O
and	CC	O
no	DT	O
intervening	NN	O
factors	NNS	O
that	WDT	O
might	MD	O
alter	VB	O
dosage	NN	O
requirements	NNS	O
(	(	O
see	VB	O
WARNINGS	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
)	)	O
,	,	O
serum	JJ	O
theophylline	NN	O
concentrations	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
at	IN	O
6	CD	O
month	NN	O
intervals	NNS	O
for	IN	O
rapidly	RB	WHO
growing	VBG	WHO
children	NNS	WHO
and	CC	WHO
at	IN	WHO
yearly	JJ	WHO
intervals	NNS	WHO
for	IN	WHO
all	DT	WHO
others	NNS	WHO
.	.	O

Many	JJ	O
parenteral	JJ	O
vitamins	NNS	O
are	VBP	O
light	JJ	O
sensitive	JJ	O
and	CC	O
exposure	NN	O
to	TO	O
light	NN	O
should	MD	O
be	VB	O
minimized	VBN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
a	DT	O
CT	NNP	O
scan	JJ	O
to	TO	O
calculate	VB	O
attenuation	NN	O
correction	NN	O
for	IN	O
reconstruction	NN	O
of	IN	O
Vizamyl	NNP	O
images	NNS	O
(	(	O
as	IN	O
done	VBN	O
in	IN	O
PET	NNP	O
/	NNP	O
CT	NNP	O
imaging	VBG	O
)	)	O
will	MD	O
add	VB	O
radiation	NN	O
exposure	NN	O
at	IN	O
the	DT	O
level	NN	O
of	IN	O
approximately	RB	O
0.1	CD	O
mSv	NNS	O
effective	JJ	O
dose	NN	O
.	.	O

If	IN	O
the	DT	O
antihypertensive	JJ	O
effect	NN	O
measured	VBN	O
at	IN	O
trough	IN	O
using	VBG	O
once	RB	O
-	:	O
daily	JJ	FREQ
monotherapy	NN	O
dosing	NN	O
is	VBZ	O
inadequate	JJ	O
,	,	O
a	DT	O
twice	RB	FREQ
-	:	FREQ
a	DT	FREQ
-	:	FREQ
day	NN	FREQ
regimen	NNS	O
at	IN	O
the	DT	O
same	JJ	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
or	CC	O
an	DT	O
increase	NN	O
in	IN	O
dose	JJ	O
may	MD	O
give	VB	O
a	DT	O
more	RBR	O
satisfactory	JJ	O
response	NN	O
.	.	O

Women	NNS	WHO
should	MD	O
expect	VB	O
to	TO	O
experience	VB	O
vaginal	JJ	O
bleeding	NN	O
or	CC	O
spotting	VBG	O
for	IN	O
an	DT	O
average	NN	O
of	IN	O
9	CD	PER
to	TO	O
16	CD	PER
days	NNS	PER
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
additional	JJ	O
doses	NNS	O
of	IN	O
COMBIVENT	NNP	O
RESPIMAT	NNP	O
beyond	IN	O
six	CD	DOS
inhalations	NNS	UNIT
/	VBP	O
24	CD	O
hours	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

To	TO	O
provide	VB	O
azithromycin	NN	O
over	IN	O
a	DT	O
concentration	NN	O
range	NN	O
of	IN	O
1.0	CD	DOS
-	:	O
2.0	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
,	,	O
transfer	VB	O
5	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
100	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
azithromycin	NN	O
solution	NN	O
into	IN	O
the	DT	O
appropriate	JJ	O
amount	NN	O
of	IN	O
any	DT	O
of	IN	O
the	DT	O
diluents	NNS	O
listed	VBN	O
below	IN	O
:	:	O

The	DT	O
maximum	JJ	O
benefit	NN	O
may	MD	O
not	RB	O
be	VB	O
achieved	VBN	O
for	IN	O
1	CD	PER
week	NN	PER
or	CC	O
longer	JJR	O
after	IN	O
beginning	VBG	O
treatment	NN	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
for	IN	O
injections	NNS	O
into	IN	O
the	DT	O
aorta	NN	O
is	VBZ	O
25	CD	DOS
to	TO	O
50	CD	DOS
mL	NN	UNIT
;	:	O
the	DT	O
celiac	NN	O
artery	NN	O
is	VBZ	O
40	CD	DOS
mL	NN	UNIT
;	:	O
the	DT	O
superior	JJ	O
mesenteric	JJ	O
artery	NN	O
is	VBZ	O
20	CD	DOS
to	TO	O
40	CD	DOS
mL	NN	UNIT
;	:	O
the	DT	O
inferior	JJ	O
mesenteric	JJ	O
artery	NN	O
is	VBZ	O
8	CD	DOS
to	TO	O
15	CD	DOS
mL	NNS	UNIT
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Patients	NNS	O
are	VBP	O
advised	VBN	O
to	TO	O
have	VB	O
a	DT	O
dietary	JJ	O
intake	NN	O
of	IN	O
calcium	NN	O
at	IN	O
a	DT	O
minimum	NN	O
of	IN	O
600	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
.	.	O

Figure	NN	O
2	CD	O
:	:	O
Injection	NN	O
Sites	VBZ	O
for	IN	O
Upper	NNP	O
Limb	NNP	O
Spasticity	NNP	O

The	DT	O
4	CD	O
liter	NN	O
reconstituted	VBD	O
NuLYTELY	NNP	O
solution	NN	O
contains	NNS	O
:	:	O
420	CD	DOS
grams	NNS	UNIT
of	IN	O
polyethylene	NN	O
glycol	NN	O
(	(	O
PEG	NNP	O
)	)	O
3350	CD	DOS
,	,	O
5.72	CD	DOS
grams	NNS	UNIT
of	IN	O
sodium	NN	O
bicarbonate	NN	O
,	,	O
11.2	CD	DOS
grams	NNS	UNIT
of	IN	O
sodium	NN	O
chloride	NN	O
,	,	O
and	CC	O
1.4	CD	DOS
grams	NNS	UNIT
of	IN	O
potassium	NN	O
chloride	NN	O
.	.	O

When	WRB	O
the	DT	O
replacement	NN	O
line	NN	O
is	VBZ	O
disconnected	VBN	O
from	IN	O
the	DT	O
luer	NN	O
connector	NN	O
,	,	O
the	DT	O
connector	NN	O
will	MD	O
close	VB	O
and	CC	O
the	DT	O
flow	NN	O
of	IN	O
the	DT	O
solution	NN	O
will	MD	O
stop	VB	O
.	.	O

Sporadic	JJ	O
cases	NNS	O
of	IN	O
hyperpyrexia	NN	O
and	CC	O
confusion	NN	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
dose	JJ	O
reductions	NNS	O
and	CC	O
withdrawal	NN	O
of	IN	O
SINEMET	NNP	O
or	CC	O
SINEMET	NNP	O
CR	NNP	O
.	.	O

DIANEAL	NNP	O
4.25	CD	O
%	NN	O
dextrose	JJ	O
-	:	O
containing	VBG	O
solution	NN	O
has	VBZ	O
the	DT	O
highest	JJS	O
osmolarity	NN	O
of	IN	O
the	DT	O
DIANEAL	NNP	O
solutions	NNS	O
and	CC	O
using	VBG	O
it	PRP	O
for	IN	O
all	DT	O
exchanges	NNS	O
may	MD	O
cause	VB	O
dehydration	NN	O
[	NNP	O
see	VBP	O
Dosage	NNP	O
Forms	NNP	O
and	CC	O
Strengths	NNP	O
]	NNP	O
.	.	O

If	IN	O
possible	JJ	O
,	,	O
a	DT	O
person	NN	O
other	JJ	O
than	IN	O
the	DT	O
victim	NN	O
should	MD	O
administer	VB	O
the	DT	O
second	JJ	O
and	CC	O
third	JJ	O
AtroPen®	NNP	O
(	(	O
atropine	NN	O
)	)	O
injections	NNS	O
.	.	O

Use	NNP	O
of	IN	O
APTIOM	NNP	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
,	,	O
and	CC	O
use	NN	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
is	VBZ	O
not	RB	O
recommended	JJ	O
[	NNS	O
see	VBP	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

When	WRB	O
transferring	VBG	O
patients	NNS	WHO
from	IN	WHO
chlorpropamide	NN	WHO
,	,	O
care	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
during	IN	O
the	DT	O
first	JJ	O
2	CD	PER
weeks	NNS	PER
because	IN	O
of	IN	O
the	DT	O
prolonged	JJ	O
retention	NN	O
of	IN	O
chlorpropamide	NN	O
in	IN	O
the	DT	O
body	NN	O
,	,	O
leading	VBG	O
to	TO	O
overlapping	VBG	O
drug	NN	O
effects	NNS	O
and	CC	O
possible	JJ	O
hypoglycemia	NN	O
.	.	O

The	DT	O
administration	NN	O
of	IN	O
hCG	NN	O
must	MD	O
be	VB	O
withheld	VBN	O
in	IN	O
cases	NNS	O
where	WRB	O
the	DT	O
ovaries	NNS	O
are	VBP	O
abnormally	RB	O
enlarged	VBN	O
on	IN	O
the	DT	O
last	JJ	O
day	NN	O
of	IN	O
therapy	NN	O
.	.	O

Patient	JJ	O
Labeling	NNP	O
and	CC	O
Drug	NNP	O
Powder	NNP	O
/	NNP	O
Diluent	NNP	O
Inspection	NNP	O

Table	JJ	O
1	CD	O
provides	VBZ	O
dosing	VBG	O
information	NN	O
for	IN	O
adult	NN	WHO
males	NNS	WHO
.	.	O

The	DT	O
daily	JJ	FREQ
dose	NN	O
may	MD	O
be	VB	O
reduced	VBN	O
by	IN	O
10	CD	O
to	TO	O
20	CD	O
%	NN	O
if	IN	O
patients	NNS	WHO
experience	JJ	WHO
side	JJ	WHO
effects	NNS	WHO
.	.	O

The	DT	O
durability	NN	O
of	IN	O
efficacy	NN	O
beyond	IN	O
24	CD	O
months	NNS	O
of	IN	O
therapy	NN	O
with	IN	O
DOSTINEX	NNP	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	O

2	CD	O
.	.	O

For	IN	O
guidelines	NNS	O
for	IN	O
dose	JJ	O
modifications	NNS	O
and	CC	O
discontinuation	NN	O
based	VBN	O
on	IN	O
depression	NN	O
or	CC	O
laboratory	NN	O
parameters	NNS	O
see	VBP	O
Tables	VBZ	O
4	CD	O
and	CC	O
5	CD	O
.	.	O

Swallow	JJ	O
capsules	NNS	O
whole	VBP	O
.	.	O

To	TO	O
calculate	VB	O
a	DT	O
patient	NN	O
's	POS	O
weight	NN	O
in	IN	O
kg	NN	O
when	WRB	O
lbs	NN	O
are	VBP	O
known	VBN	O
:	:	O

Children	$	WHO
6	CD	WHO
to	TO	WHO
under	IN	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
:	:	O
1	CD	O
/	$	O
2	CD	O
teaspoonful	JJ	O
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
3	CD	O
teaspoonsful	JJ	O
in	IN	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
highest	JJS	O
dose	NN	O
administered	VBN	O
has	VBZ	O
been	VBN	O
300	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
.	.	O

Limited	VBN	O
data	NNS	O
are	VBP	O
available	JJ	O
on	IN	O
the	DT	O
use	NN	O
of	IN	O
oral	JJ	O
itraconazole	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
.	.	O

The	DT	O
activity	NN	O
per	IN	O
test	NN	O
is	VBZ	O
comparable	JJ	O
to	TO	O
or	CC	O
greater	JJR	O
than	IN	O
5	CD	DOS
tuberculin	JJ	UNIT
units	NNS	UNIT
(	(	O
5	CD	DOS
TU	NNP	UNIT
)	)	O
administrated	VBN	O
by	IN	O
the	DT	O
Mantoux	NNP	O
method	NN	O
.	.	O

Although	IN	O
nitrogen	NN	O
requirements	NNS	O
may	MD	O
be	VB	O
higher	JJR	O
in	IN	O
stressed	JJ	WHO
or	CC	WHO
acutely	RB	WHO
uremic	JJ	WHO
patients	NNS	WHO
,	,	O
or	CC	O
those	DT	O
on	IN	O
dialysis	NN	O
,	,	O
provision	NN	O
of	IN	O
additional	JJ	O
nitrogen	NN	O
may	MD	O
not	RB	O
be	VB	O
possible	JJ	O
due	JJ	O
to	TO	O
fluid	VB	O
intake	VB	O
limits	NNS	O
or	CC	O
glucose	JJ	O
intolerance	NN	O
.	.	O

Use	NNP	O
within	IN	O
21	CD	O
days	NNS	O
after	IN	O
constitution	NN	O
.	.	O

The	DT	O
optimal	JJ	O
duration	NN	O
of	IN	O
therapy	NN	O
is	VBZ	O
unknown	JJ	O
.	.	O

Once	RB	O
the	DT	O
nasal	NN	O
spray	NN	O
applicator	NN	O
has	VBZ	O
been	VBN	O
prepared	VBN	O
,	,	O
it	PRP	O
should	MD	O
be	VB	O
discarded	VBN	O
(	(	O
with	IN	O
any	DT	O
remaining	VBG	O
drug	NN	O
in	IN	O
opened	VBN	O
vial	NN	O
after	IN	O
8	CD	O
hours	NNS	O
)	)	O
.	.	O

Instruct	NN	O
patients	NNS	O
to	TO	O
swallow	VB	O
TARGINIQ	NNP	O
ER	NNP	O
tablets	VBZ	O
intact	JJ	O
.	.	O

Therefore	RB	O
,	,	O
the	DT	O
patient	NN	O
's	POS	O
dosing	NN	O
schedule	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
so	RB	O
that	IN	O
an	DT	O
additional	JJ	O
dose	NN	O
is	VBZ	O
administered	VBN	O
after	IN	O
each	DT	O
dialysis	NN	O
.	.	O

Methadone	NNP	O
hydrochloride	NN	O
tablets	NNS	O
,	,	O
USP	NNP	O
should	MD	O
be	VB	O
prescribed	VBN	O
only	RB	O
by	IN	O
healthcare	JJ	O
professionals	NNS	O
who	WP	O
are	VBP	O
knowledgeable	JJ	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
potent	JJ	O
opioids	NNS	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
chronic	JJ	O
pain	NN	O
.	.	O

Prepare	VB	O
a	DT	O
suspension	NN	O
at	IN	O
time	NN	O
of	IN	O
dispensing	VBG	O
as	IN	O
follows	VBZ	O
:	:	O
Tap	NNP	O
bottle	NN	O
until	IN	O
all	PDT	O
the	DT	O
powder	NN	O
flows	VBZ	O
freely	RB	O
.	.	O

QVAR	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
by	IN	O
the	DT	O
oral	JJ	O
inhaled	JJ	O
route	NN	O
in	IN	O
patients	NNS	WHO
5	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
.	.	O

Chemotherapy	NN	O
courses	NNS	O
are	VBP	O
repeated	VBN	O
at	IN	O
3	CD	O
-	:	O
to	TO	O
4	CD	PER
-	:	O
week	NN	PER
intervals	NNS	O
after	IN	O
adequate	JJ	O
recovery	NN	O
from	IN	O
any	DT	O
toxicity	NN	O
.	.	O

Removal	NN	O
of	IN	O
the	DT	O
unattached	JJ	O
,	,	O
infected	JJ	O
nail	NN	O
,	,	O
as	RB	O
frequently	RB	O
as	IN	O
monthly	JJ	O
,	,	O
trimming	VBG	O
of	IN	O
onycholytic	JJ	O
nail	NN	O
,	,	O
and	CC	O
filing	NN	O
of	IN	O
excess	JJ	O
horny	JJ	O
material	NN	O
should	MD	O
be	VB	O
performed	VBN	O
by	IN	O
professionals	NNS	O
trained	VBN	O
in	IN	O
treatment	NN	O
of	IN	O
nail	NN	O
disorders	NNS	O
.	.	O

After	IN	O
injection	NN	O
,	,	O
any	DT	O
unused	JJ	O
product	NN	O
must	MD	O
be	VB	O
discarded	VBN	O
.	.	O

Failure	NN	O
of	IN	O
the	DT	O
infection	NN	O
to	TO	O
respond	VB	O
may	MD	O
be	VB	O
due	JJ	O
to	TO	O
resistance	NN	O
of	IN	O
the	DT	O
organism	NN	O
or	CC	O
to	TO	O
the	DT	O
presence	NN	O
of	IN	O
septic	JJ	O
foci	NN	O
requiring	VBG	O
surgical	JJ	O
drainage	NN	O
.	.	O

Titration	NN	O
of	IN	O
the	DT	O
dose	NN	O
as	IN	O
needed	VBN	O
based	VBN	O
on	IN	O
individual	JJ	O
clinical	JJ	O
response	NN	O
and	CC	O
tolerability	NN	O
.	.	O

If	IN	O
a	DT	O
clinical	JJ	O
(	(	O
symptomatic	JJ	O
)	)	O
hepatic	JJ	O
event	NN	O
occurs	NNS	O
,	,	O
permanently	RB	O
discontinue	JJ	O
nevirapine	NN	O
.	.	O

After	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
of	IN	O
6.25	CD	DOS
mg	NNS	UNIT
,	,	O
CAPOTEN	NNP	O
therapy	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
12.5	CD	DOS
mg	NN	UNIT
t.i.d	NN	O
.	.	O

Dosage	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
to	TO	O
the	DT	O
needs	NNS	O
of	IN	O
the	DT	O
individual	JJ	O
patients	NNS	O
.	.	O

See	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
for	IN	O
dosing	VBG	O
information	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
failure	NN	WHO
.	.	O

To	TO	O
prevent	VB	O
rebound	NN	O
hypoglycemia	NN	O
,	,	O
do	VBP	O
not	RB	O
abruptly	RB	O
discontinue	JJ	O
administration	NN	O
of	IN	O
nutritional	JJ	O
solutions	NNS	O
.	.	O

Occlusive	JJ	O
dressings	NNS	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
with	IN	O
Panretin®	NNP	O
gel	NN	O
.	.	O

Discard	NNP	O
the	DT	O
reconstituted	JJ	O
solution	NN	O
if	IN	O
not	RB	O
used	VBN	O
within	IN	O
24	CD	O
hours	NNS	O
.	.	O

A	DT	O
direct	JJ	O
push	NN	O
injection	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
due	JJ	O
to	TO	O
the	DT	O
risk	NN	O
of	IN	O
extravasation	NN	O
,	,	O
which	WDT	O
may	MD	O
occur	VB	O
even	RB	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
adequate	JJ	O
blood	NN	O
return	NN	O
upon	IN	O
needle	JJ	O
aspiration	NN	O
.	.	O

During	IN	O
chronic	JJ	O
therapy	NN	O
periodically	RB	O
reassess	VB	O
the	DT	O
continued	JJ	O
need	NN	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
opioid	JJ	O
analgesics	NNS	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
Neulasta	NNP	O
between	IN	O
14	CD	O
days	NNS	O
before	IN	O
and	CC	O
24	CD	O
hours	NNS	O
after	IN	O
administration	NN	O
of	IN	O
cytotoxic	JJ	O
chemotherapy	NN	O
.	.	O

Sterile	NNP	O
reconstituted	VBD	O
solutions	NNS	O
should	MD	O
be	VB	O
protected	VBN	O
from	IN	O
light	JJ	O
and	CC	O
may	MD	O
be	VB	O
stored	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
for	IN	O
one	CD	PER
week	NN	PER
without	IN	O
significant	JJ	O
loss	NN	O
of	IN	O
potency	NN	O
.	.	O

Flush	NN	O
with	IN	O
water	NN	O
if	IN	O
contact	NN	O
is	VBZ	O
made	VBN	O
with	IN	O
skin	NN	O
.	.	O

Adults	NNS	WHO
should	MD	O
take	VB	O
LEXIVA	NNP	O
oral	JJ	O
suspension	NN	O
without	IN	O
food	NN	O
.	.	O

Deep	JJ	O
insertion	NN	O
of	IN	O
the	DT	O
implant	NN	O
will	MD	O
not	RB	O
affect	VB	O
the	DT	O
performance	NN	O
of	IN	O
SUPPRELIN	NNP	O
LA	NNP	O
,	,	O
but	CC	O
may	MD	O
cause	VB	O
difficulty	NN	O
in	IN	O
the	DT	O
later	JJ	O
removal	NN	O
of	IN	O
the	DT	O
implant	NN	O
.	.	O

Within	IN	O
the	DT	O
above	NN	O
recommended	VBD	O
intervals	NNS	O
administration	NN	O
time	NN	O
should	MD	O
be	VB	O
determined	VBN	O
by	IN	O
abortifacient	JJ	O
progress	NN	O
,	,	O
uterine	JJ	O
contractility	NN	O
response	NN	O
,	,	O
and	CC	O
by	IN	O
patient	JJ	O
tolerance	NN	O
.	.	O

The	DT	O
effects	NNS	O
of	IN	O
the	DT	O
drug	NN	O
sometimes	RB	O
appear	VB	O
within	IN	O
30	CD	O
minutes	NNS	O
and	CC	O
are	VBP	O
usually	RB	O
maximal	JJ	O
within	IN	O
60	CD	O
to	TO	O
90	CD	O
minutes	NNS	O
.	.	O

Individual	JJ	O
response	NN	O
will	MD	O
vary	VB	O
with	IN	O
age	NN	O
,	,	O
physical	JJ	O
status	NN	O
and	CC	O
concomitant	JJ	O
medications	NNS	O
,	,	O
but	CC	O
may	MD	O
also	RB	O
vary	JJ	O
independent	JJ	O
of	IN	O
these	DT	O
factors	NNS	O
.	.	O

VELCADE	NNP	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
by	IN	O
any	DT	O
other	JJ	O
route	NN	O
.	.	O

[	NNS	O
see	VBP	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Multiple	JJ	O
doses	NNS	O
of	IN	O
RhoGAM	NNP	O
are	VBP	O
required	VBN	O
if	IN	O
a	DT	O
FMH	NNP	O
exceeds	VBZ	O
15	CD	DOS
mL	NN	UNIT
,	,	O
an	DT	O
event	NN	O
that	WDT	O
is	VBZ	O
possible	JJ	O
but	CC	O
unlikely	JJ	O
prior	JJ	O
to	TO	O
the	DT	O
third	JJ	O
trimester	NN	O
of	IN	O
pregnancy	NN	O
and	CC	O
is	VBZ	O
most	RBS	O
likely	JJ	O
at	IN	O
delivery	NN	O
.	.	O

Most	JJS	WHO
patients	NNS	WHO
do	VBP	O
not	RB	O
experience	VB	O
withdrawal	NN	O
during	IN	O
the	DT	O
72	CD	O
-	:	O
hour	NN	O
inter	NN	O
-	:	O
dose	NN	O
interval	NN	O
after	IN	O
reaching	VBG	O
pharmacological	JJ	O
steady	JJ	O
-	:	O
state	NN	O
with	IN	O
or	CC	O
without	IN	O
adjustment	NN	O
of	IN	O
the	DT	O
Friday	NNP	O
dose	NN	O
.	.	O

In	IN	O
this	DT	O
regimen	NNS	O
,	,	O
addition	NN	O
of	IN	O
a	DT	O
more	RBR	O
potent	JJ	O
diuretic	JJ	O
,	,	O
e.g	JJ	O
,	,	O
furosemide	RB	O
,	,	O
may	MD	O
also	RB	O
be	VB	O
indicated	VBN	O
.	.	O

If	IN	O
seizures	NNS	O
continue	VBP	O
or	CC	O
recur	VBP	O
after	IN	O
a	DT	O
10	CD	O
-	:	O
to	TO	O
15	CD	O
-	:	O
minute	NN	O
observation	NN	O
period	NN	O
,	,	O
an	DT	O
additional	JJ	O
4	CD	DOS
mg	NN	UNIT
intravenous	JJ	UNIT
dose	NN	UNIT
may	MD	O
be	VB	O
slowly	RB	O
administered	VBN	O
.	.	O

As	IN	O
with	IN	O
other	JJ	O
sulfonylurea	JJ	O
-	:	O
class	NN	O
hypoglycemics	NNS	O
,	,	O
many	JJ	WHO
stable	JJ	WHO
non	JJ	WHO
-	:	WHO
insulin	NN	WHO
-	:	WHO
dependent	JJ	WHO
diabetic	JJ	WHO
patients	NNS	WHO
receiving	VBG	WHO
insulin	NN	WHO
may	MD	O
be	VB	O
safely	RB	O
placed	VBN	O
on	IN	O
GLUCOTROL	NNP	O
.	.	O

Cessation	NN	O
of	IN	O
therapy	NN	O
:	:	O
If	IN	O
withdrawal	NN	O
of	IN	O
Kerlone	NNP	O
(	(	O
betaxolol	JJ	O
hydrochloride	NN	O
)	)	O
therapy	NN	O
is	VBZ	O
planned	VBN	O
,	,	O
it	PRP	O
should	MD	O
be	VB	O
achieved	VBN	O
gradually	RB	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
about	RB	O
2	CD	PER
weeks	NNS	PER
.	.	O

Treatment	NN	O
should	MD	O
be	VB	O
continued	VBN	O
for	IN	O
a	DT	O
minimum	NN	O
of	IN	O
48	CD	O
to	TO	O
72	CD	O
hours	NNS	O
beyond	IN	O
the	DT	O
time	NN	O
that	IN	O
the	DT	O
patient	NN	O
becomes	VBZ	O
asymptomatic	JJ	O
or	CC	O
evidence	NN	O
of	IN	O
bacterial	JJ	O
eradication	NN	O
has	VBZ	O
been	VBN	O
obtained	VBN	O
.	.	O

If	IN	O
a	DT	O
meal	NN	O
is	VBZ	O
occasionally	RB	O
missed	VBN	O
or	CC	O
contains	VBZ	O
no	DT	O
fat	NN	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
XENICAL	NN	O
can	MD	O
be	VB	O
omitted	VBN	O
.	.	O

For	IN	O
the	DT	O
prevention	NN	O
of	IN	O
acute	NN	O
bronchospasm	NN	O
which	WDT	O
follows	VBZ	O
exercise	NN	O
,	,	O
exposure	NN	O
to	TO	O
cold	VB	O
,	,	O
dry	JJ	O
air	NN	O
,	,	O
or	CC	O
environmental	JJ	O
agents	NNS	O
,	,	O
the	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
two	CD	DOS
metered	JJ	UNIT
inhalations	NNS	UNIT
shortly	RB	O
before	IN	O
exposure	NN	O
to	TO	O
the	DT	O
precipitating	NN	O
factor	NN	O
,	,	O
i.e	NN	O
,	,	O
within	IN	O
10	CD	O
to	TO	O
15	CD	O
minutes	NNS	O
but	CC	O
not	RB	O
more	JJR	O
than	IN	O
60	CD	O
minutes	NNS	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Recommended	VBN	O
Dose	NNP	O
Modifications	NNP	O
for	IN	O
CAMPTOSAR	NNP	O
/	NNP	O
5	CD	O
-	:	O
Fluorouracil	NN	O
(	(	O
5	CD	O
-	:	O
FU	NN	O
)	)	O
/	NN	O
Leucovorin	NNP	O
(	(	O
LV	NNP	O
)	)	O
Combination	NNP	O
Schedules	NNP	O
Patients	NNP	O
should	MD	O
return	VB	O
to	TO	O
pre	VB	O
-	:	O
treatment	NN	O
bowel	NN	O
function	NN	O
without	IN	O
requiring	VBG	O
antidiarrhea	JJ	O
medications	NNS	O
for	IN	O
at	IN	O
least	JJS	O
24	CD	O
hours	NNS	O
before	IN	O
the	DT	O
next	JJ	O
chemotherapy	NN	O
administration	NN	O
.	.	O

A	DT	O
patient	NN	O
may	MD	O
self	VB	O
-	:	O
inject	NN	O
AMJEVITA	NNP	O
or	CC	O
a	DT	O
caregiver	NN	O
may	MD	O
inject	VB	O
AMJEVITA	NNP	O
using	VBG	O
either	CC	O
the	DT	O
AMJEVITA	NNP	O
prefilled	VBD	O
SureClick®	NNP	O
autoinjector	NN	O
or	CC	O
prefilled	VBN	O
syringe	NN	O
if	IN	O
a	DT	O
physician	JJ	O
determines	NNS	O
that	IN	O
it	PRP	O
is	VBZ	O
appropriate	JJ	O
,	,	O
and	CC	O
with	IN	O
medical	JJ	O
follow	NN	O
-	:	O
up	RB	O
,	,	O
as	IN	O
necessary	JJ	O
,	,	O
after	IN	O
proper	JJ	O
training	NN	O
in	IN	O
subcutaneous	JJ	O
injection	NN	O
technique	NN	O
.	.	O

OMNIPAQUE	RB	O
180	CD	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
180	CD	DOS
mgI	NNS	UNIT
/	JJ	O
mL	NN	O
,	,	O
OMNIPAQUE	NNP	O
240	CD	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
240	CD	DOS
mgI	NNS	UNIT
/	JJ	O
mL	NN	O
,	,	O
or	CC	O
OMNIPAQUE	$	O
300	CD	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
300	CD	DOS
mgI	NNS	UNIT
/	JJ	O
mL	NN	O
is	VBZ	O
recommended	VBN	O
for	IN	O
the	DT	O
examination	NN	O
of	IN	O
the	DT	O
lumbar	NN	O
,	,	O
thoracic	NN	O
,	,	O
and	CC	O
cervical	JJ	O
regions	NNS	O
in	IN	O
adults	NNS	WHO
by	IN	O
lumbar	NN	O
or	CC	O
direct	JJ	O
cervical	JJ	O
injection	NN	O
and	CC	O
is	VBZ	O
slightly	RB	O
hypertonic	JJ	O
to	TO	O
CSF	NNP	O
.	.	O

Figure	NN	O
5b	CD	O
and	CC	O
6	CD	O

Caution	NN	O
is	VBZ	O
necessary	JJ	O
to	TO	O
avoid	VB	O
overdosage	NN	O
.	.	O

In	IN	O
controlled	JJ	O
trials	NNS	O
,	,	O
patients	NNS	O
experienced	VBD	O
greater	JJR	O
risks	NNS	O
for	IN	O
death	NN	O
,	,	O
serious	JJ	O
adverse	JJ	O
cardiovascular	NN	O
reactions	NNS	O
,	,	O
and	CC	O
stroke	VBD	O
when	WRB	O
administered	VBN	O
erythropoiesis	NN	O
-	:	O
stimulating	NN	O
agents	NNS	O
(	(	O
ESAs	NNP	O
)	)	O
to	TO	O
target	VB	O
a	DT	O
hemoglobin	JJ	O
level	NN	O
of	IN	O
greater	JJR	O
than	IN	O
11	CD	DOS
g	JJ	UNIT
/	NNP	O
dL	NN	O
.	.	O

As	IN	O
EXALGO	NNP	O
is	VBZ	O
only	RB	O
intended	VBN	O
for	IN	O
once	RB	FREQ
daily	JJ	FREQ
administration	NN	O
,	,	O
consider	VB	O
use	NN	O
of	IN	O
an	DT	O
alternate	NN	O
analgesic	NN	O
that	WDT	O
may	MD	O
permit	VB	O
more	JJR	O
flexibility	NN	O
with	IN	O
the	DT	O
dosing	VBG	O
interval	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
[	NNP	O
see	NN	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Use	NNP	O
OPANA	NNP	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
,	,	O
starting	VBG	O
with	IN	O
the	DT	O
lowest	JJS	O
dose	NN	O
(	(	O
e.g	JJ	O
,	,	O
5	CD	DOS
mg	NN	UNIT
)	)	O
and	CC	O
titrating	VBG	O
slowly	RB	O
while	IN	O
carefully	RB	O
monitoring	VBG	O
for	IN	O
signs	NNS	O
of	IN	O
respiratory	NN	O
and	CC	O
central	JJ	O
nervous	JJ	O
system	NN	O
depression	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
fail	VBP	WHO
to	TO	WHO
quit	VB	WHO
on	IN	WHO
any	DT	WHO
attempt	NN	WHO
may	MD	O
benefit	VB	O
from	IN	O
interventions	NNS	O
to	TO	O
improve	VB	O
their	PRP$	O
chances	NNS	O
for	IN	O
success	NN	O
on	IN	O
subsequent	JJ	O
attempts	NNS	O
.	.	O

Children	NNP	O
usually	RB	O
require	VBP	O
a	DT	O
volume	NN	O
reduced	VBN	O
in	IN	O
proportion	NN	O
to	TO	O
their	PRP$	O
body	NN	O
size	NN	O
.	.	O

No	DT	O
exact	JJ	O
dosage	NN	O
relationship	NN	O
exists	VBZ	O
between	IN	O
GLYNASE	NNP	O
PresTab	NNP	O
and	CC	O
the	DT	O
other	JJ	O
oral	JJ	O
hypoglycemic	JJ	O
agents	NNS	O
,	,	O
including	VBG	O
MICRONASE	NNP	O
or	CC	O
Diabeta	NNP	O
.	.	O

(	(	O
See	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
:	:	O
Special	JJ	O
Populations	NNS	O
,	,	O
WARNINGS	NNP	O
,	,	O
and	CC	O
PRECAUTIONS	NNP	O
.	.	O
)	)	O

COUMADIN	NNP	O
tablets	NNS	O
are	VBP	O
single	JJ	O
-	:	O
scored	VBN	O
with	IN	O
one	CD	DOS
face	NN	UNIT
imprinted	VBN	O
numerically	RB	O
with	IN	O
1	CD	O
,	,	O
2	CD	O
,	,	O
2	CD	O
-	:	O
1	CD	O
/	NN	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
,	,	O
5	CD	O
,	,	O
6	CD	O
,	,	O
7	CD	O
-	:	O
1	CD	O
/	NN	O
2	CD	O
,	,	O
or	CC	O
10	CD	O
superimposed	VBN	O
and	CC	O
inscribed	VBN	O
with	IN	O
“	NNP	O
COUMADIN	NNP	O
”	NNP	O
and	CC	O
with	IN	O
the	DT	O
opposite	JJ	O
face	NN	O
plain	NN	O
.	.	O

In	IN	O
some	DT	WHO
patients	NNS	WHO
,	,	O
4	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
may	MD	O
be	VB	O
sufficient	JJ	O
.	.	O

Aldara	NNP	O
Cream	NNP	O
is	VBZ	O
packaged	VBN	O
in	IN	O
single	JJ	DOS
-	:	O
use	NN	O
packets	NNS	O
,	,	O
with	IN	O
12	CD	DOS
packets	NNS	UNIT
supplied	VBN	O
per	IN	O
box	NN	O
.	.	O

If	IN	O
the	DT	O
repeat	NN	O
INR	NNP	O
is	VBZ	O
below	IN	O
the	DT	O
desired	VBN	O
therapeutic	JJ	O
range	NN	O
,	,	O
resume	VB	O
the	DT	O
infusion	NN	O
of	IN	O
Argatroban	NNP	O
Injection	NNP	O
and	CC	O
repeat	VB	O
the	DT	O
procedure	NN	O
daily	RB	FREQ
until	IN	O
the	DT	O
desired	VBN	O
therapeutic	JJ	O
range	NN	O
on	IN	O
warfarin	NN	O
alone	RB	O
is	VBZ	O
reached	VBN	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
dosed	VBN	WHO
initially	RB	WHO
at	IN	O
75	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
and	CC	O
who	WP	O
experience	VBP	O
either	DT	O
febrile	NN	O
neutropenia	NN	O
,	,	O
neutrophils	VBZ	O
<	JJ	O
500	CD	DOS
cells	NNS	UNIT
/	JJ	O
mm³	NN	O
for	IN	O
more	JJR	O
than	IN	O
one	CD	PER
week	NN	PER
,	,	O
severe	JJ	O
or	CC	O
cumulative	JJ	O
cutaneous	JJ	O
reactions	NNS	O
,	,	O
or	CC	O
other	JJ	O
grade	JJ	O
3	CD	O
/	JJ	O
4	CD	O
non	JJ	O
-	:	O
hematological	JJ	O
toxicities	NNS	O
during	IN	O
TAXOTERE	NNP	O
treatment	NN	O
should	MD	O
have	VB	O
treatment	NN	O
withheld	VBN	O
until	IN	O
resolution	NN	O
of	IN	O
the	DT	O
toxicity	NN	O
and	CC	O
then	RB	O
resumed	VBD	O
at	IN	O
55	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
.	.	O

Although	IN	O
there	EX	O
was	VBD	O
a	DT	O
threefold	JJ	O
increase	NN	O
in	IN	O
acetylcysteine	JJ	O
plasma	NN	O
concentrations	NNS	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
cirrhosis	NN	WHO
,	,	O
no	DT	O
data	NNS	O
are	VBP	O
available	JJ	O
to	TO	O
determine	VB	O
if	IN	O
a	DT	O
dose	JJ	O
adjustment	NN	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
is	VBZ	O
required	VBN	O
.	.	O

In	IN	O
cases	NNS	O
where	WRB	O
it	PRP	O
has	VBZ	O
been	VBN	O
necessary	JJ	O
to	TO	O
temporarily	RB	O
discontinue	VB	O
therapy	NN	O
or	CC	O
to	TO	O
reduce	VB	O
the	DT	O
frequency	NN	O
of	IN	O
application	NN	O
,	,	O
therapy	NN	O
may	MD	O
be	VB	O
resumed	VBN	O
or	CC	O
the	DT	O
frequency	NN	O
of	IN	O
application	NN	O
increased	VBN	O
as	IN	O
the	DT	O
patient	NN	O
becomes	VBZ	O
able	JJ	O
to	TO	O
tolerate	VB	O
the	DT	O
treatment	NN	O
.	.	O

The	DT	O
solution	NN	O
should	MD	O
be	VB	O
warmed	VBN	O
by	IN	O
holding	VBG	O
the	DT	O
bottle	NN	O
in	IN	O
the	DT	O
hand	NN	O
for	IN	O
one	CD	O
or	CC	O
two	CD	O
minutes	NNS	O
to	TO	O
avoid	VB	O
dizziness	NN	O
which	WDT	O
may	MD	O
result	VB	O
from	IN	O
the	DT	O
instillation	NN	O
of	IN	O
a	DT	O
cold	JJ	O
solution	NN	O
.	.	O

105	CD	O

4	CD	O
.	.	O

8	CD	O
.	.	O

A	DT	O
weekly	JJ	O
dosage	NN	O
of	IN	O
up	IN	O
to	TO	O
0.375	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
divided	VBD	O
into	IN	O
equal	JJ	O
doses	NNS	O
3	CD	O
to	TO	O
7	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
week	NN	FREQ
by	IN	O
subcutaneous	JJ	O
injection	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

Needles	NNS	O
should	MD	O
be	VB	O
disposed	VBN	O
of	IN	O
properly	RB	O
and	CC	O
not	RB	O
recapped	VBN	O
.	.	O

A	DT	O
similar	JJ	O
phenomenon	NN	O
has	VBZ	O
been	VBN	O
observed	VBN	O
in	IN	O
baboons	NNS	O
but	CC	O
only	RB	O
after	IN	O
a	DT	O
protracted	JJ	O
dosing	NN	O
period	NN	O
(	(	O
6	CD	O
months	NNS	O
)	)	O
at	IN	O
higher	JJR	O
dose	NN	O
levels	NNS	O
(	(	O
335	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
or	CC	O
more	JJR	O
)	)	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
STROMECTOL	NNP	O
(	(	O
ivermectin	NN	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
strongyloidiasis	NN	O
is	VBZ	O
a	DT	O
single	JJ	DOS
oral	JJ	UNIT
dose	NN	UNIT
designed	VBN	O
to	TO	O
provide	VB	O
approximately	RB	O
200	CD	DOS
mcg	NNS	UNIT
of	IN	O
ivermectin	NN	O
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
.	.	O

[	NNS	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
ADVERSE	NNP	O
REACTIONS	NNP	O
,	,	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

A	DT	O
recommended	JJ	FREQ
daily	JJ	FREQ
maintenance	NN	O
dosage	NN	O
is	VBZ	O
usually	RB	O
4	CD	DOS
to	TO	O
8	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
.	.	O

In	IN	O
small	JJ	WHO
or	CC	WHO
debilitated	JJ	WHO
patients	NNS	WHO
,	,	O
a	DT	O
dose	NN	O
of	IN	O
500	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
may	MD	O
be	VB	O
sufficient	JJ	O
.	.	O

Squeeze	NN	O
and	CC	O
release	NN	O
drip	JJ	O
chamber	NN	O
to	TO	O
establish	VB	O
proper	JJ	O
fluid	JJ	O
level	NN	O
in	IN	O
chamber	NN	O
.	.	O

The	DT	O
Humatrope	NNP	O
dosage	NN	O
and	CC	O
administration	NN	O
schedule	NN	O
should	MD	O
be	VB	O
individualized	VBN	O
for	IN	O
each	DT	O
patient	NN	O
based	VBN	O
on	IN	O
the	DT	O
growth	NN	O
response	NN	O
.	.	O

Periodically	RB	O
reassess	VB	O
the	DT	O
need	NN	O
for	IN	O
continued	JJ	O
therapy	NN	O
based	VBN	O
upon	IN	O
the	DT	O
patient	NN	O
's	POS	O
disease	NN	O
severity	NN	O
and	CC	O
level	NN	O
of	IN	O
asthma	JJ	O
control	NN	O
.	.	O

COPAXONE	NNP	O
is	VBZ	O
for	IN	O
subcutaneous	JJ	O
use	NN	O
only	RB	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Guidelines	NNS	O
for	IN	O
Dose	NNP	O
Modification	NNP	O
or	CC	O
Discontinuation	NNP	O
of	IN	O
INFERGEN	NNP	O
and	CC	O
for	IN	O
Scheduling	VBG	O
Visits	NNS	O
for	IN	O
Patients	NNS	WHO
with	IN	WHO
Depression	NNP	WHO

Total	JJ	O
daily	JJ	FREQ
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
360	CD	DOS
mg	NNS	UNIT
.	.	O

Contact	JJ	O
lenses	NNS	O
should	MD	O
be	VB	O
removed	VBN	O
prior	RB	O
to	TO	O
the	DT	O
administration	NN	O
of	IN	O
Xiidra	NNP	O
and	CC	O
may	MD	O
be	VB	O
reinserted	VBN	O
15	CD	O
minutes	NNS	O
following	VBG	O
administration	NN	O
.	.	O

NEOSALUS	NNP	O
LOTION	NNP	O
should	MD	O
be	VB	O
rubbed	VBN	O
into	IN	O
the	DT	O
skin	NN	O
until	IN	O
it	PRP	O
is	VBZ	O
completely	RB	O
absorbed	VBN	O
.	.	O

Preparation	NN	O
for	IN	O
administration	NN	O
:	:	O

USE	NN	O
IN	VBZ	O
THE	NNP	O
LUMBAR	NNP	O
AREA	NNP	O
ONLY	NNP	O
IS	NNP	O
RECOMMENDED	NNP	O
.	.	O

All	DT	O
Healthcare	NNP	O
Providers	NNPS	O
who	WP	O
intend	VBP	O
to	TO	O
prescribe	VB	O
PROBUPHINE	NNP	O
must	MD	O
successfully	RB	O
complete	VB	O
a	DT	O
live	JJ	O
training	NN	O
program	NN	O
[	NNP	O
see	VBP	O
Probuphine	NNP	O
REMS	NNP	O
]	NNP	O
.	.	O

Some	DT	WHO
patients	NNS	WHO
with	IN	WHO
Zollinger	NNP	WHO
-	:	WHO
Ellison	NNP	WHO
syndrome	NN	WHO
have	VBP	WHO
been	VBN	WHO
treated	VBN	WHO
continuously	RB	WHO
with	IN	WHO
PRILOSEC	NNP	WHO
for	IN	WHO
more	JJR	WHO
than	IN	WHO
5	CD	WHO
years	NNS	WHO
.	.	O

Electrolytes	NNS	O
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
the	DT	O
nutrient	JJ	O
solution	NN	O
as	IN	O
indicated	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
clinical	JJ	O
condition	NN	O
and	CC	O
laboratory	JJ	O
determinations	NNS	O
of	IN	O
plasma	NN	O
values	NNS	O
.	.	O

The	DT	O
usual	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
CORGARD	NNP	O
(	(	O
nadolol	NN	O
)	)	O
once	RB	FREQ
daily	JJ	FREQ
,	,	O
whether	IN	O
it	PRP	O
is	VBZ	O
used	VBN	O
alone	RB	O
or	CC	O
in	IN	O
addition	NN	O
to	TO	O
diuretic	JJ	O
therapy	NN	O
.	.	O

Such	JJ	O
a	DT	O
calculated	JJ	O
clearance	NN	O
is	VBZ	O
an	DT	O
overestimate	NN	O
of	IN	O
actual	JJ	O
clearance	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
conditions	NNS	WHO
:	:	O
(	(	O
1	CD	O
)	)	O
characterized	VBN	O
by	IN	O
decreasing	VBG	O
renal	JJ	O
function	NN	O
,	,	O
such	JJ	O
as	IN	O
shock	NN	O
,	,	O
severe	JJ	O
heart	NN	O
failure	NN	O
,	,	O
or	CC	O
oliguria	NNS	O
;	:	O
(	(	O
2	CD	O
)	)	O
in	IN	O
which	WDT	O
a	DT	O
normal	JJ	O
relationship	NN	O
between	IN	O
muscle	NN	O
mass	NN	O
and	CC	O
total	JJ	O
body	NN	O
weight	NN	O
is	VBZ	O
not	RB	O
present	JJ	O
,	,	O
such	JJ	O
as	IN	O
obese	JJ	O
patients	NNS	WHO
or	CC	WHO
those	DT	WHO
with	IN	WHO
liver	JJ	WHO
disease	NN	WHO
,	,	O
edema	NN	O
,	,	O
or	CC	O
ascites	NNS	O
;	:	O
and	CC	O
(	(	O
3	CD	O
)	)	O
accompanied	VBN	O
by	IN	O
debilitation	NN	O
,	,	O
malnutrition	NN	O
,	,	O
or	CC	O
inactivity	NN	O
.	.	O

If	IN	O
Hepatitis	NNP	O
B	NNP	O
Immune	NNP	O
Globulin	NNP	O
(	(	O
Human	NNP	O
)	)	O
is	VBZ	O
indicated	JJ	O
(	(	O
see	VB	O
Table	NNP	O
1	CD	O
)	)	O
,	,	O
an	DT	O
injection	NN	O
of	IN	O
0.06	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
should	MD	O
be	VB	O
administered	VBN	O
intramuscularly	RB	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
after	IN	O
exposure	NN	O
and	CC	O
within	IN	O
24	CD	O
hours	NNS	O
,	,	O
if	IN	O
possible	JJ	O
.	.	O

When	WRB	O
the	DT	O
CYP3A4	NNP	O
inhibitor	NN	O
is	VBZ	O
withdrawn	VBN	O
,	,	O
VRAYLAR	NNP	O
dosage	NN	O
may	MD	O
need	VB	O
to	TO	O
be	VB	O
increased	VBN	O
[	JJ	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

A	DT	O
unit	NN	O
dose	NN	O
of	IN	O
ACTIQ	NNP	O
,	,	O
if	IN	O
chewed	VBN	O
and	CC	O
swallowed	VBN	O
,	,	O
might	MD	O
result	VB	O
in	IN	O
lower	JJR	O
peak	NN	O
concentrations	NNS	O
and	CC	O
lower	JJR	O
bioavailability	NN	O
than	IN	O
when	WRB	O
consumed	VBN	O
as	IN	O
directed	JJ	O
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Fig.7	NN	O

In	IN	O
elderly	JJ	WHO
patients	NNS	WHO
,	,	O
consider	VB	O
initiating	VBG	O
SYNDROS	NNP	O
at	IN	O
2.1	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
once	RB	FREQ
daily	RB	FREQ
1	CD	O
to	TO	O
3	CD	O
hours	NNS	O
prior	RB	O
to	TO	O
chemotherapy	VB	O
to	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
CNS	NNP	O
symptoms	NNS	O
[	NNP	O
see	VBP	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

The	DT	O
potency	NN	O
is	VBZ	O
standardized	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
factor	NN	O
IX	NNP	O
content	NN	O
.	.	O

Precipitation	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
during	IN	O
24	CD	O
-	:	O
hour	NN	O
infusions	NNS	O
of	IN	O
VUMON	NNP	O
diluted	VBD	O
to	TO	O
teniposide	VB	O
concentrations	NNS	O
of	IN	O
0.1	CD	DOS
to	TO	O
0.2	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
,	,	O
resulting	VBG	O
in	IN	O
occlusion	NN	O
of	IN	O
central	JJ	O
venous	JJ	O
access	NN	O
catheters	NNS	O
in	IN	O
several	JJ	WHO
patients	NNS	WHO
.	.	O

The	DT	O
application	NN	O
site	NN	O
and	CC	O
dose	NN	O
of	IN	O
AndroGel	NNP	O
1	CD	O
%	NN	O
are	VBP	O
not	RB	O
interchangeable	JJ	O
with	IN	O
other	JJ	O
topical	JJ	O
testosterone	NN	O
products	NNS	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
hepatotoxicity	NN	O
and	CC	O
the	DT	O
recommendations	NNS	O
for	IN	O
treatment	NN	O
of	IN	O
acute	NN	O
acetaminophen	NN	O
ingestion	NN	O
(	(	O
i.e	NN	O
,	,	O
the	DT	O
Rumack	NNP	O
-	:	O
Matthew	NNP	O
nomogram	NN	O
)	)	O
do	VBP	O
not	RB	O
apply	VB	O
to	TO	O
patients	NNS	WHO
with	IN	WHO
RSI	NNP	WHO
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
below	IN	O
the	DT	O
age	NN	O
of	IN	O
16	CD	DOS
have	VBP	UNIT
not	RB	O
been	VBN	O
established	VBN	O
.	.	O

OMNIPAQUE	RB	O
300	CD	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
300	CD	DOS
mgI	NNS	UNIT
/	JJ	O
mL	NN	O
and	CC	O
OMNIPAQUE	NNP	O
350	CD	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
350	CD	DOS
mgI	NNS	UNIT
/	JJ	O
mL	NNS	O
are	VBP	O
indicated	VBN	O
in	IN	O
adults	NNS	WHO
for	IN	O
use	NN	O
in	IN	O
aortography	NN	O
and	CC	O
selective	JJ	O
visceral	JJ	O
arteriography	NN	O
including	VBG	O
studies	NNS	O
of	IN	O
the	DT	O
aortic	JJ	O
arch	NN	O
,	,	O
ascending	VBG	O
aorta	NN	O
,	,	O
and	CC	O
abdominal	JJ	O
aorta	NN	O
and	CC	O
its	PRP$	O
branches	NNS	O
(	(	O
celiac	NN	O
,	,	O
mesenteric	NN	O
,	,	O
renal	JJ	O
,	,	O
hepatic	JJ	O
and	CC	O
splenic	JJ	O
arteries	NNS	O
)	)	O
.	.	O

Grasp	NNP	O
the	DT	O
plunger	NN	O
rod	NN	O
as	IN	O
shown	VBN	O
in	IN	O
the	DT	O
diagram	NN	O
.	.	O

As	IN	O
higher	JJR	O
doses	NNS	O
or	CC	O
more	JJR	O
prolonged	JJ	O
therapy	NN	O
with	IN	O
streptomycin	NN	O
may	MD	O
be	VB	O
indicated	VBN	O
for	IN	O
more	RBR	O
severe	JJ	O
or	CC	O
fulminating	JJ	O
infections	NNS	O
(	(	O
endocarditis	NN	O
,	,	O
meningitis	NN	O
,	,	O
etc	FW	O
.	.	O

Surveillance	NN	O
,	,	O
Epidemiology	NNP	O
,	,	O
and	CC	O
End	NNP	O
Results	NNP	O
Database	NNP	O
(	(	O
SEER	NNP	O
)	)	O
Program	NNP	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
Enbrel	NNP	O
beyond	IN	O
the	DT	O
expiration	NN	O
date	NN	O
stamped	VBD	O
on	IN	O
the	DT	O
carton	NN	O
or	CC	O
barrel	NN	O
label	NN	O
.	.	O

Use	NNP	O
no	DT	O
more	RBR	O
than	IN	O
two	CD	DOS
vials	NNS	UNIT
of	IN	O
Raplixa	NNP	O
with	IN	O
the	DT	O
RaplixaSpray	NNP	O
device	NN	O
.	.	O

70	CD	O

Stability	NN	O
and	CC	O
use	NN	O
times	NNS	O
are	VBP	O
identical	JJ	O
in	IN	O
glass	NN	O
and	CC	O
plastic	JJ	O
parenteral	JJ	O
solution	NN	O
containers	NNS	O
.	.	O

Vitamins	NNS	O
and	CC	O
trace	NN	O
minerals	NNS	O
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
the	DT	O
amino	NN	O
acid	NN	O
/	NNP	O
dextrose	JJ	O
solution	NN	O
as	IN	O
needed	VBN	O
.	.	O

Use	VB	O
a	DT	O
separate	JJ	O
sterile	JJ	O
needle	NN	O
and	CC	O
sterile	JJ	O
syringe	NN	O
for	IN	O
each	DT	O
individual	NN	O
.	.	O

See	VB	O
the	DT	O
dosing	NN	O
table	NN	O
for	IN	O
specific	JJ	O
recommendations	NNS	O
.	.	O

On	IN	O
intravenous	JJ	O
administration	NN	O
of	IN	O
COSMEGEN	NNP	O
,	,	O
extravasation	NN	O
may	MD	O
occur	VB	O
with	IN	O
or	CC	O
without	IN	O
an	DT	O
accompanying	VBG	O
burning	NN	O
or	CC	O
stinging	JJ	O
sensation	NN	O
,	,	O
even	RB	O
if	IN	O
blood	NN	O
returns	NNS	O
well	RB	O
on	IN	O
aspiration	NN	O
of	IN	O
the	DT	O
infusion	NN	O
needle	NN	O
.	.	O

NIASPAN	NNP	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
significant	JJ	WHO
or	CC	WHO
unexplained	JJ	WHO
hepatic	JJ	WHO
dysfunction	NN	WHO
.	.	O

The	DT	O
prescriber	NN	O
must	MD	O
determine	VB	O
the	DT	O
number	NN	O
of	IN	O
tablets	NNS	O
per	IN	O
dose	NN	O
,	,	O
and	CC	O
the	DT	O
maximum	JJ	O
number	NN	O
of	IN	O
tablets	NNS	O
per	IN	O
24	CD	O
hours	NNS	O
,	,	O
based	VBN	O
upon	IN	O
the	DT	O
above	JJ	O
dosage	NN	O
guidance	NN	O
.	.	O

PARENTERAL	NNP	O
DRUG	NNP	O
PRODUCTS	NNP	O
SHOULD	NNP	O
BE	NNP	O
INSPECTED	NNP	O
VISUALLY	NNP	O
FOR	NNP	O
PARTICULATE	NNP	O
MATTER	NNP	O
AND	NNP	O
DISCOLORATION	NNP	O
PRIOR	NNP	O
TO	NNP	O
ADMINISTRATION	NNP	O
.	.	O

The	DT	O
reconstituted	JJ	O
solution	NN	O
has	VBZ	O
a	DT	O
concentration	NN	O
of	IN	O
either	CC	O
50	CD	DOS
meg	NN	UNIT
per	IN	O
0.5	CD	DOS
mL	NN	UNIT
,	,	O
80	CD	O
meg	NN	O
per	IN	O
0.5	CD	DOS
mL	NN	UNIT
,	,	O
120	CD	O
meg	NN	O
per	IN	O
0.5	CD	DOS
mL	NN	UNIT
,	,	O
or	CC	O
150	CD	DOS
meg	NNS	UNIT
per	IN	O
0.5	CD	DOS
mL	NN	UNIT
for	IN	O
a	DT	O
single	JJ	O
subcutaneous	JJ	O
injection	NN	O
.	.	O

Cyclophosphamide	NN	O
does	VBZ	O
not	RB	O
contain	VB	O
any	DT	O
antimicrobial	JJ	O
preservative	NN	O
and	CC	O
thus	RB	O
care	VB	O
must	MD	O
be	VB	O
taken	VBN	O
to	TO	O
assure	VB	O
the	DT	O
sterility	NN	O
of	IN	O
prepared	JJ	O
solutions	NNS	O
.	.	O

Dosage	NN	O
Information	NN	O

(	(	O
See	VB	O
HOW	NNP	O
SUPPLIED	NNP	O
,	,	O
Storage	NNP	O
.	.	O
)	)	O

As	IN	O
with	IN	O
all	DT	O
intravenous	JJ	O
fluid	NN	O
therapy	NN	O
,	,	O
the	DT	O
primary	JJ	O
aim	NN	O
is	VBZ	O
to	TO	O
provide	VB	O
sufficient	JJ	O
water	NN	O
to	TO	O
compensate	VB	O
for	IN	O
insensible	JJ	O
,	,	O
urinary	JJ	O
and	CC	O
other	JJ	O
(	(	O
nasogastric	JJ	O
suction	NN	O
,	,	O
fistula	JJ	O
drainage	NN	O
,	,	O
diarrhea	NN	O
)	)	O
fluid	NN	O
losses	NNS	O
.	.	O

To	TO	O
achieve	VB	O
maximum	JJ	O
contraceptive	JJ	O
effectiveness	NN	O
,	,	O
Mircette®	NNP	O
(	(	O
desogestrel	JJ	O
/	NNP	O
ethinyl	NN	O
estradiol	NN	O
and	CC	O
ethinyl	VB	O
estradiol	NN	O
)	)	O
Tablets	VBZ	O
must	MD	O
be	VB	O
taken	VBN	O
exactly	RB	O
as	IN	O
directed	VBN	O
and	CC	O
at	IN	O
intervals	NNS	O
not	RB	O
exceeding	VBG	O
24	CD	O
hours	NNS	O
.	.	O

This	DT	O
reduction	NN	O
may	MD	O
be	VB	O
started	VBN	O
at	IN	O
initiation	NN	O
of	IN	O
Depakote	NNP	O
therapy	NN	O
,	,	O
or	CC	O
delayed	VBN	O
by	IN	O
1	CD	PER
to	TO	O
2	CD	PER
weeks	NNS	PER
if	IN	O
there	EX	O
is	VBZ	O
a	DT	O
concern	NN	O
that	WDT	O
seizures	VBZ	O
are	VBP	O
likely	JJ	O
to	TO	O
occur	VB	O
with	IN	O
a	DT	O
reduction	NN	O
.	.	O

1	CD	O
.	.	O

In	IN	O
adults	NNS	WHO
,	,	O
a	DT	O
loading	VBG	O
dose	NN	O
of	IN	O
10	CD	DOS
to	TO	O
15	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
should	MD	O
be	VB	O
administered	VBN	O
slowly	RB	O
intravenously	RB	O
,	,	O
at	IN	O
a	DT	O
rate	NN	O
not	RB	O
exceeding	VBG	O
50	CD	DOS
mg	NNS	UNIT
per	IN	O
minute	NN	O
(	(	O
this	DT	O
will	MD	O
require	VB	O
approximately	RB	O
20	CD	O
minutes	NNS	O
in	IN	O
a	DT	O
70	CD	WHO
-	:	WHO
kg	NN	WHO
patient	NN	WHO
)	)	O
.	.	O

Ambulatory	JJ	WHO
patients	NNS	WHO
may	MD	O
need	VB	O
a	DT	O
slower	JJR	O
schedule	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
volume	NN	WHO
depletion	NN	WHO
,	,	O
correcting	VBG	O
this	DT	O
condition	NN	O
prior	RB	O
to	TO	O
initiation	NN	O
of	IN	O
FARXIGA	NNP	O
is	VBZ	O
recommended	VBN	O
[	JJ	O
see	NN	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
and	CC	O
PATIENT	NNP	O
INFORMATION	NNP	O
]	NNP	O
.	.	O

Do	NNP	O
not	RB	O
suction	VB	O
the	DT	O
infant	NN	WHO
during	IN	O
the	DT	O
first	JJ	O
hour	NN	O
after	IN	O
dosing	VBG	O
unless	IN	O
signs	NNS	O
of	IN	O
significant	JJ	O
airway	JJ	O
obstruction	NN	O
occur	NN	O
.	.	O

The	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
doses	NNS	O
greater	JJR	O
than	IN	O
400	CD	DOS
mg	NN	UNIT
3	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
(	(	O
1,200	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
)	)	O
have	VBP	O
not	RB	O
been	VBN	O
examined	VBN	O
in	IN	O
controlled	JJ	O
trials	NNS	O
.	.	O

are	VBP	O
white	JJ	O
to	TO	O
light	JJ	O
tan	NN	O
in	IN	O
color	NN	O
.	.	O

Drug	NN	O
interactions	NNS	O
can	MD	O
increase	VB	O
risk	NN	O
of	IN	O
hypertensive	JJ	O
reactions	NNS	O
.	.	O

is	VBZ	O
also	RB	O
effective	JJ	O
.	.	O

(	(	O
See	VB	O
CONTRAINDICATIONS	NNP	O
,	,	O
WARNINGS	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
)	)	O

If	IN	O
the	DT	O
original	JJ	O
injection	NN	O
needs	NNS	O
to	TO	O
be	VB	O
reinforced	VBN	O
,	,	O
further	JJ	O
treatments	NNS	O
may	MD	O
be	VB	O
administered	VBN	O
.	.	O

Gently	RB	O
swirl	VBZ	O
the	DT	O
vial	NN	O
now	RB	O
containing	VBG	O
Pentacel	NNP	O
vaccine	NN	O
until	IN	O
a	DT	O
cloudy	NN	O
,	,	O
uniform	JJ	O
,	,	O
white	JJ	O
to	TO	O
off	VB	O
-	:	O
white	JJ	O
(	(	O
yellow	JJ	O
tinge	NN	O
)	)	O
suspension	NN	O
results	NNS	O
.	.	O

The	DT	O
capsules	NNS	O
should	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
with	IN	O
water	NN	O
and	CC	O
should	MD	O
not	RB	O
be	VB	O
opened	VBN	O
or	CC	O
chewed	VBN	O
.	.	O

Once	RB	O
the	DT	O
syringe	NN	O
has	VBZ	O
been	VBN	O
withdrawn	VBN	O
,	,	O
activate	VBP	O
immediately	RB	O
the	DT	O
LuproLoc®	NNP	O
safety	NN	O
device	NN	O
by	IN	O
pushing	VBG	O
the	DT	O
arrow	NN	O
on	IN	O
the	DT	O
lock	NN	O
upward	JJ	O
towards	IN	O
the	DT	O
needle	JJ	O
tip	NN	O
with	IN	O
the	DT	O
thumb	NN	O
or	CC	O
finger	NN	O
,	,	O
as	IN	O
illustrated	JJ	O
,	,	O
until	IN	O
the	DT	O
needle	JJ	O
cover	NN	O
of	IN	O
the	DT	O
safety	NN	O
device	NN	O
is	VBZ	O
fully	RB	O
extended	VBN	O
over	IN	O
the	DT	O
needle	JJ	O
and	CC	O
a	DT	O
CLICK	NNP	O
is	VBZ	O
heard	VBN	O
or	CC	O
felt	VBN	O
.	.	O

Figure	NN	O
4	CD	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
,	,	O
discoloration	NN	O
and	CC	O
syringe	NN	O
damage	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

At	IN	O
least	JJS	O
36	CD	O
hours	NNS	O
should	MD	O
be	VB	O
allowed	VBN	O
between	IN	O
dose	JJ	O
increments	NNS	O
to	TO	O
attain	VB	O
steady	JJ	O
-	:	O
state	NN	O
plasma	JJ	O
concentrations	NNS	O
of	IN	O
sotalol	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
age	NN	WHO
-	:	WHO
adjusted	VBN	WHO
normal	JJ	WHO
renal	JJ	WHO
function	NN	WHO
.	.	O

The	DT	O
usual	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
MICARDIS	NNP	O
tablets	NNS	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Hold	VB	O
the	DT	O
container	NN	O
vertically	RB	O
with	IN	O
the	DT	O
valve	NNS	O
head	VBP	O
uppermost	JJ	O
and	CC	O
the	DT	O
spray	NN	O
orifice	NN	O
as	IN	O
close	NN	O
to	TO	O
the	DT	O
mouth	NN	O
as	IN	O
possible	JJ	O
.	.	O

Adjuvant	JJ	O
treatment	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
Dukes	NNP	WHO
'	POS	WHO
C	NNP	WHO
colon	NN	WHO
cancer	NN	WHO
is	VBZ	O
recommended	VBN	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
6	CD	PER
months	NNS	PER
[	JJ	O
ie	NN	O
,	,	O
capecitabine	NN	O
tablets	NNS	O
1250	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NNP	O
orally	RB	O
twice	RB	FREQ
daily	RB	FREQ
for	IN	O
2	CD	PER
weeks	NNS	PER
followed	VBN	O
by	IN	O
a	DT	O
1	CD	DOS
-	:	O
week	NN	PER
rest	NN	O
period	NN	O
,	,	O
given	VBN	O
as	IN	O
3	CD	DOS
-	:	O
week	NN	PER
cycles	NNS	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
8	CD	DOS
cycles	NNS	UNIT
(	(	O
24	CD	PER
weeks	NNS	PER
)	)	O
]	VBP	O
.	.	O

This	DT	O
type	NN	O
of	IN	O
bleeding	NN	O
is	VBZ	O
usually	RB	O
transient	JJ	O
and	CC	O
without	IN	O
significance	NN	O
;	:	O
however	RB	O
,	,	O
if	IN	O
the	DT	O
bleeding	NN	O
is	VBZ	O
persistent	JJ	O
or	CC	O
prolonged	VBN	O
,	,	O
the	DT	O
patient	NN	O
is	VBZ	O
advised	VBN	O
to	TO	O
consult	VB	O
her	PRP$	O
health	NN	O
care	NN	O
professional	NN	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
Gengraf®	NNP	O
varies	NNS	O
depending	VBG	O
on	IN	O
the	DT	O
transplanted	VBN	O
organ	NN	O
and	CC	O
the	DT	O
other	JJ	O
immunosuppressive	JJ	O
agents	NNS	O
included	VBN	O
in	IN	O
the	DT	O
immunosuppressive	JJ	O
protocol	NN	O
.	.	O

LOTION	NN	O
:	:	O
Shake	NNP	O
well	RB	O
before	IN	O
using	VBG	O
.	.	O

See	VB	O
DRUG	NNP	O
INTERACTIONS	NNP	O
,	,	O
for	IN	O
information	NN	O
on	IN	O
co	NN	O
-	:	O
administration	NN	O
of	IN	O
PROCARDIA	NNP	O
with	IN	O
beta	NN	O
blockers	NNS	O
or	CC	O
long	JJ	O
-	:	O
acting	NN	O
nitrates	NNS	O
.	.	O

As	IN	O
with	IN	O
other	JJ	O
corticosteroids	NNS	O
,	,	O
therapy	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
when	WRB	O
control	NN	O
is	VBZ	O
achieved	VBN	O
.	.	O

Do	NNP	O
not	RB	O
await	VB	O
results	NNS	O
of	IN	O
assays	NNS	O
for	IN	O
acetaminophen	JJ	O
level	NN	O
before	IN	O
initiating	VBG	O
treatment	NN	O
with	IN	O
acetylcysteine	JJ	O
solution	NN	O
(	(	O
n	JJ	O
-	:	O
acetyl	NN	O
-	:	O
l	NN	O
-	:	O
cysteine	NN	O
)	)	O
.	.	O

Proceed	VB	O
to	TO	O
MIXJECT	NNP	O
Activation	NNP	O
.	.	O

For	IN	O
other	JJ	O
wounds	NNS	O
,	,	O
a	DT	O
booster	NN	O
is	VBZ	O
appropriate	JJ	O
if	IN	O
the	DT	O
patient	NN	O
has	VBZ	O
not	RB	O
received	VBN	O
tetanus	NN	O
toxoid	NN	O
within	IN	O
the	DT	O
preceding	VBG	O
5	CD	O
years	NNS	O
.	.	O

Make	NNP	O
sure	NN	O
that	WDT	O
FEIBA	NNP	O
has	VBZ	O
been	VBN	O
dissolved	VBN	O
completely	RB	O
;	:	O
otherwise	RB	O
,	,	O
active	JJ	O
material	NN	O
will	MD	O
not	RB	O
pass	VB	O
through	IN	O
the	DT	O
device	NN	O
filter	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
once	RB	O
-	:	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
Tekamlo	NNP	O
is	VBZ	O
150	CD	DOS
mg	NN	UNIT
/	VBD	O
5	CD	DOS
mg.	NN	UNIT
Titrate	NNP	O
as	IN	O
needed	VBN	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
300	CD	DOS
mg	NNS	UNIT
/	VBD	O
10	CD	DOS
mg	NN	UNIT
.	.	O

Figure	NN	O
1	CD	O

Prepare	NNP	O
injection	NN	O
site	NN	O
(	(	O
s	PRP	O
)	)	O

Table	JJ	O
5	CD	O
:	:	O
Daily	JJ	FREQ
Dose	NNP	O
Calculations	NNP	O
by	IN	O
Body	NNP	O
Surface	NNP	O
Area	NNP	O
(	(	O
BSA	NNP	O
)	)	O

The	DT	O
opacity	NN	O
will	MD	O
diminish	VB	O
gradually	RB	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
benzodiazepines	NNS	O
should	MD	O
be	VB	O
prescribed	VBN	O
for	IN	O
short	JJ	O
periods	NNS	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
avoid	VB	O
potential	JJ	O
complications	NNS	O
of	IN	O
excessive	JJ	O
leukocytosis	NN	O
(	(	O
WBC	NNP	O
>	VBZ	O
50,000	CD	DOS
cells	NNS	UNIT
/	JJ	O
mm3	NN	O
,	,	O
ANC	NNP	O
>	VBZ	O
20,000	CD	DOS
cells	NNS	UNIT
/	JJ	O
mm3	NN	O
)	)	O
a	DT	O
CBC	NNP	O
with	IN	O
differential	NN	O
is	VBZ	O
recommended	VBN	O
twice	RB	FREQ
per	IN	FREQ
week	NN	FREQ
during	IN	O
LEUKINE	NNP	O
therapy	NN	O
.	.	O

Treatment	NN	O
with	IN	O
extended	JJ	O
release	NN	O
potassium	NN	O
citrate	NN	O
should	MD	O
be	VB	O
added	VBN	O
to	TO	O
a	DT	O
regimen	NNS	WHO
that	WDT	WHO
limits	VBZ	WHO
salt	JJR	WHO
intake	NN	WHO
(	(	O
avoidance	NN	O
of	IN	O
foods	NNS	O
with	IN	O
high	JJ	O
salt	NN	O
content	NN	O
and	CC	O
of	IN	O
added	JJ	O
salt	NN	O
at	IN	O
the	DT	O
table	NN	O
)	)	O
and	CC	O
encourages	VBZ	O
high	JJ	O
fluid	NNS	O
intake	VBP	O
(	(	O
urine	JJ	O
volume	NN	O
should	MD	O
be	VB	O
at	IN	O
least	JJS	O
two	CD	FREQ
liters	NNS	FREQ
per	IN	FREQ
day	NN	FREQ
)	)	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
ranges	VBZ	O
from	IN	O
30	CD	DOS
to	TO	O
300	CD	DOS
mL	NNS	UNIT
.	.	O

As	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

Sr	NNP	O
82	CD	O
(	(	O
μCi	NN	O
)	)	O
=	NN	O

If	IN	O
after	IN	O
long	JJ	O
term	NN	O
therapy	IN	O
the	DT	O
drug	NN	O
is	VBZ	O
to	TO	O
be	VB	O
stopped	VBN	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
it	PRP	O
be	VB	O
withdrawn	VBN	O
gradually	RB	O
rather	RB	O
than	IN	O
abruptly	RB	O
.	.	O

This	DT	O
reduction	NN	O
may	MD	O
lead	VB	O
to	TO	O
underdosage	VB	O
of	IN	O
the	DT	O
patient	NN	O
by	IN	O
up	IN	O
to	TO	O
30	CD	O
%	NN	O
if	IN	O
drop	NN	O
counter	NN	O
infusion	NN	O
sets	NNS	O
are	VBP	O
used	VBN	O
.	.	O

To	TO	O
maintain	VB	O
adequate	JJ	O
analgesia	NN	O
,	,	O
more	RBR	O
frequent	JJ	O
administration	NN	O
may	MD	O
be	VB	O
required	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
oral	JJ	O
dosage	NN	O
of	IN	O
ZUPLENZ	NNP	O
oral	JJ	O
soluble	JJ	O
film	NN	O
is	VBZ	O
16	CD	DOS
mg	NN	UNIT
given	VBN	O
successively	RB	O
as	IN	O
two	CD	DOS
8	CD	DOS
mg	NNS	UNIT
films	NNS	O
1	CD	O
hour	NN	O
before	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

The	DT	O
syringe	NN	O
(	(	O
s	PRP	O
)	)	O
should	MD	O
be	VB	O
labeled	VBN	O
with	IN	O
appropriate	JJ	O
information	NN	O
including	VBG	O
the	DT	O
date	NN	O
and	CC	O
time	NN	O
the	DT	O
vial	NN	O
was	VBD	O
opened	VBN	O
.	.	O

*An	RB	O
estimated	VBN	O
creatinine	JJ	O
clearance	NN	O
in	IN	O
adults	NNS	WHO
is	VBZ	O
calculated	VBN	O
from	IN	O
serum	JJ	O
creatinine	NN	O
by	IN	O
the	DT	O
following	JJ	O
formulas	NN	O
:	:	O

Treatment	NN	O
should	MD	O
be	VB	O
continued	VBN	O
until	IN	O
clinical	JJ	O
parameters	NNS	O
or	CC	O
laboratory	NN	O
tests	NNS	O
indicate	VBP	O
that	IN	O
active	JJ	O
fungal	JJ	O
infection	NN	O
has	VBZ	O
subsided	VBN	O
.	.	O

A	DT	O
response	NN	O
is	VBZ	O
generally	RB	O
evident	JJ	O
after	IN	O
5	CD	O
to	TO	O
7	CD	PER
days	NNS	PER
.	.	O

Patients	NNS	O
may	MD	O
be	VB	O
dosed	VBN	O
on	IN	O
a	DT	O
fat	JJ	O
ingestion	NN	O
-	:	O
based	VBN	O
or	CC	O
actual	JJ	O
body	NN	O
weight	VBD	O
-	:	O
based	VBN	O
dosing	VBG	O
scheme	NN	O
.	.	O

SURVANTA	NNP	O
SHOULD	NNP	O
NOT	NNP	O
BE	NNP	O
REMOVED	NNP	O
FROM	NNP	O
THE	NNP	O
REFRIGERATOR	NNP	O
FOR	NNP	O
MORE	NNP	O
THAN	NNP	O
24	CD	O
HOURS	NNP	O
.	.	O

The	DT	O
recommended	JJ	O
doses	NNS	O
of	IN	O
CEDAX	NNP	O
(	(	O
ceftibuten	VBN	O
)	)	O
Oral	NNP	O
Suspension	NNP	O
are	VBP	O
presented	VBN	O
in	IN	O
the	DT	O
table	NN	O
below	IN	O
.	.	O

No	DT	O
dose	JJ	O
adjustment	NN	O
of	IN	O
UPTRAVI	NNP	O
is	VBZ	O
necessary	JJ	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	O
Child	NNP	O
-	:	O
Pugh	NNP	O
class	NN	O
A	NNP	O
)	)	O
.	.	O

In	IN	O
switching	VBG	O
from	IN	O
a	DT	O
progestin	NN	O
-	:	O
only	RB	O
pill	NN	O
,	,	O
injection	NN	O
,	,	O
or	CC	O
implant	NN	O
,	,	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
advised	VBN	O
to	TO	O
use	VB	O
a	DT	O
non	JJ	O
-	:	O
hormonal	NN	O
back	RB	O
-	:	O
up	IN	O
method	NN	O
of	IN	O
birth	NN	O
control	NN	O
for	IN	O
the	DT	O
first	JJ	O
7	CD	O
days	NNS	O
of	IN	O
tablet	NN	O
-	:	O
taking	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

Oocyte	NNP	O
(	(	O
egg	NN	O
)	)	O
retrieval	NN	O
is	VBZ	O
performed	VBN	O
34	CD	O
to	TO	O
36	CD	O
hours	NNS	O
later	RB	O
.	.	O

5	CD	O
.	.	O

If	IN	O
particulate	JJ	O
matter	NN	O
is	VBZ	O
seen	VBN	O
,	,	O
NAVELBINE	NNP	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
.	.	O

If	IN	O
needed	VBN	O
,	,	O
refer	VBP	O
to	TO	O
the	DT	O
Hepatic	NNP	O
Insufficiency	NNP	O
subsection	NN	O
of	IN	O
the	DT	O
Precautions	NNP	O
section	NN	O
of	IN	O
this	DT	O
label	NN	O
for	IN	O
definitions	NNS	O
of	IN	O
mild	NN	O
,	,	O
moderate	JJ	O
and	CC	O
severe	JJ	O
hepatic	JJ	O
impairment	NN	O
.	.	O

Inspect	VB	O
the	DT	O
admixture	NN	O
closely	RB	O
for	IN	O
separation	NN	O
of	IN	O
the	DT	O
emulsion	NN	O
.	.	O

All	DT	O
preparation	NN	O
should	MD	O
take	VB	O
place	NN	O
in	IN	O
a	DT	O
biologic	JJ	O
safety	NN	O
hood	NN	O
with	IN	O
shielded	JJ	O
fluorescent	NN	O
light	NN	O
.	.	O

Each	DT	O
SYMLIN	NNP	O
dose	NN	O
should	MD	O
be	VB	O
administered	VBN	O
subcutaneously	RB	O
into	IN	O
the	DT	O
abdomen	NNS	O
or	CC	O
thigh	NN	O
.	.	O

Urinary	JJ	O
excretion	NN	O
is	VBZ	O
also	RB	O
a	DT	O
major	JJ	O
route	NN	O
of	IN	O
elimination	NN	O
of	IN	O
didanosine	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
,	,	O
therefore	IN	O
the	DT	O
clearance	NN	O
of	IN	O
didanosine	NN	O
may	MD	O
be	VB	O
altered	VBN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
.	.	O

Conversely	RB	O
,	,	O
at	IN	O
least	JJS	O
7	CD	PER
days	NNS	PER
should	MD	O
be	VB	O
allowed	VBN	O
after	IN	O
stopping	VBG	O
venlafaxine	JJ	O
tablets	NNS	O
,	,	O
USP	NNP	O
before	IN	O
starting	VBG	O
an	DT	O
MAOI	NNP	O
intended	VBD	O
to	TO	O
treat	VB	O
psychiatric	JJ	O
disorders	NNS	O
(	(	O
see	VB	O
CONTRAINDICATIONS	NNP	O
)	)	O
.	.	O

In	IN	O
secondary	JJ	O
glaucoma	NN	O
following	VBG	O
cataract	NN	O
surgery	NN	O
,	,	O
the	DT	O
higher	JJR	O
strengths	NNS	O
of	IN	O
the	DT	O
drug	NN	O
are	VBP	O
frequently	RB	O
needed	VBN	O
and	CC	O
are	VBP	O
ordinarily	RB	O
very	RB	O
well	RB	O
tolerated	VBN	O
.	.	O

Immediate	NNP	O
-	:	O
release	NN	O
capsules	NNS	O
are	VBP	O
usually	RB	O
given	VBN	O
t.i.d	NN	O
.	.	O

Adjust	IN	O
the	DT	O
dose	NN	O
over	IN	O
the	DT	O
first	JJ	O
week	NN	PER
of	IN	O
treatment	NN	O
based	VBN	O
on	IN	O
control	NN	O
of	IN	O
withdrawal	NN	O
symptoms	NNS	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
expected	VBN	O
peak	NN	O
activity	NN	O
(	(	O
e.g	NN	O
,	,	O
2	CD	O
to	TO	O
4	CD	O
hours	NNS	O
after	IN	O
dosing	VBG	O
)	)	O
.	.	O

Adults	NNS	WHO

Constitute	VB	O
the	DT	O
vial	NN	O
with	IN	O
10	CD	DOS
mL	NNS	UNIT
of	IN	O
sterile	JJ	O
water	NN	O
for	IN	O
injection	NN	O
or	CC	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
and	CC	O
gently	RB	O
shake	VB	O
to	TO	O
dissolve	VB	O
.	.	O

For	IN	O
repeat	NN	O
treatment	NN	O
,	,	O
no	DT	O
more	JJR	O
than	IN	O
1	CD	DOS
mg	NN	UNIT
(	(	O
given	VBN	O
as	IN	O
0.2	CD	DOS
mg	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
at	IN	O
any	DT	O
one	CD	O
time	NN	O
,	,	O
and	CC	O
no	DT	O
more	JJR	O
than	IN	O
3	CD	DOS
mg	NN	UNIT
should	MD	O
be	VB	O
given	VBN	O
in	IN	O
any	DT	O
one	CD	O
hour	NN	O
.	.	O

Components	NNS	O
of	IN	O
the	DT	O
solution	NN	O
may	MD	O
precipitate	VB	O
in	IN	O
the	DT	O
frozen	JJ	O
state	NN	O
and	CC	O
will	MD	O
dissolve	VB	O
upon	IN	O
reaching	VBG	O
room	NN	O
temperature	NN	O
with	IN	O
little	JJ	O
or	CC	O
no	DT	O
agitation	NN	O
.	.	O

The	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
4	CD	DOS
grams	NNS	UNIT
.	.	O

The	DT	O
following	JJ	O
dosage	NN	O
schedule	NN	O
is	VBZ	O
suggested	VBN	O
for	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
infections	NNS	O
:	:	O

Should	MD	O
severe	VB	O
irritation	NN	O
occur	NN	O
,	,	O
application	NN	O
of	IN	O
drug	NN	O
can	MD	O
be	VB	O
temporarily	RB	O
discontinued	VBN	O
for	IN	O
a	DT	O
few	JJ	O
days	NNS	O
until	IN	O
the	DT	O
symptoms	NNS	O
subside	NN	O
.	.	O

After	IN	O
mixing	VBG	O
,	,	O
the	DT	O
suspension	NN	O
may	MD	O
be	VB	O
kept	VBN	O
for	IN	O
14	CD	PER
days	NNS	PER
and	CC	O
must	MD	O
be	VB	O
stored	VBN	O
in	IN	O
the	DT	O
refrigerator	NN	O
.	.	O

In	IN	O
controlled	JJ	O
clinical	JJ	O
studies	NNS	O
in	IN	O
adults	NNS	WHO
with	IN	WHO
complex	JJ	WHO
partial	JJ	WHO
seizures	NNS	WHO
,	,	O
SABRIL	NNP	O
was	VBD	O
tapered	VBN	O
by	IN	O
decreasing	VBG	O
the	DT	O
daily	JJ	FREQ
dose	NN	O
1000	CD	DOS
mg	NN	UNIT
/	NNP	FREQ
day	NN	FREQ
on	IN	O
a	DT	O
weekly	JJ	FREQ
basis	NN	FREQ
until	IN	O
discontinued	VBN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
the	DT	O
solution	NN	O
if	IN	O
particulate	JJ	O
matter	NN	O
is	VBZ	O
present	JJ	O
or	CC	O
if	IN	O
the	DT	O
container	NN	O
appears	VBZ	O
damaged	VBN	O
.	.	O

It	PRP	O
would	MD	O
appear	VB	O
,	,	O
then	RB	O
,	,	O
that	IN	O
a	DT	O
disturbance	NN	O
in	IN	O
the	DT	O
diurnal	JJ	O
cycle	NN	O
with	IN	O
maintenance	NN	O
of	IN	O
elevated	JJ	O
corticoid	NN	O
values	NNS	O
during	IN	O
the	DT	O
night	NN	O
may	MD	O
play	VB	O
a	DT	O
significant	JJ	O
role	NN	O
in	IN	O
the	DT	O
development	NN	O
of	IN	O
undesirable	JJ	O
corticoid	JJ	O
effects	NNS	O
.	.	O

For	IN	O
management	NN	O
of	IN	O
bronchial	JJ	O
asthma	NN	O
in	IN	O
adults	NNS	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
(	(	WHO
5	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
over	IN	WHO
)	)	WHO
who	WP	WHO
are	VBP	WHO
able	JJ	WHO
to	TO	O
use	VB	O
the	DT	O
Inhaler	NNP	O
,	,	O
the	DT	O
usual	JJ	O
starting	NN	O
dosage	NN	O
is	VBZ	O
two	CD	DOS
metered	JJ	UNIT
inhalations	NNS	UNIT
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
at	IN	O
regular	JJ	O
intervals	NNS	O
.	.	O

In	IN	O
such	JJ	O
cases	NNS	O
,	,	O
consideration	NN	O
should	MD	O
be	VB	O
given	VBN	O
to	TO	O
therapeutic	JJ	O
drug	NN	O
monitoring	NN	O
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
)	)	O
.	.	O

Approximately	RB	O
58	CD	O
%	NN	O
of	IN	O
patients	NNS	O
randomized	VBN	O
to	TO	O
400	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
achieved	VBD	O
this	DT	O
maximal	JJ	O
dose	NN	O
in	IN	O
the	DT	O
monotherapy	NN	O
controlled	VBD	O
trial	NN	O
;	:	O
the	DT	O
mean	NN	O
dose	NN	O
achieved	VBN	O
in	IN	O
the	DT	O
trial	NN	O
was	VBD	O
275	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

Table	JJ	O
21	CD	O
:	:	O
RECOMMENDED	NNP	O
INITIAL	NNP	O
DURAGESIC	NNP	O
DOSE	NNP	O
BASED	NNP	O
UPON	NNP	O
DAILY	NNP	O
ORAL	NNP	O
MORPHINE	NNP	O
DOSE	NNP	O

Aminosyn	NNP	O
II	NNP	O
8.5	CD	O
%	NN	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
with	IN	O
electrolytes	NNS	O
)	)	O
WITH	NNP	O
ELECTROLYTES	NNP	O
is	VBZ	O
designed	VBN	O
to	TO	O
supply	VB	O
necessary	JJ	O
electrolytes	NNS	O
to	TO	O
patients	NNS	WHO
in	IN	WHO
a	DT	WHO
stable	JJ	WHO
metabolic	JJ	WHO
state	NN	WHO
(	(	O
about	IN	O
three	CD	O
-	:	O
fourths	NNS	O
of	IN	O
all	DT	WHO
patients	NNS	WHO
on	IN	O
total	JJ	O
parenteral	JJ	O
nutrition	NN	O
)	)	O
.	.	O

Avoid	NNP	O
contact	NN	O
with	IN	O
eyes	NNS	O
or	CC	O
other	JJ	O
mucous	JJ	O
membranes	NNS	O
.	.	O

When	WRB	O
reconstituted	VBN	O
as	IN	O
directed	VBN	O
,	,	O
ETOPOPHOS	NNP	O
solutions	NNS	O
can	MD	O
be	VB	O
stored	VBN	O
in	IN	O
glass	NN	O
or	CC	O
plastic	NN	O
containers	NNS	O
under	IN	O
refrigeration	NN	O
2°	CD	O
to	TO	O
8°C	CD	O
(	(	O
36°	CD	O
-	:	O
46°F	CD	O
)	)	O
for	IN	O
7	CD	PER
days	NNS	PER
;	:	O
at	IN	O
controlled	VBN	O
room	NN	O
temperature	NN	O
20°	CD	O
to	TO	O
25°C	CD	O
(	(	O
68°	CD	O
-	:	O
77°F	CD	O
)	)	O
for	IN	O
24	CD	PER
hours	NNS	PER
following	VBG	O
reconstitution	NN	O
with	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
or	CC	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
;	:	O
or	CC	O
at	IN	O
controlled	JJ	O
room	NN	O
temperature	NN	O
20°	CD	O
to	TO	O
25°C	CD	O
(	(	O
68°	CD	O
-	:	O
77°F	CD	O
)	)	O
for	IN	O
48	CD	PER
hours	NNS	PER
following	VBG	O
reconstitution	NN	O
with	IN	O
Bacteriostatic	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
with	IN	O
Benzyl	NNP	O
Alcohol	NNP	O
or	CC	O
Bacteriostatic	NNP	O
Sodium	NNP	O
Chloride	NNP	O
for	IN	O
Injection	NNP	O
with	IN	O
Benzyl	NNP	O
Alcohol	NNP	O
.	.	O

Premedicate	NN	O
patients	NNS	O
for	IN	O
nausea	NN	O
and	CC	O
vomiting	NN	O
.	.	O

Do	NNP	O
not	RB	O
increase	VB	O
the	DT	O
fentanyl	NN	O
transdermal	JJ	O
system	NN	O
dose	NN	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
until	IN	O
at	IN	PER
least	JJS	PER
3	CD	PER
days	NNS	PER
after	IN	O
the	DT	O
initial	JJ	O
application	NN	O
.	.	O

Keep	NNP	O
tightly	RB	O
closed	VBD	O
.	.	O

Based	VBN	O
on	IN	O
a	DT	O
study	NN	O
of	IN	O
50	CD	DOS
mg	NNS	UNIT
etanercept	JJ	O
twice	RB	FREQ
weekly	RB	FREQ
in	IN	O
patients	NNS	WHO
with	IN	WHO
RA	NNP	WHO
that	WDT	WHO
suggested	VBD	WHO
higher	JJR	WHO
incidence	NN	WHO
of	IN	O
adverse	JJ	O
reactions	NNS	O
but	CC	O
similar	JJ	O
American	NNP	O
College	NNP	O
of	IN	O
Rheumatology	NNP	O
(	(	O
ACR	NNP	O
)	)	O
response	NN	O
rates	NNS	O
,	,	O
doses	VBZ	O
higher	JJR	O
than	IN	O
50	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
week	NN	FREQ
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

Age	NNP	O
,	,	O
weight	NN	O
,	,	O
and	CC	O
severity	NN	O
of	IN	O
the	DT	O
infection	NN	O
are	VBP	O
important	JJ	O
factors	NNS	O
in	IN	O
determining	VBG	O
the	DT	O
proper	JJ	O
dosage	NN	O
.	.	O

For	IN	O
cardiac	JJ	O
resuscitation	NN	O
-	:	O
A	DT	O
dose	NN	O
of	IN	O
0.5	CD	DOS
mL	NN	UNIT
(	(	O
0.5	CD	DOS
mg	NN	UNIT
)	)	O
diluted	VBD	O
to	TO	O
10	CD	DOS
mL	NN	UNIT
with	IN	O
sodium	NN	O
chloride	NN	O
injection	NN	O
can	MD	O
be	VB	O
administered	VBN	O
intravenously	RB	O
or	CC	O
intracardially	RB	O
to	TO	O
restore	VB	O
myocardial	JJ	O
contrac	NN	O
-	:	O
tility	NN	O
.	.	O

Intramuscular	JJ	O
administration	NN	O
of	IN	O
TRACRIUM	NNP	O
(	(	O
atracurium	JJ	O
besylate	NN	O
)	)	O
may	MD	O
result	VB	O
in	IN	O
tissue	NN	O
irritation	NN	O
and	CC	O
there	EX	O
are	VBP	O
no	DT	O
clinical	JJ	O
data	NNS	O
to	TO	O
support	VB	O
this	DT	O
route	NN	O
of	IN	O
administration	NN	O
.	.	O

However	RB	O
,	,	O
failure	NN	O
to	TO	O
increase	VB	O
height	JJ	O
velocity	NN	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
therapy	NN	O
by	IN	O
at	IN	O
least	JJS	O
2	CD	O
cm	NN	O
/	CD	O
year	NN	O
suggests	VBZ	O
the	DT	O
need	NN	O
for	IN	O
assessment	NN	O
of	IN	O
compliance	NN	O
and	CC	O
evaluation	NN	O
of	IN	O
other	JJ	O
causes	NNS	O
of	IN	O
growth	NN	O
failure	NN	O
,	,	O
such	JJ	O
as	IN	O
hypothyroidism	NN	O
,	,	O
under	IN	O
-	:	O
nutrition	NN	O
,	,	O
and	CC	O
advanced	VBD	O
bone	NN	O
age	NN	O
.	.	O

Monitoring	NN	O
should	MD	O
include	VB	O
periodic	JJ	O
blood	NN	O
chemistries	NNS	O
,	,	O
vital	JJ	O
signs	NNS	O
,	,	O
plasma	FW	O
carnitine	NN	O
concentrations	NNS	O
,	,	O
and	CC	O
overall	JJ	O
clinical	JJ	O
condition	NN	O
.	.	O

*Since	NN	O
cefuroxime	NN	O
(	(	O
cefuroxime	NN	O
(	(	O
cefuroxime	JJ	O
injection	NN	O
)	)	O
injection	NN	O
)	)	O
is	VBZ	O
dialyzable	JJ	O
,	,	O
patients	NNS	O
on	IN	O
hemodialysis	NN	O
should	MD	O
be	VB	O
given	VBN	O
a	DT	O
further	RBR	O
dose	NN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
dialysis	NN	O
.	.	O

Phosphorus	NNP	O
P	NNP	O
32	CD	O
decays	NNS	O
by	IN	O
beta	NN	O
emission	NN	O
with	IN	O
a	DT	O
physical	JJ	O
half	NN	O
-	:	O
life	NN	O
of	IN	O
14.3	CD	O
days.1	NN	O
The	DT	O
mean	JJ	O
energy	NN	O
of	IN	O
the	DT	O
beta	NN	O
particle	NN	O
is	VBZ	O
695	CD	O
keV	NN	O
.	.	O

Midazolam	NNP	O
is	VBZ	O
a	DT	O
potent	JJ	O
sedative	JJ	O
agent	NN	O
that	WDT	O
requires	VBZ	O
slow	JJ	O
administration	NN	O
and	CC	O
individualization	NN	O
of	IN	O
dosage	NN	O
.	.	O

Any	DT	O
solution	NN	O
remaining	VBG	O
in	IN	O
the	DT	O
cartridge	NN	O
should	MD	O
be	VB	O
discarded	VBN	O
.	.	O

Geriatric	JJ	WHO
patients	NNS	WHO
may	MD	O
require	VB	O
reduced	JJ	O
doses	NNS	O
of	IN	O
etomidate	NN	O
.	.	O

The	DT	O
first	JJ	O
step	NN	O
is	VBZ	O
the	DT	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
VISUDYNE	NNP	O
.	.	O

Grapefruit	NNP	O
and	CC	O
grapefruit	NN	O
juice	NN	O
affect	JJ	O
metabolism	NN	O
,	,	O
increasing	VBG	O
blood	NN	O
concentration	NN	O
of	IN	O
cyclosporine	NN	O
,	,	O
thus	RB	O
should	MD	O
be	VB	O
avoided	VBN	O
.	.	O

Although	IN	O
solutions	NNS	O
are	VBP	O
chemically	RB	O
stable	JJ	O
under	IN	O
the	DT	O
conditions	NNS	O
indicated	VBD	O
,	,	O
precipitation	NN	O
of	IN	O
teniposide	NN	O
may	MD	O
occur	VB	O
at	IN	O
the	DT	O
recommended	JJ	O
concentrations	NNS	O
,	,	O
especially	RB	O
if	IN	O
the	DT	O
diluted	JJ	O
solution	NN	O
is	VBZ	O
subjected	VBN	O
to	TO	O
more	JJR	O
agitation	NN	O
than	IN	O
is	VBZ	O
recommended	VBN	O
to	TO	O
prepare	VB	O
the	DT	O
drug	NN	O
solution	NN	O
for	IN	O
parenteral	JJ	O
administration	NN	O
.	.	O

The	DT	O
reconstituted	JJ	O
TICE®	NNP	O
BCG	NNP	O
should	MD	O
be	VB	O
kept	VBN	O
refrigerated	JJ	O
(	(	O
2	CD	O
–	RB	O
8°C	CD	O
)	)	O
,	,	O
protected	VBN	O
from	IN	O
exposure	NN	O
to	TO	O
direct	VB	O
sunlight	NN	O
,	,	O
and	CC	O
used	VBD	O
within	IN	O
2	CD	O
hours	NNS	O
.	.	O

Due	JJ	O
to	TO	O
the	DT	O
long	JJ	O
half	NN	O
-	:	O
life	NN	O
of	IN	O
levothyroxine	NN	O
,	,	O
the	DT	O
peak	JJ	O
therapeutic	JJ	O
effect	NN	O
at	IN	O
a	DT	O
given	VBN	O
dose	NN	O
of	IN	O
levothyroxine	JJ	O
sodium	NN	O
may	MD	O
not	RB	O
be	VB	O
attained	VBN	O
for	IN	O
4	CD	PER
-	:	O
6	CD	PER
weeks	NNS	PER
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
KHEDEZLA	NNP	O
is	VBZ	O
50	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
,	,	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
of	IN	O
RAZADYNE®	NNP	O
tablets	NNS	O
and	CC	O
oral	JJ	O
solution	NN	O
is	VBZ	O
4	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
(	(	O
8	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
)	)	O
.	.	O

Pentacel	NNP	O
vaccine	NN	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
complete	VB	O
the	DT	O
first	JJ	O
4	CD	O
doses	NNS	O
of	IN	O
the	DT	O
5	CD	O
-	:	O
dose	NN	O
DTaP	NNP	O
series	NN	O
in	IN	O
infants	NNS	WHO
and	CC	WHO
children	NNS	WHO
who	WP	WHO
have	VBP	WHO
received	VBN	WHO
1	CD	WHO
or	CC	O
more	JJR	O
doses	NNS	O
of	IN	O
DAPTACEL	NNP	O
vaccine	NN	O
and	CC	O
are	VBP	O
also	RB	O
scheduled	VBN	O
to	TO	O
receive	VB	O
the	DT	O
other	JJ	O
antigens	NNS	O
of	IN	O
Pentacel	NNP	O
vaccine	NN	O
.	.	O

See	VB	O
Dose	NNP	O
Modification	NNP	O
Guidelines	NNP	O
for	IN	O
dose	JJ	O
modifications	NNS	O
for	IN	O
hematological	JJ	O
toxicity	NN	O
in	IN	O
patients	NNS	WHO
whose	WP$	WHO
platelet	NN	WHO
counts	NNS	WHO
were	VBD	WHO
100	CD	WHO
X	NNP	WHO
109	CD	WHO
/	NNP	WHO
L	NNP	WHO
or	CC	O
more	JJR	O
prior	JJ	O
to	TO	O
starting	VBG	O
treatment	NN	O
with	IN	O
ruxolitinib	NN	O
.	.	O

The	DT	O
recommendations	NNS	O
for	IN	O
Fusilev	NNP	O
rescue	NN	O
are	VBP	O
based	VBN	O
on	IN	O
a	DT	O
methotrexate	NN	O
dose	NN	O
of	IN	O
12	CD	DOS
grams	NNS	UNIT
/	VBP	O
m²	NNS	O
administered	VBN	O
by	IN	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
4	CD	O
hours	NNS	O
(	(	O
see	VB	O
methotrexate	JJ	O
package	NN	O
insert	NN	O
for	IN	O
full	JJ	O
prescribing	VBG	O
information	NN	O
)	)	O
.	.	O

A	DT	O
urethral	JJ	O
catheter	NN	O
should	MD	O
then	RB	O
be	VB	O
inserted	VBN	O
into	IN	O
the	DT	O
patient	NN	O
's	POS	O
bladder	NN	O
under	IN	O
aseptic	JJ	O
conditions	NNS	O
,	,	O
the	DT	O
bladder	NN	O
drained	VBD	O
,	,	O
and	CC	O
the	DT	O
diluted	JJ	O
75	CD	DOS
mL	NN	UNIT
VALSTAR	NNP	O
(	(	O
valrubicin	NN	O
)	)	O
solution	NN	O
instilled	VBN	O
slowly	RB	O
via	IN	O
gravity	NN	O
flow	NN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
several	JJ	O
minutes	NNS	O
.	.	O

After	IN	O
observing	VBG	O
the	DT	O
response	NN	O
to	TO	O
initial	JJ	O
therapy	NN	O
with	IN	O
CATAFLAM	NNP	O
,	,	O
the	DT	O
dose	NN	O
and	CC	O
frequency	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
to	TO	O
suit	VB	O
an	DT	O
individual	JJ	O
patient	NN	O
's	POS	O
needs	NNS	O
.	.	O

The	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
VIMOVO	NNP	O
in	IN	O
children	NNS	WHO
younger	JJR	WHO
than	IN	WHO
18	CD	WHO
years	NNS	WHO
has	VBZ	WHO
not	RB	WHO
been	VBN	WHO
established	VBN	WHO
.	.	O

The	DT	O
prescriber	NN	O
should	MD	O
carefully	RB	O
assess	VB	O
each	DT	O
patient	NN	O
to	TO	O
determine	VB	O
the	DT	O
most	RBS	O
appropriate	JJ	O
dose	NN	O
of	IN	O
epinephrine	NN	O
,	,	O
recognizing	VBG	O
the	DT	O
life	NN	O
-	:	O
threatening	JJ	O
nature	NN	O
of	IN	O
the	DT	O
reactions	NNS	O
for	IN	O
which	WDT	O
this	DT	O
drug	NN	O
is	VBZ	O
indicated	VBN	O
.	.	O

Increments	NNS	O
of	IN	O
DIPRIVAN	NNP	O
Injectable	NNP	O
Emulsion	NNP	O
25	CD	DOS
mg	NN	UNIT
(	(	O
2.5	CD	DOS
mL	NN	UNIT
)	)	O
to	TO	O
50	CD	DOS
mg	NN	UNIT
(	(	O
5	CD	DOS
mL	NN	UNIT
)	)	O
may	MD	O
be	VB	O
administered	VBN	O
with	IN	O
nitrous	JJ	O
oxide	NN	O
in	IN	O
adult	NN	WHO
patients	NNS	WHO
undergoing	VBG	WHO
general	JJ	WHO
surgery	NN	WHO
.	.	O

This	DT	O
solution	NN	O
is	VBZ	O
intended	VBN	O
for	IN	O
intravenous	JJ	O
administration	NN	O
using	VBG	O
sterile	JJ	O
equipment	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
80	CD	DOS
-	:	O
120	CD	DOS
grams	NNS	UNIT
of	IN	O
amino	NN	O
acids	NNS	O
(	(	O
12	CD	DOS
-	:	O
18	CD	DOS
grams	NNS	UNIT
of	IN	O
nitrogen	NN	O
)	)	O
as	IN	O
HepatAmine	NNP	O
(	(	O
amino	JJ	O
acid	NN	O
)	)	O
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
usual	JJ	O
daily	JJ	FREQ
dosage	NN	O
is	VBZ	O
3	CD	DOS
to	TO	O
8	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
,	,	O
divided	VBN	O
into	IN	O
two	CD	DOS
or	CC	O
three	CD	DOS
equal	JJ	UNIT
doses	NNS	UNIT
every	DT	O
8	CD	O
or	CC	O
12	CD	O
hours	NNS	O
.	.	O

(	(	O
See	VB	O
Table	JJ	O
4	CD	O
.	.	O
)	)	O

DO	MD	O
NOT	VB	O
STORE	VB	O
THE	DT	O
SUSPENSION	NNP	O
.	.	O

This	DT	O
is	VBZ	O
rarely	RB	O
a	DT	O
sign	NN	O
of	IN	O
treatment	NN	O
failure	NN	O
and	CC	O
is	VBZ	O
not	RB	O
an	DT	O
indication	NN	O
for	IN	O
retreatment	NN	O
.	.	O

After	IN	O
toxic	JJ	O
side	NN	O
effects	NNS	O
have	VBP	O
subsided	VBN	O
,	,	O
therapy	NN	O
may	MD	O
then	RB	O
be	VB	O
resumed	VBN	O
.	.	O

Peglntron™	NNP	O
/	NNP	O
REBETOL®	NNP	O
Combo	NNP	O
Pack	NNP	O
package	NN	O
should	MD	O
be	VB	O
stored	VBN	O
at	IN	O
2°	CD	O
-	:	O
8°C	CD	O
(	(	O
36°	CD	O
-	:	O
46°F	CD	O
)	)	O
.	.	O

If	IN	O
objective	JJ	O
improvement	NN	O
(	(	O
such	JJ	O
as	IN	O
reduced	JJ	O
joint	NN	O
swelling	NN	O
,	,	O
increased	JJ	O
mobility	NN	O
)	)	O
does	VBZ	O
not	RB	O
occur	VB	O
within	IN	O
six	CD	O
months	NNS	O
,	,	O
the	DT	O
drug	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
.	.	O

Similarly	RB	O
,	,	O
too	RB	O
rapid	JJ	O
reversal	NN	O
may	MD	O
induce	VB	O
nausea	NN	O
,	,	O
vomiting	NN	O
,	,	O
sweating	VBG	O
or	CC	O
circulatory	JJ	O
stress	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
creatinine	JJ	WHO
clearance	NN	WHO
10	CD	DOS
-	:	O
30	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
,	,	O
reduce	VB	O
the	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
PRINIVIL	NNP	O
to	TO	O
half	NN	O
of	IN	O
the	DT	O
usual	JJ	O
recommended	VBD	O
dose	NN	O
(	(	O
i.e	JJ	O
,	,	O
hypertension	NN	O
,	,	O
5	CD	DOS
mg	NN	UNIT
;	:	O
heart	NN	O
failure	NN	O
or	CC	O
acute	NN	O
MI	NNP	O
,	,	O
2.5	CD	DOS
mg	NN	UNIT
)	)	O
.	.	O

Addition	NN	O
or	CC	O
withdrawal	NN	O
of	IN	O
phenytoin	NN	O
and	CC	O
/	NN	O
or	CC	O
carbamazepine	NN	O
during	IN	O
adjunctive	JJ	O
therapy	NN	O
with	IN	O
TROKENDI	NNP	O
XR®	NNP	O
may	MD	O
require	VB	O
adjustment	NN	O
of	IN	O
the	DT	O
dose	NN	O
of	IN	O
TROKENDI	NNP	O
XR®	NNP	O
.	.	O

When	WRB	O
taking	VBG	O
ORTHO	NNP	O
-	:	O
CEPT®	NN	O
,	,	O
the	DT	O
first	JJ	O
light	JJ	O
orange	NN	O
``	``	O
active	JJ	O
''	''	O
tablet	NN	O
should	MD	O
be	VB	O
taken	VBN	O
on	IN	O
the	DT	O
first	JJ	O
Sunday	NNP	O
after	IN	O
menstruation	NN	O
begins	NNS	O
.	.	O

If	IN	O
converting	VBG	O
from	IN	O
NPH	NNP	O
insulin	NN	O
,	,	O
the	DT	O
change	NN	O
can	MD	O
be	VB	O
done	VBN	O
on	IN	O
a	DT	O
unit	NN	O
-	:	O
to	TO	O
-	:	O
unit	NN	O
basis	NN	O
.	.	O

Complete	JJ	O
information	NN	O
is	VBZ	O
not	RB	O
available	JJ	O
.	.	O

ZYPREXA	NNP	O
RELPREVV	NNP	O
must	MD	O
be	VB	O
administered	VBN	O
in	IN	O
a	DT	O
registered	JJ	O
healthcare	NN	O
facility	NN	O
with	IN	O
ready	JJ	O
access	NN	O
to	TO	O
emergency	NN	O
response	NN	O
services	NNS	O
.	.	O

Withdrawal	NN	O
of	IN	O
contrast	NN	O
agents	NNS	O
from	IN	O
their	PRP$	O
containers	NNS	O
should	MD	O
be	VB	O
accomplished	VBN	O
under	IN	O
aseptic	JJ	O
conditions	NNS	O
with	IN	O
sterile	JJ	O
syringes	NNS	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Schedule	NN	O
of	IN	O
Unituxin	NNP	O
Administration	NNP	O
for	IN	O
Cycles	NNP	O
2	CD	O
and	CC	O
4	CD	O

Permanently	RB	O
discontinue	VBZ	O
YONDELIS	NNP	O
for	IN	O
:	:	O

Note	NN	O
:	:	O
Do	NNP	O
not	RB	O
mix	VB	O
Nulecit™	NNP	O
with	IN	O
other	JJ	O
medications	NNS	O
,	,	O
or	CC	O
add	VB	O
to	TO	O
parenteral	JJ	O
nutrition	NN	O
solutions	NNS	O
for	IN	O
intravenous	JJ	O
infusion	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

8	CD	O
.	.	O

The	DT	O
first	JJ	O
dose	NN	O
should	MD	O
be	VB	O
administered	VBN	O
30	CD	O
minutes	NNS	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
emetogenic	JJ	O
chemotherapy	NN	O
,	,	O
with	IN	O
a	DT	O
subsequent	JJ	O
dose	NN	O
8	CD	O
hours	NNS	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
.	.	O

When	WRB	O
AZILECT	NNP	O
is	VBZ	O
used	VBN	O
in	IN	O
combination	NN	O
with	IN	O
levodopa	NN	O
,	,	O
a	DT	O
reduction	NN	O
of	IN	O
the	DT	O
levodopa	NN	O
dose	NN	O
may	MD	O
be	VB	O
considered	VBN	O
,	,	O
based	VBN	O
upon	IN	O
individual	JJ	O
response	NN	O
.	.	O

AVOID	NNP	O
ERRORS	NNP	O
,	,	O
READ	NNP	O
ENTIRE	NNP	O
PREPARATION	NNP	O
INSTRUCTIONS	NNP	O
PRIOR	NNP	O
TO	NNP	O
RECONSTITUTION	NNP	O
.	.	O

Allow	IN	O
the	DT	O
mixed	JJ	O
contents	NNS	O
to	TO	O
stand	VB	O
for	IN	O
about	RB	O
2	CD	O
minutes	NNS	O
.	.	O

On	IN	O
succeeding	VBG	O
days	NNS	O
of	IN	O
travel	NN	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
25	CD	DOS
mg	NN	UNIT
be	VB	O
taken	VBN	O
on	IN	O
arising	VBG	O
and	CC	O
again	RB	O
before	IN	O
the	DT	O
evening	NN	O
meal	NN	O
.	.	O

However	RB	O
,	,	O
as	IN	O
with	IN	O
other	JJ	O
drugs	NNS	O
used	VBN	O
to	TO	O
treat	VB	O
schizophrenia	NN	O
,	,	O
some	DT	WHO
patients	NNS	WHO
respond	VBP	O
to	TO	O
lower	VB	O
dosage	NN	O
and	CC	O
others	NNS	O
require	VBP	O
higher	JJR	O
dosage	NN	O
for	IN	O
optimal	JJ	O
benefit	NN	O
.	.	O

Depending	VBG	O
on	IN	O
the	DT	O
therapeutic	JJ	O
response	NN	O
after	IN	O
conversion	NN	O
,	,	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
may	MD	O
need	VB	O
to	TO	O
be	VB	O
adjusted	VBN	O
within	IN	O
the	DT	O
recommended	JJ	O
dosing	NN	O
instructions	NNS	O
(	(	O
Table	JJ	O
1	CD	O
)	)	O
.	.	O

The	DT	O
ULTRESA	NNP	O
-	:	O
soft	JJ	O
food	NN	O
mixture	NN	O
should	MD	O
be	VB	O
swallowed	VBN	O
immediately	RB	O
without	IN	O
crushing	VBG	O
or	CC	O
chewing	NN	O
,	,	O
and	CC	O
followed	VBD	O
with	IN	O
water	NN	O
or	CC	O
juice	NN	O
to	TO	O
ensure	VB	O
complete	JJ	O
ingestion	NN	O
.	.	O

Change	VB	O
the	DT	O
needle	NN	O
on	IN	O
the	DT	O
syringe	NN	O
to	TO	O
a	DT	O
needle	JJ	O
suitable	JJ	O
for	IN	O
subcutaneous	JJ	O
injection	NN	O
.	.	O

Admixtures	NNS	O
were	VBD	O
compounded	VBN	O
in	IN	O
a	DT	O
nonphthalate	JJ	O
polyvinylchloride	NN	O
(	(	O
PVC	NNP	O
)	)	O
flexible	JJ	O
container	NN	O
(	(	O
see	VB	O
NOTE	NNP	O
under	IN	O
WARNINGS	NNP	O
)	)	O
.	.	O

Hypotension	NN	O
and	CC	O
respiratory	NN	O
depression	NN	O
increase	NN	O
as	IN	O
anesthesia	NN	O
with	IN	O
SUPRANE	NNP	O
is	VBZ	O
deepened	VBN	O
.	.	O

for	IN	O
10	CD	PER
days	NNS	PER
.	.	O

Dose	NNP	O
can	MD	O
be	VB	O
titrated	VBN	O
at	IN	O
1	CD	PER
-	:	O
week	NN	PER
or	CC	O
longer	JJR	O
intervals	NNS	O
.	.	O

Twenty	CD	O
-	:	O
five	CD	O
percent	NN	O
of	IN	O
those	DT	O
who	WP	O
respond	VBP	O
to	TO	O
DESYREL	NNP	O
(	(	O
trazodone	JJ	O
hydrochloride	NN	O
)	)	O
require	VBZ	O
more	JJR	O
than	IN	O
two	CD	PER
weeks	NNS	PER
(	(	O
up	IN	O
to	TO	O
four	CD	PER
weeks	NNS	PER
)	)	O
of	IN	O
drug	NN	O
administration	NN	O
.	.	O

Table	JJ	O
1	CD	O
provides	VBZ	O
the	DT	O
CEPROTIN	NNP	O
dosing	NN	O
schedule	NN	O
for	IN	O
acute	NN	O
episodes	NNS	O
,	,	O
short	JJ	O
-	:	O
term	NN	O
prophylaxis	NN	O
and	CC	O
long	JJ	O
-	:	O
term	NN	O
prophylaxis	NN	O

Table	JJ	O
V.	NNP	O
Initial	NNP	O
theophylline	JJ	O
infusion	NN	O
rates	NNS	O
following	VBG	O
an	DT	O
appropriate	JJ	O
loading	NN	O
dose	NN	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
ZYPREXA	NNP	O
and	CC	O
fluoxetine	NN	O
in	IN	O
combination	NN	O
was	VBD	O
determined	VBN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
supporting	VBG	O
approval	NN	O
of	IN	O
Symbyax	NNP	O
(	(	O
fixed	VBN	O
dose	VBP	O
combination	NN	O
of	IN	O
ZYPREXA	NNP	O
and	CC	O
fluoxetine	NN	O
)	)	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
0.1	CD	DOS
mg	NN	UNIT
of	IN	O
fludrocortisone	NN	O
acetate	JJ	O
daily	RB	FREQ
,	,	O
although	IN	O
dosage	NN	O
ranging	VBG	O
from	IN	O
0.1	CD	DOS
mg	NNS	UNIT
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
week	NN	FREQ
to	TO	O
0.2	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
has	VBZ	O
been	VBN	O
employed	VBN	O
.	.	O

If	IN	O
breakthrough	IN	O
bleeding	NN	O
occurs	NNS	O
following	VBG	O
missed	JJ	O
tablets	NNS	O
,	,	O
it	PRP	O
will	MD	O
usually	RB	O
be	VB	O
transient	JJ	O
and	CC	O
of	IN	O
no	DT	O
consequence	NN	O
.	.	O

Subsequent	JJ	O
doses	NNS	O
are	VBP	O
to	TO	O
be	VB	O
administered	VBN	O
2	CD	DOS
tablets	NNS	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

Individual	JJ	O
patients	NNS	O
will	MD	O
experience	VB	O
a	DT	O
variable	JJ	O
time	NN	O
to	TO	O
onset	VB	O
and	CC	O
degree	VB	O
of	IN	O
symptom	NN	O
relief	NN	O
.	.	O

Those	DT	O
additives	NNS	O
known	VBN	O
to	TO	O
be	VB	O
incompatible	JJ	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
.	.	O

It	PRP	O
differs	VBZ	O
from	IN	O
other	JJ	O
commonly	RB	O
used	JJ	O
steroids	NNS	O
in	IN	O
that	DT	O
it	PRP	O
is	VBZ	O
irritating	VBG	O
at	IN	O
the	DT	O
place	NN	O
of	IN	O
injection	NN	O
.	.	O

There	EX	O
is	VBZ	O
inter	JJ	O
-	:	O
patient	NN	O
variability	NN	O
in	IN	O
the	DT	O
potency	NN	O
of	IN	O
opioid	JJ	O
drugs	NNS	O
and	CC	O
opioid	JJ	O
formulations	NNS	O
.	.	O

If	IN	O
an	DT	O
infection	NN	O
develops	VBZ	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
occlusive	JJ	O
dressings	NNS	O
should	MD	O
be	VB	O
discontinued	VBN	O
and	CC	O
appropriate	JJ	O
antimicrobial	JJ	O
therapy	NN	O
initiated	VBN	O
.	.	O

The	DT	O
intended	JJ	O
maintenance	NN	O
dose	NN	O
should	MD	O
be	VB	O
started	VBN	O
with	IN	O
no	DT	O
loading	VBG	O
dose	NN	O
.	.	O

10	CD	O
.	.	O

Waterproof	NNP	O
gloves	NNS	O
and	CC	O
effective	JJ	O
shielding	NN	O
should	MD	O
be	VB	O
worn	VBN	O
when	WRB	O
handling	VBG	O
the	DT	O
product	NN	O
.	.	O

One	CD	DOS
tablet	NN	UNIT
(	(	O
450	CD	DOS
mg	NN	UNIT
)	)	O
of	IN	O
FORFIVO	NNP	O
XL	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
once	RB	FREQ
daily	JJ	FREQ
without	IN	O
regard	NN	O
to	TO	O
meals	NNS	O
.	.	O

In	IN	O
breakthrough	NN	O
bleeding	NN	O
,	,	O
as	IN	O
in	IN	O
all	DT	O
cases	NNS	O
of	IN	O
irregular	JJ	O
bleeding	NN	O
from	IN	O
the	DT	O
vagina	NN	O
,	,	O
nonfunctional	JJ	O
causes	NNS	O
should	MD	O
be	VB	O
borne	VBN	O
in	IN	O
mind	NN	O
.	.	O

If	IN	O
daily	JJ	FREQ
increases	NNS	O
in	IN	O
BUN	NNP	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
10	CD	DOS
to	TO	O
15	CD	DOS
mg	NNS	UNIT
%	NN	O
for	IN	O
more	JJR	O
than	IN	O
three	CD	O
days	NNS	O
should	MD	O
occur	VB	O
,	,	O
then	RB	O
protein	SYM	O
-	:	O
sparing	VBG	O
therapy	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
and	CC	O
a	DT	O
regimen	NN	WHO
with	IN	WHO
full	JJ	WHO
nonprotein	NN	WHO
calorie	NN	WHO
substrates	NNS	WHO
should	MD	O
be	VB	O
adopted	VBN	O
.	.	O

Do	NNP	O
not	RB	O
mix	VB	O
HUMULIN	NNP	O
70	CD	O
/	VBD	O
30	CD	O
with	IN	O
any	DT	O
other	JJ	O
insulins	NNS	O
or	CC	O
diluents	NNS	O
.	.	O

A	DT	O
reduction	NN	O
in	IN	O
dose	NN	O
must	MD	O
be	VB	O
made	VBN	O
for	IN	O
a	DT	O
patient	NN	O
with	IN	O
a	DT	O
creatinine	JJ	O
clearance	NN	O
of	IN	O
≤	$	O
70	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
/	VBD	O
1.73	CD	O
m²	NN	O
and	CC	O
/	NN	O
or	CC	O
a	DT	O
body	NN	WHO
weight	NN	WHO
less	JJR	WHO
than	IN	WHO
70	CD	WHO
kg	NN	WHO
.	.	O

Ativan	NNP	O
(	(	O
lorazepam	NN	O
)	)	O
is	VBZ	O
administered	VBN	O
orally	RB	O
.	.	O

This	DT	O
will	MD	O
also	RB	O
insure	VB	O
the	DT	O
penicillinemia	NN	O
required	VBN	O
over	IN	O
a	DT	O
10	CD	O
-	:	O
day	NN	O
period	NN	O
;	:	O
however	RB	O
,	,	O
this	DT	O
alternate	NN	O
schedule	NN	O
should	MD	O
be	VB	O
used	VBN	O
only	RB	O
when	WRB	O
the	DT	O
physician	NN	O
can	MD	O
be	VB	O
assured	VBN	O
of	IN	O
the	DT	O
patient	NN	O
's	POS	O
cooperation	NN	O
.	.	O

Allow	IN	O
the	DT	O
vial	NN	O
of	IN	O
FEIBA	NNP	O
and	CC	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
(	(	O
diluent	NN	O
)	)	O
to	TO	O
reach	VB	O
room	NN	O
temperature	NN	O
.	.	O

Dosage	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
for	IN	O
children	NNS	WHO
,	,	WHO
elderly	JJ	WHO
and	CC	WHO
debilitated	JJ	WHO
patients	NNS	WHO
and	CC	WHO
patients	NNS	WHO
with	IN	WHO
cardiac	JJ	WHO
and	CC	WHO
/	JJ	WHO
or	CC	WHO
liver	JJ	WHO
disease	NN	WHO
.	.	O

The	DT	O
frequency	NN	O
of	IN	O
rebound	NN	O
hypertension	NN	O
is	VBZ	O
low	JJ	O
,	,	O
but	CC	O
it	PRP	O
can	MD	O
occur	VB	O
.	.	O

Additional	JJ	O
recommendations	NNS	O
for	IN	O
pancreatic	JJ	O
enzyme	NN	O
therapy	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
exocrine	JJ	WHO
pancreatic	JJ	WHO
insufficiency	NN	WHO
due	JJ	WHO
to	TO	WHO
chronic	JJ	WHO
pancreatitis	NN	WHO
or	CC	O
pancreatectomy	NN	O
are	VBP	O
based	VBN	O
on	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
conducted	VBN	O
in	IN	O
these	DT	O
populations	NNS	O
.	.	O

Systematic	JJ	O
evaluation	NN	O
of	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
PAXIL	NNP	O
has	VBZ	O
shown	VBN	O
that	IN	O
efficacy	NN	O
is	VBZ	O
maintained	VBN	O
for	IN	O
periods	NNS	O
of	IN	O
up	IN	O
to	TO	O
1	CD	O
year	NN	O
with	IN	O
doses	NNS	O
that	WDT	O
averaged	VBD	O
about	IN	O
30	CD	DOS
mg	NNS	UNIT
.	.	O

(	(	O
See	VB	O
PRECAUTIONS	NNP	O
.	.	O
)	)	O

One	CD	DOS
250	CD	DOS
mg	NN	UNIT
Lariam	NNP	O
(	(	O
mefloquine	NN	O
)	)	O
tablet	NN	O
should	MD	O
be	VB	O
taken	VBN	O
once	RB	FREQ
weekly	JJ	FREQ
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
weighing	VBG	WHO
over	IN	WHO
45	CD	WHO
kg	NNS	WHO
.	.	O

Due	JJ	O
to	TO	O
the	DT	O
fast	JJ	O
onset	NN	O
and	CC	O
short	JJ	O
duration	NN	O
of	IN	O
action	NN	O
of	IN	O
ULTIVA	NNP	O
(	(	O
remifentanil	NN	O
)	)	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
administration	NN	O
during	IN	O
anesthesia	NNS	O
can	MD	O
be	VB	O
titrated	VBN	O
upward	RB	O
in	IN	O
25	CD	O
%	NN	O
to	TO	O
100	CD	O
%	NN	O
increments	NNS	O
in	IN	O
adult	NN	WHO
patients	NNS	WHO
or	CC	O
up	RB	O
to	TO	O
50	CD	O
%	NN	O
increments	NNS	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
,	,	O
or	CC	O
downward	RB	O
in	IN	O
25	CD	O
%	NN	O
to	TO	O
50	CD	O
%	NN	O
decrements	NNS	O
every	DT	O
2	CD	O
to	TO	O
5	CD	O
minutes	NNS	O
to	TO	O
attain	VB	O
the	DT	O
desired	JJ	O
level	NN	O
of	IN	O
μ	NNP	O
-	:	O
opioid	JJ	O
effect	NN	O
.	.	O

Contents	NNS	O
of	IN	O
any	DT	O
partially	RB	O
used	JJ	O
container	NN	O
should	MD	O
be	VB	O
discarded	VBN	O
.	.	O

NIMBEX	NNP	O
Injection	NNP	O
diluted	VBD	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
;	:	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
;	:	O
or	CC	O
5	CD	O
%	NN	O
Dextrose	NNP	O
and	CC	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
to	TO	O
0.1	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
may	MD	O
be	VB	O
stored	VBN	O
either	DT	O
under	IN	O
refrigeration	NN	O
or	CC	O
at	IN	O
room	NN	O
temperature	NN	O
for	IN	O
24	CD	PER
hours	NNS	PER
without	IN	O
significant	JJ	O
loss	NN	O
of	IN	O
potency	NN	O
.	.	O

Sunday	NNP	O
-	:	O
Start	JJ	O
Regimen	NNS	O
:	:	O

Most	JJS	WHO
patients	NNS	WHO
will	MD	O
require	VB	O
this	DT	O
dosage	NN	O
until	IN	O
initial	JJ	O
control	NN	O
has	VBZ	O
been	VBN	O
achieved	VBN	O
,	,	O
after	IN	O
which	WDT	O
the	DT	O
dosage	NN	O
may	MD	O
be	VB	O
reduced	VBN	O
to	TO	O
meet	VB	O
individual	JJ	O
requirements	NNS	O
.	.	O

Narcolepsy	NNP	O
seldom	NN	O
occurs	VBZ	O
in	IN	O
children	NNS	WHO
under	IN	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
;	:	O
however	RB	O
,	,	O
when	WRB	O
it	PRP	O
does	VBZ	O
,	,	O
DEXEDRINE	NNP	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

The	DT	O
vial	NN	O
is	VBZ	O
for	IN	O
single	JJ	O
-	:	O
use	NN	O
only	RB	O
.	.	O

A	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
24	CD	DOS
/	JJ	O
26	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
-	:	FREQ
daily	NN	FREQ
is	VBZ	O
recommended	VBN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	O
Child	NNP	O
-	:	O
Pugh	NN	O
B	NNP	O
classification	NN	O
)	)	O
.	.	O

Do	NNP	O
not	RB	O
inject	VB	O
the	DT	O
vaccine	NN	O
in	IN	O
the	DT	O
gluteal	JJ	O
region	NN	O
or	CC	O
areas	NNS	O
where	WRB	O
there	EX	O
may	MD	O
be	VB	O
a	DT	O
major	JJ	O
nerve	NN	O
trunk	NN	O
.	.	O

Two	CD	PER
weeks	NNS	PER
later	RB	O
(	(	O
Day	NNP	O
29	CD	O
)	)	O
begin	VB	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
40	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
other	JJ	FREQ
week	NN	FREQ
.	.	O

XARTEMIS	NN	O
XR	NN	O
is	VBZ	O
given	VBN	O
orally	RB	O
.	.	O

The	DT	O
standard	JJ	O
regimen	NNS	O
used	VBN	O
to	TO	O
treat	VB	O
nephrotic	JJ	O
syndrome	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
is	VBZ	O
60	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
/	NNP	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
three	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
for	IN	O
4	CD	PER
weeks	NNS	PER
,	,	O
followed	VBN	O
by	IN	O
4	CD	PER
weeks	NNS	PER
of	IN	O
single	JJ	DOS
dose	NN	UNIT
alternate	JJ	O
-	:	O
day	NN	O
therapy	NN	O
at	IN	O
40	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

Tablets	NNS	O
:	:	O
Administer	NNP	O
in	IN	O
divided	JJ	O
doses	NNS	O
2	CD	FREQ
or	CC	O
3	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
,	,	O
preferably	RB	O
30	CD	O
to	TO	O
45	CD	O
minutes	NNS	O
before	IN	O
meals	NNS	O
.	.	O

Alternatively	RB	O
,	,	O
studies	NNS	O
have	VBP	O
documented	VBN	O
the	DT	O
stability	NN	O
of	IN	O
Liposyn®	NNP	O
II	NNP	O
(	(	O
intravenous	JJ	O
fat	JJ	O
emulsion	NN	O
)	)	O
10	CD	O
%	NN	O
and	CC	O
20	CD	O
%	NN	O
,	,	O
necessary	JJ	O
Hospira	NNP	O
electrolytes	NNS	O
,	,	O
Hospira	NNP	O
trace	NN	O
metals	NNS	O
,	,	O
and	CC	O
Hospira	NNP	O
10	CD	O
%	NN	O
through	IN	O
70	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
in	IN	O
a	DT	O
TPN	NNP	O
admixture	NN	O
container	NN	O
with	IN	O
the	DT	O
following	VBG	O
Hospira	NNP	O
amino	JJ	O
acid	JJ	O
solutions	NNS	O
:	:	O

Do	MD	O
not	RB	O
store	VB	O
solutions	NNS	O
containing	VBG	O
additives	NNS	O
.	.	O

Use	NNP	O
sterile	JJ	O
equipment	NN	O
.	.	O

KERYDIN	NNP	O
is	VBZ	O
for	IN	O
topical	JJ	O
use	NN	O
only	RB	O
and	CC	O
not	RB	O
for	IN	O
oral	JJ	O
,	,	O
ophthalmic	JJ	O
,	,	O
or	CC	O
intravaginal	JJ	O
use	NN	O
.	.	O

Renally	RB	O
impaired	JJ	O
patients	NNS	WHO
:	:	O
No	DT	O
dose	JJ	O
adjustment	NN	O
is	VBZ	O
needed	VBN	O
.	.	O

Rituxan	NNP	O
should	MD	O
only	RB	O
be	VB	O
administered	VBN	O
by	IN	O
a	DT	O
healthcare	JJ	O
professional	JJ	O
with	IN	O
appropriate	JJ	O
medical	JJ	O
support	NN	O
to	TO	O
manage	VB	O
severe	JJ	O
infusion	NN	O
reactions	NNS	O
that	WDT	O
can	MD	O
be	VB	O
fatal	JJ	O
if	IN	O
they	PRP	O
occur	VBP	O
[	JJ	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

After	IN	O
removing	VBG	O
the	DT	O
protective	JJ	O
blue	NN	O
vented	VBD	O
cap	NN	O
,	,	O
connect	VBP	O
the	DT	O
XYNTHA	NNP	O
SOLOFUSE™	NNP	O
to	TO	O
the	DT	O
vial	JJ	O
adapter	NN	O
by	IN	O
inserting	VBG	O
the	DT	O
tip	NN	O
into	IN	O
the	DT	O
adapter	NN	O
opening	VBG	O
while	IN	O
firmly	RB	O
pushing	VBG	O
and	CC	O
turning	VBG	O
the	DT	O
syringe	NN	O
clockwise	NN	O
until	IN	O
secured	VBN	O
.	.	O

5650D	CD	O
)	)	O
.	.	O

Alternatively	RB	O
,	,	O
for	IN	O
adult	NN	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
taking	VBG	WHO
opioids	NNS	WHO
or	CC	O
doses	VBZ	O
not	RB	O
listed	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
,	,	O
use	VBP	O
the	DT	O
following	JJ	O
methodology	NN	O
:	:	O

When	WRB	O
remission	NN	O
is	VBZ	O
shorter	JJR	O
than	IN	O
3	CD	O
months	NNS	O
,	,	O
maintenance	NN	O
therapy	NN	O
of	IN	O
1	CD	DOS
to	TO	O
3	CD	DOS
mg	NNS	UNIT
daily	JJ	FREQ
may	MD	O
be	VB	O
advisable	JJ	O
in	IN	O
order	NN	O
to	TO	O
keep	VB	O
the	DT	O
hematological	JJ	O
status	NN	O
under	IN	O
control	NN	O
and	CC	O
prevent	NN	O
rapid	JJ	O
relapse	NN	O
.	.	O

During	IN	O
irradiation	NN	O
,	,	O
continue	VBP	O
topical	JJ	O
instillation	NN	O
of	IN	O
PHOTREXA	NNP	O
VISCOUS	NNP	O
onto	IN	O
the	DT	O
eye	NN	O
every	DT	O
2	CD	O
minutes	NNS	O
for	IN	O
the	DT	O
30	CD	O
minute	JJ	O
irradiation	NN	O
period	NN	O
.	.	O

The	DT	O
clinician	NN	O
should	MD	O
,	,	O
nevertheless	RB	O
,	,	O
be	VB	O
aware	JJ	O
of	IN	O
the	DT	O
possibility	NN	O
of	IN	O
emergent	NN	O
symptoms	NNS	O
of	IN	O
serotonin	JJ	O
syndrome	NN	O
with	IN	O
such	JJ	O
use	NN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

The	DT	O
ratio	NN	O
between	IN	O
methadone	NN	O
and	CC	O
other	JJ	O
opioid	JJ	O
agonists	NNS	O
may	MD	O
vary	VB	O
widely	RB	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
previous	JJ	O
dose	JJ	O
exposure	NN	O
.	.	O

If	IN	O
the	DT	O
migraine	NN	O
has	VBZ	O
not	RB	O
resolved	VBN	O
by	IN	O
2	CD	O
hours	NNS	O
after	IN	O
taking	VBG	O
ZOMIG	NNP	O
,	,	O
or	CC	O
returns	NNS	O
after	IN	O
a	DT	O
transient	JJ	O
improvement	NN	O
,	,	O
a	DT	O
second	JJ	O
dose	NN	O
may	MD	O
be	VB	O
administered	VBN	O
at	IN	O
least	JJS	O
2	CD	O
hours	NNS	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

In	IN	O
outpatient	JJ	O
settings	NNS	O
there	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
usefulness	NN	O
of	IN	O
doses	NNS	O
greater	JJR	O
than	IN	O
225	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
for	IN	O
moderately	RB	WHO
depressed	JJ	WHO
patients	NNS	WHO
,	,	WHO
but	CC	WHO
more	RBR	WHO
severely	RB	WHO
depressed	JJ	WHO
inpatients	NNS	WHO
responded	VBD	O
to	TO	O
a	DT	O
mean	JJ	O
dose	NN	O
of	IN	O
350	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Self	NNP	O
-	:	O
injection	NN	O
therapy	NN	O
by	IN	O
the	DT	O
patient	NN	O
can	MD	O
be	VB	O
started	VBN	O
only	RB	O
after	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
properly	RB	O
instructed	VBN	O
and	CC	O
well	RB	O
trained	VBN	O
in	IN	O
the	DT	O
self	NN	O
-	:	O
injection	NN	O
technique	NN	O
.	.	O

Benadryl	NNP	O
in	IN	O
the	DT	O
injectable	JJ	O
form	NN	O
is	VBZ	O
indicated	VBN	O
when	WRB	O
the	DT	O
oral	JJ	O
form	NN	O
is	VBZ	O
impractical	JJ	O
.	.	O

Titrate	NNP	O
TIROSINT	NNP	O
-	:	O
SOL	NNP	O
dosing	VBG	O
per	IN	O
above	IN	O
instructions	NNS	O
until	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
clinically	RB	O
euthyroid	JJ	O
and	CC	O
the	DT	O
serum	NN	O
free	JJ	O
-	:	O
T4	NNP	O
level	NN	O
is	VBZ	O
restored	VBN	O
to	TO	O
the	DT	O
upper	JJ	O
half	NN	O
of	IN	O
the	DT	O
normal	JJ	O
range	NN	O
.	.	O

V	NNP	O
=	VBD	O
1.5	CD	DOS
mL	NN	UNIT
/	CD	O
min	NN	O

Concomitant	NNP	O
use	NN	O
of	IN	O
strong	JJ	O
CYP	NNP	O
3A4	CD	O
inducers	NNS	O
decreases	VBZ	O
exemestane	JJ	O
exposure	NN	O
,	,	O
For	IN	O
patients	NNS	WHO
receiving	VBG	WHO
AROMASIN	NNP	WHO
with	IN	O
a	DT	O
strong	JJ	O
CYP	NNP	O
3A4	CD	O
inducer	NN	O
such	JJ	O
as	IN	O
rifampicin	NN	O
or	CC	O
phenytoin	NN	O
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AROMASIN	NNP	O
is	VBZ	O
50	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
after	IN	O
a	DT	O
meal	NN	O
[	JJ	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Generally	RB	O
,	,	O
3,000	CD	DOS
ng	JJ	UNIT
/	NNP	O
mL	NN	O
and	CC	O
10,000	CD	DOS
ng	JJ	UNIT
/	NN	O
mL	NN	O
are	VBP	O
satisfactory	JJ	O
concentrations	NNS	O
to	TO	O
deliver	VB	O
between	IN	O
2	CD	DOS
to	TO	O
16	CD	DOS
ng	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
in	IN	O
adults	NNS	WHO
.	.	O

7	CD	O
.	.	O

Careful	JJ	O
consideration	NN	O
of	IN	O
the	DT	O
appropriate	JJ	O
nail	JJ	O
management	NN	O
program	NN	O
should	MD	O
be	VB	O
given	VBN	O
to	TO	O
patients	NNS	WHO
with	IN	WHO
diabetes	NNS	WHO
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

As	IN	O
a	DT	O
general	JJ	O
rule	NN	O
,	,	O
the	DT	O
smallest	JJS	O
possible	JJ	O
amount	NN	O
of	IN	O
Ethiodol	NNP	O
(	(	O
ethiodized	VBN	O
oil	NN	O
)	)	O
should	MD	O
be	VB	O
employed	VBN	O
according	VBG	O
to	TO	O
the	DT	O
anatomical	JJ	O
area	NN	O
to	TO	O
be	VB	O
visualized	VBN	O
.	.	O

At	IN	O
least	JJS	O
14	CD	O
days	NNS	O
should	MD	O
elapse	VB	O
between	IN	O
discontinuation	NN	O
of	IN	O
a	DT	O
MAOI	NNP	O
intended	VBN	O
to	TO	O
treat	VB	O
psychiatric	JJ	O
disorders	NNS	O
and	CC	O
initiation	NN	O
of	IN	O
therapy	NN	O
with	IN	O
Savella	NNP	O
.	.	O

Lower	JJR	O
dosages	NNS	O
are	VBP	O
also	RB	O
recommended	VBN	O
for	IN	O
outpatients	NNS	O
as	IN	O
compared	VBN	O
to	TO	O
hospitalized	VBN	WHO
patients	NNS	WHO
who	WP	WHO
will	MD	WHO
be	VB	WHO
under	IN	WHO
close	JJ	WHO
supervision	NN	WHO
.	.	O

No	DT	O
adjustment	NN	O
to	TO	O
the	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
XELODA	NNP	O
is	VBZ	O
recommended	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
creatinine	JJ	O
clearance	NN	O
=	VBD	O
51	CD	DOS
to	TO	O
80	CD	DOS
mL	NNS	UNIT
/	JJ	O
min	NN	O
[	NNP	O
Cockroft	NNP	O
and	CC	O
Gault	NNP	O
,	,	O
as	IN	O
shown	VBN	O
below	IN	O
]	NN	O
)	)	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
lower	JJR	O
doses	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

FOR	IN	O
INTRAVENOUS	NNP	O
USE	NNP	O
ONLY	NNP	O
”	NNP	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
one	CD	DOS
or	CC	O
two	CD	DOS
tablets	NNS	UNIT
every	DT	FREQ
four	CD	FREQ
to	TO	O
six	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

The	DT	O
usual	JJ	O
duration	NN	O
of	IN	O
administration	NN	O
is	VBZ	O
7	CD	PER
to	TO	O
10	CD	PER
days	NNS	PER
;	:	O
up	RB	O
to	TO	O
12	CD	O
days	NNS	O
administration	NN	O
has	VBZ	O
been	VBN	O
administered	VBN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
.	.	O

B	NNP	O
.	.	O

The	DT	O
dry	JJ	O
lyophillized	JJ	O
cake	NN	O
is	VBZ	O
dissolved	VBN	O
by	IN	O
adding	VBG	O
Water	NNP	O
for	IN	O
Injection	NNP	O
USP	NNP	O
in	IN	O
an	DT	O
amount	NN	O
to	TO	O
yield	VB	O
the	DT	O
desired	JJ	O
concentration	NN	O
as	IN	O
indicated	VBN	O
in	IN	O
the	DT	O
following	JJ	O
table	NN	O
:	:	O

Further	NNP	O
,	,	O
some	DT	WHO
patients	NNS	WHO
may	MD	O
tolerate	VB	O
one	CD	O
treatment	NN	O
regimen	NNS	O
better	RBR	O
than	IN	O
the	DT	O
other	JJ	O
.	.	O

Obtain	NNP	O
immediate	JJ	O
medical	JJ	O
attention	NN	O
if	IN	O
injury	NN	O
occurs	NNS	O
.	.	O

Once	RB	O
the	DT	O
retraction	NN	O
is	VBZ	O
complete	JJ	O
,	,	O
the	DT	O
Tool	NNP	O
can	MD	O
be	VB	O
fully	RB	O
withdrawn	VBN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
tolerates	VBZ	O
the	DT	O
0.3	CD	DOS
mL	NN	UNIT
(	(	O
3	CD	DOS
mg	NN	UNIT
)	)	O
test	NN	O
dose	NN	O
,	,	O
the	DT	O
initial	JJ	O
maintenance	NN	O
dose	NN	O
should	MD	O
be	VB	O
0.2	CD	DOS
mL	NN	UNIT
(	(	O
2	CD	DOS
mg	NN	UNIT
)	)	O
used	VBD	O
on	IN	O
an	DT	O
as	IN	O
needed	JJ	O
basis	NN	O
to	TO	O
treat	VB	O
existing	VBG	O
“	NNP	O
off	IN	O
”	NNP	O
episodes	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
regimen	NNS	O
for	IN	O
ZIRGAN	NNP	O
is	VBZ	O
1	CD	DOS
drop	NN	UNIT
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
5	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
day	NN	FREQ
(	(	O
approximately	RB	O
every	DT	FREQ
3	CD	FREQ
hours	NNS	FREQ
while	IN	O
awake	NN	O
)	)	O
until	IN	O
the	DT	O
corneal	JJ	O
ulcer	JJ	O
heals	NNS	O
,	,	O
and	CC	O
then	RB	O
1	CD	DOS
drop	NN	UNIT
3	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
day	NN	FREQ
for	IN	O
7	CD	PER
days	NNS	PER
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
AVODART	NNP	O
is	VBZ	O
1	CD	DOS
capsule	NN	UNIT
(	(	O
0.5	CD	DOS
mg	NN	UNIT
)	)	O
taken	VBN	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

Individual	JJ	O
titration	NN	O
should	MD	O
proceed	VB	O
in	IN	O
increments	NNS	O
of	IN	O
150	CD	DOS
mcg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
,	,	O
no	DT	O
more	RBR	O
frequently	RB	O
than	IN	O
every	DT	FREQ
4	CD	FREQ
days	NNS	FREQ
.	.	O

A	DT	O
nonhormonal	JJ	O
method	NN	O
of	IN	O
contraception	NN	O
is	VBZ	O
recommended	VBN	O
when	WRB	O
Danazol	NNP	O
is	VBZ	O
administered	VBN	O
at	IN	O
this	DT	O
dose	NN	O
,	,	O
since	IN	O
ovulation	NN	O
may	MD	O
not	RB	O
be	VB	O
suppressed	VBN	O
.	.	O

In	IN	O
conjunction	NN	O
with	IN	O
performing	NN	O
of	IN	O
the	DT	O
trabeculectomy	NN	O
,	,	O
the	DT	O
Healon	NNP	O
OVD	NNP	O
is	VBZ	O
injected	VBN	O
slowly	RB	O
and	CC	O
carefully	RB	O
through	IN	O
a	DT	O
corneal	JJ	O
paracentesis	NN	O
to	TO	O
reconstitute	VB	O
the	DT	O
anterior	JJ	O
chamber	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
with	IN	WHO
hyponatremia	NN	WHO
(	(	O
serum	JJ	O
sodium	NN	O
<	VBZ	O
130	CD	O
mEq	NN	O
/	NNP	O
L	NNP	O
)	)	O
is	VBZ	O
2.5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

In	IN	O
the	DT	O
clinical	JJ	O
trials	NNS	O
,	,	O
immediately	RB	O
before	IN	O
instilling	VBG	O
the	DT	O
first	JJ	O
quarter	NN	O
-	:	O
dose	NN	O
,	,	O
the	DT	O
infant	NN	WHO
's	POS	O
ventilator	NN	O
settings	NNS	O
were	VBD	O
changed	VBN	O
to	TO	O
rate	NN	O
60	CD	O
/	NNP	O
minute	NN	O
,	,	O
inspiratory	JJ	O
time	NN	O
0.5	CD	O
second	JJ	O
,	,	O
and	CC	O
FiO2	NNP	O
1.0	CD	O
.	.	O

Inspect	JJ	O
vials	NNS	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

Dosage	NN	O
should	MD	O
be	VB	O
tailored	VBN	O
to	TO	O
the	DT	O
individual	NN	O
,	,	O
response	NN	O
carefully	RB	O
monitored	VBD	O
and	CC	O
dosage	NN	O
adjusted	VBN	O
accordingly	RB	O
.	.	O

Do	NNP	O
not	RB	O
mix	VB	O
ZENPEP	NNP	O
capsule	NN	O
contents	NNS	O
directly	RB	O
into	IN	O
formula	NN	O
or	CC	O
breast	NN	O
milk	NN	O
prior	RB	O
to	TO	O
administration	NN	O
[	NNP	O
see	VBP	O
Administration	NNP	O
below	IN	O
]	NNP	O
.	.	O

Continuous	JJ	O
monitoring	NN	O
of	IN	O
respiratory	NN	O
and	CC	O
cardiac	JJ	O
function	NN	O
is	VBZ	O
required	VBN	O
(	(	O
ie	JJ	O
,	,	O
pulse	JJ	O
oximetry	NN	O
)	)	O
.	.	O

Dosing	VBG	O
intervals	NNS	O
less	RBR	O
than	IN	O
every	DT	FREQ
72	CD	FREQ
hours	NNS	FREQ
were	VBD	O
not	RB	O
studied	VBN	O
in	IN	O
children	NNS	WHO
and	CC	WHO
adolescents	NNS	WHO
and	CC	O
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
and	CC	O
schedules	NNS	O
are	VBP	O
:	:	O

However	RB	O
,	,	O
women	NNS	WHO
currently	RB	WHO
using	VBG	WHO
continuous	JJ	WHO
estrogen	NN	WHO
or	CC	O
combination	NN	O
estrogen	NN	O
plus	CC	O
progestin	JJ	O
therapy	NN	O
should	MD	O
complete	VB	O
the	DT	O
current	JJ	O
cycle	NN	O
of	IN	O
therapy	NN	O
,	,	O
before	IN	O
initiating	VBG	O
CombiPatch	NNP	O
therapy	NN	O
.	.	O

The	DT	O
full	JJ	O
10	CD	O
-	:	O
day	NN	O
course	NN	O
of	IN	O
therapy	NN	O
should	MD	O
be	VB	O
completed	VBN	O
for	IN	O
effective	JJ	O
treatment	NN	O
of	IN	O
tonsillitis	NN	O
and	CC	O
/	NN	O
or	CC	O
pharyngitis	NN	O
secondary	JJ	O
to	TO	O
S.	NNP	O
pyogenes	NNS	O
.	.	O

The	DT	O
solution	NN	O
for	IN	O
intravenous	JJ	O
use	NN	O
is	VBZ	O
prepared	VBN	O
by	IN	O
adding	VBG	O
the	DT	O
contents	NNS	O
of	IN	O
a	DT	O
500	CD	DOS
mg	NN	UNIT
vial	NN	UNIT
to	TO	O
100	CD	DOS
or	CC	O
200	CD	DOS
mL	NN	UNIT
of	IN	O
sterile	JJ	O
diluent	NN	O
such	JJ	O
as	IN	O
0.9	CD	O
%	NN	O
sodium	NN	O
chloride	NN	O
injection	NN	O
or	CC	O
5	CD	O
%	NN	O
dextrose	JJ	O
injection	NN	O
or	CC	O
any	DT	O
other	JJ	O
compatible	JJ	O
solution	NN	O
.	.	O

After	IN	O
all	DT	O
28	CD	O
tablets	NNS	O
have	VBP	O
been	VBN	O
taken	VBN	O
,	,	O
whether	IN	O
bleeding	NN	O
has	VBZ	O
stopped	VBN	O
or	CC	O
not	RB	O
,	,	O
the	DT	O
same	JJ	O
dosage	NN	O
schedule	NN	O
is	VBZ	O
repeated	VBN	O
beginning	VBG	O
on	IN	O
the	DT	O
following	JJ	O
day	NN	O
.	.	O

VICTRELIS	NNP	O
must	MD	O
not	RB	O
be	VB	O
administered	VBN	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
peginterferon	NN	O
alfa	NN	O
and	CC	O
ribavirin	NN	O
.	.	O

Generally	RB	O
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
up	IN	O
to	TO	O
0.375	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
/	NNP	FREQ
week	NN	FREQ
.	.	O

If	IN	O
a	DT	O
10	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
is	VBZ	O
prescribed	VBN	O
,	,	O
a	DT	O
second	JJ	O
spray	NN	O
should	MD	O
be	VB	O
administered	VBN	O
.	.	O

Do	NNP	O
not	RB	O
re	VB	O
-	:	O
escalate	VB	O
the	DT	O
KADCYLA	NNP	O
dose	NN	O
after	IN	O
a	DT	O
dose	JJ	O
reduction	NN	O
is	VBZ	O
made	VBN	O
.	.	O

For	IN	O
additional	JJ	O
patient	NN	O
instructions	NNS	O
regarding	VBG	O
missed	JJ	O
pills	NNS	O
,	,	O
see	VBP	O
the	DT	O
“	NNP	O
WHAT	NNP	O
TO	NNP	O
DO	VB	O
IF	NNP	O
YOU	NNP	O
MISS	NNP	O
PILLS	NNP	O
”	NNP	O
section	NN	O
in	IN	O
the	DT	O
FDA	NNP	O
Approved	NNP	O
Patient	NNP	O
Labeling	NNP	O
.	.	O

CLcr	NNP	O
=	NNP	O
K	NNP	O
×	NNP	O
body	NN	O
length	NN	O
or	CC	O
height	NN	O
/	NNS	O
serum	VBP	O
creatinine	NN	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
<	JJ	O
30	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
creatinine	NN	O
clearance	NN	O
)	)	O
,	,	O
the	DT	O
dosing	NN	O
intervals	NNS	O
should	MD	O
be	VB	O
increased	VBN	O
to	TO	O
Q	VB	O
24	CD	O
hours	NNS	O
.	.	O

In	IN	O
addition	NN	O
to	TO	O
the	DT	O
adverse	JJ	O
reactions	NNS	O
previously	RB	O
listed	VBN	O
,	,	O
this	DT	O
procedure	NN	O
has	VBZ	O
been	VBN	O
complicated	VBN	O
by	IN	O
intramural	JJ	O
injection	NN	O
with	IN	O
marked	JJ	O
adverse	JJ	O
effects	NNS	O
on	IN	O
cardiac	JJ	O
function	NN	O
.	.	O

Dosage	NNP	O
adjustment	NN	O
of	IN	O
carbidopa	NN	O
and	CC	O
levodopa	NN	O
extended	VBN	O
-	:	O
release	NN	O
tablets	NNS	O
may	MD	O
be	VB	O
necessary	JJ	O
when	WRB	O
these	DT	O
agents	NNS	O
are	VBP	O
added	VBN	O
.	.	O

Continually	RB	O
reevaluate	JJ	O
patients	NNS	WHO
receiving	VBG	WHO
DURAGESIC	NNP	WHO
to	TO	O
assess	VB	O
the	DT	O
maintenance	NN	O
of	IN	O
pain	NN	O
control	NN	O
and	CC	O
the	DT	O
relative	JJ	O
incidence	NN	O
of	IN	O
adverse	JJ	O
reactions	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
monitoring	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
addiction	NN	O
,	,	O
abuse	NN	O
,	,	O
or	CC	O
misuse	NN	O
.	.	O

The	DT	O
solutions	NNS	O
are	VBP	O
supplied	VBN	O
in	IN	O
two	CD	O
different	JJ	O
two	CD	O
-	:	O
compartment	NN	O
bags	NNS	O
,	,	O
one	CD	O
made	NN	O
of	IN	O
polyvinyl	JJ	O
chloride	NN	O
with	IN	O
a	DT	O
frangible	JJ	O
pin	NN	O
separating	VBG	O
compartment	NN	O
A	NNP	O
and	CC	O
B	NNP	O
(	(	O
see	VB	O
Figure	NNP	O
1	CD	O
)	)	O
and	CC	O
one	CD	O
made	NN	O
of	IN	O
polyolefin	NN	O
with	IN	O
a	DT	O
peel	NN	O
seal	NN	O
separating	VBG	O
compartment	NN	O
A	NNP	O
and	CC	O
B	NNP	O
(	(	O
see	VB	O
Figure	NNP	O
6	CD	O
)	)	O
.	.	O

Treatment	NN	O
should	MD	O
be	VB	O
continued	VBN	O
until	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
clinically	RB	O
stabilized	VBN	O
.	.	O

5	CD	O
.	.	O

These	DT	O
are	VBP	O
a	DT	O
secondary	JJ	O
technetium	NN	O
Tc99m	NNP	O
exametazime	NN	O
complex	NN	O
,	,	O
free	JJ	O
pertechnetate	NN	O
,	,	O
and	CC	O
reduced	VBD	O
-	:	O
hydrolyzed	VBN	O
-	:	O
technetium	NN	O
Tc99m	NNP	O
.	.	O

Studies	NNS	O
conducted	VBN	O
with	IN	O
EXPAREL	NNP	O
demonstrated	VBD	O
that	IN	O
the	DT	O
most	RBS	O
common	JJ	O
implantable	JJ	O
materials	NNS	O
(	(	O
polypropylene	NN	O
,	,	O
PTFE	NNP	O
,	,	O
silicone	NN	O
,	,	O
stainless	NN	O
steel	NN	O
,	,	O
and	CC	O
titanium	NN	O
)	)	O
are	VBP	O
not	RB	O
affected	VBN	O
by	IN	O
the	DT	O
presence	NN	O
of	IN	O
EXPAREL	NNP	O
any	DT	O
more	JJR	O
than	IN	O
they	PRP	O
are	VBP	O
by	IN	O
saline	NN	O
.	.	O

Insufficient	NNP	O
data	NNS	O
are	VBP	O
available	JJ	O
for	IN	O
recommendation	NN	O
of	IN	O
a	DT	O
specific	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
TRACRIUM	NNP	O
(	(	O
atracurium	JJ	O
besylate	NN	O
)	)	O
for	IN	O
administration	NN	O
following	VBG	O
the	DT	O
use	NN	O
of	IN	O
succinylcholine	NN	O
in	IN	O
children	NNS	WHO
and	CC	WHO
infants	NNS	WHO
.	.	O

One	CD	DOS
drop	NN	UNIT
of	IN	O
Istalol®	NNP	O
(	(	O
timolol	JJ	O
maleate	NN	O
ophthalmic	JJ	O
solution	NN	O
)	)	O
0.5	CD	O
%	NN	O
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
in	IN	O
the	DT	O
AM	NNP	O
.	.	O

The	DT	WHO
child	NN	WHO
is	VBZ	O
placed	VBN	O
in	IN	O
a	DT	O
lithotomy	JJ	O
position	NN	O
under	IN	O
general	JJ	O
anesthesia	NN	O
and	CC	O
cystoscopy	NN	O
is	VBZ	O
performed	VBN	O
to	TO	O
localize	VB	O
the	DT	O
ureteral	JJ	O
orifices	NNS	O
.	.	O

Precautions	NNS	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
prevent	VB	O
extravasation	NN	O
at	IN	O
the	DT	O
injection	NN	O
site	NN	O
.	.	O

Doses	NNS	O
in	IN	O
excess	NN	O
of	IN	O
6,000	CD	DOS
USP	NNP	UNIT
lipase	VBD	O
units	NNS	O
/	NNP	O
kg	NN	O
/	NNP	O
meal	NN	O
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

Each	DT	O
injection	NN	O
site	NN	O
has	VBZ	O
a	DT	O
ring	NN	O
of	IN	O
effect	NN	O
of	IN	O
up	IN	O
to	TO	O
approximately	RB	O
2	CD	DOS
cm	NNS	UNIT
in	IN	O
diameter	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
and	CC	O
the	DT	O
established	VBN	O
effective	JJ	O
dosage	NN	O
is	VBZ	O
20	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

ORENCIA	NNP	O
intravenous	JJ	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
30	CD	DOS
-	:	O
minute	NN	O
intravenous	JJ	O
infusion	NN	O
utilizing	VBG	O
the	DT	O
weight	NN	O
range	NN	O
-	:	O
based	VBN	O
dosing	VBG	O
specified	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
.	.	O

Reduction	NN	O
in	IN	O
the	DT	O
infusion	NN	O
rate	NN	O
of	IN	O
TRACRIUM	NNP	O
(	(	O
atracurium	JJ	O
besylate	NN	O
)	)	O
should	MD	O
,	,	O
therefore	VB	O
,	,	O
be	VB	O
considered	VBN	O
for	IN	O
patients	NNS	WHO
receiving	VBG	WHO
inhalation	NN	WHO
anesthesia	NN	WHO
.	.	O

Patients	NNS	O
whose	WP$	O
blood	NN	O
Phe	NNP	O
does	VBZ	O
not	RB	O
decrease	VB	O
after	IN	O
1	CD	O
month	NN	O
of	IN	O
treatment	NN	O
at	IN	O
20	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	FW	O
per	IN	FREQ
day	NN	FREQ
are	VBP	O
non	JJ	O
-	:	O
responders	NNS	O
and	CC	O
treatment	NN	O
with	IN	O
Kuvan	NNP	O
should	MD	O
be	VB	O
discontinued	VBN	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
.	.	O

If	IN	O
leucovorin	VBN	O
is	VBZ	O
given	VBN	O
orally	RB	O
,	,	O
doses	NNS	O
should	MD	O
be	VB	O
rounded	VBN	O
up	RP	O
to	TO	O
the	DT	O
next	JJ	O
higher	JJR	O
25	CD	DOS
mg	JJ	UNIT
increment	NN	O
.	.	O

It	PRP	O
is	VBZ	O
generally	RB	O
agreed	VBN	O
that	IN	O
pharmacological	JJ	O
treatment	NN	O
of	IN	O
ADHD	NNP	O
may	MD	O
be	VB	O
needed	VBN	O
for	IN	O
extended	JJ	O
periods	NNS	O
.	.	O

See	VB	O
PRECAUTIONS—General	NNP	O
.	.	O

Dosage	NN	O
must	MD	O
be	VB	O
regulated	VBN	O
carefully	RB	O
to	TO	O
prevent	VB	O
a	DT	O
more	RBR	O
rapid	JJ	O
or	CC	O
substantial	JJ	O
los	JJ	O
s	NN	O
of	IN	O
fluid	NN	O
or	CC	O
electrolyte	NN	O
than	IN	O
is	VBZ	O
indicated	VBN	O
or	CC	O
necessary	JJ	O
.	.	O

The	DT	O
system	NN	O
determines	VBZ	O
if	IN	O
Sr	NNP	O
82	CD	O
in	IN	O
the	DT	O
eluate	NN	O
exceeds	VBZ	O
an	DT	O
Alert	NNP	O
or	CC	O
Expiration	NNP	O
Limit	NNP	O
by	IN	O
dividing	VBG	O
the	DT	O
μCi	NN	O
(	(	O
or	CC	O
kBq	VB	O
)	)	O
of	IN	O
Sr	NNP	O
82	CD	O
by	IN	O
the	DT	O
mCi	NN	O
(	(	O
or	CC	O
MBq	NNP	O
)	)	O
of	IN	O
Rb	$	O
82	CD	O
at	IN	O
End	NN	O
of	IN	O
Elution	NNP	O
(	(	O
see	VB	O
below	IN	O
for	IN	O
further	JJ	O
instructions	NNS	O
based	VBN	O
on	IN	O
the	DT	O
Sr	NNP	O
82	CD	O
level	NN	O
)	)	O

Do	NNP	O
not	RB	O
mix	VB	O
MESNEX	NNP	O
injection	NN	O
with	IN	O
epirubicin	NN	O
,	,	O
cyclophosphamide	NN	O
,	,	O
cisplatin	NN	O
,	,	O
carboplatin	NN	O
,	,	O
and	CC	O
nitrogen	RB	O
mustard	NN	O
.	.	O

This	DT	O
position	NN	O
should	MD	O
be	VB	O
maintained	VBN	O
for	IN	O
five	CD	O
minutes	NNS	O
to	TO	O
facilitate	VB	O
penetration	NN	O
of	IN	O
the	DT	O
medication	NN	O
into	IN	O
the	DT	O
ear	JJ	O
canal	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
acetaZOLAMIDE	NN	O
does	VBZ	O
not	RB	O
eliminate	VB	O
the	DT	O
need	NN	O
for	IN	O
other	JJ	O
therapy	NN	O
such	JJ	O
as	IN	O
digitalis	NN	O
,	,	O
bed	VBD	O
rest	NN	O
,	,	O
and	CC	O
salt	JJ	O
restriction	NN	O
.	.	O

Physicians	NNS	O
and	CC	O
patients	NNS	O
should	MD	O
weigh	VB	O
the	DT	O
possible	JJ	O
benefits	NNS	O
of	IN	O
decreasing	VBG	O
transfusions	NNS	O
against	IN	O
the	DT	O
increased	JJ	O
risks	NNS	O
of	IN	O
death	NN	O
and	CC	O
other	JJ	O
serious	JJ	O
cardiovascular	JJ	O
adverse	JJ	O
events	NNS	O
[	JJ	O
see	VBP	O
BOXED	NNP	O
WARNING	NNP	O
and	CC	O
Clinical	NNP	O
Studies	NNP	O
]	NNP	O
.	.	O

After	IN	O
a	DT	O
favorable	JJ	O
response	NN	O
is	VBZ	O
noted	VBN	O
,	,	O
the	DT	O
proper	JJ	O
maintenance	NN	O
dosage	NN	O
should	MD	O
be	VB	O
determined	VBN	O
by	IN	O
decreasing	VBG	O
the	DT	O
initial	JJ	O
drug	NN	O
dosage	NN	O
in	IN	O
small	JJ	O
decrements	NNS	O
at	IN	O
appropriate	JJ	O
time	NN	O
intervals	NNS	O
until	IN	O
the	DT	O
lowest	JJS	O
dosage	NN	O
which	WDT	O
will	MD	O
maintain	VB	O
an	DT	O
adequate	JJ	O
clinical	JJ	O
response	NN	O
is	VBZ	O
reached	VBN	O
.	.	O

(	(	O
two	CD	DOS
full	JJ	WHO
measuring	VBG	WHO
scoops	NNS	WHO
or	CC	O
56	CD	DOS
drops	NNS	UNIT
)	)	O
per	IN	O
meal	NN	O
or	CC	O
snack	NN	O
for	IN	O
patients	NNS	WHO
over	IN	WHO
15	CD	WHO
kg	NNS	WHO
in	IN	O
body	NN	O
weight	NN	O
.	.	O

Do	NNP	O
not	RB	O
shake	VB	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
ORLAAM	NNP	O
(	(	O
levomethadyl	JJ	O
acetate	NN	O
)	)	O
in	IN	O
each	DT	O
patient	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
to	TO	O
achieve	VB	O
the	DT	O
optimal	JJ	O
therapeutic	JJ	O
benefit	NN	O
with	IN	O
acceptable	JJ	O
adverse	JJ	O
opioid	NN	O
effects	NNS	O
(	(	O
see	VB	O
INDIVIDUALIZATION	NNP	O
OF	NNP	O
DOSAGE	NNP	O
)	)	O
.	.	O

Dose	NNP	O
changes	NNS	O
should	MD	O
occur	VB	O
at	IN	O
intervals	NNS	O
of	IN	O
at	IN	O
least	JJS	O
1	CD	PER
week	NN	PER
.	.	O

If	IN	O
ovulation	NN	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
occur	VB	O
after	IN	O
the	DT	O
first	JJ	O
course	NN	O
of	IN	O
therapy	NN	O
,	,	O
a	DT	O
second	JJ	O
course	NN	O
of	IN	O
100	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
(	(	O
two	CD	DOS
50	CD	DOS
mg	JJ	UNIT
tablets	NNS	UNIT
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	FREQ
dose	NN	UNIT
)	)	O
for	IN	O
5	CD	PER
days	NNS	PER
should	MD	O
be	VB	O
given	VBN	O
.	.	O

VAPRISOL	NNP	O
is	VBZ	O
incompatible	JJ	O
with	IN	O
both	DT	O
Lactated	NNP	O
Ringer	NNP	O
's	POS	O
Injection	NNP	O
and	CC	O
furosemide	JJ	O
injection	NN	O
when	WRB	O
these	DT	O
products	NNS	O
are	VBP	O
mixed	JJ	O
in	IN	O
the	DT	O
same	JJ	O
container	NN	O
;	:	O
therefore	RB	O
,	,	O
do	VBP	O
not	RB	O
combine	VB	O
VAPRISOL	NNP	O
with	IN	O
these	DT	O
products	NNS	O
in	IN	O
the	DT	O
same	JJ	O
intravenous	JJ	O
line	NN	O
or	CC	O
container	NN	O
.	.	O

Persons	NNS	O
who	WP	O
have	VBP	O
received	VBN	O
at	IN	O
least	JJS	O
two	CD	DOS
doses	NNS	UNIT
of	IN	O
tetanus	NN	O
toxoid	NN	O
(	(	O
tetanus	NN	O
(	(	O
tetanus	IN	O
toxoid	NN	O
)	)	O
toxoid	NN	O
)	)	O
rapidly	RB	O
develop	VB	O
antitoxin	NN	O
antibodies.2	NN	O

Given	VBN	O
cyclically	RB	O
for	IN	O
short	JJ	O
-	:	O
term	NN	O
use	IN	O
only	RB	O
:	:	O

There	EX	O
is	VBZ	O
little	JJ	O
evidence	NN	O
that	IN	O
behavior	JJ	O
improvement	NN	O
in	IN	O
severely	RB	O
disturbed	VBN	O
mentally	RB	O
retarded	JJ	O
patients	NNS	O
is	VBZ	O
further	JJ	O
enhanced	VBN	O
by	IN	O
doses	NNS	O
beyond	IN	O
500	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

After	IN	O
initial	JJ	O
vial	JJ	O
use	NN	O
,	,	O
the	DT	O
contents	NNS	O
of	IN	O
the	DT	O
multi	NN	O
-	:	O
dose	JJ	O
vial	JJ	O
remain	NN	O
stable	JJ	O
up	IN	PER
to	TO	PER
3	CD	PER
days	NNS	PER
when	WRB	O
stored	VBN	O
at	IN	O
2	CD	O
-	:	O
8.C	CD	O
(	(	O
36	CD	O
-	:	O
46.F	CD	O
)	)	O
.	.	O

While	IN	O
holding	VBG	O
the	DT	O
obturator	NN	O
fixed	VBN	O
in	IN	O
place	NN	O
on	IN	O
the	DT	O
arm	NN	O
,	,	O
fully	RB	O
retract	VB	O
the	DT	O
cannula	NN	O
(	(	O
Figure	NNP	O
10	CD	O
)	)	O
.	.	O

Overhydration	NN	O
should	MD	O
be	VB	O
avoided	VBN	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
potential	JJ	WHO
for	IN	WHO
cardiac	JJ	WHO
failure	NN	WHO
.	.	O

However	RB	O
,	,	O
the	DT	O
efficacy	NN	O
of	IN	O
repeated	JJ	O
doses	NNS	O
of	IN	O
intramuscular	JJ	O
olanzapine	NN	O
for	IN	O
injection	NN	O
in	IN	O
agitated	JJ	WHO
patients	NNS	WHO
has	VBZ	WHO
not	RB	WHO
been	VBN	WHO
systematically	RB	WHO
evaluated	VBN	WHO
in	IN	WHO
controlled	JJ	WHO
clinical	JJ	WHO
trials	NNS	WHO
.	.	O

If	IN	O
it	PRP	O
is	VBZ	O
known	VBN	O
or	CC	O
suspected	VBN	O
that	IN	O
subcutaneous	JJ	O
extravasation	NN	O
has	VBZ	O
occurred	VBN	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
intermittent	JJ	O
ice	NN	O
packs	NNS	O
(	(	O
½	VB	O
hour	NN	O
immediately	RB	O
,	,	O
then	RB	O
½	VB	O
hour	NN	O
4	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
day	NN	FREQ
for	IN	O
3	CD	PER
days	NNS	PER
)	)	O
be	VB	O
placed	VBN	O
over	IN	O
the	DT	O
area	NN	O
of	IN	O
extravasation	NN	O
and	CC	O
that	IN	O
the	DT	O
affected	JJ	O
extremity	NN	O
be	VB	O
elevated	VBN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Recommended	VBN	O
Adult	NNP	WHO
Dosage	NNP	O
for	IN	O
PEGASYS	NNP	O
for	IN	O
CHC	NNP	O
Infection1	NNP	O

Simultaneous	JJ	O
or	CC	O
sequential	JJ	O
application	NN	O
of	IN	O
multiple	JJ	O
SYNERA	NNP	O
patches	NNS	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Myfortic	NNP	O
is	VBZ	O
720	CD	DOS
mg	NN	UNIT
administered	VBN	O
twice	RB	FREQ
daily	RB	FREQ
(	(	O
1440	CD	DOS
mg	NN	UNIT
total	JJ	O
daily	JJ	FREQ
dose	NN	O
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
important	JJ	O
that	IN	O
the	DT	O
injection	NN	O
is	VBZ	O
stopped	VBN	O
just	RB	O
before	IN	O
the	DT	O
needle	NN	O
is	VBZ	O
pulled	VBN	O
out	IN	O
of	IN	O
the	DT	O
skin	NN	O
to	TO	O
prevent	VB	O
material	NN	O
from	IN	O
leaking	VBG	O
out	RP	O
or	CC	O
ending	VBG	O
up	RP	O
too	RB	O
superficially	RB	O
in	IN	O
the	DT	O
skin	NN	O
.	.	O

For	IN	O
ROWEEPRA	NNP	O
tablet	NN	O
dosing	VBG	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
weighing	VBG	WHO
20	CD	WHO
to	TO	WHO
40	CD	WHO
kg	NNS	WHO
,	,	O
initiate	JJ	O
treatment	NN	O
with	IN	O
a	DT	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
500	CD	DOS
mg	NNS	UNIT
given	VBN	O
as	IN	O
twice	RB	FREQ
daily	JJ	FREQ
dosing	VBG	O
(	(	O
250	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
)	)	O
.	.	O

Because	IN	O
elderly	JJ	WHO
patients	NNS	WHO
are	VBP	WHO
more	RBR	WHO
likely	JJ	WHO
to	TO	WHO
have	VB	WHO
decreased	VBN	WHO
renal	JJ	WHO
function	NN	WHO
,	,	O
care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
in	IN	O
dose	JJ	O
selection	NN	O
,	,	O
and	CC	O
it	PRP	O
may	MD	O
be	VB	O
useful	JJ	O
to	TO	O
monitor	VB	O
renal	JJ	O
function	NN	O
.	.	O

Equally	RB	O
good	JJ	O
results	NNS	O
may	MD	O
be	VB	O
obtained	VBN	O
by	IN	O
intubating	VBG	O
the	DT	O
stomach	NN	O
and	CC	O
directly	RB	O
instilling	VBG	O
the	DT	O
material	NN	O
into	IN	O
the	DT	O
stomach	NN	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
dextrose	NN	O
or	CC	O
milk	NN	O
meal	NN	O
.	.	O

When	WRB	O
HEPARIN	NNP	O
SODIUM	NNP	O
INJECTION	NNP	O
is	VBZ	O
added	VBN	O
to	TO	O
an	DT	O
infusion	NN	O
solution	NN	O
for	IN	O
continuous	JJ	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
administration	NN	O
,	,	O
invert	VBP	O
the	DT	O
container	NN	O
at	IN	O
least	JJS	O
six	CD	FREQ
times	NNS	FREQ
to	TO	O
ensure	VB	O
adequate	JJ	O
mixing	NN	O
and	CC	O
prevent	NN	O
pooling	NN	O
of	IN	O
the	DT	O
heparin	NN	O
in	IN	O
the	DT	O
solution	NN	O
.	.	O

With	IN	O
the	DT	O
AFSTYLA	NNP	O
vial	NN	O
placed	VBD	O
firmly	RB	O
on	IN	O
a	DT	O
flat	JJ	O
surface	NN	O
,	,	O
invert	VBP	O
the	DT	O
diluents	NNS	O
vial	JJ	O
with	IN	O
the	DT	O
Mix2Vial	NNP	O
transfer	NN	O
set	NN	O
attached	VBN	O
and	CC	O
push	VB	O
the	DT	O
plastic	NN	O
spike	NN	O
of	IN	O
the	DT	O
transparent	NN	O
adapter	NN	O
firmly	RB	O
through	IN	O
the	DT	O
center	NN	O
of	IN	O
the	DT	O
stopper	NN	O
of	IN	O
the	DT	O
AFSTYLA	NNP	O
vial	NN	O
(	(	O
Fig	NNP	O
.	.	O

Intramuscular	JJ	O
-	:	O
Adults	NNS	WHO
:	:	O
Serious	JJ	O
infections—600	NN	O
mg	NN	UNIT
(	(	O
2	CD	DOS
mL	NN	UNIT
)	)	O
intramuscularly	RB	O
every	DT	FREQ
24	CD	FREQ
hours	NNS	FREQ
.	.	O

Venograms	NNS	O
are	VBP	O
obtained	VBN	O
by	IN	O
injection	NN	O
or	CC	O
infusion	NN	O
into	IN	O
an	DT	O
appropriate	JJ	O
vein	NN	O
in	IN	O
the	DT	O
upper	JJ	O
or	CC	O
lower	JJR	O
extremity	NN	O
.	.	O

More	RBR	O
frequent	JJ	O
administration	NN	O
or	CC	O
a	DT	O
higher	JJR	O
number	NN	O
of	IN	O
inhalations	NNS	O
(	(	O
more	JJR	O
than	IN	O
2	CD	DOS
inhalations	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
)	)	O
of	IN	O
the	DT	O
prescribed	JJ	O
strength	NN	O
of	IN	O
SYMBICORT	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
as	IN	O
some	DT	WHO
patients	NNS	WHO
are	VBP	O
more	RBR	O
likely	JJ	O
to	TO	O
experience	VB	O
adverse	JJ	O
effects	NNS	O
with	IN	O
higher	JJR	O
doses	NNS	O
of	IN	O
formoterol	NN	O
.	.	O

Swirl	NNP	O
the	DT	O
vial	NN	O
with	IN	O
a	DT	O
GENTLE	NNP	O
rotary	JJ	O
motion	NN	O
until	IN	O
the	DT	O
contents	NNS	O
are	VBP	O
completely	RB	O
dissolved	VBN	O
and	CC	O
the	DT	O
solution	NN	O
is	VBZ	O
clear	JJ	O
.	.	O

If	IN	O
BUSULFEX	NNP	O
or	CC	O
diluted	VBN	O
BUSULFEX	NNP	O
solution	NN	O
contacts	VBZ	O
the	DT	O
skin	NN	O
or	CC	O
mucosa	NN	O
,	,	O
wash	VBP	O
the	DT	O
skin	NN	O
or	CC	O
mucosa	VB	O
thoroughly	RB	O
with	IN	O
water	NN	O
.	.	O

Adult	NNP	WHO
should	MD	O
not	RB	O
be	VB	O
given	VBN	O
as	IN	O
a	DT	O
direct	JJ	O
,	,	O
undiluted	JJ	O
intravenous	JJ	O
injection	NN	O
as	IN	O
it	PRP	O
may	MD	O
give	VB	O
rise	NN	O
to	TO	O
dizziness	NN	O
,	,	O
faintness	NN	O
,	,	O
and	CC	O
possible	JJ	O
tissue	NN	O
irritation	NN	O
.	.	O

While	IN	O
useful	JJ	O
tables	NNS	O
of	IN	O
opioid	JJ	O
equivalents	NNS	O
are	VBP	O
readily	RB	O
available	JJ	O
,	,	O
there	EX	O
is	VBZ	O
substantial	JJ	O
inter	JJ	O
-	:	O
patient	NN	O
variability	NN	O
in	IN	O
the	DT	O
relative	JJ	O
potency	NN	O
of	IN	O
different	JJ	O
opioid	JJ	O
drugs	NNS	O
and	CC	O
products	NNS	O
.	.	O

The	DT	O
infusion	NN	O
rate	NN	O
should	MD	O
be	VB	O
increased	VBN	O
by	IN	O
increments	NNS	O
of	IN	O
5	CD	DOS
to	TO	O
10	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
(	(	O
0.3	CD	DOS
to	TO	O
0.6	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
h	NN	O
)	)	O
until	IN	O
the	DT	O
desired	JJ	O
level	NN	O
of	IN	O
sedation	NN	O
is	VBZ	O
achieved	VBN	O
.	.	O

Protect	NN	O
from	IN	O
light	NN	O
.	.	O

Methadone	NN	O
has	VBZ	O
a	DT	O
long	JJ	O
half	NN	O
-	:	O
life	NN	O
and	CC	O
can	MD	O
accumulate	VB	O
in	IN	O
the	DT	O
plasma	NN	O
.	.	O

Myxedema	NNP	O
Coma	NNP	O
-	:	O
Myxedema	NNP	O
coma	NN	O
is	VBZ	O
a	DT	O
life	NN	O
-	:	O
threatening	JJ	O
emergency	NN	O
characterized	VBN	O
by	IN	O
poor	JJ	O
circulation	NN	O
and	CC	O
hypometabolism	NN	O
,	,	O
and	CC	O
may	MD	O
result	VB	O
in	IN	O
unpredictable	JJ	O
absorption	NN	O
of	IN	O
levothyroxine	JJ	O
sodium	NN	O
from	IN	O
the	DT	O
gastrointestinal	JJ	O
tract	NN	O
.	.	O

Children	NNP	WHO
first	RB	WHO
vaccinated	VBD	WHO
when	WRB	WHO
younger	JJR	WHO
than	IN	WHO
12	CD	WHO
months	NNS	WHO
of	IN	WHO
age	NN	WHO
should	MD	O
receive	VB	O
another	DT	O
dose	NN	O
between	IN	O
12	CD	O
to	TO	O
15	CD	O
months	NNS	O
of	IN	O
age	NN	O
followed	VBN	O
by	IN	O
revaccination	NN	O
prior	RB	O
to	TO	O
elementary	JJ	O
school	NN	O
entry.59	NN	O
See	NNP	O
also	RB	O
INDICATIONS	NNP	O
AND	NNP	O
USAGE	NNP	O
,	,	O
Measles	NNP	O
Outbreak	NNP	O
Schedule	NNP	O
.	.	O

For	IN	O
patient	JJ	O
instructions	NNS	O
,	,	O
see	VBP	O
PATIENT	JJ	O
INFORMATION	NNP	O
.	.	O

Hold	VB	O
clear	JJ	O
finger	NN	O
grip	NN	O
.	.	O

In	IN	O
the	DT	O
event	NN	O
the	DT	O
implant	NN	O
is	VBZ	O
difficult	JJ	O
to	TO	O
locate	VB	O
,	,	O
ultrasound	NN	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

As	IN	O
with	IN	O
other	JJ	O
antiarrhythmic	JJ	O
agents	NNS	O
,	,	O
in	IN	O
the	DT	WHO
elderly	JJ	WHO
or	CC	WHO
in	IN	WHO
ventricular	JJ	WHO
arrhythmia	NN	WHO
patients	NNS	WHO
with	IN	WHO
marked	JJ	WHO
previous	JJ	WHO
myocardial	JJ	WHO
damage	NN	WHO
,	,	O
the	DT	O
dose	NN	O
of	IN	O
RYTHMOL	NNP	O
should	MD	O
be	VB	O
increased	VBN	O
more	RBR	O
gradually	RB	O
during	IN	O
the	DT	O
initial	JJ	O
phase	NN	O
of	IN	O
treatment	NN	O
.	.	O

Follow	NNP	O
equipment	NN	O
manufacturers	NNS	O
'	POS	O
operating	NN	O
directions	NNS	O
carefully	RB	O
.	.	O

Percutaneous	JJ	O
puncture	NN	O
with	IN	O
a	DT	O
needle	JJ	O
contaminated	VBN	O
with	IN	O
blood	NN	O
can	MD	O
transmit	VB	O
infectious	JJ	O
viruses	NNS	O
including	VBG	O
HIV	NNP	O
(	(	O
AIDS	NNP	O
)	)	O
and	CC	O
hepatitis	NN	O
.	.	O

Wipe	IN	O
the	DT	O
top	NN	O
of	IN	O
the	DT	O
vial	NN	O
with	IN	O
the	DT	O
alcohol	NN	O
swab	NN	O
provided	VBD	O
,	,	O
or	CC	O
use	VB	O
another	DT	O
antiseptic	JJ	O
solution	NN	O
,	,	O
and	CC	O
allow	VB	O
to	TO	O
dry	VB	O
.	.	O

If	IN	O
facilities	NNS	O
for	IN	O
administering	VBG	O
injectable	JJ	O
medication	NN	O
are	VBP	O
not	RB	O
available	JJ	O
,	,	O
a	DT	O
change	NN	O
to	TO	O
appropriate	VB	O
oral	JJ	O
therapy	NN	O
is	VBZ	O
indicated	VBN	O
on	IN	O
the	DT	O
patient	NN	O
's	POS	O
release	NN	O
from	IN	O
the	DT	O
hospital	NN	O
.	.	O
)	)	O

Interruptions	NNS	O
for	IN	O
longer	JJR	O
periods	NNS	O
may	MD	O
require	VB	O
the	DT	O
dose	NN	O
of	IN	O
Remodulin	NNP	O
to	TO	O
be	VB	O
re	JJ	O
-	:	O
titrated	VBN	O
.	.	O

To	TO	O
avoid	VB	O
cross	NN	O
-	:	O
contamination	NN	O
,	,	O
parenteral	JJ	O
drugs	NNS	O
should	MD	O
not	RB	O
be	VB	O
prepared	VBN	O
in	IN	O
areas	NNS	O
where	WRB	O
BCG	NNP	O
has	VBZ	O
been	VBN	O
prepared	VBN	O
.	.	O

When	WRB	O
using	VBG	O
MIVACRON	NNP	O
or	CC	O
other	JJ	O
neuromuscular	JJ	O
blocking	VBG	O
agents	NNS	O
to	TO	O
facilitate	VB	O
tracheal	JJ	O
intubation	NN	O
,	,	O
it	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
recognize	VB	O
that	IN	O
the	DT	O
most	RBS	O
important	JJ	O
factors	NNS	O
affecting	VBG	O
intubation	NN	O
are	VBP	O
the	DT	O
depth	NN	O
of	IN	O
general	JJ	O
anesthesia	NN	O
and	CC	O
the	DT	O
level	NN	O
of	IN	O
neuromuscular	JJ	O
block	NN	O
.	.	O

Do	NNP	O
not	RB	O
rush	VB	O
the	DT	O
administration	NN	O
of	IN	O
flumazenil	JJ	O
injection	NN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
periodically	RB	O
reassessed	VBN	O
to	TO	O
determine	VB	O
the	DT	O
continued	JJ	O
need	NN	O
for	IN	O
maintenance	NN	O
treatment	NN	O
.	.	O

If	IN	O
the	DT	O
lyophilized	JJ	O
vaccine	NN	O
can	MD	O
not	RB	O
be	VB	O
dissolved	VBN	O
,	,	O
discard	NN	O
.	.	O

The	DT	O
following	NN	O
is	VBZ	O
a	DT	O
summary	NN	O
of	IN	O
the	DT	O
instructions	NNS	O
given	VBN	O
to	TO	O
the	DT	O
patient	NN	O
in	IN	O
the	DT	O
``	``	O
HOW	NNP	O
TO	NNP	O
TAKE	VB	O
THE	NNP	O
PILL	NNP	O
''	''	O
section	NN	O
of	IN	O
the	DT	O
DETAILED	NNP	O
PATIENT	NNP	O
PACKAGE	NNP	O
INSERT	NNP	O
.	.	O

Additional	JJ	O
doses	NNS	O
may	MD	O
be	VB	O
given	VBN	O
every	DT	O
10	CD	O
-	:	O
12	CD	O
hours	NNS	O
if	IN	O
muscle	NN	O
weakness	NN	O
persists	NNS	O
.	.	O

This	DT	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
10	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
,	,	O
if	IN	O
necessary	JJ	O
.	.	O

The	DT	O
presence	NN	O
of	IN	O
palpable	JJ	O
induration	NN	O
(	(	O
even	RB	O
1	CD	O
to	TO	O
2	CD	O
mm	NN	O
)	)	O
indicates	VBZ	O
a	DT	O
positive	JJ	O
reaction	NN	O
.	.	O

6	CD	O
.	.	O

Dosage	NN	O
recommendations	NNS	O
for	IN	O
adult	NN	WHO
patients	NNS	WHO
with	IN	WHO
reduced	JJ	WHO
renal	JJ	WHO
function	NN	WHO
are	VBP	O
provided	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
[	NN	O
see	NN	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

In	IN	O
all	DT	O
cases	NNS	O
,	,	O
the	DT	O
period	NN	O
of	IN	O
overlapping	VBG	O
antipsychotic	JJ	O
administration	NN	O
should	MD	O
be	VB	O
minimized	VBN	O
.	.	O

Thereafter	RB	O
,	,	O
turn	VBP	O
the	DT	O
cartridge	NN	O
upside	RB	O
down	RB	O
so	RB	O
that	IN	O
the	DT	O
glass	NN	O
ball	NN	O
moves	NNS	O
from	IN	O
one	CD	O
end	NN	O
of	IN	O
the	DT	O
cartridge	NN	O
to	TO	O
the	DT	O
other	JJ	O
.	.	O

NOVOTHYROX	NNP	O
(	(	O
levothyroxine	JJ	O
sodium	NN	O
tablets	NNS	O
)	)	O
should	MD	O
be	VB	O
taken	VBN	O
at	IN	O
least	JJS	O
4	CD	O
hours	NNS	O
apart	RB	O
from	IN	O
drugs	NNS	O
that	WDT	O
are	VBP	O
known	VBN	O
to	TO	O
interfere	VB	O
with	IN	O
its	PRP$	O
absorption	NN	O
(	(	O
see	JJ	O
PRECAUTIONS	NNP	O
:	:	O
DRUG	NNP	O
INTERACTIONS	NNP	O
)	)	O
.	.	O

In	IN	O
these	DT	WHO
patients	NNS	WHO
,	,	O
a	DT	O
dose	NN	O
of	IN	O
100	CD	DOS
to	TO	O
150	CD	DOS
mL	NN	UNIT
(	(	O
1.5	CD	DOS
to	TO	O
2.0	CD	DOS
mL	NNS	UNIT
/	NNP	O
kg	NN	O
)	)	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

Psorcon	NNP	O
E	NNP	O
Emollient	NNP	O
Cream	NNP	O
(	(	O
diflorasone	NN	O
diacetate	NN	O
cream	NN	O
)	)	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
areas	NNS	O
as	IN	O
a	DT	O
thin	JJ	O
film	NN	O
from	IN	O
one	CD	FREQ
to	TO	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
depending	VBG	O
on	IN	O
the	DT	O
severity	NN	O
or	CC	O
resistant	JJ	O
nature	NN	O
of	IN	O
the	DT	O
condition	NN	O
.	.	O

If	IN	O
a	DT	O
dose	NN	O
is	VBZ	O
missed	VBN	O
,	,	O
that	IN	O
dose	NN	O
should	MD	O
be	VB	O
taken	VBN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
on	IN	O
that	DT	O
day	NN	O
.	.	O

If	IN	O
there	EX	O
is	VBZ	O
concern	NN	O
of	IN	O
impending	VBG	O
hypotension	NN	O
or	CC	O
tachycardia	NN	O
,	,	O
the	DT	O
infusion	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
.	.	O

Irritation	NN	O
of	IN	O
the	DT	O
eye	NN	O
has	VBZ	O
also	RB	O
been	VBN	O
reported	VBN	O
with	IN	O
accidental	JJ	O
exposure	NN	O
.	.	O

To	TO	O
do	VB	O
so	RB	O
,	,	O
with	IN	O
the	DT	O
canister	NN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
,	,	O
slowly	RB	O
and	CC	O
fully	RB	O
depress	VB	O
the	DT	O
actuator	NN	O
three	CD	FREQ
times	NNS	FREQ
.	.	O

For	IN	O
intravenous	JJ	O
injection	NN	O
only	RB	O

Strabismus	NN	O

Empiric	JJ	O
administration	NN	O
of	IN	O
vitamin	JJ	O
K1	NNP	O
should	MD	O
not	RB	O
replace	VB	O
proper	JJ	O
laboratory	NN	O
evaluation	NN	O
of	IN	O
the	DT	O
coagulation	NN	O
mechanism	NN	O
.	.	O

The	DT	O
drug	NN	O
-	:	O
dampened	JJ	O
applicator	NN	O
should	MD	O
be	VB	O
touched	VBN	O
to	TO	O
the	DT	O
wart	NN	O
to	TO	O
be	VB	O
treated	VBN	O
,	,	O
applying	VBG	O
the	DT	O
minimum	JJ	O
amount	NN	O
of	IN	O
solution	NN	O
necessary	JJ	O
to	TO	O
cover	VB	O
the	DT	O
lesion	NN	O
.	.	O

(	(	O
See	VB	O
WARNINGS	NNP	O
section	NN	O
)	)	O
.	.	O

Zortress	NNP	O
tablets	NNS	O
should	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
with	IN	O
a	DT	O
glass	NN	O
of	IN	O
water	NN	O
and	CC	O
not	RB	O
crushed	VBN	O
before	IN	O
use	NN	O
.	.	O

An	DT	O
antihypertensive	JJ	O
effect	NN	O
is	VBZ	O
usually	RB	O
present	JJ	O
within	IN	O
2	CD	PER
weeks	NNS	PER
,	,	O
with	IN	O
full	JJ	O
effect	NN	O
generally	RB	O
obtained	VBN	O
within	IN	O
4	CD	PER
weeks	NNS	PER
of	IN	O
treatment	NN	O
with	IN	O
ATACAND	NNP	O
.	.	O

Once	RB	O
-	:	O
daily	JJ	FREQ
dosing	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
skin	JJ	O
infections	NNS	O
;	:	O
therefore	RB	O
,	,	O
OMNICEF	NNP	O
for	IN	O
Oral	NNP	O
Suspension	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
twice	RB	FREQ
daily	RB	FREQ
in	IN	O
this	DT	O
infection	NN	O
.	.	O

7	CD	PER
-	:	O
10	CD	PER
days	NNS	PER

Unless	IN	O
otherwise	RB	O
directed	VBN	O
by	IN	O
your	PRP$	O
healthcare	NN	O
practitioner	NN	O
,	,	O
apply	VB	O
Recedo	NNP	O
evenly	RB	O
in	IN	O
a	DT	O
thin	JJ	O
layer	NN	O
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Streptomycin	NNP	O
interferes	VBZ	O
with	IN	O
in	IN	O
utero	JJ	O
development	NN	O
of	IN	O
the	DT	O
ear	NN	O
and	CC	O
may	MD	O
cause	VB	O
congenital	JJ	O
deafness	NN	O
.	.	O

There	EX	O
is	VBZ	O
limited	JJ	O
experience	NN	O
with	IN	O
doses	NNS	O
greater	JJR	O
than	IN	O
1000	CD	DOS
μg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

HALDOL	NNP	O
Decanoate	NNP	O
(	(	O
haloperidol	JJ	O
decanoate	NN	O
)	)	O
50	CD	O
and	CC	O
HALDOL	NNP	O
Decanoate	NNP	O
(	(	O
haloperidol	JJ	O
decanoate	NN	O
)	)	O
100	CD	O
should	MD	O
be	VB	O
administered	VBN	O
by	IN	O
deep	JJ	O
intramuscular	JJ	O
injection	NN	O
.	.	O

Experience	NN	O
with	IN	O
doses	NNS	O
greater	JJR	O
than	IN	O
90	CD	DOS
mg	NNS	UNIT
in	IN	O
patients	NNS	WHO
with	IN	WHO
angina	NN	WHO
is	VBZ	O
limited	VBN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
for	IN	O
acute	JJ	O
hyperammonemia	NN	O
is	VBZ	O
100	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
to	TO	O
250	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

Such	JJ	O
use	NN	O
could	MD	O
result	VB	O
in	IN	O
air	NN	O
embolism	NN	O
due	JJ	O
to	TO	O
residual	JJ	O
air	NN	O
being	VBG	O
drawn	VBN	O
from	IN	O
the	DT	O
primary	JJ	O
container	NN	O
before	IN	O
administration	NN	O
of	IN	O
the	DT	O
fluid	NN	O
from	IN	O
the	DT	O
secondary	JJ	O
container	NN	O
is	VBZ	O
complete	JJ	O
.	.	O

At	IN	O
the	DT	O
end	NN	O
of	IN	O
infusion	NN	O
,	,	O
disconnect	VBP	O
the	DT	O
empty	JJ	O
syringe	NN	O
and	CC	O
attach	NN	O
pump	NN	O
tubing	VBG	O
/	JJ	O
syringe	NN	O
containing	VBG	O
the	DT	O
Immune	NNP	O
Globulin	NNP	O
Infusion	NNP	O
10	CD	O
%	NN	O
(	(	O
Human	NNP	O
)	)	O
of	IN	O
HYQVIA	NNP	O
to	TO	O
the	DT	O
same	JJ	O
subcutaneous	JJ	O
needle	NN	O
set	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
UNASYN	NNP	O
in	IN	O
such	JJ	WHO
patients	NNS	WHO
should	MD	O
be	VB	O
administered	VBN	O
less	RBR	O
frequently	RB	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
usual	JJ	O
practice	NN	O
for	IN	O
ampicillin	NN	O
and	CC	O
according	VBG	O
to	TO	O
the	DT	O
following	JJ	O
recommendations	NNS	O
:	:	O

Additives	NNS	O
may	MD	O
be	VB	O
incompatible	JJ	O
.	.	O

If	IN	O
an	DT	O
infection	NN	O
develops	VBZ	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
occlusive	JJ	O
dressings	NNS	O
should	MD	O
be	VB	O
discontinued	VBN	O
and	CC	O
appropriate	JJ	O
antimicrobial	JJ	O
therapy	NN	O
instituted	VBN	O
.	.	O

If	IN	O
ZOMIG	NNP	O
is	VBZ	O
co	JJ	O
-	:	O
administered	VBN	O
with	IN	O
cimetidine	NN	O
,	,	O
limit	VBP	O
the	DT	O
maximum	JJ	O
single	JJ	DOS
dose	NN	UNIT
of	IN	O
ZOMIG	NNP	O
to	TO	O
2.5	CD	DOS
mg	NNS	UNIT
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
5	CD	DOS
mg	NNS	UNIT
in	IN	O
any	DT	O
24	CD	O
-	:	O
hour	NN	O
period	NN	O
[	NNP	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

3	CD	O
.	.	O

DALVANCE	NNP	O
must	MD	O
be	VB	O
reconstituted	VBN	O
under	IN	O
aseptic	JJ	O
conditions	NNS	O
,	,	O
using	VBG	O
25	CD	DOS
mL	NN	UNIT
of	IN	O
either	CC	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
or	CC	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
for	IN	O
each	DT	O
500	CD	DOS
mg	JJ	UNIT
vial	NN	UNIT
.	.	O

PCP	NNP	O
prophylaxis	NN	O
is	VBZ	O
also	RB	O
recommended	VBN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
GPA	NNP	WHO
and	CC	O
MPA	NNP	O
during	IN	O
treatment	NN	O
and	CC	O
for	IN	O
at	IN	PER
least	JJS	PER
6	CD	PER
months	NNS	PER
following	VBG	O
the	DT	O
last	JJ	O
Rituxan	NNP	O
infusion	NN	O
.	.	O

Steady	JJ	O
-	:	O
state	NN	O
plasma	NN	O
levels	NNS	O
,	,	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
normal	JJ	WHO
renal	JJ	WHO
and	CC	WHO
hepatic	JJ	WHO
function	NN	WHO
,	,	O
may	MD	O
not	RB	O
be	VB	O
achieved	VBN	O
until	IN	O
the	DT	O
patient	NN	O
has	VBZ	O
received	VBN	O
3	CD	PER
to	TO	O
5	CD	PER
days	NNS	PER
of	IN	O
therapy	NN	O
at	IN	O
a	DT	O
given	VBN	O
dose	NN	O
.	.	O

Store	NN	O
at	IN	O
controlled	JJ	O
room	NN	O
temperature	NN	O
,	,	O
15°	CD	O
to	TO	O
30°C	CD	O
(	(	O
59°	CD	O
to	TO	O
86°F	CD	O
)	)	O
,	,	O
and	CC	O
protect	VBP	O
from	IN	O
light	NN	O
.	.	O

Unused	JJ	O
portions	NNS	O
of	IN	O
solution	NN	O
not	RB	O
containing	VBG	O
preservatives	NNS	O
,	,	O
i.e	NN	O
,	,	O
those	DT	O
supplied	VBN	O
in	IN	O
single	JJ	DOS
-	:	O
dose	NN	O
ampuls	NNS	O
and	CC	O
single	JJ	DOS
-	:	O
dose	NN	O
vials	NNS	O
,	,	O
should	MD	O
be	VB	O
discarded	VBN	O
following	VBG	O
initial	JJ	O
use	NN	O
.	.	O

No	DT	O
dosing	NN	O
data	NNS	O
are	VBP	O
available	JJ	O
for	IN	O
children	NNS	WHO
who	WP	WHO
weigh	VBP	WHO
less	JJR	WHO
than	IN	WHO
15	CD	WHO
kg	NN	WHO
.	.	O

Doses	NNS	O
greater	JJR	O
than	IN	O
2000	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

Although	IN	O
dosing	NN	O
may	MD	O
be	VB	O
done	VBN	O
without	IN	O
regard	NN	O
to	TO	O
meals	NNS	O
,	,	O
dosing	VBG	O
with	IN	O
meals	NNS	O
was	VBD	O
employed	VBN	O
during	IN	O
clinical	JJ	O
trials	NNS	O
and	CC	O
is	VBZ	O
suggested	VBN	O
in	IN	O
those	DT	WHO
patients	NNS	WHO
who	WP	WHO
regularly	RB	WHO
eat	VBP	WHO
three	CD	WHO
meals	NNS	WHO
daily	RB	FREQ
.	.	O

See	JJ	O
OVERDOSAGE	NNP	O
.	.	O

Elderly	JJ	WHO
patients	NNS	WHO
should	MD	O
usually	RB	O
be	VB	O
given	VBN	O
meperidine	NN	O
at	IN	O
the	DT	O
lower	JJR	O
end	NN	O
of	IN	O
the	DT	O
dose	JJ	O
range	NN	O
and	CC	O
observed	VBD	O
closely	RB	O
.	.	O

Figure	NN	O
6	CD	O

Once	RB	O
effective	JJ	O
control	NN	O
of	IN	O
symptoms	NNS	O
has	VBZ	O
been	VBN	O
achieved	VBN	O
,	,	O
the	DT	O
dosage	NN	O
may	MD	O
be	VB	O
reduced	VBN	O
gradually	RB	O
to	TO	O
determine	VB	O
the	DT	O
minimum	JJ	O
maintenance	NN	O
dose	NN	O
.	.	O

ZENPEP	NNP	O
capsules	NNS	O
and	CC	O
capsule	NN	O
contents	NNS	O
should	MD	O
not	RB	O
be	VB	O
crushed	VBN	O
or	CC	O
chewed	VBN	O
.	.	O

Any	DT	O
time	NN	O
the	DT	O
patient	NN	WHO
misses	VBZ	WHO
two	CD	WHO
or	CC	WHO
more	JJR	WHO
pink	JJ	WHO
tablets	NNS	WHO
,	,	O
she	PRP	O
should	MD	O
also	RB	O
use	VB	O
another	DT	O
method	NN	O
of	IN	O
non	JJ	O
-	:	O
hormonal	NN	O
back	RB	O
-	:	O
up	RP	O
contraception	NN	O
until	IN	O
she	PRP	O
has	VBZ	O
taken	VBN	O
a	DT	O
pink	JJ	O
tablet	NN	O
daily	RB	FREQ
for	IN	O
seven	CD	PER
consecutive	JJ	PER
days	NNS	PER
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
intravenously	RB	O
.	.	O

Use	VB	O
this	DT	O
table	NN	O
to	TO	O
find	VB	O
the	DT	O
calculated	JJ	O
24	CD	O
-	:	O
hour	NN	O
morphine	NN	O
dose	NN	O
and	CC	O
the	DT	O
corresponding	JJ	O
fentanyl	NN	O
transdermal	JJ	O
system	NN	O
dose	NN	O
.	.	O

Store	NN	O
at	IN	O
25°C	CD	O
(	(	O
77°F	CD	O
)	)	O
;	:	O
excursions	NNS	O
permitted	VBD	O
to	TO	O
15°	CD	O
-	:	O
30°C	CD	O
(	(	O
59°	CD	O
-	:	O
86°F	CD	O
)	)	O
[	NN	O
See	NNP	O
USP	NNP	O
Controlled	NNP	O
Room	NNP	O
Temperature	NNP	O
]	NNP	O
.	.	O

Preparation	NN	O
for	IN	O
Administration	NN	O
:	:	O
To	TO	O
reconstitute	VB	O
solution	NN	O
,	,	O
add	VB	O
1	CD	DOS
mL	NN	UNIT
of	IN	O
diluent	NN	O
per	IN	O
mg	NN	O
of	IN	O
remifentanil	NN	O
.	.	O

To	TO	O
help	VB	O
avoid	VB	O
HIV	NNP	O
(	(	O
AIDS	NNP	O
)	)	O
,	,	O
HBV	NNP	O
(	(	O
Hepatitis	NNP	O
)	)	O
,	,	O
and	CC	O
other	JJ	O
infectious	JJ	O
diseases	NNS	O
due	JJ	O
to	TO	O
accidental	JJ	O
needlesticks	NNS	O
,	,	O
contaminated	VBD	O
needles	NNS	O
should	MD	O
not	RB	O
be	VB	O
recapped	VBN	O
or	CC	O
removed	VBN	O
,	,	O
unless	IN	O
there	EX	O
is	VBZ	O
no	DT	O
alternative	JJ	O
or	CC	O
that	IN	O
such	JJ	O
action	NN	O
is	VBZ	O
required	VBN	O
by	IN	O
a	DT	O
specific	JJ	O
medical	JJ	O
procedure	NN	O
.	.	O

VELCADE	NNP	O
retreatment	NN	O
may	MD	O
be	VB	O
considered	VBN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
multiple	JJ	WHO
myeloma	NN	WHO
who	WP	WHO
had	VBD	WHO
previously	RB	WHO
responded	VBN	WHO
to	TO	WHO
treatment	NN	WHO
with	IN	WHO
VELCADE	NNP	WHO
and	CC	WHO
who	WP	WHO
have	VBP	WHO
relapsed	VBN	WHO
at	IN	PER
least	JJS	PER
6	CD	PER
months	NNS	PER
after	IN	O
completing	VBG	O
prior	RB	O
VELCADE	NNP	O
treatment	NN	O
.	.	O

Physicians	NNS	O
are	VBP	O
cautioned	VBN	O
to	TO	O
use	VB	O
no	DT	O
less	JJR	O
than	IN	O
the	DT	O
above	NN	O
recommended	VBD	O
dosage	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
gonorrhea	NN	O
.	.	O

Therefore	RB	O
,	,	O
communication	NN	O
should	MD	O
be	VB	O
maintained	VBN	O
with	IN	O
the	DT	O
laboratory	NN	O
performing	VBG	O
the	DT	O
assay	NN	O
.	.	O

Individuals	NNS	O
who	WP	O
are	VBP	O
not	RB	O
successfully	RB	O
vaccinated	VBN	O
(	(	O
i.e	NN	O
,	,	O
vaccination	NN	O
failures	NNS	O
)	)	O
after	IN	O
primary	JJ	O
vaccination	NN	O
may	MD	O
be	VB	O
revaccinated	VBN	O
again	RB	O
in	IN	O
an	DT	O
attempt	NN	O
to	TO	O
achieve	VB	O
a	DT	O
satisfactory	JJ	O
take	NN	O
.	.	O

Makena	NNP	O
is	VBZ	O
a	DT	O
clear	JJ	O
,	,	O
yellow	JJ	O
solution	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
BMI	NNP	O
Conversion	NNP	O
Chart	NNP	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
by	IN	O
1.25	CD	DOS
micrograms	NNS	UNIT
to	TO	O
a	DT	O
dose	NN	O
of	IN	O
2.5	CD	DOS
micrograms	NNS	UNIT
,	,	O
followed	VBN	O
by	IN	O
an	DT	O
increment	NN	O
of	IN	O
2.5	CD	DOS
micrograms	NNS	UNIT
to	TO	O
a	DT	O
dose	NN	O
of	IN	O
5	CD	DOS
micrograms	NNS	UNIT
,	,	O
and	CC	O
then	RB	O
in	IN	O
5	CD	DOS
-	:	O
microgram	NN	O
increments	NNS	O
until	IN	O
the	DT	O
dose	NN	O
that	WDT	O
produces	VBZ	O
an	DT	O
erection	NN	O
suitable	NN	O
for	IN	O
intercourse	NN	O
and	CC	O
not	RB	O
exceeding	VBG	O
a	DT	O
duration	NN	O
of	IN	O
1	CD	O
hour	NN	O
is	VBZ	O
reached	VBN	O
.	.	O

Shake	NNP	O
bottle	NN	O
well	RB	O
before	IN	O
dispensing	VBG	O
.	.	O

Further	JJ	O
increments	NNS	O
of	IN	O
0.1	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
may	MD	O
be	VB	O
made	VBN	O
if	IN	O
necessary	JJ	O
until	IN	O
the	DT	O
desired	JJ	O
response	NN	O
is	VBZ	O
achieved	VBN	O
.	.	O

In	IN	O
trials	NNS	O
comparing	VBG	O
0.1	CD	O
,	,	O
0.5	CD	O
,	,	O
and	CC	O
1	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
,	,	O
it	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
all	DT	O
dosages	NNS	O
provided	VBN	O
initial	JJ	O
clearing	NN	O
of	IN	O
disease	NN	O
,	,	O
but	CC	O
there	RB	O
was	VBD	O
a	DT	O
greater	JJR	O
need	NN	O
for	IN	O
retreatment	NN	O
with	IN	O
the	DT	O
lower	JJR	O
dosages	NNS	O
.	.	O

If	IN	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
exceeds	VBZ	O
250	CD	DOS
mg	NN	UNIT
,	,	O
it	PRP	O
should	MD	O
be	VB	O
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

If	IN	O
either	DT	O
particulate	JJ	O
matter	NN	O
or	CC	O
discoloration	NN	O
is	VBZ	O
noted	VBN	O
,	,	O
do	VBP	O
not	RB	O
use	VB	O
.	.	O

Examples	NNS	O
(	(	O
assuming	VBG	O
patient	NN	O
's	POS	O
baseline	NN	O
factor	NN	O
IX	NNP	O
level	NN	O
is	VBZ	O
<	JJ	O
1	CD	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
:	:	O

DesOwen®	NNP	O
(	(	O
desonide	JJ	O
cream	NN	O
,	,	O
ointment	NN	O
and	CC	O
lotion	NN	O
)	)	O
Cream	NNP	O
,	,	O
Ointment	NNP	O
or	CC	O
Lotion	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
affected	JJ	O
areas	NNS	O
as	IN	O
a	DT	O
thin	JJ	O
film	NN	O
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
depending	VBG	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
condition	NN	O
.	.	O

Caution	NN	O
:	:	O
Parenteral	JJ	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

If	IN	O
symptoms	NNS	O
and	CC	O
signs	NNS	O
of	IN	O
steatorrhea	JJ	O
persist	NN	O
,	,	O
the	DT	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
by	IN	O
a	DT	O
healthcare	JJ	O
professional	NN	O
.	.	O

While	IN	O
holding	VBG	O
the	DT	O
adapter	NN	O
package	NN	O
,	,	O
place	VBP	O
the	DT	O
vial	JJ	O
adapter	NN	O
over	IN	O
the	DT	O
vial	JJ	O
and	CC	O
press	VB	O
down	RP	O
firmly	RB	O
on	IN	O
the	DT	O
package	NN	O
until	IN	O
the	DT	O
adapter	NN	O
spike	NN	O
penetrates	VBZ	O
the	DT	O
vial	JJ	O
stopper	NN	O
.	.	O

This	DT	O
product	NN	O
contains	VBZ	O
no	DT	O
preservative	NN	O
;	:	O
therefore	RB	O
,	,	O
partially	RB	O
used	JJ	O
vials	NNS	O
should	MD	O
be	VB	O
discarded	VBN	O
immediately	RB	O
.	.	O

Dosage	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
according	VBG	O
to	TO	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
pain	NN	O
and	CC	O
the	DT	O
response	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

Administer	RB	O
40	CD	DOS
-	:	O
50	CD	DOS
IU	NNP	UNIT
per	IN	O
kg	NN	O
body	NN	O
weight	VBD	O
2	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
week	NN	FREQ
.	.	O

OMNIPAQUE	NNP	O
300	CD	O
is	VBZ	O
recommended	VBN	O
for	IN	O
cerebral	JJ	O
arteriography	NN	O
at	IN	O
the	DT	O
following	JJ	O
volumes	NNS	O
:	:	O
common	JJ	O
carotid	NN	O
artery	NN	O
(	(	O
6	CD	DOS
mL	NN	UNIT
to	TO	O
12	CD	DOS
mL	NN	UNIT
)	)	O
,	,	O
internal	JJ	O
carotid	NN	O
artery	NN	O
(	(	O
8	CD	DOS
mL	NN	UNIT
to	TO	O
10	CD	DOS
mL	NN	UNIT
)	)	O
,	,	O
external	JJ	O
carotid	NN	O
artery	NN	O
(	(	O
6	CD	DOS
mL	NN	UNIT
to	TO	O
9	CD	DOS
mL	NN	UNIT
)	)	O
,	,	O
and	CC	O
vertebral	JJ	O
artery	NN	O
(	(	O
6	CD	DOS
mL	NN	UNIT
to	TO	O
10	CD	DOS
mL	NN	UNIT
)	)	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
periodically	RB	O
reassessed	VBN	O
to	TO	O
determine	VB	O
the	DT	O
need	NN	O
for	IN	O
maintenance	NN	O
treatment	NN	O
.	.	O

Decisions	NNS	O
to	TO	O
stop	VB	O
,	,	O
hold	VB	O
,	,	O
or	CC	O
restart	VB	O
Proleukin	NNP	O
therapy	NN	O
must	MD	O
be	VB	O
made	VBN	O
after	IN	O
a	DT	O
global	JJ	O
assessment	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

The	DT	O
hands	NNS	O
should	MD	O
then	RB	O
be	VB	O
used	VBN	O
to	TO	O
gently	RB	O
rub	VB	O
the	DT	O
gel	NN	O
into	IN	O
the	DT	O
skin	NN	O
.	.	O

If	IN	O
PLATINOL	NNP	O
-	:	O
AQ	NNP	O
contacts	VBZ	O
the	DT	O
skin	NN	O
or	CC	O
mucosa	NN	O
,	,	O
immediately	RB	O
and	CC	O
thoroughly	RB	O
wash	VB	O
the	DT	O
skin	NN	O
with	IN	O
soap	NN	O
and	CC	O
water	NN	O
and	CC	O
flush	VB	O
the	DT	O
mucosa	NN	O
with	IN	O
water	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
1	CD	DOS
or	CC	O
2	CD	DOS
mL	NN	UNIT
(	(	O
8,500	CD	O
to	TO	O
17,000	CD	O
I.U	NNP	O
.	.	O
)	)	O

Table	JJ	O
1	CD	O
:	:	O
CEPROTIN	NNP	O
Dosing	NNP	O
Schedule	NNP	O
for	IN	O
Acute	NNP	O
Episodes	NNP	O
,	,	O
Short	NNP	O
-	:	O
term	NN	O
Prophylaxis	NNP	O
and	CC	O
Long	NNP	O
-	:	O
term	NN	O
Prophylaxisa	NNP	O

Once	RB	O
reconstituted	VBN	O
and	CC	O
diluted	VBN	O
,	,	O
use	VBP	O
the	DT	O
infusion	NN	O
solution	NN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
.	.	O

Administration	NN	O
of	IN	O
admixtures	NNS	O
should	MD	O
be	VB	O
completed	VBN	O
within	IN	O
24	CD	O
hours	NNS	O
after	IN	O
removal	NN	O
from	IN	O
refrigeration	NN	O
.	.	O

Taper	IN	O
the	DT	O
daily	JJ	FREQ
dose	NN	O
in	IN	O
decrements	NNS	O
of	IN	O
no	DT	O
more	JJR	O
than	IN	O
1	CD	DOS
mg	JJ	UNIT
every	DT	FREQ
3	CD	FREQ
to	TO	O
7	CD	PER
days	NNS	PER
to	TO	O
avoid	VB	O
rebound	NN	O
hypertension	NN	O
.	.	O

Using	VBG	O
sterile	JJ	O
technique	NN	O
,	,	O
the	DT	O
appropriate	JJ	O
dose	NN	O
of	IN	O
Antizol	NNP	O
(	(	O
fomepizole	JJ	O
)	)	O
should	MD	O
be	VB	O
drawn	VBN	O
from	IN	O
the	DT	O
vial	NN	O
with	IN	O
a	DT	O
syringe	NN	O
and	CC	O
injected	VBN	O
into	IN	O
at	IN	O
least	JJS	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
sterile	JJ	O
0.9	CD	O
%	NN	O
sodium	NN	O
chloride	NN	O
injection	NN	O
or	CC	O
dextrose	VB	O
5	CD	O
%	NN	O
injection	NN	O
.	.	O

Hepatic	JJ	O
Insufficiency	NN	O
:	:	O
Patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
were	VBD	O
not	RB	O
included	VBN	O
in	IN	O
the	DT	O
clinical	JJ	O
studies	NNS	O
.	.	O

Dosage	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
renal	JJ	WHO
function	NN	WHO
or	CC	O
hepatic	JJ	O
disease	NN	O
.	.	O

Symptoms	NNS	O
associated	VBN	O
with	IN	O
discontinuation	NN	O
of	IN	O
other	JJ	O
SSRIs	NNP	O
or	CC	O
SNRIs	NNP	O
have	VBP	O
been	VBN	O
reported	VBN	O
.	.	O

is	VBZ	O
visually	RB	O
assured	VBN	O
by	IN	O
the	DT	O
user	NN	O
.	.	O

Therapy	NN	O
with	IN	O
a	DT	O
combination	NN	O
of	IN	O
bisoprolol	NN	O
and	CC	O
hydrochlorothiazide	NN	O
will	MD	O
be	VB	O
associated	VBN	O
with	IN	O
both	DT	O
sets	NNS	O
of	IN	O
dose	JJ	O
-	:	O
independent	JJ	O
adverse	JJ	O
effects	NNS	O
,	,	O
and	CC	O
to	TO	O
minimize	VB	O
these	DT	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
appropriate	JJ	O
to	TO	O
begin	VB	O
combination	NN	O
therapy	IN	O
only	RB	O
after	IN	O
a	DT	O
patient	NN	O
has	VBZ	O
failed	VBN	O
to	TO	O
achieve	VB	O
the	DT	O
desired	JJ	O
effect	NN	O
with	IN	O
monotherapy	NN	O
.	.	O

VARIVAX	NNP	O
,	,	O
when	WRB	O
reconstituted	VBN	O
,	,	O
is	VBZ	O
a	DT	O
clear	JJ	O
,	,	O
colorless	NN	O
to	TO	O
pale	VB	O
yellow	JJ	O
liquid	NN	O
.	.	O

The	DT	O
normal	JJ	O
whole	JJ	O
blood	NN	O
range	NN	O
for	IN	O
selenium	NN	O
is	VBZ	O
approximately	RB	O
10	CD	DOS
to	TO	O
37	CD	DOS
mcg	NNS	UNIT
/	VBD	O
100	CD	DOS
mL	NN	UNIT
.	.	O

Consequently	RB	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
plasticized	JJ	O
PVC	NNP	O
containers	NNS	O
and	CC	O
administration	NN	O
sets	NNS	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

Additional	JJ	O
Doses	NNS	O
:	:	O
If	IN	O
,	,	O
at	IN	O
any	DT	O
time	NN	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
,	,	O
the	DT	O
patient	JJ	O
develops	VBZ	O
any	DT	O
of	IN	O
the	DT	O
SEVERE	NNP	O
symptoms	NNS	O
listed	VBN	O
above	IN	O
,	,	O
administer	RB	O
two	CD	DOS
(	(	O
2	CD	DOS
)	)	O
additional	JJ	O
DuoDote	NNP	O
injections	NNS	O
in	IN	O
rapid	JJ	O
succession	NN	O
,	,	O
and	CC	O
immediately	RB	O
seek	VB	O
definitive	JJ	O
medical	JJ	O
care	NN	O
.	.	O

Ketalar	JJ	O
10	CD	DOS
mg	NN	UNIT
/	NN	O
mL	NN	O
are	VBP	O
not	RB	O
recommended	VBN	O
for	IN	O
dilution	NN	O
.	.	O

60	CD	O

At	IN	O
least	JJS	O
14	CD	O
days	NNS	O
should	MD	O
elapse	VB	O
between	IN	O
discontinuation	NN	O
of	IN	O
an	DT	O
MAOI	NNP	O
intended	VBD	O
to	TO	O
treat	VB	O
depression	NN	O
and	CC	O
initiation	NN	O
of	IN	O
therapy	NN	O
with	IN	O
WELLBUTRIN	NNP	O
SR.	NNP	O
Conversely	NNP	O
,	,	O
at	IN	O
least	JJS	O
14	CD	O
days	NNS	O
should	MD	O
be	VB	O
allowed	VBN	O
after	IN	O
stopping	VBG	O
WELLBUTRIN	NNP	O
SR	NNP	O
before	IN	O
starting	VBG	O
an	DT	O
MAOI	NNP	O
antidepressant	NN	O
[	NNP	O
see	NN	O
CONTRAINDICATIONS	NNP	O
,	,	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

Interrupt	NNP	O
treatment	NN	O
for	IN	O
bleeding	VBG	O
requiring	VBG	O
intervention	NN	O
regardless	NN	O
of	IN	O
current	JJ	O
platelet	NN	O
count	NN	O
.	.	O

Following	VBG	O
an	DT	O
anesthetic	JJ	O
induction	NN	O
dose	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
,	,	O
infusion	NN	O
rate	NN	O
requirements	NNS	O
are	VBP	O
reduced	VBN	O
by	IN	O
30	CD	O
-	:	O
50	CD	O
%	NN	O
for	IN	O
the	DT	O
first	JJ	O
hour	NN	O
of	IN	O
maintenance	NN	O
.	.	O

If	IN	O
a	DT	O
dose	NN	O
of	IN	O
ELIQUIS	NNP	O
is	VBZ	O
not	RB	O
taken	VBN	O
at	IN	O
the	DT	O
scheduled	JJ	O
time	NN	O
,	,	O
the	DT	O
dose	NN	O
should	MD	O
be	VB	O
taken	VBN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
on	IN	O
the	DT	O
same	JJ	O
day	NN	O
and	CC	O
twice	RB	O
-	:	O
daily	JJ	FREQ
administration	NN	O
should	MD	O
be	VB	O
resumed	VBN	O
.	.	O

Pentothal	NN	O

Always	NNP	O
work	NN	O
on	IN	O
a	DT	O
clean	JJ	O
surface	NN	O
and	CC	O
wash	VB	O
your	PRP$	O
hands	NNS	O
before	IN	O
performing	VBG	O
the	DT	O
following	JJ	O
procedures	NNS	O
:	:	O

Use	NNP	O
of	IN	O
estrogen	NN	O
-	:	O
alone	RB	O
,	,	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
progestin	NN	O
,	,	O
should	MD	O
be	VB	O
with	IN	O
the	DT	O
lowest	JJS	O
effective	JJ	O
dose	NN	O
and	CC	O
for	IN	O
the	DT	O
shortest	JJS	O
duration	NN	O
consistent	NN	O
with	IN	O
treatment	NN	O
goals	NNS	O
and	CC	O
risks	NNS	O
for	IN	O
the	DT	O
individual	JJ	O
woman	NN	O
.	.	O

For	IN	O
prophylactic	JJ	O
infusion	NN	O
,	,	O
the	DT	O
required	JJ	O
number	NN	O
of	IN	O
individual	JJ	O
vials	NNS	O
of	IN	O
Dantrium	NNP	O
Intravenous	NNP	O
should	MD	O
be	VB	O
reconstituted	VBN	O
as	IN	O
outlined	VBN	O
above	IN	O
.	.	O

In	IN	O
others	NNS	O
,	,	O
10	CD	DOS
to	TO	O
15	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
will	MD	O
be	VB	O
adequate	JJ	O
.	.	O

Apply	NNP	O
to	TO	O
the	DT	O
affected	JJ	O
areas	NNS	O
and	CC	O
rub	NN	O
in	IN	O
thoroughly	NN	O
.	.	O

[	NNS	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NN	O

750	CD	DOS
mg	JJ	UNIT
vial	NN	UNIT
:	:	O
Reconstitute	VB	O
the	DT	O
contents	NNS	O
of	IN	O
a	DT	O
VIBATIV	NNP	O
750	CD	DOS
mg	NN	UNIT
vial	NN	UNIT
with	IN	O
45	CD	DOS
mL	NNS	UNIT
of	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
;	:	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
;	:	O
or	CC	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
.	.	O

Administer	NNP	O
up	RB	O
to	TO	O
600	CD	DOS
mL	NNS	UNIT
per	IN	O
site	NN	O
for	IN	O
patients	NNS	WHO
greater	JJR	WHO
than	IN	WHO
or	CC	WHO
equal	JJ	WHO
to	TO	WHO
40	CD	WHO
kg	NNS	WHO
and	CC	O
up	RB	O
to	TO	O
300	CD	DOS
mL	NNS	UNIT
per	IN	O
site	NN	O
for	IN	O
patients	NNS	WHO
less	JJR	WHO
than	IN	WHO
40	CD	WHO
kg	NN	WHO
.	.	O

Thus	RB	O
,	,	O
before	IN	O
the	DT	O
needle	NN	O
is	VBZ	O
inserted	VBN	O
into	IN	O
the	DT	O
selected	VBN	O
muscle	NN	O
,	,	O
it	PRP	O
is	VBZ	O
important	JJ	O
for	IN	O
the	DT	O
operator	NN	O
to	TO	O
orient	VB	O
the	DT	O
yellow	JJ	O
rectangles	NNS	O
so	RB	O
that	IN	O
any	DT	O
blood	NN	O
which	WDT	O
may	MD	O
enter	VB	O
after	IN	O
needle	JJ	O
insertion	NN	O
and	CC	O
during	IN	O
aspiration	NN	O
can	MD	O
be	VB	O
visualized	VBN	O
in	IN	O
the	DT	O
area	NN	O
on	IN	O
the	DT	O
cartridge	NN	O
where	WRB	O
it	PRP	O
will	MD	O
appear	VB	O
and	CC	O
not	RB	O
be	VB	O
obscured	VBN	O
by	IN	O
any	DT	O
obstructions	NNS	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
every	DT	FREQ
four	CD	FREQ
to	TO	O
six	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

Monitoring	NN	O
of	IN	O
renal	JJ	O
function	NN	O
is	VBZ	O
necessary	JJ	O
to	TO	O
aid	VB	O
in	IN	O
prevention	NN	O
of	IN	O
lactic	JJ	O
acidosis	NN	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
elderly	JJ	O
[	NN	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Saxenda®	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
once	RB	FREQ
daily	JJ	FREQ
at	IN	O
any	DT	O
time	NN	O
of	IN	O
day	NN	O
,	,	O
without	IN	O
regard	NN	O
to	TO	O
the	DT	O
timing	NN	O
of	IN	O
meals	NNS	O
.	.	O

Although	IN	O
the	DT	O
optimal	JJ	O
duration	NN	O
of	IN	O
ZARXIO	NNP	O
administration	NN	O
and	CC	O
leukapheresis	NN	O
schedule	NN	O
have	VBP	O
not	RB	O
been	VBN	O
established‚	JJ	O
administration	NN	O
of	IN	O
filgrastim	NN	O
for	IN	O
6	CD	PER
to	TO	O
7	CD	PER
days	NNS	PER
with	IN	PER
leukaphereses	NNS	O
on	IN	O
days	NNS	O
5‚	CD	O
6‚	CD	O
and	CC	O
7	CD	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
safe	JJ	O
and	CC	O
effective	JJ	O
[	NNP	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

Monitor	NN	WHO
patients	NNS	WHO
frequently	RB	WHO
for	IN	WHO
adverse	JJ	WHO
events	NNS	WHO
and	CC	O
adjust	VBP	O
dose	VB	O
as	IN	O
needed	VBN	O
for	IN	O
toxicity	NN	O
[	NNP	O
see	VBP	O
Administration	NNP	O
and	CC	O
Monitoring	NNP	O
Instructions	NNP	O
,	,	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Hepatic	NNP	O
Impairment	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

The	DT	O
patient	NN	O
should	MD	O
be	VB	O
weighed	VBN	O
under	IN	O
standard	JJ	O
conditions	NNS	O
before	IN	O
and	CC	O
during	IN	O
the	DT	O
institution	NN	O
of	IN	O
diuretic	JJ	O
therapy	NN	O
with	IN	O
this	DT	O
compound	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Silenor	NNP	O
(	(	O
doxepin	JJ	O
tablets	NNS	O
)	)	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

[	NNS	O
See	NNP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
and	CC	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NN	O

Concomitant	JJ	O
Therapy	NN	O
:	:	O
Efavirenz	NNP	O
,	,	O
Nevirapine	NNP	O
,	,	O
or	CC	O
Nelfinavir	NNP	O

The	DT	O
needle	JJ	O
cap	NN	O
on	IN	O
the	DT	O
prefilled	JJ	O
syringes	NNS	O
contains	VBZ	O
dry	JJ	O
natural	JJ	O
rubber	NN	O
(	(	O
derived	VBN	O
from	IN	O
latex	NN	O
)	)	O
;	:	O
persons	NNS	O
with	IN	O
latex	JJ	O
allergies	NNS	O
should	MD	O
not	RB	O
administer	VB	O
these	DT	O
products	NNS	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
ST	NNP	WHO
segment	NN	WHO
elevation	NN	WHO
myocardial	JJ	WHO
infarction	NN	WHO
(	(	O
STEMI	NNP	O
)	)	O
continuation	NN	O
of	IN	O
the	DT	O
Bivalirudin	NNP	O
for	IN	O
Injection	NNP	O
infusion	NN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
1.75	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
h	NN	O
following	VBG	O
PCI	NNP	O
/	NNP	O
PTCA	NNP	O
for	IN	O
up	RB	O
to	TO	O
4	CD	O
hours	NNS	O
post	SYM	O
-	:	O
procedure	NN	O
should	MD	O
be	VB	O
considered	VBN	O
to	TO	O
mitigate	VB	O
risk	NN	O
of	IN	O
stent	JJ	O
thrombosis	NN	O
.	.	O

Diseases	NNS	O
contributory	NN	O
to	TO	O
hyperlipidemia	VB	O
,	,	O
such	JJ	O
as	IN	O
hypothyroidism	NN	O
or	CC	O
diabetes	NNS	O
mellitus	NNS	O
should	MD	O
be	VB	O
looked	VBN	O
for	IN	O
and	CC	O
adequately	RB	O
treated	VBD	O
.	.	O

Pharyngitis	NN	O
and	CC	O
Tonsillitis	NN	O
:	:	O
Treatment	NN	O
of	IN	O
group	NN	O
A	NNP	O
beta	NN	O
-	:	O
hemolytic	JJ	O
streptococcal	JJ	O
pharyngitis	NN	O
and	CC	O
tonsillitis	NN	O
-	:	O
1	CD	DOS
g	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
in	IN	O
single	JJ	O
(	(	O
q.d	JJ	O
.	.	O
)	)	O

Do	NNP	O
not	RB	O
use	VB	O
if	IN	O
a	DT	O
precipitate	NN	O
or	CC	O
foreign	JJ	O
matter	NN	O
is	VBZ	O
present	JJ	O
.	.	O

Maintenance	NNP	O
therapy	NN	O
may	MD	O
be	VB	O
given	VBN	O
on	IN	O
a	DT	O
once	RB	FREQ
-	:	FREQ
daily	JJ	FREQ
schedule	NN	O
for	IN	O
patient	JJ	O
convenience	NN	O
and	CC	O
compliance	NN	O
.	.	O

Higher	JJR	O
doses	NNS	O
of	IN	O
CARDIZEM	NNP	O
CD	NN	O
may	MD	O
be	VB	O
needed	VBN	O
in	IN	O
some	DT	WHO
patients	NNS	WHO
.	.	O

The	DT	O
daily	JJ	FREQ
dose	NN	O
should	MD	O
be	VB	O
taken	VBN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
each	DT	O
day	NN	O
with	IN	O
food	NN	O
or	CC	O
a	DT	O
milky	JJ	O
drink	NN	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
Gengraf®	NNP	O
varies	NNS	O
depending	VBG	O
on	IN	O
the	DT	O
transplanted	VBN	O
organ	NN	O
and	CC	O
the	DT	O
other	JJ	O
immunosuppressive	JJ	O
agents	NNS	O
included	VBN	O
in	IN	O
the	DT	O
immunosuppressive	JJ	O
protocol	NN	O
.	.	O

Determination	NN	O
of	IN	O
the	DT	O
optimal	JJ	O
Baclofen	NNP	O
Injection	NNP	O
(	(	O
Intrathecal	NNP	O
)	)	O
dose	NN	O
requires	VBZ	O
individual	JJ	O
titration	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
CAVERJECT	NNP	O
that	WDT	O
is	VBZ	O
selected	VBN	O
for	IN	O
self	PRP	O
-	:	O
injection	NN	O
treatment	NN	O
should	MD	O
provide	VB	O
the	DT	O
patient	NN	O
with	IN	O
an	DT	O
erection	NN	O
that	WDT	O
is	VBZ	O
satisfactory	JJ	O
for	IN	O
sexual	JJ	O
intercourse	NN	O
and	CC	O
that	DT	O
is	VBZ	O
maintained	VBN	O
for	IN	O
no	RB	O
longer	JJR	O
than	IN	O
1	CD	O
hour	NN	O
.	.	O

There	EX	O
is	VBZ	O
limited	JJ	O
general	JJ	O
clinical	JJ	O
experience	NN	O
with	IN	O
doses	NNS	O
above	IN	O
360	CD	DOS
mg	NN	UNIT
,	,	O
but	CC	O
doses	VBZ	O
to	TO	O
540	CD	DOS
mg	NNS	UNIT
have	VBP	O
been	VBN	O
studied	VBN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
.	.	O

The	DT	O
type	NN	O
of	IN	O
food	NN	O
does	VBZ	O
not	RB	O
affect	VB	O
the	DT	O
exposure	NN	O
to	TO	O
etravirine	VB	O
.	.	O

As	IN	O
the	DT	O
dose	NN	O
is	VBZ	O
increased	VBN	O
,	,	O
frequent	JJ	O
laboratory	NN	O
and	CC	O
clinical	JJ	O
monitoring	NN	O
is	VBZ	O
strongly	RB	O
recommended	VBN	O
,	,	O
especially	RB	O
in	IN	O
very	RB	WHO
young	JJ	WHO
patients	NNS	WHO
,	,	O
to	TO	O
avoid	VB	O
clinically	RB	O
significant	JJ	O
elevations	NNS	O
of	IN	O
serum	NN	O
ammonia	NN	O
and	CC	O
plasma	NN	O
amino	NN	O
acid	NN	O
levels	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Lumason	NNP	O
after	IN	O
reconstitution	NN	O
is	VBZ	O
1	CD	DOS
mL	NN	UNIT
.	.	O

The	DT	O
effective	JJ	O
half	NN	O
-	:	O
life	NN	O
was	VBD	O
assumed	VBN	O
to	TO	O
be	VB	O
the	DT	O
physical	JJ	O
half	NN	O
-	:	O
life	NN	O
for	IN	O
all	DT	O
calculated	JJ	O
values	NNS	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Starting	VBG	O
Dose	NNP	O
for	IN	O
Dialysis	NNP	WHO
Patients	NNPS	WHO
Switching	VBG	WHO
From	NNP	WHO
Calcium	NNP	WHO
Acetate	NNP	WHO
to	TO	O
Renagel	VB	O

Following	VBG	O
the	DT	O
initial	JJ	O
dose	NN	O
and	CC	O
with	IN	O
each	DT	O
dose	JJ	O
increase	NN	O
of	IN	O
CARDURA	NNP	O
,	,	O
monitor	NN	O
blood	NN	O
pressure	NN	O
for	IN	O
at	IN	O
least	JJS	O
6	CD	O
hours	NNS	O
following	VBG	O
administration	NN	O
.	.	O

If	IN	O
powder	NN	O
remains	VBZ	O
in	IN	O
the	DT	O
glass	NN	O
after	IN	O
drinking	NN	O
,	,	O
add	VB	O
more	JJR	O
water	NN	O
,	,	O
stir	NN	O
and	CC	O
drink	VB	O
immediately	RB	O
.	.	O

If	IN	O
breakthrough	IN	O
bleeding	NN	O
occurs	NNS	O
following	VBG	O
missed	VBD	O
light	JJ	O
-	:	O
orange	NN	O
tablets	NNS	O
,	,	O
it	PRP	O
will	MD	O
usually	RB	O
be	VB	O
transient	JJ	O
and	CC	O
of	IN	O
no	DT	O
consequence	NN	O
.	.	O

Do	NNP	O
not	RB	O
exceed	VB	O
4200	CD	DOS
IU	NNP	UNIT
per	IN	O
dose	NN	O
.	.	O

Determination	NN	O
of	IN	O
the	DT	O
adequacy	NN	O
of	IN	O
a	DT	O
serum	JJ	O
level	NN	O
for	IN	O
a	DT	O
particular	JJ	O
patient	NN	O
must	MD	O
take	VB	O
into	IN	O
consideration	NN	O
the	DT	O
susceptibility	NN	O
of	IN	O
the	DT	O
causative	JJ	O
organism	NN	O
,	,	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
infection	NN	O
,	,	O
and	CC	O
the	DT	O
status	NN	O
of	IN	O
the	DT	O
patient	NN	O
's	POS	O
host	NN	O
-	:	O
defense	NN	O
mechanisms	NN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
patients	NNS	WHO
receive	JJ	WHO
hydration	NN	WHO
with	IN	O
500	CD	DOS
to	TO	O
1,000	CD	DOS
mL	NN	UNIT
of	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
in	IN	O
0.5	CD	O
Normal	JJ	O
Saline	NNP	O
or	CC	O
equivalent	JJ	O
before	IN	O
NIPENT	NNP	O
administration	NN	O
.	.	O

If	IN	O
breakthrough	IN	O
bleeding	NN	O
occurs	NNS	O
following	VBG	O
missed	JJ	O
tablets	NNS	O
,	,	O
it	PRP	O
will	MD	O
usually	RB	O
be	VB	O
transient	JJ	O
and	CC	O
of	IN	O
no	DT	O
consequence	NN	O
.	.	O

The	DT	O
total	JJ	O
volume	NN	O
administered	VBD	O
should	MD	O
be	VB	O
adjusted	VBN	O
for	IN	O
patients	NNS	WHO
less	JJR	WHO
than	IN	WHO
40	CD	WHO
kg	NNS	WHO
and	CC	O
for	IN	O
those	DT	O
requiring	VBG	O
fluid	JJ	O
restriction	NN	O
(	(	O
see	VB	O
Tables	NNP	O
1	CD	O
and	CC	O
2	CD	O
)	)	O
.	.	O

No	DT	O
other	JJ	O
medications	NNS	O
should	MD	O
be	VB	O
added	VBN	O
to	TO	O
solutions	NNS	O
containing	VBG	O
RAPTIVA	NNP	O
(	(	O
efalizumab	NN	O
)	)	O
,	,	O
and	CC	O
RAPTIVA	NNP	O
(	(	O
efalizumab	NN	O
)	)	O
should	MD	O
not	RB	O
be	VB	O
reconstituted	VBN	O
with	IN	O
other	JJ	O
diluents	NNS	O
.	.	O

PRISTIQ	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
at	IN	O
approximately	RB	O
the	DT	O
same	JJ	O
time	NN	O
each	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
basis	NN	O
for	IN	O
successful	JJ	O
use	NN	O
and	CC	O
subsequent	JJ	O
removal	NN	O
of	IN	O
IMPLANON	NNP	O
is	VBZ	O
a	DT	O
correct	NN	O
and	CC	O
carefully	RB	O
performed	VBN	O
subdermal	JJ	O
insertion	NN	O
of	IN	O
the	DT	O
single	JJ	O
,	,	O
rod	JJ	O
-	:	O
shaped	VBD	O
implant	JJ	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
instructions	NNS	O
.	.	O

Children	$	WHO
6	CD	WHO
to	TO	WHO
under	IN	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
:	:	O
½	JJ	O
tablet	NN	O
every	DT	FREQ
4	CD	FREQ
hours	NNS	FREQ
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
3	CD	DOS
tablets	NNS	UNIT
in	IN	O
24	CD	O
hours	NNS	O
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
doctor..	NN	O

Since	IN	O
Tev	NNP	O
-	:	O
Tropin	NN	O
is	VBZ	O
a	DT	O
protein	NN	O
,	,	O
shaking	VBG	O
or	CC	O
vigorous	JJ	O
mixing	NN	O
will	MD	O
cause	VB	O
the	DT	O
solution	NN	O
to	TO	O
be	VB	O
cloudy	NN	O
.	.	O

The	DT	O
dosage	NN	O
employed	VBN	O
under	IN	O
these	DT	O
circumstances	NNS	O
,	,	O
although	IN	O
usually	RB	O
smaller	JJR	O
than	IN	O
the	DT	O
original	JJ	O
induction	NN	O
dose	NN	O
,	,	O
must	MD	O
be	VB	O
individualized	VBN	O
.	.	O

If	IN	O
propofol	VBN	O
injectable	JJ	O
emulsion	NN	O
is	VBZ	O
transferred	VBN	O
to	TO	O
a	DT	O
syringe	NN	O
or	CC	O
other	JJ	O
container	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
the	DT	O
handling	NN	O
procedures	NNS	O
for	IN	O
General	NNP	O
Anesthesia	NNP	O
/	NNP	O
MAC	NNP	O
Sedation	NNP	O
should	MD	O
be	VB	O
followed	VBN	O
and	CC	O
the	DT	O
product	NN	O
should	MD	O
be	VB	O
discarded	VBN	O
and	CC	O
administration	NN	O
lines	NNS	O
changed	VBD	O
after	IN	O
12	CD	O
hours	NNS	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

OMNIPAQUE	IN	O
350	CD	O
can	MD	O
be	VB	O
injected	VBN	O
intravenously	RB	O
as	IN	O
a	DT	O
rapid	JJ	O
bolus	NN	O
to	TO	O
provide	VB	O
arterial	JJ	O
visualization	NN	O
using	VBG	O
digital	JJ	O
subtraction	NN	O
radiography	NN	O
.	.	O

The	DT	O
LUPRON	NNP	O
DEPOT	NNP	O
powder	NN	O
should	MD	O
be	VB	O
visually	RB	O
inspected	VBN	O
and	CC	O
the	DT	O
syringe	NN	O
should	MD	O
NOT	NNP	O
BE	NNP	O
USED	NNP	O
if	IN	O
clumping	VBG	O
or	CC	O
caking	NN	O
is	VBZ	O
evident	JJ	O
.	.	O

Consider	VB	O
the	DT	O
following	NN	O
when	WRB	O
using	VBG	O
the	DT	O
information	NN	O
in	IN	O
Table	JJ	O
1	CD	O
:	:	O

Reconstitution	NNP	O
and	CC	O
Administration	NNP	O
Instructions	NNP	O

Not	RB	O
for	IN	O
oral	JJ	O
,	,	O
ophthalmic	JJ	O
or	CC	O
intravaginal	JJ	O
use	NN	O
.	.	O

Most	JJS	WHO
patients	NNS	WHO
were	VBD	WHO
treated	VBN	WHO
with	IN	WHO
maximum	JJ	WHO
doses	NNS	WHO
of	IN	O
16	CD	DOS
mg	NNS	UNIT
/	JJ	O
hour	NN	O
or	CC	O
less	JJR	O
.	.	O

Note	NN	O
:	:	O
Agglutination	NN	O
of	IN	O
red	JJ	O
blood	NN	O
cells	NNS	O
in	IN	O
the	DT	O
tubing	NN	O
/	NN	O
syringe	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
with	IN	O
the	DT	O
administration	NN	O
of	IN	O
BeneFIX	NNP	O
.	.	O

Use	NNP	O
of	IN	O
a	DT	O
wet	JJ	O
needle	NN	O
or	CC	O
syringe	NN	O
may	MD	O
cause	VB	O
the	DT	O
solution	NN	O
to	TO	O
become	VB	O
cloudy	NN	O
;	:	O
however	RB	O
,	,	O
this	DT	O
does	VBZ	O
not	RB	O
affect	VB	O
the	DT	O
potency	NN	O
of	IN	O
the	DT	O
material	NN	O
.	.	O

Pooling	VBG	O
:	:	O
If	IN	O
needing	VBG	O
more	JJR	O
than	IN	O
one	CD	DOS
vial	NN	UNIT
of	IN	O
BeneFIX	NNP	O
per	IN	O
infusion	NN	O
,	,	O
reconstitute	VB	O
each	DT	O
vial	JJ	O
according	VBG	O
to	TO	O
the	DT	O
following	JJ	O
instructions	NNS	O
.	.	O

For	IN	O
optimum	JJ	O
amino	NN	O
acid	NN	O
utilization	NN	O
,	,	O
sufficient	JJ	O
intracellular	NN	O
electrolytes	NNS	O
(	(	O
sodium	NN	O
,	,	O
magnesium	NN	O
,	,	O
and	CC	O
phosphate	NN	O
)	)	O
should	MD	O
be	VB	O
provided	VBN	O
.	.	O

Spread	VB	O
the	DT	O
product	NN	O
so	RB	O
that	IN	O
the	DT	O
entire	JJ	O
lesion	NN	O
is	VBZ	O
covered	VBN	O
with	IN	O
a	DT	O
thin	JJ	O
uniform	NN	O
film	NN	O
.	.	O

An	DT	O
audible	JJ	O
“	NN	O
click	NN	O
”	NNP	O
will	MD	O
confirm	VB	O
proper	JJ	O
activation	NN	O
of	IN	O
the	DT	O
safety	NN	O
guard	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
HEPSERA	NNP	O
in	IN	O
chronic	JJ	WHO
hepatitis	NN	WHO
B	NNP	WHO
patients	NNS	WHO
for	IN	WHO
patients	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
with	IN	WHO
adequate	JJ	WHO
renal	JJ	WHO
function	NN	WHO
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
,	,	O
once	RB	FREQ
daily	JJ	FREQ
,	,	O
taken	VBN	O
orally	RB	O
,	,	O
without	IN	O
regard	NN	O
to	TO	O
food	NN	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
1	CD	DOS
g	JJ	UNIT
daily	RB	FREQ
(	(	O
not	RB	O
to	TO	O
exceed	VB	O
20	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
)	)	O
given	VBN	O
intramuscularly	RB	O
or	CC	O
intravenously	RB	O
for	IN	O
60	CD	PER
to	TO	O
120	CD	PER
days	NNS	PER
,	,	O
followed	VBN	O
by	IN	O
1	CD	DOS
g	NN	UNIT
by	IN	O
either	DT	O
route	NN	O
2	CD	FREQ
or	CC	O
3	CD	FREQ
times	NNS	FREQ
weekly	RB	FREQ
.	.	O

[	NNS	O
See	NNP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NN	O

There	EX	O
is	VBZ	O
no	DT	O
specific	JJ	O
pediatric	NN	O
dose	NN	O
.	.	O

However	RB	O
,	,	O
thiazides	NNS	O
should	MD	O
be	VB	O
continued	VBN	O
in	IN	O
their	PRP$	O
usual	JJ	O
dosage	NN	O
,	,	O
while	IN	O
that	DT	O
of	IN	O
INVERSINE	NNP	O
(	(	O
mecamylamine	NN	O
)	)	O
is	VBZ	O
decreased	VBN	O
by	IN	O
at	IN	O
least	JJS	O
50	CD	O
percent	NN	O
.	.	O

To	TO	O
close	VB	O
the	DT	O
incision	NN	O
,	,	O
you	PRP	O
can	MD	O
use	VB	O
the	DT	O
absorbable	JJ	O
sutures	NNS	O
and	CC	O
/	NN	O
or	CC	O
the	DT	O
sterile	JJ	O
adhesive	JJ	O
surgical	JJ	O
strips	NNS	O
provided	VBD	O
.	.	O

Grasp	NNP	O
the	DT	O
needle	JJ	O
shield	NN	O
with	IN	O
the	DT	O
other	JJ	O
hand	NN	O
.	.	O

These	DT	O
pediatric	JJ	O
schedules	NNS	O
are	VBP	O
the	DT	O
best	JJS	O
approximation	NN	O
of	IN	O
an	DT	O
average	JJ	O
dose	NN	O
recommendation	NN	O
which	WDT	O
may	MD	O
be	VB	O
adjusted	VBN	O
downward	RB	O
according	VBG	O
to	TO	O
the	DT	O
overall	JJ	O
nutritional	JJ	O
status	NN	O
and	CC	O
degree	NN	O
of	IN	O
dehydration	NN	O
encountered	VBN	O
in	IN	O
the	DT	O
sick	JJ	O
child	NN	O
.	.	O

Kyleena	NNP	O
is	VBZ	O
supplied	VBN	O
in	IN	O
a	DT	O
sterile	JJ	O
package	NN	O
within	IN	O
an	DT	O
inserter	NN	O
that	WDT	O
enables	VBZ	O
single	JJ	DOS
-	:	O
handed	VBN	O
loading	NN	O
(	(	O
see	VB	O
Figure	NNP	O
1	CD	O
)	)	O
.	.	O

The	DT	O
following	VBG	O
table	NN	O
demonstrates	VBZ	O
the	DT	O
appropriate	JJ	O
individual	JJ	O
component	NN	O
doses	NNS	O
of	IN	O
PROZAC	NNP	O
and	CC	O
olanzapine	JJ	O
versus	NN	O
Symbyax	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
range	NN	O
is	VBZ	O
7.5	CD	DOS
to	TO	O
30	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
,	,	O
administered	VBN	O
in	IN	O
one	CD	DOS
or	CC	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	O
one	CD	O
hour	NN	O
before	IN	O
meals	NNS	O
.	.	O

In	IN	O
a	DT	O
24	CD	O
-	:	O
hour	NN	O
study	NN	O
under	IN	O
simulated	JJ	O
conditions	NNS	O
of	IN	O
actual	JJ	O
use	NN	O
of	IN	O
the	DT	O
product	NN	O
relative	NN	O
to	TO	O
dilution	NN	O
strength	NN	O
,	,	O
diluent	NN	O
and	CC	O
administration	NN	O
rates	NNS	O
,	,	O
dilutions	NNS	O
at	IN	O
0.1	CD	DOS
to	TO	O
1.0	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NNS	O
were	VBD	O
chemically	RB	O
stable	JJ	O
for	IN	O
at	IN	O
least	JJS	O
24	CD	O
hours	NNS	O
.	.	O

In	IN	O
some	DT	WHO
patients	NNS	WHO
,	,	O
this	DT	O
will	MD	O
be	VB	O
adequate	JJ	O
;	:	O
in	IN	O
others	NNS	O
4	CD	DOS
to	TO	O
6	CD	DOS
mg	NNS	UNIT
a	DT	FREQ
day	NN	FREQ
may	MD	O
be	VB	O
required	VBN	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
metabolize	VBP	WHO
theophylline	NN	WHO
rapidly	RB	WHO
(	(	O
e.g	UH	O
,	,	O
the	DT	O
young	JJ	O
,	,	O
smokers	NNS	O
,	,	O
and	CC	O
some	DT	WHO
nonsmoking	JJ	WHO
adults	NNS	WHO
)	)	O
and	CC	O
who	WP	O
have	VBP	O
symptoms	NNS	O
repeatedly	RB	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
a	DT	O
dosing	NN	O
interval	NN	O
,	,	O
will	MD	O
require	VB	O
either	DT	O
increased	JJ	O
doses	NNS	O
given	VBN	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
or	CC	O
preferably	RB	O
,	,	O
are	VBP	O
likely	JJ	O
to	TO	O
be	VB	O
better	RB	O
controlled	VBN	O
by	IN	O
a	DT	O
schedule	NN	O
of	IN	O
twice	JJ	O
-	:	O
daily	JJ	FREQ
dosing	NN	O
.	.	O

BayGam	NNP	O
(	(	O
immune	JJ	O
globulin	NN	O
)	)	O
is	VBZ	O
administered	VBN	O
intramuscularly	RB	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
,	,	O
preferably	RB	O
in	IN	O
the	DT	O
anterolateral	JJ	O
aspects	NNS	O
of	IN	O
the	DT	O
upper	JJ	O
thigh	NN	O
and	CC	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
of	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
.	.	O

Treatment	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
with	IN	O
a	DT	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
in	IN	O
2	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
(	(	O
10	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NNP	O
twice	RB	FREQ
daily	RB	FREQ
)	)	O
.	.	O

The	DT	O
hydrochlorothiazide	NN	O
dose	NN	O
should	MD	O
generally	RB	O
not	RB	O
be	VB	O
increased	VBN	O
until	IN	O
2	CD	PER
-	:	O
3	CD	PER
weeks	NNS	PER
have	VBP	O
elapsed	VBN	O
.	.	O

Subsequent	JJ	O
applications	NNS	O
of	IN	O
ORAVIG	NNP	O
should	MD	O
be	VB	O
made	VBN	O
to	TO	O
alternate	VB	O
sides	NNS	O
of	IN	O
the	DT	O
mouth	NN	O
.	.	O

Tap	VB	O
the	DT	O
syringe	NN	O
at	IN	O
least	JJS	O
10	CD	FREQ
times	NNS	FREQ
to	TO	O
dislodge	VB	O
any	DT	O
material	NN	O
which	WDT	O
may	MD	O
have	VB	O
settled	VBN	O
.	.	O

Dispose	NNP	O
of	IN	O
the	DT	O
syringe	NN	O
in	IN	O
an	DT	O
approved	JJ	O
sharps	NN	O
collector	NN	O
.	.	O

Standard	NNP	O
drugs	NNS	O
for	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
,	,	O
other	JJ	O
than	IN	O
levodopa	NNS	O
without	IN	O
a	DT	O
decarboxylase	NN	O
inhibitor	NN	O
,	,	O
may	MD	O
be	VB	O
used	VBN	O
concomitantly	RB	O
while	IN	O
SINEMET	NNP	O
CR	NNP	O
is	VBZ	O
being	VBG	O
administered	VBN	O
,	,	O
although	IN	O
their	PRP$	O
dosage	NN	O
may	MD	O
have	VB	O
to	TO	O
be	VB	O
adjusted	VBN	O
.	.	O

In	IN	O
most	JJS	O
cases	NNS	O
,	,	O
0.5	CD	DOS
to	TO	O
2	CD	DOS
mL	NNS	UNIT
produces	VBZ	O
satisfactory	JJ	O
miosis	NN	O
.	.	O

The	DT	O
dosage	NN	O
and	CC	O
route	NN	O
should	MD	O
be	VB	O
determined	VBN	O
by	IN	O
the	DT	O
susceptibility	NN	O
of	IN	O
the	DT	O
causative	JJ	O
organisms	NNS	O
,	,	O
the	DT	O
severity	NN	O
of	IN	O
infection	NN	O
,	,	O
and	CC	O
the	DT	O
condition	NN	O
and	CC	O
renal	JJ	O
function	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
COPEGUS	NNP	O
should	MD	O
not	RB	O
be	VB	O
further	RB	O
modified	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
.	.	O

Use	NNP	O
of	IN	O
estrogen	NN	O
,	,	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
progestin	NN	O
,	,	O
should	MD	O
be	VB	O
with	IN	O
the	DT	O
lowest	JJS	O
effective	JJ	O
dose	NN	O
and	CC	O
for	IN	O
the	DT	O
shortest	JJS	O
duration	NN	O
consistent	NN	O
with	IN	O
treatment	NN	O
goals	NNS	O
and	CC	O
risks	NNS	O
for	IN	O
the	DT	O
individual	JJ	O
woman	NN	O
.	.	O

This	DT	O
may	MD	O
be	VB	O
avoided	VBN	O
by	IN	O
lower	JJR	O
doses	NNS	O
.	.	O

The	DT	O
serum	JJ	O
concentration	NN	O
may	MD	O
be	VB	O
checked	VBN	O
at	IN	O
these	DT	O
intervals	NNS	O
,	,	O
but	CC	O
at	IN	O
a	DT	O
minimum	NN	O
should	MD	O
be	VB	O
determined	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
this	DT	O
adjustment	JJ	O
period	NN	O
.	.	O

Within	IN	O
24	CD	O
to	TO	O
48	CD	O
hours	NNS	O
the	DT	O
volume	NN	O
and	CC	O
concentration	NN	O
of	IN	O
the	DT	O
solution	NN	O
can	MD	O
be	VB	O
increased	VBN	O
until	IN	O
the	DT	O
full	JJ	O
strength	NN	O
pediatric	JJ	O
solution	NN	O
(	(	O
amino	JJ	O
acids	NNS	O
and	CC	O
dextrose	NN	O
)	)	O
is	VBZ	O
given	VBN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
125	CD	DOS
to	TO	O
150	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
initial	JJ	O
treatment	NN	O
for	IN	O
dyslipidemia	NN	O
is	VBZ	O
dietary	JJ	O
therapy	NN	O
specific	NN	O
for	IN	O
the	DT	O
type	NN	O
of	IN	O
lipoprotein	JJ	O
abnormality	NN	O
.	.	O

Do	NNP	O
not	RB	O
crush	VB	O
,	,	O
chew	VB	O
,	,	O
or	CC	O
break	VB	O
tablets	NNS	O
because	IN	O
this	DT	O
will	MD	O
increase	VB	O
the	DT	O
rate	NN	O
of	IN	O
clonidine	NN	O
release	NN	O
.	.	O

Close	JJ	O
monitoring	NN	O
is	VBZ	O
of	IN	O
particular	JJ	O
importance	NN	O
when	WRB	O
converting	VBG	O
from	IN	O
methadone	NN	O
to	TO	O
other	JJ	O
opioid	JJ	O
agonists	NNS	O
.	.	O

Indomethacin	NNP	O
immediate	JJ	O
-	:	O
release	NN	O
capsules	VBZ	O
75	CD	DOS
-	:	O
150	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
in	IN	O
3	CD	DOS
or	CC	O
4	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

Dosage	NN	O
adjustments	NNS	O
may	MD	O
be	VB	O
needed	VBN	O
with	IN	O
changes	NNS	O
in	IN	O
physical	JJ	O
activity	NN	O
,	,	O
changes	NNS	O
in	IN	O
meal	NN	O
patterns	NNS	O
(	(	O
i.e	NN	O
,	,	O
macronutrient	JJ	O
content	NN	O
or	CC	O
timing	NN	O
of	IN	O
food	NN	O
intake	NN	O
)	)	O
,	,	O
changes	NNS	O
in	IN	O
renal	NN	O
or	CC	O
hepatic	JJ	O
function	NN	O
or	CC	O
during	IN	O
acute	JJ	O
illness	JJ	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
and	CC	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Using	VBG	O
aseptic	JJ	O
technique	NN	O
withdraw	IN	O
all	DT	O
of	IN	O
the	DT	O
EYLEA	NNP	O
vial	JJ	O
contents	NNS	O
into	IN	O
the	DT	O
syringe	NN	O
,	,	O
keeping	VBG	O
the	DT	O
vial	NN	O
in	IN	O
an	DT	O
upright	JJ	O
position	NN	O
,	,	O
slightly	RB	O
inclined	VBN	O
to	TO	O
ease	VB	O
complete	JJ	O
withdrawal	NN	O
.	.	O

The	DT	O
usual	JJ	O
attempts	NNS	O
should	MD	O
be	VB	O
made	VBN	O
to	TO	O
determine	VB	O
the	DT	O
etiology	NN	O
of	IN	O
the	DT	O
arrhythmia	NN	O
,	,	O
and	CC	O
the	DT	O
surgical	JJ	O
or	CC	O
anesthetic	JJ	O
manipulations	NNS	O
necessary	JJ	O
to	TO	O
correct	VB	O
parasympathetic	JJ	O
imbalance	NN	O
should	MD	O
be	VB	O
performed	VBN	O
.	.	O

The	DT	O
recommended	JJ	O
doses	NNS	O
for	IN	O
children	NNS	WHO
ages	NNS	WHO
1	CD	WHO
month	NN	WHO
to	TO	WHO
17	CD	WHO
years	NNS	WHO
,	,	O
inclusive	JJ	O
,	,	O
are	VBP	O
provided	VBN	O
below	IN	O
.	.	O

Co	NNP	O
-	:	O
administration	NN	O
of	IN	O
calcium	JJ	O
tablets	NNS	O
and	CC	O
calcium	NN	O
-	:	O
,	,	O
aluminum	SYM	O
-	:	O
,	,	O
and	CC	O
magnesium	SYM	O
-	:	O
containing	VBG	O
medications	NNS	O
may	MD	O
interfere	VB	O
with	IN	O
the	DT	O
absorption	NN	O
of	IN	O
Actonel	NNP	O
(	(	O
see	VB	O
DRUG	NNP	O
INTERACTIONS	NNP	O
)	)	O
.	.	O

Prior	RB	O
to	TO	O
initiating	VBG	O
Vogelxo	NNP	O
,	,	O
confirm	VBP	O
the	DT	O
diagnosis	NN	O
of	IN	O
hypogonadism	NN	O
by	IN	O
ensuring	VBG	O
that	IN	O
serum	NN	O
testosterone	NN	O
concentrations	NNS	O
have	VBP	O
been	VBN	O
measured	VBN	O
in	IN	O
the	DT	O
morning	NN	O
on	IN	O
at	IN	O
least	JJS	O
two	CD	O
separate	JJ	O
days	NNS	O
and	CC	O
that	IN	O
these	DT	O
serum	VB	O
testosterone	NN	O
concentrations	NNS	O
are	VBP	O
below	IN	O
the	DT	O
normal	JJ	O
range	NN	O
.	.	O

A	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
dose	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
in	IN	O
children	NNS	WHO
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
,	,	O
Pediatric	NNP	O
Use	NNP	O
)	)	O
.	.	O

The	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
DARVOCET	NNP	O
-	:	O
N	NNP	O
(	(	O
propoxyphene	JJ	O
napsylate	NN	O
and	CC	O
acetaminophen	NN	O
)	)	O
100	CD	O
is	VBZ	O
6	CD	DOS
tablets	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

Use	NNP	O
lower	JJR	O
initial	JJ	O
doses	NNS	O
for	IN	O
patients	NNS	WHO
whose	WP$	WHO
tolerance	NN	WHO
is	VBZ	O
expected	VBN	O
to	TO	O
be	VB	O
low	JJ	O
at	IN	O
treatment	NN	O
entry	NN	O
.	.	O

Because	IN	O
of	IN	O
the	DT	O
progressive	JJ	O
nature	NN	O
of	IN	O
extravasation	NN	O
reactions	NNS	O
,	,	O
close	JJ	O
observation	NN	O
and	CC	O
plastic	NN	O
surgery	NN	O
consultation	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

Instructions	NNS	O
for	IN	O
Use	NNP	O
,	,	O
Handling	NNP	O
and	CC	O
for	IN	O
Disposal	NNP	O
:	:	O
Individuals	NNS	O
who	WP	O
have	VBP	O
contact	VBN	O
with	IN	O
anticancer	NN	O
drugs	NNS	O
or	CC	O
work	NN	O
in	IN	O
areas	NNS	O
where	WRB	O
these	DT	O
drugs	NNS	O
are	VBP	O
used	VBN	O
may	MD	O
be	VB	O
exposed	VBN	O
to	TO	O
these	DT	O
agents	NNS	O
through	IN	O
direct	JJ	O
contact	NN	O
with	IN	O
contaminated	JJ	O
objects.1	JJ	O
Potential	NNP	O
health	NN	O
effects	NNS	O
may	MD	O
be	VB	O
reduced	VBN	O
by	IN	O
adherence	NN	O
to	TO	O
institutional	JJ	O
procedures	NNS	O
,	,	O
published	VBN	O
guidelines	NNS	O
and	CC	O
local	JJ	O
regulations	NNS	O
for	IN	O
preparation	NN	O
,	,	O
administration	NN	O
,	,	O
transportation	NN	O
and	CC	O
disposal	NN	O
of	IN	O
hazardous	JJ	O
drugs	NNS	O
.	.	O

Do	VB	O
not	RB	O
take	VB	O
two	CD	DOS
LESCOL	NNP	O
40	CD	DOS
mg	NN	UNIT
capsules	NNS	UNIT
at	IN	O
one	CD	O
time	NN	O
.	.	O

No	DT	O
dosage	NN	O
adjustment	NN	O
is	VBZ	O
necessary	JJ	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
.	.	O

Omission	NN	O
of	IN	O
placebo	JJ	O
tablets	NNS	O
in	IN	O
the	DT	O
28	CD	O
-	:	O
tablet	NN	O
courses	NNS	O
does	VBZ	O
not	RB	O
increase	VB	O
the	DT	O
possibility	NN	O
of	IN	O
conception	NN	O
provided	VBD	O
that	IN	O
this	DT	O
schedule	NN	O
is	VBZ	O
followed	VBN	O
.	.	O

(	(	O
lb	NN	O
)	)	O

Part	NN	O
of	IN	O
the	DT	O
nonprotein	JJ	O
caloric	JJ	O
requirement	NN	O
may	MD	O
be	VB	O
provided	VBN	O
as	IN	O
lipid	JJ	O
emulsion	NN	O
administered	VBD	O
concurrently	RB	O
to	TO	O
provide	VB	O
up	RB	O
to	TO	O
60	CD	O
%	NN	O
of	IN	O
daily	JJ	FREQ
calories	NNS	O
at	IN	O
a	DT	O
dose	NN	O
not	RB	O
to	TO	O
exceed	VB	O
4	CD	DOS
g	JJ	UNIT
fat	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
following	JJ	O
dosage	NN	O
titration	NN	O
schedule	NN	O
is	VBZ	O
suggested	VBN	O
:	:	O

Open	VB	O
the	DT	O
package	NN	O
of	IN	O
BAXJECT	NNP	O
II	NNP	O
Hi	NNP	O
-	:	O
Flow	NNP	O
device	NN	O
by	IN	O
peeling	VBG	O
away	RB	O
the	DT	O
lid	NN	O
completely	RB	O
without	IN	O
touching	VBG	O
the	DT	O
inside	NN	O
(	(	O
Fig	NNP	O
.	.	O

Levothyroxine	NNP	O
therapy	NN	O
is	VBZ	O
usually	RB	O
initiated	VBN	O
at	IN	O
full	JJ	O
replacement	NN	O
doses	NNS	O
,	,	O
with	IN	O
the	DT	O
recommended	VBN	O
dose	NN	O
per	IN	O
body	NN	O
weight	VBD	O
decreasing	VBG	O
with	IN	O
age	NN	O
(	(	O
see	VB	O
TABLE	NNP	O
3	CD	O
)	)	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
for	IN	O
reinjection	NN	O
when	WRB	O
the	DT	O
clinical	JJ	O
effect	NN	O
of	IN	O
the	DT	O
previous	JJ	O
injection	NN	O
has	VBZ	O
diminished	VBN	O
(	(	O
median	JJ	O
time	NN	O
until	IN	O
patients	NNS	O
qualified	VBN	O
for	IN	O
the	DT	O
second	JJ	O
treatment	NN	O
of	IN	O
BOTOX	NNP	O
in	IN	O
double	JJ	O
-	:	O
blind	NN	O
,	,	O
placebo	SYM	O
-	:	O
controlled	VBN	O
clinical	JJ	O
studies	NNS	O
was	VBD	O
169	CD	PER
days	NNS	PER
[	RB	O
~24	JJ	O
weeks	NNS	O
]	NN	O
)	)	O
,	,	O
but	CC	O
no	DT	O
sooner	JJR	O
than	IN	O
12	CD	PER
weeks	NNS	PER
from	IN	O
the	DT	O
prior	JJ	O
bladder	NN	O
injection	NN	O
.	.	O

The	DT	O
solution	NN	O
must	MD	O
be	VB	O
prepared	JJ	O
prior	JJ	O
to	TO	O
intravenous	JJ	O
administration	NN	O
.	.	O

In	IN	O
adults	NNS	WHO
with	IN	WHO
ADHD	NNP	WHO
who	WP	WHO
are	VBP	WHO
either	DT	WHO
starting	VBG	WHO
treatment	NN	WHO
for	IN	WHO
the	DT	WHO
first	JJ	WHO
time	NN	WHO
or	CC	WHO
switching	VBG	WHO
from	IN	WHO
another	DT	WHO
medication	NN	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
20	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

For	IN	O
control	NN	O
of	IN	O
severe	JJ	O
,	,	O
chronic	JJ	O
pain	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
certain	JJ	WHO
terminal	JJ	WHO
diseases	NNS	WHO
,	,	O
this	DT	O
drug	NN	O
should	MD	O
be	VB	O
administered	VBN	O
on	IN	O
a	DT	O
regularly	RB	O
scheduled	VBN	O
basis	NN	O
,	,	O
every	DT	FREQ
4	CD	FREQ
hours	NNS	FREQ
,	,	O
at	IN	O
the	DT	O
lowest	JJS	O
dosage	NN	O
level	NN	O
that	WDT	O
will	MD	O
achieve	VB	O
adequate	JJ	O
analgesia	NN	O
.	.	O

Once	RB	O
non	JJ	O
-	:	O
hematologic	NN	O
toxicity	NN	O
has	VBZ	O
recovered	VBN	O
to	TO	O
≤	VB	O
Grade	NNP	O
1	CD	O
and	CC	O
/	CD	O
or	CC	O
the	DT	O
blood	NN	O
counts	NNS	O
have	VBP	O
improved	VBN	O
[	NNP	O
Absolute	NNP	O
Neutrophil	NNP	O
Count	NNP	O
(	(	O
ANC	NNP	O
)	)	O
≥	VBD	O
1	CD	O
x	JJ	O
109	CD	O
/	JJ	O
L	NNP	O
,	,	O
platelets	VBZ	O
≥	JJ	O
75	CD	O
x	JJ	O
109	CD	O
/	JJ	O
L	NNP	O
]	NNP	O
,	,	O
TREANDA	NNP	O
can	MD	O
be	VB	O
reinitiated	VBN	O
at	IN	O
the	DT	O
discretion	NN	O
of	IN	O
the	DT	O
treating	NN	O
physician	NN	O
.	.	O

ZIANA	NNP	O
Gel	NNP	O
(	(	O
clindamycin	JJ	O
phosphate	NN	O
,	,	O
tretinoin	NN	O
)	)	O
should	MD	O
be	VB	O
kept	VBN	O
away	RB	O
from	IN	O
the	DT	O
eyes	NNS	O
,	,	O
the	DT	O
mouth	NN	O
,	,	O
angles	NNS	O
of	IN	O
the	DT	O
nose	NN	O
,	,	O
and	CC	O
mucous	JJ	O
membranes	NNS	O
.	.	O

In	IN	O
adult	JJ	WHO
subjects	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
the	DT	O
apparent	JJ	O
oral	JJ	O
clearance	NN	O
of	IN	O
entecavir	NN	O
decreased	VBN	O
as	IN	O
creatinine	JJ	O
clearance	NN	O
decreased	VBD	O
[	NNP	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

For	IN	O
more	JJR	O
severe	JJ	O
infections	NNS	O
and	CC	O
infections	NNS	O
of	IN	O
the	DT	O
respiratory	NN	O
tract	NN	O
,	,	O
the	DT	O
dose	NN	O
should	MD	O
be	VB	O
one	CD	DOS
875	CD	DOS
-	:	O
mg	NN	UNIT
tablet	NN	UNIT
of	IN	O
AUGMENTIN	NNP	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
or	CC	O
one	CD	DOS
500	CD	DOS
-	:	O
mg	NN	UNIT
tablet	NN	UNIT
of	IN	O
AUGMENTIN	NNP	O
every	DT	FREQ
8	CD	FREQ
hours	NNS	FREQ
.	.	O

To	TO	O
avoid	VB	O
an	DT	O
increased	JJ	O
risk	NN	O
of	IN	O
rash	NN	O
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
and	CC	O
subsequent	JJ	O
dose	JJ	O
escalations	NNS	O
of	IN	O
LAMICTAL	NNP	O
should	MD	O
not	RB	O
be	VB	O
exceeded	VBN	O
[	NNP	O
see	VBP	O
BOXED	NNP	O
WARNING	NNP	O
]	NNP	O
.	.	O

CONTAINS	NNP	O
NO	NNP	O
PRESERVATIVE	NNP	O
.	.	O

Avoid	NNP	O
contact	NN	O
with	IN	O
the	DT	O
eyes	NNS	O
and	CC	O
other	JJ	O
mucous	JJ	O
membranes	NNS	O
.	.	O

Do	NNP	O
not	RB	O
add	VB	O
or	CC	O
simultaneously	RB	O
infuse	IN	O
other	JJ	O
drug	NN	O
substances	NNS	O
through	IN	O
the	DT	O
same	JJ	O
intravenous	JJ	O
line	NN	O
.	.	O

If	IN	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
exceeds	VBZ	O
250	CD	DOS
mg	NN	UNIT
,	,	O
it	PRP	O
should	MD	O
be	VB	O
given	VBN	O
in	IN	O
a	DT	O
divided	JJ	O
regimen	NN	O
.	.	O

Control	NN	O
may	MD	O
often	RB	O
be	VB	O
maintained	VBN	O
with	IN	O
as	RB	O
little	JJ	O
as	IN	O
5	CD	DOS
mg	NNS	UNIT
(	(	O
two	CD	DOS
tablets	NNS	UNIT
or	CC	O
10	CD	DOS
ml	NN	UNIT
of	IN	O
liquid	NN	O
)	)	O
daily	RB	FREQ
.	.	O

The	DT	O
safety	NN	O
of	IN	O
ATIVAN	NNP	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
has	VBZ	WHO
not	RB	WHO
been	VBN	WHO
established	VBN	WHO
.	.	O

Reconstitution	NN	O
and	CC	O
product	NN	O
administration	NN	O
must	MD	O
be	VB	O
done	VBN	O
with	IN	O
caution	NN	O
.	.	O

The	DT	O
tubing	NN	O
should	MD	O
be	VB	O
attached	VBN	O
to	TO	O
a	DT	O
Butterfly	NNP	O
needle	NN	O
or	CC	O
other	JJ	O
suitable	JJ	O
device	NN	O
and	CC	O
inserted	VBN	O
preferably	RB	O
into	IN	O
a	DT	O
large	JJ	O
vein	NN	O
.	.	O

Vitamin	NNP	O
B12	NNP	O
,	,	O
vitamin	NN	O
K	NNP	O
and	CC	O
folic	JJ	O
acid	NN	O
are	VBP	O
given	VBN	O
intramuscularly	RB	O
or	CC	O
added	VBN	O
to	TO	O
the	DT	O
solution	NN	O
as	IN	O
desired	VBN	O
.	.	O

XELODA	JJ	O
tablets	NNS	O
should	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
with	IN	O
water	NN	O
within	IN	O
30	CD	O
minutes	NNS	O
after	IN	O
a	DT	O
meal	NN	O
.	.	O

Do	NNP	O
not	RB	O
crush	VB	O
,	,	O
heat	NN	O
,	,	O
or	CC	O
ultrasonicate	JJ	O
during	IN	O
preparation	NN	O
.	.	O

Let	VB	O
the	DT	O
prefilled	JJ	O
syringe	NN	O
stand	NN	O
at	IN	O
room	NN	O
temperature	NN	O
for	IN	O
20	CD	O
minutes	NNS	O
to	TO	O
allow	VB	O
the	DT	O
solution	NN	O
to	TO	O
warm	VB	O
to	TO	O
room	NN	O
temperature	NN	O
.	.	O

To	TO	O
achieve	VB	O
maximum	JJ	O
contraceptive	JJ	O
effectiveness	NN	O
,	,	O
Nor	NNP	O
-	:	O
QD	NNP	O
(	(	O
norethindrone	NN	O
)	)	O
®	NN	O
must	MD	O
be	VB	O
taken	VBN	O
exactly	RB	O
as	IN	O
directed	VBN	O
.	.	O

For	IN	O
mild	JJ	WHO
arsenic	JJ	WHO
or	CC	WHO
gold	NN	WHO
poisoning	NN	WHO
,	,	O
2.5	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	VBD	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
for	IN	O
two	CD	PER
days	NNS	PER
,	,	O
two	CD	FREQ
times	NNS	FREQ
on	IN	O
the	DT	O
third	JJ	O
day	NN	O
,	,	O
and	CC	O
once	RB	FREQ
daily	JJ	FREQ
thereafter	NN	O
for	IN	O
ten	JJ	PER
days	NNS	PER
;	:	O
for	IN	O
severe	JJ	O
arsenic	NN	O
or	CC	O
gold	NN	O
poisoning	NN	O
,	,	O
3	CD	DOS
mg	NN	UNIT
/	NN	O
kg	VBD	O
every	DT	FREQ
four	CD	FREQ
hours	NNS	FREQ
for	IN	O
two	CD	PER
-	:	O
days	NNS	PER
,	,	O
four	CD	FREQ
times	NNS	FREQ
on	IN	O
the	DT	O
third	JJ	O
day	NN	O
,	,	O
then	RB	O
twice	RB	FREQ
daily	RB	FREQ
thereafter	RB	O
for	IN	O
ten	JJ	PER
days	NNS	PER
.	.	O

If	IN	O
the	DT	O
product	NN	O
is	VBZ	O
not	RB	O
used	VBN	O
right	RB	O
away	RB	O
,	,	O
it	PRP	O
should	MD	O
be	VB	O
shaken	VBN	O
vigorously	RB	O
to	TO	O
re	VB	O
-	:	O
suspend	NN	O
.	.	O

For	IN	O
nausea	NN	O
and	CC	O
vomiting	NN	O
in	IN	O
children	NNS	WHO
,	,	O
the	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
0.5	CD	DOS
mg	NN	UNIT
per	IN	O
pound	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
and	CC	O
the	DT	O
dose	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
to	TO	O
the	DT	O
age	NN	O
and	CC	O
weight	NN	O
of	IN	O
the	DT	O
patient	NN	O
and	CC	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
condition	NN	O
being	VBG	O
treated	VBN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
one	CD	DOS
or	CC	O
two	CD	DOS
tablets	NNS	UNIT
every	DT	FREQ
four	CD	FREQ
to	TO	O
six	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

The	DT	O
greater	JJR	O
the	DT	O
fluid	NN	O
intake	NN	O
,	,	O
the	DT	O
lower	JJR	O
the	DT	O
required	JJ	O
dosage	NN	O
of	IN	O
CUPRIMINE	NNP	O
.	.	O

To	TO	O
correct	VB	O
excessively	RB	O
prolonged	JJ	O
prothrombin	NN	O
time	NN	O
caused	VBN	O
by	IN	O
oral	JJ	O
anticoagulant	JJ	O
therapy—2.5	NN	O
to	TO	O
10	CD	DOS
mg	NN	UNIT
or	CC	O
up	RB	O
to	TO	O
25	CD	DOS
mg	NNS	UNIT
initially	RB	O
is	VBZ	O
recommended	VBN	O
.	.	O

See	VB	O
REBETOL	NNP	O
prescribing	VBG	O
information	NN	O
for	IN	O
dosing	VBG	O
when	WRB	O
used	VBN	O
in	IN	O
combination	NN	O
with	IN	O
REBETOL	NNP	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
.	.	O

Resuspension	NN	O
is	VBZ	O
easier	JJR	O
when	WRB	O
the	DT	O
insulin	NN	O
has	VBZ	O
reached	VBN	O
room	NN	O
temperature	NN	O
.	.	O

Preparation	NN	O
of	IN	O
Colytewith	NNP	O
flavor	NN	O
packs	NNS	O
Solution	NN	O
:	:	O

In	IN	O
the	DT	O
post	NN	O
-	:	O
cardiac	NN	O
surgery	NN	O
study	NN	O
(	(	O
see	VB	O
Clinical	NNP	O
Studies	NNPS	O
)	)	O
,	,	O
one	CD	DOS
or	CC	O
two	CD	DOS
intravenous	JJ	UNIT
infusions	NNS	UNIT
of	IN	O
0.5	CD	DOS
mg	NN	UNIT
(	(	O
0.005	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	FW	O
per	IN	O
dose	NN	O
for	IN	O
patients	NNS	WHO
weighing	VBG	WHO
less	JJR	WHO
than	IN	WHO
60	CD	WHO
kg	NN	WHO
)	)	WHO
was	VBD	WHO
effective	JJ	WHO
in	IN	WHO
terminating	VBG	WHO
atrial	JJ	WHO
fibrillation	NN	WHO
or	CC	O
atrial	JJ	O
flutter	NN	O
.	.	O

Treatment	NNP	O
history	NN	O
and	CC	O
,	,	O
when	WRB	O
available	JJ	O
,	,	O
resistance	NN	O
testing	NN	O
should	MD	O
guide	VB	O
the	DT	O
use	NN	O
of	IN	O
VITEKTA	NNP	O
-	:	O
containing	NN	O
regimens	NNS	O
.	.	O

The	DT	O
physician	NN	O
should	MD	O
periodically	RB	O
reexamine	VB	O
the	DT	O
need	NN	O
for	IN	O
continued	JJ	O
pharmacotherapy	NN	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
unless	IN	O
solution	NN	O
is	VBZ	O
clear	JJ	O
and	CC	O
seal	NN	O
is	VBZ	O
intact	JJ	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
opioid	JJ	WHO
tolerant	NN	WHO
are	VBP	O
those	DT	O
receiving	VBG	O
,	,	O
for	IN	O
one	CD	PER
week	NN	PER
or	CC	O
longer	JJR	O
,	,	O
at	IN	O
least	JJS	O
60	CD	DOS
mg	JJ	UNIT
oral	JJ	O
morphine	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
25	CD	DOS
mcg	NN	UNIT
transdermal	JJ	O
fentanyl	NN	O
per	IN	O
hour	NN	O
,	,	O
30	CD	DOS
mg	JJ	UNIT
oral	JJ	O
oxycodone	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
8	CD	DOS
mg	JJ	UNIT
oral	JJ	O
hydromorphone	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
25	CD	DOS
mg	JJ	UNIT
oral	JJ	O
oxymorphone	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
or	CC	O
an	DT	O
equianalgesic	JJ	O
dose	NN	O
of	IN	O
another	DT	O
opioid	NN	O
.	.	O

Give	VB	O
careful	JJ	O
consideration	NN	O
to	TO	O
additions	NNS	O
of	IN	O
divalent	JJ	O
cations	NNS	O
(	(	O
Ca++	NNP	O
and	CC	O
Mg++	NNP	O
)	)	O
,	,	O
which	WDT	O
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
cause	VB	O
emulsion	NN	O
instability	NN	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
Orudis	NNP	O
(	(	O
ketoprofen	NN	O
)	)	O
recommended	VBD	O
for	IN	O
mild	JJ	O
-	:	O
to	TO	O
-	:	O
moderate	VB	O
pain	NN	O
and	CC	O
dysmenorrhea	NN	O
is	VBZ	O
25	CD	DOS
to	TO	O
50	CD	DOS
mg	NN	UNIT
every	DT	FREQ
6	CD	FREQ
to	TO	O
8	CD	O
hours	NNS	O
as	IN	O
necessary	JJ	O
.	.	O

The	DT	O
recommended	JJ	O
Intermezzo	NNP	O
dose	NN	O
for	IN	O
men	NNS	WHO
and	CC	WHO
women	NNS	WHO
who	WP	WHO
are	VBP	WHO
taking	VBG	WHO
concomitant	JJ	WHO
CNS	NNP	WHO
depressants	NNS	WHO
is	VBZ	O
1.75	CD	DOS
mg	NN	UNIT
.	.	O

Maintain	NNP	O
careful	JJ	O
prescription	NN	O
records	NNS	O
,	,	O
educate	NN	O
patients	NNS	O
about	IN	O
abuse	NN	O
,	,	O
monitor	NN	O
for	IN	O
signs	NNS	O
of	IN	O
abuse	NN	O
and	CC	O
overdose	NN	O
,	,	O
and	CC	O
periodically	RB	O
re	VB	O
-	:	O
evaluate	VB	O
the	DT	O
need	NN	O
for	IN	O
ADZENYS	NNP	O
XR	NNP	O
-	:	O
ODT	NN	O
use	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
and	CC	O
Drug	NNP	O
Abuse	NNP	O
And	CC	O
Dependence	NNP	O
]	NNP	O
.	.	O

After	IN	O
initiation	NN	O
of	IN	O
treatment	NN	O
in	IN	O
children	NNS	WHO
or	CC	WHO
adults	NNS	WHO
,	,	O
dosage	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
to	TO	O
the	DT	O
smallest	JJS	O
amount	NN	O
adequate	NN	O
to	TO	O
relieve	VB	O
symptoms	NNS	O
.	.	O

If	IN	O
acceptable	JJ	O
alternatives	NNS	O
to	TO	O
linezolid	VB	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	JJ	O
treatment	NN	O
are	VBP	O
not	RB	O
available	JJ	O
and	CC	O
the	DT	O
potential	JJ	O
benefits	NNS	O
of	IN	O
linezolid	JJ	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	JJ	O
treatment	NN	O
are	VBP	O
judged	VBN	O
to	TO	O
outweigh	VB	O
the	DT	O
risks	NNS	O
of	IN	O
serotonin	JJ	O
syndrome	NN	O
in	IN	O
a	DT	O
particular	JJ	WHO
patient	NN	WHO
,	,	O
PROZAC	NNP	O
should	MD	O
be	VB	O
stopped	VBN	O
promptly	RB	O
,	,	O
and	CC	O
linezolid	VBD	O
or	CC	O
intravenous	JJ	O
methylene	NNS	O
blue	VBP	O
can	MD	O
be	VB	O
administered	VBN	O
.	.	O

THE	DT	O
INITIAL	NNP	O
RATE	NNP	O
OF	NNP	O
INFUSION	NNP	O
IN	NNP	O
OLDER	NNP	O
PEDIATRIC	NNP	O
PATIENTS	NNP	O
SHOULD	NNP	O
BE	NNP	O
NO	NNP	O
MORE	NNP	O
THAN	NNP	O
0.1	CD	DOS
ML	NNP	UNIT
/	NNP	O
MINUTE	NNP	O
FOR	NNP	O
THE	NNP	O
FIRST	NNP	O
10	CD	O
TO	NNP	O
15	CD	O
MINUTES	NNP	O
.	.	O

Cyclic	JJ	O
combination	NN	O
therapy	NN	O
of	IN	O
methotrexate	NN	O
with	IN	O
other	JJ	O
antitumor	NN	O
drugs	NNS	O
has	VBZ	O
been	VBN	O
reported	VBN	O
as	IN	O
being	VBG	O
useful	JJ	O
.	.	O

For	IN	O
patients	NNS	WHO
whose	WP$	WHO
HbA1c	NNP	WHO
is	VBZ	O
8	CD	O
%	NN	O
or	CC	O
greater	JJR	O
the	DT	O
starting	NN	O
dose	NN	O
is	VBZ	O
1	CD	DOS
or	CC	O
2	CD	DOS
mg	NNS	UNIT
orally	RB	O
before	IN	O
each	DT	O
meal	NN	O
.	.	O

Among	IN	O
such	JJ	O
populations	NNS	O
,	,	O
about	RB	O
89	CD	O
%	NN	O
become	NN	O
pregnant	JJ	O
within	IN	O
one	CD	O
year	NN	O
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
flushing	NN	O
may	MD	O
be	VB	O
reduced	VBN	O
by	IN	O
administration	NN	O
of	IN	O
TECFIDERA	NNP	O
with	IN	O
food	NN	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
oral	JJ	O
olanzapine	NN	O
,	,	O
10	CD	DOS
mg	NN	UNIT
/	NNP	FREQ
day	NN	FREQ
to	TO	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
,	,	O
in	IN	O
maintaining	VBG	O
treatment	NN	O
response	NN	O
in	IN	O
schizophrenic	JJ	WHO
patients	NNS	WHO
who	WP	WHO
had	VBD	WHO
been	VBN	WHO
stable	JJ	WHO
on	IN	WHO
ZYPREXA	NNP	WHO
for	IN	O
approximately	RB	O
8	CD	PER
weeks	NNS	PER
and	CC	O
were	VBD	O
then	RB	O
followed	VBN	O
for	IN	O
relapse	NN	O
has	VBZ	O
been	VBN	O
demonstrated	VBN	O
in	IN	O
a	DT	O
placebo	NN	O
-	:	O
controlled	VBN	O
trial	NN	O
[	NN	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

Any	DT	O
unused	JJ	O
reconstituted	VBN	O
material	NN	O
should	MD	O
be	VB	O
discarded	VBN	O
.	.	O

Capsules	NNS	O
should	MD	O
not	RB	O
be	VB	O
opened	VBN	O
,	,	O
crushed	VBN	O
,	,	O
dissolved	VBN	O
,	,	O
or	CC	O
chewed	VBN	O
.	.	O

For	IN	O
acute	NN	O
dose	JJ	O
administration	NN	O
,	,	O
adjustment	NN	O
is	VBZ	O
not	RB	O
needed	VBN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
disease	NN	WHO
.	.	O

It	PRP	O
is	VBZ	O
based	VBN	O
upon	IN	O
the	DT	O
determination	NN	O
of	IN	O
an	DT	O
International	NNP	O
Normalized	NNP	O
Ratio	NNP	O
(	(	O
INR	NNP	O
)	)	O
which	WDT	O
provides	VBZ	O
a	DT	O
common	JJ	O
basis	NN	O
for	IN	O
communication	NN	O
of	IN	O
PT	NNP	O
results	NNS	O
and	CC	O
interpretations	NNS	O
of	IN	O
therapeutic	JJ	O
ranges.17	NN	O
The	DT	O
PT	NNP	O
should	MD	O
be	VB	O
determined	VBN	O
daily	RB	FREQ
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
the	DT	O
initial	JJ	O
dose	NN	O
until	IN	O
PT	NNP	O
/	NNP	O
INR	NNP	O
results	NNS	O
stabilize	VB	O
in	IN	O
the	DT	O
therapeutic	JJ	O
range	NN	O
.	.	O

If	IN	O
the	DT	O
bleeding	NN	O
event	NN	O
has	VBZ	O
resolved	VBN	O
but	CC	O
the	DT	O
underlying	JJ	O
cause	NN	O
persists	NNS	O
,	,	O
consider	VB	O
resuming	VBG	O
treatment	NN	O
with	IN	O
Jakafi	NNP	O
at	IN	O
a	DT	O
lower	JJR	O
dose	NN	O
.	.	O

Many	JJ	O
commercially	RB	O
available	JJ	O
brands	NNS	O
of	IN	O
rubbing	VBG	O
alcohol	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
solutions	NNS	O
of	IN	O
ethyl	NN	O
alcohol	NN	O
not	RB	O
of	IN	O
USP	NNP	O
grade	NN	O
,	,	O
contain	NN	O
denaturants	NNS	O
which	WDT	O
are	VBP	O
injurious	JJ	O
to	TO	O
rubber	VB	O
and	CC	O
therefore	RB	O
are	VBP	O
not	RB	O
to	TO	O
be	VB	O
used	VBN	O
.	.	O

Therapy	NN	O
with	IN	O
AVANDIA	NNP	O
should	MD	O
not	RB	O
be	VB	O
initiated	VBN	O
if	IN	O
the	DT	O
patient	NN	O
exhibits	VBZ	O
clinical	JJ	O
evidence	NN	O
of	IN	O
active	JJ	O
liver	NN	O
disease	NN	O
or	CC	O
increased	VBN	O
serum	JJ	O
transaminase	NN	O
levels	NNS	O
(	(	O
ALT	NNP	O
>	NNP	O
2.5X	CD	O
upper	JJ	O
limit	NN	O
of	IN	O
normal	JJ	O
at	IN	O
start	NN	O
of	IN	O
therapy	NN	O
)	)	O
.	.	O

The	DT	O
capsule	NN	O
should	MD	O
be	VB	O
used	VBN	O
within	IN	O
seven	CD	O
days	NNS	O
.	.	O

Pry	NNP	O
off	RP	O
the	DT	O
small	JJ	O
metal	NN	O
disc	NN	O
in	IN	O
the	DT	O
cap	NN	O
over	IN	O
the	DT	O
diaphragms	NN	O
of	IN	O
the	DT	O
vials	NNS	O
of	IN	O
Antivenin	NNP	O
and	CC	O
diluent	NN	O
.	.	O

[	NNS	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Clinical	JJ	O
experience	NN	O
with	IN	O
daily	JJ	FREQ
doses	NNS	O
above	IN	O
1,600	CD	DOS
mg	NN	UNIT
is	VBZ	O
limited	VBN	O
.	.	O

BROVANA	NNP	O
Inhalation	NNP	O
Solution	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
by	IN	O
the	DT	O
orally	RB	O
inhaled	JJ	O
route	NN	O
via	IN	O
a	DT	O
standard	JJ	O
jet	NN	O
nebulizer	RB	O
connected	VBN	O
to	TO	O
an	DT	O
air	NN	O
compressor	NN	O
(	(	O
see	VB	O
the	DT	O
accompanying	VBG	O
Medication	NNP	O
Guide	NNP	O
)	)	O
.	.	O

If	IN	O
therapy	NN	O
has	VBZ	O
been	VBN	O
interrupted	VBN	O
for	IN	O
more	JJR	O
than	IN	O
three	CD	O
days	NNS	O
,	,	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
restarted	VBN	O
at	IN	O
the	DT	O
lowest	JJS	O
dosage	NN	O
and	CC	O
the	DT	O
dosage	NN	O
escalated	VBD	O
to	TO	O
the	DT	O
current	JJ	O
dose	NN	O
.	.	O

As	IN	O
a	DT	O
guideline	NN	O
,	,	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
oxycodone	NN	O
dose	NN	O
usually	RB	O
can	MD	O
be	VB	O
increased	VBN	O
by	IN	O
25	CD	O
%	NN	O
to	TO	O
50	CD	O
%	NN	O
of	IN	O
the	DT	O
current	JJ	O
dose	NN	O
,	,	O
each	DT	O
time	NN	O
an	DT	O
increase	NN	O
is	VBZ	O
clinically	RB	O
indicated	VBN	O
.	.	O

Initial	JJ	O
:	:	O
On	IN	O
the	DT	O
first	JJ	O
day	NN	O
,	,	O
start	NN	O
with	IN	O
one	CD	DOS
200	CD	DOS
mg	NN	UNIT
capsule	NN	UNIT
.	.	O

Table	JJ	O
2	CD	O
.	.	O

For	IN	O
intramuscular	JJ	O
use	NN	O
.	.	O

In	IN	O
rare	JJ	O
instances	NNS	O
,	,	O
patients	NNS	WHO
with	IN	WHO
congenital	JJ	WHO
neutropenia	NNS	WHO
have	VBP	O
required	VBN	O
doses	NNS	O
of	IN	O
filgrastim	NN	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
100	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
range	NN	O
of	IN	O
initial	JJ	O
doses	NNS	O
is	VBZ	O
0.11	CD	DOS
to	TO	O
1.6	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
in	IN	O
3	CD	DOS
or	CC	O
4	CD	DOS
divided	VBN	UNIT
doses	NNS	UNIT
(	(	O
3.2	CD	DOS
to	TO	O
48	CD	DOS
mg	NNS	UNIT
/	JJ	O
m²bsa	JJ	O
/	NNP	FREQ
day	NN	FREQ
)	)	O
.	.	O

Some	DT	WHO
patients	NNS	WHO
may	MD	O
be	VB	O
controlled	VBN	O
with	IN	O
lower	JJR	O
or	CC	O
higher	JJR	O
serum	NN	O
concentrations	NNS	O
[	VBP	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

For	IN	O
estimates	NNS	O
to	TO	O
be	VB	O
valid	JJ	O
,	,	O
serum	JJ	O
creatinine	NN	O
levels	NNS	O
should	MD	O
reflect	VB	O
steady	JJ	O
-	:	O
state	NN	O
levels	NNS	O
of	IN	O
renal	JJ	O
function	NN	O
.	.	O

[	NNS	O
see	VBP	O
HOW	NNP	O
SUPPLIED	NNP	O
/	NNP	O
Storage	NNP	O
and	CC	O
Handling	NNP	O
]	NNP	O
Totect®	NNP	O
should	MD	O
not	RB	O
be	VB	O
mixed	JJ	O
or	CC	O
administered	VBN	O
with	IN	O
any	DT	O
other	JJ	O
drug	NN	O
during	IN	O
the	DT	O
infusion	NN	O
.	.	O

Drug	NN	O
interactions	NNS	O
can	MD	O
increase	VB	O
risk	NN	O
of	IN	O
hypertensive	JJ	O
reactions	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
CaloMist	NNP	O
Nasal	NNP	O
Spray	NNP	O
is	VBZ	O
one	CD	DOS
spray	NN	UNIT
in	IN	O
each	DT	O
nostril	NN	O
once	RB	FREQ
daily	JJ	FREQ
(	(	O
25	CD	DOS
mcg	NN	UNIT
per	IN	O
nostril	NN	O
,	,	O
total	JJ	O
daily	JJ	FREQ
dose	VB	O
50	CD	DOS
mcg	NN	UNIT
)	)	O
.	.	O

Hemolysis	NN	O
does	VBZ	O
not	RB	O
interfere	VB	O
with	IN	O
a	DT	O
reading	NN	O
.	.	O

Revised	VBN	O
:	:	O
Nov	NN	O
2016	CD	O

For	IN	O
palliative	JJ	O
management	NN	O
of	IN	O
patients	NNS	WHO
with	IN	WHO
recurrent	NN	WHO
or	CC	O
inoperable	JJ	O
brain	NN	O
tumors	NNS	O
,	,	O
maintenance	NN	O
therapy	NN	O
with	IN	O
either	DT	O
dexamethasone	NN	O
sodium	NN	O
phosphate	NN	O
injection	NN	O
or	CC	O
dexamethasone	NN	O
tablets	NNS	O
in	IN	O
a	DT	O
dosage	NN	O
of	IN	O
2	CD	DOS
mg	JJ	UNIT
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
daily	JJ	FREQ
may	MD	O
be	VB	O
effective	JJ	O
.	.	O

Dosage	NN	O
should	MD	O
be	VB	O
individualized	VBN	O
to	TO	O
provide	VB	O
maximum	JJ	O
benefit	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
SIRTURO	NNP	O
is	VBZ	O
400	CD	DOS
mg	NN	UNIT
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
the	DT	O
first	JJ	O
two	CD	PER
weeks	NNS	PER
,	,	O
followed	VBN	O
by	IN	O
200	CD	DOS
mg	NNS	UNIT
orally	RB	O
three	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
week	NN	FREQ
(	(	O
with	IN	O
at	IN	O
least	JJS	O
48	CD	O
hours	NNS	O
between	IN	O
doses	NNS	O
)	)	O
for	IN	O
22	CD	PER
weeks	NNS	PER
(	(	O
total	JJ	O
duration	NN	O
of	IN	O
24	CD	PER
weeks	NNS	PER
)	)	O
.	.	O

When	WRB	O
further	RB	O
diluted	VBN	O
in	IN	O
500	CD	DOS
mL	NN	UNIT
to	TO	O
1,000	CD	DOS
mL	NN	UNIT
of	IN	O
compatible	JJ	O
solutions	NNS	O
(	(	O
except	IN	O
Lactated	NNP	O
Ringer	NNP	O
's	POS	O
)	)	O
,	,	O
the	DT	O
pH	NN	O
usually	RB	O
ranges	VBZ	O
from	IN	O
2.5	CD	O
to	TO	O
4.0	CD	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
pregnancy	NN	O
increases	NNS	O
with	IN	O
each	DT	O
active	JJ	O
(	(	O
white	JJ	O
)	)	O
tablet	NN	O
missed	VBN	O
.	.	O

All	DT	WHO
patients	NNS	WHO
should	MD	O
receive	VB	O
calcium	NN	O
1000	CD	DOS
mg	JJ	UNIT
daily	JJ	FREQ
and	CC	O
at	IN	O
least	JJS	O
400	CD	DOS
IU	NNP	UNIT
vitamin	NN	O
D	NNP	O
daily	JJ	FREQ
[	NNP	O
see	NN	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

If	IN	O
the	DT	O
physiologic	NN	O
and	CC	O
metabolic	JJ	O
abnormalities	NNS	O
reappear	VBP	O
,	,	O
the	DT	O
regimen	NNS	O
may	MD	O
be	VB	O
repeated	VBN	O
.	.	O

Long	NNP	O
-	:	O
term	NN	O
use	NN	O
of	IN	O
Amnesteem	NNP	O
,	,	O
even	RB	O
in	IN	O
low	JJ	O
doses	NNS	O
,	,	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
,	,	O
and	CC	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
meningitis	NN	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
the	DT	O
initial	JJ	O
therapeutic	JJ	O
dose	NN	O
be	VB	O
100	CD	DOS
mg	JJ	UNIT
/	NN	O
kg	NN	O
(	(	O
not	RB	O
to	TO	O
exceed	VB	O
4	CD	DOS
grams	NNS	UNIT
)	)	O
.	.	O

After	IN	O
two	CD	PER
weeks	NNS	PER
,	,	O
the	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
200	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
for	IN	O
at	IN	PER
least	JJS	PER
two	CD	PER
weeks	NNS	PER
.	.	O

Contents	NNS	O
should	MD	O
be	VB	O
mixed	VBN	O
thoroughly	RB	O
by	IN	O
gently	RB	O
inverting	VBG	O
the	DT	O
container	NN	O
repeatedly	RB	O
until	IN	O
a	DT	O
homogenous	JJ	O
solution	NN	O
results	NNS	O
.	.	O

CIPRO	NNP	O
Tablets	NNP	O
and	CC	O
Oral	NNP	O
Suspension	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
orally	RB	O
as	IN	O
described	VBN	O
in	IN	O
the	DT	O
appropriate	JJ	O
Dosage	NNP	O
Guidelines	NNP	O
tables	NNS	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
closely	RB	O
during	IN	O
the	DT	O
dose	JJ	O
adjustment	NN	O
period	NN	O
,	,	O
particularly	RB	O
with	IN	O
regard	NN	O
to	TO	O
appearance	VB	O
or	CC	O
worsening	VBG	O
of	IN	O
involuntary	JJ	O
movements	NNS	O
,	,	O
dyskinesias	NN	O
or	CC	O
nausea	NN	O
.	.	O

(	(	O
see	VB	O
Figure	NNP	O
6	CD	O
.	.	O
)	)	O

Females	NNS	O
who	WP	O
have	VBP	O
taken	VBN	O
TEGISON	NNP	O
(	(	O
etretinate	NN	O
)	)	O
must	MD	O
continue	VB	O
to	TO	O
follow	VB	O
the	DT	O
contraceptive	NN	O
recommendations	NNS	O
for	IN	O
TEGISON	NNP	O
.	.	O

Sodium	NN	O
hyaluronate	NN	O
is	VBZ	O
a	DT	O
natural	JJ	O
complex	JJ	O
sugar	NN	O
of	IN	O
the	DT	O
glycosaminoglycan	JJ	O
family	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
hypertension	NN	WHO
(	(	O
e.g	JJ	O
,	,	O
accelerated	VBD	O
or	CC	O
malignant	JJ	O
hypertension	NN	O
)	)	O
,	,	O
when	WRB	O
temporary	JJ	O
discontinuation	NN	O
of	IN	O
current	JJ	O
antihypertensive	JJ	O
therapy	NN	O
is	VBZ	O
not	RB	O
practical	JJ	O
or	CC	O
desirable	JJ	O
,	,	O
or	CC	O
when	WRB	O
prompt	JJ	O
titration	NN	O
to	TO	O
more	RBR	O
normotensive	JJ	O
blood	NN	O
pressure	NN	O
levels	NNS	O
is	VBZ	O
indicated	VBN	O
,	,	O
diuretic	JJ	O
should	MD	O
be	VB	O
continued	VBN	O
but	CC	O
other	JJ	O
current	JJ	O
antihypertensive	JJ	O
medication	NN	O
stopped	VBD	O
and	CC	O
CAPOTEN	NNP	O
dosage	VBP	O
promptly	RB	O
initiated	VBN	O
at	IN	O
25	CD	DOS
mg	NN	UNIT
b.i.d	NN	O
.	.	O

Instruct	NN	O
patients	NNS	O
to	TO	O
consume	VB	O
only	RB	O
clear	JJ	O
liquids	NNS	O
(	(	O
no	DT	O
solid	JJ	O
food	NN	O
or	CC	O
milk	NN	O
)	)	O
and	CC	O
to	TO	O
avoid	VB	O
alcohol	NN	O
on	IN	O
the	DT	O
day	NN	O
before	IN	O
colonoscopy	NN	O
until	IN	O
after	IN	O
completion	NN	O
of	IN	O
the	DT	O
colonoscopy	NN	O
.	.	O

In	IN	O
a	DT	O
patient	NN	WHO
who	WP	WHO
requires	VBZ	WHO
more	JJR	WHO
urgent	JJ	WHO
treatment	NN	WHO
of	IN	WHO
a	DT	WHO
psychiatric	JJ	WHO
condition	NN	WHO
,	,	O
other	JJ	O
interventions	NNS	O
,	,	O
including	VBG	O
hospitalization	NN	O
,	,	O
should	MD	O
be	VB	O
considered	VBN	O
(	(	O
see	VB	O
CONTRAINDICATIONS	NNP	O
)	)	O
.	.	O

Factors	NNS	O
of	IN	O
consideration	NN	O
are	VBP	O
the	DT	O
patient	NN	O
's	POS	O
age	NN	O
,	,	O
weight	NN	O
,	,	O
and	CC	O
condition	NN	O
.	.	O

Fluorouracil	NNP	O
Dose	NNP	O
Modifications	NNP	O
And	CC	O
Treatment	NNP	O
Delays	NNP	O

The	DT	O
procedures	NNS	O
below	IN	O
are	VBP	O
provided	VBN	O
as	IN	O
general	JJ	O
guidelines	NNS	O
for	IN	O
the	DT	O
preparation	NN	O
and	CC	O
reconstitution	NN	O
of	IN	O
BeneFIX	NNP	O
.	.	O

After	IN	O
removal	NN	O
of	IN	O
the	DT	O
corneal	NN	O
button	NN	O
,	,	O
the	DT	O
anterior	JJ	O
chamber	NN	O
is	VBZ	O
filled	VBN	O
with	IN	O
the	DT	O
Healon	NNP	O
OVD.The	NNP	O
donor	NN	O
graft	NN	O
can	MD	O
then	RB	O
be	VB	O
placed	VBN	O
on	IN	O
top	NN	O
of	IN	O
the	DT	O
bed	NN	O
of	IN	O
Healon	NNP	O
OVD	NNP	O
and	CC	O
sutured	VBN	O
in	IN	O
place.Additional	JJ	O
Healon	NNP	O
OVD	NNP	O
may	MD	O
be	VB	O
injected	VBN	O
to	TO	O
replace	VB	O
the	DT	O
Healon	NNP	O
OVD	NNP	O
lost	VBD	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
surgical	JJ	O
manipulation	NN	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
section	NN	O
)	)	O
.The	NN	O
Healon	NNP	O
OVD	NNP	O
has	VBZ	O
also	RB	O
been	VBN	O
used	VBN	O
in	IN	O
the	DT	O
anterior	JJ	O
chamber	NN	O
of	IN	O
the	DT	O
donor	NN	O
eye	NN	O
prior	RB	O
to	TO	O
trepanation	NN	O
to	TO	O
protect	VB	O
the	DT	O
corneal	JJ	O
endothelial	JJ	O
cells	NNS	O
of	IN	O
the	DT	O
graft5	NN	O
.	.	O

Pediatric	JJ	O
dosage	NN	O
depends	VBZ	O
upon	IN	O
the	DT	O
age	NN	O
and	CC	O
weight	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

The	DT	O
tiotropium	NN	O
formulation	NN	O
is	VBZ	O
dispersed	VBN	O
into	IN	O
the	DT	O
air	NN	O
stream	NN	O
when	WRB	O
the	DT	O
patient	NN	O
inhales	VBZ	O
through	IN	O
the	DT	O
mouthpiece	NN	O
[	NNP	O
see	VBP	O
PATIENT	NNP	O
INFORMATION	NNP	O
]	NN	O

Doses	NNS	O
of	IN	O
active	JJ	O
forms	NNS	O
of	IN	O
vitamin	NN	O
D	NNP	O
and	CC	O
calcium	NN	O
supplements	NNS	O
will	MD	O
need	VB	O
to	TO	O
be	VB	O
adjusted	VBN	O
when	WRB	O
using	VBG	O
NATPARA	NNP	O
.	.	O

Mircera	NNP	O
contains	VBZ	O
no	DT	O
preservatives	NNS	O
.	.	O

The	DT	O
dosage	NN	O
guideline	NN	O
for	IN	O
the	DT	O
testosterone	NN	O
pellets	NNS	O
for	IN	O
replacement	NN	O
therapy	NN	O
in	IN	O
androgendeficient	JJ	O
males	NNS	O
is	VBZ	O
150mg	CD	DOS
to	TO	O
450mg	CD	DOS
subcutaneously	RB	FREQ
every	DT	FREQ
3	CD	FREQ
to	TO	O
6	CD	FREQ
months	NNS	FREQ
.	.	O

ATACAND	NN	O
may	MD	O
be	VB	O
administered	VBN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

NOTE	NN	O
:	:	O
Treatment	NN	O
with	IN	O
the	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
usually	RB	O
given	VBN	O
at	IN	O
a	DT	O
single	JJ	O
session	NN	O
using	VBG	O
multiple	JJ	O
IM	NNP	O
sites	NNS	O
when	WRB	O
indicated	VBN	O
.	.	O

For	IN	O
NCI	NNP	O
CTCAE	NNP	O
Grade	NNP	O
3	CD	O
-	:	O
4	CD	O
diarrhea	NN	O
(	(	O
increase	NN	O
of	IN	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
7	CD	DOS
stools	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
over	IN	O
baseline	NN	O
/	NNP	O
pretreatment	NN	O
)	)	O
,	,	O
withhold	JJ	O
BOSULIF	NNP	O
until	IN	O
recovery	NN	O
to	TO	O
Grade	NNP	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
1	CD	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
after	IN	O
expiration	NN	O
date	NN	O
.	.	O

As	IN	O
with	IN	O
all	DT	O
intravenous	JJ	O
fluid	NN	O
therapy	NN	O
,	,	O
the	DT	O
goal	NN	O
is	VBZ	O
to	TO	O
provide	VB	O
adequate	JJ	O
water	NN	O
to	TO	O
compensate	VB	O
for	IN	O
insensible	JJ	O
,	,	O
urinary	JJ	O
and	CC	O
other	JJ	O
losses	NNS	O
,	,	O
and	CC	O
electrolytes	VBZ	O
for	IN	O
replacement	NN	O
and	CC	O
maintenance	NN	O
.	.	O

Evamist	NN	O
should	MD	O
not	RB	O
be	VB	O
applied	VBN	O
to	TO	O
skin	VB	O
surfaces	NNS	O
other	JJ	O
than	IN	O
the	DT	O
forearm	NN	O
.	.	O

Depacon	NNP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
physically	RB	O
compatible	JJ	O
and	CC	O
chemically	RB	O
stable	JJ	O
in	IN	O
the	DT	O
following	JJ	O
parenteral	JJ	O
solutions	NNS	O
for	IN	O
at	IN	O
least	JJS	O
24	CD	O
hours	NNS	O
when	WRB	O
stored	VBN	O
in	IN	O
glass	NN	O
or	CC	O
polyvinyl	NN	O
chloride	NN	O
(	(	O
PVC	NNP	O
)	)	O
bags	NN	O
at	IN	O
controlled	JJ	O
room	NN	O
temperature	NN	O
15	CD	O
-	:	O
30°C	CD	O
(	(	O
59	CD	O
-	:	O
86°F	CD	O
)	)	O
.	.	O

The	DT	O
dosage	NN	O
to	TO	O
provide	VB	O
relaxation	NN	O
for	IN	O
intubation	NN	O
and	CC	O
operation	NN	O
is	VBZ	O
the	DT	O
same	JJ	O
as	IN	O
for	IN	O
general	JJ	O
surgical	JJ	O
procedures	NNS	O
.	.	O

Primary	JJ	O
syphilis	NNS	O
:	:	O
30	CD	DOS
to	TO	O
40	CD	DOS
g	NNS	UNIT
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
10	CD	PER
to	TO	O
15	CD	PER
days	NNS	PER
.	.	O

CAYSTON	NNP	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
with	IN	O
any	DT	O
other	JJ	O
nebulizer	NN	O
.	.	O

Many	JJ	O
radiopaque	NN	O
contrast	NN	O
agents	NNS	O
are	VBP	O
incompatible	JJ	O
in	IN	O
vitro	NN	WHO
with	IN	WHO
some	DT	WHO
antihistamines	NNS	WHO
and	CC	O
many	JJ	O
other	JJ	O
drugs	NNS	O
;	:	O
therefore	RB	O
,	,	O
concurrent	JJ	O
drugs	NNS	O
should	MD	O
not	RB	O
be	VB	O
physically	RB	O
admixed	JJ	O
with	IN	O
contrast	NN	O
agents	NNS	O
.	.	O

(	(	O
See	VB	O
ADVERSE	NNP	O
REACTIONS	NNP	O
.	.	O
)	)	O

For	IN	O
the	DT	O
short	JJ	O
-	:	O
term	NN	O
(	(	O
generally	RB	O
less	JJR	O
than	IN	O
10	CD	O
days	NNS	O
)	)	O
management	NN	O
of	IN	O
acute	NN	O
pain	NN	O
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
VICOPROFEN	NNP	O
(	(	O
hydrocodone	NN	O
and	CC	O
ibuprofen	NN	O
)	)	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
,	,	O
as	IN	O
necessary	JJ	O
.	.	O

For	IN	O
topical	JJ	O
ophthalmic	JJ	O
use	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
a	DT	O
PRP	NNP	O
-	:	O
OMPC	NNP	O
-	:	O
containing	VBG	O
product	NN	O
,	,	O
COMVAX	NNP	O
[	NNP	O
Haemophilus	NNP	O
b	NN	O
Conjugate	NNP	O
(	(	O
Meningococcal	NNP	O
Protein	NNP	O
Conjugate	NNP	O
)	)	O
and	CC	O
Hepatitis	NNP	O
B	NNP	O
(	(	O
Recombinant	NNP	O
)	)	O
Vaccine	NNP	O
]	NNP	O
,	,	O
was	VBD	O
given	VBN	O
concomitantly	RB	O
with	IN	O
a	DT	O
booster	NN	O
dose	NN	O
of	IN	O
DTaP	NNP	O
[	NNP	O
diphtheria	NN	O
,	,	O
tetanus	NN	O
,	,	O
acellular	JJ	O
pertussis	NN	O
]	NN	O
at	IN	O
approximately	RB	O
15	CD	O
months	NNS	O
of	IN	O
age	NN	O
,	,	O
using	VBG	O
separate	JJ	O
sites	NNS	O
and	CC	O
syringes	NNS	O
for	IN	O
injectable	JJ	O
vaccines	NNS	O
.	.	O

Venofer	NN	O
should	MD	O
be	VB	O
administered	VBN	O
early	RB	O
during	IN	O
the	DT	O
dialysis	NN	O
session	NN	O
.	.	O

Urinary	JJ	O
Tract	NNP	O
Infections	NNS	O
:	:	O
For	IN	O
uncomplicated	JJ	O
lower	JJR	O
urinary	JJ	O
tract	NN	O
infections	NNS	O
(	(	O
i.e	NN	O
,	,	O
cystitis	NN	O
)	)	O
the	DT	O
usual	JJ	O
dosage	NN	O
is	VBZ	O
1	CD	DOS
or	CC	O
2	CD	DOS
g	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
in	IN	O
a	DT	O
single	JJ	O
(	(	O
q.d	JJ	O
.	.	O
)	)	O

The	DT	O
area	NN	O
where	WRB	O
the	DT	O
cream	NN	O
has	VBZ	O
been	VBN	O
applied	VBN	O
should	MD	O
then	RB	O
be	VB	O
covered	VBN	O
with	IN	O
an	DT	O
occlusive	JJ	O
,	,	O
non	JJ	O
-	:	O
absorbent	NN	O
dressing	VBG	O
for	IN	O
3	CD	PER
hours	NNS	PER
.	.	O

The	DT	O
levoleucovorin	JJ	O
injection	NN	O
dose	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
or	CC	O
rescue	NN	O
extended	VBN	O
based	VBN	O
on	IN	O
the	DT	O
following	JJ	O
guidelines	NNS	O
.	.	O

Inspect	VB	O
the	DT	O
DaTscan	NNP	O
vial	JJ	O
prior	RB	O
to	TO	O
administration	NN	O
and	CC	O
do	VBP	O
not	RB	O
use	VB	O
it	PRP	O
if	IN	O
the	DT	O
vial	JJ	O
contains	NNS	O
particulate	VBP	O
matter	NN	O
or	CC	O
discoloration	NN	O
[	NNS	O
see	VBP	O
DESCRIPTION	NNP	O
]	NNP	O
.	.	O

Take	VB	O
TAFINLAR	NN	O
at	IN	O
least	JJS	O
1	CD	O
hour	NN	O
before	IN	O
or	CC	O
2	CD	O
hours	NNS	O
after	IN	O
a	DT	O
meal	NN	O
[	NN	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Table	JJ	O
3	CD	O
:	:	O
Storage	NN	O
of	IN	O
Cyclophosphamide	NNP	O
Solutions	NNP	O

If	IN	O
either	DT	O
of	IN	O
these	DT	O
conditions	NNS	O
exists	NNS	O
,	,	O
the	DT	O
vaccine	NN	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
.	.	O

If	IN	O
ganglionic	JJ	O
blockers	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
discontinued	VBN	O
before	IN	O
Ismelin	NNP	O
(	(	O
guanethidine	JJ	O
monosulfate	NN	O
)	)	O
is	VBZ	O
started	VBN	O
,	,	O
they	PRP	O
should	MD	O
be	VB	O
gradually	RB	O
withdrawn	VBN	O
to	TO	O
prevent	VB	O
a	DT	O
spiking	JJ	O
blood	NN	O
pressure	NN	O
response	NN	O
during	IN	O
the	DT	O
transfer	NN	O
period	NN	O
.	.	O

There	EX	O
is	VBZ	O
great	JJ	O
inter	JJ	O
-	:	O
individual	JJ	O
variation	NN	O
in	IN	O
response	NN	O
to	TO	O
enzymes	NNS	O
;	:	O
thus	RB	O
,	,	O
a	DT	O
range	NN	O
of	IN	O
doses	NNS	O
is	VBZ	O
recommended	VBN	O
.	.	O

Calculation	NN	O
of	IN	O
the	DT	O
dose	NN	O
for	IN	O
a	DT	O
70	CD	WHO
kg	NN	WHO
patient	NN	WHO
would	MD	O
be	VB	O
performed	VBN	O
as	IN	O
follows	VBZ	O
:	:	O

When	WRB	O
therapy	NN	O
with	IN	O
Mysoline	NNP	O
alone	RB	O
is	VBZ	O
the	DT	O
objective	NN	O
,	,	O
the	DT	O
transition	NN	O
from	IN	O
concomitant	JJ	O
therapy	NN	O
should	MD	O
not	RB	O
be	VB	O
completed	VBN	O
in	IN	O
less	JJR	O
than	IN	O
two	CD	PER
weeks	NNS	PER
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
if	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
/	NN	O
or	CC	O
discoloration	NN	O
is	VBZ	O
observed	VBN	O
.	.	O

Serum	NNP	O
concentrations	NNS	O
of	IN	O
caffeine	NN	O
may	MD	O
need	VB	O
to	TO	O
be	VB	O
monitored	VBN	O
periodically	RB	O
throughout	IN	O
treatment	NN	O
to	TO	O
avoid	VB	O
toxicity	NN	O
.	.	O

Two	CD	DOS
doses	VBZ	UNIT
a	DT	FREQ
day	NN	FREQ
are	VBP	O
preferred	VBN	O
to	TO	O
one	CD	O
in	IN	O
order	NN	O
to	TO	O
maintain	VB	O
as	IN	O
smooth	PDT	O
a	DT	O
diurnal	JJ	O
tension	NN	O
curve	NN	O
as	IN	O
possible	JJ	O
,	,	O
although	IN	O
a	DT	O
single	JJ	DOS
dose	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
or	CC	O
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
has	VBZ	O
been	VBN	O
used	VBN	O
with	IN	O
satisfactory	JJ	WHO
results	NNS	WHO
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
caged	JJ	WHO
ball	NN	WHO
or	CC	O
caged	VBN	O
disk	NN	O
valves	NNS	O
,	,	O
a	DT	O
target	NN	O
INR	NNP	O
of	IN	O
3.0	CD	O
(	(	O
range	NN	O
,	,	O
2.5	CD	DOS
to	TO	O
3.5	CD	O
)	)	O
in	IN	O
combination	NN	O
with	IN	O
aspirin	NN	O
,	,	O
75	CD	DOS
to	TO	O
100	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
is	VBZ	O
recommended	VBN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
2,400	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
showed	VBD	O
slightly	RB	O
greater	JJR	O
efficacy	NN	O
than	IN	O
1,200	CD	DOS
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
,	,	O
but	CC	O
was	VBD	O
associated	VBN	O
with	IN	O
an	DT	O
increase	NN	O
in	IN	O
adverse	JJ	O
reactions	NNS	O
.	.	O

The	DT	O
following	JJ	O
table	NN	O
provides	VBZ	O
acceptable	JJ	O
weight	NN	O
ranges	VBZ	O
for	IN	O
each	DT	O
dose	NN	O
and	CC	O
age	NN	O
category	NN	O
,	,	O
such	JJ	O
that	IN	O
patients	NNS	O
will	MD	O
receive	VB	O
between	IN	O
90	CD	O
%	NN	O
and	CC	O
180	CD	O
%	NN	O
of	IN	O
the	DT	O
calculated	JJ	O
recommended	VBD	O
dose	NN	O
.	.	O

Children	NNS	WHO
who	WP	O
receive	VBP	O
one	CD	DOS
dose	NN	UNIT
of	IN	O
hepatitis	NN	O
B	NNP	O
vaccine	NN	O
at	IN	O
or	CC	O
shortly	RB	O
after	IN	O
birth	NN	O
may	MD	O
be	VB	O
administered	VBN	O
COMVAX	NNP	O
on	IN	O
the	DT	O
schedule	NN	O
of	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
and	CC	O
12	CD	O
-	:	O
15	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

Patients	NNS	WHO
whose	WP$	WHO
arrhythmias	NNS	WHO
have	VBP	O
been	VBN	O
suppressed	VBN	O
by	IN	O
Cordarone	NNP	O
I.V	NNP	O
.	.	O

For	IN	O
patients	NNS	WHO
on	IN	WHO
APTIOM	NNP	WHO
monotherapy	NN	WHO
,	,	O
the	DT	O
800	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
maintenance	NN	O
dose	NN	O
should	MD	O
generally	RB	O
be	VB	O
considered	VBN	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
unable	JJ	WHO
to	TO	O
tolerate	VB	O
a	DT	O
1200	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
dose	NN	O
.	.	O

When	WRB	O
the	DT	O
coadministered	VBN	O
CYP3A4	NNP	O
inducer	NN	O
is	VBZ	O
withdrawn	VBN	O
,	,	O
aripiprazole	JJ	O
dosage	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
to	TO	O
the	DT	O
original	JJ	O
level	NN	O
over	IN	O
1	CD	PER
to	TO	O
2	CD	PER
weeks	NNS	PER
.	.	O

However	RB	O
,	,	O
the	DT	O
manufacturer	NN	O
of	IN	O
Caffeine	NNP	O
Sodium	NNP	O
Benzoate	NNP	O
Injection	NNP	O
recommends	VBZ	O
intramuscular	JJ	O
,	,	O
or	CC	O
in	IN	O
emergency	NN	O
respiratory	NN	O
failure	NN	O
,	,	O
intravenous	JJ	O
injection	NN	O
of	IN	O
500	CD	DOS
mg	NN	UNIT
of	IN	O
the	DT	O
drug	NN	O
(	(	O
about	IN	O
250	CD	DOS
mg	NNS	UNIT
of	IN	O
anhydrous	JJ	O
caffeine	NN	O
)	)	O
or	CC	O
a	DT	O
maximum	JJ	O
single	JJ	DOS
dose	NN	UNIT
of	IN	O
1	CD	DOS
gram	NN	UNIT
(	(	O
about	IN	O
500	CD	DOS
mg	NNS	UNIT
of	IN	O
anhydrous	JJ	O
caffeine	NN	O
)	)	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
respiratory	JJ	O
depression	NN	O
associated	VBN	O
with	IN	O
overdosage	NN	O
of	IN	O
CNS	NNP	O
depressants	NNS	O
,	,	O
including	VBG	O
narcotic	JJ	O
analgesics	NNS	O
and	CC	O
alcohol	NN	O
,	,	O
and	CC	O
with	IN	O
electric	JJ	O
shock	NN	O
.	.	O

The	DT	O
recommended	JJ	O
oral	JJ	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
8	CD	DOS
mg	NN	UNIT
ondansetron	NN	O
hydrochloride	NN	O
tablet	NN	O
given	VBN	O
3	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

If	IN	O
flushing	NN	O
or	CC	O
nausea	NN	O
occur	VBP	O
during	IN	O
administration	NN	O
,	,	O
injection	NN	O
should	MD	O
be	VB	O
slowed	VBN	O
or	CC	O
briefly	VBN	O
interrupted	VBN	O
until	IN	O
the	DT	O
side	NN	O
effects	NNS	O
have	VBP	O
disappeared	VBN	O
.	.	O

Monitor	NNP	O
appropriately	RB	O
[	VBD	O
see	JJ	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

When	WRB	O
prolonged	JJ	O
enhancement	NN	O
is	VBZ	O
required	VBN	O
up	RB	O
to	TO	O
150	CD	DOS
mL	NNS	UNIT
can	MD	O
be	VB	O
used	VBN	O
,	,	O
usually	RB	O
with	IN	O
25	CD	DOS
-	:	O
50	CD	DOS
mL	NN	UNIT
as	IN	O
a	DT	O
rapid	JJ	O
bolus	NN	O
and	CC	O
the	DT	O
remainder	NN	O
as	IN	O
an	DT	O
infusion	NN	O
.	.	O

In	IN	O
such	JJ	WHO
patients	NNS	WHO
,	,	O
a	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
8	CD	DOS
mg	NNS	UNIT
should	MD	O
not	RB	O
be	VB	O
exceeded	VBN	O
.	.	O

3	CD	O
.	.	O

Add	NNP	O
remainder	NN	O
of	IN	O
the	DT	O
water	NN	O
and	CC	O
again	RB	O
shake	VB	O
vigorously	RB	O
.	.	O

Treatment	NN	O
with	IN	O
parenteral	JJ	O
nutrition	NN	O
may	MD	O
be	VB	O
continued	VBN	O
for	IN	O
as	RB	O
long	JJ	O
as	IN	O
is	VBZ	O
required	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
condition	NN	O
.	.	O

Taking	VBG	O
this	DT	O
product	NN	O
without	IN	O
enough	JJ	O
liquid	NN	O
may	MD	O
cause	VB	O
choking	NN	O
.	.	O

Use	VB	O
the	DT	O
lowest	JJS	O
effective	JJ	O
dosage	NN	O
for	IN	O
the	DT	O
shortest	JJS	O
duration	NN	O
consistent	NN	O
with	IN	O
individual	JJ	O
patient	NN	O
treatment	NN	O
goals	NNS	O
[	VBP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Alglucosidase	NNP	O
alfa	NN	O
does	VBZ	O
not	RB	O
contain	VB	O
any	DT	O
preservatives	NNS	O
.	.	O

Any	DT	O
time	NN	O
the	DT	O
patient	NN	O
misses	VBZ	O
two	CD	DOS
or	CC	O
more	JJR	O
light	JJ	O
-	:	O
orange	NN	O
tablets	NNS	O
,	,	O
she	PRP	O
should	MD	O
also	RB	O
use	VB	O
another	DT	O
method	NN	O
of	IN	O
contraception	NN	O
until	IN	O
she	PRP	O
has	VBZ	O
taken	VBN	O
a	DT	O
light	JJ	O
-	:	O
orange	NN	O
tablet	NN	O
daily	RB	FREQ
for	IN	O
seven	CD	PER
consecutive	JJ	PER
days	NNS	PER
.	.	O

The	DT	O
initial	JJ	O
rate	NN	O
of	IN	O
infusion	NN	O
of	IN	O
the	DT	O
nutrient	JJ	O
admixture	NN	O
in	IN	O
older	JJR	WHO
pediatric	JJ	WHO
patients	NNS	WHO
should	MD	O
be	VB	O
no	RB	O
more	JJR	O
than	IN	O
0.01	CD	DOS
g	JJ	UNIT
fat	JJ	O
/	NNP	O
minute	NN	O
for	IN	O
the	DT	O
first	JJ	O
10	CD	O
to	TO	O
15	CD	O
minutes	NNS	O
.	.	O

WESTCORT	NNP	O
Ointment	NNP	O
(	(	O
hydrocortisone	NN	O
valerate	NN	O
ointment	NN	O
)	)	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
with	IN	O
occlusive	JJ	O
dressings	NNS	O
unless	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

Consider	VB	O
reducing	VBG	O
dose	NN	O
and	CC	O
/	NN	O
or	CC	O
frequency	NN	O
of	IN	O
APLENZIN	NNP	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
Glomerular	JJ	O
filtration	NN	O
rate	NN	O
<	$	O
90	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
,	,	O
[	NNP	O
see	VBP	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Due	JJ	O
to	TO	O
the	DT	O
need	NN	O
for	IN	O
co	JJ	O
-	:	O
administration	NN	O
of	IN	O
APTIVUS	NNP	O
with	IN	O
ritonavir	NN	O
,	,	O
please	VB	O
refer	NN	O
to	TO	O
the	DT	O
ritonavir	NN	O
prescribing	VBG	O
information	NN	O
.	.	O

If	IN	O
an	DT	O
infection	NN	O
develops	VBZ	O
,	,	O
the	DT	O
use	NN	O
of	IN	O
occlusive	JJ	O
dressings	NNS	O
should	MD	O
be	VB	O
discontinued	VBN	O
and	CC	O
appropriate	JJ	O
antimicrobial	JJ	O
therapy	NN	O
instituted	VBN	O
.	.	O

Hepatic	JJ	O
Coma	NNP	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
infections	NNS	WHO
who	WP	O
would	MD	O
normally	RB	O
receive	VB	O
6	CD	DOS
grams	NNS	UNIT
of	IN	O
FORTAZ	NNP	O
daily	RB	FREQ
were	VBD	O
it	PRP	O
not	RB	O
for	IN	O
renal	JJ	O
insufficiency	NN	O
,	,	O
the	DT	O
unit	NN	O
dose	VB	O
given	VBN	O
in	IN	O
the	DT	O
table	NN	O
above	NN	O
may	MD	O
be	VB	O
increased	VBN	O
by	IN	O
50	CD	O
%	NN	O
or	CC	O
the	DT	O
dosing	JJ	O
frequency	NN	O
may	MD	O
be	VB	O
increased	VBN	O
appropriately	RB	O
.	.	O

To	TO	O
prevent	VB	O
the	DT	O
transmission	NN	O
of	IN	O
hepatitis	NN	O
viruses	NNS	O
or	CC	O
other	JJ	O
infectious	JJ	O
agents	NNS	O
from	IN	O
one	CD	O
person	NN	O
to	TO	O
another	DT	O
,	,	O
sterile	JJ	O
disposable	JJ	O
syringes	NNS	O
and	CC	O
needles	NNS	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

SUTENT	NNP	O
may	MD	O
be	VB	O
taken	VBN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

The	DT	O
lowest	JJS	O
effective	JJ	O
dose	NN	O
was	VBD	O
4	CD	DOS
mg	NN	UNIT
/	VBD	O
24	CD	O
hours	NNS	O
.	.	O

Subjects	NNS	O
who	WP	O
demonstrate	VBP	O
hyperreactivity	NN	O
to	TO	O
this	DT	O
injection	NN	O
(	(	O
cholinergic	JJ	O
reaction	NN	O
)	)	O
,	,	O
should	MD	O
be	VB	O
retested	VBN	O
after	IN	O
one	CD	O
-	:	O
half	NN	O
hour	NN	O
with	IN	O
0.2	CD	DOS
mL	NNS	UNIT
(	(	O
2mg	CD	O
)	)	O
of	IN	O
Enlon	NNP	O
(	(	O
edrophonium	JJ	O
injection	NN	O
)	)	O
®	VBZ	O
intramuscularly	JJ	O
to	TO	O
rule	VB	O
out	RP	O
false	JJ	O
-	:	O
negative	JJ	O
reactions	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
maximum	JJ	O
dosage	NN	O
of	IN	O
JUXTAPID	NNP	O
is	VBZ	O
30	CD	DOS
mg	JJ	UNIT
daily	JJ	FREQ
with	IN	O
concomitant	JJ	O
use	NN	O
of	IN	O
weak	JJ	O
CYP3A4	NNP	O
inhibit	NN	O
ors	NNS	O
(	(	O
such	JJ	O
as	IN	O
alprazolam	NN	O
,	,	O
amiodarone	NN	O
,	,	O
amlodipine	NN	O
,	,	O
atorvastatin	NN	O
,	,	O
bicalutamide	NN	O
,	,	O
cilostazol	NN	O
,	,	O
cimetidine	NN	O
,	,	O
cyclosporine	NN	O
,	,	O
fluoxetine	NN	O
,	,	O
fluvoxamine	NN	O
,	,	O
ginkgo	NN	O
,	,	O
goldenseal	NN	O
,	,	O
isoniazid	NN	O
,	,	O
lapatinib	NN	O
,	,	O
nilotinib	RB	O
,	,	O
pazopanib	NN	O
,	,	O
ranitidine	NN	O
,	,	O
ranolazine	NN	O
,	,	O
ticagrelor	NN	O
,	,	O
zileuton	NN	O
)	)	O
.	.	O

JUVISYNC	NNP	O
must	MD	O
not	RB	O
be	VB	O
split	VBN	O
or	CC	O
divided	VBN	O
before	IN	O
swallowing	NN	O
.	.	O

Doses	NNS	O
above	IN	O
400	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
600	CD	DOS
,	,	O
800	CD	DOS
or	CC	O
1,000	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
)	)	O
have	VBP	O
not	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
improve	VB	O
responses	NNS	O
in	IN	O
dose	JJ	O
-	:	O
response	NN	O
studies	NNS	O
in	IN	O
adults	NNS	WHO
with	IN	O
partial	JJ	O
onset	NN	O
seizures	NNS	O
.	.	O

Administer	NNP	O
the	DT	O
following	VBG	O
dosing	NN	O
regimens	NNS	O
for	IN	O
KEFLEX	NNP	O
to	TO	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
renal	JJ	WHO
function	NN	WHO
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
when	WRB	O
administering	VBG	O
LEVOXYL	NNP	O
to	TO	O
patients	NNS	WHO
with	IN	WHO
underlying	JJ	WHO
cardiovascular	JJ	WHO
disease	NN	WHO
,	,	O
to	TO	O
the	DT	O
elderly	JJ	O
,	,	O
and	CC	O
to	TO	O
those	DT	O
with	IN	O
concomitant	JJ	O
adrenal	JJ	O
insufficiency	NN	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

Before	IN	O
administering	VBG	O
a	DT	O
dose	NN	O
of	IN	O
vaccine	NN	O
,	,	O
shake	VB	O
the	DT	O
prefilled	JJ	O
syringe	NN	O
or	CC	O
multi	VB	O
-	:	O
dose	JJ	O
vial	NN	O
.	.	O

CYCLOCORT®	NNP	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
for	IN	O
longer	JJR	O
than	IN	O
5	CD	O
days	NNS	O
on	IN	O
the	DT	O
face	NN	O
,	,	O
axillae	NN	O
,	,	O
scrotum	NN	O
and	CC	O
scalp	NN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

Only	JJ	O
persons	NNS	O
trained	VBN	O
in	IN	O
the	DT	O
administration	NN	O
of	IN	O
general	JJ	O
anesthesia	NN	O
should	MD	O
administer	VB	O
SUPRANE	NNP	O
.	.	O

A	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
3	CD	DOS
mg	NN	UNIT
of	IN	O
GLYNASE	NNP	O
PresTab	NNP	O
Tablets	NNP	O
provides	VBZ	O
approximately	RB	O
the	DT	O
same	JJ	O
degree	NN	O
of	IN	O
blood	NN	O
glucose	NN	O
control	NN	O
as	IN	O
250	CD	DOS
to	TO	O
375	CD	DOS
mg	NNS	UNIT
chlorpropamide	RB	O
,	,	O
250	CD	DOS
to	TO	O
375	CD	DOS
mg	NNS	UNIT
tolazamide	RB	O
,	,	O
5	CD	DOS
mg	NN	UNIT
of	IN	O
glyburide	NN	O
(	(	O
nonmicronized	JJ	O
tablets	NNS	O
)	)	O
,	,	O
500	CD	DOS
to	TO	O
750	CD	DOS
mg	NNS	UNIT
acetohexamide	RB	O
,	,	O
or	CC	O
1000	CD	DOS
to	TO	O
1500	CD	DOS
mg	NN	UNIT
tolbutamide	NN	O
.	.	O

A	DT	O
suggested	JJ	O
dosing	NN	O
schedule	NN	O
of	IN	O
approximately	RB	O
4	CD	O
-	:	O
hour	NN	O
intervals	NNS	O
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O
shortly	RB	O
before	IN	O
,	,	O
or	CC	O
upon	IN	O
arising	VBG	O
in	IN	O
the	DT	O
morning	NN	O
,	,	O
midday	NN	O
and	CC	O
late	JJ	O
afternoon	NN	O
(	(	O
not	RB	O
later	RB	O
than	IN	O
6	CD	O
P.M.	NNP	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
SALAGEN®	NNP	O
Tablets	NNP	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
taken	VBN	O
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Guidelines	NNS	O
for	IN	O
Fusilev	NNP	O
Dosage	NNP	O
and	CC	O
Administration	NNP	O

Withdraw	IN	O
the	DT	O
contents	NNS	O
from	IN	O
one	CD	O
reconstituted	VBN	O
vial	NN	O
and	CC	O
add	VB	O
to	TO	O
one	CD	DOS
250	CD	DOS
mL	NN	UNIT
saline	NN	O
bag	NN	O
.	.	O

If	IN	O
available	JJ	O
,	,	O
measurements	NNS	O
of	IN	O
the	DT	O
plasma	NN	O
PAA	NNP	O
levels	NNS	O
may	MD	O
be	VB	O
useful	JJ	O
to	TO	O
guide	VB	O
dosing	VBG	O
if	IN	O
symptoms	NNS	O
of	IN	O
vomiting	VBG	O
,	,	O
nausea	NN	O
,	,	O
headache	NN	O
,	,	O
somnolence	NN	O
,	,	O
confusion	NN	O
,	,	O
or	CC	O
sleepiness	NN	O
are	VBP	O
present	JJ	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
high	JJ	O
ammonia	NN	O
or	CC	O
intercurrent	JJ	O
illness	NN	O
.	.	O

Slide	NNP	O
safety	NN	O
guard	NN	O
over	IN	O
needle	JJ	O
.	.	O

The	DT	O
volume	NN	O
of	IN	O
the	DT	O
total	JJ	O
dose	NN	O
and	CC	O
the	DT	O
rate	NN	O
of	IN	O
infusion	NN	O
depends	VBZ	O
on	IN	O
the	DT	O
patient	NN	O
's	POS	O
condition	NN	O
and	CC	O
response	NN	O
.	.	O

Dosage	NN	O
Calculation	NNP	O
Table	NNP	O

In	IN	O
the	DT	O
study	NN	O
of	IN	O
primary	JJ	O
generalized	VBN	O
tonic	JJ	O
-	:	O
clonic	NN	O
seizures	NNS	O
,	,	O
the	DT	O
initial	JJ	O
titration	NN	O
rate	NN	O
was	VBD	O
slower	JJR	O
than	IN	O
in	IN	O
previous	JJ	O
studies	NNS	O
;	:	O
the	DT	O
assigned	VBN	O
dose	NN	O
of	IN	O
6	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
was	VBD	O
reached	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
8	CD	PER
weeks	NNS	PER
[	JJ	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

They	PRP	O
may	MD	O
be	VB	O
swallowed	VBN	O
with	IN	O
saliva	NN	O
.	.	O

For	IN	O
HCV	NNP	WHO
genotype	NN	WHO
1	CD	WHO
or	CC	WHO
3	CD	WHO
patients	NNS	WHO
with	IN	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NN	WHO
B	NNP	WHO
or	CC	WHO
C	NNP	WHO
cirrhosis	NN	WHO
or	CC	WHO
post	NN	WHO
-	:	WHO
transplantation	NN	WHO
patients	NNS	WHO
,	,	O
the	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
ribavirin	NN	O
is	VBZ	O
600	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
,	,	O
increasing	VBG	O
up	RP	O
to	TO	O
1000	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
as	IN	O
tolerated	VBN	O
.	.	O

To	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
neural	JJ	O
or	CC	O
vascular	JJ	O
injury	NN	O
,	,	O
the	DT	O
implant	NN	O
should	MD	O
be	VB	O
inserted	VBN	O
at	IN	O
the	DT	O
inner	JJ	O
side	NN	O
of	IN	O
the	DT	O
non	JJ	O
-	:	O
dominant	JJ	O
upper	JJ	O
arm	NN	O
about	IN	O
8	CD	DOS
-	:	O
10	CD	DOS
cm	NN	UNIT
(	(	O
3	CD	DOS
-	:	O
4	CD	O
inches	NNS	O
)	)	O
above	IN	O
the	DT	O
medial	JJ	O
epicondyle	NN	O
of	IN	O
the	DT	O
humerus	NN	O
.	.	O

HYLENEX	NNP	O
recombinant	NN	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
intravenously	RB	O
.	.	O

The	DT	O
total	JJ	O
volume	NN	O
of	IN	O
infusion	NN	O
is	VBZ	O
determined	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
body	NN	O
weight	NN	O
and	CC	O
should	MD	O
be	VB	O
administered	VBN	O
over	IN	O
approximately	RB	O
4	CD	O
hours	NNS	O
.	.	O

WARNING	NN	O
:	:	O
Do	NNP	O
not	RB	O
use	VB	O
flexible	JJ	O
container	NN	O
in	IN	O
series	NN	O
connections	NNS	O
.	.	O

For	IN	O
adults	NNS	WHO
with	IN	WHO
uncomplicated	JJ	WHO
urethral	JJ	WHO
,	,	O
endocervical	JJ	O
,	,	O
or	CC	O
rectal	JJ	O
infections	NNS	O
caused	VBN	O
by	IN	O
Chlamydia	NNP	O
trachomatis	NN	O
,	,	O
when	WRB	O
tetracycline	NN	O
is	VBZ	O
contraindicated	VBN	O
or	CC	O
not	RB	O
tolerated	VBN	O
:	:	O
500	CD	DOS
mg	NN	UNIT
of	IN	O
erythromycin	NN	O
by	IN	O
mouth	NN	O
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
or	CC	O
two	CD	DOS
333	CD	DOS
mg	NNS	UNIT
tablets	NNS	UNIT
orally	RB	O
every	DT	FREQ
8	CD	FREQ
hours	NNS	FREQ
for	IN	O
at	IN	O
least	JJS	O
7	CD	O
days.5	NN	O

SORILUX	NNP	O
(	(	O
calcipotriene	JJ	O
foam	NN	O
)	)	O
Foam	NNP	O
is	VBZ	O
not	RB	O
for	IN	O
oral	JJ	O
,	,	O
ophthalmic	JJ	O
,	,	O
or	CC	O
intravaginal	JJ	O
use	NN	O
.	.	O

[	NNS	O
see	VBP	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NN	O

4	CD	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
experience	VBP	WHO
breakthrough	IN	WHO
pain	NN	WHO
may	MD	O
require	VB	O
dosage	NN	O
adjustment	NN	O
of	IN	O
BELBUCA	NNP	O
or	CC	O
may	MD	O
need	VB	O
rescue	JJR	O
medication	NN	O
with	IN	O
an	DT	O
appropriate	JJ	O
dose	NN	O
of	IN	O
an	DT	O
immediate	JJ	O
-	:	O
release	NN	O
analgesic	JJ	O
.	.	O

Such	JJ	O
prophylaxis	NN	O
should	MD	O
be	VB	O
reserved	VBN	O
for	IN	O
patients	NNS	WHO
over	IN	WHO
the	DT	WHO
age	NN	WHO
of	IN	WHO
40	CD	WHO
who	WP	WHO
are	VBP	WHO
undergoing	VBG	WHO
major	JJ	WHO
surgery	NN	WHO
.	.	O

The	DT	O
100	CD	DOS
mg	NN	UNIT
and	CC	O
200	CD	DOS
mg	NN	UNIT
tablets	NNS	UNIT
are	VBP	O
for	IN	O
use	NN	O
in	IN	O
severe	JJ	O
neuropsychiatric	JJ	O
conditions	NNS	O
.	.	O

In	IN	O
the	DT	O
event	NN	O
of	IN	O
breakthrough	NN	O
episodes	NNS	O
of	IN	O
VF	NNP	O
or	CC	O
hemodynamically	RB	O
unstable	JJ	O
VT	NNP	O
,	,	O
use	VBP	O
150	CD	DOS
mg	NNS	UNIT
supplemental	JJ	O
infusions	NNS	O
of	IN	O
NEXTERONE	NNP	O
(	(	O
infused	VBN	O
over	IN	O
10	CD	O
minutes	NNS	O
to	TO	O
minimize	VB	O
the	DT	O
potential	NN	O
for	IN	O
hypotension	NN	O
)	)	O
.	.	O

An	DT	WHO
adult	NN	WHO
patient	NN	WHO
in	IN	WHO
an	DT	WHO
acceptable	JJ	WHO
weight	NN	WHO
range	NN	WHO
with	IN	WHO
restricted	JJ	WHO
activity	NN	WHO
who	WP	WHO
is	VBZ	WHO
not	RB	WHO
hypermetabolic	JJ	WHO
,	,	O
requires	VBZ	O
about	IN	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

VELCADE	NNP	O
dose	NN	O
(	(	O
mg	JJ	UNIT
/	NNP	O
m²	NN	O
)	)	O
x	FW	O
patient	JJ	O
BSA	NNP	O
(	(	O
m²	NN	O
)	)	O
2.5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL=	NN	O
Total	NNP	O
VELCADE	NNP	O
volume	NN	O
(	(	O
mL	NN	O
)	)	O
to	TO	O
be	VB	O
administered	VBN	O

Use	NNP	O
an	DT	O
in	IN	O
-	:	O
line	NN	O
filter	NN	O
during	IN	O
administration	NN	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
if	IN	O
the	DT	O
packaging	NN	O
or	CC	O
contents	NNS	O
have	VBP	O
been	VBN	O
damaged	VBN	O
or	CC	O
opened	VBN	O
.	.	O

Prior	RB	O
to	TO	O
treating	VBG	WHO
children	NNS	WHO
,	,	O
adolescents	NNS	O
,	,	O
and	CC	O
adults	NNS	WHO
with	IN	WHO
CNS	NNP	WHO
stimulants	NNS	WHO
,	,	O
including	VBG	O
DYANAVEL	NNP	O
XR	NNP	O
,	,	O
assess	NN	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
cardiac	JJ	O
disease	NN	O
(	(	O
i.e	JJ	O
,	,	O
perform	VB	O
a	DT	O
careful	JJ	O
history	NN	O
,	,	O
family	NN	O
history	NN	O
of	IN	O
sudden	JJ	O
death	NN	O
or	CC	O
ventricular	JJ	O
arrhythmia	NN	O
,	,	O
and	CC	O
physical	JJ	O
exam	NN	O
)	)	O
[	FW	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

10	CD	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
intramuscularly	RB	O
or	CC	O
intravenously	RB	O
.	.	O

You	PRP	O
should	MD	O
not	RB	O
take	VB	O
the	DT	O
pill	NN	O
if	IN	O
you	PRP	O
suspect	VBP	O
you	PRP	O
are	VBP	O
pregnant	JJ	O
or	CC	O
have	VBP	O
unexplained	VBN	O
vaginal	JJ	O
bleeding	NN	O
.	.	O

A	DT	O
new	JJ	O
patch	NN	O
is	VBZ	O
applied	VBN	O
each	DT	O
week	NN	PER
for	IN	O
3	CD	PER
weeks	NNS	PER
(	(	O
21	CD	O
total	JJ	O
days	NNS	O
)	)	O
.	.	O

The	DT	O
mean	JJ	O
rate	NN	O
attained	VBN	O
by	IN	O
all	DT	WHO
patients	NNS	WHO
was	VBD	O
4.3	CD	DOS
mL	NN	UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
hr	NN	O
.	.	O

When	WRB	O
the	DT	O
CYP3A4	NNP	O
inhibitor	NN	O
is	VBZ	O
withdrawn	VBN	O
from	IN	O
the	DT	O
combination	NN	O
therapy	NN	O
,	,	O
FANAPT	NNP	O
dose	NN	O
should	MD	O
be	VB	O
increased	VBN	O
to	TO	O
where	WRB	O
it	PRP	O
was	VBD	O
before	IN	O
[	JJ	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
YONDELIS	NNP	O
to	TO	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	O
bilirubin	JJ	O
levels	NNS	O
above	IN	O
3	CD	FREQ
times	NNS	FREQ
to	TO	O
10	CD	DOS
times	NNS	UNIT
the	DT	O
upper	JJ	O
limit	NN	O
of	IN	O
normal	JJ	O
,	,	O
and	CC	O
any	DT	O
AST	NNP	O
and	CC	O
ALT	NNP	O
)	)	O
[	VBD	O
see	JJ	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
ARNUITY	NNP	O
ELLIPTA	NNP	O
more	JJR	O
than	IN	O
1	CD	O
time	NN	O
every	DT	FREQ
24	CD	FREQ
hours	NNS	FREQ
.	.	O

The	DT	O
ideal	NN	O
treatment	NN	O
for	IN	O
proven	JJ	O
congenital	JJ	O
deficiency	NN	O
of	IN	O
procoagulants	NNS	O
is	VBZ	O
prophylactic	JJ	O
administration	NN	O
.	.	O

Remove	VB	O
the	DT	O
large	JJ	O
canister	NN	O
cover	NN	O
,	,	O
and	CC	O
fully	RB	O
depress	VB	O
the	DT	O
pump	NN	O
3	CD	FREQ
times	NNS	FREQ
.	.	O

PRECOSE	NNP	O
should	MD	O
be	VB	O
started	VBN	O
at	IN	O
a	DT	O
low	JJ	O
dose	NN	O
,	,	O
with	IN	O
gradual	JJ	O
dose	JJ	O
escalation	NN	O
as	IN	O
described	VBN	O
below	IN	O
,	,	O
both	DT	O
to	TO	O
reduce	VB	O
gastrointestinal	JJ	O
side	NN	O
effects	NNS	O
and	CC	O
to	TO	O
permit	VB	O
identification	NN	O
of	IN	O
the	DT	O
minimum	JJ	O
dose	NN	O
required	VBN	O
for	IN	O
adequate	JJ	O
glycemic	JJ	O
control	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

Prevnar	NNP	O
13	CD	O
is	VBZ	O
to	TO	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
four	CD	DOS
-	:	O
dose	NN	O
series	NN	O
at	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
12	CD	O
-	:	O
15	CD	O
months	NNS	O
of	IN	O
age	NN	O
.	.	O

If	IN	O
acceptable	JJ	O
alternatives	NNS	O
to	TO	O
linezolid	VB	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	JJ	O
treatment	NN	O
are	VBP	O
not	RB	O
available	JJ	O
and	CC	O
the	DT	O
potential	JJ	O
benefits	NNS	O
of	IN	O
linezolid	JJ	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	JJ	O
treatment	NN	O
are	VBP	O
judged	VBN	O
to	TO	O
outweigh	VB	O
the	DT	O
risks	NNS	O
of	IN	O
serotonin	JJ	O
syndrome	NN	O
in	IN	O
a	DT	O
particular	JJ	O
patient	NN	O
,	,	O
Savella	NNP	O
should	MD	O
be	VB	O
stopped	VBN	O
promptly	RB	O
,	,	O
and	CC	O
linezolid	VBD	O
or	CC	O
intravenous	JJ	O
methylene	NNS	O
blue	VBP	O
can	MD	O
be	VB	O
administered	VBN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

NAMENDA	NNP	O
XR	NNP	O
capsules	NNS	O
should	MD	O
not	RB	O
be	VB	O
divided	VBN	O
,	,	O
chewed	VBN	O
,	,	O
or	CC	O
crushed	VBN	O
.	.	O

4	CD	O
.	.	O

Children	NNP	WHO
with	IN	WHO
schizophrenia	NN	WHO
:	:	O

Therapy	NN	O
with	IN	O
methotrexate	NN	O
as	IN	O
a	DT	O
single	JJ	O
agent	NN	O
appears	VBZ	O
to	TO	O
produce	VB	O
clinical	JJ	O
responses	NNS	O
in	IN	O
up	IN	O
to	TO	O
50	CD	O
%	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
.	.	O

As	IN	O
with	IN	O
other	JJ	O
nonsteroidal	JJ	O
anti	SYM	O
-	:	O
inflammatory	NN	O
drugs	NNS	O
,	,	O
the	DT	O
predominant	JJ	O
adverse	JJ	O
effects	NNS	O
of	IN	O
ketoprofen	NNS	O
are	VBP	O
gastrointestinal	JJ	O
.	.	O

For	IN	O
direct	JJ	O
intermittent	NN	O
IV	NNP	O
administration	NN	O
,	,	O
reconstitute	JJ	O
Tazicef	NNP	O
as	IN	O
directed	VBN	O
in	IN	O
Table	JJ	O
7	CD	O
with	IN	O
Sterile	JJ	O
Water	NNP	O
for	IN	O
Injection	NNP	O
.	.	O

For	IN	O
patients	NNS	WHO
receiving	VBG	WHO
doses	NNS	WHO
greater	JJR	WHO
than	IN	O
4	CD	DOS
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
,	,	O
periodically	RB	O
reassess	JJ	O
treatment	NN	O
and	CC	O
consider	VB	O
a	DT	O
reduction	NN	O
of	IN	O
dosage	NN	O
.	.	O

Because	IN	O
of	IN	O
the	DT	O
serious	JJ	O
nature	NN	O
of	IN	O
the	DT	O
arrhythmia	NN	O
and	CC	O
the	DT	O
lack	NN	O
of	IN	O
predictable	JJ	O
time	NN	O
course	NN	O
of	IN	O
effect	NN	O
,	,	O
loading	VBG	O
should	MD	O
be	VB	O
performed	VBN	O
in	IN	O
a	DT	O
hospital	NN	O
setting	NN	O
.	.	O

To	TO	O
minimize	VB	O
the	DT	O
risk	NN	O
of	IN	O
dermal	JJ	O
exposure	NN	O
,	,	O
always	RB	O
wear	VBP	O
impervious	JJ	O
gloves	NNS	O
when	WRB	O
handling	VBG	O
bottles	NNS	O
containing	VBG	O
Gleostine	NNP	O
capsules	NNS	O
.	.	O

Estrogen	NNP	WHO
-	:	WHO
replete	JJ	WHO
women	NNS	WHO
may	MD	O
need	VB	O
higher	JJR	O
doses	NNS	O
than	IN	O
men	NNS	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	NN	O
matter	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
(	(	O
see	VB	O
DESCRIPTION	NNP	O
)	)	O
.	.	O

Percutaneous	JJ	O
puncture	NN	O
with	IN	O
a	DT	O
needle	JJ	O
contaminated	VBN	O
with	IN	O
blood	NN	O
can	MD	O
transmit	VB	O
infectious	JJ	O
viruses	NNS	O
including	VBG	O
HIV	NNP	O
(	(	O
AIDS	NNP	O
)	)	O
and	CC	O
hepatitis	NN	O
.	.	O

In	IN	O
the	DT	O
event	NN	O
of	IN	O
an	DT	O
incomplete	JJ	O
antileukemic	JJ	O
response	NN	O
,	,	O
a	DT	O
second	JJ	O
induction	NN	O
course	NN	O
may	MD	O
be	VB	O
given	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
VIOXX	NNP	O
is	VBZ	O
50	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
HETLIOZ	NNP	O
is	VBZ	O
20	CD	DOS
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
taken	VBN	O
before	IN	O
bedtime	NN	O
,	,	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
every	DT	FREQ
night	NN	FREQ
.	.	O

[	NNS	O
See	NNP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NN	O

The	DT	O
infusion	NN	O
duration	NN	O
may	MD	O
be	VB	O
extended	VBN	O
up	RB	O
to	TO	O
4	CD	O
hours	NNS	O
if	IN	O
acute	JJ	O
vasomotor	NN	O
reactions	NNS	O
are	VBP	O
observed	VBN	O
.	.	O

The	DT	O
resulting	JJ	O
solution	NN	O
may	MD	O
be	VB	O
stored	VBN	O
for	IN	O
up	RB	O
to	TO	O
24	CD	O
hours	NNS	O
at	IN	O
room	NN	O
temperature	NN	O
or	CC	O
up	RB	O
to	TO	O
48	CD	O
hours	NNS	O
at	IN	O
4°C	CD	O
(	(	O
40°F	CD	O
)	)	O
.	.	O

Please	NNP	O
note	NN	O
that	IN	O
the	DT	O
implant	NN	O
,	,	O
in	IN	O
its	PRP$	O
sealed	JJ	O
vial	NN	O
,	,	O
pouch	JJ	O
,	,	O
and	CC	O
carton	NN	O
,	,	O
must	MD	O
be	VB	O
kept	VBN	O
refrigerated	JJ	O
(	(	O
2	CD	O
-	:	O
8°C	CD	O
)	)	O
until	IN	O
needed	VBN	O
for	IN	O
the	DT	O
procedure	NN	O
.	.	O

There	EX	O
are	VBP	O
insufficient	JJ	O
data	NNS	O
to	TO	O
support	VB	O
this	DT	O
use	NN	O
of	IN	O
etomidate	NN	O
for	IN	O
longer	JJR	WHO
adult	NN	WHO
procedures	NNS	WHO
or	CC	O
for	IN	O
any	DT	O
procedures	NNS	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
;	:	O
therefore	RB	O
,	,	O
such	JJ	O
use	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

Monitoring	VBG	O
T	NNP	O
-	:	O
cell	NN	O
counts	NNS	O
(	(	O
absolute	NN	O
and	CC	O
/	NN	O
or	CC	O
subsets	NNS	O
)	)	O
to	TO	O
assess	VB	O
the	DT	O
level	NN	O
of	IN	O
T	NNP	O
-	:	O
cell	NN	O
depletion	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

She	PRP	O
should	MD	O
take	VB	O
one	CD	O
yellow	JJ	O
Minastrin	NNP	O
24	CD	O
Fe	NNP	O
capsule	NN	O
daily	RB	FREQ
for	IN	O
24	CD	PER
consecutive	JJ	PER
days	NNS	PER
,	,	O
followed	VBN	O
by	IN	O
one	CD	DOS
maroon	NN	UNIT
capsule	NN	UNIT
daily	RB	FREQ
on	IN	O
days	NNS	O
25	CD	O
through	IN	O
28	CD	O
.	.	O

The	DT	O
nomogram	NN	O
may	MD	O
underestimate	VB	O
the	DT	O
hepatotoxicity	NN	O
risk	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
chronic	JJ	WHO
alcoholism	NN	WHO
,	,	O
malnutrition	NN	O
,	,	O
or	CC	O
CYP2E1	NNP	O
enzyme	VBP	O
inducing	VBG	O
drugs	NNS	O
(	(	O
e.g	NN	O
,	,	O
isoniazid	NN	O
)	)	O
,	,	O
and	CC	O
consideration	NN	O
should	MD	O
be	VB	O
given	VBN	O
to	TO	O
treating	VBG	O
these	DT	O
patients	NNS	O
even	RB	O
if	IN	O
the	DT	O
acetaminophen	NN	O
concentrations	NNS	O
are	VBP	O
in	IN	O
the	DT	O
nontoxic	JJ	O
range	NN	O
.	.	O

It	PRP	O
may	MD	O
also	RB	O
be	VB	O
the	DT	O
preferred	JJ	O
route	NN	O
of	IN	O
administration	NN	O
for	IN	O
some	DT	WHO
patients	NNS	WHO
with	IN	WHO
congestive	JJ	WHO
heart	NN	WHO
failure	NN	WHO
,	,	O
hematologic	NN	O
disorders	NNS	O
,	,	O
severe	JJ	O
burns	NNS	O
,	,	O
or	CC	O
those	DT	O
with	IN	O
reduced	JJ	O
muscle	NN	O
mass	NN	O
.	.	O

Gonorrhea	NNP	WHO
patients	NNS	WHO
sensitive	JJ	WHO
to	TO	WHO
penicillin	VB	WHO
may	MD	O
be	VB	O
treated	VBN	O
with	IN	O
MINOCIN®	NNP	O
,	,	O
administered	VBD	O
as	IN	O
200	CD	DOS
mg	NN	UNIT
initially	RB	O
,	,	O
followed	VBN	O
by	IN	O
100	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
for	IN	O
a	DT	O
minimum	NN	O
of	IN	O
4	CD	PER
days	NNS	PER
,	,	O
with	IN	O
post	NN	O
-	:	O
therapy	NN	O
cultures	NNS	O
within	IN	O
2	CD	O
to	TO	O
3	CD	PER
days	NNS	PER
.	.	O

Table	JJ	O
2	CD	O
:	:	O
20	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	FW	O
per	IN	FREQ
day	NN	FREQ
Dosing	NNP	O
Table	NNP	O
for	IN	O
Infants	NNP	WHO
Weighing	NNP	WHO
10	CD	WHO
kg	NN	WHO
or	CC	WHO
less	JJR	WHO

Initiate	NNP	O
therapy	NN	O
at	IN	O
25	CD	DOS
mg	NN	UNIT
to	TO	O
50	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	JJ	FREQ
followed	VBN	O
by	IN	O
titration	NN	O
to	TO	O
an	DT	O
effective	JJ	O
dose	NN	O
in	IN	O
increments	NNS	O
of	IN	O
25	CD	DOS
mg	NNS	UNIT
to	TO	O
50	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
week	NN	FREQ
.	.	O

For	IN	O
allergic	JJ	O
rhinitis	NN	O
,	,	O
SINGULAIR	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

VELCADE	NNP	O
is	VBZ	O
an	DT	O
antineoplastic	JJ	O
.	.	O

NOTE	NN	O

Table	JJ	O
3	CD	O
:	:	O
Premedication	NN	O
for	IN	O
GAZYVA	NNP	O
Infusion	NNP	O
to	TO	O
Reduce	NNP	O
Infusion	NNP	O
-	:	O
Related	JJ	O
Reactions	NNS	O
(	(	O
IRR	NNP	O
)	)	O

From	IN	O
Week	NNP	O
3	CD	O
onwards	NNS	O
,	,	O
if	IN	O
a	DT	O
200	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
is	VBZ	O
missed	VBN	O
,	,	O
administer	VBP	O
the	DT	O
missed	JJ	O
dose	NN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
,	,	O
and	CC	O
then	RB	O
resume	VB	O
the	DT	O
3	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
week	NN	FREQ
dosing	VBG	O
regimen	NNS	O
.	.	O

Initial	JJ	O
infusion	NN	O
rates	NNS	O
should	MD	O
be	VB	O
slow	JJ	O
,	,	O
and	CC	O
gradually	RB	O
increased	VBD	O
to	TO	O
the	DT	O
recommended	VBN	O
60	CD	DOS
-	:	O
125	CD	DOS
mL	NN	UNIT
per	IN	O
kilogram	NN	O
body	NN	O
weight	JJ	O
per	IN	FREQ
day	NN	FREQ
.	.	O

Allow	VB	O
adequate	JJ	O
time	NN	O
for	IN	O
absorption	NN	O
after	IN	O
each	DT	O
application	NN	O
before	IN	O
applying	VBG	O
an	DT	O
emollient	NN	O
.	.	O

No	DT	O
initial	JJ	O
dosage	NN	O
adjustment	NN	O
is	VBZ	O
required	VBN	O
for	IN	O
elderly	JJ	WHO
patients	NNS	WHO
,	,	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
or	CC	WHO
moderate	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
or	CC	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
or	CC	WHO
moderate	JJ	WHO
liver	NN	WHO
insufficiency	NN	WHO
.	.	O

Dose	NNP	O
adjustment	NN	O
is	VBZ	O
required	VBN	O
for	IN	O
patients	NNS	WHO
whose	WP$	WHO
creatinine	JJ	WHO
clearance	NN	WHO
is	VBZ	O
50	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
or	CC	O
less	JJR	O
.	.	O

If	IN	O
only	RB	O
the	DT	O
earliest	JJS	O
manifestations	NNS	O
of	IN	O
diabetic	JJ	O
gastric	JJ	O
stasis	NN	O
are	VBP	O
present	JJ	O
,	,	O
oral	JJ	O
administration	NN	O
of	IN	O
REGLAN	NNP	O
ODT™	NNP	O
(	(	O
metoclopramide	VB	O
orally	RB	O
disintegrating	VBG	O
tablets	NNS	O
)	)	O
may	MD	O
be	VB	O
initiated	VBN	O
.	.	O

Subsequent	JJ	O
Herceptin	NNP	O
maintenance	NN	O
doses	NNS	O
(	(	O
weekly	JJ	FREQ
schedule	NN	O
:	:	O
2	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
;	:	O
three	CD	O
-	:	O
weekly	JJ	O
schedule	NN	O
6	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
7	CD	PER
days	NNS	PER
or	CC	O
21	CD	O
days	NNS	O
later	RB	O
according	VBG	O
to	TO	O
the	DT	O
weekly	JJ	FREQ
or	CC	O
three	CD	O
-	:	O
weekly	JJ	FREQ
schedules	NNS	O
,	,	O
respectively	RB	O
.	.	O

Ten	CD	DOS
units	NNS	UNIT
of	IN	O
Pitressin	NNP	O
(	(	O
0.5	CD	DOS
mL	NN	UNIT
)	)	O
will	MD	O
usually	RB	O
elicit	VB	O
full	JJ	O
physiologic	NN	O
response	NN	O
in	IN	O
adult	NN	WHO
patients	NNS	WHO
;	:	O
5	CD	DOS
units	NNS	UNIT
will	MD	O
be	VB	O
adequate	JJ	O
in	IN	O
many	JJ	O
cases	NNS	O
.	.	O

Alternatively	RB	O
,	,	O
a	DT	O
booster	NN	O
can	MD	O
be	VB	O
administered	VBN	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
a	DT	O
titer	NN	O
determination	NN	O
.	.	O

Neuromuscular	JJ	O
block	NN	O
sufficient	NN	O
for	IN	O
intubation	NN	O
(	(	O
80	CD	O
%	NN	O
block	NN	O
or	CC	O
greater	JJR	O
)	)	O
is	VBZ	O
attained	VBN	O
in	IN	O
a	DT	O
median	NN	O
(	(	O
range	NN	O
)	)	O
time	NN	O
of	IN	O
1.3	CD	O
(	(	O
0.8	CD	O
-	:	O
6.2	CD	O
)	)	O
minute	NN	O
(	(	O
s	NN	O
)	)	O
,	,	O
and	CC	O
most	JJS	O
patients	NNS	O
have	VBP	O
intubation	NN	O
completed	VBN	O
within	IN	O
2	CD	O
minutes	NNS	O
.	.	O

Infusion	NN	O
rates	NNS	O
should	MD	O
always	RB	O
be	VB	O
titrated	VBN	O
downward	RB	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
clinical	JJ	O
signs	NNS	O
of	IN	O
light	JJ	O
sedation	NN	O
until	IN	O
mild	JJ	O
responses	NNS	O
to	TO	O
stimulation	NN	O
are	VBP	O
obtained	VBN	O
in	IN	O
order	NN	O
to	TO	O
avoid	VB	O
sedative	JJ	O
administration	NN	O
of	IN	O
DIPRIVAN	NNP	O
Injectable	NNP	O
Emulsion	NN	O
at	IN	O
rates	NNS	O
higher	JJR	O
than	IN	O
are	VBP	O
clinically	RB	O
necessary	JJ	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
DOLOBID	NNP	O
(	(	O
diflunisal	NN	O
)	)	O
may	MD	O
be	VB	O
increased	VBN	O
or	CC	O
decreased	VBN	O
according	VBG	O
to	TO	O
patient	JJ	O
response	NN	O
.	.	O

BRAVELLE®	NNP	O
may	MD	O
be	VB	O
administered	VBN	O
together	RB	O
with	IN	O
MENOPUR®	NNP	O
(	(	O
menotropins	NNS	O
for	IN	O
injection	NN	O
,	,	O
USP	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
total	JJ	O
initial	JJ	O
dose	NN	O
when	WRB	O
the	DT	O
products	NNS	O
are	VBP	O
combined	VBN	O
should	MD	O
not	RB	O
exceed	VB	O
225	CD	DOS
International	NNP	UNIT
Units	NNP	UNIT
(	(	O
150	CD	O
International	NNP	O
Units	NNS	O
of	IN	O
BRAVELLE®	NNP	O
and	CC	O
75	CD	O
International	NNP	O
Units	NNS	O
of	IN	O
MENOPUR®	NNP	O
or	CC	O
75	CD	DOS
International	NNP	UNIT
Units	NNS	UNIT
of	IN	O
BRAVELLE®	NNP	O
and	CC	O
150	CD	O
International	NNP	O
Units	NNS	O
of	IN	O
MENOPUR®	NNP	O
)	)	O
.	.	O

The	DT	O
lowest	JJS	O
dosage	NN	O
needed	VBN	O
to	TO	O
provide	VB	O
effective	JJ	O
anesthesia	NN	O
should	MD	O
be	VB	O
administered	VBN	O
.	.	O

Vials	NNS	O
of	IN	O
AmBisome	NNP	O
containing	VBG	O
50	CD	DOS
mg	NN	UNIT
of	IN	O
amphotericin	NN	O
B	NNP	O
are	VBP	O
prepared	JJ	O
as	IN	O
follows	VBZ	O
:	:	O

If	IN	O
either	DT	O
of	IN	O
these	DT	O
conditions	NNS	O
exist	VBP	O
,	,	O
the	DT	O
vaccine	NN	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
.	.	O

[	NNS	O
See	NNP	O
DOSAGE	NNP	O
AND	NNP	O
ADMINISTRATION	NNP	O
,	,	O
Localization	NNP	O
and	CC	O
Removal	NNP	O
of	IN	O
a	DT	O
Non	NNP	O
-	:	O
Palpable	JJ	O
Implant	NNP	O
.	.	O
]	NN	O

Such	JJ	O
a	DT	O
solution	NN	O
given	VBN	O
at	IN	O
the	DT	O
rate	NN	O
of	IN	O
145	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	JJ	O
/	JJ	FREQ
day	NN	FREQ
provides	VBZ	O
130	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

Fat	NNP	O
emulsion	NN	O
may	MD	O
also	RB	O
be	VB	O
infused	VBN	O
through	IN	O
a	DT	O
separate	JJ	O
peripheral	JJ	O
site	NN	O
.	.	O

Strict	JJ	O
adherence	NN	O
to	TO	O
the	DT	O
following	JJ	O
precautions	NNS	O
is	VBZ	O
advised	VBN	O
in	IN	O
order	NN	O
to	TO	O
minimize	VB	O
the	DT	O
potential	NN	O
for	IN	O
secondary	JJ	O
exposure	NN	O
to	TO	O
testosterone	VB	O
from	IN	O
Testim	NNP	O
-	:	O
treated	VBD	O
skin	NN	O
:	:	O

Apply	NNP	O
patch	NN	O
to	TO	O
the	DT	O
hip	NN	O
area	NN	O
avoiding	VBG	O
the	DT	O
waistline	NN	O
,	,	O
since	IN	O
clothing	NN	O
may	MD	O
cause	VB	O
the	DT	O
patch	NN	O
to	TO	O
rub	VB	O
off	RP	O
.	.	O

On	IN	O
-	:	O
going	VBG	O
monitoring	NN	O
of	IN	O
the	DT	O
following	JJ	O
clinical	JJ	O
responses	NNS	O
is	VBZ	O
also	RB	O
crucial	JJ	O
to	TO	O
assess	VB	O
patient	JJ	O
response	NN	O
to	TO	O
treatment	NN	O
:	:	O
neurological	JJ	O
status	NN	O
,	,	O
Glasgow	NNP	O
Coma	NNP	O
Scale	NNP	O
,	,	O
tachypnea	NN	O
,	,	O
CT	NNP	O
or	CC	O
MRI	NNP	O
scan	JJ	O
or	CC	O
fundoscopic	JJ	O
evidence	NN	O
of	IN	O
cerebral	JJ	O
edema	NN	O
,	,	O
and	CC	O
/	NNP	O
or	CC	O
of	IN	O
gray	JJ	O
matter	NN	O
and	CC	O
white	JJ	O
matter	NN	O
damage	NN	O
.	.	O

Solutions	NNS	O
at	IN	O
concentrations	NNS	O
between	IN	O
1	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
and	CC	O
40	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
in	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
;	:	O
1	CD	O
/	$	O
6	CD	O
M	NNP	O
Sodium	NNP	O
Lactate	NNP	O
Injection	NNP	O
;	:	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
;	:	O
5	CD	O
%	NN	O
Dextrose	NNP	O
and	CC	O
0.225	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
;	:	O
5	CD	O
%	NN	O
Dextrose	NNP	O
and	CC	O
0.45	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
;	:	O
5	CD	O
%	NN	O
Dextrose	NNP	O
and	CC	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
;	:	O
10	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
;	:	O
Ringer	NNP	O
's	POS	O
Injection	NNP	O
,	,	O
USP	NNP	O
;	:	O
Lactated	NNP	O
Ringer	NNP	O
's	POS	O
Injection	NNP	O
,	,	O
USP	NNP	O
;	:	O
10	CD	O
%	NN	O
Invert	NNP	O
Sugar	NNP	O
in	IN	O
Water	NNP	O
for	IN	O
Injection	NNP	O
;	:	O
and	CC	O
NORMOSOL®	NNP	O
-	:	O
M	NN	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
may	MD	O
be	VB	O
stored	VBN	O
for	IN	O
up	RB	O
to	TO	O
24	CD	O
hours	NNS	O
at	IN	O
room	NN	O
temperature	NN	O
or	CC	O
for	IN	O
7	CD	PER
days	NNS	PER
if	IN	O
refrigerated	VBN	O
.	.	O

The	DT	O
following	JJ	O
table	NN	O
is	VBZ	O
a	DT	O
suggested	JJ	O
approach	NN	O
in	IN	O
dose	JJ	O
titration	NN	O
:	:	O

The	DT	O
usual	JJ	O
dosage	NN	O
range	NN	O
is	VBZ	O
2	CD	DOS
to	TO	O
4	CD	DOS
g	NN	UNIT
(	(	O
marked	VBN	O
on	IN	O
the	DT	O
applicator	NN	O
)	)	O
daily	RB	FREQ
for	IN	O
one	CD	PER
or	CC	O
two	CD	PER
weeks	NNS	PER
,	,	O
then	RB	O
gradually	RB	O
reduced	VBN	O
to	TO	O
one	CD	DOS
half	NN	UNIT
initial	JJ	O
dosage	NN	O
for	IN	O
a	DT	O
similar	JJ	O
period	NN	O
.	.	O

In	IN	O
view	NN	O
of	IN	O
the	DT	O
dose	JJ	O
-	:	O
dependent	JJ	O
adverse	JJ	O
reactions	NNS	O
,	,	O
treatment	NN	O
with	IN	O
doses	NNS	O
above	IN	O
300	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
is	VBZ	O
not	RB	O
recommended	JJ	O
[	NNS	O
see	VBP	O
ADVERSE	JJ	O
REACTIONS	NNP	O
]	NNP	O
.	.	O

RYTHMOL	NNP	O
SR	NNP	O
can	MD	O
be	VB	O
taken	VBN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

Unless	IN	O
used	VBN	O
within	IN	O
15	CD	O
minutes	NNS	O
of	IN	O
reconstitution	NN	O
,	,	O
the	DT	O
diluted	JJ	O
solution	NN	O
must	MD	O
be	VB	O
prepared	VBN	O
using	VBG	O
cold	JJ	O
(	(	O
2°C	CD	O
-	:	O
8°C	CD	O
)	)	O
infusion	NN	O
fluids	NNS	O
and	CC	O
stored	VBN	O
at	IN	O
2°C	CD	O
-	:	O
8°C	CD	O
(	(	O
36°F	CD	O
-	:	O
46°F	CD	O
)	)	O
for	IN	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
7	CD	O
hours	NNS	O
until	IN	O
administration	NN	O
.	.	O

Reconstitute	NNP	O
RiaSTAP	NNP	O
(	(	O
fibrinogen	NN	O
concentrate	NN	O
(	(	O
human	JJ	O
)	)	O
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
at	IN	O
room	NN	O
temperature	NN	O
as	IN	O
follows	VBZ	O
:	:	O

For	IN	O
pediatric	JJ	O
juvenile	NN	O
idiopathic	JJ	O
arthritis	NN	O
,	,	O
a	DT	O
dose	NN	O
calculated	VBN	O
based	VBN	O
on	IN	O
each	DT	O
patient	NN	O
's	POS	O
body	NN	O
weight	NN	O
is	VBZ	O
used	VBN	O
[	JJ	O
see	NN	O
Juvenile	NNP	O
Idiopathic	NNP	O
Arthritis	NNP	O
below	IN	O
]	NNP	O
.	.	O

Pediatric	JJ	WHO
Patients	NNS	WHO
:	:	O
Two	CD	WHO
Months	NNS	WHO
of	IN	WHO
Age	NNP	WHO
or	CC	WHO
Older	JJR	WHO

Discard	NNP	O
any	DT	O
unused	JJ	O
portion	NN	O
.	.	O

The	DT	O
dose	NN	O
increases	NNS	O
should	MD	O
begin	VB	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
that	IN	O
the	DT	O
oral	JJ	O
contraceptive	NN	O
is	VBZ	O
introduced	VBN	O
and	CC	O
continue	VB	O
,	,	O
based	VBN	O
on	IN	O
clinical	JJ	O
response	NN	O
,	,	O
no	DT	O
more	RBR	O
rapidly	RB	O
than	IN	O
50	CD	DOS
to	TO	O
100	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
every	DT	FREQ
week	NN	FREQ
.	.	O

Ovulation	NN	O
may	MD	O
occur	VB	O
within	IN	O
10	CD	O
days	NNS	O
of	IN	O
an	DT	O
abortion	NN	O
or	CC	O
miscarriage	NN	O
.	.	O

Reduce	VB	O
the	DT	O
daily	JJ	FREQ
CABOMETYX	NNP	O
dose	NN	O
by	IN	O
20	CD	DOS
mg	NNS	UNIT
(	(	O
for	IN	O
example	NN	O
,	,	O
from	IN	O
60	CD	DOS
mg	NNS	UNIT
to	TO	O
40	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
or	CC	O
from	IN	O
40	CD	DOS
mg	NNS	UNIT
to	TO	O
20	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
)	)	O
.	.	O

In	IN	O
case	NN	O
a	DT	O
tablet	NN	O
is	VBZ	O
forgotten	VBN	O
,	,	O
it	PRP	O
should	MD	O
be	VB	O
taken	VBN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
.	.	O

Comparison	NNP	O
of	IN	O
the	DT	O
whole	JJ	O
blood	NN	O
tacrolimus	NN	O
trough	IN	O
concentrations	NNS	O
of	IN	O
patients	NNS	O
to	TO	O
those	DT	O
described	VBN	O
in	IN	O
the	DT	O
prescribing	NN	O
information	NN	O
and	CC	O
other	JJ	O
published	VBN	O
literature	NN	O
must	MD	O
be	VB	O
made	VBN	O
with	IN	O
knowledge	NN	O
of	IN	O
the	DT	O
assay	NN	O
method	NN	O
(	(	O
s	PRP	O
)	)	O
employed	VBD	O
.	.	O

In	IN	O
STEMI	NNP	O
patients	NNS	O
presenting	VBG	O
within	IN	O
12	CD	O
hours	NNS	O
of	IN	O
symptom	JJ	O
onset	NN	O
,	,	O
the	DT	O
loading	VBG	O
dose	NN	O
of	IN	O
Effient	NNP	O
was	VBD	O
administered	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
diagnosis	NN	O
,	,	O
although	IN	O
most	JJS	O
received	JJ	O
Effient	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
PCI	NNP	O
[	NNP	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

should	MD	O
not	RB	O
be	VB	O
frozen	VBN	O
.	.	O

Administer	NNP	O
the	DT	O
dose	NN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
after	IN	O
birth	NN	O
,	,	O
preferably	RB	O
within	IN	O
15	CD	O
minutes	NNS	O
.	.	O

Avoiding	VBG	O
medial	JJ	O
lower	JJR	O
lid	JJ	O
injections	NNS	O
,	,	O
and	CC	O
thereby	RB	O
reducing	VBG	O
diffusion	NN	O
into	IN	O
the	DT	O
inferior	JJ	O
oblique	NN	O
,	,	O
may	MD	O
reduce	VB	O
the	DT	O
complication	NN	O
of	IN	O
diplopia	NN	O
.	.	O

For	IN	O
children	NNS	WHO
over	IN	WHO
100	CD	WHO
pounds	NNS	WHO
the	DT	WHO
usual	JJ	WHO
adult	NN	WHO
dose	NN	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

Prior	RB	O
to	TO	O
use	VB	O
,	,	O
visually	RB	O
inspect	VBP	O
the	DT	O
prepared	JJ	O
Ga	NNP	O
68	CD	O
dotatate	NN	O
injection	NN	O
behind	IN	O
a	DT	O
lead	JJ	O
glass	NN	O
shield	NN	O
for	IN	O
radioprotection	NN	O
purposes	NNS	O
.	.	O

A	DT	O
new	JJ	O
unused	JJ	O
Mix2Vial	NNP	O
transfer	NN	O
set	NN	O
should	MD	O
be	VB	O
used	VBN	O
for	IN	O
each	DT	O
Berinert	NNP	O
vial	NN	O
.	.	O

Use	NNP	O
of	IN	O
a	DT	O
narrow	JJ	O
bore	NN	O
hypodermic	JJ	O
needle	NN	O
will	MD	O
ensure	VB	O
a	DT	O
slow	JJ	O
rate	NN	O
of	IN	O
injection	NN	O
.	.	O

fat	JJ	O
emulsion	NN	O
.	.	O

NIMBEX	NNP	O
SHOULD	NNP	O
ONLY	NNP	O
BE	NNP	O
ADMINISTERED	NNP	O
INTRAVENOUSLY	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Zemaira	NNP	O
is	VBZ	O
60	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VBZ	O
body	NN	O
weight	NN	O
administered	VBN	O
once	RB	FREQ
weekly	JJ	FREQ
.	.	O

Oral	JJ	O
:	:	O
1	CD	DOS
/	$	O
4	CD	DOS
mg	NN	UNIT
/	NNP	O
lb	VBZ	O
body	NN	O
weight	NN	O
(	(	O
e.g	UH	O
,	,	O
40	CD	DOS
lb	NN	UNIT
child—	NN	O
10	CD	DOS
mg	NN	UNIT
q4	NN	O
to	TO	O
6h	CD	O
)	)	O
.	.	O

LEXXEL	NNP	O
(	(	O
enalapril	JJ	O
maleate	NN	O
-	:	O
felodipine	NN	O
)	)	O
should	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
and	CC	O
not	RB	O
divided	VBN	O
,	,	O
crushed	VBD	O
or	CC	O
chewed	VBD	O
.	.	O

For	IN	O
children	NNS	WHO
,	,	O
a	DT	O
drop	NN	O
of	IN	O
atropine	JJ	O
sulfate	NN	O
1	CD	O
percent	NN	O
is	VBZ	O
placed	VBN	O
in	IN	O
each	DT	O
eye	NN	O
,	,	O
followed	VBD	O
in	IN	O
10	CD	O
to	TO	O
15	CD	O
minutes	NNS	O
by	IN	O
1	CD	DOS
drop	NN	UNIT
of	IN	O
NEO	NNP	O
-	:	O
SYNEPHRINE	NNP	O
(	(	O
phenylephrine	JJ	O
hydrochloride	NN	O
ophthalmic	JJ	O
solution	NN	O
)	)	O
hydrochloride	NN	O
2.5	CD	O
percent	NN	O
ophthalmic	JJ	O
solution	NN	O
and	CC	O
in	IN	O
five	CD	O
to	TO	O
ten	VB	O
minutes	NNS	O
by	IN	O
a	DT	O
second	JJ	O
drop	NN	O
of	IN	O
atropine	JJ	O
sulfate	NN	O
1	CD	O
percent	NN	O
.	.	O

Pentothal	NNP	O
(	(	O
thiopental	JJ	O
sodium	NN	O
)	)	O

30	CD	DOS
mL	NN	UNIT
/	NN	O
h	NN	O

(	(	O
See	VB	O
WARNINGS	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
:	:	O
Information	NN	O
for	IN	O
Patients	NNS	WHO
and	CC	WHO
DRUG	NNP	WHO
INTERACTIONS	NNP	WHO
.	.	O
)	)	O

It	PRP	O
is	VBZ	O
also	RB	O
normal	JJ	O
to	TO	O
see	VB	O
small	JJ	O
air	NN	O
bubbles	NNS	O
.	.	O

Commercial	JJ	O
Dextrose	NNP	O
Injection	NNP	O
usually	RB	O
has	VBZ	O
a	DT	O
pH	NN	O
above	IN	O
4.2	CD	O
;	:	O
however	RB	O
,	,	O
if	IN	O
it	PRP	O
is	VBZ	O
below	IN	O
4.2	CD	O
,	,	O
then	RB	O
1	CD	DOS
or	CC	O
2	CD	DOS
mL	NN	UNIT
of	IN	O
buffer	NN	O
should	MD	O
be	VB	O
added	VBN	O
to	TO	O
the	DT	O
Dextrose	NNP	O
Injection	NNP	O
before	IN	O
it	PRP	O
is	VBZ	O
used	VBN	O
to	TO	O
dilute	VB	O
the	DT	O
concentrated	JJ	O
solution	NN	O
of	IN	O
amphotericin	NN	O
B	NNP	O
.	.	O

ZYPREXA	NNP	O
IntraMuscular	NNP	O
reconstituted	VBD	O
with	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
should	MD	O
be	VB	O
used	VBN	O
immediately	RB	O
(	(	O
within	IN	O
1	CD	O
hour	NN	O
)	)	O
after	IN	O
reconstitution	NN	O
.	.	O

Marketed	VBN	O
by	IN	O
UCB	NNP	O
,	,	O
Inc.	NNP	O
Smyrna	NNP	O
,	,	O
GA	NNP	O
30080	CD	O
Made	NNP	O
in	IN	O
USA	NNP	O
.	.	O

Maintenance	NN	O
Dose	NNP	O
Every	NNP	O
12	CD	O
hours	NNS	O
=	RB	O
observed	VBD	O
CC	NNP	O
in	IN	O
mL	NN	O
/	NNP	O
min	NNP	O
/	NNP	O
normal	JJ	O
CC	NNP	O
in	IN	O
mL	NN	O
/	NNP	O
min	NN	O
X	NNP	O
Calculated	NNP	O
loading	VBG	O
dose	NN	O
in	IN	O
mg	NN	UNIT
(	(	O
CC	NNP	O
-	:	O
creatinine	JJ	O
clearance	NN	O
rate	NN	O
)	)	O

Dosage	NN	O
adjustments	NNS	O
may	MD	O
be	VB	O
made	VBN	O
after	IN	O
initiation	NN	O
of	IN	O
drug	NN	O
therapy	NN	O
or	CC	O
during	IN	O
exacerbations	NNS	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O

Close	RB	O
flow	JJ	O
control	NN	O
clamp	NN	O
of	IN	O
administration	NN	O
set	VBN	O
.	.	O

In	IN	O
many	JJ	WHO
patients	NNS	WHO
,	,	O
provision	NN	O
of	IN	O
adequate	JJ	O
calories	NNS	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
hypertonic	JJ	O
dextrose	NN	O
may	MD	O
require	VB	O
the	DT	O
administration	NN	O
of	IN	O
exogenous	JJ	O
insulin	NN	O
to	TO	O
prevent	VB	O
hyperglycemia	NN	O
and	CC	O
glycosuria	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
IMURAN	NNP	O
required	VBD	O
to	TO	O
prevent	VB	O
rejection	NN	O
and	CC	O
minimize	VB	O
toxicity	NN	O
will	MD	O
vary	VB	O
with	IN	O
individual	JJ	O
patients	NNS	O
;	:	O
this	DT	O
necessitates	VBZ	O
careful	JJ	O
management	NN	O
.	.	O

Do	NNP	O
not	RB	O
connect	VB	O
flexible	JJ	O
bags	NNS	O
in	IN	O
series	NN	O
to	TO	O
avoid	VB	O
air	NN	O
embolism	NN	O
due	JJ	O
to	TO	O
possible	JJ	O
residual	JJ	O
gas	NN	O
contained	VBN	O
in	IN	O
the	DT	O
primary	JJ	O
bag	NN	O
.	.	O

to	TO	O
100	CD	DOS
mg	NN	UNIT
t.i.d	NN	O
.	.	O

An	DT	O
equivocal	JJ	O
reaction	NN	O
is	VBZ	O
any	DT	O
reaction	NN	O
that	WDT	O
is	VBZ	O
not	RB	O
a	DT	O
major	JJ	O
reaction	NN	O
,	,	O
and	CC	O
indicates	VBZ	O
a	DT	O
non	JJ	O
-	:	O
take	NN	O
(	(	O
vaccination	JJ	O
failure	NN	O
)	)	O
due	NN	O
to	TO	O
impotent	VB	O
vaccine	NN	O
or	CC	O
inadequate	JJ	O
vaccination	NN	O
technique	NN	O
.	.	O

Only	RB	O
correct	NN	O
to	TO	O
100	CD	O
%	NN	O
of	IN	O
the	DT	O
desired	JJ	O
volume	NN	O
effect	NN	O
.	.	O

To	TO	O
avoid	VB	O
foaming	NN	O
,	,	O
alternate	NN	O
between	IN	O
gentle	JJ	O
swirling	NN	O
and	CC	O
inversion	NN	O
of	IN	O
the	DT	O
vial	JJ	O
until	IN	O
its	PRP$	O
contents	NNS	O
are	VBP	O
completely	RB	O
dissolved	VBN	O
.	.	O

ETRAFON	RB	O
2	CD	O
-	:	O
10	CD	DOS
Tablets	NNS	UNIT
(	(	O
2	CD	O
-	:	O
10	CD	O
)	)	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
increase	VB	O
flexibility	NN	O
in	IN	O
adjusting	VBG	O
maintenance	NN	O
dosage	NN	O
to	TO	O
the	DT	O
lowest	JJS	O
amount	NN	O
consistent	JJ	O
with	IN	O
relief	NN	O
of	IN	O
symptoms	NNS	O
.	.	O

In	IN	O
emergencies	NNS	O
,	,	O
300	CD	DOS
to	TO	O
500	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
5	CD	O
%	NN	O
Sodium	NNP	O
Bicarbonate	NNP	O
(	(	O
sodium	JJ	O
bicarbonate	VBP	O
5	CD	O
%	NN	O
injection	NN	O
)	)	O
Injection	NN	O
should	MD	O
or	CC	O
administered	VBN	O
as	RB	O
rapidly	RB	O
as	IN	O
is	VBZ	O
possible	JJ	O
without	IN	O
overalkalinizing	VBG	O
the	DT	O
patient	NN	O
.	.	O

During	IN	O
the	DT	O
first	JJ	O
15	CD	O
minutes	NNS	O
following	VBG	O
instillation	NN	O
,	,	O
the	DT	O
patient	NN	O
should	MD	O
lie	VB	O
prone	NN	O
.	.	O

The	DT	O
neuromuscular	JJ	O
blocking	VBG	O
effect	NN	O
of	IN	O
TRACRIUM	NNP	O
(	(	O
atracurium	JJ	O
besylate	NN	O
)	)	O
administered	VBN	O
by	IN	O
infusion	NN	O
is	VBZ	O
potentiated	VBN	O
by	IN	O
enflurane	NN	O
or	CC	O
isoflurane	NN	O
and	CC	O
to	TO	O
a	DT	O
lesser	JJR	O
extent	NN	O
,	,	O
by	IN	O
halothane	NN	O
.	.	O

Doses	NNS	O
may	MD	O
also	RB	O
be	VB	O
given	VBN	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
by	IN	O
administering	VBG	O
one	CD	O
-	:	O
third	NN	O
of	IN	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
every	DT	FREQ
8	CD	FREQ
hours	NNS	FREQ
.	.	O

Patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
opioid	JJ	WHO
-	:	WHO
tolerant	NN	WHO
are	VBP	O
those	DT	O
receiving	VBG	O
,	,	O
for	IN	O
one	CD	PER
week	NN	PER
or	CC	O
longer	JJR	O
,	,	O
at	IN	O
least	JJS	O
60	CD	DOS
mg	JJ	UNIT
oral	JJ	O
morphine	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
25	CD	DOS
mcg	NN	UNIT
transdermal	JJ	O
fentanyl	NN	O
per	IN	O
hour	NN	O
,	,	O
30	CD	DOS
mg	JJ	UNIT
oral	JJ	O
oxycodone	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
8	CD	DOS
mg	JJ	UNIT
oral	JJ	O
hydromorphone	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
25	CD	DOS
mg	JJ	UNIT
oral	JJ	O
oxymorphone	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
or	CC	O
an	DT	O
equianalgesic	JJ	O
dose	NN	O
of	IN	O
another	DT	O
opioid	NN	O
.	.	O

After	IN	O
estimating	VBG	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
fluid	NN	O
(	(	O
water	NN	O
)	)	O
requirements	NNS	O
,	,	O
the	DT	O
appropriate	JJ	O
volume	NN	O
to	TO	O
be	VB	O
infused	VBN	O
to	TO	O
meet	VB	O
the	DT	O
daily	JJ	FREQ
protein	NN	O
requirement	NN	O
of	IN	O
the	DT	O
patient	NN	O
,	,	O
can	MD	O
be	VB	O
determined	VBN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
to	TO	WHO
severe	VB	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NNP	WHO
score	NN	WHO
:	:	O
7	CD	O
to	TO	O
15	CD	O
)	)	O
,	,	O
the	DT	O
maximum	JJ	O
dose	NN	O
is	VBZ	O
150	CD	DOS
mg	NN	UNIT
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
.	.	O

(	(	O
SEE	VB	O
FIGURE	NNP	O
5	CD	O
.	.	O
)	)	O

Poor	NNP	O
risk	NN	O
patients	NNS	WHO
or	CC	WHO
those	DT	WHO
who	WP	WHO
are	VBP	WHO
not	RB	WHO
in	IN	WHO
an	DT	WHO
adequate	JJ	WHO
nutritional	JJ	WHO
state	NN	WHO
(	(	O
see	VB	O
CONTRAINDICATIONS	NNP	O
and	CC	O
WARNINGS	NNP	O
)	)	O
should	MD	O
receive	VB	O
6	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
for	IN	O
three	CD	PER
days	NNS	PER
.	.	O

Follow	NNP	O
applicable	JJ	O
special	JJ	O
handling	NN	O
and	CC	O
disposal	NN	O
procedures1	NN	O
.	.	O

If	IN	O
less	JJR	O
than	IN	O
1	CD	O
month	NN	O
is	VBZ	O
available	JJ	O
,	,	O
a	DT	O
single	JJ	DOS
0.5	CD	DOS
mL	NN	UNIT
dose	NN	UNIT
of	IN	O
IPOL	NNP	O
vaccine	NN	O
is	VBZ	O
recommended.28	JJ	O

A	DT	O
transient	JJ	O
increase	NN	O
in	IN	O
strength	NN	O
occurring	VBG	O
about	IN	O
30	CD	O
seconds	NNS	O
later	RBR	O
and	CC	O
lasting	VBG	O
3	CD	O
to	TO	O
5	CD	O
minutes	NNS	O
indicates	VBZ	O
insufficient	JJ	O
maintenance	NN	O
dose	NN	O
.	.	O

The	DT	O
smallest	JJS	O
dose	JJ	O
consistent	NN	O
with	IN	O
attaining	VBG	O
the	DT	O
surgical	JJ	O
objective	NN	O
is	VBZ	O
the	DT	O
desired	JJ	O
goal	NN	O
.	.	O

If	IN	O
adequate	JJ	O
suppression	NN	O
is	VBZ	O
achieved	VBN	O
on	IN	O
a	DT	O
MEXITIL	NNP	O
(	(	O
mexiletine	VB	O
hcl	NN	O
)	)	O
dose	NN	O
of	IN	O
300	CD	DOS
mg	NN	UNIT
or	CC	O
less	JJR	O
every	DT	FREQ
eight	CD	FREQ
hours	NNS	FREQ
,	,	O
the	DT	O
same	JJ	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
may	MD	O
be	VB	O
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
while	IN	O
carefully	RB	O
monitoring	VBG	O
the	DT	O
degree	NN	O
of	IN	O
suppression	NN	O
of	IN	O
ventricular	JJ	O
ectopy	NN	O
.	.	O

Thrombin	JJ	O
time	NN	O
(	(	O
TT	NNP	O
)	)	O
is	VBZ	O
not	RB	O
a	DT	O
suitable	JJ	O
test	NN	O
for	IN	O
routine	JJ	O
monitoring	NN	O
of	IN	O
Iprivask	NNP	O
therapy	NN	O
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

BiCNU	NNP	O
(	(	O
carmustine	NN	O
)	)	O
has	VBZ	O
a	DT	O
low	JJ	O
melting	NN	O
point	NN	O
(	(	O
30.5°	CD	O
-	:	O
32.0°C	CD	O
or	CC	O
86.9°	CD	O
-	:	O
89.6°F	CD	O
)	)	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Recommended	VBN	O
Dosages	NNS	O
for	IN	O
Both	DT	O
Strengths	NNP	O

As	IN	O
with	IN	O
other	JJ	O
corticosteroids	NNS	O
,	,	O
therapy	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
when	WRB	O
control	NN	O
is	VBZ	O
achieved	VBN	O
.	.	O

The	DT	O
whole	JJ	O
length	NN	O
of	IN	O
the	DT	O
needle	NN	O
should	MD	O
be	VB	O
introduced	VBN	O
into	IN	O
a	DT	O
skin	JJ	O
fold	NN	O
held	VBD	O
between	IN	O
the	DT	O
thumb	NN	O
and	CC	O
forefinger	NN	O
;	:	O
the	DT	O
skin	NN	O
fold	NN	O
should	MD	O
be	VB	O
held	VBN	O
throughout	IN	O
the	DT	O
injection	NN	O
.	.	O

Current	JJ	O
data	NNS	O
from	IN	O
clinical	JJ	WHO
trials	NNS	WHO
support	VBP	WHO
5	CD	WHO
years	NNS	WHO
of	IN	WHO
adjuvant	JJ	WHO
NOLVADEX	NNP	WHO
(	(	O
tamoxifen	JJ	O
citrate	NN	O
)	)	O
therapy	NN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
breast	JJ	WHO
cancer	NN	WHO
.	.	O

No	DT	O
more	JJR	O
than	IN	O
one	CD	DOS
and	CC	O
a	DT	O
half	JJ	O
capfuls	NN	O
of	IN	O
foam	NN	O
should	MD	O
be	VB	O
used	VBN	O
at	IN	O
each	DT	O
application	NN	O
.	.	O

A	DT	O
25	CD	O
gauge	NN	O
,	,	O
1	CD	O
”	NN	O
needle	NN	O
for	IN	O
intramuscular	JJ	O
injection	NN	O
with	IN	O
AVONEX	NNP	O
prefilled	VBD	O
syringe	NN	O
or	CC	O
injection	NN	O
of	IN	O
reconstituted	JJ	O
solution	NN	O
may	MD	O
be	VB	O
substituted	VBN	O
for	IN	O
the	DT	O
23	CD	O
gauge	NN	O
,	,	O
1	CD	O
¼	NN	O
”	NNP	O
needle	NN	O
by	IN	O
the	DT	O
healthcare	NN	O
provider	NN	O
,	,	O
if	IN	O
deemed	VBN	O
appropriate	NN	O
.	.	O

Thus	RB	O
,	,	O
many	JJ	O
experts	NNS	O
prefer	VBP	O
to	TO	O
use	VB	O
the	DT	O
shorter	NN	O
acting	VBG	O
androgen	NN	O
preparations	NNS	O
rather	RB	O
than	IN	O
those	DT	O
with	IN	O
prolonged	JJ	O
activity	NN	O
for	IN	O
treating	VBG	O
breast	NN	O
carcinoma	NN	O
,	,	O
particularly	RB	O
during	IN	O
the	DT	O
early	JJ	O
stages	NNS	O
of	IN	O
androgen	NN	O
therapy	NN	O
.	.	O

Do	NNP	O
not	RB	O
refrigerate	VB	O
the	DT	O
admixture	NN	O
as	IN	O
precipitation	NN	O
will	MD	O
occur	VB	O
.	.	O

Step	NN	O
14	CD	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
starts	VBZ	O
Yasmin	NNP	O
postpartum	NN	O
and	CC	O
has	VBZ	O
not	RB	O
yet	RB	O
had	VBD	O
a	DT	O
period	NN	O
,	,	O
evaluate	NN	O
for	IN	O
possible	JJ	O
pregnancy	NN	O
,	,	O
and	CC	O
instruct	VB	O
her	PRP$	O
to	TO	O
use	VB	O
an	DT	O
additional	JJ	O
method	NN	O
of	IN	O
contraception	NN	O
until	IN	O
she	PRP	O
has	VBZ	O
taken	VBN	O
Yasmin	NNP	O
for	IN	O
7	CD	PER
consecutive	JJ	PER
days	NNS	PER
.	.	O

Alternate	NNP	O
schedules	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
lymphocytic	JJ	O
leukemia	NN	O
employing	VBG	O
intermittent	NN	O
,	,	O
biweekly	RB	O
,	,	O
or	CC	O
once	RB	FREQ
-	:	O
monthly	JJ	O
pulse	NN	O
doses	NNS	O
of	IN	O
chlorambucil	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
.	.	O

Do	NNP	O
not	RB	O
add	VB	O
supplementary	JJ	O
medication	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ALLEGRA	NNP	O
-	:	O
D	NNP	O
(	(	O
fexofenadine	JJ	O
hcl	NN	O
and	CC	O
pseudoephedrine	VB	O
hcl	NN	O
)	)	O
12	CD	O
HOUR	NNP	O
Extended	NNP	O
-	:	O
Release	NNP	O
Tablets	NNPS	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
administered	VBN	O
on	IN	O
an	DT	O
empty	JJ	O
stomach	NN	O
with	IN	O
water	NN	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
.	.	O

A	DT	O
negative	JJ	O
reaction	NN	O
is	VBZ	O
indicated	VBN	O
by	IN	O
complete	JJ	O
absence	NN	O
of	IN	O
induration	NN	O
.	.	O

Slower	JJR	O
boluses	NNS	O
or	CC	O
infusions	NNS	O
of	IN	O
DIPRIVAN	NNP	O
Injectable	NNP	O
Emulsion	NNP	O
for	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
,	,	O
titrated	VBN	O
to	TO	O
clinical	JJ	O
responses	NNS	O
,	,	O
will	MD	O
generally	RB	O
result	VB	O
in	IN	O
reduced	JJ	O
induction	NN	O
dosage	NN	O
requirements	NNS	O
(	(	O
1	CD	DOS
to	TO	O
2	CD	DOS
mg	NNS	UNIT
/	NNP	O
kg	NN	O
)	)	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

Cardene	NNP	O
I.V	NNP	O
.	.	O

For	IN	O
inadequately	RB	WHO
vaccinated	JJ	WHO
patients	NNS	WHO
of	IN	WHO
all	DT	WHO
ages	NNS	WHO
,	,	O
completion	NN	O
of	IN	O
primary	JJ	O
vaccination	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
discharge	NN	O
or	CC	O
at	IN	O
follow	JJ	O
-	:	O
up	IN	O
visits	NNS	O
should	MD	O
be	VB	O
ensured.2	JJ	O

during	IN	O
puberty	NN	O
or	CC	O
due	JJ	O
to	TO	O
obesity	NN	O
,	,	O
the	DT	O
daily	JJ	FREQ
insulin	NN	O
requirement	NN	O
may	MD	O
be	VB	O
substantially	RB	O
higher	JJR	O
.	.	O

When	WRB	O
Pitressin	NNP	O
is	VBZ	O
administered	VBN	O
intranasally	RB	O
by	IN	O
spray	NN	O
or	CC	O
on	IN	O
pledgets	NNS	O
,	,	O
the	DT	O
dosage	NN	O
and	CC	O
interval	NN	O
between	IN	O
treatments	NNS	O
must	MD	O
be	VB	O
determined	VBN	O
for	IN	O
each	DT	O
patient	NN	O
.	.	O

Occasionally	RB	O
tolerance	NN	O
may	MD	O
occur	VB	O
,	,	O
usually	RB	O
between	IN	O
the	DT	O
second	JJ	O
and	CC	O
third	JJ	O
month	NN	O
of	IN	O
therapy	NN	O
.	.	O

Do	NNP	O
not	RB	O
substitute	VB	O
for	IN	O
other	JJ	O
amphetamine	JJ	O
products	NNS	O
on	IN	O
a	DT	O
milligram	JJ	O
-	:	O
per	IN	O
-	:	O
milligram	NN	O
basis	NN	O
because	IN	O
of	IN	O
different	JJ	O
amphetamine	JJ	O
base	NN	O
compositions	NNS	O
and	CC	O
differing	VBG	O
pharmacokinetic	JJ	O
profiles	NNS	O
[	VBP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Attach	NNP	O
the	DT	O
syringe	NN	O
to	TO	O
a	DT	O
nasogastric	JJ	O
tube	NN	O
and	CC	O
deliver	VB	O
the	DT	O
contents	NNS	O
of	IN	O
the	DT	O
syringe	NN	O
through	IN	O
the	DT	O
nasogastric	JJ	O
tube	NN	O
into	IN	O
the	DT	O
stomach	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
obese	JJ	O
individuals	NNS	O
are	VBP	O
more	RBR	O
likely	JJ	O
to	TO	O
manifest	VB	O
adverse	JJ	O
effects	NNS	O
,	,	O
when	WRB	O
treated	VBN	O
with	IN	O
a	DT	O
weight	NN	O
-	:	O
based	VBN	O
regimen	NNS	O
.	.	O

The	DT	O
maximum	JJ	O
infusion	NN	O
rate	NN	O
of	IN	O
KABIVEN®	NNP	O
is	VBZ	O
2.6	CD	DOS
mL	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	O
hour	NN	O
.	.	O

DO	NNP	O
NOT	NNP	O
SHAKE	NNP	O
or	CC	O
SWIRL	NNP	O
VIGOROUSLY	NNP	O
.	.	O

The	DT	O
initial	JJ	O
infusion	NN	O
rate	NN	O
should	MD	O
be	VB	O
no	RB	O
more	JJR	O
than	IN	O
1	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
/	NNP	O
hr	NN	O
.	.	O

Each	DT	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
Aminosyn	NNP	O
II	NNP	O
contains	VBZ	O
:	:	O

Initiate	NNP	O
the	DT	O
dosing	VBG	O
regimen	NNS	O
for	IN	O
each	DT	O
patient	NN	O
individually	RB	O
,	,	O
taking	VBG	O
into	IN	O
account	NN	O
the	DT	O
patient	NN	O
's	POS	O
severity	NN	O
of	IN	O
pain	NN	O
,	,	O
patient	JJ	O
response	NN	O
,	,	O
prior	JJ	O
analgesic	JJ	O
treatment	NN	O
experience	NN	O
,	,	O
and	CC	O
risk	NN	O
factors	NNS	O
for	IN	O
addiction	NN	O
,	,	O
abuse	NN	O
,	,	O
and	CC	O
misuse	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Topical	JJ	O
ethyl	NN	O
chloride	NN	O
spray	NN	O
may	MD	O
be	VB	O
used	VBN	O
locally	RB	O
prior	JJ	O
to	TO	O
injection	NN	O
.	.	O

This	DT	O
pharmacokinetic	JJ	O
data	NNS	O
demonstrated	VBD	O
a	DT	O
peak	JJ	O
recovery	NN	O
point	NN	O
above	IN	O
the	DT	O
pre	NN	O
-	:	O
infusion	NN	O
baseline	NN	O
of	IN	O
approximately	RB	O
2.0	CD	DOS
IU	NNP	UNIT
/	NNP	O
dL	NN	O
per	IN	O
IU	NNP	O
/	NNP	O
kg	VB	O
body	NN	O
weight	NN	O
.	.	O

Remove	VB	O
the	DT	O
protective	JJ	O
plastic	NN	O
caps	NNS	O
from	IN	O
the	DT	O
lyophilisate	NN	O
(	(	O
LYO	NNP	O
)	)	O
and	CC	O
diluents	NNS	O
bottles	NNS	O
and	CC	O
disinfect	VB	O
both	DT	O
rubber	NN	O
stoppers	NNS	O
with	IN	O
alcohol	NN	O
.	.	O

Withhold	NNP	O
COTELLIC	NNP	O
for	IN	O
up	RB	PER
to	TO	PER
4	CD	PER
weeks	NNS	PER
.	.	O

If	IN	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
exceeds	VBZ	O
250	CD	DOS
mg	NN	UNIT
,	,	O
it	PRP	O
should	MD	O
be	VB	O
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

For	IN	O
adult	NN	WHO
and	CC	WHO
adolescent	JJ	WHO
patients	NNS	WHO
weighing	VBG	WHO
≥	JJ	WHO
50	CD	WHO
kg	NN	WHO
requiring	VBG	WHO
1000	CD	DOS
mg	NN	UNIT
doses	NNS	UNIT
of	IN	O
OFIRMEV	NNP	O
,	,	O
administer	VBP	O
the	DT	O
dose	NN	O
by	IN	O
inserting	VBG	O
a	DT	O
vented	JJ	O
intravenous	JJ	O
set	VBN	O
through	IN	O
the	DT	O
septum	NN	O
of	IN	O
the	DT	O
100	CD	DOS
mL	JJ	UNIT
vial	NN	UNIT
or	CC	O
a	DT	O
non	JJ	O
-	:	O
vented	VBN	O
intravenous	JJ	O
set	VBN	O
through	IN	O
the	DT	O
administration	NN	O
spike	VBZ	O
port	NN	O
of	IN	O
the	DT	O
100	CD	DOS
mL	NN	UNIT
bag	NN	O
.	.	O

Consult	NNP	WHO
specialized	VBD	WHO
references	NNS	WHO
to	TO	O
verify	VB	O
with	IN	O
which	WDT	O
substances	NNS	O
incompatibilities	NNS	O
have	VBP	O
been	VBN	O
noted	VBN	O
,	,	O
as	IN	O
compatibility	NN	O
may	MD	O
depend	VB	O
on	IN	O
concentration	NN	O
,	,	O
temperature	NN	O
,	,	O
time	NN	O
,	,	O
and	CC	O
other	JJ	O
variables	NNS	O
.	.	O

Locate	VB	O
a	DT	O
second	JJ	O
injection	NN	O
spot	NN	O
on	IN	O
the	DT	O
stopper	NN	O
,	,	O
and	CC	O
then	RB	O
insert	VB	O
the	DT	O
18	CD	O
G	NNP	O
needle	NN	O
.	.	O

If	IN	O
there	EX	O
are	VBP	O
more	JJR	O
than	IN	O
7	CD	DOS
patch	NN	UNIT
-	:	O
free	JJ	O
days	NNS	O
,	,	O
THE	NNP	O
WOMAN	NNP	O
MAY	NNP	O
NOT	NNP	O
BE	NNP	O
PROTECTED	NNP	O
FROM	NNP	O
PREGNANCY	NNP	O
and	CC	O
back	RB	O
-	:	O
up	IN	O
contraception	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
condom	NN	O
and	CC	O
spermicide	NN	O
or	CC	O
diaphragm	NN	O
and	CC	O
spermicide	NN	O
,	,	O
must	MD	O
be	VB	O
used	VBN	O
for	IN	O
7	CD	PER
days	NNS	PER
.	.	O

Use	NNP	O
of	IN	O
NUCYNTA®	NNP	O
ER	NNP	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
is	VBZ	O
not	RB	O
recommended	JJ	O
[	NNS	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

As	IN	O
there	EX	O
are	VBP	O
significant	JJ	O
differences	NNS	O
in	IN	O
the	DT	O
half	NN	O
-	:	O
life	NN	O
of	IN	O
IgG	NNP	O
among	IN	O
patients	NNS	WHO
with	IN	WHO
primary	JJ	WHO
humoral	JJ	WHO
immunodeficiencies	NNS	WHO
,	,	O
the	DT	O
frequency	NN	O
and	CC	O
amount	NN	O
of	IN	O
immunoglobulin	JJ	O
therapy	NN	O
may	MD	O
vary	VB	O
from	IN	O
patient	NN	O
to	TO	O
patient	NN	O
.	.	O

In	IN	O
pediatric	JJ	WHO
angiocardiography	NN	WHO
,	,	O
a	DT	O
dose	NN	O
of	IN	O
10	CD	DOS
to	TO	O
20	CD	DOS
mL	NN	UNIT
may	MD	O
be	VB	O
particularly	RB	O
hazardous	JJ	O
in	IN	O
infants	NNS	WHO
weighing	VBG	WHO
less	JJR	WHO
than	IN	WHO
7	CD	WHO
kg	NN	WHO
.	.	O

Administer	NNP	O
Karbinal	NNP	O
ER	NNP	O
by	IN	O
the	DT	O
oral	JJ	O
route	NN	O
only	RB	O
.	.	O

Frozen	JJ	O
solutions	NNS	O
should	MD	O
be	VB	O
thawed	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
and	CC	O
not	RB	O
refrozen	VB	O
.	.	O

Dosing	VBG	O
with	IN	O
THALOMID	NNP	O
should	MD	O
usually	RB	O
continue	VB	O
until	IN	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
active	JJ	O
reaction	NN	O
have	VBP	O
subsided	VBN	O
,	,	O
usually	RB	O
a	DT	O
period	NN	O
of	IN	O
at	IN	PER
least	JJS	PER
2	CD	PER
weeks	NNS	PER
.	.	O

When	WRB	O
aortic	JJ	O
arch	NN	O
injections	NNS	O
(	(	O
four	CD	O
vessel	NN	O
studies	NNS	O
)	)	O
are	VBP	O
performed	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
cerebral	JJ	O
angiography	NN	O
,	,	O
the	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
40	CD	DOS
mL	NN	UNIT
(	(	O
range	NN	O
30	CD	DOS
-	:	O
50	CD	DOS
mL	NN	UNIT
)	)	O
.	.	O

Therapy	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
when	WRB	O
control	NN	O
is	VBZ	O
achieved	VBN	O
.	.	O

Central	NNP	O
nervous	JJ	O
system	NN	O
reactions	NNS	O
with	IN	O
Optiray	NNP	O
in	IN	O
controlled	JJ	O
clinical	JJ	O
studies	NNS	O
in	IN	O
cerebral	JJ	O
arteriography	NN	O
that	WDT	O
were	VBD	O
considered	VBN	O
drug	NN	O
-	:	O
related	VBN	O
and	CC	O
occurred	VBN	O
with	IN	O
frequencies	NNS	O
greater	JJR	O
than	IN	O
1	CD	O
%	NN	O
were	VBD	O
:	:	O
headache	NN	O
,	,	O
bradycardia	NN	O
,	,	O
blood	NN	O
pressure	NN	O
fluctuation	NN	O
,	,	O
disorientation	NN	O
,	,	O
nausea	NN	O
and	CC	O
vertigo	NN	O
.	.	O

Although	IN	O
the	DT	O
incidence	NN	O
of	IN	O
systemic	JJ	O
adverse	JJ	O
reactions	NNS	O
with	IN	O
EMLA	NNP	O
(	(	O
lidocaine	NN	O
and	CC	O
prilocaine	NN	O
)	)	O
Cream	NN	O
is	VBZ	O
very	RB	O
low	JJ	O
,	,	O
caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
,	,	O
particularly	RB	O
when	WRB	O
applying	VBG	O
it	PRP	O
over	IN	O
large	JJ	O
areas	NNS	O
and	CC	O
leaving	VBG	O
it	PRP	O
on	IN	O
for	IN	O
longer	JJR	O
than	IN	O
2	CD	O
hours	NNS	O
.	.	O

In	IN	O
some	DT	WHO
cases	NNS	WHO
,	,	O
a	DT	O
patient	NN	O
already	RB	O
receiving	VBG	O
NORPRAMIN	NNP	O
therapy	NN	O
may	MD	O
require	VB	O
urgent	JJ	O
treatment	NN	O
with	IN	O
linezolid	JJ	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	NN	O
.	.	O

For	IN	O
children	NNS	WHO
6	CD	WHO
to	TO	WHO
10	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
,	,	O
the	DT	O
initial	JJ	O
dosage	NN	O
is	VBZ	O
50	CD	DOS
to	TO	O
150	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
.	.	O

Insomnia	NNP	O
may	MD	O
also	RB	O
be	VB	O
minimized	VBN	O
by	IN	O
avoiding	VBG	O
bedtime	NN	O
doses	NNS	O
.	.	O

Geriatric	JJ	O
Use	NN	O
:	:	O
This	DT	O
drug	NN	O
is	VBZ	O
known	VBN	O
to	TO	O
be	VB	O
substantially	RB	O
excreted	VBN	O
by	IN	O
the	DT	O
kidney	NN	O
,	,	O
and	CC	O
the	DT	O
risk	NN	O
of	IN	O
toxic	JJ	O
reactions	NNS	O
to	TO	O
this	DT	O
drug	NN	O
may	MD	O
be	VB	O
greater	JJR	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
renal	JJ	WHO
function	NN	WHO
.	.	O

If	IN	O
available	JJ	O
,	,	O
U	NNP	O
-	:	O
PAGN	NN	O
measurements	NNS	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
help	VB	O
guide	VB	O
RAVICTI	NNP	O
dose	JJ	O
adjustment	NN	O
.	.	O

The	DT	O
administration	NN	O
of	IN	O
an	DT	O
additional	JJ	O
dose	NN	O
to	TO	O
a	DT	O
patient	NN	O
with	IN	O
a	DT	O
clinically	RB	O
significant	JJ	O
postural	JJ	O
change	NN	O
in	IN	O
systolic	JJ	O
blood	NN	O
pressure	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

Dosage	NN	O
should	MD	O
be	VB	O
increased	VBN	O
until	IN	O
the	DT	O
maximum	JJ	O
performance	NN	O
compatible	NN	O
with	IN	O
the	DT	O
dysfunction	NN	O
due	JJ	O
to	TO	O
underlying	JJ	O
disease	NN	O
is	VBZ	O
achieved	VBN	O
.	.	O

Undertreatment	NN	O
and	CC	O
overtreatment	NN	O
should	MD	O
be	VB	O
avoided	VBN	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
,	,	O
Pediatric	NNP	O
Use	NNP	O
)	)	O
.	.	O

Avoid	NNP	O
using	VBG	O
omeprazole	JJ	O
or	CC	O
esomeprazole	JJ	O
with	IN	O
Plavix	NNP	O
.	.	O

20	CD	O
-	:	O
29	CD	O
kg	SYM	O
-	:	O
900	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
29.1	CD	O
-	:	O
39	CD	O
kg	SYM	O
-	:	O
1200	CD	DOS
mg	NN	UNIT
/	NNP	FREQ
day	NN	FREQ
>	VBD	O
39	CD	O
kg	SYM	O
-	:	O
1800	CD	DOS
mg	NN	UNIT
/	NNP	FREQ
day	NN	FREQ

For	IN	O
those	DT	O
fungus	JJ	O
infections	NNS	O
more	RBR	O
difficult	JJ	O
to	TO	O
eradicate	VB	O
such	JJ	O
as	IN	O
tinea	NN	O
pedis	NN	O
and	CC	O
tinea	NN	O
unguium	NN	O
,	,	O
a	DT	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
1.0	CD	DOS
gram	NN	UNIT
is	VBZ	O
recommended	VBN	O
.	.	O

Promethazine	NNP	O
Hydrochloride	NNP	O
Injection	NNP	O
)	)	O
or	CC	O
by	IN	O
rectal	JJ	O
suppository	NN	O
.	.	O

If	IN	O
slower	JJR	O
administration	NN	O
is	VBZ	O
desired	VBN	O
,	,	O
200	CD	DOS
mL	NN	UNIT
of	IN	O
25	CD	O
%	NN	O
albumin	NN	O
may	MD	O
be	VB	O
mixed	JJ	O
with	IN	O
300	CD	DOS
mL	NNS	UNIT
of	IN	O
10	CD	O
%	NN	O
dextrose	JJ	O
solution	NN	O
and	CC	O
administered	VBN	O
by	IN	O
continuous	JJ	O
drip	NN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
this	DT	O
dextrose	JJ	O
solution	NN	O
an	DT	O
hour	NN	O
.	.	O

The	DT	O
maintenance	NN	O
dose	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
weekly	RB	FREQ
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
pretreatment	NN	O
control	NN	O
blood	NN	O
counts	NNS	O
and	CC	O
subsequent	JJ	O
blood	NN	O
counts	NNS	O
.	.	O

In	IN	O
all	DT	WHO
children	NNS	WHO
,	,	O
individualization	NN	O
of	IN	O
dosage	NN	O
is	VBZ	O
required	VBN	O
.	.	O

The	DT	O
following	JJ	O
calculation	NN	O
should	MD	O
be	VB	O
used	VBN	O
to	TO	O
determine	VB	O
the	DT	O
appropriate	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
KEPPRA	NNP	O
injection	NN	O
for	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
:	:	O

The	DT	O
effect	NN	O
of	IN	O
Novolin	NNP	O
70	CD	O
/	VBD	O
30	CD	O
begins	NNS	O
approximately	RB	O
½	VBP	O
hour	NN	O
after	IN	O
injection	NN	O
.	.	O

To	TO	O
use	VB	O
OLUX	NNP	O
(	(	O
clobetasol	JJ	O
propionate	NN	O
)	)	O
Foam	NN	O
:	:	O

Short	NNP	O
-	:	O
term	NN	O
administration	NN	O
of	IN	O
GLUCOPHAGE	NNP	O
or	CC	O
GLUCOPHAGE	NNP	O
XR	NNP	O
may	MD	O
be	VB	O
sufficient	JJ	O
during	IN	O
periods	NNS	O
of	IN	O
transient	JJ	O
loss	NN	O
of	IN	O
control	NN	O
in	IN	O
patients	NNS	WHO
usually	RB	WHO
well	RB	WHO
-	:	O
controlled	VBN	O
on	IN	O
diet	JJ	O
alone	NN	O
.	.	O

For	IN	O
intramuscular	JJ	O
use	NN	O
only	RB	O
.	.	O

However	RB	O
,	,	O
should	MD	O
dilution	VB	O
be	VB	O
necessary	JJ	O
,	,	O
it	PRP	O
should	MD	O
only	RB	O
be	VB	O
diluted	VBN	O
with	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
and	CC	O
it	PRP	O
should	MD	O
not	RB	O
be	VB	O
diluted	VBN	O
to	TO	O
a	DT	O
concentration	NN	O
less	JJR	O
than	IN	O
2	CD	DOS
mg	JJ	UNIT
/	NN	O
mL	NN	O
because	IN	O
it	PRP	O
is	VBZ	O
an	DT	O
emulsion	NN	O
.	.	O

A	DT	O
majority	NN	O
of	IN	O
patients	NNS	O
in	IN	O
clinical	JJ	O
studies	NNS	O
were	VBD	O
retreated	VBN	O
between	IN	O
12	CD	PER
-	:	O
16	CD	PER
weeks	NNS	PER
;	:	O
however	RB	O
some	DT	WHO
patients	NNS	WHO
had	VBD	O
a	DT	O
longer	RBR	O
duration	NN	O
of	IN	O
response	NN	O
,	,	O
i.e	NN	O
.	.	O

If	IN	O
serum	JJ	O
potassium	NN	O
increases	NNS	O
during	IN	O
ALDACTONE	NNP	O
administration	NN	O
but	CC	O
drops	NNS	O
when	WRB	O
ALDACTONE	NNP	O
is	VBZ	O
discontinued	VBN	O
,	,	O
a	DT	O
presumptive	JJ	O
diagnosis	NN	O
of	IN	O
primary	JJ	O
hyperaldosteronism	NN	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

To	TO	O
reduce	VB	O
the	DT	O
intestinal	JJ	O
side	NN	O
effects	NNS	O
(	(	O
see	VB	O
ADVERSE	NNP	O
REACTIONS	NNP	O
)	)	O
,	,	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
may	MD	O
be	VB	O
prepared	VBN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.12	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	NN	O
in	IN	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
USP	NNP	O
and	CC	O
given	VBN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
2	CD	DOS
mL	NNS	UNIT
per	IN	O
minute	NN	O
;	:	O
alternatively	RB	O
,	,	O
an	DT	O
intramuscular	JJ	O
dose	NN	O
of	IN	O
0.1	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	NN	O
may	MD	O
be	VB	O
given	VBN	O
.	.	O

Although	IN	O
most	JJS	O
people	NNS	O
in	IN	O
the	DT	O
military	JJ	O
since	IN	O
1941	CD	O
may	MD	O
have	VB	O
completed	VBN	O
a	DT	O
primary	JJ	O
series	NN	O
of	IN	O
tetanus	JJ	O
toxoid	NN	O
,	,	O
this	DT	O
can	MD	O
not	RB	O
be	VB	O
assumed	VBN	O
for	IN	O
each	DT	O
individual	NN	O
.	.	O

Monitoring	NN	O
may	MD	O
consist	VB	O
of	IN	O
a	DT	O
check	NN	O
for	IN	O
perfusion	NN	O
of	IN	O
the	DT	O
optic	JJ	O
nerve	NN	O
head	NN	O
immediately	RB	O
after	IN	O
the	DT	O
injection	NN	O
,	,	O
tonometry	NN	O
within	IN	O
30	CD	O
minutes	NNS	O
following	VBG	O
the	DT	O
injection	NN	O
,	,	O
and	CC	O
biomicroscopy	NN	O
between	IN	O
two	CD	PER
and	CC	O
seven	CD	O
days	NNS	O
following	VBG	O
the	DT	O
injection	NN	O
.	.	O

For	IN	O
initiation	NN	O
of	IN	O
MAC	NNP	O
sedation	NN	O
,	,	O
either	DT	O
an	DT	O
infusion	NN	O
or	CC	O
a	DT	O
slow	JJ	O
injection	NN	O
method	NN	O
may	MD	O
be	VB	O
utilized	VBN	O
while	IN	O
closely	RB	O
monitoring	VBG	O
cardiorespiratory	JJ	O
function	NN	O
.	.	O

Failure	NN	O
of	IN	O
the	DT	O
serum	NN	O
T4	NNP	O
to	TO	O
increase	VB	O
into	IN	O
the	DT	O
upper	JJ	O
half	NN	O
of	IN	O
the	DT	O
normal	JJ	O
range	NN	O
within	IN	O
2	CD	PER
weeks	NNS	PER
of	IN	O
initiation	NN	O
of	IN	O
TIROSINT	NNP	O
-	:	O
SOL	NNP	O
therapy	NN	O
and	CC	O
/	NN	O
or	CC	O
of	IN	O
the	DT	O
serum	NN	O
TSH	NNP	O
to	TO	O
decrease	VB	O
below	IN	O
20	CD	DOS
mIU	NNS	UNIT
per	IN	O
Liter	NNP	O
within	IN	O
4	CD	PER
weeks	NNS	PER
may	MD	O
indicate	VB	O
the	DT	O
child	NN	O
is	VBZ	O
not	RB	O
receiving	VBG	O
adequate	JJ	O
therapy	NN	O
.	.	O

Addition	NN	O
of	IN	O
insulin	NN	O
to	TO	O
Extraneal	NNP	O
(	(	O
icodextrin	JJ	O
peritoneal	NN	O
dialysis	NN	O
solution	NN	O
)	)	O
was	VBD	O
evaluated	VBN	O
in	IN	O
6	CD	DOS
insulin	NN	UNIT
-	:	O
dependent	JJ	O
diabetic	JJ	O
patients	NNS	O
undergoing	VBG	O
CAPD	NNP	O
for	IN	O
end	NN	O
stage	NN	O
renal	JJ	O
disease	NN	O
.	.	O

Diluted	VBN	O
Remodulin	NNP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
stable	JJ	O
at	IN	O
ambient	JJ	O
temperature	NN	O
when	WRB	O
stored	VBN	O
for	IN	O
up	RB	PER
to	TO	PER
14	CD	PER
days	NNS	PER
using	VBG	O
high	JJ	O
-	:	O
pH	NN	O
glycine	JJ	O
diluent	NN	O
at	IN	O
concentrations	NNS	O
as	RB	O
low	JJ	O
as	IN	O
0.004	CD	DOS
mg	NN	UNIT
/	NN	O
mL	NN	O
(	(	O
4,000	CD	DOS
ng	RB	UNIT
/	NNP	O
mL	NN	O
)	)	O
.	.	O

Figure	NN	O
4	CD	O
.	.	O

This	DT	O
solution	NN	O
should	MD	O
be	VB	O
protected	VBN	O
from	IN	O
light	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Dilution	NN	O
Instructions	NNS	O
for	IN	O
DYSPORT®	NNP	O
Vials	NNP	O
(	(	O
500	CD	O
Units	NNS	O
and	CC	O
300	CD	DOS
Units	NNS	UNIT
)	)	O

However	RB	O
,	,	O
no	DT	O
change	NN	O
should	MD	O
be	VB	O
instituted	VBN	O
without	IN	O
the	DT	O
knowledge	NN	O
of	IN	O
the	DT	O
physician	NN	O
.	.	O

Therapy	NN	O
should	MD	O
be	VB	O
continued	VBN	O
for	IN	O
at	IN	O
least	JJS	O
24	CD	O
-	:	O
48	CD	O
hours	NNS	O
after	IN	O
symptoms	NNS	O
and	CC	O
fever	NN	O
have	VBP	O
subsided	VBN	O
.	.	O

This	DT	O
monitoring	NN	O
should	MD	O
include	VB	O
blood	NN	O
chemistries	NNS	O
,	,	O
vital	JJ	O
signs	NNS	O
,	,	O
plasma	FW	O
carnitine	NN	O
concentrations	NNS	O
(	(	O
the	DT	O
plasma	NN	O
free	JJ	O
carnitine	NN	O
concentration	NN	O
should	MD	O
be	VB	O
between	IN	O
35	CD	DOS
and	CC	O
60	CD	DOS
μmol	NN	UNIT
/	NNP	O
L	NNP	O
)	)	O
and	CC	O
overall	JJ	O
clinical	JJ	O
condition	NN	O
.	.	O

In	IN	O
acute	JJ	O
painful	JJ	O
shoulder	NN	O
(	(	O
acute	JJ	O
subacromial	NN	O
bursitis	NN	O
/	NNP	O
supraspinatus	NN	O
tendinitis	NN	O
)	)	O
and	CC	O
acute	JJ	O
gouty	NN	O
arthritis	NN	O
,	,	O
the	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
200	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Next	JJ	O
,	,	O
calculate	VB	O
the	DT	O
volume	NN	O
of	IN	O
Nplate	NNP	O
solution	NN	O
that	WDT	O
is	VBZ	O
given	VBN	O
to	TO	O
the	DT	O
patient	NN	O
by	IN	O
dividing	VBG	O
the	DT	O
microgram	NN	O
dose	NN	O
by	IN	O
the	DT	O
concentration	NN	O
of	IN	O
the	DT	O
reconstituted	JJ	O
Nplate	NNP	O
solution	NN	O
(	(	O
500	CD	DOS
mcg	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O
.	.	O

A	DT	O
low	JJ	O
dosage	NN	O
or	CC	O
duration	NN	O
of	IN	O
treatment	NN	O
course	NN	O
is	VBZ	O
particularly	RB	O
recommended	JJ	O
if	IN	O
unusual	JJ	O
sensitivity	NN	O
to	TO	O
pituitary	JJ	O
gonadotropin	NN	O
is	VBZ	O
suspected	VBN	O
,	,	O
such	JJ	O
as	IN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
polycystic	JJ	WHO
ovary	JJ	WHO
syndrome	NN	WHO
(	(	O
see	VB	O
WARNINGS	NNP	O
;	:	O
Ovarian	JJ	O
Hyperstimulation	NNP	O
Syndrome	NNP	O
)	)	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	NN	O
matter	NN	O
prior	RB	O
to	TO	O
administration	NN	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

(	(	O
The	DT	O
first	JJ	O
day	NN	O
of	IN	O
menstruation	NN	O
is	VBZ	O
Day	NNP	O
1	CD	O
.	.	O
)	)	O

A	DT	O
weekly	JJ	O
dosage	NN	O
of	IN	O
up	IN	O
to	TO	O
0.3	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
divided	VBD	O
into	IN	O
daily	JJ	FREQ
subcutaneous	JJ	O
injections	NNS	O
is	VBZ	O
recommended	VBN	O
.	.	O

The	DT	O
clinically	RB	O
effective	JJ	O
serum	NN	O
level	NN	O
for	IN	O
primidone	NN	O
is	VBZ	O
between	IN	O
5	CD	DOS
to	TO	O
12	CD	DOS
μg	NNS	UNIT
/	JJ	O
mL	NN	O
.	.	O

Administer	NNP	O
FRAGMIN	NNP	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
approximately	RB	O
150	CD	DOS
IU	NNP	UNIT
/	NNP	O
kg	NN	O
,	,	O
subcutaneously	RB	O
once	RB	FREQ
daily	JJ	FREQ
during	IN	O
Months	NNS	O
2	CD	O
through	IN	O
6	CD	O
.	.	O

A	DT	O
clear	JJ	O
,	,	O
detailed	JJ	O
and	CC	O
convincing	JJ	O
description	NN	O
of	IN	O
the	DT	O
reaction	NN	O
is	VBZ	O
felt	VBN	O
to	TO	O
be	VB	O
sufficient	JJ	O
in	IN	O
most	JJS	O
cases	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
pediatric	JJ	O
dosage	NN	O
of	IN	O
Ferrlecit	NNP	O
for	IN	O
the	DT	O
repletion	NN	O
treatment	NN	O
of	IN	O
iron	NN	O
deficiency	NN	O
in	IN	O
hemodialysis	NN	WHO
patients	NNS	WHO
is	VBZ	O
0.12	CD	DOS
mL	NN	UNIT
/	NNP	O
kg	NN	O
Ferrlecit	NNP	O
(	(	O
1.5	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
of	IN	O
elemental	JJ	O
iron	NN	O
)	)	O
diluted	VBD	O
in	IN	O
25	CD	DOS
mL	NNS	UNIT
0.9	CD	O
%	NN	O
sodium	NN	O
chloride	NN	O
and	CC	O
administered	VBN	O
by	IN	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
1	CD	O
hour	NN	O
per	IN	O
dialysis	NN	O
session	NN	O
.	.	O

To	TO	O
achieve	VB	O
maximum	JJ	O
contraceptive	JJ	O
and	CC	O
PMDD	NNP	O
effectiveness	NN	O
,	,	O
Yaz	NNP	O
must	MD	O
be	VB	O
taken	VBN	O
exactly	RB	O
as	IN	O
directed	VBN	O
,	,	O
in	IN	O
the	DT	O
order	NN	O
directed	VBD	O
on	IN	O
the	DT	O
blister	NN	O
pack	NN	O
.	.	O

Disease	NNP	O
severity	NN	O
may	MD	O
dictate	VB	O
that	IN	O
drug	NN	O
be	VB	O
initiated	VBN	O
with	IN	O
relatively	RB	O
high	JJ	O
doses	NNS	O
or	CC	O
relatively	RB	O
frequent	JJ	O
administration	NN	O
.	.	O

To	TO	O
minimize	VB	O
the	DT	O
possibility	NN	O
of	IN	O
agglutination	NN	O
,	,	O
it	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
limit	VB	O
the	DT	O
amount	NN	O
of	IN	O
blood	NN	O
entering	VBG	O
the	DT	O
tubing	NN	O
.	.	O

If	IN	O
acceptable	JJ	O
alternatives	NNS	O
to	TO	O
linezolid	VB	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	JJ	O
treatment	NN	O
are	VBP	O
not	RB	O
available	JJ	O
and	CC	O
the	DT	O
potential	JJ	O
benefits	NNS	O
of	IN	O
linezolid	JJ	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	JJ	O
treatment	NN	O
are	VBP	O
judged	VBN	O
to	TO	O
outweigh	VB	O
the	DT	O
risks	NNS	O
of	IN	O
serotonin	JJ	O
syndrome	NN	O
in	IN	O
a	DT	O
particular	JJ	WHO
patient	NN	WHO
,	,	O
TRINTELLIX	NNP	O
should	MD	O
be	VB	O
stopped	VBN	O
promptly	RB	O
,	,	O
and	CC	O
linezolid	VBD	O
or	CC	O
intravenous	JJ	O
methylene	NNS	O
blue	VBP	O
can	MD	O
be	VB	O
administered	VBN	O
.	.	O

To	TO	O
reduce	VB	O
the	DT	O
likelihood	NN	O
of	IN	O
hypotension	NN	O
,	,	O
the	DT	O
diuretic	NN	O
should	MD	O
,	,	O
if	IN	O
possible	JJ	O
,	,	O
be	VB	O
discontinued	VBN	O
2	CD	PER
to	TO	O
3	CD	PER
days	NNS	PER
prior	RB	O
to	TO	O
beginning	VBG	O
therapy	NN	O
with	IN	O
MONOPRIL	NNP	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

The	DT	O
percentage	NN	O
of	IN	O
women	NNS	WHO
becoming	VBG	WHO
pregnant	JJ	WHO
noted	VBN	WHO
in	IN	WHO
columns	NN	WHO
(	(	O
2	CD	O
)	)	O
and	CC	O
(	(	O
3	CD	O
)	)	O
are	VBP	O
based	VBN	O
on	IN	O
data	NNS	O
from	IN	O
populations	NNS	O
where	WRB	O
contraception	NN	O
is	VBZ	O
not	RB	O
used	VBN	O
and	CC	O
from	IN	O
women	NNS	WHO
who	WP	WHO
cease	VBP	WHO
using	VBG	WHO
contraception	NN	WHO
in	IN	O
order	NN	O
to	TO	O
become	VB	O
pregnant	JJ	O
.	.	O

Do	NNP	O
not	RB	O
abruptly	RB	O
discontinue	VBP	O
TROXYCA	NNP	O
ER	NNP	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Drug	NNP	O
Abuse	NNP	O
and	CC	O
Dependence	NNP	O
]	NNP	O
.	.	O

Enstilar®	NNP	O
Foam	NNP	O
is	VBZ	O
not	RB	O
for	IN	O
oral	JJ	O
,	,	O
ophthalmic	JJ	O
,	,	O
or	CC	O
intravaginal	JJ	O
use	NN	O
.	.	O

Laboratory	NN	O
control	NN	O
to	TO	O
assure	VB	O
such	JJ	O
levels	NNS	O
is	VBZ	O
recommended	VBN	O
.	.	O

The	DT	O
application	NN	O
frequency	NN	O
should	MD	O
be	VB	O
increased	VBN	O
at	IN	O
weekly	JJ	FREQ
intervals	NNS	FREQ
to	TO	O
once	RB	FREQ
daily	JJ	FREQ
,	,	O
then	RB	O
twice	RB	FREQ
daily	RB	FREQ
,	,	O
then	RB	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
and	CC	O
finally	RB	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
according	VBG	O
to	TO	O
individual	JJ	O
lesion	NN	O
tolerance	NN	O
.	.	O

[	JJ	O
Fig	NNP	O
.	.	O

Corneal	NNP	O
and	CC	O
conjunctival	JJ	O
reflexes	NNS	O
disappear	VBP	O
during	IN	O
surgical	JJ	O
anesthesia	NN	O
.	.	O

Adjust	NNP	O
dosage	NN	O
according	VBG	O
to	TO	O
blood	NN	O
pressure	NN	O
response	NN	O
.	.	O

The	DT	O
pump	NN	O
flow	NN	O
rate	NN	O
for	IN	O
this	DT	O
example	NN	O
would	MD	O
be	VB	O
set	VBN	O
at	IN	O
1	CD	DOS
mL	NN	UNIT
/	NNP	O
hr	NN	O
.	.	O

Long	NNP	O
-	:	O
term	NN	O
use	NN	O
of	IN	O
ABSORICA	NNP	O
,	,	O
even	RB	O
in	IN	O
low	JJ	O
doses	NNS	O
,	,	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
,	,	O
and	CC	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

Griseofulvin	NNP	O
will	MD	O
not	RB	O
eradicate	VB	O
the	DT	O
bacterial	JJ	O
or	CC	O
monilial	JJ	O
infection	NN	O
.	.	O

Vital	JJ	O
signs	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
while	IN	O
initiating	VBG	O
Ventavis	NNP	O
.	.	O

A	DT	O
dose	JJ	O
decrease	NN	O
down	RB	O
to	TO	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
may	MD	O
be	VB	O
considered	VBN	O
for	IN	O
patients	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
tolerate	VB	WHO
higher	JJR	WHO
doses	NNS	WHO
[	VBP	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

They	PRP	O
should	MD	O
receive	VB	O
Tetanus	NNP	O
and	CC	O
Diphtheria	NNP	O
Toxoids	NNP	O
(	(	O
Td	NNP	O
)	)	O
for	IN	O
adult	NN	WHO
use	NN	O
for	IN	O
routine	JJ	O
booster	NN	O
immunization	NN	O
against	IN	O
tetanus	NN	O
and	CC	O
diphtheria	NN	O
.	.	O

Serum	NNP	O
lipids	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
for	IN	O
evidence	NN	O
of	IN	O
EFAD	NNP	O
in	IN	O
patients	NNS	WHO
maintained	VBN	O
on	IN	O
fat	JJ	O
-	:	O
free	JJ	O
TPN	NNP	O
.	.	O

Most	JJS	O
of	IN	O
the	DT	O
patients	NNS	O
described	VBD	O
as	IN	O
having	VBG	O
been	VBN	O
treated	VBN	O
with	IN	O
this	DT	O
regimen	NNS	O
also	RB	O
underwent	JJ	O
exchange	NN	O
transfusion	NN	O
.	.	O

AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
children	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
.	.	O

Then	RB	O
,	,	O
when	WRB	O
blood	NN	O
pressure	NN	O
has	VBZ	O
stabilized	VBN	O
,	,	O
infusion	NN	O
of	IN	O
Cardene	NNP	O
I.V	NNP	O
.	.	O

The	DT	O
opacity	NN	O
will	MD	O
diminish	VB	O
gradually	RB	O
.	.	O

The	DT	O
package	NN	O
should	MD	O
never	RB	O
be	VB	O
opened	VBN	O
with	IN	O
scissors	NNS	O
or	CC	O
other	JJ	O
sharp	JJ	O
objects	NNS	O
which	WDT	O
may	MD	O
compromise	VB	O
or	CC	O
cut	VB	O
the	DT	O
knitted	VBN	O
polyester	NN	O
pouch	NN	O
that	WDT	O
serves	VBZ	O
as	IN	O
the	DT	O
retrieval	NN	O
system	NN	O
for	IN	O
the	DT	O
polymeric	JJ	O
slab	NN	O
.	.	O

In	IN	O
some	DT	WHO
cases	NNS	WHO
,	,	O
a	DT	O
patient	NN	O
already	RB	O
receiving	VBG	O
EFFEXOR	NNP	O
XR	NNP	O
therapy	NN	O
may	MD	O
require	VB	O
urgent	JJ	O
treatment	NN	O
with	IN	O
linezolid	JJ	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	NN	O
.	.	O

When	WRB	O
concentrated	VBN	O
dextrose	JJ	O
infusion	NN	O
is	VBZ	O
abruptly	RB	O
interrupted	VBN	O
rebound	NN	O
hypoglycemia	NN	O
may	MD	O
occur	VB	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
prevented	VBN	O
by	IN	O
the	DT	O
administration	NN	O
of	IN	O
5	CD	O
%	NN	O
or	CC	O
10	CD	O
%	NN	O
dextrose	JJ	O
solutions	NNS	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Erbitux	NN	O
Dose	NNP	O
Modification	NNP	O
Guidelines	NNP	O
for	IN	O
Rash	NNP	O

Monitor	NN	O
patients	NNS	O
closely	RB	O
for	IN	O
respiratory	JJ	O
depression	NN	O
,	,	O
especially	RB	O
within	IN	O
the	DT	O
first	JJ	O
24	CD	O
to	TO	O
72	CD	O
hours	NNS	O
of	IN	O
initiating	VBG	O
therapy	NN	O
with	IN	O
fentanyl	NN	O
transdermal	NN	O
system	NN	O
when	WRB	O
serum	NN	O
concentrations	NNS	O
from	IN	O
the	DT	O
initial	JJ	O
patch	NN	O
will	MD	O
peak	VB	O
[	NNP	O
see	VB	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	JJ	O
frequency	NN	O
of	IN	O
monitoring	NN	O
of	IN	O
TSH	NNP	O
and	CC	O
total	JJ	O
or	CC	O
FT4	NNP	O
in	IN	O
children	NNS	WHO
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O
at	IN	O
2	CD	PER
and	CC	O
4	CD	PER
weeks	NNS	PER
after	IN	O
the	DT	O
initiation	NN	O
of	IN	O
treatment	NN	O
and	CC	O
following	VBG	O
dose	JJ	O
stabilization	NN	O
every	DT	FREQ
3	CD	FREQ
to	TO	O
12	CD	FREQ
months	NNS	FREQ
thereafter	RB	O
until	IN	O
growth	NN	O
is	VBZ	O
completed	VBN	O
.	.	O

Dose	NNP	O
increases	NNS	O
should	MD	O
be	VB	O
in	IN	O
increments	NNS	O
of	IN	O
up	IN	O
to	TO	O
75	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
,	,	O
as	IN	O
needed	VBN	O
,	,	O
and	CC	O
should	MD	O
be	VB	O
made	VBN	O
at	IN	O
intervals	NNS	O
of	IN	O
not	RB	O
less	JJR	O
than	IN	O
4	CD	O
days	NNS	O
,	,	O
since	IN	O
steady	JJ	O
-	:	O
state	NN	O
plasma	NN	O
levels	NNS	O
of	IN	O
venlafaxine	NN	O
and	CC	O
its	PRP$	O
major	JJ	O
metabolites	NNS	O
are	VBP	O
achieved	VBN	O
in	IN	O
most	JJS	WHO
patients	NNS	WHO
by	IN	WHO
day	NN	WHO
4	CD	O
[	NN	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Monitor	NNP	O
the	DT	O
patient	NN	O
clinically	RB	O
for	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
allergic	JJ	O
reaction	NN	O
and	CC	O
potential	JJ	O
cardiac	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
drug	NN	O
,	,	O
with	IN	O
repeat	NN	O
doses	NNS	O
titrated	VBD	O
to	TO	O
effect	NN	O
.	.	O

If	IN	O
there	EX	O
are	VBP	O
bubbles	NNS	O
,	,	O
gently	RB	O
tap	VBZ	O
the	DT	O
syringe	NN	O
with	IN	O
your	PRP$	O
finger	NN	O
until	IN	O
the	DT	O
bubbles	NNS	O
rise	VBP	O
to	TO	O
the	DT	O
top	JJ	O
(	(	O
see	VB	O
Figure	NNP	O
6	CD	O
)	)	O
.	.	O

Prepare	NNP	O
LUSEDRA	NNP	O
(	(	O
fospropofol	JJ	O
disodium	NN	O
injection	NN	O
)	)	O
following	VBG	O
strict	JJ	O
aseptic	JJ	O
techniques	NNS	O
.	.	O

Continuous	JJ	O
monitoring	NN	O
of	IN	O
respiratory	NN	O
and	CC	O
cardiac	JJ	O
function	NN	O
is	VBZ	O
required	VBN	O
.	.	O

To	TO	O
prepare	VB	O
LUCENTIS	NNP	O
for	IN	O
intravitreal	JJ	O
administration	NN	O
,	,	O
please	VB	O
adhere	RB	O
to	TO	O
these	DT	O
instructions	NNS	O
for	IN	O
use	NN	O
.	.	O

Step	NN	O
3	CD	O
:	:	O
Immediately	RB	O
Slide	NNP	O
Green	NNP	O
Safety	NNP	O
Guard	NNP	O
Over	NNP	O
Needle	NNP	O

Complete	JJ	O
reconstitution	NN	O
usually	RB	O
requires	VBZ	O
at	IN	O
least	JJS	O
30	CD	O
minutes	NNS	O
.	.	O

When	WRB	O
transferring	VBG	O
patients	NNS	O
from	IN	O
oral	JJ	O
hypoglycemic	JJ	O
agents	NNS	O
other	JJ	O
than	IN	O
chlorpropamide	NN	O
to	TO	O
GLYNASE	NNP	O
PresTab	NNP	O
,	,	O
no	DT	O
transition	NN	O
period	NN	O
and	CC	O
no	DT	O
initial	JJ	O
or	CC	O
priming	VBG	O
dose	NNS	O
are	VBP	O
necessary	JJ	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
,	,	O
alternatives	NNS	O
to	TO	O
VOTRIENT	NNP	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

The	DT	O
solution	NN	O
should	MD	O
be	VB	O
inspected	VBN	O
for	IN	O
clarity	NN	O
.	.	O

The	DT	O
dosages	NNS	O
described	VBN	O
below	IN	O
are	VBP	O
presented	VBN	O
as	IN	O
general	JJ	O
guidance	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
Targretin®	NNP	O
(	(	O
bexarotene	NN	O
)	)	O
capsules	VBZ	O
is	VBZ	O
300	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

Final	JJ	O
dosage	NN	O
adjustment	NN	O
guided	VBN	O
by	IN	O
serum	JJ	O
theophylline	JJ	O
concentration	NN	O
.	.	O

Because	IN	O
of	IN	O
variability	NN	O
in	IN	O
analytical	JJ	O
values	NNS	O
among	IN	O
diagnostic	JJ	O
laboratories	NNS	O
,	,	O
this	DT	O
laboratory	NN	O
work	NN	O
and	CC	O
later	JJ	O
analyses	NNS	O
for	IN	O
assessing	VBG	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
TESTODERM	NNP	O
(	(	O
testosterone	NN	O
(	(	O
transdermal	JJ	O
)	)	O
)	)	O
and	CC	O
TESTODERM	NNP	O
(	(	O
testosterone	NN	O
(	(	O
transdermal	JJ	O
)	)	O
)	)	O
WITH	NNP	O
ADHESIVE	NNP	O
therapy	NN	O
should	MD	O
be	VB	O
performed	VBN	O
at	IN	O
the	DT	O
same	JJ	O
laboratory	NN	O
.	.	O

Fabrazyme	NNP	O
(	(	O
agalsidase	VB	O
beta	NN	O
)	)	O
does	VBZ	O
not	RB	O
contain	VB	O
any	DT	O
preservatives	NNS	O
.	.	O

If	IN	O
excessive	JJ	O
salt	NN	O
and	CC	O
water	NN	O
retention	NN	O
results	NNS	O
in	IN	O
a	DT	O
weight	JJ	O
gain	NN	O
of	IN	O
more	JJR	O
than	IN	O
5	CD	O
pounds	NNS	O
,	,	O
diuretic	JJ	O
therapy	NN	O
should	MD	O
be	VB	O
changed	VBN	O
to	TO	O
furosemide	VB	O
;	:	O
if	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
already	RB	O
taking	VBG	O
furosemide	NN	O
,	,	O
dosage	NN	O
should	MD	O
be	VB	O
increased	VBN	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
patient	NN	O
's	POS	O
requirements	NNS	O
.	.	O

NAMZARIC	NNP	O
capsules	NNS	O
should	MD	O
not	RB	O
be	VB	O
divided	VBN	O
,	,	O
chewed	VBN	O
,	,	O
or	CC	O
crushed	VBN	O
.	.	O

irritation	NN	O
may	MD	O
benefit	VB	O
from	IN	O
administration	NN	O
of	IN	O
the	DT	O
drug	NN	O
with	IN	O
food	NN	O
or	CC	O
by	IN	O
slowly	RB	O
building	VBG	O
up	RP	O
the	DT	O
dose	NN	O
from	IN	O
an	DT	O
initial	JJ	O
low	JJ	O
level	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

GARDASIL	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
intramuscularly	RB	O
as	IN	O
a	DT	O
0.5	CD	DOS
-	:	O
mL	NN	UNIT
dose	NN	UNIT
at	IN	O
the	DT	O
following	JJ	O
schedule	NN	O
:	:	O
0	CD	O
,	,	O
2	CD	PER
months	NNS	PER
,	,	O
6	CD	PER
months	NNS	PER
.	.	O

Because	IN	O
TRIUMEQ	NNP	O
is	VBZ	O
a	DT	O
fixed	JJ	O
-	:	O
dose	JJ	O
tablet	NN	O
and	CC	O
can	MD	O
not	RB	O
be	VB	O
dose	RB	O
adjusted	VBN	O
,	,	O
TRIUMEQ	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
in	IN	O
:	:	O

To	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
renal	JJ	O
adverse	JJ	O
reactions	NNS	O
,	,	O
patients	NNS	O
must	MD	O
be	VB	O
well	RB	O
hydrated	VBN	O
prior	RB	O
to	TO	O
administration	NN	O
of	IN	O
DYLOJECT	NNP	O
.	.	O

REBETOL	NNP	O
and	CC	O
INTRON	NNP	O
A	NNP	O

The	DT	O
diluent	NN	O
should	MD	O
appear	VB	O
clear	JJ	O
.	.	O

Insert	NNP	O
needle	JJ	O
with	IN	O
aseptic	JJ	O
precautions	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
ketoprofen	NN	O
in	IN	O
otherwise	RB	O
healthy	JJ	WHO
patients	NNS	WHO
is	VBZ	O
for	IN	O
Orudis	NNP	O
(	(	O
ketoprofen	NN	O
)	)	O
75	CD	DOS
mg	NN	UNIT
three	CD	FREQ
times	NNS	FREQ
or	CC	O
50	CD	DOS
mg	NNS	UNIT
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
,	,	O
or	CC	O
for	IN	O
Oruvail	NNP	O
200	CD	DOS
mg	NN	UNIT
administered	VBN	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
dose	NN	O
of	IN	O
XIAFLEX	NNP	O
is	VBZ	O
0.58	CD	DOS
mg	NN	UNIT
per	IN	O
injection	NN	O
into	IN	O
a	DT	O
palpable	JJ	O
cord	NN	O
with	IN	O
a	DT	O
contracture	NN	O
of	IN	O
a	DT	O
metacarpophalangeal	NN	O
(	(	O
MP	NNP	O
)	)	O
joint	NN	O
or	CC	O
a	DT	O
proximal	JJ	O
interphalangeal	NN	O
(	(	O
PIP	NNP	O
)	)	O
joint	NN	O
[	NNP	O
see	VBP	O
Dosage	NNP	O
And	CC	O
Administration	NNP	O
For	IN	O
Dupuytren	NNP	O
’	NNP	O
s	JJ	O
Contracture	NNP	O
]	NNP	O
.	.	O

Intravenous	JJ	O
Administration	NNP	O
–	NNP	O
For	IN	O
intravenous	JJ	O
administration	NN	O
,	,	O
the	DT	O
usual	JJ	O
volume	NN	O
of	IN	O
diluent	NN	O
(	(	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
or	CC	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
)	)	O
is	VBZ	O
50	CD	DOS
to	TO	O
100	CD	DOS
mL	NN	UNIT
for	IN	O
adult	NN	WHO
doses	NNS	WHO
.	.	O

The	DT	O
recommended	JJ	O
doses	NNS	O
represent	VBP	O
a	DT	O
compromise	NN	O
between	IN	O
a	DT	O
desirable	JJ	O
controlled	VBN	O
reversal	NN	O
and	CC	O
the	DT	O
need	NN	O
for	IN	O
prompt	JJ	O
response	NN	O
and	CC	O
adequate	JJ	O
duration	NN	O
of	IN	O
action	NN	O
.	.	O

Perform	NNP	O
reconstitution	NN	O
,	,	O
product	NN	O
administration	NN	O
,	,	O
and	CC	O
handling	NN	O
of	IN	O
the	DT	O
administration	NN	O
set	NN	O
and	CC	O
needles	NNS	O
with	IN	O
caution	NN	O
.	.	O

The	DT	O
initial	JJ	O
regulation	NN	O
of	IN	O
dosage	NN	O
should	MD	O
be	VB	O
determined	VBN	O
by	IN	O
blood	NN	O
pressure	NN	O
readings	NNS	O
in	IN	O
the	DT	O
erect	JJ	O
position	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
maximal	JJ	O
effect	NN	O
of	IN	O
the	DT	O
drug	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
by	IN	O
other	JJ	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
orthostatic	JJ	O
hypotension	NN	O
.	.	O

Hepatitis	NN	O
B	NNP	O
Immune	NNP	O
Globulin	NNP	O
(	(	O
HBIG	NNP	O
)	)	O
products	NNS	O
are	VBP	O
most	RBS	O
effective	JJ	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
no	DT	WHO
or	CC	O
low	JJ	O
levels	NNS	O
of	IN	O
HBV	NNP	O
replication	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
transplantation.5	NN	O

One	CD	O
of	IN	O
the	DT	O
following	VBG	O
two	CD	DOS
options	NNS	UNIT
should	MD	O
be	VB	O
chosen	VBN	O
:	:	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
10	CD	DOS
g	NN	UNIT
to	TO	O
20	CD	DOS
g	NN	UNIT
of	IN	O
lactulose	JJ	O
daily	JJ	FREQ
.	.	O

Therefore	RB	O
,	,	O
addition	NN	O
of	IN	O
a	DT	O
cysteine	JJ	O
supplement	NN	O
to	TO	O
the	DT	O
TPN	NNP	O
admixture	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

As	IN	O
with	IN	O
all	DT	O
iodinated	VBN	O
contrast	NN	O
agents	NNS	O
,	,	O
lower	JJR	O
doses	NNS	O
of	IN	O
OXILAN®	NNP	O
Injection	NNP	O
may	MD	O
have	VB	O
less	JJR	O
risk	NN	O
.	.	O

Unopened	VBN	O
,	,	O
unused	JJ	O
vials	NNS	O
of	IN	O
Infasurf	NNP	O
that	WDT	O
have	VBP	O
warmed	VBN	O
to	TO	O
room	NN	O
temperature	NN	O
can	MD	O
be	VB	O
returned	VBN	O
to	TO	O
refrigerated	VBN	O
storage	NN	O
within	IN	O
24	CD	O
hours	NNS	O
for	IN	O
future	JJ	O
use	NN	O
.	.	O

Administration	NN	O
of	IN	O
the	DT	O
entire	JJ	O
vial	NN	O
constitutes	VBZ	O
a	DT	O
complete	JJ	O
starting	VBG	O
dose	NN	O
.	.	O

Because	IN	O
PRADAXA	NNP	O
can	MD	O
increase	VB	O
INR	NNP	O
,	,	O
the	DT	O
INR	NNP	O
will	MD	O
better	VB	O
reflect	VB	O
warfarin	NN	O
's	POS	O
effect	NN	O
only	RB	O
after	IN	O
PRADAXA	NNP	O
has	VBZ	O
been	VBN	O
stopped	VBN	O
for	IN	O
at	IN	PER
least	JJS	PER
2	CD	PER
days	NNS	PER
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Inspect	VB	O
the	DT	O
final	JJ	O
XYNTHA	NNP	O
solution	NN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

The	DT	O
treatment	NN	O
of	IN	O
status	NN	O
,	,	O
however	RB	O
,	,	O
requires	VBZ	O
far	RB	O
more	JJR	O
than	IN	O
the	DT	O
administration	NN	O
of	IN	O
an	DT	O
anticonvulsant	JJ	O
agent	NN	O
.	.	O

1	CD	O
)	)	O

Marqibo	NNP	O
is	VBZ	O
liposome	JJ	O
-	:	O
encapsulated	JJ	O
vincristine	NN	O
.	.	O

The	DT	O
placebo	NN	O
-	:	O
controlled	VBN	O
studies	NNS	O
that	WDT	O
demonstrated	VBD	O
the	DT	O
efficacy	NN	O
of	IN	O
REVIA	NNP	O
as	IN	O
an	DT	O
adjunctive	JJ	O
treatment	NN	O
of	IN	O
alcoholism	NN	O
used	VBN	O
a	DT	O
dose	JJ	O
regimen	NNS	O
of	IN	O
REVIA	NNP	O
50	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
for	IN	O
up	IN	PER
to	TO	PER
12	CD	PER
weeks	NNS	PER
.	.	O

Dosage	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
according	VBG	O
to	TO	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
pain	NN	O
and	CC	O
the	DT	O
response	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

The	DT	O
physician	NN	O
should	MD	O
be	VB	O
familiar	JJ	O
with	IN	O
the	DT	O
new	JJ	O
advances	NNS	O
in	IN	O
antileukemic	JJ	O
therapy	NN	O
.	.	O

Grasp	NNP	O
the	DT	O
MIXJECT	NNP	O
system	NN	O
firmly	RB	O
by	IN	O
the	DT	O
syringe	NN	O
and	CC	O
pull	VB	O
back	RB	O
the	DT	O
plunger	NN	O
rod	NN	O
slowly	RB	O
to	TO	O
draw	VB	O
the	DT	O
reconstituted	JJ	O
TRELSTAR	NNP	O
into	IN	O
the	DT	O
syringe	NN	O
.	.	O

Stability	NN	O
of	IN	O
ZOSYN	NNP	O
in	IN	O
an	DT	O
ambulatory	NN	O
intravenous	JJ	O
infusion	NN	O
pump	NN	O
has	VBZ	O
been	VBN	O
demonstrated	VBN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
12	CD	O
hours	NNS	O
at	IN	O
room	NN	O
temperature	NN	O
.	.	O

Vitamin	NNP	O
B12	NNP	O
,	,	O
vitamin	NN	O
K	NNP	O
and	CC	O
folic	JJ	O
acid	NN	O
are	VBP	O
given	VBN	O
intramuscularly	RB	O
or	CC	O
added	VBN	O
to	TO	O
the	DT	O
solution	NN	O
as	IN	O
desired	VBN	O
.	.	O

As	IN	O
reported	VBN	O
in	IN	O
the	DT	O
literature	NN	O
,	,	O
the	DT	O
dosage	NN	O
and	CC	O
constant	JJ	O
infusion	NN	O
rate	NN	O
of	IN	O
intravenous	JJ	O
dextrose	NN	O
must	MD	O
be	VB	O
selected	VBN	O
with	IN	O
caution	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
,	,	WHO
particularly	RB	WHO
neonates	NNS	WHO
and	CC	WHO
low	JJ	WHO
birth	NN	WHO
weight	NN	WHO
infants	NNS	WHO
,	,	O
because	IN	O
of	IN	O
the	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
hyperglycemia	NN	O
/	NNP	O
hypoglycemia	NN	O
.	.	O

6	CD	O
.	.	O

The	DT	O
reconstituted	JJ	O
product	NN	O
should	MD	O
be	VB	O
protected	VBN	O
from	IN	O
bright	JJ	O
light	NN	O
and	CC	O
used	VBD	O
immediately	RB	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
CELEBREX	NNP	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
is	VBZ	O
not	RB	O
recommended	JJ	O
[	NNS	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

The	DT	O
first	JJ	O
bowel	NN	O
movement	NN	O
should	MD	O
occur	VB	O
approximately	RB	O
one	CD	O
hour	NN	O
after	IN	O
the	DT	O
start	NN	O
of	IN	O
GaviLyte	NNP	O
-	:	O
N	NNP	O
administration	NN	O
.	.	O

The	DT	O
top	JJ	O
two	CD	O
arrows	NNS	O
are	VBP	O
pointing	VBG	O
to	TO	O
normal	JJ	O
preserved	JJ	O
gray	JJ	O
-	:	O
white	JJ	O
contrast	NN	O
with	IN	O
the	DT	O
cortical	JJ	O
radioactivity	NN	O
less	JJR	O
than	IN	O
the	DT	O
adjacent	JJ	O
white	JJ	O
matter	NN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
patients	NNS	O
alternate	VBP	O
sides	NNS	O
of	IN	O
the	DT	O
mouth	NN	O
when	WRB	O
administering	VBG	O
subsequent	JJ	O
doses	NNS	O
of	IN	O
FENTORA	NNP	O
in	IN	O
the	DT	O
buccal	JJ	O
cavity	NN	O
.	.	O

If	IN	O
intercourse	NN	O
has	VBZ	O
already	RB	O
occurred	VBN	O
,	,	O
pregnancy	NN	O
should	MD	O
be	VB	O
excluded	VBN	O
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
schedule	NN	O
for	IN	O
IMLYGIC	NNP	O
is	VBZ	O
shown	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
.	.	O

A	DT	O
maximum	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
of	IN	O
450	CD	DOS
mg	NN	UNIT
of	IN	O
CAPOTEN	NNP	O
should	MD	O
not	RB	O
be	VB	O
exceeded	VBN	O
.	.	O

Additionally	RB	O
,	,	O
oral	JJ	O
ZYPREXA	NNP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
in	IN	O
maintenance	NN	O
of	IN	O
treatment	NN	O
response	NN	O
in	IN	O
schizophrenia	NN	O
in	IN	O
longer	JJR	O
-	:	O
term	NN	O
use	NN	O
.	.	O

4	CD	O

In	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
weighing	VBG	WHO
less	JJR	WHO
than	IN	WHO
35	CD	WHO
kg	NN	WHO
,	,	O
the	DT	O
recommended	JJ	O
regimen	NNS	O
is	VBZ	O
two	CD	DOS
doses	NNS	UNIT
of	IN	O
10	CD	DOS
mg	NNS	UNIT
each	DT	O
.	.	O

10	CD	O
.	.	O

Concomitantly	RB	O
prescribed	VBN	O
H2	NNP	O
antagonist	JJ	O
therapy	NN	O
should	MD	O
be	VB	O
taken	VBN	O
as	IN	O
directed	JJ	O
.	.	O

For	IN	O
additional	JJ	O
patient	NN	O
instructions	NNS	O
regarding	VBG	O
missed	JJ	O
pills	NNS	O
,	,	O
see	VBP	O
the	DT	O
“	NNP	O
WHAT	NNP	O
TO	NNP	O
DO	VB	O
IF	NNP	O
YOU	NNP	O
MISS	NNP	O
PILLS	NNP	O
”	NNP	O
section	NN	O
in	IN	O
the	DT	O
DETAILED	NNP	O
PATIENT	NNP	O
LABELING	NNP	O
below	IN	O
.	.	O

Partially	RB	O
reversing	VBG	O
doses	NNS	O
of	IN	O
REVEX	NNP	O
(	(	O
1	CD	DOS
µg	NNP	UNIT
/	NNP	O
kg	NN	O
)	)	O
lose	VBP	O
their	PRP$	O
effect	NN	O
as	IN	O
the	DT	O
drug	NN	O
is	VBZ	O
redistributed	VBN	O
through	IN	O
the	DT	O
body	NN	O
,	,	O
and	CC	O
the	DT	O
effects	NNS	O
of	IN	O
these	DT	O
low	JJ	O
doses	NNS	O
may	MD	O
not	RB	O
last	JJ	O
more	JJR	O
than	IN	O
30	CD	O
-	:	O
60	CD	O
minutes	NNS	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
persistent	JJ	O
opioid	JJ	O
effects	NNS	O
.	.	O

The	DT	O
physician	NN	O
must	MD	O
impress	VB	O
upon	IN	O
the	DT	O
patient	NN	O
the	DT	O
need	NN	O
for	IN	O
further	JJ	O
toxoid	JJ	O
injections	NNS	O
in	IN	O
1	CD	O
month	NN	O
and	CC	O
1	CD	O
year	NN	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
a	DT	WHO
history	NN	WHO
of	IN	WHO
difficulty	NN	WHO
in	IN	WHO
swallowing	VBG	WHO
tablets	NNS	WHO
or	CC	WHO
who	WP	WHO
have	VBP	WHO
known	VBN	WHO
upper	JJ	WHO
gastrointestinal	JJ	WHO
narrowing	NN	WHO
or	CC	O
abnormal	JJ	O
esophageal	JJ	O
peristalsis	NN	O
should	MD	O
not	RB	O
use	VB	O
the	DT	O
24	CD	O
hour	NN	O
tablet	NN	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
,	,	O
Information	NNP	O
for	IN	O
the	DT	O
Patient	NNP	O
;	:	O
and	CC	O
ADVERSE	NNP	O
REACTIONS	NNP	O
)	)	O
.	.	O

A	DT	O
dosage	NN	O
of	IN	O
12	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NNS	O
once	RB	FREQ
daily	JJ	FREQ
may	MD	O
be	VB	O
used	VBN	O
,	,	O
based	VBN	O
on	IN	O
medical	JJ	O
judgment	NN	O
of	IN	O
the	DT	O
patient	NN	O
's	POS	O
response	NN	O
to	TO	O
therapy	NN	O
.	.	O

One	CD	DOS
tablespoon	NN	UNIT
of	IN	O
applesauce	NN	O
should	MD	O
be	VB	O
added	VBN	O
to	TO	O
an	DT	O
empty	JJ	O
bowl	NN	O
and	CC	O
the	DT	O
capsule	NN	O
should	MD	O
be	VB	O
opened	VBN	O
.	.	O

The	DT	O
recommended	JJ	O
concentration	NN	O
for	IN	O
intravenous	JJ	O
infusion	NN	O
is	VBZ	O
0.1	CD	DOS
mg	NN	UNIT
/	NN	O
mL	NN	O
(	(	O
1	CD	DOS
mg	NN	UNIT
/	VBD	O
10	CD	DOS
mL	NN	UNIT
)	)	O
.	.	O

Tables	NNS	O
10	CD	O
and	CC	O
11	CD	O
provide	NN	O
guidelines	NNS	O
for	IN	O
delivery	NN	O
,	,	O
in	IN	O
mL	JJ	O
/	NN	O
hr	NN	O
(	(	O
equivalent	JJ	O
to	TO	O
microdrops	VB	O
/	NNP	O
minute	NN	O
when	WRB	O
60	CD	DOS
microdrops	NNS	UNIT
=	RB	O
1	CD	DOS
mL	NN	UNIT
)	)	O
,	,	O
of	IN	O
NIMBEX	NNP	O
solutions	NNS	O
in	IN	O
concentrations	NNS	O
of	IN	O
0.1	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
(	(	O
10	CD	DOS
mg	NN	UNIT
/	VBD	O
100	CD	DOS
mL	NN	UNIT
)	)	O
or	CC	O
0.4	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
(	(	O
40	CD	DOS
mg	NN	UNIT
/	VBD	O
100	CD	DOS
mL	NN	UNIT
)	)	O
.	.	O

After	IN	O
removal	NN	O
from	IN	O
refrigerated	JJ	O
conditions	NNS	O
,	,	O
the	DT	O
suspension	NN	O
may	MD	O
be	VB	O
allowed	VBN	O
to	TO	O
equilibrate	VB	O
to	TO	O
room	NN	O
temperature	NN	O
for	IN	O
up	IN	O
to	TO	O
30	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

Hemodialysis	NN	O
patients	NNS	O
should	MD	O
receive	VB	O
an	DT	O
initial	JJ	O
loading	NN	O
dose	NN	O
of	IN	O
400	CD	DOS
mg	NN	UNIT
followed	VBN	O
by	IN	O
daily	JJ	FREQ
maintenance	NN	O
doses	NNS	O
of	IN	O
200	CD	DOS
mg	NN	UNIT
(	(	O
½	JJ	O
tablet	NN	O
)	)	O
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
the	DT	O
duration	NN	O
of	IN	O
treatment	NN	O
.	.	O

AFTER	IN	O
THE	DT	O
INITIAL	NNP	O
DOSE	NNP	O
,	,	O
ON	NNP	O
THE	NNP	O
NEXT	NNP	O
DAY	NNP	O
,	,	O
IF	NNP	O
ADDITIONAL	NNP	O
CHELATION	NNP	O
THERAPY	NNP	O
IS	NNP	O
INDICATED	NNP	O
,	,	O
IT	NNP	O
IS	NNP	O
PREFERABLE	NNP	O
TO	NNP	O
SWITCH	NNP	O
TO	NNP	O
ZN	NNP	O
-	:	O
DTPA	NNP	O
,	,	O
IF	NNP	O
AVAILABLE	NNP	O
(	(	O
SEE	NNP	O
ZN	NNP	O
-	:	O
DTPA	NNP	O
LABELING	NNP	O
)	)	O
DUE	NNP	O
TO	NNP	O
THE	NNP	O
SAFETY	NNP	O
CONCERNS	NNP	O
ASSOCIATED	NNP	O
WITH	NNP	O
PROLONGED	NNP	O
CA	NNP	O
-	:	O
DTPA	NNP	O
(	(	O
pentetate	JJ	O
calcium	NN	O
trisodium	NN	O
inj	NN	O
)	)	O
USE	NN	O
.	.	O

The	DT	O
diluted	JJ	O
infusion	NN	O
solution	NN	O
should	MD	O
not	RB	O
be	VB	O
stored	VBN	O
in	IN	O
a	DT	O
PVC	NNP	O
container	NN	O
due	JJ	O
to	TO	O
decreased	JJ	O
stability	NN	O
and	CC	O
the	DT	O
potential	NN	O
for	IN	O
extraction	NN	O
of	IN	O
phthalates	NNS	O
.	.	O

If	IN	O
the	DT	O
insulin	NN	O
dose	NN	O
is	VBZ	O
between	IN	O
20	CD	DOS
and	CC	O
40	CD	DOS
units	NNS	UNIT
daily	RB	FREQ
,	,	O
the	DT	O
patient	NN	O
may	MD	O
be	VB	O
placed	VBN	O
directly	RB	O
on	IN	O
MICRONASE	NNP	O
Tablets	NNP	O
5	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
.	.	O

For	IN	O
diuresis	NN	O
in	IN	O
congestive	JJ	O
heart	NN	O
failure	NN	O
,	,	O
the	DT	O
starting	VBG	O
dose	NN	O
is	VBZ	O
usually	RB	O
250	CD	DOS
to	TO	O
375	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
morning	NN	O
(	(	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
)	)	O
.	.	O

It	PRP	O
may	MD	O
be	VB	O
important	JJ	O
to	TO	O
titrate	VB	O
the	DT	O
dose	NN	O
to	TO	O
maintain	VB	O
some	DT	O
degree	NN	O
of	IN	O
muscle	NN	O
tone	NN	O
and	CC	O
allow	VB	O
occasional	JJ	O
spasms	NNS	O
to	TO	O
:	:	O
1	CD	O
)	)	O
help	NN	O
support	VB	O
circulatory	NN	O
function	NN	O
,	,	O
2	CD	O
)	)	O
possibly	RB	O
prevent	VBD	O
the	DT	O
formation	NN	O
of	IN	O
deep	JJ	O
vein	NN	O
thrombosis	NN	O
,	,	O
3	CD	O
)	)	O
optimize	NN	O
activities	NNS	O
of	IN	O
daily	JJ	FREQ
living	NN	O
and	CC	O
ease	NN	O
of	IN	O
care	NN	O
.	.	O

Metoclopramide	NNP	O
undergoes	VBZ	O
minimal	JJ	O
hepatic	JJ	O
metabolism	NN	O
,	,	O
except	IN	O
for	IN	O
simple	JJ	O
conjugation	NN	O
.	.	O

For	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
with	IN	WHO
glomerular	JJ	WHO
filtration	NN	WHO
rate	NN	O
>	$	O
30	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
/	NN	O
1.73m2	CD	O
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
0.07	CD	DOS
mg	NN	UNIT
per	IN	O
kg	NN	O
(	(	O
up	IN	O
to	TO	O
5	CD	DOS
mg	NNS	UNIT
total	JJ	O
)	)	O
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

DOSAGE	NN	O
MUST	NNP	O
BE	NNP	O
INDIVIDUALIZED	NNP	O
AND	NNP	O
MONITORED	NNP	O
DURING	NNP	O
UP	NNP	O
-	:	O
TITRATION	NN	O
.	.	O

Uncomplicated	VBN	O
Urethral	JJ	O
Gonorrhea	NNP	O
in	IN	O
Men	NNP	O
;	:	O
Endocervical	NNP	O
and	CC	O
Rectal	NNP	O
Gonorrhea	NNP	O
in	IN	O
Women	NNP	WHO

The	DT	O
volume	NN	O
and	CC	O
rate	NN	O
of	IN	O
contrast	NN	O
injection	NN	O
should	MD	O
be	VB	O
proportional	JJ	O
to	TO	O
the	DT	O
blood	NN	O
flow	NN	O
through	IN	O
the	DT	O
vessels	NNS	O
of	IN	O
interest	NN	O
,	,	O
and	CC	O
related	VBN	O
to	TO	O
the	DT	O
vascular	NN	O
and	CC	O
pathological	JJ	O
characteristics	NNS	O
of	IN	O
the	DT	O
specific	NN	O
vessels	NNS	O
being	VBG	O
studied	VBN	O
.	.	O

Some	DT	WHO
patients	NNS	WHO
will	MD	O
not	RB	O
respond	VB	O
until	IN	O
higher	JJR	O
daily	JJ	FREQ
dosage	NN	O
is	VBZ	O
achieved	VBN	O
.	.	O

After	IN	O
insertion	NN	O
of	IN	O
the	DT	O
needle	NN	O
,	,	O
aspirate	NN	O
and	CC	O
wait	NN	O
to	TO	O
see	VB	O
if	IN	O
any	DT	O
blood	NN	O
appears	VBZ	O
in	IN	O
the	DT	O
syringe	NN	O
,	,	O
which	WDT	O
will	MD	O
help	VB	O
avoid	VB	O
inadvertent	JJ	O
injection	NN	O
into	IN	O
a	DT	O
blood	NN	O
vessel	NN	O
.	.	O

It	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
limit	VB	O
the	DT	O
duration	NN	O
of	IN	O
treatment	NN	O
to	TO	O
short	JJ	O
term	NN	O
whenever	WRB	O
feasible	NN	O
.	.	O

10	CD	O
.	.	O

In	IN	O
addition	NN	O
to	TO	O
the	DT	O
general	JJ	O
adverse	JJ	O
reactions	NNS	O
previously	RB	O
described	VBN	O
,	,	O
thrombophlebitis	NN	O
,	,	O
syncope	NN	O
and	CC	O
very	RB	O
rare	JJ	O
cases	NNS	O
of	IN	O
gangrene	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
following	VBG	O
venography	NN	O
.	.	O

The	DT	O
intravenous	JJ	O
route	NN	O
is	VBZ	O
preferable	JJ	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
bacteremia	NN	WHO
,	,	O
bacterial	JJ	O
septicemia	NN	O
,	,	O
or	CC	O
other	JJ	O
severe	JJ	O
or	CC	O
life	NN	O
threatening	JJ	O
infections	NNS	O
,	,	O
or	CC	O
for	IN	O
patients	NNS	WHO
who	WP	WHO
may	MD	O
be	VB	O
poor	JJ	O
risks	NNS	O
because	IN	O
of	IN	O
lowered	JJ	O
resistance	NN	O
resulting	VBG	O
from	IN	O
such	JJ	O
debilitating	VBG	O
conditions	NNS	O
as	IN	O
malnutrition	NN	O
,	,	O
trauma	NN	O
,	,	O
surgery	NN	O
,	,	O
diabetes	VBZ	O
,	,	O
heart	NN	O
failure	NN	O
,	,	O
or	CC	O
malignancy	NN	O
,	,	O
particularly	RB	O
if	IN	O
shock	NN	O
is	VBZ	O
present	JJ	O
or	CC	O
impending	NN	O
.	.	O

For	IN	O
major	JJ	O
surgical	JJ	O
procedures	NNS	O
,	,	O
the	DT	O
factor	NN	O
VIII	NNP	O
level	NN	O
should	MD	O
be	VB	O
raised	VBN	O
to	TO	O
approximately	RB	O
100	CD	O
%	NN	O
by	IN	O
giving	VBG	O
a	DT	O
preoperative	JJ	O
dose	NN	O
of	IN	O
50	CD	DOS
IU	NNP	UNIT
/	NNP	O
kg	NN	O
.	.	O

ZONEGRAN	NNP	O
(	(	O
zonisamide	NN	O
)	)	O
is	VBZ	O
recommended	VBN	O
as	IN	O
adjunctive	JJ	O
therapy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
partial	JJ	O
seizures	NNS	O
in	IN	O
adults	NNS	WHO
.	.	O

The	DT	O
system	NN	O
should	MD	O
be	VB	O
pressed	VBN	O
firmly	RB	O
in	IN	O
place	NN	O
with	IN	O
the	DT	O
palm	NN	O
of	IN	O
the	DT	O
hand	NN	O
for	IN	O
about	IN	O
10	CD	O
seconds	NNS	O
,	,	O
making	VBG	O
sure	JJ	O
there	EX	O
is	VBZ	O
good	JJ	O
contact	NN	O
,	,	O
especially	RB	O
around	IN	O
the	DT	O
edges	NNS	O
.	.	O

Parenteral	JJ	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
develops	VBZ	O
these	DT	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
,	,	O
raise	VB	O
the	DT	O
dose	NN	O
to	TO	O
the	DT	O
previous	JJ	O
level	NN	O
and	CC	O
taper	VB	O
more	JJR	O
slowly	RB	O
,	,	O
either	RB	O
by	IN	O
increasing	VBG	O
the	DT	O
interval	NN	O
between	IN	O
decreases	NNS	O
,	,	O
decreasing	VBG	O
the	DT	O
amount	NN	O
of	IN	O
change	NN	O
in	IN	O
dose	NN	O
,	,	O
or	CC	O
both	DT	O
.	.	O

Other	JJ	O
parenteral	JJ	O
or	CC	O
oral	JJ	O
non	SYM	O
-	:	O
morphine	NN	O
opioids	NNS	O
to	TO	O
oral	JJ	O
morphine	NN	O
sulfate	NN	O
:	:	O
Specific	JJ	O
recommendations	NNS	O
are	VBP	O
not	RB	O
available	JJ	O
because	IN	O
of	IN	O
a	DT	O
lack	NN	O
of	IN	O
systematic	JJ	O
evidence	NN	O
for	IN	O
these	DT	O
types	NNS	O
of	IN	O
analgesic	JJ	O
substitutions	NNS	O
.	.	O

Erbitux	NNP	O
in	IN	O
combination	NN	O
with	IN	O
radiation	NN	O
therapy	NN	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
platinum	NN	O
-	:	O
based	VBN	O
therapy	NN	O
with	IN	O
5	CD	O
-	:	O
FU	NN	O
:	:	O

There	EX	O
are	VBP	O
insufficient	JJ	O
data	NNS	O
regarding	VBG	O
intramuscular	JJ	O
administration	NN	O
to	TO	O
pediatric	JJ	WHO
patients	NNS	WHO
or	CC	WHO
dosing	VBG	WHO
in	IN	WHO
pediatric	JJ	WHO
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
.	.	O

Experience	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
is	VBZ	O
limited	VBN	O
.	.	O

Then	RB	O
squeeze	VB	O
the	DT	O
dropper	NN	O
contents	VBZ	O
into	IN	O
a	DT	O
liquid	NN	O
or	CC	O
semi	VB	O
-	:	O
solid	JJ	O
food	NN	O
.	.	O

CAYSTON	NNP	O
should	MD	O
not	RB	O
be	VB	O
mixed	JJ	O
with	IN	O
any	DT	O
other	JJ	O
drugs	NNS	O
in	IN	O
the	DT	O
Altera	NNP	O
Nebulizer	NNP	O
Handset	NNP	O
.	.	O

The	DT	O
recommended	JJ	O
dosages	NNS	O
,	,	O
durations	NNS	O
of	IN	O
treatment	NN	O
,	,	O
and	CC	O
applicable	JJ	O
patient	JJ	O
population	NN	O
are	VBP	O
as	IN	O
described	VBN	O
in	IN	O
the	DT	O
following	JJ	O
chart	NN	O
:	:	O

Delays	NNS	O
in	IN	O
diagnosis	NN	O
and	CC	O
institution	NN	O
of	IN	O
therapy	NN	O
may	MD	O
have	VB	O
deleterious	JJ	O
effects	NNS	O
on	IN	O
the	DT	O
child	NN	O
's	POS	O
intellectual	JJ	O
and	CC	O
physical	JJ	O
growth	NN	O
and	CC	O
development	NN	O
.	.	O

If	IN	O
sprayed	VBN	O
in	IN	O
the	DT	O
eyes	NNS	O
,	,	O
flush	JJ	O
eyes	NNS	O
with	IN	O
water	NN	O
for	IN	O
at	IN	O
least	JJS	O
10	CD	O
minutes	NNS	O
.	.	O

Adult	NNP	WHO
should	MD	O
not	RB	O
be	VB	O
given	VBN	O
as	IN	O
a	DT	O
direct	JJ	O
,	,	O
undiluted	JJ	O
intravenous	JJ	O
injection	NN	O
as	IN	O
it	PRP	O
may	MD	O
give	VB	O
rise	NN	O
to	TO	O
dizziness	NN	O
,	,	O
faintness	NN	O
,	,	O
and	CC	O
possible	JJ	O
tissue	NN	O
irritation	NN	O
.	.	O

Use	VB	O
the	DT	O
1	CD	DOS
mL	NN	UNIT
screening	VBG	O
syringe	NN	O
only	RB	O
(	(	O
50	CD	DOS
mcg	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O
for	IN	O
bolus	NN	O
injection	NN	O
into	IN	O
the	DT	O
subarachnoid	JJ	O
space	NN	O
.	.	O

Keep	VB	O
the	DT	O
syringe	NN	O
UPRIGHT	NNP	O
.	.	O

Infusion	NN	O
rates	NNS	O
of	IN	O
ZEMURON	NNP	O
can	MD	O
be	VB	O
individualized	VBN	O
for	IN	O
each	DT	O
patient	NN	O
using	VBG	O
the	DT	O
following	JJ	O
tables	NNS	O
for	IN	O
3	CD	O
different	JJ	O
concentrations	NNS	O
of	IN	O
ZEMURON	NNP	O
solution	NN	O
as	IN	O
guidelines	NNS	O
:	:	O

Table	JJ	O
2	CD	O
:	:	O
Treatment	NN	O
Guidelines	NNS	O

Due	JJ	O
to	TO	O
differences	NNS	O
in	IN	O
the	DT	O
pharmacokinetic	JJ	O
properties	NNS	O
and	CC	O
individual	JJ	O
variability	NN	O
,	,	O
even	RB	O
patients	NNS	WHO
switching	VBG	WHO
from	IN	WHO
other	JJ	WHO
fentanyl	NN	WHO
containing	VBG	WHO
products	NNS	WHO
to	TO	WHO
ABSTRAL	NNP	WHO
must	MD	O
start	VB	O
with	IN	O
the	DT	O
100	CD	DOS
mcg	NN	UNIT
dose	NN	UNIT
.	.	O

(	(	O
The	DT	O
shelf	NN	O
-	:	O
life	NN	O
of	IN	O
the	DT	O
constituted	JJ	O
suspension	NN	O
is	VBZ	O
60	CD	O
days	NNS	O
.	.	O
)	)	O

Due	JJ	O
to	TO	O
the	DT	O
potential	NN	O
for	IN	O
withdrawal	NN	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
abrupt	JJ	O
discontinuation	NN	O
,	,	O
consideration	NN	O
should	MD	O
be	VB	O
given	VBN	O
to	TO	O
tapering	VBG	WHO
patients	NNS	WHO
off	IN	WHO
TALACEN	NNP	WHO
(	(	O
pentazocine	NN	O
and	CC	O
acetaminophen	NN	O
)	)	O
after	IN	O
prolonged	VBN	O
periods	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
TALACEN	NNP	O
(	(	O
See	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Drug	NNP	O
Abuse	NNP	O
and	CC	O
Dependence	NNP	O
)	)	O
.	.	O

Injection	NN	O
is	VBZ	O
supplied	VBN	O
in	IN	O
single	JJ	O
-	:	O
use	NN	O
,	,	O
ready	JJ	O
-	:	O
to	TO	O
-	:	O
use	NN	O
infusion	NN	O
bags	NNS	O
.	.	O

See	JJ	O
Dosage	NNP	O
Guidelines	NNP	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
:	:	O
1	CD	O
)	)	O
by	IN	O
incremental	JJ	O
injection	NN	O
as	IN	O
an	DT	O
analgesic	JJ	O
adjunct	NN	O
to	TO	O
anesthesia	VB	O
with	IN	O
barbiturate	JJ	O
/	NNS	O
nitrous	JJ	O
oxide	IN	O
/	NNP	O
oxygen	NN	O
for	IN	O
short	JJ	O
surgical	JJ	O
procedures	NNS	O
(	(	O
expected	VBN	O
duration	NN	O
of	IN	O
less	JJR	O
than	IN	O
one	CD	O
hour	NN	O
)	)	O
;	:	O
2	CD	O
)	)	O
by	IN	O
continuous	JJ	O
infusion	NN	O
as	IN	O
a	DT	O
maintenance	NN	O
analgesic	JJ	O
with	IN	O
nitrous	JJ	O
oxide	JJ	O
/	NNP	O
oxygen	NN	O
for	IN	O
general	JJ	O
surgical	JJ	O
procedures	NNS	O
;	:	O
and	CC	O
3	CD	O
)	)	O
by	IN	O
intravenous	JJ	O
injection	NN	O
in	IN	O
anesthetic	JJ	O
doses	NNS	O
for	IN	O
the	DT	O
induction	NN	O
of	IN	O
anesthesia	NN	O
for	IN	O
general	JJ	O
surgical	JJ	O
procedures	NNS	O
with	IN	O
a	DT	O
minimum	NN	O
expected	VBN	O
duration	NN	O
of	IN	O
45	CD	O
minutes	NNS	O
;	:	O
and	CC	O
4	CD	O
)	)	O
by	IN	O
intravenous	JJ	O
injection	NN	O
as	IN	O
the	DT	O
analgesic	JJ	O
component	NN	O
for	IN	O
monitored	JJ	O
anesthesia	NN	O
care	NN	O
(	(	O
MAC	NNP	O
)	)	O
.	.	O

Postoperative	JJ	O
sedation	NN	O
and	CC	O
adjunctive	JJ	O
use	NN	O
with	IN	O
analgesics	NNS	O
may	MD	O
be	VB	O
obtained	VBN	O
by	IN	O
the	DT	O
administration	NN	O
of	IN	O
12.5	CD	DOS
to	TO	O
25	CD	DOS
mg	NN	UNIT
in	IN	O
children	NNS	WHO
and	CC	O
25	CD	DOS
to	TO	O
50	CD	DOS
mg	NN	UNIT
doses	NNS	UNIT
in	IN	O
adults	NNS	WHO
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
XYZAL	NNP	O
is	VBZ	O
1.25	CD	DOS
mg	NN	UNIT
(	(	O
½	JJ	O
teaspoon	NN	O
oral	JJ	O
solution	NN	O
)	)	O
[	VBZ	O
2.5mL	CD	O
]	NN	O
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
evening	NN	O
.	.	O

The	DT	O
maintenance	NN	O
dose	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
weekly	RB	FREQ
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
pretreatment	NN	O
control	NN	O
blood	NN	O
counts	NNS	O
and	CC	O
subsequent	JJ	O
blood	NN	O
counts	NNS	O
.	.	O

More	RBR	O
frequent	JJ	O
administration	NN	O
or	CC	O
a	DT	O
larger	JJR	O
number	NN	O
of	IN	O
inhalations	NNS	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

regimen	NNS	O
of	IN	O
Tegretol	NNP	O
-	:	O
XR	NN	O
or	CC	O
a	DT	O
t.i.d	NN	O
.	.	O

This	DT	O
estimate	NN	O
was	VBD	O
lowered	VBN	O
slightly	RB	O
(	(	O
to	TO	O
85	CD	O
%	NN	O
)	)	O
to	TO	O
represent	VB	O
the	DT	O
percentage	NN	O
that	WDT	O
would	MD	O
become	VB	O
pregnant	JJ	O
within	IN	O
one	CD	O
year	NN	O
among	IN	O
women	NNS	O
now	RB	O
relying	VBG	O
on	IN	O
reversible	JJ	O
methods	NNS	O
of	IN	O
contraception	NN	O
if	IN	O
they	PRP	O
abandoned	VBD	O
contraception	NN	O
altogether	RB	O
.	.	O

General	JJ	O
information	NN	O
about	IN	O
Follistim®	NNP	O
AQ	NNP	O
(	(	O
follitropin	JJ	O
beta	NN	O
)	)	O

In	IN	O
addition	NN	O
to	TO	O
this	DT	O
response	NN	O
in	IN	O
non	JJ	O
-	:	O
myasthenics	NNS	O
,	,	O
the	DT	O
phenomenon	NN	O
of	IN	O
forced	VBN	O
lid	JJ	O
closure	NN	O
is	VBZ	O
often	RB	O
observed	VBN	O
in	IN	O
psychoneurotics	NNS	O
.	.	O

If	IN	O
a	DT	O
planned	VBN	O
dose	NN	O
is	VBZ	O
delayed	VBN	O
or	CC	O
missed	VBN	O
,	,	O
administer	RB	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
;	:	O
do	VB	O
not	RB	O
wait	VB	O
until	IN	O
the	DT	O
next	JJ	O
planned	JJ	O
cycle	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
continued	VBD	O
monitoring	NN	O
of	IN	O
immune	JJ	O
function	NN	O
and	CC	O
clinical	JJ	O
status	NN	O
is	VBZ	O
essential	JJ	O
in	IN	O
any	DT	WHO
patient	NN	WHO
with	IN	WHO
a	DT	WHO
primary	JJ	WHO
immunodeficiency	NN	WHO
disease	NN	WHO
and	CC	O
should	MD	O
be	VB	O
continued	VBN	O
in	IN	O
patients	NNS	WHO
undergoing	VBG	WHO
treatment	NN	WHO
with	IN	WHO
ADAGEN®	NNP	WHO
(	(	O
pegademase	VB	O
bovine	NN	O
)	)	O
Injection	NN	O
.	.	O

If	IN	O
desired	VBN	O
,	,	O
the	DT	O
preparation	NN	O
may	MD	O
be	VB	O
diluted	VBN	O
with	IN	O
sterile	JJ	O
water	NN	O
or	CC	O
sterile	JJ	O
saline	NN	O
as	IN	O
indicated	VBN	O
in	IN	O
the	DT	O
table	NN	O
below	IN	O
.	.	O

STEP	NN	O
TWO	NNP	O
-	:	O
Preparation	NN	O
of	IN	O
Admixture	NN	O

THE	DT	O
ADMIXTURE	NNP	O
MUST	NNP	O
BE	NNP	O
DISCARDED	NNP	O
IF	NNP	O
ANY	NNP	O
OF	IN	O
THE	NNP	O
ABOVE	NNP	O
IS	NNP	O
OBSERVED	NNP	O
.	.	O

Alternatively	RB	O
,	,	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
malignancy	NN	WHO
,	,	O
2,500	CD	DOS
IU	NNP	UNIT
of	IN	O
FRAGMIN	NNP	O
can	MD	O
be	VB	O
administered	VBN	O
subcutaneously	RB	O
1	CD	O
to	TO	O
2	CD	O
hours	NNS	O
before	IN	O
surgery	NN	O
followed	VBN	O
by	IN	O
2,500	CD	DOS
IU	NNP	UNIT
subcutaneously	RB	O
12	CD	O
hours	NNS	O
later	RB	O
,	,	O
and	CC	O
then	RB	O
5,000	CD	DOS
IU	NNP	UNIT
once	RB	FREQ
daily	RB	FREQ
postoperatively	RB	O
.	.	O

Changes	NNS	O
in	IN	O
dosage	NN	O
may	MD	O
require	VB	O
an	DT	O
adjustment	JJ	O
period	NN	O
of	IN	O
several	JJ	O
days	NNS	O
.	.	O

Chronic	NNP	O
Idiopathic	NNP	O
Constipation	NNP	O

The	DT	O
patient	NN	O
begins	VBZ	O
her	PRP$	O
next	JJ	O
and	CC	O
all	DT	O
subsequent	JJ	O
28	CD	O
-	:	O
day	NN	O
courses	NNS	O
of	IN	O
tablets	NNS	O
on	IN	O
the	DT	O
same	JJ	O
day	NN	O
of	IN	O
the	DT	O
week	NN	PER
(	(	O
Sunday	NNP	O
)	)	O
on	IN	O
which	WDT	O
she	PRP	O
began	VBD	O
her	PRP	O
first	JJ	O
course	NN	O
,	,	O
following	VBG	O
the	DT	O
same	JJ	O
schedule	NN	O
:	:	O
21	CD	O
days	NNS	O
on	IN	O
light	JJ	O
-	:	O
orange	NN	O
tablets—7	JJ	O
days	NNS	O
on	IN	O
pink	NN	O
inert	JJ	O
tablets	NNS	O
.	.	O

If	IN	O
this	DT	O
can	MD	O
not	RB	O
be	VB	O
confirmed	VBN	O
,	,	O
do	VBP	O
not	RB	O
give	VB	O
the	DT	O
injection	NN	O
.	.	O

Do	NNP	O
not	RB	O
open	VB	O
or	CC	O
crush	VB	O
capsules	NNS	O
.	.	O

The	DT	O
grey	NN	O
needle	JJ	O
cap	NN	O
on	IN	O
the	DT	O
single	JJ	O
-	:	O
use	NN	O
prefilled	VBD	O
syringe	NN	O
contains	NNS	O
dry	JJ	O
natural	JJ	O
rubber	NN	O
(	(	O
a	DT	O
derivative	NN	O
of	IN	O
latex	NN	O
)	)	O
;	:	O
people	NNS	O
sensitive	VBP	O
to	TO	O
latex	VB	O
should	MD	O
not	RB	O
handle	VB	O
the	DT	O
cap	NN	O
.	.	O

The	DT	O
rectal	JJ	O
delivery	NN	O
system	NN	O
includes	VBZ	O
a	DT	O
plastic	JJ	O
applicator	NN	O
with	IN	O
a	DT	O
flexible	JJ	O
,	,	O
molded	VBD	O
tip	NN	O
available	JJ	O
in	IN	O
two	CD	PER
lengths	NNS	PER
.	.	O

Dosage	NN	O
Forms	NNS	O
for	IN	O
This	DT	O
Indication	NN	O

The	DT	O
patient	NN	O
begins	VBZ	O
her	PRP$	O
next	JJ	O
and	CC	O
all	DT	O
subsequent	JJ	O
91	CD	O
-	:	O
day	NN	O
courses	NNS	O
of	IN	O
tablets	NNS	O
without	IN	O
interruption	NN	O
on	IN	O
the	DT	O
same	JJ	O
day	NN	O
of	IN	O
the	DT	O
week	NN	PER
(	(	O
Sunday	NNP	O
)	)	O
on	IN	O
which	WDT	O
she	PRP	O
began	VBD	O
her	PRP	O
first	JJ	O
course	NN	O
,	,	O
following	VBG	O
the	DT	O
same	JJ	O
schedule	NN	O
:	:	O
84	CD	O
days	NNS	O
on	IN	O
which	WDT	O
pink	VBP	O
tablets	NNS	O
are	VBP	O
taken	VBN	O
followed	VBN	O
by	IN	O
7	CD	PER
days	NNS	PER
on	IN	O
which	WDT	O
white	JJ	O
tablets	NNS	O
are	VBP	O
taken	VBN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Levothyroxine	JJ	O
Sodium	NNP	O
Dosing	NNP	O
Guidelines	NNP	O
for	IN	O
Pediatric	NNP	O
Hypothyroidism	NNP	O

Total	JJ	O
dosage	NN	O
should	MD	O
be	VB	O
decreased	VBN	O
by	IN	O
reduction	NN	O
of	IN	O
recommended	JJ	O
individual	JJ	O
doses	NNS	O
and	CC	O
/	NN	O
or	CC	O
by	IN	O
extending	VBG	O
time	NN	O
intervals	NNS	O
between	IN	O
doses	NNS	O
.	.	O

For	IN	O
optimal	JJ	O
absorption	NN	O
,	,	O
CRIXIVAN	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
without	IN	O
food	NN	O
but	CC	O
with	IN	O
water	NN	O
1	CD	O
hour	NN	O
before	IN	O
or	CC	O
2	CD	O
hours	NNS	O
after	IN	O
a	DT	O
meal	NN	O
.	.	O

QuilliChew	NNP	O
ER	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
in	IN	O
the	DT	O
morning	NN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
[	NNS	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Geriatric	JJ	O
Use	NN	O
:	:	O
No	DT	O
dosage	NN	O
adjustment	NN	O
is	VBZ	O
necessary	JJ	O
in	IN	O
elderly	JJ	WHO
patients	NNS	WHO
[	VBP	O
see	VBP	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Observe	NNP	O
that	IN	O
no	DT	O
air	NN	O
bubbles	NNS	O
are	VBP	O
present	JJ	O
and	CC	O
close	JJ	O
clamp	NN	O
.	.	O

Additional	JJ	O
separate	JJ	O
doses	NNS	O
of	IN	O
methyldopa	NN	O
or	CC	O
replacement	NN	O
of	IN	O
ALDORIL	NNP	O
(	(	O
methyldopa	SYM	O
-	:	O
hydrochlorothiazide	NN	O
)	)	O
with	IN	O
single	JJ	O
entity	NN	O
agents	NNS	O
is	VBZ	O
necessary	JJ	O
until	IN	O
the	DT	O
new	JJ	O
effective	JJ	O
dose	NN	O
ratio	NN	O
is	VBZ	O
re	JJ	O
-	:	O
established	VBN	O
by	IN	O
titration	NN	O
.	.	O

Although	IN	O
EYLEA	NNP	O
may	MD	O
be	VB	O
dosed	VBN	O
as	RB	O
frequently	RB	O
as	IN	O
2	CD	DOS
mg	NN	UNIT
every	DT	FREQ
4	CD	FREQ
weeks	NNS	FREQ
(	(	O
monthly	RB	O
)	)	O
,	,	O
additional	JJ	O
efficacy	NN	O
was	VBD	O
not	RB	O
demonstrated	VBN	O
in	IN	O
most	JJS	WHO
patients	NNS	WHO
when	WRB	WHO
EYLEA	NNP	WHO
was	VBD	WHO
dosed	VBN	WHO
every	DT	WHO
4	CD	PER
weeks	NNS	PER
compared	VBN	O
to	TO	O
every	DT	FREQ
8	CD	FREQ
weeks	NNS	FREQ
[	JJ	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

Remove	NNP	O
air	NN	O
bubbles	NNS	O

Dosage	NN	O
must	MD	O
be	VB	O
individualized	VBN	O
.	.	O

86	CD	O

The	DT	O
American	NNP	O
Heart	NNP	O
Association	NNP	O
suggests	VBZ	O
a	DT	O
dosage	NN	O
of	IN	O
250	CD	DOS
mg	NN	UNIT
of	IN	O
erythromycin	NN	O
orally	RB	O
,	,	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
in	IN	O
long	JJ	O
-	:	O
term	NN	O
prophylaxis	NN	O
of	IN	O
streptococcal	JJ	O
upper	JJ	O
respiratory	NN	O
tract	NN	O
infections	NNS	O
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
recurring	VBG	O
attacks	NNS	O
of	IN	O
rheumatic	JJ	O
fever	NN	O
in	IN	O
patients	NNS	WHO
allergic	JJ	WHO
to	TO	WHO
penicillin	VB	WHO
and	CC	O
sulfonamides.3	VB	O

If	IN	O
this	DT	O
regimen	NN	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
,	,	O
if	IN	O
the	DT	O
serum	NN	O
quinidine	NN	O
level	NN	O
is	VBZ	O
still	RB	O
well	RB	O
within	IN	O
the	DT	O
laboratory	NN	O
's	POS	O
therapeutic	JJ	O
range	NN	O
,	,	O
and	CC	O
if	IN	O
the	DT	O
average	JJ	O
time	NN	O
between	IN	O
arrhythmic	JJ	O
episodes	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
satisfactorily	RB	O
increased	VBN	O
,	,	O
then	RB	O
the	DT	O
dose	NN	O
may	MD	O
be	VB	O
cautiously	RB	O
raised	VBN	O
.	.	O

Patients	NNS	O
who	WP	O
can	MD	O
tolerate	VB	O
the	DT	O
additional	JJ	O
fluid	NN	O
load	NN	O
should	MD	O
receive	VB	O
a	DT	O
second	JJ	O
liter	NN	O
.	.	O

V.	NNP	O
Final	NNP	O
Adjustment	NNP	O
of	IN	O
Dosage	NNP	O

Stir	NNP	O
well	RB	O
and	CC	O
drink	VB	O
immediately	RB	O
.	.	O

Bivalirudin	NNP	O
for	IN	O
Injection	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
via	IN	O
an	DT	O
intravenous	JJ	O
line	NN	O
.	.	O

Drink	NNP	O
and	CC	O
void	VB	O
frequently	RB	O
during	IN	O
the	DT	O
first	JJ	O
hours	NNS	O
following	VBG	O
administration	NN	O
to	TO	O
reduce	VB	O
radiation	NN	O
exposure	NN	O
.	.	O

Dosing	VBG	O
and	CC	O
initial	JJ	O
route	NN	O
of	IN	O
therapy	NN	O
(	(	O
that	WDT	O
is	VBZ	O
,	,	O
IV	NNP	O
or	CC	O
oral	JJ	O
)	)	O
for	IN	O
cUTI	NN	O
or	CC	O
pyelonephritis	NN	O
should	MD	O
be	VB	O
determined	VBN	O
by	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
infection	NN	O
.	.	O

0.2	CD	DOS
mcg	NN	UNIT
/	NNP	O
kg	VBZ	O
body	NN	O
weight	NN	O
by	IN	O
intravenous	JJ	O
injection	NN	O
over	IN	O
1	CD	O
minute	NN	O
.	.	O

The	DT	O
following	JJ	O
gradual	JJ	O
titration	NN	O
schedule	NN	O
is	VBZ	O
suggested	VBN	O
.	.	O

Prescribe	NNP	O
the	DT	O
same	JJ	O
number	NN	O
of	IN	O
capsules	NNS	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
5	CD	O
dosing	NN	O
days	NNS	O
.	.	O

One	CD	DOS
international	JJ	UNIT
unit	NN	UNIT
(	(	O
IU	NNP	O
)	)	O
of	IN	O
factor	NN	O
VIII	NNP	O
activity	NN	O
corresponds	VBZ	O
approximately	RB	O
to	TO	O
the	DT	O
quantity	NN	O
of	IN	O
factor	NN	O
VIII	NNP	O
in	IN	O
one	CD	DOS
mL	NN	UNIT
of	IN	O
normal	JJ	O
human	JJ	O
plasma	NN	O
.	.	O

If	IN	O
serum	JJ	O
sodium	NN	O
is	VBZ	O
not	RB	O
rising	VBG	O
at	IN	O
the	DT	O
desired	JJ	O
rate	NN	O
,	,	O
VAPRISOL	NNP	O
may	MD	O
be	VB	O
titrated	VBN	O
upward	RB	O
to	TO	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
40	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
,	,	O
administered	VBN	O
in	IN	O
a	DT	O
continuous	JJ	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
24	CD	O
hours	NNS	O
.	.	O

Contents	NNS	O
of	IN	O
the	DT	O
capsule	NN	O
should	MD	O
not	RB	O
be	VB	O
mixed	JJ	O
directly	RB	O
into	IN	O
formula	NN	O
or	CC	O
breast	NN	O
milk	NN	O
as	IN	O
this	DT	O
may	MD	O
diminish	VB	O
efficacy	NN	O
.	.	O

Dosage	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
a	DT	O
low	JJ	O
level	NN	O
and	CC	O
increased	VBD	O
according	VBG	O
to	TO	O
clinical	JJ	O
response	NN	O
and	CC	O
any	DT	O
evidence	NN	O
of	IN	O
intolerance	NN	O
.	.	O

Before	IN	O
injection	NN	O
,	,	O
the	DT	O
skin	NN	O
over	IN	O
the	DT	O
site	NN	O
to	TO	O
be	VB	O
injected	VBN	O
should	MD	O
be	VB	O
cleansed	VBN	O
with	IN	O
a	DT	O
suitable	JJ	O
germicide	NN	O
.	.	O

The	DT	O
oral	JJ	O
solution	NN	O
can	MD	O
be	VB	O
substituted	VBN	O
for	IN	O
tablets	NNS	O
on	IN	O
a	DT	O
mg	JJ	UNIT
-	:	O
per	IN	O
-	:	O
mg	NN	UNIT
basis	NN	O
up	RB	O
to	TO	O
the	DT	O
25	CD	DOS
mg	NN	UNIT
dose	JJ	UNIT
level	NN	O
.	.	O

Because	IN	O
there	EX	O
is	VBZ	O
approximately	RB	O
an	DT	O
8	CD	O
%	NN	O
increase	NN	O
in	IN	O
drug	NN	O
content	NN	O
with	IN	O
the	DT	O
free	JJ	O
acid	NN	O
form	NN	O
over	IN	O
that	DT	O
of	IN	O
the	DT	O
sodium	NN	O
salt	NN	O
,	,	O
dosage	NN	O
adjustments	NNS	O
and	CC	O
serum	JJ	O
level	NN	O
monitoring	NN	O
may	MD	O
be	VB	O
necessary	JJ	O
when	WRB	O
switching	VBG	O
from	IN	O
a	DT	O
product	NN	O
formulated	VBN	O
with	IN	O
the	DT	O
free	JJ	O
acid	NN	O
to	TO	O
a	DT	O
product	NN	O
formulated	VBN	O
with	IN	O
the	DT	O
sodium	NN	O
salt	NN	O
and	CC	O
vice	NN	O
versa	NN	O
.	.	O

Caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
when	WRB	O
administering	VBG	O
LEVOTHROID®	NNP	O
(	(	O
levothyroxine	JJ	O
sodium	NN	O
)	)	O
to	TO	O
patients	NNS	WHO
with	IN	WHO
underlying	JJ	WHO
cardiovascular	JJ	WHO
disease	NN	WHO
,	,	O
to	TO	O
the	DT	O
elderly	JJ	O
,	,	O
and	CC	O
to	TO	O
those	DT	O
with	IN	O
concomitant	JJ	O
adrenal	JJ	O
insufficiency	NN	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

Patients	NNS	O
should	MD	O
not	RB	O
be	VB	O
discharged	VBN	O
from	IN	O
the	DT	O
hospital	NN	O
until	IN	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
drug	NN	O
on	IN	O
the	DT	O
standing	VBG	O
blood	NN	O
pressure	NN	O
is	VBZ	O
known	VBN	O
.	.	O

Hepatic	JJ	O
Impairment	NN	O
:	:	O
No	DT	O
dose	JJ	O
adjustment	NN	O
to	TO	O
FANAPT	NNP	O
is	VBZ	O
needed	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
DIFLUCAN	NNP	O
for	IN	O
esophageal	JJ	O
candidiasis	NN	O
is	VBZ	O
200	CD	DOS
mg	NN	UNIT
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
,	,	O
followed	VBN	O
by	IN	O
100	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
concentrations	NNS	O
and	CC	O
rates	NNS	O
of	IN	O
infusion	NN	O
provided	VBN	O
in	IN	O
DOSAGE	NNP	O
AND	NNP	O
ADMINISTRATION	NNP	O
reflect	VBP	O
doses	NNS	O
identified	VBN	O
in	IN	O
these	DT	O
studies	NNS	O
.	.	O

If	IN	O
a	DT	O
dosage	NN	O
regimen	NN	O
of	IN	O
AIRDUO	NNP	O
RESPICLICK	NNP	O
fails	VBZ	O
to	TO	O
provide	VB	O
adequate	JJ	O
control	NN	O
of	IN	O
asthma	NN	O
,	,	O
the	DT	O
therapeutic	JJ	O
regimen	NNS	O
should	MD	O
be	VB	O
re	VBN	O
-	:	O
evaluated	VBN	O
and	CC	O
additional	JJ	O
therapeutic	NN	O
options	NNS	O
(	(	O
e.g	VB	O
,	,	O
replacing	VBG	O
the	DT	O
current	JJ	O
strength	NN	O
of	IN	O
AIRDUO	NNP	O
RESPICLICK	NNP	O
with	IN	O
a	DT	O
higher	JJR	O
strength	NN	O
,	,	O
or	CC	O
adding	VBG	O
additional	JJ	O
controller	NN	O
therapies	NNS	O
)	)	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

This	DT	O
drug	NN	O
may	MD	O
potentiate	VB	O
the	DT	O
action	NN	O
of	IN	O
carbonic	JJ	O
anhydrase	NN	O
inhibitors	NNS	O
,	,	O
with	IN	O
augmentation	NN	O
of	IN	O
natriuresis	NN	O
and	CC	O
kaliuresis	NN	O
.	.	O

Do	NNP	O
not	RB	O
start	VB	O
WELLBUTRIN	NNP	O
SR	NNP	O
in	IN	O
a	DT	O
patient	NN	WHO
who	WP	WHO
is	VBZ	WHO
being	VBG	WHO
treated	VBN	WHO
with	IN	WHO
a	DT	WHO
reversible	JJ	WHO
MAOI	NNP	WHO
such	JJ	O
as	IN	O
linezolid	JJ	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	NN	O
.	.	O

In	IN	O
clinical	JJ	O
studies	NNS	O
,	,	O
an	DT	O
opioid	JJ	O
premedication	NN	O
(	(	O
fentanyl	JJ	O
citrate	NN	O
50	CD	DOS
mcg	NN	UNIT
IV	NNP	O
)	)	O
was	VBD	O
administered	VBN	O
five	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
the	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
LUSEDRA	NNP	O
(	(	O
fospropofol	JJ	O
disodium	NN	O
injection	NN	O
)	)	O
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
platelet	NN	O
counts	NNS	O
generally	RB	O
began	VBD	O
to	TO	O
rise	VB	O
within	IN	O
the	DT	O
first	JJ	O
week	NN	PER
of	IN	O
treatment	NN	O
with	IN	O
PROMACTA	NNP	O
[	NNP	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
DYAZIDE	NNP	O
(	(	O
hydrochlorothiazide	NN	O
and	CC	O
triamterene	NN	O
)	)	O
is	VBZ	O
one	CD	DOS
or	CC	O
two	CD	DOS
capsules	NNS	UNIT
given	VBN	O
once	RB	FREQ
daily	JJ	FREQ
,	,	O
with	IN	O
appropriate	JJ	O
monitoring	NN	O
of	IN	O
serum	JJ	O
potassium	NN	O
and	CC	O
of	IN	O
the	DT	O
clinical	JJ	O
effect	NN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
,	,	O
Hyperkalemia	NNP	O
)	)	O
.	.	O

Examine	VB	O
the	DT	O
insertion	NN	O
site	NN	O
one	CD	PER
week	NN	PER
following	VBG	O
insertion	NN	O
of	IN	O
PROBUPHINE	NNP	O
for	IN	O
signs	NNS	O
of	IN	O
infection	NN	O
or	CC	O
any	DT	O
problems	NNS	O
with	IN	O
wound	NN	O
healing	NN	O
,	,	O
including	VBG	O
evidence	NN	O
of	IN	O
implant	JJ	O
extrusion	NN	O
from	IN	O
the	DT	O
skin	NN	O
.	.	O

Freezing	VBG	O
solutions	NNS	O
of	IN	O
FORTAZ	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

Using	VBG	O
aseptic	JJ	O
technique	NN	O
and	CC	O
a	DT	O
sterile	JJ	O
1	CD	DOS
mL	NN	UNIT
syringe	NN	O
fitted	VBN	O
with	IN	O
a	DT	O
25	CD	O
gauge	NN	O
x	NN	O
5	CD	O
/	JJ	O
8	CD	O
”	NN	O
needle	NN	O
(	(	O
provided	VBN	O
)	)	O
,	,	O
draw	VBZ	O
up	RP	O
0.3	CD	DOS
mL	NNS	UNIT
of	IN	O
diluent	NN	O
and	CC	O
transfer	VB	O
the	DT	O
entire	JJ	O
content	NN	O
of	IN	O
the	DT	O
syringe	NN	O
to	TO	O
the	DT	O
vaccine	NN	O
vial	NN	O
.	.	O

Dynamic	NNP	O
CT	NNP	O
scanning	NN	O
is	VBZ	O
the	DT	O
procedure	NN	O
of	IN	O
choice	NN	O
for	IN	O
malignant	JJ	O
tumor	NN	O
enhancement	NN	O
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
)	)	O
.	.	O

Flush	IN	O
the	DT	O
intravenous	JJ	O
access	NN	O
line	NN	O
or	CC	O
cannula	NN	O
with	IN	O
isotonic	JJ	O
saline	NN	O
before	IN	O
and	CC	O
after	IN	O
injection	NN	O
of	IN	O
Xofigo	NNP	O
.	.	O

Dosage	NN	O
can	MD	O
be	VB	O
increased	VBN	O
by	IN	O
25	CD	DOS
-	:	O
50	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
each	DT	O
subsequent	JJ	O
week	NN	PER
as	IN	O
tolerated	VBN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Guideline	NN	O
for	IN	O
Raplixa	NNP	O
Application	NNP	O

When	WRB	O
acute	NN	O
attacks	NNS	O
have	VBP	O
been	VBN	O
absent	JJ	O
for	IN	O
six	CD	PER
months	NNS	PER
or	CC	O
more	JJR	O
and	CC	O
serum	VB	O
urate	JJ	O
levels	NNS	O
remain	VBP	O
within	IN	O
normal	JJ	O
limits	NNS	O
,	,	O
the	DT	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
probenecid	NN	O
and	CC	O
colchicine	NN	O
may	MD	O
be	VB	O
decreased	VBN	O
by	IN	O
1	CD	DOS
tablet	NN	UNIT
every	DT	FREQ
six	CD	FREQ
months	NNS	FREQ
.	.	O

Intrathecal	JJ	O
:	:	O
A	DT	O
treatment	NN	O
of	IN	O
choice	NN	O
for	IN	O
Ps	NNP	O
aeruginosameningitis	NN	O
.	.	O

2	CD	O
.	.	O

Titrating	VBG	O
in	IN	O
increments	NNS	O
of	IN	O
25	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
every	DT	FREQ
week	NN	FREQ
may	MD	O
delay	VB	O
the	DT	O
time	NN	O
to	TO	O
reach	VB	O
an	DT	O
effective	JJ	O
dose	NN	O
.	.	O

To	TO	O
prevent	VB	O
rebound	NN	O
hypoglycemia	NN	O
,	,	O
a	DT	O
solution	NN	O
containing	VBG	O
5	CD	O
%	NN	O
dextrose	NN	O
should	MD	O
be	VB	O
administered	VBN	O
when	WRB	O
hypertonic	JJ	O
dextrose	JJ	O
solutions	NNS	O
are	VBP	O
abruptly	RB	O
discontinued	VBN	O
.	.	O

If	IN	O
an	DT	O
overcorrection	NN	O
has	VBZ	O
occurred	VBN	O
,	,	O
massage	VB	O
the	DT	O
area	NN	O
firmly	RB	O
between	IN	O
your	PRP$	O
fingers	NNS	O
or	CC	O
against	IN	O
an	DT	O
underlying	JJ	O
superficial	JJ	O
bone	NN	O
to	TO	O
obtain	VB	O
optimal	JJ	O
results	NNS	O
.	.	O

However	RB	O
,	,	O
as	IN	O
with	IN	O
all	DT	O
intravenous	JJ	O
admixtures	NNS	O
,	,	O
dilution	NN	O
should	MD	O
be	VB	O
made	VBN	O
just	RB	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

The	DT	O
prescriber	NN	O
may	MD	O
wish	VB	O
to	TO	O
prescribe	VB	O
a	DT	O
second	JJ	O
dose	NN	O
of	IN	O
diazepam	JJ	O
rectal	JJ	O
gel	NN	O
.	.	O

Dosage	NN	O
and	CC	O
rate	NN	O
of	IN	O
administration	NN	O
should	MD	O
be	VB	O
individualized	VBN	O
and	CC	O
titrated	VBN	O
to	TO	O
the	DT	O
desired	JJ	O
effect	NN	O
,	,	O
according	VBG	O
to	TO	O
clinically	RB	O
relevant	JJ	O
factors	NNS	O
including	VBG	O
the	DT	O
patient	NN	O
's	POS	O
underlying	JJ	O
medical	JJ	O
problems	NNS	O
,	,	O
preinduction	NN	O
and	CC	O
concomitant	JJ	O
medications	NNS	O
,	,	O
age	NN	O
,	,	O
ASA	NNP	O
-	:	O
PS	NNP	O
classification	NN	O
,	,	O
and	CC	O
level	NN	O
of	IN	O
debilitation	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

Recommended	VBN	O
Pediatric	JJ	O
Dosage	NN	O
for	IN	O
Congenital	NNP	O
Hypothyroidism	NNP	O

This	DT	O
dose	NN	O
should	MD	O
also	RB	O
be	VB	O
maintained	VBN	O
for	IN	O
7	CD	PER
to	TO	O
14	CD	PER
days	NNS	PER
and	CC	O
can	MD	O
then	RB	O
be	VB	O
adjusted	VBN	O
upward	RB	O
to	TO	O
25	CD	DOS
mg	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
if	IN	O
tolerated	VBN	O
and	CC	O
needed	VBN	O
.	.	O

In	IN	O
either	DT	O
case	NN	O
,	,	O
a	DT	O
barrier	NN	O
method	NN	O
such	JJ	O
as	IN	O
condoms	NNS	O
with	IN	O
spermicides	NNS	O
must	MD	O
be	VB	O
used	VBN	O
until	IN	O
the	DT	O
new	JJ	O
ring	NN	O
has	VBZ	O
been	VBN	O
used	VBN	O
continuously	RB	O
for	IN	O
seven	CD	PER
days	NNS	PER
.	.	O

Therefore	RB	O
,	,	O
after	IN	O
you	PRP	O
remove	VBP	O
the	DT	O
needle	JJ	O
shield	NN	O
,	,	O
keep	VB	O
the	DT	O
applicator	NN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
until	IN	O
the	DT	O
moment	NN	O
of	IN	O
insertion	NN	O

Special	JJ	O
Patient	NNP	O
Population	NN	O
:	:	O
Dosage	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
the	DT	WHO
elderly	JJ	WHO
or	CC	WHO
debilitated	VBN	WHO
because	IN	WHO
these	DT	WHO
patients	NNS	WHO
may	MD	O
be	VB	O
more	RBR	O
sensitive	JJ	O
to	TO	O
barbiturates	NNS	O
.	.	O

Gris	NNP	O
-	:	O
PEG®	NNP	O
tablets	NNS	O
may	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
or	CC	O
crushed	VBN	O
and	CC	O
sprinkled	VBN	O
onto	IN	O
1	CD	O
tablespoonful	NN	O
of	IN	O
applesauce	NN	O
and	CC	O
swallowed	VBD	O
immediately	RB	O
without	IN	O
chewing	VBG	O
.	.	O

Discard	NNP	O
any	DT	O
prefilled	JJ	O
syringe	NN	O
left	VBD	O
at	IN	O
room	NN	O
temperature	NN	O
for	IN	O
greater	JJR	O
than	IN	O
48	CD	O
hours	NNS	O
.	.	O

Do	NNP	O
not	RB	O
exceed	VB	O
this	DT	O
daily	JJ	FREQ
dose	NN	O
.	.	O

Dosage	NN	O
should	MD	O
be	VB	O
individualized	VBN	O
according	VBG	O
to	TO	O
the	DT	O
needs	NNS	O
and	CC	O
responses	NNS	O
of	IN	O
the	DT	O
patients	NNS	O
.	.	O

dosage	NN	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
500	CD	DOS
mg	NN	UNIT
every	DT	FREQ
4	CD	FREQ
hours	NNS	FREQ
.	.	O

SEE	NNP	O
WARNINGS	NNP	O
SECTION	NNP	O
REGARDING	NNP	O
RISKS	NNP	O
ASSOCIATED	NNP	O
WITH	NNP	O
LONG	NNP	O
-	:	O
TERM	NNP	O
THERAPY	NNP	O
.	.	O

The	DT	O
suggested	JJ	O
dose	NN	O
adjustments	NNS	O
for	IN	O
single	JJ	O
agent	NN	O
or	CC	O
combination	NN	O
therapy	NN	O
shown	VBN	O
in	IN	O
the	DT	O
table	NN	O
below	NN	O
are	VBP	O
modified	VBN	O
from	IN	O
controlled	VBN	O
trials	NNS	O
in	IN	O
previously	RB	WHO
treated	VBN	WHO
and	CC	WHO
untreated	JJ	WHO
patients	NNS	WHO
with	IN	WHO
ovarian	JJ	WHO
carcinoma	NN	WHO
.	.	O

The	DT	O
vaccination	NN	O
procedures	NNS	O
should	MD	O
be	VB	O
checked	VBN	O
,	,	O
and	CC	O
vaccination	NN	O
repeated	VBN	O
with	IN	O
vaccine	NN	O
from	IN	O
another	DT	O
vial	NN	O
or	CC	O
vaccine	NN	O
lot	NN	O
,	,	O
employing	VBG	O
the	DT	O
same	JJ	O
technique	NN	O
described	VBN	O
above	IN	O
[	NNP	O
See	NNP	O
Vaccination	NNP	O
Instructions	NNP	O
]	NNP	O
.	.	O

To	TO	O
Insert	NNP	O
New	NNP	O
Refill	NNP	O
(	(	O
ORTHO	NNP	O
-	:	O
CYCLEN	NN	O
or	CC	O
ORTHO	NNP	O
TRI	NNP	O
-	:	O
CYCLEN	NN	O
)	)	O
:	:	O

Do	NNP	O
not	RB	O
rinse	VB	O
the	DT	O
dosage	NN	O
syringe	NN	O
with	IN	O
water	NN	O
or	CC	O
other	JJ	O
cleaning	NN	O
agents	NNS	O
either	CC	O
before	IN	O
or	CC	O
after	IN	O
use	NN	O
.	.	O

When	WRB	O
initiating	VBG	O
rosuvastatin	NN	O
calcium	NN	O
tablets	NNS	O
therapy	VBP	O
or	CC	O
switching	VBG	O
from	IN	O
another	DT	O
HMG	NNP	O
-	:	O
CoA	NNP	O
reductase	NN	O
inhibitor	NN	O
therapy	NN	O
,	,	O
the	DT	O
appropriate	JJ	O
rosuvastatin	NN	O
calcium	NN	O
tablets	NNS	O
starting	VBG	O
dose	NN	O
should	MD	O
first	RB	O
be	VB	O
utilized	VBN	O
,	,	O
and	CC	O
only	RB	O
then	RB	O
titrated	VBD	O
according	VBG	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
response	NN	O
and	CC	O
individualized	JJ	O
goal	NN	O
of	IN	O
therapy	NN	O
.	.	O

Simultaneous	JJ	O
or	CC	O
sequential	JJ	O
mixing	NN	O
of	IN	O
Liposyn	NNP	O
II	NNP	O
(	(	O
intravenous	JJ	O
fat	JJ	O
emulsion	NN	O
)	)	O
with	IN	O
other	JJ	O
nutritional	JJ	O
substrates	NNS	O
using	VBG	O
an	DT	O
automated	VBN	O
,	,	O
gravimetric	JJ	O
pumping	NN	O
system	NN	O
is	VBZ	O
considered	VBN	O
an	DT	O
acceptable	JJ	O
method	NN	O
for	IN	O
admixture	NN	O
compounding	NN	O
,	,	O
especially	RB	O
for	IN	O
institutions	NNS	O
with	IN	O
a	DT	O
high	JJ	O
volume	NN	O
of	IN	O
3	CD	O
-	:	O
in	IN	O
-	:	O
1	CD	O
admixtures	NNS	O
.	.	O

If	IN	O
the	DT	O
green	JJ	O
light	NN	O
still	RB	O
does	VBZ	O
not	RB	O
turn	VB	O
off	RP	O
,	,	O
discard	VB	O
the	DT	O
inhaler	NN	O
and	CC	O
use	VB	O
a	DT	O
new	JJ	O
one	CD	O
.	.	O

In	IN	O
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
persistent	JJ	WHO
night	NN	WHO
pain	NN	WHO
and	CC	O
/	NN	O
or	CC	O
morning	NN	O
stiffness	NN	O
,	,	O
the	DT	O
giving	VBG	O
of	IN	O
a	DT	O
large	JJ	O
portion	NN	O
,	,	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
100	CD	DOS
mg	NN	UNIT
(	(	O
20	CD	DOS
mL	NN	UNIT
)	)	O
,	,	O
of	IN	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
at	IN	O
bedtime	NN	O
may	MD	O
be	VB	O
helpful	JJ	O
in	IN	O
affording	VBG	O
relief	NN	O
.	.	O

INFUVITE	NNP	O
PEDIATRIC	NNP	O
is	VBZ	O
supplied	VBN	O
as	IN	O
a	DT	O
pharmacy	NN	O
bulk	JJ	O
package	NN	O
,	,	O
and	CC	O
consists	NNS	O
of	IN	O
two	CD	O
pharmacy	NN	O
bulk	NN	O
vials	NNS	O
which	WDT	O
must	MD	O
be	VB	O
combined	VBN	O
and	CC	O
diluted	VBN	O
prior	RB	O
to	TO	O
intravenous	JJ	O
administration	NN	O
[	NNP	O
see	VBP	O
Preparation	NNP	O
And	CC	O
Administration	NNP	O
Instructions	NNP	O
]	NNP	O
.	.	O

Preservative	NNP	O
-	:	O
free	JJ	O
TIMOPTIC	NNP	O
in	IN	O
OCUDOSE	NNP	O
is	VBZ	O
available	JJ	O
in	IN	O
concentrations	NNS	O
of	IN	O
0.25	CD	DOS
and	CC	O
0.5	CD	O
percent	NN	O
.	.	O

CEPTAZ	NNP	O
(	(	O
ceftazidime	NN	O
)	)	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
in	IN	O
patients	NNS	WHO
undergoing	VBG	WHO
intraperitoneal	JJ	WHO
dialysis	NN	WHO
and	CC	O
continuous	JJ	O
ambulatory	NN	O
peritoneal	JJ	O
dialysis	NN	O
.	.	O

Revised	VBN	O
:	:	O
Oct	NN	O
2016	CD	O

Place	NNP	O
small	JJ	O
volume	NN	O
pediatric	NN	O
doses	VBZ	O
up	IN	O
to	TO	O
60	CD	DOS
mL	NNS	UNIT
in	IN	O
volume	NN	O
in	IN	O
a	DT	O
syringe	NN	O
and	CC	O
administer	NN	O
over	IN	O
15	CD	O
minutes	NNS	O
using	VBG	O
a	DT	O
syringe	NN	O
pump	NN	O
.	.	O

Administration	NN	O

BUTRANS	NNP	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
.	.	O

Make	NNP	O
an	DT	O
incision	NN	O
of	IN	O
approximately	RB	O
5	CD	DOS
mm	NNS	UNIT
with	IN	O
the	DT	O
scalpel	NN	O
,	,	O
just	RB	O
through	IN	O
the	DT	O
dermis	NN	O
.	.	O

Based	VBN	O
on	IN	O
clinical	JJ	O
experience	NN	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
OMNIPAQUE	NNP	O
180	CD	O
be	VB	O
used	VBN	O
in	IN	O
children	NNS	WHO
less	JJR	WHO
than	IN	WHO
3	CD	WHO
months	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

Figure	NN	O
13b	CD	O

Sigmoidoscopic	NNP	O
examination	NN	O
and	CC	O
X	NNP	O
-	:	O
ray	NN	O
visualization	NN	O
are	VBP	O
essential	JJ	O
for	IN	O
adequate	JJ	O
monitoring	NN	O
of	IN	O
ulcerative	JJ	O
colitis	NN	O
.	.	O

Postencephalitic	JJ	WHO
patients	NNS	WHO
,	,	WHO
who	WP	WHO
are	VBP	WHO
usually	RB	WHO
more	RBR	WHO
prone	NN	WHO
to	TO	WHO
excessive	JJ	WHO
salivation	NN	WHO
,	,	O
may	MD	O
prefer	VB	O
to	TO	O
take	VB	O
it	PRP	O
after	IN	O
meals	NNS	O
and	CC	O
may	MD	O
,	,	O
in	IN	O
addition	NN	O
,	,	O
require	VBP	O
small	JJ	O
amounts	NNS	O
of	IN	O
atropine	NN	O
which	WDT	O
,	,	O
under	IN	O
such	JJ	O
circumstances	NNS	O
,	,	O
is	VBZ	O
sometimes	RB	O
an	DT	O
effective	JJ	O
adjuvant	NN	O
.	.	O

ALOCRIL®	NNP	O
(	(	O
nedocromil	NN	O
)	)	O
ophthalmic	JJ	O
solution	NN	O
should	MD	O
be	VB	O
used	VBN	O
at	IN	O
regular	JJ	O
intervals	NNS	O
.	.	O

One	CD	O
manufacturer	NN	O
recommends	VBZ	O
that	IN	O
citrated	VBD	O
caffeine	NN	O
administered	VBN	O
orally	RB	O
in	IN	O
dosages	NNS	O
of	IN	O
65	CD	DOS
-	:	O
325	CD	DOS
mg	NN	UNIT
(	(	O
about	IN	O
32	CD	DOS
-	:	O
162	CD	DOS
mg	NN	UNIT
of	IN	O
anhydrous	JJ	O
caffeine	NN	O
)	)	O
3	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

should	MD	O
be	VB	O
based	VBN	O
on	IN	O
the	DT	O
type	NN	O
or	CC	O
severity	NN	O
of	IN	O
infection	NN	O
and	CC	O
given	VBN	O
in	IN	O
equally	RB	O
divided	VBN	O
doses	NNS	O
based	VBN	O
on	IN	O
consideration	NN	O
of	IN	O
degree	NN	O
of	IN	O
susceptibility	NN	O
of	IN	O
the	DT	O
pathogen	NN	O
(	(	O
s	NN	O
)	)	O
,	,	O
renal	JJ	O
function	NN	O
,	,	O
and	CC	O
body	NN	O
weight	NN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
the	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
Rapamune	NNP	O
be	VB	O
reduced	VBN	O
by	IN	O
approximately	RB	O
one	CD	DOS
third	JJ	UNIT
in	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
or	CC	WHO
moderate	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
and	CC	O
by	IN	O
approximately	RB	O
one	CD	DOS
half	NN	UNIT
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
.	.	O

Reconstituted	VBN	O
Solutions	NNS	O

Patients	NNS	O
should	MD	O
be	VB	O
informed	VBN	O
to	TO	O
take	VB	O
Depakote	NNP	O
ER	NNP	O
every	DT	FREQ
day	NN	FREQ
as	IN	O
prescribed	NN	O
.	.	O

Methylin	NNP	O
should	MD	O
be	VB	O
periodically	RB	O
discontinued	VBN	O
to	TO	O
assess	VB	O
the	DT	O
child	NN	O
's	POS	O
condition	NN	O
.	.	O

Before	IN	O
injection	NN	O
,	,	O
the	DT	O
skin	NN	O
over	IN	O
the	DT	O
site	NN	O
to	TO	O
be	VB	O
injected	VBN	O
should	MD	O
be	VB	O
cleansed	VBN	O
with	IN	O
a	DT	O
suitable	JJ	O
germicide	NN	O
.	.	O

Therefore	RB	O
,	,	O
when	WRB	O
adding	VBG	O
EDECRIN	NNP	O
the	DT	O
initial	JJ	O
dose	NN	O
and	CC	O
changes	NNS	O
of	IN	O
dose	NN	O
should	MD	O
be	VB	O
in	IN	O
25	CD	DOS
mg	NN	UNIT
increments	NNS	O
,	,	O
to	TO	O
avoid	VB	O
electrolyte	JJ	O
depletion	NN	O
.	.	O

2	CD	O
.	.	O

The	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
methadone	NN	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
treatment	NN	O
should	MD	O
not	RB	O
ordinarily	RB	O
exceed	VBP	O
40	CD	DOS
mg	NNS	UNIT
.	.	O

Pediatric	JJ	WHO
Patients	NNS	WHO
:	:	O
The	DT	O
dosage	NN	O
for	IN	O
prevention	NN	O
of	IN	O
malaria	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
is	VBZ	O
based	VBN	O
upon	IN	O
body	NN	O
weight	NN	O
(	(	O
Table	JJ	O
1	CD	O
)	)	O
.	.	O

(	(	O
For	IN	O
severe	JJ	O
conditions	NNS	O
8	CD	DOS
grams	NNS	UNIT
a	DT	FREQ
day	NN	FREQ
may	MD	O
be	VB	O
administered	VBN	O
)	)	O
.	.	O

If	IN	O
these	DT	O
conditions	NNS	O
exist	VBP	O
,	,	O
the	DT	O
vaccine	NN	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
.	.	O

The	DT	O
following	JJ	O
drugs	NNS	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
simultaneously	RB	O
through	IN	O
the	DT	O
same	JJ	O
Y	NNP	O
-	:	O
site	NN	O
as	IN	O
tigecycline	NN	O
for	IN	O
injection	NN	O
:	:	O
amphotericin	NN	O
B	NNP	O
,	,	O
amphotericin	NN	O
B	NNP	O
lipid	NN	O
complex	NN	O
,	,	O
diazepam	NN	O
,	,	O
esomeprazole	NN	O
,	,	O
haloperidol	NN	O
and	CC	O
omeprazole	NN	O
.	.	O

[	JJ	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Thoroughly	RB	O
cleanse	NN	O
affected	VBD	O
area	NN	O
.	.	O

QVAR	NNP	O
has	VBZ	O
a	DT	O
dose	JJ	O
counter	NN	O
attached	VBN	O
to	TO	O
the	DT	O
actuator	NN	O
.	.	O

There	EX	O
are	VBP	O
no	DT	O
data	NNS	O
available	JJ	O
for	IN	O
use	NN	O
of	IN	O
STRIVERDI	NNP	O
RESPIMAT	NNP	O
in	IN	O
severe	JJ	O
hepatically	RB	O
impaired	JJ	O
patients	NNS	O
[	VBP	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Because	IN	O
of	IN	O
the	DT	O
possibility	NN	O
of	IN	O
contact	NN	O
dermatitis	NN	O
,	,	O
avoid	VBP	O
getting	VBG	O
solution	NN	O
on	IN	O
hands	NNS	O
or	CC	O
clothing	NN	O
.	.	O

149	CD	O

Proper	NNP	O
dosage	NN	O
and	CC	O
route	NN	O
of	IN	O
administratio	JJ	O
n	NNS	O
should	MD	O
be	VB	O
de	FW	O
te	FW	O
rmine	NN	O
d	NN	O
by	IN	O
the	DT	O
condition	NN	O
of	IN	O
the	DT	O
patient	NN	O
,	,	O
severity	NN	O
of	IN	O
the	DT	O
infection	NN	O
,	,	O
and	CC	O
susceptibility	NN	O
of	IN	O
the	DT	O
causative	JJ	O
o	NN	O
rg	NN	O
anism	NN	O
.	.	O

The	DT	O
supplied	JJ	O
syringe	NN	O
should	MD	O
be	VB	O
used	VBN	O
to	TO	O
withdraw	VB	O
the	DT	O
correct	JJ	O
volume	NN	O
of	IN	O
oral	JJ	O
solution	NN	O
and	CC	O
the	DT	O
oral	JJ	O
solution	NN	O
should	MD	O
be	VB	O
slowly	RB	O
squirted	VBN	O
into	IN	O
the	DT	O
corner	NN	O
of	IN	O
the	DT	O
patient	NN	O
's	POS	O
mouth	NN	O
.	.	O

ALOPRIM	NNP	O
(	(	O
allopurinol	JJ	O
sodium	NN	O
)	)	O
for	IN	O
Injection	NN	O
must	MD	O
be	VB	O
reconstituted	VBN	O
and	CC	O
diluted	VBN	O
.	.	O

If	IN	O
hypoglycemia	NN	O
occurs	VBZ	O
,	,	O
appropriate	JJ	O
adjustments	NNS	O
in	IN	O
the	DT	O
dosage	NN	O
of	IN	O
these	DT	O
agents	NNS	O
should	MD	O
be	VB	O
made	VBN	O
.	.	O

After	IN	O
determining	VBG	O
the	DT	O
appropriate	JJ	O
patient	NN	O
dose	NN	O
,	,	O
reconstitute	VB	O
each	DT	O
vial	NN	O
of	IN	O
Saizen®	NNP	O
as	IN	O
follows	VBZ	O
:	:	O
5	CD	DOS
mg	NNS	UNIT
vial	JJ	UNIT
with	IN	O
1	CD	DOS
to	TO	O
3	CD	DOS
mL	NN	UNIT
of	IN	O
Bacteriostatic	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
(	(	O
Benzyl	NNP	O
Alcohol	NNP	O
preserved	VBD	O
)	)	O
;	:	O
8.8	CD	DOS
mg	NNS	UNIT
vial	JJ	UNIT
with	IN	O
23	CD	DOS
mL	NNS	UNIT
of	IN	O
Bacteriostatic	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
(	(	O
Benzyl	NNP	O
Alcohol	NNP	O
preserved	VBD	O
)	)	O
.	.	O

Administration	NN	O
for	IN	O
more	JJR	O
than	IN	O
4	CD	PER
weeks	NNS	PER
has	VBZ	O
not	RB	O
been	VBN	O
adequately	RB	O
studied	VBN	O
.	.	O

Concurrent	NNP	O
use	NN	O
of	IN	O
analgesics	NNS	O
and	CC	O
/	NN	O
or	CC	O
antipyretics	NNS	O
on	IN	O
treatment	NN	O
days	NNS	O
may	MD	O
help	VB	O
ameliorate	VB	O
flu	JJ	O
-	:	O
like	IN	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
BETASERON	NNP	O
use	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Infasurf	NNP	O
is	VBZ	O
a	DT	O
suspension	NN	O
which	WDT	O
settles	VBZ	O
during	IN	O
storage	NN	O
.	.	O

What	WP	O
you	PRP	O
will	MD	O
need	VB	O
before	IN	O
giving	VBG	O
yourself	PRP	O
the	DT	O
injection	NN	O

Example	JJ	O
conversion	NN	O
from	IN	O
a	DT	O
single	JJ	O
opioid	NN	O
to	TO	O
methadone	VB	O
hydrochloride	JJ	O
tablets	NNS	O
:	:	O

12	CD	O
.	.	O

Remodulin	NNP	O
is	VBZ	O
indicated	VBN	O
for	IN	O
subcutaneous	JJ	O
(	(	O
SC	NNP	O
)	)	O
or	CC	O
intravenous	JJ	O
(	(	O
IV	NNP	O
)	)	O
use	VBP	O
only	RB	O
as	IN	O
a	DT	O
continuous	JJ	O
infusion	NN	O
.	.	O

Use	NNP	O
in	IN	O
Convulsive	NNP	O
States	NNS	O

This	DT	O
titration	NN	O
is	VBZ	O
intended	VBN	O
to	TO	O
reduce	VB	O
the	DT	O
gastrointestinal	NN	O
symptoms	NNS	O
associated	VBN	O
with	IN	O
initial	JJ	O
therapy	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
DARZALEX	NNP	O
is	VBZ	O
16	CD	DOS
mg	NN	UNIT
/	NN	O
kg	VBD	O
actual	JJ	O
body	NN	O
weight	NN	O
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
according	VBG	O
to	TO	O
the	DT	O
following	VBG	O
dosing	NN	O
schedule	NN	O
in	IN	O
Table	JJ	O
2	CD	O
:	:	O

The	DT	O
effect	NN	O
of	IN	O
long	JJ	O
-	:	O
term	NN	O
use	NN	O
of	IN	O
ABSORICA	NNP	O
on	IN	O
bone	NN	O
loss	NN	O
is	VBZ	O
unknown	JJ	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

For	IN	O
the	DT	O
prevention	NN	O
of	IN	O
essential	JJ	O
fatty	JJ	O
acid	NN	O
deficiency	NN	O
,	,	O
the	DT	O
recommended	JJ	O
daily	JJ	FREQ
requirement	NN	O
is	VBZ	O
approximately	RB	O
4	CD	O
%	NN	O
of	IN	O
the	DT	O
caloric	JJ	O
intake	NN	O
as	IN	O
linoleate	NN	O
.	.	O

If	IN	O
the	DT	O
above	JJ	O
maximum	NN	O
doses	NNS	O
are	VBP	O
to	TO	O
be	VB	O
maintained	VBN	O
or	CC	O
exceeded	VBN	O
,	,	O
serum	JJ	O
theophylline	NN	O
measurement	NN	O
is	VBZ	O
essential	JJ	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
:	:	O
Laboratory	NN	O
Tests	NNS	O
for	IN	O
guidance	NN	O
)	)	O
.	.	O

access	NN	O
.	.	O

NuvaRing	NN	O
should	MD	O
be	VB	O
left	VBN	O
in	IN	O
the	DT	O
vagina	NN	O
for	IN	O
a	DT	O
continuous	JJ	O
period	NN	O
of	IN	O
three	CD	PER
weeks	NNS	PER
.	.	O

Caution	NN	O
should	MD	O
be	VB	O
used	VBN	O
when	WRB	O
prescribing	VBG	O
ZITHROMAX	NNP	O
to	TO	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
renal	NN	WHO
or	CC	O
hepatic	JJ	O
function	NN	O
.	.	O

For	IN	O
biweekly	JJ	O
dosing	NN	O
,	,	O
increase	VB	O
the	DT	O
biweekly	JJ	O
dose	NN	O
by	IN	O
20	CD	DOS
mL	NNS	UNIT
.	.	O

Subsequent	JJ	O
doses	NNS	O
may	MD	O
be	VB	O
given	VBN	O
by	IN	O
the	DT	O
same	JJ	O
route	NN	O
if	IN	O
necessary	JJ	O
.	.	O

Inform	NN	O
patients	NNS	O
that	IN	O
they	PRP	O
should	MD	O
report	VB	O
symptoms	NNS	O
that	WDT	O
occur	VBP	O
during	IN	O
and	CC	O
after	IN	O
each	DT	O
infusion	NN	O
because	IN	O
they	PRP	O
may	MD	O
indicate	VB	O
a	DT	O
need	NN	O
for	IN	O
prompt	JJ	O
medical	JJ	O
intervention	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

KYNAMRO	NNP	O
is	VBZ	O
intended	VBN	O
for	IN	O
subcutaneous	JJ	O
use	NN	O
only	RB	O
.	.	O

Experience	NN	O
does	VBZ	O
suggest	VB	O
,	,	O
however	RB	O
,	,	O
that	IN	O
children	NNS	O
receiving	VBG	O
20	CD	DOS
to	TO	O
30	CD	DOS
mg	NNS	UNIT
/	JJ	O
m²	JJ	O
/	NN	O
wk	NN	O
(	(	O
0.65	CD	DOS
to	TO	O
1.0	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
/	NNP	O
wk	NN	O
)	)	O
may	MD	O
have	VB	O
better	JJR	O
absorption	NN	O
and	CC	O
fewer	JJR	O
gastrointestinal	JJ	O
side	NN	O
effects	NNS	O
if	IN	O
methotrexate	NN	O
is	VBZ	O
administered	VBN	O
either	RB	O
intramuscularly	RB	O
or	CC	O
subcutaneously	RB	O
.	.	O

Figure	NN	O
5	CD	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

The	DT	O
steady	JJ	O
-	:	O
state	NN	O
peak	NN	O
serum	NN	O
theophylline	NN	O
concentration	NN	O
is	VBZ	O
a	DT	O
function	NN	O
of	IN	O
the	DT	O
infusion	NN	O
rate	NN	O
and	CC	O
the	DT	O
rate	NN	O
of	IN	O
theophylline	JJ	O
clearance	NN	O
in	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
to	TO	WHO
severe	VB	WHO
hepatic	JJ	WHO
impairment	NN	WHO
is	VBZ	O
50	CD	DOS
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

When	WRB	O
treating	VBG	O
complicated	VBN	O
skin	NN	O
and	CC	O
skin	NN	O
structure	NN	O
infections	NNS	O
caused	VBN	O
by	IN	O
P.aeruginosa	NNP	O
,	,	O
a	DT	O
dose	NN	O
of	IN	O
1	CD	DOS
gram	NN	UNIT
every	DT	FREQ
8	CD	FREQ
hours	NNS	FREQ
is	VBZ	O
recommended	VBN	O
.	.	O

Smith	NNP	O
,	,	O
H.W	NNP	O
.	.	O

However	RB	O
,	,	O
KYTRIL	NNP	O
Injection	NNP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
stable	JJ	O
for	IN	O
at	IN	PER
least	JJS	PER
24	CD	PER
hours	NNS	PER
when	WRB	O
diluted	VBN	O
in	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
or	CC	O
5	CD	O
%	NN	O
Dextrose	NNP	O
and	CC	O
stored	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
under	IN	O
normal	JJ	O
lighting	JJ	O
conditions	NNS	O
.	.	O

Note	NN	O
:	:	O
PRIMACOR	NNP	O
Flexible	NNP	O
Containers	NNP	O
(	(	O
200	CD	DOS
mcg	NN	UNIT
/	NNP	O
mL	NN	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
)	)	O
are	VBP	O
for	IN	O
intravenous	JJ	O
infusion	NN	O
only	RB	O
and	CC	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
for	IN	O
a	DT	O
loading	NN	O
dose	NN	O
.	.	O

femhrt	JJ	O
therapy	NN	O
consists	VBZ	O
of	IN	O
a	DT	O
single	JJ	DOS
tablet	NN	UNIT
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

after	IN	O
hemodialysis	NN	O
and	CC	O
at	IN	O
12	CD	O
hour	NN	O
intervals	NNS	O
timed	VBD	O
from	IN	O
the	DT	O
end	NN	O
of	IN	O
that	DT	O
hemodialysis	NN	O
session	NN	O
.	.	O

Central	JJ	O
Cranial	NNP	O
Diabetes	NNP	O
Insipidus	NNP	O
:	:	O
DDAVP	NNP	O
Nasal	NNP	O
Spray	NNP	O
(	(	O
desmopressin	JJ	O
acetate	NN	O
nasal	NN	O
spray	NN	O
)	)	O
dosage	NN	O
must	MD	O
be	VB	O
determined	VBN	O
for	IN	O
each	DT	O
individual	JJ	O
patient	NN	O
and	CC	O
adjusted	VBD	O
according	VBG	O
to	TO	O
the	DT	O
diurnal	JJ	O
pattern	NN	O
of	IN	O
response	NN	O
.	.	O

For	IN	O
Bolus	NNP	O
Injection	NNP	O
:	:	O
The	DT	O
contents	NNS	O
of	IN	O
an	DT	O
AZACTAM	NNP	O
15	CD	DOS
mL	NN	UNIT
capacity	NN	O
vial	NN	O
should	MD	O
be	VB	O
constituted	VBN	O
with	IN	O
6	CD	DOS
to	TO	O
10	CD	DOS
mL	NNS	UNIT
Sterile	JJ	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
.	.	O

The	DT	O
health	NN	O
care	NN	O
practitioner	NN	O
who	WP	O
uses	VBZ	O
this	DT	O
medication	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
should	MD	O
be	VB	O
aware	JJ	O
of	IN	O
and	CC	O
follow	VB	O
accepted	VBN	O
professional	JJ	O
guidelines	NNS	O
for	IN	O
pediatric	JJ	O
sedation	NN	O
appropriate	NN	O
to	TO	O
their	PRP$	O
situation	NN	O
.	.	O

Therapy	NN	O
with	IN	O
a	DT	O
dose	JJ	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
may	MD	O
be	VB	O
necessary	JJ	O
for	IN	O
some	DT	O
individuals	NNS	O
.	.	O

For	IN	O
intravenous	JJ	O
administration	NN	O
only	RB	O
.	.	O

Data	NNS	O
are	VBP	O
not	RB	O
available	JJ	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
VALTREX	NNP	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
with	IN	WHO
a	DT	WHO
creatinine	JJ	WHO
clearance	NN	WHO
less	JJR	WHO
than	IN	O
50	CD	DOS
mL	JJ	UNIT
/	NNP	O
min	NN	O
/	VBD	O
1.73	CD	O
m²	NN	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Reversal	NN	O
of	IN	O
Postoperative	NNP	O
Opioid	NNP	O
Depression	NNP	O

The	DT	O
Onsolis	NNP	O
film	NN	O
should	MD	O
not	RB	O
be	VB	O
cut	VBN	O
or	CC	O
torn	VBN	O
prior	RB	O
to	TO	O
use	VB	O
.	.	O

The	DT	O
pediatric	JJ	O
dose	NN	O
of	IN	O
Gold	NNP	O
Sodium	NNP	O
Thiomalate	NNP	O
is	VBZ	O
proportional	JJ	O
to	TO	O
the	DT	O
adult	NN	WHO
dose	NN	O
on	IN	O
a	DT	O
weight	JJ	O
basis	NN	O
.	.	O

Treating	VBG	O
physicians	NNS	O
should	MD	O
target	VB	O
on	IN	O
-	:	O
treatment	NN	O
IGF	NNP	O
-	:	O
1	CD	DOS
levels	NNS	UNIT
of	IN	O
0	CD	O
to	TO	O
+2	VB	O
SD	NNP	O
score	NN	O
for	IN	O
age	NN	O
.	.	O

It	PRP	O
may	MD	O
also	RB	O
be	VB	O
appropriate	JJ	O
to	TO	O
modify	VB	O
the	DT	O
rate	NN	O
of	IN	O
subsequent	NN	O
dose	NN	O
titration	NN	O
.	.	O

If	IN	O
administration	NN	O
of	IN	O
PROGLYCEM®	NNP	O
is	VBZ	O
not	RB	O
effective	JJ	O
after	IN	O
two	CD	PER
or	CC	O
three	CD	PER
weeks	NNS	PER
,	,	O
the	DT	O
drug	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
liver	NN	WHO
function	NN	WHO
and	CC	O
serum	NN	O
albumin	JJ	O
concentration	NN	O
less	JJR	O
than	IN	O
3.5	CD	DOS
g	JJ	UNIT
/	NNP	O
dL	NN	O
,	,	O
the	DT	O
maximum	JJ	O
initial	JJ	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
Orudis	NNP	O
(	(	O
ketoprofen	NN	O
)	)	O
or	CC	O
Oruvail	NNP	O
should	MD	O
be	VB	O
100	CD	DOS
mg.	JJ	UNIT
All	DT	WHO
patients	NNS	WHO
with	IN	WHO
metabolic	JJ	WHO
impairment	NN	WHO
,	,	O
particularly	RB	O
those	DT	O
with	IN	O
both	DT	O
hypoalbuminemia	NN	O
and	CC	O
reduced	JJ	O
renal	JJ	O
function	NN	O
,	,	O
may	MD	O
have	VB	O
increased	VBN	O
levels	NNS	O
of	IN	O
free	JJ	O
(	(	O
biologically	RB	O
active	JJ	O
)	)	O
ketoprofen	NN	O
and	CC	O
should	MD	O
be	VB	O
closely	RB	O
monitored	VBN	O
.	.	O

Initial	JJ	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
AYGESTIN	NNP	O
for	IN	O
two	CD	PER
weeks	NNS	PER
.	.	O

When	WRB	O
utilized	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
exercise	NN	O
stress	NN	O
testing	NN	O
,	,	O
Thallous	NNP	O
Chloride	NNP	O
Tl	NNP	O
-	:	O
201	CD	O
should	MD	O
be	VB	O
administered	VBN	O
at	IN	O
the	DT	O
inception	NN	O
of	IN	O
a	DT	O
period	NN	O
of	IN	O
maximum	NN	O
stress	NN	O
which	WDT	O
is	VBZ	O
sustained	VBN	O
for	IN	O
approximately	RB	O
30	CD	O
seconds	NNS	O
after	IN	O
injection	NN	O
.	.	O

The	DT	O
test	NN	O
dose	NN	O
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
the	DT	O
buttock	NN	O
using	VBG	O
the	DT	O
same	JJ	O
technique	NN	O
as	IN	O
described	VBN	O
in	IN	O
the	DT	O
last	JJ	O
paragraph	NN	O
of	IN	O
this	DT	O
section	NN	O
.	.	O

Pre	NNP	O
-	:	O
treatment	NN	O
Guidelines	NNS	O

In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
meningococcal	JJ	O
carrier	NN	O
state	NN	O
,	,	O
the	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
100	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
for	IN	O
5	CD	PER
days	NNS	PER
.	.	O

1	CD	O
.	.	O

Precautions	NNS	O

The	DT	O
solution	NN	O
should	MD	O
be	VB	O
retained	VBN	O
for	IN	O
2	CD	O
hours	NNS	O
.	.	O

The	DT	O
pustule	NN	O
dries	NNS	O
and	CC	O
forms	VBZ	O
a	DT	O
scab	NN	O
,	,	O
which	WDT	O
usually	RB	O
separates	VBZ	O
within	IN	O
14	CD	O
-	:	O
21	CD	PER
days	NNS	PER
,	,	O
leaving	VBG	O
a	DT	O
pitted	JJ	O
scar	NN	O
.	.	O

Initial	JJ	O
doses	NNS	O
should	MD	O
not	RB	O
be	VB	O
determined	VBN	O
by	IN	O
previous	JJ	O
treatment	NN	O
episodes	NNS	O
or	CC	O
dollars	NNS	O
spent	JJ	O
per	IN	FREQ
day	NN	FREQ
on	IN	O
illicit	JJ	O
drug	NN	O
use	NN	O
.	.	O

TABLE	NN	O
1	CD	O
:	:	O
Recommended	VBN	O
Dosages	NNS	O
for	IN	O
ASMANEX	NNP	O
HFA	NNP	O
Treatment	NNP	O

Administer	NNP	O
the	DT	O
initial	JJ	O
dose	NN	O
no	DT	O
earlier	JJR	O
than	IN	O
6	CD	O
to	TO	O
8	CD	O
hours	NNS	O
after	IN	O
surgery	NN	O
.	.	O

There	EX	O
was	VBD	O
no	DT	O
indication	NN	O
that	IN	O
doses	VBZ	O
greater	JJR	O
than	IN	O
20	CD	DOS
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
were	VBD	O
more	RBR	O
effective	JJ	O
.	.	O

Fingernails	NNS	O
only	RB	O
:	:	O
The	DT	O
recommended	JJ	O
dosing	NN	O
regimen	NNS	O
is	VBZ	O
2	CD	O
treatment	NN	O
pulses	NNS	O
,	,	O
each	DT	O
consisting	VBG	O
of	IN	O
200	CD	DOS
mg	NN	UNIT
(	(	O
2	CD	DOS
capsules	NNS	UNIT
)	)	O
b.i.d	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

The	DT	O
breast	NN	O
should	MD	O
not	RB	O
be	VB	O
compressed	VBN	O
on	IN	O
the	DT	O
overlay	NN	O
.	.	O

drip	NN	O
using	VBG	O
a	DT	O
0.2	CD	O
%	NN	O
concentration	NN	O
in	IN	O
5	CD	O
%	NN	O
dextrose	NN	O
and	CC	O
water	NN	O
.	.	O

Leave	VB	O
the	DT	O
Mix2Vial	NNP	O
transfer	NN	O
set	NN	O
in	IN	O
the	DT	O
clear	JJ	O
package	NN	O
.	.	O

The	DT	O
unused	JJ	O
portion	NN	O
of	IN	O
diluted	JJ	O
MIVACRON	NNP	O
should	MD	O
be	VB	O
discarded	VBN	O
after	IN	O
each	DT	O
case	NN	O
.	.	O

For	IN	O
information	NN	O
concerning	VBG	O
drugs	NNS	O
given	VBN	O
in	IN	O
combination	NN	O
with	IN	O
DARZALEX	NNP	O
,	,	O
see	VBP	O
manufacturer	NN	O
's	POS	O
prescribing	NN	O
information	NN	O
.	.	O

The	DT	O
above	JJ	O
concentrations	NNS	O
are	VBP	O
specific	JJ	O
to	TO	O
the	DT	O
parent	NN	O
cyclosporine	NN	O
molecule	NN	O
and	CC	O
correlate	VB	O
directly	RB	O
to	TO	O
the	DT	O
new	JJ	O
monoclonal	JJ	O
specific	JJ	O
radioimmunoassays	NNS	O
(	(	O
mRIA	SYM	O
-	:	O
sp	NN	O
)	)	O
.	.	O

The	DT	O
initial	JJ	O
single	JJ	O
daily	JJ	FREQ
dose	NN	UNIT
is	VBZ	O
continued	VBN	O
postoperatively	RB	O
for	IN	O
1	CD	PER
to	TO	O
2	CD	PER
weeks	NNS	PER
and	CC	O
then	RB	O
tapered	VBN	O
by	IN	O
5	CD	O
%	NN	O
per	IN	O
week	NN	PER
to	TO	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
5	CD	DOS
to	TO	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

Serum	NNP	O
electrolytes	NNS	O
,	,	O
including	VBG	O
magnesium	NN	O
and	CC	O
phosphorus	NN	O
,	,	O
should	MD	O
be	VB	O
monitored	VBN	O
frequently	RB	O
.	.	O

The	DT	O
first	JJ	O
dose	NN	O
should	MD	O
be	VB	O
administered	VBN	O
30	CD	O
minutes	NNS	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
emetogenic	JJ	O
chemotherapy	NN	O
,	,	O
with	IN	O
a	DT	O
subsequent	JJ	O
dose	NN	O
8	CD	O
hours	NNS	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
.	.	O

If	IN	O
spontaneous	JJ	O
expulsion	NN	O
of	IN	O
the	DT	O
implant	NN	O
occurs	VBZ	O
after	IN	O
insertion	NN	O
,	,	O
the	DT	O
following	JJ	O
steps	NNS	O
should	MD	O
be	VB	O
taken	VBN	O
.	.	O

The	DT	O
AtroPen®	NNP	O
(	(	O
atropine	NN	O
)	)	O
is	VBZ	O
intended	VBN	O
as	IN	O
an	DT	O
initial	JJ	O
treatment	NN	O
of	IN	O
the	DT	O
muscarinic	JJ	O
symptoms	NNS	O
of	IN	O
insecticide	NN	O
or	CC	O
nerve	NN	O
agent	NN	O
poisonings	NNS	O
(	(	O
generally	RB	O
breathing	VBG	O
difficulties	NNS	O
due	JJ	O
to	TO	O
increased	JJ	O
secretions	NNS	O
)	)	O
;	:	O
definitive	JJ	O
medical	JJ	O
care	NN	O
should	MD	O
be	VB	O
sought	VBN	O
immediately	RB	O
.	.	O

The	DT	O
required	JJ	O
dose	NN	O
of	IN	O
thallium	NN	O
-	:	O
201	CD	O
should	MD	O
be	VB	O
injected	VBN	O
at	IN	O
the	DT	O
midpoint	NN	O
of	IN	O
the	DT	O
Adenoscan	NNP	O
infusion	NN	O
(	(	O
i.e	NN	O
,	,	O
after	IN	O
the	DT	O
first	JJ	O
three	CD	O
minutes	NNS	O
of	IN	O
Adenoscan	NNP	O
)	)	O
.	.	O

If	IN	O
a	DT	O
serious	JJ	O
adverse	JJ	O
reaction	NN	O
develops	VBZ	O
during	IN	O
the	DT	O
course	NN	O
of	IN	O
treatment	NN	O
(	(	O
See	NNP	O
WARNINGS	NNP	O
)	)	O
discontinue	NN	O
or	CC	O
modify	VB	O
the	DT	O
dosage	NN	O
of	IN	O
Peglntron™	NNP	O
and	CC	O
/	NNP	O
or	CC	O
REBETOL®	NNP	O
until	IN	O
the	DT	O
adverse	JJ	O
event	NN	O
abates	NNS	O
or	CC	O
decreases	NNS	O
in	IN	O
severity	NN	O
.	.	O

The	DT	O
lyophilized	JJ	O
powder	NN	O
contained	VBD	O
within	IN	O
the	DT	O
Pen	NNP	O
must	MD	O
be	VB	O
reconstituted	VBN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

Increase	NN	O
at	IN	O
weekly	JJ	FREQ
intervals	NNS	FREQ
by	IN	O
adding	VBG	O
up	RB	O
to	TO	O
200	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
using	VBG	O
a	DT	O
b.i.d	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Before	IN	O
each	DT	O
course	NN	O
of	IN	O
the	DT	O
drug	NN	O
careful	JJ	O
clinical	JJ	O
assessment	NN	O
is	VBZ	O
essential	JJ	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Recommended	VBN	O
Weight	NNP	O
-	:	O
Based	VBD	O
Dosage	NNP	O
of	IN	O
INFUVITE	NNP	O
PEDIATRIC	NNP	O

In	IN	O
acutely	RB	WHO
ill	JJ	WHO
patients	NNS	WHO
,	,	O
serum	JJ	O
theophylline	NN	O
concentrations	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
at	IN	O
frequent	JJ	O
intervals	NNS	O
,	,	O
e.g	NN	O
,	,	O
every	DT	FREQ
24	CD	FREQ
hours	NNS	FREQ
.	.	O

In	IN	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
currently	RB	WHO
being	VBG	WHO
treated	VBN	WHO
with	IN	WHO
a	DT	WHO
diuretic	JJ	WHO
,	,	O
symptomatic	JJ	O
hypotension	NN	O
occasionally	RB	O
can	MD	O
occur	VB	O
following	VBG	O
the	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
ALTACE	NNP	O
(	(	O
ramipril	JJ	O
capsules	NNS	O
)	)	O
.	.	O

Individuals	NNS	O
should	MD	O
drink	VB	O
plenty	NN	O
of	IN	O
fluids	NNS	O
and	CC	O
void	NN	O
frequently	RB	O
to	TO	O
promote	VB	O
dilution	NN	O
of	IN	O
the	DT	O
radioactive	JJ	O
chelate	NN	O
in	IN	O
the	DT	O
urine	NN	O
and	CC	O
minimize	VB	O
radiation	NN	O
exposure	NN	O
directly	RB	O
to	TO	O
the	DT	O
bladder	NN	O
.	.	O

Adverse	JJ	O
Reactions	NNS	O

Have	VBP	O
the	DT	O
patient	NN	O
lie	NN	O
on	IN	O
his	PRP$	O
back	NN	O
on	IN	O
the	DT	O
examination	NN	O
table	NN	O
,	,	O
with	IN	O
his	PRP$	O
left	JJ	O
arm	NN	O
(	(	O
if	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
left	VBN	O
-	:	O
handed	VBN	O
,	,	O
the	DT	O
right	JJ	O
arm	NN	O
)	)	O
flexed	VBD	O
at	IN	O
the	DT	O
elbow	NN	O
and	CC	O
externally	RB	O
rotated	VBD	O
so	RB	O
that	IN	O
his	PRP$	O
hand	NN	O
is	VBZ	O
out	RP	O
to	TO	O
his	PRP$	O
side	NN	O
.	.	O

3	CD	O
.	.	O

In	IN	O
more	RBR	O
serious	JJ	O
infections	NNS	O
,	,	O
otitis	NN	O
media	NNS	O
,	,	O
and	CC	O
infections	NNS	O
caused	VBN	O
by	IN	O
less	JJR	O
susceptible	JJ	O
organisms	NNS	O
,	,	O
40	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
are	VBP	O
recommended	VBN	O
,	,	O
with	IN	O
a	DT	O
maximum	JJ	O
dosage	NN	O
of	IN	O
1	CD	DOS
g	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

Dosage	NN	O
and	CC	O
Administration	NNP	O
for	IN	O
AndroGel	NNP	O
1	CD	O
%	NN	O
differs	NNS	O
from	IN	O
AndroGel	NNP	O
1.62	CD	O
%	NN	O
.	.	O

DO	NNP	O
NOT	NNP	O
USE	VB	O
IF	NNP	O
COLOR	NNP	O
IS	VBZ	O
DARKER	NNP	O
THAN	NNP	O
PALE	NNP	O
YELLOW	NNP	O
,	,	O
IF	NNP	O
IT	NNP	O
IS	NNP	O
DISCOLORED	NNP	O
IN	NNP	O
ANY	NNP	O
OTHER	NNP	O
WAY	NNP	O
OR	NNP	O
IF	NNP	O
IT	NNP	O
CONTAINS	NNP	O
A	NNP	O
PRECIPITATE	NNP	O
.	.	O

When	WRB	O
halothane	NN	O
is	VBZ	O
used	VBN	O
for	IN	O
general	JJ	O
anesthesia	NN	O
,	,	O
patients	NNS	WHO
ranging	VBG	WHO
from	IN	WHO
3	CD	WHO
months	NNS	WHO
old	JJ	WHO
through	IN	WHO
adolescence	NN	WHO
can	MD	O
be	VB	O
administered	VBN	O
ZEMURON	NNP	O
maintenance	NN	O
doses	NNS	O
of	IN	O
0.075	CD	DOS
to	TO	O
0.125	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	VBP	O
upon	IN	O
return	NN	O
of	IN	O
T1	NNP	O
to	TO	O
0.25	CD	O
%	NN	O
to	TO	O
provide	VB	O
clinical	JJ	O
relaxation	NN	O
for	IN	O
7	CD	O
to	TO	O
10	CD	O
minutes	NNS	O
.	.	O

There	EX	O
is	VBZ	O
no	DT	O
evidence	NN	O
to	TO	O
suggest	VB	O
that	IN	O
more	RBR	O
frequent	JJ	O
application	NN	O
will	MD	O
increase	VB	O
efficacy	NN	O
,	,	O
but	CC	O
additional	JJ	O
applications	NNS	O
would	MD	O
be	VB	O
expected	VBN	O
to	TO	O
increase	VB	O
the	DT	O
rate	NN	O
of	IN	O
local	JJ	O
adverse	JJ	O
reactions	NNS	O
and	CC	O
systemic	JJ	O
absorption	NN	O
.	.	O

To	TO	O
be	VB	O
sure	JJ	O
that	IN	O
ramipril	NN	O
is	VBZ	O
not	RB	O
lost	VBN	O
when	WRB	O
such	JJ	O
a	DT	O
mixture	NN	O
is	VBZ	O
used	VBN	O
,	,	O
consume	VB	O
the	DT	O
mixture	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
.	.	O

The	DT	O
usual	JJ	O
duration	NN	O
of	IN	O
treatment	NN	O
is	VBZ	O
seven	CD	PER
to	TO	O
ten	VB	O
days	NNS	O
.	.	O

Treated	VBN	O
patients	NNS	WHO
with	IN	WHO
an	DT	WHO
intact	JJ	WHO
uterus	NN	WHO
should	MD	O
be	VB	O
monitored	VBN	O
closely	RB	O
for	IN	O
signs	NNS	O
of	IN	O
endometrial	JJ	O
cancer	NN	O
,	,	O
and	CC	O
appropriate	JJ	O
diagnostic	JJ	O
measures	NNS	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
rule	VB	O
our	PRP$	O
malignancy	NN	O
in	IN	O
the	DT	O
event	NN	O
of	IN	O
persistent	NN	O
or	CC	O
recurring	VBG	O
abnormal	JJ	O
vaginal	JJ	O
bleeding	NN	O
.	.	O

Darvocet	NNP	O
-	:	O
N	NNP	O
(	(	O
propoxyphene	JJ	O
napsylate	NN	O
and	CC	O
acetaminophen	NN	O
)	)	O
100	CD	DOS
(	(	O
100	CD	DOS
mg	NN	UNIT
propoxyphene	NN	O
napsylate	NN	O
and	CC	O
650	CD	DOS
mg	NNS	UNIT
acetaminophen	NN	O
)	)	O

The	DT	O
patient	NN	O
should	MD	O
continue	VB	O
to	TO	O
take	VB	O
only	RB	O
one	CD	DOS
tablet	NN	UNIT
each	DT	FREQ
day	NN	FREQ
in	IN	O
sequence	NN	O
.	.	O

Therapy	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
when	WRB	O
control	NN	O
is	VBZ	O
achieved	VBN	O
.	.	O

Ensure	NN	O
patients	NNS	O
understand	VB	O
how	WRB	O
to	TO	O
identify	VB	O
signs	NNS	O
of	IN	O
malfunction	NN	O
of	IN	O
On	IN	O
-	:	O
body	NN	O
Injector	NNP	O
for	IN	O
Neulasta	NNP	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
PATIENT	NNP	O
INFORMATION	NNP	O
]	NNP	O
.	.	O

In	IN	O
patients	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
,	,	O
start	VBP	O
with	IN	O
10	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
;	:	O
daily	JJ	FREQ
dosage	NN	O
may	MD	O
be	VB	O
raised	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
10	CD	DOS
mg	NN	UNIT
at	IN	O
weekly	JJ	FREQ
intervals	NNS	FREQ
until	IN	O
optimal	JJ	O
response	NN	O
is	VBZ	O
obtained	VBN	O
.	.	O

BUTRANS	NNP	O
doses	NNS	O
of	IN	O
7.5	CD	O
,	,	O
10	CD	O
,	,	O
15	CD	O
,	,	O
and	CC	O
20	CD	DOS
mcg	NN	UNIT
/	FW	O
hour	NN	O
are	VBP	O
for	IN	O
opioid	JJ	O
-	:	O
experienced	JJ	O
patients	NNS	O
only	RB	O
.	.	O

The	DT	O
dose	NN	O
should	MD	O
be	VB	O
titrated	VBN	O
based	VBN	O
upon	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
's	POS	O
response	NN	O
to	TO	O
their	PRP$	O
initial	JJ	O
dose	NN	O
of	IN	O
OXECTA	NNP	O
.	.	O

Adults	NNS	WHO
:	:	O
An	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
1	CD	DOS
g	NN	UNIT
(	(	O
=	JJ	O
600	CD	DOS
mg	JJ	UNIT
base	NN	UNIT
)	)	O
followed	VBN	O
by	IN	O
an	DT	O
additional	JJ	O
500	CD	DOS
mg	NN	UNIT
(	(	O
=	JJ	O
300	CD	DOS
mg	JJ	UNIT
base	NN	UNIT
)	)	O
after	IN	O
six	CD	O
to	TO	O
eight	CD	O
hours	NNS	O
and	CC	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
of	IN	O
500	CD	DOS
mg	NN	UNIT
(	(	O
=	JJ	O
300	CD	DOS
mg	JJ	UNIT
base	NN	UNIT
)	)	O
on	IN	O
each	DT	O
of	IN	O
two	CD	PER
consecutive	JJ	PER
days	NNS	PER
.	.	O

Insufficient	NNP	O
data	NNS	O
are	VBP	O
available	JJ	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
Clcr	NNP	O
less	JJR	O
than	IN	O
20	CD	DOS
mL	JJ	UNIT
/	NNP	O
min	NN	O
)	)	O
to	TO	O
provide	VB	O
a	DT	O
dosage	NN	O
recommendation	NN	O
for	IN	O
HYCAMTIN	NNP	O
[	NNP	O
see	VBP	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Local	JJ	O
erythema	NN	O
may	MD	O
or	CC	O
may	MD	O
not	RB	O
be	VB	O
observed	VBN	O
with	IN	O
a	DT	O
positive	JJ	O
reaction	NN	O
.	.	O

The	DT	O
prescriber	NN	O
should	MD	O
demonstrate	VB	O
the	DT	O
proper	JJ	O
application	NN	O
technique	NN	O
to	TO	O
maximize	VB	O
the	DT	O
benefit	NN	O
of	IN	O
ZYCLARA	NNP	O
Cream	NNP	O
therapy	NN	O
.	.	O

No	DT	O
special	JJ	O
dose	JJ	O
adjustments	NNS	O
are	VBP	O
usually	RB	O
necessary	JJ	O
.	.	O

The	DT	O
side	NN	O
effects	NNS	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
of	IN	O
lisinopril	NN	O
are	VBP	O
generally	RB	O
rare	JJ	O
and	CC	O
apparently	RB	O
independent	JJ	O
of	IN	O
dose	NN	O
;	:	O
those	DT	O
of	IN	O
hydrochlorothiazide	NN	O
are	VBP	O
a	DT	O
mixture	NN	O
of	IN	O
dose	JJ	O
-	:	O
dependent	JJ	O
phenomena	NN	O
(	(	O
primarily	RB	O
hypokalemia	NN	O
)	)	O
and	CC	O
dose	JJ	O
-	:	O
independent	JJ	O
phenomena	NN	O
(	(	O
eg	JJ	O
,	,	O
pancreatitis	NN	O
)	)	O
,	,	O
the	DT	O
former	JJ	O
much	RB	O
more	RBR	O
common	JJ	O
than	IN	O
the	DT	O
latter	NN	O
.	.	O

Peak	NNP	O
effects	NNS	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
may	MD	O
not	RB	O
occur	VB	O
for	IN	O
up	RB	O
to	TO	O
four	CD	O
hours	NNS	O
after	IN	O
dosing	VBG	O
.	.	O

6	CD	O
.	.	O

To	TO	O
prime	VB	O
BEVESPI	NNP	O
AEROSPHERE	NNP	O
,	,	O
release	NN	O
4	CD	O
sprays	NNS	O
into	IN	O
the	DT	O
air	NN	O
away	RB	O
from	IN	O
the	DT	O
face	NN	O
,	,	O
shaking	VBG	O
well	RB	O
before	IN	O
each	DT	O
spray	NN	O
.	.	O

Once	RB	O
thawed	VBN	O
,	,	O
solutions	NNS	O
should	MD	O
not	RB	O
be	VB	O
refrozen	VBN	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
compromised	JJ	WHO
myocardial	JJ	WHO
function	NN	WHO
,	,	O
intravascular	JJ	O
volume	NN	O
depletion	NN	O
,	,	O
or	CC	O
abnormally	RB	O
low	JJ	O
vascular	JJ	O
tone	NN	O
(	(	O
e.g	UH	O
,	,	O
sepsis	NN	O
)	)	O
may	MD	O
be	VB	O
more	RBR	O
susceptible	JJ	O
to	TO	O
hypotension	NN	O
.	.	O

The	DT	O
implant	NN	O
is	VBZ	O
inserted	VBN	O
subcutaneously	RB	O
in	IN	O
the	DT	O
inner	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
and	CC	O
provides	VBZ	O
continuous	JJ	O
release	NN	O
of	IN	O
histrelin	NN	O
acetate	NN	O
(	(	O
65	CD	DOS
mcg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
)	)	O
for	IN	O
12	CD	PER
months	NNS	PER
of	IN	O
hormonal	JJ	O
therapy	NN	O
.	.	O

The	DT	O
need	NN	O
for	IN	O
additional	JJ	O
doses	NNS	O
of	IN	O
SURVANTA	NNP	O
is	VBZ	O
determined	VBN	O
by	IN	O
evidence	NN	O
of	IN	O
continuing	VBG	O
respiratory	JJ	O
distress	NN	O
.	.	O

HUMORSOL	NNP	O
(	(	O
demecarium	NN	O
)	)	O
is	VBZ	O
intended	VBN	O
solely	RB	O
for	IN	O
topical	JJ	O
use	NN	O
in	IN	O
the	DT	O
conjunctival	NN	O
sac	NN	O
.	.	O

For	IN	O
IM	NNP	O
administration	NN	O
,	,	O
Tazicef	NNP	O
should	MD	O
be	VB	O
reconstituted	VBN	O
with	IN	O
one	CD	DOS
of	IN	O
the	DT	O
following	JJ	O
diluents	NNS	O
:	:	O
Sterile	JJ	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
Bacteriostatic	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
or	CC	O
0.5	CD	O
%	NN	O
or	CC	O
1	CD	O
%	NN	O
Lidocaine	NNP	O
Hydrochloride	NNP	O
Injection	NNP	O
.	.	O

When	WRB	O
used	VBN	O
in	IN	O
streptococcal	JJ	O
infection	NN	O
,	,	O
therapy	NN	O
should	MD	O
be	VB	O
continued	VBN	O
for	IN	O
ten	JJ	PER
days	NNS	PER
.	.	O

Nebulizers	NNS	O
may	MD	O
also	RB	O
be	VB	O
attached	VBN	O
to	TO	O
plastic	VB	O
face	NN	O
masks	NNS	O
,	,	O
plastic	JJ	O
face	NN	O
tents	NNS	O
,	,	O
plastic	NN	O
mouthpieces	NNS	O
,	,	O
conventional	JJ	O
plastic	NN	O
oxygen	NN	O
tents	NNS	O
,	,	O
or	CC	O
head	NN	O
tents	NNS	O
.	.	O

Treatment	NN	O
should	MD	O
continue	VB	O
for	IN	O
the	DT	O
full	JJ	O
treatment	NN	O
course	NN	O
even	RB	O
if	IN	O
all	DT	O
actinic	JJ	O
keratoses	NNS	O
appear	VBP	O
to	TO	O
be	VB	O
gone	VBN	O
.	.	O

If	IN	O
such	JJ	O
bleeding	NN	O
occurs	NNS	O
,	,	O
discontinuance	NN	O
of	IN	O
heparin	NN	O
and	CC	O
neutralization	NN	O
with	IN	O
protamine	JJ	O
sulfate	NN	O
are	VBP	O
advisable	JJ	O
.	.	O

Maintain	NN	O
this	DT	O
dose	NN	O
for	IN	O
a	DT	O
minimum	NN	O
of	IN	O
14	CD	O
days	NNS	O
.	.	O

In	IN	O
conjunction	NN	O
with	IN	O
the	DT	O
first	JJ	O
ARISTADA	NNP	O
injection	NN	O
,	,	O
administer	NN	O
treatment	NN	O
with	IN	O
oral	JJ	O
aripiprazole	NN	O
for	IN	O
21	CD	PER
consecutive	JJ	PER
days	NNS	PER
.	.	O

0.012	CD	O
x	JJ	O
patient	NN	O
's	POS	O
actual	JJ	O
body	NN	O
weight	NN	O
(	(	O
in	IN	O
kg	NN	O
)	)	O
=	NN	O
volume	NN	O
to	TO	O
be	VB	O
administered	VBN	O
(	(	O
in	IN	O
mL	NN	O
)	)	O

The	DT	O
needle	NN	O
is	VBZ	O
inserted	VBN	O
approximately	RB	O
4	CD	DOS
mm	NNS	UNIT
in	IN	O
the	DT	O
submucosa	NN	O
of	IN	O
the	DT	O
mid	NN	O
-	:	O
to	TO	O
distal	VB	O
ureteral	JJ	O
tunnel	NN	O
at	IN	O
the	DT	O
6	CD	O
o´clock	NN	O
position	NN	O
(	(	O
Site	JJ	O
1	CD	O
;	:	O
Fig	NNP	O
.	.	O

The	DT	O
patient	NN	O
dose	NN	O
should	MD	O
be	VB	O
measured	VBN	O
by	IN	O
a	DT	O
suitable	JJ	O
radioactivity	NN	O
calibration	NN	O
system	NN	O
immediately	RB	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Oncaspar®	NNP	O
is	VBZ	O
2,500	CD	DOS
International	NNP	UNIT
Units	NNP	UNIT
/	NNP	O
m²	VBD	O
intramuscularly	RB	O
or	CC	O
intravenously	RB	O
.	.	O

Follow	NNP	O
directions	NNS	O
for	IN	O
use	NN	O
which	WDT	O
accompany	VBZ	O
the	DT	O
administration	NN	O
set	NN	O
provided	VBD	O
.	.	O

Non	NNP	O
-	:	O
occlusive	JJ	O
dressings	NNS	O
such	JJ	O
as	IN	O
cotton	NN	O
gauze	NN	O
or	CC	O
cotton	NN	O
underwear	NN	O
may	MD	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
skin	JJ	O
reactions	NNS	O
.	.	O

Peel	NNP	O
back	RB	O
the	DT	O
cover	NN	O
from	IN	O
the	DT	O
clear	JJ	O
plastic	NN	O
vial	JJ	O
adapter	NN	O
package	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
the	DT	O
oral	JJ	O
solution	NN	O
should	MD	O
be	VB	O
administered	VBN	O
using	VBG	O
a	DT	O
calibrated	JJ	O
dosing	NN	O
syringe	NN	O
.	.	O

In	IN	O
the	DT	O
absence	NN	O
of	IN	O
prospective	JJ	O
data	NNS	O
,	,	O
recommended	VBD	O
doses	NNS	O
should	MD	O
not	RB	O
be	VB	O
exceeded	VBN	O
and	CC	O
the	DT	O
concentration	NN	O
and	CC	O
infusion	NN	O
rate	NN	O
selected	VBN	O
should	MD	O
be	VB	O
the	DT	O
minimum	JJ	O
practicable	JJ	O
.	.	O

This	DT	O
should	MD	O
be	VB	O
considered	VBN	O
during	IN	O
the	DT	O
preparation	NN	O
and	CC	O
administration	NN	O
of	IN	O
BeneFIX	NNP	O
,	,	O
including	VBG	O
storage	NN	O
time	NN	O
elapsed	VBN	O
in	IN	O
a	DT	O
PVC	NNP	O
container	NN	O
following	VBG	O
reconstitution	NN	O
.	.	O

Health	NNP	O
care	NN	O
providers	NNS	O
should	MD	O
instruct	VB	O
patients	NNS	O
and	CC	O
care	NN	O
givers	NNS	O
to	TO	O
discontinue	VB	O
any	DT	O
dosage	NN	O
that	WDT	O
causes	VBZ	O
adverse	JJ	O
effects	NNS	O
,	,	O
to	TO	O
withhold	VB	O
the	DT	O
medication	NN	O
until	IN	O
these	DT	O
symptoms	NNS	O
are	VBP	O
gone	VBN	O
and	CC	O
to	TO	O
then	RB	O
resume	VB	O
therapy	NN	O
at	IN	O
a	DT	O
lower	JJR	O
,	,	O
previously	RB	O
tolerated	VBN	O
dosage	NN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
NSABP	NNP	O
B	NNP	O
-	:	O
14	CD	O
adjuvant	NN	O
study	NN	O
in	IN	O
women	NNS	WHO
with	IN	WHO
node	JJ	WHO
-	:	WHO
negative	JJ	WHO
breast	NN	WHO
cancer	NN	WHO
,	,	O
one	CD	DOS
10	CD	DOS
mg	NN	UNIT
tamoxifen	NN	O
citrate	NN	O
tablet	NN	O
was	VBD	O
given	VBN	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
at	IN	O
least	JJS	O
5	CD	O
years	NNS	O
.	.	O

If	IN	O
improvement	NN	O
is	VBZ	O
not	RB	O
observed	VBN	O
after	IN	O
appropriate	JJ	O
dosage	NN	O
adjustment	NN	O
over	IN	O
a	DT	O
one	CD	DOS
-	:	O
month	NN	O
period	NN	O
,	,	O
the	DT	O
drug	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
.	.	O

Patients	NNS	O
should	MD	O
initiate	VB	O
therapy	NN	O
at	IN	O
10	CD	DOS
to	TO	O
15	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

Care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
avoid	VB	O
injection	NN	O
into	IN	O
or	CC	O
near	IN	O
blood	NN	O
vessels	NNS	O
and	CC	O
nerves	NNS	O
.	.	O

Since	IN	O
the	DT	O
doses	NNS	O
of	IN	O
epinephrine	NN	O
delivered	VBN	O
from	IN	O
Adrenaclick	NNP	O
are	VBP	O
fixed	VBN	O
,	,	O
consider	VB	O
using	VBG	O
other	JJ	O
forms	NNS	O
of	IN	O
injectable	JJ	O
epinephrine	NN	O
if	IN	O
doses	NNS	O
lower	JJR	O
than	IN	O
0.15	CD	DOS
mg	NNS	UNIT
are	VBP	O
deemed	VBN	O
necessary	JJ	O
.	.	O

Initiate	NNP	O
treatment	NN	O
with	IN	O
OPANA	NNP	O
in	IN	O
a	DT	O
dosing	NN	O
range	NN	O
of	IN	O
10	CD	DOS
to	TO	O
20	CD	DOS
mg	NN	UNIT
every	DT	O
4	CD	O
to	TO	O
6	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

Ceftazidime	NN	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
4	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
has	VBZ	O
been	VBN	O
found	VBN	O
compatible	JJ	O
for	IN	O
24	CD	PER
hours	NNS	PER
at	IN	O
room	NN	O
temperature	NN	O
for	IN	O
7	CD	PER
days	NNS	PER
under	IN	O
refrigeration	NN	O
in	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
or	CC	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
when	WRB	O
admixed	VBN	O
with	IN	O
:	:	O
cefuroxime	NN	O
(	(	O
ZINACEF®	NNP	O
)	)	O
3	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
,	,	O
heparin	VBD	O
10	CD	DOS
U	NNP	UNIT
/	NNP	O
mL	VBD	O
or	CC	O
50	CD	DOS
U	NNP	UNIT
/	NNP	O
mL	NN	O
or	CC	O
potassium	NN	O
chloride	VBP	O
10	CD	DOS
or	CC	O
40	CD	DOS
mEq	NNS	UNIT
/	JJ	O
L	NNP	O
.	.	O

If	IN	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dosage	NN	O
exceeds	VBZ	O
300	CD	DOS
mg	NN	UNIT
,	,	O
it	PRP	O
should	MD	O
be	VB	O
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

The	DT	O
amount	NN	O
of	IN	O
infusion	NN	O
solution	NN	O
required	VBN	O
per	IN	O
minute	NN	O
will	MD	O
depend	VB	O
upon	IN	O
the	DT	O
concentration	NN	O
of	IN	O
NIMBEX	NNP	O
in	IN	O
the	DT	O
infusion	NN	O
solution	NN	O
,	,	O
the	DT	O
desired	VBN	O
dose	NN	O
of	IN	O
NIMBEX	NNP	O
,	,	O
and	CC	O
the	DT	O
patient	NN	O
's	POS	O
weight	NN	O
.	.	O

Accurate	NNP	O
diagnosis	NN	O
of	IN	O
infecting	VBG	O
organism	NN	O
is	VBZ	O
essential	JJ	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
CellCept	NNP	O
Oral	NNP	O
Suspension	NNP	O
be	VB	O
constituted	VBN	O
by	IN	O
the	DT	O
pharmacist	NN	O
prior	RB	O
to	TO	O
dispensing	VBG	O
to	TO	O
the	DT	O
patient	NN	O
.	.	O

Other	JJ	O
regimens	NNS	O
call	VBP	O
for	IN	O
higher	JJR	O
dosage	NN	O
to	TO	O
induce	VB	O
pubertal	JJ	O
changes	NNS	O
and	CC	O
lower	JJR	O
dosage	NN	O
for	IN	O
maintenance	NN	O
after	IN	O
puberty	NN	O
.	.	O

In	IN	O
adults	NNS	WHO
,	,	O
the	DT	O
use	NN	O
of	IN	O
TORADOL	NNP	O
(	(	O
ketorolac	FW	O
tromethamine	NN	O
)	)	O
ORAL	NNP	O
is	VBZ	O
only	RB	O
indicated	JJ	O
as	IN	O
continuation	NN	O
therapy	NN	O
to	TO	O
IV	NNP	O
or	CC	O
IM	NNP	O
dosing	NN	O
of	IN	O
ketorolac	NN	O
tromethamine	NN	O
.	.	O

Gradual	JJ	O
reduction	NN	O
of	IN	O
dose	NN	O
may	MD	O
begin	VB	O
after	IN	O
twelve	JJ	PER
weeks	NNS	PER
of	IN	O
initial	JJ	O
treatment	NN	O
and	CC	O
may	MD	O
last	JJ	O
for	IN	O
up	IN	PER
to	TO	PER
twelve	VB	PER
weeks	NNS	PER
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
of	IN	O
CARDURA	NNP	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
given	VBN	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

If	IN	O
Hgb	NNP	O
between	IN	O
8	CD	DOS
-	:	O
10	CD	DOS
g	NN	UNIT
/	NNP	O
dL	NN	O
,	,	O
redose	VBP	O
between	IN	O
125	CD	DOS
to	TO	O
200	CD	DOS
international	JJ	UNIT
unit	NN	UNIT
/	NNP	O
kg	NNP	O
(	(	O
25	CD	DOS
to	TO	O
40	CD	DOS
mcg	NNS	UNIT
/	NNP	O
kg	NN	O
)	)	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Dosing	NN	O
Guidelines	NNS	O
for	IN	O
Treatment	NNP	O
of	IN	O
Minor	NNP	O
and	CC	O
Major	NNP	O
Hemorrhages	NNP	O

If	IN	O
a	DT	O
mean	JJ	O
volume	NN	O
of	IN	O
distribution	NN	O
of	IN	O
about	IN	O
0.5	CD	O
L	NNP	O
/	NNP	O
kg	NN	O
is	VBZ	O
assumed	VBN	O
(	(	O
actual	JJ	O
range	NN	O
is	VBZ	O
0.3	CD	DOS
to	TO	O
0.7	CD	O
L	NNP	O
/	NNP	O
kg	NN	O
)	)	O
,	,	O
each	DT	DOS
mg	NN	UNIT
/	NN	O
kg	NN	O
(	(	O
ideal	JJ	O
body	NN	O
weight	VBD	O
)	)	O
of	IN	O
theophylline	NN	O
administered	VBN	O
as	IN	O
a	DT	O
loading	NN	O
dose	NN	O
over	IN	O
30	CD	O
minutes	NNS	O
results	NNS	O
in	IN	O
an	DT	O
average	JJ	O
2	CD	DOS
mcg	NN	UNIT
/	NNP	O
mL	NN	O
increase	NN	O
in	IN	O
serum	JJ	O
theophylline	JJ	O
concentration	NN	O
.	.	O

Instruct	NN	O
patients	NNS	O
to	TO	O
take	VB	O
XTAMPZA	NNP	O
ER	NNP	O
capsules	VBZ	O
with	IN	O
approximately	RB	O
the	DT	O
same	JJ	O
amount	NN	O
of	IN	O
food	NN	O
for	IN	O
every	DT	FREQ
dose	NN	FREQ
in	IN	O
order	NN	O
to	TO	O
ensure	VB	O
consistent	JJ	O
plasma	NN	O
levels	NNS	O
are	VBP	O
achieved	VBN	O
.	.	O

Therapy	NN	O
in	IN	O
these	DT	O
age	NN	O
groups	NNS	O
should	MD	O
be	VB	O
initiated	VBN	O
with	IN	O
Tofranil™	NNP	O
,	,	O
brand	NN	O
of	IN	O
imipramine	JJ	O
hydrochloride	NN	O
tablets	NNS	O
,	,	O
at	IN	O
a	DT	O
total	JJ	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
25	CD	DOS
to	TO	O
50	CD	DOS
mg	NN	UNIT
,	,	O
since	IN	O
Tofranil	NNP	O
-	:	O
PM	NN	O
capsules	NNS	O
are	VBP	O
not	RB	O
available	JJ	O
in	IN	O
these	DT	O
strengths	NNS	O
.	.	O

c	NNS	O
)	)	O
While	IN	O
holding	VBG	O
the	DT	O
needle	JJ	O
cap	NN	O
,	,	O
ensure	VB	O
the	DT	O
needle	NN	O
is	VBZ	O
firmly	RB	O
seated	VBN	O
on	IN	O
the	DT	O
safety	NN	O
device	NN	O
with	IN	O
a	DT	O
push	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
DigiFab®	NNP	O
(	(	O
in	IN	O
number	NN	O
of	IN	O
vials	NNS	O
)	)	O
represented	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
can	MD	O
be	VB	O
approximated	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
formula	NN	O
:	:	O

Because	IN	O
of	IN	O
improved	JJ	O
calcium	NN	O
absorption	NN	O
from	IN	O
the	DT	O
gastrointestinal	JJ	O
tract	NN	O
,	,	O
some	DT	WHO
patients	NNS	WHO
on	IN	O
Rocaltrol	NNP	O
(	(	O
calcitriol	NN	O
)	)	O
may	MD	O
be	VB	O
maintained	VBN	O
on	IN	O
a	DT	O
lower	JJR	O
calcium	NN	O
intake	NN	O
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
should	MD	O
be	VB	O
maintained	VBN	O
or	CC	O
adjusted	VBN	O
until	IN	O
a	DT	O
satisfactory	JJ	O
response	NN	O
is	VBZ	O
noted	VBN	O
.	.	O

OPANA	NNP	O
ER	NNP	O
is	VBZ	O
administered	VBN	O
at	IN	O
a	DT	O
frequency	NN	O
of	IN	O
twice	JJ	FREQ
daily	JJ	FREQ
(	(	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
)	)	O
.	.	O

Thus	RB	O
,	,	O
in	IN	O
neonates	VBZ	O
the	DT	O
time	NN	O
to	TO	O
steady	JJ	O
-	:	O
state	NN	O
may	MD	O
be	VB	O
as	RB	O
long	RB	O
as	IN	O
a	DT	O
week	NN	PER
or	CC	O
longer	JJR	O
.	.	O

As	IN	O
with	IN	O
other	JJ	O
drugs	NNS	O
administered	VBN	O
by	IN	O
injection	NN	O
,	,	O
the	DT	O
injection	NN	O
site	NN	O
should	MD	O
be	VB	O
varied	VBN	O
periodically	RB	O
.	.	O

6	CD	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Dosing	NN	O
for	IN	O
Perioperative	NNP	O
Management	NNP	O

Since	IN	O
the	DT	O
half	NN	O
-	:	O
life	NN	O
of	IN	O
sotalol	JJ	O
decreases	NNS	O
with	IN	O
decreasing	VBG	O
age	NN	O
(	(	O
below	IN	O
about	RB	O
2	CD	O
years	NNS	O
)	)	O
,	,	O
time	NN	O
to	TO	O
steady	JJ	O
-	:	O
state	NN	O
will	MD	O
also	RB	O
increase	VB	O
.	.	O

Dosage	NN	O
Adjustment	NN	O
in	IN	O
Renal	NNP	O
Impairment†Because	NNP	O
captopril	NN	O
and	CC	O
hydrochlorothiazide	NN	O
are	VBP	O
excreted	VBN	O
primarily	RB	O
by	IN	O
the	DT	O
kidneys	NNS	O
,	,	O
excretion	NN	O
rates	NNS	O
are	VBP	O
reduced	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
renal	JJ	WHO
function	NN	WHO
.	.	O

The	DT	O
data	NN	O
available	JJ	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
severely	RB	WHO
impaired	JJ	WHO
kidney	NN	WHO
function	NN	WHO
(	(	O
creatinine	JJ	O
clearance	NN	O
below	IN	O
15	CD	DOS
mL	NNS	UNIT
/	NNP	O
min	NN	O
)	)	O
are	VBP	O
too	RB	O
limited	JJ	O
to	TO	O
permit	VB	O
a	DT	O
recommendation	NN	O
for	IN	O
treatment	NN	O
.	.	O

Note	NN	O
:	:	O
Do	NNP	O
not	RB	O
refrigerate	VB	O
after	IN	O
reconstitution	NN	O
.	.	O

If	IN	O
the	DT	O
150	CD	DOS
mg	JJ	UNIT
initial	JJ	UNIT
dose	NN	UNIT
is	VBZ	O
adequately	RB	O
tolerated	VBN	O
,	,	O
an	DT	O
increase	NN	O
to	TO	O
the	DT	O
300	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
target	NN	O
dose	NN	O
,	,	O
given	VBN	O
as	IN	O
once	RB	FREQ
daily	JJ	FREQ
,	,	O
may	MD	O
be	VB	O
made	VBN	O
as	RB	O
early	JJ	O
as	IN	O
day	NN	O
4	CD	O
of	IN	O
dosing	NN	O
.	.	O

Fragments	NNS	O
of	IN	O
the	DT	O
administration	NN	O
port	NN	O
membrane	NN	O
could	MD	O
be	VB	O
dislodged	VBN	O
into	IN	O
the	DT	O
bag	NN	O
after	IN	O
spiking	VBG	O
.	.	O

Not	RB	O
for	IN	O
oral	JJ	O
,	,	O
ophthalmic	JJ	O
or	CC	O
intravaginal	JJ	O
use	NN	O
.	.	O

)	)	O
.	.	O

Maintenance	NN	O
doses	NNS	O
of	IN	O
0.1	CD	O
,	,	O
0.15	CD	O
,	,	O
and	CC	O
0.2	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NNP	O
ZEMURON	NNP	O
,	,	O
administered	VBD	O
at	IN	O
25	CD	O
%	NN	O
recovery	NN	O
of	IN	O
control	NN	O
T1	NNP	O
(	(	O
defined	VBN	O
as	IN	O
3	CD	DOS
twitches	NNS	UNIT
of	IN	O
train	NN	O
-	:	O
of	IN	O
-	:	O
four	CD	O
)	)	O
,	,	O
provide	VBP	O
a	DT	O
median	NN	O
(	(	O
range	NN	O
)	)	O
of	IN	O
12	CD	O
(	(	O
2	CD	O
-	:	O
31	CD	O
)	)	O
,	,	O
17	CD	O
(	(	O
6	CD	O
-	:	O
50	CD	O
)	)	O
,	,	O
and	CC	O
24	CD	O
(	(	O
7	CD	O
-	:	O
69	CD	O
)	)	O
minutes	NNS	O
of	IN	O
clinical	JJ	O
duration	NN	O
under	IN	O
opioid	JJ	O
/	NNP	O
nitrous	JJ	O
oxide	RB	O
/	NNP	O
oxygen	NN	O
anesthesia	NN	O
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Keep	NNP	O
bottle	NN	O
tightly	RB	O
closed	VBD	O
.	.	O

It	PRP	O
is	VBZ	O
not	RB	O
necessary	JJ	O
to	TO	O
monitor	VB	O
topiramate	JJ	O
plasma	NN	O
concentrations	NNS	O
to	TO	O
optimize	VB	O
TROKENDI	NNP	O
XR®	NNP	O
therapy	NN	O
.	.	O

Conversely	RB	O
,	,	O
at	IN	O
least	JJS	O
14	CD	O
days	NNS	O
should	MD	O
be	VB	O
allowed	VBN	O
after	IN	O
stopping	VBG	O
Celexa	NNP	O
before	IN	O
starting	VBG	O
an	DT	O
MAOI	NNP	O
intended	VBD	O
to	TO	O
treat	VB	O
psychiatric	JJ	O
disorders	NNS	O
(	(	O
see	VB	O
CONTRAINDICATIONS	NNP	O
)	)	O
.	.	O

Do	MD	O
not	RB	O
store	VB	O
undiluted	JJ	O
concentrate	NN	O
in	IN	O
a	DT	O
syringe	NN	O
,	,	O
to	TO	O
avoid	VB	O
inadvertent	JJ	O
injection	NN	O
.	.	O

However	RB	O
,	,	O
if	IN	O
one	CD	O
additive	NN	O
is	VBZ	O
added	VBN	O
to	TO	O
the	DT	O
amino	NN	O
acid	NN	O
bottle	NN	O
,	,	O
and	CC	O
the	DT	O
other	JJ	O
to	TO	O
the	DT	O
bottle	NN	O
of	IN	O
concentrated	JJ	O
dextrose	NN	O
,	,	O
and	CC	O
if	IN	O
the	DT	O
contents	NNS	O
of	IN	O
both	DT	O
bottles	NNS	O
are	VBP	O
swirled	VBN	O
before	IN	O
they	PRP	O
are	VBP	O
combined	VBN	O
,	,	O
then	RB	O
the	DT	O
likelihood	NN	O
of	IN	O
physical	JJ	O
incompatibility	NN	O
is	VBZ	O
reduced	VBN	O
.	.	O

DO	NNP	O
NOT	NNP	O
INJECT	NNP	O
INTRAVENOUSLY	NNP	O

If	IN	O
the	DT	O
gluteal	JJ	O
region	NN	O
is	VBZ	O
used	VBN	O
when	WRB	O
very	RB	O
large	JJ	O
volumes	NNS	O
are	VBP	O
to	TO	O
be	VB	O
injected	VBN	O
or	CC	O
multiple	JJ	O
doses	NNS	O
are	VBP	O
necessary	JJ	O
,	,	O
the	DT	O
central	JJ	O
region	NN	O
MUST	NNP	O
be	VB	O
avoided	VBN	O
;	:	O
only	RB	O
the	DT	O
upper	JJ	O
,	,	O
outer	JJ	O
quadrant	NN	O
should	MD	O
be	VB	O
used.10	JJ	O

The	DT	O
calcium	NN	O
should	MD	O
not	RB	O
be	VB	O
added	VBN	O
consecutively	RB	O
or	CC	O
in	IN	O
close	JJ	O
sequence	NN	O
to	TO	O
the	DT	O
phosphate	NN	O
addition	NN	O
.	.	O

More	RBR	O
rapid	JJ	O
administration	NN	O
may	MD	O
result	VB	O
in	IN	O
respiratory	NN	O
depression	NN	O
and	CC	O
enhanced	VBD	O
pressor	NN	O
response	NN	O
.	.	O

Re	NNP	O
-	:	O
initiation	NN	O
Regimen	NNP	O
After	IN	O
Missing	VBG	O
4	CD	PER
Months	NNS	PER
to	TO	O
9	CD	PER
Months	NNS	PER
of	IN	O
INVEGA	NNP	O
TRINZA®	NNP	O

SPANSULE	NNP	O
capsules	NNS	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
once	RB	O
-	:	O
a	DT	O
-	:	O
day	NN	O
dosage	VB	O
wherever	JJ	O
appropriate	NN	O
.	.	O

The	DT	O
clicking	VBG	O
sound	NN	O
does	VBZ	O
not	RB	O
assure	VB	O
a	DT	O
seal	NN	O
;	:	O
the	DT	O
vial	NN	O
must	MD	O
be	VB	O
turned	VBN	O
as	RB	O
far	RB	O
as	IN	O
it	PRP	O
will	MD	O
go	VB	O
.	.	O

In	IN	O
this	DT	O
latter	JJ	O
situation	NN	O
it	PRP	O
may	MD	O
be	VB	O
necessary	JJ	O
to	TO	O
increase	VB	O
the	DT	O
dosage	NN	O
of	IN	O
the	DT	O
corticosteroid	NN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
time	NN	O
consistent	JJ	O
with	IN	O
the	DT	O
patient	NN	O
’	NNP	O
s	JJ	O
condition	NN	O
.	.	O

Neoral®	NNP	O
Soft	NNP	O
Gelatin	NNP	O
Capsules	NNP	O
(	(	O
cyclosporine	JJ	O
capsules	NNS	O
,	,	O
USP	NNP	O
)	)	O
MODIFIED	NNP	O
and	CC	O
Neoral®	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
cyclosporine	JJ	O
oral	JJ	O
solution	NN	O
,	,	O
USP	NNP	O
)	)	O
MODIFIED	NNP	O

Add	$	O
15	CD	DOS
mL	NN	UNIT
of	IN	O
either	DT	O
sugar	NN	O
syrup	NN	O
or	CC	O
sorbitol	NN	O
syrup	NN	O
(	(	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
Type	NNP	WHO
1	CD	WHO
diabetes	NNS	WHO
or	CC	O
glucose	VB	O
intolerance	NN	O
)	)	O
OR	CC	O
3	CD	DOS
teaspoons	NNS	UNIT
of	IN	O
jam	NN	O
to	TO	O
the	DT	O
contents	NNS	O
of	IN	O
INVIRASE	NNP	O
capsules	NNS	O
that	WDT	O
are	VBP	O
in	IN	O
the	DT	O
container	NN	O
.	.	O

Administer	NNP	O
the	DT	O
dose	NN	O
in	IN	O
a	DT	O
single	JJ	DOS
injection	NN	UNIT
;	:	O
do	VB	O
not	RB	O
administer	VB	O
the	DT	O
dose	NN	O
in	IN	O
divided	JJ	O
injections	NNS	O
.	.	O

She	PRP	O
should	MD	O
be	VB	O
sure	JJ	O
that	IN	O
no	DT	O
more	JJR	O
than	IN	O
7	CD	O
days	NNS	O
pass	NN	O
after	IN	O
her	PRP$	O
previous	JJ	O
21	CD	O
-	:	O
day	NN	O
regimen	NNS	O
.	.	O

Provocative	JJ	O
Test	NNP	O
for	IN	O
Angle	NNP	O
Block	NNP	O
in	IN	O
Patients	NNP	WHO
with	IN	WHO
Glaucoma	NNP	WHO
:	:	O
The	DT	O
2.5	CD	O
percent	NN	O
ophthalmic	JJ	O
solution	NN	O
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
provocative	JJ	O
test	NN	O
when	WRB	O
latent	NN	O
increased	VBD	O
intraocular	JJ	O
pressure	NN	O
is	VBZ	O
suspected	VBN	O
.	.	O

The	DT	O
mixture	NN	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
14	CD	PER
days	NNS	PER
.	.	O

For	IN	O
more	JJR	O
severe	JJ	O
infections	NNS	O
this	DT	O
dosage	NN	O
may	MD	O
be	VB	O
doubled	VBN	O
but	CC	O
should	MD	O
not	RB	O
exceed	VB	O
4	CD	DOS
g	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

Initiate	NNP	O
treatment	NN	O
with	IN	O
a	DT	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
in	IN	O
2	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
(	(	O
10	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NNP	O
twice	RB	FREQ
daily	RB	FREQ
)	)	O
.	.	O

For	IN	O
doses	NNS	O
less	JJR	O
than	IN	O
1000	CD	DOS
mg	NN	UNIT
,	,	O
the	DT	O
appropriate	JJ	O
dose	NN	O
must	MD	O
be	VB	O
withdrawn	VBN	O
from	IN	O
the	DT	O
container	NN	O
and	CC	O
placed	VBD	O
into	IN	O
a	DT	O
separate	JJ	O
container	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

See	VB	O
PRECAUTIONS	NNP	O
-	:	O
General	NNP	O
.	.	O

Edema	NN	O
may	MD	O
be	VB	O
most	RBS	O
efficiently	RB	O
and	CC	O
safely	RB	O
mobilized	VBN	O
by	IN	O
giving	VBG	O
LASIX	NNP	O
on	IN	O
2	CD	O
to	TO	O
4	CD	PER
consecutive	JJ	PER
days	NNS	PER
each	DT	PER
week	NN	PER
.	.	O

If	IN	O
the	DT	O
QTc	NNP	O
is	VBZ	O
greater	JJR	O
than	IN	O
440	CD	DOS
msec	NN	UNIT
(	(	O
500	CD	DOS
msec	NN	UNIT
in	IN	O
patients	NNS	WHO
with	IN	WHO
ventricular	JJ	WHO
conduction	NN	WHO
abnormalities	NNS	WHO
)	)	WHO
,	,	O
TIKOSYN	NNP	O
is	VBZ	O
contraindicated	VBN	O
.	.	O

For	IN	O
treatment	NN	O
of	IN	O
joints	NNS	O
,	,	O
the	DT	O
usual	JJ	O
intra	JJ	O
-	:	O
articular	JJ	O
injection	NN	O
technique	NN	O
should	MD	O
be	VB	O
followed	VBN	O
.	.	O

2	CD	O
.	.	O

If	IN	O
the	DT	O
action	NN	O
of	IN	O
rinsing	NN	O
is	VBZ	O
inconvenient	JJ	O
or	CC	O
too	RB	O
painful	JJ	O
,	,	O
MuGard	NNP	O
can	MD	O
be	VB	O
spread	VBN	O
throughout	IN	O
the	DT	O
mouth	NN	O
by	IN	O
a	DT	O
gentle	JJ	O
rotating	VBG	O
action	NN	O
of	IN	O
the	DT	O
head	NN	O
.	.	O

SHAKE	NNP	O
VIAL	NNP	O
WELL	NNP	O
before	IN	O
withdrawing	VBG	O
each	DT	O
dose	NN	O
.	.	O

Because	IN	O
of	IN	O
the	DT	O
high	JJ	O
concentration	NN	O
of	IN	O
suspended	JJ	O
material	NN	O
in	IN	O
this	DT	O
product	NN	O
,	,	O
the	DT	O
needle	NN	O
may	MD	O
be	VB	O
blocked	VBN	O
if	IN	O
the	DT	O
injection	NN	O
is	VBZ	O
not	RB	O
made	VBN	O
at	IN	O
a	DT	O
slow	JJ	O
,	,	O
steady	JJ	O
rate	NN	O
.	.	O

Do	NNP	O
not	RB	O
reconstitute	VB	O
.	.	O

The	DT	O
suggested	JJ	O
daily	JJ	FREQ
dosage	NN	O
for	IN	O
VIPomas	NNP	O
is	VBZ	O
200	CD	DOS
-	:	O
300	CD	DOS
mcg	NN	UNIT
in	IN	O
2	CD	DOS
-	:	O
4	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
(	(	O
range	NN	O
150	CD	DOS
-	:	O
750	CD	DOS
mcg	NN	UNIT
)	)	O
;	:	O
dosage	NN	O
may	MD	O
be	VB	O
adjusted	VBN	O
on	IN	O
an	DT	O
individual	JJ	O
basis	NN	O
to	TO	O
control	VB	O
symptoms	NNS	O
but	CC	O
usually	RB	O
doses	VBZ	O
above	IN	O
450	CD	DOS
mcg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
are	VBP	O
not	RB	O
required	VBN	O
.	.	O

If	IN	O
more	JJR	O
than	IN	O
1	CD	O
topical	JJ	O
ophthalmic	JJ	O
medicinal	JJ	O
product	NN	O
is	VBZ	O
being	VBG	O
used	VBN	O
,	,	O
each	DT	O
one	CD	O
should	MD	O
be	VB	O
administered	VBN	O
at	IN	O
least	JJS	O
5	CD	O
minutes	NNS	O
apart	RB	O
.	.	O

Monitoring	NN	O
of	IN	O
aminotransferase	NN	O
levels	NNS	O
is	VBZ	O
recommended	VBN	O
for	IN	O
baseline	NN	O
and	CC	O
1	CD	O
month	NN	O
after	IN	O
maximum	NN	O
dose	NN	O
is	VBZ	O
achieved	VBN	O
,	,	O
or	CC	O
if	IN	O
hepatic	JJ	O
injury	NN	O
is	VBZ	O
suspected	VBN	O
.	.	O

ROWEEPRA	NNP	O
tablets	NNS	O
should	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
.	.	O

After	IN	O
observing	VBG	O
the	DT	O
response	NN	O
to	TO	O
initial	JJ	O
therapy	NN	O
with	IN	O
CALDOLOR	NNP	O
,	,	O
the	DT	O
dose	NN	O
and	CC	O
frequency	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
to	TO	O
suit	VB	O
an	DT	O
individual	JJ	O
patient	NN	O
's	POS	O
needs	NNS	O
.	.	O

ABSTRAL	NNP	O
is	VBZ	O
NOT	NNP	O
a	DT	O
generic	JJ	O
version	NN	O
of	IN	O
any	DT	O
other	JJ	O
fentanyl	JJ	O
product	NN	O
.	.	O

Cirrhosis	NN	O
does	VBZ	O
not	RB	O
reduce	VB	O
the	DT	O
nonrenal	JJ	O
clearance	NN	O
of	IN	O
lomefloxacin	NN	O
.	.	O

2	CD	O
)	)	O
Remove	VB	O
the	DT	O
caps	NNS	O
from	IN	O
the	DT	O
concentrate	NN	O
(	(	O
WILATE	NNP	O
)	)	O
vial	NN	O
and	CC	O
the	DT	O
diluent	JJ	O
vial	NN	O
and	CC	O
clean	VB	O
the	DT	O
rubber	NN	O
stoppers	NNS	O
with	IN	O
an	DT	O
alcohol	NN	O
swab	NN	O
.	.	O

Response	NNP	O
-	:	O
Guided	VBD	O
Therapy	NNP	O
(	(	O
RGT	NNP	O
)	)	O
is	VBZ	O
recommended	VBN	O
for	IN	O
most	JJS	O
individuals	NNS	O
,	,	O
but	CC	O
longer	JJR	O
dosing	NN	O
is	VBZ	O
recommended	VBN	O
in	IN	O
targeted	JJ	O
subgroups	NNS	O
(	(	O
e.g	NN	O
,	,	O
patients	NNS	WHO
with	IN	WHO
cirrhosis	NN	WHO
)	)	O
.	.	O

Flow	NNP	O
rates	NNS	O
of	IN	O
each	DT	O
solution	NN	O
should	MD	O
be	VB	O
controlled	VBN	O
separately	RB	O
by	IN	O
infusion	NN	O
pumps	NNS	O
,	,	O
if	IN	O
these	DT	O
are	VBP	O
used	VBN	O
.	.	O

For	IN	O
example	NN	O
,	,	O
the	DT	O
antibiotics	NNS	O
tetracycline	JJ	O
hydrochloride	NN	O
,	,	O
oxytetracycline	JJ	O
hydrochloride	NN	O
and	CC	O
erythromycin	JJ	O
lactobionate	NN	O
were	VBD	O
found	VBN	O
to	TO	O
be	VB	O
incompatible	JJ	O
when	WRB	O
mixed	VBN	O
in	IN	O
the	DT	O
same	JJ	O
solution	NN	O
.	.	O

Co	NNP	O
-	:	O
administration	NN	O
of	IN	O
BOTOX	NNP	O
Cosmetic	NNP	O
and	CC	O
aminoglycosides	NNS	O
or	CC	O
other	JJ	O
agents	NNS	O
interfering	VBG	O
with	IN	O
neuromuscular	JJ	O
transmission	NN	O
(	(	O
e.g	JJ	O
,	,	O
curare	JJ	O
-	:	O
like	IN	O
compounds	NNS	O
)	)	O
should	MD	O
only	RB	O
be	VB	O
performed	VBN	O
with	IN	O
caution	NN	O
as	IN	O
the	DT	O
effect	NN	O
of	IN	O
the	DT	O
toxin	NN	O
may	MD	O
be	VB	O
potentiated	VBN	O
.	.	O

When	WRB	O
the	DT	O
patient	NN	O
is	VBZ	O
switching	VBG	O
from	IN	O
a	DT	O
28	CD	O
-	:	O
day	NN	O
regimen	NNS	O
of	IN	O
tablets	NNS	O
,	,	O
she	PRP	O
should	MD	O
start	VB	O
her	PRP$	O
first	JJ	O
pack	NN	O
of	IN	O
Nordette®	NNP	O
-	:	O
28	CD	O
on	IN	O
the	DT	O
day	NN	O
after	IN	O
her	PRP$	O
last	JJ	O
tablet	NN	O
.	.	O

Under	IN	O
local	JJ	O
infiltration	NN	O
anesthesia	NN	O
,	,	O
a	DT	O
transverse	NN	O
,	,	O
curvilinear	VBP	O
or	CC	O
longitudinal	JJ	O
small	JJ	O
skin	NN	O
incision	NN	O
should	MD	O
be	VB	O
made	VBN	O
near	IN	O
the	DT	O
ankle	NN	O
or	CC	O
wrist	NN	O
(	(	O
just	RB	O
lateral	JJ	O
and	CC	O
distal	JJ	O
to	TO	O
the	DT	O
first	JJ	O
metatarsal	NN	O
head	NN	O
on	IN	O
the	DT	O
dorsum	NN	O
of	IN	O
the	DT	O
foot	NN	O
,	,	O
or	CC	O
just	RB	O
over	IN	O
the	DT	O
“	NNP	O
snuff	NN	O
-	:	O
box	NN	O
”	NN	O
in	IN	O
the	DT	O
dorsum	NN	O
of	IN	O
the	DT	O
hand	NN	O
)	)	O
.	.	O

Administer	NNP	O
ELLENCE	NNP	O
Injection	NNP	O
by	IN	O
intravenous	JJ	O
infusion	NN	O
.	.	O

If	IN	O
only	RB	O
a	DT	O
portion	NN	O
of	IN	O
the	DT	O
solution	NN	O
in	IN	O
a	DT	O
vial	NN	O
is	VBZ	O
used	VBN	O
,	,	O
store	VBD	O
the	DT	O
remainder	NN	O
in	IN	O
a	DT	O
refrigerator	NN	O
and	CC	O
use	NN	O
for	IN	O
inhalation	NN	O
only	RB	O
within	IN	O
96	CD	O
hours	NNS	O
.	.	O

A	DT	O
greater	JJR	O
proportion	NN	O
of	IN	O
patients	NNS	WHO
had	VBD	WHO
headache	VBN	WHO
response	NN	WHO
following	VBG	O
a	DT	O
20	CD	DOS
-	:	O
mg	NN	UNIT
dose	NN	UNIT
than	IN	O
following	VBG	O
a	DT	O
5	CD	O
-	:	O
or	CC	O
10	CD	DOS
-	:	O
mg	NN	UNIT
dose	NN	UNIT
(	(	O
see	VB	O
Clinical	NNP	O
Trials	NNP	O
)	)	O
.	.	O

OXILAN®	NNP	O
Injection	NNP	O
(	(	O
300	CD	DOS
mgI	NN	UNIT
/	NNP	O
mL	NN	O
or	CC	O
350	CD	DOS
mgI	NNS	UNIT
/	NNP	O
mL	NN	O
)	)	O
is	VBZ	O
indicated	VBN	O
for	IN	O
intravenous	JJ	O
injection	NN	O
for	IN	O
routine	JJ	O
excretory	NN	O
urography	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

For	IN	O
convenience	NN	O
,	,	O
patients	NNS	O
receiving	VBG	O
amlodipine	NN	O
and	CC	O
valsartan	NN	O
from	IN	O
separate	JJ	O
tablets	NNS	O
may	MD	O
instead	RB	O
wish	VB	O
to	TO	O
receive	VB	O
tablets	NNS	O
of	IN	O
Exforge	NNP	O
containing	VBG	O
the	DT	O
same	JJ	O
component	NN	O
doses	NNS	O
.	.	O

The	DT	O
diazepam	NN	O
rectal	JJ	O
gel	NN	O
dose	NN	O
should	MD	O
be	VB	O
individualized	VBN	O
for	IN	O
maximum	JJ	O
beneficial	JJ	O
effect	NN	O
.	.	O

If	IN	O
spotting	JJ	O
occurs	NNS	O
while	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
taking	VBG	O
light	JJ	O
yellow	NN	O
or	CC	O
pink	NN	O
tablets	NNS	O
,	,	O
continue	VBP	O
medication	NN	O
without	IN	O
interruption	NN	O
.	.	O

The	DT	O
Mono	NNP	O
-	:	O
Vacc®	NNP	O
Test	NNP	O
(	(	O
O.T	NNP	O
.	.	O
)	)	O

Dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
up	RB	O
to	TO	O
4	CD	DOS
g	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
according	VBG	O
to	TO	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
infection	NN	O
.	.	O

Patients	NNS	O
should	MD	O
take	VB	O
both	DT	O
doses	NNS	O
of	IN	O
Xyrem	NNP	O
while	IN	O
in	IN	O
bed	NN	O
and	CC	O
lie	VB	O
down	RP	O
immediately	RB	O
after	IN	O
dosing	VBG	O
as	IN	O
Xyrem	NNP	O
may	MD	O
cause	VB	O
them	PRP	O
to	TO	O
fall	VB	O
asleep	RB	O
abruptly	RB	O
without	IN	O
first	JJ	O
feeling	NN	O
drowsy	NN	O
.	.	O

After	IN	O
one	CD	O
minute	NN	O
,	,	O
if	IN	O
there	EX	O
are	VBP	O
no	DT	O
signs	NNS	O
of	IN	O
allergic	JJ	O
reaction	NN	O
,	,	O
ChiRhoStim®	NNP	O
(	(	O
human	JJ	O
secretin	NN	O
)	)	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.2	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
is	VBZ	O
injected	VBN	O
intravenously	RB	O
over	IN	O
1	CD	O
minute	NN	O
.	.	O

Renal	JJ	O
patients	NNS	O
not	RB	O
needing	VBG	O
dialysis	NN	O
require	VBP	O
0.6	CD	DOS
to	TO	O
0.8	CD	DOS
g	NN	UNIT
of	IN	O
protein	NN	O
/	NNP	O
kg	VBD	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

5	CD	O
.	.	O

2	CD	O
.	.	O

For	IN	O
these	DT	O
reasons	NNS	O
,	,	O
steady	JJ	O
-	:	O
state	NN	O
plasma	NN	O
concentrations	NNS	O
,	,	O
and	CC	O
full	JJ	O
analgesic	JJ	O
effects	NNS	O
,	,	O
are	VBP	O
usually	RB	O
not	RB	O
attained	VBN	O
until	IN	O
3	CD	PER
to	TO	O
5	CD	O
days	NNS	O
of	IN	O
dosing	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Schedule	NN	O
for	IN	O
Dose	NNP	O
Titration	NNP	O

Riomet	NNP	O
therapy	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
500	CD	DOS
mg	NN	UNIT
(	(	O
5	CD	DOS
mL	NN	UNIT
)	)	O
once	RB	FREQ
daily	JJ	FREQ
in	IN	O
patients	NNS	O
on	IN	O
insulin	JJ	O
therapy	NN	O
.	.	O

Visually	RB	O
inspect	JJ	O
CEPROTIN	NNP	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

Blood	NNP	O
pressure	NN	O
decreases	VBZ	O
associated	VBN	O
with	IN	O
any	DT	O
dose	NN	O
of	IN	O
ALTACE	NNP	O
(	(	O
ramipril	JJ	O
capsules	NNS	O
)	)	O
depend	VBP	O
,	,	O
in	IN	O
part	NN	O
,	,	O
on	IN	O
the	DT	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
volume	NN	O
depletion	NN	O
(	(	O
e.g	NN	O
,	,	O
past	JJ	O
and	CC	O
current	JJ	O
diuretic	JJ	O
use	NN	O
)	)	O
or	CC	O
the	DT	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
renal	JJ	O
artery	NN	O
stenosis	NN	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
HUMULIN	NNP	O
N	NNP	O
intravenously	RB	O
or	CC	O
intramuscularly	RB	O
and	CC	O
do	VB	O
not	RB	O
use	VB	O
HUMULIN	NNP	O
N	NNP	O
in	IN	O
an	DT	O
insulin	NN	O
infusion	NN	O
pump	NN	O
.	.	O

During	IN	O
treatment	NN	O
with	IN	O
the	DT	O
THERAKOS®	NNP	O
UVAR	NNP	O
XTS®	NNP	O
or	CC	O
THERAKOS®	NNP	O
CELLEX®	NNP	O
Photopheresis	NNP	O
System	NNP	O
,	,	O
the	DT	O
dosage	NN	O
of	IN	O
UVADEX®	NNP	O
for	IN	O
each	DT	O
treatment	NN	O
will	MD	O
be	VB	O
calculated	VBN	O
according	VBG	O
to	TO	O
the	DT	O
treatment	NN	O
volume	NN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
lying	VBG	O
down	RP	O
(	(	O
supine	NN	O
)	)	O
or	CC	O
sitting	VBG	O
and	CC	O
INNOHEP®	NNP	O
(	(	O
tinzaparin	NN	O
)	)	O
administered	VBN	O
by	IN	O
deep	JJ	O
SC	NNP	O
injection	NN	O
.	.	O

In	IN	O
the	DT	O
absence	NN	O
of	IN	O
prospective	JJ	O
data	NNS	O
,	,	O
the	DT	O
recommended	JJ	O
doses	NNS	O
should	MD	O
not	RB	O
be	VB	O
exceeded	VBN	O
and	CC	O
the	DT	O
concentration	NN	O
and	CC	O
infusion	NN	O
rate	NN	O
selected	VBN	O
should	MD	O
be	VB	O
the	DT	O
minimum	JJ	O
level	NN	O
practicable	NN	O
.	.	O

Do	NNP	O
not	RB	O
exceed	VB	O
25	CD	DOS
mg	NNS	UNIT
.	.	O

(	(	O
See	VB	O
ADVERSE	NNP	O
REACTIONS	NNP	O
.	.	O
)	)	O

IMLYGIC	NNP	O
is	VBZ	O
provided	VBN	O
in	IN	O
single	JJ	DOS
-	:	O
use	NN	O
vials	NNS	O
of	IN	O
1	CD	DOS
mL	NNS	UNIT
each	DT	O
in	IN	O
two	CD	DOS
different	JJ	UNIT
dose	JJ	UNIT
strengths	NNS	O
:	:	O

Optiray	NN	O
350	CD	O
,	,	O
Optiray	NNP	O
320	CD	O
,	,	O
Optiray	NNP	O
300	CD	O
or	CC	O
Optiray	NNP	O
240	CD	O
is	VBZ	O
recommended	VBN	O
for	IN	O
body	NN	O
imaging	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
consider	VB	O
the	DT	O
following	JJ	O
important	JJ	O
factors	NNS	O
that	WDT	O
differentiate	VBP	O
methadone	NN	O
from	IN	O
other	JJ	O
opioid	JJ	O
analgesics	NNS	O
:	:	O

Prophylaxis	NNP	O
should	MD	O
be	VB	O
continued	VBN	O
daily	JJ	FREQ
during	IN	O
travel	NN	O
in	IN	O
the	DT	O
malarious	JJ	O
area	NN	O
and	CC	O
for	IN	O
4	CD	PER
weeks	NNS	PER
after	IN	O
the	DT	O
traveler	NN	O
leaves	VBZ	O
the	DT	O
malarious	JJ	O
area	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

It	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
ensure	VB	O
adequate	JJ	O
hydration	NN	O
of	IN	O
patients	NNS	FREQ
at	IN	FREQ
all	DT	FREQ
times	NNS	FREQ
while	IN	O
taking	VBG	O
PANCRECARB®	NNP	O
(	(	O
pancrelipase	NN	O
)	)	O
.	.	O

In	IN	O
all	DT	WHO
instances	NNS	WHO
,	,	O
the	DT	O
physician	NN	O
must	MD	O
be	VB	O
guided	VBN	O
by	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
's	POS	O
arrhythmia	NN	O
and	CC	O
response	NN	O
to	TO	O
therapy	NN	O
.	.	O

Before	IN	O
initiating	VBG	O
the	DT	O
removal	NN	O
procedure	NN	O
,	,	O
the	DT	O
healthcare	NN	O
provider	NN	O
should	MD	O
carefully	RB	O
read	VB	O
the	DT	O
instructions	NNS	O
for	IN	O
removal	NN	O
and	CC	O
consult	VB	O
the	DT	O
USER	NNP	O
CARD	NNP	O
and	CC	O
/	NNP	O
or	CC	O
the	DT	O
PATIENT	NNP	O
CHART	NNP	O
LABEL	NNP	O
for	IN	O
the	DT	O
location	NN	O
of	IN	O
the	DT	O
implant	NN	O
.	.	O

Clinically	RB	O
required	VBN	O
neuromuscular	JJ	O
block	NN	O
generally	RB	O
lasts	VBZ	O
20	CD	O
to	TO	O
35	CD	O
minutes	NNS	O
under	IN	O
balanced	JJ	O
anesthesia	NN	O
.	.	O

Disinfect	VB	O
the	DT	O
injection	NN	O
site	NN	O
and	CC	O
administer	NN	O
FIRAZYR	NNP	O
by	IN	O
subcutaneous	JJ	O
injection	NN	O
over	IN	O
at	IN	O
least	JJS	O
30	CD	O
seconds	NNS	O
.	.	O

Administer	RB	O
with	IN	O
extreme	JJ	O
caution	NN	O
.	.	O

For	IN	O
control	NN	O
of	IN	O
severe	JJ	O
chronic	JJ	O
pain	NN	O
,	,	O
ROXICODONE®	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
on	IN	O
a	DT	O
regularly	RB	O
scheduled	VBN	O
basis	NN	O
,	,	O
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
,	,	O
at	IN	O
the	DT	O
lowest	JJS	O
dosage	NN	O
level	NN	O
that	WDT	O
will	MD	O
achieve	VB	O
adequate	JJ	O
analgesia	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
most	JJS	WHO
adults	NNS	WHO
is	VBZ	O
0.25	CD	DOS
mg	NN	UNIT
before	IN	O
retiring	VBG	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
unsuccessful	JJ	WHO
should	MD	O
be	VB	O
evaluated	VBN	O
to	TO	O
determine	VB	O
why	WRB	O
they	PRP	O
failed	VBD	O
.	.	O

Again	RB	O
,	,	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
observed	VBN	O
for	IN	O
an	DT	O
interval	NN	O
of	IN	O
4	CD	O
to	TO	O
8	CD	O
hours	NNS	O
.	.	O

Solutions	NNS	O
of	IN	O
CEPTAZ	NNP	O
(	(	O
ceftazidime	NN	O
)	)	O
,	,	O
like	IN	O
those	DT	O
of	IN	O
most	JJS	O
beta	SYM	O
-	:	O
lactam	NN	O
antibiotics	NNS	O
,	,	O
should	MD	O
not	RB	O
be	VB	O
added	VBN	O
to	TO	O
solutions	NNS	O
of	IN	O
aminoglycoside	NN	O
antibiotics	NNS	O
because	IN	O
of	IN	O
potential	JJ	O
interaction	NN	O
.	.	O

The	DT	O
prescribed	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
AndroGel	NNP	O
1.62	CD	O
%	NN	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
right	NN	O
and	CC	O
left	VBD	O
upper	JJ	O
arms	NNS	O
and	CC	O
shoulders	NNS	O
as	IN	O
shown	VBN	O
in	IN	O
the	DT	O
shaded	JJ	O
areas	NNS	O
in	IN	O
Figure	NN	O
1	CD	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
in	IN	O
adults	NNS	WHO
is	VBZ	O
a	DT	O
2	CD	DOS
g	NN	UNIT
dose	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
for	IN	O
3	CD	PER
days	NNS	PER
taken	VBN	O
with	IN	O
food	NN	O
.	.	O

:	:	O
600,000	CD	DOS
units	NNS	UNIT
.	.	O

Treatment	NN	O
should	MD	O
be	VB	O
limited	VBN	O
to	TO	O
les	NNS	O
s	NNS	O
than	IN	O
10	CD	DOS
cm²	NN	UNIT
of	IN	O
wart	JJ	O
tissue	NN	O
and	CC	O
to	TO	O
no	DT	O
more	JJR	O
than	IN	O
0.5	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
solution	NN	O
per	IN	FREQ
day	NN	FREQ
.	.	O

VIALS	NNP	O
should	MD	O
be	VB	O
used	VBN	O
when	WRB	O
required	JJ	O
doses	NNS	O
are	VBP	O
fractions	NNS	O
of	IN	O
a	DT	O
milliliter	NN	O
,	,	O
as	IN	O
indicated	VBN	O
below	IN	O
.	.	O

An	DT	O
initial	JJ	O
single	JJ	DOS
dose	NN	UNIT
of	IN	O
20	CD	DOS
to	TO	O
30	CD	DOS
mg	NN	UNIT
of	IN	O
Methadose	NNP	O
will	MD	O
often	RB	O
be	VB	O
sufficient	JJ	O
to	TO	O
suppress	VB	O
withdrawal	NN	O
symptoms	NNS	O
.	.	O

Table	JJ	O
3	CD	O
:	:	O
Levothyroxine	JJ	O
Dosing	NNP	O
Guidelines	NNP	O
for	IN	O
Pediatric	NNP	O
Hypothyroidism	NNP	O

The	DT	O
injection	NN	O
needle	NN	O
should	MD	O
be	VB	O
inserted	VBN	O
3.5	CD	O
-	:	O
4.0	CD	O
mm	NN	O
posterior	NN	O
to	TO	O
the	DT	O
limbus	NN	O
aiming	VBG	O
towards	IN	O
the	DT	O
center	NN	O
of	IN	O
the	DT	O
vitreous	JJ	O
cavity	NN	O
,	,	O
avoiding	VBG	O
the	DT	O
horizontal	JJ	O
meridian	NN	O
.	.	O

Initiate	NNP	O
dosing	VBG	O
with	IN	O
1.25	CD	DOS
mcg	NNS	UNIT
of	IN	O
alprostadil	NN	O
using	VBG	O
CAVERJECT	NNP	O
Sterile	NNP	O
Powder	NNP	O
.	.	O

Dosing	VBG	O
should	MD	O
be	VB	O
titrated	VBN	O
based	VBN	O
on	IN	O
individual	JJ	O
patient	NN	O
plasma	NN	O
ammonia	NN	O
levels	NNS	O
and	CC	O
clinical	JJ	O
symptoms	NNS	O
.	.	O

Postpone	NNP	O
administration	NN	O
to	TO	O
individuals	NNS	O
with	IN	O
vomiting	NN	O
and	CC	O
/	NN	O
or	CC	O
diarrhea	NN	O
because	IN	O
the	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
vaccine	NN	O
depends	VBZ	O
upon	IN	O
the	DT	O
multiplication	NN	O
of	IN	O
orally	RB	O
administered	VBN	O
live	JJ	O
adenovirus	NN	O
within	IN	O
the	DT	O
intestinal	JJ	O
tract	NN	O
.	.	O

Each	DT	O
5	CD	DOS
mL	NN	UNIT
sterile	NN	O
,	,	O
single	JJ	O
-	:	O
use	NN	O
vial	JJ	O
contains	VBZ	O
62.5	CD	DOS
mg	NN	UNIT
of	IN	O
elemental	JJ	O
iron	NN	O
(	(	O
12.5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O
.	.	O

Close	JJ	O
monitoring	NN	O
is	VBZ	O
of	IN	O
particular	JJ	O
importance	NN	O
when	WRB	O
converting	VBG	O
from	IN	O
methadone	NN	O
to	TO	O
other	JJ	O
opioid	JJ	O
agonists	NNS	O
.	.	O

Use	NNP	O
REFLUDAN	NNP	O
(	(	O
lepirudin	NN	O
)	)	O
before	IN	O
the	DT	O
expiration	NN	O
date	NN	O
given	VBN	O
on	IN	O
the	DT	O
carton	NN	O
and	CC	O
container	NN	O
.	.	O

When	WRB	O
mixed	JJ	O
with	IN	O
the	DT	O
above	JJ	O
solutions	NNS	O
in	IN	O
glass	NN	O
or	CC	O
plastic	NN	O
containers	NNS	O
,	,	O
PAVULON®	NNP	O
(	(	O
pancuronium	NN	O
bromide	IN	O
injection	NN	O
)	)	O
will	MD	O
remain	VB	O
stable	JJ	O
in	IN	O
solution	NN	O
for	IN	O
48	CD	PER
hours	NNS	PER
with	IN	O
no	DT	O
alteration	NN	O
in	IN	O
potency	NN	O
or	CC	O
pH	NN	O
;	:	O
no	DT	O
decomposition	NN	O
is	VBZ	O
observed	VBN	O
and	CC	O
there	EX	O
is	VBZ	O
no	DT	O
absorption	NN	O
to	TO	O
either	VB	O
the	DT	O
glass	NN	O
or	CC	O
plastic	NN	O
container	NN	O
.	.	O

7	CD	O
.	.	O

AVANDAMET	NNP	O
is	VBZ	O
generally	RB	O
given	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
with	IN	O
meals	NNS	O
,	,	O
with	IN	O
gradual	JJ	O
dose	JJ	O
escalation	NN	O
.	.	O

Retavase®	NNP	O
(	(	O
Reteplase	NNP	O
)	)	O
is	VBZ	O
for	IN	O
intravenous	JJ	O
administration	NN	O
only	RB	O
.	.	O

NOTE	NN	O
:	:	O
Slight	JJ	O
darkening	NN	O
of	IN	O
NUQUIN	NNP	O
HP	NNP	O
4	CD	O
%	NN	O
CREAM	NNP	O
,	,	O
NUQUIN	NNP	O
HP	NNP	O
4	CD	O
%	NN	O
GEL	NNP	O
,	,	O
MELPAQUE	NNP	O
HP	NNP	O
4	CD	O
%	NN	O
CREAM	NNP	O
,	,	O
MELQUIN	NNP	O
HP	NNP	O
4	CD	O
%	NN	O
CREAM	NNP	O
and	CC	O
MELQUIN	NNP	O
-	:	O
3	CD	O
TOPICAL	JJ	O
SOLUTION	NNP	O
(	(	O
hydroquinone	VB	O
3	CD	O
%	NN	O
topical	JJ	O
solution	NN	O
)	)	O
is	VBZ	O
normal	JJ	O
and	CC	O
does	VBZ	O
not	RB	O
affect	VB	O
potency	NN	O
of	IN	O
the	DT	O
product	NN	O
.	.	O

Due	JJ	O
to	TO	O
higher	JJR	O
rates	NNS	O
of	IN	O
resistance	NN	O
that	WDT	O
may	MD	O
develop	VB	O
with	IN	O
longer	JJR	O
term	NN	O
treatment	NN	O
among	IN	O
patients	NNS	WHO
with	IN	WHO
incomplete	JJ	WHO
viral	JJ	WHO
suppression	NN	WHO
,	,	O
treatment	NN	O
should	MD	O
only	RB	O
be	VB	O
initiated	VBN	O
,	,	O
if	IN	O
pre	JJ	O
-	:	O
treatment	NN	O
HBV	NNP	O
DNA	NNP	O
and	CC	O
ALT	NNP	O
measurements	NNS	O
are	VBP	O
known	VBN	O
,	,	O
in	IN	O
the	DT	O
following	JJ	O
patient	JJ	O
populations	NNS	O
:	:	O

92	CD	O

It	PRP	O
is	VBZ	O
also	RB	O
recommended	VBN	O
that	IN	O
subcutaneous	JJ	O
injection	NN	O
sites	NNS	O
be	VB	O
periodically	RB	O
rotated	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
ULORIC	NNP	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

If	IN	O
therapy	VBN	O
with	IN	O
a	DT	O
combination	NN	O
tablet	NN	O
containing	VBG	O
pioglitazone	NN	O
and	CC	O
glimepiride	NN	O
is	VBZ	O
considered	VBN	O
appropriate	IN	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
:	:	O

Consuming	VBG	O
TROXYCA	NNP	O
ER	NNP	O
capsules	VBZ	O
that	WDT	O
have	VBP	O
been	VBN	O
altered	VBN	O
by	IN	O
crushing	VBG	O
,	,	O
dissolving	VBG	O
,	,	O
or	CC	O
chewing	VBG	O
the	DT	O
pellets	NNS	O
can	MD	O
release	VB	O
sufficient	JJ	O
naltrexone	NN	O
to	TO	O
precipitate	VB	O
withdrawal	NN	O
in	IN	O
opioid	JJ	O
-	:	O
dependent	JJ	O
individuals	NNS	O
[	VBP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Serum	NNP	O
total	JJ	O
testosterone	NN	O
concentrations	NNS	O
should	MD	O
be	VB	O
checked	VBN	O
periodically	RB	O
,	,	O
starting	VBG	O
as	RB	O
soon	RB	O
as	IN	O
one	CD	PER
month	NN	PER
after	IN	O
initiating	VBG	O
treatment	NN	O
with	IN	O
Natesto	NNP	O
.	.	O

After	IN	O
the	DT	O
standing	NN	O
time	NN	O
,	,	O
shake	VB	O
the	DT	O
suspension	NN	O
for	IN	O
a	DT	O
minimum	NN	O
of	IN	O
1	CD	O
additional	JJ	O
minute	NN	O
.	.	O

There	EX	O
was	VBD	O
a	DT	O
significant	JJ	O
reduction	NN	O
in	IN	O
minor	JJ	O
bleeds	NNS	O
at	IN	O
the	DT	O
low	JJ	O
INR	NNP	O
.	.	O

In	IN	O
medical	JJ	WHO
patients	NNS	WHO
at	IN	WHO
risk	NN	WHO
for	IN	WHO
thromboembolic	JJ	WHO
complications	NNS	WHO
due	JJ	WHO
to	TO	WHO
severely	RB	WHO
restricted	JJ	WHO
mobility	NN	WHO
during	IN	WHO
acute	JJ	WHO
illness	NN	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Lovenox	NNP	O
is	VBZ	O
40	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
administered	VBN	O
by	IN	O
SC	NNP	O
injection	NN	O
.	.	O

Unbound	IN	O
phenytoin	JJ	O
concentrations	NNS	O
may	MD	O
be	VB	O
more	JJR	O
useful	JJ	O
in	IN	O
these	DT	O
patient	JJ	O
populations	NNS	O
.	.	O

Dispense	NNP	O
only	RB	O
the	DT	O
appropriate	JJ	O
number	NN	O
of	IN	O
Gleostine	NNP	O
capsules	NNS	O
required	VBN	O
for	IN	O
the	DT	O
administration	NN	O
of	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Dosing	NN	O
Schedule	NN	O
for	IN	O
Pediatric	NNP	WHO
Patients	NNS	WHO

Short	NNP	O
-	:	O
term	NN	O
administration	NN	O
of	IN	O
GLUCOTROL	NNP	O
may	MD	O
be	VB	O
sufficient	JJ	O
during	IN	O
periods	NNS	O
of	IN	O
transient	JJ	O
loss	NN	O
of	IN	O
control	NN	O
in	IN	O
patients	NNS	WHO
usually	RB	WHO
controlled	VBN	WHO
well	RB	WHO
on	IN	WHO
diet	NNS	WHO
.	.	O

QUILLIVANT	NNP	O
XR	NNP	O
is	VBZ	O
stable	JJ	O
for	IN	O
up	IN	PER
to	TO	PER
4	CD	PER
months	NNS	PER
after	IN	O
reconstitution	NN	O
.	.	O

It	PRP	O
is	VBZ	O
acceptable	JJ	O
to	TO	O
inject	VB	O
LEVEMIR®	NNP	O
and	CC	O
a	DT	O
GLP	NNP	O
-	:	O
1	CD	O
receptor	NN	O
agonist	NN	O
in	IN	O
the	DT	O
same	JJ	O
body	NN	O
region	NN	O
but	CC	O
the	DT	O
injections	NNS	O
should	MD	O
not	RB	O
be	VB	O
adjacent	JJ	O
to	TO	O
each	DT	O
other	JJ	O
.	.	O

The	DT	O
recommended	JJ	O
oral	JJ	O
dosage	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
2	CD	WHO
to	TO	WHO
16	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
is	VBZ	O
1.8	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VBD	O
given	VBN	O
within	IN	O
one	CD	O
hour	NN	O
before	IN	O
chemotherapy	NN	O
,	,	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
100	CD	DOS
mg.	NNS	UNIT
Safety	NNP	O
and	CC	O
effectiveness	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
under	IN	WHO
2	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
have	VBP	WHO
not	RB	WHO
been	VBN	WHO
established	VBN	WHO
.	.	O

As	IN	O
in	IN	O
the	DT	O
initial	JJ	O
cycle	NN	O
,	,	O
5,000	CD	DOS
USP	NNP	UNIT
units	NNS	UNIT
of	IN	O
hCG	NN	O
must	MD	O
be	VB	O
given	VBN	O
1	CD	FREQ
day	NN	FREQ
after	IN	O
the	DT	O
last	JJ	O
dose	NN	O
of	IN	O
Gonal	NNP	O
-	:	O
f®	NN	O
to	TO	O
complete	VB	O
follicular	JJ	O
development	NN	O
and	CC	O
induce	VB	O
ovulation	NN	O
.	.	O

Care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
not	RB	O
to	TO	O
discontinue	VB	O
therapy	NN	O
prematurely	RB	O
.	.	O

Dosage	NN	O
may	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
50	CD	DOS
mcg	NN	UNIT
t.i.d	NN	O
.	.	O

REBETOL	NNP	O
may	MD	O
be	VB	O
administered	VBN	O
without	IN	O
regard	NN	O
to	TO	O
food	NN	O
,	,	O
but	CC	O
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
a	DT	O
consistent	JJ	O
manner	NN	O
.	.	O

Step	NN	O
1	CD	O

In	IN	O
some	DT	WHO
cases	NNS	WHO
,	,	O
serum	JJ	O
blood	NN	O
level	NN	O
determinations	NNS	O
may	MD	O
be	VB	O
necessary	JJ	O
for	IN	O
optimal	JJ	O
dosage	NN	O
adjustments—the	NN	O
clinically	RB	O
effective	JJ	O
serum	NN	O
level	NN	O
is	VBZ	O
usually	RB	O
10	CD	DOS
–	JJ	O
20	CD	DOS
mcg	NN	UNIT
/	NNP	O
mL	NN	O
.	.	O

The	DT	O
recommended	VBN	O
prophylactic	JJ	O
dose	NN	O
of	IN	O
Revonto	NNP	O
is	VBZ	O
2.5	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
,	,	O
starting	VBG	O
approximately	RB	O
1.25	CD	O
hours	NNS	O
before	IN	O
anticipated	JJ	O
anesthesia	NN	O
and	CC	O
infused	VBN	O
over	IN	O
approximately	RB	O
1	CD	O
hour	NN	O
.	.	O

Therapy	NN	O
should	MD	O
be	VB	O
started	VBN	O
at	IN	O
the	DT	O
lowest	JJS	O
effective	JJ	O
dose	NN	O
and	CC	O
the	DT	O
shortest	JJS	O
duration	NN	O
consistent	NN	O
with	IN	O
the	DT	O
treatment	NN	O
goals	NNS	O
.	.	O

Monitor	NNP	O
renal	JJ	O
function	NN	O
[	NNP	O
see	NN	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

RiaSTAP	NNP	O
(	(	O
fibrinogen	NN	O
concentrate	NN	O
(	(	O
human	JJ	O
)	)	O
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
is	VBZ	O
stable	JJ	O
for	IN	O
24	CD	PER
hours	NNS	PER
after	IN	O
reconstitution	NN	O
when	WRB	O
stored	VBN	O
at	IN	O
20	CD	O
-	:	O
25ºC	CD	O
and	CC	O
should	MD	O
be	VB	O
administered	VBN	O
within	IN	O
this	DT	O
time	NN	O
period	NN	O
.	.	O

Infuse	NNP	O
LEMTRADA	NNP	O
over	IN	O
4	CD	O
hours	NNS	O
starting	VBG	O
within	IN	O
8	CD	O
hours	NNS	O
after	IN	O
dilution	NN	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Dosing	NN	O
for	IN	O
Perioperative	NNP	O
Management	NNP	O

The	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
can	MD	O
be	VB	O
increased	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
25	CD	DOS
mg	NNS	UNIT
to	TO	O
50	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
,	,	O
if	IN	O
well	RB	O
-	:	O
tolerated	VBN	O
,	,	O
to	TO	O
achieve	VB	O
a	DT	O
target	NN	O
dose	NN	O
of	IN	O
300	CD	DOS
mg	NNS	UNIT
to	TO	O
450	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
(	(	O
administered	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
)	)	O
by	IN	O
the	DT	O
end	NN	O
of	IN	O
2	CD	PER
weeks	NNS	PER
.	.	O

Dosage	NNP	O
reduction	NN	O
of	IN	O
SOVALDI	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

In	IN	O
patients	NNS	WHO
undergoing	JJ	WHO
hemodialysis	NN	WHO
or	CC	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
CLcr	NNP	O
<	VBZ	O
30	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
,	,	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
by	IN	O
50	CD	O
%	NN	O
or	CC	O
more	JJR	O
.	.	O

Tcc	NNP	O
(	(	O
Females	NNP	O
)	)	O
=	VBD	O
0.85	CD	DOS
×	NNS	UNIT
above	IN	O
value	NN	O

Handling	VBG	O
and	CC	O
Disposal	NNP	O
:	:	O
Follow	NNP	O
safe	JJ	O
cytotoxic	NN	O
agent	NN	O
handling	VBG	O
procedures	NNS	O
.	.	O

When	WRB	O
initiating	VBG	O
a	DT	O
Sunday	NNP	O
start	NN	O
regimen	NNS	O
,	,	O
another	DT	O
method	NN	O
of	IN	O
contraception	NN	O
,	,	O
such	JJ	O
as	IN	O
condoms	NNS	O
or	CC	O
spermicide	NN	O
,	,	O
should	MD	O
be	VB	O
used	VBN	O
for	IN	O
the	DT	O
first	JJ	O
7	CD	PER
consecutive	JJ	PER
days	NNS	PER
of	IN	O
taking	VBG	O
DESOGEN®	NNP	O
Tablets	NNP	O
(	(	O
desogestrel	NN	O
and	CC	O
ethinyl	NN	O
estradiol	VBP	O
tablets	NNS	O
USP	NNP	O
)	)	O
.	.	O

The	DT	O
patient	NN	O
should	MD	O
continue	VB	O
to	TO	O
use	VB	O
hair	JJ	O
removal	NN	O
techniques	NNS	O
as	IN	O
needed	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
VANIQA®	NNP	O
.	.	O

HBV	NNP	O
DNA	NNP	O
should	MD	O
be	VB	O
monitored	VBN	O
every	DT	FREQ
6	CD	FREQ
months	NNS	FREQ
to	TO	O
assure	VB	O
continued	JJ	O
response	NN	O
.	.	O

Injection	NN	O
:	:	O
200	CD	DOS
mg	NN	UNIT
/	VBD	O
40	CD	DOS
mL	NN	UNIT
(	(	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O

Although	IN	O
anaphylactic	JJ	O
reactions	NNS	O
known	VBN	O
to	TO	O
occur	VB	O
following	VBG	O
INFeD	NNP	O
administration	NN	O
are	VBP	O
usually	RB	O
evident	JJ	O
within	IN	O
a	DT	O
few	JJ	O
minutes	NNS	O
,	,	O
or	CC	O
sooner	RB	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
a	DT	O
period	NN	O
of	IN	O
an	DT	O
hour	NN	O
or	CC	O
longer	JJR	O
elapse	NN	O
before	IN	O
the	DT	O
remainder	NN	O
of	IN	O
the	DT	O
initial	JJ	O
therapeutic	JJ	O
dose	NN	O
is	VBZ	O
given	VBN	O
.	.	O

It	PRP	O
is	VBZ	O
common	JJ	O
to	TO	O
have	VB	O
medicine	NN	O
leftover	NN	O
in	IN	O
the	DT	O
cup	NN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
1	CD	DOS
inhalation	NN	UNIT
of	IN	O
BREO	NNP	O
ELLIPTA	NNP	O
200	CD	DOS
/	NNP	UNIT
25	CD	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

Aldara	NNP	O
Cream	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
2	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
week	NN	FREQ
for	IN	O
a	DT	O
full	JJ	O
16	CD	PER
weeks	NNS	PER
to	TO	O
a	DT	O
defined	VBN	O
treatment	NN	O
area	NN	O
on	IN	O
the	DT	O
face	NN	O
or	CC	O
scalp	NN	O
(	(	O
but	CC	O
not	RB	O
both	DT	O
concurrently	RB	O
)	)	O
.	.	O

DUOPA	NNP	O
is	VBZ	O
dispensed	VBN	O
from	IN	O
medication	NN	O
cassette	NN	O
reservoirs	NNS	O
that	WDT	O
are	VBP	O
specifically	RB	O
designed	VBN	O
to	TO	O
be	VB	O
connected	VBN	O
to	TO	O
the	DT	O
CADD®	NNP	O
-	:	O
Legacy	NN	O
1400	CD	O
pump	NN	O
.	.	O

Several	JJ	O
guidelines	NNS	O
on	IN	O
this	DT	O
subject	NN	O
have	VBP	O
been	VBN	O
published.1	JJ	O
-	:	O
8	CD	O

Increments	NNS	O
of	IN	O
propofol	NN	O
injectable	JJ	O
emulsion	NN	O
25	CD	DOS
mg	NN	UNIT
(	(	O
2.5	CD	DOS
mL	NN	UNIT
)	)	O
to	TO	O
50	CD	DOS
mg	NN	UNIT
(	(	O
5	CD	DOS
mL	NN	UNIT
)	)	O
may	MD	O
be	VB	O
administered	VBN	O
with	IN	O
nitrous	JJ	O
oxide	NN	O
in	IN	O
adult	NN	WHO
patients	NNS	WHO
undergoing	VBG	WHO
general	JJ	WHO
surgery	NN	WHO
.	.	O

Repeat	NNP	O
twice	NN	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
three	CD	O
rinses	NNS	O
.	.	O

The	DT	O
average	JJ	O
maintenance	NN	O
dose	NN	O
is	VBZ	O
250	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
(	(	O
range	NN	O
,	,	O
125	CD	DOS
to	TO	O
500	CD	DOS
mg	NN	UNIT
)	)	O
,	,	O
it	PRP	O
should	MD	O
not	RB	O
exceed	VB	O
500	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
.	.	O

Do	NNP	O
not	RB	O
shake	VB	O
the	DT	O
vial	NN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
misses	VBZ	O
2	CD	O
consecutive	JJ	O
white	JJ	O
tablets	NNS	O
in	IN	O
Week	JJ	WHO
1	CD	WHO
or	CC	WHO
Week	JJ	WHO
2	CD	WHO
,	,	O
the	DT	O
patient	NN	O
should	MD	O
take	VB	O
2	CD	DOS
tablets	NNS	UNIT
the	DT	O
day	NN	O
she	PRP	O
remembers	NNS	O
and	CC	O
2	CD	DOS
tablets	NNS	UNIT
the	DT	O
next	JJ	O
day	NN	O
;	:	O
thereafter	RB	O
,	,	O
the	DT	O
patient	NN	O
should	MD	O
resume	VB	O
taking	VBG	O
1	CD	DOS
tablet	JJ	UNIT
daily	RB	FREQ
until	IN	O
she	PRP	O
finishes	VBZ	O
the	DT	O
cycle	NN	O
pack	NN	O
.	.	O

These	DT	WHO
patients	NNS	WHO
may	MD	O
be	VB	O
treated	VBN	O
2	CD	FREQ
or	CC	O
3	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
week	NN	FREQ
,	,	O
as	IN	O
a	DT	O
Type	NN	O
I	PRP	O
patient	VBP	O
.	.	O

When	WRB	O
instructing	VBG	O
patients	NNS	O
to	TO	O
increase	VB	O
dosage	NN	O
according	VBG	O
to	TO	O
the	DT	O
schedule	NN	O
above	IN	O
,	,	O
they	PRP	O
should	MD	O
be	VB	O
told	VBN	O
not	RB	O
to	TO	O
take	VB	O
a	DT	O
subsequent	JJ	O
dose	NN	O
if	IN	O
apparent	JJ	O
side	NN	O
effects	NNS	O
occur	VBP	O
and	CC	O
to	TO	O
resume	VB	O
therapy	NN	O
at	IN	O
a	DT	O
lower	JJR	O
dose	NN	O
once	RB	O
adverse	JJ	O
effects	NNS	O
have	VBP	O
disappeared	VBN	O
.	.	O

Depending	VBG	O
on	IN	O
the	DT	O
area	NN	O
to	TO	O
be	VB	O
imaged	VBN	O
,	,	O
the	DT	O
usual	JJ	O
dose	NN	O
range	NN	O
per	IN	O
injection	NN	O
is	VBZ	O
30	CD	DOS
to	TO	O
50	CD	DOS
mL	NNS	UNIT
.	.	O

REGONOL®	NNP	O
(	(	O
pyridostigmine	JJ	O
bromide	NN	O
injection	NN	O
USP	NNP	O
)	)	O
is	VBZ	O
for	IN	O
intravenous	JJ	O
use	NN	O
only	RB	O
.	.	O

The	DT	O
drug	NN	O
should	MD	O
be	VB	O
titrated	VBN	O
against	IN	O
the	DT	O
patient	NN	O
's	POS	O
requirements	NNS	O
.	.	O

Discard	NNP	O
any	DT	O
unused	JJ	O
portion	NN	O
because	IN	O
the	DT	O
premix	NN	O
flexible	JJ	O
containers	NNS	O
are	VBP	O
for	IN	O
single	JJ	O
-	:	O
use	NN	O
only	RB	O
.	.	O

JEVTANA	NNP	O
requires	VBZ	O
two	CD	DOS
dilutions	NNS	UNIT
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

To	TO	O
achieve	VB	O
maximum	JJ	O
contraceptive	JJ	O
effectiveness	NN	O
,	,	O
ORTHO	NNP	O
-	:	O
CEPT®	NN	O
must	MD	O
be	VB	O
taken	VBN	O
exactly	RB	O
as	IN	O
directed	VBN	O
and	CC	O
at	IN	O
intervals	NNS	O
not	RB	O
exceeding	VBG	O
24	CD	O
hours	NNS	O
.	.	O

If	IN	O
in	IN	O
vitro	NN	O
testing	NN	O
results	NNS	O
are	VBP	O
unavailable	JJ	O
,	,	O
SIRTURO	NNP	O
treatment	NN	O
may	MD	O
be	VB	O
initiated	VBN	O
in	IN	O
combination	NN	O
with	IN	O
at	IN	O
least	JJS	O
4	CD	O
other	JJ	O
drugs	NNS	O
to	TO	O
which	WDT	O
the	DT	O
patient	NN	O
's	POS	O
MDR	NNP	O
-	:	O
TB	NN	O
isolate	NN	O
is	VBZ	O
likely	JJ	O
to	TO	O
be	VB	O
susceptible	JJ	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
50	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	VB	O
given	VBN	O
as	IN	O
a	DT	O
slow	JJ	O
2	CD	O
-	:	O
3	CD	O
minute	NN	O
bolus	NN	O
injection	NN	O
or	CC	O
by	IN	O
infusion	NN	O
.	.	O

The	DT	O
recommended	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
of	IN	O
TASMAR	NNP	O
is	VBZ	O
also	RB	O
100	CD	DOS
mg	NNS	UNIT
tid	NN	O
.	.	O

Table	JJ	O
4	CD	O
:	:	O
Dosing	NN	O
in	IN	O
Adults	NNP	WHO
with	IN	WHO
Renal	NNP	WHO
Impairment	NNP	WHO

Premixed	NNP	O
Injection	NNP	O
with	IN	O
any	DT	O
product	NN	O
in	IN	O
the	DT	O
same	JJ	O
intravenous	JJ	O
line	NN	O
or	CC	O
premixed	JJ	O
container	NN	O
.	.	O

Use	NNP	O
of	IN	O
evacuated	JJ	O
glass	NN	O
containers	NNS	O
for	IN	O
admixing	VBG	O
amiodarone	NN	O
HCl	NNP	O
injection	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
as	IN	O
incompatibility	NN	O
with	IN	O
a	DT	O
buffer	NN	O
in	IN	O
the	DT	O
container	NN	O
may	MD	O
cause	VB	O
precipitation	NN	O
.	.	O

In	IN	O
the	DT	O
unlikely	JJ	O
event	NN	O
that	IN	O
a	DT	O
patch	NN	O
remains	VBZ	O
tightly	RB	O
adhered	VBN	O
despite	IN	O
these	DT	O
measures	NNS	O
,	,	O
the	DT	O
patient	NN	O
or	CC	O
caregiver	NN	O
should	MD	O
contact	VB	O
the	DT	O
physician	NN	O
or	CC	O
pharmacist	NN	O
.	.	O

When	WRB	O
concomitant	JJ	O
diuretic	JJ	O
therapy	NN	O
is	VBZ	O
required	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
a	DT	O
loop	JJ	O
diuretic	NN	O
(	(	O
e.g	JJ	O
,	,	O
furosemide	RB	O
)	)	O
,	,	O
rather	RB	O
than	IN	O
a	DT	O
thiazide	JJ	O
diuretic	NN	O
is	VBZ	O
preferred	VBN	O
for	IN	O
use	NN	O
with	IN	O
captopril	NN	O
;	:	O
therefore	RB	O
,	,	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
dysfunction	NN	WHO
the	DT	O
captopril	NN	O
and	CC	O
hydrochlorothiazide	JJ	O
combination	NN	O
tablet	NN	O
is	VBZ	O
not	RB	O
usually	RB	O
recommended	VBN	O
.	.	O

The	DT	O
Day	NNP	O
-	:	O
Before	IN	O
regimen	NNS	O
is	VBZ	O
the	DT	O
alternative	JJ	O
dosing	NN	O
method	NN	O
for	IN	O
patients	NNS	O
for	IN	O
whom	WP	O
the	DT	O
Split	NNP	O
-	:	O
Dosing	VBG	O
regimen	NNS	O
is	VBZ	O
inappropriate	JJ	O
.	.	O

The	DT	O
patient	NN	O
must	MD	O
stay	VB	O
in	IN	O
the	DT	O
physician	NN	O
's	POS	O
office	NN	O
until	IN	O
complete	JJ	O
detumescence	NN	O
occurs	NNS	O
.	.	O

Final	JJ	O
panel	NN	O
to	TO	O
right	NN	O
shows	NNS	O
enlarged	VBD	O
picture	NN	O
of	IN	O
the	DT	O
brain	NN	O
area	NN	O
under	IN	O
the	DT	O
box	NN	O
.	.	O

Therefore	RB	O
,	,	O
Starlix	NNP	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
-	:	O
to	TO	O
-	:	O
severe	JJ	O
liver	NN	O
disease	NN	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
,	,	O
Hepatic	NNP	O
Impairment	NNP	O
)	)	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
in	IN	O
doses	NNS	O
of	IN	O
more	JJR	O
than	IN	O
20	CD	DOS
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
or	CC	O
for	IN	O
longer	JJR	O
than	IN	O
12	CD	PER
weeks	NNS	PER
.	.	O

Serum	NNP	O
levels	NNS	O
of	IN	O
ACTH	NNP	O
rise	NN	O
from	IN	O
a	DT	O
low	JJ	O
point	NN	O
about	IN	O
10	CD	O
pm	NN	O
to	TO	O
a	DT	O
peak	JJ	O
level	NN	O
about	IN	O
6	CD	O
am	VBP	O
.	.	O

If	IN	O
the	DT	O
dose	NN	O
requires	VBZ	O
more	JJR	O
than	IN	O
one	CD	DOS
vial	NN	UNIT
,	,	O
reconstitute	VB	O
each	DT	O
vial	NN	O
as	IN	O
described	VBN	O
above	IN	O
with	IN	O
the	DT	O
diluent	NN	O
syringe	NN	O
provided	VBD	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
a	DT	WHO
first	JJ	WHO
episode	NN	WHO
of	IN	WHO
idiopathic	JJ	WHO
DVT	NNP	WHO
or	CC	O
PE	NNP	O
,	,	O
warfarin	NN	O
is	VBZ	O
recommended	VBN	O
for	IN	O
at	IN	PER
least	JJS	PER
6	CD	PER
to	TO	O
12	CD	PER
months	NNS	PER
.	.	O

A	DT	O
rest	NN	O
period	NN	O
of	IN	O
several	JJ	O
days	NNS	O
may	MD	O
be	VB	O
taken	VBN	O
if	IN	O
required	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
discomfort	NN	O
or	CC	O
severity	NN	O
of	IN	O
the	DT	O
local	JJ	O
skin	NN	O
reaction	NN	O
.	.	O

The	DT	O
dose	NN	O
is	VBZ	O
400	CD	DOS
mg	NN	UNIT
intravenously	RB	O
,	,	O
followed	VBN	O
by	IN	O
400	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
4	CD	FREQ
to	TO	O
6	CD	O
hours	NNS	O
or	CC	O
100	CD	DOS
mg	NNS	UNIT
to	TO	O
200	CD	DOS
mg	NN	UNIT
every	DT	FREQ
4	CD	FREQ
hours	NNS	FREQ
as	IN	O
necessary	JJ	O
.	.	O

The	DT	O
dose	NN	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
5	CD	DOS
mg	JJ	UNIT
intramuscularly	RB	O
;	:	O
for	IN	O
children	NNS	WHO
,	,	O
3	CD	DOS
mg	NN	UNIT
.	.	O

Observe	IN	O
the	DT	O
patient	NN	O
closely	RB	O
for	IN	O
possible	JJ	O
adverse	JJ	O
effects	NNS	O
.	.	O

For	IN	O
example	NN	O
,	,	O
if	IN	O
a	DT	O
patient	NN	O
on	IN	O
a	DT	O
Mon	NNP	O
.	.	O
/	VB	O
Wed.	NNP	O
/	NNP	O
Fri	NNP	O
.	.	O

This	DT	O
may	MD	O
be	VB	O
accomplished	VBN	O
by	IN	O
reducing	VBG	O
the	DT	O
dosage	NN	O
from	IN	O
0.1	CD	DOS
to	TO	O
0.05	CD	DOS
to	TO	O
0.025	CD	DOS
to	TO	O
0.01	CD	DOS
micrograms	NNS	UNIT
per	IN	O
kilogram	NN	O
of	IN	O
body	NN	O
weight	JJ	O
per	IN	O
minute	NN	O
.	.	O

It	PRP	O
may	MD	O
be	VB	O
diluted	VBN	O
in	IN	O
volumes	NNS	O
of	IN	O
50	CD	DOS
-	:	O
200	CD	DOS
mL	NN	UNIT
and	CC	O
infused	VBD	O
intravenously	RB	O
over	IN	O
15	CD	O
-	:	O
30	CD	O
minutes	NNS	O
or	CC	O
administered	VBN	O
by	IN	O
IV	NNP	O
push	NN	O
over	IN	O
3	CD	O
minutes	NNS	O
.	.	O

With	IN	O
severe	JJ	O
persistent	NN	O
anaphylaxis	NN	O
,	,	O
repeat	NN	O
injections	NNS	O
with	IN	O
an	DT	O
additional	JJ	O
Adrenaclick	NNP	O
may	MD	O
be	VB	O
necessary	JJ	O
.	.	O

Figure	NN	O
11,12	CD	O
and	CC	O
13	CD	O

Each	DT	O
300	CD	O
Unit	NNP	O
vial	NN	O
of	IN	O
DYSPORT®	NNP	O
is	VBZ	O
to	TO	O
be	VB	O
reconstituted	VBN	O
with	IN	O
0.6	CD	DOS
mL	NNS	UNIT
of	IN	O
preservative	JJ	O
-	:	O
free	JJ	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
USP	NNP	O
to	TO	O
yield	VB	O
a	DT	O
solution	NN	O
equivalent	NN	O
to	TO	O
50	CD	DOS
Units	NNS	UNIT
per	IN	O
0.1	CD	DOS
mL	NN	UNIT
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
lesser	JJR	WHO
degrees	NNS	WHO
of	IN	WHO
impairment	NN	WHO
,	,	O
the	DT	O
initial	JJ	O
dosage	NN	O
should	MD	O
be	VB	O
2	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
and	CC	O
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
8	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
MUSTARGEN	NNP	O
varies	NNS	O
with	IN	O
the	DT	O
clinical	JJ	O
situation	NN	O
,	,	O
the	DT	O
therapeutic	JJ	O
response	NN	O
and	CC	O
the	DT	O
magnitude	NN	O
of	IN	O
hematologic	JJ	O
depression	NN	O
.	.	O

Shake	NNP	O
NASACORT	NNP	O
AQ	NNP	O
Nasal	NNP	O
Spray	NNP	O
well	RB	O
before	IN	O
each	DT	O
use	NN	O
.	.	O

Do	NNP	O
not	RB	O
open	VB	O
COMETRIQ	NNP	O
capsules	NNS	O
.	.	O

However	RB	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
,	,	O
failure	NN	O
to	TO	O
increase	VB	O
growth	NN	O
rate	NN	O
,	,	O
particularly	RB	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
therapy	NN	O
,	,	O
suggests	VBZ	O
the	DT	O
need	NN	O
for	IN	O
close	JJ	O
assessment	NN	O
of	IN	O
compliance	NN	O
and	CC	O
evaluation	NN	O
of	IN	O
other	JJ	O
causes	NNS	O
of	IN	O
growth	NN	O
failure	NN	O
,	,	O
such	JJ	O
as	IN	O
hypothyroidism	NN	O
,	,	O
undernutrition	NN	O
,	,	O
and	CC	O
advanced	VBD	O
bone	NN	O
age	NN	O
.	.	O

The	DT	O
tablets	NNS	O
must	MD	O
not	RB	O
be	VB	O
split	VBN	O
,	,	O
crushed	VBN	O
,	,	O
or	CC	O
chewed	VBD	O
before	IN	O
swallowing	NN	O
.	.	O

Avoid	NNP	O
use	NN	O
of	IN	O
ADCIRCA	NNP	O
during	IN	O
the	DT	O
initiation	NN	O
of	IN	O
ritonavir	NN	O
.	.	O

Clinical	JJ	O
improvement	NN	O
is	VBZ	O
usually	RB	O
observed	VBN	O
within	IN	O
48	CD	O
hours	NNS	O
.	.	O

Individually	RB	O
titrate	JJ	O
AVINZA	NNP	O
to	TO	O
a	DT	O
dose	NN	O
that	WDT	O
provides	VBZ	O
adequate	JJ	O
analgesia	NNS	O
and	CC	O
minimizes	VBZ	O
adverse	JJ	O
reactions	NNS	O
.	.	O

ethambutol	NN	O
)	)	O
that	WDT	O
have	VBP	O
shown	VBN	O
in	IN	O
vitro	JJ	O
activity	NN	O
against	IN	O
MAC	NNP	O
or	CC	O
clinical	JJ	O
benefit	NN	O
in	IN	O
MAC	NNP	O
treatment	NN	O
[	NNP	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

Iron	NNP	O
is	VBZ	O
added	VBN	O
to	TO	O
the	DT	O
solution	NN	O
or	CC	O
given	VBN	O
intramuscularly	RB	O
in	IN	O
depot	JJ	O
form	NN	O
as	IN	O
indicated	JJ	O
.	.	O

For	IN	O
children	NNS	WHO
2	CD	WHO
years	NNS	WHO
to	TO	WHO
under	IN	WHO
6	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
,	,	O
the	DT	O
dose	NN	O
is	VBZ	O
1.25	CD	DOS
to	TO	O
2.5	CD	DOS
mL	NN	UNIT
(	(	O
one	CD	O
-	:	O
quarter	NN	O
to	TO	O
one	CD	O
-	:	O
half	NN	O
teaspoon	NN	O
)	)	O
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
10.0	CD	DOS
mL	NNS	UNIT
in	IN	O
24	CD	O
hours	NNS	O
.	.	O

Should	MD	O
not	RB	O
be	VB	O
applied	VBN	O
more	RBR	O
frequently	RB	O
than	IN	O
required	VBN	O
to	TO	O
maintain	VB	O
control	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
cancer	NN	WHO
and	CC	WHO
symptomatic	JJ	WHO
venous	JJ	WHO
thromboembolism	NN	WHO
,	,	O
the	DT	O
recommended	JJ	O
dosing	NN	O
of	IN	O
FRAGMIN	NNP	O
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O
for	IN	O
the	DT	O
first	JJ	O
30	CD	O
days	NNS	O
of	IN	O
treatment	NN	O
administer	NN	O
FRAGMIN	NNP	O
200	CD	DOS
IU	NNP	UNIT
/	NNP	O
kg	NNP	O
total	JJ	O
body	NN	O
weight	VBD	O
subcutaneously	RB	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

The	DT	O
dose	NN	O
should	MD	O
be	VB	O
increased	VBN	O
to	TO	O
one	CD	DOS
spray	NN	UNIT
in	IN	O
each	DT	O
nostril	JJ	O
twice	RB	FREQ
daily	RB	FREQ
(	(	O
total	JJ	O
daily	RB	FREQ
dose	VBP	O
100	CD	DOS
mcg	NN	UNIT
)	)	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
an	DT	WHO
inadequate	JJ	WHO
response	NN	WHO
to	TO	O
once	RB	FREQ
daily	JJ	FREQ
dosing	NN	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
insufficiency	NN	WHO
(	(	O
GFR	NNP	O
<	VBZ	O
30	CD	DOS
ml	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
should	MD	O
be	VB	O
given	VBN	O
a	DT	O
lower	JJR	O
initial	JJ	O
dose	NN	O
(	(	O
one	CD	DOS
12	CD	DOS
hour	NN	UNIT
tablet	NN	UNIT
per	IN	FREQ
day	NN	FREQ
,	,	O
or	CC	O
one	CD	O
24	CD	O
hour	NN	UNIT
tablet	NN	UNIT
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
)	)	O
because	IN	O
they	PRP	O
have	VBP	O
reduced	VBN	O
clearance	NN	O
of	IN	O
loratadine	NN	O
and	CC	O
pseudoephedrine	NN	O
.	.	O

(	(	O
If	IN	O
Lo	NNP	O
/	NNP	O
Ovral	NNP	O
is	VBZ	O
first	RB	O
taken	VBN	O
later	RB	O
than	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
a	DT	O
menstrual	JJ	O
cycle	NN	O
or	CC	O
postpartum	NN	O
,	,	O
contraceptive	JJ	O
reliance	NN	O
should	MD	O
not	RB	O
be	VB	O
placed	VBN	O
on	IN	O
Lo	NNP	O
/	NNP	O
Ovral	NNP	O
until	IN	O
after	IN	O
the	DT	O
first	JJ	O
seven	CD	O
consecutive	JJ	O
days	NNS	O
of	IN	O
use	NN	O
and	CC	O
a	DT	O
nonhormonal	JJ	O
back	NN	O
-	:	O
up	IN	O
method	NN	O
of	IN	O
birth	NN	O
control	NN	O
should	MD	O
be	VB	O
used	VBN	O
during	IN	O
those	DT	O
7	CD	O
days	NNS	O
.	.	O

Training	NN	O
should	MD	O
aim	VB	O
to	TO	O
demonstrate	VB	O
to	TO	O
those	DT	O
patients	NNS	O
and	CC	O
caregivers	NNS	O
how	WRB	O
to	TO	O
measure	VB	O
the	DT	O
dose	NN	O
using	VBG	O
the	DT	O
prefilled	JJ	O
syringe	NN	O
,	,	O
and	CC	O
the	DT	O
focus	NN	O
should	MD	O
be	VB	O
on	IN	O
ensuring	VBG	O
that	IN	O
a	DT	O
patient	NN	WHO
or	CC	WHO
caregiver	NN	WHO
can	MD	O
successfully	RB	O
perform	VB	O
all	DT	O
of	IN	O
the	DT	O
steps	NNS	O
in	IN	O
the	DT	O
Instructions	NNP	O
for	IN	O
Use	NNP	O
of	IN	O
ZARXIO	NNP	O
prefilled	VBD	O
syringe	NN	O
with	IN	O
BD	NNP	O
UltraSafe	NNP	O
Passive®	NNP	O
Needle	NNP	O
Guard	NNP	O
.	.	O

Discard	NNP	O
any	DT	O
unused	JJ	O
portion	NN	O
of	IN	O
the	DT	O
COSMEGEN	NNP	O
solution	NN	O
.	.	O

Striant	NNP	O
should	MD	O
not	RB	O
be	VB	O
chewed	VBN	O
or	CC	O
swallowed	VBN	O
.	.	O

Reconstituted	VBN	O
Mandol	NNP	O
(	(	O
cefamandole	NN	O
)	)	O
is	VBZ	O
stable	JJ	O
for	IN	O
24	CD	PER
hours	NNS	PER
at	IN	O
room	NN	O
temperature	NN	O
(	(	O
25°C	CD	O
)	)	O
and	CC	O
for	IN	O
96	CD	O
hours	NNS	O
if	IN	O
stored	VBN	O
under	IN	O
refrigeration	NN	O
(	(	O
5°C	CD	O
)	)	O
.	.	O

The	DT	O
positive	JJ	O
scan	NN	O
shows	VBZ	O
the	DT	O
tracer	NN	O
uptake	NN	O
in	IN	O
these	DT	O
regions	NNS	O
has	VBZ	O
a	DT	O
“	NN	O
plumped	VBD	O
”	NNP	O
,	,	O
smooth	JJ	O
appearance	NN	O
due	JJ	O
to	TO	O
the	DT	O
increased	VBN	O
gray	JJ	O
matter	NN	O
signal	NN	O
(	(	O
dashed	JJ	O
line	NN	O
)	)	O
.	.	O

After	IN	O
28	CD	DOS
tablets	NNS	UNIT
have	VBP	O
been	VBN	O
taken	VBN	O
,	,	O
a	DT	O
new	JJ	O
course	NN	O
is	VBZ	O
started	VBN	O
and	CC	O
a	DT	O
rosecolored	JJ	O
“	NNP	O
active	JJ	O
”	NNP	O
tablet	NN	O
is	VBZ	O
taken	VBN	O
the	DT	O
next	JJ	O
day	NN	O
(	(	O
Sunday	NNP	O
)	)	O
.	.	O

If	IN	O
no	DT	O
clear	JJ	O
improvement	NN	O
of	IN	O
respiration	NN	O
occurs	NNS	O
after	IN	O
0.2	CD	DOS
mL	NN	UNIT
(	(	O
2	CD	DOS
mg	NN	UNIT
)	)	O
dose	NN	O
,	,	O
it	PRP	O
is	VBZ	O
usually	RB	O
wisest	JJS	O
to	TO	O
discontinue	VB	O
all	DT	O
anticholinesterase	JJ	O
drug	NN	O
therapy	NN	O
and	CC	O
secure	NN	O
controlled	VBN	O
ventilation	NN	O
by	IN	O
tracheostomy	NN	O
with	IN	O
assisted	JJ	O
respiration	NN	O
.	.	O

After	IN	O
determining	VBG	O
the	DT	O
absence	NN	O
of	IN	O
known	JJ	O
allergies	NNS	O
to	TO	O
the	DT	O
anesthetic	JJ	O
agent	NN	O
,	,	O
infiltrate	VB	O
the	DT	O
site	NN	O
with	IN	O
lidocaine	NN	O
.	.	O

In	IN	O
acutely	RB	WHO
ill	JJ	WHO
patients	NNS	WHO
,	,	O
serum	JJ	O
theophylline	NN	O
concentrations	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
at	IN	O
frequent	JJ	O
intervals	NNS	O
,	,	O
e.g	NN	O
,	,	O
every	DT	FREQ
24	CD	FREQ
hours	NNS	FREQ
.	.	O

Give	VB	O
this	DT	O
intravenous	JJ	O
infusion	NN	O
slowly	RB	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
30	CD	O
to	TO	O
60	CD	O
minutes	NNS	O
.	.	O

BRIVIACT	NNP	O
injection	NN	O
should	MD	O
be	VB	O
administered	VBN	O
intravenously	RB	O
over	IN	O
2	CD	O
to	TO	O
15	CD	O
minutes	NNS	O
.	.	O

Hyperventilation	NN	O
should	MD	O
be	VB	O
avoided	VBN	O
in	IN	O
order	NN	O
to	TO	O
minimize	VB	O
possible	JJ	O
CNS	NNP	O
excitation	NN	O
.	.	O

Repeated	VBN	O
supratherapeutic	JJ	O
acetaminophen	NN	O
ingestion	NN	O
(	(	O
RSI	NNP	O
)	)	O
is	VBZ	O
an	DT	O
ingestion	NN	O
of	IN	O
acetaminophen	NN	O
at	IN	O
dosages	VBZ	O
higher	JJR	O
than	IN	O
those	DT	O
recommended	VBN	O
for	IN	O
extended	JJ	O
periods	NNS	O
of	IN	O
time	NN	O
.	.	O

STORE	NN	O
IN	VBZ	O
A	NNP	O
FREEZER	NNP	O
NOT	NNP	O
ABOVE	NNP	O
-	:	O
20°C	CD	O
(	(	O
-	:	O
4°F	CD	O
)	)	O
BUT	NNP	O
BRING	NNP	O
TO	NNP	O
ROOM	NNP	O
TEMPERATURE	NNP	O
JUST	NNP	O
PRIOR	NNP	O
TO	NNP	O
USE	NNP	O
.	.	O

Wafers	NNS	O
broken	VBP	O
in	IN	O
half	NN	O
may	MD	O
be	VB	O
used	VBN	O
,	,	O
but	CC	O
discard	JJ	O
wafers	NNS	O
broken	VBP	O
in	IN	O
more	JJR	O
than	IN	O
two	CD	O
pieces	NNS	O
.	.	O

For	IN	O
Grade	NNP	O
3	CD	O
sensory	NN	O
neuropathy	JJ	O
hold	NN	O
treatment	NN	O
until	IN	O
resolution	NN	O
to	TO	O
Grade	VB	O
1	CD	O
or	CC	O
2	CD	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
dose	JJ	O
reduction	NN	O
for	IN	O
all	DT	O
subsequent	JJ	O
courses	NNS	O
of	IN	O
ABRAXANE	NNP	O
[	NNP	O
see	VBP	O
CONTRAINDICATIONS	NNP	O
,	,	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
ADVERSE	NNP	O
REACTIONS	NNP	O
]	NNP	O
.	.	O

Vials	NNS	O
of	IN	O
DepoDur	NNP	O
(	(	O
morphine	JJ	O
sulfate	NN	O
xr	NNP	O
liposome	NNP	O
injection	NN	O
)	)	O
should	MD	O
be	VB	O
gently	RB	O
inverted	VBN	O
to	TO	O
re	VB	O
-	:	O
suspend	VB	O
the	DT	O
particles	NNS	O
immediately	RB	O
prior	RB	O
to	TO	O
withdrawal	VB	O
from	IN	O
the	DT	O
vial	NN	O
.	.	O

Total	JJ	O
daily	JJ	FREQ
IM	NNP	O
dosages	VBZ	O
greater	JJR	O
than	IN	O
1500	CD	DOS
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

For	IN	O
more	JJR	O
details	NNS	O
,	,	O
refer	VBP	O
to	TO	O
the	DT	O
complete	JJ	O
product	NN	O
information	NN	O
for	IN	O
zidovudine	NN	O
.	.	O

Dosage	NN	O
should	MD	O
be	VB	O
individualized	VBN	O
to	TO	O
provide	VB	O
maximum	JJ	O
benefit	NN	O
.	.	O

turkey	NN	O
on	IN	O
whole	JJ	O
wheat	NN	O
bread	NN	O
w	NN	O
/	NNP	O
lettuce	NN	O
,	,	O
tomato	NN	O
,	,	O
and	CC	O
1	CD	O
packet	NN	O
mustard	NN	O
)	)	O
.	.	O

The	DT	O
marks	NNS	O
are	VBP	O
for	IN	O
reference	NN	O
only	RB	O
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
for	IN	O
patients	NNS	WHO
3	CD	WHO
to	TO	WHO
6	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
is	VBZ	O
one	CD	DOS
capsule	NN	UNIT
(	(	O
250	CD	DOS
mg	NN	UNIT
)	)	O
per	IN	FREQ
day	NN	FREQ
;	:	O
for	IN	O
patients	NNS	WHO
6	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
,	,	O
2	CD	DOS
capsules	NNS	UNIT
(	(	O
500	CD	DOS
mg	NN	UNIT
)	)	O
per	IN	FREQ
day	NN	FREQ
.	.	O

If	IN	O
patient	JJ	O
requires	VBZ	O
more	JJR	O
than	IN	O
one	CD	DOS
vial	NN	UNIT
,	,	O
pool	VBP	O
the	DT	O
contents	NNS	O
of	IN	O
multiple	JJ	O
vials	NNS	O
into	IN	O
one	CD	O
syringe	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
hypocitraturia	NN	WHO
(	(	O
urinary	JJ	O
citrate	NN	O
<	VBD	O
150	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
)	)	O
,	,	O
therapy	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
60	CD	DOS
mEq	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
30	CD	O
mEq	NN	O
two	CD	FREQ
times	NNS	FREQ
/	JJ	FREQ
day	NN	FREQ
or	CC	O
20	CD	DOS
mEq	NNS	UNIT
three	CD	FREQ
times	NNS	FREQ
/	JJ	FREQ
day	NN	FREQ
with	IN	O
meals	NNS	O
or	CC	O
within	IN	O
30	CD	O
minutes	NNS	O
after	IN	O
meals	NNS	O
or	CC	O
bedtime	VB	O
snack	NN	O
)	)	O
.	.	O

Peel	NNP	O
off	IN	O
the	DT	O
detachable	JJ	O
portion	NN	O
of	IN	O
the	DT	O
label	NN	O
(	(	O
starting	VBG	O
at	IN	O
the	DT	O
corner	NN	O
marked	VBD	O
with	IN	O
a	DT	O
black	JJ	O
triangle	NN	O
)	)	O
from	IN	O
the	DT	O
Cysview	NNP	O
(	(	O
hexaminolevulinate	JJ	O
hydrochloride	NN	O
intravesical	JJ	O
solution	NN	O
)	)	O
powder	NN	O
vial	JJ	O
and	CC	O
affix	VBZ	O
it	PRP	O
to	TO	O
the	DT	O
syringe	NN	O
containing	VBG	O
the	DT	O
solution	NN	O
of	IN	O
Cysview	NNP	O
(	(	O
hexaminolevulinate	JJ	O
hydrochloride	NN	O
intravesical	JJ	O
solution	NN	O
)	)	O
(	(	O
Figure	NNP	O
6	CD	O
)	)	O
.	.	O

Refer	NN	O
to	TO	O
the	DT	O
prescribing	NN	O
information	NN	O
for	IN	O
peginterferon	NN	O
alfa	NN	O
and	CC	O
ribavirin	NN	O
for	IN	O
additional	JJ	O
information	NN	O
about	IN	O
how	WRB	O
to	TO	O
reduce	VB	O
and	CC	O
/	VB	O
or	CC	O
discontinue	VB	O
the	DT	O
peginterferon	NN	O
alfa	NN	O
and	CC	O
/	NN	O
or	CC	O
ribavirin	NN	O
dose	NN	O
.	.	O

-	:	O
First	NNP	O
PREVACID	NNP	O
I.V	NNP	O
.	.	O

Daily	JJ	FREQ
doses	VBZ	O
up	IN	O
to	TO	O
40	CD	DOS
mg	NN	UNIT
may	MD	O
be	VB	O
necessary	JJ	O
;	:	O
controlled	VBN	O
clinical	JJ	O
studies	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
performed	VBN	O
to	TO	O
demonstrate	VB	O
safety	NN	O
of	IN	O
prolonged	JJ	O
administration	NN	O
of	IN	O
such	JJ	O
doses	NNS	O
.	.	O

In	IN	O
hemodynamically	RB	WHO
stable	JJ	WHO
patients	NNS	WHO
within	IN	WHO
24	CD	WHO
hours	NNS	WHO
of	IN	O
the	DT	O
onset	NN	O
of	IN	O
symptoms	NNS	O
of	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
,	,	O
give	VB	O
PRINIVIL	NNP	O
5	CD	DOS
mg	NN	UNIT
orally	RB	O
,	,	O
followed	VBN	O
by	IN	O
5	CD	DOS
mg	NNS	UNIT
after	IN	O
24	CD	O
hours	NNS	O
,	,	O
10	CD	DOS
mg	NN	UNIT
after	IN	O
48	CD	O
hours	NNS	O
and	CC	O
then	RB	O
10	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
volume	NN	O
of	IN	O
PegIntron	NNP	O
to	TO	O
be	VB	O
injected	VBN	O
depends	VBZ	O
on	IN	O
the	DT	O
strength	NN	O
of	IN	O
PegIntron	NNP	O
and	CC	O
patient	NN	O
's	POS	O
body	NN	O
weight	NN	O
(	(	O
see	VB	O
Table	NNP	O
1	CD	O
)	)	O
.	.	O

If	IN	O
same	JJ	O
-	:	O
day	NN	O
dosing	VBG	O
adjustments	NNS	O
are	VBP	O
to	TO	O
be	VB	O
made	VBN	O
,	,	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
asked	VBN	O
to	TO	O
wait	VB	O
2	CD	O
to	TO	O
4	CD	O
hours	NNS	O
for	IN	O
further	JJ	O
evaluation	NN	O
,	,	O
when	WRB	O
peak	NN	O
levels	NNS	O
have	VBP	O
been	VBN	O
reached	VBN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
baseline	JJ	O
creatinine	NN	O
clearance	NN	O
=	VBD	O
30	CD	DOS
to	TO	O
50	CD	DOS
mL	NNS	UNIT
/	NNP	O
min	NN	O
)	)	O
,	,	O
a	DT	O
dose	JJ	O
reduction	NN	O
to	TO	O
75	CD	O
%	NN	O
of	IN	O
the	DT	O
XELODA	NNP	O
starting	VBG	O
dose	NN	O
when	WRB	O
used	VBN	O
as	IN	O
monotherapy	NN	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
docetaxel	NN	O
(	(	O
from	IN	O
1250	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
to	TO	O
950	CD	DOS
mg	NNS	UNIT
/	JJ	O
m2	JJ	O
twice	RB	FREQ
daily	RB	FREQ
)	)	O
is	VBZ	O
recommended	JJ	O
[	NNP	O
see	NN	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Discontinuation	NN	O
of	IN	O
therapy	NN	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
achieve	VB	WHO
at	IN	WHO
least	JJS	WHO
a	DT	WHO
2	CD	WHO
log10	JJ	WHO
drop	NN	WHO
or	CC	O
loss	NN	O
of	IN	O
HCV	NNP	O
-	:	O
RNA	NN	O
at	IN	O
12	CD	PER
weeks	NNS	PER
,	,	O
or	CC	O
if	IN	O
HCV	NNP	O
-	:	O
RNA	NN	O
remains	VBZ	O
detectable	JJ	O
after	IN	O
24	CD	PER
weeks	NNS	PER
of	IN	O
therapy	NN	O
.	.	O

The	DT	O
latter	JJ	O
consist	NN	O
of	IN	O
those	DT	O
few	JJ	O
that	WDT	O
are	VBP	O
truly	RB	O
idiosyncratic	JJ	O
in	IN	O
nature	NN	O
or	CC	O
those	DT	O
that	WDT	O
occur	VBP	O
with	IN	O
such	JJ	O
low	JJ	O
frequency	NN	O
that	IN	O
a	DT	O
dose	JJ	O
relationship	NN	O
may	MD	O
be	VB	O
difficult	JJ	O
to	TO	O
discern	VB	O
.	.	O

Aseptic	JJ	O
technique	NN	O
must	MD	O
be	VB	O
strictly	RB	O
observed	VBN	O
in	IN	O
all	DT	O
handling	NN	O
since	IN	O
no	DT	O
preservative	NN	O
or	CC	O
bacteriostatic	JJ	O
agent	NN	O
is	VBZ	O
present	JJ	O
in	IN	O
AmBisome	NNP	O
or	CC	O
in	IN	O
the	DT	O
materials	NNS	O
specified	VBN	O
for	IN	O
reconstitution	NN	O
and	CC	O
dilution	NN	O
.	.	O

Patient	JJ	O
response	NN	O
should	MD	O
be	VB	O
monitored	VBN	O
and	CC	O
the	DT	O
dose	NN	O
adjusted	VBN	O
accordingly	RB	O
[	JJ	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
INFERGEN	NNP	O
monotherapy	NN	O
for	IN	O
the	DT	O
initial	JJ	O
treatment	NN	O
of	IN	O
chronic	JJ	O
HCV	NNP	O
infection	NN	O
is	VBZ	O
9	CD	DOS
mcg	NN	UNIT
administered	VBD	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
week	NN	FREQ
as	IN	O
a	DT	O
single	JJ	DOS
subcutaneous	JJ	UNIT
injection	NN	UNIT
for	IN	O
24	CD	PER
weeks	NNS	PER
[	JJ	O
see	VBP	O
Clinical	JJ	O
Studies	NNS	O
,	,	O
Medication	NNP	O
Guide	NNP	O
for	IN	O
instructions	NNS	O
]	NNP	O
.	.	O

Remove	NNP	O
and	CC	O
discard	VB	O
the	DT	O
cap	NN	O
on	IN	O
the	DT	O
bottom	NN	O
of	IN	O
the	DT	O
sterile	JJ	O
needle	JJ	O
cartridge	NN	O
by	IN	O
twisting	VBG	O
it	PRP	O
(	(	O
Figure	NNP	O
8	CD	O
)	)	O
.	.	O

Epicondylitis	NN	O
may	MD	O
be	VB	O
treated	VBN	O
by	IN	O
infiltrating	VBG	O
the	DT	O
preparation	NN	O
into	IN	O
the	DT	O
area	NN	O
of	IN	O
greatest	JJS	O
tenderness	NN	O
.	.	O

PROTONIX	NNP	O
I.V	NNP	O
.	.	O

If	IN	O
large	JJ	O
doses	NNS	O
(	(	O
greater	JJR	O
than	IN	O
5	CD	DOS
mL	NN	UNIT
)	)	O
are	VBP	O
required	VBN	O
and	CC	O
intramuscular	JJ	O
injection	NN	O
is	VBZ	O
chosen	VBN	O
,	,	O
it	PRP	O
is	VBZ	O
advisable	JJ	O
to	TO	O
administer	VB	O
Rhophylac	NNP	O
in	IN	O
divided	JJ	O
doses	NNS	O
at	IN	O
different	JJ	O
sites	NNS	O
.	.	O

10	CD	O

Bacteriologic	NNP	O
evaluation	NN	O
of	IN	O
Extra	NNP	O
pulmonary	JJ	O
tuberculosis	NN	O
may	MD	O
be	VB	O
limited	VBN	O
by	IN	O
the	DT	O
relative	JJ	O
inaccessibility	NN	O
of	IN	O
the	DT	O
sites	NNS	O
of	IN	O
disease	NN	O
.	.	O

If	IN	O
Korlym	NNP	O
treatment	NN	O
is	VBZ	O
interrupted	VBN	O
,	,	O
it	PRP	O
should	MD	O
be	VB	O
reinitiated	VBN	O
at	IN	O
the	DT	O
lowest	JJS	O
dose	NN	O
(	(	O
300	CD	DOS
mg	NN	UNIT
)	)	O
.	.	O

Patients	NNS	WHO
/	JJ	WHO
caregivers	NNS	WHO
should	MD	O
be	VB	O
instructed	VBN	O
not	RB	O
to	TO	O
discontinue	VB	O
INTUNIV®	NNP	O
without	IN	O
consulting	VBG	O
their	PRP$	O
health	NN	O
care	NN	O
provider	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
≥	JJ	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
respond	VB	WHO
adequately	RB	WHO
after	IN	WHO
2	CD	PER
weeks	NNS	PER
of	IN	O
therapy	NN	O
,	,	O
higher	JJR	O
strength	NN	O
may	MD	O
provide	VB	O
additional	JJ	O
asthma	NN	O
control	NN	O
.	.	O

Do	NNP	O
not	RB	O
inject	VB	O
in	IN	O
the	DT	O
gluteal	JJ	O
area	NN	O
or	CC	O
areas	NNS	O
where	WRB	O
there	EX	O
may	MD	O
be	VB	O
a	DT	O
major	JJ	O
nerve	NN	O
trunk	NN	O
.	.	O

If	IN	O
breakthrough	IN	O
bleeding	NN	O
occurs	NNS	O
following	VBG	O
missed	JJ	O
tablets	NNS	O
,	,	O
it	PRP	O
will	MD	O
usually	RB	O
be	VB	O
transient	JJ	O
and	CC	O
of	IN	O
no	DT	O
consequence	NN	O
.	.	O

For	IN	O
most	JJS	WHO
patients	NNS	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
50	CD	DOS
mg	NN	UNIT
taken	VBN	O
,	,	O
as	IN	O
needed	VBN	O
,	,	O
approximately	RB	O
1	CD	O
hour	NN	O
before	IN	O
sexual	JJ	O
activity	NN	O
.	.	O

Pediatric	JJ	WHO
patients	NNS	WHO
under	IN	WHO
30	CD	WHO
lbs	NN	WHO
.	.	O

Rifampin	NNP	O
is	VBZ	O
indicated	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
all	DT	O
forms	NNS	O
of	IN	O
tuberculosis	NN	O
.	.	O

Use	NNP	O
gentle	JJ	O
agitation	NN	O
during	IN	O
admixing	VBG	O
to	TO	O
minimize	VB	O
localized	JJ	O
concentration	NN	O
effects	NNS	O
;	:	O
shake	VB	O
bags	NNS	O
gently	RB	O
after	IN	O
each	DT	O
addition	NN	O
.	.	O

The	DT	O
serum	JJ	O
creatinine	NN	O
should	MD	O
represent	VB	O
a	DT	O
steady	JJ	O
state	NN	O
of	IN	O
renal	JJ	O
function	NN	O
:	:	O

After	IN	O
removing	VBG	O
the	DT	O
implant	NN	O
,	,	O
close	VB	O
the	DT	O
incision	NN	O
with	IN	O
a	DT	O
steri	JJ	O
-	:	O
strip	NN	O
and	CC	O
apply	VB	O
an	DT	O
adhesive	JJ	O
bandage	NN	O
.	.	O

Before	IN	O
administration	NN	O
,	,	O
read	JJ	O
CONTRAINDICATIONS	NNP	O
,	,	O
PRECAUTIONS	NNP	O
and	CC	O
ADVERSE	NNP	O
REACTIONS	NNP	O
sections	NNS	O
.	.	O

Central	NNP	O
nervous	JJ	O
system	NN	O
reactions	NNS	O
in	IN	O
intra	JJ	O
-	:	O
arterial	JJ	O
digital	JJ	O
angiography	NN	O
include	VBP	O
transient	JJ	O
ischemia	NN	O
attacks	NNS	O
(	(	O
1.6	CD	O
%	NN	O
)	)	O
and	CC	O
cerebral	JJ	O
infarctions	NNS	O
(	(	O
1.6	CD	O
%	NN	O
)	)	O
.	.	O

The	DT	O
two	CD	O
drugs	NNS	O
should	MD	O
be	VB	O
given	VBN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
,	,	O
starting	VBG	O
with	IN	O
no	DT	O
more	JJR	O
than	IN	O
one	CD	O
-	:	O
fifth	NN	O
(	(	O
20	CD	O
%	NN	O
)	)	O
to	TO	O
one	CD	DOS
-	:	O
fourth	JJ	O
(	(	O
25	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
previous	JJ	O
or	CC	O
recommended	JJ	FREQ
daily	JJ	FREQ
dosage	NN	O
of	IN	O
levodopa	NN	O
when	WRB	O
given	VBN	O
without	IN	O
LODOSYN	NNP	O
(	(	O
Carbidopa	NNP	O
)	)	O
.	.	O

The	DT	O
standard	JJ	O
initial	JJ	O
infusion	NN	O
rate	NN	O
given	VBN	O
in	IN	O
DOSAGE	NNP	O
AND	CC	O
ADMINISTRATION	NNP	O
:	:	O
Initial	JJ	O
Dosage	NNP	O
and	CC	O
DOSAGE	NNP	O
AND	NNP	O
ADMINISTRATION	NNP	O
:	:	O
Administration	NNP	O
;	:	O
Intravenous	NNP	O
Infusion	NNP	O
,	,	O
Table	NNP	O
8	CD	O
must	MD	O
be	VB	O
reduced	VBN	O
according	VBG	O
to	TO	O
the	DT	O
recommendations	NNS	O
given	VBN	O
in	IN	O
Table	JJ	O
6	CD	O
.	.	O

As	IN	O
with	IN	O
all	DT	O
intravenous	JJ	O
fluid	NN	O
therapy	NN	O
,	,	O
the	DT	O
primary	JJ	O
aim	NN	O
is	VBZ	O
to	TO	O
provide	VB	O
sufficient	JJ	O
water	NN	O
to	TO	O
compensate	VB	O
for	IN	O
insensible	JJ	O
,	,	O
urinary	JJ	O
and	CC	O
other	JJ	O
(	(	O
nasogastric	JJ	O
suction	NN	O
,	,	O
fistula	JJ	O
drainage	NN	O
,	,	O
diarrhea	NN	O
)	)	O
fluid	NN	O
losses	NNS	O
.	.	O

CALAN	NNP	O
120	CD	DOS
mg	NN	UNIT
tablets	NNS	UNIT
are	VBP	O
oval	JJ	O
,	,	O
brown	JJ	O
,	,	O
scored	VBD	O
,	,	O
film	NN	O
coated	VBD	O
,	,	O
with	IN	O
CALAN	NNP	O
120	CD	O
debossed	VBD	O
on	IN	O
one	CD	O
side	NN	O
,	,	O
supplied	VBN	O
as	IN	O
:	:	O

Resume	NNP	O
dosing	VBG	O
as	IN	O
according	VBG	O
to	TO	O
prescribing	VBG	O
recommendations	NNS	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Weight	NNP	O
based	VBN	O
dose	NN	O
of	IN	O
PRIFTIN	NNP	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
latent	JJ	O
tuberculosis	NN	O
infection	NN	O

The	DT	O
dosage	NN	O
of	IN	O
LUSEDRA	NNP	O
(	(	O
fospropofol	JJ	O
disodium	NN	O
injection	NN	O
)	)	O
is	VBZ	O
limited	VBN	O
by	IN	O
lower	JJR	O
and	CC	O
upper	JJ	O
weight	NN	O
bounds	NNS	O
of	IN	O
60	CD	O
kg	NNS	O
and	CC	O
90	CD	O
kg	NN	O
.	.	O

It	PRP	O
is	VBZ	O
not	RB	O
for	IN	O
oral	JJ	O
,	,	O
ophthalmic	JJ	O
,	,	O
or	CC	O
intravaginal	JJ	O
use	NN	O
.	.	O

Hoogstraten	NNP	O
et	CC	O
al	NNS	O
have	VBP	O
started	VBN	O
treatment	NN	O
with	IN	O
0.15	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
for	IN	O
7	CD	PER
days	NNS	PER
.	.	O

However	RB	O
,	,	O
liquids	NNS	O
may	MD	O
be	VB	O
taken	VBN	O
subsequent	JJ	O
to	TO	O
administration	NN	O
.	.	O

ACEON	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
creatinine	JJ	WHO
clearance	NN	WHO
<	VBD	WHO
30	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
.	.	O

For	IN	O
those	DT	O
fungal	JJ	O
infections	NNS	O
more	RBR	O
difficult	JJ	O
to	TO	O
eradicate	VB	O
,	,	O
such	JJ	O
as	IN	O
tinea	NN	O
pedis	NN	O
and	CC	O
tinea	NN	O
unguium	NN	O
,	,	O
a	DT	O
divided	VBN	O
dose	NN	O
of	IN	O
750	CD	DOS
mg	NN	UNIT
is	VBZ	O
recommended	VBN	O
.	.	O

If	IN	O
1	CD	DOS
mL	NN	UNIT
of	IN	O
diluent	NN	O
is	VBZ	O
used	VBN	O
,	,	O
the	DT	O
concentration	NN	O
of	IN	O
indomethacin	NN	O
in	IN	O
the	DT	O
solution	NN	O
will	MD	O
equal	VB	O
approximately	RB	O
0.1	CD	DOS
mg	NNS	UNIT
/	VBD	O
0.1	CD	DOS
mL	NN	UNIT
;	:	O
if	IN	O
2	CD	DOS
mL	NN	UNIT
of	IN	O
diluent	NN	O
are	VBP	O
used	VBN	O
,	,	O
the	DT	O
concentration	NN	O
of	IN	O
the	DT	O
solution	NN	O
will	MD	O
equal	VB	O
approximately	RB	O
0.05	CD	DOS
mg	NNS	UNIT
/	VBD	O
0.1	CD	DOS
mL	NN	UNIT
.	.	O

The	DT	O
intravenous	JJ	O
route	NN	O
is	VBZ	O
preferable	JJ	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
bacteremia	NN	WHO
,	,	O
bacterial	JJ	O
septicemia	NN	O
,	,	O
or	CC	O
other	JJ	O
severe	JJ	O
or	CC	O
life	NN	O
-	:	O
threatening	JJ	O
infections	NNS	O
,	,	O
or	CC	O
for	IN	O
patients	NNS	WHO
who	WP	WHO
may	MD	O
be	VB	O
poor	JJ	O
risks	NNS	O
because	IN	O
of	IN	O
lowered	JJ	O
resistance	NN	O
resulting	VBG	O
from	IN	O
such	JJ	O
debilitating	VBG	O
conditions	NNS	O
as	IN	O
malnutrition	NN	O
,	,	O
trauma	NN	O
,	,	O
surgery	NN	O
,	,	O
diabetes	VBZ	O
,	,	O
heart	NN	O
failure	NN	O
,	,	O
or	CC	O
malignancy	NN	O
,	,	O
particularly	RB	O
if	IN	O
shock	NN	O
is	VBZ	O
present	JJ	O
or	CC	O
impending	NN	O
.	.	O

If	IN	O
QTc	NNP	O
exceeds	VBZ	O
500	CD	DOS
milliseconds	NNS	UNIT
(	(	O
550	CD	DOS
msec	NN	UNIT
in	IN	O
patients	NNS	WHO
with	IN	WHO
ventricular	JJ	WHO
conduction	NN	WHO
abnormalities	NNS	WHO
)	)	WHO
,	,	O
TIKOSYN	NNP	O
therapy	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
and	CC	O
patients	NNS	O
should	MD	O
be	VB	O
carefully	RB	O
monitored	VBN	O
until	IN	O
QTc	NNP	O
returns	NNS	O
to	TO	O
baseline	VB	O
levels	NNS	O
.	.	O

Average	JJ	WHO
Adult	NNP	WHO
Dosage	NN	WHO
:	:	O
One	CD	DOS
100	CD	DOS
-	:	O
mg	NN	UNIT
tablet	NN	UNIT
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Consult	NNP	O
pump	VBP	O
manufacturer	NN	O
's	POS	O
literature	NN	O
for	IN	O
information	NN	O
on	IN	O
the	DT	O
appropriate	JJ	O
use	NN	O
and	CC	O
care	NN	O
of	IN	O
these	DT	O
devices	NNS	O
.	.	O

Table	JJ	O
4	CD	O
:	:	O
Dosage	NN	O
of	IN	O
ZINACEF	NNP	O
in	IN	O
Adults	NNP	WHO
With	IN	WHO
Reduced	NNP	WHO
Renal	NNP	WHO
Function	NNP	WHO

It	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
minimize	VB	O
the	DT	O
number	NN	O
of	IN	O
strengths	NNS	O
available	JJ	O
to	TO	O
patients	NNS	WHO
at	IN	WHO
any	DT	WHO
time	NN	WHO
to	TO	O
prevent	VB	O
confusion	NN	O
and	CC	O
possible	JJ	O
overdose	NN	O
.	.	O

The	DT	O
recommended	JJ	O
storage	NN	O
of	IN	O
unopened	JJ	O
BiCNU	NNP	O
(	(	O
carmustine	NN	O
)	)	O
vials	NNS	O
provides	VBZ	O
a	DT	O
stable	JJ	O
product	NN	O
for	IN	O
up	IN	O
to	TO	O
3	CD	O
years	NNS	O
.	.	O

The	DT	O
AtroPen®	NNP	O
(	(	O
atropine	NN	O
)	)	O
Auto	NNP	O
-	:	O
injector	NN	O
is	VBZ	O
indicated	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
poisoning	NN	O
by	IN	O
susceptible	JJ	O
organophosphorous	JJ	O
nerve	NN	O
agents	NNS	O
having	VBG	O
cholinesterase	NN	O
activity	NN	O
as	RB	O
well	RB	O
as	IN	O
organophosphorous	JJ	O
or	CC	O
carbamate	JJ	O
insecticides	NNS	O
.	.	O

Recommended	VBN	O
dosage	NN	O
is	VBZ	O
10	CD	DOS
to	TO	O
25	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
orally	RB	O
for	IN	O
4	CD	PER
to	TO	O
8	CD	PER
days	NNS	PER
.	.	O

Titrate	NNP	O
upward	NN	O
to	TO	O
maximum	VB	O
of	IN	O
40	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
as	IN	O
needed	VBN	O
to	TO	O
help	VB	O
achieve	VB	O
blood	NN	O
pressure	NN	O
goals	NNS	O
.	.	O

When	WRB	O
a	DT	O
dose	NN	O
is	VBZ	O
missed	VBN	O
,	,	O
administer	VBP	O
the	DT	O
next	JJ	O
injection	NN	O
of	IN	O
ARISTADA	NNP	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
.	.	O

If	IN	O
rapid	JJ	O
gastrointestinal	JJ	O
transit	NN	O
occurs	VBZ	O
,	,	O
there	EX	O
may	MD	O
be	VB	O
risk	NN	O
of	IN	O
incomplete	JJ	O
release	NN	O
of	IN	O
medication	NN	O
and	CC	O
medication	NN	O
residue	JJ	O
being	VBG	O
passed	VBN	O
in	IN	O
the	DT	O
stool	NN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
in	IN	O
a	DT	O
hospital	NN	O
for	IN	O
initiation	NN	O
and	CC	O
re	VB	O
-	:	O
initiation	NN	O
of	IN	O
therapy	NN	O
to	TO	O
evaluate	VB	O
the	DT	O
therapeutic	JJ	O
response	NN	O
and	CC	O
because	IN	O
too	RB	O
rapid	JJ	O
correction	NN	O
of	IN	O
hyponatremia	NN	O
can	MD	O
cause	VB	O
osmotic	JJ	O
demyelination	NN	O
resulting	VBG	O
in	IN	O
dysarthria	NN	O
,	,	O
mutism	NN	O
,	,	O
dysphagia	NN	O
,	,	O
lethargy	NN	O
,	,	O
affective	JJ	O
changes	NNS	O
,	,	O
spastic	JJ	O
quadriparesis	NN	O
,	,	O
seizures	NNS	O
,	,	O
coma	NN	O
and	CC	O
death	NN	O
.	.	O

Do	VB	O
not	RB	O
take	VB	O
the	DT	O
ORALAIR	NNP	O
tablet	NN	O
with	IN	O
food	NN	O
or	CC	O
beverage	NN	O
.	.	O

The	DT	O
intravenous	JJ	O
line	NN	O
must	MD	O
be	VB	O
flushed	VBN	O
thoroughly	RB	O
with	IN	O
at	IN	O
least	JJS	O
10	CD	DOS
mL	NN	UNIT
of	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
before	IN	O
and	CC	O
after	IN	O
administering	VBG	O
Neutrexin	NNP	O
(	(	O
trimetrexate	JJ	O
glucuronate	NN	O
inj	NN	O
)	)	O
.	.	O

Use	VB	O
the	DT	O
thumb	NN	O
and	CC	O
forefinger	NN	O
to	TO	O
hold	VB	O
firmly	RB	O
around	IN	O
both	CC	O
the	DT	O
glass	NN	O
syringe	NN	O
barrel	NN	O
and	CC	O
the	DT	O
Luer	NNP	O
-	:	O
Lok	NNP	O
adapter	NN	O
.	.	O

Ritalin	NNP	O
LA	NNP	O
and	CC	O
/	NNP	O
or	CC	O
their	PRP$	O
contents	NNS	O
should	MD	O
not	RB	O
be	VB	O
crushed	VBN	O
,	,	O
chewed	VBN	O
,	,	O
or	CC	O
divided	VBN	O
.	.	O

Store	NN	O
between	IN	O
20°	CD	O
to	TO	O
25°C	CD	O
(	(	O
68°	CD	O
to	TO	O
77°F	CD	O
)	)	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Dosing	NN	O
for	IN	O
Treatment	NNP	O
of	IN	O
Bleeding	NNP	O
Episodes	NNP	O

PAXIL	NNP	O
CR	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	FREQ
dose	NN	UNIT
,	,	O
usually	RB	O
in	IN	O
the	DT	O
morning	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WP	O
the	DT	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Adults	NNS	WHO
:	:	O
The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
4	CD	DOS
mg	NN	UNIT
(	(	O
two	CD	DOS
capsules	NNS	UNIT
)	)	O
followed	VBN	O
by	IN	O
2	CD	DOS
mg	NN	UNIT
(	(	O
one	CD	DOS
capsule	NN	UNIT
)	)	O
after	IN	O
each	DT	O
unformed	JJ	O
stool	NN	O
until	IN	O
diarrhea	NN	O
is	VBZ	O
controlled	VBN	O
,	,	O
after	IN	O
which	WDT	O
the	DT	O
dosage	NN	O
of	IN	O
IMODIUM®	NNP	O
(	(	O
loperamide	JJ	O
hcl	NN	O
)	)	O
should	MD	O
be	VB	O
reduced	VBN	O
to	TO	O
meet	VB	O
individual	JJ	O
requirements	NNS	O
.	.	O

PROLIXIN	NNP	O
(	(	O
fluphenazine	NN	O
)	)	O
Elixir	NNP	O
should	MD	O
be	VB	O
inspected	VBN	O
prior	RB	O
to	TO	O
use	VB	O
.	.	O

If	IN	O
more	JJR	O
than	IN	O
this	DT	O
is	VBZ	O
required	VBN	O
,	,	O
the	DT	O
system	NN	O
should	MD	O
be	VB	O
checked	VBN	O
.	.	O

Figure	NN	O
3	CD	O

DOSAGE	NN	O
SHOULD	MD	O
BE	VB	O
INDIVIDUALIZED	NNP	O
ACCORDING	NNP	O
TO	NNP	O
THE	NNP	O
NEEDS	NNP	O
AND	NNP	O
RESPONSE	NNP	O
OF	IN	O
THE	NNP	O
PATIENT	NNP	O
.	.	O

108	CD	O

CombiPatch	NN	O
should	MD	O
not	RB	O
be	VB	O
applied	VBN	O
to	TO	O
or	CC	O
near	IN	O
the	DT	O
breasts	NNS	O
.	.	O

Your	PRP$	O
health	NN	O
care	NN	O
provider	NN	O
will	MD	O
take	VB	O
a	DT	O
medical	JJ	O
and	CC	O
family	NN	O
history	NN	O
and	CC	O
examine	NN	O
you	PRP	O
before	IN	O
prescribing	VBG	O
oral	JJ	O
contraceptives	NNS	O
.	.	O

The	DT	O
smallest	JJS	O
dose	NN	O
and	CC	O
concentration	NN	O
required	VBN	O
to	TO	O
produce	VB	O
the	DT	O
desired	JJ	O
result	NN	O
should	MD	O
be	VB	O
administered	VBN	O
.	.	O

Dose	NNP	O
reduction	NN	O
may	MD	O
be	VB	O
necessary	JJ	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
liver	NN	WHO
impairment	NN	WHO
to	TO	O
maintain	VB	O
blood	NN	O
concentrations	NNS	O
within	IN	O
the	DT	O
recommended	JJ	O
target	NN	O
range	NN	O
(	(	O
See	NNP	O
WARNINGS	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

The	DT	O
dose	NN	O
should	MD	O
be	VB	O
increased	VBN	O
as	RB	O
rapidly	RB	O
as	IN	O
possible	JJ	O
to	TO	O
achieve	VB	O
the	DT	O
lowest	JJS	O
therapeutic	JJ	O
dose	NN	O
which	WDT	O
produces	VBZ	O
the	DT	O
desired	JJ	O
clinical	JJ	O
effect	NN	O
or	CC	O
the	DT	O
desired	JJ	O
range	NN	O
of	IN	O
plasma	JJ	O
concentrations	NNS	O
.	.	O

Cyclosporine	NNP	O
undergoes	VBZ	O
minimal	JJ	O
renal	JJ	O
elimination	NN	O
and	CC	O
its	PRP$	O
pharmacokinetics	NNS	O
do	VBP	O
not	RB	O
appear	VB	O
to	TO	O
be	VB	O
significantly	RB	O
altered	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
end	JJ	WHO
-	:	WHO
stage	NN	WHO
renal	JJ	WHO
disease	NN	WHO
who	WP	WHO
receive	VBP	WHO
routine	JJ	WHO
hemodialysis	NN	WHO
treatments	NNS	WHO
(	(	O
See	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
)	)	O
.	.	O

This	DT	O
solution	NN	O
should	MD	O
be	VB	O
replaced	VBN	O
each	DT	O
time	NN	O
the	DT	O
heparin	NN	O
lock	NN	O
is	VBZ	O
used	VBN	O
.	.	O

Aminosyn	NNP	O
II	NNP	O
in	IN	O
the	DT	O
2000	CD	DOS
mL	NN	UNIT
flexible	JJ	O
Pharmacy	NNP	O
Bulk	NNP	O
Package	NNP	O
is	VBZ	O
designed	VBN	O
for	IN	O
use	NN	O
with	IN	O
manual	JJ	O
,	,	O
gravity	NN	O
flow	NN	O
operations	NNS	O
and	CC	O
automated	VBN	O
gravimetric	JJ	O
compounding	NN	O
devices	NNS	O
for	IN	O
preparing	VBG	O
intravenous	JJ	O
nutritional	JJ	O
admixtures	NNS	O
.	.	O

Inject	VB	O
the	DT	O
entire	JJ	O
contents	NNS	O
of	IN	O
the	DT	O
syringe	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O

(	(	O
See	VB	O
Clinical	NNP	O
Studies	NNPS	O
for	IN	O
doses	NNS	O
used	VBN	O
in	IN	O
U.S.	NNP	O
Clinical	NNP	O
studies	NNS	O
.	.	O
)	)	O

For	IN	O
adults	NNS	WHO
,	,	O
4	CD	DOS
drops	NNS	UNIT
of	IN	O
the	DT	O
suspension	NN	O
should	MD	O
be	VB	O
instilled	VBN	O
into	IN	O
the	DT	O
affected	JJ	O
ear	JJ	O
3	CD	FREQ
or	CC	O
4	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Increases	NNS	O
may	MD	O
be	VB	O
made	VBN	O
if	IN	O
indicated	VBN	O
.	.	O

NutreStore™	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
cotherapy	NN	O
with	IN	O
recombinant	JJ	O
human	JJ	O
growth	NN	O
hormone	NN	O
[	NNP	O
see	VBP	O
the	DT	O
package	NN	O
insert	NN	O
for	IN	O
somatotropin	NN	O
(	(	O
rDNA	JJ	O
origin	NN	O
)	)	O
for	IN	O
injection	NN	O
for	IN	O
full	JJ	O
prescribing	NN	O
information	NN	O
]	NN	O
followed	VBN	O
by	IN	O
continued	JJ	O
NutreStore™	NNP	O
for	IN	O
up	RB	PER
to	TO	PER
16	CD	PER
weeks	NNS	PER
.	.	O

Due	JJ	O
to	TO	O
the	DT	O
half	NN	O
-	:	O
life	NN	O
of	IN	O
oral	JJ	O
aripiprazole	NN	O
,	,	O
it	PRP	O
may	MD	O
take	VB	O
up	RP	PER
to	TO	PER
2	CD	PER
weeks	NNS	PER
to	TO	O
fully	RB	O
assess	JJ	O
tolerability	NN	O
.	.	O

Because	IN	O
of	IN	O
the	DT	O
long	JJ	O
terminal	JJ	O
elimination	NN	O
half	NN	O
-	:	O
life	NN	O
of	IN	O
sotalol	NN	O
,	,	O
dosing	VBG	O
on	IN	O
more	JJR	O
than	IN	O
a	DT	O
BID	NNP	O
regimen	NNS	O
is	VBZ	O
usually	RB	O
not	RB	O
necessary	JJ	O
.	.	O

If	IN	O
significant	JJ	O
withdrawal	NN	O
symptoms	NNS	O
develop	VB	O
,	,	O
reinstitute	VB	O
the	DT	O
previous	JJ	O
stable	JJ	O
dosing	NN	O
schedule	NN	O
.	.	O

The	DT	O
initial	JJ	O
infusion	NN	O
rate	NN	O
should	MD	O
not	RB	O
exceed	VB	O
30	CD	DOS
mg	JJ	UNIT
/	NNP	O
min	NN	O
.	.	O

When	WRB	O
initiatin	NN	O
g	VBD	O
a	DT	O
weak	JJ	O
CYP3A4	NNP	O
inhibit	NN	O
or	CC	O
in	IN	O
a	DT	O
patient	NN	O
already	RB	O
taking	VBG	O
JUXTAPID	NNP	O
10	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
or	CC	O
more	JJR	O
,	,	O
decrease	VB	O
the	DT	O
dose	NN	O
of	IN	O
JUXTAPID	NNP	O
by	IN	O
half	NN	O
;	:	O
patients	NNS	WHO
taking	VBG	WHO
JUXTAPID	NNP	WHO
5	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
may	MD	O
continue	VB	O
with	IN	O
the	DT	O
same	JJ	O
dosage	NN	O
.	.	O

The	DT	O
patient	NN	O
should	MD	O
be	VB	O
instructed	VBN	O
to	TO	O
use	VB	O
a	DT	O
back	NN	O
-	:	O
up	IN	O
method	NN	O
of	IN	O
birth	NN	O
control	NN	O
such	JJ	O
as	IN	O
a	DT	O
condom	NN	O
or	CC	O
spermicide	NN	O
if	IN	O
she	PRP	O
has	VBZ	O
sex	NN	O
in	IN	O
the	DT	O
seven	CD	O
(	(	O
7	CD	O
)	)	O
days	NNS	O
after	IN	O
missing	VBG	O
pills	NNS	O
.	.	O

To	TO	O
measure	VB	O
ERPF	NNP	O
,	,	O
the	DT	O
concentration	NN	O
of	IN	O
PAH	NNP	O
in	IN	O
the	DT	O
plasma	NN	O
should	MD	O
be	VB	O
maintained	VBN	O
at	IN	O
2	CD	DOS
mg	NNS	UNIT
per	IN	O
100	CD	DOS
mL	NN	UNIT
,	,	O
which	WDT	O
can	MD	O
be	VB	O
achieved	VBN	O
with	IN	O
a	DT	O
priming	VBG	O
dose	NN	O
of	IN	O
6	CD	DOS
to	TO	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
and	CC	O
an	DT	O
infusion	NN	O
dose	NN	O
of	IN	O
10	CD	DOS
to	TO	O
24	CD	DOS
mg	NNS	UNIT
/	JJ	O
min	NN	O
.	.	O

If	IN	O
PEGASYS	NNP	O
monotherapy	NN	O
is	VBZ	O
used	VBN	O
for	IN	O
treatment	NN	O
of	IN	O
CHC	NNP	O
,	,	O
the	DT	O
recommended	VBN	O
PEGASYS	NNP	O
dosage	NN	O
is	VBZ	O
180	CD	DOS
mcg	NN	UNIT
via	IN	O
subcutaneous	JJ	O
injection	NN	O
in	IN	O
thigh	NN	WHO
or	CC	WHO
abdomen	NNS	WHO
once	RB	FREQ
weekly	JJ	FREQ
for	IN	O
48	CD	PER
weeks	NNS	PER
.	.	O

Dose	NNP	O
increases	NNS	O
should	MD	O
only	RB	O
be	VB	O
made	VBN	O
if	IN	O
the	DT	O
previous	JJ	O
dosage	NN	O
is	VBZ	O
well	RB	O
tolerated	VBN	O
and	CC	O
at	IN	O
intervals	NNS	O
of	IN	O
no	DT	O
less	JJR	O
than	IN	O
3	CD	PER
days	NNS	PER
to	TO	O
allow	VB	O
serum	JJ	O
theophylline	NN	O
concentrations	NNS	O
to	TO	O
reach	VB	O
the	DT	O
new	JJ	O
steady	JJ	O
-	:	O
state	NN	O
.	.	O

The	DT	O
following	JJ	O
table	NN	O
provides	VBZ	O
suggested	JJ	O
doses	NNS	O
of	IN	O
oral	JJ	O
amiodarone	NN	O
to	TO	O
be	VB	O
initiated	VBN	O
after	IN	O
varying	VBG	O
durations	NNS	O
of	IN	O
intravenous	JJ	O
amiodarone	NN	O
administration	NN	O
.	.	O

Temporarily	RB	O
suspend	VB	O
Avastin	NNP	O
for	IN	O
:	:	O

5	CD	WHO
years	NNS	WHO
or	CC	WHO
older	JJR	WHO
†	NNS	WHO
½	VBP	WHO
to	TO	WHO
1	CD	WHO
tablespoonful	JJ	WHO
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
(	(	O
7.515	CD	O
.	.	O

If	IN	O
satisfactory	JJ	O
response	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
achieved	VBN	O
at	IN	O
300	CD	DOS
mg	NN	UNIT
q8h	NN	O
,	,	O
and	CC	O
the	DT	O
patient	NN	O
tolerates	VBZ	O
MEXITIL	NNP	O
(	(	O
mexiletine	VB	O
hcl	NN	O
)	)	O
well	RB	O
,	,	O
a	DT	O
dose	NN	O
of	IN	O
400	CD	DOS
mg	NNS	UNIT
q8h	NN	O
may	MD	O
be	VB	O
tried	VBN	O
.	.	O

Concomitant	JJ	O
Therapy	NNP	O
–	NNP	O
Echothiophate	NNP	O
iodide	NN	O
for	IN	O
ophthalmic	JJ	O
solution	NN	O
may	MD	O
be	VB	O
used	VBN	O
concomitantly	RB	O
with	IN	O
epinephrine	NN	O
,	,	O
a	DT	O
carbonic	JJ	O
anhydrase	NN	O
inhibitor	NN	O
,	,	O
or	CC	O
both	DT	O
.	.	O

To	TO	O
diagnose	VB	O
erectile	JJ	O
dysfunction	NN	O
(	(	O
pharmacologic	JJ	O
testing	NN	O
)	)	O
,	,	O
inject	JJ	O
CAVERJECT	NNP	O
IMPULSE	NNP	O
intracavernosally	RB	O
and	CC	O
monitor	NN	O
patients	NNS	O
for	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
an	DT	O
erection	NN	O
.	.	O

If	IN	O
device	NN	O
is	VBZ	O
not	RB	O
indwelling	JJ	O
,	,	O
prime	JJ	O
and	CC	O
make	VB	O
venipuncture	NN	O
.	.	O

Typical	JJ	O
usage	NN	O
for	IN	O
each	DT	O
treatment	NN	O
session	NN	O
is	VBZ	O
specific	JJ	O
to	TO	O
the	DT	O
site	NN	O
as	RB	O
well	RB	O
amount	NN	O
of	IN	O
augmentation	NN	O
or	CC	O
rhytids	NNS	O
correction	NN	O
desired	VBD	O
.	.	O

Initiation	NN	O
of	IN	O
therapy	NN	O
at	IN	O
higher	JJR	O
doses	NNS	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

A	DT	O
guide	NN	O
for	IN	O
dosing	VBG	O
NUWIQ	NNP	O
for	IN	O
the	DT	O
on	IN	O
-	:	O
demand	NN	O
treatment	NN	O
and	CC	O
control	NN	O
of	IN	O
bleeding	VBG	O
episodes	NNS	O
is	VBZ	O
provided	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
.	.	O

If	IN	O
DDAVP	NNP	O
Injection	NNP	O
(	(	O
desmopressin	JJ	O
acetate	NN	O
injection	NN	O
)	)	O
4	CD	DOS
mcg	NN	UNIT
/	NNP	O
mL	NN	O
is	VBZ	O
used	VBN	O
preoperatively	RB	O
,	,	O
it	PRP	O
should	MD	O
be	VB	O
administered	VBN	O
30	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
the	DT	O
scheduled	JJ	O
procedure	NN	O
.	.	O

Do	VB	O
not	RB	O
allow	VB	O
the	DT	O
suspension	NN	O
to	TO	O
settle	VB	O
prior	JJ	O
to	TO	O
withdrawal	NN	O
of	IN	O
the	DT	O
dose	NN	O
.	.	O

Alfentanil	NNP	O
HCl	NNP	O
injection	NN	O
,	,	O
USP	NNP	O
is	VBZ	O
supplied	VBN	O
in	IN	O
individually	RB	O
sealed	VBN	O
dosage	NN	O
forms	NNS	O
which	WDT	O
pose	VBP	O
no	DT	O
known	VBN	O
risk	NN	O
to	TO	O
health	NN	O
care	NN	O
providers	NNS	O
having	VBG	O
incidental	JJ	O
contact	NN	O
.	.	O

Instead	RB	O
,	,	O
patients	NNS	WHO
who	WP	WHO
feel	VBP	WHO
the	DT	WHO
need	NN	WHO
for	IN	O
supplemental	JJ	O
dosing	NN	O
should	MD	O
be	VB	O
seen	VBN	O
and	CC	O
evaluated	VBN	O
promptly	RB	O
.	.	O

Patients	NNS	O
previously	RB	O
on	IN	O
intranasal	NN	O
DDAVP	NNP	O
(	(	O
desmopressin	JJ	O
acetate	NN	O
tablets	NNS	O
)	)	O
therapy	NN	O
should	MD	O
begin	VB	O
tablet	NN	O
therapy	NN	O
twelve	NN	O
hours	NNS	O
after	IN	O
the	DT	O
last	JJ	O
intranasal	NN	O
dose	NN	O
.	.	O

Compatibility	NN	O
INFORMATION	NNP	O

Unused	JJ	O
solution	NN	O
should	MD	O
be	VB	O
discarded	VBN	O
.	.	O

The	DT	O
recommended	JJ	O
maintenance	NN	O
dose	NN	O
of	IN	O
Zn	NNP	O
-	:	O
DTPA	NNP	O
(	(	O
pentetate	VB	O
zinc	NN	O
trisodium	NN	O
injection	NN	O
)	)	O
is	VBZ	O
1.0	CD	DOS
gram	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
administered	VBD	O
intravenously	RB	O
.	.	O

The	DT	O
dry	JJ	O
powder	NN	O
should	MD	O
be	VB	O
stored	VBN	O
at	IN	O
a	DT	O
temperature	NN	O
below	IN	O
25°C	CD	O
(	(	O
77°F	CD	O
)	)	O
.	.	O

11	CD	O
.	.	O

Infants	NNS	WHO
may	MD	O
be	VB	O
given	VBN	O
4,000	CD	DOS
lipase	JJ	UNIT
units	NNS	UNIT
(	(	O
one	CD	DOS
capsule	NN	UNIT
)	)	O
per	IN	O
120	CD	DOS
mL	NN	UNIT
of	IN	O
formula	NN	O
or	CC	O
breast	NN	O
-	:	O
feeding	NN	O
.	.	O

Routine	JJ	O
booster	NN	O
immunization	NN	O
against	IN	O
tetanus	NN	O
and	CC	O
diphtheria	NN	O
is	VBZ	O
recommended	VBN	O
in	IN	O
children	NNS	WHO
11	CD	WHO
-	:	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
every	DT	WHO
10	CD	WHO
years	NNS	WHO
thereafter.1	RB	WHO

Initial	JJ	O
dosage	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
daily	RB	FREQ
in	IN	O
two	CD	DOS
to	TO	O
four	CD	DOS
doses	NNS	UNIT
.	.	O

Pediatric	JJ	WHO
patients	NNS	WHO
weighing	VBG	WHO
over	IN	WHO
40	CD	WHO
kg	NNS	WHO
and	CC	WHO
with	IN	WHO
normal	JJ	WHO
renal	JJ	WHO
function	NN	WHO
should	MD	O
receive	VB	O
the	DT	O
adult	NN	WHO
dose	NN	O
.	.	O

If	IN	O
refrigerated	VBN	O
,	,	O
allow	VB	O
the	DT	O
vial	NN	O
of	IN	O
lyophilized	JJ	O
BeneFIX	NNP	O
and	CC	O
the	DT	O
pre	JJ	O
-	:	O
filled	VBN	O
diluent	JJ	O
syringe	NN	O
to	TO	O
reach	VB	O
room	NN	O
temperature	NN	O
.	.	O

This	DT	O
medication	NN	O
should	MD	O
be	VB	O
administered	VBN	O
once	RB	FREQ
every	DT	FREQ
3	CD	FREQ
months	NNS	FREQ
.	.	O

[	NN	O
If	IN	O
switching	VBG	O
directly	RB	O
from	IN	O
another	DT	O
oral	JJ	O
contraceptive	NN	O
,	,	O
the	DT	O
first	JJ	O
white	JJ	O
tablet	NN	O
should	MD	O
be	VB	O
taken	VBN	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
menstruation	NN	O
which	WDT	O
begins	VBZ	O
after	IN	O
the	DT	O
last	JJ	O
ACTIVE	NNP	O
tablet	NN	O
of	IN	O
the	DT	O
previous	JJ	O
product	NN	O
.	.	O
]	NN	O

Adults	NNS	WHO
usually	RB	O
require	VBP	O
25	CD	DOS
to	TO	O
50	CD	DOS
mg	NN	UNIT
for	IN	O
nighttime	NN	O
,	,	O
presurgical	JJ	O
,	,	O
or	CC	O
obstetrical	JJ	O
sedation	NN	O
.	.	O

There	EX	O
are	VBP	O
no	DT	O
data	NNS	O
available	JJ	O
with	IN	O
use	NN	O
of	IN	O
Tekturna	NNP	O
HCT	NNP	O
with	IN	O
angiotensin	JJ	O
-	:	O
converting	VBG	O
enzyme	JJ	O
inhibitors	NNS	O
or	CC	O
beta	NN	O
blockers	NNS	O
[	VBP	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

Additionally	RB	O
,	,	O
when	WRB	O
other	JJ	O
aluminum	NN	O
-	:	O
adsorbed	NN	O
vaccines	NNS	O
have	VBP	O
been	VBN	O
administered	VBN	O
subcutaneously	RB	O
,	,	O
an	DT	O
increased	JJ	O
incidence	NN	O
of	IN	O
local	JJ	O
reactions	NNS	O
including	VBG	O
subcutaneous	JJ	O
nodules	NNS	O
has	VBZ	O
been	VBN	O
observed	VBN	O
.	.	O

The	DT	O
appropriate	JJ	O
INTRON	NNP	O
A	NNP	O
dose	NN	O
should	MD	O
then	RB	O
be	VB	O
withdrawn	VBN	O
and	CC	O
injected	VBN	O
intramuscularly	RB	O
,	,	O
subcutaneously	RB	O
,	,	O
or	CC	O
intralesionally	RB	O
(	(	O
see	VB	O
MEDICATION	NNP	O
GUIDE	NNP	O
for	IN	O
detailed	JJ	O
instructions	NNS	O
)	)	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Recommended	VBN	O
dosages	NNS	O
for	IN	O
NAPROSYN	NNP	O
Tablets	NNP	O
,	,	O
ANAPROX	NNP	O
DS	NNP	O
,	,	O
and	CC	O
EC	NNP	O
-	:	O
NAPROSYN	NN	O

If	IN	O
doses	VBZ	O
other	JJ	O
than	IN	O
these	DT	O
are	VBP	O
required	VBN	O
,	,	O
DDAVP®	NNP	O
Injection	NNP	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

Alternation	NN	O
with	IN	O
other	JJ	O
forms	NNS	O
of	IN	O
treatment	NN	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
the	DT	O
long	JJ	O
term	NN	O
management	NN	O
of	IN	O
patients	NNS	WHO
with	IN	WHO
this	DT	WHO
life	NN	WHO
long	JJ	WHO
disease	NN	WHO
.	.	O

Before	IN	O
and	CC	O
after	IN	O
injection	NN	O
,	,	O
the	DT	O
septum	NN	O
of	IN	O
the	DT	O
vial	NN	O
should	MD	O
be	VB	O
wiped	VBN	O
with	IN	O
rubbing	VBG	O
alcohol	NN	O
or	CC	O
an	DT	O
alcoholic	JJ	O
antiseptic	JJ	O
solution	NN	O
to	TO	O
prevent	VB	O
contamination	NN	O
of	IN	O
the	DT	O
contents	NNS	O
by	IN	O
repeated	VBN	O
needle	JJ	O
insertions	NNS	O
.	.	O

Amlodipine	NNP	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
of	IN	O
hypertension	NN	O
in	IN	O
once	RB	O
-	:	O
daily	JJ	FREQ
doses	NNS	O
of	IN	O
2.5	CD	DOS
to	TO	O
10	CD	DOS
mg	NNS	UNIT
while	IN	O
benazepril	NN	O
is	VBZ	O
effective	JJ	O
in	IN	O
doses	NNS	O
of	IN	O
10	CD	DOS
to	TO	O
80	CD	DOS
mg	NNS	UNIT
.	.	O

In	IN	O
general	JJ	O
,	,	O
levothyroxine	JJ	O
therapy	NN	O
should	MD	O
be	VB	O
instituted	VBN	O
at	IN	O
full	JJ	O
replacement	NN	O
doses	NNS	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
.	.	O

(	(	O
See	VB	O
Special	JJ	O
Monitoring	NNP	O
of	IN	O
Psoriasis	NNP	WHO
Patients	NNPS	WHO
)	)	WHO

Avoid	NNP	O
contact	NN	O
with	IN	O
water	NN	O
,	,	O
such	JJ	O
as	IN	O
bathing	NN	O
,	,	O
swimming	NN	O
or	CC	O
showering	NN	O
.	.	O

Haloperidol	NNP	O
decanoate	NN	O
is	VBZ	O
usually	RB	O
administered	VBN	O
monthly	RB	O
or	CC	O
every	DT	FREQ
4	CD	FREQ
weeks	NNS	FREQ
.	.	O

Figure	NN	O
2	CD	O

Swallow	JJ	O
capsules	NNS	O
whole	VBP	O
.	.	O

Systematic	JJ	O
evaluation	NN	O
of	IN	O
continuing	VBG	O
Lexapro	NNP	O
10	CD	DOS
or	CC	O
20	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
in	IN	O
adults	NNS	WHO
patients	NNS	WHO
with	IN	WHO
major	JJ	WHO
depressive	JJ	WHO
disorder	NN	WHO
who	WP	WHO
responded	VBD	WHO
while	IN	WHO
taking	VBG	WHO
Lexapro	NNP	WHO
during	IN	WHO
an	DT	WHO
8	CD	WHO
-	:	O
week	NN	PER
,	,	O
acute	JJ	O
-	:	O
treatment	NN	O
phase	NN	O
demonstrated	VBD	O
a	DT	O
benefit	NN	O
of	IN	O
such	JJ	O
maintenance	NN	O
treatment	NN	O
[	NNP	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

Concomitant	NNP	O
use	NN	O
of	IN	O
appropriate	JJ	O
topical	JJ	O
agents	NNS	O
is	VBZ	O
usually	RB	O
required	VBN	O
,	,	O
particularly	RB	O
in	IN	O
treatment	NN	O
of	IN	O
tinea	NN	O
pedis	NN	O
.	.	O

DISPOSE	NNP	O
of	IN	O
the	DT	O
needle	NN	O
.	.	O

The	DT	O
minimum	JJ	O
quantity	NN	O
should	MD	O
be	VB	O
used	VBN	O
for	IN	O
the	DT	O
shortest	JJS	O
duration	NN	O
to	TO	O
achieve	VB	O
the	DT	O
desired	JJ	O
therapeutic	JJ	O
benefit	NN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
-	:	O
Special	JJ	O
Populations	NNS	O
,	,	O
Geriatrics	NNP	O
(	(	O
>	JJ	WHO
65	CD	WHO
Years	NNS	WHO
Of	IN	WHO
Age	NNP	WHO
)	)	WHO
)	)	WHO
.	.	O

1	CD	O
.	.	O

In	IN	O
anuric	JJ	WHO
patients	NNS	WHO
,	,	O
limit	VBP	O
the	DT	O
mean	JJ	O
infusion	NN	O
rate	NN	O
to	TO	O
1	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	FW	O
/	JJ	O
min	NN	O
.	.	O

Other	JJ	O
dose	JJ	O
regimens	NNS	O
or	CC	O
durations	NNS	O
of	IN	O
therapy	NN	O
were	VBD	O
not	RB	O
evaluated	VBN	O
in	IN	O
these	DT	O
trials	NNS	O
.	.	O

Treatment	NN	O
with	IN	O
Prussian	JJ	O
blue	NN	O
insoluble	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
after	IN	O
contamination	NN	O
is	VBZ	O
suspected	VBN	O
.	.	O

A	DT	O
450	CD	DOS
-	:	O
mg	NN	UNIT
dose	NN	UNIT
of	IN	O
tositumomab	NN	O
should	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
previously	RB	O
described	VBN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Decay	NNP	O
Correction	NNP	O
Factor	NNP	O
Table	NNP	O

Dosage	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
downward	RB	O
in	IN	O
the	DT	O
event	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
(	(	O
including	VBG	O
hypoglycemia	NN	O
)	)	O
and	CC	O
/	$	O
or	CC	O
IGF	NNP	O
-	:	O
1	CD	O
levels	NNS	O
that	WDT	O
are	VBP	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
3	CD	O
standard	JJ	O
deviations	NNS	O
above	IN	O
the	DT	O
normal	JJ	O
reference	NN	O
range	NN	O
for	IN	O
IGF	NNP	O
-	:	O
1	CD	O
.	.	O

Energy	NNP	O
intake	NN	O
may	MD	O
be	VB	O
supplemented	VBN	O
with	IN	O
intravenous	JJ	O
fat	JJ	O
emulsion	NN	O
.	.	O

90	CD	O

In	IN	O
heavily	RB	WHO
contaminated	VBN	WHO
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
dialysis	NN	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
increase	VB	O
the	DT	O
rate	NN	O
of	IN	O
elimination	NN	O
.	.	O

5	CD	DOS
days	NNS	UNIT

The	DT	O
dose	NN	O
is	VBZ	O
50	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
7	CD	PER
to	TO	O
14	CD	PER
days	NNS	PER
after	IN	O
symptom	JJ	O
resolution	NN	O
.	.	O

Prior	RB	O
to	TO	O
inserting	VBG	O
PROBUPHINE	NNP	O
,	,	O
carefully	RB	O
read	VB	O
the	DT	O
insertion	NN	O
instructions	NNS	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
full	JJ	O
prescribing	NN	O
information	NN	O
.	.	O

The	DT	O
Gengraf®	NNP	O
dose	NN	O
is	VBZ	O
subsequently	RB	O
adjusted	VBN	O
to	TO	O
achieve	VB	O
a	DT	O
pre	NN	O
-	:	O
defined	VBN	O
cyclosporine	JJ	O
blood	NN	O
concentration	NN	O
.	.	O

Infants	NNS	WHO
may	MD	O
be	VB	O
given	VBN	O
3,000	CD	DOS
lipase	JJ	UNIT
units	NNS	UNIT
(	(	O
one	CD	DOS
capsule	NN	UNIT
)	)	O
per	IN	O
120	CD	DOS
mL	NN	UNIT
of	IN	O
formula	NN	O
or	CC	O
breast	NN	O
-	:	O
feeding	NN	O
.	.	O

Deflux	NNP	O
is	VBZ	O
injected	VBN	O
submucosally	RB	O
in	IN	O
the	DT	O
urinary	JJ	O
bladder	NN	O
in	IN	O
close	JJ	O
proximity	NN	O
to	TO	O
the	DT	O
ureteral	JJ	O
orifice	NN	O
.	.	O

The	DT	O
last	JJ	O
tablet	NN	O
in	IN	O
the	DT	O
dispenser	NN	O
will	MD	O
then	RB	O
be	VB	O
taken	VBN	O
on	IN	O
a	DT	O
Saturday	NNP	O
,	,	O
followed	VBN	O
by	IN	O
no	DT	O
tablets	NNS	O
for	IN	O
a	DT	O
week	NN	PER
(	(	O
7	CD	O
days	NNS	O
)	)	O
.	.	O

OR	CC	O

For	IN	O
left	JJ	O
ventriculography	NN	O
,	,	O
the	DT	O
usual	JJ	O
adult	NN	WHO
dose	NN	O
in	IN	O
a	DT	O
single	JJ	O
injection	NN	O
is	VBZ	O
45	CD	DOS
mL	NN	UNIT
(	(	O
range	NN	O
35	CD	DOS
-	:	O
45	CD	DOS
mL	NN	UNIT
)	)	O
and	CC	O
repeated	VBN	O
as	IN	O
necessary	JJ	O
.	.	O

SERUM	NNP	O
ELECTROLYTES	NNP	O
SHOULD	NNP	O
BE	NNP	O
MONITORED	NNP	O
AS	NNP	O
INDICATED	NNP	O
.	.	O

Example	NN	O
:	:	O
17.3	CD	O
kBq	NN	O
of	IN	O
Sr	NNP	O
82	CD	O
;	:	O
1850	CD	DOS
MBq	NNP	UNIT
of	IN	O
Rb	NNP	O
82	CD	O

Any	DT	O
vial	NN	O
of	IN	O
Nabi	NNP	O
-	:	O
HB	NNP	O
,	,	O
Hepatitis	NNP	O
B	NNP	O
Immune	NNP	O
Globulin	NNP	O
(	(	O
Human	NNP	O
)	)	O
that	WDT	O
has	VBZ	O
been	VBN	O
entered	VBN	O
should	MD	O
be	VB	O
used	VBN	O
promptly	RB	O
.	.	O

Symptoms	NNP	O
usually	RB	O
subside	VBP	O
in	IN	O
1	CD	O
to	TO	O
3	CD	O
hours	NNS	O
.	.	O

Children	NNP	WHO
weighing	VBG	WHO
100	CD	WHO
pounds	NNS	WHO
or	CC	WHO
more	JJR	WHO
should	MD	O
receive	VB	O
the	DT	O
adult	NN	WHO
dose	NN	O
.	.	O

Administer	RB	O
90	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
after	IN	O
an	DT	O
ACS	NNP	O
event	NN	O
.	.	O

Clonazepam	NNP	O
is	VBZ	O
available	JJ	O
as	IN	O
a	DT	O
tablet	NN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
provided	VBN	O
specific	JJ	O
information	NN	O
on	IN	O
use	NN	O
of	IN	O
product	NN	O
.	.	O

Drugs	NNS	O
That	WDT	O
are	VBP	O
Physically	NNP	O
Incompatible	NNP	O
in	IN	O
Solution	NNP	O
with	IN	O
ALOPRIM™	NNP	O
(	(	O
allopurinol	JJ	O
sodium	NN	O
for	IN	O
injection	NN	O
)	)	O
(	(	O
allopurinol	JJ	O
sodium	NN	O
)	)	O
for	IN	O
Injection	NN	O

daily	RB	FREQ
as	IN	O
recommended	VBN	O
by	IN	O
the	DT	O
physician	NN	O
.	.	O

96	CD	O

VISUDYNE	NNP	O
may	MD	O
precipitate	VB	O
in	IN	O
saline	JJ	O
solutions	NNS	O
.	.	O

Individual	JJ	O
patients	NNS	O
may	MD	O
respond	VB	O
to	TO	O
higher	JJR	O
doses	NNS	O
of	IN	O
up	IN	O
to	TO	O
480	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Procedures	NNS	O
for	IN	O
proper	JJ	O
handling	NN	O
and	CC	O
disposal	NN	O
of	IN	O
anticancer	NN	O
drugs	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

If	IN	O
a	DT	O
patient	NN	O
is	VBZ	O
unable	JJ	O
to	TO	O
stop	VB	O
smoking	NN	O
by	IN	O
the	DT	O
fourth	JJ	O
week	NN	O
of	IN	O
therapy	NN	O
,	,	O
treatment	NN	O
should	MD	O
probably	RB	O
be	VB	O
discontinued	VBN	O
.	.	O

During	IN	O
use	NN	O
,	,	O
a	DT	O
single	JJ	DOS
reservoir	NN	UNIT
(	(	O
syringe	NN	O
)	)	O
of	IN	O
undiluted	JJ	O
Remodulin	NNP	O
can	MD	O
be	VB	O
administered	VBN	O
up	IN	O
to	TO	O
72	CD	O
hours	NNS	O
at	IN	O
37°C	CD	O
.	.	O

The	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
the	DT	O
Ga	NNP	O
68	CD	O
dotatate	NN	O
injection	NN	O
drug	NN	O
product	NN	O
prepared	VBN	O
from	IN	O
the	DT	O
NETSPOT	NNP	O
kit	NN	O
has	VBZ	O
been	VBN	O
established	VBN	O
only	RB	O
when	WRB	O
using	VBG	O
a	DT	O
Ga	NNP	O
68	CD	O
chloride	NN	O
solution	NN	O
eluted	VBN	O
from	IN	O
the	DT	O
GalliaPharm	NNP	O
generator	NN	O
.	.	O

Immediately	RB	O
upon	IN	O
opening	VBG	O
the	DT	O
blister	NN	O
,	,	O
using	VBG	O
dry	JJ	O
hands	NNS	O
,	,	O
remove	VB	O
tablet	NN	O
and	CC	O
place	NN	O
entire	JJ	O
ZYPREXA	NNP	O
ZYDIS	NNP	O
in	IN	O
the	DT	O
mouth	NN	O
.	.	O

In	IN	O
an	DT	WHO
occasional	JJ	WHO
patient	NN	WHO
,	,	O
the	DT	O
400	CD	DOS
μg	JJ	FREQ
daily	RB	FREQ
dose	VBP	O
may	MD	O
not	RB	O
produce	VB	O
amenorrhea	NN	O
.	.	O

Admixtures	NNS	O
of	IN	O
3.5	CD	O
to	TO	O
4.25	CD	O
%	NN	O
amino	JJ	O
acids	NNS	O
with	IN	O
5	CD	O
to	TO	O
10	CD	O
%	NN	O
dextrose	NN	O
may	MD	O
be	VB	O
infused	VBN	O
with	IN	O
a	DT	O
fat	JJ	O
emulsion	NN	O
by	IN	O
peripheral	JJ	O
vein	NN	O
to	TO	O
provide	VB	O
approximately	RB	O
1400	CD	O
to	TO	O
2000	CD	O
kcal	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

210	CD	O

The	DT	O
patient	NN	O
should	MD	O
be	VB	O
instructed	VBN	O
to	TO	O
use	VB	O
a	DT	O
back	NN	O
-	:	O
up	IN	O
method	NN	O
of	IN	O
birth	NN	O
control	NN	O
if	IN	O
she	PRP	O
has	VBZ	O
sex	NN	O
in	IN	O
the	DT	O
seven	CD	O
(	(	O
7	CD	O
)	)	O
days	NNS	O
after	IN	O
missing	VBG	O
pills	NNS	O
.	.	O

Higher	JJR	O
doses	NNS	O
have	VBP	O
not	RB	O
shown	VBN	O
to	TO	O
be	VB	O
of	IN	O
additional	JJ	O
benefit	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
inflammatory	JJ	O
lesions	NNS	O
of	IN	O
acne	NN	O
,	,	O
and	CC	O
may	MD	O
be	VB	O
associated	VBN	O
with	IN	O
more	RBR	O
acute	JJ	O
vestibular	JJ	O
side	NN	O
effects	NNS	O
.	.	O

The	DT	O
necessary	JJ	O
duration	NN	O
of	IN	O
treatment	NN	O
for	IN	O
panic	JJ	WHO
disorder	NN	WHO
patients	NNS	WHO
responding	VBG	WHO
to	TO	WHO
NIRAVAM	NNP	WHO
is	VBZ	O
unknown	JJ	O
.	.	O

Ketamine	NNP	O
hydrochloride	NN	O
is	VBZ	O
clinically	RB	O
compatible	JJ	O
with	IN	O
the	DT	O
commonly	RB	O
used	VBN	O
general	JJ	O
and	CC	O
local	JJ	O
anesthetic	JJ	O
agents	NNS	O
when	WRB	O
an	DT	O
adequate	JJ	O
respiratory	NN	O
exchange	NN	O
is	VBZ	O
maintained	VBN	O
.	.	O

The	DT	O
patient	NN	O
's	POS	O
medical	JJ	O
history	NN	O
for	IN	O
hypersensitivity	NN	O
reactions	NNS	O
should	MD	O
be	VB	O
evaluated	VBN	O
prior	RB	O
to	TO	O
performing	VBG	O
the	DT	O
intravitreal	JJ	O
procedure	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
ADVERSE	NNP	O
REACTIONS	NNP	O
]	NNP	O
.	.	O

COLOR	NNP	O
VARIATION	NNP	O
IN	NNP	O
THE	NNP	O
DEXTROSE	NNP	O
INJECTION	NNP	O
FROM	NNP	O
PALE	NNP	O
YELLOW	NNP	O
TO	NNP	O
YELLOW	NNP	O
IS	NNP	O
NORMAL	NNP	O
AND	NNP	O
DOES	NNP	O
NOT	NNP	O
ALTER	NNP	O
EFFICACY	NNP	O
.	.	O

The	DT	O
serum	JJ	O
creatinine	NN	O
should	MD	O
represent	VB	O
a	DT	O
steady	JJ	O
state	NN	O
of	IN	O
renal	JJ	O
function	NN	O
.	.	O

To	TO	O
avoid	VB	O
potential	JJ	O
interruptions	NNS	O
in	IN	O
drug	NN	O
delivery	NN	O
,	,	O
the	DT	O
patient	NN	O
must	MD	O
have	VB	O
immediate	JJ	O
access	NN	O
to	TO	O
a	DT	O
backup	NN	O
infusion	NN	O
pump	NN	O
and	CC	O
subcutaneous	JJ	O
infusion	NN	O
sets	NNS	O
.	.	O

F.	NNP	O
Serial	NNP	O
Puncture	NN	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
24	CD	O
-	:	O
hr	NN	O
CrCl	NNP	O
less	JJR	O
than	IN	O
30	CD	DOS
mL	JJ	UNIT
/	NNP	O
min	NN	O
,	,	O
C	NNP	O
-	:	O
G	NNP	O
)	)	O
or	CC	O
end	VB	O
-	:	O
stage	NN	O
renal	JJ	O
disease	NN	O
(	(	O
ESRD	NNP	O
)	)	O
is	VBZ	O
50	CD	DOS
mg	NN	UNIT
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
.	.	O

The	DT	O
occurrence	NN	O
of	IN	O
bradyarrhythmias	NN	O
may	MD	O
be	VB	O
reduced	VBN	O
by	IN	O
pretreatment	NN	O
with	IN	O
atropine	NN	O
(	(	O
see	JJ	O
PRECAUTIONS	NNP	O
:	:	O
Pediatric	NNP	O
Use	NNP	O
)	)	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
CLcr	NNP	O
31	CD	DOS
-	:	O
50	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
the	DT	O
recommended	VBN	O
dose	NN	O
reduction	NN	O
is	VBZ	O
to	TO	O
300	CD	DOS
mg	NNS	UNIT
(	(	O
six	CD	DOS
50	CD	DOS
mg	NNS	UNIT
capsules	NNS	UNIT
)	)	O
taken	VBN	O
twice	RB	FREQ
daily	RB	FREQ
,	,	O
for	IN	O
a	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
600	CD	DOS
mg	NN	UNIT
.	.	O

This	DT	O
does	VBZ	O
not	RB	O
affect	VB	O
the	DT	O
solution	NN	O
quality	NN	O
or	CC	O
safety	NN	O
and	CC	O
may	MD	O
often	RB	O
leave	VB	O
a	DT	O
slight	JJ	O
amount	NN	O
of	IN	O
moisture	NN	O
within	IN	O
the	DT	O
overwrap	NN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
COREG	NNP	O
CR	NNP	O
be	VB	O
started	VBN	O
at	IN	O
20	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	JJ	FREQ
and	CC	O
increased	VBD	O
after	IN	O
3	CD	PER
to	TO	O
10	CD	PER
days	NNS	PER
,	,	O
based	VBN	O
on	IN	O
tolerability	NN	O
,	,	O
to	TO	O
40	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
,	,	O
then	RB	O
again	RB	O
to	TO	O
the	DT	O
target	NN	O
dose	NN	O
of	IN	O
80	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Do	NNP	O
not	RB	O
bandage	VB	O
,	,	O
cover	VB	O
,	,	O
or	CC	O
wrap	VB	O
the	DT	O
treated	JJ	O
skin	JJ	O
area	NN	O
unless	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

The	DT	O
usefulness	NN	O
and	CC	O
safety	NN	O
in	IN	O
angina	JJ	O
pectoris	NN	O
of	IN	O
dosage	NN	O
exceeding	VBG	O
240	CD	DOS
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
have	VBP	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
develops	VBZ	O
these	DT	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
,	,	O
raise	VB	O
the	DT	O
dose	NN	O
to	TO	O
the	DT	O
previous	JJ	O
level	NN	O
and	CC	O
taper	VB	O
more	JJR	O
slowly	RB	O
,	,	O
either	RB	O
by	IN	O
increasing	VBG	O
the	DT	O
interval	NN	O
between	IN	O
decreases	NNS	O
,	,	O
decreasing	VBG	O
the	DT	O
amount	NN	O
of	IN	O
change	NN	O
in	IN	O
dose	NN	O
,	,	O
or	CC	O
both	DT	O
.	.	O

Figure	NN	O
G	NNP	O

ZINACEF®	NNP	O
(	(	O
cefuroxime	NN	O
for	IN	O
injection	NN	O
)	)	O

Combination	NNP	O
Therapy	NNP	O
with	IN	O
TAXOTERE	NNP	O
for	IN	O
Chemotherapy	NNP	O
-	:	O
naïve	NN	O
NSCLC	NNP	O

Foods	NNS	O
that	WDT	O
decrease	VBP	O
absorption	NN	O
of	IN	O
levothyroxine	NN	O
,	,	O
such	JJ	O
as	IN	O
soybean	NN	O
infant	NN	O
formula	NN	O
,	,	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
for	IN	O
administering	VBG	O
levothyroxine	JJ	O
sodium	NN	O
tablets	NNS	O
.	.	O

400	CD	DOS
mg	NN	UNIT

Do	NNP	O
not	RB	O
use	VB	O
a	DT	O
household	NN	O
teaspoon	NN	O
to	TO	O
measure	VB	O
the	DT	O
dose	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Appropriate	JJ	O
precautions	NNS	O
should	MD	O
be	VB	O
taken	VBN	O
.	.	O

The	DT	O
dosage	NN	O
recommendations	NNS	O
for	IN	O
PRIMAXIN	NNP	O
I.V	NNP	O
.	.	O

The	DT	O
possibility	NN	O
of	IN	O
ovulation	NN	O
and	CC	O
conception	NN	O
prior	RB	O
to	TO	O
initiation	NN	O
of	IN	O
medication	NN	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

TYBOST	NNP	O
must	MD	O
be	VB	O
coadministered	VBN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
as	IN	O
atazanavir	NN	O
or	CC	O
darunavir	NN	O
[	JJ	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

or	CC	O
t.i.d	NN	O
.	.	O

7	CD	O
.	.	O

Holding	VBG	O
the	DT	O
syringe	NN	O
barrel	NN	O
in	IN	O
one	CD	DOS
hand	NN	UNIT
(	(	O
avoid	JJ	O
holding	VBG	O
the	DT	O
syringe	NN	O
plunger	NN	O
)	)	O
,	,	O
unscrew	VBD	O
the	DT	O
syringe	NN	O
cap	NN	O
by	IN	O
twisting	VBG	O
it	PRP	O
anticlockwise	NN	O
.	.	O

With	IN	O
this	DT	O
selected	VBN	O
intravenous	JJ	O
infusion	NN	O
rate	NN	O
(	(	O
mL	JJ	O
/	NNP	O
hr	NN	O
)	)	O
and	CC	O
the	DT	O
patient	NN	O
's	POS	O
dose	NN	O
(	(	O
ng	JJ	O
/	NNP	O
kg	NN	O
/	NNP	O
min	NN	O
)	)	O
and	CC	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
,	,	O
the	DT	O
diluted	VBN	O
intravenous	JJ	O
Remodulin	NNP	O
concentration	NN	O
(	(	O
mg	JJ	UNIT
/	NNP	O
mL	NN	O
)	)	O
can	MD	O
be	VB	O
calculated	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
formula	NN	O
:	:	O

Leucovorin	NNP	O
15	CD	DOS
mg	NN	UNIT
(	(	O
10	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
IM	NNP	O
,	,	O
IV	NNP	O
,	,	O
or	CC	O
PO	NNP	O
every	DT	FREQ
6	CD	FREQ
hours	NNS	FREQ
until	IN	O
serum	JJ	O
methotrexate	JJ	O
level	NN	O
is	VBZ	O
less	JJR	O
than	IN	O
10	CD	O
-	:	O
8	CD	O
M.	NNP	O
In	IN	O
the	DT	O
presence	NN	O
of	IN	O
gastrointestinal	JJ	O
toxicity	NN	O
,	,	O
nausea	NN	O
,	,	O
or	CC	O
vomiting	NN	O
,	,	O
leucovorin	NN	O
should	MD	O
be	VB	O
administered	VBN	O
parenterally	RB	O
.	.	O

As	IN	O
initial	JJ	O
therapy	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
baseline	JJ	WHO
HbA1c	NNP	WHO
>	NNP	WHO
9	CD	WHO
%	NN	WHO
or	CC	O
an	DT	O
FPG	NNP	O
>	NN	O
200	CD	DOS
mg	NN	UNIT
/	NNP	O
dL	NN	O
,	,	O
a	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
GLUCOVANCE	NNP	O
1.25	CD	DOS
mg	NN	UNIT
/	VBD	O
250	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
with	IN	O
the	DT	O
morning	NN	O
and	CC	O
evening	NN	O
meals	NNS	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

Table	JJ	O
3	CD	O
:	:	O
Subcutaneous	JJ	O
Xolair	NN	O
Doses	VBZ	O
Every	DT	O
2	CD	O
or	CC	O
4	CD	O
Weeks*	NNP	O
for	IN	O
Pediatric	NNP	WHO
Patients	NNPS	WHO
with	IN	WHO
Asthma	NNP	WHO
Who	NNP	WHO
Begin	NNP	WHO
Xolair	NNP	WHO
Between	NNP	WHO
the	DT	WHO
Ages	NNP	WHO
of	IN	WHO
6	CD	WHO
to	TO	WHO
<	VB	WHO
12	CD	WHO
Years	NNS	WHO

When	WRB	O
these	DT	O
functions	NNS	O
are	VBP	O
immature	JJ	O
(	(	O
or	CC	O
seriously	RB	O
impaired	VBN	O
in	IN	O
adults	NNS	WHO
)	)	O
,	,	O
high	JJ	O
concentrations	NNS	O
of	IN	O
the	DT	O
drug	NN	O
are	VBP	O
found	VBN	O
which	WDT	O
tend	VBP	O
to	TO	O
increase	VB	O
with	IN	O
succeeding	JJ	O
doses	NNS	O
.	.	O

Do	NNP	O
not	RB	O
abruptly	RB	O
discontinue	VBP	O
EMBEDA	NNP	O
.	.	O

Assess	IN	O
the	DT	O
risk	NN	O
of	IN	O
abuse	NN	O
prior	JJ	O
to	TO	O
prescribing	VBG	O
,	,	O
and	CC	O
monitor	NN	O
for	IN	O
signs	NNS	O
of	IN	O
abuse	NN	O
and	CC	O
dependence	NN	O
while	IN	O
on	IN	O
therapy	NN	O
.	.	O

ARRANON	NNP	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
or	CC	O
hepatic	JJ	O
dysfunction	NN	O
[	NNP	O
see	NN	O
Use	NNP	O
inSpecific	JJ	O
Populations	NNP	O
]	NNP	O
.	.	O

For	IN	O
information	NN	O
on	IN	O
rate	NN	O
of	IN	O
administration	NN	O
,	,	O
see	VBP	O
Rate	NNP	O
of	IN	O
Administration	NNP	O
,	,	O
below	IN	O
.	.	O

If	IN	O
there	EX	O
is	VBZ	O
a	DT	O
need	NN	O
to	TO	O
re	VB	O
-	:	O
start	VB	O
the	DT	O
process	NN	O
at	IN	O
any	DT	O
time	NN	O
during	IN	O
the	DT	O
insertion	NN	O
procedure	NN	O
,	,	O
withdraw	VBP	O
the	DT	O
Insertion	NNP	O
Tool	NNP	O
,	,	O
carefully	RB	O
extract	VB	O
the	DT	O
implant	NN	O
from	IN	O
the	DT	O
cannula	NN	O
and	CC	O
reset	VB	O
the	DT	O
retraction	NN	O
button	NN	O
on	IN	O
the	DT	O
Tool	NNP	O
to	TO	O
its	PRP$	O
forward	JJ	O
-	:	O
most	JJS	O
position	NN	O
.	.	O

No	DT	O
adjustment	NN	O
to	TO	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Tyzeka	NNP	O
is	VBZ	O
necessary	JJ	O
in	IN	O
patients	NNS	WHO
whose	WP$	WHO
creatinine	JJ	WHO
clearance	NN	WHO
is	VBZ	WHO
greater	JJR	WHO
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
50	CD	DOS
mL	NNS	UNIT
per	IN	O
min	NN	O
.	.	O

Because	IN	O
of	IN	O
these	DT	O
factors	NNS	O
it	PRP	O
is	VBZ	O
important	JJ	O
that	IN	O
this	DT	O
product	NN	O
be	VB	O
stored	VBN	O
properly	RB	O
and	CC	O
that	IN	O
the	DT	O
directions	NNS	O
be	VB	O
followed	VBN	O
carefully	RB	O
during	IN	O
use	NN	O
.	.	O

The	DT	O
following	JJ	O
dosage	NN	O
schedule	NN	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

The	DT	O
safe	JJ	O
and	CC	O
effective	JJ	O
use	NN	O
of	IN	O
BOTOX	NNP	O
depends	VBZ	O
upon	IN	O
proper	JJ	O
storage	NN	O
of	IN	O
the	DT	O
product	NN	O
,	,	O
selection	NN	O
of	IN	O
the	DT	O
correct	NN	O
dose	NN	O
,	,	O
and	CC	O
proper	JJ	O
reconstitution	NN	O
and	CC	O
administration	NN	O
techniques	NNS	O
.	.	O

Do	NNP	O
not	RB	O
shake	VB	O
.	.	O

Monotherapy	NN	O
with	IN	O
TAXOTERE	NNP	O
for	IN	O
NSCLC	NNP	O
Treatment	NNP	O
After	IN	O
Failure	NNP	O
Of	IN	O
Prior	NNP	O
Platinum	NNP	O
-	:	O
Based	VBD	O
Chemotherapy	NNP	O

9	CD	O
.	.	O

AndroGel	RB	O
1	CD	O
%	NN	O
should	MD	O
be	VB	O
evenly	RB	O
distributed	VBN	O
between	IN	O
the	DT	O
right	NN	O
and	CC	O
left	VBD	O
upper	JJ	O
arms	NNS	O
/	VBP	O
shoulders	NNS	O
or	CC	O
both	DT	O
sides	NNS	O
of	IN	O
the	DT	O
abdomen	NNS	O
.	.	O

If	IN	O
necessary	JJ	O
,	,	O
a	DT	O
new	JJ	O
transdermal	JJ	O
system	NN	O
may	MD	O
be	VB	O
applied	VBN	O
,	,	O
in	IN	O
which	WDT	O
case	NN	O
,	,	O
the	DT	O
original	JJ	O
treatment	NN	O
schedule	NN	O
should	MD	O
be	VB	O
continued	VBN	O
.	.	O

65	CD	O

a	DT	O
.	.	O

Dose	NNP	O
must	MD	O
be	VB	O
individualized	VBN	O
to	TO	O
prevent	VB	O
overdosage	NN	O
.	.	O

Women	NNS	O
who	WP	O
choose	VBP	O
to	TO	O
use	VB	O
a	DT	O
repeat	NN	O
dose	NN	O
of	IN	O
misoprostol	NN	O
should	MD	O
have	VB	O
a	DT	O
follow	NN	O
-	:	O
up	IN	O
visit	NN	O
with	IN	O
their	PRP$	O
healthcare	NN	O
provider	NN	O
in	IN	O
approximately	RB	O
7	CD	PER
days	NNS	PER
to	TO	O
assess	VB	O
for	IN	O
complete	JJ	O
termination	NN	O
.	.	O

Beyaz	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
in	IN	O
the	DT	O
order	NN	O
directed	VBD	O
on	IN	O
the	DT	O
package	NN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
each	DT	FREQ
day	NN	FREQ
,	,	O
preferably	RB	O
after	IN	O
the	DT	O
evening	NN	O
meal	NN	O
or	CC	O
at	IN	O
bedtime	NN	O
with	IN	O
some	DT	O
liquid	NN	O
,	,	O
as	IN	O
needed	VBN	O
.	.	O

Illustrated	NNP	O
Patient	NNP	O
's	POS	O
Instructions	NNP	O
for	IN	O
Use	NNP	O
accompany	JJ	O
each	DT	O
package	NN	O
of	IN	O
BECONASE	NNP	O
AQ	NNP	O
Nasal	NNP	O
Spray	NNP	O
.	.	O

Doses	NNS	O
of	IN	O
CORTROSYN™	NNP	O
0.25	CD	DOS
to	TO	O
0.75	CD	DOS
mg	NNS	UNIT
have	VBP	O
been	VBN	O
used	VBN	O
in	IN	O
clinical	JJ	O
studies	NNS	O
and	CC	O
a	DT	O
maximal	JJ	O
response	NN	O
noted	VBD	O
with	IN	O
the	DT	O
smallest	JJS	O
dose	NN	O
.	.	O

Use	VB	O
a	DT	O
separate	JJ	O
sterile	JJ	O
needle	NN	O
and	CC	O
syringe	NN	O
for	IN	O
each	DT	O
dose	JJ	O
withdrawn	NN	O
from	IN	O
the	DT	O
multi	NN	O
-	:	O
dose	JJ	O
vial	NN	O
.	.	O

If	IN	O
any	DT	O
recommended	VBD	O
dose	NN	O
of	IN	O
pertussis	NN	O
vaccine	NN	O
can	MD	O
not	RB	O
be	VB	O
given	VBN	O
,	,	O
DT	NNP	O
(	(	O
For	IN	O
Pediatric	NNP	O
Use	NNP	O
)	)	O
vaccine	NN	O
should	MD	O
be	VB	O
given	VBN	O
as	IN	O
needed	VBN	O
to	TO	O
complete	VB	O
the	DT	O
series	NN	O
.	.	O

New	NNP	O
implants	NNS	O
may	MD	O
be	VB	O
inserted	VBN	O
subdermally	RB	O
in	IN	O
an	DT	O
area	NN	O
of	IN	O
the	DT	O
inner	JJ	O
side	NN	O
of	IN	O
either	DT	O
upper	JJ	O
arm	NN	O
that	WDT	O
has	VBZ	O
not	RB	O
been	VBN	O
previously	RB	O
used	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
removal	NN	O
,	,	O
if	IN	O
continued	VBN	O
treatment	NN	O
is	VBZ	O
desired	VBN	O
.	.	O

The	DT	O
test	NN	O
is	VBZ	O
only	RB	O
a	DT	O
diagnostic	JJ	O
aid	NN	O
in	IN	O
the	DT	O
evaluation	NN	O
of	IN	O
an	DT	O
individual	JJ	O
patient	NN	O
.	.	O

SEE	NNP	O
MIXING	NNP	O
GUIDELINES	NNP	O
AND	NNP	O
LIMITATIONS	NNP	O
SECTION	NNP	O
FOR	NNP	O
INFORMATION	NNP	O
REGARDING	NNP	O
MIXING	NN	O
THIS	NNP	O
FAT	NNP	O
EMULSION	NNP	O
WITH	NNP	O
OTHER	NNP	O
PARENTERAL	NNP	O
FLUIDS	NNP	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
instructed	VBN	O
to	TO	O
minimize	VB	O
sun	JJ	O
exposure	NN	O
.	.	O

During	IN	O
the	DT	O
first	JJ	O
cycle	NN	O
of	IN	O
medication	NN	O
,	,	O
the	DT	O
patient	NN	O
is	VBZ	O
instructed	VBN	O
to	TO	O
take	VB	O
one	CD	DOS
Lo	NNP	UNIT
/	NNP	O
Ovral	NNP	O
tablet	VBD	O
daily	RB	FREQ
for	IN	O
twenty	NN	O
-	:	O
one	CD	PER
consecutive	JJ	PER
days	NNS	PER
,	,	O
beginning	VBG	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
(	(	O
Day	NNP	O
1	CD	O
Start	NNP	O
)	)	O
of	IN	O
her	PRP$	O
menstrual	JJ	O
cycle	NN	O
or	CC	O
on	IN	O
the	DT	O
Sunday	NNP	O
after	IN	O
her	PRP$	O
period	NN	O
begins	VBZ	O
(	(	O
Sunday	NNP	O
Start	NNP	O
)	)	O
.	.	O

EMBEDA	NNP	O
should	MD	O
be	VB	O
prescribed	VBN	O
only	RB	O
by	IN	O
healthcare	JJ	O
professionals	NNS	O
who	WP	O
are	VBP	O
knowledgeable	JJ	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
potent	JJ	O
opioids	NNS	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
chronic	JJ	O
pain	NN	O
.	.	O

If	IN	O
used	VBN	O
with	IN	O
a	DT	O
primary	JJ	O
intravenous	JJ	O
fluid	NN	O
system	NN	O
,	,	O
the	DT	O
primary	JJ	O
solution	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
during	IN	O
metronidazole	JJ	O
infusion	NN	O
.	.	O

The	DT	O
pharmacy	NN	O
bulk	JJ	O
vial	NN	O
is	VBZ	O
for	IN	O
use	NN	O
in	IN	O
a	DT	O
hospital	NN	O
pharmacy	NN	O
admixture	NN	O
service	NN	O
only	RB	O
under	IN	O
a	DT	O
laminar	NN	O
flow	NN	O
hood	NN	O
.	.	O

Retreatment	NN	O
with	IN	O
XEOMIN	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
no	DT	O
more	RBR	O
frequently	RB	O
than	IN	O
every	DT	FREQ
three	CD	FREQ
months	NNS	FREQ
.	.	O

The	DT	O
dosage	NN	O
should	MD	O
be	VB	O
individualized	VBN	O
based	VBN	O
on	IN	O
the	DT	O
patient	NN	O
's	POS	O
response	NN	O
,	,	O
with	IN	O
most	JJS	WHO
patients	NNS	WHO
responding	VBG	WHO
to	TO	WHO
doses	NNS	WHO
of	IN	O
0.6	CD	DOS
mg	NNS	UNIT
to	TO	O
1	CD	DOS
mg	NN	UNIT
(	(	O
see	VB	O
Individualization	NNP	O
Of	IN	O
Dosage	NNP	O
)	)	O
.	.	O

Because	IN	O
the	DT	O
doses	NNS	O
of	IN	O
this	DT	O
fixed	JJ	O
combination	NN	O
product	NN	O
can	MD	O
not	RB	O
be	VB	O
individually	RB	O
titrated	VBN	O
,	,	O
the	DT	O
combination	NN	O
product	NN	O
should	MD	O
generally	RB	O
be	VB	O
avoided	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
and	CC	O
may	MD	O
not	RB	O
be	VB	O
appropriate	JJ	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
develop	VBP	WHO
≥	JJ	WHO
grade	NN	WHO
3	CD	WHO
peripheral	JJ	WHO
neuropathy	NN	WHO
should	MD	O
have	VB	O
DOCEFREZ	NNP	O
treatment	NN	O
discontinued	VBD	O
entirely	RB	O
.	.	O

If	IN	O
it	PRP	O
is	VBZ	O
elected	VBN	O
to	TO	O
inject	VB	O
at	IN	O
another	DT	O
site	NN	O
,	,	O
a	DT	O
new	JJ	O
TUBEX	NNP	O
cartridge	NN	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

Three	CD	PER
weeks	NNS	PER
constitutes	VBZ	O
an	DT	O
adequate	JJ	O
period	NN	O
of	IN	O
trial	NN	O
providing	NN	O
dosage	NN	O
has	VBZ	O
reached	VBN	O
300	CD	DOS
mg	JJ	UNIT
daily	JJ	FREQ
(	(	O
or	CC	O
lower	JJR	O
level	NN	O
of	IN	O
tolerance	NN	O
)	)	O
for	IN	O
at	IN	PER
least	JJS	PER
two	CD	PER
weeks	NNS	PER
.	.	O

There	EX	O
is	VBZ	O
limited	JJ	O
long	RB	O
-	:	O
term	NN	O
treatment	NN	O
data	NNS	O
.	.	O

If	IN	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
continue	VBP	O
to	TO	O
occur	VB	O
,	,	O
dosing	VBG	O
should	MD	O
be	VB	O
interrupted	VBN	O
or	CC	O
discontinued	VBN	O
as	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
lower	JJR	O
doses	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	O

Specific	JJ	O
instructions	NNS	O
for	IN	O
programming	NN	O
and	CC	O
/	NN	O
or	CC	O
refilling	VBG	O
the	DT	O
implantable	JJ	O
pump	NN	O
are	VBP	O
given	VBN	O
by	IN	O
the	DT	O
pump	NN	O
manufacturers	NNS	O
,	,	O
and	CC	O
must	MD	O
be	VB	O
strictly	RB	O
adhered	VBN	O
to	TO	O
.	.	O

NOTE	NN	O
:	:	O
Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
before	IN	O
administration	NN	O
.	.	O

Loading	VBG	O
Dose	NNP	O
(	(	O
mL	NN	O
)	)	O
Using	VBG	O
1	CD	DOS
mg	JJ	UNIT
/	NNP	O
mL	NN	O
Concentration	NN	O

The	DT	O
constituted	JJ	O
solution	NN	O
must	MD	O
be	VB	O
mixed	VBN	O
by	IN	O
repeated	JJ	O
inversion	NN	O
of	IN	O
the	DT	O
diluent	NN	O
bag	NN	O
for	IN	O
1	CD	O
minute	NN	O
.	.	O

BREO	NNP	O
ELLIPTA	NNP	O
100	CD	DOS
/	VBD	O
25	CD	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
1	CD	DOS
inhalation	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

One	CD	O
half	NN	O
of	IN	O
the	DT	O
total	JJ	O
dose	NN	O
is	VBZ	O
usually	RB	O
administered	VBN	O
to	TO	O
each	DT	O
side	NN	O
.	.	O

Myxedema	NNP	O
coma	NN	O
is	VBZ	O
usually	RB	O
precipitated	VBN	O
in	IN	O
the	DT	O
hypothyroid	JJ	O
patient	NN	O
of	IN	O
long	JJ	O
-	:	O
standing	NN	O
by	IN	O
intercurrent	JJ	O
illness	NN	O
or	CC	O
drugs	NNS	O
such	JJ	O
as	IN	O
sedatives	NNS	O
and	CC	O
anesthetics	NNS	O
and	CC	O
should	MD	O
be	VB	O
considered	VBN	O
a	DT	O
medical	JJ	O
emergency	NN	O
.	.	O

RAYOS	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
daily	RB	FREQ
with	IN	O
food	NN	O
.	.	O

Optimum	JJ	O
presentation	NN	O
of	IN	O
the	DT	O
reconstructed	JJ	O
images	NNS	O
for	IN	O
visual	JJ	O
interpretation	NN	O
is	VBZ	O
transaxial	JJ	O
slices	NNS	O
parallel	VBP	O
to	TO	O
the	DT	O
anterior	JJ	O
commissure	NN	O
-	:	O
posterior	JJ	O
commissure	NN	O
(	(	O
AC	NNP	O
-	:	O
PC	NN	O
)	)	O
line	NN	O
.	.	O

To	TO	O
make	VB	O
same	JJ	O
-	:	O
day	NN	O
dosing	VBG	O
adjustments	NNS	O
,	,	O
have	VBP	O
the	DT	O
patient	NN	O
wait	NN	O
2	CD	O
to	TO	O
4	CD	O
hours	NNS	O
for	IN	O
further	JJ	O
evaluation	NN	O
,	,	O
when	WRB	O
peak	NN	O
levels	NNS	O
have	VBP	O
been	VBN	O
reached	VBN	O
.	.	O

While	IN	O
there	EX	O
is	VBZ	O
little	JJ	O
likelihood	NN	O
of	IN	O
ovulation	NN	O
occurring	VBG	O
if	IN	O
only	RB	O
one	CD	DOS
or	CC	O
two	CD	DOS
orange	NN	UNIT
tablets	NNS	UNIT
are	VBP	O
missed	VBN	O
,	,	O
the	DT	O
possibility	NN	O
of	IN	O
ovulation	NN	O
increases	NNS	O
with	IN	O
each	DT	O
successive	JJ	O
day	NN	O
that	WDT	O
scheduled	VBD	O
orange	JJ	O
tablets	NNS	O
are	VBP	O
missed	VBN	O
.	.	O

The	DT	O
tendency	NN	O
toward	IN	O
tachyphylaxis	NN	O
(	(	O
lessening	VBG	O
of	IN	O
response	NN	O
)	)	O
with	IN	O
repeated	VBN	O
administration	NN	O
given	VBN	O
more	RBR	O
frequently	RB	O
than	IN	O
every	DT	FREQ
48	CD	FREQ
hours	NNS	FREQ
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
treating	VBG	O
each	DT	O
patient	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Recommended	VBN	O
Treatment	NNP	O
Regimen	NNP	O
in	IN	O
Patients	NNP	WHO
with	IN	WHO
Genotype	NNP	WHO
1	CD	WHO
,	,	O
2	CD	O
,	,	O
3	CD	O
,	,	O
4	CD	O
,	,	O
5	CD	O
,	,	O
or	CC	O
6	CD	O
HCV	NN	O

Refer	NN	O
to	TO	O
the	DT	O
peginterferon	NN	O
alfa	NN	O
and	CC	O
ribavirin	VB	O
prescribing	VBG	O
information	NN	O
for	IN	O
additional	JJ	O
information	NN	O
about	IN	O
how	WRB	O
to	TO	O
reduce	VB	O
and	CC	O
/	VB	O
or	CC	O
discontinue	VB	O
the	DT	O
peginterferon	NN	O
alfa	NN	O
and	CC	O
/	NN	O
or	CC	O
ribavirin	JJ	O
dosage	NN	O
.	.	O

Instruct	NN	O
patients	NNS	O
to	TO	O
:	:	O

The	DT	O
drug	NN	O
product	NN	O
must	MD	O
be	VB	O
prepared	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
instructions	NNS	O
:	:	O

Avoid	NNP	O
contact	NN	O
with	IN	O
the	DT	O
shaft	NN	O
of	IN	O
the	DT	O
plunger	NN	O
rod	NN	O
.	.	O

Each	DT	O
treatment	NN	O
course	NN	O
should	MD	O
be	VB	O
separated	VBN	O
by	IN	O
a	DT	O
rest	NN	O
period	NN	O
of	IN	O
at	IN	PER
least	JJS	PER
7	CD	PER
weeks	NNS	PER
from	IN	O
the	DT	O
date	NN	O
of	IN	O
hospital	NN	O
discharge	NN	O
.	.	O

Increase	VB	O
the	DT	O
daily	JJ	FREQ
dose	NN	FREQ
every	DT	FREQ
2	CD	FREQ
weeks	NNS	FREQ
by	IN	O
increments	NNS	O
of	IN	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
to	TO	O
the	DT	O
recommended	VBN	FREQ
daily	RB	FREQ
dose	VB	O
of	IN	O
60	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
(	(	O
30	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NNP	O
twice	RB	FREQ
daily	RB	FREQ
)	)	O
.	.	O

Each	DT	O
vial	NN	O
of	IN	O
XIAFLEX	NNP	O
and	CC	O
sterile	JJ	O
diluent	NN	O
should	MD	O
only	RB	O
be	VB	O
used	VBN	O
for	IN	O
a	DT	O
single	JJ	O
injection	NN	O
.	.	O

Sufficient	JJ	O
cream	NN	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
cover	VB	O
the	DT	O
treatment	NN	O
area	NN	O
,	,	O
including	VBG	O
1	CD	O
centimeter	NN	O
of	IN	O
skin	NN	O
surrounding	VBG	O
the	DT	O
tumor	NN	O
.	.	O

Inject	NNP	O
all	PDT	O
the	DT	O
diluent	NN	O
in	IN	O
the	DT	O
syringe	NN	O
into	IN	O
the	DT	O
vial	NN	O
of	IN	O
lyophilized	JJ	O
vaccine	NN	O
,	,	O
and	CC	O
agitate	VB	O
to	TO	O
mix	VB	O
thoroughly	RB	O
.	.	O

After	IN	O
reconstitution	NN	O
,	,	O
CernevitTM	NNP	O
(	(	O
multivitamins	NNS	O
for	IN	O
infusion	NN	O
)	)	O
should	MD	O
be	VB	O
used	VBN	O
immediately	RB	O
or	CC	O
stored	VBN	O
under	IN	O
refrigeration	NN	O
for	IN	O
no	DT	O
more	JJR	O
than	IN	O
24	CD	O
hours	NNS	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
asthma	NN	WHO
less	JJR	WHO
than	IN	WHO
18	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
who	WP	WHO
require	VBP	WHO
addition	NN	WHO
of	IN	WHO
a	DT	WHO
LABA	NNP	WHO
to	TO	WHO
an	DT	WHO
inhaled	JJ	WHO
corticosteroid	NN	WHO
,	,	O
a	DT	O
fixed	JJ	O
-	:	O
dose	JJ	O
combination	NN	O
product	NN	O
containing	VBG	O
both	DT	O
an	DT	O
inhaled	VBN	O
corticosteroid	NN	O
and	CC	O
LABA	NNP	O
should	MD	O
ordinarily	RB	O
be	VB	O
used	VBN	O
to	TO	O
ensure	VB	O
adherence	NN	O
with	IN	O
both	DT	O
drugs	NNS	O
.	.	O

As	IN	O
with	IN	O
other	JJ	O
antiarrhythmic	JJ	O
agents	NNS	O
,	,	O
sotalol	JJ	O
hydrochloride	NN	O
tablets	NNS	O
,	,	O
USP	NNP	O
should	MD	O
be	VB	O
initiated	VBN	O
and	CC	O
doses	NNS	O
increased	VBN	O
in	IN	O
a	DT	O
hospital	NN	O
with	IN	O
facilities	NNS	O
for	IN	O
cardiac	JJ	O
rhythm	NN	O
monitoring	NN	O
and	CC	O
assessment	NN	O
(	(	O
see	VB	O
INDICATIONS	NNP	O
AND	NNP	O
USAGE	NNP	O
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
safer	JJR	O
to	TO	O
underestimate	VB	O
a	DT	O
patient	NN	O
's	POS	O
24	CD	O
-	:	O
hour	NN	O
OPANA	NNP	O
dosage	NN	O
than	IN	O
to	TO	O
overestimate	VB	O
the	DT	O
24	CD	O
-	:	O
hour	NN	O
OPANA	NNP	O
dosage	NN	O
and	CC	O
manage	VB	O
an	DT	O
adverse	JJ	O
reaction	NN	O
due	JJ	O
to	TO	O
overdose	VB	O
.	.	O

If	IN	O
abdominal	JJ	O
trauma	NN	O
,	,	O
amniocentesis	NN	O
,	,	O
or	CC	O
other	JJ	O
adverse	JJ	O
event	NN	O
requires	VBZ	O
the	DT	O
administration	NN	O
of	IN	O
HyperRHO	NNP	O
S	NNP	O
/	NNP	O
D	NNP	O
Full	NNP	O
Dose	NNP	O
at	IN	O
13	CD	PER
to	TO	O
18	CD	PER
weeks	NNS	PER
'	POS	O
gestation	NN	O
,	,	O
another	DT	O
full	JJ	O
dose	NN	O
should	MD	O
be	VB	O
given	VBN	O
at	IN	O
26	CD	PER
to	TO	O
28	CD	PER
weeks	NNS	PER
.	.	O

For	IN	O
children	NNS	WHO
,	,	O
see	VBP	O
Pediatric	JJ	O
Use	NNP	O
section	NN	O
under	IN	O
PRECAUTIONS	NNP	O
.	.	O

ALDACTONE	NNP	O
may	MD	O
also	RB	O
be	VB	O
given	VBN	O
with	IN	O
diuretics	NNS	O
that	WDT	O
act	VBP	O
more	JJR	O
proximally	RB	O
in	IN	O
the	DT	O
renal	JJ	O
tubule	NN	O
or	CC	O
with	IN	O
other	JJ	O
antihypertensive	JJ	O
agents	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
PLEGRIDY	NNP	O
is	VBZ	O
125	CD	DOS
micrograms	NNS	UNIT
injected	VBD	O
subcutaneously	RB	O
every	DT	FREQ
14	CD	FREQ
days	NNS	FREQ
.	.	O

VENCLEXTA	NNP	O
can	MD	O
cause	VB	O
rapid	JJ	O
reduction	NN	O
in	IN	O
tumor	NN	O
and	CC	O
thus	RB	O
poses	VBZ	O
a	DT	O
risk	NN	O
for	IN	O
TLS	NNP	O
in	IN	O
the	DT	O
initial	JJ	O
5week	CD	DOS
ramp	NN	UNIT
-	:	O
up	RB	O
phase	NN	O
.	.	O

THE	DT	O
MAXIMUM	NNP	O
DOSAGE	NNP	O
RECOMMENDED	NNP	O
BY	NNP	O
THE	NNP	O
AMERICAN	NNP	O
ACADEMY	NNP	O
OF	IN	O
PEDIATRICS	NNP	O
IS	NNP	O
3	CD	DOS
G	NNP	UNIT
FAT	NNP	O
/	NNP	O
KG	NNP	O
/	VBD	O
24	CD	O
HOURS3	NNP	O
THE	NNP	O
INITIAL	NNP	O
RATE	NNP	O
OF	NNP	O
INFUSION	NNP	O
IN	NNP	O
OLDER	NNP	O
PEDIATRIC	NNP	O
PATIENTS	NNP	O
SHOULD	NNP	O
BE	NNP	O
NO	NNP	O
MORE	NNP	O
THAN	NNP	O
0.05	CD	DOS
ML	NNP	UNIT
/	NNP	O
MINUTE	NNP	O
FOR	NNP	O
THE	NNP	O
FIRST	NNP	O
10	CD	O
TO	NNP	O
15	CD	O
MINUTES	NNP	O
.	.	O

>	$	O
33	CD	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
difficulty	NN	WHO
swallowing	VBG	WHO
capsules	NNS	WHO
,	,	O
follow	VBP	O
the	DT	O
instructions	NNS	O
below	IN	O
for	IN	O
administration	NN	O
with	IN	O
food	NN	O
or	CC	O
liquid	NN	O
.	.	O

If	IN	O
concurrent	JJ	O
short	JJ	O
term	NN	O
(	(	O
14	CD	O
days	NNS	O
or	CC	O
less	JJR	O
)	)	O
use	NN	O
of	IN	O
moderate	JJ	O
CYP3A	NNP	O
inhibitors	NNS	O
is	VBZ	O
unavoidable	JJ	O
for	IN	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
taking	VBG	WHO
COTELLIC	NNP	WHO
60	CD	DOS
mg	NN	UNIT
,	,	O
reduce	VB	O
COTELLIC	NNP	O
dose	VB	O
to	TO	O
20	CD	DOS
mg.	NNS	UNIT
After	IN	O
discontinuation	NN	O
of	IN	O
a	DT	O
moderate	JJ	O
CYP3A	NNP	O
inhibitor	NN	O
,	,	O
resume	VBP	O
previous	JJ	O
dose	NN	O
of	IN	O
COTELLIC	NNP	O
60	CD	DOS
mg	NN	UNIT
[	NNP	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

The	DT	O
safety	NN	O
of	IN	O
treating	VBG	O
more	JJR	O
than	IN	O
5	CD	O
migraine	NN	O
attacks	NNS	O
in	IN	O
any	DT	O
given	VBN	O
month	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	O

Paclitaxel	NNP	O
Injection	NNP	O
should	MD	O
be	VB	O
diluted	VBN	O
in	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
;	:	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
;	:	O
5	CD	O
%	NN	O
Dextrose	NNP	O
and	CC	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
;	:	O
or	CC	O
5	CD	O
%	NN	O
Dextrose	NNP	O
in	IN	O
Ringer	NNP	O
's	POS	O
Injection	NNP	O
to	TO	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
0.3	CD	DOS
to	TO	O
1.2	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
.	.	O

PANCREAZE	NNP	O
capsules	NNS	O
and	CC	O
capsule	NN	O
contents	NNS	O
should	MD	O
not	RB	O
be	VB	O
crushed	VBN	O
or	CC	O
chewed	VBN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
misses	VBZ	O
one	CD	DOS
or	CC	O
more	JJR	O
pink	JJ	O
tablets	NNS	O
,	,	O
she	PRP	O
is	VBZ	O
still	RB	O
protected	VBN	O
against	IN	O
pregnancy	NN	O
provided	VBD	O
she	PRP	O
begins	VBZ	O
taking	VBG	O
light	JJ	O
-	:	O
orange	NN	O
tablets	NNS	O
again	RB	O
on	IN	O
the	DT	O
proper	JJ	FREQ
day	NN	FREQ
.	.	O

The	DT	O
patient	NN	O
should	MD	O
set	VB	O
a	DT	O
“	JJ	O
target	NN	O
quit	NN	O
date	NN	O
”	NN	O
within	IN	O
the	DT	O
first	JJ	O
2	CD	PER
weeks	NNS	PER
of	IN	O
treatment	NN	O
with	IN	O
ZYBAN	NNP	O
.	.	O

Retavase®	NNP	O
is	VBZ	O
administered	VBN	O
as	IN	O
a	DT	O
10	CD	O
+	JJ	O
10	CD	O
unit	NN	O
double	JJ	O
-	:	O
bolus	NN	O
injection	NN	O
.	.	O

On	IN	O
the	DT	O
evening	NN	O
before	IN	O
the	DT	O
colonoscopy	NN	O
:	:	O

•	NN	O
As	IN	O
stated	VBN	O
in	IN	O
DOSAGE	NNP	O
AND	CC	O
ADMINISTRATION	NNP	O
:	:	O
Initial	JJ	O
Dosage	NNP	O
,	,	O
REFLUDAN	NNP	O
(	(	O
lepirudin	NN	O
)	)	O
should	MD	O
not	RB	O
be	VB	O
started	VBN	O
in	IN	O
patients	NNS	WHO
presenting	VBG	WHO
with	IN	WHO
a	DT	WHO
baseline	NN	WHO
aPTT	NN	WHO
ratio	NN	WHO
of	IN	WHO
2.5	CD	WHO
or	CC	WHO
more	JJR	WHO
,	,	O
in	IN	O
order	NN	O
to	TO	O
avoid	VB	O
initial	JJ	O
overdosing	NN	O
.	.	O

The	DT	O
infrequent	NN	O
-	:	O
risk	NN	O
category	NN	O
,	,	O
including	VBG	O
veterinarians	NNS	O
,	,	O
animal	JJ	O
-	:	O
control	NN	O
and	CC	O
wildlife	NN	O
officers	NNS	O
working	VBG	O
in	IN	O
areas	NNS	O
of	IN	O
low	JJ	O
rabies	NNS	O
enzooticity	NN	O
(	(	O
infrequent	JJ	O
-	:	O
exposure	NN	O
group	NN	O
)	)	O
and	CC	O
international	JJ	O
travelers	NNS	O
to	TO	O
rabies	NNS	O
enzootic	JJ	O
areas	NNS	O
do	VBP	O
not	RB	O
require	VB	O
routine	JJ	O
preexposure	NN	O
booster	NN	O
doses	NNS	O
of	IN	O
RabAvert	NNP	O
after	IN	O
completion	NN	O
of	IN	O
a	DT	O
full	JJ	O
primary	JJ	O
preexposure	NN	O
vaccination	NN	O
scheme	NN	O
(	(	O
Table	JJ	O
1	CD	O
)	)	O
.	.	O

For	IN	O
central	JJ	O
injections	NNS	O
,	,	O
catheters	NNS	O
may	MD	O
be	VB	O
introduced	VBN	O
at	IN	O
the	DT	O
antecubital	JJ	O
fossa	NN	O
into	IN	O
either	CC	O
the	DT	O
basilic	NN	O
or	CC	O
cephalic	JJ	O
vein	NN	O
or	CC	O
at	IN	O
the	DT	O
leg	NN	O
into	IN	O
the	DT	O
femoral	JJ	O
vein	NN	O
and	CC	O
advanced	VBD	O
to	TO	O
the	DT	O
distal	JJ	O
segment	NN	O
of	IN	O
the	DT	O
corresponding	JJ	O
vena	NN	O
cava	NN	O
.	.	O

If	IN	O
pain	NN	O
recurs	NNS	O
,	,	O
alternative	JJ	O
routes	NNS	O
of	IN	O
administration	NN	O
should	MD	O
be	VB	O
considered	VBN	O
,	,	O
since	IN	O
experience	NN	O
with	IN	O
repeated	JJ	O
doses	NNS	O
of	IN	O
morphine	NN	O
by	IN	O
the	DT	O
intrathecal	JJ	O
route	NN	O
is	VBZ	O
limited	VBN	O
.	.	O

One	CD	O
sterile	NN	O
50	CD	O
-	:	O
mL	NN	O
preparation	NN	O
vial	NN	O

Pediatric	JJ	WHO
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
to	TO	WHO
severe	JJ	WHO
renal	JJ	WHO
insufficiency	NN	WHO
were	VBD	O
excluded	VBN	O
from	IN	O
the	DT	O
clinical	JJ	O
trial	NN	O
of	IN	O
cUTI	NN	O
and	CC	O
pyelonephritis	NN	O
.	.	O

Shake	NNP	O
vial	JJ	O
thoroughly	RB	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
SUSTOL	NNP	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
administered	VBD	O
subcutaneously	RB	O
.	.	O

No	DT	O
other	JJ	O
drugs	NNS	O
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
the	DT	O
same	JJ	O
solution	NN	O
with	IN	O
sodium	NN	O
nitroprus	JJ	O
side	NN	O
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
of	IN	O
MINOCIN®	NNP	O
Pellet	NNP	O
-	:	O
Filled	VBN	O
Capsules	NNP	O
is	VBZ	O
200	CD	DOS
mg	NN	UNIT
initially	RB	O
followed	VBN	O
by	IN	O
100	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

Note	NN	O
:	:	O
The	DT	O
table	NN	O
and	CC	O
accompanying	VBG	O
formula	NN	O
are	VBP	O
applicable	JJ	O
for	IN	O
dosage	NN	O
determinations	NNS	O
only	RB	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
iron	NN	WHO
deficiency	NN	WHO
anemia	NN	WHO
;	:	O
they	PRP	O
are	VBP	O
not	RB	O
to	TO	O
be	VB	O
used	VBN	O
for	IN	O
dosage	NN	O
determinations	NNS	O
in	IN	O
patients	NNS	WHO
requiring	VBG	WHO
iron	NN	WHO
replacement	NN	WHO
for	IN	O
blood	NN	O
loss	NN	O
.	.	O

Use	NNP	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
younger	JJR	WHO
than	IN	WHO
18	CD	WHO
years	NNS	WHO
is	VBZ	O
not	RB	O
recommended	JJ	O
because	IN	O
of	IN	O
numerically	RB	O
high	JJ	O
rates	NNS	O
of	IN	O
HPA	NNP	O
axis	JJ	O
suppression	NN	O
(	(	O
See	JJ	O
PRECAUTIONS	NNP	O
:	:	O
Pediatric	NNP	O
Use	NNP	O
)	)	O
.	.	O

Normally	RB	O
the	DT	O
HPA	NNP	O
system	NN	O
is	VBZ	O
characterized	VBN	O
by	IN	O
diurnal	JJ	O
(	(	O
circadian	JJ	O
)	)	O
rhythm	NN	O
.	.	O

As	IN	O
with	IN	O
all	DT	O
intravenous	JJ	O
fluid	NN	O
therapy	NN	O
,	,	O
the	DT	O
parenteral	JJ	O
administration	NN	O
of	IN	O
a	DT	O
solution	NN	O
of	IN	O
amino	NN	O
acids	NNS	O
and	CC	O
dextrose	JJ	O
requires	VBZ	O
an	DT	O
accurate	JJ	O
estimate	NN	O
of	IN	O
the	DT	O
total	JJ	O
fluid	NN	O
,	,	O
electrolytes	NNS	O
and	CC	O
acid	SYM	O
-	:	O
base	NN	O
needed	VBN	O
to	TO	O
compensate	VB	O
for	IN	O
the	DT	O
patient	NN	O
's	POS	O
measurable	JJ	O
urinary	JJ	O
and	CC	O
other	JJ	O
(	(	O
i.e	JJ	O
,	,	O
nasogastric	JJ	O
suction	NN	O
,	,	O
fistula	JJ	O
drainage	NN	O
,	,	O
diarrhea	NN	O
)	)	O
daily	JJ	FREQ
losses	NNS	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dose	NN	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
½	NNP	O
hour	NN	O
before	IN	O
meals	NNS	O
.	.	O

Impaired	NNP	O
Renal	NNP	O
Function	NNP	O
:	:	O
When	WRB	O
renal	JJ	O
function	NN	O
is	VBZ	O
impaired	VBN	O
,	,	O
a	DT	O
reduced	JJ	O
dosage	NN	O
must	MD	O
be	VB	O
employed	VBN	O
.	.	O

Once	RB	O
the	DT	O
protective	JJ	O
covers	NNS	O
have	VBP	O
been	VBN	O
removed	VBN	O
(	(	O
Steps	NNP	O
3	CD	O
and	CC	O
4	CD	O
)	)	O
,	,	O
do	VBP	O
not	RB	O
touch	VB	O
the	DT	O
exposed	JJ	O

Counting	VBG	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
menstruation	NN	O
as	IN	O
“	JJ	O
Day	NNP	O
1	CD	O
”	NN	O
,	,	O
the	DT	O
first	JJ	O
white	JJ	O
tablet	NN	O
should	MD	O
be	VB	O
taken	VBN	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
menstrual	JJ	O
bleeding	NN	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
switched	VBN	WHO
and	CC	WHO
who	WP	WHO
tolerate	VBP	WHO
COREG	NNP	WHO
CR	NNP	O
should	MD	O
,	,	O
as	IN	O
appropriate	JJ	O
,	,	O
have	VBP	O
their	PRP$	O
dose	NN	O
increased	VBN	O
after	IN	O
an	DT	O
interval	NN	O
of	IN	O
at	IN	PER
least	JJS	PER
2	CD	PER
weeks	NNS	PER
[	RB	O
see	VBP	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

The	DT	O
chronological	JJ	O
and	CC	O
skeletal	JJ	O
ages	NNS	O
must	MD	O
be	VB	O
taken	VBN	O
into	IN	O
consideration	NN	O
,	,	O
both	DT	O
in	IN	O
determining	VBG	O
the	DT	O
initial	JJ	O
dose	NN	O
and	CC	O
in	IN	O
adjusting	VBG	O
the	DT	O
dose	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Lexapro	NNP	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

In	IN	O
the	DT	O
study	NN	O
of	IN	O
primary	JJ	O
generalized	VBN	O
tonic	JJ	O
-	:	O
clonic	NN	O
seizures	NNS	O
,	,	O
the	DT	O
assigned	VBN	O
dose	NN	O
of	IN	O
6	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NNS	O
once	RB	FREQ
daily	RB	FREQ
was	VBD	O
reached	VBN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
8	CD	PER
weeks	NNS	PER
[	JJ	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

For	IN	O
DIANEAL	NNP	O
in	IN	O
ULTRABAG	NNP	O
,	,	O
inspect	VBP	O
the	DT	O
tubing	NN	O
and	CC	O
drain	NN	O
container	NN	O
for	IN	O
presence	NN	O
of	IN	O
solution	NN	O
.	.	O

These	DT	O
may	MD	O
be	VB	O
self	PRP	O
-	:	O
limited	JJ	O
and	CC	O
can	MD	O
subside	VB	O
within	IN	O
twelve	JJ	PER
weeks	NNS	PER
.	.	O

When	WRB	O
transitioning	VBG	O
from	IN	O
BREVIBLOC	NNP	O
to	TO	O
alternative	VB	O
drugs	NNS	O
,	,	O
the	DT	O
physician	NN	O
should	MD	O
carefully	RB	O
consider	VB	O
the	DT	O
labeling	NN	O
instructions	NNS	O
of	IN	O
the	DT	O
alternative	JJ	O
drug	NN	O
selected	VBN	O
and	CC	O
reduce	VB	O
the	DT	O
dosage	NN	O
of	IN	O
BREVIBLOC	NNP	O
as	IN	O
follows	VBZ	O
:	:	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
to	TO	O
prime	VB	O
the	DT	O
inhaler	NN	O
before	IN	O
using	VBG	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
and	CC	O
in	IN	O
cases	NNS	O
where	WRB	O
the	DT	O
inhaler	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
used	VBN	O
for	IN	O
more	JJR	O
than	IN	O
2	CD	PER
weeks	NNS	PER
by	IN	O
releasing	VBG	O
four	CD	O
“	JJ	O
test	NN	O
sprays	NNS	O
”	VBP	O
into	IN	O
the	DT	O
air	NN	O
,	,	O
away	RB	O
from	IN	O
the	DT	O
face	NN	O
.	.	O

Inject	NNP	O
all	PDT	O
the	DT	O
diluent	NN	O
in	IN	O
the	DT	O
syringe	NN	O
into	IN	O
the	DT	O
vial	NN	O
of	IN	O
lyophilized	JJ	O
vaccine	NN	O
,	,	O
and	CC	O
agitate	VB	O
to	TO	O
mix	VB	O
thoroughly	RB	O
.	.	O

Adverse	JJ	O
Reactions	NNS	O

Step	NN	O
3	CD	O
:	:	O
Transferring	NN	O
sterile	JJ	O
water	NN	O
,	,	O
USP	NNP	O
from	IN	O
the	DT	O
syringe	NN	O
to	TO	O
the	DT	O
vial	NN	O

Because	IN	O
Diazepam	NNP	O
rectal	JJ	O
gel	NN	O
is	VBZ	O
provided	VBN	O
as	IN	O
unit	NN	O
doses	NNS	O
of	IN	O
2.5	CD	O
,	,	O
5	CD	O
,	,	O
7.5	CD	O
,	,	O
10	CD	O
,	,	O
12.5	CD	O
,	,	O
15	CD	O
,	,	O
17.5	CD	O
,	,	O
and	CC	O
20	CD	DOS
mg	NN	UNIT
,	,	O
the	DT	O
prescribed	NN	O
dose	NN	O
is	VBZ	O
obtained	VBN	O
by	IN	O
rounding	VBG	O
upward	RB	O
to	TO	O
the	DT	O
next	JJ	O
available	JJ	O
dose	NN	O
.	.	O

If	IN	O
a	DT	O
dose	NN	O
is	VBZ	O
missed	VBN	O
,	,	O
it	PRP	O
should	MD	O
be	VB	O
administered	VBN	O
as	RB	O
soon	RB	O
as	IN	O
noticed	VBN	O
,	,	O
provided	VBD	O
the	DT	O
next	JJ	O
regularly	RB	O
scheduled	VBN	O
dose	NN	O
is	VBZ	O
due	JJ	O
at	IN	O
least	JJS	O
3	CD	O
days	NNS	O
later	RB	O
.	.	O

3.1	LS	O
-	:	O
6.0	CD	O

If	IN	O
the	DT	O
24	CD	O
hour	NN	O
serum	NN	O
creatinine	NN	O
has	VBZ	O
increased	VBN	O
50	CD	O
%	NN	O
over	IN	O
baseline	NN	O
or	CC	O
if	IN	O
the	DT	O
24	CD	O
hour	NN	O
methotrexate	NN	O
level	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
5	CD	O
x	JJ	O
10	CD	O
-	:	O
6	CD	O
M	NNP	O
or	CC	O
the	DT	O
48	CD	O
hour	NN	O
level	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
9	CD	O
x	JJ	O
10	CD	O
-	:	O
7	CD	O
M	NNP	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
leucovorin	NN	O
(	(	O
leucovorin	JJ	O
calcium	NN	O
)	)	O
should	MD	O
be	VB	O
increased	VBN	O
to	TO	O
100	CD	DOS
mg	NNS	UNIT
/	JJ	O
m2	NNS	O
IV	NNP	O
every	DT	FREQ
3	CD	FREQ
hours	NNS	FREQ
until	IN	O
the	DT	O
methotrexate	NN	O
level	NN	O
is	VBZ	O
less	JJR	O
than	IN	O
10	CD	O
-	:	O
8	CD	O
M	NNP	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Doses	NNS	O
for	IN	O
Adults	NNS	WHO
with	IN	WHO
Renal	NNP	WHO
Impairment	NNP	WHO

As	IN	O
with	IN	O
other	JJ	O
corticosteroids	NNS	O
,	,	O
therapy	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
when	WRB	O
control	NN	O
is	VBZ	O
achieved	VBN	O
.	.	O

For	IN	O
all	DT	WHO
pediatric	JJ	WHO
patients	NNS	WHO
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
indications	NNS	O
for	IN	O
sedation	NN	O
/	NNP	O
anxiolysis	NN	O
,	,	O
it	PRP	O
is	VBZ	O
vital	JJ	O
to	TO	O
titrate	VB	O
midazolam	NNS	O
and	CC	O
other	JJ	O
concomitant	JJ	O
medications	NNS	O
slowly	RB	O
to	TO	O
the	DT	O
desired	JJ	O
clinical	JJ	O
effect	NN	O
.	.	O

Figure	NN	O
1	CD	O
:	:	O
Reconstitution	NN	O
procedure	NN	O

Marqibo	NNP	O
takes	VBZ	O
approximately	RB	O
60	CD	O
to	TO	O
90	CD	O
minutes	NNS	O
to	TO	O
prepare	VB	O
.	.	O

Distributed	VBN	O
by	IN	O
GE	NNP	O
Healthcare	NNP	O
Inc.	NNP	O
,	,	O
Marlborough	NNP	O
,	,	O
MA	NNP	O
01752	CD	O
U.S.A	NNP	O
.	.	O

There	EX	O
is	VBZ	O
no	DT	O
evidence	NN	O
that	IN	O
doses	VBZ	O
greater	JJR	O
than	IN	O
2.5	CD	DOS
mg	NNS	UNIT
a	DT	FREQ
day	NN	FREQ
provide	IN	O
additional	JJ	O
benefit	NN	O
,	,	O
and	CC	O
they	PRP	O
should	MD	O
ordinarily	RB	O
be	VB	O
avoided	VBN	O
because	IN	O
of	IN	O
the	DT	O
potential	NN	O
increased	VBD	O
risk	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	O

Doses	NNS	O
of	IN	O
0.15	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NNS	O
administered	VBN	O
over	IN	O
5	CD	O
to	TO	O
15	CD	O
seconds	NNS	O
,	,	O
0.2	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
administered	VBD	O
over	IN	O
30	CD	O
seconds	NNS	O
,	,	O
or	CC	O
0.25	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
administered	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
(	(	O
0.15	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
followed	VBD	O
in	IN	O
30	CD	O
seconds	NNS	O
by	IN	O
0.1	CD	DOS
mg	NNS	UNIT
/	NNP	O
kg	NN	O
)	)	O
are	VBP	O
recommended	VBN	O
for	IN	O
facilitation	NN	O
of	IN	O
tracheal	JJ	O
intubation	NN	O
for	IN	O
most	JJS	WHO
patients	NNS	WHO
(	(	O
see	VB	O
Table	NNP	O
7	CD	O
)	)	O
.	.	O

Individually	RB	O
titrate	JJ	O
OPANA	NNP	O
ER	NNP	O
to	TO	O
a	DT	O
dose	NN	O
that	WDT	O
provides	VBZ	O
adequate	JJ	O
analgesia	NNS	O
and	CC	O
minimizes	VBZ	O
adverse	JJ	O
reactions	NNS	O
.	.	O

PRANDIN	NN	O
may	MD	O
be	VB	O
dosed	VBN	O
2	CD	O
,	,	O
3	CD	O
,	,	O
or	CC	O
4	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
in	IN	O
response	NN	O
to	TO	O
changes	NNS	O
in	IN	O
the	DT	O
patient	NN	O
’	NNP	O
s	NN	O
meal	NN	O
pattern	NN	O
.	.	O

Invert	NNP	O
the	DT	O
Novoeight®	NNP	O
vial	NN	O
and	CC	O
slowly	RB	O
draw	VB	O
the	DT	O
solution	NN	O
into	IN	O
the	DT	O
syringe	NN	O
.	.	O

No	DT	O
dosage	NN	O
adjustment	NN	O
of	IN	O
VEMLIDY	NNP	O
is	VBZ	O
required	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
,	,	O
moderate	JJ	O
,	,	O
or	CC	O
severe	JJ	O
renal	JJ	O
impairment	NN	O
.	.	O

In	IN	O
these	DT	O
individuals	NNS	O
with	IN	O
autonomous	JJ	O
parathyroid	JJ	O
hyperfunction	NN	O
,	,	O
oral	JJ	O
Rocaltrol	NNP	O
(	(	O
calcitriol	NN	O
)	)	O
may	MD	O
be	VB	O
useful	JJ	O
to	TO	O
maintain	VB	O
normocalcemia	NN	O
,	,	O
but	CC	O
has	VBZ	O
not	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
adequate	JJ	O
treatment	NN	O
for	IN	O
hyperparathyroidism	NN	O
.	.	O

68	CD	O

Although	IN	O
reconstituted	VBN	O
COSMEGEN	NNP	O
is	VBZ	O
chemically	RB	O
stable	JJ	O
,	,	O
the	DT	O
product	NN	O
does	VBZ	O
not	RB	O
contain	VB	O
a	DT	O
preservative	JJ	O
and	CC	O
accidental	JJ	O
microbial	JJ	O
contamination	NN	O
might	MD	O
result	VB	O
.	.	O

Mylotarg	NNP	O
(	(	O
gemtuzumab	JJ	O
ozogamicin	NN	O
for	IN	O
injection	NN	O
)	)	O
is	VBZ	O
light	JJ	O
sensitive	JJ	O
and	CC	O
must	MD	O
be	VB	O
protected	VBN	O
from	IN	O
direct	JJ	O
and	CC	O
indirect	JJ	O
sunlight	NN	O
and	CC	O
unshielded	JJ	O
fluorescent	NN	O
light	NN	O
during	IN	O
the	DT	O
preparation	NN	O
and	CC	O
administration	NN	O
of	IN	O
the	DT	O
infusion	NN	O
(	(	O
using	VBG	O
an	DT	O
ultraviolet	JJ	O
[	NN	O
UV	NNP	O
]	NNP	O
protective	JJ	O
bag	NN	O
over	IN	O
the	DT	O
IV	NNP	O
bag	NN	O
during	IN	O
infusion	NN	O
)	)	O
.	.	O

Begin	VB	O
with	IN	O
the	DT	O
lowest	JJS	O
recommended	VBD	O
dose	NN	O
.	.	O

Ceftazidime	NN	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
4	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
has	VBZ	O
been	VBN	O
found	VBN	O
compatible	JJ	O
for	IN	O
12	CD	PER
hours	NNS	PER
at	IN	O
room	NN	O
temperature	NN	O
or	CC	O
for	IN	O
3	CD	PER
days	NNS	PER
under	IN	O
refrigeration	NN	O
in	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
or	CC	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
when	WRB	O
admixed	VBN	O
with	IN	O
:	:	O
cefuroxime	NN	O
sodium	NN	O
(	(	O
ZINACEF®	NNP	O
)	)	O
3	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
,	,	O
heparin	VBZ	O
10	CD	DOS
or	CC	O
50	CD	DOS
U	NNP	UNIT
/	NNP	O
mL	NN	O
,	,	O
or	CC	O
potassium	NN	O
chloride	VBP	O
10	CD	DOS
or	CC	O
40	CD	DOS
mEq	NNS	UNIT
/	JJ	O
L	NNP	O
.	.	O

2	CD	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
Zelnorm®	NNP	O
(	(	O
tegaserod	JJ	O
maleate	NN	O
)	)	O
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
taken	VBN	O
twice	RB	FREQ
daily	JJ	FREQ
orally	RB	O
before	IN	O
meals	NNS	O
for	IN	O
4	CD	PER
to	TO	O
6	CD	PER
weeks	NNS	PER
.	.	O

Table	JJ	O
1	CD	O
displays	VBZ	O
the	DT	O
recommended	JJ	O
oral	JJ	O
dosage	NN	O
of	IN	O
TAMIFLU	NNP	O
for	IN	O
prophylaxis	NN	O
of	IN	O
influenza	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
1	CD	WHO
year	NN	WHO
to	TO	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
based	VBN	O
on	IN	O
body	NN	O
weight	NN	O
and	CC	O
provides	VBZ	O
information	NN	O
about	IN	O
prescribing	VBG	O
the	DT	O
capsule	NN	O
or	CC	O
the	DT	O
formulation	NN	O
for	IN	O
oral	JJ	O
suspension	NN	O
.	.	O

The	DT	O
starting	NN	O
dose	NN	O
for	IN	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
not	RB	WHO
opioid	JJ	WHO
tolerant	NN	WHO
is	VBZ	O
XTAMPZA	NNP	O
ER	NNP	O
9	CD	DOS
mg	NN	UNIT
orally	RB	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
with	IN	O
food	NN	O
.	.	O

In	IN	O
neonates	NNS	WHO
,	,	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
15	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
is	VBZ	O
suggested	VBN	O
,	,	O
followed	VBN	O
by	IN	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
for	IN	O
neonates	NNS	O
in	IN	O
the	DT	O
1st	CD	PER
week	NN	PER
of	IN	O
life	NN	O
and	CC	O
every	DT	O
8	CD	O
hours	NNS	O
thereafter	RB	O
up	IN	O
to	TO	O
the	DT	O
age	NN	O
of	IN	O
1	CD	O
month	NN	O
.	.	O

ELOXATIN	NNP	O
(	(	O
oxaliplatin	JJ	O
injection	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
under	IN	O
the	DT	O
supervision	NN	O
of	IN	O
a	DT	O
qualified	JJ	O
physician	NN	O
experienced	VBN	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
cancer	NN	O
chemotherapeutic	JJ	O
agents	NNS	O
.	.	O

Store	NN	O
at	IN	O
20°	CD	O
to	TO	O
25°C	CD	O
(	(	O
68°	CD	O
to	TO	O
77°F	CD	O
)	)	O
[	NN	O
see	VBP	O
USP	NNP	O
Controlled	NNP	O
Room	NNP	O
Temperature	NNP	O
]	NNP	O
.	.	O

9	CD	O
.	.	O

If	IN	O
expected	VBN	O
factor	NN	O
VIII	NNP	O
activity	NN	O
plasma	NN	O
levels	NNS	O
are	VBP	O
not	RB	O
attained	VBN	O
,	,	O
or	CC	O
if	IN	O
bleeding	NN	O
is	VBZ	O
not	RB	O
controlled	VBN	O
with	IN	O
an	DT	O
appropriate	JJ	O
dose	NN	O
,	,	O
an	DT	O
assay	NN	O
should	MD	O
be	VB	O
performed	VBN	O
to	TO	O
determine	VB	O
if	IN	O
a	DT	O
factor	NN	O
VIII	NNP	O
inhibitor	NN	O
is	VBZ	O
present	JJ	O
.	.	O

Injection	NN	O
is	VBZ	O
to	TO	O
be	VB	O
given	VBN	O
concomitantly	RB	O
with	IN	O
another	DT	O
drug	NN	O
,	,	O
each	DT	O
drug	NN	O
should	MD	O
be	VB	O
given	VBN	O
separately	RB	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
recommended	VBN	O
dosage	NN	O
and	CC	O
route	NN	O
of	IN	O
administration	NN	O
for	IN	O
each	DT	O
product	NN	O
.	.	O

Each	DT	O
vial	NN	O
should	MD	O
be	VB	O
inspected	VBN	O
for	IN	O
complete	JJ	O
dissolution	NN	O
of	IN	O
the	DT	O
drug	NN	O
.	.	O

The	DT	O
dose	NN	O
for	IN	O
patients	NNS	WHO
being	VBG	WHO
converted	VBN	WHO
to	TO	O
enalaprilat	VB	O
injection	NN	O
from	IN	O
oral	JJ	O
therapy	NN	O
for	IN	O
hypertension	NN	O
with	IN	O
enalapril	JJ	O
maleate	NN	O
is	VBZ	O
1.25	CD	DOS
mg	NN	UNIT
every	DT	FREQ
six	CD	FREQ
hours	NNS	FREQ
.	.	O

Follow	NNP	O
applicable	JJ	O
special	JJ	O
handling	NN	O
and	CC	O
disposal	NN	O
procedures.1	NN	O

Initiate	NNP	O
Felbatol®	NNP	O
at	IN	O
1200	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
three	CD	O
or	CC	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

No	DT	O
dosage	NN	O
adjustment	NN	O
is	VBZ	O
recommended	VBN	O
for	IN	O
patients	NNS	WHO
receiving	VBG	WHO
regularly	RB	WHO
scheduled	VBN	WHO
hemodialysis	NN	WHO
,	,	O
and	CC	O
DALVANCE	NNP	O
can	MD	O
be	VB	O
administered	VBN	O
without	IN	O
regard	NN	O
to	TO	O
the	DT	O
timing	NN	O
of	IN	O
hemodialysis	NN	O
[	NNP	O
see	NN	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Preferred	VBN	O
injection	NN	O
areas	NNS	O
:	:	O

The	DT	O
dose	NN	O
of	IN	O
Triglide	NNP	O
is	VBZ	O
160	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Reconstitution	NN	O
and	CC	O
further	JJ	O
dilution	NN	O
prior	RB	O
to	TO	O
intravenous	JJ	O
infusion	NN	O
is	VBZ	O
only	RB	O
recommended	JJ	O
with	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
(	(	O
preservative	JJ	O
free	NN	O
)	)	O
.	.	O

Subsequent	JJ	O
monitoring	NN	O
intervals	NNS	O
should	MD	O
be	VB	O
based	VBN	O
on	IN	O
individual	JJ	O
patient	NN	O
response	NN	O
.	.	O

For	IN	O
details	NNS	O
on	IN	O
etonogestrel	NN	O
blood	NN	O
level	NN	O
determination	NN	O
,	,	O
call	VB	O
1	CD	O
-	:	O
877	CD	O
-	:	O
IMPLANON	NNP	O
(	(	O
1	CD	O
-	:	O
877	CD	O
-	:	O
467	CD	O
-	:	O
5266	CD	O
)	)	O
for	IN	O
further	JJ	O
instructions	NNS	O
.	.	O

Although	IN	O
the	DT	O
occurrence	NN	O
of	IN	O
pregnancy	NN	O
is	VBZ	O
highly	RB	O
unlikely	JJ	O
if	IN	O
Nordette®	NNP	O
-	:	O
28	CD	O
is	VBZ	O
taken	VBN	O
according	VBG	O
to	TO	O
directions	NNS	O
,	,	O
if	IN	O
withdrawal	VBN	O
bleeding	NN	O
does	VBZ	O
not	RB	O
occur	VB	O
,	,	O
the	DT	O
possibility	NN	O
of	IN	O
pregnancy	NN	O
must	MD	O
be	VB	O
considered	VBN	O
.	.	O

Table	JJ	O
2	CD	O
presents	VBZ	O
the	DT	O
dosing	NN	O
options	NNS	O
for	IN	O
patients	NNS	WHO
undergoing	VBG	WHO
hip	JJ	WHO
replacement	NN	WHO
surgery	NN	WHO
.	.	O

A	DT	O
lesser	JJR	O
initial	JJ	O
dosage	NN	O
range	NN	O
of	IN	O
triamcinolone	NN	O
diacetate	NN	O
injectable	JJ	O
suspension	NN	O
may	MD	O
produce	VB	O
the	DT	O
desired	JJ	O
effect	NN	O
when	WRB	O
the	DT	O
drug	NN	O
is	VBZ	O
administered	VBN	O
to	TO	O
provide	VB	O
a	DT	O
localized	JJ	O
concentration	NN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
the	DT	O
patient	NN	O
be	VB	O
started	VBN	O
on	IN	O
2	CD	DOS
mg	NN	UNIT
,	,	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

as	IN	O
required	VBN	O
for	IN	O
control	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dosage	NN	O
of	IN	O
CARDURA	NNP	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
given	VBN	O
once	RB	FREQ
daily	JJ	FREQ
either	CC	O
in	IN	O
the	DT	O
morning	NN	O
or	CC	O
evening	NN	O
.	.	O

Therapy	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
the	DT	O
lowest	JJS	O
recommended	VBD	O
dose	NN	O
and	CC	O
gradually	RB	O
increased	VBD	O
.	.	O

If	IN	O
a	DT	O
patient	JJ	WHO
forgets	NNS	WHO
to	TO	WHO
take	VB	WHO
one	CD	WHO
or	CC	WHO
more	JJR	WHO
light	JJ	WHO
yellow	NN	WHO
or	CC	WHO
pink	NN	WHO
tablets	NNS	WHO
,	,	O
the	DT	O
following	NN	O
is	VBZ	O
suggested	VBN	O
:	:	O

Because	IN	O
steady	JJ	O
-	:	O
state	NN	O
plasma	NN	O
concentrations	NNS	O
are	VBP	O
approximated	VBN	O
within	IN	O
24	CD	O
to	TO	O
36	CD	O
hours	NNS	O
,	,	O
EMBEDA	NNP	O
dose	NN	O
may	MD	O
be	VB	O
adjusted	VBN	O
every	DT	FREQ
1	CD	FREQ
to	TO	O
2	CD	PER
days	NNS	PER
.	.	O

To	TO	O
insure	VB	O
the	DT	O
precise	JJ	O
delivery	NN	O
of	IN	O
the	DT	O
small	JJ	O
volumes	NNS	O
of	IN	O
fluid	NN	O
necessary	JJ	O
for	IN	O
total	JJ	O
parenteral	JJ	O
nutrition	NN	O
in	IN	O
infants	NNS	WHO
,	,	O
accurately	RB	O
calibrated	VBN	O
and	CC	O
reliable	JJ	O
infusion	NN	O
systems	NNS	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

If	IN	O
a	DT	O
pre	NN	O
-	:	O
existing	VBG	O
line	NN	O
must	MD	O
be	VB	O
used	VBN	O
,	,	O
the	DT	O
Cytogam®	NNP	O
(	(	O
cytomegalovirus	NN	O
immune	NN	O
globulin	VBP	O
intravenous	JJ	O
human	NN	O
)	)	O
should	MD	O
not	RB	O
be	VB	O
diluted	VBN	O
more	JJR	O
than	IN	O
1:2	CD	O
with	IN	O
any	DT	O
of	IN	O
the	DT	O
above	JJ	O
-	:	O
named	VBN	O
solutions	NNS	O
.	.	O

In	IN	O
all	DT	O
cases	NNS	O
,	,	O
the	DT	O
period	NN	O
of	IN	O
overlapping	VBG	O
antipsychotic	JJ	O
administration	NN	O
should	MD	O
be	VB	O
minimized	VBN	O
.	.	O

Ethylenediamine	NNP	O
is	VBZ	O
not	RB	O
required	VBN	O
for	IN	O
solubility	NN	O
of	IN	O
premixed	JJ	O
Theophylline	NNP	O
and	CC	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
.	.	O

The	DT	O
suspension	NN	O
will	MD	O
now	RB	O
have	VB	O
a	DT	O
milky	JJ	O
appearance	NN	O
.	.	O

MIVACRON	NNP	O
SHOULD	NNP	O
ONLY	NNP	O
BE	NNP	O
ADMINISTERED	NNP	O
INTRAVENOUSLY	NNP	O
.	.	O

The	DT	O
following	NN	O
is	VBZ	O
the	DT	O
recommended	JJ	O
dose	NN	O
of	IN	O
reconstituted	VBN	O
GoLYTELY	NNP	O
solution	NN	O
for	IN	O
adults	NNS	WHO
.	.	O

If	IN	O
twice	RB	O
-	:	O
a	DT	O
-	:	O
day	NN	O
dosage	NN	O
is	VBZ	O
desired	VBN	O
,	,	O
one	CD	O
-	:	O
half	NN	O
of	IN	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
may	MD	O
be	VB	O
given	VBN	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

Given	VBN	O
the	DT	O
possibility	NN	O
of	IN	O
extravasation	NN	O
,	,	O
it	PRP	O
is	VBZ	O
advisable	JJ	O
to	TO	O
closely	RB	O
monitor	VB	O
the	DT	O
infusion	NN	O
site	NN	O
for	IN	O
possible	JJ	O
infiltration	NN	O
during	IN	O
drug	NN	O
administration	NN	O
.	.	O

4	CD	O
.	.	O

Hands	NNS	O
must	MD	O
remain	VB	O
behind	IN	O
the	DT	O
needle	NN	O
at	IN	O
all	DT	FREQ
times	NNS	FREQ
during	IN	O
use	NN	O
and	CC	O
disposal	NN	O
.	.	O

An	DT	O
injection	NN	O
of	IN	O
BOTOX	NNP	O
is	VBZ	O
prepared	VBN	O
by	IN	O
drawing	VBG	O
into	IN	O
an	DT	O
appropriately	RB	O
sized	VBN	O
sterile	JJ	O
syringe	NN	O
an	DT	O
amount	NN	O
of	IN	O
the	DT	O
properly	RB	O
reconstituted	VBN	O
toxin	NN	O
slightly	RB	O
greater	JJR	O
than	IN	O
the	DT	O
intended	VBN	O
dose	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
who	WP	WHO
respond	VBP	WHO
to	TO	WHO
Azmacort	NNP	WHO
(	(	O
triamcinolone	JJ	O
acetonide	NN	O
)	)	O
Inhalation	NNP	O
Aerosol	NNP	O
improvement	NN	O
in	IN	O
pulmonary	JJ	O
function	NN	O
is	VBZ	O
usually	RB	O
apparent	JJ	O
within	IN	O
one	CD	PER
to	TO	O
two	CD	PER
weeks	NNS	PER
after	IN	O
the	DT	O
initiation	NN	O
of	IN	O
therapy	NN	O
.	.	O

Procedures	NNS	O
for	IN	O
proper	JJ	O
handling	NN	O
and	CC	O
disposal	NN	O
of	IN	O
potentially	RB	O
hazardous	JJ	O
drugs	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

WELCHOL	NNP	O
for	IN	O
Oral	NNP	O
Suspension	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
with	IN	O
meals	NNS	O
.	.	O

Occurrence	NN	O
of	IN	O
drowsiness	NN	O
may	MD	O
require	VB	O
the	DT	O
administration	NN	O
of	IN	O
a	DT	O
major	JJ	O
portion	NN	O
of	IN	O
the	DT	O
daily	JJ	FREQ
dose	NN	O
at	IN	O
bedtime	NN	O
or	CC	O
a	DT	O
reduction	NN	O
of	IN	O
dosage	NN	O
.	.	O

To	TO	O
prevent	VB	O
increased	JJ	O
toxicity	NN	O
due	JJ	O
to	TO	O
excessive	JJ	O
blood	NN	O
levels	NNS	O
,	,	O
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
5	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
unless	IN	O
serum	NN	O
levels	NNS	O
are	VBP	O
monitored	VBN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
BOX	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

If	IN	O
you	PRP	O
are	VBP	O
planning	VBG	O
to	TO	O
have	VB	O
a	DT	O
baby	NN	O
,	,	O
are	VBP	O
pregnant	JJ	O
,	,	O
or	CC	O
are	VBP	O
nursing	VBG	O
a	DT	O
baby	NN	O
,	,	O
talk	NN	O
to	TO	O
your	PRP$	O
doctor	NN	O
.	.	O

Typical	JJ	O
dosing	VBG	O
with	IN	O
BETAGAN®	NNP	O
(	(	O
levobunolol	NN	O
)	)	O
0.25	CD	O
%	NN	O
is	VBZ	O
one	CD	DOS
to	TO	O
two	CD	DOS
drops	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Amoxapine	NNP	O
(	(	O
amoxapine	NN	O
(	(	O
amoxapine	JJ	O
tablets	NNS	O
)	)	O
tablets	NNS	O
)	)	O
may	MD	O
be	VB	O
given	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	FREQ
dose	NN	UNIT
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
300	CD	DOS
mg	NNS	UNIT
,	,	O
preferably	RB	O
at	IN	O
bedtime	NN	O
.	.	O

Daily	NNP	FREQ
Dose	NNP	O
b	NN	O

Progressive	JJ	O
improvement	NN	O
can	MD	O
be	VB	O
anticipated	VBN	O
during	IN	O
succeeding	VBG	PER
weeks	NNS	PER
of	IN	O
therapy	NN	O
.	.	O

Initiate	NNP	O
dosing	NN	O
at	IN	O
2.5	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
for	IN	O
1	CD	PER
week	NN	PER
,	,	O
5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
for	IN	O
the	DT	O
next	JJ	O
3	CD	PER
weeks	NNS	PER
,	,	O
and	CC	O
then	RB	O
increase	VB	O
as	IN	O
tolerated	JJ	O
,	,	O
to	TO	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
dosage	NN	O
must	MD	O
be	VB	O
determined	VBN	O
by	IN	O
individual	JJ	O
titration	NN	O
.	.	O

3	CD	O
.	.	O

In	IN	O
either	DT	O
case	NN	O
,	,	O
the	DT	O
initial	JJ	O
infusion	NN	O
rate	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
according	VBG	O
to	TO	O
the	DT	O
response	NN	O
to	TO	O
peripheral	JJ	O
nerve	NN	O
stimulation	NN	O
and	CC	O
to	TO	O
clinical	JJ	O
criteria	NNS	O
.	.	O

Once	RB	O
thawed	VBN	O
,	,	O
the	DT	O
solution	NN	O
should	MD	O
not	RB	O
be	VB	O
refrozen	VBN	O
.	.	O

Mitchell2	NNP	O
has	VBZ	O
shown	VBN	O
that	IN	O
particles	VBZ	O
less	JJR	O
than	IN	O
10	CD	DOS
microns	NNS	UNIT
should	MD	O
be	VB	O
retained	VBN	O
in	IN	O
the	DT	O
respiratory	NN	O
tract	JJ	O
satisfactorily	RB	O
.	.	O

Consider	VB	O
increasing	VBG	O
the	DT	O
Continuous	NNP	O
Dose	NNP	O
based	VBN	O
on	IN	O
the	DT	O
number	NN	O
and	CC	O
volume	NN	O
of	IN	O
Extra	NNP	O
Doses	NNP	O
of	IN	O
DUOPA	NNP	O
(	(	O
i.e	NN	O
,	,	O
total	JJ	O
amount	NN	O
of	IN	O
levodopa	JJ	O
component	NN	O
)	)	O
that	WDT	O
were	VBD	O
needed	VBN	O
for	IN	O
the	DT	O
previous	JJ	O
day	NN	O
and	CC	O
the	DT	O
patient	NN	O
's	POS	O
clinical	JJ	O
response	NN	O
.	.	O

ROBINUL	NNP	O
Injection	NNP	O
may	MD	O
be	VB	O
used	VBN	O
during	IN	O
surgery	NN	O
to	TO	O
counteract	VB	O
drug	NN	O
-	:	O
induced	VBD	O
or	CC	O
vagal	JJ	O
reflexes	NNS	O
and	CC	O
their	PRP$	O
associated	VBN	O
arrhythmias	NN	O
(	(	O
e.g	JJ	O
,	,	O
bradycardia	NN	O
)	)	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Approximate	NNP	O
Dose	NNP	O
Correspondence	NNP	O
Between	NNP	O
Symbyax1	NNP	O
and	CC	O
the	DT	O
Combination	NNP	O
of	IN	O
PROZAC	NNP	O
and	CC	O
Olanzapine	NNP	O

Monitor	NNP	O
the	DT	O
patient	NN	O
for	IN	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
bronchospasm	NN	O
after	IN	O
ADASUVE	NNP	O
administration	NN	O
.	.	O

For	IN	O
osteoarthritis	NN	WHO
patients	NNS	WHO
of	IN	WHO
low	JJ	WHO
body	NN	WHO
weight	VBD	WHO
or	CC	WHO
with	IN	WHO
milder	JJR	WHO
disease	NN	WHO
,	,	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
one	CD	DOS
600	CD	DOS
mg	NN	UNIT
tablet	NN	UNIT
once	IN	FREQ
a	DT	FREQ
day	NN	FREQ
may	MD	O
be	VB	O
appropriate	JJ	O
.	.	O

ALLZITAL	NNP	O
(	(	O
butalbital	JJ	O
and	CC	O
acetaminophen	NN	O
,	,	O
25	CD	DOS
mg	NN	UNIT
/	VBD	O
325	CD	DOS
mg	NN	UNIT
)	)	O
tablets	NNS	O
:	:	O
Two	CD	DOS
tablets	NNS	UNIT
every	DT	FREQ
four	CD	FREQ
hours	NNS	FREQ
.	.	O

Pay	NNP	O
attention	NN	O
to	TO	O
avoid	VB	O
sticking	VBG	O
yourself	PRP	O
with	IN	O
the	DT	O
exposed	VBN	O
needle	NN	O
(	(	O
Figure	NNP	O
2	CD	O
)	)	O
.	.	O

Using	VBG	O
a	DT	O
sterile	JJ	O
30	CD	O
gauge	NN	O
needle	NN	O
,	,	O
50	CD	DOS
Units	NNS	UNIT
of	IN	O
BOTOX	NNP	O
(	(	O
2	CD	DOS
mL	NN	UNIT
)	)	O
is	VBZ	O
injected	VBN	O
intradermally	RB	O
in	IN	O
0.1	CD	DOS
to	TO	O
0.2	CD	DOS
mL	NNS	UNIT
aliquots	NNS	UNIT
to	TO	O
each	DT	O
axilla	NN	O
evenly	RB	O
distributed	VBN	O
in	IN	O
multiple	JJ	O
sites	NNS	O
(	(	O
10	CD	O
-	:	O
15	CD	O
)	)	O
approximately	RB	O
1	CD	O
-	:	O
2	CD	O
cm	JJ	O
apart	RB	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
starts	VBZ	O
on	IN	O
ORTHO	NNP	O
-	:	O
CEPT®	NNP	O
postpartum	NN	O
,	,	O
and	CC	O
has	VBZ	O
not	RB	O
yet	RB	O
had	VBD	O
a	DT	O
period	NN	O
,	,	O
she	PRP	O
should	MD	O
be	VB	O
instructed	VBN	O
to	TO	O
use	VB	O
another	DT	O
method	NN	O
of	IN	O
contraception	NN	O
until	IN	O
a	DT	O
light	JJ	O
orange	NN	O
``	``	O
active	JJ	O
''	''	O
tablet	NN	O
has	VBZ	O
been	VBN	O
taken	VBN	O
daily	RB	FREQ
for	IN	O
7	CD	PER
days	NNS	PER
.	.	O

No	DT	O
more	JJR	O
than	IN	O
10	CD	DOS
mg	JJ	UNIT
/	$	O
24	CD	O
hr	NN	O
should	MD	O
be	VB	O
administered	VBN	O
.	.	O

The	DT	O
crushed	JJ	O
tablet	NN	O
preparation	NN	O
should	MD	O
be	VB	O
followed	VBN	O
whenever	WRB	O
possible	JJ	O
by	IN	O
food	NN	O
/	NNS	O
drink	VBP	O
(	(	O
e.g	NN	O
,	,	O
milk	NN	O
,	,	O
formula	NN	O
,	,	O
pudding	NN	O
,	,	O
broth	CC	O
,	,	O
and	CC	O
porridge	NN	O
)	)	O
.	.	O

HYQVIA	NNP	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
administer	VB	O
a	DT	O
full	JJ	O
therapeutic	JJ	O
dose	NN	O
in	IN	O
one	CD	O
site	NN	O
up	RB	O
to	TO	O
every	DT	FREQ
four	CD	FREQ
weeks	NNS	FREQ
.	.	O

Rather	RB	O
,	,	O
it	PRP	O
is	VBZ	O
essential	JJ	O
to	TO	O
calculate	VB	O
the	DT	O
dosage	NN	O
to	TO	O
fit	VB	O
the	DT	O
needs	NNS	O
of	IN	O
each	DT	O
patient	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Lumason	NNP	O
after	IN	O
reconstitution	NN	O
in	IN	O
adult	NN	WHO
patients	NNS	WHO
is	VBZ	O
2.4	CD	DOS
mL	NN	UNIT
administered	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
injection	NN	O
during	IN	O
ultrasonography	NN	O
of	IN	O
the	DT	O
liver	NN	O
.	.	O

Apply	NNP	O
PENNSAID	NNP	O
to	TO	O
clean	VB	O
,	,	O
dry	JJ	O
skin	NN	O
.	.	O

Standard	NNP	O
drugs	NNS	O
for	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
,	,	O
other	JJ	O
than	IN	O
levodopa	NNS	O
without	IN	O
a	DT	O
decarboxylase	NN	O
inhibitor	NN	O
,	,	O
may	MD	O
be	VB	O
used	VBN	O
concomitantly	RB	O
while	IN	O
carbidopa	NN	O
and	CC	O
levodopa	NN	O
extended	VBN	O
-	:	O
release	NN	O
tablets	NNS	O
are	VBP	O
being	VBG	O
administered	VBN	O
,	,	O
although	IN	O
their	PRP$	O
dosage	NN	O
may	MD	O
have	VB	O
to	TO	O
be	VB	O
adjusted	VBN	O
.	.	O

EVOTAZ	NNP	O
is	VBZ	O
a	DT	O
fixed	JJ	O
-	:	O
dose	JJ	O
combination	NN	O
product	NN	O
containing	VBG	O
300	CD	DOS
mg	NN	UNIT
of	IN	O
atazanavir	NN	O
and	CC	O
150	CD	DOS
mg	NN	UNIT
of	IN	O
cobicistat	NN	O
.	.	O

Disulfiram	NNP	O
should	MD	O
never	RB	O
be	VB	O
administered	VBN	O
until	IN	O
the	DT	O
patient	NN	O
has	VBZ	O
abstained	VBN	O
from	IN	O
alcohol	NN	O
for	IN	O
at	IN	O
least	JJS	O
12	CD	O
hours	NNS	O
.	.	O

for	IN	O
Injection	NNP	O
should	MD	O
be	VB	O
reconstituted	VBN	O
with	IN	O
10	CD	DOS
mL	NNS	UNIT
of	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
to	TO	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
approximately	RB	O
4	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
.	.	O

Use	NNP	O
only	RB	O
the	DT	O
calibrated	VBN	O
dropper	NN	O
provided	VBN	O
with	IN	O
this	DT	O
product	NN	O
.	.	O

In	IN	O
the	DT	O
case	NN	O
of	IN	O
postpartum	NN	O
use	NN	O
,	,	O
the	DT	O
product	NN	O
is	VBZ	O
intended	VBN	O
for	IN	O
maternal	JJ	O
administration	NN	O
.	.	O

The	DT	O
initial	JJ	O
and	CC	O
maintenance	NN	O
dosing	NN	O
of	IN	O
Riomet	NNP	O
should	MD	O
be	VB	O
conservative	JJ	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
advanced	JJ	WHO
age	NN	WHO
,	,	O
due	JJ	O
to	TO	O
the	DT	O
potential	NN	O
for	IN	O
decreased	JJ	O
renal	JJ	O
function	NN	O
in	IN	O
this	DT	O
population	NN	O
.	.	O

Argatroban	NNP	O
Injection	NNP	O
should	MD	O
not	RB	O
be	VB	O
mixed	VBN	O
with	IN	O
other	JJ	O
drugs	NNS	O
prior	RB	O
to	TO	O
dilution	NN	O
.	.	O

When	WRB	O
reconstituted	VBN	O
as	IN	O
directed	VBN	O
,	,	O
pH	VBP	O
's	CD	O
of	IN	O
the	DT	O
solutions	NNS	O
range	VBP	O
from	IN	O
7	CD	DOS
to	TO	O
8	CD	DOS
and	CC	O
the	DT	O
tonicities	NNS	O
are	VBP	O
:	:	O
100	CD	DOS
mg	NN	UNIT
ACT	NNP	O
-	:	O
O	NNP	O
-	:	O
VIAL	NNP	O
,	,	O
0.36	CD	O
osmolar	NN	O
;	:	O
250	CD	DOS
mg	NN	UNIT
ACT	NNP	O
-	:	O
O	NNP	O
-	:	O
VIAL	NNP	O
,	,	O
500	CD	DOS
mg	NN	UNIT
ACT	NNP	O
-	:	O
O	NNP	O
-	:	O
VIAL	NNP	O
,	,	O
and	CC	O
1000	CD	DOS
mg	NN	UNIT
ACT	NNP	O
-	:	O
O	NNP	O
-	:	O
VIAL	NNP	O
,	,	O
0.57	CD	O
osmolar	NN	O
.	.	O

Interpretation	NN	O
:	:	O
When	WRB	O
intravenous	JJ	O
cholecystography	NN	O
and	CC	O
cholangiography	NN	O
are	VBP	O
used	VBN	O
as	IN	O
an	DT	O
aid	NN	O
in	IN	O
the	DT	O
differential	JJ	O
diagnosis	NN	O
of	IN	O
acute	JJ	O
abdominal	JJ	O
conditions	NNS	O
,	,	O
visualization	NN	O
of	IN	O
the	DT	O
gallbladder	NN	O
is	VBZ	O
considered	VBN	O
strong	JJ	O
evidence	NN	O
against	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
acute	JJ	O
cholecystitis	NN	O
,	,	O
while	IN	O
nonvisualization	NN	O
of	IN	O
the	DT	O
gallbladder	NN	O
two	CD	O
and	CC	O
one	CD	O
-	:	O
half	NN	O
hours	NNS	O
after	IN	O
administration	NN	O
with	IN	O
visualization	NN	O
of	IN	O
the	DT	O
bile	NN	O
ducts	VBZ	O
is	VBZ	O
considered	VBN	O
strong	JJ	O
evidence	NN	O
in	IN	O
favor	NN	O
of	IN	O
a	DT	O
diagnosis	NN	O
of	IN	O
acute	JJ	O
cholecystitis	NN	O
(	(	O
if	IN	O
the	DT	O
bile	NN	O
ducts	NNS	O
are	VBP	O
only	RB	O
faintly	RB	O
visualized	VBN	O
,	,	O
gallbladder	VB	O
films	NNS	O
four	CD	O
hours	NNS	O
after	IN	O
administration	NN	O
may	MD	O
occasionally	RB	O
show	VB	O
visualization	NN	O
of	IN	O
the	DT	O
gallbladder	NN	O
)	)	O
.	.	O

In	IN	O
some	DT	WHO
cases	NNS	WHO
,	,	O
a	DT	O
patient	NN	O
already	RB	O
receiving	VBG	O
KHEDEZLA	NNP	O
therapy	NN	O
may	MD	O
require	VB	O
urgent	JJ	O
treatment	NN	O
with	IN	O
linezolid	JJ	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	NN	O
.	.	O

Prior	RB	O
to	TO	O
use	VB	O
,	,	O
allow	VB	O
the	DT	O
solution	NN	O
to	TO	O
reach	VB	O
ambient	JJ	O
room	NN	O
temperature	NN	O
.	.	O

Dose	NNP	O
Preparation	NNP	O
-	:	O
Pulmonary	JJ	O
Embolism	NN	O
For	IN	O
administration	NN	O
,	,	O
use	VB	O
a	DT	O
programmable	JJ	O
infusion	NN	O
pump	NN	O
only	RB	O
.	.	O

12	CD	O
.	.	O

The	DT	O
powder	NN	O
will	MD	O
not	RB	O
dissolve	VB	O
and	CC	O
the	DT	O
mixture	NN	O
will	MD	O
look	VB	O
cloudy	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
levothyroxine	JJ	O
sodium	NN	O
in	IN	O
newborn	JJ	WHO
infants	NNS	WHO
is	VBZ	O
10	CD	DOS
-	:	O
15	CD	DOS
mcg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

It	PRP	O
should	MD	O
be	VB	O
kept	VBN	O
in	IN	O
mind	NN	O
that	WDT	O
constant	JJ	O
monitoring	NN	O
is	VBZ	O
needed	VBN	O
in	IN	O
regard	NN	O
to	TO	O
drug	NN	O
dosage	NN	O
.	.	O

When	WRB	O
the	DT	O
patient	NN	O
no	RB	O
longer	RBR	O
requires	VBZ	O
therapy	NN	O
with	IN	O
XTAMPZA	NNP	O
ER	NNP	O
capsules	NNS	O
,	,	O
use	VBP	O
a	DT	O
gradual	JJ	O
downward	JJ	O
titration	NN	O
of	IN	O
the	DT	O
dosage	NN	O
to	TO	O
prevent	VB	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
withdrawal	NN	O
in	IN	O
the	DT	O
physically	RB	O
-	:	O
dependent	JJ	O
patient	NN	O
.	.	O

One	CD	DOS
to	TO	O
2	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
20	CD	O
%	NN	O
or	CC	O
2	CD	DOS
to	TO	O
4	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
10	CD	O
%	NN	O
solution	NN	O
every	DT	O
1	CD	O
to	TO	O
4	CD	O
hours	NNS	O
may	MD	O
then	RB	O
be	VB	O
given	VBN	O
by	IN	O
a	DT	O
syringe	NN	O
attached	VBN	O
to	TO	O
the	DT	O
catheter	NN	O
.	.	O

If	IN	O
it	PRP	O
is	VBZ	O
more	JJR	O
than	IN	O
3	CD	O
days	NNS	O
after	IN	O
the	DT	O
missed	JJ	O
dose	NN	O
,	,	O
instruct	NN	O
patients	NNS	O
to	TO	O
wait	VB	O
until	IN	O
their	PRP$	O
next	JJ	O
regularly	RB	O
scheduled	VBN	O
weekly	RB	FREQ
dose	NN	UNIT
.	.	O

Please	NNP	O
read	VBD	O
the	DT	O
instructions	NNS	O
completely	RB	O
before	IN	O
you	PRP	O
begin	VBP	O
.	.	O

Because	IN	O
of	IN	O
the	DT	O
potential	NN	O
for	IN	O
an	DT	O
extreme	JJ	O
hypotensive	JJ	O
response	NN	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
,	,	O
therapy	NN	O
should	MD	O
be	VB	O
started	VBN	O
under	IN	O
very	RB	O
close	JJ	O
medical	JJ	O
supervision	NN	O
.	.	O

ACCUPRIL	NNP	O
is	VBZ	O
indicated	VBN	O
as	IN	O
adjunctive	JJ	O
therapy	NN	O
when	WRB	O
added	VBD	O
to	TO	O
conventional	JJ	O
therapy	NN	O
including	VBG	O
diuretics	NNS	O
and	CC	O
/	NN	O
or	CC	O
digitalis	NN	O
.	.	O

ZYPREXA	NNP	O
IntraMuscular	NNP	O
should	MD	O
not	RB	O
be	VB	O
combined	VBN	O
in	IN	O
a	DT	O
syringe	NN	O
with	IN	O
haloperidol	JJ	O
injection	NN	O
because	IN	O
the	DT	O
resulting	VBG	O
low	JJ	O
pH	NN	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
degrade	VB	O
olanzapine	NN	O
over	IN	O
time	NN	O
.	.	O

The	DT	O
patient	NN	O
should	MD	O
remain	VB	O
in	IN	O
the	DT	O
supine	JJ	O
position	NN	O
for	IN	O
ten	JJ	O
minutes	NNS	O
following	VBG	O
insertion	NN	O
.	.	O

It	PRP	O
contains	VBZ	O
no	DT	O
antibacterial	JJ	O
preservative	NN	O
.	.	O

The	DT	O
expected	VBN	O
in	IN	O
vivo	NN	O
peak	JJ	O
increase	NN	O
in	IN	O
Factor	NNP	O
VIII	NNP	O
level	NN	O
expressed	VBD	O
as	IN	O
IU	NNP	O
/	NNP	O
dL	NN	O
(	(	O
or	CC	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
can	MD	O
be	VB	O
estimated	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
formulas	NN	O
:	:	O

The	DT	O
admixture	NN	O
should	MD	O
be	VB	O
stored	VBN	O
at	IN	O
25ºC	CD	O
(	(	O
77ºF	CD	O
)	)	O
and	CC	O
should	MD	O
be	VB	O
administered	VBN	O
within	IN	O
the	DT	O
designated	JJ	O
time	NN	O
period	NN	O
as	IN	O
listed	VBN	O
in	IN	O
Table	JJ	O
6	CD	O
.	.	O

Inspect	VB	O
the	DT	O
VASOVIST	NNP	O
(	(	O
gadofosveset	VB	O
trisodium	NN	O
injection	NN	O
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
vial	NN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

Carefully	RB	O
nick	VBZ	O
the	DT	O
pseudocapsule	NN	O
to	TO	O
reveal	VB	O
the	DT	O
polymer	NN	O
tip	NN	O
of	IN	O
the	DT	O
implant	NN	O
.	.	O

Modify	NNP	O
each	DT	O
dose	NN	O
of	IN	O
Gleostine	NNP	O
according	VBG	O
to	TO	O
the	DT	O
hematologic	JJ	O
response	NN	O
of	IN	O
the	DT	O
preceding	VBG	O
dose	NN	O
as	IN	O
described	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
:	:	O

Dose	NNP	O
escalation	NN	O
should	MD	O
follow	VB	O
the	DT	O
recommended	VBN	O
guidelines	NNS	O
for	IN	O
initiating	VBG	O
adjunctive	JJ	O
therapy	NN	O
with	IN	O
LAMICTAL	NNP	O
based	VBN	O
on	IN	O
concomitant	JJ	O
AED	NNP	O
or	CC	O
other	JJ	O
concomitant	JJ	O
medications	NNS	O
(	(	O
see	VB	O
Tables	NNP	O
1	CD	O
,	,	O
2	CD	O
,	,	O
and	CC	O
5	CD	O
)	)	O
.	.	O

If	IN	O
treatment	NN	O
is	VBZ	O
missed	VBN	O
for	IN	O
3	CD	PER
days	NNS	PER
or	CC	O
more	JJR	O
,	,	O
restart	JJ	O
UPTRAVI	NNP	O
at	IN	O
a	DT	O
lower	JJR	O
dose	NN	O
and	CC	O
then	RB	O
retitrate	VB	O
.	.	O

Start	NNP	O
TIROSINT	NNP	O
-	:	O
SOL	NN	O
at	IN	O
the	DT	O
full	JJ	O
replacement	NN	O
dose	NN	O
in	IN	O
otherwise	RB	O
healthy	JJ	O
,	,	O
non	JJ	O
-	:	O
elderly	JJ	O
individuals	NNS	O
who	WP	O
have	VBP	O
been	VBN	O
hypothyroid	VBN	O
for	IN	O
only	RB	O
a	DT	O
short	JJ	O
time	NN	O
(	(	O
such	JJ	O
as	IN	O
a	DT	PER
few	JJ	PER
months	NNS	PER
)	)	O
.	.	O

During	IN	O
treatment	NN	O
,	,	O
the	DT	O
dose	NN	O
may	MD	O
be	VB	O
adjusted	VBN	O
according	VBG	O
to	TO	O
response	NN	O
of	IN	O
the	DT	O
disease	NN	O
and	CC	O
/	NN	O
or	CC	O
the	DT	O
appearance	NN	O
of	IN	O
clinical	JJ	O
side	NN	O
effects	NNS	O
-	:	O
some	DT	O
of	IN	O
which	WDT	O
may	MD	O
be	VB	O
dose	RB	O
related	VBN	O
.	.	O

Therapy	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
the	DT	O
lower	JJR	O
dosage	NN	O
,	,	O
then	RB	O
increased	VBD	O
as	IN	O
necessary	JJ	O
to	TO	O
improve	VB	O
clinical	JJ	O
response	NN	O
.	.	O

A	DT	O
thin	JJ	O
layer	NN	O
of	IN	O
powder	NN	O
on	IN	O
the	DT	O
wall	NN	O
of	IN	O
the	DT	O
syringe	NN	O
is	VBZ	O
considered	VBN	O
normal	JJ	O
prior	RB	O
to	TO	O
mixing	VBG	O
with	IN	O
the	DT	O
diluent	NN	O
.	.	O

Using	VBG	O
aseptic	JJ	O
technique	NN	O
inject	JJ	O
Lipiodol	NNP	O
into	IN	O
the	DT	O
endometrial	JJ	O
cavity	NN	O
with	IN	O
fluoroscopic	NN	O
control	NN	O
.	.	O

Gonal	NNP	O
-	:	O
f®	NN	O
must	MD	O
be	VB	O
given	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
hCG	NN	O
.	.	O

Therapy	NN	O
with	IN	O
Savella	NNP	O
may	MD	O
be	VB	O
resumed	VBN	O
24	CD	O
hours	NNS	O
after	IN	O
the	DT	O
last	JJ	O
dose	NN	O
of	IN	O
linezolid	JJ	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	JJ	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

For	IN	O
patients	NNS	WHO
whose	WP$	WHO
disease	NN	WHO
progresses	VBZ	O
on	IN	O
Vitravene	NNP	O
(	(	O
fomivirsen	VBN	O
)	)	O
†	NN	O
during	IN	O
maintenance	NN	O
,	,	O
an	DT	O
attempt	NN	O
at	IN	O
reinduction	NN	O
at	IN	O
the	DT	O
same	JJ	O
dose	NN	O
may	MD	O
result	VB	O
in	IN	O
resumed	JJ	O
disease	NN	O
control	NN	O
.	.	O

Blood	NNP	O
glucose	JJ	O
monitoring	NN	O
is	VBZ	O
essential	JJ	O
in	IN	O
all	DT	WHO
patients	NNS	WHO
receiving	VBG	WHO
insulin	JJ	WHO
therapy	NN	WHO
.	.	O

Discard	NNP	O
any	DT	O
vial	JJ	O
(	(	O
and	CC	O
replace	VB	O
with	IN	O
another	DT	O
vial	NN	O
)	)	O
if	IN	O
there	EX	O
is	VBZ	O
no	DT	O
vacuum	NN	O
present	VBD	O
when	WRB	O
reconstituting	VBG	O
the	DT	O
vial	JJ	O
with	IN	O
normal	JJ	O
saline	NN	O
.	.	O

4	CD	O
.	.	O

CARDIZEM	NNP	O
LA	NNP	O
tablets	NNS	O
are	VBP	O
white	JJ	O
,	,	O
capsule	JJ	O
-	:	O
shaped	VBN	O
,	,	O
and	CC	O
debossed	VBD	O
with	IN	O
“	NNP	O
B	NNP	O
”	NN	O
on	IN	O
one	CD	O
side	NN	O
and	CC	O
the	DT	O
diltiazem	NN	O
content	NN	O
(	(	O
mg	NN	UNIT
)	)	O
on	IN	O
the	DT	O
other	JJ	O
.	.	O

Remove	VB	O
the	DT	O
loaded	JJ	O
IUS	NNP	O
insertion	NN	O
tube	NN	O
from	IN	O
the	DT	O
pouch	JJ	O
while	IN	O
holding	VBG	O
the	DT	O
lower	JJR	O
end	NN	O
of	IN	O
the	DT	O
tube	NN	O
firmly	RB	O
between	IN	O
your	PRP$	O
fingers	NNS	O
and	CC	O
thumb	NN	O
.	.	O

Pralidoxime	NNP	O
(	(	O
if	IN	O
used	VBN	O
)	)	O
is	VBZ	O
most	RBS	O
effective	JJ	O
if	IN	O
administered	VBN	O
immediately	RB	O
or	CC	O
soon	RB	O
after	IN	O
the	DT	O
poisoning	NN	O
.	.	O

The	DT	O
preparation	NN	O
should	MD	O
be	VB	O
taken	VBN	O
at	IN	O
bedtime	NN	O
with	IN	O
the	DT	O
objective	NN	O
of	IN	O
retaining	VBG	O
it	PRP	O
all	DT	O
night	NN	O
.	.	O

After	IN	O
the	DT	O
priming	NN	O
procedure	NN	O
,	,	O
fully	RB	O
depress	VB	O
the	DT	O
actuator	NN	O
once	RB	O
for	IN	O
every	DT	O
20.25	CD	DOS
mg	NN	UNIT
of	IN	O
AndroGel	NNP	O
1.62	CD	O
%	NN	O
.	.	O

The	DT	O
reconstituted	JJ	O
solution	NN	O
can	MD	O
be	VB	O
stored	VBN	O
for	IN	O
up	RB	O
to	TO	O
24	CD	O
hours	NNS	O
at	IN	O
temperatures	NNS	O
up	RB	O
to	TO	O
25°C	CD	O
(	(	O
77°F	CD	O
)	)	O
prior	RB	O
to	TO	O
dilution	NN	O
into	IN	O
the	DT	O
infusion	NN	O
solution	NN	O
.	.	O

Changes	NNS	O
in	IN	O
vital	JJ	O
signs	NNS	O
indicating	VBG	O
a	DT	O
stress	NN	O
response	NN	O
to	TO	O
surgical	JJ	O
stimulation	NN	O
or	CC	O
the	DT	O
emergence	NN	O
from	IN	O
anesthesia	NN	O
may	MD	O
be	VB	O
controlled	VBN	O
by	IN	O
the	DT	O
administration	NN	O
of	IN	O
25	CD	DOS
mg	NN	UNIT
(	(	O
2.5	CD	DOS
mL	NN	UNIT
)	)	O
to	TO	O
50	CD	DOS
mg	NN	UNIT
(	(	O
5	CD	DOS
mL	NN	UNIT
)	)	O
incremental	NN	O
boluses	NNS	O
and	CC	O
/	NN	O
or	CC	O
by	IN	O
increasing	VBG	O
the	DT	O
infusion	NN	O
rate	NN	O
of	IN	O
propofol	NN	O
injectable	JJ	O
emulsion	NN	O
.	.	O

For	IN	O
induction	NN	O
therapy	NN	O
in	IN	O
adult	NN	WHO
patients	NNS	WHO
with	IN	WHO
AML	NNP	WHO
the	DT	WHO
following	VBG	WHO
dose	JJ	WHO
schedule	NN	WHO
is	VBZ	O
recommended	VBN	O
:	:	O

Methotrexate	NNP	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
agents	NNS	O
appears	VBZ	O
to	TO	O
be	VB	O
the	DT	O
drug	NN	O
of	IN	O
choice	NN	O
for	IN	O
securing	VBG	O
maintenance	NN	O
of	IN	O
drug	NN	O
-	:	O
induced	JJ	O
remissions	NNS	O
.	.	O

Prior	RB	O
to	TO	O
initiating	VBG	O
DEPO	NNP	O
-	:	O
Testosterone	NN	O
(	(	O
testosterone	JJ	O
cypionate	NN	O
)	)	O
,	,	O
confirm	VBP	O
the	DT	O
diagnosis	NN	O
of	IN	O
hypogonadism	NN	O
by	IN	O
ensuring	VBG	O
that	IN	O
serum	NN	O
testosterone	NN	O
concentrations	NNS	O
have	VBP	O
been	VBN	O
measured	VBN	O
in	IN	O
the	DT	O
morning	NN	O
on	IN	O
at	IN	O
least	JJS	O
two	CD	O
separate	JJ	O
days	NNS	O
and	CC	O
that	IN	O
these	DT	O
serum	VB	O
testosterone	NN	O
concentrations	NNS	O
are	VBP	O
below	IN	O
the	DT	O
normal	JJ	O
range	NN	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
in	IN	O
or	CC	O
near	IN	O
the	DT	O
eyes	NNS	O
.	.	O

However	RB	O
,	,	O
ANZEMET	NNP	O
Injection	NNP	O
solution	NN	O
when	WRB	O
administered	VBN	O
intravenously	RB	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
adult	NN	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
for	IN	O
the	DT	O
prevention	NN	O
of	IN	O
nausea	NN	O
and	CC	O
vomiting	NN	O
associated	VBN	O
with	IN	O
initial	JJ	O
and	CC	O
repeat	NN	O
courses	NNS	O
of	IN	O
emetogenic	JJ	O
cancer	NN	O
chemotherapy	NN	O
due	JJ	O
to	TO	O
dose	VB	O
dependent	JJ	O
QT	NNP	O
prolongation	NN	O
.	.	O

Oral	JJ	O
:	:	O
One	CD	DOS
tablet	NN	UNIT
one	CD	FREQ
to	TO	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Doses	NNS	O
of	IN	O
ZEMURON	NNP	O
injection	NN	O
should	MD	O
be	VB	O
individualized	VBN	O
and	CC	O
a	DT	O
peripheral	JJ	O
nerve	NN	O
stimulator	NN	O
should	MD	O
be	VB	O
used	VBN	O
to	TO	O
monitor	VB	O
drug	NN	O
effect	NN	O
,	,	O
need	NN	O
for	IN	O
additional	JJ	O
doses	NNS	O
,	,	O
adequacy	NN	O
of	IN	O
spontaneous	JJ	O
recovery	NN	O
or	CC	O
antagonism	NN	O
,	,	O
and	CC	O
to	TO	O
decrease	VB	O
the	DT	O
complications	NNS	O
of	IN	O
overdosage	NN	O
if	IN	O
additional	JJ	O
doses	NNS	O
are	VBP	O
administered	VBN	O
.	.	O

Occasionally	RB	O
,	,	O
after	IN	O
refrigeration	NN	O
,	,	O
small	JJ	O
colorless	NN	O
particles	NNS	O
may	MD	O
be	VB	O
present	JJ	O
in	IN	O
the	DT	O
Zorbtive®	NNP	O
8.8	CD	DOS
mg	NN	UNIT
solution	NN	UNIT
.	.	O

The	DT	O
range	NN	O
of	IN	O
initial	JJ	O
doses	NNS	O
is	VBZ	O
0.14	CD	DOS
to	TO	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
in	IN	O
three	CD	DOS
or	CC	O
four	CD	DOS
divided	VBN	UNIT
doses	NNS	UNIT
(	(	O
4	CD	DOS
to	TO	O
60	CD	DOS
mg	NNS	UNIT
/	JJ	O
m2bsa	JJ	O
/	NNP	FREQ
day	NN	FREQ
)	)	O
.	.	O

Tests	NNS	O
of	IN	O
anticoagulant	JJ	O
effects	NNS	O
(	(	O
including	VBG	O
the	DT	O
aPTT	NN	O
)	)	O
typically	RB	O
attain	VBP	O
steady	JJ	O
-	:	O
state	NN	O
levels	NNS	O
within	IN	O
1	CD	O
to	TO	O
3	CD	O
hours	NNS	O
following	VBG	O
initiation	NN	O
of	IN	O
Argatroban	NNP	O
Injection	NNP	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
periodically	RB	O
reassessed	VBN	O
to	TO	O
determine	VB	O
the	DT	O
need	NN	O
for	IN	O
maintenance	NN	O
treatment	NN	O
and	CC	O
the	DT	O
appropriate	JJ	O
dose	NN	O
for	IN	O
such	JJ	O
treatment	NN	O
.	.	O

Use	NNP	O
one	CD	O
IONSYS	NNP	O
at	IN	O
a	DT	O
time	NN	O
for	IN	O
up	RB	O
to	TO	O
24	CD	O
hours	NNS	O
or	CC	O
80	CD	DOS
doses	NNS	UNIT
,	,	O
whichever	WDT	O
comes	VBZ	O
first	RB	O
.	.	O

Once	RB	O
diluted	VBN	O
,	,	O
solutions	NNS	O
containing	VBG	O
LEUSTATIN	NNP	O
Injection	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
promptly	RB	O
or	CC	O
stored	VBN	O
in	IN	O
the	DT	O
refrigerator	NN	O
(	(	O
2°	CD	O
to	TO	O
8°C	CD	O
)	)	O
for	IN	O
no	DT	O
more	JJR	O
than	IN	O
8	CD	O
hours	NNS	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

Patients	NNS	WHO
over	IN	WHO
60	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
may	MD	O
require	VB	O
lower	JJR	O
doses	NNS	O
of	IN	O
heparin	NN	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
opioid	JJ	WHO
tolerant	NN	WHO
are	VBP	O
those	DT	O
receiving	VBG	O
,	,	O
for	IN	O
one	CD	PER
week	NN	PER
or	CC	O
longer	JJR	O
,	,	O
at	IN	O
least	JJS	O
60	CD	DOS
mg	JJ	UNIT
oral	JJ	O
morphine	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
25	CD	DOS
mcg	NN	UNIT
transdermal	JJ	O
fentanyl	NN	O
per	IN	O
hour	NN	O
,	,	O
30	CD	DOS
mg	JJ	UNIT
oral	JJ	O
oxycodone	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
8	CD	DOS
mg	JJ	UNIT
oral	JJ	O
hydromorphone	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
25	CD	DOS
mg	JJ	UNIT
oral	JJ	O
oxymorphone	NN	O
per	IN	FREQ
day	NN	FREQ
or	CC	O
an	DT	O
equianalgesic	JJ	O
dose	NN	O
of	IN	O
another	DT	O
opioid	NN	O
.	.	O

Management	NN	O
of	IN	O
hepatic	JJ	O
coma	NN	O
:	:	O
Adults	NNS	WHO
:	:	O
Usual	JJ	O
dose—4	NN	O
g	JJ	O
daily	RB	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
,	,	O
given	VBN	O
at	IN	O
regular	JJ	O
intervals	NNS	O
for	IN	O
five	CD	PER
to	TO	O
six	CD	PER
days	NNS	PER
.	.	O

A	DT	O
patient	NN	WHO
whose	WP$	WHO
blood	NN	WHO
pressure	NN	WHO
is	VBZ	WHO
not	RB	WHO
adequately	RB	WHO
controlled	VBN	WHO
with	IN	WHO
either	DT	WHO
lisinopril	NN	WHO
or	CC	WHO
hydrochlorothiazide	JJ	WHO
monotherapy	NN	WHO
may	MD	O
be	VB	O
switched	VBN	O
to	TO	O
lisinopril	VB	O
/	NNP	O
HCTZ	NNP	O
10	CD	O
/	NNP	O
12.5	CD	O
or	CC	O
lisinopril	JJR	O
/	NNS	O
HCTZ	NNP	O
20	CD	O
/	NNP	O
12.5	CD	O
,	,	O
depending	VBG	O
on	IN	O
current	JJ	O
monotherapy	NN	O
dose	NN	O
.	.	O

EMFLAZA	NNP	O
Tablets	NNS	O
can	MD	O
be	VB	O
administered	VBN	O
whole	JJ	O
or	CC	O
crushed	VBN	O
and	CC	O
taken	VBN	O
immediately	RB	O
after	IN	O
mixing	VBG	O
with	IN	O
applesauce	NN	O
.	.	O

Six	CD	O
different	JJ	O
“	NNS	FREQ
day	NN	FREQ
label	VBZ	O
strips	NNS	O
”	NNS	O
are	VBP	O
provided	VBN	O
with	IN	O
each	DT	O
cycle	NN	O
pack	NN	O
dispenser	NN	O
in	IN	O
order	NN	O
to	TO	O
accommodate	VB	O
a	DT	O
Day	NNP	O
1	CD	O
start	NN	O
regimen	NNS	O
.	.	O

All	DT	O
injections	NNS	O
in	IN	O
VIAFLEX	NNP	O
plastic	NN	O
containers	NNS	O
are	VBP	O
intended	VBN	O
for	IN	O
intravenous	JJ	O
administration	NN	O
using	VBG	O
sterile	JJ	O
equipment	NN	O
.	.	O

Protect	NNP	O
DepoDur	NNP	O
(	(	O
morphine	JJ	O
sulfate	NN	O
xr	NNP	O
liposome	NNP	O
injection	NN	O
)	)	O
from	IN	O
freezing	VBG	O
.	.	O

Since	IN	O
NeoProfen	NNP	O
is	VBZ	O
potentially	RB	O
irritating	VBG	O
to	TO	O
tissues	NNS	O
,	,	O
it	PRP	O
should	MD	O
be	VB	O
administered	VBN	O
carefully	RB	O
to	TO	O
avoid	VB	O
extravasation	NN	O
.	.	O

Fifteen	NNP	O
to	TO	O
40	CD	DOS
mg	NNS	UNIT
a	DT	FREQ
day	NN	FREQ
divided	VBD	O
into	IN	O
3	CD	DOS
or	CC	O
4	CD	DOS
doses	NNS	UNIT
.	.	O

Larger	JJR	O
than	IN	O
necessary	JJ	O
dosage	NN	O
of	IN	O
NARCAN	NNP	O
(	(	O
naloxone	NN	O
)	)	O
may	MD	O
result	VB	O
in	IN	O
significant	JJ	O
reversal	NN	O
of	IN	O
analgesia	NN	O
and	CC	O
increase	NN	O
in	IN	O
blood	NN	O
pressure	NN	O
.	.	O

The	DT	O
needle	NN	O
is	VBZ	O
left	VBN	O
in	IN	O
situ	NN	O
.	.	O

Bring	VBG	O
the	DT	O
vial	JJ	O
to	TO	O
room	NN	O
temperature	NN	O
prior	RB	O
to	TO	O
reconstitution	NN	O
with	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
.	.	O

5	CD	O
.	.	O

The	DT	O
appearance	NN	O
of	IN	O
any	DT	O
discoloration	NN	O
is	VBZ	O
reason	NN	O
to	TO	O
withdraw	VB	O
the	DT	O
needle	NN	O
and	CC	O
discard	VB	O
the	DT	O
TUBEX	NNP	O
.	.	O

Inspect	NNP	O
oxygen	NN	O
indicator	NN	O
and	CC	O
do	VBP	O
not	RB	O
use	VB	O
if	IN	O
oxygen	JJ	O
indicator	NN	O
is	VBZ	O
pink	JJ	O
or	CC	O
dark	JJ	O
pink	NN	O
.	.	O

Initial	JJ	O
therapy	NN	O
with	IN	O
Azor	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
in	IN	O
patients	NNS	WHO
≥75	CD	WHO
years	NNS	WHO
old	JJ	WHO
or	CC	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
[	NNP	O
See	NNP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

If	IN	O
doses	NNS	O
are	VBP	O
to	TO	O
exceed	VB	O
2,500	CD	DOS
lipase	JJ	UNIT
units	NNS	UNIT
/	VBP	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
per	IN	O
meal	NN	O
,	,	O
further	JJ	O
investigation	NN	O
is	VBZ	O
warranted	VBN	O
.	.	O

Use	NNP	O
of	IN	O
estrogen	NN	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
progestin	NN	O
,	,	O
should	MD	O
be	VB	O
with	IN	O
the	DT	O
lowest	JJS	O
effective	JJ	O
dose	NN	O
and	CC	O
the	DT	O
shortest	JJS	O
duration	NN	O
consistent	NN	O
with	IN	O
treatment	NN	O
goals	NNS	O
and	CC	O
risks	NNS	O
for	IN	O
the	DT	O
individual	JJ	O
woman	NN	O
.	.	O

She	PRP	O
starts	VBZ	O
taking	VBG	O
one	CD	DOS
white	JJ	UNIT
tablet	NN	UNIT
daily	RB	FREQ
,	,	O
beginning	VBG	O
with	IN	O
the	DT	O
first	JJ	O
white	JJ	O
tablet	NN	O
in	IN	O
the	DT	O
top	JJ	O
row	NN	O
.	.	O

Use	NNP	O
ELLENCE	NNP	O
within	IN	O
24	CD	O
hours	NNS	O
of	IN	O
first	JJ	O
penetration	NN	O
of	IN	O
the	DT	O
rubber	NN	O
stopper	NN	O
.	.	O

Expiration	NN	O
dates	NNS	O
are	VBP	O
stated	VBN	O
on	IN	O
the	DT	O
labels	NNS	O
.	.	O

therapy	NN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
marked	JJ	WHO
oliguria	NNS	WHO
or	CC	O
those	DT	O
believed	VBN	O
to	TO	O
have	VB	O
inadequate	JJ	O
renal	JJ	O
function	NN	O
.	.	O

PROTONIX	NNP	O
I.V	NNP	O
.	.	O

All	DT	O
patients	NNS	O
MUST	NNP	O
begin	VB	O
treatment	NN	O
using	VBG	O
one	CD	O
200	CD	DOS
mcg	NN	UNIT
Onsolis	NNP	O
film	NN	O
.	.	O

If	IN	O
treatment	NN	O
includes	VBZ	O
transfer	NN	O
to	TO	O
an	DT	O
oral	JJ	O
antihypertensive	JJ	O
agent	NN	O
other	JJ	O
than	IN	O
oral	JJ	O
nicardipine	NN	O
,	,	O
initiate	JJ	O
therapy	NN	O
upon	IN	O
discontinuation	NN	O
of	IN	O
Cardene	NNP	O
I.V	NNP	O
.	.	O

The	DT	O
choice	NN	O
of	IN	O
the	DT	O
dose	NN	O
of	IN	O
sumatriptan	NN	O
,	,	O
and	CC	O
of	IN	O
the	DT	O
use	NN	O
of	IN	O
a	DT	O
fixed	JJ	O
combination	NN	O
such	JJ	O
as	IN	O
in	IN	O
TREXIMET	NNP	O
85	CD	DOS
/	VBD	O
500	CD	DOS
mg	NN	UNIT
should	MD	O
be	VB	O
made	VBN	O
on	IN	O
an	DT	O
individual	JJ	O
basis	NN	O
,	,	O
weighing	VBG	O
the	DT	O
possible	JJ	O
benefit	NN	O
of	IN	O
a	DT	O
higher	JJR	O
dose	NN	O
of	IN	O
sumatriptan	NN	O
with	IN	O
the	DT	O
potential	NN	O
for	IN	O
a	DT	O
greater	JJR	O
risk	NN	O
of	IN	O
adverse	JJ	O
reactions	NNS	O
.	.	O

To	TO	O
prevent	VB	O
clot	NN	O
formation	NN	O
in	IN	O
a	DT	O
heparin	NN	O
lock	NN	O
set	NN	O
or	CC	O
central	JJ	O
venous	JJ	O
catheter	NN	O
following	VBG	O
its	PRP$	O
proper	JJ	O
insertion	NN	O
,	,	O
Heparin	NNP	O
Lock	NNP	O
Flush	NNP	O
Solution	NNP	O
,	,	O
USP	NNP	O
is	VBZ	O
injected	VBN	O
via	IN	O
the	DT	O
injection	NN	O
hub	NN	O
in	IN	O
a	DT	O
quantity	NN	O
sufficient	NN	O
to	TO	O
fill	VB	O
the	DT	O
entire	JJ	O
device	NN	O
.	.	O

The	DT	O
daily	JJ	FREQ
nutrient	NN	O
requirements	NNS	O
of	IN	O
an	DT	O
average	JJ	WHO
adult	NN	WHO
patient	NN	WHO
,	,	WHO
not	RB	WHO
hypermetabolic	JJ	WHO
,	,	WHO
in	IN	WHO
an	DT	WHO
acceptable	JJ	WHO
weight	NN	WHO
range	NN	WHO
and	CC	WHO
with	IN	WHO
restricted	JJ	WHO
physical	JJ	WHO
activity	NN	WHO
,	,	O
are	VBP	O
about	IN	O
30	CD	O
kcal	JJ	O
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
12	CD	DOS
to	TO	O
18	CD	DOS
grams	NNS	UNIT
of	IN	O
nitrogen	NN	O
(	(	O
or	CC	O
1.0	CD	DOS
to	TO	O
1.5	CD	DOS
g	NN	UNIT
amino	NN	O
acid	VBP	O
/	NNP	O
kg	FW	O
/	NNP	FREQ
day	NN	FREQ
)	)	O
and	CC	O
between	IN	O
2500	CD	DOS
and	CC	O
3000	CD	DOS
mL	NN	UNIT
of	IN	O
fluids	NNS	O
.	.	O

CRESEMBA	NNP	O
is	VBZ	O
water	NN	O
soluble	JJ	O
,	,	O
preservative	JJ	O
-	:	O
free	JJ	O
,	,	O
sterile	JJ	O
,	,	O
and	CC	O
nonpyrogenic	JJ	O
.	.	O

Because	IN	O
cross	NN	O
-	:	O
sensitivity	NN	O
with	IN	O
furosemide	NN	O
has	VBZ	O
rarely	RB	O
been	VBN	O
observed	VBN	O
,	,	O
Bumex	NNP	O
(	(	O
bumetanide	IN	O
)	)	O
can	MD	O
be	VB	O
substituted	VBN	O
at	IN	O
approximately	RB	O
a	DT	O
1:40	CD	DOS
ratio	NN	UNIT
of	IN	O
Bumex	NNP	O
(	(	O
bumetanide	NN	O
)	)	O
to	TO	O
furosemide	VB	O
in	IN	O
patients	NNS	WHO
allergic	JJ	WHO
to	TO	WHO
furosemide	VB	WHO
.	.	O

If	IN	O
the	DT	O
migraine	NN	O
recurs	NN	O
after	IN	O
initial	JJ	O
relief	NN	O
,	,	O
a	DT	O
second	JJ	O
tablet	NN	O
may	MD	O
be	VB	O
taken	VBN	O
,	,	O
providing	VBG	O
there	EX	O
is	VBZ	O
an	DT	O
interval	NN	O
of	IN	O
at	IN	O
least	JJS	O
2	CD	O
hours	NNS	O
between	IN	O
doses	NNS	O
.	.	O

-	:	O
Prime	NNP	O
administration	NN	O
set	VBN	O
in	IN	O
usual	JJ	O
manner	NN	O
and	CC	O
close	JJ	O
administration	NN	O
set	NN	O
clamp	NN	O
.	.	O

The	DT	O
dose	JJ	O
counter	NN	O
window	NN	O
displays	VBZ	O
the	DT	O
number	NN	O
of	IN	O
actuations	NNS	O
(	(	O
inhalations	NNS	O
)	)	O
left	VBD	O
in	IN	O
the	DT	O
inhaler	NN	O
in	IN	O
units	NNS	O
of	IN	O
two	CD	O
(	(	O
e.g	NN	O
,	,	O
60	CD	O
,	,	O
58	CD	O
,	,	O
56	CD	O
,	,	O
etc	FW	O
.	.	O
)	)	O
.	.	O

Anesthetize	VB	O
the	DT	O
insertion	NN	O
area	NN	O
at	IN	O
the	DT	O
incision	NN	O
site	NN	O
and	CC	O
just	RB	O
under	IN	O
the	DT	O
skin	NN	O
along	IN	O
the	DT	O
planned	JJ	O
insertion	NN	O
channels	NNS	O
using	VBG	O
local	JJ	O
anesthetic	JJ	O
(	(	O
for	IN	O
example	NN	O
,	,	O
by	IN	O
injecting	VBG	O
5	CD	DOS
mL	JJ	UNIT
lidocaine	JJ	O
1	CD	O
%	NN	O
with	IN	O
epinephrine	JJ	O
1:100,000	CD	O
)	)	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
dose	JJ	O
selection	NN	O
for	IN	O
an	DT	WHO
elderly	JJ	WHO
patient	NN	WHO
should	MD	O
be	VB	O
cautious	JJ	O
,	,	O
usually	RB	O
starting	VBG	O
at	IN	O
the	DT	O
low	JJ	O
end	NN	O
of	IN	O
the	DT	O
dosing	NN	O
range	NN	O
,	,	O
reflecting	VBG	O
the	DT	O
greater	JJR	O
frequency	NN	O
of	IN	O
decreased	JJ	O
hepatic	JJ	O
,	,	O
renal	JJ	O
,	,	O
or	CC	O
cardiac	JJ	O
function	NN	O
,	,	O
and	CC	O
of	IN	O
concomitant	JJ	O
disease	NN	O
or	CC	O
other	JJ	O
drug	NN	O
therapy	NN	O
.	.	O

Check	NNP	O
for	IN	O
minute	NN	O
leaks	NNS	O
by	IN	O
squeezing	VBG	O
bag	NN	O
firmly	RB	O
.	.	O

Dosage	NN	O
adjustments	NNS	O
,	,	O
if	IN	O
indicated	VBN	O
,	,	O
can	MD	O
be	VB	O
made	VBN	O
according	VBG	O
to	TO	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
within	IN	O
dose	JJ	O
ranges	NNS	O
of	IN	O
oral	JJ	O
olanzapine	NN	O
5	CD	DOS
to	TO	O
20	CD	DOS
mg	NNS	UNIT
and	CC	O
fluoxetine	VB	O
20	CD	DOS
to	TO	O
50	CD	DOS
mg.	NN	UNIT
Antidepressant	NNP	O
efficacy	NN	O
was	VBD	O
demonstrated	VBN	O
with	IN	O
olanzapine	NN	O
and	CC	O
fluoxetine	NN	O
in	IN	O
combination	NN	O
in	IN	O
adult	NN	WHO
patients	NNS	WHO
with	IN	WHO
a	DT	WHO
dose	JJ	WHO
range	NN	WHO
of	IN	O
olanzapine	$	O
6	CD	DOS
to	TO	O
18	CD	DOS
mg	NNS	UNIT
and	CC	O
fluoxetine	VB	O
25	CD	DOS
to	TO	O
50	CD	DOS
mg	NNS	UNIT
.	.	O

Titration	NN	O
may	MD	O
be	VB	O
needed	VBN	O
in	IN	O
some	DT	WHO
patients	NNS	WHO
.	.	O

Both	DT	O
the	DT	O
1	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
and	CC	O
5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
formulations	NNS	O
of	IN	O
midazolam	NN	O
may	MD	O
be	VB	O
diluted	VBN	O
with	IN	O
0.9	CD	O
%	NN	O
sodium	NN	O
chloride	NN	O
or	CC	O
5	CD	O
%	NN	O
dextrose	NN	O
in	IN	O
water	NN	O
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
Certiva	NNP	O
(	(	O
diphtheria	NN	O
and	CC	O
tetanus	NN	O
toxoids	NNS	O
and	CC	O
acellular	JJ	O
pertussis	NN	O
vaccine	NN	O
adsorbed	VBN	O
)	)	O
TM	NNP	O
was	VBD	O
routinely	RB	O
administered	VBN	O
,	,	O
at	IN	O
separate	JJ	O
sites	NNS	O
,	,	O
concomitantly	RB	O
with	IN	O
one	CD	DOS
or	CC	O
more	JJR	O
of	IN	O
the	DT	O
following	JJ	O
vaccines	NNS	O
:	:	O
polio	NN	O
vaccine	NN	O
live	JJ	O
oral	NN	O
(	(	O
OPV	NNP	O
)	)	O
,	,	O
hepatitis	NN	O
B	NNP	O
vaccine	NN	O
,	,	O
Haemophilus	NNP	O
influenzae	VBP	O
type	NN	O
b	NN	O
conjugate	NN	O
vaccine	NN	O
(	(	O
Hib	NNP	O
)	)	O
,	,	O
and	CC	O
measles	NNS	O
,	,	O
mumps	NNS	O
and	CC	O
rubella	NN	O
vaccine	NN	O
(	(	O
MMR	NNP	O
)	)	O
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
)	)	O
.	.	O

This	DT	O
suspension	NN	O
can	MD	O
be	VB	O
administered	VBN	O
by	IN	O
spoon	NN	O
or	CC	O
dropper	NN	O
.	.	O

A	DT	O
3	CD	DOS
to	TO	O
5	CD	DOS
mm	NN	UNIT
of	IN	O
mercury	NN	O
rise	NN	O
in	IN	O
pressure	NN	O
suggests	VBZ	O
the	DT	O
presence	NN	O
of	IN	O
angle	JJ	O
block	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
glaucoma	NN	WHO
;	:	O
however	RB	O
,	,	O
failure	NN	O
to	TO	O
obtain	VB	O
such	JJ	O
a	DT	O
rise	NN	O
does	VBZ	O
not	RB	O
preclude	VB	O
the	DT	O
presence	NN	O
of	IN	O
glaucoma	NN	O
from	IN	O
other	JJ	O
causes	NNS	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
phosphate	NN	O
added	VBN	O
to	TO	O
a	DT	O
liter	NN	O
of	IN	O
TPN	NNP	O
solution	NN	O
(	(	O
containing	VBG	O
25	CD	O
%	NN	O
dextrose	NN	O
)	)	O
is	VBZ	O
12	CD	DOS
to	TO	O
15	CD	O
mM	NNS	O
.	.	O

Pour	VB	O
the	DT	O
entire	JJ	O
contents	NNS	O
of	IN	O
a	DT	O
single	JJ	DOS
-	:	O
dose	JJ	O
sachet	NN	O
of	IN	O
MONUROL	NNP	O
into	IN	O
3	CD	O
to	TO	O
4	CD	O
ounces	NNS	O
of	IN	O
water	NN	O
(	(	O
½	JJ	O
cup	NN	O
)	)	O
and	CC	O
stir	$	O
to	TO	O
dissolve	VB	O
.	.	O

Because	IN	O
of	IN	O
the	DT	O
more	RBR	O
rapid	JJ	O
uptake	NN	O
of	IN	O
Fluothane	NNP	O
(	(	O
halothane	NN	O
)	)	O
and	CC	O
the	DT	O
increased	VBN	O
blood	NN	O
concentration	NN	O
required	VBN	O
for	IN	O
anesthesia	NN	O
in	IN	O
younger	JJR	WHO
patients	NNS	WHO
,	,	O
the	DT	O
minimum	JJ	O
alveolar	JJ	O
concentration	NN	O
(	(	O
MAC	NNP	O
)	)	O
1	CD	DOS
values	NNS	UNIT
will	MD	O
decrease	VB	O
with	IN	O
age	NN	O
as	IN	O
follows	VBZ	O
:	:	O

Alternatively	RB	O
,	,	O
in	IN	O
adult	NN	WHO
patients	NNS	WHO
an	DT	WHO
induction	NN	WHO
dose	NN	O
of	IN	O
1	CD	DOS
mg	NNS	UNIT
to	TO	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	VBP	O
intravenous	JJ	O
ketamine	NN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
0.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

Doses	NNS	O
above	IN	O
0.4	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
(	(	O
1	CD	O
to	TO	O
<	VB	O
6	CD	O
year	NN	O
olds	NNS	O
)	)	O
or	CC	O
32	CD	DOS
mg	NN	UNIT
(	(	O
6	CD	O
to	TO	O
<	VB	O
17	CD	O
year	NN	O
olds	NNS	O
)	)	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
[	VBP	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

Occasionally	RB	O
,	,	O
the	DT	O
inactive	JJ	O
ingredients	NNS	O
of	IN	O
ALLEGRA	NNP	O
-	:	O
D	NNP	O
(	(	O
fexofenadine	JJ	O
hcl	NN	O
and	CC	O
pseudoephedrine	VB	O
hcl	NN	O
)	)	O
12	CD	O
HOUR	NNP	O
may	MD	O
be	VB	O
eliminated	VBN	O
in	IN	O
the	DT	O
feces	NNS	O
in	IN	O
a	DT	O
form	NN	O
that	WDT	O
may	MD	O
resemble	VB	O
the	DT	O
original	JJ	O
tablet	NN	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
Renal	NNP	WHO
or	CC	WHO
Hepatic	JJ	WHO
Impairment	NN	WHO
:	:	O
A	DT	O
reduction	NN	O
of	IN	O
50	CD	O
%	NN	O
in	IN	O
the	DT	O
dose	NN	O
of	IN	O
vinblastine	NN	O
sulfate	NN	O
(	(	O
vinblastine	JJ	O
sulfate	NN	O
injection	NN	O
)	)	O
is	VBZ	O
recommended	VBN	O
for	IN	O
patients	NNS	WHO
having	VBG	WHO
a	DT	WHO
direct	JJ	WHO
serum	NN	WHO
bilirubin	NN	WHO
value	NN	WHO
above	IN	O
3	CD	DOS
mg	NNS	UNIT
/	VBD	O
100	CD	DOS
mL	NN	UNIT
.	.	O

One	CD	DOS
(	(	O
1	CD	O
)	)	O
tablet	NN	O
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
as	IN	O
needed	VBN	O
;	:	O
do	VB	O
not	RB	O
exceed	VB	O
six	CD	O
(	(	O
6	CD	O
)	)	O
tablets	NNS	O
in	IN	O
24	CD	O
hours	NNS	O
.	.	O

Aktipak	NNP	O
requires	VBZ	O
thorough	IN	O
mixing	NN	O
by	IN	O
the	DT	O
patient	NN	O
immediately	RB	O
prior	JJ	O
to	TO	O
each	DT	O
use	NN	O
.	.	O

Instead	RB	O
,	,	O
use	VBP	O
the	DT	O
reinitiation	NN	O
regimen	NNS	O
shown	VBN	O
in	IN	O
Table	JJ	O
2	CD	O
.	.	O

The	DT	O
normal	JJ	O
saline	NN	O
used	VBN	O
to	TO	O
reconstitute	VB	O
each	DT	O
vial	NN	O
should	MD	O
appear	VB	O
to	TO	O
be	VB	O
assisted	VBN	O
or	CC	O
pulled	VBN	O
into	IN	O
the	DT	O
vial	JJ	O
by	IN	O
the	DT	O
negative	JJ	O
pressure	NN	O
(	(	O
partial	JJ	O
vacuum	NN	O
)	)	O
present	NN	O
in	IN	O
the	DT	O
vial	NN	O
.	.	O

It	PRP	O
is	VBZ	O
important	JJ	O
that	IN	O
undue	JJ	O
pressure	NN	O
not	RB	O
be	VB	O
exerted	VBN	O
during	IN	O
the	DT	O
injection	NN	O
.	.	O

An	DT	O
initial	JJ	O
infusion	NN	O
rate	NN	O
of	IN	O
0.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
/	JJ	O
min	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	WHO
adult	NN	WHO
dose	NN	O
for	IN	O
Prevalite®	NNP	O
(	(	O
cholestyramine	NN	O
for	IN	O
oral	JJ	O
suspension	NN	O
,	,	O
USP	NNP	O
)	)	O
powder	NN	O
is	VBZ	O
one	CD	DOS
packet	NN	UNIT
or	CC	O
one	CD	DOS
level	NN	UNIT
scoopful	NN	UNIT
(	(	O
5.5	CD	DOS
grams	NNS	UNIT
of	IN	O
Prevalite®	NNP	O
[	NNP	O
cholestyramine	NN	O
for	IN	O
oral	JJ	O
suspension	NN	O
,	,	O
USP	NNP	O
]	NNP	O
powder	NN	O
contain	NN	O
4	CD	O
grams	NNS	O
of	IN	O
anhydrous	JJ	O
cholestyramine	NN	O
resin	NN	O
)	)	O
once	RB	FREQ
or	CC	O
twice	VB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

If	IN	O
the	DT	O
same	JJ	O
system	NN	O
can	MD	O
not	RB	O
be	VB	O
reapplied	VBN	O
a	DT	O
new	JJ	O
system	NN	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
another	DT	O
location	NN	O
.	.	O

AMMONUL	NNP	O
may	MD	O
not	RB	O
be	VB	O
administered	VBN	O
by	IN	O
any	DT	O
other	JJ	O
route	NN	O
.	.	O

HYLENEX	NNP	O
recombinant	NN	O
may	MD	O
be	VB	O
administered	VBN	O
for	IN	O
infiltration	NN	O
use	NN	O
,	,	O
interstitial	JJ	O
use	NN	O
,	,	O
intramuscular	JJ	O
use	NN	O
,	,	O
intraocular	JJ	O
use	NN	O
,	,	O
peribulbar	NN	O
use	NN	O
,	,	O
retrobulbar	NN	O
use	NN	O
,	,	O
soft	JJ	O
tissue	NN	O
use	NN	O
or	CC	O
subcutaneous	JJ	O
use	NN	O
.	.	O

The	DT	O
suggested	JJ	O
initial	JJ	O
3	CD	O
-	:	O
times	NNS	O
-	:	O
a	DT	O
-	:	O
week	NN	PER
dose	NN	O
of	IN	O
ORLAAM	NNP	O
(	(	O
levomethadyl	JJ	O
acetate	NN	O
)	)	O
for	IN	O
such	JJ	WHO
patients	NNS	WHO
is	VBZ	O
1.2	CD	DOS
to	TO	O
1.3	CD	FREQ
times	NNS	FREQ
the	DT	FREQ
daily	JJ	FREQ
methadone	NN	O
maintenance	NN	O
dose	NN	O
being	VBG	O
replaced	VBN	O
.	.	O

Some	DT	O
centers	NNS	O
have	VBP	O
successfully	RB	O
tapered	VBN	O
the	DT	O
maintenance	NN	O
dose	NN	O
to	TO	O
as	RB	O
low	JJ	O
as	IN	O
3	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
in	IN	O
selected	VBN	O
renal	JJ	O
transplant	NN	O
patients	NNS	O
without	IN	O
an	DT	O
apparent	JJ	O
rise	NN	O
in	IN	O
rejection	NN	O
rate	NN	O
.	.	O

During	IN	O
the	DT	O
course	NN	O
of	IN	O
treatment	NN	WHO
some	DT	WHO
patients	NNS	WHO
may	MD	O
experience	VB	O
an	DT	O
exacerbation	NN	O
of	IN	O
disease	NN	O
activity	NN	O
following	VBG	O
an	DT	O
initial	JJ	O
good	JJ	O
response	NN	O
.	.	O

If	IN	O
daily	JJ	FREQ
doses	NNS	O
exceeding	VBG	O
4	CD	DOS
g	NNS	UNIT
are	VBP	O
required	VBN	O
to	TO	O
achieve	VB	O
desired	JJ	O
effects	NNS	O
,	,	O
the	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
toxicity	NN	O
should	MD	O
be	VB	O
kept	VBN	O
in	IN	O
mind	NN	O
.	.	O

The	DT	O
average	NN	O
in	IN	O
vivo	JJ	O
release	NN	O
rate	NN	O
of	IN	O
LNG	NNP	O
is	VBZ	O
approximately	RB	O
15.6	CD	DOS
mcg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
over	IN	O
a	DT	O
period	NN	O
of	IN	O
3	CD	O
years	NNS	O
.	.	O

Seizure	NNP	O
-	:	O
prone	NN	O
patients	NNS	O
should	MD	O
be	VB	O
maintained	VBN	O
on	IN	O
anticonvulsant	JJ	O
medication	NN	O
.	.	O

If	IN	O
pregnancy	NN	O
occurs	VBZ	O
,	,	O
treatment	NN	O
may	MD	O
be	VB	O
continued	VBN	O
until	IN	O
placental	JJ	O
autonomy	NN	O
is	VBZ	O
achieved	VBN	O
,	,	O
up	RB	O
to	TO	O
10	CD	PER
-	:	O
12	CD	PER
weeks	NNS	PER
.	.	O

Patients	NNS	O
should	MD	O
not	RB	O
take	VB	O
2	CD	DOS
doses	NNS	UNIT
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
to	TO	O
make	VB	O
up	RP	O
for	IN	O
a	DT	O
missed	JJ	O
dose	NN	O
.	.	O

Shake	NNP	O
well	RB	O
before	IN	O
each	DT	O
use	NN	O
.	.	O

In	IN	O
breakthrough	NN	O
bleeding	NN	O
,	,	O
as	IN	O
in	IN	O
all	DT	O
cases	NNS	O
of	IN	O
irregular	JJ	O
bleeding	NN	O
from	IN	O
the	DT	O
vagina	NN	O
,	,	O
nonfunctional	JJ	O
causes	NNS	O
should	MD	O
be	VB	O
borne	VBN	O
in	IN	O
mind	NN	O
.	.	O

Children	NNP	O
weighing	VBG	O
over	IN	O
50	CD	DOS
pounds	NNS	UNIT
-	:	O
250mg	CD	DOS
to	TO	O
500	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
.	.	O

After	IN	O
reconstitution	NN	O
,	,	O
the	DT	O
required	JJ	O
amount	NN	O
of	IN	O
suspension	NN	O
should	MD	O
be	VB	O
placed	VBN	O
directly	RB	O
on	IN	O
the	DT	O
child	NN	O
's	POS	O
tongue	NN	O
for	IN	O
swallowing	VBG	O
.	.	O

In	IN	O
some	DT	WHO
cases	NNS	WHO
,	,	O
a	DT	O
patient	NN	O
already	RB	O
receiving	VBG	O
BRINTELLIX	NNP	O
therapy	NN	O
may	MD	O
require	VB	O
urgent	JJ	O
treatment	NN	O
with	IN	O
linezolid	JJ	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	NN	O
.	.	O

Please	NNP	O
refer	NN	O
to	TO	O
the	DT	O
guidelines	NNS	O
below	IN	O
for	IN	O
dose	JJ	O
preparation	NN	O
based	VBN	O
upon	IN	O
patient	JJ	O
weight	NN	O
.	.	O

Taking	VBG	O
LUNESTA	NNP	O
with	IN	O
or	CC	O
immediately	RB	O
after	IN	O
a	DT	O
heavy	JJ	O
,	,	O
high	JJ	O
-	:	O
fat	JJ	O
meal	NN	O
results	NNS	O
in	IN	O
slower	JJR	O
absorption	NN	O
and	CC	O
would	MD	O
be	VB	O
expected	VBN	O
to	TO	O
reduce	VB	O
the	DT	O
effect	NN	O
of	IN	O
LUNESTA	NNP	O
on	IN	O
sleep	JJ	O
latency	NN	O
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
cluster	NN	O
headache	NN	O
,	,	O
the	DT	O
efficacy	NN	O
of	IN	O
lower	JJR	O
doses	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	O

Thus	RB	O
,	,	O
the	DT	O
direct	JJ	O
administration	NN	O
to	TO	O
patients	NNS	WHO
requiring	VBG	WHO
dosing	NN	WHO
of	IN	WHO
less	JJR	WHO
than	IN	O
0.6	CD	DOS
mL	NN	UNIT
(	(	O
6	CD	DOS
mg	NN	UNIT
)	)	O
is	VBZ	O
not	RB	O
recommended	VBN	O
due	JJ	O
to	TO	O
the	DT	O
potential	NN	O
for	IN	O
dosing	VBG	O
errors	NNS	O
.	.	O

Initiate	NNP	O
treatment	NN	O
with	IN	O
one	CD	DOS
4.6	CD	DOS
mg	NN	UNIT
/	VBD	O
24	CD	O
hours	NNS	O
EXELON	NNP	O
PATCH	NNP	O
applied	VBD	O
to	TO	O
the	DT	O
skin	NN	O
once	RB	FREQ
daily	JJ	FREQ
[	NNP	O
see	NN	O
Important	NNP	O
Administration	NNP	O
Instructions	NNP	O
]	NNP	O
.	.	O

The	DT	O
syringes	NNS	O
should	MD	O
be	VB	O
of	IN	O
small	JJ	O
enough	JJ	O
volume	NN	O
so	IN	O
that	IN	O
the	DT	O
prescribed	NNS	O
dose	VBP	O
can	MD	O
be	VB	O
withdrawn	VBN	O
from	IN	O
the	DT	O
vial	JJ	O
with	IN	O
accuracy	NN	O
.	.	O

It	PRP	O
will	MD	O
take	VB	O
much	RB	O
longer	JJR	O
to	TO	O
reach	VB	O
steady	JJ	O
-	:	O
state	NN	O
with	IN	O
any	DT	O
dose	NN	O
and	CC	O
/	NN	O
or	CC	O
frequency	NN	O
of	IN	O
administration	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
0.04	CD	DOS
mcg	NN	UNIT
sincalide	NN	O
per	IN	O
kg	NN	O
(	(	O
2.8	CD	DOS
mcg	NN	UNIT
/	VBD	O
70	CD	O
kg	NN	O
)	)	O
injected	VBD	O
intravenously	RB	O
over	IN	O
a	DT	O
30	CD	O
-	:	O
to	TO	O
60	CD	O
-	:	O
second	JJ	O
interval	NN	O
;	:	O
if	IN	O
satisfactory	JJ	O
transit	NN	O
of	IN	O
the	DT	O
barium	NN	O
meal	NN	O
has	VBZ	O
not	RB	O
occurred	VBN	O
in	IN	O
30	CD	O
minutes	NNS	O
,	,	O
a	DT	O
second	JJ	O
dose	NN	O
of	IN	O
0.04	CD	DOS
mcg	NNS	UNIT
sincalide	JJ	O
per	IN	O
kg	NN	O
may	MD	O
be	VB	O
administered	VBN	O
.	.	O

Administer	NNP	O
RiaSTAP	NNP	O
(	(	O
fibrinogen	NN	O
concentrate	NN	O
(	(	O
human	JJ	O
)	)	O
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
at	IN	O
room	NN	O
temperature	NN	O
by	IN	O
slow	JJ	O
intravenous	JJ	O
injection	NN	O
at	IN	O
a	DT	O
rate	NN	O
not	RB	O
exceeding	VBG	O
5	CD	DOS
mL	NNS	UNIT
per	IN	O
minute	NN	O
.	.	O

No	DT	O
dose	JJ	O
adjustment	NN	O
is	VBZ	O
necessary	JJ	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
CLcr	NNP	O
:	:	O
50	CD	DOS
-	:	O
80	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
/	VBD	O
1.73	CD	O
m²	NN	O
)	)	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Dosing	NN	O
Information	NN	O
for	IN	O
AndroGel	NNP	O
1	CD	O
%	NN	O

In	IN	O
most	JJS	O
instances	NNS	O
,	,	O
however	RB	O
,	,	O
the	DT	O
drug	NN	O
has	VBZ	O
been	VBN	O
well	RB	O
-	:	O
tolerated	VBN	O
.	.	O

Example	JJ	O
calculations	NNS	O
for	IN	O
infusion	NN	O
rates	NNS	O
are	VBP	O
as	IN	O
follows	VBZ	O
:	:	O

When	WRB	O
blastic	JJ	O
osseous	JJ	O
lesions	NNS	O
are	VBP	O
present	JJ	O
,	,	O
significantly	RB	O
enhanced	VBN	O
localization	NN	O
of	IN	O
the	DT	O
radiopharmaceutical	NN	O
will	MD	O
occur	VB	O
,	,	O
with	IN	O
correspondingly	RB	O
higher	JJR	O
doses	NNS	O
to	TO	O
the	DT	O
lesions	NNS	O
compared	VBN	O
with	IN	O
normal	JJ	O
bones	NNS	O
and	CC	O
other	JJ	O
organs	NNS	O
.	.	O

Base	NNP	O
dosage	NN	O
increments	NNS	O
on	IN	O
the	DT	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
supplementary	JJ	O
opioids	NNS	O
,	,	O
using	VBG	O
the	DT	O
ratio	NN	O
of	IN	O
45	CD	DOS
mg	NNS	UNIT
/	VBD	O
24	CD	O
hours	NNS	O
of	IN	O
oral	JJ	O
morphine	NN	O
to	TO	O
a	DT	O
12	CD	DOS
mcg	NN	UNIT
/	FW	O
hour	NN	O
increase	NN	O
in	IN	O
DURAGESIC	NNP	O
dose	NN	O
.	.	O

Most	JJS	O
side	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
pill	NN	O
are	VBP	O
not	RB	O
serious	JJ	O
.	.	O

Figure	NN	O
18	CD	O

Patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
unable	JJ	WHO
to	TO	O
sleep	VB	O
if	IN	O
medication	NN	O
is	VBZ	O
taken	VBN	O
late	RB	O
in	IN	O
the	DT	O
day	NN	O
should	MD	O
take	VB	O
the	DT	O
last	JJ	O
dose	NN	O
before	IN	O
6	CD	O
p.m	NN	O
.	.	O

These	DT	O
dosing	VBG	O
recommendations	NNS	O
apply	VBP	O
to	TO	O
the	DT	O
initial	JJ	O
course	NN	O
of	IN	O
treatment	NN	O
.	.	O

(	(	O
See	VB	O
also	RB	O
discussion	NN	O
of	IN	O
paracervical	JJ	O
block	NN	O
in	IN	O
PRECAUTIONS	NNP	O
.	.	O
)	)	O

IMPORTANT	NN	O
:	:	O

Apprise	NNP	O
patients	NNS	O
of	IN	O
the	DT	O
high	JJ	O
risk	NN	O
of	IN	O
relapse	NN	O
to	TO	O
illicit	VB	O
drug	NN	O
use	NN	O
associated	VBN	O
with	IN	O
discontinuation	NN	O
of	IN	O
methadone	NN	O
maintenance	NN	O
treatment	NN	O
.	.	O

The	DT	O
full	JJ	O
effect	NN	O
of	IN	O
this	DT	O
dose	NN	O
will	MD	O
usually	RB	O
be	VB	O
seen	VBN	O
within	IN	O
one	CD	PER
to	TO	O
two	CD	PER
weeks	NNS	PER
.	.	O

Administer	NNP	O
the	DT	O
diluted	JJ	O
ELAPRASE	NNP	O
solution	NN	O
to	TO	O
patients	NNS	O
using	VBG	O
a	DT	O
low	JJ	O
-	:	O
protein	NN	O
-	:	O
binding	NN	O
infusion	NN	O
set	VBN	O
equipped	VBN	O
with	IN	O
a	DT	O
low	JJ	O
-	:	O
protein	NN	O
-	:	O
binding	VBG	O
0.2	CD	DOS
micrometer	NN	UNIT
(	(	O
μm	NN	O
)	)	O
in	IN	O
-	:	O
line	NN	O
filter	NN	O
.	.	O

ATRIDOX	NNP	O
(	(	O
doxycycline	JJ	O
hyclate	NN	O
)	)	O
®	NN	O
is	VBZ	O
a	DT	O
variable	JJ	O
dose	JJ	O
product	NN	O
dependent	NN	O
on	IN	O
the	DT	O
size	NN	O
,	,	O
shape	NN	O
,	,	O
and	CC	O
number	NN	O
of	IN	O
pockets	NNS	O
being	VBG	O
treated	VBN	O
.	.	O

If	IN	O
a	DT	O
satisfactory	JJ	O
reduction	NN	O
in	IN	O
blood	NN	O
pressure	NN	O
does	VBZ	O
not	RB	O
occur	VB	O
after	IN	O
this	DT	O
period	NN	O
,	,	O
the	DT	O
dose	NN	O
may	MD	O
be	VB	O
adjusted	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
at	IN	O
2	CD	O
-	:	O
4	CD	PER
week	NN	PER
intervals	NNS	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

For	IN	O
anterior	JJ	O
images	NNS	O
,	,	O
position	NN	O
the	DT	O
patient	JJ	O
supine	NN	O
with	IN	O
both	DT	O
arms	NNS	O
behind	IN	O
the	DT	O
head	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
HALAVEN	NNP	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	O
Child	NNP	O
-	:	O
Pugh	IN	O
A	DT	O
)	)	O
is	VBZ	O
1.1	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
administered	VBD	O
intravenously	RB	O
over	IN	O
2	CD	O
to	TO	O
5	CD	O
minutes	NNS	O
on	IN	O
Days	NNS	O
1	CD	O
and	CC	O
8	CD	O
of	IN	O
a	DT	O
21	CD	O
-	:	O
day	NN	O
cycle	NN	O
[	NNP	O
see	NN	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Check	VB	O
that	IN	O
the	DT	O
green	JJ	O
light	NN	O
turns	NNS	O
on	IN	O
.	.	O

INTRON	NNP	O
A	NNP	O
adjuvant	JJ	O
treatment	NN	O
of	IN	O
malignant	JJ	O
melanoma	NN	O
is	VBZ	O
given	VBN	O
in	IN	O
two	CD	O
phases	NNS	O
,	,	O
induction	NN	O
and	CC	O
maintenance	NN	O
.	.	O

Dissolution	NN	O
is	VBZ	O
facilitated	VBN	O
by	IN	O
using	VBG	O
lukewarm	JJ	O
water	NN	O
.	.	O

Confirm	VB	O
the	DT	O
presence	NN	O
of	IN	O
BRAF	NNP	O
V600E	NNP	O
or	CC	O
V600K	NNP	O
mutation	NN	O
in	IN	O
tumor	NN	O
specimens	NNS	O
prior	RB	O
to	TO	O
initiation	NN	O
of	IN	O
treatment	NN	O
with	IN	O
TAFINLAR	NNP	O
and	CC	O
trametinib	NN	O
.	.	O

Titrate	NN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
effectiveness	NN	O
and	CC	O
tolerance	NN	O
,	,	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
of	IN	O
0.6	CD	DOS
mL	NN	UNIT
(	(	O
6	CD	DOS
mg	NN	UNIT
)	)	O
[	FW	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

EUCRISA	NNP	O
is	VBZ	O
for	IN	O
topical	JJ	O
use	NN	O
only	RB	O
and	CC	O
not	RB	O
for	IN	O
ophthalmic	JJ	O
,	,	O
oral	JJ	O
,	,	O
or	CC	O
intravaginal	JJ	O
use	NN	O
.	.	O

Interrupt	NNP	O
VELCADE	NNP	O
treatment	NN	O
at	IN	O
the	DT	O
onset	NN	O
of	IN	O
any	DT	O
Grade	NNP	O
3	CD	O
hematologic	NN	O
or	CC	O
non	JJ	O
-	:	O
hematological	JJ	O
toxicities	NNS	O
,	,	O
excluding	VBG	O
neuropathy	JJ	O
[	NNP	O
see	VBP	O
Table	JJ	O
5	CD	O
and	CC	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Apply	VB	O
a	DT	O
one	CD	O
-	:	O
half	NN	O
inch	JJ	O
ribbon	NN	O
in	IN	O
the	DT	O
lower	JJR	O
conjunctival	NN	O
sac	NN	O
of	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
at	IN	O
bedtime	NN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
forgets	VBZ	O
to	TO	O
replace	VB	O
Neupro	NNP	O
,	,	O
or	CC	O
if	IN	O
the	DT	O
transdermal	JJ	O
system	NN	O
becomes	VBZ	O
dislodged	VBN	O
,	,	O
another	DT	O
transdermal	JJ	O
system	NN	O
should	MD	O
be	VB	O
applied	VBN	O
for	IN	O
the	DT	O
remainder	NN	O
of	IN	O
the	DT	O
day	NN	O
.	.	O

For	IN	O
prophylaxis	NN	O
of	IN	O
neonatal	JJ	O
gonococcal	JJ	O
or	CC	O
chlamydial	JJ	O
conjunctivitis	NN	O
,	,	O
a	DT	O
ribbon	NN	O
of	IN	O
ointment	NN	O
approximately	RB	O
1	CD	DOS
cm	NNS	UNIT
in	IN	O
length	NN	O
should	MD	O
be	VB	O
instilled	VBN	O
into	IN	O
each	DT	O
lower	JJR	O
conjunctival	NN	O
sac	NN	O
.	.	O

2	CD	O
.	.	O

For	IN	O
this	DT	O
reason	NN	O
,	,	O
buprenorphine	NN	O
monotherapy	NN	O
is	VBZ	O
recommended	VBN	O
in	IN	O
patients	NNS	WHO
taking	VBG	WHO
long	JJ	WHO
-	:	O
acting	NN	O
opioids	NNS	O
when	WRB	O
used	VBN	O
according	VBG	O
to	TO	O
approved	VBN	O
administration	NN	O
instructions	NNS	O
.	.	O

In	IN	O
postencephalitic	JJ	O
parkinsonism	NN	O
,	,	O
therapy	NN	O
may	MD	O
be	VB	O
initiated	VBN	O
in	IN	O
most	JJS	WHO
patients	NNS	WHO
with	IN	O
2	CD	DOS
mg	NNS	UNIT
a	DT	FREQ
day	NN	FREQ
in	IN	O
one	CD	DOS
or	CC	O
more	JJR	O
doses	NNS	O
.	.	O

(	(	O
The	DT	O
first	JJ	O
day	NN	O
of	IN	O
menstruation	NN	O
is	VBZ	O
Day	NNP	O
1	CD	O
.	.	O
)	)	O

VFEND	NNP	O
I.V	NNP	O
.	.	O

Hold	VB	O
the	DT	O
syringe	NN	O
assembly	NN	O
by	IN	O
the	DT	O
open	JJ	O
sides	NNS	O
of	IN	O
the	DT	O
device	NN	O
.	.	O

If	IN	O
implant	JJ	O
(	(	O
s	JJ	O
)	)	O
or	CC	O
implant	JJ	O
fragment	NN	O
(	(	O
s	NN	O
)	)	O
are	VBP	O
not	RB	O
removed	VBN	O
during	IN	O
a	DT	O
removal	NN	O
attempt	NN	O
,	,	O
the	DT	O
patient	NN	O
should	MD	O
undergo	VB	O
imaging	VBG	O
for	IN	O
localization	NN	O
as	RB	O
soon	RB	O
as	IN	O
is	VBZ	O
feasible	JJ	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
oral	JJ	O
dosage	NN	O
is	VBZ	O
1	CD	DOS
g	NN	UNIT
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

for	IN	O
suspension	NN	O
,	,	O
only	RB	O
as	RB	O
needed	VBN	O
to	TO	O
achieve	VB	O
freedom	NN	O
from	IN	O
pain	NN	O
.	.	O

It	PRP	O
is	VBZ	O
important	JJ	O
that	IN	O
(	(	O
1	CD	O
)	)	O
administration	NN	O
of	IN	O
the	DT	O
initial	JJ	O
preoperative	NN	O
dose	NN	O
be	VB	O
completed	VBN	O
approximately	RB	O
one	CD	O
hour	NN	O
before	IN	O
surgery	NN	O
so	RB	O
that	IN	O
adequate	JJ	O
drug	NN	O
levels	NNS	O
are	VBP	O
present	JJ	O
in	IN	O
the	DT	O
serum	NN	O
and	CC	O
tissues	NNS	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
initial	JJ	O
incision	NN	O
,	,	O
and	CC	O
(	(	O
2	CD	O
)	)	O
Metronidazole	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
RTU	NNP	O
be	VB	O
administered	VBN	O
,	,	O
if	IN	O
necessary	JJ	O
,	,	O
at	IN	O
6	CD	O
-	:	O
hour	NN	O
intervals	NNS	O
to	TO	O
maintain	VB	O
effective	JJ	O
drug	NN	O
levels	NNS	O
.	.	O

The	DT	O
first	JJ	O
stage	NN	O
of	IN	O
PDT	NNP	O
is	VBZ	O
the	DT	O
intravenous	JJ	O
injection	NN	O
of	IN	O
PHOTOFRIN	NNP	O
(	(	O
porfimer	JJ	O
sodium	NN	O
)	)	O
at	IN	O
2	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
.	.	O

The	DT	O
individual	NN	O
dose	NN	O
,	,	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
,	,	O
and	CC	O
the	DT	O
total	JJ	O
cumulative	JJ	O
dose	NN	O
of	IN	O
amikacin	JJ	O
sulfate	NN	O
are	VBP	O
identical	JJ	O
to	TO	O
the	DT	O
dose	NN	O
recommended	VBD	O
for	IN	O
intramuscular	JJ	O
administration	NN	O
.	.	O

Rapid	JJ	O
and	CC	O
complete	JJ	O
return	NN	O
of	IN	O
function	NN	O
usually	RB	O
follows	VBZ	O
.	.	O

Cleanse	NNP	O
both	CC	O
the	DT	O
DTP	NNP	O
(	(	O
diphtheria	NN	O
and	CC	O
tetanus	NN	O
toxoids	NNS	O
and	CC	O
pertussis	NN	O
vaccine	NN	O
adsorbed	IN	O
usp	JJ	O
)	)	O
and	CC	O
ActHIB	NNP	O
®	NNP	O
or	CC	O
OmniHIB	NNP	O
vaccine	VBP	O
vial	JJ	O
rubber	NN	O
barriers	NNS	O
with	IN	O
a	DT	O
suitable	JJ	O
germicide	NN	O
prior	RB	O
to	TO	O
reconstitution	NN	O
.	.	O

In	IN	O
most	JJS	O
cases	NNS	O
,	,	O
therapy	NN	O
should	MD	O
not	RB	O
exceed	VB	O
ten	JJ	O
days	NNS	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
OSENI	NNP	O
(	(	O
alogliptin	NN	O
and	CC	O
pioglitazone	NN	O
)	)	O
:	:	O

After	IN	O
diuresis	NN	O
has	VBZ	O
been	VBN	O
achieved	VBN	O
,	,	O
the	DT	O
minimally	RB	O
effective	JJ	O
dose	NN	O
(	(	O
usually	RB	O
from	IN	O
50	CD	DOS
to	TO	O
200	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
)	)	O
may	MD	O
be	VB	O
given	VBN	O
on	IN	O
a	DT	O
continuous	JJ	O
or	CC	O
intermittent	JJ	O
dosage	NN	O
schedule	NN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
started	VBN	O
on	IN	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

For	IN	O
initial	JJ	O
therapy	NN	O
with	IN	O
HUMORSOL	NNP	O
(	(	O
demecarium	NN	O
)	)	O
(	(	O
0.125	CD	O
percent	NN	O
or	CC	O
0.25	CD	O
percent	NN	O
)	)	O
place	NN	O
1	CD	DOS
drop	NN	UNIT
(	(	O
children	NNS	O
)	)	O
or	CC	O
1	CD	DOS
or	CC	O
2	CD	DOS
drops	NNS	UNIT
(	(	O
adults	NNS	WHO
)	)	O
in	IN	O
the	DT	O
glaucomatous	JJ	O
eye	NN	O
.	.	O

Ecchymosis	NN	O
occurs	VBZ	O
easily	RB	O
in	IN	O
the	DT	O
soft	JJ	O
eyelid	JJ	O
tissues	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
in	IN	O
adults	NNS	WHO
,	,	O
following	VBG	O
an	DT	O
8	CD	PER
week	NN	PER
course	NN	O
(	(	O
s	JJ	O
)	)	O
of	IN	O
treatment	NN	O
for	IN	O
active	JJ	O
disease	NN	O
and	CC	O
once	RB	O
the	DT	O
patient	NN	O
’	NNP	O
s	NN	O
symptoms	NNS	O
are	VBP	O
controlled	VBN	O
(	(	O
CDAI	NNP	O
less	JJR	O
than	IN	O
150	CD	O
)	)	O
,	,	O
is	VBZ	O
ENTOCORT	NNP	O
EC	NNP	O
6	CD	DOS
mg	NN	UNIT
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
maintenance	NN	O
of	IN	O
clinical	JJ	O
remission	NN	O
up	RB	PER
to	TO	PER
3	CD	PER
months	NNS	PER
.	.	O

SURFAXIN	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
by	IN	O
or	CC	O
under	IN	O
the	DT	O
supervision	NN	O
of	IN	O
clinicians	NNS	O
experienced	VBN	O
in	IN	O
intubation	NN	O
,	,	O
ventilator	NN	O
management	NN	O
,	,	O
and	CC	O
general	JJ	O
care	NN	O
of	IN	O
premature	NN	WHO
infants	NNS	WHO
.	.	O

The	DT	O
dosage	NN	O
delivered	VBN	O
by	IN	O
the	DT	O
single	JJ	O
injection	NN	O
is	VBZ	O
equivalent	JJ	O
to	TO	O
three	CD	DOS
injections	NNS	UNIT
of	IN	O
Anika	NNP	O
's	POS	O
FDA	NNP	O
approved	VBD	O
(	(	O
P030019	NNP	O
)	)	O
Orthovisc	NNP	O
HA	NNP	O
product	NN	O
.	.	O

Tablets	NNS	O
should	MD	O
be	VB	O
taken	VBN	O
with	IN	O
food	NN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
informed	VBN	O
that	IN	O
itching	VBG	O
occurs	NNS	O
after	IN	O
the	DT	O
successful	JJ	O
killing	NN	O
of	IN	O
scabies	NNS	O
(	(	O
lice	NN	O
)	)	O
and	CC	O
continued	JJ	O
itching	NN	O
is	VBZ	O
not	RB	O
necessarily	RB	O
an	DT	O
indication	NN	O
for	IN	O
retreatment	NN	O
with	IN	O
Lindane	NNP	O
Lotion	NNP	O
.	.	O

For	IN	O
fungal	JJ	O
infection	NN	O
of	IN	O
the	DT	O
feet	NNS	O
caused	VBN	O
by	IN	O
Candida	NNP	O
species	NNS	O
,	,	O
the	DT	O
powder	NN	O
should	MD	O
be	VB	O
dusted	VBN	O
on	IN	O
the	DT	O
feet	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
,	,	O
in	IN	O
all	DT	O
foot	NN	O
wear	NN	O
.	.	O

Figure	NN	O
1	CD	O
:	:	O
Cleanse	NNP	O
both	DT	O
vial	JJ	O
stoppers	NNS	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
clinically	RB	O
significant	JJ	O
responses	NNS	O
are	VBP	O
not	RB	O
seen	VBN	O
at	IN	O
doses	NNS	O
below	IN	O
1500	CD	DOS
mg	NN	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
preferred	JJ	O
site	NN	O
for	IN	O
intramuscular	JJ	O
injection	NN	O
is	VBZ	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
of	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
.	.	O

Alcoholic	JJ	O
beverages	NNS	O
should	MD	O
be	VB	O
avoided	VBN	O
when	WRB	O
taking	VBG	O
tinidazole	NN	O
and	CC	O
for	IN	O
3	CD	PER
days	NNS	PER
afterwards	NNS	O
[	JJ	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

Individualize	NNP	O
treatment	NN	O
in	IN	O
every	DT	FREQ
case	NN	FREQ
,	,	O
using	VBG	O
non	JJ	O
-	:	O
opioid	NN	O
analgesics	NNS	O
,	,	O
opioids	NNS	O
on	IN	O
an	DT	O
as	IN	O
-	:	O
needed	VBN	O
basis	NN	O
and	CC	O
/	NN	O
or	CC	O
combination	NN	O
products	NNS	O
,	,	O
and	CC	O
chronic	JJ	O
opioid	NN	O
therapy	NN	O
in	IN	O
a	DT	O
progressive	JJ	O
plan	NN	O
of	IN	O
pain	JJ	O
management	NN	O
such	JJ	O
as	IN	O
outlined	VBN	O
by	IN	O
the	DT	O
World	NNP	O
Health	NNP	O
Organization	NNP	O
,	,	O
the	DT	O
Agency	NNP	O
for	IN	O
Healthcare	NNP	O
Research	NNP	O
and	CC	O
Quality	NNP	O
,	,	O
and	CC	O
the	DT	O
American	JJ	O
Pain	NNP	O
Society	NNP	O
.	.	O

Likewise	RB	O
,	,	O
the	DT	O
interval	NN	O
of	IN	O
no	DT	O
tablets	NNS	O
will	MD	O
always	RB	O
start	VB	O
on	IN	O
the	DT	O
same	JJ	O
day	NN	O
of	IN	O
the	DT	O
week	NN	PER
.	.	O

Glycopyrrolate	NNP	O
Tablets	NNP	O
,	,	O
USP	NNP	O
are	VBP	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
under	IN	WHO
the	DT	WHO
age	NN	WHO
of	IN	WHO
12	CD	WHO
years	NNS	WHO
.	.	O

43	CD	O

The	DT	O
prepared	JJ	O
Peglntron™	NNP	O
solution	NN	O
is	VBZ	O
to	TO	O
be	VB	O
injected	VBN	O
subcutaneously	RB	O
.	.	O

For	IN	O
treatment	NN	O
and	CC	O
prophylaxis	NN	O
of	IN	O
mycobacterial	JJ	O
infections	NNS	O
in	IN	O
adults	NNS	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BIAXIN	NNP	O
is	VBZ	O
500	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

Immediately	RB	O
stop	JJ	O
and	CC	O
permanently	RB	O
discontinue	VB	O
OCREVUS	NNP	O
if	IN	O
there	EX	O
are	VBP	O
signs	NNS	O
of	IN	O
a	DT	O
life	NN	O
-	:	O
threatening	NN	O
or	CC	O
disabling	VBG	O
infusion	NN	O
reaction	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Prior	RB	O
to	TO	O
Carticel	NNP	O
implantation	NN	O
,	,	O
match	VB	O
the	DT	O
patient	NN	O
name	NN	O
and	CC	O
ID	NNP	O
number	NN	O
on	IN	O
the	DT	O
certificate	NN	O
of	IN	O
analysis	NN	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
chart	NN	O
and	CC	O
the	DT	O
patient	NN	O
ID	NNP	O
on	IN	O
the	DT	O
shipping	NN	O
box	NN	O
,	,	O
transport	NN	O
cylinder	NN	O
and	CC	O
vial	NN	O
.	.	O

During	IN	O
the	DT	O
course	NN	O
of	IN	O
primary	JJ	O
immunizations	NNS	O
,	,	O
injections	NNS	O
should	MD	O
not	RB	O
be	VB	O
made	VBN	O
more	JJR	O
than	IN	O
once	RB	O
at	IN	O
the	DT	O
same	JJ	O
site	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosing	NN	O
range	NN	O
is	VBZ	O
10	CD	DOS
-	:	O
80	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
in	IN	O
single	JJ	DOS
or	CC	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
;	:	O
the	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
is	VBZ	O
80	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
it	PRP	O
was	VBD	O
demonstrated	VBN	O
that	IN	O
smaller	JJR	O
bleeding	NN	O
sites	NNS	O
covering	VBG	O
an	DT	O
area	NN	O
of	IN	O
less	JJR	O
than	IN	O
10	CD	DOS
cm²	NNS	UNIT
used	VBD	O
0.5	CD	DOS
gram	NN	UNIT
to	TO	O
1.0	CD	DOS
gram	NN	UNIT
of	IN	O
Raplixa	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
TRUVADA	NNP	O
in	IN	O
adults	NNS	WHO
and	CC	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
with	IN	WHO
body	NN	WHO
weight	NN	WHO
greater	JJR	WHO
than	IN	WHO
or	CC	WHO
equal	JJ	WHO
to	TO	WHO
35	CD	WHO
kg	NN	WHO
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
(	(	O
containing	VBG	O
200	CD	DOS
mg	NN	UNIT
of	IN	O
emtricitabine	NN	O
and	CC	O
300	CD	DOS
mg	NN	UNIT
of	IN	O
tenofovir	NN	O
disoproxil	NN	O
fumarate	NN	O
)	)	O
once	RB	FREQ
daily	JJ	FREQ
taken	VBN	O
orally	RB	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

Pediatric	NNP	O
dosing	NN	O
recommendations	NNS	O
are	VBP	O
based	VBN	O
on	IN	O
clinical	JJ	O
experience	NN	O
.	.	O

If	IN	O
the	DT	O
moderate	JJ	O
inhibitor	NN	O
is	VBZ	O
discontinued	VBN	O
,	,	O
the	DT	O
AFINITOR	NNP	O
dose	NN	O
should	MD	O
be	VB	O
returned	VBN	O
to	TO	O
the	DT	O
dose	NN	O
used	VBN	O
prior	RB	O
to	TO	O
initiation	NN	O
of	IN	O
the	DT	O
moderate	JJ	O
CYP3A4	NNP	O
/	NNP	O
PgP	NNP	O
inhibitor	NN	O
.	.	O

Dosage	NN	O
information	NN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
specific	JJ	WHO
tumors	NNS	WHO
follows	VBZ	O
.	.	O

Thereafter	RB	O
,	,	O
therapy	EX	O
primarily	RB	O
maintains	VBZ	O
the	DT	O
improvement	NN	O
realized	VBN	O
during	IN	O
the	DT	O
first	JJ	O
24	CD	PER
weeks	NNS	PER
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
observed	VBN	O
carefully	RB	O
if	IN	O
abrupt	JJ	O
reduction	NN	O
or	CC	O
discontinuation	NN	O
of	IN	O
SINEMET	NNP	O
is	VBZ	O
required	VBN	O
,	,	O
especially	RB	O
if	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
receiving	VBG	O
neuroleptics	NNS	O
.	.	O

Therapy	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
as	RB	O
early	RB	O
as	IN	O
possible	JJ	O
following	VBG	O
onset	NN	O
of	IN	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
.	.	O

Dosage	NNP	O
depends	VBZ	O
on	IN	O
the	DT	O
severity	NN	O
of	IN	O
the	DT	O
disease	NN	O
and	CC	O
the	DT	O
response	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

Proper	NNP	O
sterile	NN	O
technique	NN	O
should	MD	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
preparation	NN	O
of	IN	O
parenteral	JJ	O
admixtures	NNS	O
to	TO	O
minimize	VB	O
the	DT	O
possibility	NN	O
of	IN	O
microbial	JJ	O
contamination	NN	O
.	.	O

100,000	CD	DOS
Units	NNS	UNIT
daily	RB	FREQ
for	IN	O
three	CD	PER
days	NNS	PER
followed	VBN	O
by	IN	O
50,000	CD	DOS
daily	JJ	FREQ
for	IN	O
two	CD	PER
weeks	NNS	PER
.	.	O

If	IN	O
there	EX	O
is	VBZ	O
still	RB	O
no	DT	O
improvement	NN	O
,	,	O
it	PRP	O
is	VBZ	O
unlikely	JJ	O
that	IN	O
further	JJ	O
dose	JJ	O
escalation	NN	O
will	MD	O
be	VB	O
beneficial	JJ	O
.	.	O

For	IN	O
a	DT	O
detailed	JJ	O
description	NN	O
of	IN	O
oral	JJ	O
administration	NN	O
of	IN	O
liquids	NNS	O
refer	VBP	O
to	TO	O
pages	NNS	O
536	CD	O
-	:	O
540	CD	O
of	IN	O
the	DT	O
5th	JJ	O
edition	NN	O
of	IN	O
Handbook	NNP	O
o	FW	O
f	VBP	O
Veterinary	NNP	O
Procedures	NNP	O
&	CC	O
Emergency	NNP	O
Treatment	NNP	O
by	IN	O
Kirk	NNP	O
et	CC	O
al	NN	O
.	.	O

THE	DT	O
SOLUTION	NNP	O
SHOULD	NNP	O
BE	NNP	O
USED	NNP	O
IMMEDIATELY	NNP	O
AS	IN	O
IT	NNP	O
CONTAINS	NNP	O
NO	NNP	O
PRESERVATIVES	NNP	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
chronic	JJ	O
ambulatory	NN	O
peritoneal	JJ	O
dialysis	NN	O
(	(	O
CAPD	NNP	O
)	)	O
and	CC	O
continuous	JJ	O
arteriovenous	JJ	O
hemofiltration	NN	O
/	JJ	O
dialysis	NN	O
(	(	O
CAVHD	NNP	O
)	)	O
on	IN	O
acyclovir	NN	O
pharmacokinetics	NNS	O
has	VBZ	O
been	VBN	O
studied	VBN	O
.	.	O

Serum	NNP	O
lipids	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
for	IN	O
evidence	NN	O
of	IN	O
essential	JJ	O
fatty	JJ	O
acid	JJ	O
deficiency	NN	O
in	IN	O
patients	NNS	WHO
maintained	VBN	O
on	IN	O
fat	JJ	O
-	:	O
free	JJ	O
TPN	NNP	O
.	.	O

CAUTION	NNP	O
-	:	O
INTRAMUSCULAR	NN	O
OR	NNP	O
SUBCUTANEOUS	NNP	O
INJECTION	NNP	O
OF	NNP	O
RECONSTITUTED	NNP	O
CYTOVENE	NNP	O
-	:	O
IV	NNP	O
SOLUTION	NNP	O
MAY	NNP	O
RESULT	NNP	O
IN	NNP	O
SEVERE	NNP	O
TISSUE	NNP	O
IRRITATION	NNP	O
DUE	NNP	O
TO	NNP	O
HIGH	NNP	O
pH	NN	O
(	(	O
11	CD	O
)	)	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
any	DT	O
diluent	NN	O
other	JJ	O
than	IN	O
the	DT	O
ones	NNS	O
recommended	VBD	O
or	CC	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
bacteriostatic	JJ	O
agent	NN	O
(	(	O
e.g	UH	O
,	,	O
benzyl	JJ	O
alcohol	NN	O
)	)	O
in	IN	O
the	DT	O
diluent	NN	O
may	MD	O
cause	VB	O
precipitation	NN	O
of	IN	O
the	DT	O
antibiotic	JJ	O
.	.	O

(	(	O
Information	NNP	O
available	JJ	O
on	IN	O
request	NN	O
.	.	O
)	)	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
DIFLUCAN	NNP	O
for	IN	O
oropharyngeal	JJ	O
candidiasis	NN	O
in	IN	O
children	NNS	WHO
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
,	,	O
followed	VBN	O
by	IN	O
3	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NNS	O
once	RB	FREQ
daily	RB	FREQ
.	.	O

†††Refer	NN	O
to	TO	O
the	DT	O
package	NN	O
circular	NN	O
for	IN	O
lidocaine	NN	O
HCl	NNP	O
for	IN	O
detailed	JJ	O
information	NN	O
concerning	VBG	O
CONTRAINDICATIONS	NNP	O
,	,	O
WARNINGS	NNP	O
,	,	O
PRECAUTIONS	NNP	O
,	,	O
and	CC	O
ADVERSE	NNP	O
REACTIONS	NNP	O
.	.	O

MONOPRIL	NNP	O
(	(	O
fosinopril	JJ	O
sodium	NN	O
)	)	O
in	IN	O
children	NNS	WHO
weighing	VBG	WHO
more	JJR	WHO
than	IN	WHO
50	CD	WHO
kg	NN	WHO
is	VBZ	O
5	CD	DOS
to	TO	O
10	CD	DOS
mg	NN	UNIT
once	RB	FREQ
per	JJ	FREQ
day	NN	FREQ
as	IN	O
monotherapy	NN	O
.	.	O

After	IN	O
8	CD	PER
weeks	NNS	PER
of	IN	O
therapy	NN	O
,	,	O
if	IN	O
there	EX	O
is	VBZ	O
no	DT	O
response	NN	O
as	IN	O
measured	VBN	O
by	IN	O
hemoglobin	NN	O
levels	NNS	O
or	CC	O
if	IN	O
RBC	JJ	O
transfusions	NNS	O
are	VBP	O
still	RB	O
required	VBN	O
,	,	O
discontinue	VB	O
Epogen	NNP	O
.	.	O

Apply	VB	O
one	CD	DOS
or	CC	O
two	CD	DOS
surgical	JJ	O
closure	NN	O
strips	NNS	O
to	TO	O
close	VB	O
the	DT	O
wound	NN	O
tightly	RB	O
,	,	O
and	CC	O
cover	NN	O
with	IN	O
an	DT	O
adhesive	JJ	O
bandage	NN	O
.	.	O

Prophylactic	JJ	O
administration	NN	O
should	MD	O
usually	RB	O
be	VB	O
stopped	VBN	O
within	IN	O
24	CD	O
hours	NNS	O
since	IN	O
continuing	VBG	O
administration	NN	O
of	IN	O
any	DT	O
antibiotic	JJ	O
increases	NNS	O
the	DT	O
possibility	NN	O
of	IN	O
adverse	JJ	O
reactions	NNS	O
but	CC	O
,	,	O
in	IN	O
the	DT	O
majority	NN	O
of	IN	O
surgical	JJ	O
procedures	NNS	O
,	,	O
does	VBZ	O
not	RB	O
reduce	VB	O
the	DT	O
incidence	NN	O
of	IN	O
subsequent	JJ	O
infection	NN	O
.	.	O

Step	NN	O
9	CD	O
.	.	O

Abrupt	NNP	O
withdrawal	NN	O
of	IN	O
treatment	NN	O
may	MD	O
result	VB	O
in	IN	O
neuroleptic	JJ	WHO
malignant	JJ	WHO
syndrome	NN	WHO
(	(	O
NMS	NNP	O
)	)	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O

Periodically	RB	O
reassess	VB	O
the	DT	O
need	NN	O
for	IN	O
maintenance	NN	O
treatment	NN	O
and	CC	O
the	DT	O
appropriate	JJ	O
dose	NN	O
for	IN	O
such	JJ	O
treatment	NN	O
.	.	O

The	DT	O
recommended	JJ	O
diluent	NN	O
is	VBZ	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
injection	NN	O
(	(	O
0.9	CD	O
%	NN	O
NaCl	NNP	O
)	)	O
.	.	O

Dose	NNP	O
decreases	NNS	O
by	IN	O
25	CD	O
%	NN	O
to	TO	O
50	CD	O
%	NN	O
should	MD	O
be	VB	O
made	VBN	O
at	IN	O
any	DT	O
time	NN	O
to	TO	O
control	VB	O
adverse	JJ	O
events	NNS	O
,	,	O
e.g	NN	O
,	,	O
hypertension	NN	O
,	,	O
elevations	NNS	O
in	IN	O
serum	JJ	O
creatinine	NN	O
(	(	O
≥	JJ	O
25	CD	O
%	NN	O
above	IN	O
the	DT	O
patient	NN	O
's	POS	O
pretreatment	JJ	O
level	NN	O
)	)	O
,	,	O
or	CC	O
clinically	RB	O
significant	JJ	O
laboratory	NN	O
abnormalities	NNS	O
.	.	O

Do	NNP	O
not	RB	O
add	VB	O
supplementary	JJ	O
medication	NN	O
.	.	O

for	IN	O
Injection	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
intravenously	RB	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
at	IN	O
least	JJS	O
2	CD	O
minutes	NNS	O
.	.	O

Manufactured	VBN	O
For	IN	O
:	:	O
Ferring	NNP	O
Pharmaceuticals	NNP	O
Inc.	NNP	O
,	,	O
Parsippany	NNP	O
,	,	O
NJ	NNP	O
07054	CD	O
.	.	O

Early	JJ	O
drug	NN	O
discontinuation	NN	O
may	MD	O
be	VB	O
considered	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
abnormal	JJ	WHO
CBC	NNP	WHO
results	NNS	WHO
that	WDT	O
do	VBP	O
not	RB	O
respond	VB	O
to	TO	O
dose	VB	O
reduction	NN	O
.	.	O

Initiate	NNP	O
treatment	NN	O
at	IN	O
62.5	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
for	IN	O
4	CD	PER
weeks	NNS	PER
and	CC	O
then	RB	O
increase	VB	O
to	TO	O
the	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
125	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

After	IN	O
toxic	JJ	O
side	NN	O
effects	NNS	O
have	VBP	O
subsided	VBN	O
,	,	O
therapy	NN	O
may	MD	O
then	RB	O
be	VB	O
resumed	VBN	O
at	IN	O
the	DT	O
discretion	NN	O
of	IN	O
the	DT	O
physician	NN	O
,	,	O
based	VBN	O
on	IN	O
clinical	JJ	O
evaluation	NN	O
and	CC	O
appropriate	JJ	O
laboratory	NN	O
studies	NNS	O
,	,	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
1	CD	DOS
to	TO	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

Add	VB	O
the	DT	O
full	JJ	O
contents	NNS	O
(	(	O
25	CD	DOS
mL	NN	UNIT
)	)	O
of	IN	O
the	DT	O
SPORANOX®	NNP	O
(	(	O
itraconazole	JJ	O
injection	NN	O
)	)	O
Injection	NN	O
ampule	NN	O
into	IN	O
the	DT	O
infusion	NN	O
bag	NN	O
provided	VBD	O
,	,	O
which	WDT	O
contains	VBZ	O
50	CD	DOS
mL	NN	UNIT
of	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
(	(	O
Normal	NNP	O
Saline	NNP	O
)	)	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
Triferic®	NNP	O
is	VBZ	O
expressed	VBN	O
as	IN	O
mg	NN	UNIT
of	IN	O
iron	NN	O
(	(	O
III	NNP	O
)	)	O
.	.	O

The	DT	O
majority	NN	O
of	IN	O
retest	NN	O
responses	NNS	O
will	MD	O
occur	VB	O
within	IN	O
72	CD	O
hours	NNS	O
;	:	O
however	RB	O
,	,	O
the	DT	O
repeat	NN	O
test	NN	O
also	RB	O
should	MD	O
be	VB	O
observed	VBN	O
for	IN	O
the	DT	O
full	JJ	O
4	CD	PER
weeks	NNS	PER
.	.	O

It	PRP	O
is	VBZ	O
generally	RB	O
agreed	VBN	O
that	IN	O
acute	JJ	O
episodes	NNS	O
of	IN	O
depression	NN	O
require	VBP	O
several	JJ	PER
months	NNS	PER
or	CC	O
longer	JJR	O
of	IN	O
antidepressant	JJ	O
treatment	NN	O
beyond	IN	O
the	DT	O
response	NN	O
in	IN	O
the	DT	O
acute	JJ	O
episode	NN	O
.	.	O

The	DT	O
reservoir	NN	O
should	MD	O
be	VB	O
made	VBN	O
of	IN	O
polyvinyl	JJ	O
chloride	NN	O
,	,	O
polypropylene	NN	O
or	CC	O
glass	NN	O
.	.	O

Figure	NN	O
3	CD	O
:	:	O
Occlusion	NN	O

REFERENCES	NNS	O

Alora	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
twice	RB	FREQ
weekly	RB	FREQ
,	,	O
as	IN	O
instructed	VBN	O
.	.	O

Do	NNP	O
not	RB	O
remove	VB	O
the	DT	O
vial	JJ	O
adapter	NN	O
from	IN	O
the	DT	O
protective	JJ	O
cap	NN	O
.	.	O

When	WRB	O
CLI	NNP	O
whole	VBD	O
-	:	O
cell	NN	O
DTP	NNP	O
(	(	O
diphtheria	NN	O
and	CC	O
tetanus	NN	O
toxoids	NNS	O
and	CC	O
pertussis	NN	O
vaccine	NN	O
adsorbed	IN	O
usp	JJ	O
)	)	O
vaccine	NN	O
is	VBZ	O
used	VBN	O
to	TO	O
reconstitute	VB	O
ActHIB	NNP	O
®	NNP	O
or	CC	O
OmniHIB	NNP	O
,	,	O
administer	RB	O
intramuscularly	RB	O
only	RB	O
.	.	O

Treatment	NN	O
should	MD	O
be	VB	O
administered	VBN	O
for	IN	O
at	IN	PER
least	JJS	PER
2	CD	PER
weeks	NNS	PER
to	TO	O
decrease	VB	O
the	DT	O
likelihood	NN	O
of	IN	O
relapse	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
a	DT	WHO
history	NN	WHO
of	IN	WHO
9	CD	WHO
or	CC	WHO
fewer	JJR	WHO
recurrences	NNS	WHO
per	IN	WHO
year	NN	WHO
,	,	O
an	DT	O
alternative	JJ	O
dose	NN	O
is	VBZ	O
500	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

No	DT	O
dosage	NN	O
reduction	NN	O
is	VBZ	O
recommended	VBN	O
at	IN	O
the	DT	O
start	NN	O
of	IN	O
therapy	NN	O
with	IN	O
NIPENT	NNP	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
anemia	NN	WHO
,	,	O
neutropenia	NN	O
,	,	O
or	CC	O
thrombocytopenia	NN	O
.	.	O

A	DT	O
suggested	JJ	O
dosage	NN	O
schedule	NN	O
is	VBZ	O
300	CD	DOS
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
for	IN	O
the	DT	O
first	JJ	O
week	NN	PER
.	.	O

The	DT	O
ratio	NN	O
between	IN	O
methadone	NN	O
and	CC	O
other	JJ	O
opioid	JJ	O
agonists	NNS	O
may	MD	O
vary	VB	O
widely	RB	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
previous	JJ	O
dose	JJ	O
exposure	NN	O
.	.	O

Dosage	NN	O
should	MD	O
also	RB	O
be	VB	O
guided	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
fluid	JJ	O
intake	NN	O
limits	NNS	O
and	CC	O
glucose	NN	O
and	CC	O
nitrogen	NN	O
tolerances	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
by	IN	O
metabolic	NN	O
and	CC	O
clinical	JJ	O
response	NN	O
.	.	O

During	IN	O
concomitant	JJ	O
use	NN	O
with	IN	O
CYP2B6	NNP	O
inhibitors	NNS	O
(	(	O
e.g	NN	O
,	,	O
ticlopidine	NN	O
or	CC	O
clopidogrel	NN	O
)	)	O
,	,	O
the	DT	O
maximum	NN	O
recommended	VBD	FREQ
daily	RB	FREQ
dose	NN	O
of	IN	O
CONTRAVE	NNP	O
is	VBZ	O
two	CD	DOS
tablets	NNS	UNIT
(	(	O
one	CD	DOS
tablet	NN	UNIT
each	DT	O
morning	NN	O
and	CC	O
evening	NN	O
)	)	O
[	VBZ	O
see	JJ	O
DRUG	NNP	O
INTERACTIONS	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

PROTONIX	NNP	O
I.V	NNP	O
.	.	O

Increase	VB	O
the	DT	O
daily	JJ	FREQ
dose	NN	FREQ
every	DT	FREQ
2	CD	FREQ
weeks	NNS	FREQ
by	IN	O
increments	NNS	O
of	IN	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
to	TO	O
the	DT	O
recommended	VBN	FREQ
daily	RB	FREQ
dose	VB	O
of	IN	O
60	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
(	(	O
30	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NNP	O
twice	RB	FREQ
daily	RB	FREQ
)	)	O
.	.	O

Therefore	RB	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
CellCept	NNP	O
be	VB	O
administered	VBN	O
on	IN	O
an	DT	O
empty	JJ	O
stomach	NN	O
.	.	O

Prolonged	NNP	O
intensive	JJ	O
therapy	NN	O
is	VBZ	O
needed	VBN	O
for	IN	O
complications	NNS	O
such	JJ	O
as	IN	O
proshtitis	NN	O
and	CC	O
epididymitis	NN	O
.	.	O

Table	JJ	O
3	CD	O
:	:	O
Migraine	NNP	O
Prophylaxis	NNP	O
Titration	NNP	O
Schedule	NNP	O
for	IN	O
Adults	NNP	WHO
and	CC	WHO
Adolescents	NNP	WHO
Patients	VBZ	WHO
12	CD	WHO
Years	NNS	WHO
and	CC	WHO
Older	JJR	WHO

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
auto	NN	O
-	:	O
injectable	JJ	O
epinephrine	NN	O
be	VB	O
made	VBN	O
available	JJ	O
to	TO	O
patients	NNS	O
prescribed	VBN	O
ORALAIR	NNP	O
.	.	O

The	DT	O
four	CD	DOS
remaining	VBG	UNIT
doses	NNS	UNIT
should	MD	O
be	VB	O
given	VBN	O
at	IN	O
intervals	NNS	O
of	IN	O
14	CD	PER
days	NNS	PER
.	.	O

Evaluate	VB	O
the	DT	O
use	NN	O
ofa	JJ	O
second	JJ	O
site	NN	O
or	CC	O
infusing	NN	O
at	IN	O
shorter	JJR	O
intervals	NNS	O
when	WRB	O
the	DT	O
volume	NN	O
of	IN	O
HYQVIA	NNP	O
is	VBZ	O
greater	JJR	O
than	IN	O
600	CD	DOS
mL	NN	UNIT
.	.	O

While	IN	O
stable	JJ	O
for	IN	O
6	CD	O
hours	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
the	DT	O
infusion	NN	O
be	VB	O
prepared	VBN	O
immediately	RB	O
prior	JJ	O
to	TO	O
the	DT	O
anticipated	VBN	O
dosage	NN	O
administration	NN	O
time	NN	O
.	.	O

Withhold	NNP	O
COMETRIQ	NNP	O
for	IN	O
NCI	NNP	O
CTCAE	NNP	O
Grade	NNP	O
4	CD	O
hematologic	JJ	O
adverse	JJ	O
reactions	NNS	O
,	,	O
Grade	NNP	O
3	CD	O
or	CC	O
greater	JJR	O
non	SYM	O
-	:	O
hematologic	JJ	O
adverse	JJ	O
reactions	NNS	O
or	CC	O
intolerable	JJ	O
Grade	NNP	O
2	CD	O
adverse	JJ	O
reactions	NNS	O
.	.	O

Frequent	JJ	O
communication	NN	O
is	VBZ	O
important	JJ	O
among	IN	O
the	DT	O
prescriber	NN	O
,	,	O
other	JJ	O
members	NNS	O
of	IN	O
the	DT	O
healthcare	NN	O
team	NN	O
,	,	O
the	DT	O
patient	NN	O
,	,	O
and	CC	O
the	DT	O
caregiver	NN	O
/	NNP	O
family	NN	O
during	IN	O
periods	NNS	O
of	IN	O
changing	VBG	O
analgesic	JJ	O
requirements	NNS	O
,	,	O
including	VBG	O
initial	JJ	O
titration	NN	O
.	.	O

Titration	NN	O
to	TO	O
doses	NNS	O
above	IN	O
90	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

8	CD	O
.	.	O

In	IN	O
others	NNS	O
,	,	O
10	CD	DOS
to	TO	O
15	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
will	MD	O
be	VB	O
adequate	JJ	O
.	.	O

For	IN	O
most	JJS	WHO
patients	NNS	WHO
older	JJR	WHO
than	IN	WHO
50	CD	WHO
years	NNS	WHO
or	CC	WHO
for	IN	WHO
patients	NNS	WHO
under	IN	WHO
50	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
with	IN	WHO
underlying	JJ	WHO
cardiac	JJ	WHO
disease	NN	WHO
,	,	O
an	DT	O
initial	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
25	CD	DOS
-	:	O
50	CD	DOS
mcg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
of	IN	O
levothyroxine	JJ	O
sodium	NN	O
is	VBZ	O
recommended	VBN	O
,	,	O
with	IN	O
gradual	JJ	O
increments	NNS	O
in	IN	O
dose	NN	O
at	IN	O
6	CD	O
-	:	O
8	CD	PER
week	NN	PER
intervals	NNS	O
,	,	O
as	IN	O
needed	VBN	O
.	.	O

Rectal	JJ	O
:	:	O
1	CD	DOS
/	$	O
2	CD	DOS
mg	NN	UNIT
/	NNP	O
lb	VBZ	O
body	NN	O
weight	VBD	O
q6	NNS	O
to	TO	O
8h	CD	O
,	,	O
p.r.n	NN	O
.	.	O

Table	JJ	O
5	CD	O
.	.	O

The	DT	O
system	NN	O
should	MD	O
be	VB	O
pressed	VBN	O
firmly	RB	O
in	IN	O
place	NN	O
with	IN	O
the	DT	O
palm	NN	O
of	IN	O
the	DT	O
hand	NN	O
for	IN	O
about	IN	O
10	CD	O
seconds	NNS	O
,	,	O
making	VBG	O
sure	JJ	O
there	EX	O
is	VBZ	O
good	JJ	O
contact	NN	O
with	IN	O
the	DT	O
skin	NN	O
,	,	O
especially	RB	O
around	IN	O
the	DT	O
edges	NNS	O
.	.	O

To	TO	O
close	VB	O
the	DT	O
incision	NN	O
,	,	O
you	PRP	O
can	MD	O
use	VB	O
the	DT	O
absorbable	JJ	O
sutures	NNS	O
and	CC	O
/	NN	O
or	CC	O
the	DT	O
sterile	JJ	O
adhesive	JJ	O
surgical	JJ	O
strips	NNS	O
provided	VBD	O
.	.	O

The	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
by	IN	O
all	DT	O
routes	NNS	O
of	IN	O
administration	NN	O
should	MD	O
not	RB	O
exceed	VB	O
15	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

Patients	NNS	O
MUST	NNP	O
wait	VBP	O
at	IN	O
least	JJS	O
2	CD	O
hours	NNS	O
before	IN	O
treating	VBG	O
another	DT	O
episode	NN	O
of	IN	O
breakthrough	NN	O
cancer	NN	O
pain	NN	O
with	IN	O
LAZANDA	NNP	O
.	.	O

Depending	VBG	O
on	IN	O
the	DT	O
response	NN	O
,	,	O
the	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
at	IN	O
intervals	NNS	O
of	IN	O
3	CD	PER
to	TO	O
4	CD	PER
days	NNS	PER
in	IN	O
increments	NNS	O
of	IN	O
no	DT	O
more	JJR	O
than	IN	O
1	CD	DOS
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

Patients	NNS	WHO
dependent	JJ	WHO
on	IN	WHO
methadone	NN	WHO
or	CC	WHO
long	JJ	WHO
-	:	WHO
acting	VBG	WHO
opioid	JJ	WHO
products	NNS	WHO
may	MD	O
be	VB	O
more	RBR	O
susceptible	JJ	O
to	TO	O
precipitated	VBN	O
and	CC	O
prolonged	VBN	O
withdrawal	NN	O
during	IN	O
induction	NN	O
than	IN	O
those	DT	O
on	IN	O
short	JJ	O
-	:	O
acting	VBG	O
opioid	JJ	O
products	NNS	O
.	.	O

There	EX	O
is	VBZ	O
no	DT	O
evidence	NN	O
from	IN	O
controlled	VBN	O
trials	NNS	O
that	WDT	O
doses	VBZ	O
greater	JJR	O
than	IN	O
0.6	CD	DOS
mL	NN	UNIT
(	(	O
6	CD	DOS
mg	NN	UNIT
)	)	O
gave	VBD	O
an	DT	O
increased	JJ	O
effect	NN	O
and	CC	O
therefore	RB	O
,	,	O
individual	JJ	O
doses	NNS	O
above	IN	O
0.6	CD	DOS
mL	NN	UNIT
(	(	O
6	CD	DOS
mg	NN	UNIT
)	)	O
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

For	IN	O
short	JJ	O
-	:	O
term	NN	O
routine	JJ	O
prophylaxis	NN	O
to	TO	O
prevent	VB	O
or	CC	O
reduce	VB	O
the	DT	O
frequency	NN	O
of	IN	O
spontaneous	JJ	O
musculoskeletal	JJ	O
hemorrhage	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hemophilia	PDT	WHO
A	NNP	O
,	,	O
ReFacto	NNP	O
(	(	O
antihemophilic	JJ	O
factor	NN	O
)	)	O
should	MD	O
be	VB	O
given	VBN	O
at	IN	O
least	JJS	O
twice	RB	FREQ
a	DT	FREQ
week	NN	FREQ
.	.	O

Dose	JJ	O
Adjustment	NN	O
:	:	O

Patients	NNS	WHO
whose	WP$	WHO
therapy	NN	WHO
is	VBZ	O
started	VBN	O
with	IN	O
CIPRO	NNP	O
IV	NNP	O
for	IN	O
UTIs	NNP	O
may	MD	O
be	VB	O
switched	VBN	O
to	TO	O
CIPRO	NNP	O
XR	NNP	O
when	WRB	O
clinically	RB	O
indicated	VBN	O
at	IN	O
the	DT	O
discretion	NN	O
of	IN	O
the	DT	O
physician	NN	O
.	.	O

ORLAAM	NNP	O
(	(	O
levomethadyl	JJ	O
acetate	NN	O
)	)	O
must	MD	O
always	RB	O
be	VB	O
diluted	VBN	O
before	IN	O
administration	NN	O
,	,	O
and	CC	O
should	MD	O
be	VB	O
mixed	JJ	O
with	IN	O
diluent	JJ	O
prior	NN	O
to	TO	O
dispensing	NN	O
.	.	O

However	RB	O
,	,	O
the	DT	O
estimated	VBN	O
lean	JJ	O
body	NN	O
mass	NN	O
(	(	O
dry	JJ	O
weight	NN	O
)	)	O
is	VBZ	O
used	VBN	O
if	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
obese	JJ	O
or	CC	O
if	IN	O
there	EX	O
has	VBZ	O
been	VBN	O
a	DT	O
spurious	JJ	O
weight	NN	O
gain	NN	O
due	JJ	O
to	TO	O
edema	VB	O
,	,	O
ascites	NNS	O
or	CC	O
other	JJ	O
forms	NNS	O
of	IN	O
abnormal	JJ	O
fluid	NN	O
retention	NN	O
.	.	O

Doses	NNS	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	JJ	FREQ
are	VBP	O
generally	RB	O
required	VBN	O
for	IN	O
the	DT	O
clinical	JJ	O
response	NN	O
.	.	O

Inspired	NNP	O
concentrations	NNS	O
of	IN	O
SUPRANE	NNP	O
greater	JJR	O
than	IN	O
12	CD	O
%	NN	O
have	VBP	O
been	VBN	O
safely	RB	O
administered	VBN	O
to	TO	O
patients	NNS	WHO
,	,	O
particularly	RB	O
during	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

The	DT	O
suspension	NN	O
is	VBZ	O
flushed	VBN	O
with	IN	O
50	CD	DOS
mL	NNS	UNIT
or	CC	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
fluid	NN	O
,	,	O
following	VBG	O
which	WDT	O
the	DT	O
tube	NN	O
is	VBZ	O
clamped	VBN	O
and	CC	O
left	VBN	O
in	IN	O
place	NN	O
.	.	O

In	IN	O
this	DT	O
case	NN	O
,	,	O
the	DT	O
patient	NN	O
should	MD	O
place	VB	O
the	DT	O
self	NN	O
-	:	O
adhesive	JJ	O
“	JJ	O
day	NN	O
label	VBD	O
strip	NN	O
”	NN	O
that	WDT	O
corresponds	VBZ	O
to	TO	O
her	PRP$	O
starting	JJ	FREQ
day	NN	FREQ
over	IN	O
the	DT	O
preprinted	JJ	O
days	NNS	O
.	.	O

Therefore	RB	O
,	,	O
all	DT	O
diluents	NNS	O
should	MD	O
be	VB	O
preservative	JJ	O
-	:	O
free	JJ	O
.	.	O

Dose	NNP	O
changes	NNS	O
should	MD	O
occur	VB	O
in	IN	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
increments	NNS	O
and	CC	O
at	IN	O
intervals	NNS	O
of	IN	O
at	IN	O
least	JJS	O
1	CD	PER
week	NN	PER
.	.	O

SUCRAID	NNP	O
should	MD	O
not	RB	O
be	VB	O
reconstituted	VBN	O
or	CC	O
consumed	VBN	O
with	IN	O
fruit	NN	O
juice	NN	O
since	IN	O
its	PRP$	O
acidity	NN	O
may	MD	O
reduce	VB	O
the	DT	O
enzyme	NN	O
activity	NN	O
.	.	O

Because	IN	O
a	DT	O
barbiturate	NN	O
-	:	O
induced	JJ	O
depression	NN	O
may	MD	O
occur	VB	O
along	IN	O
with	IN	O
a	DT	O
postictal	JJ	O
depression	NN	O
once	IN	O
the	DT	O
seizures	NNS	O
are	VBP	O
controlled	VBN	O
,	,	O
it	PRP	O
is	VBZ	O
important	JJ	O
,	,	O
therefore	RB	O
,	,	O
to	TO	O
use	VB	O
the	DT	O
minimal	JJ	O
amount	NN	O
required	VBN	O
,	,	O
and	CC	O
to	TO	O
wait	VB	O
for	IN	O
the	DT	O
anticonvulsant	JJ	O
effect	NN	O
to	TO	O
develop	VB	O
before	IN	O
administering	VBG	O
a	DT	O
second	JJ	O
dose	NN	O
.	.	O

Lactated	VBN	O
Ringers	NNS	O

Do	MD	O
not	RB	O
apply	VB	O
Locoid®	NNP	O
Lotion	NNP	O
in	IN	O
the	DT	O
diaper	JJ	O
area	NN	O
unless	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

Inject	NNP	O
GRANIX	NNP	O
subcutaneously	RB	O
as	IN	O
recommended	JJ	O
[	NNP	O
see	VBP	O
General	JJ	O
Considerations	NNP	O
for	IN	O
Administration	NNP	O
]	NNP	O
.	.	O

5	CD	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Suggested	VBN	O
Dose	NNP	O
Modifications	NNP	O
for	IN	O
Skin	NNP	O
Toxicity	NNP	O

Infusion	NNP	O
related	VBD	O
events	NNS	O
may	MD	O
occur	VB	O
,	,	O
however	RB	O
,	,	O
at	IN	O
any	DT	O
rate	NN	O
or	CC	O
concentration	NN	O
.	.	O

Serum	NNP	O
lipids	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
for	IN	O
evidence	NN	O
of	IN	O
essential	JJ	O
fatty	JJ	O
acid	JJ	O
deficiency	NN	O
in	IN	O
patients	NNS	WHO
maintained	VBN	O
on	IN	O
fat	JJ	O
-	:	O
free	JJ	O
TPN	NNP	O
.	.	O

Standard	NNP	O
therapy	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
active	JJ	O
tetanus	NN	O
including	VBG	O
the	DT	O
use	NN	O
of	IN	O
BayTet	NNP	O
(	(	O
tetanus	IN	O
immune	NN	O
globulin	NN	O
(	(	O
human	JJ	O
)	)	O
solvent	NN	O
/	JJ	O
detergent	NN	O
treated	VBD	O
250	CD	DOS
units	NNS	UNIT
)	)	O
must	MD	O
be	VB	O
implemented	VBN	O
immediately	RB	O
.	.	O

However	RB	O
,	,	O
these	DT	O
studies	NNS	O
were	VBD	O
conducted	VBN	O
with	IN	O
single	JJ	DOS
-	:	O
dose	NN	O
entacapone	NN	O
without	IN	O
levodopa	NN	O
and	CC	O
dopa	JJ	O
decarboxylase	NN	O
inhibitor	NN	O
coadministration	NN	O
,	,	O
and	CC	O
therefore	RB	O
the	DT	O
effects	NNS	O
of	IN	O
liver	JJ	O
disease	NN	O
on	IN	O
the	DT	O
kinetics	NNS	O
of	IN	O
chronically	RB	O
administered	VBN	O
entacapone	NN	O
have	VBP	O
not	RB	O
been	VBN	O
evaluated	VBN	O
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
,	,	O
Pharmacokinetics	NNP	O
Of	IN	O
Entacapone	NNP	O
)	)	O
.	.	O

The	DT	O
solution	NN	O
should	MD	O
be	VB	O
warmed	VBN	O
,	,	O
by	IN	O
holding	VBG	O
the	DT	O
container	NN	O
in	IN	O
the	DT	O
hands	NNS	O
for	IN	O
at	IN	O
least	JJS	O
1	CD	O
minute	NN	O
,	,	O
to	TO	O
minimize	VB	O
the	DT	O
dizziness	NN	O
that	WDT	O
may	MD	O
result	VB	O
from	IN	O
the	DT	O
instillation	NN	O
of	IN	O
a	DT	O
cold	JJ	O
solution	NN	O
into	IN	O
the	DT	O
ear	JJ	O
canal	NN	O
.	.	O

For	IN	O
the	DT	O
purpose	NN	O
of	IN	O
comparison	NN	O
,	,	O
the	DT	O
following	NN	O
is	VBZ	O
the	DT	O
equivalent	JJ	O
milligram	NN	O
dosage	NN	O
of	IN	O
the	DT	O
various	JJ	O
glucocorticoids	NNS	O
:	:	O

Solutions	NNS	O
of	IN	O
CEPTAZ	NNP	O
(	(	O
ceftazidime	NN	O
)	)	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
and	CC	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
are	VBP	O
stable	JJ	O
for	IN	O
at	IN	O
least	JJS	O
6	CD	O
hours	NNS	O
at	IN	O
room	NN	O
temperature	NN	O
in	IN	O
plastic	NN	O
tubing	NN	O
,	,	O
drip	NN	O
chambers	NNS	O
,	,	O
and	CC	O
volume	NN	O
control	NN	O
devices	NNS	O
of	IN	O
common	JJ	O
IV	NNP	O
infusion	NN	O
sets	NNS	O
.	.	O

Premature	NN	O
or	CC	O
Full	NNP	O
-	:	O
term	NN	O
Neonates	VBZ	O
One	CD	DOS
Week	NN	UNIT
of	IN	O
AgeorLess	NNP	O
:	:	O
5mg	CD	DOS
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

Further	JJ	O
patient	NN	O
instructions	NNS	O
on	IN	O
how	WRB	O
to	TO	O
administer	VB	O
CAYSTON	NNP	O
are	VBP	O
provided	VBN	O
in	IN	O
the	DT	O
FDA	NNP	O
-	:	O
approved	VBD	O
patient	JJ	O
labeling	NN	O
.	.	O

SUBUTEX	NNP	O
sublingual	JJ	O
tablet	NN	O
dosing	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
preferably	RB	O
when	WRB	O
moderate	JJ	O
objective	JJ	O
signs	NNS	O
of	IN	O
opioid	JJ	O
withdrawal	NN	O
appear	NN	O
.	.	O

IZBA	NNP	O
may	MD	O
be	VB	O
used	VBN	O
concomitantly	RB	O
with	IN	O
other	JJ	O
topical	JJ	O
ophthalmic	JJ	O
drug	NN	O
products	NNS	O
to	TO	O
lower	VB	O
intraocular	JJ	O
pressure	NN	O
.	.	O

Therapy	NN	O
should	MD	O
be	VB	O
directed	VBN	O
by	IN	O
physicians	NNS	O
who	WP	O
are	VBP	O
knowledgeable	JJ	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
Gaucher	NNP	O
disease	NN	O
.	.	O

Step	NN	O
1	CD	O

For	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
,	,	O
the	DT	O
dosage	NN	O
of	IN	O
nizatidine	NN	O
is	VBZ	O
150	CD	DOS
mg	NN	UNIT
b.i.d	NN	O
.	.	O

She	PRP	O
should	MD	O
switch	VB	O
from	IN	O
an	DT	O
implant	NN	O
or	CC	O
the	DT	O
IUS	NNP	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
its	PRP$	O
removal	NN	O
,	,	O
and	CC	O
from	IN	O
an	DT	O
injectable	JJ	O
on	IN	O
the	DT	O
day	NN	O
when	WRB	O
the	DT	O
next	JJ	O
injection	NN	O
would	MD	O
be	VB	O
due	JJ	O
.	.	O

Most	JJS	WHO
patients	NNS	WHO
with	IN	WHO
acute	JJ	WHO
malaria	NNS	WHO
present	JJ	WHO
with	IN	WHO
some	DT	WHO
degree	NN	WHO
of	IN	O
related	JJ	O
hepatic	JJ	O
and	CC	O
/	JJ	O
or	CC	O
renal	JJ	O
impairment	NN	O
.	.	O

Before	IN	O
administration	NN	O
of	IN	O
AdreView	NNP	O
(	(	O
iobenguane	NN	O
i	RB	O
123	CD	DOS
injection	NN	UNIT
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
,	,	O
administer	RB	O
Potassium	NNP	O
Iodide	NNP	O
Oral	NNP	O
Solution	NNP	O
or	CC	O
Lugol	NNP	O
's	POS	O
Solution	NNP	O
(	(	O
equivalent	JJ	O
to	TO	O
100	CD	DOS
mg	NNS	UNIT
iodide	RB	O
for	IN	O
adults	NNS	WHO
,	,	O
body	NN	O
-	:	O
weight	NN	O
adjusted	VBN	O
for	IN	O
children	NNS	WHO
)	)	O
or	CC	O
potassium	NN	O
perchlorate	NN	O
(	(	O
400	CD	DOS
mg	NN	UNIT
for	IN	O
adults	NNS	WHO
,	,	O
body	NN	O
-	:	O
weight	NN	O
adjusted	VBN	O
for	IN	O
children	NNS	WHO
)	)	O
to	TO	O
block	VB	O
uptake	NN	O
of	IN	O
iodine	NN	O
123	CD	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
thyroid	NN	O
.	.	O

Dose	NNP	O
reduction	NN	O
is	VBZ	O
frequently	RB	O
required	VBN	O
(	(	O
see	VB	O
Dose	NNP	O
Adjustment	NNP	O
below	IN	O
)	)	O
.	.	O

An	DT	O
oral	JJ	O
form	NN	O
should	MD	O
supplant	VB	O
the	DT	O
injectable	JJ	O
as	RB	O
soon	RB	O
as	IN	O
practicable	JJ	O
.	.	O

If	IN	O
a	DT	O
previously	RB	O
effective	JJ	O
dosage	NN	O
regimen	NNS	O
of	IN	O
BREO	NNP	O
ELLIPTA	NNP	O
fails	VBZ	O
to	TO	O
provide	VB	O
adequate	JJ	O
improvement	NN	O
in	IN	O
asthma	NN	O
control	NN	O
,	,	O
the	DT	O
therapeutic	JJ	O
regimen	NNS	O
should	MD	O
be	VB	O
reevaluated	VBN	O
and	CC	O
additional	JJ	O
therapeutic	NN	O
options	NNS	O
(	(	O
e.g	VB	O
,	,	O
replacing	VBG	O
the	DT	O
current	JJ	O
strength	NN	O
of	IN	O
BREO	NNP	O
ELLIPTA	NNP	O
with	IN	O
a	DT	O
higher	JJR	O
strength	NN	O
,	,	O
adding	VBG	O
additional	JJ	O
inhaled	VBN	O
corticosteroid	NN	O
,	,	O
initiating	VBG	O
oral	JJ	O
corticosteroids	NNS	O
)	)	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

Area	NNP	O
of	IN	O
application	NN	O
should	MD	O
be	VB	O
limited	VBN	O
to	TO	O
the	DT	O
area	NN	O
that	WDT	O
will	MD	O
be	VB	O
covered	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
short	JJ	O
sleeve	NN	O
T	NNP	O
-	:	O
shirt	NN	O
.	.	O

Warfarin	NNP	O
should	MD	O
be	VB	O
discontinued	VBN	O
and	CC	O
ELIQUIS	NNP	O
started	VBD	O
when	WRB	O
the	DT	O
international	JJ	O
normalized	JJ	O
ratio	NN	O
(	(	O
INR	NNP	O
)	)	O
is	VBZ	O
below	IN	O
2.0	CD	O
.	.	O

Conversely	RB	O
,	,	O
at	IN	O
least	JJS	O
21	CD	O
days	NNS	O
should	MD	O
be	VB	O
allowed	VBN	O
after	IN	O
stopping	VBG	O
BRINTELLIX	NNP	O
before	IN	O
starting	VBG	O
an	DT	O
MAOI	NNP	O
intended	VBD	O
to	TO	O
treat	VB	O
psychiatric	JJ	O
disorders	NNS	O
[	VBP	O
see	VBP	O
CONTRAINDICATIONS	NNP	O
]	NNP	O
.	.	O

Avoid	NNP	O
use	NN	O
on	IN	O
the	DT	O
face	NN	O
,	,	O
groin	NN	O
,	,	O
or	CC	O
axillae	NN	O
,	,	O
or	CC	O
if	IN	O
skin	JJ	O
atrophy	NN	O
is	VBZ	O
present	JJ	O
at	IN	O
the	DT	O
treatment	NN	O
site	NN	O
.	.	O

Calculate	VB	O
the	DT	O
previous	JJ	O
24	CD	O
-	:	O
hour	NN	O
analgesic	JJ	O
requirement	NN	O
.	.	O

Patients	NNS	O
receiving	VBG	O
other	JJ	O
oral	JJ	O
morphine	NN	O
formulations	NNS	O
may	MD	O
be	VB	O
converted	VBN	O
to	TO	O
EMBEDA	NNP	O
by	IN	O
administering	VBG	O
one	CD	O
-	:	O
half	NN	O
of	IN	O
the	DT	O
patient	NN	O
's	POS	O
total	JJ	O
daily	JJ	FREQ
oral	JJ	O
morphine	NN	O
dose	NN	O
as	IN	O
EMBEDA	NNP	O
twice	RB	FREQ
daily	RB	FREQ
,	,	O
or	CC	O
by	IN	O
administering	VBG	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
oral	JJ	O
morphine	NN	O
dose	NN	O
as	IN	O
EMBEDA	NNP	O
once	RB	FREQ
daily	RB	FREQ
.	.	O

Patients	NNS	O
titrated	VBD	O
to	TO	O
the	DT	O
individual	JJ	O
components	NNS	O
(	(	O
metoprolol	JJ	O
succinate	NN	O
and	CC	O
hydrochlorothiazide	NN	O
)	)	O
may	MD	O
instead	RB	O
receive	VB	O
the	DT	O
corresponding	VBG	O
dose	NN	O
of	IN	O
DUTOPROL	NNP	O
.	.	O

fat	JJ	O
emulsions	NNS	O
.	.	O

After	IN	O
implantation	NN	O
,	,	O
briefly	NN	O
cover	VBD	O
the	DT	O
site	NN	O
with	IN	O
a	DT	O
sterile	JJ	O
gauze	NN	O
pad	NN	O
and	CC	O
apply	VB	O
pressure	NN	O
to	TO	O
ensure	VB	O
hemostasis	NN	O
.	.	O

After	IN	O
administration	NN	O
of	IN	O
an	DT	O
initial	JJ	O
bolus	NN	O
dose	NN	O
of	IN	O
NIMBEX	NNP	O
,	,	O
a	DT	O
diluted	JJ	O
solution	NN	O
of	IN	O
NIMBEX	NNP	O
can	MD	O
be	VB	O
administered	VBN	O
by	IN	O
continuous	JJ	O
infusion	NN	O
to	TO	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
aged	VBD	WHO
2	CD	WHO
or	CC	WHO
more	JJR	WHO
years	NNS	WHO
for	IN	O
maintenance	NN	O
of	IN	O
neuromuscular	JJ	O
block	NN	O
during	IN	O
extended	VBN	O
surgical	JJ	O
procedures	NNS	O
.	.	O

The	DT	O
mouthpiece	NN	O
is	VBZ	O
reusable	JJ	O
and	CC	O
should	MD	O
be	VB	O
cleaned	VBN	O
regularly	RB	O
with	IN	O
soap	NN	O
and	CC	O
water	NN	O
.	.	O

Between	JJ	O
uses	NNS	O
,	,	O
return	VBP	O
the	DT	O
multi	NN	O
-	:	O
dose	JJ	O
vial	JJ	O
to	TO	O
the	DT	O
recommended	VBN	O
storage	NN	O
conditions	NNS	O
,	,	O
between	IN	O
2°	CD	O
and	CC	O
8°C	CD	O
(	(	O
36°	CD	O
and	CC	O
46°F	CD	O
)	)	O
.	.	O

The	DT	O
connector	NN	O
is	VBZ	O
now	RB	O
open	JJ	O
.	.	O

Therefore	RB	O
,	,	O
such	JJ	O
use	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
Toviaz	NNP	O
is	VBZ	O
4	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
BayRab	NNP	O
(	(	O
rabies	NNS	O
immune	VBP	O
globulin	NN	O
(	(	O
human	JJ	O
)	)	O
solvent	NN	O
/	JJ	O
detergent	NN	O
treated	VBN	O
)	)	O
is	VBZ	O
20	CD	DOS
IU	NNP	UNIT
/	NNP	O
kg	NNP	O
(	(	O
0.133	CD	DOS
mL	NN	UNIT
/	NNP	O
kg	NN	O
)	)	O
of	IN	O
body	NN	O
weight	VBD	O
given	VBN	O
preferably	RB	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
first	JJ	O
vaccine	NN	O
dose.8,9	NN	O
It	PRP	O
may	MD	O
also	RB	O
be	VB	O
given	VBN	O
through	IN	O
the	DT	O
seventh	JJ	FREQ
day	NN	FREQ
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
vaccine	NN	O
is	VBZ	O
given	VBN	O
.	.	O

For	IN	O
intravenous	JJ	O
administration	NN	O
only	RB	O
,	,	O

The	DT	O
procedures	NNS	O
below	IN	O
are	VBP	O
provided	VBN	O
as	IN	O
general	JJ	O
guidelines	NNS	O
for	IN	O
the	DT	O
preparation	NN	O
and	CC	O
reconstitution	NN	O
of	IN	O
COAGADEX	NNP	O
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
meningitis	NN	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
the	DT	O
initial	JJ	O
therapeutic	JJ	O
dose	NN	O
be	VB	O
100	CD	DOS
mg	JJ	UNIT
/	NN	O
kg	NN	O
(	(	O
not	RB	O
to	TO	O
exceed	VB	O
4	CD	DOS
grams	NNS	UNIT
)	)	O
.	.	O

Dose	JJ	O
adjustments	NNS	O
may	MD	O
be	VB	O
necessary	JJ	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
concomitant	JJ	WHO
use	NN	WHO
of	IN	O
:	:	O
strong	JJ	O
CYP1A2	NNP	O
inhibitors	NNS	O
(	(	O
e.g	NN	O
,	,	O
fluvoxamine	NN	O
,	,	O
ciprofloxacin	NN	O
,	,	O
or	CC	O
enoxacin	NN	O
)	)	O
;	:	O
moderate	JJ	O
or	CC	O
weak	JJ	O
CYP1A2	NNP	O
inhibitors	NNS	O
(	(	O
e.g	NN	O
,	,	O
oral	JJ	O
contraceptives	NNS	O
,	,	O
or	CC	O
caffeine	NN	O
)	)	O
;	:	O
CYP2D6	NNP	O
or	CC	O
CYP3A4	NNP	O
inhibitors	NNS	O
(	(	O
e.g	NN	O
,	,	O
cimetidine	NN	O
,	,	O
escitalopram	NN	O
,	,	O
erythromycin	NN	O
,	,	O
paroxetine	NN	O
,	,	O
bupropion	NN	O
,	,	O
fluoxetine	NN	O
,	,	O
quinidine	NN	O
,	,	O
duloxetine	NN	O
,	,	O
terbinafine	NN	O
,	,	O
or	CC	O
sertraline	NN	O
)	)	O
;	:	O
CYP3A4	NNP	O
inducers	NNS	O
(	(	O
e.g	NN	O
,	,	O
phenytoin	NN	O
,	,	O
carbamazepine	NN	O
,	,	O
St.	NNP	O
John	NNP	O
's	POS	O
wort	NN	O
,	,	O
and	CC	O
rifampin	NN	O
)	)	O
;	:	O
or	CC	O
CYP1A2	NNP	O
inducers	NNS	O
(	(	O
e.g	NN	O
,	,	O
tobacco	NN	O
smoking	NN	O
)	)	O
(	(	O
Table	JJ	O
1	CD	O
)	)	O
[	FW	O
See	NNP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

If	IN	O
a	DT	O
second	JJ	O
site	NN	O
is	VBZ	O
used	VBN	O
,	,	O
administer	JJ	O
half	NN	O
of	IN	O
total	JJ	O
volume	NN	O
of	IN	O
the	DT	O
Recombinant	NNP	O
Human	NNP	O
Hyaluronidase	NNP	O
of	IN	O
HYQVIA	NNP	O
in	IN	O
each	DT	O
site	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
GRALISE	NNP	O
should	MD	O
be	VB	O
adjusted	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
reduced	JJ	WHO
renal	JJ	WHO
function	NN	WHO
,	,	O
according	VBG	O
to	TO	O
Table	NNP	O
2	CD	O
.	.	O

The	DT	O
infusion	NN	O
rate	NN	O
may	MD	O
be	VB	O
slowed	VBN	O
in	IN	O
the	DT	O
event	NN	O
of	IN	O
infusion	NN	O
reactions	NNS	O
.	.	O

If	IN	O
the	DT	O
gluteal	JJ	O
region	NN	O
is	VBZ	O
used	VBN	O
,	,	O
only	RB	O
use	VBP	O
the	DT	O
upper	JJ	O
,	,	O
outer	JJ	O
quadrant	NN	O
.	.	O

Hemodialysis	NNP	O
removes	VBZ	O
significant	JJ	O
amounts	NNS	O
of	IN	O
metronidazole	NN	O
and	CC	O
its	PRP$	O
metabolites	NNS	O
from	IN	O
systemic	JJ	O
circulation	NN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
misses	VBZ	O
two	CD	DOS
(	(	O
2	CD	DOS
)	)	O
active	JJ	O
tablets	NNS	O
in	IN	O
the	DT	O
third	JJ	O
week	NN	PER
or	CC	O
misses	NNS	O
three	CD	O
(	(	O
3	CD	O
)	)	O
or	CC	O
more	RBR	O
active	JJ	O
tablets	NNS	O
in	IN	O
a	DT	O
row	NN	O
,	,	O
the	DT	O
patient	NN	O
should	MD	O
continue	VB	O
taking	VBG	O
one	CD	DOS
tablet	NN	UNIT
every	DT	FREQ
day	NN	FREQ
until	IN	O
Sunday	NNP	O
.	.	O

Not	RB	O
for	IN	O
ophthalmic	JJ	O
,	,	O
dermal	JJ	O
,	,	O
or	CC	O
oral	JJ	O
use	NN	O
.	.	O

Usually	RB	O
30	CD	DOS
grams	NNS	UNIT
is	VBZ	O
sufficient	JJ	O
for	IN	O
an	DT	O
average	JJ	WHO
adult	NN	WHO
.	.	O

The	DT	O
timing	NN	O
of	IN	O
initiation	NN	O
of	IN	O
dosing	VBG	O
with	IN	O
Tri	NNP	O
-	:	O
Sprintec	NN	O
for	IN	O
acne	NN	O
should	MD	O
follow	VB	O
the	DT	O
guidelines	NNS	O
for	IN	O
use	NN	O
of	IN	O
Tri	NNP	O
-	:	O
Sprintec	NN	O
as	IN	O
an	DT	O
oral	JJ	O
contraceptive	NN	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
clinical	JJ	O
trials	NNS	O
,	,	O
a	DT	O
reasonable	JJ	O
approach	NN	O
to	TO	O
assisting	VBG	O
patients	NNS	O
in	IN	O
their	PRP$	O
attempt	NN	O
to	TO	O
quit	VB	O
smoking	NN	O
is	VBZ	O
to	TO	O
begin	VB	O
initial	JJ	O
treatment	NN	O
,	,	O
using	VBG	O
the	DT	O
recommended	VBN	O
dosage	NN	O
(	(	O
See	NNP	O
DOSAGE	NNP	O
AND	NNP	O
ADMINISTRATION	NNP	O
)	)	O
.	.	O

To	TO	O
prevent	VB	O
unintentional	JJ	O
overdose	NN	O
,	,	O
this	DT	O
product	NN	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
who	WP	WHO
require	VBP	WHO
less	JJR	WHO
than	IN	WHO
the	DT	WHO
full	JJ	WHO
adult	NN	WHO
dose	NN	O
.	.	O

If	IN	O
the	DT	O
first	JJ	O
test	NN	O
showed	VBD	O
either	CC	O
no	DT	O
reaction	NN	O
or	CC	O
a	DT	O
small	JJ	O
reaction	NN	O
,	,	O
the	DT	O
second	JJ	O
test	NN	O
should	MD	O
be	VB	O
performed	VBN	O
one	CD	PER
to	TO	O
four	CD	PER
weeks	NNS	PER
later	RB	O
.	.	O

INVEGA®	NNP	O
should	MD	O
be	VB	O
prescribed	VBN	O
at	IN	O
the	DT	O
lowest	JJS	O
effective	JJ	O
dose	NN	O
for	IN	O
maintaining	VBG	O
clinical	JJ	O
stability	NN	O
and	CC	O
the	DT	O
physician	NN	O
should	MD	O
periodically	RB	O
reevaluate	VB	O
the	DT	O
long	JJ	O
-	:	O
term	NN	O
usefulness	NN	O
of	IN	O
the	DT	O
drug	NN	O
in	IN	O
individual	JJ	O
patients	NNS	O
.	.	O

Other	JJ	O
intravenous	JJ	O
regimens	NNS	O
include	VBP	O
10	CD	DOS
mg	JJ	UNIT
per	IN	O
kg	NN	O
to	TO	O
15	CD	DOS
mg	NNS	UNIT
per	IN	O
kg	NN	O
given	VBN	O
every	DT	O
7	CD	PER
to	TO	O
10	CD	PER
days	NNS	PER
or	CC	O
3	CD	DOS
mg	NNS	UNIT
per	IN	O
kg	NN	O
to	TO	O
5	CD	DOS
mg	NNS	UNIT
per	IN	O
kg	NN	O
twice	RB	FREQ
weekly	RB	FREQ
.	.	O

Small	JJ	O
droplets	NNS	O
are	VBP	O
acceptable	JJ	O
,	,	O
but	CC	O
if	IN	O
solution	NN	O
flows	VBZ	O
past	IN	O
the	DT	O
frangible	JJ	O
prior	NN	O
to	TO	O
use	VB	O
,	,	O
do	VB	O
not	RB	O
use	VB	O
and	CC	O
discard	VB	O
the	DT	O
units	NNS	O
.	.	O

Always	NNS	O
use	VBP	O
a	DT	O
new	JJ	O
needle	NN	O
for	IN	O
each	DT	O
injection	NN	O
to	TO	O
prevent	VB	O
contamination	NN	O
.	.	O

The	DT	O
recommended	JJ	O
duration	NN	O
of	IN	O
treatment	NN	O
with	IN	O
LUPRON	NNP	O
DEPOT	NNP	O
–	NNP	O
3	CD	DOS
Month	NNP	O
11.25	CD	DOS
mg	NN	UNIT
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
norethindrone	JJ	O
acetate	NN	O
is	VBZ	O
six	CD	PER
months	NNS	PER
.	.	O

administration	NN	O
of	IN	O
MIRALUMA®	NNP	O
(	(	O
technetium	NN	O
tc99m	NN	O
sestamibi	NN	O
)	)	O
is	VBZ	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
of	IN	O
740	CD	DOS
-	:	O
1110	CD	DOS
MBq	NNP	UNIT
(	(	O
20	CD	DOS
-	:	O
30	CD	DOS
mCi	NN	UNIT
)	)	O
.	.	O

Continually	RB	O
monitor	JJ	O
patients	NNS	O
with	IN	O
each	DT	O
uptitration	NN	O
in	IN	O
dose	NN	O
,	,	O
until	IN	O
they	PRP	O
reach	VBP	O
steady	JJ	O
state	NN	O
.	.	O

The	DT	O
potency	NN	O
expressed	VBD	O
in	IN	O
International	NNP	O
Units	NNP	O
is	VBZ	O
determined	VBN	O
using	VBG	O
the	DT	O
Berichrom	NNP	O
activity	NN	O
assay	NN	O
,	,	O
referenced	VBD	O
to	TO	O
the	DT	O
current	JJ	O
International	NNP	O
Standard	NNP	O
for	IN	O
Blood	NNP	O
Coagulation	NNP	O
Factor	NNP	O
XIII	NNP	O
,	,	O
Plasma	NNP	O
.	.	O

or	CC	O
q.i.d	NN	O
.	.	O

UVADEX®	NN	O
can	MD	O
adsorb	VB	O
onto	IN	O
PVC	NNP	O
and	CC	O
plastics	NNS	O
,	,	O
therefore	RB	O
only	RB	O
THERAKOS®	NNP	O
UVAR	NNP	O
XTS®	NNP	O
or	CC	O
THERAKOS®	NNP	O
CELLEX®	NNP	O
photopheresis	NN	O
procedural	JJ	O
kits	NNS	O
supplied	VBN	O
for	IN	O
use	NN	O
with	IN	O
the	DT	O
instrument	NN	O
should	MD	O
be	VB	O
used	VBN	O
to	TO	O
administer	VB	O
this	DT	O
medicinal	JJ	O
product	NN	O
.	.	O

The	DT	O
Zovia	NNP	O
(	(	O
ehtynodiol	JJ	O
diacetate	NN	O
and	CC	O
ethinyl	NN	O
estradiol	VBP	O
tablets	NNS	O
)	)	O
1	CD	O
/	$	O
35E	CD	O
-	:	O
28	CD	O
and	CC	O
Zovia	NNP	O
(	(	O
ehtynodiol	JJ	O
diacetate	NN	O
and	CC	O
ethinyl	NN	O
estradiol	VBP	O
tablets	NNS	O
)	)	O
1	CD	O
/	$	O
50E	CD	DOS
-	:	O
28	CD	DOS
tablet	NN	UNIT
dispensers	NNS	O
contain	VBP	O
21	CD	O
colored	VBD	O
active	JJ	O
tablets	NNS	O
arranged	VBN	O
in	IN	O
three	CD	O
numbered	JJ	O
rows	NNS	O
of	IN	O
7	CD	DOS
tablets	NNS	UNIT
each	DT	O
,	,	O
followed	VBN	O
by	IN	O
a	DT	O
fourth	JJ	O
row	NN	O
of	IN	O
7	CD	O
white	JJ	O
placebo	NN	O
tablets	NNS	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Suggested	VBN	O
doses	NNS	O
for	IN	O
pediatric	JJ	WHO
patients	NNS	WHO

Concurrent	JJ	O
administration	NN	O
of	IN	O
oxacillin	NN	O
(	(	O
oxacillin	NN	O
(	(	O
oxacillin	NN	O
for	IN	O
injection	NN	O
)	)	O
for	IN	O
injection	NN	O
)	)	O
and	CC	O
probenecid	JJ	O
increases	NNS	O
and	CC	O
prolongs	NNS	O
serum	VBP	O
penicillin	NN	O
levels	NNS	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
Mircette®	NNP	O
for	IN	O
contraception	NN	O
may	MD	O
be	VB	O
initiated	VBN	O
4	CD	PER
weeks	NNS	PER
postpartum	NN	O
in	IN	O
women	NNS	WHO
who	WP	WHO
elect	VBP	WHO
not	RB	WHO
to	TO	WHO
breast	VB	WHO
-	:	O
feed	NN	O
.	.	O

NDC	RB	O
60505	CD	O
-	:	O
3758	CD	O
-	:	O
5	CD	DOS
bottles	NNS	UNIT
of	IN	O
500	CD	O
.	.	O

Doses	NNS	O
of	IN	O
KAPVAY	NNP	O
higher	JJR	O
than	IN	O
0.4	CD	DOS
mg	JJ	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
0.2	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
)	)	O
were	VBD	O
not	RB	O
evaluated	VBN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
for	IN	O
ADHD	NNP	O
and	CC	O
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

Caution	NN	O
must	MD	O
be	VB	O
exercised	VBN	O
when	WRB	O
handling	VBG	O
Totect®	NNP	O
and	CC	O
preparing	VBG	O
the	DT	O
mixed	JJ	O
solution	NN	O
.	.	O

The	DT	O
potency	NN	O
Units	NNP	O
of	IN	O
BOTOX	NNP	O
(	(	O
onabotulinumtoxinA	NN	O
)	)	O
for	IN	O
injection	NN	O
are	VBP	O
specific	JJ	O
to	TO	O
the	DT	O
preparation	NN	O
and	CC	O
assay	VB	O
method	NN	O
utilized	JJ	O
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
(	(	O
see	VB	O
Clinical	NNP	O
Studies	NNPS	O
)	)	O
,	,	O
the	DT	O
highest	JJS	O
dose	NN	O
of	IN	O
500	CD	DOS
mcg	JJ	UNIT
BID	NNP	O
of	IN	O
TIKOSYN	NNP	O
as	IN	O
modified	VBN	O
by	IN	O
the	DT	O
dosing	VBG	O
algorithm	NN	O
led	VBD	O
to	TO	O
greater	JJR	O
effectiveness	NN	O
than	IN	O
lower	JJR	O
doses	NNS	O
of	IN	O
125	CD	DOS
or	CC	O
250	CD	DOS
mcg	JJ	UNIT
BID	NNP	O
as	IN	O
modified	VBN	O
by	IN	O
the	DT	O
dosing	NN	O
algorithm	NN	O
.	.	O

For	IN	O
recurrent	NN	O
toxicities	NNS	O
,	,	O
reduce	VB	O
the	DT	O
dose	NN	O
of	IN	O
CAPRELSA	NNP	O
to	TO	O
100	CD	DOS
mg	NN	UNIT
after	IN	O
resolution	NN	O
or	CC	O
improvement	NN	O
to	TO	O
CTCAE	NNP	O
Grade	NNP	O
1	CD	O
severity	NN	O
,	,	O
if	IN	O
continued	VBN	O
treatment	NN	O
is	VBZ	O
warranted	VBN	O
.	.	O

Delay	NNP	O
Day	NNP	O
1	CD	O
chemotherapy	NN	O
in	IN	O
subsequent	JJ	O
courses	NNS	O
of	IN	O
treatment	NN	O
until	IN	O
platelet	NN	O
counts	NNS	O
are	VBP	O
≥	JJ	O
100,000	CD	O
/	JJ	O
mm³	NN	O
,	,	O
ANC	NNP	O
≥	NN	O
1500	CD	O
/	NNP	O
mm³	NN	O
,	,	O
and	CC	O
nonhematologic	JJ	O
toxicities	NNS	O
have	VBP	O
recovered	VBN	O
to	TO	O
≤	VB	O
Grade	NNP	O
1	CD	O
.	.	O

As	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

RAXAR	NNP	O
(	(	O
grepafloxacin	NN	O
)	)	O
Tablets	NNS	O
are	VBP	O
contraindicated	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
failure	NN	WHO
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
)	)	O
.	.	O

To	TO	O
ensure	VB	O
proper	JJ	O
dosing	NN	O
,	,	O
serum	VB	O
testosterone	NN	O
concentrations	NNS	O
should	MD	O
be	VB	O
measured	VBN	O
.	.	O

Monitor	NNP	O
hemoglobin	NN	O
levels	NNS	O
at	IN	O
least	JJS	O
every	DT	FREQ
2	CD	FREQ
weeks	NNS	FREQ
until	IN	O
stable	JJ	O
,	,	O
then	RB	O
monitor	NN	O
at	IN	O
least	JJS	O
monthly	JJ	O
.	.	O

It	PRP	O
was	VBD	O
found	VBN	O
that	IN	O
FXIII	NNP	O
tetramer	NN	O
levels	NNS	O
were	VBD	O
proportional	JJ	O
to	TO	O
the	DT	O
observed	JJ	O
FXIII	NNP	O
activity	NN	O
up	RB	O
to	TO	O
the	DT	O
point	NN	O
of	IN	O
replacement	NN	O
of	IN	O
100	CD	O
%	NN	O
of	IN	O
normal	JJ	O
FXIII	NNP	O
activity	NN	O
,	,	O
but	CC	O
there	EX	O
was	VBD	O
no	DT	O
increase	NN	O
in	IN	O
FXIII	NNP	O
tetramer	NN	O
levels	NNS	O
at	IN	O
higher	JJR	O
levels	NNS	O
of	IN	O
FXIII	NNP	O
activity	NN	O
.	.	O

Typical	JJ	O
usage	NN	O
for	IN	O
each	DT	O
treatment	NN	O
session	NN	O
is	VBZ	O
specific	JJ	O
to	TO	O
the	DT	O
site	NN	O
as	RB	O
well	RB	O
as	IN	O
wrinkle	JJ	O
severity	NN	O
.	.	O

Administration	NN	O
of	IN	O
diluted	JJ	O
BENDEKA	NNP	O
(	(	O
bendamustine	VB	O
hydrochloride	NN	O
)	)	O
injection	NN	O
must	MD	O
be	VB	O
completed	VBN	O
within	IN	O
this	DT	O
period	NN	O
of	IN	O
time	NN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
responds	VBZ	O
to	TO	O
NARCAN	NNP	O
Nasal	NNP	O
Spray	NNP	O
and	CC	O
relapses	VBZ	O
back	RB	O
into	IN	O
respiratory	NN	O
depression	NN	O
before	IN	O
emergency	NN	O
assistance	NN	O
arrives	NNS	O
,	,	O
administer	RB	O
an	DT	O
additional	JJ	O
dose	NN	O
of	IN	O
NARCAN	NNP	O
Nasal	NNP	O
Spray	NNP	O
using	VBG	O
a	DT	O
new	JJ	O
NARCAN	NNP	O
Nasal	NNP	O
Spray	NNP	O
and	CC	O
continue	VB	O
surveillance	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

When	WRB	O
the	DT	O
CYP3A4	NNP	O
inducer	NN	O
is	VBZ	O
discontinued	VBN	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
SEROQUEL	NNP	O
should	MD	O
be	VB	O
reduced	VBN	O
to	TO	O
the	DT	O
original	JJ	O
level	NN	O
within	IN	O
7	CD	PER
-	:	O
14	CD	PER
days	NNS	PER
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
and	CC	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

In	IN	O
patients	NNS	WHO
taking	VBG	WHO
danazol	NN	WHO
,	,	O
diltiazem	NN	O
,	,	O
dronedarone	NN	O
or	CC	O
verapamil	NN	O
concomitantly	RB	O
with	IN	O
lovastatin	NN	O
,	,	O
therapy	NN	O
should	MD	O
begin	VB	O
with	IN	O
10	CD	DOS
mg	NNS	UNIT
of	IN	O
lovastatin	NN	O
and	CC	O
should	MD	O
not	RB	O
exceed	VB	O
20	CD	DOS
mg	JJ	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
,	,	O
Pharmacokinetics	NNP	O
,	,	O
WARNINGS	NNP	O
,	,	O
Myopathy	NNP	O
/	NNP	O
Rhabdomyolysis	NNP	O
,	,	O
PRECAUTIONS	NNP	O
:	:	O
DRUG	NN	O
INTERACTIONS	NNP	O
,	,	O
Other	JJ	O
Drug	NNP	O
Interactions	NNP	O
)	)	O
.	.	O

Do	MD	O
not	RB	O
store	VB	O
solutions	NNS	O
containing	VBG	O
additives	NNS	O
.	.	O

Breast	NNP	O
-	:	O
feeding	NN	O
was	VBD	O
permitted	VBN	O
in	IN	O
clinical	JJ	O
studies	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
DYMISTA	NNP	O
is	VBZ	O
1	CD	DOS
spray	NN	UNIT
in	IN	O
each	DT	O
nostril	JJ	O
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Generally	RB	O
,	,	O
swallow	JJ	O
ALTACE	NNP	O
capsules	NNS	O
whole	VBP	O
.	.	O

It	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
use	VB	O
a	DT	O
separate	JJ	O
vial	NN	O
,	,	O
sterile	JJ	O
syringe	NN	O
,	,	O
and	CC	O
needle	RB	O
for	IN	O
each	DT	O
individual	JJ	O
patient	NN	O
,	,	O
to	TO	O
prevent	VB	O
transmission	NN	O
of	IN	O
infectious	JJ	O
agents	NNS	O
from	IN	O
one	CD	O
person	NN	O
to	TO	O
another	DT	O
.	.	O

2.25	CD	DOS
g	NN	UNIT
,	,	O
3.375	CD	DOS
g	NN	UNIT
,	,	O
and	CC	O
4.5	CD	DOS
g	NNS	UNIT
ZOSYN	NNP	O
should	MD	O
be	VB	O
reconstituted	VBN	O
with	IN	O
10	CD	DOS
mL	NNS	UNIT
,	,	O
15	CD	DOS
mL	NN	UNIT
,	,	O
and	CC	O
20	CD	DOS
mL	NN	UNIT
,	,	O
respectively	RB	O
.	.	O

Table	JJ	O
5	CD	O
provides	VBZ	O
average	JJ	O
daily	JJ	FREQ
maintenance	NN	O
dose	NN	O
requirements	NNS	O
of	IN	O
digoxin	NN	O
tablets	NNS	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
heart	NN	WHO
failure	NN	WHO
based	VBN	O
upon	IN	O
lean	JJ	O
body	NN	O
weight	NN	O
and	CC	O
renal	JJ	O
function	NN	O
:	:	O

It	PRP	O
is	VBZ	O
advisable	JJ	O
to	TO	O
monitor	VB	O
patients	NNS	WHO
every	DT	WHO
3	CD	WHO
to	TO	WHO
6	CD	WHO
months	NNS	WHO
although	IN	WHO
some	DT	WHO
patients	NNS	WHO
may	MD	O
go	VB	O
drug	NN	O
free	RB	O
for	IN	O
extended	VBN	O
periods	NNS	O
.	.	O

For	IN	O
a	DT	O
child	NN	WHO
aged	VBD	WHO
1	CD	WHO
month	NN	WHO
,	,	O
the	DT	O
starting	VBG	O
dose	NN	O
should	MD	O
be	VB	O
multiplied	VBN	O
by	IN	O
0.68	CD	O
;	:	O
the	DT	O
initial	JJ	O
starting	NN	O
dose	NN	O
would	MD	O
be	VB	O
(	(	O
30	CD	O
X	NNP	O
0.68	CD	O
)	)	O
=20	NN	O
mg	NN	UNIT
/	NNP	O
m²	NN	O
,	,	O
administered	VBD	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Intramuscular	JJ	O
or	CC	O
subcutaneous	JJ	O
administration	NN	O
may	MD	O
be	VB	O
necessary	JJ	O
if	IN	O
the	DT	O
intravenous	JJ	O
route	NN	O
is	VBZ	O
not	RB	O
available	JJ	O
.	.	O

The	DT	O
ring	NN	O
is	VBZ	O
to	TO	O
be	VB	O
compressed	VBN	O
and	CC	O
inserted	VBN	O
into	IN	O
the	DT	O
vagina	NN	O
.	.	O

A	DT	O
heated	JJ	O
nebulizer	NN	O
may	MD	O
be	VB	O
part	NN	O
of	IN	O
the	DT	O
nebulization	NN	O
assembly	RB	O
to	TO	O
provide	VB	O
a	DT	O
warm	JJ	O
saturated	VBN	O
atmosphere	RB	O
if	IN	O
the	DT	O
acetylcysteine	NN	O
aerosol	NN	O
is	VBZ	O
introduced	VBN	O
by	IN	O
means	NNS	O
of	IN	O
a	DT	O
separate	JJ	O
unheated	JJ	O
nebulizer	NN	O
.	.	O

See	JJ	O
CONTRAINDICATIONS	NNP	O
:	:	O
Pregnancy	NN	O
:	:	O
Category	NN	O
X	NN	O
.	.	O

Not	RB	O
more	JJR	O
than	IN	O
20	CD	O
milliliters	NNS	O
should	MD	O
be	VB	O
prescribed	VBN	O
initially	RB	O
and	CC	O
the	DT	O
prescription	NN	O
should	MD	O
not	RB	O
be	VB	O
refilled	VBN	O
without	IN	O
further	JJ	O
evaluation	NN	O
as	IN	O
outlined	VBN	O
in	IN	O
PRECAUTIONS	NNP	O
above	IN	O
.	.	O

The	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
2	CD	DOS
grams	NNS	UNIT
.	.	O

*	NN	O
Study	NNP	O
medication	NN	O
to	TO	O
be	VB	O
dose	JJ	O
reduced	VBN	O
is	VBZ	O
shown	VBN	O
in	IN	O
parenthesis	NN	O

Make	NNP	O
dosage	NN	O
adjustments	NNS	O
,	,	O
if	IN	O
indicated	VBN	O
,	,	O
according	VBG	O
to	TO	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
.	.	O

Although	IN	O
carbidopa	JJ	O
-	:	O
levodopa	NN	O
is	VBZ	O
the	DT	O
most	RBS	O
frequently	RB	O
used	VBN	O
of	IN	O
carbidopa	NN	O
and	CC	O
levodopa	JJ	O
administration	NN	O
,	,	O
there	EX	O
may	MD	O
be	VB	O
an	DT	O
occasional	JJ	O
patient	NN	O
who	WP	O
requires	VBZ	O
individually	RB	O
titrated	JJ	O
doses	NNS	O
of	IN	O
these	DT	O
two	CD	O
drugs	NNS	O
.	.	O

As	IN	O
an	DT	O
initial	JJ	O
dose	NN	O
,	,	O
210	CD	DOS
to	TO	O
280	CD	DOS
mg	NN	UNIT
(	(	O
3	CD	DOS
to	TO	O
4	CD	DOS
mg	NNS	UNIT
/	NNP	O
kg	NN	O
)	)	O
of	IN	O
Pentothal	NNP	O
(	(	O
thiopental	JJ	O
sodium	NN	O
)	)	O
is	VBZ	O
usually	RB	O
required	VBN	O
for	IN	O
rapid	JJ	O
induction	NN	O
in	IN	O
the	DT	O
average	JJ	WHO
adult	NN	WHO
(	(	WHO
70	CD	WHO
kg	NN	WHO
)	)	WHO
.	.	O

The	DT	O
amount	NN	O
of	IN	O
REGRANEX	NNP	O
Gel	NNP	O
to	TO	O
be	VB	O
applied	VBN	O
should	MD	O
be	VB	O
recalculated	VBN	O
by	IN	O
the	DT	O
physician	NN	O
or	CC	O
wound	NN	O
caregiver	NN	O
at	IN	O
weekly	JJ	FREQ
or	CC	O
biweekly	JJ	O
intervals	NNS	O
depending	VBG	O
on	IN	O
the	DT	O
rate	NN	O
of	IN	O
change	NN	O
in	IN	O
ulcer	JJ	O
area	NN	O
.	.	O

When	WRB	O
tetanus	NN	O
toxoid	NN	O
and	CC	O
TIG	NNP	O
(	(	O
Human	NNP	O
)	)	O
are	VBP	O
given	VBN	O
concurrently	RB	O
,	,	O
separate	JJ	O
syringes	NNS	O
and	CC	O
separate	JJ	O
sites	NNS	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

Carbamazepine	NNP	O
treatment	NN	O
should	MD	O
generally	RB	O
be	VB	O
initiated	VBN	O
with	IN	O
an	DT	O
oral	JJ	O
carbamazepine	NN	O
formulation	NN	O
.	.	O

Tablets	NNS	O
should	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
and	CC	O
not	RB	O
chewed	VBD	O
or	CC	O
broken	JJ	O
apart	NN	O
.	.	O

When	WRB	O
coadministering	VBG	O
TYBOST	NNP	O
with	IN	O
tenofovir	JJ	O
disoproxil	NN	O
fumarate	NN	O
(	(	O
tenofovir	JJ	O
DF	NNP	O
)	)	O
,	,	O
assess	RB	O
estimated	VBN	O
creatinine	JJ	O
clearance	NN	O
,	,	O
urine	JJ	O
glucose	NN	O
,	,	O
and	CC	O
urine	JJ	O
protein	NN	O
at	IN	O
baseline	JJ	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

When	WRB	O
administered	VBN	O
during	IN	O
halothane	NN	O
anesthesia	NN	O
,	,	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
0.03	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
(	(	O
ED95	NNP	O
)	)	O
produces	VBZ	O
maximum	JJ	O
neuromuscular	JJ	O
block	NN	O
in	IN	O
about	IN	O
7	CD	O
minutes	NNS	O
(	(	O
range	NN	O
:	:	O
5	CD	DOS
to	TO	O
11	CD	O
)	)	O
and	CC	O
clinically	RB	O
effective	JJ	O
block	NN	O
for	IN	O
an	DT	O
average	NN	O
of	IN	O
30	CD	O
minutes	NNS	O
(	(	O
range	NN	O
:	:	O
12	CD	O
to	TO	O
54	CD	O
)	)	O
.	.	O

Aluminum	NNP	O
-	:	O
or	CC	O
magnesium	VB	O
-	:	O
containing	NN	O
antacids	NNS	O
,	,	O
if	IN	O
needed	VBN	O
,	,	O
should	MD	O
be	VB	O
taken	VBN	O
at	IN	O
least	JJS	O
two	CD	O
hours	NNS	O
after	IN	O
taking	VBG	O
SKELID	NNP	O
(	(	O
tiludronate	NN	O
)	)	O
.	.	O

For	IN	O
noncircumferential	JJ	O
endobronchial	JJ	O
tumors	NNS	O
that	WDT	O
are	VBP	O
soft	JJ	O
enough	RB	O
to	TO	O
penetrate	VB	O
,	,	O
interstitial	JJ	O
fiber	NN	O
placement	NN	O
is	VBZ	O
preferred	VBN	O
to	TO	O
intraluminal	JJ	O
activation	NN	O
,	,	O
since	IN	O
this	DT	O
method	NN	O
produces	VBZ	O
better	JJR	O
efficacy	NN	O
and	CC	O
results	NNS	O
in	IN	O
less	JJR	O
exposure	NN	O
of	IN	O
the	DT	O
normal	JJ	O
bronchial	JJ	O
mucosa	NN	O
to	TO	O
light	NN	O
.	.	O

SHAKE	NNP	O
WELL	NNP	O
BEFORE	IN	O
USING	NNP	O
.	.	O

Chloramphenicol	NNP	O
,	,	O
like	IN	O
other	JJ	O
potent	NN	O
drugs	NNS	O
,	,	O
should	MD	O
be	VB	O
prescribed	VBN	O
at	IN	O
recommended	JJ	O
doses	NNS	O
known	VBN	O
to	TO	O
have	VB	O
therapeutic	JJ	O
activity	NN	O
.	.	O

Patients	NNS	WHO
receiving	VBG	WHO
cortisone	NN	WHO
,	,	O
hydrocortisone	NN	O
or	CC	O
spironolactone	NN	O
should	MD	O
omit	VB	O
their	PRP$	O
pre	NN	O
-	:	O
test	NN	O
doses	NNS	O
on	IN	O
the	DT	O
day	NN	O
selected	VBD	O
for	IN	O
testing	VBG	O
.	.	O

Promethazine	NNP	O
HCl	NNP	O
in	IN	O
12.5	CD	O
-	:	O
to	TO	O
25	CD	DOS
-	:	O
mg	NN	UNIT
doses	NNS	O
for	IN	O
children	NNS	WHO
and	CC	O
50	CD	DOS
-	:	O
mg	NN	UNIT
doses	NNS	O
for	IN	O
adults	NNS	WHO
the	DT	O
night	NN	O
before	IN	O
surgery	NN	O
relieves	NNS	O
apprehension	NN	O
and	CC	O
produces	VBZ	O
a	DT	O
quiet	JJ	O
sleep	NN	O
.	.	O

Intravenous	JJ	O
administration	NN	O
should	MD	O
be	VB	O
given	VBN	O
slowly	RB	O
,	,	O
over	IN	O
at	IN	O
least	JJS	O
2	CD	O
to	TO	O
3	CD	O
minutes	NNS	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
dose	NN	O
.	.	O

If	IN	O
well	RB	O
tolerated	VBN	O
,	,	O
this	DT	O
dose	NN	O
may	MD	O
be	VB	O
gradually	RB	O
increased	VBN	O
to	TO	O
5	CD	DOS
mg	NNS	UNIT
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
and	CC	O
occasionally	RB	O
5	CD	DOS
mg	NNS	UNIT
given	VBN	O
before	IN	O
retiring	VBG	O
.	.	O

The	DT	O
maximum	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
for	IN	O
adults	NNS	WHO
is	VBZ	O
usually	RB	O
24	CD	DOS
g	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
although	IN	O
higher	JJR	O
doses	NNS	O
have	VBP	O
been	VBN	O
used	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
dosage	NN	WHO
of	IN	WHO
UNASYN	NNP	WHO
is	VBZ	O
1.5	CD	DOS
g	NN	UNIT
(	(	O
1	CD	DOS
g	NN	UNIT
ampicillin	NN	O
as	IN	O
the	DT	O
sodium	NN	O
salt	NN	O
plus	CC	O
0.5	CD	DOS
g	NN	UNIT
sulbactam	NN	UNIT
as	IN	O
the	DT	O
sodium	NN	O
salt	NN	O
)	)	O
to	TO	O
3	CD	DOS
g	NN	UNIT
(	(	O
2	CD	DOS
g	NN	UNIT
ampicillin	NN	O
as	IN	O
the	DT	O
sodium	NN	O
salt	NN	O
plus	CC	O
1	CD	DOS
g	NN	UNIT
sulbactam	NN	O
as	IN	O
the	DT	O
sodium	NN	O
salt	NN	O
)	)	O
every	DT	FREQ
six	CD	FREQ
hours	NNS	FREQ
.	.	O

Table	JJ	O
1	CD	O
:	:	O
CONCERTA®	NN	O
Recommended	VBD	O
Starting	NNP	O
Doses	NNP	O
and	CC	O
Dose	NNP	O
Ranges	NNP	O

DO	NNP	O
NOT	NNP	O
inject	VB	O
the	DT	O
contents	NNS	O
if	IN	O
the	DT	O
solution	NN	O
is	VBZ	O
cloudy	JJ	O
or	CC	O
discolored	VBN	O
;	:	O
discard	VB	O
the	DT	O
vial	NN	O
.	.	O

Macugen	NN	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

Reconstitution	NN	O
Directions	NNS	O
:	:	O
Reconstitute	NNP	O
each	DT	O
gram	NN	O
of	IN	O
PIPRACIL	NNP	O
(	(	O
piperacillin	JJ	O
sodium	NN	O
)	)	O
with	IN	O
2	CD	DOS
mL	NNS	UNIT
of	IN	O
a	DT	O
suitable	JJ	O
diluent	NN	O
listed	VBN	O
above	IN	O
to	TO	O
achieve	VB	O
a	DT	O
concentration	NN	O
of	IN	O
1	CD	DOS
g	NNS	UNIT
per	IN	O
2.5	CD	DOS
mL	NN	UNIT
.	.	O

If	IN	O
a	DT	O
dose	NN	O
of	IN	O
Xgeva	NNP	O
is	VBZ	O
missed	VBN	O
,	,	O
administer	VBP	O
the	DT	O
injection	NN	O
as	RB	O
soon	RB	O
as	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
available	JJ	O
.	.	O

If	IN	O
this	DT	O
initial	JJ	O
dose	NN	O
can	MD	O
not	RB	O
be	VB	O
tolerated	VBN	O
because	IN	O
of	IN	O
systemic	JJ	O
effects	NNS	O
,	,	O
reduce	VB	O
the	DT	O
infusion	NN	O
rate	NN	O
to	TO	O
0.625	CD	DOS
ng	NNS	UNIT
/	JJ	O
kg	FW	O
/	JJ	O
min	NN	O
.	.	O

The	DT	O
loading	VBG	O
dose	NN	O
of	IN	O
CEREBYX	NNP	O
is	VBZ	O
10	CD	DOS
-	:	O
20	CD	DOS
mg	NN	UNIT
PE	NNP	O
/	NNP	O
kg	VBD	O
given	VBN	O
IV	NNP	O
or	CC	O
IM	NNP	O
.	.	O

In	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
,	,	O
a	DT	O
total	JJ	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
25	CD	DOS
to	TO	O
50	CD	DOS
mg	NNS	UNIT
per	IN	O
kg	NN	O
(	(	O
approximately	RB	O
10	CD	DOS
to	TO	O
20	CD	DOS
mg	NNS	UNIT
per	IN	O
pound	NN	O
)	)	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
divided	VBD	O
into	IN	O
3	CD	DOS
or	CC	O
4	CD	O
equal	JJ	O
doses	NNS	O
,	,	O
is	VBZ	O
effective	JJ	O
for	IN	O
most	JJS	O
mild	JJ	O
to	TO	O
moderately	RB	O
severe	JJ	O
infections	NNS	O
.	.	O

In	IN	O
addition	NN	O
to	TO	O
meeting	VBG	O
protein	JJ	O
needs	NNS	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
administration	NN	O
is	VBZ	O
governed	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
glucose	JJ	O
tolerance	NN	O
estimated	VBN	O
by	IN	O
glucose	JJ	O
levels	NNS	O
in	IN	O
blood	NN	O
and	CC	O
urine	NN	O
.	.	O

(	(	O
See	VB	O
PRECAUTIONS	NNP	O
.	.	O
)	)	O

Administered	VBN	O
as	IN	O
monotherapy	NN	O
,	,	O
perindopril	JJ	O
erbumine	NN	O
is	VBZ	O
an	DT	O
effective	JJ	O
treatment	NN	O
for	IN	O
hypertension	NN	O
in	IN	O
oncedaily	JJ	O
doses	NNS	O
ranging	VBG	O
from	IN	O
4	CD	DOS
mg	NNS	UNIT
to	TO	O
16	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
but	CC	O
data	NNS	O
are	VBP	O
lacking	VBG	O
to	TO	O
link	VB	O
these	DT	O
doses	NNS	O
of	IN	O
perindopril	JJ	O
erbumine	NN	O
to	TO	O
doses	NNS	O
of	IN	O
PRESTALIA	NNP	O
.	.	O

Use	NNP	O
aseptic	JJ	O
techniques	NNS	O
.	.	O

Occlusion	NN	O
for	IN	O
3	CD	PER
Hours	NNS	PER

In	IN	O
general	JJ	O
,	,	O
begin	VB	O
with	IN	O
half	NN	O
of	IN	O
the	DT	O
estimated	VBN	O
daily	JJ	FREQ
morphine	NN	O
requirement	NN	O
as	IN	O
the	DT	O
initial	JJ	O
dose	NN	O
,	,	O
managing	VBG	O
inadequate	JJ	O
analgesia	NN	O
by	IN	O
supplementation	NN	O
with	IN	O
immediate	JJ	O
-	:	O
release	NN	O
morphine	NN	O
.	.	O

Prior	RB	O
to	TO	O
treatment	NN	O
,	,	O
care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
exclude	VB	O
the	DT	O
possibility	NN	O
of	IN	O
malignant	JJ	O
gastric	JJ	O
ulceration	NN	O
.	.	O

For	IN	O
INTRAVENOUS	NNP	O
infusion	NN	O
:	:	O
Reconstitute	VB	O
a	DT	O
single	JJ	DOS
PROTOPAM	NNP	UNIT
(	(	O
pralidoxime	JJ	O
chloride	NN	O
)	)	O
1000	CD	DOS
mg	JJ	UNIT
vial	JJ	UNIT
by	IN	O
adding	VBG	O
20	CD	DOS
mL	NN	UNIT
of	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
which	WDT	O
results	NNS	O
in	IN	O
a	DT	O
50	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
concentration	NN	O
.	.	O

Whole	JJ	O
blood	NN	O
is	VBZ	O
the	DT	O
matrix	NN	O
of	IN	O
choice	NN	O
and	CC	O
specimens	NNS	O
should	MD	O
be	VB	O
collected	VBN	O
into	IN	O
tubes	NNS	O
containing	VBG	O
ethylene	JJ	O
diamine	JJ	O
tetraacetic	JJ	O
acid	NN	O
(	(	O
EDTA	NNP	O
)	)	O
anti	VBP	O
-	:	O
coagulant	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Dosing	VBG	O
Recommendation	NNP	O
Based	VBD	O
on	IN	O
Blood	NNP	O
Count	NNP	O

As	IN	O
with	IN	O
all	DT	O
drugs	NNS	O
effective	JJ	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
major	JJ	O
depressive	JJ	O
disorder	NN	O
,	,	O
the	DT	O
full	JJ	O
effect	NN	O
may	MD	O
be	VB	O
delayed	VBN	O
.	.	O

This	DT	O
is	VBZ	O
a	DT	O
clear	JJ	O
,	,	O
colorless	NN	O
to	TO	O
pale	VB	O
yellow	JJ	O
solution	NN	O
;	:	O
a	DT	O
slight	JJ	O
yellowish	JJ	O
discoloration	NN	O
will	MD	O
not	RB	O
alter	VB	O
potency	NN	O
.	.	O

Adults	NNS	WHO
And	CC	WHO
Pediatric	NNP	WHO
Patients	NNP	WHO
13	CD	WHO
Years	NNS	WHO
Of	IN	WHO
Age	NNP	WHO
And	CC	WHO
Older	JJR	WHO

These	DT	O
doses	NNS	O
may	MD	O
be	VB	O
repeated	VBN	O
as	IN	O
necessary	JJ	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
observed	VBN	O
carefully	RB	O
if	IN	O
abrupt	JJ	O
reduction	NN	O
or	CC	O
discontinuation	NN	O
of	IN	O
carbidopa	NN	O
-	:	O
levodopa	NN	O
or	CC	O
carbidopa	VB	O
-	:	O
levodopa	NN	O
Extended	NNP	O
-	:	O
Release	NN	O
is	VBZ	O
required	VBN	O
,	,	O
especially	RB	O
if	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
receiving	VBG	O
neuroleptics	NNS	O
.	.	O

Optimum	JJ	O
dosage	NN	O
of	IN	O
Celontin	NNP	O
must	MD	O
be	VB	O
determined	VBN	O
by	IN	O
trial	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
dose	JJ	O
reduction	NN	O
may	MD	O
be	VB	O
warranted	VBN	O
.	.	O

Administration	NN	O
Precautions	NNS	O
:	:	O
Procedures	NNS	O
for	IN	O
proper	JJ	O
handling	NN	O
and	CC	O
disposal	NN	O
of	IN	O
anticancer	NN	O
drugs	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

PAY	NNP	O
PARTICULAR	NNP	O
ATTENTION	NNP	O
:	:	O
It	PRP	O
is	VBZ	O
essential	JJ	O
to	TO	O
start	VB	O
the	DT	O
reconstitution	NN	O
process	NN	O
only	RB	O
after	IN	O
the	DT	O
injection	NN	O
kit	NN	O
has	VBZ	O
reached	VBN	O
room	NN	O
temperature	NN	O
.	.	O

Talk	NN	O
to	TO	O
your	PRP$	O
physician	JJ	O
if	IN	O
extended	VBN	O
use	NN	O
recommended	VBD	O
.	.	O

Generally	RB	O
,	,	O
single	JJ	DOS
doses	NNS	UNIT
or	CC	O
daily	JJ	FREQ
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
2	CD	DOS
g	NNS	UNIT
.	.	O

Erythrocin	NNP	O
Lactobionate	NNP	O
-	:	O
IV	NNP	O
(	(	O
erythromycin	JJ	O
lactobionate	NN	O
for	IN	O
injection	NN	O
,	,	O
USP	NNP	O
)	)	O
must	MD	O
be	VB	O
administered	VBN	O
by	IN	O
continuous	JJ	O
or	CC	O
intermittent	JJ	O
intravenous	JJ	O
infusion	NN	O
only	RB	O
.	.	O

Be	NNP	O
aware	JJ	O
that	IN	O
there	EX	O
are	VBP	O
two	CD	DOS
ZYPREXA	NNP	UNIT
intramuscular	JJ	O
formulations	NNS	O
with	IN	O
different	JJ	O
dosing	VBG	O
schedules	NNS	O
.	.	O

Published	VBN	O
relative	JJ	O
potency	NN	O
data	NNS	O
are	VBP	O
available	JJ	O
,	,	O
but	CC	O
such	JJ	O
ratios	NNS	O
are	VBP	O
approximations	NNS	O
.	.	O

Subsequent	JJ	O
dosage	NN	O
and	CC	O
administration	NN	O
intervals	NNS	O
should	MD	O
be	VB	O
adjusted	VBN	O
according	VBG	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
clinical	JJ	O
response	NN	O
.	.	O

The	DT	O
solution	NN	O
is	VBZ	O
more	RBR	O
palatable	JJ	O
if	IN	O
chilled	VBN	O
before	IN	O
administration	NN	O
.	.	O

Intramuscular	NN	O
:	:	O
CEPTAZ	NNP	O
(	(	O
ceftazidime	NN	O
)	)	O
,	,	O
when	WRB	O
constituted	VBN	O
as	IN	O
directed	VBN	O
with	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
Bacteriostatic	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
or	CC	O
0.5	CD	O
%	NN	O
or	CC	O
1	CD	O
%	NN	O
Lidocaine	NNP	O
Hydrochloride	NNP	O
Injection	NNP	O
,	,	O
maintains	VBZ	O
satisfactory	JJ	O
potency	NN	O
for	IN	O
18	CD	PER
hours	NNS	PER
at	IN	O
room	NN	O
temperature	NN	O
or	CC	O
for	IN	O
7	CD	PER
days	NNS	PER
under	IN	O
refrigeration	NN	O
.	.	O

Do	NNP	O
not	RB	O
add	VB	O
other	JJ	O
medications	NNS	O
to	TO	O
the	DT	O
OFIRMEV	NNP	O
vial	NN	O
or	CC	O
infusion	NN	O
device	NN	O
.	.	O

On	IN	O
succeeding	VBG	O
days	NNS	O
of	IN	O
travel	NN	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
25	CD	DOS
mg	NN	UNIT
be	VB	O
given	VBN	O
on	IN	O
arising	VBG	O
and	CC	O
again	RB	O
before	IN	O
the	DT	O
evening	NN	O
meal	NN	O
.	.	O

The	DT	O
ratio	NN	O
between	IN	O
methadone	NN	O
and	CC	O
other	JJ	O
opioid	JJ	O
agonists	NNS	O
may	MD	O
vary	VB	O
widely	RB	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
previous	JJ	O
dose	JJ	O
exposure	NN	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
these	DT	O
recommendations	NNS	O
should	MD	O
serve	VB	O
as	IN	O
the	DT	O
upper	JJ	O
limit	NN	O
for	IN	O
dos	JJ	O
age	NN	O
adjustments	NNS	O
in	IN	O
order	NN	O
to	TO	O
decrease	VB	O
the	DT	O
risk	NN	O
of	IN	O
potentially	RB	O
serious	JJ	O
adverse	JJ	O
events	NNS	O
associated	VBN	O
with	IN	O
unexpected	JJ	O
large	JJ	O
increases	NNS	O
in	IN	O
serum	JJ	O
theophylline	JJ	O
concentration	NN	O
.	.	O

However	RB	O
,	,	O
if	IN	O
the	DT	O
next	JJ	O
scheduled	VBN	O
dose	NN	O
is	VBZ	O
due	JJ	O
,	,	O
the	DT	O
patient	NN	O
should	MD	O
not	RB	O
take	VB	O
the	DT	O
missed	VBN	O
dose	NN	O
,	,	O
and	CC	O
should	MD	O
be	VB	O
instructed	VBN	O
to	TO	O
take	VB	O
the	DT	O
next	JJ	O
dose	NN	O
on	IN	O
time	NN	O
.	.	O

In	IN	O
Combination	NNP	O
:	:	O
Cerubidine	NNP	O
(	(	O
daunorubicin	NN	O
)	)	O
25	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
IV	NNP	O
on	IN	O
day	NN	O
1	CD	O
every	DT	FREQ
week	NN	FREQ
,	,	O
vincristine	VBP	O
1.5	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
IV	NNP	O
on	IN	O
day	NN	O
1	CD	O
every	DT	FREQ
week	NN	FREQ
,	,	O
prednisone	NN	O
40	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
PO	NNP	O
daily	RB	FREQ
.	.	O

5	CD	O

A	DT	O
previously	RB	WHO
unvaccinated	JJ	WHO
child	NN	WHO
12	CD	WHO
to	TO	WHO
14	CD	WHO
months	NNS	WHO
of	IN	WHO
age	NN	WHO
should	MD	O
receive	VB	O
one	CD	DOS
dose	NN	UNIT
of	IN	O
Haemophilus	NNP	O
b	NN	O
Conjugate	NNP	O
Vaccine	NNP	O
followed	VBN	O
by	IN	O
a	DT	O
booster	NN	O
dose	NN	O
at	IN	O
15	CD	O
to	TO	O
18	CD	O
months	NNS	O
of	IN	O
age	NN	O
(	(	O
doses	VBZ	O
to	TO	O
be	VB	O
separated	VBN	O
by	IN	O
an	DT	O
interval	NN	O
of	IN	O
8	CD	PER
weeks	NNS	PER
)	)	O
.	.	O

or	CC	O
t.i.d	NN	O
.	.	O

Because	IN	O
both	DT	O
therapeutic	JJ	O
and	CC	O
adverse	JJ	O
responses	NNS	O
occur	VBP	O
more	RBR	O
rapidly	RB	O
with	IN	O
combined	JJ	O
therapy	NN	O
than	IN	O
when	WRB	O
only	JJ	O
levodopa	NN	O
is	VBZ	O
given	VBN	O
,	,	O
patients	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
closely	RB	O
during	IN	O
the	DT	O
dose	JJ	O
adjustment	NN	O
period	NN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
reevaluated	VBN	O
periodically	RB	O
as	IN	O
clinically	RB	O
appropriate	JJ	O
(	(	O
e.g	JJ	O
,	,	O
3	CD	O
-	:	O
month	NN	O
to	TO	O
6	CD	O
-	:	O
month	NN	O
intervals	NNS	O
)	)	O
to	TO	O
determine	VB	O
if	IN	O
treatment	NN	O
is	VBZ	O
still	RB	O
necessary	JJ	O
(	(	O
See	VB	O
BOXED	NNP	O
WARNINGS	NNP	O
and	CC	O
WARNINGS	NNP	O
)	)	O
.	.	O

Dosage	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
patients	NNS	O
response	NN	O
.	.	O

Hepatic	JJ	O
Insufficiency	NN	O

When	WRB	O
these	DT	O
substances	NNS	O
or	CC	O
their	PRP$	O
derivatives	NNS	O
are	VBP	O
injected	VBN	O
intramuscularly	RB	O
or	CC	O
into	IN	O
joint	JJ	O
spaces	NNS	O
,	,	O
their	PRP$	O
relative	JJ	O
properties	NNS	O
may	MD	O
be	VB	O
greatly	RB	O
altered	VBN	O
.	.	O

Ordinarily	RB	O
,	,	O
a	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
DynaCirc	NNP	O
CR®	NNP	O
(	(	O
isradipine	NN	O
)	)	O
5	CD	DOS
mg	NN	UNIT
once	RB	FREQ
-	:	FREQ
daily	NN	FREQ
should	MD	O
be	VB	O
used	VBN	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
.	.	O

Patients	NNS	O
should	MD	O
use	VB	O
up	RP	O
to	TO	O
0.25	CD	DOS
grams	NNS	UNIT
(	(	O
one	CD	DOS
packet	NN	UNIT
or	CC	O
one	CD	DOS
full	JJ	UNIT
actuation	NN	UNIT
of	IN	O
the	DT	O
pump	NN	O
)	)	O
at	IN	O
each	DT	O
application	NN	O
,	,	O
which	WDT	O
is	VBZ	O
a	DT	O
sufficient	JJ	O
amount	NN	O
of	IN	O
cream	NN	O
to	TO	O
cover	VB	O
the	DT	O
wart	JJ	O
area	NN	O
.	.	O

Tablets	NNS	O
are	VBP	O
taken	VBN	O
without	IN	O
interruption	NN	O
as	IN	O
follows	VBZ	O
:	:	O
One	CD	DOS
light	NN	WHO
orange	NN	WHO
``	``	WHO
active	JJ	WHO
''	''	WHO
tablet	NN	WHO
daily	RB	FREQ
for	IN	O
21	CD	PER
days	NNS	PER
,	,	O
then	RB	O
one	CD	DOS
green	JJ	UNIT
``	``	WHO
reminder	NN	WHO
''	''	WHO
tablet	NN	WHO
daily	RB	FREQ
for	IN	O
7	CD	PER
days	NNS	PER
.	.	O

If	IN	O
the	DT	O
patient	NN	O
has	VBZ	O
adhered	VBN	O
to	TO	O
the	DT	O
prescribed	VBN	O
regimen	NNS	O
and	CC	O
misses	NNS	O
two	CD	O
consecutive	JJ	O
periods	NNS	O
,	,	O
pregnancy	NN	O
should	MD	O
be	VB	O
ruled	VBN	O
out	RP	O
.	.	O

The	DT	O
currently	RB	O
recommended	VBN	O
dosage	NN	O
regimen	NNS	O
in	IN	O
rheumatoid	JJ	O
arthritis	NN	O
begins	VBZ	O
with	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	FREQ
dose	NN	UNIT
of	IN	O
125	CD	DOS
mg	NNS	UNIT
or	CC	O
250	CD	DOS
mg	NN	UNIT
,	,	O
which	WDT	O
is	VBZ	O
thereafter	RB	O
increased	VBN	O
at	IN	O
one	CD	O
to	TO	O
three	CD	O
month	NN	O
intervals	NNS	O
,	,	O
by	IN	O
125	CD	DOS
mg	NNS	UNIT
or	CC	O
250	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
as	IN	O
patient	JJ	O
response	NN	O
and	CC	O
tolerance	NN	O
indicate	NN	O
.	.	O

It	PRP	O
is	VBZ	O
also	RB	O
desirable	JJ	O
to	TO	O
remove	VB	O
,	,	O
with	IN	O
forceps	NNS	O
and	CC	O
scissors	NNS	O
,	,	O
as	IN	O
much	JJ	O
loosened	VBD	O
detritus	NN	O
as	IN	O
can	MD	O
be	VB	O
done	VBN	O
readily	RB	O
.	.	O

CAUTION	NN	O
:	:	O
Do	NNP	O
not	RB	O
use	VB	O
plastic	JJ	O
containers	NNS	O
in	IN	O
series	NN	O
connections	NNS	O
.	.	O

For	IN	O
patients	NNS	WHO
needing	VBG	WHO
additional	JJ	WHO
glycemic	NN	WHO
control	NN	WHO
,	,	O
the	DT	O
dose	NN	O
of	IN	O
the	DT	O
thiazolidinedione	NN	O
can	MD	O
be	VB	O
increased	VBN	O
based	VBN	O
on	IN	O
its	PRP$	O
recommended	JJ	O
titration	NN	O
schedule	NN	O
.	.	O

For	IN	O
deep	JJ	O
intramuscular	JJ	O
deltoid	NN	O
or	CC	O
gluteal	NN	O
injection	NN	O
by	IN	O
healthcare	NN	O
professionals	NNS	O
only	RB	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
started	VBN	O
at	IN	O
Cenestin	NNP	O
0.45	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
.	.	O

The	DT	O
data	NN	O
in	IN	O
kidney	NN	O
transplant	NN	O
patients	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
Black	NNP	O
patients	NNS	O
required	VBD	O
a	DT	O
higher	JJR	O
dose	NN	O
to	TO	O
attain	VB	O
comparable	JJ	O
trough	JJ	O
concentrations	NNS	O
compared	VBN	O
to	TO	O
Caucasian	JJ	O
patients	NNS	O
(	(	O
Table	JJ	O
2	CD	O
)	)	O
.	.	O

therapy	NN	O
at	IN	O
15	CD	DOS
mg	NN	UNIT
/	NN	O
dose	NN	O
,	,	O
and	CC	O
this	DT	O
regimen	NNS	O
should	MD	O
be	VB	O
used	VBN	O
when	WRB	O
lesions	NNS	O
are	VBP	O
present	JJ	O
,	,	O
so	RB	O
long	RB	O
as	IN	O
it	PRP	O
is	VBZ	O
tolerated	VBN	O
(	(	O
see	VB	O
ADVERSE	NNP	O
REACTIONS	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
pivotal	JJ	O
clinical	JJ	O
study	NN	O
,	,	O
the	DT	O
Lovenox	NNP	O
treatment	NN	O
duration	NN	O
was	VBD	O
8	CD	O
days	NNS	O
or	CC	O
until	IN	O
hospital	JJ	O
discharge	NN	O
,	,	O
whichever	WDT	O
came	VBD	O
first	RB	O
.	.	O

These	DT	O
types	NNS	O
of	IN	O
reactions	NNS	O
are	VBP	O
generally	RB	O
procedurally	RB	O
dependent	JJ	O
and	CC	O
of	IN	O
greater	JJR	O
frequency	NN	O
when	WRB	O
doublecontrast	NN	O
technique	NN	O
is	VBZ	O
employed	VBN	O
.	.	O

Pre	NNP	O
-	:	O
puberty	NN	O
requirements	NNS	O
are	VBP	O
the	DT	O
same	JJ	O
for	IN	O
both	DT	O
sexes	NNS	O
,	,	O
but	CC	O
adult	NN	WHO
females	NNS	WHO
require	VBP	WHO
less	JJR	WHO
than	IN	WHO
adult	NN	WHO
males	NNS	WHO
.	.	O

Administer	IN	O
the	DT	O
adjusted	JJ	O
TIKOSYN	NNP	O
dose	NN	O
and	CC	O
begin	VB	O
continuous	JJ	O
ECG	NNP	O
monitoring	NN	O
.	.	O

Remodulin	NNP	O
is	VBZ	O
administered	VBN	O
subcutaneously	RB	O
by	IN	O
continuous	JJ	O
infusion	NN	O
without	IN	O
further	JJ	O
dilution	NN	O
,	,	O
via	IN	O
a	DT	O
subcutaneous	JJ	O
catheter	NN	O
,	,	O
using	VBG	O
an	DT	O
infusion	NN	O
pump	NN	O
designed	VBN	O
for	IN	O
subcutaneous	JJ	O
drug	NN	O
delivery	NN	O
.	.	O

To	TO	O
correct	VB	O
for	IN	O
physical	JJ	O
decay	NN	O
of	IN	O
this	DT	O
radionuclide	NN	O
,	,	O
the	DT	O
percentages	NNS	O
that	WDT	O
remain	VBP	O
at	IN	O
selected	VBN	O
time	NN	O
intervals	NNS	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
day	NN	O
of	IN	O
calibration	NN	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
2	CD	O
.	.	O

Adults	NNS	WHO
and	CC	WHO
Children	NNP	WHO
over	IN	WHO
15	CD	WHO
kg	NNS	WHO
(	(	O
33	CD	O
lbs	NN	O
)	)	O
:	:	O
See	JJ	O
Dosage	NNP	O
Table	NNP	O
.	.	O

Rub	NNP	O
in	IN	O
Enstilar®	NNP	O
Foam	NNP	O
gently	RB	O
.	.	O

Doses	NNS	O
may	MD	O
be	VB	O
increased	VBN	O
every	DT	FREQ
2	CD	FREQ
weeks	NNS	FREQ
according	VBG	O
to	TO	O
clinical	JJ	O
response	NN	O
,	,	O
serum	JJ	O
drug	NN	O
levels	NNS	O
,	,	O
and	CC	O
toxicity	NN	O
.	.	O

0.5	CD	DOS
mg	NN	UNIT

Reassess	NNP	O
the	DT	O
woman	NN	O
for	IN	O
continued	JJ	O
need	NN	O
for	IN	O
BONJESTA	NNP	O
as	IN	O
her	PRP$	O
pregnancy	NN	O
progresses	VBZ	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Alternatively	RB	O
,	,	O
AndroGel	NNP	O
1	CD	O
%	NN	O
can	MD	O
be	VB	O
applied	VBN	O
directly	RB	O
to	TO	O
the	DT	O
application	NN	O
sites	VBZ	O
.	.	O

Blood	NNP	O
pressure	NN	O
and	CC	O
pulse	NN	O
should	MD	O
be	VB	O
monitored	VBN	O
during	IN	O
infusion	NN	O
.	.	O

The	DT	O
drug	NN	O
should	MD	O
not	RB	O
be	VB	O
taken	VBN	O
on	IN	O
an	DT	O
empty	JJ	O
stomach	NN	O
and	CC	O
should	MD	O
be	VB	O
administered	VBN	O
with	IN	O
ample	JJ	O
water	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
LAMICTAL	NNP	O
may	MD	O
then	RB	O
be	VB	O
further	RB	O
adjusted	VBN	O
to	TO	O
the	DT	O
target	NN	O
dose	NN	O
(	(	O
200	CD	DOS
mg	NN	UNIT
)	)	O
as	IN	O
clinically	RB	O
indicated	VBN	O
.	.	O

Post	NNP	O
-	:	O
venography	NN	O
thrombophlebitis	NN	O
,	,	O
as	IN	O
detected	VBN	O
by	IN	O
fibrinogen	NN	O
I	PRP	O
-	:	O
125	CD	O
uptake	JJ	O
studies	NNS	O
,	,	O
is	VBZ	O
significantly	RB	O
less	RBR	O
in	IN	O
patients	NNS	WHO
receiving	VBG	WHO
HEXABRIX	NNP	WHO
when	WRB	WHO
compared	VBN	O
to	TO	O
conventional	JJ	O
contrast	NN	O
agents	NNS	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
develop	VBP	WHO
≥	JJ	WHO
grade	NN	WHO
3	CD	WHO
peripheral	JJ	WHO
neuropathy	NN	WHO
should	MD	O
have	VB	O
TAXOTERE	NNP	O
treatment	NN	O
discontinued	VBD	O
entirely	RB	O
.	.	O

Single	NNP	O
Dose	NNP	O
Vial	NNP	O
First	NNP	O
withdraw	VBZ	O
the	DT	O
entire	JJ	O
volume	NN	O
of	IN	O
diluent	NN	O
into	IN	O
the	DT	O
syringe	NN	O
to	TO	O
be	VB	O
used	VBN	O
for	IN	O
reconstitution	NN	O
.	.	O

Prescribe	NNP	O
no	DT	O
more	JJR	O
than	IN	O
2	CD	DOS
boxes	NNS	UNIT
(	(	O
56	CD	DOS
packets	NNS	UNIT
)	)	O
or	CC	O
two	CD	DOS
7.5	CD	DOS
g	NNS	UNIT
pumps	NNS	O
for	IN	O
the	DT	O
total	JJ	O
2	CD	O
-	:	O
cycle	NN	O
treatment	NN	O
course	NN	O
.	.	O

The	DT	O
daily	JJ	FREQ
dose	NN	O
should	MD	O
be	VB	O
titrated	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
no	DT	O
more	JJR	O
than	IN	O
5	CD	DOS
mg	JJ	UNIT
/	$	O
500	CD	DOS
mg	NN	UNIT
up	RB	O
to	TO	O
the	DT	O
minimum	JJ	O
effective	JJ	O
dose	NN	O
to	TO	O
achieve	VB	O
adequate	JJ	O
control	NN	O
of	IN	O
blood	NN	O
glucose	NN	O
or	CC	O
to	TO	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	O
2000	CD	DOS
mg	NN	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

Therefore	RB	O
,	,	O
aPTT	JJ	O
ratios	NNS	O
with	IN	O
a	DT	O
given	VBN	O
plasma	JJ	O
level	NN	O
of	IN	O
lepirudin	NNS	O
are	VBP	O
usually	RB	O
higher	JJR	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
receive	VBP	WHO
concomitant	NN	WHO
thrombolysis	NN	WHO
than	IN	O
in	IN	O
those	DT	O
who	WP	O
do	VBP	O
not	RB	O
(	(	O
see	VB	O
also	RB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
:	:	O
Pharmacodynamic	NNP	O
Properties	NNPS	O
)	)	O
.	.	O

The	DT	O
cystoscope	NN	O
is	VBZ	O
pulled	VBN	O
back	RB	O
towards	IN	O
the	DT	O
bladder	NN	O
neck	NN	O
to	TO	O
visualize	VB	O
the	DT	O
full	JJ	O
injection	NN	O
.	.	O

Provision	NN	O
of	IN	O
multiple	JJ	O
refills	NNS	O
is	VBZ	O
not	RB	O
advised	VBN	O
early	RB	O
in	IN	O
treatment	NN	WHO
or	CC	WHO
without	IN	WHO
appropriate	JJ	WHO
patient	NN	WHO
follow	SYM	WHO
-	:	WHO
up	RP	WHO
visits	NNS	WHO
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
doses	NNS	O
above	IN	O
10	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
showed	VBD	O
an	DT	O
increased	VBN	O
blood	NN	O
pressure	NN	O
response	NN	O
but	CC	O
a	DT	O
large	JJ	O
increase	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
peripheral	JJ	O
edema	NN	O
and	CC	O
other	JJ	O
vasodilatory	JJ	O
adverse	JJ	O
events	NNS	O
(	(	O
see	VB	O
ADVERSE	NNP	O
REACTIONS	NNP	O
)	)	O
.	.	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dosage	NN	O
range	NN	O
is	VBZ	O
2.5	CD	DOS
mg	NN	UNIT
to	TO	O
20	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
or	CC	O
in	IN	O
two	CD	DOS
equally	RB	UNIT
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

For	IN	O
Grade	NNP	O
4	CD	O
peripheral	JJ	O
neuropathy	NN	O
,	,	O
ADCETRIS	NNP	O
should	MD	O
be	VB	O
discontinued	VBN	O
.	.	O

VIDAZA	NNP	O
suspension	NN	O
is	VBZ	O
administered	VBN	O
subcutaneously	RB	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
a	DT	WHO
second	JJ	WHO
tuberculin	NN	WHO
test	NN	WHO
(	(	O
booster	NN	O
)	)	O
response	NN	O
of	IN	O
≥	$	O
10	CD	DOS
mm	NN	UNIT
should	MD	O
be	VB	O
considered	VBN	O
to	TO	O
have	VB	O
experienced	VBN	O
past	IN	O
TB	NNP	O
infection	NN	O
.	.	O

Studies	NNS	O
to	TO	O
date	NN	O
have	VB	O
indicated	VBN	O
that	IN	O
Vibramycin	NNP	O
at	IN	O
the	DT	O
usual	JJ	O
recommended	JJ	O
doses	NNS	O
does	VBZ	O
not	RB	O
lead	VB	O
to	TO	O
excessive	JJ	O
accumulation	NN	O
of	IN	O
doxycycline	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
200	CD	DOS
mg	NN	UNIT
(	(	O
one	CD	DOS
tablet	NN	UNIT
)	)	O
once	RB	FREQ
daily	JJ	FREQ
for	IN	O
12	CD	PER
consecutive	JJ	PER
weeks	NNS	PER
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
2.5	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
titrated	VBD	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
10	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
,	,	O
as	IN	O
tolerated	VBN	O
.	.	O

Panic	JJ	O
disorder	NN	O
is	VBZ	O
a	DT	O
chronic	JJ	O
condition	NN	O
,	,	O
and	CC	O
it	PRP	O
is	VBZ	O
reasonable	JJ	O
to	TO	O
consider	VB	O
continuation	NN	O
for	IN	O
a	DT	O
responding	JJ	WHO
patient	NN	WHO
.	.	O

Increasing	VBG	O
levels	NNS	O
of	IN	O
ACTH	NNP	O
stimulate	JJ	O
adrenocortical	JJ	O
activity	NN	O
resulting	VBG	O
in	IN	O
a	DT	O
rise	NN	O
in	IN	O
plasma	NN	O
cortisol	NN	O
with	IN	O
maximal	JJ	O
levels	NNS	O
occurring	VBG	O
between	IN	O
2	CD	O
am	VBP	O
and	CC	O
8	CD	O
am	VBP	O
.	.	O

Each	DT	O
wafer	NN	O
is	VBZ	O
packaged	VBN	O
within	IN	O
two	CD	O
nested	JJ	O
aluminum	NN	O
foil	NN	O
laminate	NN	O
pouches	NNS	O
.	.	O

EGRIFTA™	NNP	O
should	MD	O
be	VB	O
injected	VBN	O
subcutaneously	RB	O
into	IN	O
the	DT	O
skin	NN	O
on	IN	O
the	DT	O
abdomen	NNS	O
.	.	O

At	IN	O
treatment	NN	O
initiation	NN	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
SUBUTEX	NNP	O
sublingual	JJ	O
tablet	NN	O
should	MD	O
be	VB	O
administered	VBN	O
at	IN	O
least	JJS	O
4	CD	O
hours	NNS	O
after	IN	O
the	DT	O
patient	NN	O
last	JJ	O
used	JJ	O
opioids	NNS	O
or	CC	O
preferably	RB	O
when	WRB	O
moderate	JJ	O
objective	JJ	O
signs	NNS	O
of	IN	O
opioid	JJ	O
withdrawal	NN	O
appear	NN	O
.	.	O

Gengraf®	NNP	O
and	CC	O
Sandimmune®	NNP	O
are	VBP	O
not	RB	O
bioequivalent	JJ	O
and	CC	O
can	MD	O
not	RB	O
be	VB	O
used	VBN	O
interchangeably	RB	O
without	IN	O
physician	JJ	O
supervision	NN	O
.	.	O

It	PRP	O
is	VBZ	O
not	RB	O
known	VBN	O
if	IN	O
clobazam	NN	O
or	CC	O
its	PRP$	O
active	JJ	O
metabolite	NN	O
,	,	O
N	NNP	O
-	:	O
desmethylclobazam	NN	O
,	,	O
is	VBZ	O
dialyzable	JJ	O
[	NNS	O
see	VBP	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Failure	NN	O
to	TO	O
increase	VB	O
height	JJ	O
velocity	NN	O
,	,	O
particularly	RB	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
treatment	NN	O
,	,	O
should	MD	O
prompt	VB	O
close	JJ	O
assessment	NN	O
of	IN	O
compliance	NN	O
and	CC	O
evaluation	NN	O
of	IN	O
other	JJ	O
causes	NNS	O
of	IN	O
poor	JJ	O
growth	NN	O
,	,	O
such	JJ	O
as	IN	O
hypothyroidism	NN	O
,	,	O
under	IN	O
-	:	O
nutrition	NN	O
,	,	O
advanced	VBD	O
bone	NN	O
age	NN	O
and	CC	O
antibodies	NNS	O
to	TO	O
recombinant	VB	O
human	JJ	O
growth	NN	O
hormone	NN	O
.	.	O

If	IN	O
possible	JJ	O
,	,	O
discontinue	VB	O
the	DT	O
patient	NN	O
's	POS	O
previous	JJ	O
antihypertensive	JJ	O
drug	NN	O
regimen	NNS	O
for	IN	O
one	CD	PER
week	NN	PER
before	IN	O
starting	VBG	O
CAPOTEN	NNP	O
.	.	O

9	CD	O
.	.	O

The	DT	O
product	NN	O
may	MD	O
be	VB	O
filtered	VBN	O
using	VBG	O
a	DT	O
sterile	JJ	O
filter	NN	O
if	IN	O
particles	NNS	O
are	VBP	O
seen	VBN	O
subsequent	JJ	O
to	TO	O
opening	NN	O
of	IN	O
the	DT	O
ampoule	NN	O
.	.	O

When	WRB	O
rabies	NNS	O
exposure	VBP	O
occurs	VBZ	O
in	IN	O
a	DT	O
previously	RB	O
vaccinated	VBN	O
person	NN	O
,	,	O
then	RB	O
that	IN	O
person	NN	O
should	MD	O
receive	VB	O
two	CD	DOS
IM	NNP	UNIT
(	(	O
deltoid	NN	O
)	)	O
doses	VBZ	O
(	(	O
1.0	CD	DOS
mL	RB	UNIT
each	DT	UNIT
)	)	O
of	IN	O
RabAvert	NN	O
:	:	O
one	CD	O
immediately	RB	O
and	CC	O
one	CD	DOS
3	CD	PER
days	NNS	PER
later	RB	O
.	.	O

Direct	JJ	O
reconstitution	NN	O
with	IN	O
Baxter	NNP	O
's	POS	O
MINI	NNP	O
-	:	O
BAG	NNP	O
Plus	NNP	O
Container	NNP	O
.	.	O

There	EX	WHO
were	VBD	WHO
few	JJ	WHO
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
in	IN	O
clinical	JJ	O
studies	NNS	O
.	.	O

Follow	IN	O
the	DT	O
steps	NNS	O
below	IN	O
and	CC	O
use	VB	O
aseptic	JJ	O
technique	NN	O
to	TO	O
administer	VB	O
Hizentra	NNP	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Current	JJ	O
assay	NN	O
results	NNS	O
are	VBP	O
also	RB	O
not	RB	O
interchangeable	JJ	O
and	CC	O
their	PRP$	O
use	NN	O
should	MD	O
be	VB	O
guided	VBN	O
by	IN	O
their	PRP$	O
approved	JJ	O
labeling	NN	O
.	.	O

A	DT	O
cumulative	JJ	O
dose	NN	O
of	IN	O
at	IN	O
least	JJS	O
3	CD	DOS
g	NN	UNIT
of	IN	O
amphotericin	NN	O
B	NNP	O
is	VBZ	O
recommended	VBN	O
to	TO	O
treat	VB	O
rhinocerebral	JJ	O
phycomycosis	NN	O
.	.	O

If	IN	O
the	DT	O
24	CD	O
hour	NN	O
serum	NN	O
creatinine	NN	O
has	VBZ	O
increased	VBN	O
50	CD	O
%	NN	O
over	IN	O
baseline	NN	O
or	CC	O
if	IN	O
the	DT	O
24	CD	O
hour	NN	O
methotrexate	NN	O
level	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
5	CD	O
x	JJ	O
10	CD	O
-	:	O
6	CD	O
M	NNP	O
or	CC	O
the	DT	O
48	CD	O
hour	NN	O
level	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
9	CD	O
x	JJ	O
10	CD	O
-	:	O
7	CD	O
M	NNP	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
leucovorin	NN	O
should	MD	O
be	VB	O
increased	VBN	O
to	TO	O
150	CD	DOS
mg	NN	UNIT
(	(	O
100	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
)	)	O
IV	NNP	O
every	DT	FREQ
3	CD	FREQ
hours	NNS	FREQ
until	IN	O
the	DT	O
methotrexate	NN	O
level	NN	O
is	VBZ	O
less	JJR	O
than	IN	O
10	CD	O
-	:	O
8	CD	O
M.	NNP	O
Doses	NNP	O
greater	JJR	O
then	RB	O
25	CD	DOS
mg	NNS	UNIT
should	MD	O
be	VB	O
given	VBN	O
parenterally	RB	O
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
)	)	O
.	.	O

First	RB	O
dose	NN	O
...	:	O
...	:	O
...	:	O
...	:	O
...	:	O
...	:	O
...	:	O
...	:	O
...	:	O
3.7	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	NN	O
bsa	NN	O

If	IN	O
the	DT	O
solution	NN	O
is	VBZ	O
shaken	VBN	O
,	,	O
the	DT	O
solution	NN	O
may	MD	O
become	VB	O
cloudy	NN	O
or	CC	O
develop	VB	O
particulate	JJ	O
matter	NN	O
.	.	O

Add	NNP	O
remainder	NN	O
of	IN	O
the	DT	O
water	NN	O
and	CC	O
again	RB	O
shake	VB	O
vigorously	RB	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
suspected	JJ	WHO
poor	JJ	WHO
absorption	NN	WHO
of	IN	O
Sandimmune®*	NNP	O
(	(	O
cyclosporine	NN	O
)	)	O
require	VBP	O
different	JJ	O
dosing	NN	O
strategies	NNS	O
(	(	O
see	VB	O
DOSAGE	NNP	O
AND	NNP	O
ADMINISTRATION	NNP	O
-	:	O
Transplant	JJ	O
Patients	NNS	O
with	IN	O
Poor	NNP	O
Absorption	NNP	O
of	IN	O
Sandimmune®*	NNP	O
(	(	O
cyclosporine	NN	O
)	)	O
,	,	O
below	IN	O
)	)	O
.	.	O

The	DT	O
spray	NN	O
solution	NN	O
has	VBZ	O
a	DT	O
pH	NN	O
between	IN	O
6.5	CD	O
and	CC	O
7.5	CD	O
.	.	O

If	IN	O
a	DT	O
dose	NN	O
is	VBZ	O
missed	VBN	O
during	IN	O
the	DT	O
first	JJ	O
2	CD	PER
weeks	NNS	PER
of	IN	O
treatment	NN	O
,	,	O
do	VBP	O
not	RB	O
administer	VB	O
the	DT	O
missed	VBN	O
dose	NN	O
(	(	O
skip	VB	O
the	DT	O
dose	NN	O
and	CC	O
then	RB	O
continue	VB	O
the	DT	O
daily	JJ	FREQ
dosing	VBG	O
regimen	NNS	O
)	)	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
creatinine	JJ	WHO
clearance	NN	WHO
(	(	WHO
CrCl	NNP	WHO
)	)	O
>	VBD	O
30	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
PRADAXA	NNP	O
is	VBZ	O
150	CD	DOS
mg	NN	UNIT
taken	VBN	O
orally	RB	O
,	,	O
twice	RB	FREQ
daily	RB	FREQ
.	.	O

CALAN	NNP	O
40	CD	DOS
mg	NN	UNIT
tablets	NNS	UNIT
are	VBP	O
round	VBN	O
,	,	O
pink	VB	O
,	,	O
film	NN	O
coated	VBD	O
,	,	O
with	IN	O
CALAN	NNP	O
debossed	VBD	O
on	IN	O
one	CD	O
side	NN	O
and	CC	O
40	CD	DOS
on	IN	O
the	DT	O
other	JJ	O
,	,	O
supplied	VBN	O
as	IN	O
:	:	O

Subsequently	RB	O
,	,	O
instruct	NN	O
patients	NNS	O
to	TO	O
peel	VB	O
the	DT	O
blister	NN	O
pack	NN	O
open	JJ	O
,	,	O
and	CC	O
to	TO	O
place	VB	O
the	DT	O
orally	RB	O
disintegrating	VBG	O
tablet	NN	O
on	IN	O
the	DT	O
tongue	NN	O
,	,	O
where	WRB	O
it	PRP	O
will	MD	O
dissolve	VB	O
and	CC	O
it	PRP	O
will	MD	O
be	VB	O
swallowed	VBN	O
with	IN	O
the	DT	O
saliva	NN	O
.	.	O

When	WRB	O
heat	NN	O
is	VBZ	O
applied	VBN	O
to	TO	O
Daytrana	NNP	O
after	IN	O
patch	NN	O
application	NN	O
,	,	O
both	CC	O
the	DT	O
rate	NN	O
and	CC	O
the	DT	O
extent	NN	O
of	IN	O
absorption	NN	O
are	VBP	O
significantly	RB	O
increased	VBN	O
.	.	O

Solutions	NNS	O
of	IN	O
FORTAZ	NNP	O
,	,	O
like	IN	O
those	DT	O
of	IN	O
most	JJS	O
beta	SYM	O
-	:	O
lactam	NN	O
antibiotics	NNS	O
,	,	O
should	MD	O
not	RB	O
be	VB	O
added	VBN	O
to	TO	O
solutions	NNS	O
of	IN	O
aminoglycoside	NN	O
antibiotics	NNS	O
because	IN	O
of	IN	O
potential	JJ	O
interaction	NN	O
.	.	O

For	IN	O
severe	JJ	O
bleeds	NNS	O
,	,	O
dosing	VBG	O
should	MD	O
continue	VB	O
at	IN	O
3	CD	O
-	:	O
6	CD	O
hour	NN	O
intervals	NNS	O
after	IN	O
hemostasis	NN	O
is	VBZ	O
achieved	VBN	O
,	,	O
to	TO	O
maintain	VB	O
the	DT	O
hemostatic	JJ	O
plug	NN	O
.	.	O

Depakene	NNP	O
has	VBZ	O
not	RB	O
been	VBN	O
systematically	RB	O
studied	VBN	O
as	IN	O
initial	JJ	O
therapy	NN	O
.	.	O

In	IN	O
another	DT	O
study	NN	O
,	,	O
severe	JJ	O
adverse	JJ	O
effects	NNS	O
including	VBG	O
deaths	NNS	O
were	VBD	O
noted	VBN	O
in	IN	O
children	NNS	WHO
with	IN	WHO
previously	RB	WHO
untreated	VBN	WHO
,	,	O
Ph	NNP	O
-	:	O
negative	JJ	O
,	,	O
juvenile	JJ	O
CML	NNP	O
,	,	O
who	WP	O
received	VBD	O
interferon	JJ	O
doses	NNS	O
of	IN	O
30	CD	DOS
MIU	NNP	UNIT
/	NNP	O
m²	NN	O
/	NNP	O
day12	NN	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
erythrodermic	JJ	WHO
psoriasis	NN	WHO
should	MD	O
be	VB	O
treated	VBN	O
with	IN	O
special	JJ	O
attention	NN	O
because	IN	O
pre	JJ	O
-	:	O
existing	VBG	O
erythema	NN	O
may	MD	O
obscure	VB	O
observations	NNS	O
of	IN	O
possible	JJ	O
treatment	NN	O
-	:	O
related	JJ	O
phototoxic	NN	O
erythema	NN	O
.	.	O

NOTE	NN	O
:	:	O
CONTAINS	NNP	O
BENZYL	NNP	O
ALCOHOL	NNP	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O

The	DT	O
suggested	JJ	O
dosage	NN	O
for	IN	O
androgens	JJ	O
varies	NNS	O
depending	VBG	O
on	IN	O
the	DT	O
age	NN	O
,	,	O
sex	NN	O
,	,	O
and	CC	O
diagnosis	NN	O
of	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
.	.	O

The	DT	O
usual	JJ	O
dietary	JJ	O
potassium	NN	O
intake	NN	O
by	IN	O
the	DT	O
average	JJ	WHO
adult	NN	WHO
is	VBZ	O
50	CD	DOS
to	TO	O
100	CD	DOS
mEq	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

Thyroid	NNP	O
hormone	NN	O
products	NNS	O
formulated	VBN	O
for	IN	O
intravenous	JJ	O
administration	NN	O
should	MD	O
be	VB	O
administered	VBN	O
.	.	O

If	IN	O
exposed	VBN	O
to	TO	O
low	JJ	O
temperatures	NNS	O
,	,	O
Nesacaine	NNP	O
(	(	O
chloroprocaine	NN	O
)	)	O
and	CC	O
Nesacaine	NNP	O
-	:	O
MPF	NNP	O
Injections	NNPS	O
may	MD	O
deposit	VB	O
crystals	NNS	O
of	IN	O
chloroprocaine	NN	O
HCl	NNP	O
which	WDT	O
will	MD	O
redissolve	VB	O
with	IN	O
shaking	VBG	O
when	WRB	O
returned	VBN	O
to	TO	O
room	NN	O
temperature	NN	O
.	.	O

Precautions	NNS	O

In	IN	O
the	DT	O
clinical	JJ	O
trial	NN	O
,	,	O
the	DT	O
mean	JJ	O
daily	JJ	FREQ
dose	NN	O
was	VBD	O
35	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
in	IN	O
this	DT	O
age	NN	O
group	NN	O
.	.	O

The	DT	O
contents	NNS	O
of	IN	O
each	DT	O
vial	NN	O
are	VBP	O
sterile	JJ	O
and	CC	O
non	JJ	O
-	:	O
pyrogenic	NN	O
.	.	O

Ecoza	NNP	O
topical	JJ	O
foam	NN	O
,	,	O
1	CD	O
%	NN	O
is	VBZ	O
not	RB	O
for	IN	O
oral	JJ	O
,	,	O
ophthalmic	JJ	O
,	,	O
or	CC	O
intravaginal	JJ	O
use	NN	O
.	.	O

To	TO	O
take	VB	O
pill	NN	O
“	NNP	O
2	CD	O
,	,	O
”	NNP	O
turn	VBP	O
the	DT	O
dial	NN	O
on	IN	O
the	DT	O
DIALPAK	NNP	O
in	IN	O
a	DT	O
clockwise	NN	O
direction	NN	O
to	TO	O
the	DT	O
next	JJ	O
day	NN	O
.	.	O

For	IN	O
prolonged	JJ	O
therapy	NN	O
,	,	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
may	MD	O
be	VB	O
reduced	VBN	O
to	TO	O
2	CD	DOS
g	NN	UNIT
after	IN	O
the	DT	O
initial	JJ	O
treatment	NN	O
period	NN	O
.	.	O

All	DT	O
susceptible	JJ	O
persons	NNS	O
whose	WP$	O
sexual	JJ	O
partners	NNS	O
have	VBP	O
acute	VBN	O
hepatitis	NN	O
B	NNP	O
infection	NN	O
should	MD	O
receive	VB	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
of	IN	O
HepaGam	NNP	O
B™	NNP	O
(	(	O
Hepatitis	NNP	O
B	NNP	O
Immune	NNP	O
Globulin	NNP	O
Intravenous	NNP	O
[	NNP	O
Human	NNP	O
]	NNP	O
)	)	O
(	(	O
0.06	CD	DOS
mL	NN	UNIT
/	NNP	O
kg	NN	O
)	)	O
and	CC	O
should	MD	O
begin	VB	O
the	DT	O
Hepatitis	NNP	O
B	NNP	O
Vaccine	NNP	O
series	NN	O
,	,	O
if	IN	O
not	RB	O
contraindicated	VBN	O
,	,	O
within	IN	O
14	CD	O
days	NNS	O
of	IN	O
the	DT	O
last	JJ	O
sexual	JJ	O
contact	NN	O
or	CC	O
if	IN	O
sexual	JJ	O
contact	NN	O
with	IN	O
the	DT	O
infected	JJ	O
person	NN	O
will	MD	O
continue	VB	O
.	.	O

Neupro	NNP	O
is	VBZ	O
applied	VBN	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Following	VBG	O
therapy	NN	O
,	,	O
tumors	NNS	O
may	MD	O
show	VB	O
decreased	VBD	O
or	CC	O
no	DT	O
enhancement	NN	O
.	.	O

For	IN	O
the	DT	O
relief	NN	O
of	IN	O
withdrawal	NN	O
symptoms	NNS	O
of	IN	O
acute	JJ	O
alcoholism	NN	O
,	,	O
the	DT	O
parenteral	JJ	O
form*	NN	O
is	VBZ	O
usually	RB	O
used	VBN	O
initially	RB	O
.	.	O

If	IN	O
indicated	VBN	O
,	,	O
an	DT	O
increase	NN	O
to	TO	O
60	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
total	JJ	O
daily	JJ	FREQ
dose	NN	O
is	VBZ	O
often	RB	O
effective	JJ	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

The	DT	O
maintenance	NN	O
dose	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
according	VBG	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
anesthetic	JJ	O
needs	NNS	O
and	CC	O
whether	IN	O
an	DT	O
additional	JJ	O
anesthetic	JJ	O
agent	NN	O
is	VBZ	O
employed	VBN	O
.	.	O

Usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
50	CD	DOS
mg	JJ	UNIT
Promethazine	NNP	O
HCl	NNP	O
Syrup	NNP	O
(	(	O
promethazine	JJ	O
hydrochloride	NN	O
syrup	NN	O
plain	NN	O
)	)	O
Plain	NN	O
with	IN	O
an	DT	O
appropriately	RB	O
reduced	VBN	O
dose	NN	O
of	IN	O
narcotic	JJ	O
or	CC	O
barbiturate	NN	O
and	CC	O
the	DT	O
required	JJ	O
amount	NN	O
of	IN	O
a	DT	O
belladonna	NN	O
alkaloid	NN	O
.	.	O

The	DT	O
timing	NN	O
of	IN	O
the	DT	O
switch	NN	O
to	TO	O
oral	JJ	O
therapy	NN	O
should	MD	O
be	VB	O
done	VBN	O
at	IN	O
the	DT	O
discretion	NN	O
of	IN	O
the	DT	O
physician	NN	O
and	CC	O
in	IN	O
accordance	NN	O
with	IN	O
clinical	JJ	O
response	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ALECENSA	NNP	O
is	VBZ	O
600	CD	DOS
mg	NN	UNIT
orally	RB	O
twice	JJ	FREQ
daily	RB	FREQ
with	IN	O
food	NN	O
[	NNS	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Step	NN	O
B	NNP	O
:	:	O
Once	RB	O
the	DT	O
total	JJ	O
Number	NNP	O
of	IN	O
Tablets	NNP	O
and	CC	O
Volume	NN	O
are	VBP	O
determined	VBN	O
then	RB	O
follow	VB	O
the	DT	O
procedures	NNS	O
below	IN	O
for	IN	O
compounding	VBG	O
the	DT	O
oral	JJ	O
suspension	NN	O
(	(	O
10	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O
from	IN	O
Flumadine	NNP	O
(	(	O
rimantadine	NN	O
)	)	O
Tablets	VBZ	O
100	CD	DOS
mg	NN	UNIT

Aminoglycosides	NNS	O
administered	VBN	O
by	IN	O
any	DT	O
of	IN	O
the	DT	O
above	JJ	O
routes	NNS	O
should	MD	O
not	RB	O
be	VB	O
physically	RB	O
premixed	VBN	O
with	IN	O
other	JJ	O
drugs	NNS	O
but	CC	O
should	MD	O
be	VB	O
administered	VBN	O
separately	RB	O
.	.	O

Preanesthetic	JJ	O
medication	NN	O
is	VBZ	O
generally	RB	O
advisable	JJ	O
.	.	O

Doses	NNS	O
above	IN	O
this	DT	O
amount	NN	O
generally	RB	O
do	VBP	O
not	RB	O
increase	VB	O
the	DT	O
effectiveness	NN	O
of	IN	O
the	DT	O
drug	NN	O
.	.	O

Advise	NN	O
patients	NNS	O
to	TO	O
swallow	VB	O
the	DT	O
capsules	NNS	O
whole	VBP	O
with	IN	O
water	NN	O
[	NNP	O
see	NN	O
BOX	NNP	O
WARNING	NNP	O
,	,	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
not	RB	WHO
been	VBN	WHO
receiving	VBG	WHO
opioid	JJ	WHO
analgesics	NNS	WHO
should	MD	O
be	VB	O
started	VBN	O
on	IN	O
ROXICODONE®	NNP	O
in	IN	O
a	DT	O
dosing	NN	O
range	NN	O
of	IN	O
5	CD	DOS
to	TO	O
15	CD	DOS
mg	NN	UNIT
every	DT	O
4	CD	O
to	TO	O
6	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

After	IN	O
each	DT	O
dose	NN	O
,	,	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
advised	VBN	O
to	TO	O
rinse	VB	O
his	PRP$	O
/	NN	O
her	PRP$	O
mouth	NN	O
with	IN	O
water	NN	O
without	IN	O
swallowing	VBG	O
.	.	O

PEDIATRIC	NNP	O
DOSING	NNP	O
(	(	O
FOR	NNP	WHO
PATIENTS	NNP	WHO
16	CD	WHO
YEARS	NNP	WHO
AND	NNP	WHO
UNDER	NNP	WHO
)	)	WHO

Dexferrum	NNP	O
is	VBZ	O
administered	VBN	O
by	IN	O
intravenous	JJ	O
injection	NN	O
.	.	O

Prior	NNP	O
to	TO	O
and	CC	O
following	VBG	O
each	DT	O
infusion	NN	O
,	,	O
flush	VBP	O
the	DT	O
indwelling	NN	O
catheter	NN	O
line	NN	O
with	IN	O
approximately	RB	O
5	CD	DOS
mL	NNS	UNIT
of	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
or	CC	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
.	.	O

Table	JJ	O
3	CD	O
gives	VBZ	O
a	DT	O
dose	JJ	O
titration	NN	O
guideline	NN	O
.	.	O

After	IN	O
the	DT	O
priming	NN	O
procedure	NN	O
,	,	O
PENNSAID	NNP	O
is	VBZ	O
properly	RB	O
dispensed	VBN	O
by	IN	O
completely	RB	O
depressing	VBG	O
the	DT	O
pump	NN	O
2	CD	O
times	NNS	O
to	TO	O
achieve	VB	O
the	DT	O
prescribed	JJ	O
dosage	NN	O
for	IN	O
one	CD	PER
knee	NN	PER
.	.	O

Discard	NNP	O
unused	JJ	O
portion	NN	O
of	IN	O
NEUPOGEN	NNP	O
in	IN	O
vials	NNS	O
or	CC	O
prefilled	VBN	O
syringes	NNS	O
;	:	O
do	VB	O
not	RB	O
re	VB	O
-	:	O
enter	NN	O
the	DT	O
vial	NN	O
.	.	O

If	IN	O
ultrasound	JJ	O
fails	VBZ	O
to	TO	O
locate	VB	O
the	DT	O
implant	NN	O
,	,	O
other	JJ	O
imaging	VBG	O
techniques	NNS	O
such	JJ	O
as	IN	O
CT	NNP	O
or	CC	O
MRI	NNP	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
locate	VB	O
it	PRP	O
(	(	O
plain	JJ	O
films	NNS	O
are	VBP	O
not	RB	O
recommended	VBN	O
as	IN	O
the	DT	O
implant	NN	O
is	VBZ	O
not	RB	O
radiopaque	JJ	O
)	)	O
.	.	O

For	IN	O
intraperitoneal	JJ	O
injection	NN	O
it	PRP	O
is	VBZ	O
given	VBN	O
through	IN	O
a	DT	O
rubber	NN	O
catheter	NN	O
inserted	VBN	O
into	IN	O
the	DT	O
trocar	NN	O
used	VBN	O
for	IN	O
paracentesis	NN	O
or	CC	O
through	IN	O
a	DT	O
No	NNP	O
.	.	O

Kuvan	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
orally	RB	O
with	IN	O
a	DT	O
meal	NN	O
to	TO	O
increase	VB	O
absorption	NN	O
,	,	O
preferably	RB	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
each	DT	FREQ
day	NN	FREQ
.	.	O

Subclinical	JJ	O
Hypothyroidism	NNP	O
-	:	O
If	IN	O
this	DT	O
condition	NN	O
is	VBZ	O
treated	VBN	O
,	,	O
lower	JJR	O
levothyroxine	NN	O
sodium	NN	O
dose	NN	O
(	(	O
e.g	JJ	O
,	,	O
1	CD	DOS
mcg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
)	)	O
than	IN	O
that	DT	O
used	VBD	O
for	IN	O
full	JJ	O
replacement	NN	O
may	MD	O
be	VB	O
adequate	JJ	O
to	TO	O
normalize	VB	O
the	DT	O
serum	NN	O
TSH	NNP	O
level	NN	O
.	.	O

A	DT	O
total	JJ	O
dose	NN	O
of	IN	O
not	RB	O
more	JJR	O
than	IN	O
120	CD	DOS
g	NN	UNIT
over	IN	O
the	DT	O
course	NN	O
of	IN	O
therapy	NN	O
should	MD	O
be	VB	O
given	VBN	O
unless	IN	O
there	EX	O
are	VBP	O
no	DT	O
other	JJ	O
therapeutic	JJ	O
options	NNS	O
.	.	O

Figure	NN	O
21	CD	O

The	DT	O
dose	NN	O
of	IN	O
Gengraf®	NNP	O
should	MD	O
be	VB	O
titrated	VBN	O
individually	RB	O
based	VBN	O
on	IN	O
cyclosporine	NN	O
trough	IN	O
concentrations	NNS	O
,	,	O
tolerability	NN	O
,	,	O
and	CC	O
clinical	JJ	O
response	NN	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
promethazine	JJ	O
hydrochloride	NN	O
(	(	O
promethazine	JJ	O
hydrochloride	NN	O
injection	NN	O
)	)	O
if	IN	O
solution	NN	O
has	VBZ	O
developed	VBN	O
color	NN	O
or	CC	O
contains	NNS	O
precipitate	VBP	O
.	.	O

Salicylates	NNS	O
,	,	O
nonsteroidal	JJ	O
anti	SYM	O
-	:	O
inflammatory	NN	O
agents	NNS	O
,	,	O
and	CC	O
oral	JJ	O
corticosteroids	NNS	O
may	MD	O
be	VB	O
continued	VBN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
-	:	O
DRUG	NNP	O
INTERACTIONS	NNP	O
)	)	O
.	.	O

After	IN	O
reconstitution	NN	O
,	,	O
infuse	VB	O
immediately	RB	O
or	CC	O
within	IN	O
4	CD	O
hours	NNS	O
.	.	O

After	IN	O
transferring	VBG	O
,	,	O
thoroughly	RB	O
mix	VBZ	O
the	DT	O
contents	NNS	O
of	IN	O
the	DT	O
infusion	NN	O
bag	NN	O
.	.	O

Check	NNP	O
for	IN	O
minute	NN	O
leaks	NNS	O
by	IN	O
squeezing	VBG	O
container	NN	O
firmly	RB	O
.	.	O

Apply	VB	O
a	DT	O
pressure	NN	O
bandage	NN	O
with	IN	O
sterile	JJ	O
gauze	NN	O
to	TO	O
minimize	VB	O
bruising	NN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
hypertensive	JJ	O
or	CC	O
recently	RB	O
post	VBN	O
-	:	O
myocardial	JJ	O
infarction	NN	O
,	,	O
ALTACE	NNP	O
can	MD	O
also	RB	O
be	VB	O
given	VBN	O
as	IN	O
a	DT	O
divided	VBN	O
dose	NN	O
.	.	O

SABRIL	NNP	O
powder	NN	O
for	IN	O
oral	JJ	O
solution	NN	O
should	MD	O
be	VB	O
mixed	JJ	O
with	IN	O
water	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

No	DT	O
further	JJ	O
reconstitution	NN	O
or	CC	O
dilution	NN	O
is	VBZ	O
required	VBN	O
.	.	O

Assess	NNP	O
renal	JJ	O
function	NN	O
prior	RB	O
to	TO	O
initiation	NN	O
of	IN	O
treatment	NN	O
with	IN	O
PRADAXA	NNP	O
.	.	O

After	IN	O
removing	VBG	O
the	DT	O
overwrap	NN	O
,	,	O
inspect	VBP	O
the	DT	O
container	NN	O
for	IN	O
leakage	NN	O
by	IN	O
pressing	VBG	O
firmly	RB	O
on	IN	O
the	DT	O
bag	NN	O
.	.	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dose	NN	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Such	JJ	O
exposures	NNS	O
should	MD	O
be	VB	O
treated	VBN	O
like	IN	O
sexual	JJ	O
exposures	NNS	O
.	.	O

RiaSTAP	NNP	O
(	(	O
fibrinogen	NN	O
concentrate	NN	O
(	(	O
human	JJ	O
)	)	O
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
dosing	NN	O
,	,	O
duration	NN	O
of	IN	O
dosing	VBG	O
and	CC	O
frequency	NN	O
of	IN	O
administration	NN	O
should	MD	O
be	VB	O
individualized	VBN	O
based	VBN	O
on	IN	O
the	DT	O
extent	NN	O
of	IN	O
bleeding	NN	O
,	,	O
laboratory	NN	O
values	NNS	O
,	,	O
and	CC	O
the	DT	O
clinical	JJ	O
condition	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

Excessive	JJ	O
platelet	NN	O
count	NN	O
responses	NNS	O
,	,	O
as	IN	O
outlined	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
,	,	O
or	CC	O
important	JJ	O
liver	JJ	O
test	NN	O
abnormalities	NNS	O
also	RB	O
necessitate	VBP	O
discontinuation	NN	O
of	IN	O
PROMACTA	NNP	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Twenty	CD	O
percent	JJ	O
solutions	NNS	O
may	MD	O
be	VB	O
used	VBN	O
so	RB	O
that	IN	O
a	DT	O
small	JJ	O
volume	NN	O
can	MD	O
contain	VB	O
a	DT	O
large	JJ	O
dose	NN	O
.	.	O

Continually	RB	O
reevaluate	JJ	O
patients	NNS	WHO
receiving	VBG	WHO
TARGINIQ	NNP	WHO
ER	NNP	WHO
to	TO	O
assess	VB	O
the	DT	O
maintenance	NN	O
of	IN	O
pain	NN	O
control	NN	O
and	CC	O
the	DT	O
relative	JJ	O
incidence	NN	O
of	IN	O
adverse	JJ	O
reactions	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
monitoring	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
addiction	NN	O
,	,	O
abuse	NN	O
,	,	O
and	CC	O
misuse	NN	O
.	.	O

GENERESS	NNP	O
Fe	NNP	O
may	MD	O
be	VB	O
administered	VBN	O
without	IN	O
regard	NN	O
to	TO	O
meals	NNS	O
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

To	TO	O
show	VB	O
the	DT	O
position	NN	O
of	IN	O
the	DT	O
needle	JJ	O
bevel	NN	O
,	,	O
there	EX	O
is	VBZ	O
a	DT	O
square	JJ	O
mark	NN	O
8	CD	O
mm	NN	O
from	IN	O
the	DT	O
needle	JJ	O
tip	NN	O
.	.	O

The	DT	O
resultant	JJ	O
solution	NN	O
contains	VBZ	O
1	CD	DOS
mg	NN	UNIT
of	IN	O
mechlorethamine	JJ	O
hydrochloride	NN	O
per	IN	O
mL	NN	O
.	.	O

This	DT	O
portion	NN	O
should	MD	O
be	VB	O
discarded	VBN	O
to	TO	O
ensure	VB	O
proper	JJ	O
priming	NN	O
of	IN	O
the	DT	O
pump	NN	O
.	.	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
titrated	VBN	O
up	RP	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
300	CD	DOS
/	JJ	O
320	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Administer	NNP	O
the	DT	O
oral	JJ	O
suspension	NN	O
immediately	RB	O
after	IN	O
preparation	NN	O
.	.	O

Remove	VB	O
any	DT	O
intrauterine	JJ	O
device	NN	O
(	(	O
“	JJ	O
IUD	NNP	O
”	NNP	O
)	)	O
before	IN	O
treatment	NN	O
with	IN	O
MIFEPREX	NNP	O
begins	VBZ	O
[	NNP	O
see	VBP	O
CONTRAINDICATIONS	NNP	O
]	NNP	O
.	.	O

Its	PRP$	O
presence	NN	O
should	MD	O
be	VB	O
substantiated	VBN	O
and	CC	O
the	DT	O
inhibitor	NN	O
level	NN	O
quantitated	VBN	O
by	IN	O
appropriate	JJ	O
laboratory	NN	O
tests	NNS	O
.	.	O

If	IN	O
a	DT	O
dose	NN	O
is	VBZ	O
missed	VBN	O
it	PRP	O
should	MD	O
be	VB	O
taken	VBN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
,	,	O
unless	IN	O
it	PRP	O
is	VBZ	O
almost	RB	O
time	NN	O
for	IN	O
the	DT	O
next	JJ	O
dose	NN	O
.	.	O

For	IN	O
example	NN	O
,	,	O
a	DT	O
patient	NN	WHO
weighing	VBG	WHO
60	CD	WHO
kg	NN	WHO
with	IN	WHO
a	DT	WHO
serum	JJ	WHO
creatinine	NN	WHO
level	NN	WHO
of	IN	O
2	CD	DOS
mg	NNS	UNIT
/	VBD	O
100	CD	DOS
mL	NN	UNIT
could	MD	O
be	VB	O
given	VBN	O
60	CD	DOS
mg	NN	UNIT
(	(	O
1	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
)	)	O
every	DT	FREQ
16	CD	FREQ
hours	NNS	FREQ
(	(	O
2	CD	O
x	RB	O
8	CD	O
)	)	O
.	.	O

As	IN	O
a	DT	O
guideline	NN	O
for	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
11	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
,	,	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
oxycodone	NN	O
dosage	NN	O
usually	RB	O
can	MD	O
be	VB	O
increased	VBN	O
by	IN	O
25	CD	O
%	NN	O
of	IN	O
the	DT	O
current	JJ	O
total	JJ	O
daily	JJ	FREQ
dosage	NN	O
.	.	O

Magnesium	NNP	O
-	:	O
,	,	O
aluminum	SYM	O
-	:	O
,	,	O
or	CC	O
calcium	NN	O
-	:	O
containing	NN	O
antacids	NNS	O
,	,	O
bismuth	NN	O
subsalicylate	NN	O
,	,	O
products	NNS	O
containing	VBG	O
iron	NN	O
,	,	O
or	CC	O
multivitamins	NNS	O
containing	VBG	O
zinc	NN	O
,	,	O
or	CC	O
Videx	NNP	O
,	,	O
(	(	O
Didanosine	NNP	O
)	)	O
,	,	O
chewable	JJ	O
/	NN	O
buffered	VBD	O
tablets	NNS	O
or	CC	O
the	DT	O
pediatric	JJ	O
powder	NN	O
for	IN	O
oral	JJ	O
solution	NN	O
should	MD	O
not	RB	O
be	VB	O
taken	VBN	O
within	IN	O
8	CD	O
hours	NNS	O
before	IN	O
or	CC	O
2	CD	O
hours	NNS	O
after	IN	O
enoxacin	DT	O
administration	NN	O
.	.	O

As	RB	O
much	JJ	O
as	IN	O
400	CD	DOS
mEq	NN	UNIT
may	MD	O
be	VB	O
administered	VBN	O
in	IN	O
a	DT	O
24	CD	O
-	:	O
hour	NN	O
period	NN	O
while	IN	O
monitoring	VBG	O
blood	NN	O
electrolyte	NN	O
concentrations	NNS	O
carefully	RB	O
.	.	O

TABLE	NN	O
3	CD	O

Because	IN	O
heparin	NN	O
disappears	NNS	O
rapidly	RB	O
from	IN	O
the	DT	O
circulation	NN	O
,	,	O
the	DT	O
dose	NN	O
of	IN	O
protamine	NN	O
(	(	O
protamines	NNS	O
)	)	O
sulfate	NN	O
required	VBN	O
also	RB	O
decreases	VBZ	O
rapidly	RB	O
with	IN	O
the	DT	O
time	NN	O
elapsed	VBD	O
following	VBG	O
intravenous	JJ	O
injection	NN	O
of	IN	O
heparin.For	JJ	O
example	NN	O
,	,	O
if	IN	O
the	DT	O
protamine	NN	O
sulfate	NN	O
(	(	O
protamine	NN	O
(	(	O
protamines	NNS	O
)	)	O
s	NN	O
)	)	O
is	VBZ	O
administered	VBN	O
30	CD	O
minutes	NNS	O
after	IN	O
the	DT	O
heparin	NN	O
,	,	O
one	CD	O
-	:	O
half	PDT	O
the	DT	O
usual	JJ	O
dose	NN	O
may	MD	O
be	VB	O
sufficient	JJ	O
.	.	O

A	DT	O
child	NN	WHO
15	CD	WHO
to	TO	WHO
71	CD	WHO
months	NNS	WHO
of	IN	WHO
age	NN	WHO
should	MD	O
receive	VB	O
one	CD	DOS
dose	NN	UNIT
of	IN	O
a	DT	O
product	NN	O
containing	VBG	O
PRP	NNP	O
-	:	O
OMPC	NN	O
.	.	O

The	DT	O
patient	NN	O
or	CC	O
operator	NN	O
should	MD	O
not	RB	O
be	VB	O
able	JJ	O
to	TO	O
touch	VB	O
any	DT	O
live	JJ	O
electrical	JJ	O
parts	NNS	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Dosing	NN	O
and	CC	O
Administration	NNP	O
for	IN	O
Juvenile	NNP	O
Idiopathic	NNP	O
Arthritis	NNP	O

In	IN	O
all	DT	WHO
patients	NNS	WHO
,	,	O
dosage	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
gradually	RB	O
when	WRB	O
discontinuing	VBG	O
therapy	NN	O
or	CC	O
when	WRB	O
decreasing	VBG	O
the	DT	O
daily	JJ	FREQ
dosage	NN	O
.	.	O

Adjust	NNP	O
dosage	NN	O
,	,	O
if	IN	O
indicated	VBN	O
,	,	O
with	IN	O
the	DT	O
individual	JJ	O
components	NNS	O
according	VBG	O
to	TO	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
.	.	O

These	DT	O
data	NNS	O
indicate	VBP	O
that	IN	O
FLUAD	NNP	O
Pediatric™	NNP	O
may	MD	O
be	VB	O
given	VBN	O
to	TO	O
children	NNS	O
in	IN	O
more	JJR	O
than	IN	O
1	CD	O
influenza	NN	O
season	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
adolescents	NNS	WHO
12	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
is	VBZ	O
one	CD	DOS
capsule	NN	UNIT
administered	VBN	O
orally	RB	O
,	,	O
every	DT	O
4	CD	O
to	TO	O
6	CD	FREQ
hours	NNS	FREQ
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

For	IN	O
most	JJS	WHO
patients	NNS	WHO
,	,	O
their	PRP$	O
maintenance	NN	O
dose	NN	O
was	VBD	O
that	IN	O
associated	VBN	O
with	IN	O
response	NN	O
during	IN	O
acute	JJ	O
treatment	NN	O
.	.	O

To	TO	O
minimize	VB	O
the	DT	O
risk	NN	O
of	IN	O
toxicity	NN	O
use	VBP	O
the	DT	O
lowest	JJS	O
possible	JJ	O
dose	NN	O
and	CC	O
the	DT	O
shortest	JJS	O
possible	JJ	O
treatment	NN	O
period	NN	O
to	TO	O
control	VB	O
the	DT	O
condition	NN	O
.	.	O

There	EX	O
are	VBP	O
no	DT	O
data	NNS	O
to	TO	O
provide	VB	O
dosing	VBG	O
recommendations	NNS	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO

The	DT	O
clinical	JJ	O
study	NN	O
was	VBD	O
conducted	VBN	O
by	IN	O
mixing	VBG	O
0.2cc	CD	O
of	IN	O
2	CD	O
%	NN	O
lidocaine	NN	O
with	IN	O
1.3cc	CD	O
of	IN	O
RADIESSE	NNP	O
injectable	JJ	O
implant	NN	O
in	IN	O
the	DT	O
3.0cc	CD	O
BD	NNP	O
syringe	NN	O
.	.	O

When	WRB	O
fully	RB	O
inserted	VBN	O
,	,	O
the	DT	O
implant	JJ	O
rests	NNS	O
inside	IN	O
the	DT	O
cannula	NN	O
so	IN	O
that	DT	O
just	RB	O
the	DT	O
tip	NN	O
of	IN	O
the	DT	O
implant	NN	O
is	VBZ	O
visible	JJ	O
at	IN	O
the	DT	O
beveled	JJ	O
end	NN	O
of	IN	O
the	DT	O
cannula	NN	O
.	.	O

If	IN	O
satisfactory	JJ	O
clinical	JJ	O
response	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
achieved	VBN	O
,	,	O
plasma	JJ	O
levels	NNS	O
should	MD	O
be	VB	O
measured	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
or	CC	O
not	RB	O
they	PRP	O
are	VBP	O
in	IN	O
the	DT	O
therapeutic	JJ	O
range	NN	O
.	.	O

Note	NN	O
:	:	O
As	IN	O
with	IN	O
antibiotic	JJ	O
therapy	NN	O
in	IN	O
general	JJ	O
,	,	O
administration	NN	O
of	IN	O
ZINACEF	NNP	O
should	MD	O
be	VB	O
continued	VBN	O
for	IN	O
a	DT	O
minimum	NN	O
of	IN	O
48	CD	O
to	TO	O
72	CD	O
hours	NNS	O
after	IN	O
the	DT	O
patient	NN	O
becomes	VBZ	O
asymptomatic	JJ	O
or	CC	O
after	IN	O
evidence	NN	O
of	IN	O
bacterial	JJ	O
eradication	NN	O
has	VBZ	O
been	VBN	O
obtained	VBN	O
;	:	O
a	DT	O
minimum	NN	O
of	IN	O
10	CD	PER
days	NNS	PER
of	IN	O
treatment	NN	O
is	VBZ	O
recommended	VBN	O
in	IN	O
infections	NNS	O
caused	VBN	O
by	IN	O
Streptococcus	NNP	O
pyogenes	NNS	O
in	IN	O
order	NN	O
to	TO	O
guard	VB	O
against	IN	O
the	DT	O
risk	NN	O
of	IN	O
rheumatic	JJ	O
fever	NN	O
or	CC	O
glomerulonephritis	NN	O
;	:	O
frequent	JJ	O
bacteriologic	NN	O
and	CC	O
clinical	JJ	O
appraisal	NN	O
is	VBZ	O
necessary	JJ	O
during	IN	O
therapy	NN	O
of	IN	O
chronic	JJ	O
urinary	JJ	O
tract	NN	O
infection	NN	O
and	CC	O
may	MD	O
be	VB	O
required	VBN	O
for	IN	O
several	JJ	PER
months	NNS	PER
after	IN	O
therapy	NN	O
has	VBZ	O
been	VBN	O
completed	VBN	O
;	:	O
persistent	JJ	O
infections	NNS	O
may	MD	O
require	VB	O
treatment	NN	O
for	IN	O
several	JJ	PER
weeks	NNS	PER
;	:	O
and	CC	O
doses	VBZ	O
smaller	JJR	O
than	IN	O
those	DT	O
indicated	VBN	O
above	RB	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
.	.	O

If	IN	O
none	NN	O
are	VBP	O
available	JJ	O
,	,	O
the	DT	O
hair	NN	O
at	IN	O
the	DT	O
site	NN	O
should	MD	O
be	VB	O
clipped	VBN	O
,	,	O
not	RB	O
shaven	RB	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
blastomycosis	NN	O
,	,	O
histoplasmosis	NN	O
and	CC	O
aspergillosis	NN	O
,	,	O
SPORANOX®	NNP	O
(	(	O
itraconazole	JJ	O
injection	NN	O
)	)	O
can	MD	O
be	VB	O
given	VBN	O
as	IN	O
oral	JJ	O
capsules	NNS	O
or	CC	O
intravenously	RB	O
.	.	O

The	DT	O
applesauce	NN	O
should	MD	O
not	RB	O
be	VB	O
warm	JJ	O
because	IN	O
it	PRP	O
could	MD	O
affect	VB	O
the	DT	O
modified	VBN	O
-	:	O
release	NN	O
properties	NNS	O
of	IN	O
this	DT	O
formulation	NN	O
.	.	O

To	TO	O
be	VB	O
certain	JJ	O
the	DT	O
solution	NN	O
reaches	VBZ	O
the	DT	O
systemic	JJ	O
circulation	NN	O
,	,	O
it	PRP	O
should	MD	O
be	VB	O
administered	VBN	O
either	DT	O
directly	RB	O
into	IN	O
a	DT	O
vein	NN	O
or	CC	O
,	,	O
if	IN	O
given	VBN	O
into	IN	O
an	DT	O
IV	NNP	O
line	NN	O
,	,	O
it	PRP	O
should	MD	O
be	VB	O
given	VBN	O
as	IN	O
close	RB	O
to	TO	O
the	DT	O
patient	NN	O
as	IN	O
possible	JJ	O
and	CC	O
followed	VBN	O
by	IN	O
a	DT	O
rapid	JJ	O
saline	NN	O
flush	NN	O
.	.	O

TAXOTERE	NNP	O
final	JJ	O
dilution	NN	O
for	IN	O
infusion	NN	O
,	,	O
if	IN	O
stored	VBN	O
between	IN	O
2°C	CD	O
and	CC	O
25°C	CD	O
(	(	O
36°F	CD	O
and	CC	O
77°F	CD	O
)	)	O
is	VBZ	O
stable	JJ	O
for	IN	O
6	CD	PER
hours	NNS	PER
.	.	O

Although	IN	O
no	DT	O
pharmacokinetic	JJ	O
data	NNS	O
are	VBP	O
available	JJ	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
,	,	O
IMODIUM	NNP	O
(	(	O
loperamide	JJ	O
hcl	NN	O
)	)	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
such	JJ	WHO
patients	NNS	WHO
because	IN	WHO
of	IN	WHO
reduced	JJ	WHO
first	JJ	WHO
pass	NN	WHO
metabolism	NN	WHO
.	.	O

Patients	NNS	WHO
receiving	VBG	WHO
concomitant	JJ	WHO
antiepileptic	JJ	WHO
drugs	NNS	WHO
may	MD	O
be	VB	O
converted	VBN	O
to	TO	O
monotherapy	VB	O
by	IN	O
initiating	VBG	O
treatment	NN	O
with	IN	O
Trileptal	NNP	O
at	IN	O
approximately	RB	O
8	CD	DOS
-	:	O
10	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
a	DT	O
twice	JJ	FREQ
-	:	FREQ
a	DT	O
-	:	O
day	NN	O
regimen	NNS	O
,	,	O
while	IN	O
simultaneously	RB	O
initiating	VBG	O
the	DT	O
reduction	NN	O
of	IN	O
the	DT	O
dose	NN	O
of	IN	O
the	DT	O
concomitant	JJ	O
antiepileptic	JJ	O
drugs	NNS	O
.	.	O

After	IN	O
4	CD	O
minutes	NNS	O
,	,	O
add	VB	O
small	JJ	O
quantities	NNS	O
of	IN	O
water	NN	O
to	TO	O
hair	NN	O
until	IN	O
a	DT	O
good	JJ	O
lather	NN	O
forms	NNS	O
.	.	O

Administer	NNP	O
ZEMPLAR	NNP	O
capsules	NNS	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
week	NN	FREQ
[	NN	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

Prescribers	NNS	O
should	MD	O
monitor	VB	O
patients	NNS	O
for	IN	O
adverse	JJ	O
reactions	NNS	O
and	CC	O
treatment	NN	O
response	NN	O
for	IN	O
several	JJ	PER
weeks	NNS	PER
after	IN	O
starting	VBG	O
VRAYLAR	NNP	O
and	CC	O
after	IN	O
each	DT	O
dosage	NN	O
change	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

DANGER	NNP	O
–	NNP	O
Ultraviolet	NNP	O
radiation	NN	O
–	NNP	O
Follow	NNP	O
your	PRP$	O
physician	NN	O
's	POS	O
instructions	NNS	O
–	VBP	O
Failure	NN	O
to	TO	O
use	VB	O
protective	JJ	O
eyewear	NN	O
may	MD	O
result	VB	O
in	IN	O
eye	NN	O
injury	NN	O
.	.	O

Extensions	NNS	O
of	IN	O
this	DT	O
testing	NN	O
are	VBP	O
the	DT	O
use	NN	O
of	IN	O
CAVERJECT	NNP	O
as	IN	O
an	DT	O
adjunct	NN	O
to	TO	O
laboratory	JJ	O
investigations	NNS	O
,	,	O
such	JJ	O
as	IN	O
duplex	NN	O
or	CC	O
Doppler	NNP	O
imaging	NN	O
,	,	O
133Xenon	CD	O
washout	NN	O
tests	NNS	O
,	,	O
radioisotope	NN	O
penogram	NN	O
,	,	O
and	CC	O
penile	JJ	O
arteriography	NN	O
,	,	O
to	TO	O
allow	VB	O
visualization	NN	O
and	CC	O
assessment	NN	O
of	IN	O
penile	JJ	O
vasculature	NN	O
.	.	O

Tolvaptan	NNP	O
is	VBZ	O
metabolized	VBN	O
by	IN	O
CYP	NNP	O
3A	CD	O
,	,	O
and	CC	O
use	NN	O
with	IN	O
strong	JJ	O
CYP	NNP	O
3A	CD	O
inhibitors	NNS	O
causes	VBZ	O
a	DT	O
marked	JJ	O
(	(	O
5	CD	O
-	:	O
fold	NN	O
)	)	O
increase	NN	O
in	IN	O
exposure	JJ	O
[	NNP	O
see	NN	O
CONTRAINDICATIONS	NNP	O
]	NNP	O
.	.	O

Estrogen	NNP	O
therapy	NN	O
,	,	O
thiazide	IN	O
diuretics	NNS	O
and	CC	O
beta	SYM	O
-	:	O
blockers	NNS	O
,	,	O
are	VBP	O
sometimes	RB	O
associated	VBN	O
with	IN	O
massive	JJ	O
rises	NNS	O
in	IN	O
plasma	NN	O
triglycerides	NNS	O
,	,	O
especially	RB	O
in	IN	O
subjects	NNS	WHO
with	IN	WHO
familial	JJ	WHO
hypertriglyceridemia	NN	WHO
.	.	O

Dextrose	NNP	O
in	IN	O
a	DT	O
final	JJ	O
concentration	NN	O
of	IN	O
up	IN	O
to	TO	O
10	CD	O
%	NN	O
and	CC	O
/	NN	O
or	CC	O
lipid	JJ	O
emulsion	NN	O
may	MD	O
be	VB	O
administered	VBN	O
.	.	O

There	EX	O
is	VBZ	O
little	JJ	O
controlled	JJ	O
experience	NN	O
with	IN	O
the	DT	O
transfer	NN	O
of	IN	O
methadone	NN	O
-	:	O
maintained	VBD	O
patients	NNS	O
to	TO	O
buprenorphine	VB	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
's	POS	O
IOP	NNP	O
is	VBZ	O
not	RB	O
at	IN	O
a	DT	O
satisfactory	JJ	O
level	NN	O
on	IN	O
this	DT	O
regimen	NNS	O
,	,	O
concomitant	JJ	O
therapy	NN	O
with	IN	O
dipivefrin	NN	O
and	CC	O
/	NN	O
or	CC	O
epinephrine	NN	O
,	,	O
and	CC	O
/	NNP	O
or	CC	O
pilocarpine	NN	O
and	CC	O
other	JJ	O
miotics	NNS	O
,	,	O
and	CC	O
/	NNP	O
or	CC	O
systemically	RB	O
administered	VBN	O
carbonic	JJ	O
anhydrase	NN	O
inhibitors	NNS	O
,	,	O
such	JJ	O
as	IN	O
acetazolamide	NN	O
,	,	O
can	MD	O
be	VB	O
instituted	VBN	O
.	.	O

This	DT	O
is	VBZ	O
not	RB	O
complicated	VBN	O
by	IN	O
an	DT	O
overshoot	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
.	.	O

The	DT	O
syringes	NNS	O
should	MD	O
be	VB	O
of	IN	O
small	JJ	O
enough	JJ	O
volume	NN	O
that	IN	O
the	DT	O
prescribed	NNS	O
dose	VBP	O
can	MD	O
be	VB	O
drawn	VBN	O
from	IN	O
the	DT	O
vial	JJ	O
with	IN	O
reasonable	JJ	O
accuracy	NN	O
.	.	O

Ideally	RB	O
,	,	O
the	DT	O
response	NN	O
to	TO	O
therapy	VB	O
should	MD	O
be	VB	O
evaluated	VBN	O
using	VBG	O
HbA	NNP	O
(	(	O
glycosylated	VBN	O
hemoglobin	NN	O
)	)	O
,	,	O
which	WDT	O
is	VBZ	O
a	DT	O
better	JJR	O
indicator	NN	O
of	IN	O
long	JJ	O
-	:	O
term	NN	O
glycemic	VBZ	O
control	NN	O
than	IN	O
FPG	NNP	O
alone	RB	O
.	.	O

Shake	VB	O
the	DT	O
single	JJ	O
-	:	O
dose	JJ	UNIT
vial	JJ	UNIT
or	CC	O
single	JJ	O
-	:	O
dose	NN	UNIT
prefilled	VBD	O
syringe	RB	O
well	RB	O
to	TO	O
obtain	VB	O
a	DT	O
slightly	RB	O
opaque	JJ	O
,	,	O
white	JJ	O
suspension	NN	O
before	IN	O
withdrawal	NN	O
and	CC	O
use	NN	O
.	.	O

Use	NNP	O
only	RB	O
if	IN	O
solution	NN	O
is	VBZ	O
clear	JJ	O
and	CC	O
the	DT	O
seal	NN	O
is	VBZ	O
intact	JJ	O
.	.	O

Because	IN	O
of	IN	O
the	DT	O
patient	NN	O
-	:	O
to	TO	O
-	:	O
patient	NN	O
variation	NN	O
in	IN	O
melphalan	NN	O
plasma	NN	O
levels	NNS	O
following	VBG	O
oral	JJ	O
administration	NN	O
of	IN	O
the	DT	O
drug	NN	O
,	,	O
several	JJ	O
investigators	NNS	O
have	VBP	O
recommended	VBN	O
that	IN	O
the	DT	O
dosage	NN	O
of	IN	O
ALKERAN	NNP	O
(	(	O
melphalan	NN	O
)	)	O
be	VB	O
cautiously	RB	O
escalated	VBN	O
until	IN	O
some	DT	O
myelosuppression	NN	O
is	VBZ	O
observed	VBN	O
in	IN	O
order	NN	O
to	TO	O
assure	VB	O
that	DT	O
potentially	RB	O
therapeutic	JJ	O
levels	NNS	O
of	IN	O
the	DT	O
drug	NN	O
have	VBP	O
been	VBN	O
reached	VBN	O
.	.	O

5	CD	DOS
mg	NN	UNIT
:	:	O
opaque	NN	O
green	JJ	O
cap	NN	O
and	CC	O
opaque	JJ	O
pale	NN	O
green	JJ	O
body	NN	O
with	IN	O
“	JJ	O
5	CD	DOS
mg	NN	UNIT
”	NN	O
on	IN	O
the	DT	O
cap	NN	O
and	CC	O
“	NNP	O
SONATA	NNP	O
”	NNP	O
on	IN	O
the	DT	O
body	NN	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
regimen	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
bacterial	JJ	O
corneal	NN	O
ulcer	NN	O
is	VBZ	O
:	:	O

Appropriate	JJ	O
diluents	NNS	O
include	VBP	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
USP	NNP	O
(	(	O
normal	JJ	O
saline	NN	O
)	)	O
,	,	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
USP	NNP	O
(	(	O
D5W	NNP	O
)	)	O
,	,	O
or	CC	O
Lactated	VBD	O
Ringers	NNPS	O
Solution	NNP	O
.	.	O

RAZADYNE®	NNP	O
ER	NNP	O
extended	VBD	O
-	:	O
release	NN	O
capsules	NNS	O
should	MD	O
be	VB	O
administered	VBN	O
once	RB	FREQ
daily	JJ	FREQ
in	IN	O
the	DT	O
morning	NN	O
,	,	O
preferably	RB	O
with	IN	O
food	NN	O
.	.	O

Figure	NN	O
5	CD	O

As	IN	O
improvement	NN	O
occurs	VBZ	O
dosage	NN	O
can	MD	O
usually	RB	O
be	VB	O
reduced	VBN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

(	(	O
See	VB	O
PRECAUTIONS	NNP	O
:	:	O
Pediatric	JJ	O
Use	NNP	O
.	.	O
)	)	O

If	IN	O
dilution	NN	O
is	VBZ	O
required	VBN	O
,	,	O
GAMUNEX	NNP	O
(	(	O
immune	JJ	O
globulin	NN	O
intravenous	JJ	O
(	(	O
human	JJ	O
)	)	O
10	CD	O
%	NN	O
)	)	O
may	MD	O
be	VB	O
diluted	VBN	O
with	IN	O
5	CD	O
%	NN	O
dextrose	NN	O
in	IN	O
water	NN	O
(	(	O
D5	NNP	O
/	NNP	O
W	NNP	O
)	)	O
.	.	O

PROTONIX	NNP	O
I.V	NNP	O
.	.	O

Serum	NNP	O
calcium	NN	O
and	CC	O
serum	NN	O
phosphorus	NN	O
should	MD	O
be	VB	O
measured	VBN	O
within	IN	O
1	CD	PER
week	NN	PER
and	CC	O
intact	JJ	O
parathyroid	NN	O
hormone	NN	O
(	(	O
iPTH	NN	O
)	)	O
should	MD	O
be	VB	O
measured	VBN	O
1	CD	PER
to	TO	O
4	CD	PER
weeks	NNS	PER
after	IN	O
initiation	NN	O
or	CC	O
dose	JJ	O
adjustment	NN	O
of	IN	O
Sensipar	NNP	O
[	NNP	O
see	VBP	O
Monitoring	VBG	O
for	IN	O
Hypocalcemia	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
Fluvoxamine	NNP	O
Maleate	NNP	O
Tablets	NNP	O
in	IN	O
pediatric	JJ	WHO
populations	NNS	WHO
(	(	WHO
ages	VBZ	WHO
8	CD	WHO
-	:	WHO
17	CD	WHO
years	NNS	WHO
)	)	WHO
is	VBZ	O
25	CD	DOS
mg	NN	UNIT
,	,	O
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	FREQ
dose	NN	O
at	IN	O
bedtime	NN	O
.	.	O

[	NNS	O
See	NNP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
.	.	O
]	NN	O

Specific	JJ	O
dosing	VBG	O
recommendations	NNS	O
are	VBP	O
provided	VBN	O
depending	VBG	O
upon	IN	O
concomitant	JJ	O
AEDs	NNP	O
or	CC	O
other	JJ	O
concomitant	JJ	O
medications	NNS	O
.	.	O

When	WRB	O
administering	VBG	O
Dopamine	NNP	O
Hydrochloride	NNP	O
(	(	O
or	CC	O
any	DT	O
potent	JJ	O
medication	NN	O
)	)	O
by	IN	O
continuous	JJ	O
intravenous	JJ	O
infusion	NN	O
,	,	O
it	PRP	O
is	VBZ	O
advisable	JJ	O
to	TO	O
use	VB	O
a	DT	O
precision	NN	O
volume	NN	O
control	NN	O
intravenous	JJ	O
set	NN	O
.	.	O

Initiate	NNP	O
treatment	NN	O
with	IN	O
a	DT	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
14	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
in	IN	O
2	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
(	(	O
7	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NNP	O
twice	RB	FREQ
daily	RB	FREQ
)	)	O
.	.	O

If	IN	O
there	EX	O
is	VBZ	O
a	DT	O
partial	JJ	O
response	NN	O
,	,	O
the	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
by	IN	O
2.5	CD	DOS
micrograms	NNS	UNIT
to	TO	O
a	DT	O
dose	NN	O
of	IN	O
5	CD	DOS
micrograms	NNS	UNIT
and	CC	O
then	RB	O
in	IN	O
increments	NNS	O
of	IN	O
5	CD	DOS
to	TO	O
10	CD	DOS
micrograms	NNS	UNIT
,	,	O
depending	VBG	O
upon	IN	O
erectile	JJ	O
response	NN	O
,	,	O
until	IN	O
the	DT	O
dose	NN	O
that	WDT	O
produces	VBZ	O
an	DT	O
erection	NN	O
suitable	NN	O
for	IN	O
intercourse	NN	O
and	CC	O
not	RB	O
exceeding	VBG	O
a	DT	O
duration	NN	O
of	IN	O
1	CD	O
hour	NN	O
is	VBZ	O
reached	VBN	O
.	.	O

The	DT	O
following	VBG	O
recommended	VBD	O
dosages	NNS	O
for	IN	O
Tofranil	NNP	O
-	:	O
PM	NN	O
should	MD	O
be	VB	O
modified	VBN	O
as	IN	O
necessary	JJ	O
by	IN	O
the	DT	O
clinical	JJ	O
response	NN	O
and	CC	O
any	DT	O
evidence	NN	O
of	IN	O
intolerance	NN	O
.	.	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dosage	NN	O
is	VBZ	O
100	CD	DOS
to	TO	O
150	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
.	.	O

False	NNP	O
positive	JJ	O
tuberculin	NN	O
reactions	NNS	O
can	MD	O
occur	VB	O
in	IN	O
individuals	NNS	WHO
who	WP	WHO
have	VBP	WHO
been	VBN	WHO
infected	VBN	WHO
with	IN	WHO
other	JJ	WHO
mycobacteria	NNS	WHO
,	,	O
including	VBG	O
vaccination	NN	O
with	IN	O
BCG	NNP	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
started	VBN	O
on	IN	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

The	DT	O
admixed	JJ	O
solution	NN	O
may	MD	O
be	VB	O
stored	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
and	CC	O
must	MD	O
be	VB	O
used	VBN	O
within	IN	O
24	CD	O
hours	NNS	O
from	IN	O
the	DT	O
time	NN	O
of	IN	O
initial	JJ	O
reconstitution	NN	O
.	.	O

During	IN	O
treatment	NN	O
,	,	O
the	DT	O
following	JJ	O
information	NN	O
should	MD	O
be	VB	O
collected	VBN	O
:	:	O

Intravenous	JJ	O
infusions	NNS	O
of	IN	O
tigecycline	NN	O
for	IN	O
injection	NN	O
should	MD	O
be	VB	O
administered	VBN	O
over	IN	O
approximately	RB	O
30	CD	O
to	TO	O
60	CD	O
minutes	NNS	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

Do	VB	O
not	RB	O
take	VB	O
a	DT	O
missed	JJ	O
dose	NN	O
of	IN	O
TAFINLAR	NNP	O
within	IN	O
6	CD	O
hours	NNS	O
of	IN	O
the	DT	O
next	JJ	O
dose	NN	O
of	IN	O
TAFINLAR	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
starting	VBG	O
dosage	NN	O
of	IN	O
SYNDROS	NNP	O
is	VBZ	O
2.1	CD	DOS
mg	NN	UNIT
orally	RB	O
twice	JJ	FREQ
daily	RB	FREQ
,	,	O
one	CD	O
hour	NN	O
before	IN	O
lunch	NN	O
and	CC	O
one	CD	O
hour	NN	O
before	IN	O
dinner	NN	O
.	.	O

If	IN	O
the	DT	O
infusion	NN	O
reaction	NN	O
recurs	NN	O
,	,	O
stop	VB	O
the	DT	O
EMPLICITI	NNP	O
infusion	NN	O
and	CC	O
do	VBP	O
not	RB	O
restart	VB	O
on	IN	O
that	DT	O
day	NN	O
[	VBD	O
see	JJ	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Each	DT	O
dose	NN	O
should	MD	O
be	VB	O
administered	VBN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
at	IN	O
least	JJS	O
60	CD	O
minutes	NNS	O
.	.	O

Solutions	NNS	O
that	WDT	O
are	VBP	O
discolored	VBN	O
and	CC	O
or	CC	O
contain	VB	O
particulate	JJ	O
matter	NN	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
and	CC	O
any	DT	O
unused	JJ	O
portion	NN	O
of	IN	O
a	DT	O
cartridge	NN	O
of	IN	O
2	CD	O
%	NN	O
Xylocaine	JJ	O
DENTAL	NNP	O
should	MD	O
be	VB	O
discarded	VBN	O
.	.	O

Concomitant	JJ	O
Therapy	NNP	O
(	(	O
See	NNP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
,	,	O
Drug	NNP	O
Interactions	NNP	O
,	,	O
and	CC	O
/	NNP	O
or	CC	O
PRECAUTIONS	NNP	O
:	:	O
DRUG	NN	O
INTERACTIONS	NNP	O
.	.	O
)	)	O

The	DT	O
Following	NNP	O
Equipment	NNP	O
is	VBZ	O
Needed	VBN	O
for	IN	O
Implant	JJ	O
Insertion	NN	O
:	:	O

Precedex	NN	O
infusion	NN	O
should	MD	O
not	RB	O
be	VB	O
co	JJ	O
-	:	O
administered	VBN	O
through	IN	O
the	DT	O
same	JJ	O
intravenous	JJ	O
catheter	NN	O
with	IN	O
blood	NN	O
or	CC	O
plasma	NN	O
because	IN	O
physical	JJ	O
compatibility	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	O

OPANA	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
on	IN	O
an	DT	O
empty	JJ	O
stomach	NN	O
,	,	O
at	IN	O
least	JJS	O
one	CD	O
hour	NN	O
prior	RB	O
to	TO	O
or	CC	O
two	CD	O
hours	NNS	O
after	IN	O
eating	VBG	O
[	JJ	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Store	NN	O
in	IN	O
a	DT	O
freezer	NN	O
capable	JJ	O
of	IN	O
maintaining	VBG	O
a	DT	O
temperature	NN	O
at	IN	O
or	CC	O
below	IN	O
-	:	O
20°C	CD	O
(	(	O
-	:	O
4°F	CD	O
)	)	O
.	.	O

Such	JJ	O
observations	NNS	O
should	MD	O
be	VB	O
taken	VBN	O
into	IN	O
consideration	NN	O
when	WRB	O
determining	VBG	O
the	DT	O
advisability	NN	O
of	IN	O
continuing	VBG	O
therapy	NN	O
with	IN	O
EPIVIR	NNP	O
-	:	O
HBV	NN	O
.	.	O

The	DT	O
need	NN	O
for	IN	O
continued	JJ	O
treatment	NN	O
should	MD	O
be	VB	O
reassessed	VBN	O
periodically	RB	O
,	,	O
as	IN	O
spontaneous	JJ	O
improvement	NN	O
of	IN	O
PBA	NNP	O
occurs	VBZ	O
in	IN	O
some	DT	WHO
patients	NNS	WHO
.	.	O

However	RB	O
,	,	O
it	PRP	O
is	VBZ	O
advisable	JJ	O
to	TO	O
ensure	VB	O
that	IN	O
patients	NNS	O
are	VBP	O
well	RB	O
hydrated	VBN	O
prior	RB	O
to	TO	O
examination	NN	O
.	.	O

Administration	NN	O
of	IN	O
dexamethasone	NN	O
on	IN	O
days	NNS	O
2	CD	O
to	TO	O
4	CD	O
is	VBZ	O
not	RB	O
necessary	JJ	O
[	NNS	O
see	VBP	O
Clinical	JJ	O
Studies	NNS	O
,	,	O
Table	JJ	O
7	CD	O
]	NN	O
.	.	O

Do	NNP	O
not	RB	O
swallow	VB	O
ARIDOL	NNP	O
(	(	O
mannitol	JJ	O
inhalation	NN	O
powder	NN	O
)	)	O
capsules	NNS	O
.	.	O

Pediatric	NNP	O
Dose	NNP	O
:	:	O
The	DT	O
weekly	JJ	O
suppressive	JJ	O
dosage	NN	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
calculated	VBN	O
as	IN	O
base	NN	O
,	,	O
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
but	CC	O
should	MD	O
not	RB	O
exceed	VB	O
the	DT	WHO
adult	NN	WHO
dose	JJ	O
regardless	NN	O
of	IN	O
weight	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
incomplete	JJ	WHO
viral	JJ	WHO
suppression	NN	WHO
(	(	O
HBV	NNP	O
DNA	NNP	O
greater	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
300	CD	DOS
copies	NNS	UNIT
per	IN	O
mL	NN	O
)	)	O
after	IN	O
24	CD	PER
weeks	NNS	PER
of	IN	O
treatment	NN	O
,	,	O
alternate	JJ	O
therapy	NN	O
should	MD	O
be	VB	O
instituted	VBN	O
.	.	O

If	IN	O
an	DT	O
excessive	JJ	O
amount	NN	O
of	IN	O
synovial	JJ	O
fluid	NN	O
is	VBZ	O
present	JJ	O
in	IN	O
the	DT	O
joint	NN	O
,	,	O
some	DT	O
,	,	O
but	CC	O
not	RB	O
all	DT	O
,	,	O
should	MD	O
be	VB	O
aspirated	VBN	O
to	TO	O
aid	VB	O
in	IN	O
the	DT	O
relief	NN	O
of	IN	O
pain	NN	O
and	CC	O
to	TO	O
prevent	VB	O
undue	JJ	O
dilution	NN	O
of	IN	O
the	DT	O
steroid	NN	O
.	.	O

Physician	JJ	O
supervision	NN	O
of	IN	O
the	DT	O
dosage	NN	O
is	VBZ	O
required	VBN	O
.	.	O

Velphoro	NNP	O
must	MD	O
be	VB	O
administered	VBN	O
with	IN	O
meals	NNS	O
.	.	O

Alfentanil	NN	O

The	DT	O
intake	NN	O
of	IN	O
cysteine	NN	O
by	IN	O
the	DT	O
preterm	NN	WHO
infant	NN	WHO
ingesting	VBG	O
maternal	JJ	O
milk	NN	O
is	VBZ	O
approximately	RB	O
78	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

Lower	JJR	O
Neoral®	NNP	O
doses	NNS	O
may	MD	O
be	VB	O
sufficient	JJ	O
as	IN	O
maintenance	NN	O
therapy	NN	O
.	.	O

During	IN	O
shipment	NN	O
,	,	O
to	TO	O
insure	VB	O
that	IN	O
there	EX	O
is	VBZ	O
no	DT	O
loss	NN	O
of	IN	O
potency	NN	O
,	,	O
the	DT	O
vaccine	NN	O
must	MD	O
be	VB	O
maintained	VBN	O
at	IN	O
a	DT	O
temperature	NN	O
of	IN	O
10°C	CD	O
(	(	O
50°F	CD	O
)	)	O
or	CC	O
less	JJR	O
.	.	O

KALETRA	NNP	O
oral	JJ	O
solution	NN	O
contains	VBZ	O
42.4	CD	O
%	NN	O
(	(	O
v	JJ	O
/	NNP	O
v	NN	O
)	)	O
alcohol	NN	O
and	CC	O
15.3	CD	O
%	NN	O
(	(	O
w	JJ	O
/	NNP	O
v	NN	O
)	)	O
propylene	NN	O
glycol	NN	O
.	.	O

Since	IN	O
a	DT	O
doxorubicin	NN	O
dose	JJ	O
reduction	NN	O
is	VBZ	O
recommended	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
hyperbilirubinemia	NN	O
,	,	O
the	DT	O
ZINECARD	NNP	O
dosage	NN	O
should	MD	O
be	VB	O
proportionately	RB	O
reduced	VBN	O
(	(	O
maintaining	VBG	O
the	DT	O
10:1	CD	O
ratio	NN	O
)	)	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
.	.	O

Administer	NNP	O
ARZERRA	NNP	O
in	IN	O
an	DT	O
environment	NN	O
where	WRB	O
facilities	NNS	O
to	TO	O
adequately	RB	O
monitor	VB	O
and	CC	O
treat	VB	O
infusion	NN	O
reactions	NNS	O
are	VBP	O
available	JJ	O
[	JJ	O
see	NN	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Do	NNP	O
not	RB	O
ingest	VB	O
foods	NNS	O
(	(	O
e.g	NN	O
,	,	O
grapefruit	NN	O
,	,	O
grapefruit	NN	O
juice	NN	O
)	)	O
or	CC	O
nutritional	JJ	O
supplements	NNS	O
that	WDT	O
are	VBP	O
known	VBN	O
to	TO	O
inhibit	VB	O
cytochrome	JJ	O
P450	NNP	O
while	IN	O
taking	VBG	O
COMETRIQ	NNP	O
.	.	O

If	IN	O
back	JJ	O
leakage	NN	O
occurs	NN	O
,	,	O
the	DT	O
hips	NNS	O
are	VBP	O
elevated	VBN	O
on	IN	O
pillows	NNS	O
or	CC	O
a	DT	O
knee	JJ	O
-	:	O
chest	JJS	O
position	NN	O
is	VBZ	O
taken	VBN	O
temporarily	RB	O
.	.	O

Selection	NN	O
of	IN	O
the	DT	O
appropriate	JJ	O
dosage	NN	O
strength	NN	O
(	(	O
Auvi	NNP	O
-	:	O
Q	VBZ	O
0.3	CD	DOS
mg	NN	UNIT
or	CC	O
Auvi	NNP	O
-	:	O
Q	VBZ	O
0.15	CD	DOS
mg	NN	UNIT
)	)	O
is	VBZ	O
determined	JJ	O
according	VBG	O
to	TO	O
patient	NN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
recommended	JJ	O
doses	NNS	O
for	IN	O
women	NNS	WHO
and	CC	WHO
men	NNS	WHO
are	VBP	O
different	JJ	O
because	IN	O
women	NNS	O
clear	JJ	O
zolpidem	NN	O
from	IN	O
the	DT	O
body	NN	O
at	IN	O
a	DT	O
lower	JJR	O
rate	NN	O
than	IN	O
men	NNS	O
[	VBP	O
see	NN	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Skin	NNP	O
reactions	NNS	O
may	MD	O
occur	VB	O
with	IN	O
accidental	JJ	O
exposure	NN	O
,	,	O
and	CC	O
the	DT	O
use	NN	O
of	IN	O
gloves	NNS	O
during	IN	O
dose	JJ	O
preparation	NN	O
and	CC	O
administration	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

Discontinue	VB	O
the	DT	O
injection	NN	O
and	CC	O
discard	VB	O
the	DT	O
syringe	NN	O
and	CC	O
the	DT	O
needle	NN	O
(	(	O
reconstitute	VB	O
a	DT	O
new	JJ	O
dose	NN	O
for	IN	O
the	DT	O
patient	NN	O
)	)	O
.	.	O

For	IN	O
prophylaxis	NN	O
of	IN	O
nausea	NN	O
and	CC	O
vomiting	NN	O
,	,	O
as	IN	O
during	IN	O
surgery	NN	O
and	CC	O
the	DT	O
postoperative	JJ	O
period	NN	O
,	,	O
the	DT	O
average	NN	O
dose	NN	O
is	VBZ	O
25	CD	DOS
mg	NN	UNIT
repeated	VBN	O
at	IN	O
4	CD	O
-	:	O
to	TO	O
6	CD	O
-	:	O
hour	NN	O
intervals	NNS	O
,	,	O
as	IN	O
necessary	JJ	O
.	.	O

If	IN	O
you	PRP	O
must	MD	O
administer	VB	O
JADENU	NNP	O
with	IN	O
1	CD	O
of	IN	O
these	DT	O
agents	NNS	O
,	,	O
consider	VB	O
increasing	VBG	O
the	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
JADENU	NNP	O
by	IN	O
50	CD	O
%	NN	O
,	,	O
and	CC	O
monitor	NN	O
serum	NN	O
ferritin	NN	O
levels	NNS	O
and	CC	O
clinical	JJ	O
responses	NNS	O
for	IN	O
further	JJ	O
dose	JJ	O
modification	NN	O
[	NNP	O
see	VBP	O
Transfusional	NNP	O
Iron	NNP	O
Overload	NNP	O
,	,	O
Iron	NNP	O
Overload	NNP	O
In	IN	O
Non	NNP	O
-	:	O
Transfusion	NN	O
-	:	O
Dependent	JJ	O
Thalassemia	NNP	O
Syndromes	NNP	O
,	,	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

DESOGEN®	NNP	O
may	MD	O
be	VB	O
initiated	VBN	O
using	VBG	O
either	CC	O
a	DT	O
Sunday	NNP	O
start	NN	O
or	CC	O
a	DT	O
Day	NNP	O
1	CD	O
start	NN	O
.	.	O

A	DT	O
decrease	NN	O
in	IN	O
intraocular	JJ	O
pressure	NN	O
should	MD	O
occur	VB	O
within	IN	O
a	DT	O
few	JJ	O
hours	NNS	O
.	.	O

Recommended	VBN	O
Dose	NNP	O
and	CC	O
Schedule	NNP	O
for	IN	O
IMLYGIC	NNP	O

Because	IN	O
of	IN	O
the	DT	O
potential	NN	O
for	IN	O
accumulation	NN	O
of	IN	O
rimantadine	NN	O
metabolites	NNS	O
during	IN	O
multiple	JJ	O
dosing	NN	O
,	,	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
or	CC	WHO
renal	JJ	WHO
impairment	NN	WHO
should	MD	O
be	VB	O
monitored	VBN	O
for	IN	O
adverse	JJ	O
effects	NNS	O
.	.	O

after	IN	O
2	CD	O
courses	NNS	O
,	,	O
surgery	NN	O
may	MD	O
be	VB	O
necessary	JJ	O
for	IN	O
closure	NN	O
of	IN	O
the	DT	O
ductus	NN	O
arteriosus	NN	O
.	.	O

Tablets	NNS	O
must	MD	O
be	VB	O
taken	VBN	O
in	IN	O
the	DT	O
order	NN	O
directed	VBD	O
on	IN	O
the	DT	O
blister	NN	O
pack	NN	O
.	.	O

Zithranol	NNP	O
Shampoo	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
onto	IN	O
wet	JJ	O
scalp	JJ	O
3	CD	FREQ
to	TO	O
4	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
week	NN	FREQ
(	(	O
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
the	DT	O
physician	NN	O
)	)	O
.	.	O

Junel®	NNP	O
Fe	NNP	O
28	CD	O
provides	VBZ	O
a	DT	O
continuous	JJ	O
administration	NN	O
regimen	NNS	O
consisting	VBG	O
of	IN	O
21	CD	O
light	JJ	O
yellow	NN	O
or	CC	O
pink	JJ	O
tablets	NNS	O
of	IN	O
Junel®	NNP	O
and	CC	O
7	CD	O
brown	JJ	O
nonhormone	RB	O
containing	VBG	O
tablets	NNS	O
of	IN	O
ferrous	JJ	O
fumarate	NN	O
.	.	O

Tables	NNS	O
1	CD	O
and	CC	O
2	CD	O
provide	VBP	O
the	DT	O
weight	NN	O
-	:	O
based	VBN	O
loading	NN	O
and	CC	O
maintenance	NN	O
doses	NNS	O
,	,	O
respectively	RB	O
,	,	O
of	IN	O
CETYLEV	NNP	O
for	IN	O
patients	NNS	WHO
weighing	VBG	WHO
20	CD	WHO
kg	NN	WHO
and	CC	WHO
greater	JJR	WHO
.	.	O

EXCEEDING	IN	O
THE	NNP	O
RECOMMENDED	NNP	O
DOSAGE	NNP	O
MAY	NNP	O
RESULT	NNP	O
IN	NNP	O
AN	NNP	O
INCREASED	NNP	O
INCIDENCE	NNP	O
OF	NNP	O
SIDE	NNP	O
EFFECTS	NNP	O
.	.	O

Once	RB	O
the	DT	O
yellow	NN	O
flare	NN	O
is	VBZ	O
observed	VBN	O
,	,	O
perform	VB	O
ultrasound	JJ	O
pachymetry	NN	O
.	.	O

Inject	VB	O
the	DT	O
entire	JJ	O
contents	NNS	O
of	IN	O
the	DT	O
syringe	NN	O
intramuscularly	RB	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
length	NN	O
and	CC	O
density	NN	O
of	IN	O
hair	NN	O
,	,	O
some	DT	WHO
patients	NNS	WHO
may	MD	O
require	VB	O
2	CD	O
ounces	NNS	O
of	IN	O
Lindane	NNP	O
Shampoo	NNP	O
.	.	O

where	WRB	O
age	NN	O
is	VBZ	O
in	IN	O
years	NNS	O
,	,	O
weight	NN	O
is	VBZ	O
in	IN	O
kilograms	NNS	O
and	CC	O
SCr	NNP	O
is	VBZ	O
serum	JJ	O
creatinine	NN	O
in	IN	O
mg	NN	UNIT
/	NN	O
dL	NN	O
.	.	O

The	DT	O
usual	JJ	O
schedule	NN	O
should	MD	O
be	VB	O
resumed	VBN	O
thereafter	RB	O
.	.	O

If	IN	O
necessary	JJ	O
,	,	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
drug	NN	O
can	MD	O
be	VB	O
abolished	VBN	O
promptly	RB	O
by	IN	O
atropine	NN	O
(	(	O
see	VB	O
OVERDOSAGE	NNP	O
)	)	O
.	.	O

If	IN	O
significant	JJ	O
healing	NN	O
or	CC	O
pain	NN	O
reduction	NN	O
has	VBZ	O
not	RB	O
occurred	VBN	O
in	IN	O
10	CD	PER
days	NNS	PER
,	,	O
consult	VB	O
your	PRP$	O
dentist	NN	O
or	CC	O
physician	NN	O
.	.	O

Additional	NNP	O
body	NN	O
garments	NNS	O
should	MD	O
be	VB	O
used	VBN	O
based	VBN	O
upon	IN	O
the	DT	O
task	NN	O
being	VBG	O
performed	VBN	O
(	(	O
e.g	NN	O
,	,	O
sleevelets	NNS	O
,	,	O
apron	NN	O
,	,	O
gauntlets	NNS	O
,	,	O
disposable	JJ	O
suits	NNS	O
)	)	O
to	TO	O
avoid	VB	O
exposed	JJ	O
skin	NN	O
surfaces	NNS	O
and	CC	O
inhalation	NN	O
of	IN	O
vapors	NNS	O
and	CC	O
dust	NN	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Dose	JJ	O
Modifications	NNS	O
during	IN	O
Cycles	NNS	O
of	IN	O
Combination	NNP	O
VELCADE	NNP	O
,	,	O
Melphalan	NNP	O
and	CC	O
Prednisone	NNP	O
Therapy	NNP	O

These	DT	O
recommendations	NNS	O
apply	VBP	O
also	RB	O
to	TO	O
distention	VB	O
complicating	VBG	O
pneumonia	NN	O
or	CC	O
other	JJ	O
acute	JJ	O
toxemias	NN	O
.	.	O

Patients	NNS	WHO
100	CD	WHO
kg	NNS	WHO
and	CC	WHO
over	RB	WHO
will	MD	O
require	VB	O
a	DT	O
minimum	NN	O
of	IN	O
2	CD	O
bags	NNS	O
.	.	O

Manufactured	VBN	O
by	IN	O
GE	NNP	O
Healthcare	NNP	O
AS	NNP	O
,	,	O
Oslo	NNP	O
,	,	O
Norway	NNP	O
.	.	O

When	WRB	O
clinically	RB	O
indicated	VBN	O
,	,	O
crosshatching	VBG	O
thick	JJ	O
eschar	NN	O
with	IN	O
a	DT	O
#	#	O
10	CD	O
blade	NN	O
allows	NNS	O
Collagenase	NNP	O
Santyl®	NNP	O
Ointment	NNP	O
more	JJR	O
surface	NN	O
contact	NN	O
with	IN	O
necrotic	JJ	O
debris	NN	O
.	.	O

This	DT	O
usually	RB	O
occurs	VBZ	O
within	IN	O
2	CD	O
-	:	O
3	CD	PER
days	NNS	PER
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ATROVENT	NNP	O
Nasal	NNP	O
Spray	NNP	O
0.06	CD	O
%	NN	O
is	VBZ	O
two	CD	DOS
sprays	NNS	UNIT
(	(	O
84	CD	DOS
mcg	NN	UNIT
)	)	O
per	IN	FREQ
nostril	FW	FREQ
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
(	(	O
total	JJ	O
dose	RB	O
672	CD	DOS
mcg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
)	)	O
in	IN	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
age	NN	WHO
5	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
therapy	NN	O
be	VB	O
initiated	VBN	O
at	IN	O
25	CD	DOS
to	TO	O
50	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
followed	VBN	O
by	IN	O
titration	NN	O
to	TO	O
an	DT	O
effective	JJ	O
dose	NN	O
in	IN	O
increments	NNS	O
of	IN	O
25	CD	DOS
to	TO	O
50	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
every	DT	FREQ
week	NN	FREQ
.	.	O

Multiple	JJ	O
administration	NN	O
of	IN	O
ZINGO®	NNP	O
at	IN	O
the	DT	O
same	JJ	O
location	NN	O
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
for	IN	O
MDD	NNP	O
is	VBZ	O
150	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
morning	NN	O
.	.	O

Re	NNP	O
-	:	O
evaluate	NN	O
eGFR	VBZ	O
48	CD	O
hours	NNS	O
after	IN	O
the	DT	O
imaging	JJ	O
procedure	NN	O
;	:	O
restart	VB	O
INVOKAMET	NNP	O
XR	NNP	O
if	IN	O
renal	JJ	O
function	NN	O
is	VBZ	O
stable	JJ	O
[	JJ	O
see	NN	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Except	IN	O
when	WRB	O
opened	VBN	O
and	CC	O
sprinkled	VBN	O
on	IN	O
applesauce	NN	O
,	,	O
as	IN	O
described	VBN	O
above	IN	O
,	,	O
NAMZARIC	NNP	O
capsules	NNS	O
should	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
.	.	O

While	IN	O
methadone	NN	O
's	POS	O
duration	NN	O
of	IN	O
analgesic	JJ	O
action	NN	O
(	(	O
typically	RB	O
4	CD	O
to	TO	O
8	CD	O
hours	NNS	O
)	)	O
in	IN	O
the	DT	O
setting	NN	O
of	IN	O
single	JJ	DOS
-	:	O
dose	JJ	O
studies	NNS	O
approximates	VBZ	O
that	IN	O
of	IN	O
morphine	NN	O
,	,	O
methadone	NN	O
's	POS	O
plasma	JJ	O
elimination	NN	O
half	NN	O
-	:	O
life	NN	O
is	VBZ	O
substantially	RB	O
longer	JJR	O
than	IN	O
that	DT	O
of	IN	O
morphine	NN	O
(	(	O
typically	RB	O
8	CD	O
to	TO	O
59	CD	O
hours	NNS	O
vs.	FW	O
1	CD	O
to	TO	O
5	CD	O
hours	NNS	O
)	)	O
.	.	O

While	IN	O
there	EX	O
are	VBP	O
useful	JJ	O
tables	NNS	O
of	IN	O
opioid	JJ	O
equivalents	NNS	O
readily	RB	O
available	JJ	O
,	,	O
there	EX	O
is	VBZ	O
substantial	JJ	O
inter	JJ	O
-	:	O
patient	NN	O
variability	NN	O
in	IN	O
the	DT	O
relative	JJ	O
potency	NN	O
of	IN	O
different	JJ	O
opioid	JJ	O
drugs	NNS	O
and	CC	O
products	NNS	O
.	.	O

The	DT	O
benzyl	NN	O
alcohol	NN	O
contained	VBN	O
in	IN	O
MESNEX	NNP	O
injection	NN	O
vials	NNS	O
can	MD	O
reduce	VB	O
the	DT	O
stability	NN	O
of	IN	O
ifosfamide	NN	O
.	.	O

If	IN	O
unacceptable	JJ	O
opioid	JJ	O
-	:	O
related	JJ	O
adverse	JJ	O
reactions	NNS	O
are	VBP	O
observed	VBN	O
,	,	O
consider	VB	O
reducing	VBG	O
the	DT	O
dosage	NN	O
.	.	O

Treatment	NN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
anxiety	NN	WHO
should	MD	O
be	VB	O
initiated	VBN	O
with	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.25	CD	DOS
to	TO	O
0.5	CD	DOS
mg	NNS	UNIT
given	VBN	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

DO	NNP	O
NOT	NNP	O
USE	NNP	O
EQUIPMENT	NNP	O
CONTAINING	NNP	O
ALUMINUM	NNP	O
(	(	O
e.g	NN	O
,	,	O
NEEDLES	NNP	O
,	,	O
CANNULAE	NNP	O
)	)	O
THAT	NNP	O
WOULD	NNP	O
COME	NNP	O
IN	NNP	O
CONTACT	NNP	O
WITH	NNP	O
THE	NNP	O
DRUG	NNP	O
SOLUTION	NNP	O
.	.	O

Table	JJ	O
3	CD	O
:	:	O
Myelofibrosis	NN	O
:	:	O
Dosing	NN	O
Recommendations	NNS	O
for	IN	O
Thrombocytopenia	NNP	O
for	IN	O
Patients	NNPS	WHO
Starting	VBG	WHO
Treatment	NNP	WHO
with	IN	WHO
a	DT	WHO
Platelet	NNP	WHO
Count	NNP	WHO
of	IN	WHO
100	CD	WHO
X	$	WHO
109	CD	WHO
/	JJ	O
L	NNP	O
or	CC	O
Greaterr	NNP	O

Each	DT	O
treatment	NN	O
field	NN	O
is	VBZ	O
limited	VBN	O
to	TO	O
an	DT	O
area	NN	O
of	IN	O
80	CD	O
x	JJ	O
180	CD	O
mm	NN	O
.	.	O

Complete	JJ	O
instructions	NNS	O
to	TO	O
facilitate	VB	O
patient	JJ	O
counseling	VBG	O
on	IN	O
proper	NN	O
pill	NN	O
usage	NN	O
may	MD	O
be	VB	O
found	VBN	O
in	IN	O
the	DT	O
Detailed	NNP	O
Patient	NNP	O
Labeling	NNP	O
(	(	O
“	VB	O
How	WRB	O
to	TO	O
Take	VB	O
the	DT	O
Pill	NNP	O
”	NNP	O
section	NN	O
)	)	O
.	.	O

In	IN	O
patients	NNS	WHO
experiencing	VBG	WHO
inadequate	JJ	WHO
analgesia	NN	WHO
with	IN	O
once	RB	O
-	:	O
daily	JJ	FREQ
dosing	NN	O
of	IN	O
EMBEDA	NNP	O
,	,	O
consider	VB	O
a	DT	O
twice	NN	O
-	:	O
daily	JJ	FREQ
regimen	NNS	O
.	.	O

For	IN	O
continuous	JJ	O
drip	NN	O
,	,	O
the	DT	O
average	JJ	O
rate	NN	O
of	IN	O
administration	NN	O
is	VBZ	O
about	IN	O
3	CD	DOS
mL	NN	UNIT
of	IN	O
a	DT	O
0.2	CD	O
%	NN	O
solution	NN	O
/	NNP	O
minute	NN	O
(	(	O
1	CD	DOS
drop	NN	UNIT
/	NNP	O
second	NN	O
)	)	O
.	.	O

In	IN	O
the	DT	O
newborn	JJ	O
period	NN	O
,	,	O
renal	JJ	O
clearance	NN	O
of	IN	O
digoxin	NN	O
is	VBZ	O
diminished	VBN	O
and	CC	O
suitable	JJ	O
dosage	NN	O
adjustments	NNS	O
must	MD	O
be	VB	O
observed	VBN	O
.	.	O

CellCept	NNP	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
cardiac	NN	WHO
or	CC	WHO
hepatic	JJ	WHO
transplant	NN	WHO
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
chronic	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
if	IN	O
the	DT	O
potential	JJ	O
benefits	NNS	O
outweigh	VBP	O
the	DT	O
potential	JJ	O
risks	NNS	O
.	.	O

Other	JJ	O
recommendations	NNS	O
include	VBP	O
:	:	O
oxygen	NN	O
,	,	O
carbogen	NN	O
(	(	O
95	CD	O
%	NN	O
oxygen	NN	O
and	CC	O
5	CD	O
%	NN	O
carbon	NN	O
dioxide	NN	O
)	)	O
,	,	O
vitamin	FW	O
C	NNP	O
intravenously	RB	O
in	IN	O
massive	JJ	O
doses	NNS	O
(	(	O
1	CD	DOS
g	NN	UNIT
)	)	O
and	CC	O
ephedrine	JJ	O
sulfate	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
0.142	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
minute	NN	O
(	(	O
0.57	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NNP	O
total	NN	O
)	)	O
infused	VBD	O
over	IN	O
4	CD	O
minutes	NNS	O
.	.	O

The	DT	O
smallest	JJS	O
dosage	NN	O
of	IN	O
meclofenamate	NN	O
sodium	NN	O
that	WDT	O
yields	VBZ	O
clinical	JJ	O
control	NN	O
should	MD	O
be	VB	O
employed	VBN	O
.	.	O

[	NNS	O
see	VBP	O
Clinical	JJ	O
Studies	NNS	O
]	VBP	O

The	DT	O
products	NNS	O
of	IN	O
these	DT	O
reactions	NNS	O
are	VBP	O
often	RB	O
blue	JJ	O
,	,	O
green	JJ	O
,	,	O
or	CC	O
red	JJ	O
,	,	O
much	RB	O
brighter	JJR	O
than	IN	O
the	DT	O
faint	NN	O
brownish	JJ	O
color	NN	O
of	IN	O
unreacted	JJ	O
Sodium	NNP	O
Nitroprusside	NNP	O
.	.	O

Titrate	VB	O
the	DT	O
dose	NN	O
according	VBG	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
response	NN	O
.	.	O

Select	JJ	WHO
patients	NNS	WHO
for	IN	WHO
treatment	NN	WHO
of	IN	WHO
unresectable	JJ	WHO
or	CC	WHO
metastatic	JJ	WHO
melanoma	NN	WHO
with	IN	WHO
MEKINIST	NNP	WHO
based	VBN	O
on	IN	O
the	DT	O
presence	NN	O
of	IN	O
BRAF	NNP	O
V600E	NNP	O
or	CC	O
V600K	NNP	O
mutation	NN	O
in	IN	O
tumor	NN	O
specimens	NNS	O
[	VBP	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
dosed	VBN	WHO
initially	RB	WHO
at	IN	O
75	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
and	CC	O
who	WP	O
experience	VBP	O
either	DT	O
febrile	NN	O
neutropenia	NN	O
,	,	O
neutrophils	VBZ	O
<	JJ	O
500	CD	DOS
cells	NNS	UNIT
/	JJ	O
mm³for	RB	O
more	JJR	O
than	IN	O
one	CD	PER
week	NN	PER
,	,	O
severe	JJ	O
or	CC	O
cumulative	JJ	O
cutaneous	JJ	O
reactions	NNS	O
,	,	O
or	CC	O
other	JJ	O
grade	JJ	O
3	CD	O
/	JJ	O
4	CD	O
nonhematological	JJ	O
toxicities	NNS	O
during	IN	O
DOCEFREZ	NNP	O
treatment	NN	O
should	MD	O
have	VB	O
treatment	NN	O
withheld	VBN	O
until	IN	O
resolution	NN	O
of	IN	O
the	DT	O
toxicity	NN	O
and	CC	O
then	RB	O
resumed	VBD	O
at	IN	O
55	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
.	.	O

Hepatic	JJ	O
Impairment	NN	O
:	:	O
Patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
should	MD	O
be	VB	O
closely	RB	O
monitored	VBN	O
for	IN	O
toxicity	NN	O
.	.	O

In	IN	O
the	DT	O
clinical	JJ	O
trials	NNS	O
,	,	O
doses	VBZ	O
up	IN	O
to	TO	O
400	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
as	IN	O
monotherapy	NN	O
were	VBD	O
evaluated	VBN	O
;	:	O
however	RB	O
,	,	O
no	DT	O
additional	JJ	O
benefit	NN	O
was	VBD	O
seen	VBN	O
at	IN	O
400	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
compared	VBN	O
with	IN	O
200	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
[	NNP	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

Oral	JJ	O
Dosage	NN	O
:	:	O
For	IN	O
children	NNS	WHO
2	CD	WHO
to	TO	WHO
12	CD	WHO
years	NNS	WHO
,	,	O
starting	VBG	O
dosage	NN	O
is	VBZ	O
21	CD	DOS
/	JJ	O
2	CD	DOS
mg	NN	UNIT
2	CD	FREQ
or	CC	O
3	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Long	NNP	O
-	:	O
term	NN	O
maintenance	NN	O
of	IN	O
efficacy	NN	O
with	IN	O
the	DT	O
immediate	JJ	O
-	:	O
release	NN	O
formulation	NN	O
of	IN	O
paroxetine	NN	O
was	VBD	O
demonstrated	VBN	O
in	IN	O
a	DT	O
3	CD	PER
-	:	O
month	NN	O
relapse	NN	O
prevention	NN	O
trial	NN	O
.	.	O

Occlusive	JJ	O
dressings	NNS	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
psoriasis	NN	O
or	CC	O
recalcitrant	JJ	O
conditions	NNS	O
.	.	O

Included	VBN	O
in	IN	O
the	DT	O
situations	NNS	O
which	WDT	O
may	MD	O
make	VB	O
dosage	NN	O
adjustments	NNS	O
necessary	JJ	O
are	VBP	O
changes	NNS	O
in	IN	O
clinical	JJ	O
status	NN	O
secondary	JJ	O
to	TO	O
remissions	NNS	O
or	CC	O
exacerbations	NNS	O
in	IN	O
the	DT	O
disease	NN	O
process	NN	O
,	,	O
the	DT	O
patient	NN	O
's	POS	O
individual	JJ	O
drug	NN	O
responsiveness	NN	O
,	,	O
and	CC	O
the	DT	O
effect	NN	O
of	IN	O
patient	NN	O
exposure	NN	O
to	TO	O
stressful	VB	O
situations	NNS	O
not	RB	O
directly	RB	O
related	VBN	O
to	TO	O
the	DT	O
disease	NN	O
entity	NN	O
under	IN	O
treatment	NN	O
;	:	O
in	IN	O
this	DT	O
latter	JJ	O
situation	NN	O
it	PRP	O
may	MD	O
be	VB	O
necessary	JJ	O
to	TO	O
increase	VB	O
the	DT	O
dosage	NN	O
of	IN	O
MEDROL	NNP	O
(	(	O
methylprednisolone	NN	O
)	)	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
time	NN	O
consistent	JJ	O
with	IN	O
the	DT	O
patient	NN	O
's	POS	O
condition	NN	O
.	.	O

Figure	NN	O
A	NNP	O
,	,	O
B	NNP	O
and	CC	O
C	NNP	O

(	(	O
See	VB	O
WARNINGS	NNP	O
)	)	O
Missed	VBD	O
menstrual	JJ	O
periods	NNS	O
.	.	O

X	LS	O
-	:	O
rays	NNS	O
should	MD	O
be	VB	O
taken	VBN	O
at	IN	O
appropriate	JJ	O
intervals	NNS	O
to	TO	O
determine	VB	O
the	DT	O
amount	NN	O
of	IN	O
bone	NN	O
maturation	NN	O
and	CC	O
skeletal	JJ	O
development	NN	O
(	(	O
see	VB	O
INDICATIONS	NNP	O
AND	NNP	O
USAGE	NNP	O
,	,	O
and	CC	O
WARNINGS	NNP	O
)	)	O
.	.	O

Intravenous	JJ	O
erythromycin	NN	O
should	MD	O
be	VB	O
replaced	VBN	O
by	IN	O
oral	JJ	O
erythromycin	NN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
.	.	O

The	DT	O
following	JJ	O
Table	NN	O
is	VBZ	O
a	DT	O
guide	NN	O
for	IN	O
the	DT	O
initial	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
Depakene	NNP	O
(	(	O
valproic	JJ	O
acid	NN	O
)	)	O
(	(	O
15	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
)	)	O
:	:	O

Figure	NN	O
F	NNP	O

Dosing	VBG	O
of	IN	O
LAMICTAL	NNP	O
XR	NNP	O
should	MD	O
be	VB	O
based	VBN	O
on	IN	O
therapeutic	JJ	O
response	NN	O
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

When	WRB	O
the	DT	O
tablets	NNS	O
are	VBP	O
administered	VBN	O
during	IN	O
the	DT	O
postpartum	JJ	O
period	NN	O
,	,	O
the	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
thromboembolic	JJ	O
disease	NN	O
associated	VBN	O
with	IN	O
the	DT	O
postpartum	JJ	O
period	NN	O
must	MD	O
be	VB	O
considered	VBN	O
.	.	O

Do	VB	O
not	RB	O
take	VB	O
the	DT	O
tablet	NN	O
with	IN	O
food	NN	O
or	CC	O
beverage	NN	O
.	.	O

Addition	NN	O
or	CC	O
withdrawal	NN	O
of	IN	O
phenytoin	NN	O
and	CC	O
/	NN	O
or	CC	O
carbamazepine	NN	O
during	IN	O
adjunctive	JJ	O
therapy	NN	O
with	IN	O
TOPAMAX®	NNP	O
may	MD	O
require	VB	O
adjustment	NN	O
of	IN	O
the	DT	O
dose	NN	O
of	IN	O
TOPAMAX®	NNP	O
.	.	O

When	WRB	O
these	DT	O
substances	NNS	O
or	CC	O
their	PRP$	O
derivatives	NNS	O
are	VBP	O
injected	VBN	O
intramuscularly	RB	O
or	CC	O
into	IN	O
joint	JJ	O
spaces	NNS	O
,	,	O
their	PRP$	O
relative	JJ	O
properties	NNS	O
may	MD	O
be	VB	O
greatly	RB	O
altered	VBN	O
.	.	O

Patients	NNS	WHO
receiving	VBG	WHO
concomitant	JJ	WHO
AEDs	NNP	WHO
may	MD	O
be	VB	O
converted	VBN	O
to	TO	O
monotherapy	VB	O
by	IN	O
initiating	VBG	O
treatment	NN	O
with	IN	O
Trileptal	NNP	O
at	IN	O
600	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
given	VBN	O
in	IN	O
a	DT	O
twice	JJ	FREQ
-	:	FREQ
a	DT	FREQ
-	:	FREQ
day	NN	FREQ
regimen	NNS	O
)	)	O
while	IN	O
simultaneously	RB	O
initiating	VBG	O
the	DT	O
reduction	NN	O
of	IN	O
the	DT	O
dose	NN	O
of	IN	O
the	DT	O
concomitant	JJ	O
AEDs	NNP	O
.	.	O

If	IN	O
not	RB	O
used	VBN	O
within	IN	O
2	CD	O
hours	NNS	O
,	,	O
discard	VBP	O
the	DT	O
solution	NN	O
.	.	O

5	CD	O
.	.	O

Do	NNP	O
not	RB	O
begin	VB	O
anticoagulation	NN	O
until	IN	O
the	DT	O
aPTT	NN	O
has	VBZ	O
decreased	VBN	O
to	TO	O
less	JJR	O
than	IN	O
twice	RB	O
the	DT	O
normal	JJ	O
control	NN	O
value	NN	O
.	.	O

More	RBR	O
frequent	JJ	O
administration	NN	O
or	CC	O
higher	JJR	O
doses	NNS	O
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

When	WRB	O
reconstituted	VBN	O
with	IN	O
41	CD	DOS
mL	NNS	UNIT
Sterile	JJ	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
the	DT	O
resulting	VBG	O
solution	NN	O
will	MD	O
contain	VB	O
2.5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
temozolomide	NN	O
.	.	O

Double	RB	O
the	DT	O
dose	JJ	O
every	DT	FREQ
two	CD	FREQ
weeks	NNS	FREQ
to	TO	O
the	DT	O
highest	JJS	O
dosage	NN	O
level	NN	O
tolerated	VBN	O
by	IN	O
the	DT	O
patient	NN	O
or	CC	O
up	RB	O
to	TO	O
200	CD	DOS
mg	NN	UNIT
of	IN	O
TOPROL	NNP	O
-	:	O
XL	NN	O
.	.	O

In	IN	O
more	RBR	O
serious	JJ	O
urinary	JJ	O
tract	NN	O
infections	NNS	O
,	,	O
a	DT	O
dosage	NN	O
of	IN	O
1	CD	DOS
g	NN	UNIT
every	DT	FREQ
8	CD	FREQ
hours	NNS	FREQ
may	MD	O
be	VB	O
needed	VBN	O
.	.	O

Patients	NNS	O
without	IN	O
17p	CD	DOS
deletion	NN	UNIT
at	IN	O
diagnosis	NN	O
should	MD	O
be	VB	O
retested	VBN	O
at	IN	O
relapse	NN	O
because	IN	O
acquisition	NN	O
of	IN	O
17p	CD	DOS
deletion	NN	UNIT
can	MD	O
occur	VB	O
.	.	O

Tetanus	NNP	O
Toxoid	NNP	O
is	VBZ	O
interchangeable	JJ	O
with	IN	O
Tetanus	NNP	O
Toxoid	NNP	O
(	(	O
tetanus	NN	O
(	(	O
tetanus	IN	O
toxoid	NN	O
)	)	O
toxoid	NN	O
)	)	O
Adsorbed	NNP	O
(	(	O
contains	VBZ	O
aluminum	NN	O
adjuvant	NN	O
)	)	O
as	IN	O
a	DT	O
booster	NN	O
,	,	O
and	CC	O
would	MD	O
only	RB	O
be	VB	O
preferred	VBN	O
if	IN	O
aluminum	NN	O
was	VBD	O
to	TO	O
be	VB	O
avoided	VBN	O
.	.	O

may	MD	O
be	VB	O
efficacious	JJ	O
and	CC	O
well	RB	O
tolerated	VBN	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
HYCAMTIN	NNP	O
capsules	NNS	O
to	TO	O
patients	NNS	WHO
with	IN	WHO
Grade	NNP	WHO
3	CD	WHO
or	CC	WHO
4	CD	WHO
diarrhea	NN	WHO
.	.	O

A	DT	O
guideline	NN	O
for	IN	O
initiation	NN	O
of	IN	O
carbidopa	NN	O
and	CC	O
levodopa	NN	O
extended	VBN	O
-	:	O
release	NN	O
tablets	NNS	O
is	VBZ	O
shown	VBN	O
in	IN	O
Table	JJ	O
3	CD	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Dosing	NN	O
for	IN	O
Control	NNP	O
of	IN	O
Bleeding	NNP	O
Episodes	NNP	O

In	IN	O
order	NN	O
to	TO	O
ensure	VB	O
that	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
fully	RB	O
aware	JJ	O
of	IN	O
the	DT	O
correct	JJ	O
method	NN	O
of	IN	O
therapy	NN	O
and	CC	O
to	TO	O
identify	VB	O
which	WDT	O
specific	JJ	O
warts	NNS	O
should	MD	O
be	VB	O
treated	VBN	O
,	,	O
the	DT	O
technique	NN	O
for	IN	O
initial	JJ	O
application	NN	O
of	IN	O
the	DT	O
medication	NN	O
should	MD	O
be	VB	O
demonstrated	VBN	O
by	IN	O
the	DT	O
prescriber	NN	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
infusion	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
to	TO	O
sustain	VB	O
the	DT	O
desired	JJ	O
level	NN	O
of	IN	O
respiratory	JJ	O
stimulation	NN	O
with	IN	O
a	DT	O
minimum	NN	O
of	IN	O
side	NN	O
effects	NNS	O
.	.	O

5	CD	DOS
mL	NN	UNIT
every	DT	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
as	IN	O
needed	VBN	O
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
4	CD	DOS
doses	NNS	UNIT
(	(	O
20	CD	DOS
mL	NN	UNIT
)	)	O
in	IN	O
24	CD	O
hours	NNS	O
.	.	O

Administer	NNP	O
the	DT	O
VENCLEXTA	NNP	O
dose	NN	O
according	VBG	O
to	TO	O
a	DT	O
weekly	JJ	FREQ
ramp	NN	FREQ
-	:	O
up	RB	O
schedule	NN	PER
over	IN	O
5	CD	PER
weeks	NNS	PER
to	TO	O
the	DT	O
recommended	VBN	FREQ
daily	RB	FREQ
dose	VB	O
of	IN	O
400	CD	DOS
mg	NN	UNIT
as	IN	O
shown	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
.	.	O

When	WRB	O
applying	VBG	O
EMLA	NNP	O
(	(	O
lidocaine	NN	O
and	CC	O
prilocaine	NN	O
)	)	O
Cream	NN	O
to	TO	O
the	DT	O
skin	NN	O
of	IN	O
young	JJ	WHO
children	NNS	WHO
,	,	O
care	NN	O
must	MD	O
be	VB	O
taken	VBN	O
to	TO	O
maintain	VB	O
careful	JJ	O
observation	NN	O
of	IN	O
the	DT	O
child	NN	O
to	TO	O
prevent	VB	O
accidental	JJ	O
ingestion	NN	O
of	IN	O
EMLA	NNP	O
(	(	O
lidocaine	NN	O
and	CC	O
prilocaine	NN	O
)	)	O
Cream	NN	O
or	CC	O
the	DT	O
occlusive	JJ	O
dressing	NN	O
.	.	O

From	IN	O
Cycle	NNP	O
13	CD	O
,	,	O
omit	VBP	O
the	DT	O
Day	NNP	O
8	CD	O
and	CC	O
9	CD	DOS
doses	NNS	UNIT
of	IN	O
Kyprolis	NNP	O
(	(	O
see	VB	O
Table	NNP	O
3	CD	O
)	)	O
.	.	O

As	IN	O
a	DT	O
precaution	NN	O
against	IN	O
the	DT	O
adverse	JJ	O
experience	NN	O
sometimes	RB	O
observed	VBD	O
following	JJ	O
unintentional	JJ	O
penetration	NN	O
of	IN	O
the	DT	O
subarachnoid	JJ	O
space	NN	O
,	,	O
a	DT	O
test	NN	O
dose	NN	O
such	JJ	O
as	IN	O
2	CD	DOS
to	TO	O
3	CD	DOS
mL	NN	UNIT
of	IN	O
1.5	CD	O
%	NN	O
lidocaine	JJ	O
HCl	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
at	IN	O
least	JJS	O
5	CD	O
minutes	NNS	O
prior	RB	O
to	TO	O
injecting	VBG	O
the	DT	O
total	JJ	O
volume	NN	O
required	VBN	O
for	IN	O
a	DT	O
lumbar	NN	O
or	CC	O
caudal	JJ	O
epidural	JJ	O
block	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
EXALGO	NNP	O
is	VBZ	O
50	CD	O
%	NN	O
of	IN	O
the	DT	O
calculated	JJ	O
estimate	NN	O
of	IN	O
daily	JJ	FREQ
hydromorphone	NN	O
requirement	NN	O
.	.	O

Appropriate	JJ	O
precautions	NNS	O
should	MD	O
be	VB	O
taken	VBN	O
(	(	O
see	JJ	O
Package	NNP	O
Insert	NNP	O
of	IN	O
the	DT	O
respective	JJ	O
sulfonylurea	NN	O
)	)	O
.	.	O

Note	NN	O
:	:	O
DO	NNP	O
NOT	NNP	O
filter	VB	O
the	DT	O
contents	NNS	O
of	IN	O
the	DT	O
TICE®	NNP	O
BCG	NNP	O
vial	NN	O
.	.	O

If	IN	O
the	DT	O
serum	NN	O
ferritin	NN	O
falls	VBZ	O
consistently	RB	O
below	IN	O
500	CD	DOS
mcg	NNS	UNIT
/	JJ	O
L	NNP	O
,	,	O
consider	VB	O
temporarily	RB	O
interrupting	VBG	O
Ferriprox	NNP	O
therapy	NN	O
.	.	O

Consider	VB	O
use	NN	O
of	IN	O
alternate	JJ	O
buprenorphine	NN	O
products	NNS	O
for	IN	O
maintenance	NN	O
of	IN	O
treatment	NN	O
.	.	O

If	IN	O
side	JJ	O
effects	NNS	O
occur	VBP	O
at	IN	O
the	DT	O
recommended	JJ	O
starting	NN	O
dose	NN	O
,	,	O
the	DT	O
dose	NN	O
may	MD	O
be	VB	O
lowered	VBN	O
.	.	O

Table	JJ	O
1.0	CD	O
-	:	O
Radiation	NN	O
Absorbed	NNP	O
Doses	VBZ	O
from	IN	O
Tc99m	NNP	O
Sestamibi	NNP	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
migraine	NN	O
,	,	O
if	IN	O
side	JJ	O
effects	NNS	O
are	VBP	O
dose	JJ	O
limiting	NN	O
,	,	O
a	DT	O
lower	JJR	O
dose	NN	O
(	(	O
4	CD	DOS
mg	NN	UNIT
)	)	O
may	MD	O
be	VB	O
used	VBN	O
[	NNP	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

It	PRP	O
is	VBZ	O
often	RB	O
necessary	JJ	O
to	TO	O
continue	VB	O
medication	NN	O
even	RB	O
when	WRB	O
clinical	JJ	O
symptoms	NNS	O
,	,	O
including	VBG	O
diarrhea	NN	O
,	,	O
have	VBP	O
been	VBN	O
controlled	VBN	O
.	.	O

VALSTAR	NNP	O
(	(	O
valrubicin	NN	O
)	)	O
solutions	NNS	O
should	MD	O
be	VB	O
prepared	VBN	O
and	CC	O
stored	VBN	O
in	IN	O
glass	NN	O
,	,	O
polypropylene	NN	O
,	,	O
or	CC	O
polyolefin	NN	O
containers	NNS	O
and	CC	O
tubing	VBG	O
.	.	O

For	IN	O
dosages	NNS	O
requiring	VBG	O
more	JJR	O
than	IN	O
one	CD	DOS
sublingual	JJ	UNIT
tablet	NN	UNIT
,	,	O
place	NN	O
all	DT	O
tablets	NNS	O
in	IN	O
different	JJ	O
places	NNS	O
under	IN	O
the	DT	O
tongue	NN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
.	.	O

On	IN	O
the	DT	O
day	NN	O
after	IN	O
Week	NNP	O
Four	NNP	O
ends	VBZ	O
,	,	O
a	DT	O
new	JJ	O
four	CD	DOS
-	:	O
week	NN	PER
cycle	NN	O
is	VBZ	O
started	VBN	O
by	IN	O
applying	VBG	O
a	DT	O
new	JJ	O
patch	NN	O
.	.	O

VIDAZA	NNP	O
reconstituted	VBD	O
with	IN	O
non	JJ	O
-	:	O
refrigerated	JJ	O
water	NN	O
for	IN	O
injection	NN	O
for	IN	O
subcutaneous	JJ	O
administration	NN	O
may	MD	O
be	VB	O
stored	VBN	O
for	IN	O
up	RB	O
to	TO	O
1	CD	O
hour	NN	O
at	IN	O
25°C	CD	O
(	(	O
77°F	CD	O
)	)	O
or	CC	O
for	IN	O
up	IN	O
to	TO	O
8	CD	O
hours	NNS	O
between	IN	O
2°C	CD	O
and	CC	O
8°C	CD	O
(	(	O
36°F	CD	O
and	CC	O
46°F	CD	O
)	)	O
;	:	O
when	WRB	O
reconstituted	VBN	O
with	IN	O
refrigerated	VBN	O
(	(	O
2°C	CD	O
-	:	O
8°C	CD	O
,	,	O
36°F	CD	O
-	:	O
46°F	CD	O
)	)	O
water	NN	O
for	IN	O
injection	NN	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
stored	VBN	O
for	IN	O
22	CD	O
hours	NNS	O
between	IN	O
2°C	CD	O
and	CC	O
8°C	CD	O
(	(	O
36°F	CD	O
and	CC	O
46°F	CD	O
)	)	O
.	.	O

Further	RB	O
dose	JJ	O
escalations	NNS	O
should	MD	O
be	VB	O
based	VBN	O
on	IN	O
tolerability	NN	O
and	CC	O
need	NN	O
for	IN	O
efficacy	NN	O
.	.	O

The	DT	O
effect	NN	O
was	VBD	O
maintained	VBN	O
during	IN	O
an	DT	O
additional	JJ	O
12	CD	PER
weeks	NNS	PER
of	IN	O
therapy	NN	O
.	.	O

The	DT	O
suggested	VBN	O
dose	NN	O
range	NN	O
employed	VBN	O
in	IN	O
the	DT	WHO
average	JJ	WHO
patient	NN	WHO
(	(	WHO
70	CD	WHO
kg	NN	WHO
)	)	WHO
is	VBZ	O
:	:	O

Orapred	VBN	O
ODT	NNP	O
(	(	O
prednisolone	NN	O
sodium	NN	O
phosphate	NN	O
)	)	O
are	VBP	O
packaged	VBN	O
in	IN	O
a	DT	O
blister	NN	O
.	.	O

Serum	NNP	O
lipids	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
for	IN	O
evidence	NN	O
of	IN	O
EFAD	NNP	O
in	IN	O
patients	NNS	WHO
maintained	VBN	O
on	IN	O
fat	JJ	O
free	JJ	O
total	NN	O
parenteral	JJ	O
nutrition	NN	O
.	.	O

Aminosyn	NNP	O
II	NNP	O
solution	NN	O
,	,	O
when	WRB	O
mixed	JJ	O
with	IN	O
an	DT	O
appropriate	JJ	O
volume	NN	O
of	IN	O
concentrated	JJ	O
dextrose	NN	O
,	,	O
offers	VBZ	O
a	DT	O
higher	JJR	O
concentration	NN	O
of	IN	O
calories	NNS	O
and	CC	O
nitrogen	JJ	O
per	IN	O
unit	NN	O
volume	NN	O
.	.	O

The	DT	O
infusion	NN	O
rate	NN	O
should	MD	O
be	VB	O
increased	VBN	O
by	IN	O
increments	NNS	O
of	IN	O
5	CD	DOS
to	TO	O
10	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
(	(	O
0.3	CD	DOS
to	TO	O
0.6	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
h	NN	O
)	)	O
until	IN	O
the	DT	O
desired	JJ	O
level	NN	O
of	IN	O
sedation	NN	O
is	VBZ	O
achieved	VBN	O
.	.	O

The	DT	O
dose	NN	O
should	MD	O
be	VB	O
increased	VBN	O
in	IN	O
5	CD	DOS
mg	NN	UNIT
increments	NNS	O
to	TO	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
2.5	CD	DOS
mL	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
)	)	O
,	,	O
15	CD	DOS
mg	NN	UNIT
/	NNP	FREQ
day	NN	FREQ
(	(	O
2.5	CD	DOS
mL	NN	UNIT
and	CC	O
5	CD	DOS
mL	NN	UNIT
as	IN	O
separate	JJ	O
doses	NNS	O
)	)	O
,	,	O
and	CC	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
5	CD	DOS
mL	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
)	)	O
.	.	O

Slow	NNP	O
IV	NNP	O
injection	NN	O
is	VBZ	O
essential	JJ	O
,	,	O
and	CC	O
patients	NNS	O
should	MD	O
be	VB	O
carefully	RB	O
observed	VBN	O
during	IN	O
administration	NN	O
.	.	O

Dose	NNP	O
interruption	NN	O
and	CC	O
/	NN	O
or	CC	O
dose	JJ	O
modification	NN	O
in	IN	O
12.5	CD	DOS
mg	JJ	UNIT
increments	NNS	WHO
or	CC	WHO
decrements	NNS	WHO
is	VBZ	O
recommended	VBN	O
based	VBN	O
on	IN	O
individual	JJ	O
safety	NN	O
and	CC	O
tolerability	NN	O
.	.	O

Saxenda®	NNP	O
solution	NN	O
should	MD	O
be	VB	O
inspected	VBN	O
prior	RB	O
to	TO	O
each	DT	O
injection	NN	O
,	,	O
and	CC	O
the	DT	O
solution	NN	O
should	MD	O
be	VB	O
used	VBN	O
only	RB	O
if	IN	O
it	PRP	O
is	VBZ	O
clear	JJ	O
,	,	O
colorless	NN	O
,	,	O
and	CC	O
contains	VBZ	O
no	DT	O
particles	NNS	O
.	.	O

Example	JJ	O
2	CD	O
:	:	O
for	IN	O
a	DT	O
70	CD	PER
-	:	O
kg	NN	O
person	NN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
16	CD	DOS
ng	JJ	UNIT
/	NNP	O
kg	NN	O
/	NNP	O
min	NN	O
using	VBG	O
a	DT	O
15,000	CD	DOS
-	:	O
ng	NN	O
/	JJ	O
mL	NN	O
concentration	NN	O
,	,	O
the	DT	O
infusion	NN	O
rate	NN	O
would	MD	O
be	VB	O
as	IN	O
follows	VBZ	O
:	:	O

A	DT	O
reliably	RB	O
absorbed	VBN	O
slow	JJ	O
-	:	O
release	NN	O
formulation	NN	O
will	MD	O
decrease	VB	O
fluctuations	NNS	O
and	CC	O
permit	NN	O
longer	JJR	O
dosing	VBG	O
intervals	NNS	O
.	.	O

The	DT	O
suspension	NN	O
should	MD	O
be	VB	O
administered	VBN	O
immediately	RB	O
after	IN	O
reconstitution	NN	O
.	.	O

8	CD	O
.	.	O

DULERA	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
two	CD	DOS
inhalations	NNS	UNIT
twice	RB	FREQ
daily	JJ	FREQ
every	DT	FREQ
day	NN	FREQ
(	(	O
morning	NN	O
and	CC	O
evening	NN	O
)	)	O
by	IN	O
the	DT	O
orally	RB	O
inhaled	JJ	O
route	NN	O
.	.	O

DO	NNP	O
NOT	NNP	O
INJECT	NNP	O
INTRAVENOUSLY	NNP	O
.	.	O

One	CD	DOS
pink	NN	UNIT
tablet	NN	UNIT
should	MD	O
be	VB	O
taken	VBN	O
daily	RB	FREQ
for	IN	O
21	CD	PER
consecutive	JJ	PER
days	NNS	PER
,	,	O
followed	VBN	O
by	IN	O
one	CD	DOS
light	NN	UNIT
-	:	O
green	JJ	UNIT
inert	JJ	UNIT
tablet	NN	UNIT
daily	RB	FREQ
for	IN	O
7	CD	PER
consecutive	JJ	PER
days	NNS	PER
.	.	O

While	IN	O
holding	VBG	O
onto	IN	O
the	DT	O
diluent	JJ	O
vial	NN	O
,	,	O
remove	VB	O
the	DT	O
outer	JJ	O
package	NN	O
from	IN	O
the	DT	O
Mix2Vial™	NNP	O
,	,	O
leaving	VBG	O
the	DT	O
Mix2Vial™	NNP	O
attached	VBD	O
firmly	RB	O
to	TO	O
the	DT	O
diluent	NN	O
vial	NN	O
(	(	O
Fig	NNP	O
.	.	O

HAVRIX	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
by	IN	O
intramuscular	JJ	O
injection	NN	O
only	RB	O
.	.	O

Cleanse	NNP	O
volar	JJ	O
surface	NN	O
of	IN	O
mid	JJ	O
-	:	O
forearm	NN	O
with	IN	O
alcohol	NN	O
,	,	O
ether	RB	O
,	,	O
or	CC	O
acetone	NN	O
and	CC	O
allow	VB	O
to	TO	O
dry	VB	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
hypothyroidism	NN	WHO
(	(	O
TSH	NNP	O
<	VBZ	O
10	CD	DOS
mIU	NN	UNIT
per	IN	O
Liter	NNP	O
)	)	O
,	,	O
start	VBP	O
TIROSINT	NNP	O
-	:	O
SOL	NN	O
at	IN	O
1.0	CD	DOS
mcg	NNS	UNIT
per	IN	O
kg	NN	O
body	NN	O
weight	JJ	O
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
left	NN	O
image	NN	O
shows	VBZ	O
a	DT	O
white	JJ	O
matter	NN	O
sulcal	JJ	O
pattern	NN	O
in	IN	O
the	DT	O
inferior	JJ	O
parietal	NN	O
(	(	O
ip	NN	O
)	)	O
regions	NNS	O
that	WDT	O
is	VBZ	O
not	RB	O
evident	JJ	O
in	IN	O
the	DT	O
right	JJ	O
image	NN	O
.	.	O

Photodynamic	NNP	O
therapy	NN	O
(	(	O
PDT	NNP	O
)	)	O
for	IN	O
non	JJ	O
-	:	O
hyperkeratotic	JJ	O
actinic	JJ	O
keratoses	NNS	O
with	IN	O
Metvixia	NNP	O
(	(	O
methyl	JJ	O
aminolevulinate	NN	O
cream	NN	O
)	)	O
Cream	NNP	O
is	VBZ	O
a	DT	O
multi	JJ	O
-	:	O
stage	NN	O
process	NN	O
as	IN	O
described	VBN	O
below	IN	O
:	:	O
Two	CD	O
treatment	NN	O
sessions	NNS	O
one	CD	PER
week	NN	PER
apart	NN	O
should	MD	O
be	VB	O
administered	VBN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
MAXIPIME	NNP	O
for	IN	O
hemodialysis	NN	WHO
patients	NNS	WHO
is	VBZ	O
1	CD	DOS
g	NN	UNIT
on	IN	O
Day	NNP	O
1	CD	O
followed	VBN	O
by	IN	O
500	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
24	CD	FREQ
hours	NNS	FREQ
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
all	DT	O
infections	NNS	O
except	IN	O
febrile	JJ	O
neutropenia	NN	O
,	,	O
which	WDT	O
is	VBZ	O
1	CD	DOS
g	NN	UNIT
every	DT	FREQ
24	CD	FREQ
hours	NNS	FREQ
.	.	O

Vacuum	NNP	O
Transfer	NNP	O

In	IN	O
titrating	VBG	O
to	TO	O
clinical	JJ	O
effect	NN	O
,	,	O
allow	VB	O
approximately	RB	O
2	CD	O
minutes	NNS	O
for	IN	O
onset	NN	O
of	IN	O
peak	JJ	O
drug	NN	O
effect	NN	O
.	.	O

Discontinue	NNP	O
treatment	NN	O
with	IN	O
CHOLBAM	NNP	O
at	IN	O
any	DT	O
time	NN	O
if	IN	O
there	EX	O
are	VBP	O
persistent	JJ	O
clinical	JJ	O
or	CC	O
laboratory	JJ	O
indicators	NNS	O
of	IN	O
worsening	VBG	O
liver	JJ	O
function	NN	O
or	CC	O
cholestasis	NN	O
[	NNS	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
patient	NN	O
should	MD	O
be	VB	O
instructed	VBN	O
to	TO	O
avoid	VB	O
contamination	NN	O
of	IN	O
the	DT	O
tip	NN	O
of	IN	O
the	DT	O
tube	NN	O
when	WRB	O
instilling	VBG	O
the	DT	O
suspension	NN	O
or	CC	O
the	DT	O
ointment	NN	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
wait	VBP	O
7	CD	PER
to	TO	O
14	CD	PER
days	NNS	PER
between	IN	O
titration	NN	O
steps	NNS	O
.	.	O

WARNING	NN	O
:	:	O
Do	NNP	O
not	RB	O
use	VB	O
flexible	JJ	O
container	NN	O
in	IN	O
series	NN	O
connections	NNS	O
.	.	O

Administer	NNP	O
intravenously	RB	O
25	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	NN	O
within	IN	O
5	CD	O
minutes	NNS	O
and	CC	O
then	RB	O
0.15	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	FW	O
(	(	O
or	CC	O
0.075	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
creatinine	JJ	WHO
clearance	NN	WHO
≤60	NNP	WHO
mL	NN	WHO
/	NNP	O
min	NN	O
)	)	O
,	,	O
for	IN	O
up	IN	O
to	TO	O
18	CD	O
hours	NNS	O
.	.	O

1	CD	O
.	.	O

This	DT	O
requires	VBZ	O
that	IN	O
blood	NN	O
pressure	NN	O
,	,	O
respiration	NN	O
,	,	O
and	CC	O
cardiac	JJ	O
function	NN	O
be	VB	O
maintained	VBN	O
,	,	O
vital	JJ	O
signs	NNS	O
be	VB	O
recorded	VBN	O
and	CC	O
equipment	NN	O
for	IN	O
resuscitation	NN	O
and	CC	O
artificial	JJ	O
ventilation	NN	O
be	VB	O
available	JJ	O
.	.	O

The	DT	O
resulting	VBG	O
initial	JJ	O
diluted	VBN	O
JEVTANA	NNP	O
solution	NN	O
(	(	O
cabazitaxel	JJ	O
10	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O
requires	VBZ	O
further	JJ	O
dilution	NN	O
before	IN	O
administration	NN	O
.	.	O

Dose	JJ	O
increments	NNS	O
should	MD	O
be	VB	O
0.5	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	FW	O
daily	RB	FREQ
,	,	O
up	RB	O
to	TO	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
2.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NNS	O
per	IN	FREQ
day	NN	FREQ
.	.	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
at	IN	O
8	CD	PER
-	:	O
week	NN	PER
intervals	NNS	O
by	IN	O
2.5	CD	DOS
mcg	NNS	UNIT
if	IN	O
iPTH	NN	O
is	VBZ	O
not	RB	O
lowered	VBN	O
by	IN	O
50	CD	O
%	NN	O
and	CC	O
fails	VBZ	O
to	TO	O
reach	VB	O
the	DT	O
target	NN	O
range	NN	O
.	.	O

Further	JJ	O
reductions	NNS	O
of	IN	O
the	DT	O
concomitant	NN	O
AEDs	NNP	O
dosage	NN	O
may	MD	O
be	VB	O
necessary	JJ	O
to	TO	O
minimize	VB	O
side	NN	O
effects	NNS	O
due	JJ	O
to	TO	O
drug	NN	O
interactions	NNS	O
.	.	O

Step	NN	O
3	CD	O
–	NN	O
Setting	VBG	O
the	DT	O
Flange	NN	O

However	RB	O
,	,	O
it	PRP	O
is	VBZ	O
advisable	JJ	O
to	TO	O
insure	VB	O
that	IN	O
patients	NNS	O
are	VBP	O
well	RB	O
hydrated	VBN	O
prior	RB	O
to	TO	O
examination	NN	O
.	.	O

The	DT	O
dosage	NN	O
is	VBZ	O
the	DT	O
same	JJ	O
as	IN	O
for	IN	O
the	DT	O
general	JJ	O
population	NN	O
.	.	O

Its	PRP$	O
use	NN	O
is	VBZ	O
not	RB	O
advised	VBN	O
for	IN	O
6	CD	PER
months	NNS	PER
after	IN	O
termination	NN	O
of	IN	O
pregnancy	NN	O
or	CC	O
30	CD	O
days	NNS	O
after	IN	O
conization	NN	O
or	CC	O
curettage	NN	O
.	.	O

A	DT	O
therapeutic	JJ	O
plasma	NN	O
concentration	NN	O
range	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
for	IN	O
lamotrigine	NN	O
.	.	O

Refer	NN	O
to	TO	O
carboplatin	VB	O
prescribing	VBG	O
information	NN	O
for	IN	O
additional	JJ	O
information	NN	O
.	.	O

Infants	NNS	WHO
29	CD	WHO
days	NNS	WHO
to	TO	WHO
2	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
:	:	O
the	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
OFIRMEV	NNP	O
is	VBZ	O
15	CD	DOS
mg	NN	UNIT
/	NN	O
kg	NN	O
every	DT	FREQ
6	CD	FREQ
hours	NNS	FREQ
,	,	O
to	TO	O
a	DT	O
maximum	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
of	IN	O
acetaminophen	NN	O
of	IN	O
60	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NNS	O
per	IN	FREQ
day	NN	FREQ
,	,	O
with	IN	O
a	DT	O
minimum	JJ	O
dosing	NN	O
interval	NN	O
of	IN	O
6	CD	O
hours	NNS	O
.	.	O

Examine	NNP	O
image	NN	O
performed	VBD	O
at	IN	O
Count	NNP	O
3	CD	O
as	IN	O
needed	VBN	O
to	TO	O
resolve	VB	O
ambiguities	NNS	O
.	.	O

Postmenopausal	NNP	O
women	NNS	O
should	MD	O
be	VB	O
reevaluated	VBN	O
periodically	RB	O
as	IN	O
clinically	RB	O
appropriate	JJ	O
to	TO	O
determine	VB	O
if	IN	O
treatment	NN	O
is	VBZ	O
still	RB	O
necessary	JJ	O
.	.	O

There	EX	O
is	VBZ	O
no	DT	O
experience	NN	O
with	IN	O
inserting	VBG	O
additional	JJ	O
implants	NNS	O
into	IN	O
other	JJ	O
sites	NNS	O
in	IN	O
the	DT	O
arm	NN	O
to	TO	O
recommend	VB	O
an	DT	O
approach	NN	O
to	TO	O
a	DT	O
second	JJ	O
insertion	NN	O
into	IN	O
a	DT	O
previously	RB	O
-	:	O
used	VBN	O
arm	NN	O
.	.	O

As	IN	O
initial	JJ	O
therapy	NN	O
for	IN	O
parkinsonism	NN	O
,	,	O
1	CD	DOS
mg	NN	UNIT
of	IN	O
ARTANE	NNP	O
(	(	O
trihexyphenidyl	NN	O
)	)	O
in	IN	O
tablet	NN	O
or	CC	O
elixir	JJ	O
form	NN	O
may	MD	O
be	VB	O
administered	VBN	O
the	DT	O
first	JJ	O
day	NN	O
.	.	O

Leave	VB	O
the	DT	O
capsules	NNS	O
in	IN	O
the	DT	O
liquid	NN	O
for	IN	O
at	IN	O
least	JJS	O
10	CD	O
minutes	NNS	O
.	.	O

The	DT	O
side	NN	O
effects	NNS	O
of	IN	O
olmesartan	JJ	O
medoxomil	NN	O
are	VBP	O
generally	RB	O
rare	JJ	O
and	CC	O
apparently	RB	O
independent	JJ	O
of	IN	O
dose	NN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
's	POS	O
IOP	NNP	O
is	VBZ	O
not	RB	O
at	IN	O
a	DT	O
satisfactory	JJ	O
level	NN	O
on	IN	O
this	DT	O
regimen	NNS	O
,	,	O
concomitant	JJ	O
therapy	NN	O
with	IN	O
pilocarpine	NN	O
and	CC	O
other	JJ	O
miotics	NNS	O
,	,	O
and	CC	O
/	NNP	O
or	CC	O
epinephrine	NN	O
or	CC	O
dipivefrin	NN	O
,	,	O
and	CC	O
/	NNP	O
or	CC	O
systemically	RB	O
administered	VBN	O
carbonic	JJ	O
anhydrase	NN	O
inhibitors	NNS	O
,	,	O
such	JJ	O
as	IN	O
acetazolamide	NN	O
,	,	O
can	MD	O
be	VB	O
instituted	VBN	O
.	.	O

Instruct	IN	O
the	DT	O
patient	NN	O
to	TO	O
use	VB	O
a	DT	O
non	JJ	O
-	:	O
hormonal	JJ	O
contraceptive	NN	O
as	IN	O
back	RB	O
-	:	O
up	RP	O
during	IN	O
the	DT	O
first	JJ	O
7	CD	O
days	NNS	O
if	IN	O
she	PRP	O
starts	VBZ	O
taking	VBG	O
Lo	NNP	O
Loestrin	NNP	O
Fe	NNP	O
other	JJ	O
than	IN	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
of	IN	O
her	PRP$	O
menstrual	JJ	O
cycle	NN	O
.	.	O

When	WRB	O
transferring	VBG	O
patients	NNS	WHO
from	IN	WHO
other	JJ	WHO
antihypertensive	JJ	WHO
drugs	NNS	WHO
,	,	O
Trandate	NNP	O
(	(	O
labetalol	NN	O
)	)	O
Tablets	NNS	O
should	MD	O
be	VB	O
introduced	VBN	O
as	IN	O
recommended	JJ	O
and	CC	O
the	DT	O
dosage	NN	O
of	IN	O
the	DT	O
existing	VBG	O
therapy	NN	O
progressively	RB	O
decreased	VBN	O
.	.	O

After	IN	O
mixing	VBG	O
,	,	O
the	DT	O
suspension	NN	O
can	MD	O
be	VB	O
stored	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
(	(	O
25°C	CD	O
/	RB	O
77°F	CD	O
)	)	O
.	.	O

However	RB	O
,	,	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
failure	NN	WHO
to	TO	WHO
increase	VB	WHO
growth	NN	WHO
rate	NN	WHO
,	,	O
particularly	RB	O
during	IN	O
the	DT	O
first	JJ	O
year	NN	O
of	IN	O
therapy	NN	O
,	,	O
suggests	VBZ	O
the	DT	O
need	NN	O
for	IN	O
close	JJ	O
assessment	NN	O
of	IN	O
compliance	NN	O
and	CC	O
evaluation	NN	O
of	IN	O
other	JJ	O
causes	NNS	O
of	IN	O
growth	NN	O
failure	NN	O
,	,	O
such	JJ	O
as	IN	O
hypothyroidism	NN	O
,	,	O
under	IN	O
-	:	O
nutrition	NN	O
,	,	O
advanced	VBD	O
bone	NN	O
age	NN	O
and	CC	O
antibodies	NNS	O
to	TO	O
recombinant	VB	O
human	JJ	O
GH	NNP	O
(	(	O
rhGH	NN	O
)	)	O
.	.	O

Increases	NNS	O
in	IN	O
the	DT	O
patient	NN	O
's	POS	O
symptoms	NNS	O
of	IN	O
PAH	NNP	O
should	MD	O
be	VB	O
first	RB	O
treated	VBN	O
with	IN	O
increases	NNS	O
in	IN	O
the	DT	O
dose	NN	O
of	IN	O
Remodulin	NNP	O
.	.	O

One	CD	O
unit	NN	O
of	IN	O
Humalog	NNP	O
has	VBZ	O
the	DT	O
same	JJ	O
glucose	JJ	O
-	:	O
lowering	VBG	O
effect	NN	O
as	IN	O
one	CD	DOS
unit	NN	UNIT
of	IN	O
Regular	JJ	O
human	JJ	O
insulin	NN	O
,	,	O
but	CC	O
its	PRP$	O
effect	NN	O
is	VBZ	O
more	RBR	O
rapid	JJ	O
and	CC	O
of	IN	O
shorter	JJR	O
duration	NN	O
.	.	O

When	WRB	O
an	DT	O
inhibitor	NN	O
is	VBZ	O
present	JJ	O
,	,	O
the	DT	O
dosage	NN	O
requirement	NN	O
for	IN	O
FVIII	NNP	O
could	MD	O
be	VB	O
extremely	RB	O
variable	JJ	O
among	IN	O
different	JJ	O
patients	NNS	O
,	,	O
and	CC	O
the	DT	O
optimal	JJ	O
treatment	NN	O
can	MD	O
be	VB	O
determined	VBN	O
only	RB	O
by	IN	O
the	DT	O
clinical	JJ	O
response	NN	O
.	.	O

Patients	NNS	O
should	MD	O
dispose	VB	O
of	IN	O
used	JJ	O
patches	NNS	O
immediately	RB	O
upon	IN	O
removal	NN	O
by	IN	O
folding	VBG	O
the	DT	O
adhesive	JJ	O
side	NN	O
of	IN	O
the	DT	O
patch	NN	O
to	TO	O
itself	PRP	O
,	,	O
then	RB	O
flushing	VBG	O
down	RP	O
the	DT	O
toilet	NN	O
.	.	O

Titrate	NNP	O
QUDEXY	NNP	O
XR	NNP	O
according	VBG	O
to	TO	O
the	DT	O
following	JJ	O
schedule	NN	O
:	:	O

ROWEEPRA	NNP	O
tablets	NNS	O
should	MD	O
not	RB	O
be	VB	O
chewed	VBN	O
or	CC	O
crushed	VBN	O
.	.	O

The	DT	O
spray	NN	O
pump	NN	O
must	MD	O
be	VB	O
primed	VBN	O
prior	RB	O
to	TO	O
the	DT	O
first	JJ	O
use	NN	O
.	.	O

In	IN	O
severe	JJ	O
poisonings	NNS	O
,	,	O
it	PRP	O
may	MD	O
also	RB	O
be	VB	O
desirable	JJ	O
to	TO	O
concurrently	RB	O
administer	VB	O
an	DT	O
anticonvulsant	JJ	O
if	IN	O
seizure	NN	O
is	VBZ	O
suspected	VBN	O
in	IN	O
the	DT	O
unconscious	JJ	O
individual	JJ	O
since	IN	O
the	DT	O
classic	JJ	O
tonic	JJ	O
-	:	O
clonic	JJ	O
jerking	NN	O
may	MD	O
not	RB	O
be	VB	O
apparent	JJ	O
due	JJ	O
to	TO	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
poison	NN	O
.	.	O

Using	VBG	O
an	DT	O
appropriately	RB	O
sized	VBN	O
sterile	JJ	O
syringe	NN	O
,	,	O
needle	JJ	O
and	CC	O
aseptic	JJ	O
technique	NN	O
,	,	O
draw	VB	O
up	RP	O
the	DT	O
required	JJ	O
volume	NN	O
(	(	O
Table	JJ	O
1	CD	O
)	)	O
of	IN	O
preservative	JJ	O
-	:	O
free	JJ	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
USP	NNP	O
.	.	O

The	DT	O
stability	NN	O
of	IN	O
Pentothal	NNP	O
(	(	O
thiopental	JJ	O
sodium	NN	O
)	)	O
solutions	NNS	O
depends	VBZ	O
upon	IN	O
several	JJ	O
factors	NNS	O
,	,	O
including	VBG	O
the	DT	O
diluent	NN	O
,	,	O
temperature	NN	O
of	IN	O
storage	NN	O
and	CC	O
the	DT	O
amount	NN	O
of	IN	O
carbon	NN	O
dioxide	NN	O
from	IN	O
room	NN	O
air	NN	O
that	WDT	O
gains	NNS	O
access	NN	O
to	TO	O
the	DT	O
solution	NN	O
.	.	O

Localization	NN	O
of	IN	O
extra	JJ	O
-	:	O
thyroidal	NN	O
metastases	NNS	O
:	:	O
37	CD	O
megabecquerels	NNS	O
(	(	O
1000	CD	DOS
microcuries	NNS	UNIT
)	)	O
.	.	O

Reconstitute	NNP	O
each	DT	O
40	CD	DOS
mg	NNS	UNIT
vial	JJ	UNIT
with	IN	O
5	CD	DOS
mL	NNS	UNIT
each	DT	O
of	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
.	.	O

Carefully	RB	O
remove	VB	O
the	DT	O
clear	JJ	O
package	NN	O
from	IN	O
the	DT	O
Mix2Vial	NNP	O
transfer	NN	O
set	NN	O
.	.	O

To	TO	O
properly	RB	O
administer	VB	O
the	DT	O
product	NN	O
,	,	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
in	IN	O
a	DT	O
dorsal	JJ	O
position	NN	O
with	IN	O
the	DT	O
cervix	NN	O
visualized	VBD	O
using	VBG	O
a	DT	O
speculum	NN	O
.	.	O

In	IN	O
contrast	NN	O
,	,	O
if	IN	O
the	DT	O
second	JJ	O
sample	NN	O
demonstrates	VBZ	O
a	DT	O
higher	JJR	O
level	NN	O
,	,	O
accumulation	NN	O
of	IN	O
the	DT	O
drug	NN	O
can	MD	O
be	VB	O
assumed	VBN	O
,	,	O
and	CC	O
the	DT	O
infusion	NN	O
rate	NN	O
should	MD	O
be	VB	O
decreased	VBN	O
before	IN	O
the	DT	O
concentration	NN	O
exceeds	VBZ	O
20	CD	DOS
mcg	NN	UNIT
/	NNP	O
mL	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Pediatric	JJ	WHO
Patients	NNS	WHO
(	(	WHO
ages	VBZ	WHO
10	CD	WHO
to	TO	WHO
15	CD	WHO
years	NNS	WHO
)	)	WHO
:	:	O

Since	IN	O
grapefruit	NN	O
juice	NN	O
is	VBZ	O
known	VBN	O
to	TO	O
inhibit	VB	O
CYP3A4	NNP	O
-	:	O
mediated	VBD	O
metabolism	NN	O
of	IN	O
oral	JJ	O
amiodarone	NN	O
in	IN	O
the	DT	O
intestinal	JJ	O
mucosa	NN	O
,	,	O
resulting	VBG	O
in	IN	O
increased	VBN	O
plasma	NN	O
levels	NNS	O
of	IN	O
amiodarone	NN	O
,	,	O
grapefruit	NN	O
juice	NN	O
should	MD	O
not	RB	O
be	VB	O
taken	VBN	O
during	IN	O
treatment	NN	O
with	IN	O
oral	JJ	O
amiodarone	NN	O
(	(	O
see	VB	O
“	JJ	O
PRECAUTIONS	NNP	O
:	:	O
DRUG	NN	O
INTERACTIONS	NNP	O
”	NNP	O
)	)	O
.	.	O

The	DT	O
optimal	JJ	O
schedule	NN	O
for	IN	O
catch	NN	O
up	IN	O
of	IN	O
missed	JJ	O
or	CC	O
delayed	JJ	O
booster	NN	O
doses	NNS	O
is	VBZ	O
unknown	JJ	O
.	.	O

Extreme	JJ	O
caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
sotalol	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
failure	NN	WHO
undergoing	JJ	WHO
hemodialysis	NN	WHO
.	.	O

Because	IN	O
of	IN	O
the	DT	O
poor	JJ	O
correlation	NN	O
between	IN	O
symptoms	NNS	O
and	CC	O
endoscopic	JJ	O
appearance	NN	O
of	IN	O
the	DT	O
esophagus	NN	O
,	,	O
therapy	NN	O
directed	VBD	O
at	IN	O
esophageal	JJ	O
lesions	NNS	O
is	VBZ	O
best	RB	O
guided	VBN	O
by	IN	O
endoscopic	JJ	O
evaluation	NN	O
.	.	O

Once	RB	O
a	DT	O
successful	JJ	O
dose	NN	O
has	VBZ	O
been	VBN	O
found	VBN	O
(	(	O
i.e	NN	O
,	,	O
an	DT	O
average	JJ	O
episode	NN	O
is	VBZ	O
treated	VBN	O
with	IN	O
a	DT	O
single	JJ	O
unit	NN	O
)	)	O
,	,	O
patients	NNS	O
should	MD	O
limit	VB	O
consumption	NN	O
to	TO	O
four	CD	DOS
or	CC	O
fewer	JJR	DOS
units	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

With	IN	O
the	DT	O
needle	JJ	O
pointing	VBG	O
away	RB	O
from	IN	O
youâ€¦	NN	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
ITP	NNP	WHO
and	CC	O
mild	VB	O
,	,	O
moderate	VB	O
,	,	O
or	CC	O
severe	JJ	O
hepatic	JJ	O
impairment	NN	O
(	(	O
Child	NNP	O
-	:	O
Pugh	NNP	O
Class	NNP	O
A	NNP	O
,	,	O
B	NNP	O
,	,	O
C	NNP	O
)	)	O
,	,	O
initiate	JJ	O
PROMACTA	NNP	O
at	IN	O
a	DT	O
reduced	JJ	O
dose	NN	O
of	IN	O
25	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	JJ	FREQ
[	NNP	O
see	NN	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Long	NNP	O
-	:	O
term	NN	O
use	NN	O
of	IN	O
Claravis	NNP	O
,	,	O
even	RB	O
in	IN	O
low	JJ	O
doses	NNS	O
,	,	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
,	,	O
and	CC	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

Each	DT	O
200	CD	DOS
mg	NNS	UNIT
tablet	NN	UNIT
should	MD	O
be	VB	O
dispersed	VBN	O
in	IN	O
a	DT	O
minimum	NN	O
of	IN	O
2.5	CD	DOS
mL	NN	UNIT
of	IN	O
water	NN	O
and	CC	O
taken	VBN	O
immediately	RB	O
.	.	O

On	IN	O
those	DT	O
occasions	NNS	O
when	WRB	O
the	DT	O
breakthrough	NN	O
pain	NN	O
episode	NN	O
is	VBZ	O
not	RB	O
relieved	VBN	O
15	CD	O
minutes	NNS	O
after	IN	O
completion	NN	O
of	IN	O
the	DT	O
ACTIQ	NNP	O
unit	NN	O
,	,	O
patient	NN	O
may	MD	O
take	VB	O
ONLY	NNP	O
ONE	NNP	O
additional	JJ	O
dose	NN	O
using	VBG	O
the	DT	O
same	JJ	O
strength	NN	O
for	IN	O
that	DT	O
episode	NN	O
.	.	O

Contraindications	NNS	O

If	IN	O
not	RB	O
used	VBN	O
for	IN	O
more	JJR	O
than	IN	O
14	CD	O
days	NNS	O
,	,	O
rinse	VBP	O
the	DT	O
applicator	NN	O
and	CC	O
reprime	NN	O
with	IN	O
two	CD	DOS
sprays	NNS	UNIT
or	CC	O
until	IN	O
a	DT	O
fine	JJ	O
spray	NN	O
appears	VBZ	O
.	.	O

Acthar	NNP	O
Gel	NNP	O
after	IN	O
prolonged	VBN	O
use	NN	O
may	MD	O
lead	VB	O
to	TO	O
adrenal	JJ	O
insufficiency	NN	O
or	CC	O
recurrent	NN	O
symptoms	NNS	O
which	WDT	O
make	VBP	O
it	PRP	O
difficult	JJ	O
to	TO	O
stop	VB	O
the	DT	O
treatment	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
tolerating	VBG	WHO
therapy	NN	WHO
with	IN	WHO
normalization	NN	WHO
of	IN	O
ALT	NNP	O
at	IN	O
16	CD	PER
weeks	NNS	PER
of	IN	O
treatment	NN	O
,	,	O
INTRON	NNP	O
A	NNP	O
therapy	NN	O
should	MD	O
be	VB	O
extended	VBN	O
to	TO	O
18	CD	PER
to	TO	O
24	CD	PER
months	NNS	PER
(	(	O
72	CD	O
to	TO	O
96	CD	PER
weeks	NNS	PER
)	)	O
at	IN	O
3	CD	O
million	CD	O
IU	NNP	O
TIW	NNP	O
to	TO	O
improve	VB	O
the	DT	O
sustained	JJ	O
response	NN	O
rate	NN	O
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
,	,	O
Chronic	NNP	O
Hepatitis	NNP	O
C	NNP	O
)	)	O
.	.	O

Fat	NNP	O
emulsion	NN	O
administration	NN	O
should	MD	O
be	VB	O
considered	VBN	O
when	WRB	O
prolonged	JJ	O
parenteral	JJ	O
nutrition	NN	O
is	VBZ	O
required	VBN	O
in	IN	O
order	NN	O
to	TO	O
prevent	VB	O
essential	JJ	O
fatty	JJ	O
acid	NN	O
deficiency	NN	O
(	(	O
E.F.A.D	NNP	O
.	.	O
)	)	O
.	.	O

Single	NNP	DOS
dose	VBD	O
0.5	CD	DOS
mL	JJ	UNIT
vial	JJ	UNIT
contains	VBZ	O
no	DT	O
preservative	NN	O
.	.	O

BELSOMRA	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
with	IN	O
strong	JJ	O
CYP3A	NNP	O
inhibitors	NNS	O
[	NNP	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

Repeat	NN	O
this	DT	O
procedure	NN	O
with	IN	O
each	DT	O
vial	NN	O
in	IN	O
turn	NN	O
.	.	O

Also	RB	O
reduce	VB	O
dose	RB	O
accordingly	RB	O
when	WRB	O
using	VBG	O
with	IN	O
other	JJ	O
myelosuppressive	JJ	O
drugs	NNS	O
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
CONCERTA®	NNP	O
for	IN	O
long	RB	O
-	:	O
term	NN	O
use	NN	O
,	,	O
i.e	NN	O
,	,	O
for	IN	O
more	JJR	O
than	IN	O
7	CD	PER
weeks	NNS	PER
,	,	O
has	VBZ	O
not	RB	O
been	VBN	O
systematically	RB	O
evaluated	VBN	O
in	IN	O
controlled	JJ	O
trials	NNS	O
.	.	O

In	IN	O
clinical	JJ	O
studies	NNS	O
,	,	O
patients	NNS	WHO
were	VBD	WHO
treated	VBN	WHO
with	IN	WHO
CAVERJECT	NNP	WHO
in	IN	O
doses	NNS	O
ranging	VBG	O
from	IN	O
0.2	CD	DOS
to	TO	O
140	CD	DOS
micrograms	NNS	UNIT
;	:	O
however	RB	O
,	,	O
since	IN	O
99	CD	O
%	NN	O
of	IN	O
patients	NNS	O
received	JJ	O
doses	NNS	O
of	IN	O
60	CD	DOS
micrograms	NNS	UNIT
or	CC	O
less	JJR	O
,	,	O
doses	NNS	O
of	IN	O
greater	JJR	O
than	IN	O
60	CD	DOS
micrograms	NNS	UNIT
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

1	CD	O
.	.	O

See	VB	O
Table	JJ	O
1	CD	O
below	IN	O
for	IN	O
storage	NN	O
and	CC	O
administration	NN	O
time	NN	O
limits	NNS	O
for	IN	O
the	DT	O
different	JJ	O
diluents	NNS	O
.	.	O

SPECTRACEF®	NNP	O
(	(	O
cefditoren	JJ	WHO
pivoxil	NN	WHO
)	)	WHO
Dosage	NN	WHO
and	CC	WHO
Administration*	NNP	WHO
Adults	NNP	WHO
and	CC	WHO
Adolescents	NNP	WHO
(	(	WHO
≥	JJ	WHO
12	CD	WHO
Years	NNS	WHO
)	)	WHO

Label	NNP	O
appropriately	RB	O
.	.	O

CHILDREN	NN	O
:	:	O
weighing	NN	O
less	JJR	O
than	IN	O
100	CD	O
pounds	NNS	O
(	(	O
45	CD	O
kg	NN	O
)	)	O
;	:	O
1	CD	DOS
mg	NN	UNIT
/	NN	O
lb	NN	O
(	(	O
2.2	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
)	)	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
60	CD	PER
days	NNS	PER
.	.	O

The	DT	O
fill	NN	O
volume	NN	O
depends	VBZ	O
on	IN	O
body	NN	O
size	NN	O
,	,	O
usually	RB	O
from	IN	O
2.0	CD	DOS
to	TO	O
2.5	CD	DOS
liters	NNS	UNIT
per	IN	O
1.73m²	CD	O
for	IN	O
adults	NNS	WHO
.	.	O

Subsequently	RB	O
,	,	O
the	DT	O
health	NN	O
care	NN	O
provider	NN	O
may	MD	O
continue	VB	O
decreasing	VBG	O
the	DT	O
dose	NN	O
but	CC	O
at	IN	O
a	DT	O
more	RBR	O
gradual	JJ	O
rate	NN	O
.	.	O

No	DT	O
dose	JJ	O
adjustment	NN	O
recommendations	NNS	O
can	MD	O
be	VB	O
made	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
[	NNP	O
see	NN	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Adults	NNS	WHO
with	IN	O
uncertain	JJ	O
histories	NNS	O
of	IN	O
a	DT	O
complete	JJ	O
primary	JJ	O
vaccination	NN	O
series	NN	O
should	MD	O
receive	VB	O
a	DT	O
primary	JJ	O
series	NN	O
using	VBG	O
the	DT	O
combined	JJ	O
Td	NNP	O
toxoid	NN	O
.	.	O

Generally	RB	O
,	,	O
only	RB	O
increase	VB	O
the	DT	O
SUBSYS	NNP	O
dose	NN	O
when	WRB	O
a	DT	O
single	JJ	DOS
administration	NN	UNIT
of	IN	O
the	DT	O
current	JJ	O
dose	NN	O
fails	NNS	O
to	TO	O
adequately	RB	O
treat	VB	O
the	DT	O
breakthrough	NN	O
pain	NN	O
episode	NN	O
for	IN	O
several	JJ	O
consecutive	JJ	O
episodes	NNS	O
.	.	O

Care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
allow	VB	O
the	DT	O
gel	NN	O
to	TO	O
dry	VB	O
before	IN	O
allowing	VBG	O
the	DT	O
return	NN	O
of	IN	O
opposing	VBG	O
skin	JJ	O
surfaces	NNS	O
to	TO	O
their	PRP$	O
normal	JJ	O
positions	NNS	O
.	.	O

However	RB	O
,	,	O
it	PRP	O
is	VBZ	O
advisable	JJ	O
to	TO	O
ensure	VB	O
that	IN	O
patients	NNS	O
are	VBP	O
well	RB	O
hydrated	VBN	O
.	.	O

Patients	NNS	O
currently	RB	O
on	IN	O
immediate	JJ	O
release	NN	O
prednisone	NN	O
,	,	O
prednisolone	NN	O
,	,	O
or	CC	O
methylprednisolone	NN	O
should	MD	O
be	VB	O
switched	VBN	O
to	TO	O
RAYOS	NNP	O
at	IN	O
an	DT	O
equivalent	NN	O
dose	NN	O
based	VBN	O
on	IN	O
relative	JJ	O
potency	NN	O
(	(	O
2.4	CD	O
)	)	O
.	.	O

Treatment	NN	O
may	MD	O
be	VB	O
initiated	VBN	O
with	IN	O
or	CC	O
without	IN	O
a	DT	O
loading	NN	O
dose	NN	O
,	,	O
depending	VBG	O
upon	IN	O
the	DT	O
patient	NN	O
's	POS	O
risk	NN	O
of	IN	O
ARAVA	NNP	O
-	:	O
associated	VBN	O
hepatotoxicity	NN	O
and	CC	O
ARAVA	NNP	O
-	:	O
associated	VBN	O
myelosuppression	NN	O
.	.	O

Do	NNP	O
not	RB	O
exceed	VB	O
60	CD	DOS
doses	NNS	UNIT
for	IN	O
induction	NN	O
.	.	O

Although	IN	O
serum	NN	O
ferritin	NN	O
is	VBZ	O
usually	RB	O
a	DT	O
good	JJ	O
guide	NN	O
to	TO	O
body	NN	O
iron	NN	O
stores	NNS	O
,	,	O
the	DT	O
correlation	NN	O
of	IN	O
body	NN	O
iron	NN	O
stores	NNS	O
and	CC	O
serum	NN	O
ferritin	NN	O
may	MD	O
not	RB	O
be	VB	O
valid	JJ	O
in	IN	O
patients	NNS	WHO
on	IN	WHO
chronic	JJ	WHO
renal	JJ	WHO
dialysis	NN	WHO
who	WP	O
are	VBP	O
also	RB	O
receiving	VBG	O
iron	NN	O
dextran	NN	O
complex	NN	O
.	.	O

Frequent	JJ	O
communication	NN	O
is	VBZ	O
important	JJ	O
among	IN	O
the	DT	O
prescriber	NN	O
,	,	O
other	JJ	O
members	NNS	O
of	IN	O
the	DT	O
healthcare	NN	O
team	NN	O
,	,	O
the	DT	O
patient	NN	O
,	,	O
and	CC	O
the	DT	O
caregiver	NN	O
/	NNP	O
family	NN	O
during	IN	O
periods	NNS	O
of	IN	O
changing	VBG	O
analgesic	JJ	O
requirements	NNS	O
,	,	O
including	VBG	O
initial	JJ	O
titration	NN	O
.	.	O

Administer	NNP	O
Immune	NNP	O
Globulin	NNP	O
Infusion	NNP	O
10	CD	O
%	NN	O
(	(	O
Human	NNP	O
)	)	O
of	IN	O
HYQVIA	NNP	O
at	IN	O
rates	NNS	O
as	IN	O
shown	VBN	O
in	IN	O
Table	JJ	O
3	CD	O
for	IN	O
the	DT	O
initial	JJ	O
infusions	NNS	O
.	.	O

Assisted	NNP	O
Reproductive	NNP	O
Technologies	NNPS	O
:	:	O
As	IN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	WHO
with	IN	WHO
polycystic	JJ	WHO
ovary	JJ	WHO
syndrome	NN	WHO
,	,	O
the	DT	O
dose	NN	O
of	IN	O
Fertinex	NNP	O
(	(	O
urofollitropin	JJ	O
)	)	O
TM	NNP	O
to	TO	O
stimulate	VB	O
development	NN	O
of	IN	O
the	DT	O
follicle	NN	O
must	MD	O
be	VB	O
individualized	VBN	O
for	IN	O
each	DT	O
patient	NN	O
.	.	O

Plasma	NNP	O
-	:	O
LyteÒ	NNP	O
56	CD	O
and	CC	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
(	(	O
Multiple	NNP	O
Electrolytes	NNP	O
and	CC	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
Type	NNP	O
1	CD	O
,	,	O
USP	NNP	O
)	)	O

Grades	NNS	O
of	IN	O
Erythema	NNP	O

Therefore	RB	O
,	,	O
GLUCOTROL	NNP	O
XL	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
at	IN	O
least	JJS	O
4	CD	O
hours	NNS	O
prior	RB	O
to	TO	O
colesevelam	VB	O
.	.	O

Initiate	NNP	O
treatment	NN	O
with	IN	O
OPANA	NNP	O
ER	NNP	O
with	IN	O
the	DT	O
5	CD	DOS
mg	NNS	UNIT
tablet	VBP	UNIT
orally	RB	O
every	DT	FREQ
12	CD	FREQ
-	:	O
hours	NNS	O
.	.	O

If	IN	O
anatomically	RB	O
feasible	JJ	O
,	,	O
the	DT	O
FULL	NNP	O
DOSE	NNP	O
of	IN	O
HRIG	NNP	O
should	MD	O
be	VB	O
thoroughly	RB	O
infiltrated	VBN	O
in	IN	O
the	DT	O
area	NN	O
around	RB	O
and	CC	O
into	IN	O
the	DT	O
wounds	NNS	O
.	.	O

Geriatric	JJ	WHO
patients	NNS	WHO
may	MD	O
require	VB	O
reduced	JJ	O
doses	NNS	O
of	IN	O
etomidate	NN	O
.	.	O

If	IN	O
upon	JJ	O
visual	JJ	O
inspection	NN	O
there	EX	O
is	VBZ	O
cloudiness	NN	O
or	CC	O
evidence	NN	O
of	IN	O
crystallization	NN	O
after	IN	O
mixing	VBG	O
,	,	O
the	DT	O
solution	NN	O
should	MD	O
be	VB	O
discarded	VBN	O
and	CC	O
a	DT	O
fresh	JJ	O
solution	NN	O
prepared	VBN	O
.	.	O

Discard	NNP	O
any	DT	O
unused	JJ	O
portion	NN	O
.	.	O

Take	VB	O
Amitiza	NNP	O
orally	RB	O
with	IN	O
food	NN	O
and	CC	O
water	NN	O
.	.	O

Impaired	JJ	O
Methotrexate	NNP	O
Elimination	NNP	O
or	CC	O
Inadvertent	NNP	O
Overdosage	NN	O
:	:	O
Leucovorin	NNP	O
(	(	O
leucovorin	JJ	O
calcium	NN	O
)	)	O
rescue	NN	O
should	MD	O
begin	VB	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
after	IN	O
an	DT	O
inadvertent	JJ	O
overdosage	NN	O
and	CC	O
within	IN	O
24	CD	O
hours	NNS	O
of	IN	O
methotrexate	JJ	O
administration	NN	O
when	WRB	O
there	EX	O
is	VBZ	O
a	DT	O
delayed	JJ	O
excretion	NN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

Hold	VB	O
the	DT	O
syringe	NN	O
with	IN	O
either	DT	O
hand	NN	O
and	CC	O
use	VB	O
your	PRP$	O
other	JJ	O
hand	NN	O
to	TO	O
twist	VB	O
the	DT	O
rigid	JJ	O
needle	JJ	O
guard	NN	O
(	(	O
covers	VBZ	O
the	DT	O
needle	NN	O
)	)	O
counter	NN	O
-	:	O
clockwise	NN	O
.	.	O

If	IN	O
the	DT	O
contralateral	JJ	O
eye	NN	O
requires	VBZ	O
treatment	NN	O
,	,	O
a	DT	O
new	JJ	O
vial	NN	O
should	MD	O
be	VB	O
used	VBN	O
and	CC	O
the	DT	O
sterile	JJ	O
field	NN	O
,	,	O
syringe	NN	O
,	,	O
gloves	NNS	O
,	,	O
drapes	NNS	O
,	,	O
eyelid	JJ	O
speculum	NN	O
,	,	O
filter	NN	O
,	,	O
and	CC	O
injection	NN	O
needles	NNS	O
should	MD	O
be	VB	O
changed	VBN	O
before	IN	O
EYLEA	NNP	O
is	VBZ	O
administered	VBN	O
to	TO	O
the	DT	O
other	JJ	O
eye	NN	O
.	.	O

Although	IN	O
there	EX	O
is	VBZ	O
experience	NN	O
with	IN	O
doses	NNS	O
up	RB	O
to	TO	O
30	CD	DOS
mg	NNS	UNIT
/	JJ	O
m²	JJ	O
/	NN	O
wk	NN	O
in	IN	O
children	NNS	WHO
,	,	O
there	EX	O
are	VBP	O
too	RB	O
few	JJ	O
published	VBN	O
data	NNS	O
to	TO	O
assess	VB	O
how	WRB	O
doses	NNS	O
over	IN	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	O
m²	JJ	O
/	NNP	O
wk	NN	O
might	MD	O
affect	VB	O
the	DT	O
risk	NN	O
of	IN	O
serious	JJ	O
toxicity	NN	O
in	IN	O
children	NNS	WHO
.	.	O

The	DT	O
following	JJ	O
table	NN	O
provides	VBZ	O
acceptable	JJ	O
weight	NN	O
ranges	VBZ	O
for	IN	O
each	DT	O
dose	NN	O
and	CC	O
age	NN	O
category	NN	O
,	,	O
such	JJ	O
that	IN	O
patients	NNS	O
will	MD	O
receive	VB	O
between	IN	O
90	CD	O
%	NN	O
and	CC	O
180	CD	O
%	NN	O
of	IN	O
the	DT	O
calculated	JJ	O
recommended	VBD	O
dose	NN	O
.	.	O

Closely	RB	O
monitor	NN	O
for	IN	O
signs	NNS	O
of	IN	O
sedation	NN	O
and	CC	O
respiratory	NN	O
depression	NN	O
,	,	O
including	VBG	O
at	IN	O
each	DT	O
dosage	NN	O
increase	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Solutions	NNS	O
of	IN	O
MEFOXIN	NNP	O
,	,	O
like	IN	O
those	DT	O
of	IN	O
most	JJS	O
beta	SYM	O
-	:	O
lactam	NN	O
antibiotics	NNS	O
,	,	O
should	MD	O
not	RB	O
be	VB	O
added	VBN	O
to	TO	O
aminoglycoside	VB	O
solutions	NNS	O
(	(	O
e.g	NN	O
,	,	O
gentamicin	NN	O
sulfate	NN	O
,	,	O
tobramycin	JJ	O
sulfate	NN	O
,	,	O
amikacin	JJ	O
sulfate	NN	O
)	)	O
because	IN	O
of	IN	O
potential	JJ	O
interaction	NN	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
DERMATOP	NNP	O
Emollient	NNP	O
Cream	NNP	O
(	(	O
prednicarbate	JJ	O
emollient	NN	O
cream	NN	O
)	)	O
0.1	CD	O
%	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
for	IN	WHO
more	JJR	WHO
than	IN	O
3	CD	PER
weeks	NNS	PER
of	IN	O
use	NN	O
have	VBP	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	O

It	PRP	O
is	VBZ	O
not	RB	O
necessary	JJ	O
to	TO	O
monitor	VB	O
topiramate	JJ	O
plasma	NN	O
concentrations	NNS	O
to	TO	O
optimize	VB	O
QUDEXY	NNP	O
XR	NNP	O
therapy	NN	O
.	.	O

In	IN	O
ganglions	NNS	O
of	IN	O
joint	JJ	O
capsules	NNS	O
and	CC	O
tendon	JJ	O
sheaths	NNS	O
,	,	O
injection	NN	O
of	IN	O
0.5	CD	DOS
mL	NNS	UNIT
directly	RB	O
into	IN	O
the	DT	O
ganglion	NN	O
cysts	NNS	O
has	VBZ	O
produced	VBN	O
marked	VBN	O
reduction	NN	O
in	IN	O
the	DT	O
size	NN	O
of	IN	O
the	DT	O
lesions	NNS	O
.	.	O

To	TO	O
obtain	VB	O
a	DT	O
full	JJ	O
first	JJ	O
dose	NN	O
,	,	O
it	PRP	O
is	VBZ	O
necessary	JJ	O
to	TO	O
prime	VB	O
the	DT	O
canister	NN	O
pump	NN	O
.	.	O

Frequent	JJ	O
communication	NN	O
is	VBZ	O
important	JJ	O
among	IN	O
the	DT	O
prescriber	NN	O
,	,	O
other	JJ	O
members	NNS	O
of	IN	O
the	DT	O
healthcare	NN	O
team	NN	O
,	,	O
the	DT	O
patient	NN	O
,	,	O
and	CC	O
the	DT	O
caregiver	NN	O
/	NNP	O
family	NN	O
during	IN	O
periods	NNS	O
of	IN	O
changing	VBG	O
analgesic	JJ	O
requirements	NNS	O
,	,	O
including	VBG	O
initial	JJ	O
titration	NN	O
.	.	O

Using	VBG	O
the	DT	O
selected	VBN	O
syringe	NN	O
,	,	O
withdraw	VB	O
the	DT	O
volume	NN	O
of	IN	O
raxibacumab	NN	O
as	IN	O
calculated	VBN	O
in	IN	O
step	NN	O
2	CD	O
.	.	O

Table	JJ	O
7	CD	O
.	.	O

For	IN	O
other	JJ	O
wounds	NNS	O
,	,	O
a	DT	O
booster	NN	O
is	VBZ	O
appropriate	JJ	O
if	IN	O
the	DT	O
patient	NN	O
has	VBZ	O
not	RB	O
received	VBN	O
tetanus	NN	O
toxoid	NN	O
within	IN	O
the	DT	O
preceding	VBG	O
five	CD	O
years	NNS	O
.	.	O

It	PRP	O
may	MD	O
also	RB	O
be	VB	O
preferred	VBN	O
when	WRB	O
impairment	NN	O
of	IN	O
peripheral	JJ	O
conversion	NN	O
of	IN	O
levothyroxine	NN	O
(	(	O
T4	NNP	O
)	)	O
and	CC	O
liothyronine	NN	O
(	(	O
T3	NNP	O
)	)	O
is	VBZ	O
suspected	VBN	O
.	.	O

Multivitamins	NNS	O
,	,	O
other	JJ	O
products	NNS	O
containing	VBG	O
iron	NN	O
or	CC	O
zinc	NN	O
,	,	O
antacids	NNS	O
containing	VBG	O
magnesium	NN	O
and	CC	O
aluminum	NN	O
,	,	O
sucralfate	NN	O
,	,	O
or	CC	O
Videx®	NNP	O
(	(	O
Didanosine	NNP	O
)	)	O
,	,	O
chewable	JJ	O
/	NN	O
buffered	VBD	O
tablets	NNS	O
or	CC	O
the	DT	O
pediatric	JJ	O
powder	NN	O
for	IN	O
oral	JJ	O
solution	NN	O
,	,	O
should	MD	O
not	RB	O
be	VB	O
taken	VBN	O
within	IN	O
2	CD	O
hours	NNS	O
of	IN	O
administration	NN	O
of	IN	O
norfloxacin	NNS	O
.	.	O

After	IN	O
discontinuation	NN	O
of	IN	O
amiodarone	NN	O
,	,	O
sotalol	JJ	O
hydrochloride	NN	O
tablets	NNS	O
,	,	O
USP	NNP	O
should	MD	O
not	RB	O
be	VB	O
initiated	VBN	O
until	IN	O
the	DT	O
QT	NNP	O
interval	NN	O
is	VBZ	O
normalized	VBN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

Initiate	NNP	O
the	DT	O
dosing	VBG	O
regimen	NNS	O
for	IN	O
each	DT	O
patient	NN	O
individually	RB	O
,	,	O
taking	VBG	O
into	IN	O
account	NN	O
the	DT	O
patient	NN	O
's	POS	O
prior	JJ	O
analgesic	JJ	O
treatment	NN	O
experience	NN	O
and	CC	O
risk	NN	O
factors	NNS	O
for	IN	O
addiction	NN	O
,	,	O
abuse	NN	O
,	,	O
and	CC	O
misuse	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

For	IN	O
the	DT	O
prefilled	JJ	O
syringes	NNS	O
,	,	O
attach	VBP	O
a	DT	O
sterile	JJ	O
needle	NN	O
and	CC	O
administer	RB	O
intramuscularly	RB	O
.	.	O

With	IN	O
tip	JJ	O
lying	VBG	O
free	JJ	O
and	CC	O
movable	JJ	O
between	IN	O
skin	NN	O
and	CC	O
muscle	NN	O
,	,	O
begin	VB	O
clysis	NN	O
;	:	O
fluid	NN	O
should	MD	O
start	VB	O
in	IN	O
readily	RB	O
without	IN	O
pain	NN	O
or	CC	O
lump	NN	O
.	.	O

FOR	NNP	O
TOPICAL	NNP	O
OPHTHALMIC	NNP	O
USE	NNP	O
ONLY	NNP	O
.	.	O

Do	NNP	O
not	RB	O
crush	VB	O
or	CC	O
cut	VB	O
XELODA	JJ	O
tablets	NNS	O
.	.	O

Penetrate	VB	O
the	DT	O
stopper	NN	O
of	IN	O
the	DT	O
Cysview	NNP	O
(	(	O
hexaminolevulinate	JJ	O
hydrochloride	NN	O
intravesical	JJ	O
solution	NN	O
)	)	O
powder	NN	O
vial	NN	O
with	IN	O
the	DT	O
needle	NN	O
and	CC	O
inject	JJ	O
10	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
diluent	NN	O
from	IN	O
the	DT	O
syringe	NN	O
into	IN	O
the	DT	O
powder	NN	O
vial	NN	O
(	(	O
Figure	NNP	O
2	CD	O
)	)	O
.	.	O

9	CD	O

Serum	NNP	O
concentrations	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
in	IN	O
changing	VBG	O
from	IN	O
extended	VBN	O
phenytoin	NN	O
sodium	NN	O
capsules	NNS	O
,	,	O
USP	NNP	O
,	,	O
to	TO	O
prompt	VB	O
phenytoin	JJ	O
sodium	NN	O
capsules	NNS	O
,	,	O
USP	NNP	O
,	,	O
and	CC	O
from	IN	O
the	DT	O
sodium	NN	O
salt	NN	O
to	TO	O
the	DT	O
free	JJ	O
acid	NN	O
form	NN	O
.	.	O

Treatment	NN	O
may	MD	O
be	VB	O
repeated	VBN	O
every	DT	FREQ
3	CD	FREQ
weeks.3,4	NN	FREQ

If	IN	O
particulate	JJ	O
matter	NN	O
or	CC	O
discoloration	NN	O
is	VBZ	O
observed	VBN	O
,	,	O
the	DT	O
vaccine	NN	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
and	CC	O
the	DT	O
vial	NN	O
should	MD	O
be	VB	O
disposed	VBN	O
safely	RB	O
.	.	O

Administer	NNP	O
dose	NN	O
by	IN	O
gently	RB	O
squeezing	VBG	O
liquid	NN	O
into	IN	O
infant	NN	WHO
's	POS	O
mouth	NN	O
toward	IN	O
the	DT	O
inner	JJ	O
cheek	NN	O
until	IN	O
dosing	VBG	O
tube	NN	O
is	VBZ	O
empty	JJ	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
IMPLANON	NNP	O
does	VBZ	O
not	RB	O
depend	VB	O
on	IN	O
daily	JJ	FREQ
,	,	O
weekly	JJ	FREQ
or	CC	O
monthly	JJ	O
administration	NN	O
.	.	O

After	IN	O
observing	VBG	O
the	DT	O
response	NN	O
to	TO	O
initial	JJ	O
therapy	NN	O
with	IN	O
meloxicam	JJ	O
tablets	NNS	O
,	,	O
USP	NNP	O
the	DT	O
dose	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
to	TO	O
suit	VB	O
an	DT	O
individual	JJ	O
patient	NN	O
's	POS	O
needs	NNS	O
.	.	O

Do	VBP	O
not	RB	O
make	VB	O
a	DT	O
large	JJ	O
incision	NN	O
.	.	O

The	DT	O
efficacy	NN	O
of	IN	O
therapy	NN	O
should	MD	O
be	VB	O
monitored	VBN	O
by	IN	O
repeated	JJ	O
urine	JJ	O
cultures	NNS	O
.	.	O

As	IN	O
noted	VBN	O
above	IN	O
,	,	O
it	PRP	O
is	VBZ	O
essential	JJ	O
that	IN	O
qualified	JJ	O
personnel	NNS	O
and	CC	O
adequate	VB	O
facilities	NNS	O
be	VB	O
available	JJ	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
respiratory	NN	O
depression	NN	O
.	.	O

Adjustments	NNS	O
should	MD	O
be	VB	O
made	VBN	O
at	IN	O
intervals	NNS	O
of	IN	O
4	CD	PER
weeks	NNS	PER
or	CC	O
more	JJR	O
.	.	O

In	IN	O
these	DT	O
studies	NNS	O
,	,	O
GFR	NNP	O
was	VBD	O
measured	VBN	O
by	IN	O
Cr	NNP	O
-	:	O
EDTA	JJ	O
clearance	NN	O
.	.	O

Use	VB	O
a	DT	O
separate	JJ	O
unused	JJ	O
Mix2Vial	NNP	O
transfer	NN	O
set	NN	O
for	IN	O
each	DT	O
product	NN	O
vial	NN	O
.	.	O

Illustrations	NNS	O
are	VBP	O
also	RB	O
pictured	VBN	O
below	IN	O
.	.	O

Transition	NN	O
from	IN	O
IV	NNP	O
or	CC	O
IM	NNP	O
dosing	NN	O
of	IN	O
ketorolac	NN	O
tromethamine	NN	O
(	(	O
single	JJ	O
-	:	O
or	CC	O
multiple	JJ	O
-	:	O
dose	NN	O
)	)	O
to	TO	O
multiple	VB	O
-	:	O
dose	NN	O
TORADOL	NNP	O
(	(	O
ketorolac	FW	O
tromethamine	NN	O
)	)	O
ORAL	NN	O
:	:	O

However	RB	O
,	,	O
there	EX	O
are	VBP	O
no	DT	O
clinical	JJ	O
data	NNS	O
with	IN	O
this	DT	O
dose	JJ	O
adjustment	NN	O
in	IN	O
patients	NNS	WHO
receiving	VBG	WHO
strong	JJ	WHO
CYP3A4	NNP	WHO
/	NNP	O
PgP	NNP	O
inducers	NNS	O
.	.	O

When	WRB	O
changing	VBG	O
strengths	NNS	O
of	IN	O
pancreatic	JJ	O
enzyme	NN	O
products	NNS	O
,	,	O
care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
maintain	VB	O
equivalent	JJ	O
lipase	NN	O
units	NNS	O
for	IN	O
each	DT	O
divided	JJ	O
dosage	NN	O
.	.	O

Fat	NNP	O
,	,	O
however	RB	O
,	,	O
should	MD	O
not	RB	O
provide	VB	O
more	JJR	O
than	IN	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
total	JJ	O
caloric	JJ	O
intake	NN	O
.	.	O

In	IN	O
adolescents	NNS	WHO
≥	VBP	WHO
16	CD	WHO
years	NNS	WHO
and	CC	WHO
adults	NNS	WHO
,	,	O
including	VBG	O
the	DT	O
elderly	JJ	O
,	,	O
the	DT	O
final	JJ	O
theophylline	NN	O
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
400	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
risk	NN	O
factors	NNS	O
for	IN	O
reduced	JJ	O
theophylline	JJ	O
clearance	NN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
or	CC	O
if	IN	O
it	PRP	O
is	VBZ	O
not	RB	O
feasible	JJ	O
to	TO	O
monitor	VB	O
serum	JJ	O
theophylline	NN	O
concentrations	NNS	O
.	.	O

(	(	O
See	VB	O
also	RB	O
WARNINGS	NNP	O
)	)	O

The	DT	O
final	JJ	O
solution	NN	O
is	VBZ	O
clear	JJ	O
or	CC	O
slightly	RB	O
opalescent	JJ	O
,	,	O
colorless	NN	O
or	CC	O
slightly	RB	O
yellow	JJ	O
.	.	O

Step	NN	O
8	CD	O
.	.	O

When	WRB	O
these	DT	O
substances	NNS	O
or	CC	O
their	PRP$	O
derivatives	NNS	O
are	VBP	O
injected	VBN	O
intramuscularly	RB	O
or	CC	O
into	IN	O
joint	JJ	O
spaces	NNS	O
,	,	O
their	PRP$	O
relative	JJ	O
properties	NNS	O
may	MD	O
be	VB	O
greatly	RB	O
altered	VBN	O
.	.	O

After	IN	O
reconstitution	NN	O
and	CC	O
thorough	JJ	O
agitation	NN	O
,	,	O
ActHIB	NNP	O
®	NNP	O
or	CC	O
OmniHIBwill	NNP	O
appear	VBP	O
whitish	JJ	O
in	IN	O
color	NN	O
.	.	O

Refer	NN	O
to	TO	O
directions	NNS	O
accompanying	VBG	O
ancillary	JJ	O
equipment	NN	O
for	IN	O
CAPD	NNP	O
and	CC	O
APD	NNP	O
system	NN	O
preparation	NN	O
.	.	O

Attach	NNP	O
a	DT	O
30	CD	O
-	:	O
gauge	NN	O
x	NN	O
½	NNP	O
-	:	O
inch	NN	O
sterile	JJ	O
injection	NN	O
needle	JJ	O
firmly	RB	O
onto	IN	O
the	DT	O
syringe	NN	O
by	IN	O
screwing	VBG	O
it	PRP	O
tightly	RB	O
onto	IN	O
the	DT	O
Luer	NNP	O
lock	NN	O
.	.	O

The	DT	O
capsules	NNS	O
are	VBP	O
stable	JJ	O
for	IN	O
24	CD	PER
months	NNS	PER
under	IN	O
such	JJ	O
refrigeration	NN	O
conditions	NNS	O
.	.	O

If	IN	O
the	DT	O
NEURONTIN	NNP	O
dose	NN	O
is	VBZ	O
reduced	VBN	O
,	,	O
discontinued	VBN	O
,	,	O
or	CC	O
substituted	VBN	O
with	IN	O
an	DT	O
alternative	JJ	O
medication	NN	O
,	,	O
this	DT	O
should	MD	O
be	VB	O
done	VBN	O
gradually	RB	O
over	IN	O
a	DT	O
minimum	NN	O
of	IN	O
1	CD	PER
week	NN	PER
(	(	O
a	DT	O
longer	JJR	O
period	NN	O
may	MD	O
be	VB	O
needed	VBN	O
at	IN	O
the	DT	O
discretion	NN	O
of	IN	O
the	DT	O
prescriber	NN	O
)	)	O
.	.	O

For	IN	O
the	DT	O
prefilled	JJ	O
syringes	NNS	O
,	,	O
attach	VBP	O
a	DT	O
sterile	JJ	O
needle	NN	O
and	CC	O
administer	RB	O
intramuscularly	RB	O
.	.	O

Patients	NNS	O
who	WP	O
tolerate	VBP	O
the	DT	O
5	CD	O
%	NN	O
concentration	NN	O
at	IN	O
4	CD	DOS
mL	NN	UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
Hr	NNP	O
can	MD	O
be	VB	O
infused	VBN	O
with	IN	O
the	DT	O
10	CD	O
%	NN	O
concentration	NN	O
starting	VBG	O
at	IN	O
0.5	CD	DOS
mL	NN	UNIT
/	NNP	O
kg	NNP	O
/	NNP	O
Hr	NNP	O
.	.	O

For	IN	O
Patients	NNS	WHO
with	IN	WHO
CKD	NNP	WHO
not	RB	WHO
on	IN	WHO
dialysis	NN	WHO
:	:	O

If	IN	O
adequate	JJ	O
response	NN	O
is	VBZ	O
not	RB	O
obtained	VBN	O
with	IN	O
180	CD	DOS
mg	NNS	UNIT
of	IN	O
ISOPTIN	NNP	O
SR	NNP	O
,	,	O
the	DT	O
dose	NN	O
may	MD	O
be	VB	O
titrated	VBN	O
upward	RB	O
in	IN	O
the	DT	O
following	JJ	O
manner	NN	O
:	:	O

Table	JJ	O
1	CD	O
:	:	O
Amount	NN	O
of	IN	O
PLIAGLIS	NNP	O
Cream	NNP	O
According	VBG	O
to	TO	O
Treatment	NNP	O
Site	NNP	O
Surface	NNP	O
Area	NNP	O

Table	JJ	O
1	CD	O
:	:	O
Dosing	NN	O
Recommendations	NNS	O
In	IN	O
Patients	NNP	WHO
Less	NNP	WHO
Than	NNP	WHO
18	CD	WHO
Years	NNS	WHO
Of	IN	WHO
Age	NNP	WHO

Insert	NNP	O
the	DT	O
needle	NN	O
into	IN	O
the	DT	O
injection	NN	O
area	NN	O
as	IN	O
instructed	VBN	O
above	IN	O
.	.	O

When	WRB	O
reconstituting	VBG	O
the	DT	O
vaccine	NN	O
,	,	O
use	NN	O
only	RB	O
the	DT	O
sterile	JJ	O
diluent	NN	O
supplied	VBN	O
with	IN	O
VARIVAX	NNP	O
.	.	O

For	IN	O
HCV	NNP	WHO
genotype	NN	WHO
3	CD	WHO
patients	NNS	WHO
with	IN	WHO
compensated	JJ	WHO
cirrhosis	NN	WHO
(	(	O
Child	NNP	O
-	:	O
Pugh	IN	O
A	NNP	O
)	)	O
,	,	O
the	DT	O
recommended	JJ	O
dosing	NN	O
of	IN	O
ribavirin	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
weight	NN	O
(	(	O
1000	CD	DOS
mg	NN	UNIT
for	IN	O
patients	NNS	WHO
weighing	VBG	WHO
less	JJR	WHO
than	IN	WHO
75	CD	WHO
kg	NNS	WHO
and	CC	O
1200	CD	DOS
mg	NN	UNIT
for	IN	O
those	DT	O
weighing	VBG	O
at	IN	O
least	JJS	O
75	CD	O
kg	NNS	O
administered	VBN	O
orally	RB	O
in	IN	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
with	IN	O
food	NN	O
)	)	O
.	.	O

The	DT	O
initial	JJ	O
levothyroxine	NN	O
dosage	NN	O
is	VBZ	O
based	VBN	O
on	IN	O
the	DT	O
age	NN	O
,	,	O
weight	NN	O
,	,	O
and	CC	O
cardiac	JJ	O
status	NN	O
of	IN	O
the	DT	O
patient	NN	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
severity	NN	O
and	CC	O
duration	NN	O
of	IN	O
the	DT	O
hypothyroidism	NN	O
.	.	O

Reposition	NNP	O
the	DT	O
infant	NN	WHO
for	IN	O
instillation	NN	O
of	IN	O
the	DT	O
next	JJ	O
quarter	NN	O
-	:	O
dose	NN	O
.	.	O

Examples	NNS	O
(	(	O
assuming	VBG	O
patient	NN	O
's	POS	O
baseline	NN	O
factor	NN	O
IX	NNP	O
level	NN	O
is	VBZ	O
<	JJ	O
1	CD	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
:	:	O

Nitrogen	NNP	O
mustard	NN	O
has	VBZ	O
been	VBN	O
used	VBN	O
by	IN	O
intracavitary	JJ	O
administration	NN	O
with	IN	O
varying	VBG	O
success	NN	O
in	IN	O
certain	JJ	O
malignant	JJ	O
conditions	NNS	O
for	IN	O
the	DT	O
control	NN	O
of	IN	O
pleural,4	JJ	O
-	:	O
13	CD	O
peritoneal,5,6,9,11	NN	O
-	:	O
16	CD	O
and	CC	O
pericardial,5,11	VB	O
-	:	O
13	CD	O
effusions	NNS	O
caused	VBN	O
by	IN	O
malignant	JJ	O
cells	NNS	O
.	.	O

Step	NN	O
5	CD	O
.	.	O

In	IN	O
order	NN	O
to	TO	O
reduce	VB	O
the	DT	O
potential	NN	O
for	IN	O
extravasation	NN	O
during	IN	O
peripheral	JJ	O
injection	NN	O
,	,	O
a	DT	O
catheter	NN	O
of	IN	O
approximately	RB	O
20	CD	DOS
cm	NNS	UNIT
in	IN	O
length	NN	O
should	MD	O
be	VB	O
employed	VBN	O
.	.	O

In	IN	O
the	DT	O
controlled	JJ	O
clinical	JJ	O
trials	NNS	O
of	IN	O
fluoxetine	NN	O
supporting	VBG	O
its	PRP$	O
effectiveness	NN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
OCD	NNP	O
,	,	O
patients	NNS	O
were	VBD	O
administered	VBN	O
fixed	VBN	O
daily	JJ	FREQ
doses	NNS	O
of	IN	O
20	CD	DOS
,	,	O
40	CD	DOS
,	,	O
or	CC	O
60	CD	DOS
mg	NN	UNIT
of	IN	O
fluoxetine	NN	O
or	CC	O
placebo	NN	O
[	NNS	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

2	CD	O
.	.	O

GH	NNP	O
and	CC	O
IGF	NNP	O
-	:	O
1	CD	O
levels	NNS	O
should	MD	O
be	VB	O
obtained	VBN	O
6	CD	PER
weeks	NNS	PER
after	IN	O
this	DT	O
change	NN	O
in	IN	O
dosing	VBG	O
regimen	NNS	O
to	TO	O
evaluate	VB	O
persistence	NN	O
of	IN	O
patient	JJ	O
response	NN	O
.	.	O

A	DT	O
rest	NN	O
period	NN	O
of	IN	O
several	JJ	O
days	NNS	O
may	MD	O
be	VB	O
taken	VBN	O
if	IN	O
required	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
discomfort	NN	O
or	CC	O
severity	NN	O
of	IN	O
the	DT	O
local	JJ	O
skin	NN	O
reaction	NN	O
.	.	O

Solutions	NNS	O
prepared	VBD	O
for	IN	O
infusion	NN	O
(	(	O
MERREM	NNP	O
I.V	NNP	O
.	.	O

Bacteriostatic	JJ	O
diluents	NNS	O
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

Doses	NNS	O
greater	JJR	O
than	IN	O
2,500	CD	DOS
lipase	JJ	UNIT
units	NNS	UNIT
/	VBP	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
per	IN	O
meal	NN	O
(	(	O
or	CC	O
greater	JJR	O
than	IN	O
10,000	CD	DOS
lipase	JJ	UNIT
units	NNS	UNIT
/	VBP	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
per	IN	FREQ
day	NN	FREQ
)	)	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
and	CC	O
only	RB	O
if	IN	O
they	PRP	O
are	VBP	O
documented	VBN	O
to	TO	O
be	VB	O
effective	JJ	O
by	IN	O
3	CD	O
-	:	O
day	NN	O
fecal	JJ	O
fat	NN	O
measures	NNS	O
that	WDT	O
indicate	VBP	O
a	DT	O
significantly	RB	O
improved	VBN	O
coefficient	NN	O
of	IN	O
fat	JJ	O
absorption	NN	O
.	.	O

If	IN	O
the	DT	O
woman	NN	O
does	VBZ	O
not	RB	O
have	VB	O
scheduled	VBN	O
or	CC	O
withdrawal	VBN	O
bleeding	NN	O
(	(	O
bleeding	VBG	O
that	DT	O
should	MD	O
occur	VB	O
during	IN	O
the	DT	O
patch	NN	O
-	:	O
free	JJ	O
week	NN	PER
)	)	O
,	,	O
she	PRP	O
should	MD	O
resume	VB	O
treatment	NN	O
on	IN	O
the	DT	O
next	JJ	O
scheduled	JJ	O
Change	NNP	O
Day	NNP	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
if	IN	O
contamination	NN	O
is	VBZ	O
suspected	VBN	O
.	.	O

The	DT	O
vial	JJ	O
must	MD	O
be	VB	O
discarded	VBN	O
after	IN	O
reconstitution	NN	O
and	CC	O
withdrawal	NN	O
of	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
.	.	O

Clean	VB	O
the	DT	O
insertion	NN	O
site	NN	O
with	IN	O
an	DT	O
antiseptic	JJ	O
solution	NN	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Dilution	NN	O
of	IN	O
TEPADINA	NNP	O
in	IN	O
the	DT	O
infusion	NN	O
bag	NN	O

Adults	NNS	WHO
and	CC	WHO
Children	NNP	WHO
over	IN	WHO
15	CD	WHO
kg	NNS	WHO
(	(	O
33	CD	O
lbs	NN	O
)	)	O
:	:	O
See	JJ	O
Dosage	NNP	O
Table	NNP	O
.	.	O

Esophageal	JJ	O
Candidiasis	NN	O
:	:	O
For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
esophageal	JJ	O
candidiasis	NN	O
,	,	O
the	DT	O
recommended	JJ	O
dosage	NN	O
of	IN	O
fluconazole	NN	O
in	IN	O
children	NNS	WHO
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
on	IN	O
the	DT	O
first	JJ	O
day	NN	O
,	,	O
followed	VBN	O
by	IN	O
3	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NNS	O
once	RB	FREQ
daily	RB	FREQ
.	.	O

If	IN	O
dose	JJ	O
reduction	NN	O
is	VBZ	O
not	RB	O
effective	JJ	O
in	IN	O
controlling	VBG	O
abnormalities	NNS	O
,	,	O
or	CC	O
if	IN	O
the	DT	O
adverse	JJ	O
event	NN	O
or	CC	O
abnormality	NN	O
is	VBZ	O
severe	JJ	O
,	,	O
Gengraf®	NNP	O
should	MD	O
be	VB	O
discontinued	VBN	O
.	.	O

The	DT	O
clinical	JJ	O
response	NN	O
to	TO	O
Exforge	NNP	O
should	MD	O
be	VB	O
subsequently	RB	O
evaluated	VBN	O
and	CC	O
if	IN	O
blood	NN	O
pressure	NN	O
remains	VBZ	O
uncontrolled	JJ	O
after	IN	O
3	CD	PER
to	TO	O
4	CD	PER
weeks	NNS	PER
of	IN	O
therapy	NN	O
,	,	O
the	DT	O
dose	NN	O
may	MD	O
be	VB	O
titrated	VBN	O
up	RP	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
10	CD	DOS
/	JJ	O
320	CD	DOS
mg	NN	UNIT
.	.	O

Dosage	NN	O
Adjustment	NNP	O
for	IN	O
Patients	NNPS	WHO
with	IN	WHO
Altered	NNP	WHO
Creatinine	NNP	WHO
Clearance	NNP	WHO

1	CD	O
.	.	O

Frequent	JJ	O
laboratory	NN	O
determinations	NNS	O
and	CC	O
clinical	JJ	O
evaluation	NN	O
are	VBP	O
essential	JJ	O
to	TO	O
monitor	VB	O
changes	NNS	O
in	IN	O
blood	NN	O
glucose	NN	O
and	CC	O
electrolyte	JJ	O
concentrations	NNS	O
,	,	O
and	CC	O
fluid	NN	O
and	CC	O
electrolyte	JJ	O
balance	NN	O
during	IN	O
prolonged	JJ	O
parenteral	JJ	O
therapy	NN	O
.	.	O

The	DT	O
sagittal	JJ	O
slices	NNS	O
are	VBP	O
slightly	RB	O
off	IN	O
midline	NN	O
in	IN	O
one	CD	O
hemisphere	NN	O
and	CC	O
shown	VBN	O
using	VBG	O
a	DT	O
rainbow	NN	O
color	NN	O
scale	NN	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
high	JJ	WHO
acetylation	NN	WHO
rates	NNS	WHO
,	,	WHO
or	CC	WHO
who	WP	WHO
are	VBP	WHO
receiving	VBG	WHO
treatment	NN	WHO
affecting	VBG	WHO
acetylation	NN	WHO
may	MD	O
require	VB	O
an	DT	O
adjustment	NN	O
in	IN	O
dosage	NN	O
.	.	O

Patients	NNS	WHO
already	RB	WHO
taking	VBG	WHO
naproxen	JJ	WHO
250	CD	DOS
mg	NN	UNIT
,	,	O
375	CD	DOS
mg	NN	UNIT
,	,	O
or	CC	O
500	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
(	(	O
morning	NN	O
and	CC	O
evening	NN	O
)	)	O
may	MD	O
have	VB	O
their	PRP$	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
replaced	VBD	O
with	IN	O
NAPRELAN	NNP	O
Tablets	NNP	O
as	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	FREQ
dose	NN	O
.	.	O

every	DT	O
10	CD	O
minutes	NNS	O
(	(	O
see	VB	O
PATIENT	NNP	O
INFORMATION	NNP	O
)	)	O
.	.	O

IMPORTANT	NN	O
:	:	O
Skin	NNP	O
should	MD	O
be	VB	O
clean	JJ	O
and	CC	O
dry	JJ	O
before	IN	O
tape	NN	O
is	VBZ	O
applied	VBN	O
.	.	O

After	IN	O
the	DT	O
solution	NN	O
is	VBZ	O
diluted	VBN	O
for	IN	O
intravenous	JJ	O
use	NN	O
,	,	O
the	DT	O
solution	NN	O
should	MD	O
be	VB	O
used	VBN	O
immediately	RB	O
.	.	O

As	IN	O
with	IN	O
other	JJ	O
antidepressants	NNS	O
,	,	O
the	DT	O
full	JJ	O
antidepressant	JJ	O
effect	NN	O
of	IN	O
BUDEPRION	NNP	O
XL™	NNP	O
may	MD	O
not	RB	O
be	VB	O
evident	JJ	O
until	IN	O
4	CD	PER
weeks	NNS	PER
of	IN	O
treatment	NN	O
or	CC	O
longer	JJR	O
.	.	O

DO	NNP	O
NOT	NNP	O
USE	NNP	O
BACTERIOSTATIC	NNP	O
WATER	NNP	O
FOR	NNP	O
INJECTION	NNP	O
CONTAINING	NNP	O
BENZYL	NNP	O
ALCOHOL	NNP	O
OR	NNP	O
PARABENS	NNP	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Maintenance	NN	O
of	IN	O
trough	JJ	O
protein	NN	O
C	NNP	O
activity	NN	O
levels	NNS	O
above	IN	O
25	CD	O
%	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

Dispose	NNP	O
of	IN	O
IONSYS	NNP	O
in	IN	O
accordance	NN	O
with	IN	O
state	NN	O
and	CC	O
federal	JJ	O
regulations	NNS	O
for	IN	O
controlled	JJ	O
substances	NNS	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
gloves	NNS	O
when	WRB	O
preparing	VBG	O
and	CC	O
administering	VBG	O
Hizentra	NNP	O
is	VBZ	O
optional	JJ	O
.	.	O

CAUTION	NN	O
!	.	O

Treatment	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
with	IN	O
a	DT	O
dose	NN	O
of	IN	O
1,000	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

immediate	JJ	O
-	:	O
release	NN	O
morphine	NN	O
)	)	O
than	IN	O
to	TO	O
overestimate	VB	O
the	DT	O
24	CD	O
-	:	O
hour	NN	O
oral	JJ	O
morphine	NN	O
requirements	NNS	O
which	WDT	O
could	MD	O
result	VB	O
in	IN	O
an	DT	O
adverse	JJ	O
reaction	NN	O
.	.	O

Children	$	WHO
6	CD	WHO
to	TO	WHO
12	CD	WHO
Years	NNS	WHO
of	IN	WHO
Age	NNP	WHO
:	:	O
The	DT	O
usual	JJ	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
or	CC	O
two	CD	DOS
inhalations	NNS	UNIT
(	(	O
75	CD	DOS
to	TO	O
150	CD	DOS
mcg	NN	UNIT
)	)	O
given	VBN	O
three	CD	O
to	TO	O
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
or	CC	O
two	CD	DOS
to	TO	O
four	CD	DOS
inhalations	NNS	UNIT
(	(	O
150	CD	DOS
to	TO	O
300	CD	DOS
mcg	NN	UNIT
)	)	O
given	VBN	O
twice	JJ	FREQ
daily	RB	FREQ
.	.	O

FOSCAVIR	NNP	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
abnormal	JJ	WHO
renal	JJ	WHO
function	NN	WHO
because	IN	O
reduced	VBN	O
plasma	JJ	O
clearance	NN	O
of	IN	O
foscarnet	NN	O
will	MD	O
result	VB	O
in	IN	O
elevated	JJ	O
plasma	NN	O
levels	NNS	O
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
)	)	O
.	.	O

Females	NNS	O
of	IN	O
reproductive	JJ	O
potential	NN	O
must	MD	O
have	VB	O
negative	JJ	O
pregnancy	NN	O
testing	VBG	O
and	CC	O
use	VB	O
contraception	NN	O
methods	NNS	O
before	IN	O
initiating	VBG	O
POMALYST	NNP	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Physical	JJ	O
incompatibility	NN	O
with	IN	O
other	JJ	O
IV	NNP	O
drugs	NNS	O
has	VBZ	O
also	RB	O
been	VBN	O
reported	VBN	O
including	VBG	O
acyclovir	JJ	O
sodium	NN	O
,	,	O
ganciclovir	NN	O
,	,	O
trimetrexate	NN	O
glucuronate	NN	O
,	,	O
pentamidine	NN	O
isethionate	NN	O
,	,	O
vancomycin	NN	O
,	,	O
trimethoprim	JJ	O
/	JJ	O
sulfamethoxazole	NN	O
,	,	O
diazepam	NN	O
,	,	O
midazolam	NN	O
,	,	O
digoxin	NN	O
,	,	O
phenytoin	NN	O
,	,	O
leucovorin	NN	O
,	,	O
and	CC	O
proclorperazine	NN	O
.	.	O

Aminosyn	NNP	O
-	:	O
PF	VBD	O
10	CD	O
%	NN	O
should	MD	O
be	VB	O
diluted	VBN	O
with	IN	O
dextrose	JJ	O
prior	NNS	O
to	TO	O
use	VB	O
.	.	O

Continue	NNP	O
treatment	NN	O
for	IN	O
the	DT	O
full	JJ	O
7	CD	O
days	NNS	O
,	,	O
even	RB	O
if	IN	O
there	EX	O
is	VBZ	O
improvement	NN	O
.	.	O

Loading	VBG	O
doses	NNS	O
of	IN	O
800	CD	DOS
to	TO	O
1,600	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
are	VBP	O
required	VBN	O
for	IN	O
1	CD	PER
to	TO	PER
3	CD	PER
weeks	NNS	PER
(	(	O
occasionally	RB	O
longer	RB	O
)	)	O
until	IN	O
initial	JJ	O
therapeutic	JJ	O
response	NN	O
occurs	VBZ	O
.	.	O

The	DT	O
total	JJ	O
daily	JJ	FREQ
dosage	NN	O
for	IN	O
adults	NNS	WHO
should	MD	O
not	RB	O
exceed	VB	O
131	CD	O
/	JJ	O
2	CD	O
teaspoonfuls	NN	O
.	.	O

During	IN	O
surgery	NN	O
,	,	O
phentolamine	NN	O
mesylate	NN	O
(	(	O
phentolamine	JJ	O
mesylate	NN	O
)	)	O
(	(	O
5	CD	DOS
mg	NN	UNIT
for	IN	O
adults	NNS	WHO
,	,	O
1	CD	DOS
mg	NN	UNIT
for	IN	O
children	NNS	WHO
)	)	O
is	VBZ	O
administered	VBN	O
intravenously	RB	O
as	IN	O
indicated	VBN	O
,	,	O
to	TO	O
help	VB	O
prevent	VB	O
or	CC	O
control	VB	O
paroxysms	NNS	O
of	IN	O
hypertension	NN	O
,	,	O
tachycardia	NN	O
,	,	O
respiratory	JJ	O
depression	NN	O
,	,	O
convulsions	NNS	O
,	,	O
or	CC	O
other	JJ	O
effects	NNS	O
of	IN	O
epinephrine	JJ	O
intoxication	NN	O
.	.	O

A	DT	O
negative	JJ	O
response	NN	O
is	VBZ	O
indicated	VBN	O
when	WRB	O
the	DT	O
blood	NN	O
pressure	NN	O
is	VBZ	O
elevated	VBN	O
,	,	O
unchanged	JJ	O
,	,	O
or	CC	O
reduced	VBD	O
less	JJR	O
than	IN	O
35	CD	O
mm	JJ	O
Hg	NNP	O
systolic	NN	O
and	CC	O
25	CD	O
mm	NN	O
Hg	NNP	O
diastolic	NN	O
after	IN	O
injection	NN	O
of	IN	O
phentolamine	NN	O
.	.	O

The	DT	O
usual	JJ	O
pediatric	JJ	O
dosage	NN	O
is	VBZ	O
5	CD	DOS
mg	NN	UNIT
to	TO	O
10	CD	DOS
mg	NNS	UNIT
per	IN	O
pound	NN	O
(	(	O
10	CD	DOS
mg	NN	UNIT
/	NN	O
kg	NN	O
to	TO	O
20	CD	DOS
mg	NNS	UNIT
/	NNP	O
kg	NN	O
)	)	O
per	IN	FREQ
day	NN	FREQ
in	IN	O
single	JJ	DOS
or	CC	O
two	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
375	CD	DOS
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
(	(	O
2.5	CD	DOS
mL	NN	UNIT
to	TO	O
7.5	CD	DOS
mL	NN	UNIT
or	CC	O
½	NN	O
to	TO	O
1½	CD	O
teaspoonfuls	NNS	O
of	IN	O
the	DT	O
oral	JJ	O
suspension	NN	O
daily	RB	FREQ
)	)	O
in	IN	O
infants	NNS	WHO
up	RB	WHO
to	TO	WHO
2	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
or	CC	O
1000	CD	DOS
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
in	IN	O
children	NNS	WHO
2	CD	WHO
to	TO	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

Before	IN	O
applying	VBG	O
the	DT	O
first	JJ	O
dose	NN	O
from	IN	O
a	DT	O
new	JJ	O
applicator	NN	O
,	,	O
the	DT	O
pump	NN	O
should	MD	O
be	VB	O
primed	VBN	O
by	IN	O
spraying	VBG	O
3	CD	O
sprays	NNS	O
with	IN	O
the	DT	O
cover	NN	O
on	IN	O
.	.	O

Example	NNS	O
:	:	O

Titration	NN	O
steps	NNS	O
:	:	O
If	IN	O
adequate	JJ	O
analgesia	NN	O
is	VBZ	O
not	RB	O
achieved	VBN	O
with	IN	O
the	DT	O
first	JJ	O
100	CD	DOS
mcg	NN	UNIT
dose	NN	UNIT
,	,	O
dose	JJ	O
escalate	NN	O
in	IN	O
a	DT	O
step	NN	O
-	:	O
wise	NN	O
manner	NN	O
over	IN	O
consecutive	JJ	O
episodes	NNS	O
of	IN	O
breakthrough	NN	O
pain	NN	O
until	IN	O
adequate	JJ	O
analgesia	NNS	O
with	IN	O
tolerable	JJ	O
side	NN	O
effects	NNS	O
is	VBZ	O
achieved	VBN	O
.	.	O

If	IN	O
unnecessary	JJ	O
fluid	NN	O
expansion	NN	O
is	VBZ	O
of	IN	O
concern	NN	O
,	,	O
adjustment	NN	O
of	IN	O
drug	NN	O
concentration	NN	O
may	MD	O
be	VB	O
preferred	VBN	O
over	IN	O
increasing	VBG	O
the	DT	O
flow	NN	O
rate	NN	O
of	IN	O
a	DT	O
less	RBR	O
concentrated	JJ	O
dilution	NN	O
.	.	O

Apply	VB	O
the	DT	O
gel	NN	O
(	(	O
4	CD	DOS
g	NN	UNIT
)	)	O
to	TO	O
the	DT	O
affected	JJ	O
foot	NN	O
,	,	O
ankle	NN	O
,	,	O
or	CC	O
knee	VB	O
4	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
loading	VBG	O
dose	NN	O
should	MD	O
be	VB	O
followed	VBN	O
by	IN	O
maintenance	NN	O
doses	NNS	O
of	IN	O
oral	JJ	O
or	CC	O
intravenous	JJ	O
Dilantin	NNP	O
every	DT	FREQ
6	CD	FREQ
-	:	O
8	CD	O
hours	NNS	O
.	.	O

The	DT	O
mean	JJ	O
total	NN	O
dose	NN	O
administered	VBN	O
in	IN	O
the	DT	O
pediatric	JJ	O
clinical	JJ	O
trial	NN	O
of	IN	O
flumazenil	NN	O
was	VBD	O
0.65	CD	DOS
mg	NN	UNIT
(	(	O
range	NN	O
:	:	O
0.08	CD	DOS
mg	NN	UNIT
to	TO	O
1.00	CD	DOS
mg	NN	UNIT
)	)	O
.	.	O

Sterile	JJ	O
Diluent	NNP	O
for	IN	O
Flolan	NNP	O
or	CC	O
Sterile	NNP	O
Diluent	NNP	O
for	IN	O
Epoprostenol	NNP	O
Sodium	NNP	O
)	)	O
,	,	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
or	CC	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

Tyzeka	NN	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
chronic	JJ	O
hepatitis	NN	O
B	NNP	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
renal	JJ	WHO
function	NN	WHO
.	.	O

Adult	NNP	WHO
(	(	O
10	CD	DOS
mL	NN	UNIT
)	)	O
added	VBD	O
directly	RB	O
to	TO	O
not	RB	O
less	JJR	O
than	IN	O
500	CD	DOS
mL	NN	UNIT
,	,	O
pre	NN	O
ferably	RB	O
1,000	CD	DOS
mL	NN	UNIT
,	,	O
of	IN	O
intravenous	JJ	O
dextrose	NN	O
,	,	O
saline	NN	O
or	CC	O
similar	JJ	O
infusion	NN	O
solutions	NNS	O
.	.	O

Insert	NNP	O
one	CD	O
implant	NN	O
into	IN	O
the	DT	O
cannula	NN	O
(	(	O
Figure	NNP	O
8	CD	O
)	)	O
,	,	O
re	SYM	O
-	:	O
insert	VB	O
the	DT	O
obturator	NN	O
,	,	O
and	CC	O
gently	RB	O
push	VB	O
the	DT	O
obturator	NN	O
forward	NN	O
(	(	O
mild	JJ	O
resistance	NN	O
should	MD	O
be	VB	O
felt	VBN	O
)	)	O
until	IN	O
the	DT	O
obturator	NN	O
stop	JJ	O
line	NN	O
is	VBZ	O
level	JJ	O
with	IN	O
the	DT	O
bevel	NN	O
-	:	O
up	RB	O
stop	VB	O
marking	NN	O
,	,	O
which	WDT	O
indicates	VBZ	O
the	DT	O
implant	NN	O
is	VBZ	O
positioned	VBN	O
at	IN	O
the	DT	O
tip	NN	O
of	IN	O
the	DT	O
cannula	NN	O
(	(	O
Figure	NNP	O
9	CD	O
)	)	O
.	.	O

For	IN	O
example	NN	O
,	,	O
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
increased	VBN	WHO
spasms	NNS	WHO
at	IN	WHO
night	NN	WHO
may	MD	O
require	VB	O
a	DT	O
20	CD	O
%	NN	O
increase	NN	O
in	IN	O
their	PRP$	O
hourly	JJ	O
infusion	NN	O
rate	NN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
does	VBZ	O
not	RB	O
tolerate	VB	O
a	DT	O
test	NN	O
dose	NN	O
of	IN	O
0.4	CD	DOS
mL	NN	UNIT
(	(	O
4	CD	DOS
mg	NN	UNIT
)	)	O
,	,	O
a	DT	O
test	NN	O
dose	NN	O
of	IN	O
0.3	CD	DOS
mL	NN	UNIT
(	(	O
3	CD	DOS
mg	NN	UNIT
)	)	O
may	MD	O
be	VB	O
administered	VBN	O
during	IN	O
a	DT	O
separate	JJ	O
“	NN	O
off	IN	O
”	JJ	O
period	NN	O
under	IN	O
medical	JJ	O
supervision	NN	O
,	,	O
at	IN	O
least	JJS	O
2	CD	O
hours	NNS	O
after	IN	O
the	DT	O
previous	JJ	O
dose	NN	O
.	.	O

The	DT	O
patient	NN	O
should	MD	O
be	VB	O
studied	VBN	O
in	IN	O
a	DT	O
fasting	NN	O
,	,	O
basal	NN	O
state	NN	O
.	.	O

Step	NN	O
23	CD	O
.	.	O

More	RBR	O
frequent	JJ	O
administration	NN	O
or	CC	O
a	DT	O
greater	JJR	O
number	NN	O
of	IN	O
inhalations	NNS	O
(	(	O
more	JJR	O
than	IN	O
1	CD	DOS
inhalation	JJ	UNIT
daily	RB	FREQ
)	)	O
of	IN	O
the	DT	O
prescribed	JJ	O
strength	NN	O
of	IN	O
BREO	NNP	O
ELLIPTA	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
as	IN	O
some	DT	WHO
patients	NNS	WHO
are	VBP	O
more	RBR	O
likely	JJ	O
to	TO	O
experience	VB	O
adverse	JJ	O
effects	NNS	O
with	IN	O
higher	JJR	O
doses	NNS	O
.	.	O

3	CD	O
.	.	O

(	(	O
See	VB	O
WARNINGS	NNP	O
.	.	O
)	)	O

There	EX	O
is	VBZ	O
a	DT	O
greater	JJR	O
risk	NN	O
of	IN	O
injury	NN	O
to	TO	O
neural	JJ	O
and	CC	O
vascular	JJ	O
structures	NNS	O
during	IN	O
removal	NN	O
of	IN	O
implants	NNS	O
located	VBN	O
deeper	JJR	O
than	IN	O
the	DT	O
subdermal	JJ	O
space	NN	O
.	.	O

unless	IN	O
hemodialysis	NN	O
is	VBZ	O
instituted	VBN	O
within	IN	O
48	CD	O
hours	NNS	O
.	.	O

The	DT	O
maximum	JJ	FREQ
daily	JJ	FREQ
recommended	VBN	O
dose	NN	O
is	VBZ	O
two	CD	DOS
inhalations	NNS	UNIT
of	IN	O
DULERA	NNP	O
200	CD	DOS
mcg	NN	UNIT
/	VBD	O
5	CD	DOS
mcg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

A	DT	O
24gauge	CD	O
or	CC	O
larger	JJR	O
needle	NNS	O
on	IN	O
a	DT	O
dry	JJ	O
syringe	NN	O
may	MD	O
be	VB	O
inserted	VBN	O
into	IN	O
the	DT	O
joint	JJ	O
and	CC	O
excess	JJ	O
fluid	NN	O
aspirated	VBD	O
.	.	O

Day	NNP	O
-	:	O
1	CD	O
Start	NNP	O
Regimen	NNS	O
:	:	O

IPLEX	NNP	O
(	(	O
mecasermin	JJ	O
rinfabate	NN	O
[	NNP	O
rdna	NN	O
origin	NN	O
]	NNP	O
injection	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
via	IN	O
subcutaneous	JJ	O
injection	NN	O
at	IN	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
0.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
,	,	O
to	TO	O
be	VB	O
increased	VBN	O
into	IN	O
the	DT	O
therapeutic	JJ	O
dose	NN	O
range	NN	O
of	IN	O
1	CD	DOS
to	TO	O
2	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
,	,	O
given	VBN	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

(	(	O
5	CD	O
)	)	O
Door	NNP	O
and	CC	O
latches	NNS	O
:	:	O
Patients	NNS	O
should	MD	O
be	VB	O
able	JJ	O
to	TO	O
open	VB	O
the	DT	O
door	NN	O
from	IN	O
the	DT	O
inside	NN	O
with	IN	O
only	JJ	O
slight	JJ	O
pressure	NN	O
to	TO	O
the	DT	O
door	NN	O
.	.	O

As	IN	O
a	DT	O
general	JJ	O
guide	NN	O
,	,	O
reference	NN	O
is	VBZ	O
made	VBN	O
especially	RB	O
to	TO	O
the	DT	O
techniques	NNS	O
of	IN	O
Weisberger	NNP	O
et	FW	O
al.5,11	SYM	O
-	:	O
13	CD	O
Intracavitary	NNP	O
use	NN	O
is	VBZ	O
indicated	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
pleural	JJ	O
,	,	O
peritoneal	JJ	O
,	,	O
or	CC	O
pericardial	JJ	O
effusion	NN	O
due	JJ	O
to	TO	O
metastatic	JJ	O
tumors	NNS	O
.	.	O

Push	VB	O
the	DT	O
implant	NN	O
gently	RB	O
towards	VBZ	O
the	DT	O
incision	NN	O
with	IN	O
the	DT	O
fingers	NNS	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
administration	NN	O
is	VBZ	O
dependent	JJ	O
on	IN	O
the	DT	O
size	NN	O
of	IN	O
the	DT	O
vein	NN	O
,	,	O
and	CC	O
the	DT	O
dosage	NN	O
.	.	O

Therapy	NN	O
Guided	VBN	O
By	IN	O
Clinical	JJ	O
Effect	NN	O
:	:	O
A	DT	O
patient	NN	O
whose	WP$	O
blood	NN	O
pressure	NN	O
is	VBZ	O
not	RB	O
adequately	RB	O
controlled	VBN	O
with	IN	O
felodipine	NN	O
(	(	O
or	CC	O
another	DT	O
dihydropyridine	NN	O
)	)	O
or	CC	O
enalapril	$	O
(	(	O
or	CC	O
another	DT	O
ACE	NNP	O
inhibitor	NN	O
)	)	O
alone	NN	O
may	MD	O
be	VB	O
switched	VBN	O
to	TO	O
combination	VB	O
therapy	NN	O
with	IN	O
LEXXEL	NNP	O
(	(	O
enalapril	JJ	O
maleate	NN	O
-	:	O
felodipine	NN	O
)	)	O
,	,	O
initially	RB	O
one	CD	DOS
tablet	JJ	UNIT
daily	NN	FREQ
of	IN	O
LEXXEL	NNP	O
(	(	O
enalapril	JJ	O
maleate	NN	O
-	:	O
felodipine	NN	O
)	)	O
.	.	O

ReFacto	NNP	O
(	(	O
antihemophilic	JJ	O
factor	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
within	IN	O
3	CD	O
hours	NNS	O
after	IN	O
reconstitution	NN	O
.	.	O

See	VB	O
the	DT	O
Suggested	NNP	O
Insertion	NNP	O
Procedure	NNP	O
above	IN	O
for	IN	O
further	JJ	O
instructions	NNS	O
.	.	O

INJECTABLE	NNP	O
,	,	O
100	CD	DOS
mg	NN	UNIT
/	NN	O
mL	NN	O
(	(	O
Not	RB	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
)	)	WHO

After	IN	O
a	DT	O
test	NN	O
dose	NN	O
,	,	O
Pentothal	NNP	O
(	(	O
Thiopental	NNP	O
Sodium	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
)	)	O
is	VBZ	O
injected	VBN	O
at	IN	O
a	DT	O
slow	JJ	O
rate	NN	O
of	IN	O
100	CD	DOS
mg	NNS	UNIT
/	JJ	O
mm	NN	O
(	(	O
4	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
of	IN	O
a	DT	O
2.5	CD	O
%	NN	O
solution	NN	O
)	)	O
with	IN	O
the	DT	O
patient	NN	O
counting	VBG	O
backwards	NNS	O
from	IN	O
100	CD	O
.	.	O

TYLOX	NNP	O
(	(	O
oxycodone	NN	O
and	CC	O
acetaminophen	JJ	O
capsules	NNS	O
)	)	O
are	VBP	O
given	VBN	O
orally	RB	O
.	.	O

Sterilize	VB	O
the	DT	O
rubber	NN	O
stopper	NN	O
in	IN	O
the	DT	O
usual	JJ	O
manner	NN	O
and	CC	O
insert	JJ	O
needle	NN	O
squarely	RB	O
through	IN	O
the	DT	O
center	NN	O
of	IN	O
the	DT	O
plunger	NN	O
-	:	O
stopper	NN	O
until	IN	O
tip	NN	O
is	VBZ	O
just	RB	O
visible	JJ	O
.	.	O

More	RBR	O
frequent	JJ	O
administration	NN	O
or	CC	O
administration	NN	O
of	IN	O
a	DT	O
larger	JJR	O
number	NN	O
of	IN	O
inhalations	NNS	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

If	IN	O
the	DT	O
contralateral	JJ	O
eye	NN	O
requires	VBZ	O
treatment	NN	O
,	,	O
a	DT	O
new	JJ	O
applicator	NN	O
must	MD	O
be	VB	O
used	VBN	O
,	,	O
and	CC	O
the	DT	O
sterile	JJ	O
field	NN	O
,	,	O
syringe	NN	O
,	,	O
gloves	NNS	O
,	,	O
drapes	NNS	O
,	,	O
and	CC	O
eyelid	JJ	O
speculum	NN	O
should	MD	O
be	VB	O
changed	VBN	O
before	IN	O
OZURDEX®	NNP	O
is	VBZ	O
administered	VBN	O
to	TO	O
the	DT	O
other	JJ	O
eye	NN	O
.	.	O

The	DT	O
patient	NN	O
begins	VBZ	O
her	PRP$	O
next	JJ	O
and	CC	O
all	DT	O
subsequent	JJ	O
28	CD	O
-	:	O
day	NN	O
courses	NNS	O
of	IN	O
tablets	NNS	O
on	IN	O
the	DT	O
same	JJ	O
day	NN	O
of	IN	O
the	DT	O
week	NN	PER
(	(	O
Sunday	NNP	O
)	)	O
on	IN	O
which	WDT	O
she	PRP	O
began	VBD	O
her	PRP	O
first	JJ	O
course	NN	O
,	,	O
following	VBG	O
the	DT	O
same	JJ	O
schedule	NN	O
:	:	O
21	CD	O
days	NNS	O
on	IN	O
orange	NN	O
tablets—	NN	O
7	CD	O
days	NNS	O
on	IN	O
green	JJ	O
inert	JJ	O
tablets	NNS	O
.	.	O

A	DT	O
dose	NN	O
of	IN	O
1500	CD	DOS
international	JJ	UNIT
units	NNS	UNIT
of	IN	O
RIXUBIS	NNP	O
,	,	O
administered	VBD	O
to	TO	O
a	DT	O
20	CD	WHO
kg	NN	WHO
patient	NN	WHO
should	MD	O
be	VB	O
expect	VB	O
to	TO	O
result	VB	O
in	IN	O
a	DT	O
peak	NN	O
post	NN	O
-	:	O
infusion	NN	O
factor	NN	O
IX	NNP	O
increase	NN	O
of	IN	O
1500	CD	DOS
international	JJ	UNIT
units	NNS	UNIT
x	VBP	O
{	(	O
[	JJ	O
0.7	CD	DOS
IU	NNP	UNIT
/	NNP	O
dL	NN	O
]	NNP	O
/	NNP	O
[	NNP	O
IU	NNP	O
/	NNP	O
kg	NN	O
}	)	O
/	NNP	O
[	$	O
20	CD	O
kg	NN	O
]	NNP	O
=	VBZ	O
53.6	CD	DOS
international	JJ	UNIT
units	NNS	UNIT
/	VBP	O
dL	NN	O
(	(	O
53.6	CD	O
%	NN	O
of	IN	O
normal	JJ	O
)	)	O
.	.	O

Weigh	IN	O
the	DT	O
potential	JJ	O
risks	NNS	O
against	IN	O
the	DT	O
benefits	NNS	O
of	IN	O
continuing	VBG	O
treatment	NN	O
with	IN	O
OCALIVA	NNP	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
experienced	VBN	WHO
clinically	RB	WHO
significant	JJ	WHO
liver	SYM	WHO
-	:	O
related	JJ	O
adverse	JJ	O
reactions	NNS	O
.	.	O

Prescribe	NNP	O
up	RB	O
to	TO	O
2	CD	DOS
boxes	NNS	UNIT
(	(	O
56	CD	DOS
packets	NNS	UNIT
)	)	O
or	CC	O
two	CD	DOS
7.5	CD	DOS
g	NNS	UNIT
pumps	NNS	O
for	IN	O
the	DT	O
total	JJ	O
treatment	NN	O
course	NN	O
.	.	O

The	DT	O
following	JJ	O
dosage	NN	O
regimens	NNS	O
are	VBP	O
recommended	VBN	O
.	.	O

Step	NN	O
4	CD	O
.	.	O

Spontaneous	JJ	O
recovery	NN	O
from	IN	O
neuromuscular	JJ	O
block	NN	O
following	VBG	O
discontinuation	NN	O
of	IN	O
infusion	NN	O
of	IN	O
NIMBEX	NNP	O
may	MD	O
be	VB	O
expected	VBN	O
to	TO	O
proceed	VB	O
at	IN	O
a	DT	O
rate	NN	O
comparable	JJ	O
to	TO	O
that	DT	O
following	VBG	O
administration	NN	O
of	IN	O
a	DT	O
single	JJ	DOS
bolus	NN	UNIT
dose	NN	UNIT
.	.	O

The	DT	O
dissolve	NN	O
time	NN	O
for	IN	O
ZUBSOLV	NNP	O
varies	NNS	O
between	IN	O
individuals	NNS	O
,	,	O
and	CC	O
the	DT	O
median	JJ	O
dissolve	NN	O
time	NN	O
observed	VBD	O
was	VBD	O
5	CD	O
minutes	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
flumazenil	JJ	O
injection	NN	O
be	VB	O
administered	VBN	O
as	IN	O
the	DT	O
series	NN	O
of	IN	O
small	JJ	O
injections	NNS	O
described	VBN	O
(	(	O
not	RB	O
as	IN	O
a	DT	O
single	JJ	DOS
bolus	NN	UNIT
injection	NN	UNIT
)	)	O
to	TO	O
allow	VB	O
the	DT	O
practitioner	NN	O
to	TO	O
control	VB	O
the	DT	O
reversal	NN	O
of	IN	O
sedation	NN	O
to	TO	O
the	DT	O
approximate	JJ	O
endpoint	NN	O
desired	VBD	O
and	CC	O
to	TO	O
minimize	VB	O
the	DT	O
possibility	NN	O
of	IN	O
adverse	JJ	O
effects	NNS	O
(	(	O
see	VB	O
Individualization	NNP	O
Of	IN	O
Dosage	NNP	O
)	)	O
.	.	O

Saxenda®	NNP	O
should	MD	O
be	VB	O
discontinued	VBN	O
,	,	O
however	RB	O
,	,	O
if	IN	O
a	DT	O
patient	NN	O
can	MD	O
not	RB	O
tolerate	VB	O
the	DT	O
3	CD	DOS
mg	NN	UNIT
dose	NN	UNIT
,	,	O
as	IN	O
efficacy	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
at	IN	O
lower	JJR	O
doses	NNS	O
(	(	O
0.6	CD	O
,	,	O
1.2	CD	O
,	,	O
1.8	CD	O
,	,	O
and	CC	O
2.4	CD	DOS
mg	NN	UNIT
)	)	O
.	.	O

Instruct	IN	O
the	DT	O
patient	NN	O
to	TO	O
use	VB	O
a	DT	O
nonhormonal	JJ	O
contraceptive	NN	O
as	IN	O
back	RB	O
-	:	O
up	RP	O
during	IN	O
the	DT	O
first	JJ	O
7	CD	O
days	NNS	O
.	.	O

Adjust	IN	O
the	DT	O
dosage	NN	O
to	TO	O
obtain	VB	O
an	DT	O
appropriate	JJ	O
balance	NN	O
between	IN	O
management	NN	O
of	IN	O
pain	NN	O
and	CC	O
opioid	JJ	O
-	:	O
related	JJ	O
adverse	JJ	O
reactions	NNS	O
.	.	O

Dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
5	CD	DOS
tablets	NNS	UNIT
in	IN	O
a	DT	O
24	CD	O
-	:	O
hour	NN	O
period	NN	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Guidelines	NNS	O
for	IN	O
Dose	NNP	O
Modification	NNP	O
or	CC	O
Discontinuation	NNP	O
of	IN	O
INFERGEN	NNP	O
for	IN	O
Hematologic	NNP	O
Toxicities	NNP	O

Preoperative	JJ	O
Prophylaxis	NNP	O
for	IN	O
Elective	NNP	O
Colorectal	NNP	O
Surgery	NNP	O

Therapy	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
when	WRB	O
control	NN	O
is	VBZ	O
achieved	VBN	O
.	.	O

The	DT	O
dose	NN	O
to	TO	O
achieve	VB	O
a	DT	O
desired	VBN	O
in	IN	O
vivo	NN	O
peak	JJ	O
increase	NN	O
in	IN	O
Factor	NNP	O
VIII	NNP	O
level	NN	O
may	MD	O
be	VB	O
calculated	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
formula	NN	O
:	:	O

The	DT	O
following	JJ	O
specifications	NNS	O
should	MD	O
be	VB	O
met	VBN	O
with	IN	O
the	DT	O
window	NN	O
of	IN	O
the	DT	O
detector	NN	O
held	VBD	O
in	IN	O
a	DT	O
vertical	JJ	O
plane	NN	O
:	:	O

Premixed	NNP	O
Injection	NNP	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Discard	NNP	O
any	DT	O
unused	JJ	O
portion	NN	O
after	IN	O
24	CD	O
hours	NNS	O
if	IN	O
stored	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
(	(	O
20°C	CD	O
to	TO	O
25°C	CD	O
[	NNS	O
68°F	CD	O
to	TO	O
77°F	CD	O
]	NN	O
)	)	O
,	,	O
or	CC	O
after	IN	O
48	CD	O
hours	NNS	O
if	IN	O
stored	VBN	O
at	IN	O
refrigerated	JJ	O
temperature	NN	O
(	(	O
2°C	CD	O
to	TO	O
8°C	CD	O
[	NNS	O
36°F	CD	O
to	TO	O
46°F	CD	O
]	NN	O
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
therefore	RB	O
recommended	JJ	O
,	,	O
when	WRB	O
both	DT	O
drugs	NNS	O
are	VBP	O
to	TO	O
be	VB	O
administered	VBN	O
by	IN	O
intermittent	JJ	O
IV	NNP	O
infusion	NN	O
,	,	O
that	IN	O
they	PRP	O
be	VB	O
given	VBN	O
separately	RB	O
,	,	O
flushing	VBG	O
the	DT	O
IV	NNP	O
lines	NNS	O
(	(	O
with	IN	O
1	CD	O
of	IN	O
the	DT	O
compatible	JJ	O
IV	NNP	O
fluids	NNS	O
)	)	O
between	IN	O
the	DT	O
administration	NN	O
of	IN	O
these	DT	O
2	CD	O
agents	NNS	O
.	.	O

CONVERSION	NN	O
FACTORS	NNP	O
TO	NNP	O
OPANA	NNP	O
ER	NNP	O

AVOID	NNP	O
bending	NN	O
or	CC	O
pinching	VBG	O
the	DT	O
implant	NN	O
.	.	O

-	:	O
25	CD	DOS
mg	NNS	UNIT
three	CD	FREQ
or	CC	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
;	:	O
dosage	NN	O
should	MD	O
begin	VB	O
at	IN	O
a	DT	O
low	JJ	O
level	NN	O
and	CC	O
be	VB	O
increased	VBN	O
as	IN	O
required	VBN	O
.	.	O

The	DT	O
protease	NN	O
inhibitor	NN	O
and	CC	O
ritonavir	NN	O
dosing	NN	O
regimens	NNS	O
presented	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
are	VBP	O
the	DT	O
recommended	JJ	O
regimens	NNS	O
for	IN	O
use	NN	O
with	IN	O
VITEKTA	NNP	O
.	.	O

All	DT	O
injections	NNS	O
should	MD	O
be	VB	O
made	VBN	O
slowly	RB	O
and	CC	O
only	RB	O
after	IN	O
all	DT	O
steps	NNS	O
have	VBP	O
been	VBN	O
taken	VBN	O
to	TO	O
insure	VB	O
precise	JJ	O
placement	NN	O
of	IN	O
the	DT	O
alcohol	NN	O
.	.	O

When	WRB	O
administering	VBG	O
as	IN	O
a	DT	O
slow	JJ	O
intravenous	JJ	O
push	NN	O
,	,	O
give	VB	O
at	IN	O
the	DT	O
rate	NN	O
of	IN	O
approximately	RB	O
100	CD	DOS
mg	NNS	UNIT
(	(	O
2	CD	DOS
mL	NN	UNIT
)	)	O
per	IN	O
minute	NN	O
.	.	O

As	IN	O
in	IN	O
all	DT	O
cases	NNS	O
of	IN	O
organophosphate	NN	O
poisoning	NN	O
,	,	O
care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
keep	VB	O
the	DT	O
patient	NN	O
under	IN	O
observation	NN	O
for	IN	O
at	IN	O
least	JJS	O
48	CD	O
to	TO	O
72	CD	O
hours	NNS	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
Renal	NNP	WHO
or	CC	WHO
Hepatic	JJ	WHO
Disease	NN	WHO
:	:	O
Due	NNP	O
to	TO	O
an	DT	O
increased	VBN	O
fraction	NN	O
of	IN	O
unbound	JJ	O
phenytoin	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
or	CC	WHO
hepatic	JJ	WHO
disease	NN	WHO
,	,	O
or	CC	O
in	IN	O
those	DT	O
with	IN	O
hypoalbuminemia	NN	O
,	,	O
the	DT	O
interpretation	NN	O
of	IN	O
total	JJ	O
phenytoin	NN	O
plasma	NN	O
concentrations	NNS	O
should	MD	O
be	VB	O
made	VBN	O
with	IN	O
caution	NN	O
.	.	O

No	DT	O
dosage	NN	O
adjustments	NNS	O
are	VBP	O
needed	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
(	(	O
creatinine	JJ	O
clearance	NN	O
50	CD	DOS
to	TO	O
80	CD	DOS
mL	NNS	UNIT
/	NNP	O
min	NN	O
)	)	O
or	CC	O
moderate	JJ	O
(	(	O
creatinine	JJ	O
clearance	NN	O
30	CD	DOS
to	TO	O
50	CD	DOS
mL	NNS	UNIT
/	NNP	O
min	NN	O
)	)	O
renal	JJ	O
impairment	NN	O
.	.	O

First	RB	O
withdraw	VBZ	O
the	DT	O
entire	JJ	O
volume	NN	O
of	IN	O
diluent	NN	O
into	IN	O
the	DT	O
syringe	NN	O
to	TO	O
be	VB	O
used	VBN	O
for	IN	O
reconstitution	NN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
for	IN	O
vitamin	NN	O
A	NNP	O
and	CC	O
thiamine	JJ	O
deficiencies	NNS	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Recommended	VBN	O
Infusion	NNP	O
Volumes	NNP	O
and	CC	O
Rates	NNS	O

Patients	NNS	O
should	MD	O
avoid	VB	O
ingesting	VBG	O
food	NN	O
or	CC	O
liquids	NNS	O
for	IN	O
5	CD	O
minutes	NNS	O
before	IN	O
and	CC	O
after	IN	O
taking	VBG	O
ZELAPAR	NNP	O
.	.	O

SPORANOX®	NNP	O
(	(	O
itraconazole	JJ	O
injection	NN	O
)	)	O
Injection	NN	O
administered	VBN	O
for	IN	O
greater	JJR	O
than	IN	O
14	CD	O
days	NNS	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
maintained	VBN	O
in	IN	O
an	DT	O
optimal	JJ	O
state	NN	O
of	IN	O
hydration	NN	O
prior	RB	O
to	TO	O
the	DT	O
procedure	NN	O
.	.	O

Each	DT	O
cartridge	NN	O
of	IN	O
Omnitrope	NNP	O
must	MD	O
be	VB	O
inserted	VBN	O
into	IN	O
its	PRP$	WHO
corresponding	VBG	WHO
Omnitrope	NNP	WHO
Pen	NNP	WHO
5	CD	WHO
or	CC	WHO
Omnitrope	NNP	WHO
Pen	NNP	WHO
10	CD	WHO
delivery	NN	WHO
system	NN	WHO
.	.	O

Maintain	VB	O
the	DT	O
route	NN	O
of	IN	O
administration	NN	O
(	(	O
intravenous	JJ	O
or	CC	O
subcutaneous	JJ	O
injection	NN	O
)	)	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
2	CD	DOS
tablets	NNS	UNIT
every	DT	FREQ
6	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

Occlusive	JJ	O
dressings	NNS	O
may	MD	O
be	VB	O
a	DT	O
valuable	JJ	O
therapeutic	JJ	O
adjunct	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
psoriasis	NN	O
or	CC	O
recalcitrant	JJ	O
conditions	NNS	O
.	.	O

Accidental	NNP	O
dermal	JJ	O
exposure	NN	O
should	MD	O
be	VB	O
treated	VBN	O
by	IN	O
the	DT	O
removal	NN	O
of	IN	O
any	DT	O
contaminated	JJ	O
clothing	NN	O
and	CC	O
rinsing	VBG	O
the	DT	O
affected	JJ	O
area	NN	O
with	IN	O
water	NN	O
.	.	O

Figure	NN	O
3	CD	O
:	:	O
Shake	VB	O
the	DT	O
vial	JJ	O
well	NN	O
.	.	O

To	TO	O
ensure	VB	O
the	DT	O
precise	JJ	O
delivery	NN	O
of	IN	O
the	DT	O
small	JJ	O
volumes	NNS	O
of	IN	O
fluid	NN	O
necessary	JJ	O
for	IN	O
total	JJ	O
parenteral	JJ	O
nutrition	NN	O
in	IN	O
infants	NNS	WHO
,	,	O
accurately	RB	O
calibrated	VBN	O
and	CC	O
reliable	JJ	O
infusion	NN	O
systems	NNS	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

These	DT	O
dose	JJ	O
relationships	NNS	O
apply	RB	O
only	RB	O
to	TO	O
oral	JJ	O
or	CC	O
intravenous	JJ	O
administration	NN	O
of	IN	O
these	DT	O
compounds	NNS	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
BLINCYTO	NNP	O
Recommended	VBD	O
Dosage	NN	O

When	WRB	O
heparin	NN	O
is	VBZ	O
added	VBN	O
to	TO	O
an	DT	O
infusion	NN	O
solution	NN	O
for	IN	O
continuous	JJ	O
intravenous	JJ	O
administration	NN	O
,	,	O
the	DT	O
container	NN	O
should	MD	O
be	VB	O
inverted	VBN	O
at	IN	O
least	JJS	O
six	CD	FREQ
times	NNS	FREQ
to	TO	O
ensure	VB	O
adequate	JJ	O
mixing	NN	O
and	CC	O
prevent	NN	O
pooling	NN	O
of	IN	O
the	DT	O
heparin	NN	O
in	IN	O
the	DT	O
solution	NN	O
.	.	O

CIMZIA	NN	O
does	VBZ	O
not	RB	O
contain	VB	O
preservatives	NNS	O
;	:	O
therefore	RB	O
,	,	O
unused	JJ	O
portions	NNS	O
of	IN	O
drug	NN	O
remaining	VBG	O
in	IN	O
the	DT	O
syringe	NN	O
or	CC	O
vial	NN	O
should	MD	O
be	VB	O
discarded	VBN	O
.	.	O

A	DT	O
lower	JJR	O
dose	NN	O
of	IN	O
ZEMURON	NNP	O
(	(	O
0.45	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
)	)	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

It	PRP	O
may	MD	O
take	VB	O
up	RP	O
to	TO	O
6	CD	O
days	NNS	O
for	IN	O
fentanyl	NN	O
levels	NNS	O
to	TO	O
reach	VB	O
equilibrium	NN	O
on	IN	O
a	DT	O
new	JJ	O
dose	JJ	O
[	NNS	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Thyroid	NNP	O
hormone	NN	O
products	NNS	O
formulated	VBN	O
for	IN	O
intravenous	JJ	O
administration	NN	O
should	MD	O
be	VB	O
administered	VBN	O
.	.	O

Changes	NNS	O
to	TO	O
concomitant	VB	O
medications	NNS	O
should	MD	O
be	VB	O
avoided	VBN	O
.	.	O

Reconstitution	NN	O
of	IN	O
the	DT	O
50,000	CD	O
unit	NN	O
vial	JJ	O
with	IN	O
9.8	CD	DOS
mL	NNS	UNIT
of	IN	O
diluent	NN	O
will	MD	O
result	VB	O
in	IN	O
a	DT	O
concentration	NN	O
of	IN	O
5,000	CD	DOS
units	NNS	UNIT
per	IN	O
mL	NN	O
.	.	O

at	IN	O
doses	VBZ	O
up	RB	O
to	TO	O
90	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
,	,	O
not	RB	O
exceeding	VBG	O
4.0	CD	DOS
g	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

It	PRP	O
is	VBZ	O
further	RBR	O
recommended	VBD	O
that	IN	O
short	JJ	O
course	NN	O
,	,	O
or	CC	O
``	``	O
burst	JJ	O
''	''	O
therapy	NN	O
,	,	O
be	VB	O
continued	VBN	O
until	IN	O
a	DT	O
child	NN	O
achieves	VBZ	O
a	DT	O
peak	JJ	O
expiratory	NN	O
flow	NN	O
rate	NN	O
of	IN	O
80	CD	O
%	NN	O
of	IN	O
his	PRP$	O
or	CC	O
her	PRP$	O
personal	JJ	O
best	NN	O
or	CC	O
symptoms	NNS	O
resolve	VBP	O
.	.	O

Do	NNP	O
not	RB	O
increase	VB	O
DOXIL	NNP	O
after	IN	O
a	DT	O
dose	JJ	O
reduction	NN	O
for	IN	O
toxicity	NN	O
.	.	O

Propping	VBG	O
the	DT	O
arm	NN	O
with	IN	O
pillows	NNS	O
may	MD	O
help	VB	O
the	DT	O
patient	NN	O
more	JJR	O
easily	RB	O
hold	VB	O
the	DT	O
position	NN	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
Tables	NNS	O
1	CD	O
and	CC	O
2	CD	O
to	TO	O
convert	VB	O
from	IN	O
DURAGESIC	NNP	O
to	TO	O
other	JJ	O
therapies	NNS	O
to	TO	O
avoid	VB	O
overestimating	VBG	O
the	DT	O
dose	NN	O
of	IN	O
the	DT	O
new	JJ	O
agent	NN	O
resulting	VBG	O
in	IN	O
overdose	NN	O
of	IN	O
the	DT	O
new	JJ	O
analgesic	JJ	O
and	CC	O
possibly	RB	O
death	NN	O
.	.	O

Rotate	NNP	O
sites	NNS	O
for	IN	O
injection	NN	O
(	(	O
thigh	JJ	O
,	,	O
abdomen	NNS	O
,	,	O
upper	JJ	O
outer	NN	O
buttock	NN	O
,	,	O
or	CC	O
upper	JJ	O
arm	NN	O
)	)	O
.	.	O

For	IN	O
current	JJ	O
information	NN	O
regarding	VBG	O
compatibilities	NNS	O
of	IN	O
clindamycin	NN	O
phosphate	NN	O
under	IN	O
specific	JJ	O
conditions	NNS	O
,	,	O
please	VB	O
contact	VB	O
the	DT	O
Medical	NNP	O
and	CC	O
Drug	NNP	O
Information	NNP	O
Unit	NNP	O
,	,	O
Pharmacia	NNP	O
&	CC	O
Upjohn	NNP	O
Company	NNP	O
(	(	O
Division	NNP	O
of	IN	O
Pfizer	NNP	O
Inc	NNP	O
)	)	O
..	NN	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
REVLIMID	NNP	O
is	VBZ	O
10	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
.	.	O

Proton	NNP	O
pump	NN	O
inhibitor	NN	O
treatment	NN	O
should	MD	O
only	RB	O
be	VB	O
initiated	VBN	O
and	CC	O
continued	VBN	O
if	IN	O
the	DT	O
benefits	NNS	O
outweigh	VBP	O
the	DT	O
risks	NNS	O
of	IN	O
treatment	NN	O
.	.	O

MONUROL	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
immediately	RB	O
after	IN	O
dissolving	VBG	O
in	IN	O
water	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
ZYKADIA	NNP	O
Dose	NNP	O
Interruption	NNP	O
,	,	O
Reduction	NNP	O
,	,	O
or	CC	O
Discontinuation	NNP	O
Recommendations	NNS	O

Promethazine	NNP	O
HCl	NNP	O
Syrup	NNP	O
(	(	O
promethazine	JJ	O
hydrochloride	NN	O
syrup	NN	O
plain	NN	O
)	)	O
Plain	NNP	O
is	VBZ	O
contraindicated	VBN	O
for	IN	O
children	NNS	WHO
under	IN	WHO
2	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

It	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
only	RB	O
use	VB	O
a	DT	O
catheter	NN	O
tipped	VBD	O
syringe	NN	O
when	WRB	O
administering	VBG	O
esomeprazole	JJ	O
magnesium	NN	O
delayed	VBN	O
-	:	O
release	NN	O
capsules	VBZ	O
through	IN	O
a	DT	O
nasogastric	JJ	O
tube	NN	O
.	.	O

If	IN	O
required	VBN	O
,	,	O
more	RBR	O
dilute	JJ	O
solutions	NNS	O
could	MD	O
be	VB	O
utilized	VBN	O
.	.	O

The	DT	O
treatment	NN	O
duration	NN	O
is	VBZ	O
28	CD	O
consecutive	JJ	O
days	NNS	O
.	.	O

Consider	VB	O
increments	NNS	O
in	IN	O
dose	JJ	O
if	IN	O
symptoms	NNS	O
of	IN	O
pulmonary	JJ	O
hypertension	NN	O
persist	NN	O
or	CC	O
recur	NN	O
.	.	O

Recommended	VBN	O
dosage	NN	O
is	VBZ	O
250	CD	DOS
to	TO	O
375	CD	DOS
mg	NN	UNIT
of	IN	O
acetaZOLAMIDE	NN	O
once	IN	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
one	CD	PER
or	CC	O
two	CD	PER
days	NNS	PER
,	,	O
alternating	VBG	O
with	IN	O
a	DT	O
day	NN	O
of	IN	O
rest	NN	O
.	.	O

Because	IN	O
of	IN	O
these	DT	O
factors	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
important	JJ	O
that	IN	O
this	DT	O
product	NN	O
be	VB	O
stored	VBN	O
properly	RB	O
and	CC	O
that	IN	O
the	DT	O
directions	NNS	O
be	VB	O
followed	VBN	O
carefully	RB	O
during	IN	O
use	NN	O
.	.	O

Systematic	JJ	O
evaluation	NN	O
of	IN	O
continuing	VBG	O
PAXIL	NNP	O
for	IN	O
periods	NNS	O
of	IN	O
up	IN	PER
to	TO	PER
24	CD	PER
weeks	NNS	PER
in	IN	O
patients	NNS	WHO
with	IN	WHO
Generalized	NNP	WHO
Anxiety	NNP	WHO
Disorder	NNP	WHO
who	WP	WHO
had	VBD	WHO
responded	VBN	WHO
while	IN	WHO
taking	VBG	WHO
PAXIL	NNP	WHO
during	IN	O
an	DT	O
8	CD	O
-	:	O
week	NN	PER
acute	JJ	O
treatment	NN	O
phase	NN	O
has	VBZ	O
demonstrated	VBN	O
a	DT	O
benefit	NN	O
of	IN	O
such	JJ	O
maintenance	NN	O
(	(	O
see	VB	O
Clinical	NNP	O
Trials	NNP	O
)	)	O
.	.	O

67	CD	O

In	IN	O
renal	JJ	WHO
transplant	NN	WHO
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
chronic	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
GFR	NNP	O
<	VBZ	O
25	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
/	VBD	O
1.73	CD	O
m²	NN	O
)	)	O
outside	IN	O
the	DT	O
immediate	JJ	O
posttransplant	JJ	O
period	NN	O
,	,	O
doses	NNS	O
of	IN	O
CellCept	NNP	O
greater	JJR	O
than	IN	O
1	CD	DOS
g	NN	UNIT
administered	VBN	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
should	MD	O
be	VB	O
avoided	VBN	O
.	.	O

To	TO	O
calculate	VB	O
the	DT	O
number	NN	O
of	IN	O
sites	NNS	O
to	TO	O
be	VB	O
used	VBN	O
,	,	O
divide	VB	O
the	DT	O
total	JJ	O
volume	NN	O
to	TO	O
be	VB	O
infused	VBN	O
by	IN	O
the	DT	O
maximum	JJ	O
volume	NN	O
/	NNP	O
site	NN	O
(	(	O
up	IN	O
to	TO	O
60	CD	DOS
mL	NNS	UNIT
/	NNP	O
site	NN	O
)	)	O
to	TO	O
be	VB	O
infused	VBN	O
.	.	O

Maintenance	NN	O
doses	NNS	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
more	RBR	O
frequently	RB	O
than	IN	O
weekly	RB	FREQ
.	.	O

From	IN	O
Day	NNP	O
3	CD	O
onward	NN	O
,	,	O
patients	NNS	WHO
received	VBD	WHO
either	RB	WHO
SUBOXONE	NNP	WHO
sublingual	JJ	WHO
tablet	NN	WHO
or	CC	O
SUBUTEX	NNP	O
sublingual	JJ	O
tablet	NN	O
at	IN	O
the	DT	O
same	JJ	O
buprenorphine	NN	O
dose	NN	O
as	IN	O
Day	NNP	O
2	CD	O
based	VBN	O
on	IN	O
their	PRP$	O
assigned	VBN	O
treatment	NN	O
.	.	O

Patients	NNS	O
should	MD	O
not	RB	O
drink	VB	O
fluids	NNS	O
for	IN	O
4	CD	O
hours	NNS	O
before	IN	O
treatment	NN	O
and	CC	O
should	MD	O
empty	VB	O
their	PRP$	O
bladder	NN	O
prior	RB	O
to	TO	O
TICE®	NNP	O
BCG	NNP	O
administration	NN	O
.	.	O

Beyond	IN	O
the	DT	O
immediate	JJ	O
newborn	JJ	O
period	NN	O
,	,	O
children	NNS	O
generally	RB	O
require	VBP	O
proportionally	RB	O
larger	JJR	O
doses	NNS	O
than	IN	O
adults	NNS	WHO
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
body	NN	O
weight	NN	O
or	CC	O
body	NN	O
sur	JJ	O
face	NN	O
area	NN	O
.	.	O

Subsequent	JJ	O
dosage	NN	O
adjustment	NN	O
may	MD	O
be	VB	O
made	VBN	O
based	VBN	O
upon	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
response	NN	O
.	.	O

No	DT	O
further	JJ	O
priming	NN	O
of	IN	O
the	DT	O
bottle	NN	O
should	MD	O
be	VB	O
required	VBN	O
.	.	O

If	IN	O
a	DT	O
woman	NN	O
begins	VBZ	O
using	VBG	O
Xulane	NNP	O
postpartum	NN	O
,	,	O
and	CC	O
has	VBZ	O
not	RB	O
yet	RB	O
had	VBD	O
a	DT	O
period	NN	O
,	,	O
consider	VB	O
the	DT	O
possibility	NN	O
of	IN	O
ovulation	NN	O
and	CC	O
conception	NN	O
occurring	VBG	O
prior	RB	O
to	TO	O
use	VB	O
of	IN	O
Xulane	NN	O
,	,	O
and	CC	O
instruct	VB	O
her	PRP$	O
to	TO	O
use	VB	O
an	DT	O
additional	JJ	O
method	NN	O
of	IN	O
contraception	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
condom	NN	O
and	CC	O
spermicide	NN	O
or	CC	O
diaphragm	NN	O
and	CC	O
spermicide	NN	O
,	,	O
for	IN	O
the	DT	O
first	JJ	O
7	CD	O
days	NNS	O
.	.	O

To	TO	O
prepare	VB	O
the	DT	O
Nutropin	NNP	O
solution	NN	O
,	,	O
inject	VBP	O
the	DT	O
Bacteriostatic	JJ	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
(	(	O
benzylalcohol	NN	O
preserved	VBN	O
)	)	O
into	IN	O
the	DT	O
Nutropin	NNP	O
vial	NN	O
,	,	O
aiming	VBG	O
the	DT	O
stream	NN	O
of	IN	O
liquid	NN	O
against	IN	O
the	DT	O
glass	NN	O
wall	NN	O
.	.	O

Subsequent	JJ	O
vitamin	NN	O
B12	NNP	O
injections	NNS	O
may	MD	O
be	VB	O
given	VBN	O
the	DT	O
same	JJ	O
day	NN	O
as	IN	O
treatment	NN	O
with	IN	O
FOLOTYN	NNP	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

REBETOL	NNP	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
creatinine	JJ	WHO
clearance	NN	WHO
less	JJR	WHO
than	IN	O
50	CD	DOS
mL	JJ	UNIT
/	NNP	O
min	NN	O
.	.	O

In	IN	O
elderly	JJ	WHO
patients	NNS	WHO
,	,	O
increase	NN	O
dosage	NN	O
no	DT	O
more	RBR	O
frequently	RB	O
than	IN	O
every	DT	FREQ
2	CD	FREQ
weeks	NNS	FREQ
during	IN	O
titration	NN	O
[	NNP	O
see	NN	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

If	IN	O
ALT	NNP	O
increases	NNS	O
are	VBP	O
progressive	JJ	O
despite	IN	O
dose	JJ	O
reduction	NN	O
or	CC	O
accompanied	VBN	O
by	IN	O
increased	JJ	O
bilirubin	NN	O
or	CC	O
evidence	NN	O
of	IN	O
hepatic	JJ	O
decompensation	NN	O
,	,	O
therapy	NN	O
should	MD	O
be	VB	O
immediately	RB	O
discontinued	VBN	O
.	.	O

BUDEPRION	NNP	O
XL™	NNP	O
(	(	O
bupropion	NN	O
hydrochloride	NN	O
extended	VBD	O
-	:	O
release	NN	O
tablets	NNS	O
)	)	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
extreme	JJ	O
caution	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
hepatic	JJ	WHO
cirrhosis	NN	WHO
.	.	O

Intravenous	JJ	O
:	:	O
1	CD	DOS
to	TO	O
4	CD	DOS
g	NNS	UNIT
magnesium	NN	O
sulfate	NN	O
(	(	O
magnesium	JJ	O
sulfate	NN	O
(	(	O
magnesium	JJ	O
sulfate	NN	O
injection	NN	O
)	)	O
injection	NN	O
)	)	O
may	MD	O
be	VB	O
given	VBN	O
intravenously	RB	O
in	IN	O
10	CD	O
%	NN	O
to	TO	O
20	CD	O
%	NN	O
solution	NN	O
,	,	O
but	CC	O
only	RB	O
with	IN	O
great	JJ	O
caution	NN	O
;	:	O
the	DT	O
rate	NN	O
should	MD	O
not	RB	O
exceed	VB	O
1.5	CD	DOS
mL	NNS	UNIT
of	IN	O
10	CD	O
%	NN	O
solution	NN	O
or	CC	O
equivalent	JJ	O
per	IN	O
minute	NN	O
until	IN	O
relaxation	NN	O
is	VBZ	O
obtained	VBN	O
.	.	O

Assess	NNP	O
lipid	JJ	O
levels	NNS	O
before	IN	O
initiating	VBG	O
therapy	NN	O
.	.	O

To	TO	O
ensure	VB	O
continued	JJ	O
protection	NN	O
,	,	O
booster	NN	O
doses	NNS	O
of	IN	O
Td	NNP	O
should	MD	O
be	VB	O
given	VBN	O
every	DT	O
10	CD	O
years.2	NN	O

Use	VB	O
a	DT	O
new	JJ	O
sterile	JJ	O
syringe	NN	O
after	IN	O
each	DT	O
injection	NN	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
if	IN	O
the	DT	O
individual	JJ	O
pouch	JJ	O
seal	NN	O
is	VBZ	O
broken	VBN	O
or	CC	O
if	IN	O
the	DT	O
patch	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
damaged	VBN	O
.	.	O

Some	DT	O
studies	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
BayGam	NNP	O
(	(	O
immune	JJ	O
globulin	NN	O
)	)	O
in	IN	O
exposed	VBN	O
,	,	O
susceptible	JJ	O
women	NNS	O
can	MD	O
lessen	VB	O
the	DT	O
likelihood	NN	O
of	IN	O
infection	NN	O
and	CC	O
fetal	JJ	O
damage	NN	O
;	:	O
therefore	RB	O
,	,	O
BayGam	NNP	O
(	(	O
immune	JJ	O
globulin	NN	O
)	)	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.55	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	NN	O
may	MD	O
benefit	VB	O
those	DT	O
women	NNS	WHO
who	WP	WHO
will	MD	WHO
not	RB	WHO
consider	VB	WHO
a	DT	WHO
therapeutic	JJ	WHO
abortion.4	NN	WHO

Continue	NNP	O
LENVIMA	NNP	O
plus	CC	O
everolimus	JJ	O
until	IN	O
disease	JJ	O
progression	NN	O
or	CC	O
until	IN	O
unacceptable	JJ	O
toxicity	NN	O
.	.	O

As	IN	O
initial	JJ	O
therapy	NN	O
and	CC	O
in	IN	O
patients	NNS	WHO
not	RB	WHO
adequately	RB	WHO
controlled	VBN	WHO
on	IN	WHO
valsartan	NN	WHO
80	CD	DOS
mg	NN	UNIT
or	CC	O
nebivolol	VB	O
up	RP	O
to	TO	O
and	CC	O
including	VBG	O
10	CD	DOS
mg	NN	UNIT
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
BYVALSON	NNP	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
,	,	O
5	CD	DOS
mg	NN	UNIT
/	VBD	O
80	CD	DOS
mg	NN	UNIT
(	(	O
nebivolol	JJ	O
/	NNP	O
valsartan	NN	O
)	)	O
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

TEVETEN®	NN	O
can	MD	O
be	VB	O
administered	VBN	O
once	RB	FREQ
or	CC	O
twice	JJ	FREQ
daily	RB	FREQ
with	IN	O
total	JJ	O
daily	JJ	FREQ
doses	NNS	O
ranging	VBG	O
from	IN	O
400	CD	DOS
mg	NNS	UNIT
to	TO	O
800	CD	DOS
mg	NNS	UNIT
.	.	O

If	IN	O
no	DT	O
effect	NN	O
is	VBZ	O
observed	VBN	O
after	IN	O
6	CD	PER
weeks	NNS	PER
,	,	O
a	DT	O
trial	NN	O
of	IN	O
400	CD	DOS
mg	NNS	UNIT
daily	JJ	FREQ
may	MD	O
be	VB	O
worthwhile	JJ	O
.	.	O

Iron	NNP	O
supplementation	NN	O
is	VBZ	O
more	RBR	O
critical	JJ	O
in	IN	O
the	DT	WHO
child	NN	WHO
than	IN	O
the	DT	WHO
adult	NN	WHO
because	IN	O
of	IN	O
the	DT	O
increasing	VBG	O
red	JJ	O
cell	NN	O
mass	NN	O
required	VBN	O
by	IN	O
the	DT	O
growing	VBG	O
child	NN	O
.	.	O

COMPLETE	JJ	O
INFORMATION	NNP	O
IS	NNP	O
NOT	NNP	O
AVAILABLE	NNP	O
.	.	O

In	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
cyclosporine	NN	O
doses	NNS	O
at	IN	O
the	DT	O
lower	JJR	O
end	NN	O
of	IN	O
the	DT	O
recommended	JJ	O
dosage	NN	O
range	NN	O
were	VBD	O
effective	JJ	O
in	IN	O
maintaining	VBG	O
a	DT	O
satisfactory	JJ	O
response	NN	O
in	IN	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
patients	NNS	O
.	.	O

Transperitoneal	NNP	O
absorption	NN	O
of	IN	O
Sulfur	NNP	O
Colloid	NNP	O
may	MD	O
occur	VB	O
,	,	O
but	CC	O
it	PRP	O
occurs	VBZ	O
slowly	RB	O
.	.	O

edex®	NN	O
(	(	O
alprostadil	NN	O
for	IN	O
injection	NN	O
)	)	O
is	VBZ	O
given	VBN	O
as	IN	O
an	DT	O
intracavernous	JJ	O
injection	NN	O
over	IN	O
a	DT	O
5	CD	O
to	TO	O
10	CD	O
second	JJ	O
interval	NN	O
.	.	O

Maintain	NNP	O
careful	JJ	O
prescription	NN	O
records	NNS	O
,	,	O
educate	NN	O
patients	NNS	O
about	IN	O
abuse	NN	O
,	,	O
monitor	NN	O
for	IN	O
signs	NNS	O
of	IN	O
abuse	NN	O
and	CC	O
overdose	NN	O
,	,	O
and	CC	O
periodically	RB	O
re	VB	O
-	:	O
evaluate	VB	O
the	DT	O
need	NN	O
for	IN	O
DYANAVEL	NNP	O
XR	NNP	O
use	NN	O
[	NNP	O
see	NN	O
PRECAUTIONS	NNP	O
,	,	O
and	CC	O
Drug	NNP	O
Abuse	NNP	O
and	CC	O
Dependence	NNP	O
]	NNP	O
.	.	O

Therefore	RB	O
,	,	O
a	DT	O
conservative	JJ	O
approach	NN	O
is	VBZ	O
advised	VBN	O
when	WRB	O
determining	VBG	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
TROXYCA	NNP	O
ER	NNP	O
.	.	O

The	DT	O
infant	NN	WHO
should	MD	O
be	VB	O
allowed	VBN	O
to	TO	O
stabilize	VB	O
before	IN	O
proceeding	VBG	O
with	IN	O
dosing	NN	O
.	.	O

Note	NN	O
:	:	O
Shake	NNP	O
oral	JJ	O
suspension	NN	O
well	RB	O
before	IN	O
using	VBG	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
to	TO	WHO
moderate	VB	WHO
liver	NN	WHO
impairment	NN	WHO
(	(	WHO
Child	NNP	WHO
Pugh	NNP	WHO
Classes	VBZ	WHO
A	NNP	WHO
and	CC	WHO
B	NNP	WHO
)	)	WHO
,	,	O
a	DT	O
maximum	JJ	O
continuous	JJ	O
infusion	NN	O
of	IN	O
esomeprazole	JJ	O
6	CD	DOS
mg	NN	UNIT
/	NN	O
h	NN	O
should	MD	O
not	RB	O
be	VB	O
exceeded	VBN	O
.	.	O

Each	DT	O
dose	NN	O
consists	VBZ	O
of	IN	O
four	CD	DOS
PROBUPHINE	NNP	UNIT
implants	NNS	UNIT
inserted	VBD	O
subdermally	RB	O
in	IN	O
the	DT	O
inner	JJ	O
side	NN	O
of	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
.	.	O

The	DT	O
couple	NN	O
should	MD	O
be	VB	O
encouraged	VBN	O
to	TO	O
have	VB	O
intercourse	JJ	O
daily	JJ	FREQ
,	,	O
beginning	VBG	O
on	IN	O
the	DT	O
day	NN	O
prior	RB	O
to	TO	O
the	DT	O
administration	NN	O
of	IN	O
hCG	NN	O
until	IN	O
ovulation	NN	O
becomes	NNS	O
apparent	VBP	O
from	IN	O
the	DT	O
indices	NNS	O
employed	VBN	O
for	IN	O
the	DT	O
determination	NN	O
of	IN	O
progestational	JJ	O
activity	NN	O
.	.	O

Later	RB	O
incremental	JJ	O
doses	NNS	O
starting	VBG	O
at	IN	O
0.01	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

Once	RB	O
an	DT	O
effective	JJ	O
dosage	NN	O
is	VBZ	O
established	VBN	O
,	,	O
amoxapine	NN	O
(	(	O
amoxapine	NN	O
(	(	O
amoxapine	JJ	O
tablets	NNS	O
)	)	O
tablets	NNS	O
)	)	O
may	MD	O
conveniently	RB	O
be	VB	O
given	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
bedtime	NN	UNIT
dose	NN	UNIT
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
300	CD	DOS
mg	NNS	UNIT
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

54	CD	O

The	DT	O
actual	JJ	O
radiation	NN	O
dose	NN	O
is	VBZ	O
operator	JJ	O
and	CC	O
scanner	JJ	O
dependent	NN	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
Venofer	NNP	O
is	VBZ	O
expressed	VBN	O
in	IN	O
mg	NN	UNIT
of	IN	O
elemental	JJ	O
iron	NN	O
.	.	O

A	DT	O
20	CD	O
-	:	O
gaugc	NN	O
needle	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

The	DT	O
strip	NN	O
of	IN	O
EMLA	NNP	O
(	(	O
lidocaine	NN	O
and	CC	O
prilocaine	NN	O
)	)	O
cream	NN	O
should	MD	O
be	VB	O
contained	VBN	O
within	IN	O
the	DT	O
lines	NNS	O
of	IN	O
the	DT	O
diagram	NN	O
shown	VBN	O
below	IN	O
.	.	O

Individual	JJ	O
patients	NNS	O
will	MD	O
experience	VB	O
a	DT	O
variable	JJ	O
time	NN	O
to	TO	O
onset	VB	O
and	CC	O
degree	VB	O
of	IN	O
symptom	NN	O
relief	NN	O
.	.	O

For	IN	O
topical	JJ	O
use	NN	O
only	RB	O
.	.	O

as	IN	O
diluent	NN	O
.	.	O

Assessment	NN	O
of	IN	O
hematologic	NN	O
,	,	O
hepatic	JJ	O
,	,	O
renal	JJ	O
,	,	O
and	CC	O
pulmonary	JJ	O
function	NN	O
should	MD	O
be	VB	O
made	VBN	O
by	IN	O
history	NN	O
,	,	O
physical	JJ	O
examination	NN	O
,	,	O
and	CC	O
laboratory	NN	O
tests	NNS	O
before	IN	O
beginning	VBG	O
,	,	O
periodically	RB	O
during	IN	O
,	,	O
and	CC	O
before	IN	O
reinstituting	VBG	O
methotrexate	NN	O
therapy	NN	O
.	.	O

Store	RB	O
reconstituted	JJ	O
solution	NN	O
for	IN	O
intramuscular	JJ	O
injection	NN	O
in	IN	O
a	DT	O
refrigerator	NN	O
2°	CD	O
to	TO	O
8°C	CD	O
(	(	O
36°	CD	O
to	TO	O
46°F	CD	O
)	)	O
or	CC	O
between	IN	O
20°	CD	O
to	TO	O
25°C	CD	O
(	(	O
68°	CD	O
to	TO	O
77°F	CD	O
)	)	O
and	CC	O
use	VB	O
within	IN	O
7	CD	PER
days	NNS	PER
.	.	O

Please	NNP	O
consult	NN	O
manufacturer	NN	O
's	POS	O
manual	NN	O
for	IN	O
specific	JJ	O
recommendations	NNS	O
.	.	O

Rinse	NNP	O
thoroughly	RB	O
with	IN	O
water	NN	O
and	CC	O
pat	NN	O
dry	NN	O
.	.	O

Based	VBN	O
on	IN	O
efficacy	NN	O
and	CC	O
tolerability	NN	O
,	,	O
dosages	NNS	O
may	MD	O
be	VB	O
increased	VBN	O
gradually	RB	O
,	,	O
not	RB	O
more	RBR	O
frequently	RB	O
than	IN	O
every	DT	FREQ
5	CD	FREQ
to	TO	O
7	CD	PER
days	NNS	PER
,	,	O
first	RB	O
to	TO	O
0.75	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
and	CC	O
then	RB	O
by	IN	O
0.75	CD	DOS
mg	NN	UNIT
increments	NNS	O
up	RB	O
to	TO	O
a	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
of	IN	O
4.5	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

At	IN	O
least	JJS	O
1	CD	O
month	NN	O
should	MD	O
elapse	VB	O
between	IN	O
a	DT	O
dose	NN	O
of	IN	O
a	DT	O
measles	NNS	O
-	:	O
containing	VBG	O
vaccine	NN	O
such	JJ	O
as	IN	O
M	NNP	O
-	:	O
M	NNP	O
-	:	O
R®	NNP	O
II	NNP	O
(	(	O
measles	NNS	O
,	,	O
mumps	NNS	O
,	,	O
and	CC	O
rubella	NN	O
virus	NN	O
vaccine	NN	O
live	VBP	O
)	)	O
and	CC	O
a	DT	O
dose	NN	O
of	IN	O
ProQuad	NNP	O
.	.	O

For	IN	O
osteoarthritis	NN	O
,	,	O
the	DT	O
dosage	NN	O
for	IN	O
maximal	JJ	O
GI	NNP	O
mucosal	NN	O
protection	NN	O
is	VBZ	O
ARTHROTEC	NNP	O
50	CD	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Avoid	NNP	O
interruption	NN	O
of	IN	O
Stalevo	NNP	O
dosing	NN	O
because	IN	O
hyperpyrexia	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
suddenly	RB	WHO
discontinue	VBP	WHO
or	CC	O
reduce	VB	O
their	PRP$	O
use	NN	O
of	IN	O
levodopa	JJ	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

With	IN	O
continued	JJ	O
application	NN	O
,	,	O
further	JJ	O
benefit	NN	O
may	MD	O
be	VB	O
attained	VBN	O
.	.	O

In	IN	O
the	DT	O
clinical	JJ	O
trials	NNS	O
,	,	O
antacids	NNS	O
were	VBD	O
used	VBN	O
concomitantly	RB	O
with	IN	O
PRILOSEC	NNP	O
.	.	O

Administer	NNP	O
in	IN	O
divided	JJ	O
doses	NNS	O
2	CD	FREQ
or	CC	O
3	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
,	,	O
preferably	RB	O
30	CD	O
to	TO	O
45	CD	O
minutes	NNS	O
before	IN	O
meals	NNS	O
.	.	O

Room	JJ	O
temperature	NN	O
:	:	O
6	CD	DOS
,	,	O
9	CD	DOS
and	CC	O
12	CD	DOS
mg	NN	UNIT
/	NN	O
mL	NN	O
(	(	O
equivalent	JJ	O
to	TO	O
clindamycin	VB	O
base	NN	O
)	)	O
in	IN	O
dextrose	JJ	O
injection	NN	O
5	CD	O
%	NN	O
,	,	O
sodium	NN	O
chloride	NN	O
injection	NN	O
0.9	CD	O
%	NN	O
,	,	O
or	CC	O
Lactated	VBD	O
Ringers	NNPS	O
Injection	NNP	O
in	IN	O
glass	NN	O
bottles	NNS	O
or	CC	O
minibags	NNS	O
,	,	O
demonstrated	VBD	O
physical	JJ	O
and	CC	O
chemical	JJ	O
stability	NN	O
for	IN	O
at	IN	PER
least	JJS	PER
16	CD	PER
days	NNS	PER
at	IN	O
25°C	CD	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
intravenously	RB	O
or	CC	O
intradermally	RB	O

The	DT	O
following	JJ	O
formula	NN	O
provides	VBZ	O
a	DT	O
guide	NN	O
to	TO	O
dosage	VB	O
calculations	NNS	O
:	:	O

A	DT	O
back	NN	O
-	:	O
up	IN	O
birth	NN	O
control	NN	O
method	NN	O
is	VBZ	O
not	RB	O
required	VBN	O
during	IN	O
this	DT	O
time	NN	O
.	.	O

The	DT	O
recommended	VBN	O
adult	NN	WHO
oral	JJ	O
dose	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
patients	NNS	WHO
with	IN	WHO
symptomatic	JJ	WHO
GERD	NNP	WHO
and	CC	O
no	DT	O
esophageal	JJ	O
lesions	NNS	O
is	VBZ	O
20	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
for	IN	O
up	IN	PER
to	TO	PER
4	CD	PER
weeks	NNS	PER
.	.	O

With	IN	O
the	DT	O
exception	NN	O
of	IN	O
the	DT	O
procerus	NN	O
muscle	NN	O
,	,	O
which	WDT	O
should	MD	O
be	VB	O
injected	VBN	O
at	IN	O
one	CD	O
site	NN	O
(	(	O
midline	NN	O
)	)	O
,	,	O
all	DT	O
muscles	NNS	O
should	MD	O
be	VB	O
injected	VBN	O
bilaterally	RB	O
with	IN	O
half	PDT	O
the	DT	O
number	NN	O
of	IN	O
injection	NN	O
sites	NNS	O
administered	VBD	O
to	TO	O
the	DT	O
left	NN	O
,	,	O
and	CC	O
half	NN	O
to	TO	O
the	DT	O
right	JJ	O
side	NN	O
of	IN	O
the	DT	O
head	NN	O
and	CC	O
neck	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Conversion	NN	O
Factors	NNS	O
to	TO	O
DOLOPHINE	VB	O

Initiate	NNP	O
dosing	VBG	O
using	VBG	O
ARYMO	NNP	O
ER	NNP	O
15	CD	DOS
mg	NN	UNIT
orally	RB	O
every	DT	O
8	CD	O
to	TO	O
12	CD	O
hours	NNS	O
.	.	O

After	IN	O
administering	VBG	O
the	DT	O
pellets	NNS	O
,	,	O
the	DT	O
nasogastric	JJ	O
tube	NN	O
should	MD	O
be	VB	O
flushed	VBN	O
with	IN	O
additional	JJ	O
water	NN	O
.	.	O

Due	NNP	O
to	TO	O
an	DT	O
increased	VBN	O
fraction	NN	O
of	IN	O
unbound	JJ	O
phenytoin	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
or	CC	WHO
hepatic	JJ	WHO
disease	NN	WHO
,	,	O
or	CC	O
in	IN	O
those	DT	O
with	IN	O
hypoalbuminemia	NN	O
,	,	O
the	DT	O
interpretation	NN	O
of	IN	O
total	JJ	O
phenytoin	NN	O
plasma	NN	O
concentrations	NNS	O
should	MD	O
be	VB	O
made	VBN	O
with	IN	O
caution	NN	O
.	.	O

Even	RB	O
if	IN	O
you	PRP	O
are	VBP	O
not	RB	O
eating	VBG	O
,	,	O
you	PRP	O
will	MD	O
still	RB	O
require	VB	O
insulin	NN	O
.	.	O

Rates	NNS	O
greater	JJR	O
than	IN	O
0.2	CD	DOS
mcg	JJ	UNIT
/	NNP	O
kg	NN	O
/	NNP	O
min	NN	O
are	VBP	O
generally	RB	O
associated	VBN	O
with	IN	O
respiratory	JJ	O
depression	NN	O
(	(	O
respiratory	JJ	O
rates	NNS	O
less	RBR	O
than	IN	O
8	CD	DOS
breaths	NNS	UNIT
/	NNP	O
min	NN	O
)	)	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
EMBEDA	NNP	O
pellets	NNS	O
through	IN	O
a	DT	O
nasogastric	JJ	WHO
or	CC	WHO
gastric	JJ	WHO
tube	NN	WHO
.	.	O

During	IN	O
a	DT	O
single	JJ	O
examination	NN	O
,	,	O
a	DT	O
second	JJ	O
injection	NN	O
of	IN	O
2	CD	DOS
mL	NN	UNIT
may	MD	O
be	VB	O
administered	VBN	O
to	TO	O
prolong	VB	O
contrast	NN	O
enhancement	NN	O
.	.	O

Gently	RB	O
shake	VB	O
the	DT	O
device	NN	O
and	CC	O
remove	VB	O
needle	JJ	O
cap	NN	O

Care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
insure	VB	O
insemination	NN	O
.	.	O

Step	NN	O
1	CD	O
:	:	O
Prepare	VB	O
the	DT	O
medication	NN	O
port	NN	O
by	IN	O
removal	NN	O
of	IN	O
aluminum	NN	O
foil	NN	O
(	(	O
Figure	NNP	O
5a	CD	O
)	)	O
.	.	O

The	DT	O
effect	NN	O
of	IN	O
other	JJ	O
hormonal	JJ	O
contraceptive	JJ	O
preparations	NNS	O
or	CC	O
hormone	NN	O
replacement	NN	O
therapy	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
lamotrigine	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
systematically	RB	O
evaluated	VBN	O
.	.	O

Consider	VB	O
interruption	NN	O
or	CC	O
reduction	NN	O
in	IN	O
LANOXIN	NNP	O
dose	VBP	O
prior	JJ	O
to	TO	O
electrical	JJ	O
cardioversion	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
nasal	JJ	O
polyps	NNS	O
is	VBZ	O
2	CD	DOS
sprays	NNS	UNIT
(	(	O
50	CD	DOS
mcg	NN	UNIT
of	IN	O
mometasone	NN	O
furoate	NN	O
in	IN	O
each	DT	O
spray	NN	O
)	)	O
in	IN	O
each	DT	O
nostril	JJ	O
twice	RB	FREQ
daily	RB	FREQ
(	(	O
total	JJ	O
daily	RB	FREQ
dose	NN	O
of	IN	O
400	CD	DOS
mcg	NN	UNIT
)	)	O
.	.	O

When	WRB	O
the	DT	O
patient	NN	O
no	RB	O
longer	RBR	O
requires	VBZ	O
therapy	NN	O
with	IN	O
morphine	JJ	O
sulfate	NN	O
extended	VBD	O
-	:	O
release	NN	O
tablets	NNS	O
,	,	O
use	VBP	O
a	DT	O
gradual	JJ	O
downward	JJ	O
titration	NN	O
of	IN	O
the	DT	O
dose	NN	O
to	TO	O
prevent	VB	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
withdrawal	NN	O
in	IN	O
the	DT	O
physicallydependent	JJ	O
patient	NN	O
.	.	O

Therefore	RB	O
,	,	O
comparison	NN	O
between	IN	O
concentrations	NNS	O
in	IN	O
the	DT	O
published	JJ	O
literature	NN	O
and	CC	O
an	DT	O
individual	JJ	O
patient	NN	O
concentration	NN	O
using	VBG	O
current	JJ	O
assays	NNS	O
must	MD	O
be	VB	O
made	VBN	O
with	IN	O
detailed	JJ	O
knowledge	NN	O
of	IN	O
the	DT	O
assay	NN	O
methods	NNS	O
employed	VBN	O
.	.	O

Beyaz	NNP	O
can	MD	O
be	VB	O
taken	VBN	O
without	IN	O
regard	NN	O
to	TO	O
meals	NNS	O
.	.	O

Frequent	JJ	O
communication	NN	O
is	VBZ	O
important	JJ	O
among	IN	O
the	DT	O
prescriber	NN	O
,	,	O
other	JJ	O
members	NNS	O
of	IN	O
the	DT	O
healthcare	NN	O
team	NN	O
,	,	O
the	DT	O
patient	NN	O
,	,	O
and	CC	O
the	DT	O
caregiver	NN	O
/	NNP	O
family	NN	O
during	IN	O
periods	NNS	O
of	IN	O
changing	VBG	O
analgesic	JJ	O
requirements	NNS	O
,	,	O
including	VBG	O
initial	JJ	O
titration	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
CAPOTEN	NNP	O
for	IN	O
long	JJ	O
term	NN	O
use	NN	O
to	TO	O
treat	VB	O
diabetic	JJ	O
nephropathy	NN	O
is	VBZ	O
25	CD	DOS
mg	NN	UNIT
t.i.d	NN	O
.	.	O

Treatment	NN	O
should	MD	O
be	VB	O
withheld	VBN	O
for	IN	O
renal	JJ	O
deterioration	NN	O
.	.	O

Use	VB	O
the	DT	O
reconstituted	JJ	O
ELOCTATE	NNP	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
,	,	O
but	CC	O
no	DT	O
later	RB	O
than	IN	O
3	CD	O
hours	NNS	O
after	IN	O
reconstitution	NN	O
.	.	O

Consult	NN	WHO
with	IN	WHO
pharmacist	NN	WHO
.	.	O

For	IN	O
optimum	JJ	O
effect	NN	O
,	,	O
measured	VBN	O
as	IN	O
lack	NN	O
of	IN	O
recall	NN	O
,	,	O
intramuscular	JJ	O
lorazepam	NN	O
should	MD	O
be	VB	O
administered	VBN	O
at	IN	O
least	JJS	O
2	CD	O
hours	NNS	O
before	IN	O
the	DT	O
anticipated	JJ	O
operative	JJ	O
procedure	NN	O
.	.	O

ORTHO	NNP	O
TRI	NNP	O
-	:	O
CYCLEN	NNP	O
Lo	NNP	O
may	MD	O
be	VB	O
started	VBN	O
using	VBG	O
either	CC	O
a	DT	O
Day	NNP	O
1	CD	O
start	NN	O
or	CC	O
a	DT	O
Sunday	NNP	O
start	NN	O
(	(	O
see	VB	O
Table	NNP	O
1	CD	O
)	)	O
.	.	O

Patients	NNS	WHO
Maintained	VBD	WHO
on	IN	WHO
Systemic	NNP	WHO
Corticosteroids	NNP	WHO
:	:	O

In	IN	O
view	NN	O
of	IN	O
the	DT	O
dose	JJ	O
-	:	O
dependent	JJ	O
adverse	JJ	O
reactions	NNS	O
and	CC	O
the	DT	O
higher	JJR	O
rate	NN	O
of	IN	O
treatment	NN	O
discontinuation	NN	O
due	JJ	O
to	TO	O
adverse	JJ	O
reactions	NNS	O
,	,	O
reserve	VBP	O
dosing	VBG	O
above	IN	O
300	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
for	IN	O
those	DT	O
patients	NNS	O
who	WP	O
have	VBP	O
on	IN	O
-	:	O
going	VBG	O
pain	NN	O
and	CC	O
are	VBP	O
tolerating	VBG	O
300	CD	DOS
mg	JJ	UNIT
daily	JJ	FREQ
[	NNP	O
see	VBP	O
ADVERSE	NNP	O
REACTIONS	NNP	O
]	NNP	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
maintained	VBN	WHO
on	IN	WHO
hemodialysis	NN	WHO
,	,	O
the	DT	O
dose	JJ	O
frequency	NN	O
should	MD	O
be	VB	O
3	CD	FREQ
times	NNS	FREQ
/	JJ	FREQ
week	NN	FREQ
after	IN	O
hemodialysis	NN	O
.	.	O

Mylotarg	NNP	O
(	(	O
gemtuzumab	JJ	O
ozogamicin	NN	O
for	IN	O
injection	NN	O
)	)	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
,	,	O
once	RB	O
in	IN	O
the	DT	O
transfer	NN	O
syringe	NN	O
.	.	O

When	WRB	O
methyldopa	NN	O
is	VBZ	O
given	VBN	O
to	TO	O
patients	NNS	WHO
on	IN	WHO
other	JJ	WHO
antihypertensives	NNS	WHO
,	,	O
the	DT	O
dose	NN	O
of	IN	O
these	DT	O
agents	NNS	O
may	MD	O
need	VB	O
to	TO	O
be	VB	O
adjusted	VBN	O
to	TO	O
effect	NN	O
a	DT	O
smooth	JJ	O
transition	NN	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
if	IN	O
the	DT	O
solution	NN	O
is	VBZ	O
cloudy	JJ	O
or	CC	O
precipitated	VBN	O
or	CC	O
if	IN	O
seals	NNS	O
are	VBP	O
not	RB	O
intact	JJ	O
.	.	O

The	DT	WHO
adult	NN	WHO
starting	VBG	O
indapamide	NN	O
dose	NN	O
for	IN	O
hypertension	NN	O
is	VBZ	O
1.25	CD	DOS
mg	NN	UNIT
as	IN	O
a	DT	O
single	JJ	DOS
daily	JJ	FREQ
dose	NN	UNIT
taken	VBN	O
in	IN	O
the	DT	O
morning	NN	O
.	.	O

Methotrexate	NNP	O
(	(	O
MTX	NNP	O
)	)	O
,	,	O
other	JJ	O
non	SYM	O
-	:	O
biologic	NN	O
DMARDS	NNP	O
,	,	O
glucocorticoids	NNS	O
,	,	O
nonsteroidal	JJ	O
anti	SYM	O
-	:	O
inflammatory	NN	O
drugs	NNS	O
(	(	O
NSAIDs	NNP	O
)	)	O
,	,	O
and	CC	O
/	NNP	O
or	CC	O
analgesics	NNS	O
may	MD	O
be	VB	O
continued	VBN	O
during	IN	O
treatment	NN	O
with	IN	O
HUMIRA	NNP	O
.	.	O

VANTRELA	NNP	O
ER	NNP	O
treatment	NN	O
may	MD	O
be	VB	O
initiated	VBN	O
18	CD	O
hours	NNS	O
following	VBG	O
the	DT	O
removal	NN	O
of	IN	O
the	DT	O
transdermal	JJ	O
fentanyl	NN	O
patch	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
ÂRecommended	VBN	O
Dose	NNP	O
Adjustments	NNS	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

If	IN	O
the	DT	O
drug	NN	O
to	TO	O
be	VB	O
administered	VBN	O
is	VBZ	O
incompatible	JJ	O
with	IN	O
heparin	NN	O
,	,	O
the	DT	O
entire	JJ	O
device	NN	O
should	MD	O
be	VB	O
flushed	VBN	O
with	IN	O
normal	JJ	O
saline	NN	O
before	IN	O
and	CC	O
after	IN	O
the	DT	O
medication	NN	O
is	VBZ	O
administered	VBN	O
;	:	O
following	VBG	O
the	DT	O
second	JJ	O
saline	NN	O
flush	NN	O
,	,	O
Preservative	NNP	O
-	:	O
Free	JJ	O
Heparin	NNP	O
Lock	NNP	O
Flush	NNP	O
Solution	NNP	O
,	,	O
USP	NNP	O
may	MD	O
be	VB	O
reinstilled	VBN	O
into	IN	O
the	DT	O
device	NN	O
.	.	O

Care	NN	O
must	MD	O
be	VB	O
taken	VBN	O
to	TO	O
avoid	VB	O
incompatible	JJ	O
admixtures	NNS	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
a	DT	O
household	NN	O
teaspoon	NN	O
to	TO	O
measure	VB	O
the	DT	O
dose	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

For	IN	O
persons	NNS	O
who	WP	O
refuse	VBP	O
Hepatitis	NNP	O
B	NNP	O
Vaccine	NNP	O
,	,	O
a	DT	O
second	JJ	O
dose	NN	O
of	IN	O
Hepatitis	NNP	O
B	NNP	O
Immune	NNP	O
Globulin	NNP	O
(	(	O
Human	NNP	O
)	)	O
should	MD	O
be	VB	O
given	VBN	O
1	CD	O
month	NN	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
.	.	O

The	DT	O
implant	NN	O
is	VBZ	O
inserted	VBN	O
subcutaneously	RB	O
in	IN	O
the	DT	O
inner	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
and	CC	O
provides	VBZ	O
continuous	JJ	O
release	NN	O
of	IN	O
histrelin	NN	O
(	(	O
50	CD	DOS
mcg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
)	)	O
for	IN	O
12	CD	PER
months	NNS	PER
of	IN	O
hormonal	JJ	O
therapy	NN	O
.	.	O

The	DT	O
solution	NN	O
may	MD	O
be	VB	O
kept	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
and	CC	O
should	MD	O
be	VB	O
used	VBN	O
within	IN	O
24	CD	O
hours	NNS	O
of	IN	O
reconstitution	NN	O
,	,	O
after	IN	O
which	WDT	O
time	NN	O
any	DT	O
unused	JJ	O
portion	NN	O
should	MD	O
be	VB	O
discarded	VBN	O
.	.	O

Taking	VBG	O
this	DT	O
product	NN	O
without	IN	O
enough	JJ	O
liquid	NN	O
may	MD	O
cause	VB	O
choking	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
an	DT	O
in	IN	O
-	:	O
line	NN	O
filter	NN	O
is	VBZ	O
optional	JJ	O
.	.	O

Intravenous	JJ	O
therapy	NN	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
rapid	JJ	O
relief	NN	O
of	IN	O
ocular	JJ	O
tension	NN	O
in	IN	O
acute	JJ	O
cases	NNS	O
.	.	O

Total	JJ	O
doses	NNS	O
and	CC	O
frequency	NN	O
of	IN	O
administration	NN	O
must	MD	O
be	VB	O
determined	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
response	NN	O
,	,	O
starting	VBG	O
with	IN	O
low	JJ	O
doses	NNS	O
and	CC	O
increasing	VBG	O
gradually	RB	O
.	.	O

Interruption	NN	O
of	IN	O
the	DT	O
recommended	JJ	O
schedule	NN	O
with	IN	O
a	DT	O
delay	NN	O
between	IN	O
doses	NNS	O
does	VBZ	O
not	RB	O
interfere	VB	O
with	IN	O
the	DT	O
final	JJ	O
immunity	NN	O
.	.	O

A	DT	O
.	.	O

If	IN	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
fail	VBP	O
to	TO	O
improve	VB	O
after	IN	O
two	CD	PER
days	NNS	PER
,	,	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
re	VBN	O
-	:	O
evaluated	VBN	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

Use	NNP	O
aseptic	JJ	O
techniques	NNS	O
.	.	O

Using	VBG	O
your	PRP$	O
fingertips	NNS	O
,	,	O
gently	RB	O
massage	NN	O
OLUX	NNP	O
(	(	O
clobetasol	JJ	O
propionate	NN	O
)	)	O
Foam	NNP	O
into	IN	O
the	DT	O
affected	JJ	O
areas	NNS	O
until	IN	O
the	DT	O
foam	NN	O
disappears	VBZ	O
.	.	O

Due	JJ	O
to	TO	O
a	DT	O
decrease	NN	O
in	IN	O
unbound	JJ	O
clearance	NN	O
of	IN	O
valproate	NN	O
and	CC	O
possibly	RB	O
a	DT	O
greater	JJR	O
sensitivity	NN	O
to	TO	O
somnolence	VB	O
in	IN	O
the	DT	WHO
elderly	JJ	WHO
,	,	O
the	DT	O
starting	VBG	O
dose	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
.	.	O

The	DT	O
currently	RB	O
recommended	VBN	O
regimens	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
3	CD	O
.	.	O

In	IN	O
some	DT	O
cases	NNS	O
,	,	O
however	RB	O
,	,	O
hysterectomized	VBD	WHO
women	NNS	WHO
with	IN	O
a	DT	O
history	NN	O
of	IN	O
endometriosis	NN	O
may	MD	O
need	VB	O
a	DT	O
progestin	NN	O
[	NN	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Hyperactivity	NNP	O
in	IN	O
an	DT	WHO
older	JJR	WHO
child	NN	WHO
can	MD	O
be	VB	O
minimized	VBN	O
if	IN	O
the	DT	O
starting	NN	O
dose	NN	O
is	VBZ	O
one	CD	DOS
-	:	O
fourth	JJ	O
of	IN	O
the	DT	O
recommended	VBN	O
full	JJ	O
replacement	NN	O
dose	NN	O
,	,	O
and	CC	O
the	DT	O
dose	NN	O
is	VBZ	O
then	RB	O
increased	VBN	O
on	IN	O
a	DT	O
weekly	JJ	O
basis	NN	O
by	IN	O
an	DT	O
amount	NN	O
equal	JJ	O
to	TO	O
one	CD	O
-	:	O
fourth	JJ	O
the	DT	O
full	JJ	O
-	:	O
recommended	JJ	O
replacement	NN	O
dose	NN	O
until	IN	O
the	DT	O
full	JJ	O
recommended	VBD	O
replacement	NN	O
dose	NN	O
is	VBZ	O
reached	VBN	O
.	.	O

AVANDAMET	NNP	O
and	CC	O
rosiglitazone	NN	O
are	VBP	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
.	.	O

THIOLA®	NN	O
may	MD	O
also	RB	O
be	VB	O
substituted	VBN	O
for	IN	O
d	NN	O
-	:	O
penicillamine	NN	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
developed	VBN	WHO
toxicity	NN	WHO
to	TO	O
the	DT	O
latter	JJ	O
drug	NN	O
.	.	O

Visually	RB	O
inspect	VBP	O
the	DT	O
reconstituted	JJ	O
ABRAXANE	NNP	O
suspension	NN	O
in	IN	O
the	DT	O
intravenous	JJ	O
bag	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

Intramuscular	JJ	O
administration	NN	O
should	MD	O
not	RB	O
exceed	VB	O
2	CD	DOS
g	JJ	UNIT
per	IN	O
injection	NN	O
at	IN	O
any	DT	O
one	CD	O
site	NN	O
.	.	O

If	IN	O
INVANZ	NNP	O
is	VBZ	O
given	VBN	O
at	IN	O
least	JJS	O
6	CD	O
hours	NNS	O
prior	RB	O
to	TO	O
hemodialysis	NN	O
,	,	O
no	DT	O
supplementary	JJ	O
dose	NN	O
is	VBZ	O
needed	VBN	O
.	.	O

FOR	IN	O
OPHTHALMIC	NNP	O
USE	NNP	O
ONLY	NNP	O

A	DT	O
clinical	JJ	O
response	NN	O
is	VBZ	O
usually	RB	O
seen	VBN	O
within	IN	O
15	CD	O
minutes	NNS	O
.	.	O

Nutropin	NNP	O
AQ	NNP	O
therapy	NN	O
may	MD	O
be	VB	O
continued	VBN	O
up	RP	O
to	TO	O
the	DT	O
time	NN	O
of	IN	O
renal	JJ	O
transplantation	NN	O
.	.	O

In	IN	O
cerebral	JJ	O
edema	NN	O
,	,	O
Dexamethasone	NNP	O
Sodium	NNP	O
Phosphate	NNP	O
injection	NN	O
,	,	O
USP	NNP	O
is	VBZ	O
generally	RB	O
administered	VBN	O
initially	RB	O
in	IN	O
a	DT	O
dosage	NN	O
of	IN	O
10	CD	DOS
mg	NN	UNIT
intravenously	RB	O
followed	VBN	O
by	IN	O
4	CD	DOS
mg	NNS	UNIT
every	DT	FREQ
six	CD	FREQ
hours	NNS	FREQ
intramuscularly	RB	FREQ
until	IN	O
the	DT	O
symptoms	NNS	O
of	IN	O
cerebral	JJ	O
edema	NN	O
subside	NN	O
.	.	O

Therefore	RB	O
,	,	O
increases	NNS	O
in	IN	O
dosage	NN	O
should	MD	O
be	VB	O
made	VBN	O
no	DT	O
more	RBR	O
frequently	RB	O
than	IN	O
once	RB	FREQ
every	DT	FREQ
four	CD	FREQ
days	NNS	FREQ
,	,	O
since	IN	O
during	IN	O
the	DT	O
first	JJ	O
2	CD	PER
to	TO	O
3	CD	PER
days	NNS	PER
of	IN	O
therapy	NN	O
the	DT	O
optimal	JJ	O
effect	NN	O
of	IN	O
a	DT	O
given	VBN	O
dose	NN	O
may	MD	O
not	RB	O
be	VB	O
achieved	VBN	O
.	.	O

Care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
inject	VB	O
the	DT	O
test	NN	O
antigen	NN	O
intradermally	RB	O
.	.	O

If	IN	O
IV	NNP	O
therapy	NN	O
is	VBZ	O
necessary	JJ	O
,	,	O
conversion	NN	O
from	IN	O
IV	NNP	O
to	TO	O
oral	JJ	O
Prograf	NNP	O
is	VBZ	O
recommended	VBN	O
as	RB	O
soon	RB	O
as	IN	O
oral	JJ	O
therapy	NN	O
can	MD	O
be	VB	O
tolerated	VBN	O
.	.	O

BUDEPRION	NNP	O
XL™	NNP	O
(	(	O
bupropion	NN	O
hydrochloride	NN	O
extended	VBD	O
-	:	O
release	NN	O
tablets	NNS	O
)	)	O
may	MD	O
be	VB	O
taken	VBN	O
without	IN	O
regard	NN	O
to	TO	O
meals	NNS	O
.	.	O

8	CD	O
)	)	O
.	.	O

Dibasic	NNP	O
sodium	NN	O
phosphate	NN	O
(	(	O
anhydrous	JJ	O
)	)	O
1.59	CD	DOS
g	JJ	UNIT
Monobasic	NNP	O
sodium	NN	O
phosphate	NN	O
(	(	O
anhydrous	JJ	O
)	)	O
0.96	CD	DOS
g	JJ	UNIT
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
qs	VBZ	O
100.0	CD	DOS
Ml	NN	UNIT

Serious	JJ	O
neurological	JJ	O
reactions	NNS	O
that	WDT	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
cerebral	JJ	O
angiography	NN	O
and	CC	O
not	RB	O
listed	VBN	O
under	IN	O
Adverse	NNP	O
Reactions	NNP	O
,	,	O
General	NNP	O
,	,	O
include	VBP	O
stroke	NN	O
,	,	O
amnesia	NN	O
and	CC	O
respiratory	NN	O
difficulties	NNS	O
.	.	O

Prior	RB	O
to	TO	O
administering	VBG	O
ADASUVE	NNP	O
,	,	O
screen	NN	O
all	DT	O
patients	NNS	O
for	IN	O
a	DT	O
history	NN	O
of	IN	O
asthma	NN	O
,	,	O
COPD	NNP	O
,	,	O
or	CC	O
other	JJ	O
pulmonary	JJ	O
disease	NN	O
,	,	O
and	CC	O
examine	NN	O
patients	NNS	O
(	(	O
including	VBG	O
chest	JJS	O
auscultation	NN	O
)	)	O
for	IN	O
respiratory	NN	O
signs	NNS	O
(	(	O
e.g	NN	O
.	.	O

The	DT	O
Evomela	NNP	O
admixture	NN	O
solution	NN	O
is	VBZ	O
stable	JJ	O
for	IN	O
4	CD	PER
hours	NNS	PER
at	IN	O
room	NN	O
temperature	NN	O
in	IN	O
addition	NN	O
to	TO	O
the	DT	O
1	CD	O
hour	NN	O
following	VBG	O
reconstitution	NN	O
.	.	O

It	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
establish	VB	O
a	DT	O
therapeutic	JJ	O
goal	NN	O
(	(	O
regain	NN	O
and	CC	O
maintain	VB	O
a	DT	O
specific	JJ	O
function	NN	O
such	JJ	O
as	IN	O
therapeutic	JJ	O
exercise	NN	O
program	NN	O
,	,	O
utilization	NN	O
of	IN	O
braces	NNS	O
,	,	O
transfer	NN	O
maneuvers	NNS	O
,	,	O
etc	FW	O
.	.	O
)	)	O

Inject	NNP	O
NEUPOGEN	NNP	O
subcutaneously	RB	O
in	IN	O
the	DT	O
outer	JJ	O
area	NN	O
of	IN	O
upper	JJ	O
arms	NNS	O
,	,	O
abdomen	NNS	O
,	,	O
thighs	NNS	O
,	,	O
or	CC	O
upper	JJ	O
outer	NN	O
areas	NNS	O
of	IN	O
the	DT	O
buttock	NN	O
.	.	O

The	DT	O
solution	NN	O
should	MD	O
be	VB	O
clear	JJ	O
immediately	RB	O
after	IN	O
removal	NN	O
from	IN	O
the	DT	O
refrigerator	NN	O
.	.	O

For	IN	O
Eclampsia	NNP	O
:	:	O
Initially	RB	O
1	CD	DOS
to	TO	O
2	CD	DOS
g	NNS	UNIT
in	IN	O
25	CD	O
%	NN	O
or	CC	O
50	CD	O
%	NN	O
solution	NN	O
is	VBZ	O
given	VBN	O
intramuscularly	RB	O
.	.	O

or	CC	O
q.i.d	NN	O
.	.	O

Adjust	IN	O
the	DT	O
dose	NN	O
to	TO	O
obtain	VB	O
an	DT	O
appropriate	JJ	O
balance	NN	O
between	IN	O
management	NN	O
of	IN	O
pain	NN	O
and	CC	O
opioid	JJ	O
-	:	O
related	JJ	O
adverse	JJ	O
reactions	NNS	O
.	.	O

Stability	NN	O
of	IN	O
TEQUIN	NNP	O
(	(	O
gatifloxacin	NN	O
(	(	O
removed	VBN	O
from	IN	O
us	PRP	O
market	NN	O
-	:	O
may	MD	O
2006	CD	O
)	)	O
)	)	O
Injection	NN	O
as	IN	O
Supplied	NNP	O

BELBUCA	NNP	O
may	MD	O
not	RB	O
provide	VB	O
adequate	JJ	O
analgesia	NN	O
for	IN	O
patients	NNS	WHO
requiring	VBG	WHO
greater	JJR	WHO
than	IN	O
160	CD	DOS
mg	JJ	UNIT
oral	JJ	O
MSE	NNP	O
per	IN	FREQ
day	NN	FREQ
.	.	O

It	PRP	O
is	VBZ	O
strongly	RB	O
recommended	VBN	O
that	IN	O
an	DT	O
accurate	NN	O
measuring	NN	O
device	NN	O
be	VB	O
used	VBN	O
.	.	O

No	DT	O
starting	VBG	O
dose	JJ	O
adjustment	NN	O
is	VBZ	O
required	VBN	O
when	WRB	O
administering	VBG	O
INLYTA	NNP	O
to	TO	O
patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	O
Child	NNP	O
-	:	O
Pugh	NNP	O
class	NN	O
A	NNP	O
)	)	O
.	.	O

In	IN	O
patients	NNS	WHO
who	WP	WHO
continue	VBP	WHO
to	TO	O
take	VB	O
their	PRP$	O
chronic	JJ	O
opioid	NN	O
therapy	NN	O
for	IN	O
persistent	JJ	O
pain	NN	O
but	CC	O
no	DT	O
longer	JJR	O
require	VB	O
treatment	NN	O
for	IN	O
breakthrough	NN	O
pain	NN	O
,	,	O
LAZANDA	NNP	O
therapy	NN	O
can	MD	O
usually	RB	O
be	VB	O
discontinued	VBN	O
immediately	RB	O
[	JJ	O
see	VBP	O
Drug	NNP	O
Abuse	NNP	O
and	CC	O
Dependence	NNP	O
]	NNP	O
.	.	O

Adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
:	:	O
15,000	CD	DOS
to	TO	O
25,000	CD	DOS
units	NNS	UNIT
/	VBP	O
kg	VB	O
body	NN	O
weight	JJ	O
/	NNP	FREQ
day	NN	FREQ
in	IN	O
individuals	NNS	O
with	IN	O
normal	JJ	O
kidney	NN	O
function.This	NN	O
amount	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
from	IN	O
15,000	CD	DOS
units	NNS	UNIT
/	VBP	O
kg	VB	O
downward	NN	O
for	IN	O
individuals	NNS	O
with	IN	O
kidney	NN	O
impairment	NN	O
.	.	O

Individual	JJ	O
patients	NNS	O
may	MD	O
require	VB	O
more	JJR	O
flexibility	NN	O
in	IN	O
the	DT	O
use	NN	O
of	IN	O
LACRISERT	NNP	O
(	(	O
cellulose	NN	O
)	)	O
;	:	O
some	DT	WHO
patients	NNS	WHO
may	MD	O
require	VB	O
twice	RB	FREQ
daily	JJ	FREQ
use	NN	O
for	IN	O
optimal	JJ	O
results	NNS	O
.	.	O

Cysteine	NN	O
is	VBZ	O
considered	VBN	O
to	TO	O
be	VB	O
an	DT	O
essential	JJ	O
amino	NN	O
acid	NN	O
for	IN	O
infants	NNS	WHO
,	,	WHO
especially	RB	WHO
preterm	JJ	WHO
infants	NNS	WHO
with	IN	WHO
potentially	RB	WHO
immature	JJ	WHO
enzyme	NN	WHO
pathways	NNS	WHO
.	.	O

If	IN	O
the	DT	O
patient	NN	O
's	POS	O
symptoms	NNS	O
are	VBP	O
well	RB	O
controlled	VBN	O
,	,	O
there	EX	O
are	VBP	O
no	DT	O
apparent	JJ	O
adverse	JJ	O
effects	NNS	O
,	,	O
and	CC	O
no	DT	O
intervening	NN	O
factors	NNS	O
that	WDT	O
might	MD	O
alter	VB	O
dosage	NN	O
requirements	NNS	O
(	(	O
see	VB	O
WARNINGS	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
)	)	O
,	,	O
serum	JJ	O
theophylline	NN	O
concentrations	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
at	IN	O
6	CD	O
month	NN	O
intervals	NNS	O
for	IN	O
rapidly	RB	WHO
growing	VBG	WHO
children	NNS	WHO
and	CC	WHO
at	IN	WHO
yearly	JJ	WHO
intervals	NNS	WHO
for	IN	WHO
all	DT	WHO
others	NNS	WHO
.	.	O

It	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
be	VB	O
familiar	JJ	O
with	IN	O
all	DT	O
of	IN	O
these	DT	O
products	NNS	O
in	IN	O
order	NN	O
to	TO	O
select	VB	O
the	DT	O
appropriate	JJ	O
refill	NN	O
kit	NN	O
for	IN	O
the	DT	O
particular	JJ	O
pump	NN	O
in	IN	O
use	NN	O
.	.	O

It	PRP	O
is	VBZ	O
generally	RB	O
agreed	VBN	O
,	,	O
however	RB	O
,	,	O
that	IN	O
pharmacological	JJ	O
treatment	NN	O
of	IN	O
ADHD	NNP	O
may	MD	O
be	VB	O
needed	VBN	O
for	IN	O
extended	JJ	O
periods	NNS	O
.	.	O

The	DT	O
potential	JJ	O
hazards	NNS	O
associated	VBN	O
with	IN	O
cytotoxic	NN	O
agents	NNS	O
are	VBP	O
well	RB	O
established	VBN	O
and	CC	O
proper	JJ	O
precautions	NNS	O
should	MD	O
be	VB	O
taken	VBN	O
when	WRB	O
handling	VBG	O
,	,	O
preparing	NN	O
,	,	O
and	CC	O
administering	VBG	O
LEUSTATIN	NNP	O
Injection	NNP	O
.	.	O

Ambulatory	JJ	WHO
patients	NNS	WHO
may	MD	O
need	VB	O
a	DT	O
slower	JJR	O
schedule	NN	O
.	.	O

Appropriate	JJ	O
measures	NNS	O
(	(	O
e.g	NN	O
,	,	O
hydration	NN	O
,	,	O
urine	JJ	O
alkalinization	NN	O
,	,	O
and	CC	O
prophylaxis	NN	O
with	IN	O
allopurinol	NN	O
)	)	O
must	MD	O
be	VB	O
taken	VBN	O
to	TO	O
prevent	VB	O
hyperuricemia	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

TABLE	NN	O
3	CD	O
:	:	O
Temozolomide	NN	O
Dose	NNP	O
Reduction	NNP	O
or	CC	O
Discontinuation	NNP	O
During	IN	O
Maintenance	NNP	O
Treatment	NNP	O

Gastrointestinal	JJ	O
system	NN	O
:	:	O
Diarrhea	NNP	O
(	(	O
3	CD	O
%	NN	O
)	)	O
and	CC	O
flatulence	NN	O
(	(	O
10	CD	O
%	NN	O
)	)	O
.	.	O

Only	RB	O
in	IN	O
very	RB	O
exceptional	JJ	O
cases	NNS	O
should	MD	O
intramuscular	VB	O
dosage	NN	O
exceed	VBP	O
10	CD	DOS
mg	NNS	UNIT
within	IN	O
24	CD	O
hours	NNS	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
instructed	VBN	O
to	TO	O
familiarize	VB	O
themselves	PRP	O
with	IN	O
the	DT	O
position	NN	O
of	IN	O
the	DT	O
spray	NN	O
orifice	NN	O
,	,	O
which	WDT	O
can	MD	O
be	VB	O
identified	VBN	O
by	IN	O
the	DT	O
finger	NN	O
rest	VB	O
on	IN	O
top	NN	O
of	IN	O
the	DT	O
valve	NN	O
,	,	O
in	IN	O
order	NN	O
to	TO	O
facilitate	VB	O
orientation	NN	O
for	IN	O
administration	NN	O
at	IN	O
night	NN	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
otitis	NN	O
media	NNS	O
,	,	O
the	DT	O
recommended	JJ	O
daily	JJ	FREQ
dose	NN	O
is	VBZ	O
75	CD	DOS
to	TO	O
100	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	VB	O
given	VBN	O
in	IN	O
equally	RB	O
divided	JJ	UNIT
doses	NNS	UNIT
.	.	O

Immediately	RB	O
discard	VB	O
the	DT	O
syringe	NN	O
assembly	RB	O
after	IN	O
a	DT	O
single	JJ	O
use	NN	O
into	IN	O
a	DT	O
suitable	JJ	O
sharps	NN	O
container	NN	O
.	.	O

If	IN	O
a	DT	O
total	JJ	O
dose	NN	O
of	IN	O
1.5	CD	DOS
mg	NNS	UNIT
/	VBD	O
70	CD	O
kg	NN	O
has	VBZ	O
been	VBN	O
administered	VBN	O
without	IN	O
clinical	JJ	O
response	NN	O
,	,	O
additional	JJ	O
REVEX	NNP	O
(	(	O
nalmefene	JJ	O
hydrochloride	NN	O
injection	NN	O
)	)	O
is	VBZ	O
unlikely	JJ	O
to	TO	O
have	VB	O
an	DT	O
effect	NN	O
.	.	O

See	JJ	O
package	NN	O
insert	NN	O
for	IN	O
oral	JJ	O
amiodarone	NN	O
.	.	O

Instill	NNP	O
one	CD	DOS
drop	NN	UNIT
of	IN	O
BETOPTIC	NNP	O
S®	NNP	O
(	(	O
betaxolol	JJ	O
hydrochloride	NN	O
ophthalmic	JJ	O
suspension	NN	O
)	)	O
Ophthalmic	NNP	O
Suspension	NNP	O
0.25	CD	O
%	NN	O
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Use	NNP	O
twice	JJ	FREQ
daily	RB	FREQ
or	CC	O
as	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

Following	VBG	O
the	DT	O
injection	NN	O
,	,	O
patients	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
for	IN	O
elevation	NN	O
in	IN	O
intraocular	JJ	O
pressure	NN	O
and	CC	O
for	IN	O
endophthalmitis	NN	O
.	.	O

Once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
therapy	NN	O
is	VBZ	O
usually	RB	O
satisfactory	JJ	O
.	.	O

VESIcare	NN	O
can	MD	O
be	VB	O
administered	VBN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

Note	NN	O
:	:	O
Some	DT	WHO
patients	NNS	WHO
have	VBP	O
found	VBN	O
that	IN	O
lactulose	JJ	O
solution	NN	O
may	MD	O
be	VB	O
more	RBR	O
acceptable	JJ	O
when	WRB	O
mixed	JJ	O
with	IN	O
fruit	NN	O
juice	NN	O
,	,	O
water	NN	O
or	CC	O
milk	NN	O
.	.	O

For	IN	O
oral	JJ	O
inhalation	NN	O
only	RB	O
.	.	O

Mix	NNP	O
thoroughly	RB	O
when	WRB	O
additives	NNS	O
have	VBP	O
been	VBN	O
introduced	VBN	O
.	.	O

The	DT	O
best	JJS	O
results	NNS	O
to	TO	O
date	NN	O
have	VB	O
been	VBN	O
seen	VBN	O
in	IN	O
petit	JJ	O
mal	NN	O
in	IN	O
children	NNS	WHO
.	.	O

Oral	JJ	O
:	:	O
1	CD	DOS
/	$	O
4	CD	DOS
mg	NN	UNIT
/	NNP	O
lb	VBZ	O
body	NN	O
weight	VBD	O
q4	NNS	O
to	TO	O
6h	CD	O
,	,	O
p.r.n	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
hypertension	NN	WHO
and	CC	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
1.25	CD	DOS
mg	JJ	UNIT
ALTACE	NNP	O
once	RB	FREQ
daily	RB	FREQ
.	.	O

For	IN	O
very	RB	O
small	JJ	O
doses	NNS	O
,	,	O
a	DT	O
reconstituted	JJ	O
vial	NN	O
can	MD	O
be	VB	O
diluted	VBN	O
with	IN	O
34	CD	DOS
mL	NNS	UNIT
of	IN	O
sterile	JJ	O
isotonic	JJ	O
saline	NN	O
to	TO	O
achieve	VB	O
a	DT	O
concentration	NN	O
of	IN	O
1	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
.	.	O

However	RB	O
,	,	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
high	JJ	WHO
-	:	WHO
risk	NN	WHO
tumors	NNS	WHO
,	,	O
the	DT	O
target	NN	O
level	NN	O
for	IN	O
TSH	NNP	O
suppression	NN	O
may	MD	O
be	VB	O
<	JJ	O
0.01	CD	O
mU	NN	O
/	NNP	O
L	NNP	O
.	.	O

The	DT	O
response	NN	O
of	IN	O
acute	JJ	O
ulcerative	JJ	O
colitis	NN	O
to	TO	O
AZULFIDINE	NNP	O
Tablets	NNP	O
can	MD	O
be	VB	O
evaluated	VBN	O
by	IN	O
clinical	JJ	O
criteria	NNS	O
,	,	O
including	VBG	O
the	DT	O
presence	NN	O
of	IN	O
fever	NN	O
,	,	O
weight	NN	O
changes	NNS	O
,	,	O
and	CC	O
degree	NN	O
and	CC	O
frequency	NN	O
of	IN	O
diarrhea	NN	O
and	CC	O
bleeding	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
by	IN	O
sigmoidoscopy	NN	O
and	CC	O
the	DT	O
evaluation	NN	O
of	IN	O
biopsy	NN	O
samples	NNS	O
.	.	O

For	IN	O
those	DT	O
patients	NNS	WHO
requiring	VBG	WHO
additional	JJ	WHO
glycemic	NN	WHO
control	NN	WHO
,	,	O
Riomet	NNP	O
may	MD	O
be	VB	O
given	VBN	O
to	TO	O
a	DT	O
maximum	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
of	IN	O
2550	CD	DOS
mg	NN	UNIT
(	(	O
25.5	CD	DOS
mL	NN	UNIT
)	)	O
per	IN	FREQ
day	NN	FREQ
.	.	O

When	WRB	O
treating	VBG	O
conditions	NNS	O
such	JJ	O
as	IN	O
epicondylitis	NN	O
,	,	O
the	DT	O
area	NN	O
of	IN	O
greatest	JJS	O
tenderness	NN	O
should	MD	O
be	VB	O
outlined	VBN	O
carefully	RB	O
and	CC	O
the	DT	O
suspension	NN	O
infiltrated	VBD	O
into	IN	O
the	DT	O
area	NN	O
.	.	O

Intramuscular	NNP	O
(	(	O
for	IN	O
prompt	NN	O
control	NN	O
of	IN	O
severe	JJ	O
symptoms	NNS	O
)	)	O
:	:	O
Usual	JJ	O
dosage	NN	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
to	TO	O
2	CD	DOS
mg	NN	UNIT
(	(	O
V2	NNP	O
to	TO	O
1	CD	DOS
mL	NNS	UNIT
)	)	O
by	IN	O
deep	JJ	O
intramuscular	JJ	O
injection	NN	O
q4	NN	O
to	TO	O
6h	CD	O
,	,	O
p.r.n	NN	O
.	.	O

Doses	VBZ	O
higher	JJR	O
than	IN	O
the	DT	WHO
adult	NN	WHO
maximum	JJ	O
dose	NN	O
of	IN	O
2500	CD	DOS
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
children	NNS	WHO
.	.	O

If	IN	O
administration	NN	O
should	MD	O
fall	VB	O
behind	IN	O
schedule	NN	O
,	,	O
no	DT	O
attempt	NN	O
to	TO	O
‘	VB	O
‘	NNP	O
catch	VB	O
up	RP	O
''	''	O
to	TO	O
planned	VBN	O
intake	NN	O
should	MD	O
be	VB	O
made	VBN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
LASIX	NNP	O
may	MD	O
be	VB	O
carefully	RB	O
titrated	VBN	O
up	RP	O
to	TO	O
600	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
in	IN	O
patients	NNS	WHO
with	IN	WHO
clinically	RB	WHO
severe	JJ	WHO
edematous	JJ	WHO
states	NNS	WHO
.	.	O

The	DT	O
dose	NN	O
,	,	O
the	DT	O
rate	NN	O
of	IN	O
injection	NN	O
,	,	O
and	CC	O
the	DT	O
type	NN	O
of	IN	O
solution	NN	O
(	(	O
saline	NN	O
,	,	O
glucose	NN	O
,	,	O
Ringer	NNP	O
's	POS	O
,	,	O
etc	FW	O
.	.	O
)	)	O

Discard	NNP	O
any	DT	O
unused	JJ	O
portion	NN	O
.	.	O

For	IN	O
pharmacokinetics	NNS	O
of	IN	O
excretion	NN	O
in	IN	O
adults	NNS	WHO
,	,	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
-	:	O
Intravascular	NN	O
.	.	O

For	IN	O
adults	NNS	WHO
,	,	O
the	DT	O
usual	JJ	O
suppressive	JJ	O
dose	NN	O
of	IN	O
levothyroxine	NN	O
(	(	O
T4	NNP	O
)	)	O
is	VBZ	O
1.56	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
of	IN	O
body	NN	O
weight	JJ	O
per	IN	FREQ
day	NN	FREQ
given	VBN	O
for	IN	O
7	CD	PER
to	TO	O
10	CD	PER
days	NNS	PER
.	.	O

ULTRESA	NNP	O
is	VBZ	O
available	JJ	O
in	IN	O
a	DT	O
4,000	CD	O
lipase	NN	O
unit	NN	O
capsule	NN	O
.	.	O

Start	VB	O
the	DT	O
infusion	NN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
1.0	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
hour	NN	O
.	.	O

During	IN	O
the	DT	O
first	JJ	O
cycle	NN	O
of	IN	O
medication	NN	O
,	,	O
the	DT	O
patient	NN	O
is	VBZ	O
instructed	VBN	O
to	TO	O
begin	VB	O
taking	VBG	O
Ayuna™	NNP	O
on	IN	O
the	DT	O
first	JJ	O
Sunday	NNP	O
after	IN	O
the	DT	O
onset	NN	O
of	IN	O
menstruation	NN	O
.	.	O

With	IN	O
cutaneous	JJ	O
deformities	NNS	O
the	DT	O
best	JJS	O
results	NNS	O
are	VBP	O
obtained	VBN	O
if	IN	O
the	DT	O
defect	NN	O
can	MD	O
be	VB	O
manually	RB	O
stretched	VBN	O
to	TO	O
the	DT	O
point	NN	O
where	WRB	O
it	PRP	O
is	VBZ	O
eliminated	VBN	O
.	.	O

As	IN	O
with	IN	O
other	JJ	O
agents	NNS	O
given	VBN	O
subcutaneously	RB	O
,	,	O
only	RB	O
the	DT	O
preferred	JJ	O
sites	NNS	O
of	IN	O
injection	NN	O
,	,	O
as	IN	O
set	VBN	O
forth	NN	O
in	IN	O
standard	JJ	WHO
texts	NNS	WHO
,	,	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

The	DT	O
drug	NN	O
is	VBZ	O
administered	VBN	O
intravenously	RB	O
at	IN	O
weekly	JJ	FREQ
intervals	NNS	FREQ
.	.	O

Use	NNP	O
within	IN	O
one	CD	O
hour	NN	O
of	IN	O
opening	NN	O
.	.	O

Individualize	VB	O
the	DT	O
dose	NN	O
of	IN	O
ZEMPLAR	NNP	O
based	VBN	O
on	IN	O
iPTH	NN	O
,	,	O
serum	JJ	O
calcium	NN	O
and	CC	O
phosphorus	NN	O
levels	NNS	O
.	.	O

Ensure	NN	O
that	IN	O
patients	NNS	WHO
with	IN	WHO
pre	JJ	WHO
-	:	WHO
existing	VBG	WHO
renal	JJ	WHO
insufficiency	NN	WHO
are	VBP	WHO
not	RB	WHO
volume	NN	WHO
depleted	VBD	WHO
;	:	O
discontinue	VB	O
GAMUNEX	NNP	O
(	(	O
immune	JJ	O
globulin	NN	O
intravenous	JJ	O
(	(	O
human	JJ	O
)	)	O
10	CD	O
%	NN	O
)	)	O
if	IN	O
renal	JJ	O
function	NN	O
deteriorates	NNS	O
.	.	O

To	TO	O
prevent	VB	O
needle	JJ	O
-	:	O
stick	NN	O
injuries	NNS	O
,	,	O
needles	NNS	O
should	MD	O
not	RB	O
be	VB	O
recapped	VBN	O
,	,	O
purposely	RB	O
bent	JJ	O
,	,	O
or	CC	O
broken	VBN	O
by	IN	O
hand	NN	O
.	.	O

Prolonged	VBN	O
treatment	NN	O
(	(	O
>	JJ	O
12	CD	PER
weeks	NNS	PER
)	)	O
with	IN	O
metoclopramide	NN	O
should	MD	O
be	VB	O
avoided	VBN	O
in	IN	O
all	DT	O
but	CC	O
rare	JJ	O
cases	NNS	O
where	WRB	O
therapeutic	JJ	O
benefit	NN	O
is	VBZ	O
thought	VBN	O
to	TO	O
counterbalance	VB	O
the	DT	O
risks	NNS	O
to	TO	O
the	DT	O
patient	NN	O
of	IN	O
developing	VBG	O
tardive	JJ	O
dyskinesia	NN	O
.	.	O

If	IN	O
gastric	JJ	O
irritation	NN	O
occurs	VBZ	O
,	,	O
doxycycline	NN	O
may	MD	O
be	VB	O
given	VBN	O
with	IN	O
food	NN	O
or	CC	O
milk	NN	O
.	.	O

Product	NN	O

While	IN	O
adjusting	VBG	O
the	DT	O
dosage	NN	O
of	IN	O
ZYLOPRIM	NNP	O
(	(	O
allopurinol	NN	O
)	)	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
being	VBG	WHO
treated	VBN	WHO
with	IN	WHO
colchicine	NN	WHO
and	CC	O
/	NN	O
or	CC	O
anti	VB	O
-	:	O
inflammatory	NN	O
agents	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
wise	JJ	O
to	TO	O
continue	VB	O
the	DT	O
latter	JJ	O
therapy	NN	O
until	IN	O
serum	JJ	O
uric	JJ	O
acid	NN	O
has	VBZ	O
been	VBN	O
normalized	VBN	O
and	CC	O
there	EX	O
has	VBZ	O
been	VBN	O
freedom	VBN	O
from	IN	O
acute	JJ	O
gouty	NN	O
attacks	NNS	O
for	IN	O
several	JJ	PER
months	NNS	PER
.	.	O

The	DT	O
subcutaneous	JJ	O
route	NN	O
of	IN	O
administration	NN	O
of	IN	O
urographic	JJ	O
contrast	NN	O
media	NNS	O
is	VBZ	O
indicated	VBN	O
when	WRB	O
intravenous	JJ	O
administration	NN	O
can	MD	O
not	RB	O
be	VB	O
successfully	RB	O
accomplished	JJ	O
,	,	O
particularly	RB	O
in	IN	O
infants	NNS	WHO
and	CC	WHO
small	JJ	WHO
children	NNS	WHO
.	.	O

With	IN	O
spermicidal	JJ	O
cream	NN	O
or	CC	O
jelly	RB	O
.	.	O

Shake	VB	O
the	DT	O
syringe	NN	O
well	RB	O
before	RB	O
use	NN	O
.	.	O

Discard	NNP	O
if	IN	O
vaccine	NN	O
can	MD	O
not	RB	O
be	VB	O
resuspended	VBN	O
.	.	O

A	DT	O
woman	NN	O
without	IN	O
a	DT	O
uterus	NN	O
does	VBZ	O
not	RB	O
need	VB	O
a	DT	O
progestin	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
use	VB	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Standard	NNP	O
drugs	NNS	O
for	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
,	,	O
other	JJ	O
than	IN	O
levodopa	NNS	O
without	IN	O
a	DT	O
decarboxylase	NN	O
inhibitor	NN	O
,	,	O
may	MD	O
be	VB	O
used	VBN	O
concomitantly	RB	O
while	IN	O
SINEMET	NNP	O
is	VBZ	O
being	VBG	O
administered	VBN	O
,	,	O
although	IN	O
dosage	NN	O
adjustments	NNS	O
may	MD	O
be	VB	O
required	VBN	O
.	.	O

Gently	RB	O
mix	VBZ	O
the	DT	O
solution	NN	O
.	.	O

The	DT	O
admixture	NN	O
should	MD	O
be	VB	O
prepared	VBN	O
as	RB	O
close	RB	O
as	IN	O
possible	JJ	O
to	TO	O
the	DT	O
time	NN	O
of	IN	O
patient	JJ	O
administration	NN	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
been	VBN	WHO
receiving	VBG	WHO
other	JJ	WHO
drugs	NNS	WHO
may	MD	O
be	VB	O
transferred	VBN	O
to	TO	O
procyclidine	VB	O
hydrochloride	NN	O
.	.	O

Frequently	RB	O
,	,	O
therapy	NN	O
is	VBZ	O
required	VBN	O
day	NN	O
and	CC	O
night	NN	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
penicillin	NN	O
V	NNP	O
should	MD	O
be	VB	O
determined	VBN	O
according	VBG	O
to	TO	O
the	DT	O
sensitivity	NN	O
of	IN	O
the	DT	O
causative	JJ	O
microorganisms	NN	O
and	CC	O
the	DT	O
severity	NN	O
of	IN	O
infection	NN	O
,	,	O
and	CC	O
adjusted	VBD	O
to	TO	O
the	DT	O
clinical	JJ	O
response	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

Total	JJ	O
daily	JJ	FREQ
doses	NNS	O
greater	JJR	O
than	IN	O
30	CD	DOS
mg	NNS	UNIT
have	VBP	O
been	VBN	O
tolerated	VBN	O
by	IN	O
some	DT	WHO
patients	NNS	WHO
,	,	O
but	CC	O
their	PRP$	O
safety	NN	O
and	CC	O
usefulness	NN	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
systematically	RB	O
or	CC	O
established	VBN	O
.	.	O

The	DT	O
greater	JJR	O
the	DT	O
interval	NN	O
of	IN	O
time	NN	O
since	IN	O
the	DT	O
previous	JJ	O
dose	NN	O
,	,	O
the	DT	O
greater	JJR	O
consideration	NN	O
should	MD	O
be	VB	O
given	VBN	O
to	TO	O
restarting	VBG	O
with	IN	O
the	DT	O
initial	JJ	O
dosing	NN	O
recommendations	NNS	O
.	.	O

For	IN	O
example	NN	O
,	,	O
in	IN	O
a	DT	WHO
child	NN	WHO
of	IN	WHO
5	CD	WHO
years	NNS	WHO
weighing	VBG	WHO
50	CD	WHO
lbs	NN	WHO
(	(	WHO
23	CD	WHO
kg	NN	WHO
)	)	WHO
,	,	O
the	DT	O
dose	NN	O
of	IN	O
chloroprocaine	NN	O
HCl	NNP	O
without	IN	O
epinephrine	NN	O
would	MD	O
be	VB	O
250	CD	DOS
mg	NN	UNIT
.	.	O

During	IN	O
treatment	NN	O
with	IN	O
ethacrynic	JJ	O
acid	NN	O
,	,	O
salt	NN	O
may	MD	O
be	VB	O
liberalized	VBN	O
to	TO	O
a	DT	O
greater	JJR	O
extent	NN	O
than	IN	O
with	IN	O
other	JJ	O
diuretics	NNS	O
.	.	O

If	IN	O
a	DT	O
patient	NN	O
can	MD	O
not	RB	O
tolerate	VB	O
a	DT	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
50	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
,	,	O
the	DT	O
daily	JJ	FREQ
dose	NN	O
may	MD	O
be	VB	O
reduced	VBN	O
.	.	O

The	DT	O
physician	NN	O
should	MD	O
initiate	VB	O
dosage	NN	O
at	IN	O
a	DT	O
low	JJ	O
level	NN	O
and	CC	O
increase	VB	O
it	PRP	O
gradually	RB	O
,	,	O
checking	VBG	O
the	DT	O
clinical	JJ	O
response	NN	O
carefully	RB	O
and	CC	O
noting	VBG	O
any	DT	O
evidence	NN	O
of	IN	O
intolerance	NN	O
.	.	O

If	IN	O
the	DT	O
treated	JJ	O
area	NN	O
is	VBZ	O
swollen	VBN	O
directly	RB	O
after	IN	O
the	DT	O
injection	NN	O
,	,	O
an	DT	O
ice	NN	O
pack	NN	O
can	MD	O
be	VB	O
applied	VBN	O
on	IN	O
the	DT	O
site	NN	O
for	IN	O
a	DT	O
short	JJ	O
period	NN	O
.	.	O

3	CD	O
.	.	O

fat	JJ	O
emulsions	NNS	O
.	.	O

Studies	NNS	O
comparing	VBG	O
fluoxetine	NN	O
20	CD	DOS
,	,	O
40	CD	DOS
,	,	O
and	CC	O
60	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
to	TO	O
placebo	VB	O
indicate	NN	O
that	IN	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
is	VBZ	O
sufficient	JJ	O
to	TO	O
obtain	VB	O
a	DT	O
satisfactory	JJ	O
response	NN	O
in	IN	O
Major	NNP	O
Depressive	NNP	O
Disorder	NNP	O
in	IN	O
most	JJS	O
cases	NNS	O
[	VBP	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

For	IN	O
most	JJS	WHO
pediatric	JJ	WHO
patients	NNS	WHO
on	IN	WHO
intravenous	JJ	WHO
nutrition	NN	WHO
,	,	O
2.5	CD	DOS
grams	NNS	UNIT
amino	JJ	O
acids	NNS	O
/	VBP	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
with	IN	O
dextrose	JJ	O
alone	NNS	O
or	CC	O
with	IN	O
I.V	NNP	O
.	.	O

When	WRB	O
DOTAREM	NNP	O
is	VBZ	O
to	TO	O
be	VB	O
injected	VBN	O
using	VBG	O
plastic	NN	O
disposable	JJ	O
syringes	NNS	O
,	,	O
the	DT	O
contrast	NN	O
medium	NN	O
should	MD	O
be	VB	O
drawn	VBN	O
into	IN	O
the	DT	O
syringe	NN	O
and	CC	O
used	VBD	O
immediately	RB	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
observed	VBN	O
during	IN	O
the	DT	O
infusion	NN	O
and	CC	O
for	IN	O
at	IN	O
least	JJS	O
30	CD	O
minutes	NNS	O
after	IN	O
infusion	NN	O
.	.	O

Further	RB	O
,	,	O
there	EX	O
is	VBZ	O
no	DT	O
experience	NN	O
with	IN	O
Vivotif	NNP	O
as	IN	O
a	DT	O
booster	NN	O
in	IN	O
persons	NNS	O
previously	RB	O
immunized	VBN	O
with	IN	O
parenteral	JJ	O
typhoid	JJ	O
vaccine	NN	O
.	.	O

Geriatric	JJ	O
Use	NN	O
:	:	O
This	DT	O
drug	NN	O
is	VBZ	O
known	VBN	O
to	TO	O
be	VB	O
substantially	RB	O
excreted	VBN	O
by	IN	O
the	DT	O
kidney	NN	O
,	,	O
and	CC	O
the	DT	O
risk	NN	O
of	IN	O
toxic	JJ	O
reactions	NNS	O
to	TO	O
this	DT	O
drug	NN	O
may	MD	O
be	VB	O
greater	JJR	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
impaired	JJ	WHO
renal	JJ	WHO
function	NN	WHO
.	.	O

Discard	NNP	O
bag	NN	O
if	IN	O
leaks	NNS	O
are	VBP	O
found	VBN	O
as	IN	O
sterility	NN	O
may	MD	O
be	VB	O
impaired	VBN	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
serial	JJ	O
determinations	NNS	O
of	IN	O
lomefloxacin	NN	O
levels	NNS	O
be	VB	O
performed	VBN	O
to	TO	O
determine	VB	O
any	DT	O
necessary	JJ	O
alteration	NN	O
in	IN	O
the	DT	O
appropriate	JJ	O
next	JJ	O
dosing	NN	O
interval	NN	O
.	.	O

ATACAND	NN	O
may	MD	O
be	VB	O
administered	VBN	O
once	RB	FREQ
daily	JJ	FREQ
or	CC	O
divided	VBN	O
into	IN	O
two	CD	DOS
equal	JJ	UNIT
doses	NNS	UNIT
.	.	O

If	IN	O
significant	JJ	O
clinical	JJ	O
toxicity	NN	O
is	VBZ	O
observed	VBN	O
,	,	O
leucovorin	FW	O
(	(	O
leucovorin	JJ	O
calcium	NN	O
)	)	O
rescue	NN	O
should	MD	O
be	VB	O
extended	VBN	O
for	IN	O
an	DT	O
additional	JJ	O
24	CD	O
hours	NNS	O
(	(	O
total	NN	O
of	IN	O
14	CD	DOS
doses	NNS	UNIT
over	IN	O
84	CD	O
hours	NNS	O
)	)	O
in	IN	O
subsequent	JJ	O
courses	NNS	O
of	IN	O
therapy	NN	O
.	.	O

Total	JJ	O
cumulative	JJ	O
units	NNS	O
is	VBZ	O
the	DT	O
sum	NN	O
of	IN	O
cumulative	JJ	O
units	NNS	O
for	IN	O
each	DT	O
concentration	NN	O
administered	VBN	O
.	.	O

DIANEAL	NNP	O
4.25	CD	O
%	NN	O
dextrose	JJ	O
-	:	O
containing	VBG	O
solution	NN	O
has	VBZ	O
the	DT	O
highest	JJS	O
osmolarity	NN	O
of	IN	O
the	DT	O
DIANEAL	NNP	O
solutions	NNS	O
and	CC	O
using	VBG	O
it	PRP	O
for	IN	O
all	DT	O
exchanges	NNS	O
may	MD	O
cause	VB	O
dehydration	NN	O
[	NNP	O
see	VBP	O
Dosage	NNP	O
Forms	NNP	O
and	CC	O
Strengths	NNP	O
]	NNP	O
.	.	O

SURVANTA	NNP	O
is	VBZ	O
administered	VBN	O
intratracheally	RB	O
by	IN	O
instillation	NN	O
through	IN	O
a	DT	O
5	CD	O
French	JJ	O
end	NN	O
-	:	O
hole	NN	O
catheter	NN	O
.	.	O

First	LS	O
-	:	O
trimester	NN	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
prevention	NN	O
of	IN	O
postoperative	JJ	O
nausea	NN	O
and	CC	O
vomiting	NN	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
of	IN	O
KYTRIL	NNP	O
,	,	O
undiluted	VBD	O
,	,	O
administered	VBD	O
intravenously	RB	O
over	IN	O
30	CD	O
seconds	NNS	O
,	,	O
before	IN	O
induction	NN	O
of	IN	O
anesthesia	NN	O
or	CC	O
immediately	RB	O
before	IN	O
reversal	NN	O
of	IN	O
anesthesia	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
TRESIBA	NNP	O
in	IN	O
insulin	NN	WHO
naïve	NN	WHO
patients	NNS	WHO
with	IN	WHO
type	JJ	WHO
2	CD	WHO
diabetes	NNS	WHO
mellitus	NN	WHO
is	VBZ	O
10	CD	DOS
units	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

For	IN	O
intramuscular	JJ	O
use	NN	O
only	RB	O
.	.	O

Additional	NNP	O
dose	NN	O
modifications	NNS	O
should	MD	O
be	VB	O
made	VBN	O
with	IN	O
careful	JJ	O
monitoring	NN	O
of	IN	O
safety	NN	O
and	CC	O
efficacy	NN	O
.	.	O

For	IN	O
more	JJR	O
severe	JJ	O
infections	NNS	O
this	DT	O
dosage	NN	O
may	MD	O
be	VB	O
doubled	VBN	O
.	.	O

Inspect	NNP	O
vial	JJ	O
contents	NNS	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
and	CC	O
repeat	NN	O
inspection	NN	O
when	WRB	O
drug	NN	O
product	NN	O
is	VBZ	O
withdrawn	VBN	O
from	IN	O
vial	JJ	O
into	IN	O
syringe	NN	O
.	.	O

Add	VB	O
a	DT	O
4	CD	DOS
mL	NN	UNIT
ampul	NN	UNIT
(	(	O
4	CD	DOS
mg	NN	UNIT
)	)	O
of	IN	O
LEVOPHED	NNP	O
to	TO	O
1,000	CD	DOS
mL	NN	UNIT
of	IN	O
a	DT	O
5	CD	O
percent	NN	O
dextrose	NN	O
containing	VBG	O
solution	NN	O
.	.	O

Dosage	NN	O
is	VBZ	O
dependent	JJ	O
upon	IN	O
the	DT	O
age	NN	O
,	,	O
weight	NN	O
and	CC	O
clinical	JJ	O
condition	NN	O
of	IN	O
the	DT	O
patient	NN	O
as	RB	O
well	RB	O
as	IN	O
laboratory	NN	O
determinations	NNS	O
.	.	O

Treatment	NN	O
is	VBZ	O
usually	RB	O
initiated	VBN	O
with	IN	O
a	DT	O
dose	NN	O
of	IN	O
1	CD	DOS
to	TO	O
2	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
of	IN	O
estradiol	NN	O
,	,	O
adjusted	VBN	O
as	IN	O
necessary	JJ	O
to	TO	O
control	VB	O
presenting	VBG	O
symptoms	NNS	O
;	:	O
the	DT	O
minimal	JJ	O
effective	JJ	O
dose	NN	O
for	IN	O
maintenance	NN	O
therapy	NN	O
should	MD	O
be	VB	O
determined	VBN	O
by	IN	O
titration	NN	O
.	.	O

The	DT	O
risks	NNS	O
of	IN	O
toxicity	NN	O
multiply	NN	O
as	IN	O
the	DT	O
length	NN	O
of	IN	O
treatment	NN	O
increases	NNS	O
.	.	O

hepatic	JJ	O
impairment	NN	O
(	(	O
Child	NNP	O
-	:	O
Pugh	NNP	O
Class	NNP	O
B	NNP	O
)	)	O
[	NN	O
see	VBP	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Pediatric	JJ	WHO
patients	NNS	WHO
tolerate	VBP	O
the	DT	O
local	JJ	O
anesthetic	NN	O
as	RB	O
well	RB	O
as	IN	O
adults	NNS	WHO
.	.	O

Over	IN	O
the	DT	O
course	NN	O
of	IN	O
treatment	NN	O
,	,	O
patients	NNS	WHO
who	WP	WHO
tolerate	VBP	WHO
INLYTA	NNP	WHO
for	IN	O
at	IN	PER
least	JJS	PER
two	CD	PER
consecutive	JJ	PER
weeks	NNS	PER
with	IN	O
no	DT	O
adverse	JJ	O
reactions	NNS	O
>	VBP	O
Grade	NNP	O
2	CD	O
(	(	O
according	VBG	O
to	TO	O
the	DT	O
Common	NNP	O
Toxicity	NNP	O
Criteria	NNP	O
for	IN	O
Adverse	NNP	O
Events	NNP	O
[	NNP	O
CTCAE	NNP	O
]	NNP	O
)	)	O
,	,	O
are	VBP	O
normotensive	JJ	O
,	,	O
and	CC	O
are	VBP	O
not	RB	O
receiving	VBG	O
anti	SYM	O
-	:	O
hypertension	NN	O
medication	NN	O
,	,	O
may	MD	O
have	VB	O
their	PRP$	O
dose	NN	O
increased	VBN	O
.	.	O

CAUTION	NN	O
:	:	O
A	DT	O
sterile	JJ	O
syringe	NN	O
free	JJ	O
of	IN	O
preservatives	NNS	O
,	,	O
antiseptics	NNS	O
,	,	O
and	CC	O
detergents	NNS	O
should	MD	O
be	VB	O
used	VBN	O
for	IN	O
each	DT	O
injection	NN	O
and	CC	O
/	NN	O
or	CC	O
reconstitution	NN	O
of	IN	O
the	DT	O
vaccine	NN	O
because	IN	O
these	DT	O
substances	NNS	O
may	MD	O
inactivate	VB	O
the	DT	O
live	JJ	O
virus	NN	O
vaccine	NN	O
.	.	O

Instill	NNP	O
two	CD	DOS
drops	NNS	UNIT
of	IN	O
VASOCIDIN	NNP	O
(	(	O
sulfacetamide	NN	O
and	CC	O
prednisolone	NN	O
)	)	O
Ophthalmic	NNP	O
Solution	NNP	O
topically	RB	O
in	IN	O
the	DT	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
every	DT	FREQ
four	CD	FREQ
hours	NNS	FREQ
.	.	O

ETOPOPHOS	NNP	O
solutions	NNS	O
may	MD	O
be	VB	O
administered	VBN	O
at	IN	O
infusion	NN	O
rates	NNS	O
from	IN	O
5	CD	O
to	TO	O
210	CD	O
minutes	NNS	O
.	.	O

Ordinarily	RB	O
spotting	VBG	O
or	CC	O
breakthrough	IN	O
bleeding	NN	O
will	MD	O
stop	VB	O
within	IN	O
a	DT	O
week	NN	PER
.	.	O

The	DT	O
initial	JJ	O
dose	NN	O
is	VBZ	O
50	CD	DOS
to	TO	O
150	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

Persons	NNS	O
20	CD	DOS
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
:	:	O
A	DT	O
series	NN	O
of	IN	O
3	CD	DOS
doses	NNS	UNIT
(	(	O
1.0	CD	DOS
mL	RB	UNIT
each	DT	UNIT
)	)	O
given	VBN	O
on	IN	O
a	DT	O
0	CD	O
-	:	O
,	,	O
1	CD	O
-	:	O
,	,	O
and	CC	O
6	CD	O
-	:	O
month	NN	O
schedule	NN	O
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
streptococcal	JJ	O
infections	NNS	O
of	IN	O
the	DT	O
upper	JJ	O
respiratory	NN	O
tract	NN	O
(	(	O
e.g	JJ	O
,	,	O
tonsillitis	NN	O
or	CC	O
pharyngitis	NN	O
)	)	O
,	,	O
the	DT	O
therapeutic	JJ	O
dosage	NN	O
of	IN	O
erythromycin	NN	O
should	MD	O
be	VB	O
administered	VBN	O
for	IN	O
at	IN	PER
least	JJS	PER
ten	JJ	PER
days	NNS	PER
.	.	O

When	WRB	O
switching	VBG	O
a	DT	O
patient	NN	O
from	IN	O
immediate	JJ	O
-	:	O
release	NN	O
capsules	NNS	O
to	TO	O
ESKALITH	NNP	O
(	(	O
lithium	JJ	O
carbonate	NN	O
)	)	O
CR	NNP	O
Controlled	NNP	O
-	:	O
Release	NN	O
Tablets	NNS	O
,	,	O
give	VBP	O
the	DT	O
same	JJ	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
when	WRB	O
possible	JJ	O
.	.	O

137	CD	O

Discard	NNP	O
the	DT	O
resulting	VBG	O
solution	NN	O
if	IN	O
it	PRP	O
is	VBZ	O
not	RB	O
clear	JJ	O
(	(	O
or	CC	O
free	VB	O
of	IN	O
particles	NNS	O
)	)	O
and	CC	O
colorless	NN	O
.	.	O

0.45	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O

Dantrolene	NNP	O
sodium	NN	O
capsules	NNS	O
,	,	O
4	CD	DOS
to	TO	O
8	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
,	,	O
in	IN	O
four	CD	DOS
divided	JJ	UNIT
doses	NNS	UNIT
should	MD	O
be	VB	O
administered	VBN	O
for	IN	O
1	CD	PER
to	TO	PER
3	CD	PER
days	NNS	PER
following	VBG	O
a	DT	O
malignant	JJ	O
hyperthermia	NN	O
crisis	NN	O
to	TO	O
prevent	VB	O
recurrence	NN	O
of	IN	O
the	DT	O
manifestations	NNS	O
of	IN	O
malignant	JJ	O
hyperthermia	NN	O
.	.	O

If	IN	O
preferred	VBN	O
,	,	O
a	DT	O
cotton	NN	O
wick	NN	O
may	MD	O
be	VB	O
inserted	VBN	O
into	IN	O
the	DT	O
canal	NN	O
and	CC	O
then	RB	O
the	DT	O
cotton	NN	O
may	MD	O
be	VB	O
saturated	VBN	O
with	IN	O
the	DT	O
suspension	NN	O
.	.	O

Blistering	NNP	O
,	,	O
ulceration	NN	O
and	CC	O
/	NN	O
or	CC	O
persistent	JJ	O
pain	NN	O
are	VBP	O
indications	NNS	O
for	IN	O
wide	JJ	O
excision	NN	O
surgery	NN	O
,	,	O
followed	VBN	O
by	IN	O
split	NN	O
-	:	O
thickness	NN	O
skin	NN	O
grafting	NN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
's	POS	O
blood	NN	O
pressure	NN	O
is	VBZ	O
not	RB	O
controlled	VBN	O
with	IN	O
univasc®	JJ	O
alone	RB	O
,	,	O
diuretic	JJ	O
therapy	NN	O
may	MD	O
then	RB	O
be	VB	O
reinstituted	VBN	O
.	.	O

Total	JJ	O
daily	JJ	FREQ
doses	NNS	O
were	VBD	O
divided	VBN	O
into	IN	O
two	CD	DOS
equal	JJ	UNIT
daily	JJ	FREQ
doses	NNS	O
.	.	O

Thereafter	RB	O
,	,	O
treatment	NN	O
can	MD	O
be	VB	O
resumed	VBN	O
as	IN	O
appropriate	JJ	O
depending	VBG	O
on	IN	O
the	DT	O
initial	JJ	O
severity	NN	O
of	IN	O
the	DT	O
event	NN	O
.	.	O

500	CD	DOS
mcg	NN	UNIT
intravenously	RB	O
on	IN	O
Days	NNS	O
1	CD	O
and	CC	O
2	CD	O
as	IN	O
part	NN	O
of	IN	O
a	DT	O
combination	NN	O
regimen	NN	O
with	IN	O
etoposide	NN	O
,	,	O
methotrexate	NN	O
,	,	O
folinic	JJ	O
acid	NN	O
,	,	O
vincristine	NN	O
,	,	O
cyclophosphamide	NN	O
and	CC	O
cisplatin	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Dosing	NN	O
for	IN	O
Pediatric	JJ	WHO
Patients	NNPS	WHO
Weighing	VBG	WHO
17	CD	WHO
kg	NN	WHO
to	TO	WHO
less	JJR	WHO
than	IN	WHO
35	CD	WHO
kg	NNS	WHO
using	VBG	WHO
TRUVADA	NNP	WHO
Low	NNP	WHO
Strength	NNP	WHO
Tablets	NNS	WHO

SUPRANE	NNP	O
is	VBZ	O
administered	VBN	O
by	IN	O
inhalation	NN	O
.	.	O

If	IN	O
the	DT	O
test	NN	O
implantation	NN	O
response	NN	O
is	VBZ	O
equivocal	JJ	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
a	DT	O
second	JJ	O
test	NN	O
implantation	NN	O
be	VB	O
administered	VBN	O
in	IN	O
the	DT	O
opposite	JJ	O
arm	NN	O
and	CC	O
evaluated	VBD	O
prior	RB	O
to	TO	O
the	DT	O
initiation	NN	O
of	IN	O
treatment	NN	O
.	.	O

The	DT	O
cannula	NN	O
can	MD	O
be	VB	O
extended	VBN	O
and	CC	O
retracted	VBN	O
.	.	O

Caution	NN	O
:	:	O
It	PRP	O
is	VBZ	O
extremely	RB	O
important	JJ	O
that	IN	O
the	DT	O
intravenous	JJ	O
needle	NN	O
or	CC	O
catheter	NN	O
be	VB	O
properly	RB	O
positioned	VBN	O
before	IN	O
any	DT	O
vinblastine	JJ	O
sulfate	NN	O
(	(	O
vinblastine	JJ	O
sulfate	NN	O
injection	NN	O
)	)	O
is	VBZ	O
injected	VBN	O
.	.	O

Initiate	NNP	O
treatment	NN	O
with	IN	O
morphine	JJ	O
sulfate	NN	O
extended	VBD	O
-	:	O
release	NN	O
tablets	NNS	O
with	IN	O
15	CD	DOS
mg	NNS	UNIT
tablets	NNS	UNIT
orally	RB	O
every	DT	O
8	CD	O
or	CC	O
12	CD	O
hours	NNS	O
.	.	O

45	CD	O

Treatment	NN	O
should	MD	O
be	VB	O
continued	VBN	O
until	IN	O
adequate	JJ	O
follicular	JJ	O
development	NN	O
is	VBZ	O
indicated	VBN	O
as	IN	O
determined	VBN	O
by	IN	O
ultrasound	NN	O
in	IN	O
combination	NN	O
with	IN	O
measurement	NN	O
of	IN	O
serum	NN	O
estradiol	NN	O
levels	NNS	O
.	.	O

Again	RB	O
,	,	O
hydration	NN	O
to	TO	O
establish	VB	O
diuresis	NN	O
both	DT	O
prior	JJ	O
to	TO	O
and	CC	O
during	IN	O
treatment	NN	O
is	VBZ	O
recommended	VBN	O
to	TO	O
minimize	VB	O
renal	JJ	O
toxicity	NN	O
,	,	O
provided	VBN	O
there	EX	O
are	VBP	O
no	DT	O
clinical	JJ	O
contraindications	NNS	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

FLUDARA	NNP	O
(	(	O
fludarabine	NN	O
)	)	O
FOR	IN	O
INJECTION	NNP	O
should	MD	O
be	VB	O
prepared	VBN	O
for	IN	O
parenteral	JJ	O
use	NN	O
by	IN	O
aseptically	RB	O
adding	VBG	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
.	.	O

Addition	NN	O
of	IN	O
iron	NN	O
is	VBZ	O
more	RBR	O
critical	JJ	O
in	IN	O
the	DT	WHO
infant	NN	WHO
than	IN	O
the	DT	WHO
adult	NN	WHO
because	IN	O
of	IN	O
the	DT	O
increasing	VBG	O
red	JJ	O
cell	NN	O
mass	NN	O
required	VBN	O
for	IN	O
the	DT	O
growing	VBG	O
infant	NN	WHO
.	.	O

The	DT	O
gel	NN	O
is	VBZ	O
applied	VBN	O
onto	IN	O
the	DT	O
skin	NN	O
in	IN	O
a	DT	O
thin	JJ	O
layer	NN	O
.	.	O

At	IN	O
least	JJS	O
14	CD	O
days	NNS	O
should	MD	O
elapse	VB	O
between	IN	O
discontinuation	NN	O
of	IN	O
an	DT	O
MAOI	NNP	O
intended	VBD	O
to	TO	O
treat	VB	O
psychiatric	JJ	O
disorders	NNS	O
and	CC	O
initiation	NN	O
of	IN	O
therapy	NN	O
with	IN	O
Anafranil	NNP	O
.	.	O

Even	RB	O
though	IN	O
loading	VBG	O
doses	NNS	O
of	IN	O
CEREBYX	NNP	O
have	VBP	O
been	VBN	O
given	VBN	O
by	IN	O
the	DT	O
IM	NNP	O
route	NN	O
for	IN	O
other	JJ	O
indications	NNS	O
when	WRB	O
IV	NNP	O
access	NN	O
is	VBZ	O
impossible	JJ	O
,	,	O
IM	NNP	O
CEREBYX	NNP	O
should	MD	O
ordinarily	RB	O
not	RB	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
status	NN	O
epilepticus	NN	O
because	IN	O
therapeutic	JJ	O
phenytoin	NN	O
concentrations	NNS	O
may	MD	O
not	RB	O
be	VB	O
reached	VBN	O
as	RB	O
quickly	RB	O
as	IN	O
with	IN	O
IV	NNP	O
administration	NN	O
.	.	O

Remove	VB	O
the	DT	O
protective	JJ	O
covers	NNS	O
from	IN	O
the	DT	O
top	NN	O
of	IN	O
the	DT	O
vial	NN	O
and	CC	O
the	DT	O
vial	JJ	O
port	NN	O
on	IN	O
the	DT	O
diluent	NN	O
container	NN	O
as	IN	O
follows	VBZ	O
:	:	O

In	IN	O
addition	NN	O
,	,	O
physical	JJ	O
and	CC	O
chemical	NN	O
in	IN	O
-	:	O
use	NN	O
stability	NN	O
of	IN	O
the	DT	O
infusion	NN	O
solution	NN	O
prepared	VBD	O
as	IN	O
recommended	VBN	O
has	VBZ	O
been	VBN	O
demonstrated	VBN	O
in	IN	O
non	JJ	O
-	:	O
PVC	NN	O
bags	VBZ	O
up	IN	O
to	TO	O
48	CD	O
hours	NNS	O
when	WRB	O
stored	VBN	O
between	IN	O
2°C	CD	O
and	CC	O
8°C	CD	O
(	(	O
36°F	CD	O
and	CC	O
46°F	CD	O
)	)	O
.	.	O

If	IN	O
Antivenin	NNP	O
is	VBZ	O
given	VBN	O
intramuscularly	RB	O
,	,	O
it	PRP	O
should	MD	O
be	VB	O
given	VBN	O
into	IN	O
a	DT	O
large	JJ	O
muscle	NN	O
mass	NN	O
,	,	O
preferably	RB	O
the	DT	O
gluteal	JJ	O
area	NN	O
,	,	O
with	IN	O
care	NN	O
to	TO	O
avoid	VB	O
nerve	JJ	O
trunks	NNS	O
.	.	O

When	WRB	O
the	DT	O
patient	NN	O
receives	VBZ	O
the	DT	O
inhaler	NN	O
,	,	O
a	DT	O
black	JJ	O
dot	NN	O
will	MD	O
appear	VB	O
in	IN	O
the	DT	O
viewing	NN	O
window	NN	O
until	IN	O
it	PRP	O
has	VBZ	O
been	VBN	O
primed	VBN	O
3	CD	FREQ
times	NNS	FREQ
,	,	O
at	IN	O
which	WDT	O
point	VBP	O
the	DT	O
number	NN	O
200	CD	O
will	MD	O
be	VB	O
displayed	VBN	O
.	.	O

Adjust	IN	O
the	DT	O
dosage	NN	O
according	VBG	O
to	TO	O
blood	NN	O
pressure	NN	O
response	NN	O
.	.	O

EYLEA	NN	O
must	MD	O
only	RB	O
be	VB	O
administered	VBN	O
by	IN	O
a	DT	O
qualified	JJ	O
physician	NN	O
.	.	O

Sonata	NNP	O
(	(	O
zaleplon	NN	O
)	)	O
capsules	NNS	O
are	VBP	O
supplied	VBN	O
as	IN	O
follows	VBZ	O
:	:	O

Patients	NNS	O
can	MD	O
be	VB	O
converted	VBN	O
from	IN	O
NUCYNTAR®	NNP	O
to	TO	O
NUCYNTA®	NNP	O
ER	NNP	O
using	VBG	O
the	DT	O
equivalent	JJ	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
NUCYNTAR®	NNP	O
and	CC	O
dividing	VBG	O
it	PRP	O
into	IN	O
two	CD	DOS
equal	JJ	UNIT
doses	NNS	UNIT
of	IN	O
NUCYNTA®	NNP	O
ER	NNP	O
separated	VBN	O
by	IN	O
approximately	RB	O
12	CD	O
-	:	O
hour	NN	O
intervals	NNS	O
.	.	O

Individually	RB	O
titrate	VB	O
Methadose	NNP	O
to	TO	O
a	DT	O
dose	NN	O
that	WDT	O
provides	VBZ	O
adequate	JJ	O
analgesia	NNS	O
and	CC	O
minimizes	VBZ	O
adverse	JJ	O
reactions	NNS	O
.	.	O

The	DT	O
sites	NNS	O
of	IN	O
application	NN	O
must	MD	O
be	VB	O
rotated	VBN	O
,	,	O
with	IN	O
an	DT	O
interval	NN	O
of	IN	O
at	IN	O
least	JJS	O
1	CD	PER
week	NN	PER
allowed	VBN	O
between	IN	O
applications	NNS	O
to	TO	O
a	DT	O
particular	JJ	O
site	NN	O
.	.	O

Fluzone	CD	O
Intradermal	JJ	O
Quadrivalent	NNP	O
should	MD	O
not	RB	O
be	VB	O
combined	VBN	O
through	IN	O
reconstitution	NN	O
or	CC	O
mixed	JJ	O
with	IN	O
any	DT	O
other	JJ	O
vaccine	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
poorly	RB	WHO
compliant	JJ	WHO
,	,	O
Desferal	NNP	O
may	MD	O
be	VB	O
administered	VBN	O
prior	JJ	O
to	TO	O
or	CC	O
following	VBG	O
same	JJ	O
day	NN	O
blood	NN	O
transfusion	NN	O
(	(	O
for	IN	O
example	NN	O
1	CD	O
gram	NN	O
over	IN	O
4	CD	O
hours	NNS	O
on	IN	O
the	DT	O
day	NN	O
of	IN	O
transfusion	NN	O
)	)	O
;	:	O
however	RB	O
,	,	O
the	DT	O
contribution	NN	O
of	IN	O
this	DT	O
mode	NN	O
of	IN	O
administration	NN	O
to	TO	O
iron	VB	O
balance	NN	O
is	VBZ	O
limited	VBN	O
.	.	O

VANTRELA	NNP	O
ER	NNP	O
is	VBZ	O
administered	VBN	O
orally	RB	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

Most	JJS	O
of	IN	O
the	DT	O
effect	NN	O
of	IN	O
Serostim®	NNP	O
on	IN	O
work	NN	O
output	NN	O
and	CC	O
lean	JJ	O
body	NN	O
mass	NN	O
was	VBD	O
apparent	JJ	O
after	IN	O
12	CD	PER
weeks	NNS	PER
of	IN	O
treatment	NN	O
.	.	O

For	IN	O
example	NN	O
,	,	O
a	DT	O
patient	NN	O
who	WP	O
is	VBZ	O
on	IN	O
maintenance	NN	O
dosage	NN	O
of	IN	O
an	DT	O
oral	JJ	O
diuretic	NN	O
may	MD	O
require	VB	O
additional	JJ	O
intermittent	NN	O
diuretic	JJ	O
therapy	NN	O
,	,	O
such	JJ	O
as	IN	O
an	DT	O
organomercurial	JJ	O
,	,	O
for	IN	O
the	DT	O
maintenance	NN	O
of	IN	O
basal	NN	O
weight	NN	O
.	.	O

An	DT	O
infant	JJ	WHO
2	CD	WHO
to	TO	WHO
10	CD	WHO
months	NNS	WHO
of	IN	WHO
age	NN	WHO
should	MD	O
receive	VB	O
three	CD	DOS
doses	NNS	UNIT
of	IN	O
a	DT	O
product	NN	O
containing	VBG	O
PRP	NNP	O
-	:	O
OMPC	NN	O
.	.	O

COLOR	NNP	O
VARIATION	NNP	O
IN	NNP	O
THE	NNP	O
DEXTROSE	NNP	O
INJECTION	NNP	O
FROM	NNP	O
PALE	NNP	O
YELLOW	NNP	O
TO	NNP	O
YELLOW	NNP	O
IS	NNP	O
NORMAL	NNP	O
AND	NNP	O
DOES	NNP	O
NOT	NNP	O
ALTER	NNP	O
EFFICACY	NNP	O
.	.	O

Medical	JJ	O
attention	NN	O
should	MD	O
be	VB	O
sought	VBN	O
immediately	RB	O
.	.	O

NDC	RB	O
60505	CD	O
-	:	O
3759	CD	O
-	:	O
5	CD	DOS
bottles	NNS	UNIT
of	IN	O
500	CD	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
an	DT	WHO
inadequate	JJ	WHO
blood	NN	WHO
pressure	NN	WHO
response	NN	WHO
to	TO	O
50	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	JJ	FREQ
increase	VB	O
the	DT	O
dosage	NN	O
of	IN	O
INSPRA	NNP	O
to	TO	O
50	CD	DOS
mg	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

NOROXIN	NNP	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
urinary	JJ	O
tract	NN	O
infections	NNS	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
insufficiency	NN	WHO
.	.	O

Appropriate	JJ	O
precautions	NNS	O
should	MD	O
be	VB	O
taken	VBN	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
Section	NNP	O
)	)	O
.	.	O

When	WRB	O
the	DT	O
patient	NN	O
no	RB	O
longer	RBR	O
requires	VBZ	O
therapy	NN	O
with	IN	O
OXYCONTIN	NNP	O
,	,	O
gradually	RB	O
titrate	VB	O
the	DT	O
dosage	NN	O
downward	RB	O
to	TO	O
prevent	VB	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
withdrawal	NN	O
in	IN	O
the	DT	O
physically	RB	O
dependent	JJ	O
patient	NN	O
.	.	O

These	DT	O
solutions	NNS	O
contain	VBP	O
no	DT	O
bacteriostatic	JJ	O
agent	NN	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
instilled	VBD	O
in	IN	O
affected	JJ	O
eyes	NNS	O
four	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
day	NN	FREQ
.	.	O

However	RB	O
,	,	O
there	EX	O
were	VBD	O
confounding	VBG	O
factors	NNS	O
that	WDT	O
may	MD	O
have	VB	O
contributed	VBN	O
to	TO	O
the	DT	O
occurrence	NN	O
of	IN	O
seizures	NNS	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
with	IN	WHO
bipolar	JJ	WHO
disorder	NN	WHO
.	.	O

Note	NN	O
:	:	O
When	WRB	O
administering	VBG	O
an	DT	O
intramuscular	JJ	O
injection	NN	O
,	,	O
place	NN	O
fingers	NNS	O
in	IN	O
contact	NN	O
with	IN	O
syringe	NN	O
barrel	NN	O
through	IN	O
windows	NNS	O
in	IN	O
shield	NN	O
to	TO	O
prevent	VB	O
possible	JJ	O
premature	JJ	O
activation	NN	O
of	IN	O
safety	NN	O
guard	NN	O
.	.	O

PRESTALIA	NN	O
may	MD	O
be	VB	O
taken	VBN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
[	NNS	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

The	DT	O
dosage	NN	O
may	MD	O
then	RB	O
be	VB	O
increased	VBN	O
after	IN	O
2	CD	PER
to	TO	O
3	CD	PER
weeks	NNS	PER
as	RB	O
needed	VBN	O
to	TO	O
help	VB	O
achieve	VB	O
blood	NN	O
pressure	NN	O
goals	NNS	O
.	.	O

When	WRB	O
one	CD	O
depot	NN	O
is	VBZ	O
administered	VBN	O
,	,	O
surgery	NN	O
should	MD	O
be	VB	O
performed	VBN	O
at	IN	O
four	CD	PER
weeks	NNS	PER
.	.	O

Patients	NNS	WHO
who	WP	WHO
fail	VBP	WHO
to	TO	WHO
achieve	VB	WHO
at	IN	WHO
least	JJS	WHO
a	DT	WHO
2	CD	WHO
log10	JJ	WHO
drop	NN	WHO
at	IN	O
12	CD	PER
weeks	NNS	PER
or	CC	O
undetectable	JJ	O
HCV	NNP	O
-	:	O
RNA	NN	O
at	IN	O
week	NN	PER
24	CD	O
are	VBP	O
highly	RB	O
unlikely	JJ	O
to	TO	O
achieve	VB	O
SVR	NNP	O
and	CC	O
discontinuation	NN	O
of	IN	O
therapy	NN	O
should	MD	O
be	VB	O
considered	VBN	O
[	NNP	O
See	NNP	O
Clinical	NNP	O
Studies	NNP	O
]	NNP	O
.	.	O

To	TO	O
achieve	VB	O
maximum	JJ	O
contraceptive	JJ	O
effectiveness	NN	O
,	,	O
FEMCON	NNP	O
Fe	NNP	O
(	(	O
norethindrone	NN	O
and	CC	O
ethinyl	NN	O
estradiol	VBP	O
tablets	NNS	O
)	)	O
must	MD	O
be	VB	O
taken	VBN	O
exactly	RB	O
as	IN	O
directed	VBN	O
and	CC	O
at	IN	O
intervals	NNS	O
not	RB	O
exceeding	VBG	O
24	CD	O
hours	NNS	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
one	CD	DOS
drop	NN	UNIT
in	IN	O
each	DT	O
eye	NN	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Do	NNP	O
not	RB	O
touch	VB	O
the	DT	O
syringe	NN	O
tip	NN	O
or	CC	O
the	DT	O
inside	NN	O
of	IN	O
the	DT	O
cap	NN	O
.	.	O

Before	IN	O
injection	NN	O
,	,	O
the	DT	O
skin	NN	O
over	IN	O
the	DT	O
site	NN	O
to	TO	O
be	VB	O
injected	VBN	O
should	MD	O
be	VB	O
cleansed	VBN	O
with	IN	O
a	DT	O
suitable	JJ	O
germicide	NN	O
.	.	O

Adults	NNS	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
over	IN	WHO
60	CD	WHO
lbs	NNS	WHO
.	.	O

8.0	CD	DOS
mL	NN	UNIT

7	CD	O
.	.	O

Table	JJ	O
4	CD	O
:	:	O
Infusion	NN	O
Rates	NNS	O
of	IN	O
TRACRIUM	NNP	O
(	(	O
atracurium	JJ	O
besylate	NN	O
)	)	O
for	IN	O
a	DT	O
Concentration	NNP	O
of	IN	O
0.5	CD	DOS
mg	NNS	UNIT
/	CD	DOS
mL	NNS	UNIT

Table	JJ	O
1	CD	O
:	:	O
Combination	NN	O
-	:	O
Agent	JJ	O
Dosage	NNP	O
Regimens	NNP	O
and	CC	O
Dose	NNP	O
Modificationsa	NNP	O

ALBENZA	NNP	O
tablets	NNS	O
and	CC	O
ALBENZA	NNP	O
chewable	JJ	O
tablets	NNS	O
should	MD	O
be	VB	O
taken	VBN	O
with	IN	O
food	NN	O
[	NNS	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Prophylaxis	NNP	O
Guidelines	NNP	O
for	IN	O
Adults	NNP	WHO

Care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
with	IN	O
this	DT	O
kind	NN	O
of	IN	O
injection	NN	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
deltoid	JJ	O
region	NN	O
,	,	O
to	TO	O
avoid	VB	O
injecting	VBG	O
the	DT	O
gel	NN	O
suspension	NN	O
into	IN	O
the	DT	O
tissues	NNS	O
surrounding	VBG	O
the	DT	O
site	NN	O
,	,	O
since	IN	O
this	DT	O
may	MD	O
lead	VB	O
to	TO	O
tissue	VB	O
atrophy	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
undergoing	VBG	WHO
hip	JJ	WHO
fracture	NN	WHO
surgery	NN	WHO
,	,	O
an	DT	O
extended	JJ	O
prophylaxis	NN	O
course	NN	O
of	IN	O
up	IN	O
to	TO	O
24	CD	O
additional	JJ	O
days	NNS	O
is	VBZ	O
recommended	VBN	O
.	.	O

Therapy	NN	O
with	IN	O
streptomycin	NN	O
may	MD	O
be	VB	O
terminated	VBN	O
when	WRB	O
toxic	NN	O
symptoms	NNS	O
have	VBP	O
appeared	VBN	O
,	,	O
when	WRB	O
impending	VBG	O
toxicity	NN	O
is	VBZ	O
feared	VBN	O
,	,	O
when	WRB	O
organisms	JJ	O
become	NN	O
resistant	JJ	O
,	,	O
or	CC	O
when	WRB	O
full	JJ	O
treatment	NN	O
effect	NN	O
has	VBZ	O
been	VBN	O
obtained	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
TEPADINA	NNP	O
for	IN	O
treatment	NN	O
of	IN	O
adenocarcinoma	NN	O
of	IN	O
the	DT	O
breast	NN	O
or	CC	O
ovary	JJ	O
is	VBZ	O
0.3	CD	DOS
to	TO	O
0.4	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	VBD	O
intravenously	RB	O
.	.	O

INFUVITE	NNP	O
ADULT	NNP	O
(	(	O
Pharmacy	NNP	O
Bulk	NNP	O
Package	NNP	O
)	)	O
is	VBZ	O
a	DT	O
pharmacy	NN	O
bulk	JJ	O
package	NN	O
.	.	O

Children	$	WHO
6	CD	WHO
to	TO	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
:	:	O
The	DT	O
usual	JJ	O
recommended	JJ	O
dosage	NN	O
for	IN	O
children	NNS	WHO
6	CD	WHO
through	IN	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
is	VBZ	O
4	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

Azor	NNP	O
may	MD	O
be	VB	O
taken	VBN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

Gently	RB	O
pierce	VBZ	O
the	DT	O
skin	NN	O
over	IN	O
the	DT	O
deltoid	JJ	O
region	NN	O

The	DT	O
treatment	NN	O
regimens	VBZ	O
described	VBN	O
below	IN	O
are	VBP	O
based	VBN	O
on	IN	O
those	DT	O
used	VBN	O
in	IN	O
controlled	JJ	O
clinical	JJ	O
trials	NNS	O
of	IN	O
Anafranil	NNP	O
in	IN	O
520	CD	WHO
adults	NNS	WHO
,	,	O
and	CC	O
91	CD	WHO
children	NNS	WHO
and	CC	WHO
adolescents	NNS	WHO
with	IN	WHO
OCD	NNP	WHO
.	.	O

Recommended	VBN	O
Daily	NNP	FREQ
Dose	NNP	O

MIRAPEX	NNP	O
ER	NNP	O
tablets	NNS	O
are	VBP	O
taken	VBN	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
,	,	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

It	PRP	O
is	VBZ	O
important	JJ	O
that	IN	O
Accutane	NNP	O
(	(	O
isotretinoin	NN	O
)	)	O
be	VB	O
given	VBN	O
at	IN	O
the	DT	O
recommended	JJ	O
doses	NNS	O
for	IN	O
no	DT	O
longer	JJR	O
than	IN	O
the	DT	O
recommended	JJ	O
duration	NN	O
.	.	O

The	DT	O
dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
the	DT	O
range	NN	O
recommended	VBD	O
for	IN	O
the	DT	O
general	JJ	O
population	NN	O
,	,	O
if	IN	O
necessary	JJ	O
,	,	O
only	RB	O
after	IN	O
good	JJ	O
individual	JJ	O
tolerance	NN	O
has	VBZ	O
been	VBN	O
ascertained	VBN	O
.	.	O

(	(	O
see	VB	O
WARNINGS	NNP	O
concerning	VBG	O
cardiac	JJ	O
/	NNP	O
respiratory	NN	O
arrest	NN	O
/	NN	O
airway	NN	O
obstruction	NN	O
/	NNP	O
hypoventilation	NN	O
)	)	O
.	.	O

Alternatively	RB	O
,	,	O
SURVANTA	NNP	O
can	MD	O
be	VB	O
instilled	VBN	O
through	IN	O
the	DT	O
catheter	NN	O
by	IN	O
briefly	NN	O
disconnecting	VBG	O
the	DT	O
endotracheal	JJ	O
tube	NN	O
from	IN	O
the	DT	O
ventilator	NN	O
.	.	O

The	DT	O
dosages	NNS	O
for	IN	O
therapy	NN	O
with	IN	O
JUVISYNC	NNP	O
are	VBP	O
100	CD	DOS
mg	JJ	UNIT
/	$	O
10	CD	DOS
mg	NN	UNIT
,	,	O
100	CD	DOS
mg	NN	UNIT
/	VBD	O
20	CD	DOS
mg	NN	UNIT
,	,	O
100	CD	DOS
mg	NN	UNIT
/	VBD	O
40	CD	DOS
mg	NN	UNIT
,	,	O
50	CD	DOS
mg	NN	UNIT
/	VBD	O
10	CD	DOS
mg	NN	UNIT
,	,	O
50	CD	DOS
mg	NN	UNIT
/	VBD	O
20	CD	DOS
mg	NN	UNIT
,	,	O
and	CC	O
50	CD	DOS
mg	NN	UNIT
/	VBD	O
40	CD	DOS
mg	NN	UNIT
(	(	O
sitagliptin	JJ	O
/	NNP	O
simvastatin	NN	O
)	)	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

Do	VB	O
not	RB	O
take	VB	O
2	CD	DOS
doses	NNS	UNIT
on	IN	O
the	DT	O
same	JJ	O
day	NN	O
.	.	O

With	IN	O
increasing	VBG	O
age	NN	O
,	,	O
plasma	JJ	O
concentrations	NNS	O
of	IN	O
perphenazine	NN	O
(	(	O
perphenazine	NN	O
)	)	O
per	IN	O
daily	RB	FREQ
ingested	VBN	O
dose	JJ	O
increase	NN	O
.	.	O

As	IN	O
in	IN	O
adults	NNS	WHO
the	DT	WHO
following	JJ	WHO
precautionary	JJ	WHO
measures	NNS	WHO
should	MD	O
be	VB	O
considered	VBN	O
when	WRB	O
initiating	VBG	O
sotalol	NN	O
treatment	NN	O
in	IN	O
children	NNS	WHO
:	:	O
initiation	NN	O
of	IN	O
treatment	NN	O
in	IN	O
the	DT	O
hospital	NN	O
after	IN	O
appropriate	JJ	O
clinical	JJ	O
assessment	NN	O
;	:	O
individualized	VBN	O
regimen	NNS	O
as	IN	O
appropriate	NN	O
;	:	O
gradual	JJ	O
increase	NN	O
of	IN	O
doses	NNS	O
if	IN	O
required	VBN	O
;	:	O
careful	JJ	O
assessment	NN	O
of	IN	O
therapeutic	JJ	O
response	NN	O
and	CC	O
tolerability	NN	O
;	:	O
and	CC	O
frequent	JJ	O
monitoring	NN	O
of	IN	O
the	DT	O
QTc	NNP	O
interval	NN	O
and	CC	O
heart	NN	O
rate	NN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
vomits	VBZ	O
following	VBG	O
dosing	VBG	O
,	,	O
no	DT	O
additional	JJ	O
dose	NN	O
should	MD	O
be	VB	O
taken	VBN	O
that	DT	FREQ
day	NN	FREQ
.	.	O

Response	NN	O
to	TO	O
therapy	VB	O
can	MD	O
be	VB	O
assessed	VBN	O
during	IN	O
treatment	NN	O
by	IN	O
measuring	VBG	O
biochemical	JJ	O
markers	NNS	O
of	IN	O
bone	NN	O
formation	NN	O
/	NNP	O
resorption	NN	O
,	,	O
and	CC	O
/	NNP	O
or	CC	O
bone	VB	O
mineral	JJ	O
density	NN	O
.	.	O

Colyte	NN	O
with	IN	O
flavor	NN	O
packs	NNS	O
is	VBZ	O
administered	VBN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
20	CD	DOS
-	:	O
30	CD	DOS
mL	NNS	UNIT
per	IN	O
minute	NN	O
(	(	O
1.2	CD	O
-	:	O
1.8	CD	O
L	NNP	O
/	NNP	O
hour	NN	O
)	)	O
.	.	O

Doses	NNS	O
lower	JJR	O
than	IN	O
0.1	CD	DOS
mcg	JJ	UNIT
/	NNP	O
kg	NN	O
/	NNP	O
min	NN	O
and	CC	O
slow	VB	O
up	RP	O
-	:	O
titration	NN	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
less	JJR	O
reflex	JJ	O
tachycardia	NN	O
.	.	O

For	IN	O
the	DT	O
reversal	NN	O
of	IN	O
the	DT	O
sedative	JJ	O
effects	NNS	O
of	IN	O
benzodiazepines	NNS	O
administered	VBN	O
for	IN	O
conscious	JJ	O
sedation	NN	O
,	,	O
the	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
flumazenil	JJ	O
injection	NN	O
is	VBZ	O
0.2	CD	DOS
mg	NN	UNIT
(	(	O
2	CD	DOS
mL	NN	UNIT
)	)	O
administered	VBD	O
intravenously	RB	O
over	IN	O
15	CD	O
seconds	NNS	O
.	.	O

Dispense	NNP	O
in	IN	O
a	DT	O
well	NN	O
-	:	O
closed	VBD	O
container	NN	O
,	,	O
as	IN	O
defined	VBN	O
in	IN	O
the	DT	O
USP	NNP	O
.	.	O

These	DT	O
dosages	NNS	O
should	MD	O
be	VB	O
reduced	VBN	O
for	IN	O
elderly	JJ	WHO
or	CC	WHO
debilitated	JJ	WHO
patients	NNS	WHO
.	.	O

Adjustments	NNS	O
to	TO	O
dose	VB	O
may	MD	O
be	VB	O
considered	VBN	O
after	IN	O
five	CD	PER
days	NNS	PER
based	VBN	O
on	IN	O
the	DT	O
patient	NN	O
's	POS	O
response	NN	O
;	:	O
subsequently	RB	O
dosage	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
no	DT	O
more	RBR	O
frequently	RB	O
than	IN	O
every	DT	FREQ
3	CD	FREQ
-	:	O
5	CD	O
days	NNS	O
and	CC	O
by	IN	O
no	DT	O
more	JJR	O
than	IN	O
75	CD	DOS
-	:	O
150	CD	DOS
IU	NNP	UNIT
additionally	RB	O
at	IN	O
each	DT	O
adjustment	NN	O
.	.	O

Sexual	JJ	O
stimulation	NN	O
is	VBZ	O
required	VBN	O
for	IN	O
a	DT	O
response	NN	O
to	TO	O
treatment	NN	O
.	.	O

Adult	NNP	WHO
doses	NNS	O
of	IN	O
codeine	NN	O
higher	JJR	O
than	IN	O
60	CD	DOS
mg	JJ	UNIT
fail	NN	UNIT
to	TO	O
give	VB	O
commensurate	NN	O
relief	NN	O
of	IN	O
pain	NN	O
but	CC	O
merely	RB	O
prolong	JJ	O
analgesia	NN	O
and	CC	O
are	VBP	O
associated	VBN	O
with	IN	O
an	DT	O
appreciably	RB	O
increased	JJ	O
incidence	NN	O
of	IN	O
undesirable	JJ	O
side	NN	O
effects	NNS	O
.	.	O

If	IN	O
symptoms	NNS	O
arise	VBP	O
in	IN	O
the	DT	O
period	NN	O
between	IN	O
doses	NNS	O
,	,	O
an	DT	O
inhaled	JJ	O
,	,	O
short	JJ	O
-	:	O
acting	VBG	O
beta2	SYM	O
-	:	O
agonist	NN	O
should	MD	O
be	VB	O
taken	VBN	O
for	IN	O
immediate	JJ	O
relief	NN	O
.	.	O

ADMIXTURE	NNP	O
OF	NNP	O
DOXAPRAM	NNP	O
WITH	NNP	O
ALKALINE	NNP	O
SOLUTIONS	NNP	O
SUCH	NNP	O
AS	IN	O
2.5	CD	O
%	NN	O
THIOPENTAL	NNP	O
SODIUM	NNP	O
,	,	O
SODIUM	NNP	O
BICARBONATE	NNP	O
,	,	O
FUROSEMIDE	NNP	O
,	,	O
OR	NNP	O
AMINOPHYLLINE	NNP	O
WILL	MD	O
RESULT	VB	O
IN	NNP	O
PRECIPITATION	NNP	O
OR	NNP	O
GAS	NNP	O
FORMATION	NNP	O
.	.	O

Primary	JJ	O
immunization	NN	O
for	IN	O
persons	NNS	WHO
20	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
consists	NNS	WHO
of	IN	O
a	DT	O
series	NN	O
of	IN	O
3	CD	DOS
doses	NNS	UNIT
(	(	O
1	CD	DOS
mL	RB	UNIT
each	DT	UNIT
)	)	O
given	VBN	O
on	IN	O
a	DT	O
0	CD	O
-	:	O
,	,	O
1	CD	O
-	:	O
,	,	O
and	CC	O
6	CD	O
-	:	O
month	NN	O
schedule	NN	O
.	.	O

Dispensing	VBG	O
from	IN	O
Pharmacy	NNP	O
Bulk	NNP	O
Vial	NNP	O
should	MD	O
be	VB	O
completed	VBN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
after	IN	O
initial	JJ	O
entry	NN	O
.	.	O

PRIMAXIN	NNP	O
I.M	NNP	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
has	VBZ	O
not	RB	O
adhered	VBN	O
to	TO	O
the	DT	O
prescribed	JJ	O
dosing	NN	O
schedule	NN	O
(	(	O
missed	JJ	O
one	CD	DOS
or	CC	O
more	JJR	O
active	JJ	O
tablets	NNS	O
or	CC	O
started	VBD	O
taking	VBG	O
them	PRP	O
on	IN	O
a	DT	O
day	NN	O
later	RB	O
than	IN	O
she	PRP	O
should	MD	O
have	VB	O
)	)	O
,	,	O
consider	VB	O
the	DT	O
possibility	NN	O
of	IN	O
pregnancy	NN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
first	JJ	O
missed	JJ	O
period	NN	O
and	CC	O
take	VB	O
appropriate	JJ	O
diagnostic	JJ	O
measures	NNS	O
.	.	O

Administer	NNP	O
in	IN	O
divided	JJ	O
doses	NNS	O
2	CD	FREQ
or	CC	O
3	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
,	,	O
preferably	RB	O
30	CD	O
to	TO	O
45	CD	O
minutes	NNS	O
before	IN	O
meals	NNS	O
.	.	O

If	IN	O
a	DT	O
planned	VBN	O
dose	NN	O
of	IN	O
DARZALEX	NNP	O
is	VBZ	O
missed	VBN	O
,	,	O
administer	VBP	O
the	DT	O
dose	NN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
and	CC	O
adjust	VBP	O
the	DT	O
dosing	NN	O
schedule	NN	O
accordingly	RB	O
,	,	O
maintaining	VBG	O
the	DT	O
treatment	NN	O
interval	NN	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
SYMMETREL	NNP	O
(	(	O
amantadine	JJ	O
hydrochloride	NN	O
)	)	O
is	VBZ	O
100	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
pH	NN	O
of	IN	O
the	DT	O
reconstituted	JJ	O
solutions	NNS	O
is	VBZ	O
about	IN	O
5	CD	O
.	.	O

CEFOTAN™	NNP	O
(	(	O
cefotetan	NN	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
)	)	O
reconstituted	VBD	O
as	IN	O
described	VBN	O
above	IN	O
(	(	O
see	VB	O
DOSAGE	NNP	O
AND	NNP	O
ADMINISTRATION	NNP	O
,	,	O
Preparation	NNP	O
Of	IN	O
Solution	NNP	O
)	)	O
maintains	VBZ	O
satisfactory	JJ	O
potency	NN	O
for	IN	O
24	CD	PER
hours	NNS	PER
at	IN	O
room	NN	O
temperature	NN	O
(	(	O
25°C	CD	O
/	RB	O
77°F	CD	O
)	)	O
,	,	O
for	IN	O
96	CD	O
hours	NNS	O
under	IN	O
refrigeration	NN	O
(	(	O
5°C	CD	O
/	RB	O
41°F	CD	O
)	)	O
,	,	O
and	CC	O
for	IN	O
at	IN	PER
least	JJS	PER
1	CD	PER
week	NN	PER
in	IN	O
the	DT	O
frozen	JJ	O
state	NN	O
(	(	O
-	:	O
20°C	CD	O
/	$	O
4°F	CD	O
)	)	O
.	.	O

100	CD	DOS
mg	NN	UNIT
,	,	O
by	IN	O
mouth	NN	O
,	,	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
7	CD	PER
days	NNS	PER
.	.	O

Shadow	JJ	O
Test	NNP	O
(	(	O
Retinoscopy	NNP	O
)	)	O
:	:	O
When	WRB	O
dilatation	NN	O
of	IN	O
the	DT	O
pupil	NN	O
without	IN	O
cycloplegic	JJ	O
action	NN	O
is	VBZ	O
desired	VBN	O
for	IN	O
the	DT	O
shadow	JJ	O
test	NN	O
,	,	O
the	DT	O
2.5	CD	O
percent	NN	O
ophthalmic	JJ	O
solution	NN	O
may	MD	O
be	VB	O
used	VBN	O
alone	RB	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

If	IN	O
a	DT	O
minor	JJ	O
reaction	NN	O
occurs	VBZ	O
during	IN	O
administration	NN	O
,	,	O
the	DT	O
injection	NN	O
should	MD	O
be	VB	O
slowed	VBN	O
or	CC	O
stopped	VBN	O
until	IN	O
the	DT	O
reaction	NN	O
has	VBZ	O
subsided	VBN	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
other	JJ	O
drugs	NNS	O
in	IN	O
the	DT	O
same	JJ	O
solution	NN	O
with	IN	O
sodium	NN	O
nitroprusside	NN	O
.	.	O

Unused	JJ	O
solution	NN	O
should	MD	O
be	VB	O
discarded	VBN	O
after	IN	O
2	CD	O
hours	NNS	O
.	.	O

The	DT	O
segments	NNS	O
should	MD	O
be	VB	O
washed	VBN	O
down	RB	O
unchewed	JJ	O
,	,	O
with	IN	O
water	NN	O
,	,	O
keeping	VBG	O
the	DT	O
segments	NNS	O
in	IN	O
the	DT	O
mouth	NN	O
can	MD	O
reveal	VB	O
a	DT	O
bitter	JJ	O
taste	NN	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
heparin	NN	O
and	CC	O
Retavase®	NNP	O
simultaneously	RB	O
in	IN	O
the	DT	O
same	JJ	O
intravenous	JJ	O
line	NN	O
.	.	O

Therapy	NN	O
should	MD	O
not	RB	O
be	VB	O
continued	VBN	O
if	IN	O
epiphyseal	JJ	O
fusion	NN	O
has	VBZ	O
occurred	VBN	O
.	.	O

3	CD	DOS
mL	NN	UNIT
in	IN	O
4	CD	DOS
mL	JJ	UNIT
bottle	NN	O
NDC	NNP	O
0065	CD	O
-	:	O
0002	CD	O
-	:	O
03	CD	O

In	IN	O
addition	NN	O
,	,	O
all	DT	WHO
patients	NNS	WHO
with	IN	WHO
low	JJ	WHO
performance	NN	WHO
status	NN	WHO
were	VBD	WHO
treated	VBN	WHO
with	IN	WHO
the	DT	WHO
latter	JJ	WHO
schedule	NN	WHO
(	(	O
100	CD	DOS
mg	NN	UNIT
/	NN	O
m2	NN	O
every	DT	FREQ
2	CD	FREQ
weeks	NNS	FREQ
)	)	O
.	.	O

50	CD	O

This	DT	O
is	VBZ	O
normal	JJ	O
and	CC	O
does	VBZ	O
not	RB	O
affect	VB	O
the	DT	O
solution	NN	O
quality	NN	O
or	CC	O
safety	NN	O
.	.	O

Fentanyl	NN	O

Bacteriologic	NNP	O
studies	NNS	O
to	TO	O
determine	VB	O
the	DT	O
causative	JJ	O
organisms	NNS	O
and	CC	O
their	PRP$	O
susceptibility	NN	O
to	TO	O
nafcillin	VB	O
should	MD	O
always	RB	O
be	VB	O
performed	VBN	O
.	.	O

However	RB	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
the	DT	O
infusion	NN	O
begin	NN	O
as	RB	O
promptly	RB	O
as	IN	O
is	VBZ	O
practical	JJ	O
.	.	O

With	IN	O
the	DT	O
abatement	NN	O
of	IN	O
these	DT	O
adverse	JJ	O
reactions	NNS	O
,	,	O
the	DT	O
drug	NN	O
may	MD	O
be	VB	O
started	VBN	O
at	IN	O
a	DT	O
lower	JJR	O
dose	NN	O
or	CC	O
at	IN	O
the	DT	O
previous	JJ	O
dose	NN	O
based	VBN	O
on	IN	O
clinical	JJ	O
judgment	NN	O
.	.	O

An	DT	O
appropriately	RB	O
calibrated	JJ	O
syringe	NN	O
should	MD	O
be	VB	O
used	VBN	O
to	TO	O
assure	VB	O
withdrawal	NN	O
of	IN	O
the	DT	O
correct	JJ	O
volume	NN	O
of	IN	O
drug	NN	O
from	IN	O
INNOHEP®	NNP	O
(	(	O
tinzaparin	NN	O
)	)	O
vials	NNS	O
.	.	O

If	IN	O
this	DT	O
happens	VBZ	O
,	,	O
the	DT	O
eye	NN	O
should	MD	O
be	VB	O
flushed	VBN	O
with	IN	O
water	NN	O
immediately	RB	O
and	CC	O
thoroughly	RB	O
.	.	O

Locate	VB	O
the	DT	O
implant	NN	O
by	IN	O
palpation	NN	O
and	CC	O
mark	VB	O
the	DT	O
distal	JJ	O
end	NN	O
(	(	O
end	JJ	O
closest	NN	O
to	TO	O
the	DT	O
elbow	NN	O
)	)	O
,	,	O
for	IN	O
example	NN	O
,	,	O
with	IN	O
a	DT	O
sterile	JJ	O
marker	NN	O
(	(	O
Figure	NNP	O
13	CD	O
)	)	O
.	.	O

Individualize	NNP	O
dosing	NN	O
and	CC	O
use	VB	O
the	DT	O
lowest	JJS	O
dose	NN	O
of	IN	O
PROCRIT	NNP	O
sufficient	NN	O
to	TO	O
reduce	VB	O
the	DT	O
need	NN	O
for	IN	O
RBC	NNP	O
transfusions	NNS	O
[	VBP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

This	DT	O
determination	NN	O
is	VBZ	O
made	VBN	O
only	RB	O
in	IN	O
the	DT	O
cerebral	JJ	O
cortex	NN	O
;	:	O
the	DT	O
signal	JJ	O
uptake	NN	O
in	IN	O
the	DT	O
cerebellum	NN	O
does	VBZ	O
not	RB	O
contribute	VB	O
to	TO	O
the	DT	O
scan	JJ	O
interpretation	NN	O
(	(	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
positive	JJ	O
scan	NN	O
may	MD	O
show	VB	O
retained	JJ	O
cerebellar	JJ	O
gray	JJ	O
-	:	O
white	JJ	O
contrast	NN	O
even	RB	O
when	WRB	O
the	DT	O
cortical	JJ	O
gray	JJ	O
-	:	O
white	JJ	O
contrast	NN	O
is	VBZ	O
lost	VBN	O
)	)	O
.	.	O

0	CD	O

Do	NNP	O
not	RB	O
touch	VB	O
the	DT	O
clear	JJ	O
spike	NN	O
.	.	O

For	IN	O
adult	NN	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
(	(	WHO
2	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
)	)	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
DOTAREM	NNP	O
is	VBZ	O
0.2	CD	DOS
mL	NN	UNIT
/	NN	O
kg	NN	O
(	(	O
0.1	CD	DOS
mmol	NN	UNIT
/	NNP	O
kg	NN	O
)	)	O
body	NN	O
weight	JJ	O
administered	VBN	O
as	IN	O
an	DT	O
intravenous	JJ	O
bolus	NN	O
injection	NN	O
,	,	O
manually	RB	O
or	CC	O
by	IN	O
power	NN	O
injector	NN	O
,	,	O
at	IN	O
a	DT	O
flow	JJ	O
rate	NN	O
of	IN	O
approximately	RB	O
2	CD	DOS
mL	NNS	UNIT
/	JJ	O
second	JJ	O
for	IN	O
adults	NNS	WHO
and	CC	O
1	CD	DOS
-	:	O
2	CD	DOS
mL	NN	UNIT
/	JJ	O
second	NN	O
for	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
.	.	O

For	IN	O
the	DT	O
therapy	NN	O
of	IN	O
patients	NNS	WHO
with	IN	WHO
solid	JJ	WHO
tumors	NNS	WHO
(	(	O
ovary	JJ	O
,	,	O
breast	NN	O
,	,	O
and	CC	O
NSCLC	NNP	O
)	)	O
,	,	O
courses	NNS	O
of	IN	O
paclitaxel	JJ	O
injection	NN	O
should	MD	O
not	RB	O
be	VB	O
repeated	VBN	O
until	IN	O
the	DT	O
neutrophil	JJ	O
count	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
1500	CD	DOS
cells	NNS	UNIT
/	JJ	O
mm³	NN	O
and	CC	O
the	DT	O
platelet	NN	O
count	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
100,000	CD	DOS
cells	NNS	UNIT
/	JJ	O
mm³	NN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
LAMICTAL	NNP	O
XR	NNP	O
not	RB	O
be	VB	O
restarted	VBN	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
discontinued	VBD	WHO
due	JJ	WHO
to	TO	O
rash	VB	O
associated	VBN	O
with	IN	O
prior	JJ	O
treatment	NN	O
with	IN	O
lamotrigine	NN	O
unless	IN	O
the	DT	O
potential	JJ	O
benefits	NNS	O
clearly	RB	O
outweigh	VBP	O
the	DT	O
risks	NNS	O
.	.	O

If	IN	O
patients	NNS	O
do	VBP	O
not	RB	O
convert	VB	O
to	TO	O
normal	JJ	O
sinus	NN	O
rhythm	NN	O
within	IN	O
24	CD	O
hours	NNS	O
of	IN	O
initiation	NN	O
of	IN	O
TIKOSYN	NNP	O
therapy	NN	O
,	,	O
electrical	JJ	O
conversion	NN	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

Carboplatin	NNP	O
injection	NN	O
is	VBZ	O
a	DT	O
premixed	JJ	O
aqueous	JJ	O
solution	NN	O
of	IN	O
10	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
carboplatin	NN	O
.	.	O

Shake	NNP	O
lightly	RB	O
before	IN	O
use	NN	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
administering	VBG	O
methylene	NN	O
blue	NN	O
by	IN	O
non	JJ	O
-	:	O
intravenous	JJ	O
routes	NNS	O
(	(	O
such	JJ	O
as	IN	O
oral	JJ	O
tablets	NNS	O
or	CC	O
by	IN	O
local	JJ	O
injection	NN	O
)	)	O
or	CC	O
in	IN	O
intravenous	JJ	O
doses	NNS	O
much	RB	O
lower	JJR	O
than	IN	O
1	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
with	IN	O
KHEDEZLA	NNP	O
is	VBZ	O
unclear	JJ	O
.	.	O

(	(	O
A	DT	O
residual	JJ	O
drop	NN	O
may	MD	O
remain	VB	O
in	IN	O
the	DT	O
tip	NN	O
of	IN	O
the	DT	O
tube	NN	O
.	.	O
)	)	O

Continually	RB	O
reevaluate	JJ	O
patients	NNS	WHO
receiving	VBG	WHO
DOLOPHINE	NNP	WHO
to	TO	O
assess	VB	O
the	DT	O
maintenance	NN	O
of	IN	O
pain	NN	O
control	NN	O
and	CC	O
the	DT	O
relative	JJ	O
incidence	NN	O
of	IN	O
adverse	JJ	O
reactions	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
monitoring	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
addiction	NN	O
,	,	O
abuse	NN	O
,	,	O
or	CC	O
misuse	NN	O
.	.	O

While	IN	O
most	JJS	O
cases	NNS	O
of	IN	O
renal	JJ	O
insufficiency	NN	O
have	VBP	O
occurred	VBN	O
in	IN	O
patients	NNS	WHO
receiving	VBG	WHO
total	JJ	WHO
doses	NNS	WHO
of	IN	O
350	CD	DOS
mg	NNS	UNIT
Ig	NNP	O
/	NNP	O
kg	NN	O
or	CC	O
greater	JJR	O
,	,	O
no	DT	O
prospective	JJ	O
data	NNS	O
are	VBP	O
presently	RB	O
available	JJ	O
to	TO	O
identify	VB	O
a	DT	O
maximum	JJ	O
safe	JJ	O
dose	NN	O
,	,	O
concentration	NN	O
or	CC	O
rate	NN	O
of	IN	O
infusion	NN	O
in	IN	O
patients	NNS	O
determined	VBN	O
to	TO	O
be	VB	O
at	IN	O
increased	JJ	O
risk	NN	O
of	IN	O
acute	JJ	O
renal	JJ	O
failure	NN	O
.	.	O

This	DT	O
is	VBZ	O
a	DT	O
normal	JJ	O
observation	NN	O
.	.	O

Little	NNP	O
or	CC	O
no	DT	O
benefit	NN	O
follows	VBZ	O
injection	NN	O
into	IN	O
surrounding	VBG	O
tissue	NN	O
.	.	O

Use	NNP	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
for	IN	O
reconstitution	NN	O
and	CC	O
then	RB	O
either	RB	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
or	CC	O
2.5	CD	O
%	NN	O
Dextrose	NNP	O
/	NNP	O
0.45	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
for	IN	O
dilution	NN	O
,	,	O
as	IN	O
outlined	VBN	O
above	IN	O
.	.	O

Avoid	NNP	O
bony	NN	O
prominences	NNS	O
,	,	O
or	CC	O
areas	NNS	O
that	WDT	O
are	VBP	O
scarred	VBN	O
,	,	O
inflamed	VBD	O
or	CC	O
infected	VBN	O
.	.	O

While	IN	O
atazanavir	JJ	O
/	FW	O
ritonavir	NN	O
does	VBZ	O
reduce	VB	O
the	DT	O
lamotrigine	NN	O
plasma	NN	O
concentration	NN	O
,	,	O
no	DT	O
adjustments	NNS	O
to	TO	O
the	DT	O
recommended	VBN	O
dose	NN	O
-	:	O
escalation	NN	O
guidelines	NNS	O
for	IN	O
LAMICTAL	NNP	O
XR	NNP	O
should	MD	O
be	VB	O
necessary	JJ	O
solely	RB	O
based	VBN	O
on	IN	O
the	DT	O
use	NN	O
of	IN	O
atazanavir	NN	O
/	NNP	O
ritonavir	NN	O
.	.	O

Care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
ensure	VB	O
that	DT	O
CREON	NNP	O
is	VBZ	O
not	RB	O
crushed	VBN	O
or	CC	O
chewed	VBN	O
or	CC	O
retained	VBN	O
in	IN	O
the	DT	O
mouth	NN	O
,	,	O
to	TO	O
avoid	VB	O
irritation	NN	O
of	IN	O
the	DT	O
oral	JJ	O
mucosa	NN	O
.	.	O

In	IN	O
patients	NNS	O
administered	VBN	O
high	JJ	O
doses	NNS	O
of	IN	O
SUFENTA	NNP	O
,	,	O
it	PRP	O
is	VBZ	O
essential	JJ	O
that	IN	O
qualified	JJ	O
personnel	NNS	O
and	CC	O
adequate	JJ	O
facilities	NNS	O
are	VBP	O
available	JJ	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
postoper	NN	O
-	:	O
ative	JJ	O
respiratory	NN	O
depression	NN	O
.	.	O

If	IN	O
the	DT	O
original	JJ	O
maintenance	NN	O
treatment	NN	O
schedule	NN	O
is	VBZ	O
unable	JJ	O
to	TO	O
control	VB	O
the	DT	O
psoriasis	NN	O
,	,	O
the	DT	O
schedule	NN	O
may	MD	O
be	VB	O
changed	VBN	O
to	TO	O
a	DT	O
more	RBR	O
frequent	JJ	O
regimen	NNS	O
.	.	O

With	IN	O
either	DT	O
regimen	NNS	O
,	,	O
the	DT	O
patient	NN	O
takes	VBZ	O
one	CD	DOS
tablet	NN	UNIT
daily	NN	FREQ
for	IN	O
21	CD	PER
consecutive	JJ	PER
days	NNS	PER
followed	VBN	O
by	IN	O
one	CD	PER
week	NN	PER
of	IN	O
no	DT	O
tablets	NNS	O
.	.	O

Complete	JJ	O
information	NN	O
is	VBZ	O
not	RB	O
available	JJ	O
.	.	O

The	DT	O
woman	NN	O
should	MD	O
not	RB	O
try	VB	O
to	TO	O
reapply	VB	O
a	DT	O
patch	NN	O
if	IN	O
it	PRP	O
is	VBZ	O
no	RB	O
longer	RBR	O
sticky	JJ	O
,	,	O
if	IN	O
it	PRP	O
has	VBZ	O
become	VBN	O
stuck	VBN	O
to	TO	O
itself	PRP	O
or	CC	O
another	DT	O
surface	NN	O
,	,	O
or	CC	O
if	IN	O
it	PRP	O
has	VBZ	O
other	JJ	O
material	JJ	O
stuck	VBN	O
to	TO	O
it	PRP	O
.	.	O

There	EX	O
are	VBP	O
no	DT	O
systematically	RB	O
collected	VBN	O
data	NNS	O
to	TO	O
specifically	RB	O
address	VB	O
switching	VBG	O
patients	NNS	WHO
from	IN	WHO
VRAYLAR	NNP	WHO
to	TO	WHO
other	JJ	WHO
antipsychotics	NNS	WHO
or	CC	WHO
concerning	VBG	WHO
concomitant	JJ	WHO
administration	NN	WHO
with	IN	WHO
other	JJ	WHO
antipsychotics	NNS	WHO
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
GERD	NNP	O
and	CC	O
maintenance	NN	O
of	IN	O
healing	NN	O
of	IN	O
erosive	JJ	O
esophagitis	NN	O
,	,	O
the	DT	O
recommended	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
for	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
1	CD	WHO
to	TO	WHO
16	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
is	VBZ	O
as	IN	O
follows	VBZ	O
:	:	O

4.8	CD	DOS
mL	NN	UNIT

Blood	NN	O
counts	NNS	O
were	VBD	O
done	VBN	O
weekly	JJ	O
,	,	O
and	CC	O
the	DT	O
recommendations	NNS	O
are	VBP	O
based	VBN	O
on	IN	O
the	DT	O
lowest	JJS	O
post	NN	O
-	:	O
treatment	NN	O
platelet	NN	O
or	CC	O
neutrophil	JJ	O
value	NN	O
.	.	O

Treatment	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
with	IN	O
supervised	JJ	O
administration	NN	O
,	,	O
progressing	VBG	O
to	TO	O
unsupervised	JJ	O
administration	NN	O
as	IN	O
the	DT	O
patient	NN	O
's	POS	O
clinical	JJ	O
stability	NN	O
permits	NNS	O
.	.	O

Discontinue	NNP	O
therapy	NN	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
show	VBP	WHO
no	DT	WHO
evidence	NN	WHO
of	IN	O
therapeutic	JJ	O
benefit	NN	O
by	IN	O
Week	JJ	O
14	CD	O
.	.	O

Withdraw	NNP	O
protein	NN	O
from	IN	O
diet	JJ	O
.	.	O

The	DT	O
proper	JJ	O
amount	NN	O
can	MD	O
be	VB	O
determined	VBN	O
by	IN	O
monitoring	VBG	O
clinical	JJ	O
response	NN	O
.	.	O

Patients	NNS	O
who	WP	O
may	MD	O
be	VB	O
receiving	VBG	O
a	DT	O
combination	NN	O
of	IN	O
strong	JJ	O
,	,	O
moderate	JJ	O
,	,	O
and	CC	O
weak	JJ	O
inhibitors	NNS	O
of	IN	O
CYP3A4	NNP	O
and	CC	O
CYP2D6	NNP	O
(	(	O
e.g	NN	O
,	,	O
a	DT	O
strong	JJ	O
CYP3A4	NNP	O
inhibitor	NN	O
and	CC	O
a	DT	O
moderate	JJ	O
CYP2D6	NNP	O
inhibitor	NN	O
or	CC	O
a	DT	O
moderate	JJ	O
CYP3A4	NNP	O
inhibitor	NN	O
with	IN	O
a	DT	O
moderate	JJ	O
CYP2D6	NNP	O
inhibitor	NN	O
)	)	O
,	,	O
the	DT	O
dosing	NN	O
may	MD	O
be	VB	O
reduced	VBN	O
to	TO	O
one	CD	DOS
-	:	O
quarter	NN	O
(	(	O
25	CD	O
%	NN	O
)	)	O
of	IN	O
the	DT	O
usual	JJ	O
dose	NN	O
initially	RB	O
and	CC	O
then	RB	O
adjusted	VBD	O
to	TO	O
achieve	VB	O
a	DT	O
favorable	JJ	O
clinical	JJ	O
response	NN	O
.	.	O

Follow	NNP	O
applicable	JJ	O
special	JJ	O
handling	NN	O
and	CC	O
disposal	NN	O
procedures.1	NN	O

ENGERIX	NNP	O
-	:	O
B	NN	O
can	MD	O
be	VB	O
given	VBN	O
on	IN	O
either	DT	O
dosing	VBG	O
schedule	NN	O
(	(	O
0	CD	O
,	,	O
1	CD	O
,	,	O
and	CC	O
6	CD	O
months	NNS	O
or	CC	O
0,2	CD	O
,	,	O
and	CC	O
12	CD	O
months	NNS	O
)	)	O
.	.	O

Consult	NN	WHO
with	IN	WHO
pharmacist	NN	WHO
,	,	O
if	IN	O
available	JJ	O
.	.	O

Use	NNP	O
of	IN	O
filter	NN	O
devices	NNS	O
such	JJ	O
as	IN	O
IVEX	NNP	O
-	:	O
2®	CD	O
filters	NNS	O
which	WDT	O
incorporate	VBP	O
short	JJ	O
inlet	NN	O
and	CC	O
outlet	NN	O
PVC	NNP	O
-	:	O
coated	VBD	O
tubing	NN	O
has	VBZ	O
not	RB	O
resulted	VBN	O
in	IN	O
significant	JJ	O
leaching	NN	O
of	IN	O
DEHP	NNP	O
.	.	O

Remove	VB	O
cover	NN	O
from	IN	O
outlet	JJ	O
port	NN	O
at	IN	O
bottom	NN	O
of	IN	O
container	NN	O
.	.	O

Adults	NNS	WHO
and	CC	WHO
Adolescents	NNS	WHO
:	:	O
A	DT	O
single	JJ	DOS
1.0	CD	DOS
gram	JJ	UNIT
initial	JJ	O
dose	NN	O
of	IN	O
Ca	NNP	O
-	:	O
DTPA	NNP	O
(	(	O
pentetate	JJ	O
calcium	NN	O
trisodium	NN	O
inj	NN	O
)	)	O
administered	VBD	O
intravenously	RB	O
.	.	O

Keep	NNP	O
container	NN	O
tightly	RB	O
closed	VBD	O
.	.	O

Eighteen	JJ	O
hours	NNS	O
following	VBG	O
the	DT	O
removal	NN	O
of	IN	O
the	DT	O
transdermal	JJ	O
fentanyl	NN	O
patch	NN	O
,	,	O
TARGINIQ	NNP	O
ER	NNP	O
treatment	NN	O
can	MD	O
be	VB	O
initiated	VBN	O
.	.	O

For	IN	O
patients	NNS	WHO
whodevelop	JJ	WHO
ALT	NNP	WHO
/	NNP	O
SGPTelevations	NNP	O
greater	JJR	O
than	IN	O
two	CD	O
times	NNS	O
the	DT	O
upper	JJ	O
limit	NN	O
of	IN	O
normal	JJ	O
,	,	O
the	DT	O
dose	NN	O
and	CC	O
monitoring	VBG	O
regimen	NNS	O
should	MD	O
be	VB	O
modified	VBN	O
as	IN	O
described	VBN	O
in	IN	O
Table	JJ	O
4	CD	O
.	.	O

Take	VB	O
LENVIMA	NNP	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
each	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
table	NN	O
and	CC	O
formula	NN	O
described	VBN	O
under	IN	O
I	PRP	O
.	.	O

Geriatric	JJ	O
Use	NN	O
:	:	O
In	IN	O
studies	NNS	WHO
where	WRB	WHO
geriatric	JJ	WHO
patients	NNS	WHO
(	(	WHO
65	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
or	CC	WHO
older	JJR	WHO
,	,	O
see	VBP	O
PRECAUTIONS	NNP	O
)	)	O
have	VBP	O
been	VBN	O
treated	VBN	O
with	IN	O
CUTIVATE	NNP	O
Ointment	NNP	O
(	(	O
fluticasone	JJ	O
propionate	NN	O
ointment	NN	O
)	)	O
,	,	O
safety	NN	O
did	VBD	O
not	RB	O
differ	VB	O
from	IN	O
that	DT	O
in	IN	O
younger	JJR	WHO
patients	NNS	WHO
;	:	O
therefore	RB	O
,	,	O
no	DT	O
dosage	NN	O
adjustment	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

In	IN	O
adults	NNS	WHO
,	,	O
the	DT	O
initial	JJ	O
dose	NN	O
is	VBZ	O
1000	CD	DOS
mg	NN	UNIT
of	IN	O
DURICEF	NNP	O
(	(	O
cefadroxil	NN	O
)	)	O
and	CC	O
the	DT	O
maintenance	NN	O
dose	NN	O
(	(	O
based	VBN	O
on	IN	O
the	DT	O
creatinine	JJ	O
clearance	NN	O
rate	NN	O
[	NNP	O
mL	NN	O
/	NNP	O
min	NN	O
/	VBD	O
1.73	CD	O
M2	NNP	O
]	NNP	O
)	)	O
is	VBZ	O
500	CD	DOS
mg	NN	UNIT
at	IN	O
the	DT	O
time	NN	O
intervals	NNS	O
listed	VBN	O
below	IN	O
.	.	O

In	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
under	IN	WHO
3	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
or	CC	WHO
weighing	VBG	WHO
less	JJR	WHO
than	IN	O
30	CD	O
lb	JJ	O
concentrations	NNS	O
less	JJR	O
than	IN	O
2	CD	O
%	NN	O
(	(	O
e.g	JJ	O
,	,	O
0.5	CD	O
%	NN	O
to	TO	O
1.5	CD	O
%	NN	O
)	)	O
should	MD	O
be	VB	O
employed	VBN	O
.	.	O

At	IN	O
that	DT	O
time	NN	O
,	,	O
the	DT	O
efficacy	NN	O
and	CC	O
safety	NN	O
of	IN	O
the	DT	O
therapy	NN	O
should	MD	O
be	VB	O
assessed	VBN	O
,	,	O
and	CC	O
the	DT	O
dose	NN	O
of	IN	O
edex®	NN	O
(	(	O
alprostadil	NN	O
for	IN	O
injection	NN	O
)	)	O
should	MD	O
be	VB	O
adjusted	VBN	O
,	,	O
if	IN	O
needed	VBN	O
.	.	O

This	DT	O
requirement	NN	O
is	VBZ	O
related	VBN	O
to	TO	O
the	DT	O
carbohydrate	NN	O
calories	NNS	O
delivered	VBN	O
.	.	O

5	CD	O
)	)	O
With	IN	O
both	DT	O
vials	NNS	O
still	RB	O
attached	VBN	O
,	,	O
gently	RB	O
swirl	VBZ	O
the	DT	O
concentrate	NN	O
(	(	O
WILATE	NNP	O
)	)	O
vial	NN	O
to	TO	O
ensure	VB	O
the	DT	O
powder	NN	O
is	VBZ	O
fully	RB	O
dissolved	VBN	O
to	TO	O
a	DT	O
clear	JJ	O
solution	NN	O
.	.	O

Avoid	NNP	O
overburdening	VBG	O
the	DT	O
circulation	NN	O
with	IN	O
a	DT	O
large	JJ	O
volume	NN	O
of	IN	O
fluid	NN	O
.	.	O

The	DT	O
usual	JJ	O
recommended	VBD	O
starting	VBG	O
dose	NN	O
of	IN	O
candesartan	NN	O
cilexetil	NN	O
is	VBZ	O
16	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
when	WRB	O
it	PRP	O
is	VBZ	O
used	VBN	O
as	IN	O
monotherapy	NN	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
not	RB	WHO
volume	NN	WHO
depleted	VBD	WHO
.	.	O

The	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
doses	NNS	O
higher	JJR	O
than	IN	O
800	CD	DOS
mcg	NNS	UNIT
have	VBP	O
not	RB	O
been	VBN	O
evaluated	VBN	O
in	IN	O
clinical	JJ	O
studies	NNS	O
.	.	O

1a	CD	O
.	.	O

Administer	RBR	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
of	IN	O
VARIZIG	NNP	O
intramuscularly	RB	O
as	RB	O
recommended	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
.	.	O

Individualize	NNP	O
and	CC	O
titrate	VB	O
ZEMPLAR	NNP	O
dose	VB	O
based	VBN	O
on	IN	O
iPTH	NN	O
,	,	O
serum	JJ	O
calcium	NN	O
and	CC	O
phosphorus	NN	O
levels	NNS	O
to	TO	O
maintain	VB	O
an	DT	O
iPTH	JJ	O
level	NN	O
within	IN	O
target	NN	O
range	NN	O
.	.	O

If	IN	O
a	DT	O
patient	NN	O
shows	VBZ	O
no	DT	O
clinical	JJ	O
improvement	NN	O
after	IN	O
the	DT	O
treatment	NN	O
period	NN	O
,	,	O
the	DT	O
diagnosis	NN	O
should	MD	O
be	VB	O
redetermined	VBN	O
.	.	O

must	MD	O
not	RB	O
be	VB	O
infused	VBN	O
concomitantly	RB	O
with	IN	O
any	DT	O
blood	NN	O
product	NN	O
or	CC	O
short	JJ	O
-	:	O
term	NN	O
infusion	NN	O
of	IN	O
concentrated	JJ	O
electrolytes	NNS	O
,	,	O
even	RB	O
if	IN	O
the	DT	O
two	CD	O
infusions	NNS	O
are	VBP	O
running	VBG	O
in	IN	O
separate	JJ	O
intravenous	JJ	O
lines	NNS	O
(	(	O
or	CC	O
cannulas	NN	O
)	)	O
.	.	O

These	DT	O
dosages	NNS	O
can	MD	O
often	RB	O
be	VB	O
gradually	RB	O
lowered	VBN	O
as	IN	O
treatment	NN	O
progresses	NNS	O
.	.	O

EMEND	NNP	O
for	IN	O
oral	JJ	O
suspension	NN	O
should	MD	O
be	VB	O
prepared	VBN	O
by	IN	O
a	DT	O
healthcare	NN	O
provider	NN	O
.	.	O

Close	JJ	O
observation	NN	O
and	CC	O
frequent	JJ	O
titration	NN	O
are	VBP	O
warranted	VBN	O
until	IN	O
pain	JJ	O
management	NN	O
is	VBZ	O
stable	JJ	O
on	IN	O
the	DT	O
new	JJ	O
opioid	NN	O
.	.	O

Some	DT	O
of	IN	O
these	DT	O
patients	NNS	O
have	VBP	O
been	VBN	O
controlled	VBN	O
on	IN	O
doses	NNS	O
as	RB	O
low	JJ	O
as	IN	O
25	CD	DOS
–	$	O
50	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

Total	JJ	O
dosage	NN	O
should	MD	O
be	VB	O
decreased	VBN	O
by	IN	O
reduction	NN	O
of	IN	O
recommended	JJ	O
individual	JJ	O
doses	NNS	O
and	CC	O
/	NN	O
or	CC	O
by	IN	O
extending	VBG	O
time	NN	O
intervals	NNS	O
between	IN	O
doses	NNS	O
.	.	O

A	DT	O
serum	JJ	O
concentration	NN	O
obtained	VBD	O
30	CD	O
minutes	NNS	O
after	IN	O
an	DT	O
intravenous	JJ	O
loading	NN	O
dose	NN	O
,	,	O
when	WRB	O
distribution	NN	O
is	VBZ	O
complete	JJ	O
,	,	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
assess	VB	O
the	DT	O
need	NN	O
for	IN	O
and	CC	O
size	NN	O
of	IN	O
subsequent	JJ	O
loading	NN	O
doses	NNS	O
,	,	O
if	IN	O
clinically	RB	O
indicated	VBN	O
,	,	O
and	CC	O
for	IN	O
guidance	NN	O
of	IN	O
continuing	VBG	O
therapy	NN	O
.	.	O

Write	IN	O
the	DT	O
expiration	NN	O
date	NN	O
of	IN	O
the	DT	O
re	NN	O
-	:	O
constituted	JJ	O
oral	JJ	O
suspension	NN	O
on	IN	O
the	DT	O
bottle	NN	O
label	NN	O
.	.	O

Apply	VB	O
a	DT	O
small	JJ	O
amount	NN	O
(	(	O
approximately	RB	O
½	NNP	O
inch	JJ	O
ribbon	NN	O
)	)	O
into	IN	O
the	DT	O
conjunctival	NN	O
sac	NN	O
(	(	O
s	PRP	O
)	)	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
beginning	VBG	O
24	CD	O
hours	NNS	O
after	IN	O
surgery	NN	O
and	CC	O
continuing	VBG	O
throughout	IN	O
the	DT	O
first	JJ	O
2	CD	PER
weeks	NNS	PER
of	IN	O
the	DT	O
post	NN	O
-	:	O
operative	JJ	O
period	NN	O
.	.	O

A	DT	O
once	RB	O
-	:	O
monthly	JJ	O
visit	NN	O
schedule	NN	O
may	MD	O
be	VB	O
reasonable	JJ	O
for	IN	O
patients	NNS	WHO
on	IN	WHO
a	DT	WHO
stable	JJ	WHO
dosage	NN	WHO
of	IN	O
medication	NN	O
who	WP	O
are	VBP	O
making	VBG	O
progress	RB	O
toward	IN	O
their	PRP$	O
treatment	NN	O
objectives	NNS	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
for	IN	O
children	NNS	WHO
is	VBZ	O
1.0	CD	DOS
mL	NN	UNIT
/	NN	O
kg	NN	O
to	TO	O
1.5	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	NN	O
.	.	O

Caloric	JJ	O
intake	NN	O
should	MD	O
be	VB	O
based	VBN	O
upon	IN	O
the	DT	O
“	NN	O
Recommended	VBD	O
Dietary	NNP	O
Allowances	NNP	O
”	NNP	O
,	,	O
10th	CD	O
ed	NN	O
.	.	O
,	,	O
Food	NNP	O
and	CC	O
Nutrition	NNP	O
Board	NNP	O
,	,	O
National	NNP	O
Research	NNP	O
Council	NNP	O
,	,	O
National	NNP	O
Academy	NNP	O
of	IN	O
Sciences	NNPS	O
,	,	O
1989	CD	O
.	.	O

Patients	NNS	WHO
not	RB	WHO
currently	RB	WHO
receiving	VBG	WHO
theophylline	NN	WHO
products	NNS	WHO
:	:	O

NOTE	NN	O
:	:	O
If	IN	O
at	IN	O
any	DT	O
time	NN	O
after	IN	O
the	DT	O
second	JJ	O
dose	NN	O
of	IN	O
TIKOSYN	NNP	O
is	VBZ	O
given	VBN	O
the	DT	O
QTc	NNP	O
is	VBZ	O
greater	JJR	O
than	IN	O
500	CD	DOS
msec	NN	UNIT
(	(	O
550	CD	DOS
msec	NN	UNIT
in	IN	O
patients	NNS	WHO
with	IN	WHO
ventricular	JJ	WHO
conduction	NN	WHO
abnormalities	NNS	WHO
)	)	WHO
,	,	O
TIKOSYN	NNP	O
should	MD	O
be	VB	O
discontinued	VBN	O
.	.	O

The	DT	O
dose	NN	O
should	MD	O
not	RB	O
be	VB	O
increased	VBN	O
more	JJR	O
than	IN	O
twice	RB	O
in	IN	O
any	DT	O
cycle	NN	O
or	CC	O
by	IN	O
more	JJR	O
than	IN	O
one	CD	DOS
ampule	NN	UNIT
(	(	O
75	CD	DOS
IU	NNP	UNIT
)	)	O
per	IN	O
adjustment	NN	O
.	.	O

Evidence	NN	O
from	IN	O
controlled	VBN	O
trials	NNS	O
suggests	VBZ	O
that	IN	O
ZONEGRAN	NNP	O
doses	NNS	O
of	IN	O
100	CD	DOS
–	JJ	O
600	CD	DOS
mg	JJ	UNIT
/	JJ	FREQ
day	NN	FREQ
are	VBP	O
effective	JJ	O
,	,	O
but	CC	O
there	EX	O
is	VBZ	O
no	DT	O
suggestion	NN	O
of	IN	O
increasing	VBG	O
response	NN	O
above	IN	O
400	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
,	,	O
Clinical	NNP	O
Studies	NNP	O
)	)	O
.	.	O

In	IN	O
the	DT	O
event	NN	O
that	IN	O
a	DT	O
system	NN	O
should	MD	O
fall	VB	O
off	RP	O
,	,	O
the	DT	O
same	JJ	O
system	NN	O
may	MD	O
be	VB	O
reapplied	VBN	O
.	.	O

For	IN	O
other	JJ	O
cisplatin	JJ	O
dosage	NN	O
adjustments	NNS	O
,	,	O
also	RB	O
refer	VBP	O
to	TO	O
the	DT	O
manufacturers	NNS	O
'	POS	O
prescribing	VBG	O
information	NN	O
.	.	O

If	IN	O
patients	NNS	WHO
or	CC	WHO
caregivers	NNS	WHO
are	VBP	O
to	TO	O
administer	VB	O
NEUPOGEN	NNP	O
,	,	O
instruct	VB	O
them	PRP	O
in	IN	O
appropriate	JJ	O
injection	NN	O
technique	NN	O
and	CC	O
ask	VB	O
them	PRP	O
to	TO	O
follow	VB	O
the	DT	O
subcutaneous	JJ	O
injection	NN	O
procedures	NNS	O
in	IN	O
the	DT	O
Patient	NNP	O
Information	NNP	O
.	.	O

Discard	NNP	O
any	DT	O
unused	JJ	O
portion	NN	O
.	.	O

An	DT	O
infusion	NN	O
rate	NN	O
of	IN	O
11	CD	DOS
to	TO	O
13	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
(	(	O
range	NN	O
:	:	O
4.5	CD	O
to	TO	O
29.5	CD	O
)	)	O
should	MD	O
provide	VB	O
adequate	JJ	O
neuromuscular	JJ	O
block	NN	O
in	IN	O
adult	NN	WHO
patients	NNS	WHO
in	IN	WHO
an	DT	WHO
ICU	NNP	WHO
.	.	O

Propofol	NNP	O
injectable	JJ	O
emulsion	NN	O
is	VBZ	O
a	DT	O
single	JJ	DOS
-	:	O
use	NN	O
parenteral	JJ	O
product	NN	O
which	WDT	O
contains	VBZ	O
benzyl	NN	O
alcohol	NN	O
1.5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
and	CC	O
sodium	NN	O
benzoate	NN	O
0.7	CD	DOS
mg	NN	UNIT
/	NN	O
mL	NN	O
to	TO	O
inhibit	VB	O
the	DT	O
rate	NN	O
of	IN	O
growth	NN	O
of	IN	O
microorganisms	NNS	O
,	,	O
up	RB	O
to	TO	O
12	CD	O
hours	NNS	O
,	,	O
in	IN	O
the	DT	O
event	NN	O
of	IN	O
accidental	JJ	O
extrinsic	JJ	O
contamination	NN	O
.	.	O

The	DT	O
side	NN	O
effects	NNS	O
of	IN	O
irbesartan	NN	O
are	VBP	O
generally	RB	O
rare	JJ	O
and	CC	O
apparently	RB	O
independent	JJ	O
of	IN	O
dose	NN	O
;	:	O
those	DT	O
of	IN	O
hydrochlorothiazide	NN	O
are	VBP	O
a	DT	O
mixture	NN	O
of	IN	O
dose	JJ	O
-	:	O
dependent	NN	O
(	(	O
primarily	RB	O
hypokalemia	NN	O
)	)	O
and	CC	O
dose	JJ	O
-	:	O
independent	JJ	O
phenomena	NN	O
(	(	O
e.g	JJ	O
,	,	O
pancreatitis	NN	O
)	)	O
,	,	O
the	DT	O
former	JJ	O
much	RB	O
more	RBR	O
common	JJ	O
than	IN	O
the	DT	O
latter	NN	O
.	.	O

Bicarbonate	NNP	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
during	IN	O
infusion	NN	O
of	IN	O
the	DT	O
nutritional	JJ	O
solution	NN	O
unless	IN	O
deemed	VBN	O
absolutely	RB	O
necessary	JJ	O
.	.	O

In	IN	O
patients	NNS	WHO
who	WP	WHO
present	VBP	WHO
with	IN	WHO
eligible	JJ	WHO
lesions	NNS	WHO
in	IN	WHO
both	DT	WHO
eyes	NNS	WHO
,	,	O
physicians	NNS	O
should	MD	O
evaluate	VB	O
the	DT	O
potential	JJ	O
benefits	NNS	O
and	CC	O
risks	NNS	O
of	IN	O
treating	VBG	O
both	DT	O
eyes	NNS	O
concurrently	RB	O
.	.	O

For	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
<	VBP	WHO
16	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
weighing	VBG	WHO
<	$	WHO
70	CD	WHO
kg	NN	WHO
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
should	MD	O
be	VB	O
calculated	VBN	O
according	VBG	O
to	TO	O
patient	NN	O
body	NN	O
weight	VBD	O
as	IN	O
shown	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
[	NN	O
see	VB	O
Clinical	JJ	O
Studies	NNPS	O
]	NNP	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
NINLARO	NNP	O
Dose	NNP	O
Reductions	NNP	O
due	JJ	O
to	TO	O
Adverse	NNP	O
Reactions	NNP	O

Single	NNP	DOS
dose	NN	UNIT

Discontinue	NNP	O
all	DT	O
other	JJ	O
around	IN	O
-	:	O
the	DT	O
-	:	O
clock	NN	O
opioid	NN	O
drugs	NNS	O
when	WRB	O
PALLADONE	NNP	O
therapy	NN	O
is	VBZ	O
initiated	VBN	O
.	.	O

Angiomax	NNP	O
is	VBZ	O
intended	VBN	O
for	IN	O
use	NN	O
with	IN	O
aspirin	NN	O
(	(	O
300	CD	DOS
-	:	O
325	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
)	)	O
and	CC	O
has	VBZ	O
been	VBN	O
studied	VBN	O
only	RB	O
in	IN	O
patients	NNS	WHO
receiving	VBG	WHO
concomitant	JJ	WHO
aspirin	NN	WHO
.	.	O

The	DT	O
occurrence	NN	O
of	IN	O
involuntary	JJ	O
movements	NNS	O
may	MD	O
require	VB	O
dosage	NN	O
reduction	NN	O
.	.	O

Inspect	VB	O
the	DT	O
integrity	NN	O
of	IN	O
the	DT	O
RECOTHROM	NNP	O
package	NN	O
and	CC	O
contents	NNS	O
.	.	O

The	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
NutreStore™	NNP	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
beyond	IN	O
16	CD	PER
weeks	NNS	PER
of	IN	O
treatment	NN	O
.	.	O

The	DT	O
duration	NN	O
of	IN	O
therapy	NN	O
should	MD	O
be	VB	O
guided	VBN	O
by	IN	O
the	DT	O
severity	NN	O
and	CC	O
site	NN	O
of	IN	O
the	DT	O
infection	NN	O
and	CC	O
the	DT	O
patient	NN	O
's	POS	O
clinical	JJ	O
progress	NN	O
.	.	O

Both	DT	O
tests	NNS	O
should	MD	O
be	VB	O
read	VBN	O
and	CC	O
recorded	VBN	O
at	IN	O
48	CD	O
to	TO	O
72	CD	O
hours	NNS	O
.	.	O

Table	JJ	O
3	CD	O
:	:	O
Preparation	NN	O
of	IN	O
Teflaro	NNP	O
for	IN	O
Intravenous	NNP	O
Use	NNP	O

for	IN	O
3	CD	PER
days	NNS	PER
15	CD	DOS
mg	JJ	UNIT
t.i.d	NN	O
.	.	O

Mestinon	NNP	O
(	(	O
pyridostigmine	NN	O
)	)	O
is	VBZ	O
available	JJ	O
in	IN	O
three	CD	O
dosage	NN	O
forms	NNS	O
:	:	O

PEDIATRIC	NNP	O
INTRAMUSCULAR	NNP	O
DOSING	NN	O

When	WRB	O
serum	NN	O
creatinine	NN	O
is	VBZ	O
given	VBN	O
in	IN	O
μmol	NNP	O
/	NNP	O
L	NNP	O
,	,	O
divide	IN	O
the	DT	O
value	NN	O
by	IN	O
88.4	CD	DOS
(	(	O
1	CD	DOS
mg	NN	UNIT
/	NNP	O
dL	NN	O
=	VBD	O
88.4	CD	DOS
μmol	NNP	UNIT
/	NNP	O
L	NNP	O
)	)	O
.	.	O

At	IN	O
least	JJS	O
14	CD	O
days	NNS	O
should	MD	O
elapse	VB	O
between	IN	O
discontinuation	NN	O
of	IN	O
an	DT	O
MAOI	NNP	O
intended	VBD	O
to	TO	O
treat	VB	O
psychiatric	JJ	O
disorders	NNS	O
and	CC	O
initiation	NN	O
of	IN	O
therapy	NN	O
with	IN	O
NORPRAMIN	NNP	O
.	.	O

Take	VB	O
DUAVEE	NNP	O
once	RB	FREQ
daily	RB	FREQ
,	,	O
without	IN	O
regard	NN	O
to	TO	O
meals	NNS	O
.	.	O

(	(	O
see	VB	O
PRECAUTIONS	NNP	O
-	:	O
Pediatric	NNP	O
Use	NNP	O
)	)	O

Some	DT	O
countries	NNS	O
may	MD	O
require	VB	O
for	IN	O
entry	NN	O
evidence	NN	O
of	IN	O
a	DT	O
valid	JJ	O
yellow	NN	O
fever	NN	O
vaccination	NN	O
(	(	O
i.e	JJ	O
,	,	O
ICVP	NNP	O
)	)	O
within	IN	O
the	DT	O
previous	JJ	O
10	CD	O
years	NNS	O
for	IN	O
certain	JJ	O
individuals	NNS	O
,	,	O
depending	VBG	O
on	IN	O
prior	JJ	O
travel	NN	O
itinerary	NN	O
.	.	O

AMIODARONE	NNP	O
HCl	NNP	O
SOLUTION	NNP	O
STABILITY	NNP	O

Remove	VB	O
the	DT	O
needle	NN	O
used	VBN	O
to	TO	O
reconstitute	VB	O
the	DT	O
product	NN	O
and	CC	O
attach	VBP	O
an	DT	O
appropriately	RB	O
sized	JJ	O
new	JJ	O
sterile	JJ	O
needle	NN	O
.	.	O

The	DT	O
medication	NN	O
should	MD	O
not	RB	O
be	VB	O
dispensed	VBN	O
directly	RB	O
on	IN	O
the	DT	O
face	NN	O
.	.	O

Frozen	JJ	O
solutions	NNS	O
should	MD	O
only	RB	O
be	VB	O
thawed	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
.	.	O

Periostat®	NNP	O
(	(	O
doxycycline	JJ	O
hyclate	NN	O
)	)	O
20	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
as	IN	O
an	DT	O
adjunct	NN	O
following	VBG	O
scaling	NN	O
and	CC	O
root	NN	O
planing	NN	O
may	MD	O
be	VB	O
administered	VBN	O
for	IN	O
up	IN	PER
to	TO	PER
9	CD	PER
months	NNS	PER
.	.	O

Figure	NN	O
1	CD	O
.	.	O

Because	IN	O
elderly	JJ	WHO
patients	NNS	WHO
are	VBP	WHO
more	RBR	WHO
likely	JJ	WHO
to	TO	WHO
have	VB	WHO
decreased	VBN	WHO
renal	JJ	WHO
function	NN	WHO
,	,	O
care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
in	IN	O
dose	JJ	O
selection	NN	O
,	,	O
and	CC	O
it	PRP	O
may	MD	O
be	VB	O
useful	JJ	O
to	TO	O
monitor	VB	O
renal	JJ	O
function	NN	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
,	,	O
General	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
,	,	O
Geriatric	NNP	O
Use	NNP	O
)	)	O
.	.	O

Step	NN	O
8	CD	O
.	.	O

Medical	JJ	O
personnel	NNS	O
should	MD	O
monitor	VB	O
patients	NNS	O
for	IN	O
adverse	JJ	O
events	NNS	O
during	IN	O
and	CC	O
after	IN	O
infusion	NN	O
.	.	O

Information	NN	O
concerning	VBG	O
the	DT	O
insertion	NN	O
and	CC	O
removal	NN	O
of	IN	O
NEXPLANON	NNP	O
will	MD	O
be	VB	O
sent	VBN	O
upon	IN	O
request	JJS	O
free	JJ	O
of	IN	O
charge	NN	O
[	$	O
1	CD	O
-	:	O
877	CD	O
-	:	O
467	CD	O
-	:	O
5266	CD	O
]	NN	O
.	.	O

2	CD	WHO
to	TO	WHO
3	CD	WHO
years	NNS	WHO
:	:	O
3.75	CD	DOS
mL	NN	UNIT
to	TO	O
5	CD	DOS
mL	NN	UNIT
(	(	O
3	CD	DOS
to	TO	O
4	CD	DOS
mg	NN	UNIT
)	)	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Acetaminophen	NNP	O
levels	NNS	O
and	CC	O
ALT	NNP	O
/	NNP	O
AST	NNP	O
&	CC	O
INR	NNP	O
should	MD	O
be	VB	O
checked	VBN	O
before	IN	O
the	DT	O
end	NN	O
of	IN	O
the	DT	O
21	CD	O
-	:	O
hour	NN	O
infusion	NN	O
.	.	O

Pigmentation	NN	O
may	MD	O
begin	VB	O
after	IN	O
a	DT	O
few	JJ	O
weeks	NNS	PER
but	CC	O
significant	JJ	O
repigmentation	NN	O
may	MD	O
require	VB	O
6	CD	PER
to	TO	O
9	CD	PER
months	NNS	PER
of	IN	O
treatment	NN	O
.	.	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
to	TO	O
500	CD	DOS
micrograms	NNS	UNIT
(	(	O
2	CD	DOS
mL	NN	UNIT
)	)	O
if	IN	O
uterine	JJ	O
contractility	NN	O
is	VBZ	O
judged	VBN	O
to	TO	O
be	VB	O
inadequate	JJ	O
after	IN	O
several	JJ	O
doses	NNS	O
of	IN	O
250	CD	DOS
micrograms	NNS	UNIT
(	(	O
1	CD	DOS
mL	NN	UNIT
)	)	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
a	DT	O
single	JJ	DOS
parenteral	NN	UNIT
dose	VBD	UNIT
4	CD	FREQ
to	TO	O
7	CD	DOS
times	NNS	UNIT
the	DT	O
oral	JJ	O
daily	JJ	FREQ
dose	NN	O
may	MD	O
be	VB	O
expected	VBN	O
to	TO	O
control	VB	O
the	DT	O
patient	NN	O
from	IN	O
4	CD	PER
to	TO	O
7	CD	PER
days	NNS	PER
up	RB	O
to	TO	O
3	CD	PER
to	TO	O
4	CD	PER
weeks	NNS	PER
.	.	O

Complete	JJ	O
these	DT	O
steps	NNS	O
before	IN	O
applying	VBG	O
IONSYS	NNP	O
to	TO	O
the	DT	O
patient	NN	O
:	:	O

DO	NNP	O
NOT	NNP	O
USE	VB	O
IF	NNP	O
AMINOSYN	NNP	O
II	NNP	O
IS	NNP	O
DISCOLORED	NNP	O
OR	NNP	O
IF	NNP	O
CLAMP	NNP	O
IS	NNP	O
OPEN	NNP	O
OR	NNP	O
MISSING	NNP	O
.	.	O

Oral	JJ	O
anticoagulation	NN	O
therapy	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
by	IN	O
properly	RB	O
designed	VBN	O
clinical	JJ	O
trials	NNS	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
valvular	JJ	WHO
disease	NN	WHO
associated	VBN	WHO
with	IN	WHO
atrial	JJ	WHO
fibrillation	NN	WHO
,	,	WHO
patients	NNS	WHO
with	IN	WHO
mitral	JJ	WHO
stenosis	NN	WHO
,	,	O
and	CC	O
patients	NNS	WHO
with	IN	WHO
recurrent	JJ	WHO
systemic	JJ	WHO
embolism	NN	WHO
of	IN	O
unknown	JJ	O
etiology	NN	O
.	.	O

An	DT	O
applicator	NN	O
and	CC	O
its	PRP$	O
parts	NNS	O
are	VBP	O
shown	VBN	O
below	IN	O
(	(	O
Figures	NNS	O
1a	CD	O
and	CC	O
1b	CD	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
LUPRON	NNP	O
DEPOT	NNP	O
–	NNP	O
3	CD	DOS
Month	NNP	O
11.25	CD	DOS
mg	NN	UNIT
is	VBZ	O
one	CD	DOS
injection	NN	UNIT
.	.	O

The	DT	O
dosage	NN	O
recommended	VBD	O
for	IN	O
use	NN	O
in	IN	O
children	NNS	WHO
for	IN	O
excretory	NN	O
urography	NN	O
is	VBZ	O
1.2	CD	DOS
mL	NN	UNIT
/	NN	O
kg	NN	O
to	TO	O
3.6	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	NN	O
for	IN	O
ISOVUE	NNP	O
-	:	O
250	CD	DOS
and	CC	O
1.0	CD	DOS
mL	NN	UNIT
/	NN	O
kg	NN	O
to	TO	O
3.0	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	NN	O
for	IN	O
ISOVUE	NNP	O
-	:	O
300	CD	O
.	.	O

The	DT	O
bias	NN	O
may	MD	O
depend	VB	O
upon	IN	O
the	DT	O
specific	JJ	O
assay	NN	O
and	CC	O
laboratory	NN	O
.	.	O

The	DT	O
patient	NN	O
should	MD	O
stop	VB	O
using	VBG	O
ELIDEL	NNP	O
Cream	NNP	O
,	,	O
1	CD	O
%	NN	O
when	WRB	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
(	(	O
e.g	NN	O
,	,	O
itch	NN	O
,	,	O
rash	NN	O
and	CC	O
redness	NN	O
)	)	O
resolve	NN	O
and	CC	O
should	MD	O
be	VB	O
instructed	VBN	O
on	IN	O
what	WP	O
actions	NNS	O
to	TO	O
take	VB	O
if	IN	O
symptoms	NNS	O
recur	VBP	O
.	.	O

If	IN	O
no	DT	O
response	NN	O
is	VBZ	O
obtained	VBN	O
by	IN	O
then	RB	O
,	,	O
continued	JJ	O
administration	NN	O
is	VBZ	O
unlikely	JJ	O
to	TO	O
help	VB	O
.	.	O

Carefully	RB	O
consider	VB	O
the	DT	O
potential	JJ	O
benefits	NNS	O
and	CC	O
risks	NNS	O
of	IN	O
TOLECTIN	NNP	O
(	(	O
tolmetin	JJ	O
sodium	NN	O
)	)	O
and	CC	O
other	JJ	O
treatment	NN	O
options	NNS	O
before	IN	O
deciding	VBG	O
to	TO	O
use	VB	O
TOLECTIN	NNP	O
(	(	O
tolmetin	JJ	O
sodium	NN	O
)	)	O
.	.	O

Caution	NN	O
:	:	O
Do	NNP	O
not	RB	O
mix	VB	O
or	CC	O
reconstitute	VB	O
EMEND	NNP	O
for	IN	O
injection	NN	O
with	IN	O
solutions	NNS	O
for	IN	O
which	WDT	O
physical	JJ	O
and	CC	O
chemical	JJ	O
compatibility	NN	O
have	VBP	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	O

Unused	JJ	O
portions	NNS	O
of	IN	O
each	DT	O
ampule	NN	O
should	MD	O
be	VB	O
discarded	VBN	O
properly	RB	O
.	.	O

The	DT	O
usual	JJ	O
starting	NN	O
dosage	NN	O
is	VBZ	O
50	CD	DOS
-	:	O
75	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

Use	NNP	O
in	IN	O
Epidural	NNP	O
Anesthesia	NNP	O
:	:	O
During	IN	O
epidural	JJ	O
administration	NN	O
of	IN	O
MARCAINE	NNP	O
,	,	O
0.5	CD	O
%	NN	O
and	CC	O
0.75	CD	O
%	NN	O
solutions	NNS	O
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
incremental	JJ	O
doses	NNS	O
of	IN	O
3	CD	DOS
mL	NNS	UNIT
to	TO	O
5	CD	DOS
mL	NN	UNIT
with	IN	O
sufficient	JJ	O
time	NN	O
between	IN	O
doses	NNS	O
to	TO	O
detect	VB	O
toxic	JJ	O
manifestations	NNS	O
of	IN	O
unintentional	JJ	O
intravascular	NN	O
or	CC	O
intrathecal	JJ	O
injection	NN	O
.	.	O

In	IN	O
the	DT	O
controlled	JJ	O
clinical	JJ	O
trials	NNS	O
,	,	O
400	CD	DOS
mg	NN	UNIT
3	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
showed	VBD	O
limited	JJ	O
evidence	NN	O
of	IN	O
additional	JJ	O
improvement	NN	O
in	IN	O
seizure	NN	O
reduction	NN	O
,	,	O
but	CC	O
an	DT	O
increase	NN	O
in	IN	O
adverse	JJ	O
events	NNS	O
and	CC	O
discontinuations	NNS	O
,	,	O
compared	VBN	O
to	TO	O
the	DT	O
300	CD	DOS
mg	NN	UNIT
3	CD	FREQ
times	NNS	FREQ
daily	JJ	FREQ
dosage	NN	O
.	.	O

Occasionally	RB	O
tolerance	NN	O
may	MD	O
occur	VB	O
,	,	O
usually	RB	O
between	IN	O
the	DT	O
second	JJ	O
and	CC	O
third	JJ	O
month	NN	O
of	IN	O
therapy	NN	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
a	DT	O
DEXILANT	NNP	O
capsule	NN	O
or	CC	O
DEXILANT	NNP	O
SoluTab	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	O
Child	NNP	O
-	:	O
Pugh	NNP	O
Class	NNP	O
C	NNP	O
)	)	O
[	NNP	O
see	VBP	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

In	IN	O
instances	NNS	O
where	WRB	O
vaccines	NNS	O
are	VBP	O
given	VBN	O
concomitantly	RB	O
,	,	O
administer	JJ	O
injections	NNS	O
using	VBG	O
separate	JJ	O
syringes	NNS	O
at	IN	O
separate	JJ	O
sites	NNS	O
.	.	O

Some	DT	O
of	IN	O
the	DT	O
factors	NNS	O
to	TO	O
be	VB	O
considered	VBN	O
in	IN	O
determining	VBG	O
the	DT	O
dose	NN	O
are	VBP	O
age	NN	O
,	,	O
body	NN	O
weight	NN	O
,	,	O
physical	JJ	O
status	NN	O
,	,	O
underlying	VBG	O
pathological	JJ	O
condition	NN	O
,	,	O
use	NN	O
of	IN	O
other	JJ	O
drugs	NNS	O
,	,	O
type	NN	O
of	IN	O
anesthesia	NN	O
to	TO	O
be	VB	O
used	VBN	O
and	CC	O
the	DT	O
surgical	JJ	O
procedure	NN	O
involved	VBN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Incremental	JJ	O
Adjustment	NNP	O
(	(	O
mL	NN	O
)	)	O
*	NN	O
of	IN	O
the	DT	O
Hizentra	NNP	O
Dose†	NNP	O
Based	VBD	O
on	IN	O
the	DT	O
Difference	NNP	O
(	(	O
±mg	JJ	O
/	NNP	O
dL	NN	O
)	)	O
from	IN	O
the	DT	O
Target	NNP	O
Serum	NNP	O
IgG	NNP	O
Trough	NNP	O
Level	NNP	O

Manufactured	VBN	O
for	IN	O
:	:	O
Endo	NNP	O
Pharmaceuticals	NNP	O
Inc.	NNP	O
,	,	O
Malvern	NNP	O
,	,	O
PA	NNP	O
19355	CD	O
,	,	O
www.endo.com	NN	O
or	CC	O
call	VB	O
1	CD	O
-	:	O
800	CD	O
-	:	O
462	CD	O
-	:	O
3636	CD	O
OPANA®	NNP	O
is	VBZ	O
a	DT	O
registered	JJ	O
trademark	NN	O
of	IN	O
Endo	NNP	O
Pharmaceuticals	NNP	O
Inc.	NNP	O
Revised	VBD	O
:	:	O
April	NNP	O
2014	CD	O

Failure	NN	O
to	TO	O
take	VB	O
Accutane	NNP	O
(	(	O
isotretinoin	NN	O
)	)	O
with	IN	O
food	NN	O
will	MD	O
significantly	RB	O
decrease	VB	O
absorption	NN	O
.	.	O

Although	IN	O
optimal	JJ	O
dosage	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
,	,	O
doses	VBZ	O
utilized	VBN	O
in	IN	O
reported	JJ	O
clinical	JJ	O
data	NNS	O
were	VBD	O
1	CD	DOS
to	TO	O
4	CD	DOS
g	NNS	UNIT
daily	RB	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

The	DT	O
injection	NN	O
should	MD	O
be	VB	O
given	VBN	O
on	IN	O
the	DT	O
same	JJ	FREQ
day	NN	FREQ
every	DT	FREQ
week	NN	FREQ
,	,	O
but	CC	O
if	IN	O
a	DT	O
dose	NN	O
is	VBZ	O
missed	VBN	O
,	,	O
the	DT	O
injection	NN	O
should	MD	O
be	VB	O
given	VBN	O
at	IN	PER
least	JJS	PER
3	CD	PER
days	NNS	PER
from	IN	O
the	DT	O
next	JJ	O
weekly	JJ	FREQ
dose	NN	O
.	.	O

To	TO	O
discontinue	VB	O
use	NN	O
of	IN	O
IONSYS	NNP	O
,	,	O
remove	VB	O
and	CC	O
dispose	VB	O
of	IN	O
IONSYS	NNP	O
according	VBG	O
to	TO	O
the	DT	O
preceding	VBG	O
directions	NNS	O
.	.	O

Although	IN	O
the	DT	O
maximum	JJ	O
tolerated	JJ	O
dose	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
determined	VBN	O
,	,	O
clinical	JJ	O
experience	NN	O
suggests	VBZ	O
that	IN	O
a	DT	O
total	JJ	O
dose	JJ	O
beyond	IN	O
60	CD	DOS
mg	NN	UNIT
is	VBZ	O
not	RB	O
needed	VBN	O
for	IN	O
any	DT	WHO
patient	NN	WHO
.	.	O

GRALISE	NNP	O
tablets	NNS	O
should	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
.	.	O

Prophylaxis	NNP	O
for	IN	O
neutropenic	JJ	O
infections	NNS	O
should	MD	O
be	VB	O
administered	VBN	O
.	.	O

If	IN	O
back	JJ	O
leakage	NN	O
occurs	NN	O
,	,	O
the	DT	O
hips	NNS	O
are	VBP	O
elevated	VBN	O
on	IN	O
pillows	NNS	O
or	CC	O
a	DT	O
knee	JJ	O
-	:	O
chest	JJS	O
position	NN	O
is	VBZ	O
taken	VBN	O
temporarily	RB	O
.	.	O

Continued	VBN	O
treatment	NN	O
up	RB	O
to	TO	O
4	CD	PER
weeks	NNS	PER
results	NNS	O
in	IN	O
greater	JJR	O
lesion	NN	O
reduction	NN	O
.	.	O

In	IN	O
case	NN	O
of	IN	O
severe	JJ	O
vomiting	VBG	O
or	CC	O
diarrhea	NN	O
,	,	O
absorption	NN	O
may	MD	O
not	RB	O
be	VB	O
complete	JJ	O
and	CC	O
additional	JJ	O
contraceptive	NN	O
measures	NNS	O
should	MD	O
be	VB	O
taken	VBN	O
.	.	O

In	IN	O
some	DT	WHO
cases	NNS	WHO
,	,	O
a	DT	O
patient	NN	O
already	RB	O
receiving	VBG	O
therapy	NN	O
with	IN	O
WELLBUTRIN	NNP	O
SR	NNP	O
may	MD	O
require	VB	O
urgent	JJ	O
treatment	NN	O
with	IN	O
linezolid	JJ	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	NN	O
.	.	O

IC	NNP	O
-	:	O
GREEN™	NNP	O
also	RB	O
has	VBZ	O
the	DT	O
property	NN	O
of	IN	O
being	VBG	O
nearly	RB	O
98	CD	O
%	NN	O
bound	NN	O
to	TO	O
blood	NN	O
protein	NN	O
,	,	O
and	CC	O
therefore	RB	O
,	,	O
excessive	JJ	O
dye	NN	O
extravasation	NN	O
does	VBZ	O
not	RB	O
take	VB	O
place	NN	O
in	IN	O
the	DT	O
highly	RB	O
fenestrated	VBN	O
choroidal	JJ	O
vasculature	NN	O
.	.	O

After	IN	O
combining	VBG	O
contents	NNS	O
of	IN	O
the	DT	O
two	CD	O
vials	NNS	O
,	,	O
a	DT	O
specified	JJ	O
volume	NN	O
of	IN	O
INFUVITE	NNP	O
PEDIATRIC	NNP	O
is	VBZ	O
added	VBN	O
to	TO	O
intravenous	JJ	O
fluids	NNS	O
prior	RB	O
to	TO	O
intravenous	JJ	O
administration	NN	O
[	NNP	O
see	VBP	O
Preparation	NNP	O
And	CC	O
Administration	NNP	O
Instructions	NNP	O
]	NNP	O
.	.	O

Didronel	NNP	O
therapy	NN	O
should	MD	O
begin	VB	O
as	RB	O
soon	RB	O
as	IN	O
medically	RB	O
feasible	JJ	O
following	VBG	O
the	DT	O
injury	NN	O
,	,	O
preferably	RB	O
prior	RB	O
to	TO	O
evidence	NN	O
of	IN	O
heterotopic	NN	O
ossification	NN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	JJ	O
dosage	NN	O
is	VBZ	O
0.1	CD	DOS
mg	NN	UNIT
/	NN	O
kg	VBD	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
not	RB	O
to	TO	O
exceed	VB	O
1.5	CD	DOS
-	:	O
3	CD	DOS
mg	NN	UNIT
per	IN	O
dose	NN	O
based	VBN	O
upon	IN	O
weight	NN	O
.	.	O

Medication	NN	O
errors	NNS	O
associated	VBN	O
with	IN	O
CEREBYX	NNP	O
have	VBP	O
resulted	VBN	O
in	IN	O
patients	NNS	WHO
receiving	VBG	WHO
the	DT	WHO
wrong	JJ	WHO
dose	NN	O
of	IN	O
fosphenytoin	NN	O
.	.	O

IMPORTANT	NN	O
:	:	O
Allow	VB	O
the	DT	O
product	NN	O
to	TO	O
reach	VB	O
room	NN	O
temperature	NN	O
before	IN	O
mixing	NN	O
.	.	O

Interrupt	NNP	O
ODOMZO	NNP	O
for	IN	O

Care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
avoid	VB	O
use	NN	O
by	IN	O
the	DT	O
intracavitary	JJ	O
route	NN	O
when	WRB	O
other	JJ	O
agents	NNS	O
which	WDT	O
may	MD	O
suppress	VB	O
bone	NN	O
marrow	NN	O
function	NN	O
are	VBP	O
being	VBG	O
used	VBN	O
systemically	RB	O
.	.	O

After	IN	O
instillation	NN	O
of	IN	O
each	DT	O
quarter	NN	O
-	:	O
dose	NN	O
,	,	O
remove	VB	O
the	DT	O
dosing	VBG	O
catheter	NN	O
from	IN	O
the	DT	O
endotracheal	NN	O
tube	NN	O
and	CC	O
ventilate	VB	O
the	DT	O
infant	NN	WHO
for	IN	O
at	IN	O
least	JJS	O
30	CD	O
seconds	NNS	O
or	CC	O
until	IN	O
stable	JJ	O
.	.	O

No	DT	O
change	NN	O
in	IN	O
the	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
Korlym	NNP	O
is	VBZ	O
required	VBN	O
in	IN	O
mild	NN	O
to	TO	O
moderate	VB	O
hepatic	JJ	O
impairment	NN	O
.	.	O

The	DT	O
site	NN	O
should	MD	O
stop	VB	O
bleeding	NN	O
in	IN	O
a	DT	O
minute	NN	O
or	CC	O
two	CD	O
.	.	O

Based	VBN	O
on	IN	O
the	DT	O
randomized	JJ	O
clinical	JJ	O
study	NN	O
,	,	O
acceptable	JJ	O
light	JJ	O
intensity	NN	O
for	IN	O
the	DT	O
balloon	NN	O
/	NNP	O
diffuser	NN	O
combinations	NNS	O
range	VBP	O
from	IN	O
200	CD	DOS
-	:	O
270	CD	DOS
mW	NN	UNIT
/	NNP	O
cm	NN	O
of	IN	O
diffuser	NN	O
length	NN	O
.	.	O

Edarbi	NN	O
may	MD	O
be	VB	O
taken	VBN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
[	NNS	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Withhold	NNP	O
or	CC	O
dose	VB	O
-	:	O
reduce	VB	O
Tasigna	NNP	O
for	IN	O
hematological	JJ	O
toxicities	NNS	O
(	(	O
neutropenia	NN	O
,	,	O
thrombocytopenia	NN	O
)	)	O
that	WDT	O
are	VBP	O
not	RB	O
related	VBN	O
to	TO	O
underlying	VBG	O
leukemia	NN	O
(	(	O
Table	JJ	O
2	CD	O
)	)	O
.	.	O

DO	NNP	O
NOT	NNP	O
INJECT	NNP	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NN	O

The	DT	O
therapeutic	JJ	O
dose	NN	O
may	MD	O
also	RB	O
be	VB	O
derived	VBN	O
by	IN	O
using	VBG	O
the	DT	O
GlaxoSmithKline	NNP	O
BEXXAR	NNP	O
therapeutic	JJ	O
regimen	NNS	O
Patient	NNP	O
Management	NNP	O
Templates	NNP	O
(	(	O
refer	VBP	O
to	TO	O
the	DT	O
Site	NNP	O
Training	NNP	O
Manual	NNP	O
)	)	O
.	.	O

Dosages	NNS	O
over	IN	O
200	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

After	IN	O
removing	VBG	O
the	DT	O
overwrap	NN	O
,	,	O
check	NN	O
for	IN	O
minute	NN	O
leaks	NNS	O
by	IN	O
squeezing	VBG	O
the	DT	O
container	NN	O
firmly	RB	O
.	.	O

Treatment	NNP	O
-	:	O
naive	JJ	WHO
patients	NNS	WHO
with	IN	WHO
end	JJ	WHO
stage	NN	WHO
renal	JJ	WHO
disease	NN	WHO
managed	VBD	WHO
with	IN	WHO
hemodialysis	NN	WHO
should	MD	O
receive	VB	O
REYATAZ	NNP	O
300	CD	DOS
mg	NN	UNIT
with	IN	O
ritonavir	JJ	O
100	CD	DOS
mg.	NN	UNIT
REYATAZ	NNP	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
to	TO	O
HIV	NNP	O
-	:	O
treatmentexperienced	VBD	O
patients	NNS	WHO
with	IN	WHO
end	JJ	WHO
stage	NN	WHO
renal	JJ	WHO
disease	NN	WHO
managed	VBD	O
with	IN	O
hemodialysis	NN	O
.	.	O

Wait	NNP	O
at	IN	O
least	JJS	O
3	CD	O
hours	NNS	O
before	IN	O
giving	VBG	O
the	DT	O
next	JJ	O
dose	NN	O
;	:	O
a	DT	O
maximum	NN	O
of	IN	O
four	CD	DOS
doses	NNS	UNIT
may	MD	O
be	VB	O
given	VBN	O
in	IN	O
a	DT	O
12	CD	O
-	:	O
hour	NN	O
period	NN	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Dosage	NN	O
Adjustment	NN	O
for	IN	O
Patients	NNS	WHO
with	IN	WHO
Renal	NNP	WHO
Impairment	NNP	WHO

In	IN	O
cases	NNS	O
of	IN	O
normal	JJ	O
bilateral	JJ	O
tubal	NN	O
patency	NN	O
,	,	O
the	DT	O
pressure	NN	O
falls	VBZ	O
immediately	RB	O
to	TO	O
below	IN	O
60	CD	O
mm	NN	O
Hg	NNP	O
.	.	O

Daily	JJ	FREQ
dosage	NN	O
above	IN	O
60	CD	DOS
mg	NN	UNIT
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

Initiate	NNP	O
treatment	NN	O
with	IN	O
a	DT	O
dose	NN	O
of	IN	O
1000	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
given	VBN	O
as	IN	O
twice	RB	O
-	:	O
daily	JJ	FREQ
dosing	NN	O
(	(	O
500	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
)	)	O
.	.	O

Dosage	NN	O
may	MD	O
be	VB	O
titrated	VBN	O
to	TO	O
the	DT	O
maximum	JJ	O
hemodynamic	JJ	O
effect	NN	O
and	CC	O
should	MD	O
not	RB	O
exceed	VB	O
1.13	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

Ritalin	NNP	O
should	MD	O
be	VB	O
periodically	RB	O
discontinued	VBN	O
to	TO	O
assess	VB	O
the	DT	O
child	NN	O
's	POS	O
condition	NN	O
.	.	O

Occlusive	JJ	O
dressings	NNS	O
may	MD	O
be	VB	O
a	DT	O
valuable	JJ	O
therapeutic	JJ	O
adjunct	NN	O
for	IN	O
the	DT	O
management	NN	O
of	IN	O
psoriasis	NN	O
or	CC	O
recalcitrant	JJ	O
conditions	NNS	O
.	.	O

regimen	NNS	O
of	IN	O
Tegretol	NNP	O
-	:	O
XR	NN	O
or	CC	O
a	DT	O
t.i.d	NN	O
.	.	O

Taper	NNP	O
and	CC	O
discontinue	VB	O
APLENZIN	NNP	O
in	IN	O
early	JJ	O
spring	NN	O
.	.	O

(	(	O
see	VB	O
PRECAUTIONS	NNP	O
.	.	O
)	)	O

An	DT	O
initial	JJ	O
Cleviprex	NNP	O
infusion	NN	O
rate	NN	O
of	IN	O
1	CD	DOS
-	:	O
2	CD	DOS
mg	NN	UNIT
/	FW	O
hour	NN	O
is	VBZ	O
appropriate	JJ	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Up	RB	O
to	TO	O
two	CD	DOS
repeat	NN	UNIT
doses	NNS	UNIT
of	IN	O
1.25	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	JJ	O
birth	NN	O
weight	VBD	O
each	DT	O
may	MD	O
be	VB	O
administered	VBN	O
at	IN	O
approximately	RB	O
12	CD	O
-	:	O
hour	NN	O
intervals	NNS	O
in	IN	O
infants	NNS	WHO
who	WP	WHO
remain	VBP	WHO
intubated	JJ	WHO
and	CC	WHO
in	IN	WHO
whom	WP	WHO
RDS	NNP	WHO
is	VBZ	O
considered	VBN	O
responsible	JJ	O
for	IN	O
their	PRP$	O
persisting	NN	O
or	CC	O
deteriorating	VBG	O
respiratory	JJ	O
status	NN	O
.	.	O

RHOFADE	NNP	O
is	VBZ	O
not	RB	O
for	IN	O
oral	JJ	O
,	,	O
ophthalmic	JJ	O
,	,	O
or	CC	O
intravaginal	JJ	O
use	NN	O
.	.	O

Limited	VBN	O
data	NNS	O
available	JJ	O
from	IN	O
long	JJ	O
-	:	O
term	NN	O
studies	NNS	O
in	IN	O
adults	NNS	WHO
indicate	VBP	O
that	IN	O
the	DT	O
initial	JJ	O
clinical	JJ	O
improvement	NN	O
is	VBZ	O
maintained	VBN	O
for	IN	O
at	IN	WHO
least	JJS	WHO
two	CD	WHO
years	NNS	WHO
with	IN	WHO
continued	JJ	WHO
therapy	NN	WHO
.	.	O

Draw	VB	O
a	DT	O
single	JJ	DOS
patient	NN	UNIT
dose	NN	UNIT
of	IN	O
DYSPORT®	NNP	O
into	IN	O
a	DT	O
sterile	JJ	O
syringe	NN	O
.	.	O

Table	JJ	O
4	CD	O
summarizes	VBZ	O
the	DT	O
recommended	JJ	O
daily	JJ	FREQ
dosing	VBG	O
regimen	NNS	O
for	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
14	CD	WHO
days	NNS	WHO
to	TO	WHO
6	CD	WHO
months	NNS	WHO
.	.	O

<	RB	O
1	CD	O
wk	NN	O
of	IN	O
age	NN	O
:	:	O
25	CD	DOS
mg	NN	UNIT
/	NN	O
kg	NN	O
every	DT	O
12	CD	O
hrs	NN	O
1	CD	O
-	:	O
4	CD	O
wks	NN	O
of	IN	O
age	NN	O
:	:	O
25	CD	DOS
mg	NN	UNIT
/	NN	O
kg	NN	O
every	DT	FREQ
8	CD	FREQ
hrs	NN	O
4	CD	O
wks	NN	O
-	:	O
3	CD	O
mos	NN	O
.	.	O

Use	NNP	O
minimum	JJ	O
effective	JJ	O
dose	NN	O
for	IN	O
the	DT	O
individual	JJ	O
patient	NN	O

The	DT	O
maximum	NN	O
recommended	VBD	O
daily	RB	FREQ
dose	JJ	O
is	VBZ	O
60	CD	DOS
mL	NN	UNIT
(	(	O
960	CD	DOS
mg	RB	UNIT
trimethoprim	JJ	UNIT
)	)	O
per	IN	FREQ
day	NN	FREQ
.	.	O

Use	NNP	O
of	IN	O
a	DT	O
final	JJ	O
filter	NN	O
is	VBZ	O
recommended	VBN	O
during	IN	O
administration	NN	O
of	IN	O
all	DT	O
parenteral	JJ	O
solutions	NNS	O
,	,	O
where	WRB	O
possible	JJ	O
.	.	O

Close	JJ	O
monitoring	NN	O
is	VBZ	O
of	IN	O
particular	JJ	O
importance	NN	O
when	WRB	O
converting	VBG	O
from	IN	O
methadone	NN	O
to	TO	O
other	JJ	O
opioid	JJ	O
agonists	NNS	O
.	.	O

Adjust	IN	O
the	DT	O
dose	NN	O
to	TO	O
obtain	VB	O
an	DT	O
appropriate	JJ	O
balance	NN	O
between	IN	O
management	NN	O
of	IN	O
pain	NN	O
and	CC	O
opioid	JJ	O
-	:	O
related	JJ	O
adverse	JJ	O
reactions	NNS	O
.	.	O

It	PRP	O
is	VBZ	O
supplied	VBN	O
in	IN	O
a	DT	O
5.0	CD	DOS
mL	NN	UNIT
syringe	NN	O
containing	VBG	O
4.0	CD	DOS
mL	NN	UNIT
of	IN	O
Monovisc™	NNP	O
The	DT	O
contents	NNS	O
of	IN	O
the	DT	O
syringe	NN	O
are	VBP	O
sterile	JJ	O
,	,	O
non	JJ	O
-	:	O
pyrogenic	NN	O
and	CC	O
non	JJ	O
-	:	O
inflammatory	NN	O
.	.	O

Consequently	RB	O
,	,	O
no	DT	O
dosage	NN	O
adjustment	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

4	CD	O
.	.	O

VIOKACE	NNP	O
is	VBZ	O
not	RB	O
interchangeable	JJ	O
with	IN	O
any	DT	O
other	JJ	O
pancrelipase	NN	O
product	NN	O
.	.	O

Each	DT	O
vial	NN	O
of	IN	O
Revonto	NNP	O
(	(	O
dantrolene	JJ	O
sodium	NN	O
for	IN	O
injection	NN	O
)	)	O
should	MD	O
be	VB	O
reconstituted	VBN	O
by	IN	O
adding	VBG	O
60	CD	DOS
mL	NN	UNIT
of	IN	O
sterile	JJ	O
water	NN	O
for	IN	O
injection	NN	O
USP	NNP	O
(	(	O
without	IN	O
a	DT	O
bacteriostatic	JJ	O
agent	NN	O
)	)	O
,	,	O
and	CC	O
the	DT	O
vial	JJ	O
shaken	NN	O
for	IN	O
approximately	RB	O
20	CD	O
seconds	NNS	O
or	CC	O
until	IN	O
the	DT	O
solution	NN	O
is	VBZ	O
clear	JJ	O
.	.	O

Concomitant	JJ	O
administration	NN	O
of	IN	O
ALTACE	NNP	O
(	(	O
ramipril	JJ	O
capsules	NNS	O
)	)	O
with	IN	O
potassium	NN	O
supplements	NNS	O
,	,	O
potassium	NN	O
salt	NN	O
substitutes	NNS	O
,	,	O
or	CC	O
potassium	NN	O
-	:	O
sparing	VBG	O
diuretics	NNS	O
can	MD	O
lead	VB	O
to	TO	O
increases	NNS	O
of	IN	O
serum	JJ	O
potassium	NN	O
.	.	O

Inject	VB	O
the	DT	O
correct	JJ	O
amount	NN	O
of	IN	O
dye	NN	O
into	IN	O
the	DT	O
lumen	NNS	O
of	IN	O
an	DT	O
arm	NN	O
vein	NN	O
as	RB	O
rapidly	RB	O
as	IN	O
possible	JJ	O
,	,	O
without	IN	O
allowing	VBG	O
the	DT	O
dye	NN	O
to	TO	O
escape	VB	O
outside	IN	O
the	DT	O
vein	NN	O
.	.	O

Do	NNP	O
not	RB	O
abruptly	RB	O
discontinue	VBP	O
ARYMO	NNP	O
ER	NNP	O
.	.	O

A	DT	O
BMI	NNP	O
conversion	NN	O
chart	NN	O
(	(	O
Table	JJ	O
1	CD	O
)	)	O
based	VBN	O
on	IN	O
height	JJ	O
[	NN	O
inches	NNS	O
(	(	O
in	IN	O
)	)	O
or	CC	O
centimeters	NNS	O
(	(	O
cm	NN	O
)	)	O
]	NN	O
and	CC	O
weight	NN	O
[	NN	O
pounds	NNS	O
(	(	O
lb	NN	O
)	)	O
or	CC	O
kilograms	NNS	O
(	(	O
kg	NN	O
)	)	O
]	NN	O
is	VBZ	O
provided	VBN	O
below	IN	O
.	.	O

Significant	JJ	O
amounts	NNS	O
of	IN	O
fentanyl	NN	O
continue	NN	O
to	TO	O
be	VB	O
absorbed	VBN	O
from	IN	O
the	DT	O
skin	NN	O
for	IN	O
24	CD	PER
hours	NNS	PER
or	CC	O
more	JJR	O
after	IN	O
the	DT	O
patch	NN	O
is	VBZ	O
removed	VBN	O
[	JJ	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Breakthrough	IN	O
bleeding	NN	O
,	,	O
spotting	NN	O
,	,	O
and	CC	O
amenorrhea	NNS	O
are	VBP	O
frequent	JJ	O
reasons	NNS	O
for	IN	O
patients	NNS	WHO
discontinuing	VBG	WHO
oral	JJ	WHO
contraceptives	NNS	WHO
.	.	O

Sevoflurane	NN	O
can	MD	O
be	VB	O
administered	VBN	O
with	IN	O
any	DT	O
type	NN	O
of	IN	O
anesthesia	NN	O
circuit	NN	O
.	.	O

With	IN	O
discontinuation	NN	O
of	IN	O
RENOVA	NNP	O
(	(	O
tretinoin	JJ	O
emollient	NN	O
cream	NN	O
0.05	CD	O
%	NN	O
)	)	O
0.05	CD	O
%	NN	O
therapy	NN	O
,	,	O
a	DT	O
majority	NN	WHO
of	IN	WHO
patients	NNS	WHO
will	MD	O
lose	VB	O
most	RBS	O
mitigating	JJ	O
effects	NNS	O
of	IN	O
RENOVA	NNP	O
(	(	O
tretinoin	JJ	O
emollient	NN	O
cream	NN	O
0.05	CD	O
%	NN	O
)	)	O
0.05	CD	O
%	NN	O
on	IN	O
fine	JJ	O
wrinkles	NNS	O
,	,	O
mottled	VBN	O
hyperpigmentation	NN	O
,	,	O
and	CC	O
tactile	JJ	O
roughness	NN	O
of	IN	O
facial	JJ	O
skin	NN	O
;	:	O
however	RB	O
,	,	O
the	DT	O
safety	NN	O
and	CC	O
effectiveness	NN	O
of	IN	O
using	VBG	O
RENOVA	NNP	O
(	(	O
tretinoin	JJ	O
emollient	NN	O
cream	NN	O
0.05	CD	O
%	NN	O
)	)	O
0.05	CD	O
%	NN	O
daily	NN	FREQ
for	IN	O
greater	JJR	O
than	IN	O
48	CD	PER
weeks	NNS	PER
have	VBP	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	O

When	WRB	O
converting	VBG	O
from	IN	O
PRADAXA	NNP	O
to	TO	O
warfarin	VB	O
,	,	O
adjust	VB	O
the	DT	O
starting	JJ	O
time	NN	O
of	IN	O
warfarin	NNS	O
based	VBN	O
on	IN	O
creatinine	JJ	O
clearance	NN	O
as	IN	O
follows	VBZ	O
:	:	O

The	DT	O
intravenous	JJ	O
line	NN	O
should	MD	O
be	VB	O
flushed	VBN	O
before	IN	O
and	CC	O
after	IN	O
administration	NN	O
of	IN	O
PROTONIX	NNP	O
I.V	NNP	O
.	.	O

Table	JJ	O
6	CD	O
.	.	O

Follow	NNP	O
applicable	JJ	O
special	JJ	O
handling	NN	O
and	CC	O
disposal	NN	O
procedures.1	NN	O

Pharmacokinetic	NNP	O
data	NNS	O
indicate	VBP	O
that	IN	O
perindoprilat	JJ	O
elimination	NN	O
is	VBZ	O
decreased	VBN	O
in	IN	O
renally	RB	O
impaired	JJ	O
patients	NNS	O
.	.	O

In	IN	O
bone	NN	O
and	CC	O
joint	JJ	O
infections	NNS	O
,	,	O
150	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
(	(	O
not	RB	O
to	TO	O
exceed	VB	O
the	DT	O
maximum	JJ	WHO
adult	NN	WHO
dosage	NN	WHO
)	)	O
is	VBZ	O
recommended	VBN	O
in	IN	O
equally	RB	O
divided	JJ	O
doses	NNS	O
every	DT	FREQ
8	CD	FREQ
hours	NNS	FREQ
.	.	O

3	CD	O
.	.	O

Children	NNP	WHO
(	(	WHO
2	CD	WHO
-	:	WHO
18	CD	WHO
years	NNS	WHO
)	)	WHO
:	:	O
The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ProHance	NNP	O
is	VBZ	O
0.1	CD	DOS
mmol	NN	UNIT
/	NN	O
kg	NN	O
(	(	O
0.2	CD	DOS
mL	NN	UNIT
/	NNP	O
kg	NN	O
)	)	O
administered	VBD	O
as	IN	O
a	DT	O
rapid	JJ	O
intravenous	JJ	O
infusion	NN	O
(	(	O
10	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NNP	O
-	:	O
60	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
or	CC	O
bolus	NN	O
(	(	O
>	JJ	O
60	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
.	.	O

Failure	NN	O
of	IN	O
the	DT	O
infection	NN	O
to	TO	O
respond	VB	O
may	MD	O
be	VB	O
due	JJ	O
to	TO	O
resistance	NN	O
of	IN	O
the	DT	O
organism	NN	O
or	CC	O
to	TO	O
the	DT	O
presence	NN	O
of	IN	O
septic	JJ	O
foci	NN	O
requiring	VBG	O
surgical	JJ	O
drainage	NN	O
.	.	O

PREPARING	VBG	O
THE	DT	O
INJECTION	NN	O

Patients	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
closely	RB	O
for	IN	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
hypoglycemia	NN	O
following	VBG	O
such	JJ	O
a	DT	O
switch	NN	O
and	CC	O
the	DT	O
dose	NN	O
of	IN	O
GLUCOVANCE	NNP	O
should	MD	O
be	VB	O
titrated	VBN	O
as	IN	O
described	VBN	O
above	IN	O
to	TO	O
achieve	VB	O
adequate	JJ	O
control	NN	O
of	IN	O
blood	NN	O
glucose	NN	O
.	.	O

EVOTAZ	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
any	DT	WHO
degree	NN	WHO
of	IN	O
hepatic	JJ	O
impairment	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
,	,	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Avoid	NNP	O
cleansing	VBG	O
with	IN	O
hydrogen	NN	O
peroxide	JJ	O
solution	NN	O
as	IN	O
it	PRP	O
may	MD	O
inactivate	VB	O
the	DT	O
papain	NN	O
.	.	O

SUBOXONE	NNP	O
sublingual	JJ	O
film	NN	O
is	VBZ	O
subject	JJ	O
to	TO	O
diversion	NN	O
and	CC	O
abuse	NN	O
.	.	O

The	DT	O
tablet	NN	O
should	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
.	.	O

Or	CC	O

Doses	NNS	O
in	IN	O
excess	NN	O
of	IN	O
20	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	JJ	FREQ
day	NN	FREQ
are	VBP	O
not	RB	O
recommended	VBN	O
.	.	O

Before	IN	O
prescribing	VBG	O
COMBIVIR	NNP	O
tablets	NNS	O
,	,	O
children	NNS	O
should	MD	O
be	VB	O
assessed	VBN	O
for	IN	O
the	DT	O
ability	NN	O
to	TO	O
swallow	VB	O
tablets	NNS	O
.	.	O

In	IN	O
a	DT	O
patient	NN	WHO
who	WP	WHO
requires	VBZ	WHO
more	JJR	WHO
urgent	JJ	WHO
treatment	NN	WHO
of	IN	WHO
a	DT	WHO
psychiatric	JJ	WHO
condition	NN	WHO
,	,	O
other	JJ	O
interventions	NNS	O
,	,	O
including	VBG	O
hospitalization	NN	O
,	,	O
should	MD	O
be	VB	O
considered	VBN	O
(	(	O
see	VB	O
CONTRAINDICATIONS	NNP	O
)	)	O
.	.	O

Use	VB	O
it	PRP	O
only	RB	O
if	IN	O
it	PRP	O
is	VBZ	O
clear	JJ	O
and	CC	O
colorless	NN	O
.	.	O

The	DT	O
following	JJ	O
volumes	NNS	O
per	IN	O
injection	NN	O
,	,	O
have	VBP	O
been	VBN	O
used	VBN	O
,	,	O
and	CC	O
may	MD	O
be	VB	O
repeated	VBN	O
as	IN	O
necessary	JJ	O
:	:	O

In	IN	O
-	:	O
line	NN	O
filters	NNS	O
must	MD	O
not	RB	O
be	VB	O
used	VBN	O
when	WRB	O
administering	VBG	O
DepoCyt	NNP	O
.	.	O

Clinical	NNP	O
data	NNS	O
indicate	VBP	O
effects	NNS	O
of	IN	O
GILENYA	NNP	O
on	IN	O
heart	NN	O
rate	NN	O
are	VBP	O
maximal	VBN	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
although	IN	O
milder	NN	O
effects	NNS	O
on	IN	O
heart	NN	O
rate	NN	O
may	MD	O
persist	VB	O
for	IN	O
,	,	O
on	IN	O
average	NN	O
,	,	O
2	CD	PER
to	TO	O
4	CD	PER
weeks	NNS	PER
after	IN	O
initiation	NN	O
of	IN	O
therapy	NN	O
at	IN	O
which	WDT	O
time	NN	O
heart	NN	O
rate	NN	O
generally	RB	O
returns	VBZ	O
to	TO	O
baseline	VB	O
.	.	O

Use	NNP	O
Table	JJ	O
1	CD	O
to	TO	O
calculate	VB	O
the	DT	O
decay	NN	O
factor	NN	O
for	IN	O
Rb	NNP	O
-	:	O
82	CD	O
;	:	O
step	NN	O
4	CD	O
(	(	O
above	IN	O
)	)	O
.	.	O

The	DT	O
use	NN	O
of	IN	O
anticholinergic	JJ	O
drugs	NNS	O
is	VBZ	O
a	DT	O
matter	NN	O
of	IN	O
choice	NN	O
.	.	O

For	IN	O
prophylaxis	NN	O
of	IN	O
nausea	NN	O
and	CC	O
vomiting	NN	O
,	,	O
as	IN	O
during	IN	O
surgery	NN	O
and	CC	O
the	DT	O
postoperative	JJ	O
period	NN	O
,	,	O
the	DT	O
average	NN	O
dose	NN	O
is	VBZ	O
25	CD	DOS
mg	NN	UNIT
repeated	VBN	O
at	IN	O
4	CD	O
-	:	O
to	TO	O
6	CD	O
-	:	O
hour	NN	O
intervals	NNS	O
,	,	O
as	IN	O
necessary	JJ	O
.	.	O

Rinsing	VBG	O
the	DT	O
mouth	NN	O
after	IN	O
inhalation	NN	O
is	VBZ	O
advised	VBN	O
.	.	O

Studies	NNS	O
show	VBP	O
that	IN	O
peripheral	JJ	O
dopa	NN	O
decarboxylase	NN	O
is	VBZ	O
saturated	VBN	O
by	IN	O
carbidopa	NN	O
at	IN	O
approximately	RB	O
70	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
to	TO	O
100	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

If	IN	O
the	DT	O
ACT	NNP	O
is	VBZ	O
greater	JJR	O
than	IN	O
450	CD	O
seconds	NNS	O
,	,	O
decrease	VB	O
the	DT	O
infusion	NN	O
rate	NN	O
to	TO	O
15	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
,	,	O
and	CC	O
check	VB	O
the	DT	O
ACT	NNP	O
5	CD	O
to	TO	O
10	CD	O
minutes	NNS	O
later	RB	O
(	(	O
Table	JJ	O
3	CD	O
)	)	O
.	.	O

These	DT	O
doses	NNS	O
may	MD	O
be	VB	O
repeated	VBN	O
as	IN	O
necessary	JJ	O
.	.	O

METADATE	NNP	O
ER	NNP	O
Tablets	NNP	O
must	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
and	CC	O
never	RB	O
crushed	VBD	O
or	CC	O
chewed	VBD	O
.	.	O

An	DT	O
AVOSTARTGRIP™	NNP	O
kit	NN	O
containing	VBG	O
3	CD	O
titration	NN	O
devices	NNS	O
can	MD	O
be	VB	O
used	VBN	O
for	IN	O
titration	NN	O
and	CC	O
is	VBZ	O
to	TO	O
be	VB	O
used	VBN	O
only	RB	O
with	IN	O
AVONEX	NNP	O
Prefilled	NNP	O
Syringes	NNP	O
.	.	O

Used	VBN	O
needles	NNS	O
,	,	O
or	CC	O
lancets	NNS	O
should	MD	O
be	VB	O
placed	VBN	O
in	IN	O
sharps	JJ	O
containers	NNS	O
(	(	O
such	JJ	O
as	IN	O
red	JJ	O
biohazard	IN	O
containers	NNS	O
)	)	O
,	,	O
hard	JJ	O
plastic	NN	O
containers	NNS	O
(	(	O
such	JJ	O
as	IN	O
detergent	JJ	O
bottles	NNS	O
)	)	O
,	,	O
or	CC	O
metal	NN	O
containers	NNS	O
(	(	O
such	JJ	O
as	IN	O
an	DT	O
empty	JJ	O
coffee	NN	O
can	MD	O
)	)	O
.	.	O

After	IN	O
shaking	VBG	O
,	,	O
the	DT	O
vaccine	NN	O
is	VBZ	O
a	DT	O
homogeneous	JJ	O
white	JJ	O
suspension	NN	O
.	.	O

For	IN	O
a	DT	O
child	NN	WHO
aged	VBD	WHO
1	CD	WHO
month	NN	WHO
,	,	O
the	DT	O
starting	VBG	O
dose	NN	O
should	MD	O
be	VB	O
multiplied	VBN	O
by	IN	O
0.68	CD	O
;	:	O
the	DT	O
initial	JJ	O
starting	NN	O
dose	NN	O
would	MD	O
be	VB	O
(	(	O
30	CD	O
X	NNP	O
0.68	CD	O
)	)	O
=20	NN	O
mg	NN	UNIT
/	NNP	O
m²	NN	O
,	,	O
administered	VBD	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

In	IN	O
HCV	NNP	O
genotype	NN	O
1	CD	O
,	,	O
interferon	SYM	O
-	:	O
alfa	NN	O
-	:	O
naïve	NN	O
patients	NNS	O
receiving	VBG	O
PegIntron	NNP	O
in	IN	O
combination	NN	O
with	IN	O
ribavirin	NN	O
,	,	O
discontinuation	NN	O
of	IN	O
therapy	NN	O
is	VBZ	O
recommended	VBN	O
if	IN	O
there	EX	O
is	VBZ	O
not	RB	O
at	IN	O
least	JJS	O
a	DT	O
2	CD	O
log10	JJ	O
drop	NN	O
or	CC	O
loss	NN	O
of	IN	O
HCV	NNP	O
-	:	O
RNA	NN	O
at	IN	O
12	CD	PER
weeks	NNS	PER
of	IN	O
therapy	NN	O
,	,	O
or	CC	O
if	IN	O
HCV	NNP	O
-	:	O
RNA	NN	O
levels	NNS	O
remain	VBP	O
detectable	JJ	O
after	IN	O
24	CD	PER
weeks	NNS	PER
of	IN	O
therapy	NN	O
.	.	O

Lamprene	NNP	O
(	(	O
clofazimine	NN	O
)	)	O
should	MD	O
be	VB	O
used	VBN	O
preferably	RB	O
in	IN	O
combination	NN	O
with	IN	O
one	CD	DOS
or	CC	O
more	JJR	O
other	JJ	O
antileprosy	JJ	O
agents	NNS	O
to	TO	O
prevent	VB	O
the	DT	O
emergence	NN	O
of	IN	O
drug	NN	O
resistance	NN	O
.	.	O

Fludeoxyglucose	NNP	O
F	NNP	O
18	CD	O
Injection	NNP	O
(	(	O
fdg	NN	O
)	)	O
,	,	O
like	IN	O
other	JJ	O
radioactive	JJ	O
drugs	NNS	O
,	,	O
must	MD	O
be	VB	O
handled	VBN	O
with	IN	O
care	NN	O
and	CC	O
appropriate	JJ	O
safety	NN	O
measures	NNS	O
should	MD	O
be	VB	O
used	VBN	O
to	TO	O
minimize	VB	O
radiation	NN	O
exposure	NN	O
to	TO	O
clinical	JJ	O
personnel	NNS	O
.	.	O

No	DT	O
dosage	NN	O
adjustment	NN	O
is	VBZ	O
necessary	JJ	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
.	.	O

The	DT	O
dose	JJ	O
-	:	O
dependent	JJ	O
side	NN	O
effects	NNS	O
of	IN	O
verapamil	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
decreased	VBN	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
trandolapril	NN	O
nor	CC	O
vice	NN	O
versa	NN	O
.	.	O

If	IN	O
a	DT	O
sequential	JJ	O
mode	NN	O
of	IN	O
administration	NN	O
is	VBZ	O
preferred	VBN	O
,	,	O
patients	NNS	O
should	MD	O
follow	VB	O
the	DT	O
same	JJ	O
manner	NN	O
of	IN	O
dosing	VBG	O
with	IN	O
continued	JJ	O
use	NN	O
of	IN	O
the	DT	O
product	NN	O
,	,	O
to	TO	O
ensure	VB	O
consistency	NN	O
in	IN	O
bioavailability	NN	O
.	.	O

After	IN	O
one	CD	PER
or	CC	O
two	CD	PER
weeks	NNS	PER
the	DT	O
drug	NN	O
should	MD	O
be	VB	O
withdrawn	VBN	O
to	TO	O
determine	VB	O
the	DT	O
continued	JJ	O
need	NN	O
for	IN	O
it	PRP	O
.	.	O

One	CD	DOS
full	JJ	UNIT
applicator	NN	UNIT
(	(	O
5	CD	DOS
g	NN	UNIT
)	)	O
of	IN	O
TERAZOL®	NNP	O
7	CD	O
Vaginal	NNP	O
Cream	NNP	O
(	(	O
20	CD	DOS
mg	RB	UNIT
terconazole	NN	UNIT
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
intravaginally	RB	O
once	RB	FREQ
daily	JJ	FREQ
at	IN	O
bedtime	NN	O
for	IN	O
seven	CD	PER
consecutive	JJ	PER
days	NNS	PER
.	.	O

The	DT	O
usual	JJ	O
dosage	NN	O
is	VBZ	O
250	CD	DOS
mg	NN	UNIT
every	DT	FREQ
6	CD	FREQ
hours	NNS	FREQ
;	:	O
or	CC	O
500	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

The	DT	O
contents	NNS	O
of	IN	O
the	DT	O
entire	JJ	O
capsule	NN	O
should	MD	O
be	VB	O
taken	VBN	O
,	,	O
and	CC	O
patients	NNS	O
should	MD	O
not	RB	O
take	VB	O
anything	NN	O
less	JJR	O
than	IN	O
one	CD	DOS
capsule	NN	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

Primary	JJ	O
immunization	NN	O
for	IN	O
adults	NNS	WHO
consists	NNS	WHO
of	IN	O
a	DT	O
single	JJ	DOS
1	CD	DOS
-	:	O
mL	NN	O
dose	NN	O
and	CC	O
a	DT	O
1	CD	DOS
-	:	O
mL	NN	O
booster	NN	O
dose	NN	O
administered	VBD	O
anytime	RB	O
between	IN	O
6	CD	PER
and	CC	O
12	CD	PER
months	NNS	PER
later	RB	O
.	.	O

Instill	NNP	O
1	CD	DOS
drop	NN	UNIT
every	DT	O
5	CD	O
to	TO	O
10	CD	O
minutes	NNS	O
for	IN	O
5	CD	DOS
to	TO	O
7	CD	DOS
doses	NNS	UNIT
.	.	O

IMPORTANT	NN	O
:	:	O
Be	VB	O
careful	JJ	O
not	RB	O
to	TO	O
over	IN	O
twist	VB	O
the	DT	O
syringe	NN	O
.	.	O

To	TO	O
avoid	VB	O
confusion	NN	O
between	IN	O
prepared	JJ	O
doses	NNS	O
of	IN	O
ORLAAM	NNP	O
(	(	O
levomethadyl	JJ	O
acetate	NN	O
)	)	O
and	CC	O
methadone	NN	O
,	,	O
the	DT	O
liquid	NN	O
used	VBN	O
to	TO	O
dilute	VB	O
ORLAAM	NNP	O
(	(	O
levomethadyl	JJ	O
acetate	NN	O
)	)	O
should	MD	O
be	VB	O
a	DT	O
different	JJ	O
color	NN	O
from	IN	O
that	DT	O
used	VBN	O
to	TO	O
dilute	VB	O
methadone	NN	O
in	IN	O
any	DT	O
specific	JJ	O
clinic	JJ	O
setting	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Dose	JJ	O
Adjustment	NNP	O
in	IN	O
Congestive	NNP	O
Heart	NNP	O
Failure	NNP	O
Post	NNP	O
-	:	O
MI	NN	O

Continuous	JJ	O
Combined	VBN	O
Regimen	NNS	O

For	IN	O
single	JJ	O
-	:	O
use	NN	O
ophthalmic	JJ	O
intravitreal	NN	O
injection	NN	O
only	RB	O
.	.	O

Depakote	NNP	O
ER	NNP	O
(	(	O
divalproex	JJ	O
sodium	NN	O
)	)	O
extended	VBD	O
release	NN	O
tablets	NNS	O
are	VBP	O
administered	VBN	O
orally	RB	O
,	,	O
and	CC	O
must	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
.	.	O

The	DT	O
recommended	JJ	FREQ
daily	JJ	FREQ
dose	NN	O
of	IN	O
CABOMETYX	NNP	O
is	VBZ	O
60	CD	DOS
mg.	NN	UNIT
Do	NNP	O
not	RB	O
administer	VB	O
CABOMETYX	NNP	O
with	IN	O
food	NN	O
.	.	O

For	IN	O
comprehensive	JJ	O
patient	NN	O
monitoring	NN	O
recommendations	NNS	O
for	IN	O
other	JJ	O
antiretroviral	JJ	O
therapies	NNS	O
,	,	O
physicians	NNS	O
should	MD	O
refer	VB	O
to	TO	O
the	DT	O
complete	JJ	O
product	NN	O
information	NN	O
for	IN	O
these	DT	O
drugs	NNS	O
.	.	O

Recommended	JJ	O
evaluations	NNS	O
include	VBP	O
cystoscopy	NN	O
,	,	O
biop	SYM	O
-	:	O
sy	NN	O
,	,	O
and	CC	O
urine	JJ	O
cytology	NN	O
every	DT	FREQ
3	CD	FREQ
months	NNS	FREQ
.	.	O

The	DT	O
majority	NN	O
of	IN	O
patients	NNS	O
will	MD	O
experience	VB	O
some	DT	O
decrease	NN	O
in	IN	O
renal	JJ	O
function	NN	O
due	JJ	O
to	TO	O
FOSCAVIR	NNP	O
administration	NN	O
.	.	O

In	IN	O
the	DT	O
elderly	JJ	O
,	,	O
greater	JJR	O
dosage	NN	O
reductions	NNS	O
than	IN	O
expected	VBN	O
may	MD	O
be	VB	O
necessary	JJ	O
because	IN	O
of	IN	O
decreased	JJ	O
renal	JJ	O
function	NN	O
.	.	O

Directions	NNS	O
For	IN	O
Use	NN	O
:	:	O
Intramuscular	JJ	O
Administration	NN	O
:	:	O
Reconstitute	NNP	O
Rocephin	NNP	O
powder	NN	O
with	IN	O
the	DT	O
appropriate	JJ	O
diluent	NN	O
(	(	O
see	VB	O
Compatibility	NNP	O
And	CC	O
Stability	NNP	O
)	)	O
.	.	O

The	DT	O
larger	JJR	O
doses	NNS	O
may	MD	O
be	VB	O
required	VBN	O
for	IN	O
short	JJ	O
-	:	O
term	NN	O
management	NN	O
of	IN	O
severe	JJ	O
,	,	O
acute	JJ	O
conditions	NNS	O
.	.	O

The	DT	O
dose	NN	O
should	MD	O
be	VB	O
increased	VBN	O
daily	RB	FREQ
in	IN	O
increments	NNS	O
of	IN	O
25	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
-	:	O
50	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
to	TO	O
an	DT	O
effective	JJ	O
dose	NN	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
clinical	JJ	O
response	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

Table	JJ	O
1	CD	O
presents	NNS	O
the	DT	O
units	NNS	O
insulin	VBP	O
glargine	NN	O
and	CC	O
the	DT	O
micrograms	NNS	O
of	IN	O
lixisenatide	NN	O
in	IN	O
each	DT	O
dosage	NN	O
of	IN	O
SOLIQUA	NNP	O
100	CD	O
/	NN	O
33	CD	O
.	.	O

Apply	NNP	O
Solagé	NNP	O
to	TO	O
the	DT	O
solar	JJ	O
lentigines	NNS	O
using	VBG	O
the	DT	O
applicator	NN	O
tip	NN	O
while	IN	O
avoiding	VBG	O
application	NN	O
to	TO	O
the	DT	O
surrounding	VBG	O
skin	NN	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
mild	JJ	WHO
hepatic	JJ	WHO
insufficiency	NN	WHO
do	VBP	O
not	RB	O
require	VB	O
dosage	NN	O
reductions	NNS	O
.	.	O

Children	NNS	WHO
:	:	O
Pediatric	JJ	O
requirements	NNS	O
for	IN	O
Aminosyn	NNP	O
-	:	O
RF	VBD	O
5.2	CD	O
%	NN	O
vary	JJ	O
greatly	RB	O
depending	VBG	O
upon	IN	O
growth	NN	O
,	,	O
nutritional	JJ	O
state	NN	O
and	CC	O
degree	NN	O
of	IN	O
renal	JJ	O
insufficiency	NN	O
.	.	O

Duration	NN	O
of	IN	O
treatment	NN	O
should	MD	O
be	VB	O
dictated	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
clinical	JJ	O
and	CC	O
microbiological	JJ	O
response	NN	O
.	.	O

Careful	JJ	O
and	CC	O
continuous	JJ	O
follow	NN	O
-	:	O
up	IN	O
of	IN	O
the	DT	O
patient	NN	O
while	IN	O
in	IN	O
the	DT	O
self	NN	O
-	:	O
injection	NN	O
program	NN	O
must	MD	O
be	VB	O
exercised	VBN	O
.	.	O

For	IN	O
cystic	JJ	O
fibrosis	NN	O
patients	NNS	O
,	,	O
typical	JJ	O
doses	NNS	O
are	VBP	O
1,500	CD	DOS
-	:	O
3,000	CD	O
USP	NNP	O
lipase	VBD	O
units	NNS	O
/	NNP	O
kg	NN	O
/	NNP	O
meal	NN	O
.	.	O

Constitute	VB	O
the	DT	O
500	CD	DOS
mg	NN	UNIT
,	,	O
1	CD	DOS
g	NN	UNIT
,	,	O
or	CC	O
2	CD	DOS
g	JJ	UNIT
vial	NN	UNIT
,	,	O
and	CC	O
add	VB	O
an	DT	O
appropriate	JJ	O
quantity	NN	O
of	IN	O
the	DT	O
resulting	VBG	O
solution	NN	O
to	TO	O
an	DT	O
intravenous	JJ	O
container	NN	O
with	IN	O
one	CD	O
of	IN	O
the	DT	O
compatible	JJ	O
intravenous	JJ	O
fluids	NNS	O
listed	VBN	O
in	IN	O
the	DT	O
Compatibility	NNP	O
and	CC	O
Stability	NNP	O
subsection	NN	O
.	.	O

It	PRP	O
is	VBZ	O
not	RB	O
compatible	JJ	O
with	IN	O
protein	JJ	O
hydrolysate	NN	O
,	,	O
ascorbic	JJ	O
acid	NN	O
,	,	O
or	CC	O
any	DT	O
solution	NN	O
with	IN	O
an	DT	O
acid	JJ	O
pH	NN	O
.	.	O

The	DT	O
unused	JJ	O
portion	NN	O
of	IN	O
diluted	JJ	O
Quelicin	NNP	O
should	MD	O
be	VB	O
discarded	VBN	O
.	.	O

Creatinine	JJ	O
clearance	NN	O
is	VBZ	O
difficult	JJ	O
to	TO	O
measure	VB	O
in	IN	O
outpatients	NNS	O
.	.	O

Figure	NN	O
1	CD	O
:	:	O
Applied	VBN	O
Transdermal	NNP	O
System	NNP	O

Closely	RB	O
monitor	JJ	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
for	IN	O
respiratory	NN	O
and	CC	O
central	JJ	O
nervous	JJ	O
system	NN	O
depression	NN	O
during	IN	O
initiation	NN	O
of	IN	O
therapy	NN	O
with	IN	O
PALLADONE	NNP	O
and	CC	O
during	IN	O
dose	JJ	O
titration	NN	O
.	.	O

External	JJ	O
cardiac	JJ	O
massage	NN	O
should	MD	O
follow	VB	O
intracardial	JJ	O
administration	NN	O
to	TO	O
permit	VB	O
the	DT	O
drug	NN	O
to	TO	O
enter	VB	O
coronary	JJ	O
circulation	NN	O
.	.	O

If	IN	O
suspended	VBN	O
,	,	O
the	DT	O
drug	NN	O
should	MD	O
be	VB	O
restarted	VBN	O
at	IN	O
a	DT	O
dose	NN	O
that	WDT	O
is	VBZ	O
1	CD	DOS
mcg	NN	UNIT
lower	JJR	O
.	.	O

In	IN	O
renally	RB	O
impaired	JJ	O
subjects	NNS	O
(	(	O
creatinine	JJ	O
clearance	NN	O
less	JJR	O
than	IN	O
70	CD	DOS
mL	JJ	UNIT
/	NNP	O
min	NN	O
/	VBD	O
1.73	CD	O
m²	NN	O
)	)	O
,	,	O
one	CD	O
-	:	O
half	NN	O
of	IN	O
the	DT	O
usual	JJ	O
adult	NN	WHO
dose	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

If	IN	O
there	EX	O
is	VBZ	O
no	DT	O
response	NN	O
,	,	O
then	RB	O
the	DT	O
next	JJ	O
higher	JJR	O
dose	NN	O
may	MD	O
be	VB	O
given	VBN	O
within	IN	O
1	CD	O
hour	NN	O
.	.	O

If	IN	O
AT	NNP	O
activity	NN	O
level	NN	O
is	VBZ	O
below	IN	O
80	CD	O
%	NN	O
,	,	O
an	DT	O
additional	JJ	O
bolus	NN	O
dose	NN	O
may	MD	O
be	VB	O
administered	VBN	O
to	TO	O
rapidly	RB	O
restore	VB	O
decreased	JJ	O
AT	NNP	O
activity	NN	O
level	NN	O
.	.	O

A	DT	O
dose	JJ	O
range	NN	O
of	IN	O
20	CD	DOS
to	TO	O
60	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
is	VBZ	O
recommended	VBN	O
.	.	O

An	DT	O
alternate	NN	O
rough	NN	O
guide	NN	O
for	IN	O
determining	VBG	O
reduced	JJ	O
dosage	NN	O
at	IN	O
12	CD	PER
-	:	O
hours	NNS	O
intervals	NNS	O
(	(	O
for	IN	O
patients	NNS	WHO
whose	WP$	WHO
steady	JJ	WHO
state	NN	WHO
serum	NN	WHO
creatinine	NN	WHO
values	NNS	WHO
are	VBP	WHO
known	VBN	WHO
)	)	WHO
is	VBZ	O
to	TO	O
divide	VB	O
the	DT	O
normally	RB	O
recommended	VBN	O
dose	NN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
serum	JJ	O
creatinine	NN	O
.	.	O

Repeat	NN	O
,	,	O
if	IN	O
necessary	JJ	O
,	,	O
for	IN	O
the	DT	O
opposite	JJ	O
ear	NN	O
.	.	O

Sterile	JJ	O
gloves	NNS	O
are	VBP	O
recommended	VBN	O
while	IN	O
injecting	VBG	O
Perlane	NNP	O
-	:	O
L	NN	O
.	.	O

The	DT	O
pellets	NNS	O
/	VBP	O
applesauce	JJ	O
mixture	NN	O
should	MD	O
not	RB	O
be	VB	O
stored	VBN	O
for	IN	O
future	JJ	O
use	NN	O
.	.	O

Complete	JJ	O
information	NN	O
is	VBZ	O
not	RB	O
available	JJ	O
.	.	O

40	CD	DOS

For	IN	O
patients	NNS	WHO
with	IN	WHO
asthma	NNS	WHO
aged	VBN	WHO
4	CD	WHO
to	TO	WHO
11	CD	WHO
years	NNS	WHO
who	WP	WHO
are	VBP	WHO
not	RB	WHO
controlled	VBN	WHO
on	IN	WHO
an	DT	WHO
inhaled	JJ	WHO
corticosteroid	NN	WHO
,	,	O
the	DT	O
dosage	NN	O
is	VBZ	O
1	CD	DOS
inhalation	NN	UNIT
of	IN	O
ADVAIR	NNP	O
DISKUS	NNP	O
100	CD	O
/	VBD	O
50	CD	O
twice	RB	FREQ
daily	RB	FREQ
,	,	O
approximately	RB	O
12	CD	O
hours	NNS	O
apart	RB	O
.	.	O

For	IN	O
this	DT	O
reason	NN	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
the	DT	O
drug	NN	O
be	VB	O
given	VBN	O
no	DT	O
more	RBR	O
frequently	RB	O
than	IN	O
once	RB	FREQ
every	DT	FREQ
7	CD	FREQ
days	NNS	FREQ
.	.	O

2	CD	O
.	.	O

Use	NNP	O
sodium	NN	O
phosphate	NN	O
if	IN	O
adding	VBG	O
phosphate	NN	O
to	TO	O
bag	VB	O
.	.	O

Dissolve	VB	O
the	DT	O
contents	NNS	O
of	IN	O
one	CD	DOS
ampule	NN	UNIT
of	IN	O
Metrodin®	NNP	O
(	(	O
urofollitropin	NN	O
for	IN	O
injection	NN	O
)	)	O
in	IN	O
one	CD	DOS
to	TO	O
two	CD	DOS
mL	NN	UNIT
of	IN	O
sterile	JJ	O
saline	NN	O
and	CC	O
ADMINISTER	NNP	O
INTRAMUSCULARLY	NNP	O
immediately	RB	O
.	.	O

Patients	NNS	O
receiving	VBG	O
the	DT	O
highest	JJS	O
dose	NN	O
of	IN	O
XOPENEX	NNP	O
Inhalation	NNP	O
Solution	NNP	O
should	MD	O
be	VB	O
monitored	VBN	O
closely	RB	O
for	IN	O
adverse	JJ	O
systemic	JJ	O
effects	NNS	O
,	,	O
and	CC	O
the	DT	O
risks	NNS	O
of	IN	O
such	JJ	O
effects	NNS	O
should	MD	O
be	VB	O
balanced	VBN	O
against	IN	O
the	DT	O
potential	NN	O
for	IN	O
improved	JJ	O
efficacy	NN	O
.	.	O

If	IN	O
CARDURA	NNP	O
XL	NNP	O
administration	NN	O
is	VBZ	O
discontinued	VBN	O
for	IN	O
several	JJ	O
days	NNS	PER
,	,	O
therapy	NN	O
should	MD	O
be	VB	O
restarted	VBN	O
using	VBG	O
the	DT	O
4	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
dose	NN	O
.	.	O

Generally	RB	O
,	,	O
little	JJ	O
is	VBZ	O
accomplished	VBN	O
if	IN	O
PROTOPAM	NNP	O
(	(	O
pralidoxime	JJ	O
chloride	NN	O
)	)	O
is	VBZ	O
given	VBN	O
more	JJR	O
than	IN	O
36	CD	O
hours	NNS	O
after	IN	O
termination	NN	O
of	IN	O
exposure	NN	O
to	TO	O
the	DT	O
poison	NN	O
.	.	O

Shake	NNP	O
each	DT	O
pre	NN	O
-	:	O
filled	VBN	O
syringe	NN	O
to	TO	O
aid	VB	O
inspection	NN	O
before	IN	O
administering	VBG	O
the	DT	O
vaccine	NN	O
and	CC	O
shake	VB	O
the	DT	O
multi	NN	O
-	:	O
dose	JJ	O
vial	JJ	O
each	DT	O
time	NN	O
before	IN	O
withdrawing	VBG	O
a	DT	O
dose	NN	O
of	IN	O
vaccine	NN	O
.	.	O

DO	NNP	O
NOT	NNP	O
FREEZE	NNP	O
.	.	O

Cordarone	NNP	O
I.V	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
oral	JJ	O
dose	NN	O
of	IN	O
INLYTA	NNP	O
is	VBZ	O
5	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Consider	VB	O
a	DT	O
starting	NN	O
dose	NN	O
of	IN	O
25	CD	DOS
mg	NNS	UNIT
in	IN	O
patients	NNS	WHO
>	JJ	WHO
65	CD	WHO
years	NNS	WHO
,	,	WHO
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	O
e.g	JJ	O
,	,	O
cirrhosis	NN	O
)	)	O
,	,	O
and	CC	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
creatinine	JJ	O
clearance	NN	O
<	VBD	O
30	CD	DOS
mL	NNS	UNIT
/	NNP	O
minute	NN	O
)	)	O
because	IN	O
administration	NN	O
of	IN	O
VIAGRA	NNP	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
resulted	VBD	O
in	IN	O
higher	JJR	O
plasma	NN	O
levels	NNS	O
of	IN	O
sildenafil	NN	O
[	NNP	O
see	NN	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

The	DT	O
decrease	NN	O
in	IN	O
dose	NN	O
of	IN	O
LAMICTAL	NNP	O
should	MD	O
not	RB	O
exceed	VB	O
25	CD	O
%	NN	O
of	IN	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
per	IN	O
week	NN	PER
over	IN	O
a	DT	O
2	CD	O
-	:	O
week	NN	PER
period	NN	O
,	,	O
unless	IN	O
clinical	JJ	O
response	NN	O
or	CC	O
lamotrigine	JJ	O
plasma	NN	O
levels	NNS	O
indicate	VBP	O
otherwise	RB	O
[	JJ	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

For	IN	O
all	DT	O
subsequent	JJ	O
cycles	NNS	O
,	,	O
the	DT	O
patient	NN	O
then	RB	O
begins	VBZ	O
a	DT	O
new	JJ	O
21	CD	O
-	:	O
tablet	NN	O
regimen	NNS	O
on	IN	O
the	DT	O
eighth	JJ	O
day	NN	O
,	,	O
Sunday	NNP	O
,	,	O
after	IN	O
taking	VBG	O
her	PRP$	O
last	JJ	O
tablet	NN	O
.	.	O

The	DT	O
following	JJ	O
dosage	NN	O
schedule	NN	O
for	IN	O
normal	JJ	WHO
adult	NN	WHO
joints	NNS	WHO
should	MD	O
serve	VB	O
only	RB	O
as	IN	O
a	DT	O
guide	NN	O
since	IN	O
joints	NNS	O
may	MD	O
require	VB	O
more	JJR	O
or	CC	O
less	RBR	O
contrast	JJ	O
medium	NN	O
for	IN	O
optimal	JJ	O
visualization	NN	O
.	.	O

Fig	NNP	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Guidelines	NNS	O
for	IN	O
Levoleucovorin	NNP	O
Injection	NNP	O
Dosage	NNP	O
and	CC	O
Administration	NNP	O

Administer	RB	O
with	IN	O
extreme	JJ	O
caution	NN	O
.	.	O

Reconstitute	NNP	O
immediately	RB	O
before	IN	O
use	NN	O
and	CC	O
use	NN	O
only	RB	O
once	RB	O
.	.	O

Lower	JJR	O
dosages	NNS	O
are	VBP	O
also	RB	O
recommended	VBN	O
for	IN	O
outpatients	NNS	O
as	IN	O
compared	VBN	O
to	TO	O
hospitalized	VBN	WHO
patients	NNS	WHO
who	WP	WHO
will	MD	WHO
be	VB	WHO
under	IN	WHO
close	JJ	WHO
supervision	NN	WHO
.	.	O

If	IN	O
the	DT	O
CYP3A4	NNP	O
inhibitor	NN	O
or	CC	O
CYP2D6	NNP	O
inhibitor	NN	O
is	VBZ	O
withdrawn	VBN	O
,	,	O
the	DT	O
ABILIFY	NNP	O
MAINTENA	NNP	O
dosage	NN	O
may	MD	O
need	VB	O
to	TO	O
be	VB	O
increased	VBN	O
[	NNP	O
see	VBP	O
Dosage	NNP	O
Overview	NNP	O
for	IN	O
the	DT	O
Treatment	NNP	O
of	IN	O
Schizophrenia	NNP	O
above	IN	O
]	NNP	O
.	.	O

(	(	O
See	VB	O
PRECAUTIONS	NNP	O
section	NN	O
for	IN	O
patients	NNS	WHO
at	IN	WHO
increased	VBN	WHO
risk	NN	WHO
.	.	O
)	)	O

Always	NNP	O
work	NN	O
on	IN	O
a	DT	O
clean	JJ	O
surface	NN	O
and	CC	O
wash	VB	O
your	PRP$	O
hands	NNS	O
before	IN	O
performing	VBG	O
the	DT	O
following	JJ	O
procedures	NNS	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
fluoxetine	NN	O
in	IN	O
combination	NN	O
with	IN	O
olanzapine	NN	O
was	VBD	O
determined	VBN	O
in	IN	O
clinical	JJ	O
trials	NNS	O
supporting	VBG	O
approval	NN	O
of	IN	O
Symbyax	NNP	O
(	(	O
fixed	VBN	O
-	:	O
dose	JJ	O
combination	NN	O
of	IN	O
olanzapine	NN	O
and	CC	O
fluoxetine	NN	O
)	)	O
.	.	O

The	DT	O
user	NN	O
can	MD	O
choose	VB	O
the	DT	O
insertion	NN	O
position	NN	O
that	WDT	O
is	VBZ	O
most	RBS	O
comfortable	JJ	O
to	TO	O
her	PRP$	O
,	,	O
for	IN	O
example	NN	O
,	,	O
standing	VBG	O
with	IN	O
one	CD	O
leg	NN	O
up	RB	O
,	,	O
squatting	VBG	O
,	,	O
or	CC	O
lying	VBG	O
down	RP	O
.	.	O

Dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
by	IN	O
one	CD	DOS
tablet	NN	UNIT
every	DT	FREQ
day	NN	FREQ
or	CC	O
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
,	,	O
as	IN	O
necessary	JJ	O
,	,	O
until	IN	O
a	DT	O
dosage	NN	O
of	IN	O
eight	CD	DOS
tablets	NNS	UNIT
of	IN	O
SINEMET	NNP	O
25	CD	O
-	:	O
100	CD	O
a	DT	O
day	NN	O
is	VBZ	O
reached	VBN	O
.	.	O

Esophageal	JJ	O
Candidiasis	NN	O

If	IN	O
the	DT	O
diuretic	NN	O
can	MD	O
not	RB	O
be	VB	O
discontinued	VBN	O
,	,	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
1.25	CD	DOS
mg	NNS	UNIT
ALTACE	NNP	O
(	(	O
ramipril	JJ	O
capsules	NNS	O
)	)	O
should	MD	O
be	VB	O
used	VBN	O
to	TO	O
avoid	VB	O
excess	JJ	O
hypotension	NN	O
.	.	O

FOSCAVIR	NNP	O
dosing	NN	O
must	MD	O
be	VB	O
individualized	VBN	O
according	VBG	O
to	TO	O
the	DT	O
patient	NN	O
’	NNP	O
s	VBD	O
renal	JJ	O
function	NN	O
status	NN	O
.	.	O

Digitalis	NNP	O
is	VBZ	O
not	RB	O
required	VBN	O
for	IN	O
MONOPRIL	NNP	O
(	(	O
fosinopril	JJ	O
sodium	NN	O
)	)	O
to	TO	O
manifest	JJS	O
improvements	NNS	O
in	IN	O
exercise	NN	O
tolerance	NN	O
and	CC	O
symptoms	NNS	O
.	.	O

Switching	VBG	O
from	IN	O
XARELTO	NNP	O
to	TO	O
Anticoagulants	NNP	O
other	JJ	O
than	IN	O
Warfarin	NNP	O
-	:	O
For	IN	O
patients	NNS	WHO
currently	RB	WHO
taking	VBG	WHO
XARELTO	NNP	WHO
and	CC	WHO
transitioning	VBG	WHO
to	TO	WHO
an	DT	WHO
anticoagulant	NN	WHO
with	IN	WHO
rapid	JJ	WHO
onset	NN	WHO
,	,	O
discontinue	NN	O
XARELTO	NNP	O
and	CC	O
give	VB	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
the	DT	O
other	JJ	O
anticoagulant	NN	O
(	(	O
oral	JJ	O
or	CC	O
parenteral	JJ	O
)	)	O
at	IN	O
the	DT	O
time	NN	O
that	IN	O
the	DT	O
next	JJ	O
XARELTO	NN	O
dose	NN	O
would	MD	O
have	VB	O
been	VBN	O
taken	VBN	O
[	JJ	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

In	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
insufficiency	NN	WHO
,	,	O
the	DT	O
dosage	NN	O
and	CC	O
frequency	NN	O
of	IN	O
dosage	NN	O
should	MD	O
be	VB	O
modified	VBN	O
consistent	JJ	O
with	IN	O
the	DT	O
recommendations	NNS	O
for	IN	O
adults	NNS	WHO
(	(	O
see	VB	O
Table	NNP	O
4	CD	O
)	)	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
once	RB	FREQ
daily	JJ	FREQ
dose	NN	O
is	VBZ	O
15	CD	DOS
mg.	NN	UNIT
Doses	NNS	O
above	IN	O
15	CD	DOS
mg	NN	UNIT
should	MD	O
ordinarily	RB	O
be	VB	O
divided	VBN	O
and	CC	O
given	VBN	O
before	IN	O
meals	NNS	O
of	IN	O
adequate	JJ	O
caloric	JJ	O
content	NN	O
.	.	O

READY	NNP	O
for	IN	O
Injection	NNP	O

For	IN	O
extended	VBN	O
therapy	NN	O
of	IN	O
more	JJR	O
than	IN	O
8	CD	DOS
cycles	NNS	UNIT
,	,	O
VELCADE	NNP	O
may	MD	O
be	VB	O
administered	VBN	O
on	IN	O
the	DT	O
standard	JJ	O
schedule	NN	O
or	CC	O
,	,	O
for	IN	O
relapsed	VBN	O
multiple	JJ	O
myeloma	NN	O
,	,	O
on	IN	O
a	DT	O
maintenance	NN	O
schedule	NN	O
of	IN	O
once	RB	FREQ
weekly	JJ	FREQ
for	IN	O
4	CD	PER
weeks	NNS	PER
(	(	O
Days	NNPS	O
1	CD	O
,	,	O
8	CD	O
,	,	O
15	CD	O
,	,	O
and	CC	O
22	CD	O
)	)	O
followed	VBN	O
by	IN	O
a	DT	O
13	CD	O
-	:	O
day	NN	O
rest	VB	O
period	NN	O
(	(	O
Days	VBZ	O
23	CD	O
to	TO	O
35	CD	O
)	)	O
[	NN	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

By	IN	O
:	:	O
Heritage	NN	O
Pharma	NNP	O
Labs	NNP	O
Inc.	NNP	O
,	,	O
East	NNP	O
Brunswick	NNP	O
,	,	O
NJ	NNP	O
08816	CD	O
USA	NNP	O
.	.	O

INFUVITE	NNP	O
ADULT	NNP	O
is	VBZ	O
a	DT	O
combination	NN	O
product	NN	O
that	WDT	O
contains	VBZ	O
the	DT	O
following	JJ	O
vitamins	NNS	O
:	:	O
ascorbic	JJ	O
acid	NN	O
,	,	O
vitamin	FW	O
A	NNP	O
,	,	O
vitamin	NN	O
D	NNP	O
,	,	O
thiamine	NN	O
,	,	O
riboflavin	NN	O
,	,	O
pyridoxine	NN	O
,	,	O
niacinamide	RB	O
,	,	O
dexpanthenol	NN	O
,	,	O
vitamin	NN	O
E	NNP	O
,	,	O
vitamin	NN	O
K1	NNP	O
,	,	O
folic	JJ	O
acid	NN	O
,	,	O
biotin	NN	O
,	,	O
and	CC	O
vitamin	NN	O
B12	NNP	O
.	.	O

These	DT	O
requirements	NNS	O
should	MD	O
be	VB	O
determined	VBN	O
frequently	RB	O
and	CC	O
appropriately	RB	O
administered	VBN	O
.	.	O

Figure	NN	O
2	CD	O
:	:	O
Do	NNP	O
NOT	NNP	O
pull	VB	O
in	IN	O
a	DT	O
downward	JJ	O
motion	NN	O
rolling	VBG	O
knuckles	NNS	O
over	IN	O
the	DT	O
pouch	JJ	O
.	.	O

These	DT	O
dose	JJ	O
relationships	NNS	O
apply	RB	O
only	RB	O
to	TO	O
oral	JJ	O
or	CC	O
intravenous	JJ	O
administration	NN	O
of	IN	O
these	DT	O
compounds	NNS	O
.	.	O

In	IN	O
such	JJ	O
situations	NNS	O
,	,	O
continuation	NN	O
of	IN	O
the	DT	O
injection	NN	O
will	MD	O
result	VB	O
in	IN	O
unnecessary	JJ	O
introduction	NN	O
of	IN	O
contrast	NN	O
material	NN	O
in	IN	O
the	DT	O
venous	JJ	O
system	NN	O
via	IN	O
the	DT	O
lymphovenous	JJ	O
communication	NN	O
channels	NNS	O
.	.	O

Sections	NNS	O
or	CC	O
subsections	NNS	O
omitted	VBN	O
from	IN	O
the	DT	O
full	JJ	O
prescribing	NN	O
information	NN	O
are	VBP	O
not	RB	O
listed	VBN	O
.	.	O

Periodically	RB	O
reexamine	VB	O
the	DT	O
need	NN	O
for	IN	O
continued	JJ	O
pharmacotherapy	NN	O
.	.	O

One	CD	DOS
to	TO	O
two	CD	DOS
drops	NNS	UNIT
instilled	VBD	O
into	IN	O
the	DT	O
conjunctival	NN	O
sac	NN	O
(	(	O
s	PRP	O
)	)	O
four	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

When	WRB	O
sodium	NN	O
nitroprusside	NN	O
is	VBZ	O
used	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
congestive	JJ	O
heart	NN	O
failure	NN	O
,	,	O
titration	NN	O
of	IN	O
the	DT	O
infusion	NN	O
rate	NN	O
must	MD	O
be	VB	O
guided	VBN	O
by	IN	O
the	DT	O
results	NNS	O
of	IN	O
invasive	JJ	O
hemodynamic	JJ	O
monitoring	NN	O
with	IN	O
simultaneous	JJ	O
monitoring	NN	O
of	IN	O
urine	JJ	O
output	NN	O
.	.	O

Phenytoin	NNP	O
clearance	NN	O
is	VBZ	O
decreased	VBN	O
slightly	RB	O
in	IN	O
elderly	JJ	WHO
patients	NNS	WHO
and	CC	WHO
lower	JJR	WHO
or	CC	WHO
less	RBR	WHO
frequent	JJ	WHO
dosing	NN	WHO
may	MD	O
be	VB	O
required	VBN	O
.	.	O

5	CD	DOS
-	:	O
5.0	CD	DOS
ml	NN	UNIT
)	)	O

When	WRB	O
deciding	VBG	O
among	IN	O
the	DT	O
alternative	JJ	O
treatments	NNS	O
available	JJ	O
for	IN	O
depression	NN	O
,	,	O
the	DT	O
prescriber	NN	O
should	MD	O
consider	VB	O
the	DT	O
risk	NN	O
of	IN	O
hepatic	JJ	O
failure	NN	O
associated	VBN	O
with	IN	O
SERZONE	NNP	O
treatment	NN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

The	DT	O
commonly	RB	O
employed	JJ	O
radiographic	JJ	O
techniques	NNS	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

Excess	JJ	O
solution	NN	O
around	IN	O
the	DT	O
eye	NN	O
should	MD	O
be	VB	O
removed	VBN	O
with	IN	O
tissue	NN	O
and	CC	O
any	DT	O
medication	NN	O
on	IN	O
the	DT	O
hands	NNS	O
should	MD	O
be	VB	O
rinsed	VBN	O
off	RP	O
.	.	O

The	DT	O
intermittent	NN	O
use	NN	O
of	IN	O
ethacrynic	JJ	O
acid	NNS	O
orally	RB	O
may	MD	O
eliminate	VB	O
the	DT	O
need	NN	O
for	IN	O
injections	NNS	O
of	IN	O
organomercurials	NNS	O
.	.	O

If	IN	O
the	DT	O
implant	NN	O
can	MD	O
not	RB	O
be	VB	O
found	VBN	O
in	IN	O
the	DT	O
arm	NN	O
after	IN	O
comprehensive	JJ	O
localization	NN	O
attempts	NNS	O
,	,	O
consider	VB	O
applying	VBG	O
imaging	VBG	O
techniques	NNS	O
to	TO	O
the	DT	O
chest	NN	O
as	IN	O
events	NNS	O
of	IN	O
migration	NN	O
to	TO	O
the	DT	O
pulmonary	JJ	O
vasculature	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
.	.	O

Results	NNS	O
from	IN	O
clinical	JJ	O
studies	NNS	O
indicate	VBP	O
that	IN	O
Liquid	NNP	O
PedvaxHIB	NNP	O
can	MD	O
be	VB	O
administered	VBN	O
concomitantly	RB	O
with	IN	O
DTP	NNP	O
,	,	O
OPV	NNP	O
,	,	O
eIPV	NN	O
(	(	O
enhanced	VBN	O
inactivated	VBN	O
poliovirus	JJ	O
vaccine	NN	O
)	)	O
,	,	O
VARIVAX	NNP	O
[	NNP	O
Varicella	NNP	O
Virus	NNP	O
Vaccine	NNP	O
Live	NNP	O
(	(	O
Oka	NNP	O
/	NNP	O
Merck	NNP	O
)	)	O
]	NN	O
,	,	O
M	NNP	O
-	:	O
M	NNP	O
-	:	O
R	NN	O
II	NNP	O
(	(	O
Measles	NNP	O
,	,	O
Mumps	NNP	O
,	,	O
and	CC	O
Rubella	NNP	O
Virus	NNP	O
Vaccine	NNP	O
Live	NNP	O
)	)	O
or	CC	O
RECOMBIVAX	NNP	O
HB	NNP	O
[	NNP	O
Hepatitis	NNP	O
B	NNP	O
Vaccine	NNP	O
(	(	O
Recombinant	NNP	O
)	)	O
]	NN	O
.	.	O

Good	JJ	O
control	NN	O
of	IN	O
diabetes	NNS	O
is	VBZ	O
especially	RB	O
important	JJ	O
for	IN	O
you	PRP	O
and	CC	O
your	PRP$	O
unborn	JJ	O
baby	NN	O
.	.	O

Instruct	IN	O
the	DT	O
patient	NN	O
to	TO	O
use	VB	O
the	DT	O
entire	JJ	O
film	NN	O
.	.	O

The	DT	O
duration	NN	O
of	IN	O
action	NN	O
of	IN	O
REVEX	NNP	O
is	VBZ	O
as	RB	O
long	RB	O
as	IN	O
most	JJS	O
opioid	JJ	O
analgesics	NNS	O
.	.	O

Post	NNP	O
-	:	O
Hemostatic	JJ	O
Dosing	NN	O
:	:	O
The	DT	O
appropriate	JJ	O
duration	NN	O
of	IN	O
post	NN	O
-	:	O
hemostatic	JJ	O
dosing	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

The	DT	O
sodium	NN	O
hyaluronate	NN	O
polymer	NN	O
consists	VBZ	O
of	IN	O
repeating	VBG	O
disaccharide	JJ	O
units	NNS	O
of	IN	O
sodium	NN	O
glucuronate	NN	O
-	:	O
N	NNP	O
-	:	O
acetylglucosamine	NN	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
AIRDUO	NNP	O
RESPICLICK	NNP	O
with	IN	O
a	DT	O
spacer	NN	O
or	CC	O
volume	NN	O
holding	VBG	O
chamber	NN	O
.	.	O

With	IN	O
the	DT	O
opposite	JJ	O
hand	NN	O
pull	VBZ	O
the	DT	O
needle	JJ	O
cap	NN	O
upward	RB	O
without	IN	O
twisting	VBG	O
.	.	O

For	IN	O
JRA	NNP	O
,	,	O
the	DT	O
dosage	NN	O
for	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
(	(	WHO
age	NN	WHO
2	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
)	)	WHO
is	VBZ	O
based	VBN	O
on	IN	O
weight	NN	O
.	.	O

Methylin	NNP	O
should	MD	O
be	VB	O
periodically	RB	O
discontinued	VBN	O
to	TO	O
assess	VB	O
the	DT	O
child	NN	O
's	POS	O
condition	NN	O
.	.	O

The	DT	O
intermittent	NN	O
use	NN	O
of	IN	O
EDECRIN	NNP	O
orally	RB	O
may	MD	O
eliminate	VB	O
the	DT	O
need	NN	O
for	IN	O
injections	NNS	O
of	IN	O
organomercurials	NNS	O
.	.	O

Remove	NNP	O
needle	JJ	O
cover	NN	O
.	.	O

The	DT	O
reservoir	NN	O
was	VBD	O
fitted	VBN	O
to	TO	O
a	DT	O
preprogrammed	JJ	O
ambulatory	NN	O
intravenous	JJ	O
infusion	NN	O
pump	NN	O
per	IN	O
the	DT	O
manufacturer	NN	O
's	POS	O
instructions	NNS	O
.	.	O

Swirl	NNP	O
the	DT	O
contents	NNS	FREQ
a	DT	FREQ
few	JJ	FREQ
times	NNS	FREQ
and	CC	O
swallow	VB	O
the	DT	O
additional	JJ	O
liquid	NN	O
.	.	O

Following	VBG	O
insertion	NN	O
of	IN	O
the	DT	O
needle	NN	O
into	IN	O
the	DT	O
muscle	NN	O
,	,	O
aspiration	NN	O
should	MD	O
be	VB	O
maintained	VBN	O
for	IN	O
several	JJ	O
seconds	NNS	O
to	TO	O
ensure	VB	O
that	IN	O
no	DT	O
blood	NN	O
is	VBZ	O
drawn	VBN	O
into	IN	O
the	DT	O
syringe	NN	O
.	.	O

Figure	NN	O
D	NNP	O

Table	JJ	O
1	CD	O
:	:	O
Dosage	NN	O
Reduction	NNP	O
Guidelines	NNP	O
for	IN	O
Gemzar	NNP	O
for	IN	O
Myelosuppression	NNP	O
on	IN	O
Day	NNP	O
of	IN	O
Treatment	NNP	O
in	IN	O
Ovarian	JJ	O
Cancer	NNP	O

Patients	NNS	O
should	MD	O
be	VB	O
maintained	VBN	O
on	IN	O
Sandostatin	NNP	O
Injection	NNP	O
subcutaneous	JJ	O
for	IN	O
at	IN	PER
least	JJS	PER
2	CD	PER
weeks	NNS	PER
to	TO	O
determine	VB	O
tolerance	NN	O
to	TO	O
octreotide	VB	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
LEVEMIR®	NNP	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
type	JJ	WHO
2	CD	WHO
diabetes	NNS	WHO
inadequately	RB	WHO
controlled	VBN	O
on	IN	O
a	DT	O
GLP	NNP	O
-	:	O
1	CD	O
receptor	NN	O
agonist	NN	O
is	VBZ	O
10	CD	DOS
Units	NNS	UNIT
given	VBN	O
once	RB	FREQ
daily	JJ	FREQ
in	IN	O
the	DT	O
evening	NN	O
.	.	O

Calcium	NN	O
and	CC	O
phosphorus	NN	O
are	VBP	O
added	VBN	O
to	TO	O
the	DT	O
solution	NN	O
as	IN	O
indicated	VBN	O
.	.	O

To	TO	O
calculate	VB	O
the	DT	O
estimated	JJ	O
DOLOPHINE	NNP	O
dose	NN	O
using	VBG	O
Table	JJ	O
1	CD	O
:	:	O

The	DT	O
dose	NN	O
should	MD	O
not	RB	O
be	VB	O
diluted	VBN	O
in	IN	O
large	JJ	O
volumes	NNS	O
of	IN	O
diluent	NN	O
(	(	O
i.e	JJ	O
,	,	O
100	CD	DOS
to	TO	O
250	CD	DOS
mL	NN	UNIT
)	)	O
or	CC	O
given	VBN	O
intravenously	RB	O
for	IN	O
prolonged	VBN	O
periods	NNS	O
(	(	O
ranging	VBG	O
from	IN	O
30	CD	O
to	TO	O
60	CD	O
minutes	NNS	O
or	CC	O
more	JJR	O
)	)	O
,	,	O
since	IN	O
this	DT	O
frequently	RB	O
results	NNS	O
in	IN	O
irritation	NN	O
of	IN	O
the	DT	O
vein	NN	O
and	CC	O
increases	VBZ	O
the	DT	O
chance	NN	O
of	IN	O
extravasation	NN	O
.	.	O

Therefore	RB	O
,	,	O
dose	JJ	O
escalation	NN	O
should	MD	O
follow	VB	O
the	DT	O
recommended	VBN	O
guidelines	NNS	O
for	IN	O
initiating	VBG	O
adjunctive	JJ	O
therapy	NN	O
with	IN	O
LAMICTAL	NNP	O
based	VBN	O
on	IN	O
the	DT	O
concomitant	JJ	O
AED	NNP	O
or	CC	O
other	JJ	O
concomitant	JJ	O
medications	NNS	O
(	(	O
see	VB	O
Table	JJ	O
1	CD	O
or	CC	O
Table	JJ	O
5	CD	O
)	)	O
.	.	O

In	IN	O
elderly	JJ	WHO
,	,	O
debilitated	VBN	O
,	,	O
or	CC	O
malnourished	VBD	O
patients	NNS	O
,	,	O
or	CC	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
,	,	O
hepatic	JJ	O
,	,	O
or	CC	O
adrenal	JJ	O
insufficiency	NN	O
,	,	O
the	DT	O
starting	VBG	O
dose	NN	O
,	,	O
dose	JJ	O
increments	NNS	O
,	,	O
and	CC	O
maintenance	NN	O
dosage	NN	O
of	IN	O
AVANDARYL	NNP	O
should	MD	O
be	VB	O
conservative	JJ	O
to	TO	O
avoid	VB	O
hypoglycemic	JJ	O
reactions	NNS	O
.	.	O

(	(	O
See	VB	O
WARNINGS	NNP	O
.	.	O
)	)	O

For	IN	O
caudal	JJ	O
anesthesia	NN	O
,	,	O
the	DT	O
initial	JJ	O
dose	NN	O
is	VBZ	O
15	CD	DOS
to	TO	O
25	CD	DOS
mL	NN	UNIT
of	IN	O
a	DT	O
2	CD	O
%	NN	O
or	CC	O
3	CD	O
%	NN	O
solution	NN	O
.	.	O

Neumega	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
subcutaneously	RB	O
as	IN	O
a	DT	O
single	JJ	DOS
injection	NN	UNIT
in	IN	O
either	CC	O
the	DT	O
abdomen	NNS	O
,	,	O
thigh	JJ	O
,	,	O
or	CC	O
hip	NN	O
(	(	O
or	CC	O
upper	JJ	O
arm	NN	O
if	IN	O
not	RB	O
self	PRP	O
-	:	O
injecting	NN	O
)	)	O
.	.	O

Several	JJ	O
guidelines	NNS	O
on	IN	O
this	DT	O
subject	NN	O
have	VBP	O
been	VBN	O
published.1^	VBN	O
To	TO	O
minimize	VB	O
the	DT	O
risk	NN	O
of	IN	O
dermal	JJ	O
exposure	NN	O
,	,	O
always	RB	O
wear	VBP	O
impervious	JJ	O
gloves	NNS	O
when	WRB	O
handling	VBG	O
vials	NNS	O
containing	VBG	O
TAXOL	NNP	O
Injection	NNP	O
.	.	O

Procedures	NNS	O
for	IN	O
proper	JJ	O
handling	NN	O
and	CC	O
disposal	NN	O
of	IN	O
anticancer	NN	O
drugs	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

Treatment	NN	O
with	IN	O
Lovenox	NNP	O
should	MD	O
be	VB	O
prescribed	VBN	O
for	IN	O
a	DT	O
minimum	NN	O
of	IN	O
2	CD	O
days	NNS	O
and	CC	O
continued	VBN	O
until	IN	O
clinical	JJ	O
stabilization	NN	O
.	.	O

Concomitant	JJ	O
administration	NN	O
of	IN	O
ciprofloxacin	NN	O
with	IN	O
milk	NN	O
products	NNS	O
or	CC	O
calcium	NN	O
-	:	O
fortified	JJ	O
juices	NNS	O
alone	RB	O
should	MD	O
be	VB	O
avoided	VBN	O
since	IN	O
decreased	VBN	O
absorption	NN	O
is	VBZ	O
possible	JJ	O
[	JJ	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
opioid	JJ	WHO
-	:	WHO
tolerant	NN	WHO
are	VBP	O
those	DT	O
receiving	VBG	O
,	,	O
for	IN	O
one	CD	PER
week	NN	PER
or	CC	O
longer	JJR	O
,	,	O
at	IN	O
least	JJS	O
60	CD	DOS
mg	JJ	UNIT
oral	JJ	O
morphine	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
25	CD	DOS
mcg	NN	UNIT
transdermal	JJ	O
fentanyl	NN	O
per	IN	O
hour	NN	O
,	,	O
30	CD	DOS
mg	JJ	UNIT
oral	JJ	O
oxycodone	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
8	CD	DOS
mg	JJ	UNIT
oral	JJ	O
hydromorphone	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
25	CD	DOS
mg	JJ	UNIT
oral	JJ	O
oxymorphone	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
60	CD	DOS
mg	JJ	UNIT
oral	JJ	O
hydrocodone	NN	O
per	IN	FREQ
day	NN	FREQ
,	,	O
or	CC	O
an	DT	O
equianalgesic	JJ	O
dose	NN	O
of	IN	O
another	DT	O
opioid	NN	O
.	.	O

For	IN	O
Treatment	NNP	O
:	:	O
5	CD	DOS
to	TO	O
10	CD	DOS
mg	NN	UNIT
of	IN	O
phentolamine	NN	O
mesylate	NN	O
(	(	O
phentolamine	JJ	O
mesylate	NN	O
)	)	O
in	IN	O
10	CD	DOS
mL	NN	UNIT
of	IN	O
saline	NN	O
is	VBZ	O
injected	VBN	O
into	IN	O
the	DT	O
area	NN	O
of	IN	O
extravasation	NN	O
within	IN	O
12	CD	O
hours	NNS	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
poor	JJ	WHO
bone	NN	WHO
marrow	NN	WHO
reserve	NN	WHO
,	,	O
particularly	RB	O
those	DT	O
patients	NNS	WHO
with	IN	WHO
advanced	JJ	WHO
symptomatic	JJ	WHO
HIV	NNP	WHO
disease	NN	WHO
,	,	O
frequent	JJ	O
monitoring	NN	O
of	IN	O
hematologic	JJ	O
indices	NNS	O
is	VBZ	O
recommended	VBN	O
to	TO	O
detect	VB	O
serious	JJ	O
anemia	NN	O
or	CC	O
granulocytopenia	NN	O
.	.	O

Undertreatment	NN	O
and	CC	O
overtreatment	NN	O
should	MD	O
be	VB	O
avoided	VBN	O
[	NNP	O
See	NNP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

The	DT	O
effective	JJ	O
therapeutic	JJ	O
dose	NN	O
administered	VBN	O
varies	NNS	O
from	IN	O
50mg	CD	O
to	TO	O
100mg	CD	O
2	CD	FREQ
or	CC	O
3	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
.	.	O

Figure	NN	O
A	DT	O

Information	NN	O
on	IN	O
FDA	NNP	O
-	:	O
approved	VBD	O
tests	NNS	O
for	IN	O
the	DT	O
detection	NN	O
of	IN	O
EGFR	NNP	O
mutations	NNS	O
in	IN	O
NSCLC	NNP	O
is	VBZ	O
available	JJ	O
at	IN	O
:	:	O
http	NN	O
:	:	O
/	JJ	O
/	NNP	O
www.fda.gov	NN	O
/	NN	O
CompanionDiagnostics	NNP	O
.	.	O

Step	NN	O
3	CD	O
.	.	O

The	DT	O
physician	NN	O
should	MD	O
review	VB	O
the	DT	O
Patient	NNP	O
Package	NNP	O
Insert	NNP	O
.	.	O

The	DT	O
evening	NN	O
before	IN	O
the	DT	O
colonoscopy	NN	O
procedure	NN	O
:	:	O
Take	VB	O
3	CD	O
Visicol	NNP	O
Tablets	NNP	O
(	(	O
the	DT	O
last	JJ	O
dose	NN	O
will	MD	O
be	VB	O
2	CD	O
Visicol	NNP	O
Tablets	NNPS	O
)	)	O
with	IN	O
8	CD	O
ounces	NNS	O
of	IN	O
clear	JJ	O
liquids	NNS	O
every	DT	O
15	CD	O
minutes	NNS	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
20	CD	DOS
tablets	NNS	UNIT
.	.	O

Patients	NNS	WHO
experiencing	VBG	WHO
persistent	JJ	WHO
somnolence	NN	WHO
may	MD	O
benefit	VB	O
from	IN	O
administering	VBG	O
half	PDT	O
the	DT	O
daily	JJ	FREQ
dose	JJ	O
twice	JJ	FREQ
daily	RB	FREQ
.	.	O

The	DT	O
following	VBG	O
table	NN	O
shows	VBZ	O
the	DT	O
amount	NN	O
of	IN	O
solvent	NN	O
required	VBN	O
for	IN	O
solution	NN	O
of	IN	O
various	JJ	O
concentrations	NNS	O
:	:	O

TRAVATAN	NNP	O
Z®	NNP	O
(	(	O
travoprost	JJ	O
ophthalmic	JJ	O
solution	NN	O
)	)	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
more	JJR	O
than	IN	O
once	RB	FREQ
daily	JJ	FREQ
since	IN	O
it	PRP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
that	IN	O
more	RBR	O
frequent	JJ	O
administration	NN	O
of	IN	O
prostaglandin	JJ	O
analogs	NNS	O
may	MD	O
decrease	VB	O
the	DT	O
intraocular	JJ	O
pressure	NN	O
lowering	VBG	O
effect	NN	O
.	.	O

If	IN	O
settling	JJ	O
occurs	NNS	O
during	IN	O
storage	NN	O
,	,	O
swirl	VBD	O
the	DT	O
vial	JJ	O
gently	NN	O
(	(	O
DO	NNP	O
NOT	NNP	O
SHAKE	NNP	O
)	)	O
to	TO	O
redisperse	VB	O
.	.	O

If	IN	O
the	DT	O
response	NN	O
to	TO	O
10	CD	DOS
mg	NN	UNIT
is	VBZ	O
insufficient	JJ	O
,	,	O
add	VB	O
another	DT	O
antihypertensive	JJ	O
agent	NN	O
to	TO	O
the	DT	O
treatment	NN	O
regimen	NNS	O
.	.	O

Inject	NNP	O
slowly	RB	O
,	,	O
five	CD	O
minutes	NNS	O
between	IN	O
sides	NNS	O
.	.	O

2	CD	O
.	.	O

Assess	NNP	O
left	VBD	O
ventricular	JJ	O
ejection	NN	O
fraction	NN	O
(	(	O
LVEF	NNP	O
)	)	O
prior	RB	O
to	TO	O
initiation	NN	O
of	IN	O
Herceptin	NNP	O
and	CC	O
at	IN	O
regular	JJ	O
intervals	NNS	O
during	IN	O
treatment	NN	O
.	.	O

Re	NNP	O
-	:	O
image	NN	O
at	IN	O
24	CD	O
or	CC	O
48	CD	O
hours	NNS	O
to	TO	O
evaluate	VB	O
nodal	JJ	O
architecture	NN	O
.	.	O

If	IN	O
needed	VBN	O
,	,	O
the	DT	O
dose	NN	O
can	MD	O
be	VB	O
increased	VBN	O
in	IN	O
0.1	CD	DOS
mL	NN	UNIT
(	(	O
1	CD	DOS
mg	NN	UNIT
)	)	O
increments	VBZ	O
every	DT	FREQ
few	JJ	FREQ
days	NNS	FREQ
on	IN	O
an	DT	O
outpatient	JJ	O
basis	NN	O
.	.	O

Therefore	RB	O
,	,	O
communication	NN	O
should	MD	O
be	VB	O
maintained	VBN	O
with	IN	O
the	DT	O
laboratory	NN	O
performing	VBG	O
the	DT	O
assay	NN	O
.	.	O

Repeat	NNP	O
application	NN	O
after	IN	O
7	CD	PER
days	NNS	PER
.	.	O

Although	IN	O
anaphylactic	JJ	O
reactions	NNS	O
known	VBN	O
to	TO	O
occur	VB	O
following	VBG	O
Dexferrum	NNP	O
administration	NN	O
are	VBP	O
usually	RB	O
evident	JJ	O
within	IN	O
a	DT	O
few	JJ	O
minutes	NNS	O
,	,	O
or	CC	O
sooner	RB	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
a	DT	O
period	NN	O
of	IN	O
an	DT	O
hour	NN	O
or	CC	O
longer	JJR	O
elapse	NN	O
before	IN	O
the	DT	O
remainder	NN	O
of	IN	O
the	DT	O
initial	JJ	O
therapeutic	JJ	O
dose	NN	O
is	VBZ	O
given	VBN	O
.	.	O

Dobutamine	NNP	O
was	VBD	O
compatible	JJ	O
at	IN	O
concentrations	NNS	O
up	RB	O
to	TO	O
4	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NNS	O
but	CC	O
incompatible	JJ	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
12.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
.	.	O

Included	VBN	O
in	IN	O
the	DT	O
situations	NNS	O
which	WDT	O
may	MD	O
make	VB	O
dosage	NN	O
adjustments	NNS	O
necessary	JJ	O
are	VBP	O
changes	NNS	O
in	IN	O
clinical	JJ	O
status	NN	O
secondary	JJ	O
to	TO	O
remissions	NNS	O
or	CC	O
exacerbations	NNS	O
in	IN	O
the	DT	O
disease	NN	O
process	NN	O
,	,	O
the	DT	O
patient	NN	O
's	POS	O
individual	JJ	O
drug	NN	O
responsiveness	NN	O
,	,	O
and	CC	O
the	DT	O
effect	NN	O
of	IN	O
patient	NN	O
exposure	NN	O
to	TO	O
stressful	VB	O
situations	NNS	O
not	RB	O
directly	RB	O
related	VBN	O
to	TO	O
the	DT	O
disease	NN	O
entity	NN	O
under	IN	O
treatment	NN	O
;	:	O
in	IN	O
this	DT	O
latter	JJ	O
situation	NN	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
necessary	JJ	O
to	TO	O
increase	VB	O
the	DT	O
dosage	NN	O
of	IN	O
prednisone	NN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
time	NN	O
consistent	JJ	O
with	IN	O
the	DT	O
patient	NN	O
's	POS	O
condition	NN	O
.	.	O

Administer	NNP	O
the	DT	O
diluted	JJ	O
solution	NN	O
at	IN	O
a	DT	O
dosage	NN	O
of	IN	O
5	CD	DOS
to	TO	O
10mg	CD	DOS
bretylium	NN	UNIT
(	(	O
bretylium	JJ	O
tosylate	NN	O
injection	NN	O
)	)	O
tosylate	NN	O
per	IN	O
kg	NN	O
of	IN	O
body	NN	O
weight	VBN	O
by	IN	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
a	DT	O
period	NN	O
greater	JJR	O
than	IN	O
8	CD	O
minutes	NNS	O
.	.	O

Figure	NN	O
2	CD	O

20	CD	DOS
mg	NN	UNIT
/	NNP	O
m2	VBZ	O
intravenously	RB	O
as	IN	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
via	IN	O
a	DT	O
functioning	VBG	O
intravenous	JJ	O
catheter	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
insufficiency	NN	WHO
,	,	O
it	PRP	O
may	MD	O
exceed	VB	O
20	CD	O
hours	NNS	O
,	,	O
reaching	VBG	O
approximately	RB	O
24hours	CD	O
in	IN	O
anuric	JJ	WHO
patients	NNS	WHO
.	.	O

The	DT	O
incidence	NN	O
of	IN	O
spotting	NN	O
,	,	O
breakthrough	IN	O
bleeding	NN	O
or	CC	O
nausea	NN	O
is	VBZ	O
minimal	JJ	O
,	,	O
most	JJS	O
frequently	RB	O
occurring	VBG	O
in	IN	O
the	DT	O
first	JJ	O
cycle	NN	O
.	.	O

The	DT	O
following	JJ	O
equipment	NN	O
is	VBZ	O
needed	VBN	O
for	IN	O
the	DT	O
implant	JJ	O
insertion	NN	O
:	:	O

It	PRP	O
is	VBZ	O
especially	RB	O
important	JJ	O
to	TO	O
drink	VB	O
about	IN	O
a	DT	O
pint	NN	O
of	IN	O
fluid	NN	O
at	IN	O
bedtime	NN	O
and	CC	O
another	DT	O
pint	NN	O
once	RB	O
during	IN	O
the	DT	O
night	NN	O
when	WRB	O
urine	NN	O
is	VBZ	O
more	RBR	O
concentrated	JJ	O
and	CC	O
more	RBR	O
acid	JJ	O
than	IN	O
during	IN	O
the	DT	O
day	NN	O
.	.	O

OMNIPAQUE	NN	O
may	MD	O
be	VB	O
diluted	VBN	O
with	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
as	IN	O
indicated	VBN	O
in	IN	O
the	DT	O
table	NN	O
below	IN	O
:	:	O

Unopened	VBN	O
vials	NNS	O
of	IN	O
lyophilized	VBN	O
material	NN	O
are	VBP	O
to	TO	O
be	VB	O
stored	VBN	O
at	IN	O
temperatures	NNS	O
up	RB	O
to	TO	O
25°	CD	O
C	NNP	O
(	(	O
77°	CD	O
F	NNP	O
)	)	O
.	.	O

With	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
hold	VBP	O
the	DT	O
IXINITY	NNP	O
vial	NNP	O
tightly	RB	O
on	IN	O
a	DT	O
clean	JJ	O
,	,	O
flat	JJ	O
surface	NN	O
.	.	O

Place	NN	O
gauze	NN	O
over	IN	O
the	DT	O
injection	NN	O
site	NN	O
.	.	O

To	TO	O
prevent	VB	O
any	DT	O
traces	NNS	O
of	IN	O
scopolamine	NN	O
from	IN	O
coming	VBG	O
into	IN	O
direct	JJ	O
contact	NN	O
with	IN	O
the	DT	O
eyes	NNS	O
,	,	O
after	IN	O
administration	NN	O
of	IN	O
the	DT	O
patch	NN	O
,	,	O
the	DT	O
hands	NNS	O
and	CC	O
the	DT	O
application	NN	O
site	NN	O
should	MD	O
be	VB	O
washed	VBN	O
thoroughly	RB	O
with	IN	O
soap	NN	O
and	CC	O
water	NN	O
and	CC	O
dried	VBN	O
.	.	O

Safety	NN	O
and	CC	O
effectiveness	NN	O
of	IN	O
ZUPLENZ	NNP	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
have	VBP	WHO
not	RB	WHO
been	VBN	WHO
established	VBN	O
for	IN	O
this	DT	O
indication	NN	O
.	.	O

The	DT	O
usual	JJ	O
duration	NN	O
of	IN	O
administration	NN	O
is	VBZ	O
5	CD	PER
to	TO	O
10	CD	PER
days	NNS	PER
.	.	O

If	IN	O
a	DT	O
patient	NN	O
can	MD	O
not	RB	O
tolerate	VB	O
a	DT	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
60	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
,	,	O
the	DT	O
daily	JJ	FREQ
dose	NN	O
may	MD	O
be	VB	O
reduced	VBN	O
.	.	O

1	CD	O
)	)	O
.	.	O

PREVACID	NNP	O
products	NNS	O
SHOULD	NNP	O
NOT	NNP	O
BE	NNP	O
CRUSHED	NNP	O
OR	NNP	O
CHEWED	NNP	O
.	.	O

The	DT	O
total	JJ	O
duration	NN	O
of	IN	O
the	DT	O
once	RB	FREQ
daily	JJ	FREQ
lead	SYM	O
-	:	O
in	IN	O
dosing	VBG	O
period	NN	O
should	MD	O
not	RB	O
exceed	VB	O
28	CD	PER
days	NNS	PER
at	IN	O
which	WDT	O
point	VBP	O
an	DT	O
alternative	JJ	O
regimen	NNS	O
should	MD	O
be	VB	O
sought	VBN	O
.	.	O

Picture	NN	O
4	CD	O

Do	NNP	O
not	RB	O
use	VB	O
material	NN	O
if	IN	O
there	EX	O
is	VBZ	O
any	DT	O
evidence	NN	O
of	IN	O
precipitation	NN	O
or	CC	O
foreign	JJ	O
matter	NN	O
.	.	O

It	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
the	DT	O
dose	NN	O
be	VB	O
reduced	VBN	O
by	IN	O
no	DT	O
more	JJR	O
than	IN	O
0.5	CD	DOS
mg	JJ	UNIT
every	DT	FREQ
3	CD	FREQ
days	NNS	FREQ
,	,	O
with	IN	O
the	DT	O
understanding	NN	O
that	IN	O
some	DT	WHO
patients	NNS	WHO
may	MD	O
benefit	VB	O
from	IN	O
an	DT	O
even	RB	O
more	RBR	O
gradual	JJ	O
discontinuation	NN	O
.	.	O

The	DT	O
refrigerated	JJ	O
solution	NN	O
should	MD	O
then	RB	O
be	VB	O
equilibrated	VBN	O
to	TO	O
room	NN	O
temperature	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

0.9	CD	DOS
-	:	O
2.4	CD	DOS
grams	NNS	UNIT
daily	RB	FREQ
in	IN	O
3	CD	DOS
or	CC	O
4	CD	DOS
equally	RB	UNIT
divided	VBN	UNIT
doses	NNS	UNIT
(	(	O
i.e	NN	O
,	,	O
300	CD	DOS
-	:	O
600	CD	DOS
mg	NN	UNIT
3	CD	FREQ
or	CC	O
4	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
)	)	O
.	.	O

It	PRP	O
is	VBZ	O
strongly	RB	O
recommended	VBN	O
that	IN	O
the	DT	O
same	JJ	O
dye	NN	O
that	WDT	O
was	VBD	O
used	VBN	O
for	IN	O
the	DT	O
injections	NNS	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
preparation	NN	O
of	IN	O
these	DT	O
standard	JJ	O
dilutions	NNS	O
.	.	O

The	DT	O
combination	NN	O
may	MD	O
be	VB	O
substituted	VBN	O
for	IN	O
the	DT	O
titrated	JJ	O
individual	JJ	O
components	NNS	O
.	.	O

2	CD	O
.	.	O

Crushing	NNP	O
,	,	O
chewing	VBG	O
,	,	O
or	CC	O
dissolving	VBG	O
PALLADONE	NNP	O
capsules	NNS	O
will	MD	O
result	VB	O
in	IN	O
uncontrolled	JJ	O
delivery	NN	O
of	IN	O
hydromorphone	NN	O
and	CC	O
can	MD	O
lead	VB	O
to	TO	O
overdose	VB	O
or	CC	O
death	NN	O
[	NNS	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Do	NNP	O
not	RB	O
force	VB	O
thaw	NN	O
by	IN	O
immersion	NN	O
in	IN	O
water	NN	O
baths	NNS	O
or	CC	O
by	IN	O
microwave	JJ	O
irradiation	NN	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
if	IN	O
this	DT	O
occurs	NN	O
and	CC	O
discard	NN	O
.	.	O

Repeated	VBN	O
injections	NNS	O
may	MD	O
be	VB	O
performed	VBN	O
if	IN	O
indicated	VBN	O
,	,	O
but	CC	O
the	DT	O
total	JJ	O
volume	NN	O
should	MD	O
not	RB	O
exceed	VB	O
291	CD	DOS
mL	NNS	UNIT
of	IN	O
OMNIPAQUE	NNP	O
300	CD	DOS
or	CC	O
250	CD	DOS
mL	NN	UNIT
of	IN	O
OMNIPAQUE	NNP	O
350	CD	O
(	(	O
87.5	CD	O
gI	NN	O
)	)	O
.	.	O

Use	NNP	O
only	RB	O
if	IN	O
container	NN	O
and	CC	O
seals	NNS	O
are	VBP	O
intact	JJ	O
.	.	O

[	NNS	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NN	O

Serum	NNP	O
lipids	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
for	IN	O
evidence	NN	O
of	IN	O
EFAD	NNP	O
in	IN	O
patients	NNS	WHO
maintained	VBN	O
on	IN	O
fat	JJ	O
-	:	O
free	JJ	O
TPN	NNP	O
.	.	O

4	CD	O
.	.	O

The	DT	O
usual	JJ	O
individual	JJ	O
injection	NN	O
volumes	NNS	O
for	IN	O
visualization	NN	O
of	IN	O
various	JJ	O
peripheral	JJ	O
arteries	NNS	O
are	VBP	O
as	IN	O
follows	VBZ	O
:	:	O

Do	NNP	O
not	RB	O
start	VB	O
KHEDEZLA	NNP	O
in	IN	O
a	DT	O
patient	NN	WHO
who	WP	WHO
is	VBZ	WHO
being	VBG	WHO
treated	VBN	WHO
with	IN	WHO
linezolid	JJ	WHO
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	NN	O
because	IN	O
there	EX	O
is	VBZ	O
increased	VBN	O
risk	NN	O
of	IN	O
serotonin	JJ	O
syndrome	NN	O
.	.	O

TABLE	NN	O
5	CD	O
:	:	O
DOSE	NN	O
MODIFICATIONS	NNP	O
FOR	NNP	O
HEMATOLOGIC	NNP	O
TOXICITY	NNP	O

administration	NN	O
)	)	O
a	DT	O
minimum	NN	O
of	IN	O
500	CD	DOS
mL	NN	UNIT
(	(	O
2	CD	O
cups	NNS	O
)	)	O
of	IN	O
fluids	NNS	O
prior	RB	O
to	TO	O
injection	NN	O
and	CC	O
should	MD	O
void	VB	O
as	RB	O
often	RB	O
as	IN	O
possible	JJ	O
after	IN	O
injection	NN	O
to	TO	O
minimize	VB	O
radiation	NN	O
exposure	NN	O
to	TO	O
the	DT	O
bladder	NN	O
.	.	O

AFINITOR	NNP	O
Tablets	NNP	O
should	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
with	IN	O
a	DT	O
glass	NN	O
of	IN	O
water	NN	O
.	.	O

Strict	JJ	O
adherence	NN	O
to	TO	O
the	DT	O
following	JJ	O
precautions	NNS	O
is	VBZ	O
advised	VBN	O
in	IN	O
order	NN	O
to	TO	O
minimize	VB	O
the	DT	O
potential	NN	O
for	IN	O
secondary	JJ	O
exposure	NN	O
to	TO	O
estradiol	VB	O
from	IN	O
Evamist	NNP	O
-	:	O
treated	VBD	O
skin	NN	O
.	.	O

Note	NN	O
:	:	O
Filter	NNP	O
needle	NN	O
is	VBZ	O
not	RB	O
to	TO	O
be	VB	O
used	VBN	O
for	IN	O
intravitreal	JJ	O
injection	NN	O
.	.	O

Intravenous	JJ	O
doses	NNS	O
are	VBP	O
given	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
1	CD	DOS
gram	NN	UNIT
of	IN	O
lincomycin	NN	O
diluted	VBN	O
in	IN	O
not	RB	O
less	JJR	O
than	IN	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
appropriate	JJ	O
solution	NN	O
(	(	O
see	VB	O
Physical	NNP	O
Compatibilities	NNPS	O
)	)	O
and	CC	O
infused	VBN	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
not	RB	O
less	JJR	O
than	IN	O
one	CD	O
hour	NN	O
.	.	O

For	IN	O
elderly	JJ	WHO
patients	NNS	WHO
or	CC	WHO
patients	NNS	WHO
with	IN	WHO
underlying	JJ	WHO
cardiovascular	JJ	WHO
disease	NN	WHO
,	,	O
start	NN	O
with	IN	O
a	DT	O
dose	NN	O
of	IN	O
12.5	CD	DOS
to	TO	O
25	CD	DOS
mcg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

For	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
,	,	O
dosage	NN	O
can	MD	O
be	VB	O
based	VBN	O
on	IN	O
30	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
fluid	NN	O
requirements	NNS	O
of	IN	O
the	DT	O
patient	NN	O
and	CC	O
duration	NN	O
of	IN	O
anesthesia	NN	O
must	MD	O
be	VB	O
considered	VBN	O
when	WRB	O
selecting	VBG	O
the	DT	O
appropriate	JJ	O
dilution	NN	O
of	IN	O
Ketalar	NNP	O
.	.	O

A	DT	O
pharmacokinetic	JJ	O
study	NN	O
was	VBD	O
conducted	VBN	O
in	IN	O
the	DT	O
FXIII	NNP	O
congenitally	RB	O
deficient	JJ	O
population	NN	O
evaluating	VBG	O
five	CD	DOS
dose	JJ	UNIT
cohorts	NNS	UNIT
(	(	O
2	CD	DOS
,	,	O
7	CD	DOS
,	,	O
24	CD	DOS
,	,	O
60	CD	DOS
and	CC	O
89	CD	DOS
IU	NNP	UNIT
/	NNP	O
kg	NN	O
)	)	O
with	IN	O
blood	NN	O
sampling	VBG	O
at	IN	O
0.5	CD	O
,	,	O
1	CD	O
,	,	O
4	CD	O
,	,	O
8	CD	O
,	,	O
24	CD	O
,	,	O
48	CD	O
,	,	O
72	CD	O
hours	NNS	O
,	,	O
and	CC	O
7	CD	O
,	,	O
14	CD	O
,	,	O
and	CC	O
28	CD	O
days	NNS	O
.	.	O

Table	JJ	O
2	CD	O
:	:	O
Dosage	NN	O
of	IN	O
AVYCAZ	NNP	O
in	IN	O
Patients	NNP	WHO
with	IN	WHO
Renal	NNP	WHO
Impairment	NNP	WHO

Patients	NNS	WHO
with	IN	WHO
a	DT	WHO
history	NN	WHO
of	IN	WHO
renal	JJ	WHO
or	CC	WHO
liver	JJ	WHO
disease	NN	WHO
should	MD	O
not	RB	O
receive	VB	O
the	DT	O
oral	JJ	O
loading	NN	O
regimen	NNS	O
.	.	O

VERDESO	NNP	O
Foam	NNP	O
is	VBZ	O
not	RB	O
for	IN	O
oral	JJ	O
,	,	O
ophthalmic	JJ	O
,	,	O
or	CC	O
intravaginal	JJ	O
use	NN	O
.	.	O

In	IN	O
these	DT	WHO
patients	NNS	WHO
,	,	O
Trileptal	NNP	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
8	CD	DOS
-	:	O
10	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
a	DT	O
twice	JJ	FREQ
-	:	FREQ
a	DT	O
-	:	O
day	NN	O
regimen	NNS	O
.	.	O

Pull	VB	O
the	DT	O
plunger	NN	O
out	RP	O
slowly	RB	O
until	IN	O
the	DT	O
desired	JJ	O
amount	NN	O
of	IN	O
medication	NN	O
is	VBZ	O
withdrawn	VBN	O
into	IN	O
the	DT	O
oral	JJ	O
dispenser	NN	O
.	.	O

CAUTION	NN	O
:	:	O
Do	NNP	O
not	RB	O
reuse	VB	O
any	DT	O
solution	NN	O
remaining	VBG	O
in	IN	O
the	DT	O
cartridge	NN	O
due	JJ	O
to	TO	O
the	DT	O
possibility	NN	O
of	IN	O
bacterial	JJ	O
contamination	NN	O
.	.	O

Strict	NNP	O
aseptic	JJ	O
administration	NN	O
technique	NN	O
is	VBZ	O
mandatory	JJ	O
.	.	O

Strict	JJ	O
adherence	NN	O
to	TO	O
the	DT	O
following	JJ	O
precautions	NNS	O
is	VBZ	O
advised	VBN	O
in	IN	O
order	NN	O
to	TO	O
minimize	VB	O
the	DT	O
potential	NN	O
for	IN	O
secondary	JJ	O
exposure	NN	O
to	TO	O
testosterone	VB	O
from	IN	O
FORTESTA	NNP	O
-	:	O
treated	VBD	O
skin	NN	O
:	:	O

NOTE	NN	O
:	:	O
Read	VB	O
all	DT	O
instructions	NNS	O
completely	RB	O
before	IN	O
beginning	VBG	O
reconstitution	NN	O
and	CC	O
administration	NN	O
.	.	O

If	IN	O
the	DT	O
ovaries	NNS	O
are	VBP	O
abnormally	RB	O
enlarged	VBN	O
or	CC	O
abdominal	JJ	O
pain	NN	O
occurs	NNS	O
,	,	O
Metrodin®	NNP	O
(	(	O
urofollitropin	NN	O
for	IN	O
injection	NN	O
)	)	O
treatment	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
,	,	O
hCG	NN	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
,	,	O
and	CC	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
advised	VBN	O
not	RB	O
to	TO	O
have	VB	O
intercourse	NN	O
;	:	O
this	DT	O
will	MD	O
reduce	VB	O
the	DT	O
chance	NN	O
of	IN	O
development	NN	O
of	IN	O
the	DT	O
Ovarian	JJ	O
Hyperstimulation	NNP	O
Syndrome	NNP	O
and	CC	O
,	,	O
should	MD	O
spontaneous	JJ	O
ovulation	NN	O
occur	NN	O
,	,	O
reduce	VB	O
the	DT	O
chance	NN	O
of	IN	O
multiple	JJ	O
gestation	NN	O
.	.	O

Follow	NNP	O
recommendations	NNS	O
of	IN	O
appropriate	JJ	O
pediatric	JJ	O
reference	NN	O
texts	NN	O
.	.	O

Severe	NNP	O
hepatic	JJ	O
impairment	NN	O
results	NNS	O
in	IN	O
a	DT	O
reduced	JJ	O
clearance	NN	O
of	IN	O
naloxone	NN	O
to	TO	O
a	DT	O
much	RB	O
greater	JJR	O
extent	NN	O
than	IN	O
buprenorphine	NN	O
,	,	O
and	CC	O
moderate	JJ	O
hepatic	JJ	O
impairment	NN	O
also	RB	O
results	NNS	O
in	IN	O
a	DT	O
reduced	JJ	O
clearance	NN	O
of	IN	O
naloxone	NN	O
to	TO	O
a	DT	O
greater	JJR	O
extent	NN	O
than	IN	O
buprenorphine	NN	O
.	.	O

Single	NNP	O
photon	NN	O
emission	NN	O
computed	VBN	O
tomography	NN	O
(	(	O
SPECT	NNP	O
)	)	O
may	MD	O
be	VB	O
performed	VBN	O
following	VBG	O
planar	NN	O
scintigraphy	NN	O
,	,	O
as	IN	O
appropriate	JJ	O
[	NNP	O
see	VBP	O
Clinical	JJ	O
studies	NNS	O
]	VBP	O
.	.	O

Absolute	NNP	O
dosage	NN	O
for	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
6	CD	WHO
to	TO	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
is	VBZ	O
not	RB	O
established	VBN	O
.	.	O

Repeat	NNP	O
steps	NNS	O
3	CD	O
through	IN	O
5	CD	O
.	.	O

2	CD	O
.	.	O

Next	JJ	O
,	,	O
withdraw	JJ	O
and	CC	O
discard	JJ	O
5	CD	DOS
mL	NN	UNIT
from	IN	O
a	DT	O
500	CD	DOS
mL	NN	UNIT
infusion	NN	O
bag	NN	O
containing	VBG	O
5	CD	O
%	NN	O
Dextrose	NNP	O
in	IN	O
Water	NNP	O
or	CC	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
for	IN	O
Injection	NNP	O
.	.	O

HyperTET	NNP	O
S	NNP	O
/	NNP	O
D	NNP	O
is	VBZ	O
supplied	VBN	O
with	IN	O
a	DT	O
syringe	NN	O
and	CC	O
an	DT	O
attached	JJ	O
UltraSafe®	NNP	O
Needle	NNP	O
Guard	NNP	O
for	IN	O
your	PRP$	O
protection	NN	O
and	CC	O
convenience	NN	O
.	.	O

Usual	JJ	O
Adult	NNP	WHO
Dosage	NN	WHO
:	:	O

Conversely	RB	O
,	,	O
at	IN	O
least	JJS	O
5	CD	O
days	NNS	O
should	MD	O
be	VB	O
allowed	VBN	O
after	IN	O
stopping	VBG	O
Savella	NNP	O
before	IN	O
starting	VBG	O
a	DT	O
MAOI	NNP	O
intended	VBN	O
to	TO	O
treat	VB	O
psychiatric	JJ	O
disorders	NNS	O
[	VBP	O
see	VBP	O
CONTRAINDICATIONS	NNP	O
]	NNP	O
.	.	O

Directions	NNS	O
for	IN	O
use	NN	O
of	IN	O
One	CD	O
Point	NN	O
Cut	NNP	O
(	(	O
OPC	NNP	O
)	)	O
Ampules	NNP	O
for	IN	O
DDAVP	NNP	O
Injection	NNP	O
(	(	O
desmopressin	JJ	O
acetate	NN	O
injection	NN	O
)	)	O
:	:	O

When	WRB	O
DIPRIVAN	NNP	O
Injectable	NNP	O
Emulsion	NNP	O
is	VBZ	O
administered	VBN	O
slowly	RB	O
over	IN	O
3	CD	O
to	TO	O
5	CD	O
minutes	NNS	O
,	,	O
most	JJS	WHO
patients	NNS	WHO
will	MD	O
be	VB	O
adequately	RB	O
sedated	VBN	O
,	,	O
and	CC	O
the	DT	O
peak	JJ	O
drug	NN	O
effect	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
while	IN	O
minimizing	VBG	O
undesirable	JJ	O
cardiorespiratory	NN	O
effects	NNS	O
occurring	VBG	O
at	IN	O
high	JJ	O
plasma	NN	O
levels	NNS	O
.	.	O

(	(	O
See	VB	O
PRECAUTIONS	NNP	O
.	.	O
)	)	O

The	DT	O
infusion	NN	O
must	MD	O
be	VB	O
discontinued	VBN	O
immediately	RB	O
if	IN	O
the	DT	O
patient	NN	O
experiences	VBZ	O
a	DT	O
serious	JJ	O
hypersensitivity	NN	O
reaction	NN	O
[	NNP	O
see	NN	O
CONTRAINDICATIONS	NNP	O
,	,	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
intravenous	JJ	O
line	NN	O
should	MD	O
always	RB	O
be	VB	O
flushed	VBN	O
with	IN	O
either	DT	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
Lactated	NNP	O
Ringer	NNP	O
's	POS	O
Injection	NNP	O
,	,	O
USP	NNP	O
or	CC	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
both	DT	O
prior	JJ	O
to	TO	O
and	CC	O
after	IN	O
administration	NN	O
of	IN	O
NEXIUM	NNP	O
I.V	NNP	O
.	.	O

Aristospan	NNP	O
suspension	NN	O
may	MD	O
also	RB	O
be	VB	O
mixed	JJ	O
with	IN	O
1	CD	O
%	NN	O
or	CC	O
2	CD	O
%	NN	O
Lidocaine	NNP	O
Hydrochloride	NNP	O
,	,	O
using	VBG	O
the	DT	O
formulations	NNS	O
which	WDT	O
do	VBP	O
not	RB	O
contain	VB	O
parabens	NNS	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
quinidine	NN	O
varies	NNS	O
considerably	RB	O
depending	VBG	O
upon	IN	O
the	DT	O
general	JJ	O
condition	NN	O
and	CC	O
the	DT	O
cardiovascular	JJ	O
state	NN	O
of	IN	O
the	DT	O
patient	NN	O
.	.	O

Do	NNP	O
not	RB	O
substitute	VB	O
CABOMETYX	NNP	O
tablets	NNS	O
with	IN	O
cabozantinib	JJ	O
capsules	NNS	O
.	.	O

Table	JJ	O
4	CD	O
.	.	O

For	IN	O
iron	NN	O
maintenance	NN	O
treatment	NN	O
:	:	O
Administer	NN	O
Venofer	NNP	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NNS	O
,	,	O
not	RB	O
to	TO	O
exceed	VB	O
100	CD	DOS
mg	JJ	UNIT
per	IN	O
dose	NN	O
,	,	O
every	DT	FREQ
four	CD	FREQ
weeks	NNS	FREQ
for	IN	O
12	CD	PER
weeks	NNS	PER
given	VBN	O
undiluted	JJ	O
by	IN	O
slow	JJ	O
intravenous	JJ	O
injection	NN	O
over	IN	O
5	CD	O
minutes	NNS	O
or	CC	O
diluted	VBN	O
in	IN	O
25	CD	DOS
mL	NN	UNIT
of	IN	O
0.9	CD	O
%	NN	O
NaCl	NNP	O
and	CC	O
administered	VBN	O
over	IN	O
5	CD	O
to	TO	O
60	CD	O
minutes	NNS	O
.	.	O

At	IN	O
least	JJS	O
14	CD	O
days	NNS	O
should	MD	O
elapse	VB	O
between	IN	O
discontinuation	NN	O
of	IN	O
an	DT	O
MAOI	NNP	O
intended	VBD	O
to	TO	O
treat	VB	O
psychiatric	JJ	O
disorders	NNS	O
and	CC	O
initiation	NN	O
of	IN	O
therapy	NN	O
with	IN	O
Fluvoxamine	NNP	O
Maleate	NNP	O
Tablets	NNP	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
congenital	JJ	WHO
hypothyroidism	NN	WHO
,	,	O
assess	IN	O
the	DT	O
adequacy	NN	O
of	IN	O
replacement	NN	O
therapy	NN	O
by	IN	O
measuring	VBG	O
both	DT	O
serum	JJ	O
TSH	NNP	O
and	CC	O
total	JJ	O
or	CC	O
free	JJ	O
-	:	O
T4	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
who	WP	WHO
continue	VBP	WHO
to	TO	O
take	VB	O
their	PRP$	O
chronic	JJ	O
opioid	NN	O
therapy	NN	O
for	IN	O
persistent	JJ	O
pain	NN	O
but	CC	O
no	DT	O
longer	JJR	O
require	VB	O
treatment	NN	O
for	IN	O
breakthrough	NN	O
pain	NN	O
,	,	O
ABSTRAL	NNP	O
therapy	NN	O
can	MD	O
usually	RB	O
be	VB	O
discontinued	VBN	O
immediately	RB	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
the	DT	O
induction	NN	O
of	IN	O
remission	NN	O
and	CC	O
the	DT	O
symptomatic	JJ	O
treatment	NN	O
of	IN	O
mildly	RB	O
to	TO	O
moderately	RB	O
active	JJ	O
ulcerative	JJ	O
colitis	NN	O
is	VBZ	O
1g	CD	DOS
(	(	O
4	CD	DOS
PENTASA	NNP	O
250	CD	DOS
mg	NN	UNIT
capsules	NNS	UNIT
or	CC	O
2	CD	DOS
PENTASA	NNP	O
500	CD	DOS
mg	NN	UNIT
capsules	NNS	UNIT
)	)	O
4	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
for	IN	O
a	DT	O
total	JJ	O
daily	JJ	FREQ
dosage	NN	O
of	IN	O
4g	CD	O
.	.	O

Diuretic	NNP	O
dose	NN	O
may	MD	O
need	VB	O
to	TO	O
be	VB	O
adjusted	VBN	O
to	TO	O
help	VB	O
minimize	VB	O
hypovolemia	NN	O
,	,	O
which	WDT	O
may	MD	O
contribute	VB	O
to	TO	O
hypotension	VB	O
[	NNP	O
see	VB	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
insufficiency	NN	WHO
must	MD	O
be	VB	O
carefully	RB	O
monitored	VBN	O
for	IN	O
drug	NN	O
toxicity	NN	O
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
benign	JJ	O
nodules	NNS	O
and	CC	O
nontoxic	JJ	O
multinodular	JJ	O
goiter	NN	O
,	,	O
TSH	NNP	O
is	VBZ	O
generally	RB	O
suppressed	VBN	O
to	TO	O
a	DT	O
higher	JJR	O
target	NN	O
(	(	O
e.g	JJ	O
,	,	O
0.1	CD	O
to	TO	O
either	DT	O
0.5	CD	DOS
or	CC	O
1.0	CD	DOS
mU	NNS	UNIT
/	NNP	O
L	NNP	O
)	)	O
than	IN	O
that	DT	O
used	VBD	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
thyroid	JJ	O
cancer	NN	O
.	.	O

The	DT	O
success	NN	O
or	CC	O
failure	NN	O
of	IN	O
smoking	VBG	O
cessation	NN	O
is	VBZ	O
influenced	VBN	O
by	IN	O
the	DT	O
quality	NN	O
,	,	O
intensity	NN	O
and	CC	O
frequency	NN	O
of	IN	O
supportive	JJ	O
care	NN	O
.	.	O

Keep	VB	O
pouch	NN	O
sealed	VBN	O
until	IN	O
just	RB	O
prior	RB	O
to	TO	O
injection	NN	O
.	.	O

INTRALIPID®	NNP	O
20	CD	O
%	NN	O
(	(	O
A	DT	O
20	CD	O
%	NN	O
I.V	NNP	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
(	(	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NNP	WHO
B	NNP	WHO
)	)	WHO
,	,	O
a	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
5	CD	DOS
mg	NN	UNIT
LEVITRA	NNP	O
is	VBZ	O
recommended	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ZOMIG	NNP	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
to	TO	WHO
severe	VB	WHO
hepatic	JJ	WHO
impairment	NN	WHO
is	VBZ	O
1.25	CD	DOS
mg	NN	UNIT
(	(	O
one	CD	O
-	:	O
half	NN	O
of	IN	O
one	CD	DOS
2.5	CD	DOS
mg	NN	UNIT
ZOMIG	NNP	O
tablet	NN	O
)	)	O
because	IN	O
of	IN	O
increased	JJ	O
zolmitriptan	NN	O
blood	NN	O
levels	NNS	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
and	CC	O
elevation	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
in	IN	O
some	DT	WHO
of	IN	WHO
these	DT	WHO
patients	NNS	WHO
.	.	O

Discard	NNP	O
the	DT	O
solution	NN	O
that	WDT	O
was	VBD	O
withdrawn	VBN	O
from	IN	O
the	DT	O
bag	NN	O
.	.	O

This	DT	O
does	VBZ	O
not	RB	O
affect	VB	O
the	DT	O
solution	NN	O
quality	NN	O
or	CC	O
safety	NN	O
and	CC	O
may	MD	O
often	RB	O
leave	VB	O
a	DT	O
slight	JJ	O
amount	NN	O
of	IN	O
moisture	NN	O
within	IN	O
the	DT	O
overwrap	NN	O
.	.	O

When	WRB	O
changing	VBG	O
strengths	NNS	O
of	IN	O
pancreatic	JJ	O
enzyme	NN	O
products	NNS	O
,	,	O
care	NN	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
maintain	VB	O
equivalent	JJ	O
lipase	NN	O
units	NNS	O
for	IN	O
each	DT	O
divided	JJ	O
dosage	NN	O
.	.	O

If	IN	O
general	JJ	O
anesthesia	NN	O
is	VBZ	O
required	VBN	O
,	,	O
therapy	NN	O
may	MD	O
be	VB	O
continued	VBN	O
as	RB	O
long	RB	O
as	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
permitted	VBN	O
to	TO	O
take	VB	O
fluids	NNS	O
and	CC	O
medication	NN	O
by	IN	O
mouth	NN	O
.	.	O

Freezing	VBG	O
may	MD	O
adversely	RB	O
affect	VB	O
the	DT	O
modified	JJ	O
release	NN	O
mechanism	NN	O
of	IN	O
DepoDur	NNP	O
(	(	O
morphine	JJ	O
sulfate	NN	O
xr	NNP	O
liposome	NNP	O
injection	NN	O
)	)	O
.	.	O

The	DT	O
table	NN	O
below	IN	O
provides	VBZ	O
additional	JJ	O
information	NN	O
on	IN	O
dosing	VBG	O
conversion	NN	O
to	TO	O
JADENU	NNP	O
tablets	NNS	O
.	.	O

See	VB	O
Table	JJ	O
4	CD	O
below	IN	O
for	IN	O
examples	NNS	O
.	.	O

Routine	JJ	O
monitoring	NN	O
of	IN	O
estimated	VBN	O
creatinine	NN	O
clearance	NN	O
,	,	O
serum	NN	O
phosphorus	NN	O
,	,	O
urine	JJ	O
glucose	NN	O
,	,	O
and	CC	O
urine	JJ	O
protein	NN	O
should	MD	O
be	VB	O
performed	VBN	O
in	IN	O
all	DT	WHO
individuals	NNS	WHO
with	IN	WHO
mild	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
.	.	O

IMPORTANT	NN	O
:	:	O
If	IN	O
blood	NN	O
appears	VBZ	O
in	IN	O
the	DT	O
syringe	NN	O
,	,	O
the	DT	O
product	NN	O
should	MD	O
not	RB	O
be	VB	O
injected	VBN	O
.	.	O

3	CD	O
.	.	O

The	DT	O
precautions	NNS	O
described	VBD	O
above	IN	O
should	MD	O
be	VB	O
followed	VBN	O
to	TO	O
minimize	VB	O
the	DT	O
chance	NN	O
of	IN	O
development	NN	O
of	IN	O
the	DT	O
Ovarian	JJ	O
Hyperstimulation	NNP	O
Syndrome	NNP	O
.	.	O

Tablets	NNS	O
must	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
with	IN	O
fluid	NN	O
and	CC	O
not	RB	O
divided	VBN	O
,	,	O
crushed	VBN	O
,	,	O
chewed	VBN	O
,	,	O
or	CC	O
dissolved	VBN	O
.	.	O

Reconstitution	NN	O

Intravenous	JJ	O
administration	NN	O
of	IN	O
the	DT	O
sodium	NN	O
salt	NN	O
is	VBZ	O
indicated	VBN	O
only	RB	O
in	IN	O
patients	NNS	WHO
unable	JJ	WHO
to	TO	O
tolerate	VB	O
oral	JJ	O
medications	NNS	O
.	.	O

Evomela	NNP	O
is	VBZ	O
light	JJ	O
sensitive	JJ	O
.	.	O

Figure	NN	O
5	CD	O
:	:	O
Pull	NN	O
on	IN	O
the	DT	O
threads	NNS	O
to	TO	O
pull	VB	O
the	DT	O
IUS	NNP	O
into	IN	O
the	DT	O
tube	NN	O
.	.	O

These	DT	O
scans	NNS	O
have	VBP	O
one	CD	DOS
or	CC	O
more	JJR	O
regions	NNS	O
with	IN	O
increased	JJ	O
cortical	JJ	O
grey	NN	O
matter	RBR	O
signal	NN	O
(	(	O
above	IN	O
50	CD	O
-	:	O
60	CD	O
%	NN	O
peak	JJ	O
intensity	NN	O
)	)	O
and	CC	O
/	$	O
or	CC	O
reduced	VBN	O
(	(	O
or	CC	O
absent	NN	O
)	)	O
grey	FW	O
-	:	O
white	JJ	O
matter	NN	O
contrast	NN	O
(	(	O
white	JJ	O
matter	NN	O
sulcal	JJ	O
pattern	NN	O
is	VBZ	O
less	RBR	O
distinct	JJ	O
)	)	O
.	.	O

Repeat	NNP	O
DYSPORT®	NNP	O
treatment	NN	O
should	MD	O
be	VB	O
administered	VBN	O
when	WRB	O
the	DT	O
effect	NN	O
of	IN	O
a	DT	O
previous	JJ	O
injection	NN	O
has	VBZ	O
diminished	VBN	O
,	,	O
but	CC	O
no	DT	O
sooner	JJR	O
than	IN	O
12	CD	PER
weeks	NNS	PER
after	IN	O
the	DT	O
previous	JJ	O
injection	NN	O
.	.	O

STENDRA	NNP	O
may	MD	O
be	VB	O
taken	VBN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

Although	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
LUVOX	NNP	O
CR	NNP	O
Capsules	NNP	O
beyond	IN	O
12	CD	PER
weeks	NNS	PER
of	IN	O
dosing	VBG	O
has	VBZ	O
not	RB	O
been	VBN	O
documented	VBN	O
in	IN	O
controlled	JJ	O
trials	NNS	O
,	,	O
OCD	NNP	O
is	VBZ	O
a	DT	O
chronic	JJ	O
condition	NN	O
,	,	O
and	CC	O
it	PRP	O
is	VBZ	O
reasonable	JJ	O
to	TO	O
consider	VB	O
continuation	NN	O
for	IN	O
a	DT	O
responding	JJ	WHO
patient	NN	WHO
.	.	O

SUPRANE	NNP	O
also	RB	O
decreases	VBZ	O
the	DT	O
doses	NNS	O
of	IN	O
neuromuscular	JJ	O
blocking	VBG	O
agents	NNS	O
required	VBN	O
[	JJ	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
,	,	O
Table	NNP	O
4	CD	O
)	)	O
]	NN	O
.	.	O

DIPROLENE	NNP	O
Lotion	NNP	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
with	IN	O
occlusive	JJ	O
dressings	NNS	O
unless	IN	O
directed	VBN	O
by	IN	O
a	DT	O
physician	NN	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
unless	IN	O
solution	NN	O
is	VBZ	O
clear	JJ	O
and	CC	O
seal	NN	O
is	VBZ	O
intact	JJ	O
.	.	O

The	DT	O
total	JJ	O
power	NN	O
output	NN	O
at	IN	O
the	DT	O
fiber	NN	O
tip	NN	O
is	VBZ	O
set	VBN	O
to	TO	O
deliver	VB	O
the	DT	O
appropriate	JJ	O
light	NN	O
dose	NN	O
using	VBG	O
exposure	JJ	O
times	NNS	O
of	IN	O
8	CD	O
minutes	NNS	O
and	CC	O
20	CD	O
seconds	NNS	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
impairment	NN	WHO
of	IN	O
renal	JJ	O
function	NN	O
the	DT	O
elimination	NN	O
kinetics	NNS	O
of	IN	O
ampicillin	NN	O
and	CC	O
sulbactam	NN	O
are	VBP	O
similarly	RB	O
affected	VBN	O
,	,	O
hence	VB	O
the	DT	O
ratio	NN	O
of	IN	O
one	CD	DOS
to	TO	O
the	DT	O
other	JJ	O
will	MD	O
remain	VB	O
constant	JJ	O
whatever	IN	O
the	DT	O
renal	JJ	O
function	NN	O
.	.	O

Administration	NN	O
of	IN	O
exogenous	JJ	O
insulin	NN	O
may	MD	O
be	VB	O
required	VBN	O
in	IN	O
order	NN	O
to	TO	O
control	VB	O
hyperglycemia	NN	O
and	CC	O
glycosuria	NNS	O
which	WDT	O
may	MD	O
occur	VB	O
upon	IN	O
infusion	NN	O
of	IN	O
concentrated	JJ	O
glucose	JJ	O
solutions	NNS	O
.	.	O

If	IN	O
you	PRP	O
can	MD	O
not	RB	O
feel	VB	O
the	DT	O
implant	NN	O
or	CC	O
are	VBP	O
in	IN	O
doubt	NN	O
of	IN	O
its	PRP$	O
presence	NN	O
,	,	O
the	DT	O
implant	NN	O
may	MD	O
not	RB	O
have	VB	O
been	VBN	O
inserted	VBN	O
or	CC	O
it	PRP	O
may	MD	O
have	VB	O
been	VBN	O
inserted	VBN	O
deeply	NN	O
:	:	O

A	DT	O
patient	NN	O
whose	WP$	O
blood	NN	O
pressure	NN	O
is	VBZ	O
not	RB	O
adequately	RB	O
controlled	VBN	O
with	IN	O
amlodipine	NN	O
(	(	O
or	CC	O
another	DT	O
dihydropyridine	NN	O
calcium	NN	O
-	:	O
channel	NN	O
blocker	NN	O
)	)	O
alone	RB	O
or	CC	O
with	IN	O
valsartan	JJ	O
(	(	O
or	CC	O
another	DT	O
angiotensin	NN	O
II	NNP	O
receptor	NN	O
blocker	NN	O
)	)	O
alone	NN	O
may	MD	O
be	VB	O
switched	VBN	O
to	TO	O
combination	VB	O
therapy	NN	O
with	IN	O
Exforge	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Elitek	NNP	O
is	VBZ	O
0.2	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
as	IN	O
a	DT	O
30	CD	DOS
minute	NN	UNIT
intravenous	JJ	UNIT
infusion	NN	UNIT
daily	RB	FREQ
for	IN	O
up	IN	PER
to	TO	PER
5	CD	PER
days	NNS	PER
.	.	O

Swallow	NNP	O
tablet	NN	O
whole	NN	O
with	IN	O
water	NN	O
after	IN	O
a	DT	O
low	JJ	O
-	:	O
fat	NN	O
meal	NN	O
that	WDT	O
contains	VBZ	O
less	JJR	O
than	IN	O
600	CD	O
calories	NNS	O
and	CC	O
less	JJR	O
than	IN	O
30	CD	O
%	NN	O
fat	JJ	O
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Do	NNP	O
not	RB	O
break	VB	O
or	CC	O
use	VB	O
partial	JJ	O
Orapred	NNP	O
ODT	NNP	O
(	(	O
prednisolone	NN	O
sodium	NN	O
phosphate	NN	O
)	)	O
tablets	NNS	O
.	.	O

(	(	O
see	VB	O
Instruction	NNP	O
For	IN	O
Application	NNP	O
)	)	O
.	.	O

Place	NN	O
the	DT	O
diluent	NN	O
bottle	NN	O
on	IN	O
a	DT	O
flat	JJ	O
surface	NN	O
and	CC	O
,	,	O
while	IN	O
holding	VBG	O
the	DT	O
bottle	NN	O
to	TO	O
prevent	VB	O
slipping	NN	O
,	,	O
insert	VBP	O
the	DT	O
spike	NN	O
of	IN	O
the	DT	O
transfer	NN	O
device	NN	O
perpendicularly	RB	O
through	IN	O
the	DT	O
center	NN	O
of	IN	O
the	DT	O
bottle	NN	O
stopper	NN	O
.	.	O

Discard	NNP	O
any	DT	O
solution	NN	O
more	JJR	O
than	IN	O
24	CD	O
hours	NNS	O
old	JJ	O
.	.	O

Lather	NNP	O
and	CC	O
leave	VBP	O
on	IN	O
hair	NN	O
and	CC	O
scalp	NN	O
for	IN	O
3	CD	O
minutes	NNS	O
.	.	O

Do	NNP	O
not	RB	O
exceed	VB	O
5	CD	DOS
mg	NNS	UNIT
.	.	O

b	NN	O
)	)	O
Vertically	RB	O
shake	VBP	O
the	DT	O
syringe	NN	O
vigorously	RB	O
for	IN	O
20	CD	O
seconds	NNS	O
until	IN	O
drug	NN	O
is	VBZ	O
uniformly	JJ	O
milky	SYM	O
-	:	O
white	JJ	O
(	(	O
See	VB	O
Figure	NNP	O
2	CD	O
)	)	O
.	.	O

The	DT	O
next	JJ	O
dose	NN	O
should	MD	O
be	VB	O
taken	VBN	O
as	IN	O
scheduled	JJ	O
.	.	O

DO	NNP	O
NOT	NNP	O
USE	VB	O
IF	NNP	O
AMINOSYN	NNP	O
II	NNP	O
IS	NNP	O
DISCOLORED	NNP	O
OR	NNP	O
IF	NNP	O
CLAMP	NNP	O
IS	NNP	O
OPEN	NNP	O
OR	NNP	O
MISSING	NNP	O
.	.	O

For	IN	O
a	DT	O
“	JJ	O
one	CD	O
application	NN	O
method	NN	O
,	,	O
”	NNP	O
NEO	NNP	O
-	:	O
SYNEPHRINE	NNP	O
(	(	O
phenylephrine	JJ	O
hydrochloride	NN	O
ophthalmic	JJ	O
solution	NN	O
)	)	O
hydrochloride	NN	O
2.5	CD	O
percent	NN	O
ophthalmic	JJ	O
solution	NN	O
may	MD	O
be	VB	O
combined	VBN	O
with	IN	O
a	DT	O
cycloplegic	NN	O
to	TO	O
elicit	VB	O
synergistic	JJ	O
action	NN	O
.	.	O

When	WRB	O
initiating	VBG	O
TANZEUM	NNP	O
,	,	O
consider	VB	O
reducing	VBG	O
the	DT	O
dosage	NN	O
of	IN	O
concomitantly	RB	O
administered	VBN	O
insulin	NN	O
secretagogues	NNS	O
(	(	O
e.g	NN	O
,	,	O
sulfonylureas	NNS	O
)	)	O
or	CC	O
insulin	NN	O
to	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
hypoglycemia	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Infuse	NNP	O
over	IN	O
30	CD	O
minutes	NNS	O
via	IN	O
an	DT	O
injection	NN	O
port	NN	O
or	CC	O
central	JJ	O
venous	JJ	O
catheter	NN	O
.	.	O

dose	NN	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
any	DT	O
other	JJ	O
medications	NNS	O
through	IN	O
the	DT	O
same	JJ	O
intravenous	JJ	O
line	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Adult	NN	WHO
Patients	NNS	WHO
and	CC	WHO
Pediatric	NNP	WHO
Patients	NNP	WHO
Dosage	NNP	WHO
Guidelines	NNP	WHO
for	IN	WHO
CEFTIN	NNP	WHO
Tablets	NNS	WHO

The	DT	O
dose	NN	O
should	MD	O
be	VB	O
slowly	RB	O
injected	VBN	O
directly	RB	O
into	IN	O
a	DT	O
vein	NN	O
,	,	O
or	CC	O
the	DT	O
tubing	NN	O
of	IN	O
a	DT	O
suitable	JJ	O
administration	NN	O
set	VBN	O
,	,	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
3	CD	O
to	TO	O
5	CD	O
minutes	NNS	O
(	(	O
see	VB	O
next	JJ	O
paragraph	NN	O
regarding	VBG	O
flushing	NN	O
of	IN	O
tubing	VBG	O
)	)	O
.	.	O

Vials	NNS	O
of	IN	O
DepoDur	NNP	O
(	(	O
morphine	JJ	O
sulfate	NN	O
xr	NNP	O
liposome	NNP	O
injection	NN	O
)	)	O
should	MD	O
be	VB	O
gently	RB	O
inverted	VBN	O
to	TO	O
re	VB	O
-	:	O
suspend	VB	O
the	DT	O
particles	NNS	O
immediately	RB	O
prior	RB	O
to	TO	O
withdrawal	VB	O
from	IN	O
the	DT	O
vial	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
(	(	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NNP	WHO
Class	NNP	WHO
B	NNP	WHO
)	)	WHO
and	CC	WHO
severe	JJ	WHO
(	(	WHO
Child	NNP	WHO
-	:	WHO
Pugh	NNP	WHO
Class	NNP	WHO
C	NNP	WHO
)	)	WHO
hepatic	JJ	WHO
impairment	NN	WHO
,	,	O
initiate	VB	O
VAPRISOL	NNP	O
with	IN	O
a	DT	O
loading	VBG	O
dose	NN	O
of	IN	O
10	CD	DOS
mg	NN	UNIT
over	IN	O
30	CD	O
minutes	NNS	O
followed	VBN	O
by	IN	O
10	CD	DOS
mg	NNS	UNIT
per	JJ	FREQ
day	NN	FREQ
as	IN	O
a	DT	O
continuous	JJ	O
infusion	NN	O
for	IN	O
2	CD	PER
to	TO	O
4	CD	PER
days	NNS	PER
.	.	O

If	IN	O
the	DT	O
resealable	JJ	O
rubber	NN	O
plug	NN	O
on	IN	O
the	DT	O
medication	NN	O
port	NN	O
is	VBZ	O
missing	VBG	O
or	CC	O
partly	RB	O
removed	VBN	O
,	,	O
do	VBP	O
not	RB	O
use	VB	O
the	DT	O
product	NN	O
if	IN	O
medication	NN	O
is	VBZ	O
to	TO	O
be	VB	O
added	VBN	O
.	.	O

Heparin	NNP	O
anti	SYM	O
-	:	O
coagulation	NN	O
is	VBZ	O
not	RB	O
recommended	JJ	O
because	IN	O
of	IN	O
the	DT	O
tendency	NN	O
to	TO	O
form	VB	O
clots	NNS	O
on	IN	O
storage	NN	O
.	.	O

Although	IN	O
there	EX	O
has	VBZ	O
been	VBN	O
no	DT	O
systematic	JJ	O
assessment	NN	O
of	IN	O
such	JJ	O
conversion	NN	O
,	,	O
start	NN	O
with	IN	O
a	DT	O
conservative	JJ	O
conversion	NN	O
:	:	O
substitute	NN	O
10	CD	DOS
mg	NN	UNIT
of	IN	O
OXYCONTIN	NNP	O
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
for	IN	O
each	DT	O
25	CD	O
mcg	NNS	O
per	IN	O
hour	NN	O
fentanyl	NN	O
transdermal	JJ	O
patch	NN	O
.	.	O

Discard	NNP	O
the	DT	O
syringe	NN	O
assembly	NN	O
in	IN	O
approved	JJ	O
containers	NNS	O
.	.	O

TEMODAR	NNP	O
for	IN	O
Injection	NNP	O
may	MD	O
be	VB	O
administered	VBN	O
in	IN	O
the	DT	O
same	JJ	O
intravenous	JJ	O
line	NN	O
with	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
injection	NN	O
only	RB	O
.	.	O

If	IN	O
either	DT	O
of	IN	O
these	DT	O
conditions	NNS	O
exist	VBP	O
,	,	O
the	DT	O
vaccine	NN	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
.	.	O

Dosage	NN	O
increases	NNS	O
should	MD	O
occur	VB	O
at	IN	O
weekly	JJ	FREQ
intervals	NNS	FREQ
based	VBN	O
on	IN	O
the	DT	O
patient	NN	O
’	NNP	O
s	VBD	O
clinical	JJ	O
response	NN	O
and	CC	O
tolerability	NN	O
.	.	O

The	DT	O
dose	NN	O
of	IN	O
ALFENTA	NNP	O
(	(	O
alfenta	NN	O
(	(	O
alfenta	JJ	O
(	(	O
alfentanil	NN	O
)	)	O
nil	NN	O
)	)	O
nil	NN	O
)	)	O
should	MD	O
be	VB	O
reduced	VBN	O
in	IN	O
elderly	JJ	WHO
or	CC	WHO
debilitated	JJ	WHO
patients	NNS	WHO
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
FLECTOR	NNP	O
PATCH	NNP	O
is	VBZ	O
one	CD	DOS
(	(	O
1	CD	DOS
)	)	O
patch	NN	UNIT
to	TO	O
the	DT	O
most	RBS	O
painful	JJ	O
area	NN	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Rapid	JJ	O
and	CC	O
complete	JJ	O
return	NN	O
of	IN	O
function	NN	O
usually	RB	O
follows	VBZ	O
.	.	O

Position	NN	O
the	DT	O
device	NN	O
in	IN	O
your	PRP$	O
hand	NN	O
between	IN	O
the	DT	O
thumb	NN	O
and	CC	O
middle	JJ	O
finger	NN	O
,	,	O
keeping	VBG	O
the	DT	O
index	NN	O
finger	VBD	O
free	JJ	O

The	DT	O
nebulized	JJ	O
solution	NN	O
may	MD	O
be	VB	O
inhaled	VBN	O
directly	RB	O
from	IN	O
the	DT	O
nebulizer	NN	O
.	.	O

Ensure	NN	O
use	NN	O
of	IN	O
aseptic	JJ	O
technique	NN	O
throughout	IN	O
the	DT	O
entire	JJ	O
procedure	NN	O
.	.	O

The	DT	O
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
once	RB	FREQ
daily	JJ	FREQ
since	IN	O
it	PRP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
that	IN	O
more	RBR	O
frequent	JJ	O
administration	NN	O
of	IN	O
prostaglandin	JJ	O
analogs	NNS	O
may	MD	O
lessen	VB	O
the	DT	O
intraocular	JJ	O
pressure	NN	O
lowering	VBG	O
effect	NN	O
.	.	O

For	IN	O
example	NN	O
,	,	O
if	IN	O
a	DT	O
patient	NN	WHO
with	IN	WHO
a	DT	WHO
body	NN	WHO
weight	NN	WHO
of	IN	WHO
70	CD	WHO
kg	NN	WHO
has	VBZ	O
an	DT	O
actual	JJ	O
IgG	NNP	O
trough	IN	O
level	NN	O
of	IN	O
900	CD	DOS
mg	NNS	UNIT
/	JJ	O
dL	NN	O
and	CC	O
the	DT	O
target	NN	O
trough	IN	O
level	NN	O
is	VBZ	O
1000	CD	DOS
mg	NN	UNIT
/	NNP	O
dL	NN	O
,	,	O
this	DT	O
results	NNS	O
in	IN	O
a	DT	O
difference	NN	O
of	IN	O
100	CD	DOS
mg	NNS	UNIT
/	JJ	O
dL	NN	O
.	.	O

The	DT	WHO
average	NN	WHO
depleted	VBD	WHO
major	JJ	WHO
surgical	JJ	WHO
patient	NN	WHO
with	IN	WHO
complications	NNS	WHO
requires	VBZ	O
between	IN	O
2500	CD	O
and	CC	O
4000	CD	O
kcal	JJ	O
and	CC	O
between	IN	O
12	CD	DOS
and	CC	O
24	CD	DOS
grams	NNS	UNIT
of	IN	O
nitrogen	JJ	O
per	IN	FREQ
day	NN	FREQ
.	.	O

Since	IN	O
initiation	NN	O
of	IN	O
GILENYA	NNP	O
treatment	NN	O
results	NNS	O
in	IN	O
decreased	JJ	O
heart	NN	O
rate	NN	O
and	CC	O
may	MD	O
prolong	VB	O
the	DT	O
QT	NNP	O
interval	NN	O
,	,	O
patients	NNS	WHO
with	IN	WHO
a	DT	WHO
prolonged	JJ	WHO
QTc	NNP	WHO
interval	NN	WHO
(	(	O
>	JJ	O
450	CD	O
msec	NN	O
males	NNS	O
,	,	O
>	VBP	O
470	CD	O
msec	JJ	O
females	NNS	O
)	)	O
before	IN	O
dosing	VBG	O
or	CC	O
during	IN	O
6	CD	O
hour	NN	O
observation	NN	O
,	,	O
or	CC	O
at	IN	O
additional	JJ	O
risk	NN	O
for	IN	O
QT	NNP	O
prolongation	NN	O
(	(	O
e.g	JJ	O
,	,	O
hypokalemia	NN	O
,	,	O
hypomagnesemia	NN	O
,	,	O
congenital	NN	O
long	RB	O
-	:	O
QT	NNP	O
syndrome	NN	O
)	)	O
,	,	O
or	CC	O
on	IN	O
concurrent	JJ	O
therapy	NN	O
with	IN	O
QT	NNP	O
prolonging	VBG	O
drugs	NNS	O
with	IN	O
a	DT	O
known	VBN	O
risk	NN	O
of	IN	O
torsades	NNS	O
de	FW	O
pointes	NNS	O
(	(	O
e.g	NN	O
,	,	O
citalopram	NN	O
,	,	O
chlorpromazine	NN	O
,	,	O
haloperidol	NN	O
,	,	O
methadone	NN	O
,	,	O
erythromycin	NN	O
)	)	O
should	MD	O
be	VB	O
monitored	VBN	O
overnight	JJ	O
with	IN	O
continuous	JJ	O
ECG	NNP	O
in	IN	O
a	DT	O
medical	JJ	O
facility	NN	O
[	NNP	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

Discard	NNP	O
unused	VBD	O
reconstituted	VBN	O
solution	NN	O
after	IN	O
3	CD	PER
days	NNS	PER
.	.	O

Long	NNP	O
-	:	O
acting	VBG	O
beta2	SYM	O
-	:	O
adrenergic	JJ	O
agonists	NNS	O
(	(	O
LABA	NNP	O
)	)	O
,	,	O
such	JJ	O
as	IN	O
formoterol	NN	O
,	,	O
the	DT	O
active	JJ	O
ingredient	NN	O
in	IN	O
FORADIL	NNP	O
AEROLIZER	NNP	O
,	,	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
asthma	JJ	O
-	:	O
related	VBN	O
death	NN	O
[	NN	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

See	VB	O
OVERDOSAGE	NNP	O
section	NN	O
for	IN	O
information	NN	O
regarding	VBG	O
dialysis	NN	O
.	.	O

As	IN	O
reported	VBN	O
in	IN	O
the	DT	O
literature	NN	O
,	,	O
the	DT	O
dosage	NN	O
and	CC	O
constant	JJ	O
infusion	NN	O
rate	NN	O
of	IN	O
intravenous	JJ	O
dextrose	NN	O
must	MD	O
be	VB	O
selected	VBN	O
with	IN	O
caution	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
,	,	WHO
particularly	RB	WHO
neonates	NNS	WHO
and	CC	WHO
low	JJ	WHO
weight	NN	WHO
infants	NNS	WHO
,	,	O
because	IN	O
of	IN	O
the	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
hyperglycemia	NN	O
/	NNP	O
hypoglycemia	NN	O
.	.	O

After	IN	O
administration	NN	O
,	,	O
any	DT	O
unused	JJ	O
solution	NN	O
and	CC	O
the	DT	O
administration	NN	O
equipment	NN	O
should	MD	O
be	VB	O
discarded	VBN	O
.	.	O

These	DT	O
volumes	NNS	O
yield	VBP	O
concentrations	NNS	O
specific	JJ	O
for	IN	O
the	DT	O
use	NN	O
for	IN	O
each	DT	O
indication	NN	O
(	(	O
Table	JJ	O
1	CD	O
)	)	O
.	.	O

The	DT	O
recommended	VBN	O
AMJEVITA	NNP	O
dose	JJ	O
regimen	NNS	O
for	IN	O
adult	NN	WHO
patients	NNS	WHO
with	IN	WHO
Crohn	NNP	WHO
's	POS	WHO
disease	NN	WHO
(	(	O
CD	NN	O
)	)	O
is	VBZ	O
160	CD	DOS
mg	NN	UNIT
initially	RB	O
on	IN	O
Day	NNP	O
1	CD	O
(	(	O
given	VBN	O
as	IN	O
four	CD	DOS
40	CD	DOS
mg	NN	UNIT
injections	NNS	UNIT
in	IN	O
one	CD	PER
day	NN	PER
or	CC	O
as	IN	O
two	CD	DOS
40	CD	DOS
mg	NNS	UNIT
injections	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
for	IN	O
two	CD	PER
consecutive	JJ	PER
days	NNS	PER
)	)	O
,	,	O
followed	VBN	O
by	IN	O
80	CD	DOS
mg	NNS	UNIT
two	CD	PER
weeks	NNS	PER
later	RB	O
(	(	O
Day	NNP	O
15	CD	O
)	)	O
.	.	O

For	IN	O
the	DT	O
treatment	NN	O
of	IN	O
status	NN	O
epilepticus	NN	O
,	,	O
the	DT	O
usual	JJ	O
recommended	VBD	O
dose	NN	O
of	IN	O
ATIVAN	NNP	O
Injection	NNP	O
is	VBZ	O
4	CD	DOS
mg	NN	UNIT
given	VBN	O
slowly	RB	O
(	(	O
2	CD	DOS
mg	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
for	IN	O
patients	NNS	WHO
18	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
.	.	O

Step	NN	O
3	CD	O
.	.	O

If	IN	O
Varicella	NNP	O
-	:	O
Zoster	NNP	O
Immune	NNP	O
Globulin	NNP	O
(	(	O
Human	NNP	O
)	)	O
is	VBZ	O
unavailable	JJ	O
,	,	O
GamaSTAN®	NNP	O
S	NNP	O
/	NNP	O
D	NNP	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
0.6	CD	DOS
to	TO	O
1.2	CD	DOS
mL	NNS	UNIT
/	JJ	O
kg	NN	O
,	,	O
promptly	RB	O
given	VBN	O
,	,	O
may	MD	O
also	RB	O
modify	VB	O
varicella	NN	O
(	(	O
5	CD	O
)	)	O
.	.	O

Caution	NN	O
:	:	O
Do	NNP	O
not	RB	O
use	VB	O
plastic	JJ	O
containers	NNS	O
in	IN	O
series	NN	O
connections	NNS	O
.	.	O

The	DT	O
complexities	NNS	O
associated	VBN	O
with	IN	O
methadone	NN	O
dosing	NN	O
can	MD	O
contribute	VB	O
to	TO	O
cases	NNS	O
of	IN	O
iatrogenic	JJ	O
overdose	JJ	O
,	,	O
particularly	RB	O
during	IN	O
treatment	NN	O
initiation	NN	O
and	CC	O
dose	JJ	O
titration	NN	O
.	.	O

To	TO	O
achieve	VB	O
maximum	JJ	O
contraceptive	JJ	O
and	CC	O
PMDD	NNP	O
effectiveness	NN	O
,	,	O
Beyaz	NNP	O
must	MD	O
be	VB	O
taken	VBN	O
as	IN	O
directed	JJ	O
,	,	O
in	IN	O
the	DT	O
order	NN	O
directed	VBD	O
on	IN	O
the	DT	O
blister	NN	O
pack	NN	O
.	.	O

Administer	NNP	O
Evomela	NNP	O
by	IN	O
injecting	VBG	O
slowly	RB	O
into	IN	O
a	DT	O
fast	JJ	O
-	:	O
running	VBG	O
IV	NNP	O
infusion	NN	O
via	IN	O
a	DT	O
central	JJ	O
venous	JJ	O
access	NN	O
line	NN	O
.	.	O

When	WRB	O
estrogen	NN	O
is	VBZ	O
prescribed	VBN	O
for	IN	O
a	DT	O
postmenopausal	JJ	O
woman	NN	O
with	IN	O
a	DT	O
uterus	NN	O
,	,	O
a	DT	O
progestin	NN	O
should	MD	O
also	RB	O
be	VB	O
initiated	VBN	O
to	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
endometrial	JJ	O
cancer	NN	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
intravenously	RB	O
or	CC	O
intramuscularly	RB	O
.	.	O

Before	IN	O
applying	VBG	O
VUSION	NNP	O
(	(	O
miconazole	JJ	O
nitrate	NN	O
,	,	O
15	CD	O
%	NN	O
zinc	NN	O
oxide	NN	O
,	,	O
and	CC	O
81.35	CD	O
%	NN	O
white	JJ	O
petrolatum	NN	O
)	)	O
,	,	O
gently	RB	O
cleanse	VBZ	O
the	DT	O
skin	NN	O
with	IN	O
lukewarm	JJ	O
water	NN	O
and	CC	O
pat	NN	O
dry	NN	O
with	IN	O
a	DT	O
soft	JJ	O
towel	NN	O
.	.	O

If	IN	O
Stimate®	NNP	O
Nasal	NNP	O
Spray	NNP	O
is	VBZ	O
used	VBN	O
preoperatively	RB	O
,	,	O
it	PRP	O
should	MD	O
be	VB	O
administered	VBN	O
2	CD	O
hours	NNS	O
prior	RB	O
to	TO	O
the	DT	O
scheduled	VBN	O
procedure.3,4	NN	O

Depressed	JJ	WHO
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
currently	RB	WHO
being	VBG	WHO
treated	VBN	WHO
at	IN	O
a	DT	O
therapeutic	JJ	O
dose	NN	O
with	IN	O
Effexor	NNP	O
(	(	O
immediate	JJ	O
release	NN	O
)	)	O
may	MD	O
be	VB	O
switched	VBN	O
to	TO	O
EFFEXOR	NNP	O
XR	NNP	O
at	IN	O
the	DT	O
nearest	JJS	O
equivalent	NN	O
dose	NN	O
(	(	O
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
)	)	O
,	,	O
e.g	RB	O
,	,	O
37.5	CD	DOS
mg	NN	UNIT
venlafaxine	NN	O
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
to	TO	O
75	CD	DOS
mg	NNS	UNIT
EFFEXOR	NNP	O
XR	NNP	O
once	RB	FREQ
daily	RB	FREQ
.	.	O

5	CD	O
.	.	O

However	RB	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
Antivenin	NNP	O
therapy	NN	O
be	VB	O
given	VBN	O
in	IN	O
severe	JJ	O
poisonings	NNS	O
,	,	O
even	RB	O
if	IN	O
24	CD	O
hours	NNS	O
have	VBP	O
elapsed	VBN	O
since	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
bite	NN	O
.	.	O

VIEKIRA	NNP	O
XR	NNP	O
is	VBZ	O
used	VBN	O
in	IN	O
combination	NN	O
with	IN	O
ribavirin	NN	O
(	(	O
RBV	NNP	O
)	)	O
in	IN	O
certain	JJ	O
patient	JJ	O
populations	NNS	O
(	(	O
see	VB	O
Table	NNP	O
1	CD	O
)	)	O
.	.	O

If	IN	O
VISTIDE	NNP	O
contacts	VBZ	O
the	DT	O
skin	NN	O
,	,	O
wash	NN	O
membranes	NNS	O
and	CC	O
flush	JJ	O
thoroughly	RB	O
with	IN	O
water	NN	O
.	.	O

A	DT	O
lower	JJR	O
starting	NN	O
dosage	NN	O
,	,	O
16.25	CD	DOS
mg	NN	UNIT
/	NNP	FREQ
day	NN	FREQ
,	,	O
is	VBZ	O
recommended	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
longstanding	JJ	WHO
myxedema	NNS	WHO
,	,	O
particularly	RB	O
if	IN	O
cardiovascular	JJ	O
impairment	NN	O
is	VBZ	O
suspected	VBN	O
,	,	O
in	IN	O
which	WDT	O
case	NN	O
extreme	NN	O
caution	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

When	WRB	O
initiating	VBG	O
therapy	NN	O
or	CC	O
upon	IN	O
increasing	VBG	O
dose	NN	O
,	,	O
blood	NN	O
pressure	NN	O
should	MD	O
be	VB	O
measured	VBN	O
2	CD	O
to	TO	O
4	CD	O
hours	NNS	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
or	CC	O
dose	JJ	O
increase	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
at	IN	O
the	DT	O
end	NN	O
of	IN	O
a	DT	O
dosing	NN	O
interval	NN	O
.	.	O

(	(	O
Note	NN	O
:	:	O
Each	DT	O
vial	NN	O
contains	VBZ	O
a	DT	O
6	CD	O
%	NN	O
overage	NN	O
.	.	O

If	IN	O
leaks	NNS	O
are	VBP	O
found	VBN	O
,	,	O
discard	JJ	O
solution	NN	O
as	IN	O
sterility	NN	O
may	MD	O
be	VB	O
impaired	VBN	O
.	.	O

Figure	NN	O
2	CD	O
:	:	O
After	IN	O
expelling	VBG	O
air	NN	O
bubble	JJ	O
and	CC	O
excess	JJ	O
drug	NN	O

After	IN	O
3	CD	PER
months	NNS	PER
,	,	O
dosage	NN	O
may	MD	O
be	VB	O
adjusted	VBN	O
as	IN	O
follows	VBZ	O
:	:	O

Sites	NNS	O
of	IN	O
active	JJ	O
infection	NN	O
may	MD	O
also	RB	O
be	VB	O
enhanced	VBN	O
following	VBG	O
contrast	NN	O
medium	JJ	O
administration	NN	O
.	.	O

Restart	NNP	O
PRADAXA	NNP	O
as	RB	O
soon	RB	O
as	IN	O
medically	RB	O
appropriate	JJ	O
.	.	O

Doses	NNS	O
administered	VBN	O
should	MD	O
be	VB	O
titrated	VBN	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
clinical	JJ	O
response	NN	O
.	.	O

Long	NNP	O
-	:	O
term	NN	O
administration	NN	O
of	IN	O
DUOPA	NNP	O
requires	VBZ	O
placement	NN	O
of	IN	O
a	DT	O
PEG	NNP	O
-	:	O
J	NNP	O
outer	MD	O
transabdominal	VB	O
tube	NN	O
and	CC	O
inner	JJ	O
jejunal	JJ	O
tube	NN	O
by	IN	O
percutaneous	JJ	O
endoscopic	NN	O
gastrostomy	NN	O
.	.	O

Maintenance	NN	O
doses	NNS	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
more	RBR	O
frequently	RB	O
than	IN	O
weekly	RB	FREQ
.	.	O

The	DT	O
Eckert	NNP	O
&	CC	O
Ziegler	NNP	O
GalliaPharm	NNP	O
Ge	NNP	O
68	CD	O
/	NNP	O
Ga	NNP	O
68	CD	O
generator	NN	O
(	(	O
“	JJ	O
GalliaPharm	NNP	O
generator	NN	O
”	NN	O
)	)	O
is	VBZ	O
not	RB	O
supplied	VBN	O
with	IN	O
the	DT	O
NETSPOT	NNP	O
kit	NN	O
.	.	O

Table	JJ	O
3	CD	O
:	:	O
Immune	NNP	O
Globulin	NNP	O
Infusion	NNP	O
10	CD	O
%	NN	O
(	(	O
Human	NNP	O
)	)	O
Infusion	NN	O
Rates	NNS	O

AUGMENTIN	$	O
250	CD	DOS
mg	NN	UNIT
/	VBD	O
5	CD	DOS
mL	NN	UNIT
Suspension	NN	UNIT

In	IN	O
the	DT	O
controlled	JJ	O
trial	NN	O
,	,	O
few	JJ	O
patients	NNS	O
received	VBD	O
a	DT	O
total	JJ	O
dose	NN	O
of	IN	O
greater	JJR	O
than	IN	O
75	CD	DOS
Units	NNS	UNIT
.	.	O

The	DT	O
solution	NN	O
should	MD	O
be	VB	O
clear	JJ	O
to	TO	O
slightly	RB	O
opalescent	JJ	O
and	CC	O
colorless	NN	O
to	TO	O
pale	VB	O
yellow	JJ	O
when	WRB	O
diluted	VBN	O
.	.	O

(	(	O
see	VB	O
Figure	NNP	O
4	CD	O
.	.	O
)	)	O

SILIQ	NNP	O
is	VBZ	O
intended	VBN	O
for	IN	O
use	NN	O
under	IN	O
the	DT	O
guidance	NN	O
and	CC	O
supervision	NN	O
of	IN	O
a	DT	O
healthcare	JJ	O
professional	NN	O
.	.	O

Additives	NNS	O
may	MD	O
be	VB	O
incompatible	JJ	O
.	.	O

Hospitalized	VBN	WHO
patients	NNS	WHO
may	MD	O
require	VB	O
100	CD	DOS
mg	NNS	UNIT
a	DT	FREQ
day	NN	FREQ
initially	RB	O
.	.	O

Therapy	NN	O
,	,	O
thus	RB	O
,	,	O
should	MD	O
aim	VB	O
at	IN	O
not	RB	O
only	RB	O
replenishment	NN	O
of	IN	O
hemoglobin	NN	O
iron	NN	O
but	CC	O
iron	NN	O
stores	NNS	O
as	IN	O
well	RB	O
.	.	O

Testing	VBG	O
for	IN	O
TPMT	NNP	O
gene	NN	O
polymorphism	NN	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
patients	NNS	WHO
who	WP	WHO
experience	VBP	WHO
severe	JJ	WHO
bone	NN	WHO
marrow	NN	WHO
toxicities	NNS	WHO
[	VBP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

In	IN	O
children	NNS	WHO
24	CD	WHO
months	NNS	WHO
through	IN	WHO
5	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
,	,	O
lower	JJR	O
antibody	NN	O
concentrations	NNS	O
were	VBD	O
observed	VBN	O
for	IN	O
some	DT	WHO
serotypes	NNS	WHO
,	,	O
compared	VBN	O
to	TO	O
antibody	VB	O
concentrations	NNS	O
following	VBG	O
3	CD	DOS
doses	NNS	UNIT
of	IN	O
Prevnar	NNP	O
13	CD	O
(	(	O
given	VBN	O
at	IN	O
2	CD	O
,	,	O
4	CD	O
,	,	O
and	CC	O
6	CD	O
months	NNS	O
)	)	O

General	NNP	O
:	:	O
The	DT	O
duration	NN	O
of	IN	O
infusion	NN	O
may	MD	O
vary	VB	O
with	IN	O
the	DT	O
dose	NN	O
(	(	O
100	CD	DOS
to	TO	O
200	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
)	)	O
,	,	O
but	CC	O
is	VBZ	O
usually	RB	O
one	CD	O
to	TO	O
four	CD	O
hours	NNS	O
.	.	O

Adult	NNP	WHO
dosage	NN	WHO
:	:	O
The	DT	O
maximum	NN	O
recommended	VBD	O
initial	JJ	O
dose	NN	O
of	IN	O
INAPSINE	NNP	O
(	(	O
droperidol	NN	O
)	)	O
is	VBZ	O
2.5	CD	DOS
mg	NN	UNIT
IM	NNP	O
or	CC	O
slow	VB	O
IV	NNP	O
.	.	O

The	DT	O
acetaminophen	JJ	O
concentration	NN	O
was	VBD	O
in	IN	O
the	DT	O
non	JJ	O
-	:	O
toxic	NN	O
range	NN	O
,	,	O
but	CC	O
time	NN	O
of	IN	O
ingestion	NN	O
was	VBD	O
unknown	JJ	O
or	CC	O
less	JJR	O
than	IN	O
4	CD	O
hours	NNS	O
:	:	O

Sedative	JJ	O
medication	NN	O
may	MD	O
be	VB	O
employed	VBN	O
prior	RB	O
to	TO	O
use	VB	O
.	.	O

2	CD	O
.	.	O

The	DT	O
spring	NN	O
-	:	O
mechanism	NN	O
of	IN	O
the	DT	O
needle	JJ	O
guard	NN	O
apparatus	NN	O
affixed	VBD	O
to	TO	O
the	DT	O
prefilled	JJ	O
syringe	NN	O
interferes	NNS	O
with	IN	O
the	DT	O
visibility	NN	O
of	IN	O
the	DT	O
graduation	NN	O
markings	NNS	O
on	IN	O
the	DT	O
syringe	NN	O
barrel	NN	O
corresponding	VBG	O
to	TO	O
0.1	CD	DOS
mL	NNS	UNIT
and	CC	O
0.2	CD	DOS
mL	NN	UNIT
.	.	O

Clinical	JJ	O
symptoms	NNS	O
usually	RB	O
subside	VBP	O
promptly	RB	O
within	IN	O
3	CD	PER
to	TO	O
5	CD	PER
days	NNS	PER
.	.	O

Although	IN	O
efficacy	NN	O
has	VBZ	O
been	VBN	O
demonstrated	VBN	O
in	IN	O
studies	NNS	O
of	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
with	IN	WHO
bipolar	JJ	WHO
mania	NN	WHO
at	IN	O
doses	NNS	O
between	IN	O
0.5	CD	DOS
mg	NNS	UNIT
and	CC	O
6	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
,	,	O
no	DT	O
additional	JJ	O
benefit	NN	O
was	VBD	O
observed	VBN	O
above	IN	O
2.5	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
,	,	O
and	CC	O
higher	JJR	O
doses	NNS	O
were	VBD	O
associated	VBN	O
with	IN	O
more	RBR	O
adverse	JJ	O
events	NNS	O
.	.	O

On	IN	O
Sunday	NNP	O
the	DT	O
patient	NN	O
should	MD	O
throw	VB	O
out	RP	O
the	DT	O
rest	NN	O
of	IN	O
that	DT	O
cycle	NN	O
pack	NN	O
and	CC	O
start	VB	O
a	DT	O
new	JJ	O
cycle	NN	O
pack	NN	O
that	WDT	O
same	JJ	FREQ
day	NN	FREQ
.	.	O

However	RB	O
,	,	O
if	IN	O
intercourse	NN	O
has	VBZ	O
already	RB	O
occurred	VBN	O
,	,	O
pregnancy	NN	O
should	MD	O
be	VB	O
excluded	VBN	O
before	IN	O
the	DT	O
start	NN	O
of	IN	O
combined	JJ	O
oral	JJ	O
contraceptive	NN	O
use	NN	O
or	CC	O
the	DT	O
patient	NN	O
must	MD	O
wait	VB	O
for	IN	O
her	PRP$	O
first	JJ	O
menstrual	JJ	O
period	NN	O
.	.	O

For	IN	O
less	JJR	O
severe	JJ	O
poisoning	VBG	O
the	DT	O
dose	NN	O
can	MD	O
be	VB	O
reduced	VBN	O
to	TO	O
3	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
.	.	O

When	WRB	O
changing	VBG	O
the	DT	O
system	NN	O
,	,	O
instruct	NN	O
patients	NNS	O
to	TO	O
remove	VB	O
BUTRANS	NNP	O
and	CC	O
dispose	NN	O
of	IN	O
it	PRP	O
properly	JJ	O
[	NNP	O
see	NN	O
Disposal	NNP	O
Instructions	NNP	O
]	NNP	O
.	.	O

Initiate	NNP	O
therapy	NN	O
using	VBG	O
the	DT	O
expected	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
warfarin	NN	O
.	.	O

Assumption	NN	O
:	:	O
Patient	NN	O
's	POS	O
weight	NN	O
=	VBZ	O
75	CD	O
kg	NN	O
,	,	O
patient	NN	O
's	POS	O
IVR	NNP	O
=	VBZ	O
1.8	CD	DOS
(	(	O
IU	NNP	O
/	NNP	O
dL	NN	O
)	)	O
/	NN	O
(	(	O
IU	NNP	O
/	NNP	O
kg	NN	O
)	)	O

Do	NNP	O
not	RB	O
filter	VB	O
SURVANTA	NNP	O
and	CC	O
avoid	VB	O
shaking	NN	O
.	.	O

This	DT	O
is	VBZ	O
to	TO	O
ensure	VB	O
that	IN	O
the	DT	O
amount	NN	O
of	IN	O
inactive	JJ	O
solid	JJ	O
particles	NNS	O
per	IN	O
dose	NN	O
remains	VBZ	O
constant	JJ	O
throughout	IN	O
the	DT	O
duration	NN	O
of	IN	O
use	NN	O
.	.	O

After	IN	O
all	DT	O
28	CD	O
tablets	NNS	O
have	VBP	O
been	VBN	O
taken	VBN	O
,	,	O
whether	IN	O
bleeding	NN	O
has	VBZ	O
stopped	VBN	O
or	CC	O
not	RB	O
,	,	O
the	DT	O
same	JJ	O
dosage	NN	O
schedule	NN	O
is	VBZ	O
repeated	VBN	O
beginning	VBG	O
on	IN	O
the	DT	O
following	JJ	O
day	NN	O
.	.	O

(	(	O
Saddle	NNP	O
block	NN	O
has	VBZ	O
been	VBN	O
suggested	VBN	O
.	.	O
)	)	O

In	IN	O
addition	NN	O
to	TO	O
the	DT	O
Viadur®	NNP	O
(	(	O
leuprolide	JJ	O
acetate	NN	O
implant	NN	O
)	)	O
Kit	NNP	O
,	,	O
sterile	JJ	O
gloves	NNS	O
are	VBP	O
required	VBN	O
for	IN	O
the	DT	O
insertion	NN	O
procedure	NN	O
and	CC	O
subsequent	JJ	O
removal	NN	O
of	IN	O
the	DT	O
implant	NN	O
.	.	O

However	RB	O
,	,	O
older	JJR	WHO
pediatric	JJ	WHO
patients	NNS	WHO
can	MD	O
receive	VB	O
Aminosyn	NNP	O
II	NNP	O
3.5	CD	O
%	NN	O
in	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
(	(	O
amino	JJ	O
acid	NN	O
injection	NN	O
in	IN	O
dextrose	JJ	O
injection	NN	O
)	)	O
Injection	NN	O
.	.	O

Table	JJ	O
1.0	CD	O
-	:	O
Radiation	NN	O
Absorbed	NNP	O
Doses	VBZ	O
from	IN	O
Tc99m	NNP	O
Sestamibi	NNP	O

Safely	RB	O
discard	IN	O
the	DT	O
gel	NN	O
from	IN	O
the	DT	O
first	JJ	O
three	CD	O
actuations	NNS	O
.	.	O

Apply	VB	O
a	DT	O
thin	JJ	O
film	NN	O
of	IN	O
Clindagel®	NNP	O
once	RB	FREQ
daily	RB	FREQ
to	TO	O
the	DT	O
skin	NN	O
where	WRB	O
acne	NN	O
lesions	NNS	O
appear	VBP	O
.	.	O

Dosage	NN	O
is	VBZ	O
a	DT	O
patient	JJ	O
dependent	NN	O
variable	NN	O
,	,	O
therefore	RB	O
increased	VBD	O
dosage	NN	O
may	MD	O
be	VB	O
required	VBN	O
to	TO	O
achieve	VB	O
adequate	JJ	O
analgesia	NN	O
.	.	O

Aldara	NNP	O
Cream	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
prior	JJ	O
to	TO	O
normal	JJ	O
sleeping	NN	O
hours	NNS	O
and	CC	O
left	VBD	O
on	IN	O
the	DT	O
skin	NN	O
for	IN	O
approximately	RB	O
8	CD	O
hours	NNS	O
,	,	O
after	IN	O
which	WDT	O
time	NN	O
the	DT	O
cream	NN	O
should	MD	O
be	VB	O
removed	VBN	O
by	IN	O
washing	VBG	O
the	DT	O
area	NN	O
with	IN	O
mild	JJ	O
soap	NN	O
and	CC	O
water	NN	O
.	.	O

Upon	IN	O
evidence	NN	O
of	IN	O
hematologic	NN	O
or	CC	O
other	JJ	O
toxicity	NN	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
section	NN	O
)	)	O
,	,	O
the	DT	O
drug	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
until	IN	O
there	EX	O
has	VBZ	O
been	VBN	O
satisfactory	JJ	O
recovery	NN	O
,	,	O
based	VBN	O
on	IN	O
clinical	JJ	O
evaluation	NN	O
and	CC	O
appropriate	JJ	O
laboratory	NN	O
tests	NNS	O
.	.	O

Clearance	NN	O
measurements	NNS	O
using	VBG	O
single	JJ	DOS
injection	NN	UNIT
techniques	NNS	UNIT
are	VBP	O
generally	RB	O
inaccurate	JJ	O
,	,	O
particularly	RB	O
in	IN	O
the	DT	O
measurement	NN	O
of	IN	O
ERPF	NNP	O
.	.	O

Total	JJ	O
daily	JJ	FREQ
doses	NNS	O
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
divided	JJ	O
doses	NNS	O
(	(	O
b.i.d	NN	O
.	.	O
)	)	O
.	.	O

Consult	NNP	O
recommendations	NNS	O
of	IN	O
the	DT	O
Advisory	NNP	O
Committee	NNP	O
on	IN	O
Immunization	NNP	O
Practices	NNP	O
for	IN	O
additional	JJ	O
interventions	NNS	O
for	IN	O
diphtheria	NN	O
prophylaxis	NN	O
in	IN	O
close	JJ	O
contacts	NNS	O
of	IN	O
diphtheria	NN	O
patients.1	NN	O

This	DT	O
has	VBZ	O
not	RB	O
interfered	VBN	O
with	IN	O
the	DT	O
procedure	NN	O
.	.	O

The	DT	O
lowest	JJS	O
effective	JJ	O
dose	NN	O
should	MD	O
be	VB	O
used	VBN	O
.	.	O

A	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
LEVITRA	NNP	O
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
patients	NNS	WHO
≥	JJ	WHO
65	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
[	NNP	O
see	NN	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Because	IN	O
desglymidodrine	NN	O
is	VBZ	O
excreted	VBN	O
renally	RB	O
,	,	O
dosing	VBG	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
abnormal	JJ	WHO
renal	JJ	WHO
function	NN	WHO
should	MD	O
be	VB	O
cautious	JJ	O
;	:	O
although	IN	O
this	DT	O
has	VBZ	O
not	RB	O
been	VBN	O
systematically	RB	O
studied	VBN	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
treatment	NN	O
of	IN	O
these	DT	WHO
patients	NNS	WHO
be	VB	WHO
initiated	VBN	WHO
using	VBG	WHO
2.5	CD	DOS
-	:	O
mg	NN	UNIT
doses	NNS	UNIT
.	.	O

Preterm	JJ	WHO
infants	NNS	WHO
should	MD	O
be	VB	O
vaccinated	VBN	O
according	VBG	O
to	TO	O
their	PRP$	O
chronological	JJ	O
age	NN	O
from	IN	O
birth.3,22	NN	O

Each	DT	O
carton	NN	O
of	IN	O
DepoDur	NNP	O
(	(	O
morphine	JJ	O
sulfate	NN	O
xr	NNP	O
liposome	NNP	O
injection	NN	O
)	)	O
includes	VBZ	O
a	DT	O
freeze	NN	O
indicator	NN	O
that	WDT	O
should	MD	O
be	VB	O
checked	VBN	O
prior	RB	O
to	TO	O
administration	NN	O
of	IN	O
the	DT	O
product	NN	O
.	.	O

The	DT	O
described	JJ	O
mixtures	NNS	O
can	MD	O
be	VB	O
pre	JJ	O
-	:	O
prepared	JJ	O
and	CC	O
stored	VBD	O
for	IN	O
up	IN	O
to	TO	O
24	CD	O
hours	NNS	O
at	IN	O
room	NN	O
temperature	NN	O
or	CC	O
up	RB	O
to	TO	O
48	CD	O
hours	NNS	O
under	IN	O
refrigeration	NN	O
.	.	O

An	DT	O
alternate	NN	O
rough	NN	O
guide	NN	O
for	IN	O
determining	VBG	O
reduced	JJ	O
dosage	NN	O
at	IN	O
12	CD	O
-	:	O
hour	NN	O
intervals	NNS	O
(	(	O
for	IN	O
patients	NNS	WHO
whose	WP$	WHO
steady	JJ	WHO
state	NN	WHO
serum	NN	WHO
creatinine	NN	WHO
values	NNS	WHO
are	VBP	WHO
known	VBN	WHO
)	)	WHO
is	VBZ	O
to	TO	O
divide	VB	O
the	DT	O
normally	RB	O
recommended	VBN	O
dose	NN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
serum	JJ	O
creatinine	NN	O
.	.	O

For	IN	O
patients	NNS	O
judged	VBN	O
to	TO	O
be	VB	O
at	IN	O
risk	NN	O
for	IN	O
developing	VBG	O
renal	JJ	O
dysfunction	NN	O
,	,	O
Carimune®	NNP	O
NF	NNP	O
should	MD	O
be	VB	O
infused	VBN	O
at	IN	O
a	DT	O
rate	NN	O
less	JJR	O
than	IN	O
2	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
/	NNP	O
min	NN	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
DILAUDID	NNP	O
-	:	O
HP	NN	O
for	IN	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
not	RB	WHO
tolerant	JJ	WHO
to	TO	WHO
the	DT	WHO
respiratory	NN	WHO
depressant	NN	WHO
or	CC	O
sedating	VBG	O
effects	NNS	O
of	IN	O
opioids	NNS	O
.	.	O

It	PRP	O
must	MD	O
be	VB	O
handled	VBN	O
with	IN	O
adequate	JJ	O
security	NN	O
,	,	O
accountability	NN	O
,	,	O
and	CC	O
proper	JJ	O
disposal	NN	O
,	,	O
per	IN	O
facility	NN	O
procedure	NN	O
for	IN	O
a	DT	O
Schedule	NNP	O
III	NNP	O
drug	NN	O
product	NN	O
,	,	O
and	CC	O
per	IN	O
applicable	JJ	O
federal	JJ	O
,	,	O
state	NN	O
,	,	O
and	CC	O
local	JJ	O
regulations	NNS	O
.	.	O

NARCAN	NNP	O
(	(	O
naloxone	NN	O
)	)	O
may	MD	O
be	VB	O
administered	VBN	O
intravenously	RB	O
,	,	O
intramuscularly	RB	O
,	,	O
or	CC	O
subcutaneously	RB	O
.	.	O

In	IN	O
the	DT	O
case	NN	O
of	IN	O
first	JJ	O
-	:	O
trimester	NN	O
abortion	NN	O
,	,	O
if	IN	O
the	DT	O
patient	NN	O
starts	VBZ	O
Lo	NNP	O
/	NNP	O
Ovral	NNP	O
immediately	RB	O
,	,	O
additional	JJ	O
contraceptive	NN	O
measures	NNS	O
are	VBP	O
not	RB	O
needed	VBN	O
.	.	O

The	DT	O
maximum	JJ	O
daily	JJ	FREQ
dose	NN	O
was	VBD	O
3000	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

When	WRB	O
colesevelam	NN	O
is	VBZ	O
coadministered	VBN	O
with	IN	O
glimepiride	NN	O
,	,	O
maximum	JJ	O
plasma	JJ	O
concentration	NN	O
and	CC	O
total	JJ	O
exposure	NN	O
to	TO	O
glimepiride	VB	O
is	VBZ	O
reduced	VBN	O
.	.	O

324	CD	O

VERAPAMIL	NNP	O
HYDROCHLORIDE	NNP	O
INJECTION	NNP	O
SHOULD	NNP	O
BE	NNP	O
GIVEN	NNP	O
AS	IN	O
A	NNP	O
SLOW	NNP	O
INTRAVENOUS	NNP	O
INJECTION	NNP	O
OVER	NNP	O
AT	NNP	O
LEAST	NNP	O
A	NNP	O
TWO	NNP	O
-	:	O
MINUTE	NNP	O
PERIOD	NNP	O
OF	IN	O
TIME	NNP	O
UNDER	NNP	O
CONTINUOUS	NNP	O
ELECTROCARDIOGRAPHIC	NNP	O
(	(	O
ECG	NNP	O
)	)	O
AND	NNP	O
BLOOD	NNP	O
PRESSURE	NNP	O
MONITORING	NNP	O
.	.	O

ConZip™	NNP	O
is	VBZ	O
an	DT	O
extended	JJ	O
-	:	O
release	NN	O
formulation	NN	O
intended	VBN	O
for	IN	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
dosing	VBG	O
in	IN	O
adults	NNS	WHO
aged	VBN	WHO
18	CD	WHO
years	NNS	WHO
and	CC	WHO
older	JJR	WHO
.	.	O

Check	NNP	O
for	IN	O
minute	NN	O
leaks	NNS	O
by	IN	O
squeezing	VBG	O
container	NN	O
firmly	RB	O
.	.	O

IMPORTANT	NN	O
:	:	O
Do	VBP	O
not	RB	O
rub	VB	O
the	DT	O
injection	NN	O
site	NN	O
after	IN	O
retracting	VBG	O
the	DT	O
needle	NN	O
.	.	O

3	CD	O
.	.	O

Daytrana	NNP	O
patches	NNS	O
should	MD	O
be	VB	O
peeled	VBN	O
off	RP	O
slowly	RB	O
.	.	O

(	(	O
Two	CD	DOS
capsules	NNS	UNIT
daily	RB	FREQ
produce	VBP	O
a	DT	O
standard	JJ	O
response	NN	O
in	IN	O
the	DT	O
average	NN	O
uncomplicated	JJ	O
case	NN	O
of	IN	O
pernicious	JJ	O
anemia	NN	O
.	.	O
)	)	O

The	DT	O
initial	JJ	O
dose	NN	O
and	CC	O
dose	JJ	O
titrations	NNS	O
should	MD	O
be	VB	O
performed	VBN	O
by	IN	O
a	DT	O
healthcare	NN	O
provider	NN	O
.	.	O

For	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
3	CD	WHO
months	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
,	,	O
the	DT	O
MERREM	NNP	O
I.V	NNP	O
.	.	O

In	IN	O
clinical	JJ	O
studies	NNS	O
,	,	O
patients	NNS	WHO
with	IN	WHO
creatinine	JJ	WHO
clearance	NN	WHO
≥	VBD	WHO
45	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
required	VBD	O
no	DT	O
dose	JJ	O
adjustments	NNS	O
other	JJ	O
than	IN	O
those	DT	O
recommended	VBN	O
for	IN	O
all	DT	WHO
patients	NNS	WHO
.	.	O

Discard	NNP	O
any	DT	O
unused	JJ	O
portion	NN	O
of	IN	O
product	NN	O
remaining	VBG	O
in	IN	O
the	DT	O
2	CD	DOS
mL	NN	UNIT
vial	NN	UNIT
.	.	O

The	DT	O
single	JJ	DOS
-	:	O
dose	JJ	O
vial	NN	O
of	IN	O
CernevitTM	NNP	O
(	(	O
multivitamins	NNS	O
for	IN	O
infusion	NN	O
)	)	O
is	VBZ	O
reconstituted	VBN	O
by	IN	O
adding	VBG	O
5	CD	DOS
mL	NN	UNIT
of	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
into	IN	O
the	DT	O
vial	JJ	O
and	CC	O
gently	RB	O
mixing	VBG	O
to	TO	O
dissolve	VB	O
the	DT	O
lyophilized	JJ	O
powder	NN	O
.	.	O

Dosage	NN	O
should	MD	O
then	RB	O
be	VB	O
adjusted	VBN	O
according	VBG	O
to	TO	O
response	NN	O
.	.	O

Units	NNS	O
required	VBN	O
to	TO	O
raise	VB	O
blood	NN	O
level	NN	O
percentages	NNS	O
:	:	O

Because	IN	O
of	IN	O
the	DT	O
insufficient	NN	O
data	NNS	O
,	,	O
miliary	JJ	O
tuberculosis	NN	O
,	,	O
bone	NN	O
/	VBD	O
joint	JJ	O
tuberculosis	NN	O
,	,	O
and	CC	O
tuberculosis	NN	O
meningitis	NN	O
in	IN	O
infants	NNS	WHO
and	CC	WHO
children	NNS	WHO
should	MD	O
receive	VB	O
12	CD	O
month	NN	O
therapy	NN	O
.	.	O

Allow	IN	O
the	DT	O
vial	NN	O
of	IN	O
ELOCTATE	NNP	O
and	CC	O
pre	SYM	O
-	:	O
filled	VBN	O
diluent	JJ	O
syringe	NN	O
to	TO	O
reach	VB	O
room	NN	O
temperature	NN	O
before	IN	O
use	NN	O
.	.	O

After	IN	O
removal	NN	O
of	IN	O
all	DT	O
four	CD	O
implants	NNS	O
,	,	O
clean	VBP	O
the	DT	O
incision	NN	O
site	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
type	JJ	WHO
2	CD	WHO
diabetes	NNS	WHO
,	,	O
EXUBERA	NNP	O
(	(	O
insulin	JJ	O
human	JJ	O
[	NN	O
rdna	NN	O
origin	IN	O
]	NNP	O
)	)	O
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
monotherapy	NN	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
oral	JJ	O
agents	NNS	O
or	CC	O
longer	JJR	O
-	:	O
acting	NN	O
insulin	NN	O
.	.	O

Alternatively	RB	O
,	,	O
four	CD	DOS
injections	NNS	UNIT
of	IN	O
3.6	CD	DOS
mg	NNS	UNIT
depot	NN	O
can	MD	O
be	VB	O
administered	VBN	O
at	IN	O
28	CD	O
-	:	O
day	NN	O
intervals	NNS	O
,	,	O
two	CD	O
depots	NNS	O
preceding	VBG	O
and	CC	O
two	CD	O
during	IN	O
radiotherapy	NN	O
.	.	O

Both	DT	O
of	IN	O
these	DT	O
methods	NNS	O
are	VBP	O
suggested	VBN	O
as	IN	O
guides	NNS	O
to	TO	O
be	VB	O
used	VBN	O
when	WRB	O
serum	JJ	O
levels	NNS	O
of	IN	O
tobramycin	NN	O
can	MD	O
not	RB	O
be	VB	O
measured	VBN	O
directly	RB	O
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
varies	NNS	O
from	IN	O
0.75	CD	DOS
to	TO	O
9	CD	DOS
mg	NNS	UNIT
a	DT	FREQ
day	NN	FREQ
depending	VBG	O
on	IN	O
the	DT	O
disease	NN	O
being	VBG	O
treated	VBN	O
.	.	O

Drug	NN	O
Interactions	NNP	O
-	:	O
Vincristine	NNP	O
Sulfate	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
(	(	O
vincristine	JJ	O
sulfate	NN	O
)	)	O
should	MD	O
not	RB	O
be	VB	O
diluted	VBN	O
in	IN	O
solutions	NNS	O
that	WDT	O
raise	VBP	O
or	CC	O
lower	JJR	O
the	DT	O
pH	NN	O
outside	IN	O
the	DT	O
range	NN	O
of	IN	O
3.5	CD	O
to	TO	O
5.5	CD	O
.	.	O

For	IN	O
patients	NNS	WHO
not	RB	WHO
adequately	RB	WHO
controlled	VBN	WHO
on	IN	WHO
either	DT	WHO
glyburide	NN	WHO
(	(	O
or	CC	O
another	DT	O
sulfonylurea	NN	O
)	)	O
or	CC	O
metformin	VB	O
alone	RB	O
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
GLUCOVANCE	NNP	O
is	VBZ	O
2.5	CD	DOS
mg	NN	UNIT
/	VBD	O
500	CD	DOS
mg	NN	UNIT
or	CC	O
5	CD	DOS
mg	NNS	UNIT
/	VBD	O
500	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
with	IN	O
the	DT	O
morning	NN	O
and	CC	O
evening	NN	O
meals	NNS	O
.	.	O

Keep	VB	O
this	DT	O
leaflet	NN	O
in	IN	O
a	DT	O
safe	JJ	O
place	NN	O
and	CC	O
refer	NN	O
to	TO	O
it	PRP	O
when	WRB	O
questions	NNS	O
arise	VBP	O
.	.	O

Each	DT	O
sprayer	NN	O
contains	VBZ	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
;	:	O
approximately	RB	O
one	CD	O
-	:	O
half	NN	O
of	IN	O
the	DT	O
contents	NNS	O
should	MD	O
be	VB	O
administered	VBN	O
into	IN	O
each	DT	O
nostril	NN	O
.	.	O

Patients	NNS	O
should	MD	O
complete	VB	O
any	DT	O
necessary	JJ	O
immunizations	NNS	O
at	IN	O
least	JJS	O
6	CD	PER
weeks	NNS	PER
prior	RB	O
to	TO	O
treatment	NN	O
with	IN	O
LEMTRADA	NNP	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

To	TO	O
do	VB	O
so	RB	O
,	,	O
with	IN	O
the	DT	O
canister	NN	O
in	IN	O
the	DT	O
upright	JJ	O
position	NN	O
,	,	O
slowly	RB	O
and	CC	O
fully	RB	O
depress	VB	O
the	DT	O
actuator	NN	O
three	CD	FREQ
times	NNS	FREQ
.	.	O

INVOKANA	NNP	O
is	VBZ	O
contraindicated	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
an	DT	WHO
eGFR	NN	WHO
less	JJR	WHO
than	IN	O
30	CD	DOS
mL	JJ	UNIT
/	NNP	O
min	NN	O
/	VBD	O
1.73	CD	O
m2	NN	O
[	NNP	O
see	VBP	O
CONTRAINDICATIONS	NNP	O
]	NNP	O
.	.	O

2	CD	O
.	.	O

Several	JJ	O
guidelines	NNS	O
on	IN	O
this	DT	O
subject	NN	O
have	VBP	O
been	VBN	O
published	VBN	O
(	(	O
1	CD	DOS
-	:	O
5	CD	O
)	)	O
.	.	O

Potency	NN	O
is	VBZ	O
not	RB	O
affected	VBN	O
.	.	O

Table	JJ	O
3	CD	O
:	:	O
Ascending	JJ	O
Dosage	NNP	O
Schedule	NNP	O
of	IN	O
MIRAPEX	NNP	O
tablets	NNS	O
for	IN	O
RLS	NNP	O

Multiple	NNP	O
-	:	O
drug	NN	O
resistant	JJ	O
tuberculosis	NN	O
(	(	O
i.e	JJ	O
,	,	O
resistance	NN	O
to	TO	O
at	IN	O
least	JJS	O
isoniazid	NN	O
and	CC	O
rifampin	NN	O
)	)	O
presents	VBZ	O
difficult	JJ	O
treatment	NN	O
problems	NNS	O
.	.	O

COPEGUS	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
with	IN	O
food	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
is	VBZ	O
two	CD	DOS
NAPRELAN	NNP	O
500	CD	DOS
mg	NN	UNIT
tablets	NNS	UNIT
(	(	O
1000	CD	DOS
mg	NN	UNIT
)	)	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

The	DT	O
expiration	NN	O
date	NN	O
,	,	O
when	WRB	O
stored	VBN	O
in	IN	O
these	DT	O
temperatures	NNS	O
,	,	O
is	VBZ	O
two	CD	O
years	NNS	O
from	IN	O
date	NN	O
of	IN	O
manufacture	NN	O
.	.	O

After	IN	O
selection	NN	O
of	IN	O
the	DT	O
proper	JJ	O
site	NN	O
and	CC	O
insertion	NN	O
of	IN	O
the	DT	O
needle	NN	O
into	IN	O
the	DT	O
selected	VBN	O
muscle	NN	O
,	,	O
aspirate	NN	O
by	IN	O
pulling	VBG	O
back	RB	O
on	IN	O
the	DT	O
plunger	NN	O
.	.	O

For	IN	O
postpartum	JJ	WHO
women	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
breastfeed	VB	WHO
or	CC	O
after	IN	O
a	DT	O
second	JJ	O
trimester	NN	O
abortion	NN	O
,	,	O
GENERESS	NNP	O
Fe	NNP	O
may	MD	O
be	VB	O
started	VBN	O
no	DT	O
earlier	JJR	O
than	IN	O
4	CD	PER
weeks	NNS	PER
postpartum	NN	O
.	.	O

Examples	NNS	O
of	IN	O
3	CD	FREQ
times	NNS	FREQ
per	IN	FREQ
week	NN	FREQ
application	NN	O
schedules	NNS	O
are	VBP	O
:	:	O
Monday	NNP	O
,	,	O
Wednesday	NNP	O
,	,	O
Friday	NNP	O
or	CC	O
Tuesday	NNP	O
,	,	O
Thursday	NNP	O
,	,	O
Saturday	NNP	O
.	.	O

1	CD	O
rev	NN	O
.	.	O
,	,	O
Soc	NNP	O
.	.	O

One	CD	DOS
to	TO	O
2	CD	DOS
mg	NN	UNIT
of	IN	O
COGENTIN	NNP	O
two	CD	FREQ
or	CC	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
usually	RB	O
provides	VBZ	O
relief	NN	O
within	IN	O
one	CD	PER
or	CC	O
two	CD	PER
days	NNS	PER
.	.	O

For	IN	O
prophylaxis	NN	O
against	IN	O
hemorrhage	NN	O
during	IN	O
times	NNS	O
of	IN	O
extensive	JJ	O
physical	JJ	O
activity	NN	O
,	,	O
the	DT	O
plasma	NN	O
factor	NN	O
IX	NNP	O
levels	NNS	O
should	MD	O
be	VB	O
raised	VBN	O
to	TO	O
15	CD	O
to	TO	O
30	CD	O
percent	NN	O
.	.	O

For	IN	O
most	JJS	WHO
adults	NNS	WHO
,	,	O
the	DT	O
satisfactory	JJ	O
maintenance	NN	O
dosage	NN	O
will	MD	O
be	VB	O
six	CD	O
to	TO	O
eight	CD	O
Infatabs	NNP	O
daily	RB	FREQ
;	:	O
an	DT	O
increase	NN	O
to	TO	O
twelve	VB	O
Infatabs	NNP	O
daily	JJ	FREQ
may	MD	O
be	VB	O
made	VBN	O
,	,	O
if	IN	O
necessary	JJ	O
.	.	O

The	DT	O
maximum	JJ	O
dose	NN	O
is	VBZ	O
6	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
a	DT	FREQ
day	NN	FREQ
(	(	O
12	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
)	)	O
.	.	O

Continued	JJ	O
administration	NN	O
for	IN	O
several	JJ	O
days	NNS	PER
may	MD	O
be	VB	O
useful	JJ	O
in	IN	O
such	JJ	WHO
patients	NNS	WHO
.	.	O

Infants	NNS	WHO
may	MD	O
absorb	VB	O
the	DT	O
active	JJ	O
compound	NN	O
in	IN	O
pHisoHex	NN	WHO
more	RBR	WHO
readily	RB	WHO
than	IN	WHO
older	JJR	WHO
children	NNS	WHO
and	CC	WHO
adults	NNS	WHO
.	.	O

To	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
lipodystrophy	NN	O
,	,	O
rotate	VB	O
the	DT	O
injection	NN	O
site	NN	O
within	IN	O
the	DT	O
same	JJ	O
region	NN	O
from	IN	O
one	CD	DOS
injection	NN	UNIT
to	TO	O
the	DT	O
next	JJ	O
[	NN	O
see	VBP	O
ADVERSE	JJ	O
REACTIONS	NNP	O
]	NNP	O
.	.	O

Pick	NNP	O
up	RP	O
small	JJ	O
amounts	NNS	O
of	IN	O
EXTINA®	NNP	O
Foam	NNP	O
with	IN	O
the	DT	O
fingertips	NNS	O
,	,	O
and	CC	O
gently	RB	O
massage	VB	O
into	IN	O
the	DT	O
affected	JJ	O
area	NN	O
(	(	O
s	PRP	O
)	)	O
until	IN	O
the	DT	O
foam	NN	O
disappears	VBZ	O
.	.	O

Protect	NN	O
from	IN	O
direct	JJ	O
sunlight	NN	O
.	.	O

a	DT	O
Start	NNP	O
subsequent	NN	O
dose	NN	O
on	IN	O
Day	NNP	O
2	CD	O
of	IN	O
dosing	NN	O
.	.	O

5	CD	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
secondary	JJ	WHO
(	(	WHO
pituitary	JJ	WHO
)	)	WHO
or	CC	WHO
tertiary	JJ	WHO
(	(	O
hypothalamic	JJ	O
)	)	O
hypothyroidism	NN	O
,	,	O
the	DT	O
levothyroxine	NN	O
sodium	NN	O
dose	NN	O
should	MD	O
be	VB	O
titrated	VBN	O
until	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
clinically	RB	O
euthyroid	JJ	O
and	CC	O
the	DT	O
serum	NN	O
free	JJ	O
-	:	O
T4	NNP	O
level	NN	O
is	VBZ	O
restored	VBN	O
to	TO	O
the	DT	O
upper	JJ	O
half	NN	O
of	IN	O
the	DT	O
normal	JJ	O
range	NN	O
.	.	O

As	IN	O
the	DT	O
Depacon	NNP	O
dosage	NN	O
is	VBZ	O
titrated	VBN	O
upward	RB	O
,	,	O
blood	NN	O
concentrations	NNS	O
of	IN	O
phenobarbital	NN	O
and	CC	O
/	NN	O
or	CC	O
phenytoin	NN	O
may	MD	O
be	VB	O
affected	VBN	O
[	NNP	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
UPTRAVI	NNP	O
is	VBZ	O
200	CD	DOS
micrograms	NNS	UNIT
(	(	O
mcg	NN	O
)	)	O
given	VBN	O
twice	JJ	FREQ
daily	RB	FREQ
.	.	O

Use	NNP	O
an	DT	O
administration	NN	O
set	NN	O
with	IN	O
an	DT	O
air	NN	O
-	:	O
inlet	NN	O
in	IN	O
the	DT	O
plastic	NN	O
spike	NN	O
since	IN	O
the	DT	O
bottle	NN	O
does	VBZ	O
not	RB	O
contain	VB	O
a	DT	O
separate	JJ	O
airway	NN	O
tube	NN	O
.	.	O

The	DT	O
minimum	JJ	O
amount	NN	O
of	IN	O
GELFOAM	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
to	TO	O
the	DT	O
bleeding	NN	O
site	NN	O
(	(	O
see	VB	O
Directions	NNP	O
For	IN	O
Use	NNP	O
)	)	O
with	IN	O
pressure	NN	O
until	IN	O
hemostasis	NN	O
is	VBZ	O
observed	VBN	O
.	.	O

DOSAGE	NNP	O
RANGE	NNP	O
CHART	NNP	O

frontal	NN	O
,	,	O
lateral	JJ	O
temporal	JJ	O
,	,	O
or	CC	O
inferolateral	JJ	O
parietal	JJ	O
lobes	NNS	O
:	:	O
high	JJ	O
intensity	NN	O
seen	VBN	O
to	TO	O
the	DT	O
periphery	NN	O
of	IN	O
the	DT	O
brain	NN	O
,	,	O
with	IN	O
sharp	JJ	O
reduction	NN	O
of	IN	O
intensity	NN	O
at	IN	O
the	DT	O
brain	NN	O
margin	NN	O
;	:	O
sulci	CC	O
not	RB	O
distinct	JJ	O
due	JJ	O
to	TO	O
fill	VB	O
-	:	O
in	IN	O
by	IN	O
high	JJ	O
intensity	NN	O
grey	VBP	O
matter	NN	O
resulting	VBG	O
in	IN	O
a	DT	O
convex	JJ	O
surface	NN	O
at	IN	O
the	DT	O
edge	NN	O
of	IN	O
the	DT	O
brain	NN	O
,	,	O
or	CC	O
posterior	JJ	O
cingulate	NN	O
and	CC	O
precuneus	NN	O
:	:	O
grey	JJ	O
matter	NN	O
uptake	VBP	O
above	IN	O
50	CD	O
-	:	O
60	CD	O
%	NN	O
of	IN	O
peak	JJ	O
intensity	NN	O
;	:	O
high	JJ	O
grey	NN	O
matter	NN	O
intensity	NN	O
that	WDT	O
closes	VBZ	O
the	DT	O
gap	NN	O
between	IN	O
the	DT	O
two	CD	O
hemispheres	NNS	O
on	IN	O
coronal	JJ	O
view	NN	O
,	,	O
or	CC	O
striatum	NN	O
:	:	O
intensity	NN	O
above	IN	O
50	CD	O
-	:	O
60	CD	O
%	NN	O
of	IN	O
peak	JJ	O
intensity	NN	O
;	:	O
gap	NN	O
between	IN	O
thalamus	NN	O
and	CC	O
frontal	JJ	O
white	JJ	O
matter	NN	O
not	RB	O
distinct	JJ	O
If	IN	O
any	DT	O
one	CD	O
of	IN	O
the	DT	O
brain	NN	O
regions	NNS	O
systematically	RB	O
reviewed	VBN	O
for	IN	O
flutemetamol	NN	O
F	NNP	O
18	CD	O
uptake	NN	O
(	(	O
see	VB	O
Image	NNP	O
Orientation	NNP	O
and	CC	O
Display	NNP	O
above	IN	O
)	)	O
is	VBZ	O
positive	JJ	O
in	IN	O
either	DT	O
hemisphere	NN	O
,	,	O
then	RB	O
the	DT	O
scan	NN	O
is	VBZ	O
considered	VBN	O
positive	JJ	O
.	.	O

COMVAX	NNP	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
to	TO	O
any	DT	O
infant	NN	WHO
before	IN	O
the	DT	O
age	NN	O
of	IN	O
6	CD	PER
weeks	NNS	PER
.	.	O

Avoid	IN	O
the	DT	O
use	NN	O
of	IN	O
strong	JJ	O
CYP3A4	NNP	O
/	NNP	O
PgP	NNP	O
inhibitors	NNS	O
(	(	O
e.g	NN	O
,	,	O
ketoconazole	NN	O
,	,	O
itraconazole	NN	O
,	,	O
clarithromycin	NN	O
,	,	O
atazanavir	NN	O
,	,	O
nefazodone	NN	O
,	,	O
saquinavir	NN	O
,	,	O
telithromycin	NN	O
,	,	O
ritonavir	NN	O
,	,	O
indinavir	NN	O
,	,	O
nelfinavir	RB	O
,	,	O
voriconazole	NN	O
)	)	O
[	FW	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
and	CC	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

Mark	NNP	O
the	DT	O
location	NN	O
of	IN	O
the	DT	O
implants	NNS	O
with	IN	O
a	DT	O
surgical	JJ	O
marker	NN	O
.	.	O

Neuromuscular	JJ	O
Blocking	VBG	O
Agents	NNS	O
:	:	O
The	DT	O
neuromuscular	JJ	O
blocking	NN	O
agent	NN	O
selected	VBN	O
should	MD	O
be	VB	O
compatible	JJ	O
with	IN	O
the	DT	O
patient	NN	O
's	POS	O
condition	NN	O
,	,	O
taking	VBG	O
into	IN	O
account	NN	O
the	DT	O
hemodynamic	JJ	O
effects	NNS	O
of	IN	O
a	DT	O
particular	JJ	O
muscle	NN	O
relaxant	NN	O
and	CC	O
the	DT	O
degree	NN	O
of	IN	O
skeletal	JJ	O
muscle	NN	O
relaxation	NN	O
required	VBN	O
(	(	O
see	VB	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
,	,	O
WARNINGS	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
sections	NNS	O
)	)	O
.	.	O

To	TO	O
avoid	VB	O
swallowing	VBG	O
allergen	JJ	O
extract	NN	O
,	,	O
food	NN	O
or	CC	O
beverage	NN	O
should	MD	O
not	RB	O
be	VB	O
taken	VBN	O
for	IN	O
5	CD	O
minutes	NNS	O
following	VBG	O
dissolution	NN	O
of	IN	O
the	DT	O
tablet	NN	O
.	.	O

When	WRB	O
changing	VBG	O
to	TO	O
oral	JJ	O
Cordarone	NNP	O
therapy	NN	O
,	,	O
clinical	JJ	O
monitoring	NN	O
is	VBZ	O
recommended	VBN	O
,	,	O
particularly	RB	O
for	IN	O
elderly	JJ	WHO
patients	NNS	WHO
.	.	O

No	DT	O
therapy	NN	O
is	VBZ	O
given	VBN	O
on	IN	O
the	DT	O
5th	CD	O
,	,	O
7th	CD	O
,	,	O
9th	CD	O
or	CC	O
11th	CD	O
days	NNS	O
.	.	O

If	IN	O
,	,	O
in	IN	O
the	DT	O
informed	JJ	O
judgment	NN	O
of	IN	O
the	DT	O
physician	NN	O
,	,	O
it	PRP	O
is	VBZ	O
deemed	VBN	O
advisable	JJ	O
to	TO	O
introduce	VB	O
additives	NNS	O
,	,	O
use	VBP	O
aseptic	JJ	O
technique	NN	O
.	.	O

The	DT	O
usual	JJ	O
individual	JJ	O
injection	NN	O
volumes	NNS	O
for	IN	O
visualization	NN	O
for	IN	O
the	DT	O
aorta	NN	O
and	CC	O
various	JJ	O
visceral	JJ	O
arteries	NNS	O
are	VBP	O
as	IN	O
follows	VBZ	O
:	:	O

Thus	RB	O
,	,	O
patients	NNS	WHO
should	MD	O
be	VB	O
periodically	RB	O
reassessed	VBN	O
to	TO	O
determine	VB	O
the	DT	O
need	NN	O
for	IN	O
maintenance	NN	O
treatment	NN	O
.	.	O

For	IN	O
amebic	JJ	O
liver	NN	O
abscess	NN	O
:	:	O
500	CD	DOS
mg	NN	UNIT
or	CC	O
750	CD	DOS
mg	NNS	UNIT
orally	RB	O
three	CD	FREQ
times	NNS	FREQ
daily	RB	FREQ
for	IN	O
5	CD	PER
to	TO	O
10	CD	PER
days	NNS	PER
.	.	O

In	IN	O
some	DT	O
cases	NNS	O
,	,	O
however	RB	O
,	,	O
hysterectomized	VBD	WHO
women	NNS	WHO
with	IN	O
a	DT	O
history	NN	O
of	IN	O
endometriosis	NN	O
may	MD	O
need	VB	O
a	DT	O
progestin	NN	O
[	NN	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
Erbitux	NNP	O
as	IN	O
an	DT	O
intravenous	JJ	O
push	NN	O
or	CC	O
bolus	NN	O
.	.	O

Carefully	RB	O
consider	VB	O
the	DT	O
potential	JJ	O
benefits	NNS	O
and	CC	O
risks	NNS	O
of	IN	O
DUEXIS	NNP	O
and	CC	O
other	JJ	O
treatment	NN	O
options	NNS	O
before	IN	O
deciding	VBG	O
to	TO	O
use	VB	O
DUEXIS	NNP	O
.	.	O

If	IN	O
a	DT	O
2.5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
concentration	NN	O
was	VBD	O
used	VBN	O
for	IN	O
the	DT	O
dilution	NN	O
curves	NNS	O
,	,	O
1	CD	DOS
mL	NN	UNIT
of	IN	O
the	DT	O
2.5	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
dye	NN	O
is	VBZ	O
added	VBN	O
to	TO	O
3	CD	DOS
mL	NN	UNIT
of	IN	O
distilled	JJ	O
water	NN	O
to	TO	O
make	VB	O
the	DT	O
most	RBS	O
concentrated	JJ	O
“	JJ	O
standard	NN	O
”	NNP	O
solution	NN	O
.	.	O

Do	NNP	O
not	RB	O
start	VB	O
SURMONTIL	NNP	O
in	IN	O
a	DT	O
patient	NN	WHO
who	WP	WHO
is	VBZ	WHO
being	VBG	WHO
treated	VBN	WHO
with	IN	WHO
linezolid	JJ	WHO
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	NN	O
because	IN	O
there	EX	O
is	VBZ	O
increased	VBN	O
risk	NN	O
of	IN	O
serotonin	JJ	O
syndrome	NN	O
.	.	O

Continually	RB	O
reevaluate	JJ	O
patients	NNS	WHO
receiving	VBG	WHO
MS	NNP	WHO
CONTIN	NNP	WHO
to	TO	O
assess	VB	O
the	DT	O
maintenance	NN	O
of	IN	O
pain	NN	O
control	NN	O
and	CC	O
the	DT	O
relative	JJ	O
incidence	NN	O
of	IN	O
adverse	JJ	O
reactions	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
monitoring	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
addiction	NN	O
,	,	O
abuse	NN	O
,	,	O
or	CC	O
misuse	NN	O
.	.	O

Dosage	NN	O
is	VBZ	O
dependent	JJ	O
upon	IN	O
the	DT	O
age	NN	O
,	,	O
weight	NN	O
and	CC	O
clinical	JJ	O
condition	NN	O
of	IN	O
the	DT	O
patient	NN	O
as	RB	O
well	RB	O
as	IN	O
laboratory	NN	O
determinations	NNS	O
.	.	O

TAPAZOLE	NNP	O
is	VBZ	O
administered	VBN	O
orally	RB	O
.	.	O

Appropriate	NNP	O
premedication	NN	O
,	,	O
which	WDT	O
may	MD	O
include	VB	O
a	DT	O
barbiturate	NN	O
,	,	O
tranquilizer	NN	O
or	CC	O
analgesic	JJ	O
drug	NN	O
,	,	O
may	MD	O
be	VB	O
administered	VBN	O
prior	RB	O
to	TO	O
the	DT	O
examination	NN	O
.	.	O

Specifically	RB	O
,	,	O
involuntary	JJ	O
movements	NNS	O
will	MD	O
occur	VB	O
more	RBR	O
rapidly	RB	O
when	WRB	O
LODOSYN	NNP	O
and	CC	O
levodopa	NN	O
are	VBP	O
given	VBN	O
concomitantly	RB	O
than	IN	O
when	WRB	O
levodopa	NN	O
is	VBZ	O
given	VBN	O
without	IN	O
LODOSYN	NNP	O
.	.	O

6	CD	O
-	:	O
16	CD	O
Yrs	NN	O

Continuous	JJ	O
IV	NNP	O
infusions	NNS	O
of	IN	O
ULTIVA	NNP	O
(	(	O
remifentanil	NN	O
)	)	O
should	MD	O
be	VB	O
administered	VBN	O
only	RB	O
by	IN	O
an	DT	O
infusion	NN	O
device	NN	O
.	.	O

During	IN	O
interpretation	NN	O
of	IN	O
the	DT	O
steady	JJ	O
-	:	O
state	NN	O
images	NNS	O
,	,	O
VASOVIST	NNP	O
(	(	O
gadofosveset	VB	O
trisodium	NN	O
injection	NN	O
for	IN	O
intravenous	JJ	O
use	NN	O
)	)	O
within	IN	O
the	DT	O
venous	JJ	O
system	NN	O
may	MD	O
limit	VB	O
or	CC	O
confound	VB	O
the	DT	O
detection	NN	O
of	IN	O
arterial	JJ	O
lesions	NNS	O
.	.	O

Carefully	RB	O
consider	VB	O
the	DT	O
potential	JJ	O
benefits	NNS	O
and	CC	O
risks	NNS	O
of	IN	O
PREVACID	NNP	O
NapraPAC	NNP	O
(	(	O
lansoprazole	NN	O
)	)	O
and	CC	O
other	JJ	O
treatment	NN	O
options	NNS	O
before	IN	O
deciding	VBG	O
to	TO	O
use	VB	O
PREVACID	NNP	O
NapraPAC	NNP	O
(	(	O
lansoprazole	NN	O
)	)	O
.	.	O

TEMODAR	NNP	O
for	IN	O
Injection	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
only	RB	O
by	IN	O
intravenous	JJ	O
infusion	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
whose	WP$	WHO
acetaminophen	JJ	WHO
concentrations	NNS	WHO
are	VBP	O
at	IN	O
or	CC	O
above	IN	O
the	DT	O
“	NNP	O
possible	JJ	O
”	NNP	O
toxicity	NN	O
line	NN	O
(	(	O
dotted	JJ	O
line	NN	O
in	IN	O
nomogram	NN	O
)	)	O
:	:	O

PRIOR	NNP	O
TO	NNP	O
THE	NNP	O
FIRST	NNP	O
DEXFERRUM	NNP	O
THERAPEUTIC	NNP	O
DOSE	NNP	O
,	,	O
ADMINISTER	NNP	O
A	NNP	O
TEST	NNP	O
DOSE	NNP	O
OF	IN	O
0.5	CD	DOS
ML	NNP	UNIT
INTRAVENOUSLY	NNP	O
(	(	O
See	NNP	O
BOXED	NNP	O
WARNING	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

To	TO	O
ensure	VB	O
adequate	JJ	O
control	NN	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
additional	JJ	O
PT	NNP	O
tests	NNS	O
be	VB	O
done	VBN	O
when	WRB	O
other	JJ	O
warfarin	NN	O
products	NNS	O
are	VBP	O
interchanged	VBN	O
with	IN	O
warfarin	JJ	O
sodium	NN	O
tablets	NNS	O
,	,	O
USP	NNP	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
whenever	WRB	O
other	JJ	O
medications	NNS	O
are	VBP	O
initiated	VBN	O
,	,	O
discontinued	VBN	O
,	,	O
or	CC	O
taken	VBN	O
irregularly	RB	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

The	DT	O
initial	JJ	O
dosage	NN	O
should	MD	O
be	VB	O
maintained	VBN	O
or	CC	O
adjusted	VBN	O
until	IN	O
a	DT	O
satisfactory	JJ	O
response	NN	O
is	VBZ	O
noted	VBN	O
.	.	O

Saizen®	NNP	O
therapy	NN	O
should	MD	O
be	VB	O
supervised	VBN	O
by	IN	O
a	DT	O
physician	NN	O
who	WP	O
is	VBZ	O
experienced	VBN	O
in	IN	O
the	DT	O
diagnosis	NN	O
and	CC	O
management	NN	O
of	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
with	IN	WHO
growth	NN	WHO
hormone	NN	WHO
deficiency	NN	WHO
or	CC	WHO
adult	NN	WHO
patients	NNS	WHO
with	IN	WHO
either	DT	WHO
childhood	NN	WHO
-	:	WHO
onset	NN	WHO
or	CC	WHO
adult	NN	WHO
-	:	O
onset	NN	O
growth	NN	O
hormone	NN	O
deficiency	NN	O
.	.	O

The	DT	O
possibility	NN	O
of	IN	O
ovulation	NN	O
and	CC	O
conception	NN	O
prior	RB	O
to	TO	O
initiation	NN	O
of	IN	O
medication	NN	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

Note	NN	O
:	:	O
Slow	NNP	O
-	:	O
K	NNP	O
(	(	O
potassium	JJ	O
chloride	NN	O
)	)	O
extended	VBD	O
-	:	O
release	NN	O
tablets	NNS	O
must	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
and	CC	O
never	RB	O
crushed	VBN	O
,	,	O
chewed	VBN	O
,	,	O
or	CC	O
sucked	VBD	O
.	.	O

In	IN	O
such	JJ	O
circumstances	NNS	O
,	,	O
admixture	NN	O
or	CC	O
Y	NNP	O
-	:	O
site	NN	O
administration	NN	O
with	IN	O
vitamin	JJ	O
solutions	NNS	O
should	MD	O
be	VB	O
avoided	VBN	O
.	.	O

Thereafter	RB	O
,	,	O
allow	VB	O
the	DT	O
patient	NN	O
to	TO	O
be	VB	O
in	IN	O
an	DT	O
upright	JJ	O
position	NN	O
.	.	O

Draw	NNP	O
1	CD	DOS
ml	NN	UNIT
of	IN	O
sterile	NN	O
,	,	O
preservative	JJ	O
-	:	O
free	JJ	O
saline	NN	O
(	(	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
U.S.P	NNP	O
.	.	O
)	)	O

Serum	NNP	O
lipids	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
for	IN	O
evidence	NN	O
of	IN	O
EFAD	NNP	O
in	IN	O
patients	NNS	WHO
maintained	VBN	O
on	IN	O
fat	JJ	O
-	:	O
free	JJ	O
TPN	NNP	O
.	.	O

INTUNIV®	NNP	O
has	VBZ	O
significantly	RB	O
reduced	VBN	O
C	NNP	O
(	(	O
60	CD	O
%	NN	O
lower	JJR	O
)	)	O
,	,	O
bioavailability	NN	O
(	(	O
43	CD	O
%	NN	O
lower	JJR	O
)	)	O
,	,	O
and	CC	O
a	DT	O
delayed	VBN	O
Tmax	NNP	O
(	(	O
3	CD	O
hours	NNS	O
later	RB	O
)	)	O
compared	VBN	O
to	TO	O
those	DT	O
of	IN	O
the	DT	O
same	JJ	O
dose	NN	O
of	IN	O
immediate	JJ	O
-	:	O
release	NN	O
guanfacine	NN	O
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

However	RB	O
,	,	O
GLYSET	NNP	O
given	VBN	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
sulfonylurea	NN	O
will	MD	O
cause	VB	O
a	DT	O
further	JJ	O
lowering	NN	O
of	IN	O
blood	NN	O
glucose	NN	O
and	CC	O
may	MD	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
hypoglycemia	NN	O
due	JJ	O
to	TO	O
the	DT	O
additive	JJ	O
effects	NNS	O
of	IN	O
the	DT	O
two	CD	O
agents	NNS	O
.	.	O

Figure	NN	O
6	CD	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
unable	JJ	WHO
to	TO	WHO
swallow	VB	WHO
whole	JJ	WHO
tablets	NNS	WHO
,	,	O
Adempas	NNP	O
may	MD	O
be	VB	O
crushed	VBN	O
and	CC	O
mixed	JJ	O
with	IN	O
water	NN	O
or	CC	O
soft	JJ	O
foods	NNS	O
(	(	O
such	JJ	O
as	IN	O
applesauce	NN	O
)	)	O
immediately	RB	O
before	IN	O
administration	NN	O
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Levothyroxine	NNP	O
sodium	NN	O
is	VBZ	O
contraindicated	VBN	O
if	IN	O
the	DT	O
serum	NN	O
TSH	NNP	O
is	VBZ	O
already	RB	O
suppressed	VBN	O
due	JJ	O
to	TO	O
the	DT	O
risk	NN	O
of	IN	O
precipitating	VBG	O
overt	JJ	O
thyrotoxicosis	NN	O
(	(	O
see	VB	O
CONTRAINDICATIONS	NNP	O
,	,	O
WARNINGS	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

This	DT	O
concentrate	NN	O
should	MD	O
immediately	RB	O
be	VB	O
diluted	VBN	O
in	IN	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
sterile	JJ	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
,	,	O
USP	NNP	O
,	,	O
or	CC	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
following	VBG	O
proper	JJ	O
aseptic	JJ	O
technique	NN	O
,	,	O
and	CC	O
administered	VBD	O
to	TO	O
the	DT	O
patient	NN	O
by	IN	O
infusion	NN	O
.	.	O

[	NNS	O
see	VBP	O
DESCRIPTION	NNP	O
]	NNP	O
If	IN	O
either	DT	O
condition	NN	O
exists	NNS	O
,	,	O
do	VBP	O
not	RB	O
administer	VB	O
the	DT	O
vaccine	NN	O
.	.	O

Proper	NNP	O
administration	NN	O
technique	NN	O
should	MD	O
be	VB	O
demonstrated	VBN	O
to	TO	O
the	DT	O
patient	NN	O
.	.	O

For	IN	O
classical	JJ	O
HL	NNP	O
post	NN	O
-	:	O
auto	NN	O
-	:	O
HSCT	NNP	O
consolidation	NN	O
treatment	NN	O
,	,	O
initiate	JJ	O
ADCETRIS	NNP	O
treatment	NN	O
within	IN	O
4	CD	PER
–	JJ	O
6	CD	PER
weeks	NNS	PER
post	NN	O
-	:	O
auto	NN	O
-	:	O
HSCT	NN	O
or	CC	O
upon	JJ	O
recovery	NN	O
from	IN	O
auto	NN	O
-	:	O
HSCT	NN	O
.	.	O

I.V	NNP	O
.	.	O

If	IN	O
unacceptable	JJ	O
opioid	JJ	O
-	:	O
related	JJ	O
adverse	JJ	O
reactions	NNS	O
are	VBP	O
observed	VBN	O
,	,	O
the	DT	O
subsequent	JJ	O
dose	NN	O
may	MD	O
be	VB	O
reduced	VBN	O
.	.	O

Since	IN	O
concomitant	JJ	O
administration	NN	O
of	IN	O
MONOPRIL	NNP	O
(	(	O
fosinopril	JJ	O
sodium	NN	O
)	)	O
with	IN	O
potassium	NN	O
supplements	NNS	O
,	,	O
or	CC	O
potassium	NN	O
-	:	O
containing	NN	O
salt	NN	O
substitutes	VBZ	O
or	CC	O
potassium	NN	O
-	:	O
sparing	VBG	O
diuretics	NNS	O
may	MD	O
lead	VB	O
to	TO	O
increases	NNS	O
in	IN	O
serum	NN	O
potassium	NN	O
,	,	O
they	PRP	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

Post	NNP	O
-	:	O
treatment	NN	O
compression	NN	O
is	VBZ	O
necessary	JJ	O
to	TO	O
reduce	VB	O
the	DT	O
risk	NN	O
of	IN	O
deep	JJ	O
vein	NN	O
thrombosis	NN	O
.	.	O

For	IN	O
all	DT	O
subsequent	JJ	O
cycles	NNS	O
,	,	O
the	DT	O
patient	NN	O
then	RB	O
begins	VBZ	O
a	DT	O
new	JJ	O
28	CD	O
-	:	O
tablet	NN	O
regimen	NNS	O
on	IN	O
the	DT	O
next	JJ	O
day	NN	O
(	(	O
Sunday	NNP	O
)	)	O
after	IN	O
taking	VBG	O
the	DT	O
last	JJ	O
green	JJ	O
(	(	O
inactive	JJ	O
)	)	O
tablet	NN	O
.	.	O

No	DT	O
drug	NN	O
or	CC	O
chemical	NN	O
agent	NN	O
should	MD	O
be	VB	O
added	VBN	O
to	TO	O
an	DT	O
erythromycin	NN	O
lactobionate	NN	O
-	:	O
IV	NNP	O
fluid	NN	O
admixture	NN	O
unless	IN	O
its	PRP$	O
effect	NN	O
on	IN	O
the	DT	O
chemical	NN	O
and	CC	O
physical	JJ	O
stability	NN	O
of	IN	O
the	DT	O
solution	NN	O
has	VBZ	O
first	RB	O
been	VBN	O
determined	VBN	O
.	.	O

Initiate	NNP	O
the	DT	O
dosing	VBG	O
regimen	NNS	O
for	IN	O
each	DT	O
patient	NN	O
individually	RB	O
;	:	O
take	VB	O
into	IN	O
account	NN	O
the	DT	O
patient	NN	O
's	POS	O
prior	JJ	O
analgesic	JJ	O
treatment	NN	O
experience	NN	O
and	CC	O
risk	NN	O
factors	NNS	O
for	IN	O
addiction	NN	O
,	,	O
abuse	NN	O
,	,	O
and	CC	O
misuse	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

However	RB	O
,	,	O
greater	JJR	O
sensitivity	NN	O
of	IN	O
some	DT	O
individuals	NNS	O
to	TO	O
nateglinide	VB	O
tablets	NNS	O
therapy	VB	O
can	MD	O
not	RB	O
be	VB	O
ruled	VBN	O
out	RP	O
.	.	O

For	IN	O
patients	NNS	WHO
who	WP	WHO
weigh	VBP	WHO
more	JJR	WHO
than	IN	O
130	CD	O
%	NN	O
of	IN	O
their	PRP$	O
ideal	NN	O
body	NN	O
weight	VBD	O
,	,	O
body	NN	O
surface	JJ	O
area	NN	O
should	MD	O
be	VB	O
calculated	VBN	O
based	VBN	O
on	IN	O
adjusted	JJ	O
ideal	NN	O
body	NN	O
weight	NN	O
.	.	O

Crinone	RB	O
8	CD	O
%	NN	O
is	VBZ	O
administered	VBN	O
vaginally	RB	O
at	IN	O
a	DT	O
dose	NN	O
of	IN	O
90	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
women	NNS	WHO
who	WP	WHO
require	VBP	WHO
progesterone	NN	WHO
supplementation	NN	WHO
.	.	O

Patients	NNS	O
should	MD	O
dispose	VB	O
of	IN	O
any	DT	O
patches	NNS	O
remaining	VBG	O
from	IN	O
a	DT	O
prescription	NN	O
as	RB	O
soon	RB	O
as	IN	O
they	PRP	O
are	VBP	O
no	RB	O
longer	RB	O
needed	VBN	O
.	.	O

The	DT	O
initial	JJ	O
recommended	VBD	O
dose	NN	O
of	IN	O
DETROL	NNP	O
Tablets	NNP	O
is	VBZ	O
2	CD	DOS
mg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Although	IN	O
individual	JJ	O
patients	NNS	O
may	MD	O
respond	VB	O
to	TO	O
any	DT	O
dosage	NN	O
level	NN	O
,	,	O
the	DT	O
average	JJ	O
optimum	JJ	O
dosage	NN	O
range	NN	O
appears	VBZ	O
to	TO	O
be	VB	O
180	CD	DOS
to	TO	O
360	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

To	TO	O
avoid	VB	O
rapid	JJ	O
drops	NNS	O
in	IN	O
topiramate	NN	O
plasma	NN	O
concentration	NN	O
during	IN	O
hemodialysis	NN	O
,	,	O
a	DT	O
supplemental	JJ	O
dose	NN	O
of	IN	O
topiramate	NN	O
may	MD	O
be	VB	O
required	VBN	O
.	.	O

Symptomatic	JJ	O
relief	NN	O
may	MD	O
be	VB	O
seen	VBN	O
during	IN	O
the	DT	O
first	JJ	O
week	NN	PER
,	,	O
with	IN	O
optimal	JJ	O
antidepressant	JJ	O
effects	NNS	O
typically	RB	O
evident	JJ	O
within	IN	O
two	CD	PER
weeks	NNS	PER
.	.	O

In	IN	O
breakthrough	NN	O
bleeding	NN	O
,	,	O
as	IN	O
in	IN	O
all	DT	O
cases	NNS	O
of	IN	O
irregular	JJ	O
bleeding	NN	O
from	IN	O
the	DT	O
vagina	NN	O
,	,	O
nonfunctional	JJ	O
causes	NNS	O
should	MD	O
be	VB	O
borne	VBN	O
in	IN	O
mind	NN	O
.	.	O

1	CD	O
.	.	O

Do	NNP	O
not	RB	O
administer	VB	O
Hydase	NNP	O
intravenously	RB	O
because	IN	O
hyaluronidase	NN	O
enzyme	NN	O
is	VBZ	O
rapidly	RB	O
inactivated	VBN	O
with	IN	O
intravenous	JJ	O
administration	NN	O
.	.	O

For	IN	O
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
dosing	NN	O
,	,	O
VANDAZOLE	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
at	IN	O
bedtime	NN	O
[	NNP	O
see	VBP	O
PATIENT	NNP	O
INFORMATION	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	JJ	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
QUDEXY	NNP	O
XR	NNP	O
as	IN	O
adjunctive	JJ	O
therapy	NN	O
for	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
with	IN	WHO
partial	JJ	WHO
onset	NN	WHO
seizures	NNS	WHO
,	,	O
primary	JJ	O
generalized	VBD	O
tonic	JJ	O
-	:	O
clonic	NN	O
seizures	NNS	O
,	,	O
or	CC	O
seizures	NNS	O
associated	VBN	O
with	IN	O
Lennox	NNP	O
-	:	O
Gastaut	NNP	O
syndrome	NN	O
is	VBZ	O
approximately	RB	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
to	TO	O
9	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NNP	O
orally	RB	O
once	RB	FREQ
daily	JJ	FREQ
.	.	O

Call	VB	O
[	$	O
1	CD	O
888	CD	O
292	CD	O
9617	CD	O
]	NN	O
if	IN	O
you	PRP	O
have	VBP	O
questions	NNS	O
about	IN	O
the	DT	O
preparation	NN	O
of	IN	O
Marqibo	NNP	O
.	.	O

A	DT	O
patient	NN	WHO
whose	WP$	WHO
blood	NN	WHO
pressure	NN	WHO
is	VBZ	WHO
not	RB	WHO
adequately	RB	WHO
controlled	VBN	WHO
with	IN	WHO
aliskiren	NN	WHO
alone	RB	WHO
or	CC	O
valsartan	JJ	O
(	(	O
or	CC	O
another	DT	O
angiotensin	NN	O
receptor	NN	O
blocker	NN	O
)	)	O
alone	NN	O
may	MD	O
be	VB	O
switched	VBN	O
to	TO	O
combination	VB	O
therapy	NN	O
with	IN	O
Valturna	NNP	O
.	.	O

The	DT	O
dosage	NN	O
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
a	DT	O
low	JJ	O
level	NN	O
and	CC	O
increased	VBD	O
gradually	RB	O
,	,	O
noting	VBG	O
the	DT	O
clinical	JJ	O
response	NN	O
and	CC	O
any	DT	O
evidence	NN	O
of	IN	O
intolerance	NN	O
.	.	O

Restart	NNP	O
treatment	NN	O
when	WRB	O
the	DT	O
LIC	NNP	O
rises	VBZ	O
again	RB	O
to	TO	O
more	JJR	O
than	IN	O
5	CD	DOS
mg	JJ	UNIT
Fe	NNP	O
/	NNP	O
g	NN	O
dw	NN	O
.	.	O

There	EX	O
is	VBZ	O
no	DT	O
need	NN	O
for	IN	O
the	DT	O
patient	NN	O
to	TO	O
count	VB	O
days	NNS	O
between	IN	O
cycles	NNS	O
because	IN	O
there	EX	O
are	VBP	O
no	DT	O
“	NNP	O
off	RP	O
-	:	O
tablet	NN	O
days	NNS	O
.	.	O
”	NN	O

To	TO	O
ensure	VB	O
continued	JJ	O
protection	NN	O
,	,	O
booster	NN	O
doses	NNS	O
of	IN	O
Td	NNP	O
should	MD	O
be	VB	O
given	VBN	O
every	DT	O
10	CD	O
years.2	NN	O

LIORESAL	NNP	O
Intrathecal	NNP	O
proved	VBD	O
to	TO	O
be	VB	O
stable	JJ	O
in	IN	O
the	DT	O
implanted	JJ	O
SynchroMed	NNP	O
Programmable	NNP	O
Infusion	NNP	O
System	NNP	O
for	IN	O
11	CD	PER
weeks	NNS	PER
.	.	O

Accordingly	RB	O
,	,	O
the	DT	O
following	JJ	O
formula	NN	O
is	VBZ	O
provided	VBN	O
for	IN	O
dosage	NN	O
calculations	NNS	O
:	:	O

Dosing	VBG	O
regimens	NNS	O
for	IN	O
the	DT	O
use	NN	O
of	IN	O
quinidine	NN	O
sulfate	NN	O
(	(	O
quinidine	JJ	O
sulfate	NN	O
(	(	O
quinidine	JJ	O
sulfate	NN	O
(	(	O
quinidine	JJ	O
sulfate	NN	O
tablet	NN	O
,	,	O
film	NN	O
coated	VBD	O
,	,	O
extended	VBD	O
release	NN	O
)	)	O
tablet	NN	O
,	,	O
film	NN	O
coated	VBD	O
,	,	O
extended	VBD	O
release	NN	O
)	)	O
tablet	NN	O
,	,	O
film	NN	O
coated	VBD	O
,	,	O
extended	VBD	O
release	NN	O
)	)	O
in	IN	O
suppressing	VBG	O
life	NN	O
-	:	O
threatening	VBG	O
ventricular	JJ	O
arrhythmias	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
adequately	RB	O
studied	VBN	O
.	.	O

Oral	NNP	O
estrogen	CC	O
administration	NN	O
may	MD	O
increase	VB	O
the	DT	O
dose	JJ	O
requirements	NNS	O
in	IN	O
women	NNS	WHO
.	.	O

If	IN	O
possible	JJ	O
,	,	O
discontinue	JJ	O
PRADAXA	NNP	O
1	CD	O
to	TO	O
2	CD	O
days	NNS	O
(	(	O
CrCl	NNP	O
≥	VBZ	O
50	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
or	CC	O
3	CD	PER
to	TO	O
5	CD	DOS
days	NNS	UNIT
(	(	O
CrCl	NNP	O
<	VBZ	O
50	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
before	IN	O
invasive	JJ	O
or	CC	O
surgical	JJ	O
procedures	NNS	O
because	IN	O
of	IN	O
the	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
bleeding	NN	O
.	.	O

Postmenopausal	NNP	O
women	NNS	O
should	MD	O
be	VB	O
re	VBN	O
-	:	O
evaluated	VBN	O
periodically	RB	O
as	IN	O
clinically	RB	O
appropriate	JJ	O
to	TO	O
determine	VB	O
if	IN	O
treatment	NN	O
is	VBZ	O
still	RB	O
necessary	JJ	O
.	.	O

RETISERT	NNP	O
should	MD	O
not	RB	O
be	VB	O
resterilized	VBN	O
by	IN	O
any	DT	O
method	NN	O
.	.	O

The	DT	O
subsequent	JJ	O
doses	NNS	O
can	MD	O
be	VB	O
increased	VBN	O
or	CC	O
decreased	VBN	O
based	VBN	O
on	IN	O
individual	JJ	O
safety	NN	O
and	CC	O
tolerability	NN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
instructed	VBN	O
to	TO	O
contact	VB	O
the	DT	O
prescriber	NN	O
immediately	RB	O
if	IN	O
these	DT	O
tests	NNS	O
are	VBP	O
abnormal	JJ	O
.	.	O

Its	PRP$	O
use	NN	O
usually	RB	O
requires	VBZ	O
titration	NN	O
,	,	O
using	VBG	O
heart	NN	O
rate	NN	O
,	,	O
PR	NNP	O
interval	NN	O
,	,	O
blook	NN	O
pressure	NN	O
and	CC	O
/	NN	O
or	CC	O
patient	NN	O
's	POS	O
symptoms	NNS	O
as	IN	O
a	DT	O
guide	NN	O
for	IN	O
having	VBG	O
reached	VBN	O
an	DT	O
appropriate	JJ	O
dose	NN	O
.	.	O

Pediatric	NN	O
:	:	O
A	DT	O
loading	VBG	O
dose	NN	O
of	IN	O
15	CD	DOS
-	:	O
20	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
of	IN	O
Dilantin	NNP	O
intravenously	RB	O
will	MD	O
usually	RB	O
produce	VB	O
plasma	JJ	O
concentrations	NNS	O
of	IN	O
phenytoin	NN	O
within	IN	O
the	DT	O
generally	RB	O
accepted	VBN	O
therapeutic	JJ	O
range	NN	O
(	(	O
10	CD	DOS
-	:	O
20	CD	DOS
mcg	NN	UNIT
/	NNP	O
mL	NN	O
)	)	O
.	.	O

CLOZARIL	NN	O
can	MD	O
be	VB	O
taken	VBN	O
with	IN	O
or	CC	O
without	IN	O
food	NN	O
[	NNS	O
see	VBP	O
Pharmacokinetics	NNPS	O
]	NNP	O
.	.	O

Note	NN	O
:	:	O
Once	RB	O
vial	JJ	O
is	VBZ	O
seated	VBN	O
,	,	O
do	VBP	O
not	RB	O
attempt	VB	O
to	TO	O
remove	VB	O
(	(	O
see	VB	O
Figure	NNP	O
4	CD	O
)	)	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dose	NN	O
for	IN	O
children	NNS	WHO
is	VBZ	O
30	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
;	:	O
doses	VBZ	O
greater	JJR	O
than	IN	O
30	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
of	IN	O
ADDERALL	NNP	O
XR	NNP	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
in	IN	O
children	NNS	WHO
.	.	O

It	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
measure	VB	O
both	DT	O
peak	NN	O
and	CC	O
trough	JJ	O
serum	NN	O
concentrations	NNS	O
intermittently	RB	O
during	IN	O
therapy	NN	O
.	.	O

Without	IN	O
Concomitant	NNP	O
Efavirenz	NNP	O
,	,	O
Nevirapine	NNP	O
,	,	O
or	CC	O
Nelfinavir	NNP	O

ALBENZA	NNP	O
chewable	JJ	O
tablets	NNS	O
are	VBP	O
also	RB	O
available	JJ	O
for	IN	O
children	NNS	WHO
and	CC	WHO
patients	NNS	WHO
who	WP	O
may	MD	O
experience	VB	O
swallowing	VBG	O
difficulties	NNS	O
.	.	O

For	IN	O
the	DT	O
prefilled	JJ	O
syringes	NNS	O
,	,	O
attach	VBP	O
a	DT	O
sterile	JJ	O
needle	NN	O
and	CC	O
administer	RB	O
intramuscularly	RB	O
.	.	O

During	IN	O
the	DT	O
first	JJ	O
cycle	NN	O
of	IN	O
use	NN	O
,	,	O
the	DT	O
patient	NN	O
is	VBZ	O
instructed	VBN	O
to	TO	O
begin	VB	O
taking	VBG	O
FEMCON	NNP	O
Fe	NNP	O
(	(	O
norethindrone	NN	O
and	CC	O
ethinyl	NN	O
estradiol	VBP	O
tablets	NNS	O
)	)	O
on	IN	O
either	DT	O
Day	NNP	O
1	CD	O
or	CC	O
the	DT	O
first	JJ	O
Sunday	NNP	O
after	IN	O
the	DT	O
onset	NN	O
of	IN	O
menstruation	NN	O
.	.	O

Adequate	NNP	O
therapy	NN	O
usually	RB	O
results	NNS	O
in	IN	O
normal	JJ	O
TSH	NNP	O
and	CC	O
T4	NNP	O
levels	NNS	O
after	IN	O
2	CD	O
or	CC	O
3	CD	PER
weeks	NNS	PER
of	IN	O
therapy	NN	O
.	.	O

When	WRB	O
initiating	VBG	O
MICARDIS	NNP	O
therapy	NN	O
for	IN	O
cardiovascular	JJ	O
risk	NN	O
reduction	NN	O
,	,	O
monitoring	NN	O
of	IN	O
blood	NN	O
pressure	NN	O
is	VBZ	O
recommended	VBN	O
,	,	O
and	CC	O
if	IN	O
appropriate	JJ	O
,	,	O
adjustment	NN	O
of	IN	O
medications	NNS	O
that	WDT	O
lower	JJR	O
blood	NN	O
pressure	NN	O
may	MD	O
be	VB	O
necessary	JJ	O
.	.	O

Generally	RB	O
,	,	O
TSH	NNP	O
is	VBZ	O
suppressed	VBN	O
to	TO	O
<	VB	O
0.1	CD	DOS
mU	NN	UNIT
/	NNP	O
L	NNP	O
,	,	O
and	CC	O
this	DT	O
usually	RB	O
requires	VBZ	O
a	DT	O
levothyroxine	JJ	O
sodium	NN	O
dose	NN	O
of	IN	O
greater	JJR	O
than	IN	O
2	CD	DOS
mcg	JJ	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
sterile	JJ	O
Insertion	NNP	O
Tool	NNP	O
is	VBZ	O
comprised	VBN	O
of	IN	O
a	DT	O
fixed	JJ	O
handle	NN	O
attached	VBN	O
to	TO	O
a	DT	O
retractable	JJ	O
,	,	O
bevel	JJ	O
-	:	O
tipped	VBD	O
cannula	NN	O
,	,	O
into	IN	O
the	DT	O
chamber	NN	O
of	IN	O
which	WDT	O
the	DT	O
implant	NN	O
is	VBZ	O
to	TO	O
be	VB	O
placed	VBN	O
for	IN	O
subcutaneous	JJ	O
insertion	NN	O
.	.	O

If	IN	O
excitement	NN	O
is	VBZ	O
to	TO	O
be	VB	O
avoided	VBN	O
,	,	O
a	DT	O
hypnotic	JJ	O
dose	NN	O
of	IN	O
a	DT	O
short	JJ	O
-	:	O
acting	VBG	O
barbiturate	NN	O
should	MD	O
be	VB	O
used	VBN	O
to	TO	O
induce	VB	O
unconsciousness	JJ	O
,	,	O
followed	VBN	O
by	IN	O
the	DT	O
enflurane	NN	O
mixture	NN	O
.	.	O

Dosing	VBG	O
regimen	NNS	O
should	MD	O
be	VB	O
adjusted	VBN	O
according	VBG	O
to	TO	O
each	DT	O
patient	NN	O
's	POS	O
need	NN	O
at	IN	O
the	DT	O
discretion	NN	O
of	IN	O
the	DT	O
physician	NN	O
.	.	O

Repeat	VB	O
the	DT	O
procedure	NN	O
with	IN	O
the	DT	O
infant	NN	WHO
in	IN	O
the	DT	O
left	NN	O
decubitus	NN	O
position	NN	O
while	IN	O
maintaining	VBG	O
adequate	JJ	O
positive	JJ	O
pressure	NN	O
ventilation	NN	O
.	.	O

Given	VBN	O
cyclically	RB	O
for	IN	O
short	JJ	O
term	NN	O
use	IN	O
only	RB	O
:	:	O

Food	NNP	O
containing	VBG	O
grapefruit	NN	O
or	CC	O
Seville	NNP	O
oranges	NNS	O
should	MD	O
be	VB	O
avoided	VBN	O
[	NNP	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
,	,	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
,	,	O
and	CC	O
PATIENT	NNP	O
INFORMATION	NNP	O
]	NNP	O
.	.	O

Older	JJR	WHO
children	NNS	WHO
:	:	O
Dosage	NN	O
must	MD	O
be	VB	O
individualized	VBN	O
by	IN	O
physician	NN	O
.	.	O

Increase	NN	O
in	IN	O
increments	NNS	O
of	IN	O
200	CD	DOS
mcg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
at	IN	O
weekly	JJ	FREQ
intervals	NNS	FREQ
,	,	O
as	IN	O
tolerated	JJ	O
[	NNP	O
see	NN	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
,	,	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

Additional	JJ	O
dosage	NN	O
modifications	NNS	O
should	MD	O
be	VB	O
made	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hepatic	JJ	WHO
disease	NN	WHO
and	CC	O
renal	JJ	O
impairment	NN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
observed	VBN	O
with	IN	O
continuous	JJ	O
ECG	NNP	O
monitoring	NN	O
for	IN	O
at	IN	O
least	JJS	O
4	CD	O
hours	NNS	O
following	VBG	O
infusion	NN	O
or	CC	O
until	IN	O
QTc	NNP	O
has	VBZ	O
returned	VBN	O
to	TO	O
baseline	VB	O
.	.	O

IMPORTANT	NN	O
:	:	O
Do	VBP	O
not	RB	O
touch	VB	O
the	DT	O
vial	JJ	O
adapter	NN	O
.	.	O

VICODIN®	NNP	O
(	(	O
Hydrocodone	NNP	O
Bitartrate	NNP	O
and	CC	O
Acetaminophen	NNP	O
Tablets	NNP	O
,	,	O
USP	NNP	O
5	CD	DOS
mg	NN	UNIT
/	VBD	O
300	CD	DOS
mg	NN	UNIT
)	)	O
:	:	O
The	DT	O
usual	JJ	O
adult	NN	WHO
dosage	NN	O
is	VBZ	O
one	CD	DOS
or	CC	O
two	CD	DOS
tablets	NNS	UNIT
every	DT	FREQ
four	CD	FREQ
to	TO	O
six	CD	FREQ
hours	NNS	FREQ
as	IN	O
needed	VBN	O
for	IN	O
pain	NN	O
.	.	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
increased	VBN	O
according	VBG	O
to	TO	O
individual	JJ	O
patient	NN	O
requirements	NNS	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
0.0125	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
(	(	O
12.5	CD	DOS
μg	NNP	UNIT
/	NNP	O
kg	NN	O
)	)	O
daily	RB	FREQ
.	.	O

The	DT	O
suitability	NN	O
of	IN	O
the	DT	O
plastic	NN	O
has	VBZ	O
been	VBN	O
confirmed	VBN	O
in	IN	O
tests	NNS	O
in	IN	O
animals	NNS	O
according	VBG	O
to	TO	O
USP	NNP	O
biological	JJ	O
tests	NNS	O
for	IN	O
plastic	JJ	O
containers	NNS	O
as	RB	O
well	RB	O
as	IN	O
by	IN	O
tissue	NN	O
culture	NN	O
toxicity	NN	O
studies	NNS	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
dose	JJ	O
ranges	NNS	O
from	IN	O
2.5	CD	DOS
mg	NNS	UNIT
to	TO	O
10	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Co	NNP	O
-	:	O
administration	NN	O
of	IN	O
SAMSCA	NNP	O
with	IN	O
potent	JJ	O
CYP	NNP	O
3A	CD	O
inducers	NNS	O
(	(	O
e.g	NN	O
,	,	O
rifampin	NN	O
)	)	O
reduces	VBZ	O
tolvaptan	JJ	O
plasma	NN	O
concentrations	NNS	O
by	IN	O
85	CD	O
%	NN	O
.	.	O

Use	NNP	O
enough	JJ	O
to	TO	O
cover	VB	O
the	DT	O
entire	JJ	O
affected	JJ	O
area	NN	O
.	.	O

Opioid	NNP	O
Overdose	NNP	O
-	:	O
Known	VBN	O
or	CC	O
Suspected	VBN	O
:	:	O
An	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
0.4	CD	DOS
mg	NNS	UNIT
to	TO	O
2	CD	DOS
mg	NN	UNIT
of	IN	O
NARCAN	NNP	O
(	(	O
naloxone	NN	O
)	)	O
may	MD	O
be	VB	O
administered	VBN	O
intravenously	RB	O
.	.	O

Monitor	NNP	O
clinical	JJ	O
hematology	NN	O
and	CC	O
liver	NN	O
tests	NNS	O
regularly	RB	O
throughout	IN	O
therapy	NN	O
with	IN	O
PROMACTA	NNP	O
and	CC	O
modify	VB	O
the	DT	O
dosage	NN	O
regimen	NNS	O
of	IN	O
PROMACTA	NNP	O
based	VBN	O
on	IN	O
platelet	NN	O
counts	NNS	O
as	IN	O
outlined	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
.	.	O

Intramuscular	JJ	O
doses	NNS	O
,	,	O
in	IN	O
a	DT	O
range	NN	O
of	IN	O
9	CD	DOS
to	TO	O
13	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
(	(	O
4	CD	DOS
to	TO	O
6	CD	DOS
mg	NNS	UNIT
/	NNP	O
lb	NN	O
)	)	O
usually	RB	O
produce	VBP	O
surgical	JJ	O
anesthesia	NN	O
within	IN	O
3	CD	O
to	TO	O
4	CD	O
minutes	NNS	O
following	VBG	O
injection	NN	O
,	,	O
with	IN	O
the	DT	O
anesthetic	JJ	O
effect	NN	O
usually	RB	O
lasting	VBG	O
12	CD	O
to	TO	O
25	CD	O
minutes	NNS	O
.	.	O

Never	RB	O
administer	RB	O
Dilaudid	NNP	O
-	:	O
HP	NNP	O
injection	NN	O
to	TO	O
opioid	VB	O
-	:	O
naïve	NN	O
patients	NNS	O
.	.	O

As	IN	O
noted	VBN	O
in	IN	O
the	DT	O
WARNINGS	NNP	O
section	NN	O
,	,	O
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
underlying	VBG	WHO
renal	JJ	WHO
disease	NN	WHO
or	CC	O
who	WP	O
are	VBP	O
judged	VBN	O
to	TO	O
be	VB	O
at	IN	O
risk	NN	O
of	IN	O
developing	VBG	O
thrombotic	JJ	O
events	NNS	O
should	MD	O
not	RB	O
be	VB	O
infused	VBN	O
rapidly	RB	O
with	IN	O
any	DT	O
IGIV	NNP	O
product	NN	O
.	.	O

for	IN	O
Injection	NNP	O
is	VBZ	O
a	DT	O
single	JJ	DOS
dose	NN	UNIT
unpreserved	VBD	O
sterile	JJ	O
lyophile	NN	O
.	.	O

OFIRMEV	NN	O
may	MD	O
be	VB	O
given	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
or	CC	O
repeated	VBN	O
dose	NN	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acute	JJ	O
pain	NN	O
or	CC	O
fever	NN	O
.	.	O

Therefore	RB	O
,	,	O
a	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
Serostim®	NNP	O
0.1	CD	DOS
mg	NN	UNIT
/	NN	O
kg	NN	O
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
should	MD	O
be	VB	O
considered	VBN	O
in	IN	O
patients	NNS	WHO
at	IN	O
increased	VBN	O
risk	NN	O
for	IN	O
adverse	JJ	O
effects	NNS	O
related	VBN	O
to	TO	O
recombinant	VB	O
human	JJ	O
growth	NN	O
hormone	NN	O
therapy	NN	O
(	(	O
i.e	JJ	O
,	,	O
glucose	JJ	O
intolerance	NN	O
)	)	O
.	.	O

For	IN	O
lasting	JJ	O
benefit	NN	O
,	,	O
eliminate	VB	O
any	DT	O
factors	NNS	O
that	WDT	O
perpetuate	VBP	O
the	DT	O
trigger	NN	O
mechanism	NN	O
.	.	O

1	CD	O
.	.	O

INDOCIN	NNP	O
I.V	NNP	O
.	.	O

DUOPA	NNP	O
is	VBZ	O
administered	VBN	O
over	IN	O
a	DT	O
16	CD	O
-	:	O
hour	NN	O
infusion	NN	O
period	NN	O
.	.	O

There	EX	O
is	VBZ	O
no	DT	O
known	JJ	O
benefit	NN	O
from	IN	O
injecting	VBG	O
the	DT	O
extravasation	NN	O
site	NN	O
with	IN	O
another	DT	O
substance	NN	O
.	.	O

FOLOTYN	NNP	O
is	VBZ	O
a	DT	O
cytotoxic	JJ	O
anticancer	NN	O
agent	NN	O
.	.	O

Nevertheless	RB	O
,	,	O
consider	VB	O
the	DT	O
possibility	NN	O
of	IN	O
pregnancy	NN	O
,	,	O
especially	RB	O
if	IN	O
absence	NN	O
of	IN	O
withdrawal	NN	O
bleeding	NN	O
occurs	VBZ	O
in	IN	O
2	CD	O
consecutive	JJ	O
cycles	NNS	O
.	.	O

176	CD	O

The	DT	O
Intron	NNP	O
A	NNP	O
Injection	NNP	O
is	VBZ	O
supplied	VBN	O
as	IN	O
a	DT	O
clear	JJ	O
and	CC	O
colorless	JJ	O
solution	NN	O
.	.	O

If	IN	O
a	DT	O
patient	NN	O
misses	VBZ	O
1	CD	DOS
active	JJ	UNIT
tablet	NN	UNIT
in	IN	O
Weeks	NNP	O
1	CD	O
,	,	O
2	CD	O
,	,	O
or	CC	O
3	CD	O
,	,	O
she	PRP	O
should	MD	O
take	VB	O
the	DT	O
missed	JJ	O
tablet	NN	O
as	RB	O
soon	RB	O
as	IN	O
she	PRP	O
remembers	VBZ	O
.	.	O

The	DT	O
maintenance	NN	O
dose	NN	O
in	IN	O
mL	NN	O
/	NN	O
hr	NN	O
by	IN	O
patient	JJ	O
body	NN	O
weight	NN	O
(	(	O
kg	NN	O
)	)	O
may	MD	O
be	VB	O
determined	VBN	O
by	IN	O
reference	NN	O
to	TO	O
the	DT	O
following	VBG	O
table	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
,	,	O
start	VBP	O
with	IN	O
10	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
;	:	O
daily	JJ	FREQ
dosage	NN	O
may	MD	O
be	VB	O
raised	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
10	CD	DOS
mg	NN	UNIT
at	IN	O
weekly	JJ	FREQ
intervals	NNS	FREQ
until	IN	O
an	DT	O
optimal	JJ	O
response	NN	O
is	VBZ	O
obtained	VBN	O
.	.	O

Remove	VB	O
the	DT	O
plastic	JJ	O
cap	NN	O
from	IN	O
the	DT	O
vial	NN	O
and	CC	O
wipe	VB	O
the	DT	O
rubber	NN	O
stopper	NN	O
of	IN	O
the	DT	O
vial	NN	O
with	IN	O
an	DT	O
alcohol	NN	O
wipe	NN	O
.	.	O

The	DT	O
ring	NN	O
is	VBZ	O
to	TO	O
remain	VB	O
in	IN	O
place	NN	O
continuously	RB	O
for	IN	O
three	CD	PER
weeks	NNS	PER
.	.	O

KHEDEZLA	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
at	IN	O
approximately	RB	O
the	DT	O
same	JJ	O
time	NN	O
each	DT	FREQ
day	NN	FREQ
.	.	O

MYAMBUTOL	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
under	IN	WHO
thirteen	JJ	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
since	IN	O
safe	JJ	O
conditions	NNS	O
for	IN	O
use	NN	O
have	VBP	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	O

Consider	VB	O
additional	JJ	O
dose	NN	O
increases	NNS	O
after	IN	O
several	JJ	O
more	JJR	PER
weeks	NNS	PER
if	IN	O
insufficient	JJ	O
clinical	JJ	O
improvement	NN	O
is	VBZ	O
observed	VBN	O
.	.	O

Discard	NNP	O
unused	JJ	O
portion	NN	O
after	IN	O
14	CD	O
days	NNS	O
.	.	O

Interrupt	NNP	O
treatment	NN	O
for	IN	O
platelet	NN	O
counts	NNS	O
less	RBR	O
than	IN	O
25	CD	O
X	JJ	O
109	CD	O
/	JJ	O
L	NNP	O
or	CC	O
ANC	NNP	O
less	JJR	O
than	IN	O
0.5	CD	O
X	JJ	O
109	CD	O
/	JJ	O
L	NNP	O
.	.	O

Improvement	NN	O
should	MD	O
be	VB	O
seen	VBN	O
within	IN	O
48	CD	O
hours	NNS	O
to	TO	O
3	CD	PER
weeks	NNS	PER
after	IN	O
starting	VBG	O
therapy	NN	O
.	.	O

Dissolve	NNP	O
contents	NNS	O
of	IN	O
packet	NN	O
in	IN	O
half	PDT	O
a	DT	O
glass	NN	O
(	(	O
4	CD	O
ounces	NNS	O
)	)	O
of	IN	O
water	NN	O
.	.	O

Using	VBG	O
aseptic	JJ	O
technique	NN	O
,	,	O
reconstitute	NN	O
FLOLAN	NNP	O
only	RB	O
with	IN	O
STERILE	NNP	O
DILUENT	NNP	O
for	IN	O
FLOLAN	NNP	O
or	CC	O
pH	VB	O
12	CD	O
STERILE	NNP	O
DILUENT	NNP	O
for	IN	O
FLOLAN	NNP	O
.	.	O

Persistent	NNP	O
bleeding	NN	O
which	WDT	O
is	VBZ	O
not	RB	O
controlled	VBN	O
by	IN	O
this	DT	O
method	NN	O
indicates	VBZ	O
the	DT	O
need	NN	O
for	IN	O
reexamination	NN	O
of	IN	O
the	DT	O
patient	NN	O
,	,	O
at	IN	O
which	WDT	O
time	NN	O
nonfunctional	JJ	O
causes	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	O

It	PRP	O
is	VBZ	O
not	RB	O
for	IN	O
oral	JJ	O
,	,	O
ophthalmic	JJ	O
,	,	O
or	CC	O
intravaginal	JJ	O
use	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
more	RBR	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
loop	NN	O
diuretics	NNS	O
are	VBP	O
preferred	VBN	O
to	TO	O
thiazides	NNS	O
,	,	O
so	IN	O
AVALIDE	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

In	IN	O
the	DT	O
case	NN	O
of	IN	O
postpartum	NN	O
use	NN	O
,	,	O
the	DT	O
product	NN	O
is	VBZ	O
intended	VBN	O
for	IN	O
maternal	JJ	O
administration	NN	O
.	.	O

It	PRP	O
Should	MD	O
Be	VB	O
Emphasized	VBN	O
That	DT	O
Dosage	NN	O
Requirements	NNS	O
Are	VBP	O
Variable	JJ	O
and	CC	O
Must	NNP	O
Be	NNP	O
Individualized	VBN	O
on	IN	O
the	DT	O
Basis	NNP	O
of	IN	O
the	DT	O
Disease	NNP	O
Under	IN	O
Treatment	NNP	O
and	CC	O
the	DT	O
Response	NNP	O
of	IN	O
the	DT	O
Patient	NNP	O
.	.	O

Do	VB	O
not	RB	O
take	VB	O
without	IN	O
food	NN	O
.	.	O

Caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
when	WRB	O
this	DT	O
drug	NN	O
is	VBZ	O
administered	VBN	O
in	IN	O
this	DT	O
patient	JJ	O
population	NN	O
.	.	O

In	IN	O
the	DT	O
treatment	NN	O
of	IN	O
diarrhea	NN	O
,	,	O
if	IN	O
clinical	JJ	O
improvement	NN	O
is	VBZ	O
not	RB	O
observed	VBN	O
in	IN	O
48	CD	O
hours	NNS	O
,	,	O
continued	VBD	O
administration	NN	O
of	IN	O
this	DT	O
type	NN	O
of	IN	O
medication	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

NOTE	NN	O
:	:	O
Do	NNP	O
not	RB	O
refrigerate	VB	O
after	IN	O
reconstitution	NN	O
.	.	O

Premedicate	NNP	O
before	IN	O
each	DT	O
infusion	NN	O
with	IN	O
acetaminophen	NN	O
and	CC	O
an	DT	O
antihistamine	NN	O
.	.	O

It	PRP	O
can	MD	O
not	RB	O
be	VB	O
overemphasized	VBN	O
that	IN	O
both	DT	O
the	DT	O
adult	NN	WHO
and	CC	O
pediatric	JJ	O
dosage	NN	O
guidelines	NNS	O
provided	VBN	O
are	VBP	O
based	VBN	O
upon	JJ	O
average	JJ	O
patient	JJ	O
response	NN	O
and	CC	O
substantial	JJ	O
individual	JJ	O
variation	NN	O
can	MD	O
be	VB	O
expected	VBN	O
.	.	O

Such	JJ	O
doses	NNS	O
will	MD	O
normally	RB	O
produce	VB	O
the	DT	O
desired	JJ	O
serum	NN	O
lithium	NN	O
level	NN	O
ranging	VBG	O
between	IN	O
1.0	CD	O
and	CC	O
1.5	CD	O
mEq	NN	O
/	NNP	O
L	NNP	O
.	.	O

Subsequent	JJ	O
monitoring	NN	O
intervals	NNS	O
should	MD	O
be	VB	O
based	VBN	O
on	IN	O
individual	JJ	O
patient	NN	O
response	NN	O
.	.	O

NOTE	NN	O
:	:	O
CONTAINS	NNP	O
BENZYL	NNP	O
ALCOHOL	NNP	O
(	(	O
see	VB	O
WARNINGS	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
:	:	O
Pediatric	NNP	O
Use	NNP	O
)	)	O

Diazepam	NNP	O
rectal	JJ	O
gel	NN	O
2.5	CD	DOS
mg	NN	UNIT
is	VBZ	O
also	RB	O
available	JJ	O
with	IN	O
a	DT	O
4.4	CD	O
cm	NN	O
tip	NN	O
.	.	O

When	WRB	O
doses	NNS	O
are	VBP	O
repeated	VBN	O
,	,	O
vary	VBP	O
the	DT	O
injection	NN	O
site	NN	O
.	.	O

After	IN	O
a	DT	O
satisfactory	JJ	O
response	NN	O
has	VBZ	O
been	VBN	O
achieved	VBN	O
,	,	O
the	DT	O
patient	NN	O
's	POS	O
dose	NN	O
should	MD	O
be	VB	O
reviewed	VBN	O
and	CC	O
adjusted	VBN	O
as	IN	O
required	VBN	O
.	.	O

Pediatrics	NNS	O
:	:	O
Excretory	NN	O
Urography	NN	O

Exceeding	VBG	O
a	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
60	CD	DOS
mg	NNS	UNIT
rarely	RB	O
increases	VBZ	O
the	DT	O
beneficial	JJ	O
response	NN	O
.	.	O

Dosage	NN	O
is	VBZ	O
increased	VBN	O
or	CC	O
decreased	VBN	O
according	VBG	O
to	TO	O
blood	NN	O
pressure	NN	O
response	NN	O
.	.	O

Narcolepsy	NNP	O
seldom	NN	O
occurs	VBZ	O
in	IN	O
children	NNS	WHO
under	IN	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
;	:	O
however	RB	O
,	,	O
when	WRB	O
it	PRP	O
does	VBZ	O
,	,	O
Evekeo	NNP	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

There	EX	O
are	VBP	O
insufficient	JJ	O
data	NNS	O
to	TO	O
support	VB	O
the	DT	O
use	NN	O
of	IN	O
higher	JJR	O
doses	NNS	O
for	IN	O
those	DT	O
patients	NNS	WHO
who	WP	WHO
show	VBP	WHO
inadequate	JJ	WHO
or	CC	WHO
no	DT	WHO
response	NN	WHO
to	TO	O
20	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
.	.	O

See	VB	O
Precautions	NNS	O
,	,	O
Pediatric	NNP	O
Use	NNP	O
.	.	O

CHILDREN	NN	O

The	DT	O
7.5	CD	DOS
mg	NNS	UNIT
dose	JJ	UNIT
can	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
splitting	VBG	O
the	DT	O
15	CD	DOS
mg	JJ	UNIT
tablet	NN	UNIT
along	IN	O
the	DT	O
score	NN	O
line	NN	O
.	.	O

Local	JJ	O
anesthesia	NN	O
may	MD	O
also	RB	O
be	VB	O
supplemented	VBN	O
by	IN	O
the	DT	O
use	NN	O
of	IN	O
distraction	NN	O
techniques	NNS	O
.	.	O

This	DT	O
product	NN	O
contains	VBZ	O
a	DT	O
built	JJ	O
-	:	O
in	IN	O
spacer	NN	O
.	.	O

Admixtures	NNS	O
of	IN	O
the	DT	O
product	NN	O
,	,	O
with	IN	O
approved	JJ	O
diluents	NNS	O
,	,	O
are	VBP	O
chemically	RB	O
and	CC	O
physically	RB	O
stable	JJ	O
for	IN	O
24	CD	PER
hours	NNS	PER
at	IN	O
room	NN	O
temperature	NN	O
(	(	O
15°	CD	O
to	TO	O
30°	CD	O
C	NNP	O
or	CC	O
59°	CD	O
to	TO	O
86°	CD	O
F	NNP	O
)	)	O
and	CC	O
for	IN	O
48	CD	PER
hours	NNS	PER
at	IN	O
refrigerated	JJ	O
temperatures	NNS	O
(	(	O
2°	CD	O
to	TO	O
8°C	CD	O
or	CC	O
36°	CD	O
to	TO	O
46°F	CD	O
)	)	O
.	.	O

Aredia	NNP	O
must	MD	O
not	RB	O
be	VB	O
mixed	JJ	O
with	IN	O
calcium	JJ	O
-	:	O
containing	VBG	O
infusion	NN	O
solutions	NNS	O
,	,	O
such	JJ	O
as	IN	O
Ringer	NNP	O
's	POS	O
solution	NN	O
,	,	O
and	CC	O
should	MD	O
be	VB	O
given	VBN	O
in	IN	O
a	DT	O
single	JJ	DOS
intravenous	JJ	UNIT
solution	NN	UNIT
and	CC	O
line	NN	O
separate	VBP	O
from	IN	O
all	DT	O
other	JJ	O
drugs	NNS	O
.	.	O

Figure	NN	O
2	CD	O
.	.	O

The	DT	O
type	NN	O
,	,	O
frequency	NN	O
,	,	O
and	CC	O
severity	NN	O
of	IN	O
adverse	JJ	O
experiences	NNS	O
observed	VBN	O
with	IN	O
M	NNP	O
-	:	O
M	NNP	O
-	:	O
R	NN	O
II	NNP	O
were	VBD	O
similar	JJ	O
to	TO	O
those	DT	O
seen	VBN	O
when	WRB	O
each	DT	O
vaccine	NN	O
was	VBD	O
given	VBN	O
alone	RB	O
.	.	O

The	DT	O
usual	JJ	O
dose	NN	O
is	VBZ	O
0.5	CD	DOS
to	TO	O
2	CD	DOS
mg	NNS	UNIT
Neostigmine	NNP	O
Methylsulfate	NNP	O
(	(	O
neostigmine	JJ	O
methylsulfate	NN	O
(	(	O
neostigmine	JJ	O
methylsulfate	NN	O
injection	NN	O
)	)	O
injection	NN	O
)	)	O
Injection	NN	O
,	,	O
USP	NNP	O
given	VBN	O
by	IN	O
slow	JJ	O
intravenous	JJ	O
injection	NN	O
,	,	O
repeated	VBN	O
as	IN	O
required.Only	RB	O
in	IN	O
exceptional	JJ	O
cases	NNS	O
should	MD	O
the	DT	O
total	JJ	O
dose	NN	O
of	IN	O
Neostigmine	NNP	O
Methylsulfate	NNP	O
(	(	O
neostigmine	JJ	O
methylsulfate	NN	O
(	(	O
neostigmine	JJ	O
methylsulfate	NN	O
injection	NN	O
)	)	O
injection	NN	O
)	)	O
exceed	VBP	O
5	CD	DOS
mg.It	NN	UNIT
is	VBZ	O
recommended	VBN	O
that	IN	O
the	DT	O
patient	NN	O
be	VB	O
well	RB	O
ventilated	VBN	O
and	CC	O
a	DT	O
patent	NN	O
airway	RB	O
maintained	VBD	O
until	IN	O
complete	JJ	O
recovery	NN	O
of	IN	O
normal	JJ	O
respiration	NN	O
is	VBZ	O
assured.The	JJ	O
optimum	JJ	O
time	NN	O
for	IN	O
administration	NN	O
of	IN	O
the	DT	O
drug	NN	O
is	VBZ	O
during	IN	O
hyperventilation	NN	O
when	WRB	O
the	DT	O
carbon	NN	O
dioxide	NN	O
level	NN	O
of	IN	O
the	DT	O
blood	NN	O
is	VBZ	O
low	JJ	O
.	.	O

If	IN	O
used	VBN	O
as	IN	O
preoperative	JJ	O
medication	NN	O
,	,	O
50	CD	DOS
to	TO	O
100	CD	DOS
mg	NNS	UNIT
IM*	NNP	O
1	CD	O
hour	NN	O
prior	RB	O
to	TO	O
surgery	NN	O
.	.	O

A	DT	O
patient	NN	WHO
whose	WP$	WHO
blood	NN	WHO
pressure	NN	WHO
is	VBZ	WHO
not	RB	WHO
adequately	RB	WHO
controlled	VBN	WHO
with	IN	WHO
aliskiren	NN	WHO
alone	RB	WHO
or	CC	O
hydrochlorothiazide	VB	O
alone	RB	O
may	MD	O
be	VB	O
switched	VBN	O
to	TO	O
combination	VB	O
therapy	NN	O
with	IN	O
Tekturna	NNP	O
HCT	NNP	O
.	.	O

Although	IN	O
the	DT	O
efficacy	NN	O
of	IN	O
PAXIL	NNP	O
CR	NNP	O
beyond	IN	O
12	CD	PER
weeks	NNS	PER
of	IN	O
dosing	VBG	O
has	VBZ	O
not	RB	O
been	VBN	O
demonstrated	VBN	O
in	IN	O
controlled	JJ	O
clinical	JJ	O
trials	NNS	O
,	,	O
social	JJ	O
anxiety	NN	O
disorder	NN	O
is	VBZ	O
recognized	VBN	O
as	IN	O
a	DT	O
chronic	JJ	O
condition	NN	O
,	,	O
and	CC	O
it	PRP	O
is	VBZ	O
reasonable	JJ	O
to	TO	O
consider	VB	O
continuation	NN	O
of	IN	O
treatment	NN	O
for	IN	O
a	DT	O
responding	JJ	WHO
patient	NN	WHO
.	.	O

It	PRP	O
has	VBZ	O
been	VBN	O
given	VBN	O
less	RBR	O
frequently	RB	O
with	IN	O
etoposide	NN	O
,	,	O
cisplatin	NN	O
,	,	O
cytarabine	NN	O
,	,	O
paclitaxel	NN	O
,	,	O
and	CC	O
aminoglutethimide	RB	O
.	.	O

Response	NN	O
to	TO	O
somatropin	VB	O
treatment	NN	O
tends	NNS	O
to	TO	O
decrease	VB	O
with	IN	O
time	NN	O
.	.	O

During	IN	O
chronic	JJ	O
therapy	NN	O
,	,	O
periodically	RB	O
reassess	VB	O
the	DT	O
continued	JJ	O
need	NN	O
for	IN	O
opioid	JJ	O
analgesics	NNS	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

There	EX	O
is	VBZ	O
no	DT	O
experience	NN	O
with	IN	O
inserting	VBG	O
additional	JJ	O
implants	NNS	O
into	IN	O
other	JJ	O
sites	NNS	O
in	IN	O
the	DT	O
arm	NN	O
to	TO	O
recommend	VB	O
an	DT	O
approach	NN	O
to	TO	O
a	DT	O
second	JJ	O
insertion	NN	O
into	IN	O
a	DT	O
previously	RB	O
-	:	O
used	VBN	O
arm	NN	O
.	.	O

Atropine	NNP	O
sulfate	NN	O
,	,	O
0.3	CD	DOS
to	TO	O
0.4	CD	DOS
mg	NN	UNIT
,	,	O
or	CC	O
scopolamine	JJ	O
hydrobromide	NN	O
,	,	O
0.25	CD	DOS
to	TO	O
0.4	CD	DOS
mg	NN	UNIT
,	,	O
in	IN	O
sterile	JJ	O
solution	NN	O
may	MD	O
be	VB	O
mixed	VBN	O
in	IN	O
the	DT	O
same	JJ	O
syringe	NN	O
with	IN	O
Mepergan	NNP	O
(	(	O
meperidine	NN	O
and	CC	O
promethazine	NN	O
)	)	O
.	.	O

The	DT	O
maximum	JJ	O
loading	NN	O
dose	NN	O
and	CC	O
the	DT	O
daily	JJ	FREQ
maintenance	NN	O
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
70	CD	DOS
mg	NNS	UNIT
,	,	O
regardless	RB	O
of	IN	O
the	DT	O
patient	NN	O
's	POS	O
calculated	VBN	O
dose	NN	O
.	.	O

Following	VBG	O
catheter	NN	O
procedure	NN	O
,	,	O
gentle	JJ	O
pressure	NN	O
hemostasis	NN	O
is	VBZ	O
advised	VBN	O
,	,	O
followed	VBN	O
by	IN	O
observation	NN	O
and	CC	O
immobilization	NN	O
of	IN	O
the	DT	O
limb	NN	O
for	IN	O
several	JJ	O
hours	NNS	O
to	TO	O
prevent	VB	O
hemorrhage	NN	O
from	IN	O
the	DT	O
site	NN	O
of	IN	O
arterial	JJ	O
puncture	NN	O
.	.	O

-	:	O
Pumps	NNS	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
downstream	NN	O
of	IN	O
filter	NN	O
.	.	O

All	DT	O
components	NNS	O
used	VBN	O
in	IN	O
the	DT	O
reconstitution	NN	O
and	CC	O
administration	NN	O
of	IN	O
this	DT	O
product	NN	O
should	MD	O
be	VB	O
used	VBN	O
as	RB	O
soon	RB	O
as	IN	O
possible	JJ	O
after	IN	O
opening	VBG	O
their	PRP$	O
sterile	JJ	O
containers	NNS	O
to	TO	O
minimize	VB	O
unnecessary	JJ	O
exposure	NN	O
to	TO	O
the	DT	O
atmosphere	NN	O
.	.	O

The	DT	O
dose	NN	O
may	MD	O
be	VB	O
titrated	VBN	O
up	RP	O
to	TO	O
a	DT	O
maximum	NN	O
of	IN	O
aliskiren	$	O
300	CD	DOS
mg	NN	UNIT
/	NNP	O
hydrochlorothiazide	RB	O
25	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

If	IN	O
more	JJR	O
accurate	JJ	O
results	NNS	O
are	VBP	O
desired	VBN	O
,	,	O
a	DT	O
curve	NN	O
using	VBG	O
the	DT	O
patient	NN	O
's	POS	O
blood	NN	O
and	CC	O
the	DT	O
vial	NN	O
of	IN	O
IC	NNP	O
-	:	O
GREEN™	NNP	O
being	VBG	O
used	VBN	O
in	IN	O
the	DT	O
determination	NN	O
can	MD	O
be	VB	O
constructed	VBN	O
as	IN	O
follows	VBZ	O
:	:	O

Other	JJ	O
than	IN	O
the	DT	O
5	CD	O
flavors	NNS	O
listed	VBN	O
above	IN	O
,	,	O
GlaxoSmithKline	NNP	O
has	VBZ	O
not	RB	O
evaluated	VBN	O
the	DT	O
stability	NN	O
of	IN	O
AUGMENTIN	NNP	O
ES	NNP	O
-	:	O
600	CD	O
when	WRB	O
mixed	JJ	O
with	IN	O
other	JJ	O
flavors	NNS	O
distributed	VBN	O
by	IN	O
FLAVORx	NNP	O
.	.	O

(	(	O
See	VB	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
)	)	O

Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
must	MD	O
be	VB	O
used	VBN	O
as	IN	O
the	DT	O
diluent	NN	O
.	.	O

INVANZ	NNP	O
MUST	NNP	O
BE	NNP	O
RECONSTITUTED	NNP	O
AND	NNP	O
THEN	NNP	O
DILUTED	NNP	O
PRIOR	NNP	O
TO	NNP	O
ADMINISTRATION	NNP	O
.	.	O

After	IN	O
Reconstitution	NNP	O
with	IN	O
Bacteriostatic	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
(	(	O
0.9	CD	O
%	NN	O
Benzyl	NNP	O
Alcohol	NNP	O
)	)	O
:	:	O
The	DT	O
reconstituted	JJ	O
solution	NN	O
should	MD	O
be	VB	O
stored	VBN	O
under	IN	O
refrigeration	NN	O
(	(	O
2	CD	O
-	:	O
8oC	CD	O
/	$	O
36	CD	O
-	:	O
46oF	CD	O
)	)	O
for	IN	O
up	IN	PER
to	TO	PER
14	CD	PER
days	NNS	PER
.	.	O

Deliver	NN	O
at	IN	O
a	DT	O
rate	NN	O
of	IN	O
6.25	CD	DOS
mg	NNS	UNIT
/	JJ	O
hour	NN	O
(	(	O
e.g	NN	O
,	,	O
150	CD	DOS
mg	NN	UNIT
[	VBD	O
6	CD	DOS
mL	NN	UNIT
]	NN	O
of	IN	O
ZANTAC	NNP	O
Injection	NNP	O
(	(	O
ranitidine	VB	O
hydrochloride	NN	O
injection	NN	O
)	)	O
in	IN	O
250	CD	DOS
mL	NN	UNIT
of	IN	O
5	CD	O
%	NN	O
dextrose	JJ	O
injection	NN	O
at	IN	O
10.7	CD	DOS
mL	NNS	UNIT
/	RB	O
hour	NN	O
)	)	O
.	.	O

Reduction	NN	O
of	IN	O
the	DT	O
intraocular	JJ	O
pressure	NN	O
starts	VBZ	O
approximately	RB	O
2	CD	O
to	TO	O
4	CD	O
hours	NNS	O
after	IN	O
the	DT	O
first	JJ	O
administration	NN	O
with	IN	O
the	DT	O
maximum	JJ	O
effect	NN	O
reached	VBD	O
after	IN	O
12	CD	O
hours	NNS	O
.	.	O

Revised	VBN	O
:	:	O
Nov	NN	O
2016	CD	O

The	DT	O
table	NN	O
below	IN	O
provides	VBZ	O
the	DT	O
ratio	NN	O
of	IN	O
2	CD	O
%	NN	O
lidocaine	NN	O
to	TO	O
be	VB	O
mixed	JJ	O
with	IN	O
the	DT	O
various	JJ	O
syringe	NN	O
volumes	NNS	O
of	IN	O
RADIESSE	NNP	O
injectable	JJ	O
implant	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
type	JJ	WHO
2	CD	WHO
diabetes	NNS	WHO
whose	WP$	WHO
hyperglycemia	NN	WHO
can	MD	O
not	RB	O
be	VB	O
satisfactorily	RB	O
managed	VBN	O
with	IN	O
diet	JJ	O
and	CC	O
exercise	NN	O
alone	RB	O
,	,	O
the	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
GLUCOVANCE	NNP	O
is	VBZ	O
1.25	CD	DOS
mg	NN	UNIT
/	VBD	O
250	CD	DOS
mg	NN	UNIT
once	RB	FREQ
a	DT	FREQ
day	NN	FREQ
with	IN	O
a	DT	O
meal	NN	O
.	.	O

Periodic	JJ	O
determination	NN	O
of	IN	O
serum	JJ	O
lipids	NNS	O
should	MD	O
be	VB	O
obtained	VBN	O
during	IN	O
initial	JJ	O
therapy	NN	O
in	IN	O
order	NN	O
to	TO	O
establish	VB	O
the	DT	O
lowest	JJS	O
effective	JJ	O
dose	NN	O
of	IN	O
LIPOFEN	NNP	O
.	.	O

Insert	NNP	O
needle	NN	O
(	(	O
s	NN	O
)	)	O

NOTE	NN	O
:	:	O
Status	NNP	O
asthmaticus	NN	O
should	MD	O
be	VB	O
considered	VBN	O
a	DT	O
medical	JJ	O
emergency	NN	O
and	CC	O
is	VBZ	O
defined	VBN	O
as	IN	O
that	DT	O
degree	NN	O
of	IN	O
bronchospasm	NN	O
which	WDT	O
is	VBZ	O
not	RB	O
rapidly	RB	O
responsive	JJ	O
to	TO	O
usual	JJ	O
doses	NNS	O
of	IN	O
conventional	JJ	O
bronchodilators	NNS	O
.	.	O

If	IN	O
a	DT	O
patient	NN	O
has	VBZ	O
discontinued	VBN	O
lamotrigine	NN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
more	JJR	O
than	IN	O
5	CD	DOS
half	JJ	UNIT
-	:	O
lives	NNS	O
,	,	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
initial	JJ	O
dosing	VBG	O
recommendations	NNS	O
and	CC	O
guidelines	NNS	O
be	VB	O
followed	VBN	O
.	.	O

Elevated	VBN	O
liver	JJ	O
transaminases	NNS	O
:	:	O
If	IN	O
elevations	NNS	O
in	IN	O
liver	NN	O
transaminases	NNS	O
greater	JJR	O
than	IN	O
5xinstitutional	CD	O
upper	JJ	O
limit	NN	O
of	IN	O
normal	JJ	O
(	(	O
ULN	NNP	O
)	)	O
occur	VBP	O
,	,	O
withhold	JJ	O
BOSULIF	NNP	O
until	IN	O
recovery	NN	O
to	TO	O
less	JJR	O
than	IN	O
or	CC	O
equal	JJ	O
to	TO	O
2.5xULN	CD	O
and	CC	O
resume	VB	O
at	IN	O
400	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	JJ	FREQ
thereafter	NN	O
.	.	O

Loxapine	NNP	O
(	(	O
loxapine	NN	O
(	(	O
loxapine	NN	O
(	(	O
loxapine	JJ	O
succinate	NN	O
)	)	O
succinate	NN	O
)	)	O
succinate	NN	O
)	)	O
Capsules	NNP	O
USP	NNP	O
are	VBP	O
administered	VBN	O
,	,	O
usually	RB	O
in	IN	O
divided	JJ	O
doses	NNS	O
,	,	O
two	CD	FREQ
to	TO	O
four	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
.	.	O

Ultrasound	IN	O
scanning	VBG	O
(	(	O
USS	NNP	O
)	)	O
with	IN	O
a	DT	O
high	JJ	O
-	:	O
frequency	NN	O
linear	JJ	O
array	NN	O
transducer	NN	O
(	(	O
10	CD	DOS
MHz	NNP	UNIT
or	CC	O
greater	JJR	O
)	)	O
or	CC	O
magnetic	JJ	O
resonance	NN	O
imaging	NN	O
(	(	O
MRI	NNP	O
)	)	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

Reduction	NN	O
of	IN	O
the	DT	O
intraocular	JJ	O
pressure	NN	O
starts	VBZ	O
approximately	RB	O
4	CD	O
hours	NNS	O
after	IN	O
the	DT	O
first	JJ	O
administration	NN	O
with	IN	O
maximum	JJ	O
effect	NN	O
reached	VBD	O
within	IN	O
approximately	RB	O
8	CD	O
to	TO	O
12	CD	O
hours	NNS	O
.	.	O

After	IN	O
several	JJ	PER
months	NNS	PER
on	IN	O
treatment	NN	O
,	,	O
bleeding	NN	O
may	MD	O
be	VB	O
reduced	VBN	O
to	TO	O
a	DT	O
point	NN	O
of	IN	O
virtual	JJ	O
absence	NN	O
.	.	O

If	IN	O
this	DT	O
is	VBZ	O
evident	JJ	O
,	,	O
the	DT	O
BiCNU	NNP	O
(	(	O
carmustine	NN	O
)	)	O
is	VBZ	O
suitable	JJ	O
for	IN	O
use	NN	O
and	CC	O
should	MD	O
be	VB	O
refrigerated	VBN	O
immediately	RB	O
.	.	O

The	DT	O
lyophilized	JJ	O
vaccine	NN	O
should	MD	O
be	VB	O
a	DT	O
white	JJ	O
or	CC	O
off	RP	O
-	:	O
white	JJ	O
color	NN	O
to	TO	O
a	DT	O
light	JJ	O
beige	NN	O
color	NN	O
.	.	O

For	IN	O
serum	JJ	O
creatinine	NN	O
increases	NNS	O
while	IN	O
receiving	VBG	O
Exjade	NNP	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
modify	VB	O
the	DT	O
dose	NN	O
as	IN	O
follows	VBZ	O
:	:	O

Advise	NN	O
patients	NNS	O
to	TO	O
establish	VB	O
a	DT	O
routine	JJ	O
pattern	NN	O
with	IN	O
regard	NN	O
to	TO	O
meals	NNS	O
.	.	O

Doses	NNS	O
larger	JJR	O
than	IN	O
300	CD	DOS
IU	NNP	UNIT
of	IN	O
FSH	NNP	O
per	IN	FREQ
day	NN	FREQ
are	VBP	O
not	RB	O
routinely	RB	O
recommended	VBN	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
is	VBZ	O
25	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

The	DT	O
suspension	NN	O
should	MD	O
be	VB	O
shaken	VBN	O
well	RB	O
before	RB	O
use	NN	O
.	.	O

Syphilis	NNP	O
-	:	O
Aqueous	JJ	O
penicillin	NN	O
G	NNP	O
may	MD	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
acquired	VBN	O
and	CC	O
congenital	JJ	O
syphilis	NN	O
,	,	O
but	CC	O
because	IN	O
of	IN	O
the	DT	O
necessity	NN	O
of	IN	O
frequent	JJ	O
dosage	NN	O
,	,	O
hospitalization	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

No	DT	O
data	NN	O
are	VBP	O
available	JJ	O
for	IN	O
subjects	NNS	WHO
with	IN	WHO
severe	JJ	WHO
hepatic	JJ	WHO
impairment	NN	WHO
[	NNP	O
see	VBP	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

For	IN	O
example	NN	O
,	,	O
the	DT	O
administration	NN	O
of	IN	O
one	CD	DOS
4	CD	DOS
mg	NN	UNIT
albuterol	NN	O
extended	VBD	O
-	:	O
release	NN	O
tablet	NN	O
every	DT	O
12	CD	O
hours	NNS	O
is	VBZ	O
comparable	JJ	O
to	TO	O
one	CD	DOS
2	CD	DOS
mg	NN	UNIT
albuterol	NN	O
tablet	NN	O
,	,	O
USP	NNP	O
every	DT	FREQ
6	CD	FREQ
hours	NNS	FREQ
.	.	O

Sprinkling	VBG	O
Contents	NNS	O
on	IN	O
Food	NN	O
:	:	O
Micro	NNP	O
-	:	O
K	NNP	O
LS	NNP	O
may	MD	O
be	VB	O
given	VBN	O
on	IN	O
soft	JJ	O
food	NN	O
that	WDT	O
may	MD	O
be	VB	O
swallowed	VBN	O
easily	RB	O
without	IN	O
chewing	VBG	O
,	,	O
such	JJ	O
as	IN	O
applesauce	NN	O
or	CC	O
pudding	NN	O
.	.	O

These	DT	O
patients	NNS	O
often	RB	O
have	VBP	O
reduced	VBN	O
nefazodone	JJ	O
clearance	NN	O
and	CC	O
/	NN	O
or	CC	O
increased	JJ	O
sensitivity	NN	O
to	TO	O
the	DT	O
side	NN	O
effects	NNS	O
of	IN	O
CNS	NNP	O
-	:	O
active	JJ	O
drugs	NNS	O
.	.	O

During	IN	O
the	DT	O
four	CD	O
-	:	O
week	NN	PER
titration	NN	O
period	NN	O
,	,	O
dosing	VBG	O
can	MD	O
be	VB	O
increased	VBN	O
with	IN	O
the	DT	O
recommended	VBN	O
dose	JJ	O
titration	NN	O
schedule	NN	O
while	IN	O
ensuring	VBG	O
that	IN	O
the	DT	O
anticholinergic	JJ	O
adverse	JJ	O
events	NNS	O
are	VBP	O
tolerable	JJ	O
.	.	O

Avoid	NNP	O
freezing	VBG	O
the	DT	O
accompanying	VBG	O
diluent	NN	O
.	.	O

No	DT	O
dose	JJ	O
adjustment	NN	O
is	VBZ	O
needed	VBN	O
.	.	O

Patients	NNS	O
should	MD	O
follow	VB	O
-	:	O
up	IN	O
with	IN	O
their	PRP$	O
healthcare	NN	O
provider	NN	O
approximately	RB	O
7	CD	PER
to	TO	O
14	CD	PER
days	NNS	PER
after	IN	O
the	DT	O
administration	NN	O
of	IN	O
MIFEPREX	NNP	O
.	.	O

Removing	VBG	O
the	DT	O
Implant	NN	O

To	TO	O
prevent	VB	O
rebound	NN	O
hypoglycemia	NN	O
,	,	O
do	VBP	O
not	RB	O
abruptly	RB	O
discontinue	JJ	O
administration	NN	O
of	IN	O
nutritional	JJ	O
solutions	NNS	O
.	.	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dose	NN	O
is	VBZ	O
30	CD	DOS
mg	NN	UNIT
to	TO	O
60	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Multiples	NNS	O
of	IN	O
this	DT	O
regimen	VBZ	O
up	RP	O
to	TO	O
the	DT	O
maximum	NN	O
recommended	VBD	FREQ
daily	RB	FREQ
dose	RB	O
also	RB	O
apply	VB	O
.	.	O

This	DT	O
dosage	NN	O
may	MD	O
be	VB	O
repeated	VBN	O
whenever	WRB	O
necessary	JJ	O
.	.	O

Prior	RB	O
to	TO	O
initiating	VBG	O
Natesto	NNP	O
,	,	O
confirm	VBP	O
the	DT	O
diagnosis	NN	O
of	IN	O
hypogonadism	NN	O
by	IN	O
ensuring	VBG	O
that	IN	O
serum	NN	O
testosterone	NN	O
concentrations	NNS	O
have	VBP	O
been	VBN	O
measured	VBN	O
in	IN	O
the	DT	O
morning	NN	O
on	IN	O
at	IN	O
least	JJS	O
two	CD	O
separate	JJ	O
days	NNS	O
and	CC	O
that	IN	O
these	DT	O
serum	VB	O
testosterone	NN	O
concentrations	NNS	O
are	VBP	O
below	IN	O
the	DT	O
normal	JJ	O
range	NN	O
.	.	O

Do	NNP	O
not	RB	O
prescribe	VB	O
a	DT	O
replacement	NN	O
dose	NN	O
for	IN	O
emesis	NN	O
.	.	O

Initial	JJ	O
Dosage	NNP	O
.	.	O

DO	NNP	O
NOT	NNP	O
divide	VB	O
dose	RB	O
into	IN	O
multiple	JJ	O
injections	NNS	O
.	.	O

Efficacy	NN	O
was	VBD	O
demonstrated	VBN	O
with	IN	O
FANAPT	NNP	O
in	IN	O
a	DT	O
dose	JJ	O
range	NN	O
of	IN	O
6	CD	DOS
to	TO	O
12	CD	DOS
mg	NNS	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

for	IN	O
males	NNS	O
:	:	O
CrCl	NNP	O
=	NNP	O
(	(	O
140	CD	DOS
-	:	O
age	NN	O
)	)	O
(	(	O
weight	NN	O
)	)	O
/	NN	O
[	NNP	O
(	(	O
72	CD	O
)	)	O
(	(	O
SCr	NNP	O
)	)	O
]	NN	O

Healthcare	NNP	O
professionals	NNS	O
who	WP	O
prescribe	VBP	O
Onsolis	NNP	O
on	IN	O
an	DT	O
outpatient	JJ	O
basis	NN	O
must	MD	O
enroll	VB	O
in	IN	O
the	DT	O
TIRF	NNP	O
REMS	NNP	O
Access	NNP	O
program	NN	O
and	CC	O
comply	NN	O
with	IN	O
the	DT	O
requirements	NNS	O
of	IN	O
the	DT	O
REMS	NNP	O
to	TO	O
ensure	VB	O
safe	JJ	O
use	NN	O
of	IN	O
Onsolis	NNP	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

4	CD	O
.	.	O

A	DT	O
series	NN	O
of	IN	O
three	CD	DOS
doses	NNS	UNIT
of	IN	O
0.5	CD	DOS
mL	NNS	UNIT
each	DT	O
,	,	O
of	IN	O
Tetanus	NNP	O
Toxoid	NNP	O
Adsorbed	NNP	O
vaccine	NN	O
should	MD	O
be	VB	O
given	VBN	O
intramuscularly	RB	O
;	:	O
the	DT	O
second	JJ	O
dose	NN	O
of	IN	O
0.5	CD	DOS
mL	NN	UNIT
is	VBZ	O
given	VBN	O
4	CD	PER
to	TO	O
8	CD	PER
weeks	NNS	PER
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
;	:	O
and	CC	O
the	DT	O
third	JJ	O
dose	NN	O
of	IN	O
0.5	CD	DOS
mL	NN	UNIT
is	VBZ	O
given	VBN	O
6	CD	PER
to	TO	O
12	CD	PER
months	NNS	PER
after	IN	O
the	DT	O
second	JJ	O
dose	NN	O
.	.	O

Use	VB	O
the	DT	O
sterile	JJ	O
gauze	NN	O
and	CC	O
apply	VB	O
gentle	JJ	O
pressure	NN	O
for	IN	O
five	CD	PER
minutes	NNS	PER
to	TO	O
the	DT	O
incision	NN	O
site	NN	O
to	TO	O
ensure	VB	O
hemostasis	NN	O
.	.	O

Follow	NNP	O
-	:	O
up	RB	O
films	NNS	O
at	IN	O
24	CD	O
or	CC	O
48	CD	O
hours	NNS	O
provide	VBP	O
better	JJR	O
demonstration	NN	O
of	IN	O
lymph	NN	O
nodes	NNS	O
and	CC	O
permit	NN	O
more	JJR	O
concise	JJ	O
evaluation	NN	O
of	IN	O
nodal	JJ	O
architecture	NN	O
.	.	O

Retreatment	NN	O
:	:	O
In	IN	O
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
received	VBN	WHO
previous	JJ	WHO
antituberculous	JJ	WHO
therapy	NN	WHO
,	,	O
administer	RB	O
MYAMBUTOL	NNP	O
25	CD	DOS
mg	NN	UNIT
/	NN	O
kg	NN	O
(	(	O
11	CD	DOS
mg	NN	UNIT
/	NNP	O
lb	NN	O
)	)	O
of	IN	O
body	NN	O
weight	NN	O
,	,	O
as	IN	O
a	DT	O
single	JJ	DOS
oral	JJ	UNIT
dose	NN	UNIT
once	RB	FREQ
every	DT	FREQ
24	CD	FREQ
hours	NNS	FREQ
.	.	O

The	DT	O
final	JJ	O
volume	NN	O
is	VBZ	O
approximately	RB	O
11.4	JJ	O
mL	NN	O
.	.	O

Please	NNP	O
refer	NN	O
to	TO	O
amoxicillin	VB	O
and	CC	O
clarithromycin	VB	O
prescribing	VBG	O
information	NN	O
for	IN	O
Contraindications	NNP	O
,	,	O
Warnings	NNP	O
,	,	O
and	CC	O
dosing	VBG	O
in	IN	O
elderly	JJ	WHO
and	CC	WHO
renally	RB	WHO
-	:	WHO
impaired	JJ	WHO
patients	NNS	WHO
.	.	O

For	IN	O
Intravenous	NNP	O
Use	NNP	O
After	IN	O
Reconstitution	NNP	O
Only	RB	O
.	.	O

Luminescence	NNP	O
usually	RB	O
appears	VBZ	O
in	IN	O
the	DT	O
retina	NN	O
and	CC	O
choroidal	NN	O
vessels	NNS	O
in	IN	O
7	CD	O
to	TO	O
14	CD	O
seconds	NNS	O
and	CC	O
can	MD	O
be	VB	O
observed	VBN	O
by	IN	O
standard	JJ	O
viewing	VBG	O
equipment	NN	O
.	.	O

In	IN	O
this	DT	O
latter	JJ	O
situation	NN	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
necessary	JJ	O
to	TO	O
increase	VB	O
the	DT	O
dosage	NN	O
of	IN	O
the	DT	O
corticosteroid	NN	O
for	IN	O
a	DT	O
period	NN	O
of	IN	O
time	NN	O
consistent	JJ	O
with	IN	O
the	DT	O
patient	NN	O
's	POS	O
condition	NN	O
.	.	O

Contents	NNS	O
of	IN	O
the	DT	O
capsule	NN	O
may	MD	O
also	RB	O
be	VB	O
administered	VBN	O
directly	RB	O
to	TO	O
the	DT	O
mouth	NN	O
.	.	O

Azor	NNP	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
provide	VB	O
additional	JJ	O
blood	NN	O
pressure	NN	O
lowering	VBG	O
for	IN	O
patients	NNS	WHO
not	RB	WHO
adequately	RB	WHO
controlled	VBN	WHO
with	IN	WHO
amlodipine	NN	WHO
(	(	O
or	CC	O
another	DT	O
dihydropyridine	JJ	O
calcium	NN	O
channel	NN	O
blocker	NN	O
)	)	O
alone	RB	O
or	CC	O
with	IN	O
olmesartan	JJ	O
medoxomil	NN	O
(	(	O
or	CC	O
another	DT	O
angiotensin	NN	O
receptor	NN	O
blocker	NN	O
)	)	O
alone	RB	O
.	.	O

If	IN	O
you	PRP	O
must	MD	O
administer	VB	O
Exjade	NNP	O
with	IN	O
1	CD	O
of	IN	O
these	DT	O
agents	NNS	O
,	,	O
consider	VB	O
increasing	VBG	O
the	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
Exjade	NNP	O
by	IN	O
50	CD	O
%	NN	O
,	,	O
and	CC	O
monitor	NN	O
serum	NN	O
ferritin	NN	O
levels	NNS	O
and	CC	O
clinical	JJ	O
responses	NNS	O
for	IN	O
further	JJ	O
dose	JJ	O
modification	NN	O
[	NNP	O
see	VBP	O
Transfusional	NNP	O
Iron	NNP	O
Overload	NNP	O
and	CC	O
Iron	NNP	O
Overload	NNP	O
in	IN	O
Non	NNP	O
-	:	O
Transfusion	NN	O
-	:	O
Dependent	JJ	O
Thalassemia	NNP	O
Syndromes	NNP	O
,	,	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

Oral	NNP	O
penicillin	NN	O
V	NNP	O
(	(	O
phenoxymethyl	JJ	O
penicillin	NN	O
)	)	O
,	,	O
500	CD	DOS
mg	NN	UNIT
for	IN	O
adults	NNS	WHO
or	CC	O
250	CD	DOS
mg	NN	UNIT
for	IN	O
children	NNS	WHO
less	JJR	WHO
than	IN	WHO
60	CD	WHO
lb	NNS	WHO
,	,	O
should	MD	O
be	VB	O
given	VBN	O
every	DT	FREQ
6	CD	FREQ
hours	NNS	FREQ
for	IN	O
8	CD	DOS
doses	NNS	UNIT
.	.	O

If	IN	O
a	DT	O
patient	NN	O
has	VBZ	O
a	DT	O
serious	JJ	O
adverse	JJ	O
reaction	NN	O
potentially	RB	O
related	VBN	O
to	TO	O
peginterferon	VB	O
alfa	NN	O
and	CC	O
/	NN	O
or	CC	O
ribavirin	NN	O
,	,	O
the	DT	O
peginterferon	NN	O
alfa	NN	O
and	CC	O
/	NN	O
or	CC	O
ribavirin	NN	O
dose	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
or	CC	O
discontinued	VBN	O
.	.	O

In	IN	O
children	NNS	WHO
with	IN	WHO
ADHD	NNP	WHO
who	WP	WHO
are	VBP	WHO
6	CD	WHO
-	:	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
are	VBP	WHO
either	DT	WHO
starting	VBG	WHO
treatment	NN	WHO
for	IN	WHO
the	DT	WHO
first	JJ	WHO
time	NN	WHO
or	CC	WHO
switching	VBG	WHO
from	IN	WHO
another	DT	WHO
medication	NN	WHO
,	,	O
start	VBP	O
with	IN	O
10	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
in	IN	O
the	DT	O
morning	NN	O
;	:	O
daily	JJ	FREQ
dosage	NN	O
may	MD	O
be	VB	O
adjusted	VBN	O
in	IN	O
increments	NNS	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
or	CC	O
10	CD	DOS
mg	NN	UNIT
at	IN	O
weekly	JJ	FREQ
intervals	NNS	FREQ
.	.	O

Doses	NNS	O
cited	VBD	O
in	IN	O
Table	NNP	O
3	CD	O
are	VBP	O
based	VBN	O
on	IN	O
a	DT	O
patient	NN	WHO
with	IN	WHO
normal	JJ	WHO
renal	JJ	WHO
function	NN	WHO
and	CC	O
a	DT	O
body	NN	O
weight	NN	O
of	IN	O
70	CD	O
kg	NNS	O
.	.	O

The	DT	O
dose	NN	O
is	VBZ	O
adjusted	VBN	O
,	,	O
as	IN	O
required	VBN	O
,	,	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
blood	NN	O
counts	NNS	O
done	VBN	O
at	IN	O
approximately	RB	O
weekly	JJ	FREQ
intervals	NNS	FREQ
.	.	O

Increasing	VBG	O
the	DT	O
volume	NN	O
of	IN	O
gel	NN	O
administered	VBN	O
does	VBZ	O
not	RB	O
increase	VB	O
the	DT	O
amount	NN	O
of	IN	O
progesterone	NN	O
absorbed	VBN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
a	DT	O
patient	NN	WHO
who	WP	WHO
experiences	VBZ	WHO
moderate	JJ	WHO
depression	NN	WHO
(	(	O
persistent	JJ	O
low	JJ	O
mood	NN	O
,	,	O
loss	NN	O
of	IN	O
interest	NN	O
,	,	O
p.o	NN	O
.	.	O

During	IN	O
withdrawal	NN	O
,	,	O
some	DT	WHO
patients	NNS	WHO
may	MD	O
experience	VB	O
symptoms	NNS	O
of	IN	O
systemic	JJ	O
corticosteroid	NN	O
withdrawal	NN	O
;	:	O
e.g	NN	O
.	.	O

If	IN	O
menstruation	NN	O
begins	VBZ	O
on	IN	O
a	DT	O
Sunday	NNP	O
,	,	O
the	DT	O
first	JJ	O
tablet	NN	O
(	(	O
white	JJ	O
)	)	O
is	VBZ	O
taken	VBN	O
that	DT	O
day	NN	O
.	.	O

Further	RB	O
dose	JJ	O
increases	NNS	O
of	IN	O
the	DT	O
same	JJ	O
magnitude	NN	O
could	MD	O
be	VB	O
made	VBN	O
,	,	O
if	IN	O
necessary	JJ	O
,	,	O
every	DT	FREQ
seven	CD	FREQ
days	NNS	FREQ
.	.	O

Solutions	NNS	O
in	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
that	WDT	O
are	VBP	O
frozen	JJ	O
immediately	RB	O
after	IN	O
constitution	NN	O
in	IN	O
the	DT	O
original	JJ	O
container	NN	O
are	VBP	O
stable	JJ	O
for	IN	O
6	CD	PER
months	NNS	PER
when	WRB	O
stored	VBN	O
at	IN	O
-	:	O
20°C	CD	O
.	.	O

Note	NN	O
:	:	O
Following	VBG	O
reconstitution	NN	O
(	(	O
activation	NN	O
)	)	O
,	,	O
product	NN	O
must	MD	O
be	VB	O
used	VBN	O
within	IN	O
24	CD	O
hours	NNS	O
if	IN	O
stored	VBN	O
at	IN	O
room	NN	O
temperature	NN	O
or	CC	O
within	IN	O
7	CD	O
days	NNS	O
if	IN	O
stored	VBN	O
under	IN	O
refrigeration	NN	O
.	.	O

Risk	NN	O
of	IN	O
ptosis	NN	O
can	MD	O
be	VB	O
mitigated	VBN	O
by	IN	O
careful	JJ	O
examination	NN	O
of	IN	O
the	DT	O
upper	JJ	O
lid	NN	O
for	IN	O
separation	NN	O
or	CC	O
weakness	NN	O
of	IN	O
the	DT	O
levator	NN	O
palpebrae	NN	O
muscle	NN	O
(	(	O
true	JJ	O
ptosis	NN	O
)	)	O
,	,	O
identification	NN	O
of	IN	O
lash	JJ	O
ptosis	NN	O
,	,	O
and	CC	O
evaluation	NN	O
of	IN	O
the	DT	O
range	NN	O
of	IN	O
lid	JJ	O
excursion	NN	O
while	IN	O
manually	RB	O
depressing	VBG	O
the	DT	O
frontalis	NN	O
to	TO	O
assess	VB	O
compensation	NN	O
.	.	O

Position	NN	O
the	DT	O
patient	JJ	O
supine	NN	O
with	IN	O
the	DT	O
brain	NN	O
(	(	O
including	VBG	O
the	DT	O
cerebellum	NN	O
)	)	O
within	IN	O
a	DT	O
single	JJ	O
field	NN	O
of	IN	O
view	NN	O
.	.	O

Different	NNP	O
tapering	VBG	O
dosage	NN	O
schedules	NNS	O
of	IN	O
prednisone	NN	O
appear	VBP	O
to	TO	O
achieve	VB	O
similar	JJ	O
results	NNS	O
.	.	O

The	DT	O
usual	JJ	O
duration	NN	O
of	IN	O
administration	NN	O
is	VBZ	O
5	CD	DOS
to	TO	O
8	CD	PER
days	NNS	PER
.	.	O

ZOSYN	NNP	O
Injection	NNP	O
is	VBZ	O
to	TO	O
be	VB	O
administered	VBN	O
using	VBG	O
sterile	JJ	O
equipment	NN	O
,	,	O
after	IN	O
thawing	VBG	O
to	TO	O
room	NN	O
temperature	NN	O
.	.	O

Urinary	JJ	O
excretion	NN	O
is	VBZ	O
also	RB	O
a	DT	O
major	JJ	O
route	NN	O
of	IN	O
elimination	NN	O
of	IN	O
didanosine	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
,	,	O
therefore	IN	O
the	DT	O
clearance	NN	O
of	IN	O
didanosine	NN	O
may	MD	O
be	VB	O
altered	VBN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
with	IN	WHO
renal	JJ	WHO
impairment	NN	WHO
.	.	O

GAMUNEX	NNP	O
(	(	O
immune	JJ	O
globulin	NN	O
intravenous	JJ	O
(	(	O
human	JJ	O
)	)	O
10	CD	O
%	NN	O
)	)	O
consists	VBZ	O
of	IN	O
9	CD	O
%	NN	O
–	JJ	O
11	CD	O
%	NN	O
protein	NN	O
in	IN	O
0.16	CD	O
–	JJ	O
0.24	CD	O
M	NNP	O
glycine	NN	O
.	.	O

Strict	NNP	O
aseptic	JJ	O
administration	NN	O
technique	NN	O
must	MD	O
be	VB	O
followed	VBN	O
.	.	O

If	IN	O
paradoxical	JJ	O
aggravation	NN	O
of	IN	O
symptoms	NNS	O
or	CC	O
other	JJ	O
adverse	JJ	O
events	NNS	O
occur	VBP	O
,	,	O
the	DT	O
dosage	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
,	,	O
or	CC	O
,	,	O
if	IN	O
necessary	JJ	O
,	,	O
the	DT	O
drug	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
.	.	O

The	DT	O
need	NN	O
for	IN	O
active	JJ	O
immunization	NN	O
with	IN	O
a	DT	O
tetanus	NN	O
toxoid	SYM	O
-	:	O
containing	VBG	O
preparation	NN	O
,	,	O
with	IN	O
or	CC	O
without	IN	O
Tetanus	NNP	O
Immune	NNP	O
Globulin	NNP	O
(	(	O
TIG	NNP	O
)	)	O
(	(	O
Human	NNP	O
)	)	O
depends	VBZ	O
on	IN	O
both	DT	O
the	DT	O
condition	NN	O
of	IN	O
the	DT	O
wound	NN	O
and	CC	O
the	DT	O
patient	NN	O
's	POS	O
vaccination	NN	O
history	NN	O
(	(	O
Table	JJ	O
1	CD	O
)	)	O
.	.	O

c	NNS	O
)	)	O
Slowly	RB	O
inject	VBP	O
the	DT	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
into	IN	O
the	DT	O
vial	JJ	O
containing	VBG	O
the	DT	O
ABILIFY	NNP	O
MAINTENA	NNP	O
lyophilized	VBD	O
powder	NN	O
(	(	O
see	VB	O
Figure	NNP	O
10	CD	O
)	)	O
.	.	O

Undue	JJ	O
pressure	NN	O
should	MD	O
not	RB	O
be	VB	O
exerted	VBN	O
during	IN	O
injection	NN	O
.	.	O

FORTAZ	NN	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
in	IN	O
patients	NNS	WHO
undergoing	VBG	WHO
intraperitoneal	JJ	WHO
dialysis	NN	WHO
and	CC	O
continuous	JJ	O
ambulatory	NN	O
peritoneal	JJ	O
dialysis	NN	O
.	.	O

In	IN	O
hospitalized	JJ	WHO
patients	NNS	WHO
,	,	O
a	DT	O
daily	JJ	FREQ
reduction	NN	O
of	IN	O
20	CD	O
%	NN	O
of	IN	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
may	MD	O
be	VB	O
tolerated	VBN	O
.	.	O

ADIPEX	NNP	O
-	:	O
P®	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
≤	VBP	WHO
16	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

The	DT	O
same	JJ	O
initial	JJ	O
dose	NN	O
and	CC	O
dosage	NN	O
range	NN	O
should	MD	O
be	VB	O
used	VBN	O
if	IN	O
Gengraf®	NNP	O
is	VBZ	O
combined	VBN	O
with	IN	O
the	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
methotrexate	NN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
AMARYL	NNP	O
is	VBZ	O
1	CD	DOS
mg	NN	UNIT
or	CC	O
2	CD	DOS
mg	NNS	UNIT
once	RB	FREQ
daily	RB	FREQ
.	.	O

Table	JJ	O
4	CD	O
:	:	O
Infusion	NN	O
Rates	NNS	O
for	IN	O
VELETRI	NNP	O
at	IN	O
a	DT	O
Concentration	NNP	O
of	IN	O
5,000	CD	DOS
ng	JJ	UNIT
/	NN	O
mL	NN	O

Dissolve	NNP	O
500,000	CD	O
polymyxin	NN	O
B	NNP	O
(	(	O
polymyxin	NN	O
b	NN	O
sulfate	NN	O
)	)	O
units	NNS	O
in	IN	O
10	CD	DOS
mL	JJ	UNIT
sodium	NN	O
chloride	NN	O
injection	NN	O
USP	NNP	O
for	IN	O
50,000	CD	DOS
units	NNS	UNIT
per	IN	O
mL	NN	O
dosage	NN	O
unit	NN	O
.	.	O

Table	JJ	O
5	CD	O
:	:	O
Dosage	NN	O
Modification	NN	O
for	IN	O
Renal	NNP	O
Impairment	NNP	O

BIAXIN	NNP	O
XL	NNP	O
Filmtab	NNP	O
should	MD	O
be	VB	O
taken	VBN	O
with	IN	O
food	NN	O
.	.	O

Recommended	VBN	O
Dosages	NNS	O
of	IN	O
AGENERASE	NNP	O
Oral	NNP	O
Solution	NNP	O
(	(	O
amprenavir	JJ	O
oral	JJ	O
solution	NN	O
)	)	O

NOTE	NN	O
:	:	O
Contact	NN	O
of	IN	O
undiluted	JJ	O
VUMON	NNP	O
with	IN	O
plastic	JJ	O
equipment	NN	O
or	CC	O
devices	NNS	O
used	VBN	O
to	TO	O
prepare	VB	O
solutions	NNS	O
for	IN	O
infusion	NN	O
may	MD	O
result	VB	O
in	IN	O
softening	NN	O
or	CC	O
cracking	NN	O
and	CC	O
possible	JJ	O
drug	NN	O
product	NN	O
leakage	NN	O
.	.	O

TENORMIN	NNP	O
I.V	NNP	O
.	.	O

ATTENUVAX	NNP	O
(	(	O
measles	NNS	O
virus	VBP	O
vaccine	JJ	O
live	NN	O
)	)	O
,	,	O
when	WRB	O
reconstituted	VBN	O
,	,	O
is	VBZ	O
clear	JJ	O
yellow	NN	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
sustained	JJ	WHO
VT	NNP	WHO
,	,	O
no	DT	O
matter	NN	O
what	WP	O
their	PRP$	O
cardiac	JJ	O
status	NN	O
,	,	O
TAMBOCOR	NNP	O
(	(	O
flecainide	NN	O
)	)	O
,	,	O
like	IN	O
other	JJ	O
antiarrhythmics	NNS	O
,	,	O
should	MD	O
be	VB	O
initiated	VBN	O
in	IN	O
-	:	O
hospital	NN	O
with	IN	O
rhythm	JJ	O
monitoring	NN	O
.	.	O

As	RB	O
soon	RB	O
as	IN	O
the	DT	O
overwrap	NN	O
is	VBZ	O
removed	VBN	O
,	,	O
the	DT	O
reconstitution	NN	O
of	IN	O
compartments	NNS	O
A	NNP	O
and	CC	O
B	NNP	O
should	MD	O
be	VB	O
done	VBN	O
and	CC	O
the	DT	O
mixed	JJ	O
solution	NN	O
should	MD	O
be	VB	O
used	VBN	O
immediately	RB	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
respond	VB	WHO
to	TO	O
a	DT	O
100	CD	DOS
mcg	NN	UNIT
intrathecal	JJ	O
bolus	NN	O
should	MD	O
not	RB	O
be	VB	O
considered	VBN	O
candidates	NNS	O
for	IN	O
an	DT	O
implanted	JJ	O
pump	NN	O
for	IN	O
chronic	JJ	O
infusion	NN	O
.	.	O

The	DT	O
suggested	JJ	O
dosage	NN	O
ranges	VBZ	O
for	IN	O
the	DT	O
five	CD	O
trace	NN	O
elements	NNS	O
are	VBP	O
:	:	O

Following	VBG	O
the	DT	O
administration	NN	O
of	IN	O
each	DT	O
titrated	VBN	O
dose	NN	O
,	,	O
discard	RB	O
any	DT	O
remaining	VBG	O
product	NN	O
.	.	O

Non	NNP	O
-	:	O
weight	NN	O
based	VBN	O
—	NNP	O
based	VBN	O
on	IN	O
published	VBN	O
consensus	NN	O
guidelines	NNS	O
,	,	O
a	DT	O
starting	VBG	O
dose	NN	O
of	IN	O
approximately	RB	O
0.2	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
range	NN	O
,	,	O
0.15	CD	DOS
-	:	O
0.30	CD	DOS
mg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
)	)	O
may	MD	O
be	VB	O
used	VBN	O
without	IN	O
consideration	NN	O
of	IN	O
body	NN	O
weight	NN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dosage	NN	O
of	IN	O
ARICEPT	NNP	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
moderate	JJ	WHO
to	TO	WHO
severe	VB	WHO
Alzheimer	NNP	WHO
’	NNP	WHO
s	JJ	WHO
disease	NN	WHO
is	VBZ	O
23	CD	DOS
mg	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

A	DT	O
second	JJ	O
site	NN	O
can	MD	O
be	VB	O
used	VBN	O
at	IN	O
the	DT	O
discretion	NN	O
of	IN	O
the	DT	O
physician	NN	O
and	CC	O
patient	NN	O
based	VBN	O
on	IN	O
tolerability	NN	O
and	CC	O
total	JJ	O
volume	NN	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
when	WRB	O
such	PDT	O
a	DT	O
combination	NN	O
is	VBZ	O
used	VBN	O
,	,	O
fluids	NNS	O
and	CC	O
other	JJ	O
countermeasures	NNS	O
to	TO	O
manage	VB	O
hypotension	NN	O
should	MD	O
be	VB	O
available	JJ	O
[	JJ	O
see	NN	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ALLEGRA	NNP	O
-	:	O
D	VBZ	O
24	CD	O
HOUR	NNP	O
(	(	O
fexofenadine	JJ	O
hcl	NN	O
180	CD	O
and	CC	O
pseudoephendrine	VB	O
hcl	NN	O
240	CD	O
)	)	O
Extended	VBN	O
-	:	O
Release	NNP	O
Tablets	NNPS	O
is	VBZ	O
one	CD	DOS
tablet	NN	UNIT
once	RB	FREQ
daily	RB	FREQ
administered	VBN	O
on	IN	O
an	DT	O
empty	JJ	O
stomach	NN	O
with	IN	O
water	NN	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
.	.	O

4	CD	O
.	.	O

Dosage	NN	O
may	MD	O
be	VB	O
gradually	RB	O
adjusted	VBN	O
to	TO	O
achieve	VB	O
optimal	JJ	O
clinical	JJ	O
response	NN	O
;	:	O
30	CD	DOS
mg	NN	UNIT
/	NN	FREQ
week	NN	FREQ
should	MD	O
not	RB	O
ordinarily	RB	O
be	VB	O
exceeded	VBN	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
Omnitrope	NNP	O
must	MD	O
be	VB	O
adjusted	VBN	O
for	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
.	.	O

For	IN	O
prescriptions	NNS	O
where	WRB	O
a	DT	O
dosing	NN	O
spoon	NN	O
is	VBZ	O
not	RB	O
provided	VBN	O
,	,	O
a	DT	O
pharmacist	NN	O
can	MD	O
provide	VB	O
an	DT	O
appropriate	JJ	O
measuring	NN	O
device	NN	O
and	CC	O
can	MD	O
provide	VB	O
instructions	NNS	O
for	IN	O
measuring	VBG	O
the	DT	O
correct	NN	O
dose	NN	O
.	.	O

Doses	NNS	O
administered	VBN	O
should	MD	O
be	VB	O
titrated	VBN	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
response	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Care	NN	O
in	IN	O
the	DT	O
administration	NN	O
of	IN	O
IDAMYCIN	NNP	O
will	MD	O
reduce	VB	O
the	DT	O
chance	NN	O
of	IN	O
perivenous	JJ	O
infiltration	NN	O
.	.	O

Adults	NNS	WHO
and	CC	WHO
pediatric	JJ	WHO
patients	NNS	WHO
6	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
or	CC	WHO
older	JJR	WHO
,	,	O
apply	VB	O
a	DT	O
thin	JJ	O
ribbon	NN	O
of	IN	O
EtheDent™	NNP	O
(	(	O
sodium	JJ	O
fluoride	NN	O
)	)	O
to	TO	O
a	DT	O
toothbrush	NN	O
.	.	O

Also	RB	O
record	NN	O
presence	NN	O
and	CC	O
size	NN	O
(	(	O
if	IN	O
present	VBN	O
)	)	O
of	IN	O
necrosis	NN	O
and	CC	O
edema	NN	O
,	,	O
although	IN	O
these	DT	O
are	VBP	O
not	RB	O
used	VBN	O
in	IN	O
the	DT	O
interpretation	NN	O
of	IN	O
the	DT	O
test	NN	O
.	.	O

OMNIPAQUE	RB	O
300	CD	O
at	IN	O
a	DT	O
concentration	NN	O
of	IN	O
300	CD	DOS
mgI	NNS	UNIT
/	JJ	O
mL	NN	O
is	VBZ	O
indicated	VBN	O
in	IN	O
children	NNS	WHO
for	IN	O
excretory	NN	O
urography	NN	O
.	.	O

No	DT	O
dosage	NN	O
regimen	NNS	O
for	IN	O
enalaprilat	JJ	O
injection	NN	O
has	VBZ	O
been	VBN	O
clearly	RB	O
demonstrated	VBN	O
to	TO	O
be	VB	O
more	RBR	O
effective	JJ	O
in	IN	O
treating	VBG	O
hypertension	NN	O
than	IN	O
1.25	CD	DOS
mg	JJ	UNIT
every	DT	FREQ
six	CD	FREQ
hours	NNS	FREQ
.	.	O

Before	IN	O
prescribing	VBG	O
ZIAGEN	NNP	O
tablets	NNS	O
,	,	O
children	NNS	O
should	MD	O
be	VB	O
assessed	VBN	O
for	IN	O
the	DT	O
ability	NN	O
to	TO	O
swallow	VB	O
tablets	NNS	O
.	.	O

In	IN	O
children	NNS	WHO
under	IN	WHO
13	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
,	,	O
use	NN	O
Lomotil	NNP	O
liquid	NN	O
.	.	O

The	DT	O
likelihood	NN	O
of	IN	O
this	DT	O
occurrence	NN	O
in	IN	O
humans	NNS	O
is	VBZ	O
considered	VBN	O
to	TO	O
be	VB	O
low	JJ	O
,	,	O
since	IN	O
ceftriaxone	NN	O
(	(	O
ceftriaxone	JJ	O
sodium	NN	O
and	CC	O
dextrose	VB	O
injection	NN	O
)	)	O
has	VBZ	O
a	DT	O
greater	JJR	O
plasma	NN	O
half	NN	O
-	:	O
life	NN	O
in	IN	O
humans	NNS	O
,	,	O
the	DT	O
calcium	NN	O
salt	NN	O
of	IN	O
ceftriaxone	NN	O
(	(	O
ceftriaxone	JJ	O
sodium	NN	O
and	CC	O
dextrose	VB	O
injection	NN	O
)	)	O
is	VBZ	O
more	RBR	O
soluble	JJ	O
in	IN	O
human	JJ	O
gallbladder	NN	O
bile	NN	O
and	CC	O
the	DT	O
calcium	NN	O
content	NN	O
of	IN	O
human	JJ	O
gallbladder	NN	O
bile	NN	O
is	VBZ	O
relatively	RB	O
low	JJ	O
.	.	O

For	IN	O
adults	NNS	WHO
,	,	O
maximum	JJ	O
total	JJ	O
daily	JJ	FREQ
doses	NNS	O
should	MD	O
not	RB	O
exceed	VB	O
8	CD	DOS
sprays	NNS	UNIT
in	IN	O
each	DT	O
nostril	JJ	O
per	IN	FREQ
day	NN	FREQ
(	(	O
464	CD	DOS
mcg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
)	)	O
.	.	O

Alternatively	RB	O
,	,	O
the	DT	O
contents	NNS	O
of	IN	O
the	DT	O
AVINZA	NNP	O
capsules	NNS	O
(	(	O
pellets	NNS	O
)	)	O
may	MD	O
be	VB	O
sprinkled	VBN	O
over	IN	O
applesauce	NN	O
and	CC	O
then	RB	O
swallowed	VBD	O
.	.	O

Since	IN	O
the	DT	O
product	NN	O
contains	VBZ	O
no	DT	O
preservatives	NNS	O
,	,	O
the	DT	O
final	JJ	O
prepared	JJ	O
product	NN	O
(	(	O
which	WDT	O
has	VBZ	O
undergone	JJ	O
reconstitution	NN	O
and	CC	O
dilution	NN	O
)	)	O
must	MD	O
be	VB	O
used	VBN	O
within	IN	O
4	CD	O
hours	NNS	O
of	IN	O
initial	JJ	O
reconstitution	NN	O
when	WRB	O
stored	VBN	O
at	IN	O
ambient	JJ	O
room	NN	O
temperature	NN	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
the	DT	O
vial	NN	O
more	JJR	O
than	IN	O
one	CD	O
time	NN	O
.	.	O

Therapy	NN	O
with	IN	O
SURMONTIL	NNP	O
may	MD	O
be	VB	O
resumed	VBN	O
24	CD	O
hours	NNS	O
after	IN	O
the	DT	O
last	JJ	O
dose	NN	O
of	IN	O
linezolid	JJ	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	NN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

All	DT	O
schedules	NNS	O
should	MD	O
be	VB	O
continually	RB	O
tailored	VBN	O
to	TO	O
the	DT	O
individual	JJ	O
patient	NN	O
.	.	O

55	CD	O

Solutions	NNS	O
thus	RB	O
prepared	VBD	O
should	MD	O
be	VB	O
used	VBN	O
within	IN	O
24	CD	O
hours	NNS	O
of	IN	O
first	JJ	O
entry	NN	O
into	IN	O
a	DT	O
sealed	JJ	O
bottle	NN	O
.	.	O

Patients	NNS	WHO
Receiving	VBG	WHO
Insulinγ¢††Some	NNP	WHO
Type	NNP	WHO
II	NNP	WHO
diabetic	JJ	WHO
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
been	VBN	WHO
treated	VBN	WHO
only	RB	WHO
with	IN	WHO
insulin	NN	WHO
may	MD	O
respond	VB	O
satisfactorily	RB	O
to	TO	O
therapy	VB	O
with	IN	O
TOLINASE	NNP	O
(	(	O
tolazamide	NN	O
)	)	O
.	.	O

Pediatric	JJ	O
Dosage	NNP	O
Calculations	NNS	O

Boluses	NNS	O
of	IN	O
propofol	NN	O
injectable	JJ	O
emulsion	NN	O
may	MD	O
be	VB	O
administered	VBN	O
via	IN	O
small	JJ	O
veins	NNS	O
if	IN	O
pretreated	VBN	O
with	IN	O
lidocaine	NN	O
or	CC	O
via	IN	O
antecubital	JJ	O
or	CC	O
larger	JJR	O
veins	NNS	O
.	.	O

Neither	DT	O
freezing	VBG	O
nor	CC	O
refrigeration	NN	O
adversely	RB	O
affects	VBZ	O
the	DT	O
stability	NN	O
of	IN	O
the	DT	O
product	NN	O
.	.	O

A	DT	O
back	NN	O
-	:	O
up	IN	O
birth	NN	O
control	NN	O
method	NN	O
is	VBZ	O
not	RB	O
required	VBN	O
during	IN	O
this	DT	O
time	NN	O
.	.	O

If	IN	O
no	DT	O
blood	NN	O
or	CC	O
discoloration	NN	O
appears	VBZ	O
,	,	O
inject	VB	O
the	DT	O
contents	NNS	O
of	IN	O
the	DT	O
TUBEXslowly	NNP	O
.	.	O

Transitioning	VBG	O
patients	NNS	O
to	TO	O
the	DT	O
20	CD	DOS
mcg	NN	UNIT
/	NNP	O
mL	NN	O
concentration	NN	O
using	VBG	O
the	DT	O
Ineb®AAD®	NNP	O
System	NNP	O
will	MD	O
decrease	VB	O
treatment	NN	O
times	NNS	O
to	TO	O
help	VB	O
maintain	VB	O
patient	JJ	O
compliance	NN	O
.	.	O

MARINOL	NNP	O
Capsules	NNP	O
is	VBZ	O
best	RB	O
administered	VBN	O
at	IN	O
an	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
5	CD	DOS
mg	NNS	UNIT
/	JJ	O
m²	NN	O
,	,	O
given	VBN	O
1	CD	O
to	TO	O
3	CD	O
hours	NNS	O
prior	RB	O
to	TO	O
the	DT	O
administration	NN	O
of	IN	O
chemotherapy	NN	O
,	,	O
then	RB	O
every	DT	O
2	CD	O
to	TO	O
4	CD	O
hours	NNS	O
after	IN	O
chemotherapy	NN	O
is	VBZ	O
given	VBN	O
,	,	O
for	IN	O
a	DT	O
total	NN	O
of	IN	O
4	CD	DOS
to	TO	O
6	CD	DOS
doses	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

The	DT	O
morning	NN	O
and	CC	O
evening	NN	O
doses	NNS	O
do	VBP	O
not	RB	O
have	VB	O
to	TO	O
be	VB	O
equal	JJ	O
in	IN	O
size	NN	O
and	CC	O
administration	NN	O
of	IN	O
the	DT	O
drug	NN	O
more	RBR	O
frequently	RB	O
than	IN	O
twice	RB	FREQ
daily	JJ	FREQ
does	VBZ	O
not	RB	O
generally	RB	O
make	VB	O
a	DT	O
difference	NN	O
in	IN	O
response	NN	O
.	.	O

Published	VBN	O
uncontrolled	JJ	O
clinical	JJ	O
studies	NNS	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
1	CD	WHO
-	:	WHO
16	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
have	VBP	O
employed	VBN	O
doses	VBZ	O
up	IN	O
to	TO	O
1	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
for	IN	O
peptic	JJ	O
ulcer	NN	O
and	CC	O
2	CD	DOS
mg	NN	UNIT
/	NNP	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
for	IN	O
GERD	NNP	O
with	IN	O
or	CC	O
without	IN	O
esophagitis	NN	O
including	VBG	O
erosions	NNS	O
and	CC	O
ulcerations	NNS	O
.	.	O

Crinone	RB	O
4	CD	O
%	NN	O
is	VBZ	O
administered	VBN	O
vaginally	RB	O
every	DT	FREQ
other	JJ	FREQ
day	NN	FREQ
up	IN	O
to	TO	O
a	DT	O
total	NN	O
of	IN	O
six	CD	DOS
doses	NNS	UNIT
.	.	O

The	DT	O
effectiveness	NN	O
of	IN	O
Daytrana	NNP	O
for	IN	O
long	RB	O
-	:	O
term	NN	O
use	NN	O
,	,	O
i.e	NN	O
,	,	O
for	IN	O
more	JJR	O
than	IN	O
7	CD	PER
weeks	NNS	PER
,	,	O
has	VBZ	O
not	RB	O
been	VBN	O
systematically	RB	O
evaluated	VBN	O
in	IN	O
controlled	JJ	O
trials	NNS	O
.	.	O

The	DT	O
patient	NN	O
should	MD	O
be	VB	O
monitored	VBN	O
for	IN	O
symptoms	NNS	O
of	IN	O
serotonin	JJ	O
syndrome	NN	O
for	IN	O
7	CD	PER
days	NNS	PER
or	CC	O
until	IN	O
24	CD	O
hours	NNS	O
after	IN	O
the	DT	O
last	JJ	O
dose	NN	O
of	IN	O
linezolid	JJ	O
or	CC	O
intravenous	JJ	O
methylene	NN	O
blue	NN	O
,	,	O
whichever	WDT	O
comes	VBZ	O
first	RB	O
.	.	O

6	CD	O
.	.	O

The	DT	O
combination	NN	O
of	IN	O
Neoral®	NNP	O
solution	NN	O
with	IN	O
milk	NN	O
can	MD	O
be	VB	O
unpalatable	JJ	O
.	.	O

The	DT	O
dose	NN	O
,	,	O
therefore	RB	O
,	,	O
should	MD	O
be	VB	O
maintained	VBN	O
for	IN	O
at	IN	PER
least	JJS	PER
three	CD	PER
days	NNS	PER
before	IN	O
reduction	NN	O
,	,	O
if	IN	O
respiratory	JJ	O
activity	NN	O
and	CC	O
other	JJ	O
vitals	NNS	O
signs	NNS	O
are	VBP	O
adequate	JJ	O
.	.	O

Total	JJ	O
weekly	JJ	FREQ
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
five	CD	DOS
tablets	NNS	UNIT
(	(	O
10	CD	DOS
mg	NN	UNIT
)	)	O
in	IN	O
any	DT	O
one	CD	PER
week	NN	PER
.	.	O

Using	VBG	O
a	DT	O
Sunday	NNP	O
start	NN	O
,	,	O
tablets	NNS	O
are	VBP	O
taken	VBN	O
daily	RB	FREQ
without	IN	O
interruption	NN	O
as	IN	O
follows	VBZ	O
:	:	O
The	DT	O
first	JJ	O
white	JJ	O
tablet	NN	O
should	MD	O
be	VB	O
taken	VBN	O
on	IN	O
the	DT	O
first	JJ	O
Sunday	NNP	O
after	IN	O
menstruation	NN	O
begins	NNS	O
(	(	O
if	IN	O
menstruation	NN	O
begins	VBZ	O
on	IN	O
Sunday	NNP	O
,	,	O
the	DT	O
first	JJ	O
white	JJ	O
tablet	NN	O
is	VBZ	O
taken	VBN	O
on	IN	O
that	DT	O
day	NN	O
)	)	O
.	.	O

Epilepsy	NN	O
:	:	O
For	IN	O
patients	NNS	WHO
receiving	VBG	WHO
LAMICTAL	NNP	WHO
in	IN	WHO
combination	NN	WHO
with	IN	WHO
other	JJ	WHO
AEDs	NNP	WHO
,	,	O
a	DT	O
re	NN	O
-	:	O
evaluation	NN	O
of	IN	O
all	DT	O
AEDs	NNP	O
in	IN	O
the	DT	O
regimen	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
if	IN	O
a	DT	O
change	NN	O
in	IN	O
seizure	NN	O
control	NN	O
or	CC	O
an	DT	O
appearance	NN	O
or	CC	O
worsening	NN	O
of	IN	O
adverse	JJ	O
reactions	NNS	O
is	VBZ	O
observed	VBN	O
.	.	O

Irradiance	NNP	O
Uniformity	NN	O
:	:	O
(	(	O
For	IN	O
photopheresis	NN	O
,	,	O
refer	VBP	O
to	TO	O
the	DT	O
UVAR*	NNP	O
System	NNP	O
Operator	NNP	O
's	POS	O
Manual	NNP	O
.	.	O
)	)	O

Initial	JJ	O
combination	NN	O
therapy	NN	O
or	CC	O
maintenance	NN	O
of	IN	O
combination	NN	O
therapy	NN	O
should	MD	O
be	VB	O
individualized	VBN	O
and	CC	O
left	VBN	O
to	TO	O
the	DT	O
discretion	NN	O
of	IN	O
the	DT	O
healthcare	NN	O
provider	NN	O
.	.	O

The	DT	O
rate	NN	O
of	IN	O
injection	NN	O
should	MD	O
not	RB	O
exceed	VB	O
2.0	CD	DOS
mg	NNS	UNIT
per	IN	O
minute	NN	O
.	.	O

Large	JJ	O
controlled	VBD	O
studies	NNS	O
with	IN	O
other	JJ	O
nitrates	NNS	O
suggest	VBP	O
that	IN	O
no	DT	O
dosing	VBG	O
regimen	NNS	O
with	IN	O
dilatrate®	JJ	O
-	:	O
SR	NN	O
should	MD	O
be	VB	O
expected	VBN	O
to	TO	O
provide	VB	O
more	JJR	O
than	IN	O
about	RB	O
12	CD	O
hours	NNS	O
of	IN	O
continuous	JJ	O
antianginal	JJ	O
efficacy	NN	O
per	IN	FREQ
day	NN	FREQ
.	.	O

For	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
12	CD	WHO
to	TO	WHO
23	CD	WHO
months	NNS	WHO
of	IN	WHO
age	NN	WHO
:	:	O
one	CD	DOS
packet	NN	UNIT
of	IN	O
4	CD	DOS
-	:	O
mg	NN	UNIT
oral	JJ	O
granules	NNS	O
.	.	O

NOTE	NN	O
:	:	O
Haemophilus	CC	O
b	VB	O
Conjugate	NNP	O
Vaccine	NNP	O
(	(	O
Tetanus	NNP	O
Toxoid	NNP	O
Conjugate	NNP	O
)	)	O
ActHIB	NNP	O
®	NNP	O
is	VBZ	O
identical	JJ	O
to	TO	O
Haemophilus	NNP	O
b	NN	O
Conjugate	NNP	O
Vaccine	NNP	O
(	(	O
Tetanus	NNP	O
Toxoid	NNP	O
Conjugate	NNP	O
)	)	O
OmniHIB	NNP	O
(	(	O
distributed	VBN	O
by	IN	O
SmithKline	NNP	O
Beecham	NNP	O
Pharmaceuticals	NNP	O
)	)	O
;	:	O
both	DT	O
products	NNS	O
are	VBP	O
manufactured	VBN	O
by	IN	O
Pasteur	NNP	O
Mérieux	NNP	O
Sérums	NNP	O
&	CC	O
Vaccins	NNP	O
S.	NNP	O
A	NNP	O
.	.	O

The	DT	O
mean	JJ	O
incremental	JJ	O
increase	NN	O
was	VBD	O
2	CD	DOS
to	TO	O
3	CD	DOS
ng	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	FREQ
min	NN	FREQ
every	DT	FREQ
3	CD	FREQ
weeks	NNS	FREQ
.	.	O

Reconstitute	NNP	O
Cyclophosphamide	NNP	O
with	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
only	RB	O
,	,	O
using	VBG	O
the	DT	O
volumes	NNS	O
listed	VBN	O
below	IN	O
in	IN	O
Table	JJ	O
1	CD	O
.	.	O

lipid	JJ	O
calories	NNS	O
of	IN	O
100	CD	O
to	TO	O
130	CD	O
kcal	JJ	O
/	NN	O
kg	NN	O
/	NNP	FREQ
day	NN	FREQ
is	VBZ	O
recommended	VBN	O
.	.	O

XTAMPZA	NNP	O
ER	NNP	O
may	MD	O
also	RB	O
be	VB	O
administered	VBN	O
through	IN	O
a	DT	O
gastrostomy	NN	O
or	CC	O
nasogastric	JJ	O
feeding	NN	O
tube	NN	O
[	NNP	O
see	VBP	O
Administration	NNP	O
of	IN	O
XTAMPZA	NNP	O
ER	NNP	O
]	NNP	O
.	.	O

ELOXATIN	NNP	O
is	VBZ	O
incompatible	JJ	O
in	IN	O
solution	NN	O
with	IN	O
alkaline	JJ	O
medications	NNS	O
or	CC	O
media	NNS	O
(	(	O
such	JJ	O
as	IN	O
basic	JJ	O
solutions	NNS	O
of	IN	O
5	CD	O
-	:	O
fluorouracil	NN	O
)	)	O
and	CC	O
must	MD	O
not	RB	O
be	VB	O
mixed	JJ	O
with	IN	O
these	DT	O
or	CC	O
administered	VBD	O
simultaneously	RB	O
through	IN	O
the	DT	O
same	JJ	O
infusion	NN	O
line	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
Prolia	NNP	O
is	VBZ	O
60	CD	DOS
mg	NN	UNIT
administered	VBN	O
as	IN	O
a	DT	O
single	JJ	DOS
subcutaneous	JJ	UNIT
injection	NN	UNIT
once	RB	FREQ
every	DT	FREQ
6	CD	FREQ
months	NNS	FREQ
.	.	O

For	IN	O
vascular	JJ	O
opacification	NN	O
,	,	O
a	DT	O
bolus	JJ	O
injection	NN	O
of	IN	O
25	CD	DOS
to	TO	O
50	CD	DOS
mL	NN	UNIT
may	MD	O
be	VB	O
used	VBN	O
,	,	O
repeated	VBD	O
as	IN	O
necessary	JJ	O
.	.	O

The	DT	O
risk	NN	O
of	IN	O
administering	VBG	O
methylene	NN	O
blue	NN	O
by	IN	O
nonintravenous	JJ	O
routes	NNS	O
(	(	O
such	JJ	O
as	IN	O
oral	JJ	O
tablets	NNS	O
or	CC	O
by	IN	O
local	JJ	O
injection	NN	O
)	)	O
or	CC	O
in	IN	O
intravenous	JJ	O
doses	NNS	O
much	RB	O
lower	JJR	O
than	IN	O
1	CD	DOS
mg	JJ	UNIT
/	NNP	O
kg	NN	O
with	IN	O
FORFIVO	NNP	O
XL	NNP	O
is	VBZ	O
unclear	JJ	O
.	.	O

When	WRB	O
only	RB	O
the	DT	O
serum	NN	O
creatinine	NN	O
is	VBZ	O
available	JJ	O
,	,	O
the	DT	O
following	JJ	O
formula	NN	O
(	(	O
based	VBN	O
on	IN	O
sex	NN	O
,	,	O
weight	NN	O
,	,	O
and	CC	O
age	NN	O
of	IN	O
the	DT	O
patient	NN	O
)	)	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
convert	VB	O
this	DT	O
value	NN	O
into	IN	O
creatinine	JJ	O
clearance	NN	O
(	(	O
CLcr	NNP	O
,	,	O
ml	NN	O
/	NNP	O
min	NN	O
)	)	O
.	.	O

In	IN	O
HCV	NNP	O
genotype	NN	O
1	CD	O
,	,	O
interferon	SYM	O
-	:	O
alfa	NN	O
-	:	O
naïve	NN	WHO
patients	NNS	WHO
receiving	VBG	WHO
PegIntron	NNP	WHO
,	,	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
REBETOL	NNP	O
,	,	O
discontinuation	NN	O
of	IN	O
therapy	NN	O
is	VBZ	O
recommended	VBN	O
if	IN	O
there	EX	O
is	VBZ	O
not	RB	O
at	IN	O
least	JJS	O
a	DT	O
2	CD	O
log10	JJ	O
drop	NN	O
or	CC	O
loss	NN	O
of	IN	O
HCV	NNP	O
-	:	O
RNA	NN	O
at	IN	O
12	CD	PER
weeks	NNS	PER
of	IN	O
therapy	NN	O
,	,	O
or	CC	O
if	IN	O
HCV	NNP	O
-	:	O
RNA	NN	O
levels	NNS	O
remain	VBP	O
detectable	JJ	O
after	IN	O
24	CD	PER
weeks	NNS	PER
of	IN	O
therapy	NN	O
.	.	O

See	VB	O
Patient	JJ	O
Instructions	NNS	O
for	IN	O
Use	NNP	O
for	IN	O
complete	JJ	O
administration	NN	O
instructions	NNS	O
with	IN	O
illustrations	NNS	O
.	.	O

Re	NNP	O
-	:	O
evaluate	NN	O
eGFR	VBZ	O
48	CD	O
hours	NNS	O
after	IN	O
the	DT	O
imaging	JJ	O
procedure	NN	O
;	:	O
restart	VB	O
INVOKAMET	NNP	O
if	IN	O
renal	JJ	O
function	NN	O
is	VBZ	O
stable	JJ	O
[	JJ	O
see	NN	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

The	DT	O
dose	NN	O
for	IN	O
any	DT	O
age	NN	O
is	VBZ	O
0.5	CD	DOS
mL	NN	UNIT
administered	VBD	O
subcutaneously	RB	O
,	,	O
preferably	RB	O
into	IN	O
the	DT	O
outer	JJ	O
aspect	NN	O
of	IN	O
the	DT	O
upper	JJ	O
arm	NN	O
.	.	O

Dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
by	IN	O
0.25	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
weekly	VBD	FREQ
up	RP	O
to	TO	O
a	DT	O
dosage	NN	O
of	IN	O
1	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
a	DT	FREQ
week	NN	FREQ
according	VBG	O
to	TO	O
the	DT	O
patient	NN	O
's	POS	O
serum	NN	O
prolactin	NN	O
level	NN	O
.	.	O

Use	VB	O
the	DT	O
tongue	NN	O
to	TO	O
wet	VB	O
the	DT	O
inside	NN	O
of	IN	O
the	DT	O
cheek	NN	O
or	CC	O
rinse	VB	O
the	DT	O
mouth	NN	O
with	IN	O
water	NN	O
to	TO	O
wet	VB	O
the	DT	O
area	NN	O
for	IN	O
placement	NN	O
of	IN	O
Onsolis	NNP	O
.	.	O

During	IN	O
the	DT	O
course	NN	O
of	IN	O
primary	JJ	O
immunizations	NNS	O
,	,	O
injections	NNS	O
should	MD	O
not	RB	O
be	VB	O
made	VBN	O
more	JJR	O
than	IN	O
once	RB	O
at	IN	O
the	DT	O
same	JJ	O
site	NN	O
.	.	O

This	DT	O
initial	JJ	O
dosing	VBG	O
regimen	NNS	O
should	MD	O
be	VB	O
strictly	RB	O
observed	VBN	O
to	TO	O
minimize	VB	O
the	DT	O
potential	NN	O
for	IN	O
severe	JJ	O
hypotensive	JJ	O
effects	NNS	O
.	.	O

USE	NN	O
IN	NNP	O
OTHER	NNP	O
FOODS	NNP	O
AND	NNP	O
LIQUIDS	NNP	O
HAS	NNP	O
NOT	NNP	O
BEEN	NNP	O
STUDIED	NNP	O
CLINICALLY	NNP	O
AND	NNP	O
IS	NNP	O
THEREFORE	NNP	O
NOT	NNP	O
RECOMMENDED	NNP	O
.	.	O

In	IN	O
the	DT	O
event	NN	O
of	IN	O
breakthrough	NN	O
episodes	NNS	O
of	IN	O
VF	NNP	O
or	CC	O
hemodynamically	RB	O
unstable	JJ	O
VT	NNP	O
,	,	O
150	CD	DOS
-	:	O
mg	NN	UNIT
supplemental	JJ	O
infusions	NNS	O
of	IN	O
Cordarone	NNP	O
I.V	NNP	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
Methyltestosterone	NNP	O
for	IN	O
androgen	NN	O
therapy	NN	O
in	IN	O
breast	NN	O
carcinoma	NN	O
in	IN	O
females	NNS	O
is	VBZ	O
from	IN	O
50	CD	DOS
-	:	O
200	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
.	.	O

Administration	NN	O
with	IN	O
Water	NNP	O
in	IN	O
an	DT	O
Oral	JJ	O
Syringe	NN	O

Table	JJ	O
1	CD	O
:	:	O
Recommended	VBN	O
Daily	NNP	FREQ
Dose	NNP	O
of	IN	O
DAYPRO	NNP	O
by	IN	O
Body	NNP	O
Weight	NNP	O
in	IN	O
Pediatric	NNP	WHO
Patients	NNS	WHO

In	IN	O
addition	NN	O
to	TO	O
the	DT	O
general	JJ	O
precautions	NNS	O
previously	RB	O
described	VBN	O
,	,	O
it	PRP	O
is	VBZ	O
advisable	JJ	O
to	TO	O
monitor	VB	O
for	IN	O
ECG	NNP	O
and	CC	O
vital	JJ	O
signs	NNS	O
changes	NNS	O
throughout	IN	O
the	DT	O
procedure	NN	O
.	.	O

Patients	NNS	WHO
who	WP	WHO
experience	VBP	WHO
breakthrough	IN	WHO
pain	NN	WHO
may	MD	O
require	VB	O
a	DT	O
dose	JJ	O
increase	NN	O
of	IN	O
TARGINIQ	NNP	O
ER	NNP	O
or	CC	O
may	MD	O
need	VB	O
rescue	JJR	O
medication	NN	O
with	IN	O
an	DT	O
appropriate	JJ	O
dose	NN	O
of	IN	O
an	DT	O
immediate	JJ	O
-	:	O
release	NN	O
analgesic	JJ	O
.	.	O

After	IN	O
a	DT	O
period	NN	O
of	IN	O
extended	VBN	O
freedom	NN	O
from	IN	O
attacks	NNS	O
,	,	O
a	DT	O
carefully	RB	O
supervised	VBN	O
tapered	JJ	O
discontinuation	NN	O
may	MD	O
be	VB	O
attempted	VBN	O
,	,	O
but	CC	O
there	EX	O
is	VBZ	O
evidence	NN	O
that	IN	O
this	DT	O
may	MD	O
often	RB	O
be	VB	O
difficult	JJ	O
to	TO	O
accomplish	VB	O
without	IN	O
recurrence	NN	O
of	IN	O
symptoms	NNS	O
and	CC	O
/	NN	O
or	CC	O
the	DT	O
manifestation	NN	O
of	IN	O
withdrawal	NN	O
phenomena	NN	O
.	.	O

3	CD	O
.	.	O

The	DT	O
capsule	NN	O
and	CC	O
tablet	NN	O
may	MD	O
be	VB	O
administered	VBN	O
without	IN	O
regard	NN	O
to	TO	O
food	NN	O
.	.	O

Vials	NNS	O
are	VBP	O
single	JJ	O
-	:	O
use	NN	O
only	RB	O
.	.	O

CAUTION	NN	O
:	:	O
THE	DT	O
SUSPENSION	NNP	O
IS	NNP	O
NOT	NNP	O
FOR	NNP	O
DIRECT	NNP	O
INFUSION	NNP	O
.	.	O

The	DT	O
recommended	JJ	O
initial	JJ	O
dose	NN	O
of	IN	O
Rocaltrol	NNP	O
(	(	O
calcitriol	NN	O
)	)	O
is	VBZ	O
0.25	CD	DOS
mcg	JJ	UNIT
/	NNP	FREQ
day	NN	FREQ
.	.	O

99	CD	O

Alternate	NNP	O
means	NNS	O
of	IN	O
administration	NN	O
are	VBP	O
to	TO	O
add	VB	O
the	DT	O
required	JJ	O
amount	NN	O
of	IN	O
suspension	NN	O
to	TO	O
formula	VB	O
,	,	O
milk	NN	O
,	,	O
fruit	NN	O
juice	NN	O
,	,	O
water	NN	O
,	,	O
ginger	NN	O
ale	NN	O
,	,	O
or	CC	O
cold	JJ	O
drinks	NNS	O
.	.	O

FARYDAK	NNP	O
capsules	NNS	O
should	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
with	IN	O
a	DT	O
cup	NN	O
of	IN	O
water	NN	O
.	.	O

However	RB	O
,	,	O
in	IN	O
certain	JJ	O
overwhelming	JJ	O
,	,	O
acute	NN	O
,	,	O
life	NN	O
threatening	VBG	O
situations	NNS	O
,	,	O
administration	NN	O
in	IN	O
dosages	NNS	O
exceeding	VBG	O
the	DT	O
usual	JJ	O
dosages	NNS	O
may	MD	O
be	VB	O
justified	VBN	O
and	CC	O
may	MD	O
be	VB	O
in	IN	O
multiples	NNS	O
of	IN	O
the	DT	O
oral	JJ	O
dosages	NNS	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
ABSORICA	NNP	O
Dosing	NNP	O
by	IN	O
Body	NNP	O
Weight	NNP	O
(	(	O
Based	VBN	O
on	IN	O
Administration	NNP	O
With	IN	O
or	CC	O
Without	IN	O
Food	NNP	O
)	)	O

-	:	O
Hold	NN	O
filter	NN	O
below	IN	O
the	DT	O
level	NN	O
of	IN	O
solution	NN	O
container	NN	O
.	.	O

Table	JJ	O
3	CD	O
also	RB	O
includes	VBZ	O
recommended	JJ	O
frequency	NN	O
of	IN	O
psychiatric	JJ	O
visits	NNS	O
.	.	O

For	IN	O
gluteal	JJ	O
administration	NN	O
:	:	O

Dosage	NN	O
is	VBZ	O
usually	RB	O
adjusted	VBN	O
within	IN	O
the	DT	O
range	NN	O
of	IN	O
40	CD	DOS
mg	NNS	UNIT
to	TO	O
80	CD	DOS
mg	NNS	UNIT
,	,	O
depending	VBG	O
upon	IN	O
patient	JJ	O
response	NN	O
and	CC	O
duration	NN	O
of	IN	O
relief	NN	O
.	.	O

IT	NNP	O
SHOULD	NNP	O
BE	NNP	O
EMPHASIZED	NNP	O
THAT	NNP	O
DOSAGE	NNP	O
REQUIREMENTS	NNP	O
ARE	NNP	O
VARIABLE	NNP	O
AND	NNP	O
MUST	NNP	O
BE	NNP	O
INDIVIDUALIZED	NNP	O
ON	NNP	O
THE	NNP	O
BASIS	NNP	O
OF	IN	O
THE	NNP	O
DISEASE	NNP	O
UNDER	NNP	O
TREATMENT	NNP	O
AND	NNP	O
THE	NNP	O
RESPONSE	NNP	O
OF	IN	O
THE	NNP	O
PATIENT	NNP	O
.	.	O

The	DT	O
tube	NN	O
is	VBZ	O
intended	VBN	O
for	IN	O
single	JJ	O
use	NN	O
;	:	O
discard	CC	O
any	DT	O
unused	JJ	O
portion	NN	O
.	.	O

The	DT	O
usual	JJ	O
adult	NN	WHO
single	JJ	O
injection	NN	O
volume	NN	O
is	VBZ	O
50	CD	DOS
mL	NN	UNIT
,	,	O
with	IN	O
a	DT	O
range	NN	O
of	IN	O
20	CD	DOS
mL	NNS	UNIT
to	TO	O
75	CD	DOS
mL	NNS	UNIT
.	.	O

Do	VB	O
not	RB	O
freeze	VB	O
.	.	O

The	DT	O
recommended	JJ	O
dosage	NN	O
for	IN	O
treating	VBG	O
the	DT	O
salt	NN	O
-	:	O
losing	NN	O
adrenogenital	JJ	O
syndrome	NN	O
is	VBZ	O
0.1	CD	DOS
mg	NN	UNIT
to	TO	O
0.2	CD	DOS
mg	NN	UNIT
of	IN	O
Florinef	NNP	O
(	(	O
fludrocortisone	NN	O
)	)	O
Acetate	NNP	O
daily	RB	FREQ
.	.	O

Each	DT	O
dose	NN	O
of	IN	O
tobramycin	JJ	O
inhalation	NN	O
solution	NN	O
is	VBZ	O
administered	VBN	O
by	IN	O
oral	JJ	O
inhalation	NN	O
using	VBG	O
only	RB	O
the	DT	O
co	NN	O
-	:	O
packaged	VBN	O
PARI	NNP	O
LC	NNP	O
PLUS	NNP	O
Reusable	NNP	O
Nebulizer	NNP	O
(	(	O
Model	NNP	O
No	NNP	O
.	.	O

As	IN	O
with	IN	O
all	DT	O
contrast	NN	O
media	NNS	O
,	,	O
other	JJ	O
drugs	NNS	O
should	MD	O
not	RB	O
be	VB	O
mixed	JJ	O
with	IN	O
ioversol	JJ	O
solutions	NNS	O
because	IN	O
of	IN	O
the	DT	O
potential	NN	O
for	IN	O
chemical	JJ	O
incompatibility	NN	O
.	.	O

Suspend	NNP	O
container	NN	O
from	IN	O
hanger	NN	O
.	.	O

TO	NNP	O
MINIMIZE	NNP	O
LOSS	NNP	O
OF	NNP	O
POTENCY	NNP	O
,	,	O
THE	NNP	O
VACCINE	NNP	O
SHOULD	NNP	O
BE	NNP	O
ADMINISTERED	NNP	O
IMMEDIATELY	NNP	O
AFTER	NNP	O
RECONSTITUTION	NNP	O
.	.	O

Published	VBN	O
relative	JJ	O
potency	NN	O
data	NNS	O
are	VBP	O
available	JJ	O
,	,	O
but	CC	O
such	JJ	O
ratios	NNS	O
are	VBP	O
approximations	NNS	O
.	.	O

The	DT	O
maximum	JJ	O
total	JJ	O
daily	JJ	FREQ
dosage	NN	O
should	MD	O
not	RB	O
exceed	VB	O
1	CD	DOS
actuation	NN	UNIT
in	IN	O
each	DT	O
nostril	NN	O
(	(	O
74	CD	DOS
mcg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
)	)	O
.	.	O

Matulane	NNP	O
therapy	NN	O
,	,	O
single	JJ	DOS
or	CC	UNIT
divided	JJ	UNIT
doses	NNS	UNIT
of	IN	O
2	CD	DOS
to	TO	O
4	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	JJ	O
/	NNP	FREQ
day	NN	FREQ
for	IN	O
the	DT	PER
first	JJ	PER
week	NN	PER
are	VBP	O
recommended	VBN	O
.	.	O

Observe	NNP	O
these	DT	O
patients	NNS	O
closely	RB	O
for	IN	O
signs	NNS	O
and	CC	O
symptoms	NNS	O
of	IN	O
bleeding	NN	O
.	.	O

Do	NNP	O
not	RB	O
try	VB	O
to	TO	O
remove	VB	O
the	DT	O
air	NN	O
bubbles	VBZ	O
from	IN	O
the	DT	O
syringe	NN	O
before	IN	O
giving	VBG	O
the	DT	O
injection	NN	O
.	.	O

Ingestion	NN	O
of	IN	O
food	NN	O
prior	RB	O
to	TO	O
each	DT	O
dose	NN	O
of	IN	O
probenecid	NN	O
may	MD	O
reduce	VB	O
drug	NN	O
-	:	O
related	VBN	O
nausea	NN	O
and	CC	O
vomiting	NN	O
.	.	O

The	DT	O
maximum	NN	O
recommended	VBD	O
dosage	NN	O
of	IN	O
OCALIVA	NNP	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
[	NNP	O
see	NN	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Upon	IN	O
storage	NN	O
,	,	O
a	DT	O
white	JJ	O
deposit	NN	O
and	CC	O
clear	JJ	O
supernatant	NN	O
may	MD	O
be	VB	O
observed	VBN	O
in	IN	O
the	DT	O
syringe	NN	O
.	.	O

Once	RB	O
adequate	JJ	O
control	NN	O
is	VBZ	O
achieved	VBN	O
,	,	O
the	DT	O
dosage	NN	O
should	MD	O
be	VB	O
decreased	VBN	O
to	TO	O
1	CD	DOS
spray	NN	UNIT
in	IN	O
each	DT	O
nostril	NN	O
once	RB	FREQ
daily	RB	FREQ
.	.	O

Infusion	NN	O
time	NN	O
must	MD	O
be	VB	O
at	IN	O
least	JJS	O
30	CD	O
minutes	NNS	O
.	.	O

Discard	NNP	O
syringe	NN	O
(	(	O
s	NN	O
)	)	O
after	IN	O
use	NN	O
.	.	O

Activase	NNP	O
may	MD	O
be	VB	O
administered	VBN	O
as	IN	O
reconstituted	VBN	O
at	IN	O
1	CD	DOS
mg	NN	UNIT
/	NNP	O
mL	NN	O
or	CC	O
further	RB	O
diluted	VBN	O
immediately	RB	O
before	IN	O
administration	NN	O
in	IN	O
an	DT	O
equal	JJ	O
volume	NN	O
of	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
or	CC	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
to	TO	O
yield	VB	O
a	DT	O
concentration	NN	O
of	IN	O
0.5	CD	DOS
mg	NNS	UNIT
/	JJ	O
mL	NN	O
,	,	O
using	VBG	O
either	CC	O
polyvinyl	JJ	O
chloride	NN	O
bags	NNS	O
or	CC	O
glass	NN	O
vials	NNS	O
.	.	O

In	IN	O
addition	NN	O
,	,	O
diazepam	NN	O
in	IN	O
2	CD	DOS
mg	NN	UNIT
to	TO	O
5	CD	DOS
mg	NN	UNIT
doses	NNS	UNIT
,	,	O
administered	VBN	O
in	IN	O
a	DT	O
separate	JJ	O
syringe	NN	O
over	IN	O
60	CD	O
seconds	NNS	O
,	,	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O

Figure	NN	O
4	CD	O

CORVERT	NNP	O
may	MD	O
be	VB	O
added	VBN	O
to	TO	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
or	CC	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
before	IN	O
infusion	NN	O
.	.	O

The	DT	O
dose	NN	O
should	MD	O
be	VB	O
titrated	VBN	O
based	VBN	O
on	IN	O
the	DT	O
clinical	JJ	O
response	NN	O
and	CC	O
tolerability	NN	O
of	IN	O
the	DT	O
individual	JJ	O
patient	NN	O
.	.	O

The	DT	O
recommended	VBN	O
dose	NN	O
of	IN	O
ALIMTA	NNP	O
is	VBZ	O
500	CD	DOS
mg	NN	UNIT
/	NNP	O
m²	NN	O
administered	VBD	O
as	IN	O
an	DT	O
intravenous	JJ	O
infusion	NN	O
over	IN	O
10	CD	O
minutes	NNS	O
on	IN	O
Day	NNP	O
1	CD	O
of	IN	O
each	DT	O
21	CD	O
-	:	O
day	NN	O
cycle	NN	O
.	.	O

The	DT	O
bolus	JJ	O
injection	NN	O
may	MD	O
be	VB	O
given	VBN	O
over	IN	O
10	CD	O
seconds	NNS	O
,	,	O
into	IN	O
an	DT	O
existing	VBG	O
intravenous	JJ	O
line	NN	O
.	.	O

The	DT	O
physician	NN	O
should	MD	O
make	VB	O
a	DT	O
careful	JJ	O
assessment	NN	O
of	IN	O
the	DT	O
patient	NN	O
's	POS	O
skills	NNS	O
and	CC	O
competence	NN	O
with	IN	O
the	DT	O
self	NN	O
-	:	O
injection	NN	O
procedure	NN	O
.	.	O

No	DT	O
controlled	JJ	O
clinical	JJ	O
studies	NNS	O
have	VBP	O
been	VBN	O
done	VBN	O
with	IN	O
Triostat	NNP	O
.	.	O

9	CD	O
.	.	O

Concomitant	JJ	O
administration	NN	O
of	IN	O
Lotensin	NNP	O
with	IN	O
potassium	NN	O
supplements	NNS	O
,	,	O
potassium	NN	O
salt	NN	O
substitutes	NNS	O
,	,	O
or	CC	O
potassium	NN	O
-	:	O
sparing	VBG	O
diuretics	NNS	O
can	MD	O
lead	VB	O
to	TO	O
increases	NNS	O
of	IN	O
serum	NN	O
potassium	NN	O
(	(	O
see	VB	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

Discard	NNP	O
any	DT	O
unused	JJ	O
portion	NN	O
after	IN	O
reconstitution	NN	O
.	.	O

Consider	VB	O
continuing	VBG	O
treatment	NN	O
for	IN	O
an	DT	O
additional	JJ	O
8	CD	O
cycles	NNS	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
clinical	JJ	WHO
benefit	NN	WHO
who	WP	WHO
do	VBP	WHO
not	RB	WHO
experience	VB	WHO
unresolved	JJ	WHO
severe	JJ	WHO
or	CC	WHO
medically	RB	WHO
significant	JJ	WHO
toxicity	NN	WHO
.	.	O

Initiate	NNP	O
intravenous	JJ	O
infusions	NNS	O
of	IN	O
FLOLAN	NNP	O
at	IN	O
2	CD	O
ng	JJ	O
/	NNP	O
kg	NN	O
/	NNP	O
min	NN	O
.	.	O

Gonal	NNP	O
-	:	O
f®	NN	O
may	MD	O
need	VB	O
to	TO	O
be	VB	O
administered	VBN	O
for	IN	O
up	IN	PER
to	TO	PER
18	CD	PER
months	NNS	PER
to	TO	O
achieve	VB	O
adequate	JJ	O
spermatogenesis	NN	O
.	.	O

Calcium	NN	O
and	CC	O
phosphorus	NN	O
are	VBP	O
added	VBN	O
to	TO	O
the	DT	O
solution	NN	O
as	IN	O
indicated	VBN	O
.	.	O

If	IN	O
leaks	NNS	O
are	VBP	O
found	VBN	O
,	,	O
discard	JJ	O
solution	NN	O
as	IN	O
sterility	NN	O
may	MD	O
be	VB	O
impaired	VBN	O
.	.	O

Rotate	NNP	O
injection	NN	O
sites	NNS	O
and	CC	O
do	VBP	O
not	RB	O
give	VB	O
injections	NNS	O
into	IN	O
areas	NNS	O
where	WRB	O
the	DT	O
skin	NN	O
is	VBZ	O
tender	NN	O
,	,	O
bruised	VBN	O
,	,	O
red	JJ	O
or	CC	O
hard	JJ	O
.	.	O

In	IN	O
a	DT	O
patient	NN	WHO
who	WP	WHO
requires	VBZ	WHO
more	JJR	WHO
urgent	JJ	WHO
treatment	NN	WHO
of	IN	WHO
a	DT	WHO
psychiatric	JJ	WHO
condition	NN	WHO
,	,	O
other	JJ	O
interventions	NNS	O
,	,	O
including	VBG	O
hospitalization	NN	O
,	,	O
should	MD	O
be	VB	O
considered	VBN	O
(	(	O
see	VB	O
CONTRAINDICATIONS	NNP	O
)	)	O
.	.	O

Collagenase	NNP	O
Santyl®	NNP	O
Ointment	NNP	O
should	MD	O
be	VB	O
applied	VBN	O
once	RB	FREQ
daily	JJ	FREQ
(	(	O
or	CC	O
more	RBR	O
frequently	RB	O
if	IN	O
the	DT	O
dressing	NN	O
becomes	VBZ	O
soiled	VBN	O
,	,	O
as	IN	O
from	IN	O
incontinence	NN	O
)	)	O
.	.	O

During	IN	O
dose	JJ	O
titration	NN	O
,	,	O
serum	JJ	O
calcium	NN	O
levels	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
frequently	RB	O
and	CC	O
if	IN	O
levels	NNS	O
decrease	VBP	O
below	IN	O
the	DT	O
normal	JJ	O
range	NN	O
,	,	O
appropriate	JJ	O
steps	NNS	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
increase	VB	O
serum	JJ	O
calcium	NN	O
levels	NNS	O
,	,	O
such	JJ	O
as	IN	O
by	IN	O
providing	VBG	O
supplemental	JJ	O
calcium	NN	O
,	,	O
initiating	VBG	O
or	CC	O
increasing	VBG	O
the	DT	O
dose	NN	O
of	IN	O
calcium	NN	O
-	:	O
based	VBN	O
phosphate	NN	O
binder	NN	O
,	,	O
initiating	VBG	O
or	CC	O
increasing	VBG	O
the	DT	O
dose	NN	O
of	IN	O
vitamin	NN	O
D	NNP	O
sterols	VBZ	O
,	,	O
or	CC	O
temporarily	RB	O
withholding	VBG	O
treatment	NN	O
with	IN	O
Sensipar	NNP	O
[	NNP	O
seeSecondary	JJ	O
Hyperparathyroidism	NNP	O
In	IN	O
Adult	NNP	WHO
Patients	NNPS	WHO
With	IN	WHO
Chronic	NNP	WHO
Kidney	NNP	WHO
Disease	NNP	WHO
On	IN	O
Dialysis	NNP	O
,	,	O
Parathyroid	NNP	O
Carcinoma	NNP	O
And	CC	O
Primary	NNP	O
Hyperparathyroidismand	NNP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Because	IN	O
of	IN	O
the	DT	O
potential	NN	O
for	IN	O
life	NN	O
-	:	O
threatening	JJ	O
events	NNS	O
,	,	O
caution	NN	O
should	MD	O
be	VB	O
taken	VBN	O
to	TO	O
ensure	VB	O
that	IN	O
precipitates	NNS	O
have	VBP	O
not	RB	O
formed	VBN	O
in	IN	O
any	DT	O
parenteral	JJ	O
nutrient	JJ	O
mixture	NN	O
.	.	O

Dose	NNP	O
selection	NN	O
for	IN	O
the	DT	O
elderly	JJ	O
should	MD	O
be	VB	O
made	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
renal	JJ	O
function	NN	O
[	NNP	O
see	NN	O
Use	NNP	O
In	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Maximum	NN	O
Recommended	VBD	O
Dose	NNP	O
of	IN	O
Stalevo	NNP	O
in	IN	O
a	DT	O
24	CD	O
-	:	O
hour	NN	O
Period	NN	O

When	WRB	O
Serostim®	NNP	O
is	VBZ	O
reconstituted	VBN	O
with	IN	O
Bacteriostatic	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
(	(	O
0.9	CD	O
%	NN	O
Benzyl	NNP	O
Alcohol	NNP	O
preserved	VBD	O
)	)	O
the	DT	O
reconstituted	JJ	O
solution	NN	O
may	MD	O
be	VB	O
refrigerated	VBN	O
(	(	O
2	CD	DOS
-	:	O
8oC	CD	O
/	$	O
36	CD	O
-	:	O
46oF	CD	O
)	)	O
for	IN	O
up	IN	PER
to	TO	PER
14	CD	PER
days	NNS	PER
.	.	O

Use	NNP	O
only	RB	O
if	IN	O
solution	NN	O
is	VBZ	O
clear	JJ	O
and	CC	O
container	NN	O
and	CC	O
seals	NNS	O
are	VBP	O
intact	JJ	O
.	.	O

Individually	RB	O
titrate	JJ	O
BELBUCA	NNP	O
to	TO	O
a	DT	O
dose	NN	O
that	WDT	O
provides	VBZ	O
adequate	JJ	O
analgesia	NNS	O
and	CC	O
minimizes	VBZ	O
adverse	JJ	O
reactions	NNS	O
Continually	RB	O
reevaluate	VBP	O
patients	NNS	WHO
receiving	VBG	WHO
BELBUCA	NNP	WHO
to	TO	O
assess	VB	O
the	DT	O
maintenance	NN	O
of	IN	O
pain	NN	O
control	NN	O
and	CC	O
the	DT	O
relative	JJ	O
incidence	NN	O
of	IN	O
adverse	JJ	O
reactions	NNS	O
and	CC	O
monitor	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
addiction	NN	O
,	,	O
abuse	NN	O
,	,	O
or	CC	O
misuse	VB	O
[	JJ	O
see	NN	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Many	JJ	WHO
patients	NNS	WHO
with	IN	WHO
edema	JJ	WHO
respond	NN	WHO
to	TO	O
intermittent	VB	O
therapy	NN	O
,	,	O
i.e	NN	O
,	,	O
administration	NN	O
on	IN	O
alternate	JJ	O
days	NNS	O
or	CC	O
on	IN	O
three	CD	O
to	TO	O
five	CD	PER
days	NNS	PER
each	DT	PER
week	NN	PER
.	.	O

The	DT	O
following	JJ	O
chart	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
guide	VB	O
dosing	VBG	O
in	IN	O
bleeding	VBG	O
episodes	NNS	O
and	CC	O
surgery	NN	O
:	:	O

Keep	VB	O
Dovonex®	NNP	O
(	(	O
calcipotriene	JJ	O
solution	NN	O
)	)	O
Scalp	NNP	O
Solution	NNP	O
,	,	O
0.005	CD	O
%	NN	O
,	,	O
well	RB	O
away	RB	O
from	IN	O
the	DT	O
eyes	NNS	O
.	.	O

As	IN	O
with	IN	O
other	JJ	O
highly	RB	O
active	JJ	O
corticosteroids	NNS	O
,	,	O
therapy	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
when	WRB	O
control	NN	O
has	VBZ	O
been	VBN	O
achieved	VBN	O
.	.	O

Since	IN	O
the	DT	O
premix	NN	O
flexible	JJ	O
bags	NNS	O
are	VBP	O
for	IN	O
single	JJ	O
use	NN	O
only	RB	O
,	,	O
any	DT	O
unused	JJ	O
portion	NN	O
should	MD	O
be	VB	O
discarded	VBN	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
thyroid	JJ	O
hormones	NNS	O
is	VBZ	O
determined	VBN	O
by	IN	O
the	DT	O
indication	NN	O
and	CC	O
must	MD	O
in	IN	O
every	DT	FREQ
case	NN	O
be	VB	O
individualized	VBN	O
according	VBG	O
to	TO	O
patient	JJ	O
response	NN	O
and	CC	O
laboratory	JJ	O
findings	NNS	O
.	.	O

Infusion	NN	O
time	NN	O
must	MD	O
be	VB	O
at	IN	O
least	JJS	O
10	CD	O
minutes	NNS	O
.	.	O

Where	WRB	O
possible	JJ	O
,	,	O
therapy	NN	O
should	MD	O
be	VB	O
guided	VBN	O
by	IN	O
the	DT	O
results	NNS	O
of	IN	O
programmed	JJ	O
electrical	JJ	O
stimulation	NN	O
and	CC	O
/	NN	O
or	CC	O
Holter	NNP	O
monitoring	NN	O
with	IN	O
exercise	NN	O
.	.	O

The	DT	O
total	JJ	O
duration	NN	O
of	IN	O
the	DT	O
once	RB	FREQ
daily	JJ	FREQ
lead	SYM	O
-	:	O
in	IN	O
dosing	VBG	O
period	NN	O
should	MD	O
not	RB	O
exceed	VB	O
28	CD	PER
days	NNS	PER
at	IN	O
which	WDT	O
point	VBP	O
an	DT	O
alternative	JJ	O
regimen	NNS	O
should	MD	O
be	VB	O
sought	VBN	O
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dose	NN	O
of	IN	O
MERIDIA	NNP	O
(	(	O
sibutramine	JJ	O
hydrochloride	NN	O
monohydrate	NN	O
)	)	O
is	VBZ	O
10	CD	DOS
mg	NN	UNIT
administered	VBN	O
once	RB	FREQ
daily	JJ	FREQ
with	IN	O
or	CC	O
without	IN	O
food	NN	O
.	.	O

Monitor	NNP	O
appropriate	JJ	O
clinical	JJ	O
and	CC	O
laboratory	JJ	O
measures	NNS	O
[	VBP	O
see	VB	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

In	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
up	IN	WHO
to	TO	WHO
the	DT	WHO
age	NN	WHO
of	IN	WHO
1	CD	WHO
month	NN	WHO
,	,	O
the	DT	O
total	JJ	O
daily	JJ	FREQ
intravenous	JJ	O
dosage	NN	O
may	MD	O
be	VB	O
lower	JJR	O
.	.	O

Prior	RB	O
to	TO	O
initiating	VBG	O
heparinization	NN	O
the	DT	O
physician	NN	O
should	MD	O
rule	VB	O
out	RP	O
bleeding	VBG	O
disorders	NNS	O
by	IN	O
appropriate	JJ	O
history	NN	O
and	CC	O
laboratory	NN	O
tests	NNS	O
,	,	O
and	CC	O
appropriate	JJ	O
coagulation	NN	O
tests	NNS	O
should	MD	O
be	VB	O
repeated	VBN	O
just	RB	O
prior	RB	O
to	TO	O
surgery	NN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
switching	VBG	O
from	IN	O
a	DT	O
progestin	NN	O
-	:	O
only	RB	O
method	NN	O
such	JJ	O
as	IN	O
a	DT	O
:	:	O

For	IN	O
children	NNS	WHO
aged	VBN	WHO
about	IN	WHO
2	CD	WHO
years	NNS	WHO
and	CC	WHO
greater	JJR	WHO
,	,	O
with	IN	O
normal	JJ	O
renal	JJ	O
function	NN	O
,	,	O
doses	VBZ	O
normalized	VBN	O
for	IN	O
body	NN	O
surface	JJ	O
area	NN	O
are	VBP	O
appropriate	JJ	O
for	IN	O
both	DT	O
initial	JJ	O
and	CC	O
incremental	JJ	O
dosing	NN	O
.	.	O

Most	JJS	WHO
adult	NN	WHO
patients	NNS	WHO
require	VBP	WHO
maintenance	NN	WHO
rates	NNS	WHO
of	IN	O
5	CD	DOS
to	TO	O
50	CD	DOS
mcg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
min	NN	O
(	(	O
0.3	CD	DOS
to	TO	O
3	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
h	NN	O
)	)	O
or	CC	O
higher	JJR	O
.	.	O

If	IN	O
a	DT	O
dose	NN	O
of	IN	O
ZOVIRAX®	NNP	O
is	VBZ	O
missed	VBN	O
,	,	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
advised	VBN	O
to	TO	O
take	VB	O
it	PRP	O
as	RB	O
soon	RB	O
as	IN	O
he	PRP	O
/	VBZ	O
she	PRP	O
remembers	NNS	O
,	,	O
and	CC	O
then	RB	O
continue	VB	O
with	IN	O
the	DT	O
next	JJ	O
dose	NN	O
at	IN	O
the	DT	O
proper	JJ	O
time	NN	O
interval	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
an	DT	WHO
ulcer	JJ	WHO
present	NN	WHO
at	IN	O
the	DT	O
time	NN	O
of	IN	O
initiation	NN	O
of	IN	O
therapy	NN	O
,	,	O
an	DT	O
additional	JJ	O
18	CD	O
days	NNS	O
of	IN	O
PRILOSEC	NNP	O
20	CD	DOS
mg	NN	UNIT
once	RB	FREQ
daily	JJ	FREQ
is	VBZ	O
recommended	VBN	O
for	IN	O
ulcer	JJ	O
healing	NN	O
and	CC	O
symptom	JJ	O
relief	NN	O
.	.	O

The	DT	O
ambulatory	JJ	O
infusion	NN	O
pump	NN	O
used	VBN	O
to	TO	O
administer	VB	O
Remodulin	NNP	O
should	MD	O
:	:	O
(	(	O
1	CD	O
)	)	O
be	VB	O
small	JJ	O
and	CC	O
lightweight	JJ	O
,	,	O
(	(	O
2	CD	O
)	)	O
be	VB	O
adjustable	JJ	O
to	TO	O
approximately	RB	O
0.002	CD	DOS
mL	NNS	UNIT
/	JJ	O
hr	NN	O
,	,	O
(	(	O
3	CD	O
)	)	O
have	VBP	O
occlusion	VBN	O
/	NNP	O
no	DT	O
delivery	NN	O
,	,	O
low	JJ	O
battery	NN	O
,	,	O
programming	VBG	O
error	NN	O
and	CC	O
motor	NN	O
malfunction	NN	O
alarms	NNS	O
,	,	O
(	(	O
4	CD	O
)	)	O
have	VBP	O
delivery	NN	O
accuracy	NN	O
of	IN	O
±6	NNP	O
%	NN	O
or	CC	O
better	JJR	O
and	CC	O
(	(	O
5	CD	O
)	)	O
be	VB	O
positive	JJ	O
pressure	NN	O
driven	VBN	O
.	.	O

However	RB	O
,	,	O
there	EX	O
were	VBD	O
no	DT	O
major	JJ	O
differences	NNS	O
reported	VBN	O
in	IN	O
the	DT	O
drug	NN	O
disposition	NN	O
in	IN	O
elderly	JJ	WHO
patients	NNS	WHO
with	IN	WHO
diarrhea	JJ	WHO
relative	NN	WHO
to	TO	WHO
young	JJ	WHO
patients	NNS	WHO
.	.	O

These	DT	O
matrix	JJ	O
tablets	NNS	O
usually	RB	O
contain	VBP	O
little	JJ	O
or	CC	O
no	DT	O
residual	JJ	O
theophylline	NN	O
.	.	O

If	IN	O
the	DT	O
BUN	NNP	O
or	CC	O
the	DT	O
serum	JJ	O
creatinine	NN	O
is	VBZ	O
elevated	VBN	O
,	,	O
or	CC	O
if	IN	O
there	EX	O
are	VBP	O
other	JJ	O
signs	NNS	O
of	IN	O
renal	JJ	O
impairment	NN	O
,	,	O
the	DT	O
initial	JJ	O
dose	NN	O
should	MD	O
be	VB	O
at	IN	O
the	DT	O
lower	JJR	O
level	NN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

Remove	NNP	O
cap	NN	O
by	IN	O
turning	VBG	O
it	PRP	O
counterclockwise	NN	O
.	.	O

The	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
should	MD	O
not	RB	O
exceed	VB	O
1600	CD	DOS
mg	JJ	UNIT
sulfamethoxazole	NN	UNIT
and	CC	O
320	CD	DOS
mg	NN	UNIT
trimethoprim.9	VBD	O
The	DT	O
following	JJ	O
table	NN	O
is	VBZ	O
a	DT	O
guideline	NN	O
for	IN	O
the	DT	O
attainment	NN	O
of	IN	O
this	DT	O
dosage	NN	O
in	IN	O
children	NNS	WHO
:	:	O

One	CD	DOS
4	CD	DOS
mg	NN	UNIT
ZUPLENZ	NNP	O
oral	JJ	O
soluble	JJ	O
film	NN	O
should	MD	O
be	VB	O
administered	VBN	O
three	CD	FREQ
times	NNS	FREQ
a	DT	FREQ
day	NN	FREQ
(	(	O
every	DT	FREQ
8	CD	FREQ
hours	NNS	FREQ
)	)	O
for	IN	O
1	CD	PER
to	TO	O
2	CD	O
days	NNS	O
after	IN	O
completion	NN	O
of	IN	O
chemotherapy	NN	O
[	NNP	O
see	VBP	O
Important	NNP	O
Administration	NNP	O
Instructions	NNP	O
]	NNP	O
.	.	O

If	IN	O
the	DT	O
same	JJ	O
incision	NN	O
is	VBZ	O
being	VBG	O
used	VBN	O
to	TO	O
insert	VB	O
a	DT	O
new	JJ	O
implant	NN	O
,	,	O
anesthetize	VB	O
the	DT	O
insertion	NN	O
site	NN	O
[	NN	O
for	IN	O
example	NN	O
,	,	O
2	CD	DOS
mL	NN	UNIT
lidocaine	NN	O
(	(	O
1	CD	O
%	NN	O
)	)	O
]	VBZ	O
applying	VBG	O
it	PRP	O
just	RB	O
under	IN	O
the	DT	O
skin	NN	O
along	IN	O
the	DT	O
'insertion	NNP	O
canal	NN	O
.	.	O
'	''	O

Inform	NN	O
patients	NNS	O
that	WDT	O
KOMBIGLYZE	NNP	O
XR	NNP	O
tablets	NNS	O
must	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
and	CC	O
never	RB	O
crushed	VBN	O
,	,	O
cut	VB	O
,	,	O
or	CC	O
chewed	VBN	O
.	.	O

KEPPRA	NNP	O
injection	NN	O
should	MD	O
be	VB	O
administered	VBN	O
as	IN	O
a	DT	O
15	CD	O
-	:	O
minute	NN	O
IV	NNP	O
infusion	NN	O
.	.	O

BEVESPI	NNP	O
AEROSPHERE	NNP	O
must	MD	O
be	VB	O
re	JJ	O
-	:	O
primed	VBD	O
when	WRB	O
the	DT	O
inhaler	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
used	VBN	O
for	IN	O
more	JJR	O
than	IN	O
7	CD	PER
days	NNS	PER
.	.	O

Reduced	NNP	O
Intravenous	NNP	O
Schedule	NNP	O
for	IN	O
Adults	NNP	WHO
with	IN	WHO
Impaired	NNP	WHO
Renal	NNP	WHO
Function	NNP	WHO
and	CC	WHO
/	NNP	WHO
or	CC	WHO
Body	NNP	WHO
Weight	NNP	WHO
<	VBZ	WHO
70	CD	WHO
kg	NN	WHO

Discard	NNP	O
any	DT	O
unused	JJ	O
portion	NN	O
left	VBD	O
in	IN	O
a	DT	O
vial	JJ	O
,	,	O
as	IN	O
the	DT	O
product	NN	O
contains	VBZ	O
no	DT	O
preservatives	NNS	O
.	.	O

In	IN	O
patients	NNS	WHO
receiving	VBG	WHO
an	DT	WHO
IV	NNP	WHO
infusion	NN	WHO
,	,	O
the	DT	O
first	JJ	O
dose	NN	O
of	IN	O
oral	JJ	O
therapy	NN	O
should	MD	O
be	VB	O
given	VBN	O
8	CD	O
-	:	O
12	CD	O
hours	NNS	O
after	IN	O
discontinuing	VBG	O
the	DT	O
IV	NNP	O
infusion	NN	O
.	.	O

MICRONASE	NNP	O
Tablets	NNP	O
should	MD	O
be	VB	O
added	VBN	O
gradually	RB	O
to	TO	O
the	DT	O
dosing	VBG	O
regimen	NNS	WHO
of	IN	WHO
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
not	RB	WHO
responded	VBN	WHO
to	TO	O
the	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
metformin	NN	O
monotherapy	NN	O
after	IN	O
four	CD	PER
weeks	NNS	PER
(	(	O
see	VB	O
Usual	NNP	O
Starting	NNP	O
Dose	NNP	O
and	CC	O
Titration	NNP	O
to	TO	O
Maintenance	NNP	O
Dose	NNP	O
)	)	O
.	.	O

Consider	VB	O
another	DT	O
antihyperglycemic	JJ	O
agent	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
an	DT	WHO
eGFR	NN	WHO
of	IN	O
45	CD	O
to	TO	O
less	JJR	O
than	IN	O
60	CD	DOS
mL	JJ	UNIT
/	NNP	O
min	NN	O
/	VBD	O
1.73	CD	O
m²	NN	O
receiving	VBG	O
concurrent	JJ	O
therapy	NN	O
with	IN	O
a	DT	O
UGT	NNP	O
inducer	NN	O
.	.	O

Wash	VB	O
your	PRP$	O
hands	NNS	O
after	IN	O
applying	VBG	O
CLOBEX®	NNP	O
Shampoo	NNP	O
(	(	O
clobetasol	JJ	O
propionate	NN	O
shampoo	NN	O
)	)	O
.	.	O

This	DT	O
type	NN	O
of	IN	O
bleeding	NN	O
is	VBZ	O
usually	RB	O
transient	JJ	O
and	CC	O
without	IN	O
significance	NN	O
;	:	O
however	RB	O
,	,	O
if	IN	O
the	DT	O
bleeding	NN	O
is	VBZ	O
persistent	JJ	O
or	CC	O
prolonged	VBN	O
,	,	O
the	DT	O
patient	NN	O
is	VBZ	O
advised	VBN	O
to	TO	O
consult	VB	O
her	PRP$	O
physician	NN	O
.	.	O

Accidental	NNP	O
dermal	JJ	O
exposure	NN	O
to	TO	O
alfentanil	VB	O
should	MD	O
be	VB	O
treated	VBN	O
by	IN	O
rinsing	VBG	O
the	DT	O
affected	JJ	O
area	NN	O
with	IN	O
water	NN	O
.	.	O

Serum	NNP	O
concentrations	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
in	IN	O
changing	VBG	O
from	IN	O
Dilantin	NNP	O
(	(	O
extended	VBN	O
phenytoin	NN	O
sodium	NN	O
capsules	NNS	O
,	,	O
USP	NNP	O
)	)	O
to	TO	O
Prompt	NNP	O
Phenytoin	NNP	O
Sodium	NNP	O
Capsules	NNP	O
,	,	O
USP	NNP	O
,	,	O
and	CC	O
from	IN	O
the	DT	O
sodium	NN	O
salt	NN	O
to	TO	O
the	DT	O
free	JJ	O
acid	NN	O
form	NN	O
.	.	O

The	DT	O
patient	NN	O
dose	NN	O
should	MD	O
be	VB	O
measured	VBN	O
by	IN	O
a	DT	O
suitable	JJ	O
radioactivity	NN	O
calibration	NN	O
system	NN	O
immediately	RB	O
prior	RB	O
to	TO	O
administration	NN	O
of	IN	O
the	DT	O
dose	NN	O
.	.	O

Due	JJ	O
to	TO	O
the	DT	O
chemical	NN	O
instability	NN	O
of	IN	O
tacrolimus	NN	O
in	IN	O
alkaline	JJ	O
media	NNS	O
,	,	O
Prograf	NNP	O
injection	NN	O
should	MD	O
not	RB	O
be	VB	O
mixed	JJ	O
or	CC	O
co	JJ	O
-	:	O
infused	VBN	O
with	IN	O
solutions	NNS	O
of	IN	O
pH	NN	O
9	CD	O
or	CC	O
greater	JJR	O
(	(	O
e.g	NN	O
,	,	O
ganciclovir	NN	O
or	CC	O
acyclovir	NN	O
)	)	O
.	.	O

Slide	NNP	O
safety	NN	O
guard	NN	O
over	IN	O
needle	JJ	O
.	.	O

Serum	NNP	O
blood	NN	O
level	NN	O
determinations	NNS	O
are	VBP	O
especially	RB	O
helpful	JJ	O
when	WRB	O
possible	JJ	O
drug	NN	O
interactions	NNS	O
are	VBP	O
suspected	VBN	O
.	.	O

Periodic	JJ	O
monitoring	NN	O
of	IN	O
plasma	JJ	O
levels	NNS	O
of	IN	O
Zinc	NNP	O
,	,	O
Copper	NNP	O
,	,	O
Manganese	NNP	O
,	,	O
Chromium	NNP	O
and	CC	O
Selenium	NNP	O
is	VBZ	O
suggested	VBN	O
as	IN	O
a	DT	O
guideline	NN	O
for	IN	O
administration	NN	O
.	.	O

Patients	NNS	WHO
whose	WP$	WHO
arrhythmias	NNS	WHO
have	VBP	WHO
been	VBN	WHO
suppressed	VBN	WHO
by	IN	WHO
intravenous	JJ	WHO
amiodarone	NN	WHO
may	MD	O
be	VB	O
switched	VBN	O
to	TO	O
oral	JJ	O
amiodarone	NN	O
.	.	O

A	DT	O
number	NN	O
of	IN	O
clinical	JJ	O
settings	NNS	O
may	MD	O
predispose	VB	O
to	TO	O
increased	VBN	O
toxicity	NN	O
from	IN	O
FLUDARA	NNP	O
(	(	O
fludarabine	NN	O
)	)	O
FOR	IN	O
INJECTION	NNP	O
.	.	O

Late	JJ	O
evening	NN	O
doses	NNS	O
should	MD	O
be	VB	O
avoided	VBN	O
because	IN	O
of	IN	O
resulting	VBG	O
insomnia	NN	O
.	.	O

Dosage	NN	O
may	MD	O
be	VB	O
gradually	RB	O
increased	VBN	O
in	IN	O
40	CD	DOS
to	TO	O
80	CD	DOS
mg	NN	UNIT
increments	NNS	O
at	IN	O
3	CD	PER
to	TO	O
7	CD	FREQ
day	NN	FREQ
intervals	NNS	FREQ
until	IN	O
optimum	JJ	O
clinical	JJ	O
response	NN	O
is	VBZ	O
obtained	VBN	O
or	CC	O
there	EX	O
is	VBZ	O
pronounced	JJ	O
slowing	NN	O
of	IN	O
the	DT	O
heart	NN	O
rate	NN	O
.	.	O

More	RBR	O
frequent	JJ	O
administration	NN	O
or	CC	O
a	DT	O
greater	JJR	O
number	NN	O
of	IN	O
inhalations	NNS	O
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	O

For	IN	O
patients	NNS	WHO
being	VBG	WHO
converted	VBN	WHO
from	IN	WHO
Actiq	NNP	WHO
,	,	O
prescribers	NNS	O
must	MD	O
use	VB	O
the	DT	O
Initial	NNP	O
Dosing	NNP	O
Recommendations	NNP	O
for	IN	O
Patients	NNPS	O
on	IN	O
Actiq	NNP	O
table	NN	O
below	IN	O
(	(	O
Table	JJ	O
1	CD	O
)	)	O
.	.	O

The	DT	O
tablets	NNS	O
must	MD	O
not	RB	O
be	VB	O
split	VBN	O
before	IN	O
swallowing	VBG	O
.	.	O

Step	NN	O
3	CD	O
:	:	O
Immediately	RB	O
Slide	NNP	O
Green	NNP	O
Safety	NNP	O
Guard	NNP	O
Over	NNP	O
Needle	NNP	O

The	DT	O
200	CD	DOS
mg	NN	UNIT
/	VBD	O
5	CD	DOS
mL	JJ	UNIT
suspension	NN	UNIT
or	CC	O
the	DT	O
400	CD	DOS
mg	NN	UNIT
/	VBD	O
5	CD	DOS
mL	NNS	UNIT
suspension	NN	UNIT
may	MD	O
be	VB	O
used	VBN	O
in	IN	O
place	NN	O
of	IN	O
the	DT	O
875	CD	DOS
-	:	O
mg	NN	UNIT
tablet	NN	UNIT
.	.	O

The	DT	O
skin	JJ	O
test	NN	O
should	MD	O
be	VB	O
read	VBN	O
at	IN	O
48	CD	O
hours	NNS	O
by	IN	O
visually	RB	O
inspecting	VBG	O
the	DT	O
test	NN	O
site	NN	O
and	CC	O
palpating	VBG	O
the	DT	O
indurated	JJ	O
area	NN	O
.	.	O

Patients	NNS	WHO
with	IN	WHO
creatinine	JJ	WHO
clearance	NN	WHO
of	IN	WHO
≤	$	WHO
70	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
/	VBD	O
1.73	CD	O
m²	NN	O
and	CC	O
/	NN	O
or	CC	O
body	NN	O
weight	NN	O
less	JJR	O
than	IN	O
70	CD	O
kg	JJ	O
require	NN	O
dosage	NN	O
reduction	NN	O
of	IN	O
PRIMAXIN	NNP	O
I.V	NNP	O
.	.	O

Only	RB	O
the	DT	O
patient	NN	O
may	MD	O
activate	VB	O
IONSYS	NNP	O
.	.	O

When	WRB	O
solutions	NNS	O
devoid	VBP	O
of	IN	O
inorganic	JJ	O
electrolytes	NNS	O
are	VBP	O
given	VBN	O
by	IN	O
hypodermoclysis	NN	O
,	,	O
hypovolemia	NN	O
may	MD	O
occur	VB	O
.	.	O

In	IN	O
:	:	O
Hatcher	NNP	O
RA	NNP	O
,	,	O
Trussell	NNP	O
J	NNP	O
,	,	O
Stewart	NNP	O
F	NNP	O
,	,	O
Cates	NNP	O
W	NNP	O
,	,	O
Stewart	NNP	O
GK	NNP	O
,	,	O
Kowal	NNP	O
D	NNP	O
,	,	O
Guest	NNP	O
F	NNP	O
,	,	O
Contraceptive	NNP	O
Technology	NNP	O
:	:	O
Seventeenth	NNP	O
Revised	VBD	O
Edition	NNP	O
.	.	O

Volumes	NNS	O
in	IN	O
excess	NN	O
of	IN	O
1500	CD	DOS
mL	JJ	UNIT
per	IN	FREQ
day	NN	FREQ
have	VBP	O
been	VBN	O
used	VBN	O
where	WRB	O
severe	JJ	O
blood	NN	O
loss	NN	O
has	VBZ	O
occurred	VBN	O
although	IN	O
generally	RB	O
only	RB	O
in	IN	O
conjunction	NN	O
with	IN	O
the	DT	O
administration	NN	O
of	IN	O
blood	NN	O
and	CC	O
blood	NN	O
products	NNS	O
(	(	O
see	VB	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
)	)	O
.	.	O

Table	JJ	O
5	CD	O
.	.	O

If	IN	O
the	DT	O
level	NN	O
of	IN	O
pain	NN	O
increases	NNS	O
after	IN	O
dose	JJ	O
stabilization	NN	O
,	,	O
attempt	NN	O
to	TO	O
identify	VB	O
the	DT	O
source	NN	O
of	IN	O
increased	VBN	O
pain	NN	O
before	IN	O
increasing	VBG	O
OPANA	NNP	O
ER	NNP	O
dose	NN	O
.	.	O

SPRIX	NNP	O
is	VBZ	O
not	RB	O
an	DT	O
inhaled	JJ	O
product	NN	O
.	.	O

Leucovorin	NNP	O
protection	NN	O
may	MD	O
be	VB	O
administered	VBN	O
prior	JJ	O
to	TO	O
or	CC	O
following	VBG	O
Neutrexin	NNP	O
(	(	O
trimetrexate	JJ	O
glucuronate	NN	O
inj	NN	O
)	)	O
.	.	O

Dosage	NN	O
for	IN	O
infants	NNS	WHO
and	CC	WHO
children	NNS	WHO
should	MD	O
be	VB	O
administered	VBN	O
in	IN	O
proportion	NN	O
to	TO	O
age	NN	O
and	CC	O
body	NN	O
weight	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

As	IN	O
with	IN	O
all	DT	O
HFA	NNP	O
-	:	O
containing	VBG	O
albuterol	NN	O
inhalers	NNS	O
,	,	O
to	TO	O
maintain	VB	O
proper	JJ	O
use	NN	O
of	IN	O
this	DT	O
product	NN	O
and	CC	O
to	TO	O
prevent	VB	O
medication	NN	O
build	SYM	O
-	:	O
up	RB	O
and	CC	O
blockage	NN	O
,	,	O
it	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
clean	VB	O
the	DT	O
plastic	NN	O
mouthpiece	VBD	O
regularly	RB	O
.	.	O

This	DT	O
dosing	VBG	O
regimen	NN	O
is	VBZ	O
suggested	VBN	O
only	RB	O
as	IN	O
a	DT	O
guide	NN	O
.	.	O

Careful	NNP	O
,	,	O
frequent	NN	O
(	(	O
weekly	JJ	FREQ
)	)	O
monitoring	NN	O
of	IN	O
serum	NN	O
ALT	NNP	O
/	NNP	O
SGPT	NNP	O
should	MD	O
be	VB	O
undertaken	VBN	O
when	WRB	O
rechallenging	VBG	O
such	JJ	O
patients	NNS	O
.	.	O

Recommend	NNP	O
use	NN	O
of	IN	O
a	DT	O
non	JJ	O
-	:	O
hormonal	NN	O
back	RB	O
-	:	O
up	RP	O
method	NN	O
for	IN	O
the	DT	O
first	JJ	O
7	CD	O
days	NNS	O
.	.	O

The	DT	O
pulse	JJ	O
rate	NN	O
should	MD	O
be	VB	O
determined	VBN	O
before	IN	O
and	CC	O
during	IN	O
administration	NN	O
of	IN	O
Bioclate	NNP	O
(	(	O
antihemophilic	JJ	O
factor	NN	O
)	)	O
TM	NNP	O
.	.	O

Hospitalized	VBN	WHO
patients	NNS	WHO
who	WP	WHO
have	VBP	WHO
been	VBN	WHO
refractory	JJ	WHO
to	TO	WHO
antidepressant	VB	WHO
therapy	NN	WHO
and	CC	WHO
who	WP	WHO
have	VBP	WHO
no	DT	WHO
history	NN	WHO
of	IN	WHO
convulsive	JJ	WHO
seizures	NNS	WHO
may	MD	O
have	VB	O
dosage	NN	O
raised	VBN	O
cautiously	RB	O
up	IN	O
to	TO	O
600	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
in	IN	O
divided	JJ	O
doses	NNS	O
.	.	O

Do	NNP	O
not	RB	O
mix	VB	O
an	DT	O
aminoglycoside	NN	O
with	IN	O
Mandol	NNP	O
(	(	O
cefamandole	NN	O
)	)	O
in	IN	O
the	DT	O
same	JJ	O
intravenous	JJ	O
fluid	NN	O
container	NN	O
.	.	O

Use	VB	O
the	DT	O
lowest	JJS	O
dose	NN	O
of	IN	O
PROMACTA	NNP	O
to	TO	O
achieve	VB	O
and	CC	O
maintain	VB	O
a	DT	O
hematologic	JJ	O
response	NN	O
.	.	O

The	DT	O
ring	NN	O
is	VBZ	O
to	TO	O
remain	VB	O
in	IN	O
place	NN	O
continuously	RB	O
for	IN	O
three	CD	PER
months	NNS	PER
,	,	O
after	IN	O
which	WDT	O
it	PRP	O
is	VBZ	O
to	TO	O
be	VB	O
removed	VBN	O
and	CC	O
,	,	O
if	IN	O
appropriate	JJ	O
,	,	O
replaced	VBN	O
by	IN	O
a	DT	O
new	JJ	O
ring	NN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
acute	JJ	WHO
uncomplicated	JJ	WHO
malaria	NN	WHO
and	CC	WHO
severe	JJ	WHO
chronic	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
,	,	O
the	DT	O
following	JJ	O
dosage	NN	O
regimen	NNS	O
is	VBZ	O
recommended	VBN	O
:	:	O
one	CD	DOS
loading	VBG	UNIT
dose	NN	UNIT
of	IN	O
648	CD	DOS
mg	NNS	UNIT
QUALAQUIN	NNP	O
followed	VBD	O
12	CD	O
hours	NNS	O
later	RB	O
by	IN	O
maintenance	NN	O
doses	NNS	O
of	IN	O
324	CD	DOS
mg	NN	UNIT
every	DT	FREQ
12	CD	FREQ
hours	NNS	FREQ
.	.	O

Use	NNP	O
of	IN	O
gloves	NNS	O
and	CC	O
other	JJ	O
protective	JJ	O
clothing	NN	O
to	TO	O
prevent	VB	O
skin	JJ	O
contact	NN	O
is	VBZ	O
recommended	VBN	O
.	.	O

Effective	JJ	O
use	NN	O
of	IN	O
theophylline	NN	O
(	(	O
i.e	NN	O
,	,	O
the	DT	O
concentration	NN	O
of	IN	O
drug	NN	O
in	IN	O
the	DT	O
serum	NN	O
associated	VBN	O
with	IN	O
optimal	JJ	O
benefit	NN	O
and	CC	O
minimal	JJ	O
risk	NN	O
of	IN	O
toxicity	NN	O
)	)	O
is	VBZ	O
considered	VBN	O
to	TO	O
occur	VB	O
when	WRB	O
the	DT	O
theophylline	NN	O
concentration	NN	O
is	VBZ	O
maintained	VBN	O
from	IN	O
10	CD	DOS
to	TO	O
20	CD	DOS
pg	NNS	UNIT
/	JJ	O
mL	NN	O
.	.	O

If	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
stable	JJ	O
,	,	O
alglucosidase	JJ	O
alfa	NN	O
may	MD	O
be	VB	O
administered	VBN	O
at	IN	O
the	DT	O
maximum	JJ	O
rate	NN	O
of	IN	O
7	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
/	FW	O
hr	NN	O
until	IN	O
the	DT	O
infusion	NN	O
is	VBZ	O
completed	VBN	O
.	.	O

Any	DT	O
change	NN	O
in	IN	O
therapy	NN	O
of	IN	O
type	NN	O
2	CD	O
diabetes	NNS	O
should	MD	O
be	VB	O
undertaken	VBN	O
with	IN	O
care	NN	O
and	CC	O
appropriate	JJ	O
monitoring	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
whenever	WRB	O
the	DT	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Subsequent	JJ	O
dosing	NN	O
should	MD	O
be	VB	O
tailored	VBN	O
to	TO	O
the	DT	O
individual	JJ	O
patient	NN	O
,	,	O
based	VBN	O
on	IN	O
response	NN	O
,	,	O
up	RB	O
to	TO	O
a	DT	O
maximum	JJ	O
dose	NN	O
of	IN	O
35	CD	DOS
Units	NNS	UNIT
per	IN	O
eye	NN	O
[	NN	O
see	VBP	O
Clinical	JJ	O
Studies	NNP	O
]	NNP	O
.	.	O

The	DT	O
ma	NN	O
ximum	JJ	O
total	JJ	O
dosage	NN	O
by	IN	O
I.V	NNP	O
.	.	O

For	IN	O
use	NN	O
as	IN	O
an	DT	O
adjunct	NN	O
in	IN	O
the	DT	O
management	NN	O
of	IN	O
hepatic	JJ	O
coma	NN	O
,	,	O
the	DT	O
recommended	VBN	O
dose	NN	O
is	VBZ	O
4	CD	DOS
-	:	O
12	CD	DOS
grams	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
given	VBN	O
in	IN	O
the	DT	O
following	JJ	O
regimen	NNS	O
:	:	O

Rub	NNP	O
in	IN	O
gently	RB	O
.	.	O

If	IN	O
the	DT	O
implant	NN	O
migrates	VBZ	O
within	IN	O
the	DT	O
arm	NN	O
,	,	O
removal	NN	O
may	MD	O
require	VB	O
a	DT	O
minor	JJ	O
surgical	JJ	O
procedure	NN	O
with	IN	O
a	DT	O
larger	JJR	O
incision	NN	O
or	CC	O
a	DT	O
surgical	JJ	O
procedure	NN	O
in	IN	O
an	DT	O
operating	NN	O
room	NN	O
.	.	O

The	DT	O
plunger	NN	O
will	MD	O
then	RB	O
rise	VB	O
automatically	RB	O
while	IN	O
the	DT	O
needle	JJ	O
withdraws	NN	O
from	IN	O
the	DT	O
skin	NN	O
and	CC	O
retracts	VBZ	O
into	IN	O
the	DT	O
security	NN	O
sleeve	NN	O
.	.	O

Thereafter	RB	O
,	,	O
the	DT	O
dose	NN	O
may	MD	O
be	VB	O
reduced	VBN	O
by	IN	O
0.375	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

If	IN	O
the	DT	O
neonatal	JJ	O
suction	NN	O
valve	NN	O
is	VBZ	O
used	VBN	O
,	,	O
the	DT	O
catheter	NN	O
should	MD	O
be	VB	O
rigid	JJ	O
enough	RB	O
to	TO	O
pass	VB	O
easily	RB	O
into	IN	O
the	DT	O
endotracheal	JJ	O
tube	NN	O
.	.	O

Alkalization	NN	O
of	IN	O
the	DT	O
urine	NN	O
is	VBZ	O
recommended	VBN	O
until	IN	O
the	DT	O
serum	JJ	O
urate	JJ	O
level	NN	O
returns	NNS	O
to	TO	O
normal	JJ	O
limits	NNS	O
and	CC	O
tophaceous	JJ	O
deposits	NNS	O
disappear	VBP	O
,	,	O
i.e	JJ	O
,	,	O
during	IN	O
the	DT	O
period	NN	O
when	WRB	O
urinary	JJ	O
excretion	NN	O
of	IN	O
uric	JJ	O
acid	NN	O
is	VBZ	O
at	IN	O
a	DT	O
high	JJ	O
level	NN	O
.	.	O

Store	NN	O
SEEBRI	NNP	O
capsules	NNS	O
in	IN	O
the	DT	O
blister	NN	O
,	,	O
and	CC	O
only	RB	O
remove	VB	O
IMMEDIATELY	NNP	O
BEFORE	NNP	O
USE	NNP	O
with	IN	O
the	DT	O
NEOHALER	NNP	O
device	NN	O
.	.	O

Provision	NN	O
of	IN	O
multiple	JJ	O
refills	NNS	O
is	VBZ	O
not	RB	O
advised	VBN	O
early	RB	O
in	IN	O
treatment	NN	WHO
or	CC	WHO
without	IN	WHO
appropriate	JJ	WHO
patient	NN	WHO
follow	SYM	WHO
-	:	WHO
up	RP	WHO
visits	NNS	WHO
.	.	O

Usually	RB	O
7,500	CD	DOS
USP	NNP	UNIT
units	NNS	UNIT
of	IN	O
heparin	NN	O
sodium	NN	O
are	VBP	O
added	VBN	O
to	TO	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
(	(	O
or	CC	O
75,000	CD	DOS
USP	NNP	UNIT
units	NNS	UNIT
/	VBD	O
1,000	CD	DOS
mL	NN	UNIT
of	IN	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
)	)	O
and	CC	O
mixed	JJ	O
;	:	O
and	CC	O
from	IN	O
this	DT	O
sterile	JJ	O
solution	NN	O
,	,	O
6	CD	DOS
to	TO	O
8	CD	DOS
mL	NNS	UNIT
are	VBP	O
added	VBN	O
per	IN	O
100	CD	DOS
mL	NN	UNIT
of	IN	O
whole	JJ	O
blood	NN	O
.	.	O

While	IN	O
there	EX	O
is	VBZ	O
little	JJ	O
likelihood	NN	O
of	IN	O
ovulation	NN	O
occurring	VBG	O
if	IN	O
only	RB	O
one	CD	DOS
tablet	NN	UNIT
is	VBZ	O
missed	VBN	O
,	,	O
the	DT	O
possibility	NN	O
of	IN	O
spotting	VBG	O
or	CC	O
bleeding	NN	O
is	VBZ	O
increased	VBN	O
.	.	O

TOPROL	NNP	O
-	:	O
XL	NN	O
is	VBZ	O
not	RB	O
recommended	VBN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
<	VBP	WHO
6	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
[	NNP	O
see	NN	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
]	NNP	O
.	.	O

The	DT	O
patient	NN	O
should	MD	O
be	VB	O
fully	RB	O
informed	VBN	O
of	IN	O
the	DT	O
risks	NNS	O
involved	VBN	O
and	CC	O
should	MD	O
be	VB	O
under	IN	O
constant	JJ	O
supervision	NN	O
of	IN	O
the	DT	O
physician	NN	O
.	.	O

IONSYS	NNP	O
contains	VBZ	O
two	CD	DOS
hydrogels	NNS	UNIT
(	(	O
see	VB	O
Figure	NNP	O
4a	CD	O
)	)	O
,	,	O
one	CD	O
of	IN	O
which	WDT	O
contains	VBZ	O
fentanyl	JJ	O
[	NNP	O
see	NN	O
DESCRIPTION	NNP	O
]	NNP	O
.	.	O

It	PRP	O
has	VBZ	O
usually	RB	O
been	VBN	O
found	VBN	O
that	IN	O
a	DT	O
dosage	NN	O
in	IN	O
excess	NN	O
of	IN	O
1	CD	DOS
g	NNS	UNIT
per	IN	O
24	CD	O
hours	NNS	O
does	VBZ	O
not	RB	O
produce	VB	O
an	DT	O
increased	JJ	O
effect	NN	O
.	.	O

Discard	NNP	O
bag	NN	O
if	IN	O
leaks	NNS	O
are	VBP	O
found	VBN	O
as	IN	O
sterility	NN	O
may	MD	O
be	VB	O
impaired	VBN	O
.	.	O

In	IN	O
such	JJ	O
cases	NNS	O
,	,	O
discontinuation	NN	O
of	IN	O
the	DT	O
specific	JJ	O
etiologic	JJ	O
agent	NN	O
may	MD	O
obviate	VB	O
the	DT	O
need	NN	O
for	IN	O
specific	JJ	O
drug	NN	O
therapy	NN	O
of	IN	O
hypertriglyceridemia	NN	O
.	.	O

Prior	RB	O
to	TO	O
treating	VBG	WHO
pediatric	JJ	WHO
patients	NNS	WHO
and	CC	WHO
adults	NNS	WHO
with	IN	WHO
CNS	NNP	WHO
stimulants	NNS	WHO
including	VBG	WHO
APTENSIO	NNP	WHO
XR	NNP	WHO
,	,	O
assess	NN	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
cardiac	JJ	O
disease	NN	O
(	(	O
i.e	JJ	O
,	,	O
perform	VB	O
a	DT	O
careful	JJ	O
history	NN	O
,	,	O
family	NN	O
history	NN	O
of	IN	O
sudden	JJ	O
death	NN	O
or	CC	O
ventricular	JJ	O
arrhythmia	NN	O
,	,	O
and	CC	O
physical	JJ	O
exam	NN	O
)	)	O
[	FW	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

ORLAAM	NNP	O
(	(	O
levomethadyl	JJ	O
acetate	NN	O
)	)	O
is	VBZ	O
a	DT	O
solution	NN	O
of	IN	O
a	DT	O
potent	JJ	O
narcotic	JJ	O
(	(	O
LAAM	NNP	O
)	)	O
.	.	O

The	DT	O
Advisory	NNP	O
Council	NNP	O
for	IN	O
the	DT	O
Elimination	NNP	O
of	IN	O
Tuberculosis	NNP	O
,	,	O
the	DT	O
American	JJ	O
Thoracic	NNP	O
Society	NNP	O
,	,	O
and	CC	O
the	DT	O
Centers	NNPS	O
for	IN	O
Disease	NNP	O
Control	NNP	O
and	CC	O
Prevention	NNP	O
recommend	VBP	O
that	IN	O
either	DT	O
streptomycin	NN	O
or	CC	O
ethambutol	NN	O
be	VB	O
added	VBN	O
as	IN	O
a	DT	O
fourth	JJ	O
drug	NN	O
in	IN	O
a	DT	O
regimen	NNS	O
containing	VBG	O
isoniazid	NN	O
(	(	O
INH	NNP	O
)	)	O
,	,	O
rifampin	NN	O
and	CC	O
pyrazinamide	NN	O
for	IN	O
initial	JJ	O
treatment	NN	O
of	IN	O
tuberculosis	NN	O
unless	IN	O
the	DT	O
likelihood	NN	O
of	IN	O
INH	NNP	O
or	CC	O
rifampin	VB	O
resistance	NN	O
is	VBZ	O
very	RB	O
low	JJ	O
.	.	O

To	TO	O
prepare	VB	O
the	DT	O
reconstituted	JJ	O
solution	NN	O
,	,	O
add	VB	O
5	CD	DOS
mL	NN	UNIT
of	IN	O
Sterile	NNP	O
Water	NNP	O
for	IN	O
Injection	NNP	O
,	,	O
USP	NNP	O
,	,	O
using	VBG	O
aseptic	JJ	O
technique	NN	O
,	,	O
to	TO	O
the	DT	O
vial	JJ	O
containing	VBG	O
the	DT	O
Simulect	NNP	O
(	(	O
basiliximab	NN	O
)	)	O
powder	NN	O
.	.	O

Instill	NNP	O
one	CD	DOS
to	TO	O
two	CD	DOS
drops	NNS	UNIT
in	IN	O
the	DT	O
affected	JJ	O
eye	NN	O
(	(	O
s	JJ	O
)	)	O
very	RB	O
1	CD	O
to	TO	O
4	CD	O
hours	NNS	O
while	IN	O
awake	NN	O
.	.	O

MTX	NNP	O
,	,	O
glucocorticoids	NNS	O
,	,	O
NSAIDs	NNP	O
,	,	O
and	CC	O
/	NNP	O
or	CC	O
analgesics	NNS	O
may	MD	O
be	VB	O
continued	VBN	O
during	IN	O
treatment	NN	O
with	IN	O
AMJEVITA	NNP	O
.	.	O

Store	NN	O
at	IN	O
controlled	JJ	O
room	NN	O
temperature	NN	O
15°	CD	O
-	:	O
30°C	CD	O
(	(	O
59°	CD	O
-	:	O
86°F	CD	O
)	)	O
.	.	O

The	DT	O
preferred	JJ	O
site	NN	O
for	IN	O
injection	NN	O
is	VBZ	O
the	DT	O
deltoid	JJ	O
muscle	NN	O
.	.	O

If	IN	O
excessive	JJ	O
opioid	JJ	O
side	NN	O
effects	NNS	O
are	VBP	O
observed	VBN	O
early	RB	O
in	IN	O
the	DT	O
dosing	NN	O
interval	NN	O
,	,	O
reduce	VB	O
the	DT	O
hydromorphone	NN	O
hydrochloride	NN	O
dose	NN	O
.	.	O

Injection	NN	O
sites	NNS	O
should	MD	O
be	VB	O
rotated	VBN	O
within	IN	O
the	DT	O
sameregion	NN	O
.	.	O

Insert	NNP	O
a	DT	O
urethral	JJ	O
catheter	NN	O
into	IN	O
the	DT	O
bladder	NN	O
under	IN	O
aseptic	JJ	O
conditions	NNS	O
,	,	O
drain	VBP	O
the	DT	O
bladder	NN	O
,	,	O
instill	VB	O
50	CD	DOS
mL	JJ	UNIT
suspension	NN	UNIT
of	IN	O
TheraCys	NNP	O
slowly	RB	O
by	IN	O
gravity	NN	O
,	,	O
and	CC	O
then	RB	O
withdraw	VB	O
the	DT	O
catheter	NN	O
.	.	O

Transition	NN	O
from	IN	O
oral	JJ	O
to	TO	O
intravenous	JJ	O
and	CC	O
from	IN	O
intravenous	JJ	O
to	TO	O
oral	JJ	O
formulations	NNS	O
of	IN	O
gastric	JJ	O
acid	JJ	O
inhibitors	NNS	O
should	MD	O
be	VB	O
performed	VBN	O
in	IN	O
such	JJ	O
a	DT	O
manner	NN	O
to	TO	O
ensure	VB	O
continuity	NN	O
of	IN	O
effect	NN	O
of	IN	O
suppression	NN	O
of	IN	O
acid	JJ	O
secretion	NN	O
.	.	O

Avoid	IN	O
the	DT	O
use	NN	O
of	IN	O
fluconazole	JJ	O
doses	NNS	O
of	IN	O
greater	JJR	O
than	IN	O
200	CD	DOS
mg	JJ	UNIT
daily	RB	FREQ
concomitantly	RB	O
with	IN	O
Jakafi	NNP	O
.	.	O

There	EX	O
are	VBP	O
no	DT	O
established	JJ	O
conversion	NN	O
ratios	NNS	O
for	IN	O
conversion	NN	O
from	IN	O
other	JJ	O
opioids	NNS	O
to	TO	O
morphine	VB	O
sulfate	NN	O
extended	VBN	O
-	:	O
release	NN	O
tablets	NNS	O
defined	VBN	O
by	IN	O
clinical	JJ	O
trials	NNS	O
.	.	O

In	IN	O
the	DT	O
event	NN	O
of	IN	O
either	CC	O
being	VBG	O
observed	VBN	O
,	,	O
discard	VB	O
the	DT	O
vaccine	NN	O
.	.	O

Treatment	NN	O
with	IN	O
the	DT	O
aminoglycoside	NN	O
should	MD	O
be	VB	O
continued	VBN	O
in	IN	O
patients	NNS	WHO
from	IN	WHO
whom	WP	WHO
P.	NNP	WHO
aeruginosa	NN	WHO
is	VBZ	O
isolated	VBN	O
.	.	O

The	DT	O
Advisory	NNP	O
Committee	NNP	O
on	IN	O
Immunization	NNP	O
Practices	NNP	O
(	(	O
ACIP	NNP	O
)	)	O
has	VBZ	O
recommendations	NNS	O
for	IN	O
revaccination	NN	O
against	IN	O
pneumococcal	JJ	O
disease	NN	O
for	IN	O
persons	NNS	WHO
at	IN	WHO
high	JJ	WHO
risk	NN	WHO
who	WP	WHO
were	VBD	WHO
previously	RB	WHO
vaccinated	VBN	WHO
with	IN	WHO
PNEUMOVAX	NNP	WHO
23	CD	WHO
.	.	O

Vital	JJ	O
signs	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
routinely	RB	O
.	.	O

Therefore	RB	O
,	,	O
it	PRP	O
is	VBZ	O
necessary	JJ	O
to	TO	O
firmly	VB	O
attach	RP	O
a	DT	O
desired	VBN	O
needle	NN	O
to	TO	O
the	DT	O
syringe	NN	O
.	.	O

Safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
TIVICAY	NNP	O
have	VBP	O
not	RB	O
been	VBN	O
established	VBN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
INSTI	NNP	WHO
-	:	WHO
experienced	VBD	WHO
with	IN	WHO
documented	JJ	WHO
or	CC	O
clinically	RB	O
suspected	VBN	O
resistance	NN	O
to	TO	O
other	JJ	O
INSTIs	NNP	O
(	(	O
raltegravir	NN	O
,	,	O
elvitegravir	NN	O
)	)	O
.	.	O

Simultaneous	JJ	O
transfer	NN	O
of	IN	O
amino	NN	O
acid	NN	O
injection	NN	O
,	,	O
dextrose	JJ	O
injection	NN	O
,	,	O
and	CC	O
Smoflipid	NNP	O
to	TO	O
the	DT	O
PN	NNP	O
container	NN	O
is	VBZ	O
also	RB	O
permitted	VBN	O
.	.	O

for	IN	O
suspension	NN	O
(	(	O
200	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
)	)	O
.	.	O

For	IN	O
single	JJ	O
use	NN	O
only	RB	O

For	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
12	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
and	CC	WHO
older	JJR	WHO
,	,	O
the	DT	O
dosage	NN	O
is	VBZ	O
the	DT	O
same	JJ	O
as	IN	O
for	IN	O
adults	NNS	WHO
.	.	O

Patients	NNS	O
should	MD	O
discontinue	VB	O
therapy	NN	O
if	IN	O
Grade	NNP	O
3	CD	O
or	CC	O
4	CD	O
neurotoxicity	NN	O
is	VBZ	O
experienced	VBN	O
.	.	O

The	DT	O
patient	NN	O
should	MD	O
be	VB	O
advised	VBN	O
to	TO	O
use	VB	O
a	DT	O
non	JJ	O
-	:	O
hormonal	NN	O
back	RB	O
-	:	O
up	RP	O
method	NN	O
for	IN	O
the	DT	O
first	JJ	O
7	CD	O
days	NNS	O
of	IN	O
tablet	NN	O
taking	NN	O
.	.	O

Some	DT	WHO
patients	NNS	WHO
may	MD	O
require	VB	O
an	DT	O
even	RB	O
slower	JJR	O
dosage	NN	O
reduction	NN	O
.	.	O

Initiate	NNP	O
the	DT	O
dosing	VBG	O
regimen	NNS	O
for	IN	O
each	DT	O
patient	NN	O
individually	RB	O
,	,	O
taking	VBG	O
into	IN	O
account	NN	O
the	DT	O
patient	NN	O
's	POS	O
severity	NN	O
of	IN	O
pain	NN	O
,	,	O
patient	JJ	O
response	NN	O
,	,	O
prior	JJ	O
analgesic	JJ	O
treatment	NN	O
experience	NN	O
,	,	O
and	CC	O
risk	NN	O
factors	NNS	O
for	IN	O
addiction	NN	O
,	,	O
abuse	NN	O
,	,	O
and	CC	O
misuse	NN	O
[	NNP	O
see	VBP	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

Concomitant	NNP	O
use	NN	O
of	IN	O
bile	NN	O
acid	NN	O
sequestrants	NNS	O
decreases	VBZ	O
JADENU	NNP	O
systemic	JJ	O
exposure	NN	O
.	.	O

Treatment	NN	O
has	VBZ	O
been	VBN	O
initiated	VBN	O
in	IN	O
some	DT	WHO
patients	NNS	WHO
receiving	VBG	WHO
I.V	NNP	WHO
.	.	O

fluids	NNS	O
or	CC	O
additives	NNS	O
.	.	O

Neither	DT	O
hemodialysis	NN	O
nor	CC	O
peritoneal	JJ	O
dialysis	NN	O
removes	VBZ	O
significant	JJ	O
amounts	NNS	O
of	IN	O
drug	NN	O
from	IN	O
the	DT	O
body	NN	O
.	.	O

Twenty	NNP	O
(	(	O
20	CD	O
)	)	O
to	TO	O
25	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	FW	O
body	NN	O
weight	NN	O
.	.	O

If	IN	O
bleeding	NN	O
does	VBZ	O
not	RB	O
occur	VBN	O
by	IN	O
the	DT	O
end	NN	O
of	IN	O
this	DT	O
period	NN	O
,	,	O
the	DT	O
same	JJ	O
dosage	NN	O
schedule	NN	O
is	VBZ	O
repeated	VBN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
three	CD	O
additional	JJ	O
cycles	NNS	O
of	IN	O
FLUDARA	NNP	O
(	(	O
fludarabine	NN	O
)	)	O
FOR	IN	O
INJECTION	NNP	O
be	VB	O
administered	VBN	O
following	VBG	O
the	DT	O
achievement	NN	O
of	IN	O
a	DT	O
maximal	JJ	O
response	NN	O
and	CC	O
then	RB	O
the	DT	O
drug	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
.	.	O

Dispensing	VBG	O
directly	RB	O
onto	IN	O
hands	NNS	O
is	VBZ	O
not	RB	O
recommended	JJ	O
,	,	O
as	IN	O
the	DT	O
foam	NN	O
will	MD	O
begin	VB	O
to	TO	O
melt	VB	O
immediately	RB	O
upon	IN	O
contact	NN	O
with	IN	O
warm	JJ	O
skin	NN	O
.	.	O

The	DT	O
highest	JJS	O
recommended	JJ	O
dose	NN	O
is	VBZ	O
232	CD	DOS
mcg	JJ	UNIT
twice	RB	FREQ
daily	RB	FREQ
.	.	O

Daily	JJ	FREQ
dosage	NN	O
of	IN	O
200	CD	DOS
mg	NN	UNIT
is	VBZ	O
not	RB	O
unusual	JJ	O
.	.	O

It	PRP	O
is	VBZ	O
important	JJ	O
to	TO	O
shake	VB	O
the	DT	O
syringe	NN	O
vigorously	RB	O
for	IN	O
at	IN	O
least	JJS	O
15	CD	O
seconds	NNS	O
to	TO	O
ensure	VB	O
a	DT	O
homogeneous	JJ	O
suspension	NN	O
.	.	O

Table	JJ	O
1	CD	O
:	:	O
Dosage	NN	O
of	IN	O
AVYCAZ	NNP	O
2.5	CD	DOS
grams	NNS	UNIT
(	(	O
ceftazidime	JJ	O
2	CD	DOS
grams	NNS	UNIT
and	CC	O
avibactam	$	O
0.5	CD	DOS
grams	NNS	UNIT
)	)	O
by	IN	O
Indication	NN	O

The	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
acetaminophen	NN	O
should	MD	O
not	RB	O
exceed	VB	O
4	CD	DOS
grams	NNS	UNIT
.	.	O

Table	JJ	O
2	CD	O
gives	VBZ	O
dosage	NN	O
estimates	NNS	O
in	IN	O
number	NN	O
of	IN	O
vials	NNS	O
for	IN	O
adult	NN	WHO
patients	NNS	WHO
for	IN	WHO
whom	WP	WHO
a	DT	WHO
steady	JJ	WHO
-	:	O
state	NN	O
serum	NN	O
digoxin	NN	O
concentration	NN	O
is	VBZ	O
known	VBN	O
.	.	O

13	CD	O

This	DT	O
position	NN	O
should	MD	O
be	VB	O
maintained	VBN	O
for	IN	O
5	CD	O
minutes	NNS	O
to	TO	O
facilitate	VB	O
penetration	NN	O
of	IN	O
the	DT	O
drops	NNS	O
into	IN	O
the	DT	O
ear	JJ	O
canal	NN	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
,	,	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

Prior	RB	O
to	TO	O
reconstitution	NN	O
,	,	O
the	DT	O
vial	NN	O
should	MD	O
be	VB	O
stored	VBN	O
at	IN	O
controlled	JJ	O
room	NN	O
temperature	NN	O
,	,	O
59°to	CD	O
86°F	CD	O
(	(	O
15°to	CD	O
30°C	CD	O
)	)	O
.	.	O

In	IN	O
the	DT	O
controlled	JJ	O
clinical	JJ	O
trials	NNS	O
establishing	VBG	O
the	DT	O
effectiveness	NN	O
of	IN	O
Fluvoxamine	NNP	O
Maleate	NNP	O
Tablets	NNP	O
in	IN	O
OCD	NNP	O
,	,	O
patients	NNS	O
were	VBD	O
titrated	VBN	O
within	IN	O
a	DT	O
dose	JJ	O
range	NN	O
of	IN	O
100	CD	DOS
to	TO	O
300	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
.	.	O

If	IN	O
patients	NNS	O
require	VBP	O
co	JJ	O
-	:	O
administration	NN	O
of	IN	O
a	DT	O
moderate	JJ	O
CYP3A4	NNP	O
/	NNP	O
PgP	NNP	O
inhibitor	NN	O
,	,	O
reduce	VB	O
the	DT	O
AFINITOR	NNP	O
dose	NN	O
to	TO	O
2.5	CD	DOS
mg	NNS	UNIT
daily	RB	FREQ
.	.	O

Obtain	NNP	O
serum	NN	O
digoxin	NN	O
concentrations	NNS	O
just	RB	O
before	IN	O
the	DT	O
next	JJ	O
scheduled	JJ	O
LANOXIN	NNP	O
dose	NN	O
or	CC	O
at	IN	O
least	JJS	O
6	CD	O
hours	NNS	O
after	IN	O
the	DT	O
last	JJ	O
dose	NN	O
.	.	O

Do	NNP	O
not	RB	O
use	VB	O
if	IN	O
the	DT	O
seal	NN	O
is	VBZ	O
broken	VBN	O
.	.	O

Pharmacological	JJ	O
treatment	NN	O
of	IN	O
ADHD	NNP	O
may	MD	O
be	VB	O
needed	VBN	O
for	IN	O
extended	JJ	O
periods	NNS	O
.	.	O

No	DT	O
further	JJ	O
dilution	NN	O
of	IN	O
these	DT	O
preparations	NNS	O
are	VBP	O
necessary	JJ	O
.	.	O

Usual	JJ	O
Starting	NNP	O
Dose	NNP	O

If	IN	O
there	EX	O
is	VBZ	O
a	DT	O
response	NN	O
,	,	O
then	RB	O
there	EX	O
should	MD	O
be	VB	O
at	IN	O
least	JJS	O
a	DT	O
1	CD	O
-	:	O
day	NN	O
interval	NN	O
before	IN	O
the	DT	O
next	JJ	O
dose	NN	O
is	VBZ	O
given	VBN	O
.	.	O

To	TO	O
calculate	VB	O
the	DT	O
estimated	VBN	O
PALLADONE	NNP	O
dose	JJ	O
using	VBG	O
Table	JJ	O
1	CD	O
:	:	O

Although	IN	O
tables	NNS	O
of	IN	O
oral	JJ	O
and	CC	O
parenteral	JJ	O
equivalents	NNS	O
are	VBP	O
readily	RB	O
available	JJ	O
,	,	O
there	EX	O
is	VBZ	O
substantial	JJ	O
inter	JJ	O
-	:	O
patient	NN	O
variability	NN	O
in	IN	O
the	DT	O
relative	JJ	O
potency	NN	O
of	IN	O
different	JJ	O
opioid	JJ	O
drugs	NNS	O
and	CC	O
formulations	NNS	O
.	.	O

DIPRIVAN	NNP	O
Injectable	NNP	O
Emulsion	NNP	O
has	VBZ	O
been	VBN	O
well	RB	O
-	:	O
studied	VBN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
coronary	JJ	WHO
artery	NN	WHO
disease	NN	WHO
,	,	O
but	CC	O
experience	NN	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
hemodynamically	RB	WHO
significant	JJ	WHO
valvular	NN	WHO
or	CC	O
congenital	JJ	O
heart	NN	O
disease	NN	O
is	VBZ	O
limited	VBN	O
.	.	O

Dosing	VBG	O
recommendations	NNS	O
for	IN	O
patients	NNS	WHO
with	IN	WHO
a	DT	WHO
CrCl	NNP	WHO
≤	NNP	WHO
30	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
or	CC	O
on	IN	O
dialysis	NN	O
can	MD	O
not	RB	O
be	VB	O
provided	VBN	O
[	NNP	O
see	VBP	O
Use	NNP	O
in	IN	O
Specific	NNP	O
Populations	NNP	O
and	CC	O
CLINICAL	NNP	O
PHARMACOLOGY	NNP	O
]	NNP	O
.	.	O

ZOSYN	NNP	O
contains	VBZ	O
no	DT	O
preservatives	NNS	O
.	.	O

If	IN	O
menstruation	NN	O
begins	VBZ	O
on	IN	O
a	DT	O
Sunday	NNP	O
,	,	O
the	DT	O
first	JJ	O
tablet	NN	O
(	(	O
orange	NN	O
)	)	O
is	VBZ	O
taken	VBN	O
that	DT	O
day	NN	O
.	.	O

To	TO	O
administer	VB	O
the	DT	O
dose	NN	O
,	,	O
patients	NNS	O
should	MD	O
be	VB	O
instructed	VBN	O
to	TO	O
perform	VB	O
the	DT	O
following	JJ	O
steps	NNS	O
:	:	O

Patients	NNS	WHO
who	WP	WHO
are	VBP	WHO
responding	VBG	WHO
to	TO	WHO
therapy	VB	WHO
may	MD	O
benefit	VB	O
from	IN	O
continued	JJ	O
treatment	NN	O
.	.	O

Then	RB	O
remove	VB	O
the	DT	O
needle	JJ	O
shield	NN	O
,	,	O
while	IN	O
holding	VBG	O
the	DT	O
applicator	NN	O
upright	NN	O
.	.	O

In	IN	O
general	JJ	O
,	,	O
expect	VBP	O
progressive	JJ	O
increases	NNS	O
in	IN	O
dose	NN	O
.	.	O

Use	VB	O
the	DT	O
lowest	JJS	O
possible	JJ	O
effective	JJ	O
dose	NN	O
,	,	O
and	CC	O
periodically	RB	O
reassess	VB	O
the	DT	O
need	NN	O
for	IN	O
continued	JJ	O
treatment..	NN	O

Each	DT	O
250	CD	DOS
mL	NN	UNIT
of	IN	O
NephrAmine®	NNP	O
is	VBZ	O
typically	RB	O
mixed	JJ	O
aseptically	RB	O
with	IN	O
500	CD	DOS
mL	NNS	UNIT
of	IN	O
70	CD	O
%	NN	O
dextrose	NN	O
to	TO	O
yield	VB	O
a	DT	O
solution	NN	O
of	IN	O
1.8	CD	O
%	NN	O
NephrAmine®	NNP	O
in	IN	O
47	CD	O
%	NN	O
dextrose	NN	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
periodically	RB	O
reassessed	VBN	O
to	TO	O
determine	VB	O
the	DT	O
need	NN	O
for	IN	O
maintenance	NN	O
treatment	NN	O
and	CC	O
the	DT	O
appropriate	JJ	O
dose	NN	O
for	IN	O
such	JJ	O
treatment	NN	O
.	.	O

Limited	VBN	O
data	NNS	O
are	VBP	O
available	JJ	O
related	VBN	O
to	TO	O
administration	NN	O
of	IN	O
YF	NNP	O
-	:	O
VAX	NN	O
with	IN	O
other	JJ	O
vaccines	NNS	O
and	CC	O
the	DT	O
potential	NN	O
for	IN	O
immune	JJ	O
interference	NN	O
.	.	O

Do	NNP	O
not	RB	O
exceed	VB	O
the	DT	O
recommended	JJ	O
dose	NN	O
as	IN	O
desloratadine	NN	O
and	CC	O
pseudoephedrine	NN	O
,	,	O
the	DT	O
active	JJ	O
components	NNS	O
of	IN	O
CLARINEX	NNP	O
-	:	O
D	VBZ	O
12	CD	O
HOUR	NNP	O
Extended	NNP	O
Release	NNP	O
Tablets	NNP	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
adverse	JJ	O
effects	NNS	O
at	IN	O
higher	JJR	O
doses	NNS	O
[	VBP	O
see	VBP	O
OVERDOSAGE	NNP	O
]	NNP	O
.	.	O

If	IN	O
deviating	VBG	O
from	IN	O
the	DT	O
recommended	JJ	O
timing	NN	O
of	IN	O
insertion	NN	O
,	,	O
the	DT	O
woman	NN	O
should	MD	O
be	VB	O
advised	VBN	O
to	TO	O
use	VB	O
a	DT	O
barrier	NN	O
method	NN	O
until	IN	O
7	CD	O
days	NNS	O
after	IN	O
insertion	NN	O
.	.	O

2	CD	O
.	.	O

Re	NNP	O
-	:	O
evaluate	NN	O
eGFR	VBZ	O
48	CD	O
hours	NNS	O
after	IN	O
the	DT	O
imaging	JJ	O
procedure	NN	O
;	:	O
restart	VB	O
SYNJARDY	NNP	O
XR	NNP	O
if	IN	O
renal	JJ	O
function	NN	O
is	VBZ	O
stable	JJ	O
[	JJ	O
see	NN	O
WARNINGS	NNP	O
AND	NNP	O
PRECAUTIONS	NNP	O
]	NNP	O
.	.	O

If	IN	O
other	JJ	O
vitamin	NN	O
deficiencies	NNS	O
are	VBP	O
present	JJ	O
,	,	O
they	PRP	O
should	MD	O
be	VB	O
treated	VBN	O
.	.	O

If	IN	O
the	DT	O
inhibitor	NN	O
can	MD	O
not	RB	O
be	VB	O
avoided	VBN	O
,	,	O
reduce	VB	O
the	DT	O
Lynparza	NNP	O
dose	NN	O
to	TO	O
150	CD	DOS
mg	NN	UNIT
(	(	O
three	CD	DOS
50	CD	DOS
mg	NNS	UNIT
capsules	NNS	UNIT
)	)	O
taken	VBN	O
twice	RB	FREQ
daily	RB	FREQ
for	IN	O
a	DT	O
strong	JJ	O
CYP3A	NNP	O
inhibitor	NN	O
or	CC	O
200	CD	DOS
mg	NNS	UNIT
(	(	O
four	CD	DOS
50	CD	DOS
mg	NN	UNIT
capsules	NNS	UNIT
)	)	O
taken	VBN	O
twice	RB	FREQ
daily	RB	FREQ
for	IN	O
a	DT	O
moderate	JJ	O
CYP3A	NNP	O
inhibitor	NN	O
[	NNP	O
see	VBP	O
DRUG	NNP	O
INTERACTIONS	NNP	O
]	NNP	O
.	.	O

After	IN	O
a	DT	O
favorable	JJ	O
initial	JJ	O
response	NN	O
is	VBZ	O
obtained	VBN	O
in	IN	O
terms	NNS	O
of	IN	O
prevention	NN	O
of	IN	O
episodes	NNS	O
of	IN	O
edematous	JJ	O
attacks	NNS	O
,	,	O
the	DT	O
proper	JJ	O
continuing	VBG	O
dosage	NN	O
should	MD	O
be	VB	O
determined	VBN	O
by	IN	O
decreasing	VBG	O
the	DT	O
dosage	NN	O
at	IN	O
intervals	NNS	O
of	IN	O
one	CD	DOS
to	TO	O
three	CD	PER
months	NNS	PER
to	TO	O
a	DT	O
maintenance	NN	O
dosage	NN	O
of	IN	O
2	CD	DOS
mg	NNS	UNIT
a	DT	FREQ
day	NN	FREQ
.	.	O

The	DT	O
recommended	VBN	O
starting	NN	O
dosage	NN	O
and	CC	O
the	DT	O
highest	JJS	O
recommended	JJ	O
dosage	NN	O
of	IN	O
AEROSPAN	NNP	O
Inhalation	NNP	O
Aerosol	NNP	O
are	VBP	O
listed	VBN	O
in	IN	O
Table	JJ	O
1	CD	O
.	.	O

Therefore	RB	O
,	,	O
clinical	JJ	O
response	NN	O
to	TO	O
treatment	NN	O
and	CC	O
renal	JJ	O
function	NN	O
should	MD	O
be	VB	O
closely	RB	O
monitored	VBN	O
in	IN	O
these	DT	WHO
patients	NNS	WHO
.	.	O

These	DT	O
are	VBP	O
suggested	VBN	O
dose	JJ	O
adjustments	NNS	O
based	VBN	O
on	IN	O
pharmacokinetics	NNS	O
following	VBG	O
administration	NN	O
of	IN	O
multiple	JJ	O
doses	NNS	O
.	.	O

Bivalirudin	NNP	O
for	IN	O
Injection	NNP	O
infusion	NN	O
may	MD	O
be	VB	O
continued	VBN	O
following	VBG	O
PCI	NNP	O
/	NNP	O
PTCA	NNP	O
for	IN	O
up	RB	O
to	TO	O
4	CD	O
hours	NNS	O
postprocedure	NN	O
at	IN	O
the	DT	O
discretion	NN	O
of	IN	O
the	DT	O
treating	NN	O
physician	NN	O
.	.	O

Analysis	NN	O
of	IN	O
numerous	JJ	O
variable	JJ	O
s	NN	O
has	VBZ	O
indicated	VBN	O
that	IN	O
approximately	RB	O
60	CD	O
%	NN	O
of	IN	O
patients	NNS	WHO
who	WP	WHO
lose	VBP	WHO
at	IN	WHO
least	JJS	WHO
4	CD	WHO
pounds	NNS	WHO
in	IN	O
the	DT	O
first	JJ	O
4	CD	PER
weeks	NNS	PER
of	IN	O
treatment	NN	O
with	IN	O
a	DT	O
given	VBN	O
dose	NN	O
of	IN	O
MERIDIA	NNP	O
(	(	O
sibutramine	JJ	O
hydrochloride	NN	O
monohydrate	NN	O
)	)	O
in	IN	O
combination	NN	O
with	IN	O
a	DT	O
reduced	VBN	O
-	:	O
calorie	NN	O
diet	JJ	O
lose	NN	O
at	IN	O
least	JJS	O
5	CD	O
%	NN	O
(	(	O
placebo	JJ	O
-	:	O
subtracted	VBN	O
)	)	O
of	IN	O
their	PRP$	O
initial	JJ	O
body	NN	O
weight	NN	O
by	IN	O
the	DT	O
end	NN	O
of	IN	O
6	CD	O
months	NNS	O
to	TO	O
1	CD	O
year	NN	O
of	IN	O
treatment	NN	O
on	IN	O
that	DT	O
dose	NN	O
of	IN	O
MERIDIA	NNP	O
(	(	O
sibutramine	JJ	O
hydrochloride	NN	O
monohydrate	NN	O
)	)	O
.	.	O

Dosing	VBG	O
should	MD	O
be	VB	O
titrated	VBN	O
based	VBN	O
on	IN	O
clinical	JJ	O
assessments	NNS	O
of	IN	O
rejection	NN	O
and	CC	O
tolerability	NN	O
.	.	O

Vancomycin	NNP	O
in	IN	O
the	DT	O
GALAXY	NNP	O
Container	NNP	O
(	(	O
PL	NNP	O
2040	CD	O
Plastic	NNP	O
)	)	O
is	VBZ	O
not	RB	O
to	TO	O
be	VB	O
administered	VBN	O
orally	RB	O
.	.	O

The	DT	O
prescribed	JJ	O
amount	NN	O
of	IN	O
product	NN	O
should	MD	O
be	VB	O
delivered	VBN	O
directly	RB	O
into	IN	O
the	DT	O
palm	NN	O
of	IN	O
the	DT	O
hand	NN	O
and	CC	O
immediately	RB	O
applied	VBN	O
to	TO	O
the	DT	O
shoulders	NNS	O
and	CC	O
/	NN	O
or	CC	O
upper	JJ	O
arms	NNS	O
(	(	O
area	NN	O
of	IN	O
application	NN	O
should	MD	O
be	VB	O
limited	VBN	O
to	TO	O
the	DT	O
area	NN	O
that	WDT	O
will	MD	O
be	VB	O
covered	VBN	O
by	IN	O
the	DT	O
patient	NN	O
's	POS	O
short	JJ	O
sleeve	NN	O
t	SYM	O
-	:	O
shirt	NN	O
[	JJ	O
see	NN	O
figure	NN	O
below	IN	O
]	NN	O
)	)	O

Adults	NNS	WHO
:	:	O
500	CD	DOS
mg	NN	UNIT
diluted	VBN	O
in	IN	O
20	CD	DOS
mL	NN	UNIT
sterile	NN	O
distilled	VBD	O
water	NN	O
may	MD	O
be	VB	O
instilled	VBN	O
through	IN	O
a	DT	O
polyethylene	NN	O
catheter	NN	O
sutured	VBD	O
into	IN	O
the	DT	O
wound	NN	O
at	IN	O
closure	NN	O
.	.	O

The	DT	O
intra	JJ	O
-	:	O
arterial	JJ	O
route	NN	O
of	IN	O
administration	NN	O
has	VBZ	O
the	DT	O
advantages	NNS	O
of	IN	O
allowing	VBG	O
a	DT	O
lower	JJR	O
total	JJ	O
dose	NN	O
of	IN	O
contrast	NN	O
agent	NN	O
since	IN	O
there	EX	O
is	VBZ	O
less	JJR	O
hemodilution	NN	O
than	IN	O
with	IN	O
the	DT	O
intravenous	JJ	O
route	NN	O
of	IN	O
administration	NN	O
.	.	O

Single	NNP	O
doses	VBZ	O
greater	JJR	O
than	IN	O
16	CD	DOS
mg	NNS	UNIT
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	O

Infusion	NN	O
rates	NNS	O
should	MD	O
not	RB	O
exceed	VB	O
30	CD	DOS
mg	NNS	UNIT
per	IN	O
minute	NN	O
.	.	O

If	IN	O
the	DT	O
stinging	NN	O
continues	VBZ	O
,	,	O
contact	VB	O
your	PRP$	O
doctor	NN	O
right	RB	O
away	RB	O
.	.	O

For	IN	O
administration	NN	O
,	,	O
select	VBP	O
the	DT	O
19	CD	O
-	:	O
gauge	NN	O
,	,	O
1.5	CD	O
-	:	O
inch	NN	O
(	(	O
38	CD	DOS
mm	NN	UNIT
)	)	O
Hypodermic	NNP	O
Needle	NNP	O
-	:	O
Pro	NNP	O
needle	FW	O
with	IN	O
needle	JJ	O
protection	NN	O
device	NN	O
.	.	O

Such	JJ	O
pretreatment	NN	O
may	MD	O
require	VB	O
3	CD	O
to	TO	O
6	CD	O
months	NNS	O
and	CC	O
the	DT	O
dose	NN	O
of	IN	O
hCG	NN	O
may	MD	O
need	VB	O
to	TO	O
be	VB	O
increased	VBN	O
to	TO	O
achieve	VB	O
normal	JJ	O
serum	NN	O
testosterone	NN	O
levels	NNS	O
.	.	O

Demonstrate	NNP	O
proper	JJ	O
administration	NN	O
technique	NN	O
to	TO	O
the	DT	O
patient	NN	O
[	NNP	O
see	VBP	O
PATIENT	NNP	O
INFORMATION	NNP	O
]	NNP	O
.	.	O

It	PRP	O
is	VBZ	O
necessary	JJ	O
to	TO	O
counsel	NN	O
the	DT	O
patient	NN	O
and	CC	O
discuss	VB	O
the	DT	O
appropriate	JJ	O
indication	NN	O
,	,	O
risks	NNS	O
,	,	O
benefits	NNS	O
and	CC	O
expected	VBN	O
responses	NNS	O
to	TO	O
the	DT	O
Restylane	NNP	O
Silk	NNP	O
treatment	NN	O
.	.	O

Two	CD	DOS
consecutive	JJ	UNIT
tablets	NNS	UNIT
are	VBP	O
missed	VBN	O
(	(	O
Week	JJ	O
3	CD	O
)	)	O

Note	NN	O
:	:	O
For	IN	O
proper	JJ	O
dispensing	NN	O
of	IN	O
foam	NN	O
,	,	O
hold	VBP	O
the	DT	O
can	MD	O
upside	VB	O
down	RB	O
and	CC	O
depress	VB	O
the	DT	O
actuator	NN	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
three	CD	O
(	(	O
3	CD	O
)	)	O
AtroPen®	NNP	O
(	(	O
atropine	NN	O
)	)	O
auto	NN	O
-	:	O
injectors	NNS	O
be	VB	O
available	JJ	O
for	IN	O
use	NN	O
in	IN	O
each	DT	O
person	NN	O
at	IN	O
risk	NN	O
for	IN	O
nerve	NN	O
agent	NN	O
or	CC	O
organophosphate	VB	O
insecticide	JJ	O
poisoning	NN	O
;	:	O
one	CD	DOS
(	(	O
1	CD	DOS
)	)	O
for	IN	O
mild	NN	O
symptoms	NNS	O
plus	CC	O
two	CD	O
(	(	O
2	CD	O
)	)	O
more	JJR	O
for	IN	O
severe	JJ	O
symptoms	NNS	O
as	IN	O
described	VBN	O
below	IN	O
.	.	O

In	IN	O
patients	NNS	WHO
with	IN	WHO
hyperchloremic	JJ	WHO
or	CC	WHO
other	JJ	WHO
metabolic	JJ	WHO
acidosis	NN	WHO
,	,	O
sodium	NN	O
and	CC	O
potassium	NN	O
may	MD	O
be	VB	O
added	VBN	O
as	IN	O
the	DT	O
acetate	NN	O
or	CC	O
lactate	NN	O
salts	NNS	O
to	TO	O
provide	VB	O
bicarbonate	NN	O
alternates	NNS	O
.	.	O

Buffered	VBN	O
Pfizerpen	NNP	O
(	(	O
penicillin	JJ	O
g	NN	O
potassium	NN	O
)	)	O
(	(	O
penicillin	JJ	O
G	NNP	O
potassium	NN	O
)	)	O
for	IN	O
Injection	NNP	O
is	VBZ	O
highly	RB	O
water	NN	O
soluble	JJ	O
.	.	O

Patients	NNS	O
should	MD	O
be	VB	O
advised	VBN	O
that	IN	O
the	DT	O
effect	NN	O
of	IN	O
cromolyn	NN	O
sodium	NN	O
ophthalmic	JJ	O
solution	NN	O
therapy	NN	O
is	VBZ	O
dependent	JJ	O
upon	IN	O
its	PRP$	O
administration	NN	O
at	IN	O
regular	JJ	O
intervals	NNS	O
,	,	O
as	IN	O
directed	VBN	O
.	.	O

Areas	NNS	O
to	TO	O
be	VB	O
treated	VBN	O
should	MD	O
be	VB	O
cleansed	VBN	O
before	IN	O
application	NN	O
of	IN	O
NORITATE	NNP	O
(	(	O
metronidazole	NN	O
)	)	O
.	.	O

Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
prior	RB	O
to	TO	O
administration	NN	O
.	.	O

Figure	NN	O
11	CD	O
:	:	O
Hold	VB	O
the	DT	O
rod	NN	O
still	RB	O
and	CC	O
pull	VB	O
back	RB	O
the	DT	O
tube	NN	O
to	TO	O
the	DT	O
ring	NN	O
on	IN	O
the	DT	O
rod	NN	O
.	.	O

DO	NNP	O
NOT	NNP	O
SHAKE	NNP	O
.	.	O

Probenecid	NNP	O
decreases	VBZ	O
the	DT	O
apparent	JJ	O
volume	NN	O
of	IN	O
distribution	NN	O
and	CC	O
slows	VBZ	O
the	DT	O
rate	NN	O
of	IN	O
excretion	NN	O
by	IN	O
competitively	RB	O
inhibiting	VBG	O
renal	JJ	O
tubular	JJ	O
secretion	NN	O
of	IN	O
penicillin	NN	O
.	.	O

The	DT	O
dosage	NN	O
of	IN	O
PANCREAZE	NNP	O
should	MD	O
be	VB	O
individualized	VBN	O
based	VBN	O
on	IN	O
clinical	JJ	O
symptoms	NNS	O
,	,	O
the	DT	O
degree	NN	O
of	IN	O
steatorrhea	NN	O
present	NN	O
,	,	O
and	CC	O
the	DT	O
fat	JJ	O
content	NN	O
of	IN	O
the	DT	O
diet	NN	O
(	(	O
see	VB	O
Limitations	NNS	O
on	IN	O
Dosing	NNP	O
below	IN	O
)	)	O
.	.	O

Patients	NNS	O
should	MD	O
refer	VB	O
to	TO	O
the	DT	O
Instructions	NNP	O
for	IN	O
Use	NNP	O
for	IN	O
proper	JJ	O
disposal	NN	O
of	IN	O
BUTRANS	NNP	O
.	.	O

To	TO	O
obtain	VB	O
a	DT	O
full	JJ	O
first	JJ	O
dose	NN	O
,	,	O
it	PRP	O
is	VBZ	O
necessary	JJ	O
to	TO	O
prime	VB	O
the	DT	O
canister	NN	O
pump	NN	O
.	.	O

The	DT	O
total	JJ	O
daily	JJ	FREQ
dose	NN	O
of	IN	O
MESNEX	NNP	O
is	VBZ	O
60	CD	O
%	NN	O
of	IN	O
the	DT	O
ifosfamide	NN	O
dose	NN	O
.	.	O

Dose	JJ	O
adjustments	NNS	O
are	VBP	O
based	VBN	O
upon	IN	O
the	DT	O
platelet	NN	O
count	NN	O
response	NN	O
.	.	O

A	DT	O
gradual	JJ	O
reduction	NN	O
in	IN	O
the	DT	O
dose	NN	O
rather	RB	O
than	IN	O
abrupt	JJ	O
cessation	NN	O
is	VBZ	O
recommended	VBN	O
whenever	WRB	O
possible	JJ	O
.	.	O

Intal	JJ	O
Inhaler	NNP	O
should	MD	O
be	VB	O
introduced	VBN	O
into	IN	O
the	DT	O
patient	NN	O
's	POS	O
therapeutic	JJ	O
regimen	NNS	O
when	WRB	O
the	DT	O
acute	NN	O
episode	NN	O
has	VBZ	O
been	VBN	O
controlled	VBN	O
,	,	O
the	DT	O
airway	NN	O
has	VBZ	O
been	VBN	O
cleared	VBN	O
,	,	O
and	CC	O
the	DT	O
patient	NN	O
is	VBZ	O
able	JJ	O
to	TO	O
inhale	VB	O
adequately	RB	O
.	.	O

When	WRB	O
used	VBN	O
for	IN	O
sedation	NN	O
/	NNP	O
anxiolysis	NN	O
/	NNP	O
amnesia	NN	O
for	IN	O
a	DT	O
procedure	NN	O
,	,	O
dosage	NN	O
must	MD	O
be	VB	O
individualized	VBN	O
and	CC	O
titrated	VBN	O
.	.	O

Continually	RB	O
reevaluate	JJ	O
patients	NNS	O
receiving	VBG	O
methadone	NN	O
hydrochloride	NN	O
tablets	NNS	O
to	TO	O
assess	VB	O
the	DT	O
maintenance	NN	O
of	IN	O
pain	NN	O
control	NN	O
and	CC	O
the	DT	O
relative	JJ	O
incidence	NN	O
of	IN	O
adverse	JJ	O
reactions	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
monitoring	NN	O
for	IN	O
the	DT	O
development	NN	O
of	IN	O
addiction	NN	O
,	,	O
abuse	NN	O
,	,	O
or	CC	O
misuse	NN	O
.	.	O

The	DT	O
plunger	NN	O
rod	NN	O
may	MD	O
rise	VB	O
slightly	RB	O
after	IN	O
this	DT	O
process	NN	O
.	.	O

For	IN	O
proper	JJ	O
use	NN	O
,	,	O
refer	VBP	O
to	TO	O
the	DT	O
Instructions	NNP	O
for	IN	O
Use	NNP	O
provided	VBD	O
with	IN	O
the	DT	O
administration	NN	O
device	NN	O
.	.	O

Heparin	NNP	O
solution	NN	O
can	MD	O
cause	VB	O
precipitation	NN	O
of	IN	O
teniposide	NN	O
,	,	O
therefore	RB	O
,	,	O
the	DT	O
administration	NN	O
apparatus	NN	O
should	MD	O
be	VB	O
flushed	VBN	O
thoroughly	RB	O
with	IN	O
5	CD	O
%	NN	O
Dextrose	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
or	CC	O
0.9	CD	O
%	NN	O
Sodium	NNP	O
Chloride	NNP	O
Injection	NNP	O
,	,	O
USP	NNP	O
before	IN	O
and	CC	O
after	IN	O
administration	NN	O
of	IN	O
VUMON	NNP	O
.	.	O

Dosage	NN	O
may	MD	O
be	VB	O
increased	VBN	O
gradually	RB	O
until	IN	O
symptoms	NNS	O
are	VBP	O
controlled	VBN	O
or	CC	O
until	IN	O
side	JJ	O
effects	NNS	O
become	VBP	O
troublesome	JJ	O
.	.	O

Caudal	NNP	O
and	CC	O
Lumbar	NNP	O
Epidural	NNP	O
Block	NNP	O
:	:	O
NESACAINE	NNP	O
(	(	O
chloroprocaine	NN	O
)	)	O
-	:	O
MPF	NNP	O
INJECTION	NNP	O
.	.	O

Intravenous	JJ	O
injection	NN	O
is	VBZ	O
restricted	VBN	O
to	TO	O
conditions	NNS	O
in	IN	O
which	WDT	O
other	JJ	O
routes	NNS	O
are	VBP	O
not	RB	O
feasible	JJ	O
,	,	O
either	RB	O
because	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
unconscious	JJ	O
(	(	O
as	IN	O
in	IN	O
cerebral	JJ	O
hemorrhage	NN	O
,	,	O
eclampsia	NN	O
,	,	O
or	CC	O
status	NN	O
epilepticus	NN	O
)	)	O
,	,	O
because	IN	O
the	DT	O
patient	NN	O
resists	NNS	O
(	(	O
as	IN	O
in	IN	O
delirium	NN	O
)	)	O
,	,	O
or	CC	O
because	IN	O
prompt	JJ	O
action	NN	O
is	VBZ	O
imperative	JJ	O
.	.	O

The	DT	O
clinician	NN	O
should	MD	O
,	,	O
nevertheless	RB	O
,	,	O
be	VB	O
aware	JJ	O
of	IN	O
the	DT	O
possibility	NN	O
of	IN	O
emergent	NN	O
symptoms	NNS	O
of	IN	O
serotonin	JJ	O
syndrome	NN	O
with	IN	O
should	MD	O
,	,	O
nevertheless	RB	O
,	,	O
be	VB	O
aware	JJ	O
of	IN	O
the	DT	O
possibility	NN	O
of	IN	O
emergent	NN	O
symptoms	NNS	O
of	IN	O
serotonin	JJ	O
syndrome	NN	O
with	IN	O
such	JJ	O
use	NN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

Carefully	RB	O
consider	VB	O
the	DT	O
potential	JJ	O
benefits	NNS	O
and	CC	O
risks	NNS	O
of	IN	O
etodolac	NN	O
extended	VBN	O
-	:	O
release	NN	O
tablets	NNS	O
and	CC	O
other	JJ	O
treatment	NN	O
options	NNS	O
before	IN	O
deciding	VBG	O
to	TO	O
use	VB	O
etodolac	NN	O
extended	VBN	O
-	:	O
release	NN	O
tablets	NNS	O
.	.	O

Remove	VB	O
the	DT	O
cap	NN	O
and	CC	O
push	NN	O
bottle	NN	O
adapter	NN	O
into	IN	O
neck	NN	O
of	IN	O
bottle	NN	O
.	.	O

Carefully	RB	O
consider	VB	O
the	DT	O
potential	JJ	O
benefits	NNS	O
and	CC	O
risks	NNS	O
of	IN	O
CLINORIL	NNP	O
(	(	O
sulindac	NN	O
)	)	O
and	CC	O
other	JJ	O
treatment	NN	O
options	NNS	O
before	IN	O
deciding	VBG	O
to	TO	O
use	VB	O
CLINORIL	NNP	O
(	(	O
sulindac	NN	O
)	)	O
.	.	O

For	IN	O
topical	JJ	O
use	NN	O
only	RB	O
.	.	O

It	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
patients	NNS	O
initiate	JJ	O
oral	JJ	O
therapy	NN	O
with	IN	O
Prograf	NNP	O
capsules	NNS	O
if	IN	O
possible	JJ	O
.	.	O

Phendimetrazine	NNP	O
Tartrate	NNP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
for	IN	O
use	NN	O
in	IN	O
children	NNS	WHO
under	IN	WHO
twelve	CD	WHO
years	NNS	WHO
of	IN	WHO
age	NN	WHO
.	.	O

TESSALON	NNP	O
should	MD	O
be	VB	O
swallowed	VBN	O
whole	JJ	O
.	.	O

To	TO	O
ensure	VB	O
proper	JJ	O
dosing	NN	O
and	CC	O
to	TO	O
prevent	VB	O
actuator	NN	O
orifice	JJ	O
blockage	NN	O
,	,	O
wash	VBP	O
the	DT	O
actuator	NN	O
with	IN	O
warm	JJ	O
water	NN	O
and	CC	O
let	VB	O
it	PRP	O
air	VB	O
-	:	O
dry	NN	O
completely	RB	O
at	IN	O
least	JJS	O
once	RB	FREQ
a	DT	FREQ
week	NN	FREQ
.	.	O

Wet	NNP	O
face	NN	O
with	IN	O
water	NN	O
.	.	O

Before	IN	O
using	VBG	O
Follistim®	NNP	O
AQ	NNP	O
(	(	O
follitropin	JJ	O
beta	NN	O
injection	NN	O
)	)	O
for	IN	O
the	DT	O
first	JJ	O
time	NN	O
,	,	O
read	VB	O
these	DT	O
instructions	NNS	O
carefully	RB	O
.	.	O

When	WRB	O
only	RB	O
serum	JJ	O
creatinine	NN	O
is	VBZ	O
available	JJ	O
,	,	O
the	DT	O
following	JJ	O
formula	NN	O
(	(	O
Cockcroft	NNP	O
's	POS	O
equation	NN	O
)	)	O
4	CD	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
estimate	VB	O
creatinine	JJ	O
clearance	NN	O
.	.	O

However	RB	O
,	,	O
hepatitis	NN	O
B	NNP	O
vaccines	NNS	O
are	VBP	O
known	VBN	O
to	TO	O
result	VB	O
in	IN	O
lower	JJR	O
antibody	NN	O
response	NN	O
when	WRB	O
administered	VBN	O
subcutaneously.3	NN	O
Additionally	RB	O
,	,	O
when	WRB	O
other	JJ	O
aluminum	NN	O
-	:	O
adsorbed	NN	O
vaccines	NNS	O
have	VBP	O
been	VBN	O
administered	VBN	O
subcutaneously	RB	O
,	,	O
an	DT	O
increased	JJ	O
incidence	NN	O
of	IN	O
local	JJ	O
reactions	NNS	O
including	VBG	O
subcutaneous	JJ	O
nodules	NNS	O
has	VBZ	O
been	VBN	O
observed	VBN	O
.	.	O

Patients	NNS	WHO
not	RB	WHO
currently	RB	WHO
receiving	VBG	WHO
octreotide	RP	WHO
acetate	NN	WHO
should	MD	O
begin	VB	O
therapy	NN	O
with	IN	O
Sandostatin	NNP	O
Injection	NNP	O
given	VBN	O
subcutaneously	RB	O
.	.	O

For	IN	O
patients	NNS	WHO
with	IN	WHO
severe	JJ	WHO
renal	JJ	WHO
impairment	NN	WHO
(	(	O
indicated	VBN	O
by	IN	O
an	DT	O
estimated	VBN	O
creatinine	NN	O
clearance	NN	O
of	IN	O
5	CD	DOS
-	:	O
29	CD	DOS
mL	NN	UNIT
/	NNP	O
min	NN	O
)	)	O
,	,	O
the	DT	O
maintenance	NN	O
dose	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
by	IN	O
50	CD	O
%	NN	O
to	TO	O
50	CD	DOS
mg	NNS	UNIT
/	JJ	FREQ
day	NN	FREQ
(	(	O
25	CD	DOS
mg	NN	UNIT
twice	RB	FREQ
daily	RB	FREQ
)	)	O
.	.	O

Note	NN	O
:	:	O
Parenteral	JJ	O
drug	NN	O
products	NNS	O
should	MD	O
be	VB	O
inspected	VBN	O
visually	RB	O
for	IN	O
particulate	JJ	O
matter	NN	O
and	CC	O
discoloration	NN	O
before	IN	O
administration	NN	O
whenever	WRB	O
solution	NN	O
and	CC	O
container	NN	O
permit	NN	O
.	.	O

AZOPT	NNP	O
(	(	O
brinzolamide	IN	O
ophthalmic	JJ	O
suspension	NN	O
)	)	O
1	CD	O
%	NN	O
may	MD	O
be	VB	O
used	VBN	O
concomitantly	RB	O
with	IN	O
other	JJ	O
topical	JJ	O
ophthalmic	JJ	O
drug	NN	O
products	NNS	O
to	TO	O
lower	VB	O
intraocular	JJ	O
pressure	NN	O
.	.	O

Chorionic	JJ	O
gonadotropin	NN	O
should	MD	O
be	VB	O
withheld	VBN	O
if	IN	O
the	DT	O
serum	NN	O
estradiol	NN	O
is	VBZ	O
greater	JJR	O
than	IN	O
2,000	CD	DOS
pg	JJ	UNIT
/	NNP	O
mL	NN	O
.	.	O

For	IN	O
some	DT	WHO
patients	NNS	WHO
,	,	O
it	PRP	O
may	MD	O
be	VB	O
desirable	JJ	O
to	TO	O
start	VB	O
at	IN	O
37.5	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
for	IN	O
4	CD	PER
to	TO	O
7	CD	PER
days	NNS	PER
to	TO	O
allow	VB	O
new	JJ	O
patients	NNS	O
to	TO	O
adjust	VB	O
to	TO	O
the	DT	O
medication	NN	O
before	IN	O
increasing	VBG	O
to	TO	O
75	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

Calibration	NN	O
by	IN	O
the	DT	O
operator	NN	O
is	VBZ	O
not	RB	O
required	VBN	O
.	.	O

When	WRB	O
the	DT	O
tablets	NNS	O
are	VBP	O
administered	VBN	O
in	IN	O
the	DT	O
postpartum	NN	O
period	NN	O
,	,	O
the	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
thromboembolic	JJ	O
disease	NN	O
associated	VBN	O
with	IN	O
the	DT	O
postpartum	JJ	O
period	NN	O
must	MD	O
be	VB	O
considered	VBN	O
(	(	O
See	VB	O
CONTRAINDICATIONS	NNP	O
,	,	O
WARNINGS	NNP	O
and	CC	O
PRECAUTIONS	NNP	O
concerning	VBG	O
thromboembolic	JJ	O
disease	NN	O
)	)	O
.	.	O

Acceptable	JJ	O
intervals	NNS	O
for	IN	O
PT	NNP	O
/	NNP	O
INR	NNP	O
determinations	NNS	O
are	VBP	O
normally	RB	O
within	IN	O
the	DT	O
range	NN	O
of	IN	O
one	CD	PER
to	TO	O
four	CD	PER
weeks	NNS	PER
after	IN	O
a	DT	O
stable	JJ	O
dosage	NN	O
has	VBZ	O
been	VBN	O
determined	VBN	O
.	.	O

TABLE	NN	O
1	CD	O
:	:	O
SUGGESTED	JJ	O
DILUTIONS	NNP	O
AND	NNP	O
INFUSION	NNP	O
RATES	NNS	O

Counsel	NNP	O
her	PRP$	O
that	IN	O
this	DT	O
type	NN	O
of	IN	O
bleeding	NN	O
is	VBZ	O
usually	RB	O
transient	JJ	O
and	CC	O
without	IN	O
significance	NN	O
;	:	O
however	RB	O
,	,	O
advise	VB	O
her	PRP$	O
that	IN	O
if	IN	O
the	DT	O
bleeding	NN	O
is	VBZ	O
persistent	JJ	O
or	CC	O
prolonged	VBN	O
,	,	O
she	PRP	O
should	MD	O
consult	VB	O
her	PRP$	O
healthcare	NN	O
provider	NN	O
.	.	O

At	IN	O
the	DT	O
time	NN	O
an	DT	O
implant	NN	O
is	VBZ	O
removed	VBN	O
,	,	O
another	DT	O
implant	NN	O
may	MD	O
be	VB	O
inserted	VBN	O
to	TO	O
continue	VB	O
therapy	NN	O
.	.	O

Please	NNP	O
follow	JJ	O
instructions	NNS	O
below	IN	O
for	IN	O
proper	JJ	O
use	NN	O
of	IN	O
syringe	NN	O
and	CC	O
UltraSafe®	NNP	O
Needle	NNP	O
Guard	NNP	O
.	.	O

Treatment	NN	O
may	MD	O
be	VB	O
continued	VBN	O
after	IN	O
14	CD	O
days	NNS	O
if	IN	O
corneal	JJ	O
reepithelialization	NN	O
has	VBZ	O
not	RB	O
occurred	VBN	O
.	.	O

Administer	NNP	O
the	DT	O
initial	JJ	O
methadone	NN	O
dose	NN	O
under	IN	O
supervision	NN	O
,	,	O
when	WRB	O
there	EX	O
are	VBP	O
no	DT	O
signs	NNS	O
of	IN	O
sedation	NN	O
or	CC	O
intoxication	NN	O
,	,	O
and	CC	O
the	DT	O
patient	NN	O
shows	VBZ	O
symptoms	NNS	O
of	IN	O
withdrawal	NN	O
.	.	O

Always	NNS	O
remove	VBP	O
the	DT	O
needle	NN	O
after	IN	O
each	DT	O
injection	NN	O
and	CC	O
store	VBD	O
the	DT	O
3	CD	DOS
mL	NN	UNIT
PenFill®	NNP	O
cartridge	NN	O
compatible	JJ	O
delivery	NN	O
device	NN	O
without	IN	O
a	DT	O
needle	JJ	O
attached	VBN	O
.	.	O

The	DT	O
dose	NN	O
for	IN	O
adults	NNS	WHO
and	CC	WHO
children	NNS	WHO
is	VBZ	O
the	DT	O
entire	JJ	O
contents	NNS	O
of	IN	O
a	DT	O
restored	JJ	O
vial	NN	O
(	(	O
2.5	CD	DOS
mL	NN	UNIT
)	)	O
of	IN	O
Antivenin	NNP	O
.	.	O

The	DT	O
dose	NN	O
can	MD	O
be	VB	O
increased	VBN	O
to	TO	O
4	CD	DOS
mg	NNS	UNIT
/	JJ	O
kg	NN	O
every	DT	FREQ
4	CD	FREQ
weeks	NNS	FREQ
if	IN	O
the	DT	O
clinical	JJ	O
response	NN	O
is	VBZ	O
not	RB	O
adequate	JJ	O
.	.	O

Maintain	NNP	O
adequate	JJ	O
hydration	NN	O
and	CC	O
sufficient	JJ	O
urinary	JJ	O
output	NN	O
,	,	O
as	IN	O
required	VBN	O
for	IN	O
ifosfamide	JJ	O
treatment	NN	O
,	,	O
and	CC	O
monitor	NN	O
urine	NN	O
for	IN	O
the	DT	O
presence	NN	O
of	IN	O
hematuria	NN	O
.	.	O

GAMMAGARD	NNP	O
LIQUID	NNP	O
(	(	O
immune	JJ	O
globulin	NN	O
intravenous	JJ	O
(	(	O
human	JJ	O
)	)	O
10	CD	O
%	NN	O
)	)	O
should	MD	O
be	VB	O
at	IN	O
room	NN	O
temperature	NN	O
during	IN	O
administration	NN	O
.	.	O

If	IN	O
intolerance	NN	O
persists	NNS	O
after	IN	O
dose	JJ	O
adjustment	NN	O
,	,	O
REBETOL	NNP	O
/	NNP	O
INTRON	NNP	O
A	NNP	O
therapy	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
.	.	O

Allow	VB	O
adequate	JJ	O
time	NN	O
for	IN	O
onset	NN	O
of	IN	O
anesthesia	NN	O
following	VBG	O
administration	NN	O
of	IN	O
each	DT	O
test	NN	O
dose	NN	O
.	.	O

150	CD	O

MARCAINE	NNP	O
is	VBZ	O
not	RB	O
approved	VBN	O
for	IN	O
this	DT	O
use	NN	O
(	(	O
see	VB	O
WARNINGS	NNP	O
)	)	O
.	.	O

or	CC	O
250	CD	DOS
mg	JJ	UNIT
q.i.d	NN	O
.	.	O

Early	JJ	O
relief	NN	O
of	IN	O
symptoms	NNS	O
is	VBZ	O
experienced	VBN	O
by	IN	O
the	DT	O
majority	NN	O
of	IN	O
patients	NNS	WHO
and	CC	WHO
clinical	JJ	WHO
improvement	NN	WHO
may	MD	O
be	VB	O
seen	VBN	O
fairly	RB	O
soon	RB	O
after	IN	O
treatment	NN	O
is	VBZ	O
begun	VBN	O
;	:	O
however	RB	O
,	,	O
candidal	JJ	O
infections	NNS	O
and	CC	O
tinea	NN	O
cruris	NNS	O
and	CC	O
corporis	NN	O
should	MD	O
be	VB	O
treated	VBN	O
for	IN	O
two	CD	PER
weeks	NNS	PER
and	CC	O
tinea	NN	O
pedis	NN	O
for	IN	O
one	CD	PER
month	NN	PER
in	IN	O
order	NN	O
to	TO	O
reduce	VB	O
the	DT	O
possibility	NN	O
of	IN	O
recurrence	NN	O
.	.	O

Table	JJ	O
1	CD	O

Immediately	RB	O
discontinue	JJ	O
PEGASYS	NNP	O
for	IN	O
hepatic	JJ	O
decompensation	NN	O
(	(	O
Child	NNP	O
-	:	O
Pugh	NNP	O
score	NN	O
greater	JJR	O
than	IN	O
6	CD	O
[	JJ	O
class	NN	O
B	NNP	O
and	CC	O
C	NNP	O
]	NNP	O
)	)	O
.	.	O

The	DT	O
lowest	JJS	O
effective	JJ	O
dose	NN	O
should	MD	O
be	VB	O
used	VBN	O
to	TO	O
prevent	VB	O
the	DT	O
occurrence	NN	O
of	IN	O
side	NN	O
effects	NNS	O
.	.	O

Treatment	NN	O
of	IN	O
tinea	NN	O
corporis	NN	O
or	CC	O
tinea	NN	O
cruris	NNS	O
:	:	O

Gently	RB	O
shake	VB	O
the	DT	O
vial	NN	O
of	IN	O
DTaP	NNP	O
-	:	O
IPV	NNP	O
component	NN	O
.	.	O

See	VB	O
CONTRAINDICATIONS	NNP	O
regarding	VBG	O
mixing	VBG	O
this	DT	O
emulsion	NN	O
with	IN	O
other	JJ	O
I.V	NNP	O
.	.	O

Do	MD	O
not	RB	O
store	VB	O
.	.	O

In	IN	O
all	DT	O
cases	NNS	O
,	,	O
the	DT	O
dosage	NN	O
should	MD	O
be	VB	O
adjusted	VBN	O
with	IN	O
careful	JJ	O
individual	JJ	O
attention	NN	O
both	DT	O
to	TO	O
symptomatology	NN	O
and	CC	O
ocular	JJ	O
tension	NN	O
.	.	O

On	IN	O
the	DT	O
other	JJ	O
hand	NN	O
,	,	O
failure	NN	O
to	TO	O
provide	VB	O
maintenance	NN	O
therapy	NN	O
in	IN	O
some	DT	WHO
patients	NNS	WHO
may	MD	O
lead	VB	O
to	TO	O
unnecessary	JJ	O
relapse	NN	O
;	:	O
complete	JJ	O
remissions	NNS	O
in	IN	O
patients	NNS	WHO
with	IN	WHO
testicular	JJ	WHO
cancer	NN	WHO
,	,	O
unless	IN	O
maintained	VBN	O
for	IN	O
at	IN	WHO
least	JJS	WHO
2	CD	WHO
years	NNS	WHO
,	,	WHO
often	RB	WHO
result	NN	WHO
in	IN	WHO
early	JJ	WHO
relapse	NN	WHO
.	.	O

Dose	NNP	O
reduction	NN	O
in	IN	O
pediatric	JJ	WHO
patients	NNS	WHO
is	VBZ	O
accomplished	VBN	O
by	IN	O
modifying	VBG	O
the	DT	O
recommended	VBN	O
dose	NN	O
in	IN	O
a	DT	O
2	CD	O
-	:	O
step	NN	O
process	NN	O
from	IN	O
the	DT	O
original	JJ	O
starting	VBG	O
dose	NN	O
of	IN	O
60	CD	DOS
mcg	NNS	UNIT
/	JJ	O
m²	NNS	O
/	JJ	O
week	NN	PER
,	,	O
to	TO	O
40	CD	DOS
mcg	NNS	UNIT
/	JJ	O
m²	NNS	O
/	JJ	O
week	NN	PER
,	,	O
then	RB	O
to	TO	O
20	CD	DOS
mcg	NNS	UNIT
/	JJ	O
m²	NNS	O
/	JJ	O
week	NN	PER
,	,	O
if	IN	O
needed	VBN	O
(	(	O
see	VB	O
Tables	NNP	O
4	CD	O
and	CC	O
5	CD	O
)	)	O
.	.	O

Otitis	NN	O
Externa	NN	O
:	:	O
The	DT	O
recommended	JJ	O
dosage	NN	O
regimen	NNS	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
otitis	NN	O
externa	NN	O
is	VBZ	O
:	:	O

This	DT	O
compounding	JJ	O
procedure	NN	O
results	NNS	O
in	IN	O
a	DT	O
1	CD	O
%	NN	O
w	NN	O
/	NNP	O
v	NN	O
suspension	NN	O
containing	VBG	O
10	CD	DOS
mg	JJ	UNIT
rifampin	NN	O
/	NNP	O
mL	NN	O
.	.	O

The	DT	O
usual	JJ	O
maintenance	NN	O
dosage	NN	O
of	IN	O
amitriptyline	JJ	O
HCl	NNP	O
is	VBZ	O
50	CD	DOS
to	TO	O
100	CD	DOS
mg	NNS	UNIT
per	IN	FREQ
day	NN	FREQ
.	.	O

Individually	RB	O
titrate	JJ	O
Onsolis	NNP	O
to	TO	O
a	DT	O
dose	NN	O
that	WDT	O
provides	VBZ	O
adequate	JJ	O
analgesia	NN	O
with	IN	O
tolerable	JJ	O
side	NN	O
effects	NNS	O
.	.	O

One	CD	DOS
application	NN	UNIT
of	IN	O
the	DT	O
shampoo	NN	O
should	MD	O
be	VB	O
sufficient	JJ	O
.	.	O


